Binding	O
of	O
dimemorfan	B-CHEMICAL
to	O
sigma	B-GENE-Y
-	I-GENE-Y
1	I-GENE-Y
receptor	I-GENE-Y
and	O
its	O
anticonvulsant	O
and	O
locomotor	O
effects	O
in	O
mice	O
,	O
compared	O
with	O
dextromethorphan	B-CHEMICAL
and	O
dextrorphan	B-CHEMICAL
.	O

Dextromethorphan	B-CHEMICAL
(	O
(	B-CHEMICAL
+	I-CHEMICAL
)	I-CHEMICAL
-	I-CHEMICAL
3	I-CHEMICAL
-	I-CHEMICAL
methoxy	I-CHEMICAL
-	I-CHEMICAL
N	I-CHEMICAL
-	I-CHEMICAL
methylmorphinan	I-CHEMICAL
,	O
DM	B-CHEMICAL
)	O
has	O
been	O
shown	O
to	O
have	O
both	O
anticonvulsant	O
and	O
neuroprotective	O
effects	O
.	O

The	O
mechanisms	O
of	O
these	O
CNS	O
effects	O
of	O
DM	B-CHEMICAL
have	O
been	O
suggested	O
to	O
be	O
associated	O
with	O
the	O
low	O
-	O
affinity	O
,	O
noncompetitive	O
,	O
N	B-CHEMICAL
-	I-CHEMICAL
methyl	I-CHEMICAL
-	I-CHEMICAL
d	I-CHEMICAL
-	I-CHEMICAL
aspartate	I-CHEMICAL
(	O
NMDA	B-CHEMICAL
)	O
antagonism	O
of	O
DM	B-CHEMICAL
and	O
/	O
or	O
the	O
high	O
-	O
affinity	O
DM	B-CHEMICAL
/	O
sigma	O
receptors	O
.	O

DM	B-CHEMICAL
is	O
largely	O
O	B-CHEMICAL
-	O
demethylated	O
into	O
the	O
phencyclidine	B-CHEMICAL
(	O
PCP	B-CHEMICAL
)	O
-	O
like	O
compound	O
dextrorphan	B-CHEMICAL
(	O
DR	B-CHEMICAL
)	O
,	O
which	O
may	O
limit	O
its	O
therapeutic	O
use	O
by	O
producing	O
PCP	B-CHEMICAL
-	O
like	O
adverse	O
effects	O
,	O
such	O
as	O
hyperlocomotion	O
.	O

Dimemorfan	B-CHEMICAL
(	O
(	B-CHEMICAL
+	I-CHEMICAL
)	I-CHEMICAL
-	I-CHEMICAL
3	I-CHEMICAL
-	I-CHEMICAL
methyl	I-CHEMICAL
-	I-CHEMICAL
N	I-CHEMICAL
-	I-CHEMICAL
methylmorphinan	I-CHEMICAL
,	O
DF	B-CHEMICAL
)	O
,	O
an	O
analog	O
of	O
DM	B-CHEMICAL
,	O
which	O
has	O
been	O
safely	O
used	O
as	O
an	O
antitussive	O
for	O
more	O
than	O
20	O
years	O
,	O
is	O
also	O
known	O
not	O
to	O
form	O
DR	B-CHEMICAL
.	O

This	O
study	O
therefore	O
characterized	O
the	O
binding	O
of	O
DF	B-CHEMICAL
to	O
the	O
sigma	B-GENE-N
receptors	I-GENE-N
and	O
NMDA	B-CHEMICAL
-	O
linked	O
PCP	B-CHEMICAL
sites	O
and	O
examined	O
the	O
anticonvulsant	O
as	O
well	O
as	O
locomotor	O
effects	O
of	O
DF	B-CHEMICAL
in	O
mice	O
in	O
comparison	O
with	O
those	O
of	O
DM	B-CHEMICAL
and	O
DR	B-CHEMICAL
.	O

We	O
found	O
that	O
DF	B-CHEMICAL
,	O
DM	B-CHEMICAL
,	O
and	O
DR	B-CHEMICAL
were	O
relative	O
high	O
-	O
affinity	O
ligands	O
at	O
sigma	B-GENE-Y
-	I-GENE-Y
1	I-GENE-Y
receptors	I-GENE-Y
(	O
Ki	O
=	O
151	O
,	O
205	O
,	O
144	O
nM	O
,	O
respectively	O
)	O
while	O
all	O
of	O
them	O
were	O
with	O
low	O
affinity	O
at	O
sigma	B-GENE-N
-	I-GENE-N
2	I-GENE-N
receptors	I-GENE-N
(	O
Ki	O
=	O
4	O
-	O
11	O
microM	O
)	O
.	O

Only	O
DR	B-CHEMICAL
exhibited	O
moderate	O
affinity	O
for	O
PCP	B-CHEMICAL
sites	O
(	O
Ki	O
=	O
0	O
.	O
9	O
microM	O
)	O
,	O
whereas	O
DF	B-CHEMICAL
(	O
Ki	O
=	O
17	O
microM	O
)	O
and	O
DM	B-CHEMICAL
(	O
Ki	O
=	O
7	O
microM	O
)	O
were	O
much	O
less	O
active	O
.	O

DF	O
,	O
DM	B-CHEMICAL
and	O
DR	B-CHEMICAL
produced	O
prominent	O
anticonvulsant	O
effects	O
in	O
mice	O
as	O
measured	O
by	O
the	O
supramaximal	O
electroshock	O
test	O
with	O
comparable	O
potency	O
(	O
ED50	O
approximately	O
70	O
micromol	O
/	O
kg	O
,	O
i	O
.	O
p	O
.	O
)	O
.	O

At	O
the	O
tested	O
doses	O
(	O
20	O
-	O
260	O
micromol	O
/	O
kg	O
,	O
i	O
.	O
p	O
.	O
)	O
,	O
DM	B-CHEMICAL
and	O
DR	B-CHEMICAL
exhibited	O
biphasic	O
effects	O
on	O
the	O
locomotor	O
activity	O
whereas	O
DF	B-CHEMICAL
produced	O
a	O
consistent	O
dose	O
-	O
dependent	O
decrease	O
.	O

These	O
results	O
revealed	O
that	O
,	O
unlike	O
DM	B-CHEMICAL
and	O
DR	B-CHEMICAL
,	O
DF	B-CHEMICAL
did	O
not	O
cause	O
a	O
PCP	B-CHEMICAL
-	O
like	O
hyperlocomotion	O
adverse	O
effect	O
that	O
is	O
parallel	O
with	O
the	O
PCP	B-CHEMICAL
sites	O
binding	O
data	O
.	O

Furthermore	O
,	O
since	O
they	O
have	O
equipotent	O
anticonvulsant	O
effects	O
and	O
similar	O
binding	O
affinities	O
to	O
sigma	B-GENE-Y
-	I-GENE-Y
1	I-GENE-Y
receptors	I-GENE-Y
,	O
the	O
very	O
low	O
affinity	O
of	O
DF	B-CHEMICAL
at	O
PCP	B-CHEMICAL
sites	O
may	O
suggest	O
that	O
acting	O
on	O
the	O
PCP	B-CHEMICAL
sites	O
may	O
not	O
be	O
the	O
requisite	O
for	O
mediating	O
the	O
anticonvulsant	O
activity	O
of	O
these	O
DM	B-CHEMICAL
analogs	O
.	O

With	O
the	O
history	O
of	O
safety	O
and	O
relative	O
less	O
adverse	O
effects	O
,	O
DF	B-CHEMICAL
appears	O
to	O
be	O
worth	O
further	O
studying	O
on	O
its	O
CNS	O
effects	O
other	O
than	O
the	O
antitussive	O
effect	O
.	O

Angiotensin	B-GENE-N
II	I-GENE-N
receptor	I-GENE-N
blockade	O
in	O
normotensive	O
subjects	O
:	O
A	O
direct	O
comparison	O
of	O
three	O
AT1	B-GENE-Y
receptor	I-GENE-Y
antagonists	O
.	O

Use	O
of	O
angiotensin	B-GENE-Y
(	I-GENE-Y
Ang	I-GENE-Y
)	I-GENE-Y
II	I-GENE-Y
AT1	I-GENE-Y
receptor	I-GENE-Y
antagonists	O
for	O
treatment	O
of	O
hypertension	O
is	O
rapidly	O
increasing	O
,	O
yet	O
direct	O
comparisons	O
of	O
the	O
relative	O
efficacy	O
of	O
antagonists	O
to	O
block	O
the	O
renin	O
-	O
angiotensin	O
system	O
in	O
humans	O
are	O
lacking	O
.	O

In	O
this	O
study	O
,	O
the	O
Ang	B-GENE-N
II	I-GENE-N
receptor	I-GENE-N
blockade	O
induced	O
by	O
the	O
recommended	O
starting	O
dose	O
of	O
3	O
antagonists	O
was	O
evaluated	O
in	O
normotensive	O
subjects	O
in	O
a	O
double	O
-	O
blind	O
,	O
placebo	O
-	O
controlled	O
,	O
randomized	O
,	O
4	O
-	O
way	O
crossover	O
study	O
.	O

At	O
1	O
-	O
week	O
intervals	O
,	O
12	O
subjects	O
received	O
a	O
single	O
dose	O
of	O
losartan	B-CHEMICAL
(	O
50	O
mg	O
)	O
,	O
valsartan	B-CHEMICAL
(	O
80	O
mg	O
)	O
,	O
irbesartan	B-CHEMICAL
(	O
150	O
mg	O
)	O
,	O
or	O
placebo	O
.	O

Blockade	O
of	O
the	O
renin	B-GENE-Y
-	O
angiotensin	B-CHEMICAL
system	O
was	O
assessed	O
before	O
and	O
4	O
,	O
24	O
,	O
and	O
30	O
hours	O
after	O
drug	O
intake	O
by	O
3	O
independent	O
methods	O
:	O
inhibition	O
of	O
the	O
blood	O
pressure	O
response	O
to	O
exogenous	O
Ang	B-CHEMICAL
II	I-CHEMICAL
,	O
in	O
vitro	O
Ang	B-GENE-N
II	I-GENE-N
receptor	I-GENE-N
assay	O
,	O
and	O
reactive	O
changes	O
in	O
plasma	O
Ang	B-CHEMICAL
II	I-CHEMICAL
levels	O
.	O

At	O
4	O
hours	O
,	O
losartan	O
blocked	O
43	O
%	O
of	O
the	O
Ang	B-CHEMICAL
II	I-CHEMICAL
-	O
induced	O
systolic	O
blood	O
pressure	O
increase	O
;	O
valsartan	B-CHEMICAL
,	O
51	O
%	O
;	O
and	O
irbesartan	B-CHEMICAL
,	O
88	O
%	O
(	O
P	O
<	O
0	O
.	O
01	O
between	O
drugs	O
)	O
.	O

The	O
effect	O
of	O
each	O
drug	O
declined	O
with	O
time	O
.	O

At	O
24	O
hours	O
,	O
a	O
residual	O
effect	O
was	O
found	O
with	O
all	O
3	O
drugs	O
,	O
but	O
at	O
30	O
hours	O
,	O
only	O
irbesartan	B-CHEMICAL
induced	O
a	O
marked	O
,	O
significant	O
blockade	O
versus	O
placebo	O
.	O

Similar	O
results	O
were	O
obtained	O
when	O
Ang	B-GENE-N
II	I-GENE-N
receptor	I-GENE-N
blockade	O
was	O
assessed	O
with	O
an	O
in	O
vitro	O
receptor	O
assay	O
and	O
by	O
the	O
reactive	O
rise	O
in	O
plasma	O
Ang	B-CHEMICAL
II	I-CHEMICAL
levels	O
.	O

This	O
study	O
thus	O
demonstrates	O
that	O
the	O
first	O
administration	O
of	O
the	O
recommended	O
starting	O
dose	O
of	O
irbesartan	B-CHEMICAL
induces	O
a	O
greater	O
and	O
longer	O
lasting	O
Ang	B-GENE-N
II	I-GENE-N
receptor	I-GENE-N
blockade	O
than	O
that	O
of	O
valsartan	B-CHEMICAL
and	O
losartan	B-CHEMICAL
in	O
normotensive	O
subjects	O
.	O

Characterisation	O
of	O
the	O
5	B-GENE-N
-	I-GENE-N
HT	I-GENE-N
receptor	I-GENE-N
binding	O
profile	O
of	O
eletriptan	B-CHEMICAL
and	O
kinetics	O
of	O
[	B-CHEMICAL
3H	I-CHEMICAL
]	I-CHEMICAL
eletriptan	I-CHEMICAL
binding	O
at	O
human	B-GENE-Y
5	I-GENE-Y
-	I-GENE-Y
HT1B	I-GENE-Y
and	O
5	B-GENE-Y
-	I-GENE-Y
HT1D	I-GENE-Y
receptors	O
.	O

The	O
affinity	O
of	O
eletriptan	B-CHEMICAL
(	O
(	B-CHEMICAL
R	I-CHEMICAL
)	I-CHEMICAL
-	I-CHEMICAL
3	I-CHEMICAL
-	I-CHEMICAL
(	I-CHEMICAL
1	I-CHEMICAL
-	I-CHEMICAL
methyl	I-CHEMICAL
-	I-CHEMICAL
2	I-CHEMICAL
-	I-CHEMICAL
pyrrolidinylmethyl	I-CHEMICAL
)	I-CHEMICAL
-	I-CHEMICAL
5	I-CHEMICAL
-	I-CHEMICAL
[	I-CHEMICAL
2	I-CHEMICAL
-	I-CHEMICAL
(	I-CHEMICAL
phenylsulphonyl	I-CHEMICAL
)	I-CHEMICAL
ethyl	I-CHEMICAL
]	I-CHEMICAL
-	I-CHEMICAL
1H	I-CHEMICAL
-	I-CHEMICAL
indole	I-CHEMICAL
)	O
for	O
a	O
range	O
of	O
5	B-GENE-N
-	I-GENE-N
HT	I-GENE-N
receptors	I-GENE-N
was	O
compared	O
to	O
values	O
obtained	O
for	O
other	O
5	B-GENE-N
-	I-GENE-N
HT1B	I-GENE-N
/	I-GENE-N
1D	I-GENE-N
receptor	O
agonists	O
known	O
to	O
be	O
effective	O
in	O
the	O
treatment	O
of	O
migraine	O
.	O

Eletriptan	B-CHEMICAL
,	O
like	O
sumatriptan	B-CHEMICAL
,	O
zolmitriptan	B-CHEMICAL
,	O
naratriptan	B-CHEMICAL
and	O
rizatriptan	B-CHEMICAL
had	O
highest	O
affinity	O
for	O
the	O
human	B-GENE-Y
5	I-GENE-Y
-	I-GENE-Y
HT1B	I-GENE-Y
,	O
5	B-GENE-Y
-	I-GENE-Y
HT1D	I-GENE-Y
and	O
putative	O
5	B-GENE-Y
-	I-GENE-Y
ht1f	I-GENE-Y
receptor	O
.	O

Kinetic	O
studies	O
comparing	O
the	O
binding	O
of	O
[	B-CHEMICAL
3H	I-CHEMICAL
]	I-CHEMICAL
eletriptan	I-CHEMICAL
and	O
[	B-CHEMICAL
3H	I-CHEMICAL
]	I-CHEMICAL
sumatriptan	I-CHEMICAL
to	O
the	O
human	B-GENE-Y
recombinant	I-GENE-Y
5	I-GENE-Y
-	I-GENE-Y
HT1B	I-GENE-Y
and	O
5	B-GENE-Y
-	I-GENE-Y
HT1D	I-GENE-Y
receptors	O
expressed	O
in	O
HeLa	O
cells	O
revealed	O
that	O
both	O
radioligands	O
bound	O
with	O
high	O
specificity	O
(	O
>	O
90	O
%	O
)	O
and	O
reached	O
equilibrium	O
within	O
10	O
-	O
15	O
min	O
.	O

However	O
,	O
[	B-CHEMICAL
3H	I-CHEMICAL
]	I-CHEMICAL
eletriptan	I-CHEMICAL
had	O
over	O
6	O
-	O
fold	O
higher	O
affinity	O
than	O
[	B-CHEMICAL
3H	I-CHEMICAL
]	I-CHEMICAL
sumatriptan	I-CHEMICAL
at	O
the	O
5	B-GENE-Y
-	I-GENE-Y
HT1D	I-GENE-Y
receptor	O
(	O
K	O
(	O
D	O
)	O
)	O
:	O
0	O
.	O
92	O
and	O
6	O
.	O
58	O
nM	O
,	O
respectively	O
)	O
and	O
over	O
3	O
-	O
fold	O
higher	O
affinity	O
than	O
[	B-CHEMICAL
3H	I-CHEMICAL
]	I-CHEMICAL
sumatriptan	I-CHEMICAL
at	O
the	O
5	B-GENE-Y
-	I-GENE-Y
HT1B	I-GENE-Y
receptor	O
(	O
K	O
(	O
D	O
)	O
:	O
3	O
.	O
14	O
and	O
11	O
.	O
07	O
nM	O
,	O
respectively	O
)	O
.	O

Association	O
and	O
dissociation	O
rates	O
for	O
both	O
radioligands	O
could	O
only	O
be	O
accurately	O
determined	O
at	O
the	O
5	B-GENE-Y
-	I-GENE-Y
HT1D	I-GENE-Y
receptor	O
and	O
then	O
only	O
at	O
4	O
degrees	O
C	O
.	O

At	O
this	O
temperature	O
,	O
[	B-CHEMICAL
3H	I-CHEMICAL
]	I-CHEMICAL
eletriptan	I-CHEMICAL
had	O
a	O
significantly	O
(	O
P	O
<	O
0	O
.	O
05	O
)	O
faster	O
association	O
rate	O
(	O
K	O
(	O
on	O
)	O
0	O
.	O
249	O
min	O
(	O
-	O
1	O
)	O
nM	O
(	O
-	O
1	O
)	O
)	O
than	O
[	B-CHEMICAL
3H	I-CHEMICAL
]	I-CHEMICAL
sumatriptan	I-CHEMICAL
(	O
K	O
(	O
on	O
)	O
0	O
.	O
024	O
min	O
(	O
-	O
1	O
)	O
nM	O
(	O
-	O
1	O
)	O
)	O
and	O
a	O
significantly	O
(	O
P	O
<	O
0	O
.	O
05	O
)	O
slower	O
off	O
-	O
rate	O
(	O
K	O
(	O
off	O
)	O
0	O
.	O
027	O
min	O
(	O
-	O
1	O
)	O
compared	O
to	O
0	O
.	O
037	O
min	O
(	O
-	O
1	O
)	O
for	O
[	B-CHEMICAL
3H	I-CHEMICAL
]	I-CHEMICAL
sumatriptan	I-CHEMICAL
)	O
.	O

These	O
data	O
indicate	O
that	O
eletriptan	O
is	O
a	O
potent	O
ligand	O
at	O
the	O
human	B-GENE-Y
5	I-GENE-Y
-	I-GENE-Y
HT1B	I-GENE-Y
,	O
5	B-GENE-Y
-	I-GENE-Y
HT1D	I-GENE-Y
,	O
and	O
5	B-GENE-Y
-	I-GENE-Y
ht1f	I-GENE-Y
receptors	O
and	O
are	O
consistent	O
with	O
its	O
potent	O
vasoconstrictor	O
activity	O
and	O
use	O
as	O
a	O
drug	O
for	O
the	O
acute	O
treatment	O
of	O
migraine	O
headache	O
.	O

Pharmacological	O
profile	O
of	O
neuroleptics	B-CHEMICAL
at	O
human	B-GENE-N
monoamine	I-GENE-N
transporters	I-GENE-N
.	O

Using	O
radioligand	O
binding	O
techniques	O
,	O
we	O
determined	O
the	O
equilibrium	O
dissociation	O
constants	O
(	O
K	O
(	O
D	O
)	O
)	O
for	O
37	O
neuroleptics	B-CHEMICAL
and	O
one	O
metabolite	O
of	O
a	O
neuroleptic	O
(	O
haloperidol	B-CHEMICAL
metabolite	O
)	O
for	O
the	O
human	B-GENE-N
serotonin	I-GENE-N
,	I-GENE-N
norepinephrine	I-GENE-N
,	I-GENE-N
and	I-GENE-N
dopamine	I-GENE-N
transporters	I-GENE-N
with	O
[	B-CHEMICAL
3H	I-CHEMICAL
]	I-CHEMICAL
imipramine	I-CHEMICAL
,	O
[	B-CHEMICAL
3H	I-CHEMICAL
]	I-CHEMICAL
nisoxetine	I-CHEMICAL
,	O
and	O
[	B-CHEMICAL
3H	I-CHEMICAL
]	I-CHEMICAL
WIN35428	I-CHEMICAL
,	O
respectively	O
.	O

Among	O
neuroleptics	B-CHEMICAL
,	O
the	O
four	O
most	O
potent	O
compounds	O
at	O
the	O
human	B-GENE-Y
serotonin	I-GENE-Y
transporter	I-GENE-Y
were	O
triflupromazine	B-CHEMICAL
,	O
fluperlapine	B-CHEMICAL
,	O
chlorpromazine	B-CHEMICAL
,	O
and	O
ziprasidone	B-CHEMICAL
(	O
K	O
(	O
D	O
)	O
24	O
-	O
39	O
nM	O
)	O
;	O
and	O
at	O
the	O
norepinephrine	B-GENE-Y
transporter	I-GENE-Y
,	O
chlorpromazine	B-CHEMICAL
,	O
zotepine	B-CHEMICAL
,	O
chlorprothixene	B-CHEMICAL
,	O
and	O
promazine	B-CHEMICAL
(	O
K	O
(	O
D	O
)	O
19	O
-	O
25	O
nM	O
)	O
.	O

At	O
the	O
human	B-GENE-Y
dopamine	I-GENE-Y
transporter	I-GENE-Y
,	O
only	O
pimozide	B-CHEMICAL
(	O
K	O
(	O
D	O
)	O
=	O
69	O
+	O
/	O
-	O
3	O
)	O
ziprasidone	B-CHEMICAL
(	O
K	O
(	O
D	O
)	O
=	O
76	O
+	O
/	O
-	O
5	O
)	O
had	O
notable	O
potency	O
.	O

These	O
data	O
may	O
be	O
useful	O
in	O
predicting	O
therapeutic	O
and	O
adverse	O
effects	O
,	O
including	O
drug	O
interactions	O
of	O
neuroleptics	B-CHEMICAL
.	O

Disodium	B-CHEMICAL
cromoglycate	I-CHEMICAL
does	O
not	O
prevent	O
terbutaline	B-CHEMICAL
-	O
induced	O
desensitization	O
of	O
beta	B-GENE-Y
2	I-GENE-Y
-	I-GENE-Y
adrenoceptor	I-GENE-Y
-	O
mediated	O
cardiovascular	O
in	O
vivo	O
functions	O
in	O
human	O
volunteers	O
.	O

In	O
humans	O
,	O
prolonged	O
administration	O
of	O
the	O
beta	B-GENE-Y
2	I-GENE-Y
-	I-GENE-Y
adrenoceptor	I-GENE-Y
agonist	O
terbutaline	B-CHEMICAL
leads	O
to	O
a	O
desensitization	O
of	O
beta	B-GENE-Y
2	I-GENE-Y
-	I-GENE-Y
adrenoceptor	I-GENE-Y
-	O
mediated	O
cardiovascular	O
responses	O
,	O
which	O
can	O
be	O
blunted	O
by	O
concomitant	O
administration	O
of	O
the	O
antianaphylactic	O
drug	O
ketotifen	B-CHEMICAL
.	O

This	O
study	O
investigated	O
the	O
effect	O
of	O
disodium	B-CHEMICAL
cromoglycate	I-CHEMICAL
,	O
another	O
antiallergic	O
drug	O
,	O
on	O
terbutaline	B-CHEMICAL
-	O
induced	O
desensitization	O
of	O
beta	B-GENE-N
-	I-GENE-N
adrenoceptor	I-GENE-N
-	O
mediated	O
cardiovascular	O
and	O
noncardiovascular	O
responses	O
.	O

In	O
a	O
double	O
-	O
blind	O
,	O
placebo	O
-	O
controlled	O
,	O
randomized	O
design	O
,	O
nine	O
healthy	O
male	O
volunteers	O
received	O
disodium	B-CHEMICAL
cromoglycate	I-CHEMICAL
(	O
4	O
x	O
200	O
mg	O
/	O
day	O
,	O
p	O
.	O
o	O
.	O
)	O
or	O
placebo	O
for	O
3	O
weeks	O
with	O
terbutaline	B-CHEMICAL
(	O
3	O
x	O
5	O
mg	O
/	O
day	O
,	O
p	O
.	O
o	O
.	O
)	O
administered	O
concomitantly	O
during	O
the	O
last	O
2	O
weeks	O
.	O
beta	B-GENE-Y
2	I-GENE-Y
-	I-GENE-Y
Adrenoceptor	I-GENE-Y
cardiovascular	O
function	O
was	O
assessed	O
by	O
the	O
increase	O
in	O
heart	O
rate	O
and	O
reduction	O
of	O
diastolic	O
blood	O
pressure	O
induced	O
by	O
an	O
incremental	O
intravenous	O
infusion	O
of	O
the	O
unselective	O
beta	B-GENE-N
-	I-GENE-N
adrenoceptor	I-GENE-N
agonist	O
isoprenaline	B-CHEMICAL
;	O
beta	B-GENE-Y
1	I-GENE-Y
-	I-GENE-Y
adrenoceptor	I-GENE-Y
cardiovascular	O
function	O
was	O
assessed	O
by	O
exercise	O
-	O
induced	O
tachycardia	O
.	O

Tremulousness	O
was	O
monitored	O
as	O
a	O
beta	B-GENE-Y
2	I-GENE-Y
-	I-GENE-Y
adrenoceptor	I-GENE-Y
-	O
mediated	O
noncardiovascular	O
effect	O
.	O

After	O
2	O
weeks	O
'	O
administration	O
of	O
terbutaline	B-CHEMICAL
,	O
there	O
was	O
a	O
marked	O
and	O
significant	O
(	O
p	O
<	O
0	O
.	O
001	O
)	O
attenuation	O
of	O
isoprenaline	B-CHEMICAL
-	O
induced	O
tachycardia	O
(	O
mean	O
percentage	O
attenuation	O
,	O
53	O
.	O
3	O
%	O
)	O
and	O
of	O
the	O
isoprenaline	B-CHEMICAL
-	O
induced	O
decrease	O
in	O
diastolic	O
blood	O
pressure	O
(	O
mean	O
percentage	O
attenuation	O
,	O
55	O
.	O
6	O
%	O
)	O
.	O

Exercise	O
-	O
induced	O
tachycardia	O
also	O
was	O
significantly	O
(	O
p	O
<	O
0	O
.	O
001	O
)	O
blunted	O
,	O
but	O
the	O
magnitude	O
of	O
this	O
attenuation	O
was	O
only	O
very	O
small	O
(	O
mean	O
attenuation	O
,	O
5	O
.	O
6	O
%	O
)	O
.	O

Disodium	B-CHEMICAL
cromoglycate	I-CHEMICAL
affected	O
neither	O
the	O
rightward	O
shift	O
of	O
beta	B-GENE-Y
2	I-GENE-Y
-	I-GENE-Y
adrenoceptor	I-GENE-Y
-	O
mediated	O
responses	O
nor	O
the	O
small	O
rightward	O
shift	O
in	O
beta	B-GENE-Y
1	I-GENE-Y
-	I-GENE-Y
adrenoceptor	I-GENE-Y
-	O
mediated	O
exercise	O
tachycardia	O
after	O
2	O
weeks	O
'	O
administration	O
of	O
terbutaline	B-CHEMICAL
.	O

Tremulousness	O
observed	O
during	O
the	O
first	O
few	O
days	O
of	O
terbutaline	B-CHEMICAL
administration	O
disappeared	O
after	O
4	O
to	O
8	O
days	O
,	O
indicating	O
development	O
of	O
desensitization	O
of	O
beta	B-GENE-Y
2	I-GENE-Y
-	I-GENE-Y
adrenoceptor	I-GENE-Y
-	O
mediated	O
noncardiovascular	O
responses	O
.	O

This	O
was	O
not	O
prevented	O
by	O
disodium	B-CHEMICAL
cromoglycate	I-CHEMICAL
.	O

These	O
results	O
confirm	O
that	O
long	O
-	O
term	O
beta	B-GENE-Y
2	I-GENE-Y
-	I-GENE-Y
adrenoceptor	I-GENE-Y
agonist	O
therapy	O
leads	O
to	O
a	O
desensitization	O
of	O
beta	B-GENE-Y
2	I-GENE-Y
-	I-GENE-Y
adrenoceptor	I-GENE-Y
-	O
mediated	O
cardiovascular	O
and	O
noncardiovascular	O
effects	O
in	O
humans	O
in	O
vivo	O
.	O

However	O
,	O
unlike	O
ketotifen	B-CHEMICAL
,	O
cromolyn	B-CHEMICAL
sodium	I-CHEMICAL
is	O
not	O
able	O
to	O
attenuate	O
this	O
desensitization	O
.	O

A	O
multicenter	O
,	O
randomized	O
study	O
of	O
argatroban	B-CHEMICAL
versus	O
heparin	O
as	O
adjunct	O
to	O
tissue	B-GENE-Y
plasminogen	I-GENE-Y
activator	I-GENE-Y
(	O
TPA	B-GENE-Y
)	O
in	O
acute	O
myocardial	O
infarction	O
:	O
myocardial	O
infarction	O
with	O
novastan	B-CHEMICAL
and	O
TPA	B-GENE-Y
(	O
MINT	O
)	O
study	O
.	O

OBJECTIVES	O
:	O
This	O
study	O
examined	O
the	O
effect	O
of	O
a	O
small	O
-	O
molecule	O
,	O
direct	O
thrombin	B-GENE-Y
inhibitor	O
,	O
argatroban	B-CHEMICAL
,	O
on	O
reperfusion	O
induced	O
by	O
tissue	B-GENE-Y
plasminogen	I-GENE-Y
activator	I-GENE-Y
(	O
TPA	B-GENE-Y
)	O
in	O
patients	O
with	O
acute	O
myocardial	O
infarction	O
(	O
AMI	O
)	O
.	O

BACKGROUND	O
:	O
Thrombin	B-GENE-Y
plays	O
a	O
crucial	O
role	O
in	O
thrombosis	O
and	O
thrombolysis	O
.	O

In	O
vitro	O
and	O
in	O
vivo	O
studies	O
have	O
shown	O
that	O
argatroban	B-CHEMICAL
has	O
advantages	O
over	O
heparin	O
for	O
the	O
inhibition	O
of	O
clot	O
-	O
bound	O
thrombin	B-GENE-Y
and	O
for	O
the	O
enhancement	O
of	O
thrombolysis	O
with	O
TPA	B-GENE-Y
.	O

METHODS	O
:	O
One	O
hundred	O
and	O
twenty	O
-	O
five	O
patients	O
with	O
AMI	O
within	O
6	O
h	O
were	O
randomized	O
to	O
heparin	O
,	O
low	O
-	O
dose	O
argatroban	B-CHEMICAL
or	O
high	O
-	O
dose	O
argatroban	B-CHEMICAL
in	O
addition	O
to	O
TPA	B-GENE-Y
.	O

The	O
primary	O
end	O
point	O
was	O
the	O
rate	O
of	O
thrombolysis	O
in	O
myocardial	O
infarction	O
(	O
TIMI	O
)	O
grade	O
3	O
flow	O
at	O
90	O
min	O
.	O

RESULTS	O
:	O
TIMI	O
grade	O
3	O
flow	O
was	O
achieved	O
in	O
42	O
.	O
1	O
%	O
of	O
heparin	O
,	O
56	O
.	O
8	O
%	O
of	O
low	O
-	O
dose	O
argatroban	B-CHEMICAL
(	O
p	O
=	O
0	O
.	O
20	O
vs	O
.	O
heparin	O
)	O
and	O
58	O
.	O
7	O
%	O
of	O
high	O
-	O
dose	O
argatroban	B-CHEMICAL
patients	O
(	O
p	O
=	O
0	O
.	O
13	O
vs	O
.	O
heparin	O
)	O
.	O

In	O
patients	O
presenting	O
after	O
3	O
h	O
,	O
TIMI	O
grade	O
3	O
flow	O
was	O
significantly	O
more	O
frequent	O
in	O
high	O
-	O
dose	O
argatroban	B-CHEMICAL
versus	O
heparin	O
patients	O
:	O
57	O
.	O
1	O
%	O
versus	O
20	O
.	O
0	O
%	O
(	O
p	O
=	O
0	O
.	O
03	O
vs	O
.	O
heparin	O
)	O
.	O

Major	O
bleeding	O
was	O
observed	O
in	O
10	O
.	O
0	O
%	O
of	O
heparin	O
,	O
and	O
in	O
2	O
.	O
6	O
%	O
and	O
4	O
.	O
3	O
%	O
of	O
low	O
-	O
dose	O
and	O
high	O
-	O
dose	O
argatroban	B-CHEMICAL
patients	O
,	O
respectively	O
.	O

The	O
composite	O
of	O
death	O
,	O
recurrent	O
myocardial	O
infarction	O
,	O
cardiogenic	O
shock	O
or	O
congestive	O
heart	O
failure	O
,	O
revascularization	O
and	O
recurrent	O
ischemia	O
at	O
30	O
days	O
occurred	O
in	O
37	O
.	O
5	O
%	O
of	O
heparin	O
,	O
32	O
.	O
0	O
%	O
of	O
low	O
-	O
dose	O
argatroban	B-CHEMICAL
and	O
25	O
.	O
5	O
%	O
of	O
high	O
-	O
dose	O
argatroban	B-CHEMICAL
patients	O
(	O
p	O
=	O
0	O
.	O
23	O
)	O
.	O

CONCLUSIONS	O
:	O
Argatroban	B-CHEMICAL
,	O
as	O
compared	O
with	O
heparin	O
,	O
appears	O
to	O
enhance	O
reperfusion	O
with	O
TPA	B-GENE-Y
in	O
patients	O
with	O
AMI	O
,	O
particularly	O
in	O
those	O
patients	O
with	O
delayed	O
presentation	O
.	O

The	O
incidences	O
of	O
major	O
bleeding	O
and	O
adverse	O
clinical	O
outcome	O
were	O
lower	O
in	O
the	O
patients	O
receiving	O
argatroban	B-CHEMICAL
.	O

Mechanistic	O
differences	O
of	O
various	O
AT1	B-GENE-Y
-	O
receptor	O
blockers	O
in	O
isolated	O
vessels	O
of	O
different	O
origin	O
.	O

The	O
functional	O
inhibitory	O
characteristics	O
of	O
the	O
angiotensin	B-GENE-N
II	I-GENE-N
type	I-GENE-N
1	I-GENE-N
receptor	I-GENE-N
blockers	O
(	O
ARB	O
)	O
candesartan	B-CHEMICAL
;	O
irbesartan	B-CHEMICAL
;	O
and	O
losartan	B-CHEMICAL
and	O
its	O
active	O
metabolite	O
EXP	B-CHEMICAL
3174	I-CHEMICAL
(	O
EXP	B-CHEMICAL
)	O
were	O
studied	O
in	O
rabbit	O
aortic	O
strips	O
and	O
rat	O
portal	O
vein	O
preparations	O
in	O
vitro	O
.	O

Moreover	O
,	O
plasma	O
-	O
protein	O
binding	O
was	O
determined	O
,	O
and	O
the	O
binding	O
was	O
high	O
(	O
>	O
98	O
.	O
5	O
%	O
)	O
for	O
all	O
ARBs	O
.	O

These	O
values	O
were	O
needed	O
to	O
relate	O
the	O
concentrations	O
of	O
the	O
ARBs	O
used	O
in	O
vitro	O
to	O
the	O
nonprotein	O
bound	O
concentrations	O
in	O
clinical	O
use	O
.	O

In	O
both	O
vascular	O
preparations	O
,	O
candesartan	B-CHEMICAL
caused	O
a	O
marked	O
decrease	O
in	O
the	O
maximal	O
contractile	O
response	O
of	O
the	O
angiotensin	B-CHEMICAL
II	I-CHEMICAL
(	O
Ang	B-CHEMICAL
II	I-CHEMICAL
)	O
concentration	O
-	O
response	O
curve	O
.	O

Losartan	B-CHEMICAL
,	O
EXP	B-CHEMICAL
,	O
and	O
irbesartan	B-CHEMICAL
caused	O
a	O
rightward	O
parallel	O
shift	O
without	O
any	O
major	O
effects	O
on	O
the	O
maximal	O
response	O
to	O
Ang	B-CHEMICAL
II	I-CHEMICAL
.	O

The	O
inhibitory	O
effect	O
of	O
candesartan	B-CHEMICAL
developed	O
slowly	O
(	O
maximal	O
effect	O
after	O
>	O
30	O
minutes	O
)	O
and	O
lasted	O
>	O
2	O
hours	O
despite	O
repeated	O
washing	O
of	O
the	O
vessels	O
.	O

The	O
effect	O
of	O
losartan	B-CHEMICAL
,	O
irbesartan	B-CHEMICAL
,	O
and	O
EXP	B-CHEMICAL
had	O
a	O
faster	O
onset	O
,	O
and	O
most	O
of	O
the	O
inhibitory	O
effect	O
disappeared	O
after	O
washing	O
.	O

The	O
duration	O
of	O
the	O
inhibitory	O
effects	O
of	O
the	O
ARBs	O
were	O
not	O
related	O
to	O
lipophilicity	O
of	O
the	O
compounds	O
.	O

Cooling	O
of	O
the	O
rat	O
portal	O
vein	O
preparations	O
to	O
4	O
degrees	O
C	O
before	O
administration	O
of	O
candesartan	B-CHEMICAL
prevented	O
the	O
persistent	O
inhibition	O
of	O
Ang	B-CHEMICAL
II	I-CHEMICAL
response	O
seen	O
at	O
37	O
degrees	O
C	O
.	O

For	O
the	O
other	O
ARBs	O
studied	O
,	O
the	O
magnitude	O
of	O
inhibition	O
and	O
the	O
speed	O
of	O
recovery	O
of	O
the	O
Ang	B-CHEMICAL
II	I-CHEMICAL
response	O
were	O
independent	O
of	O
the	O
incubation	O
temperature	O
before	O
washing	O
.	O

In	O
addition	O
,	O
when	O
candesartan	B-CHEMICAL
was	O
given	O
to	O
conscious	O
rats	O
,	O
the	O
inhibitory	O
effect	O
on	O
Ang	B-CHEMICAL
II	I-CHEMICAL
-	O
induced	O
blood	O
pressure	O
responses	O
persisted	O
during	O
the	O
24	O
-	O
hour	O
period	O
despite	O
nondetectable	O
plasma	O
concentrations	O
of	O
candesartan	B-CHEMICAL
at	O
24	O
hours	O
.	O

It	O
is	O
concluded	O
that	O
functional	O
inhibitory	O
characteristics	O
of	O
candesartan	B-CHEMICAL
differ	O
from	O
those	O
of	O
the	O
other	O
ARBs	O
tested	O
.	O

At	O
clinically	O
relevant	O
concentrations	O
,	O
candesartan	B-CHEMICAL
is	O
an	O
insurmountable	O
and	O
long	O
-	O
lasting	O
antagonist	O
of	O
the	O
vascular	O
contractile	O
responses	O
to	O
Ang	B-CHEMICAL
II	I-CHEMICAL
.	O

Dose	O
-	O
dependent	O
inhibition	O
of	O
platelet	O
cyclooxygenase	B-GENE-Y
-	I-GENE-Y
1	I-GENE-Y
and	O
monocyte	O
cyclooxygenase	B-GENE-Y
-	I-GENE-Y
2	I-GENE-Y
by	O
meloxicam	B-CHEMICAL
in	O
healthy	O
subjects	O
.	O

We	O
evaluated	O
whether	O
therapeutic	O
blood	O
levels	O
of	O
meloxicam	B-CHEMICAL
are	O
associated	O
with	O
selective	O
inhibition	O
of	O
monocyte	O
cyclooxygenase	B-GENE-Y
(	I-GENE-Y
COX	I-GENE-Y
)	I-GENE-Y
-	I-GENE-Y
2	I-GENE-Y
in	O
vitro	O
and	O
ex	O
vivo	O
.	O

Concentration	O
-	O
response	O
curves	O
for	O
the	O
inhibition	O
of	O
monocyte	O
COX	B-GENE-Y
-	I-GENE-Y
2	I-GENE-Y
and	O
platelet	O
COX	B-GENE-Y
-	I-GENE-Y
1	I-GENE-Y
were	O
obtained	O
in	O
vitro	O
after	O
the	O
incubation	O
of	O
meloxicam	B-CHEMICAL
with	O
whole	O
blood	O
samples	O
.	O

Moreover	O
,	O
11	O
healthy	O
volunteers	O
received	O
placebo	O
or	O
7	O
.	O
5	O
or	O
15	O
mg	O
/	O
day	O
meloxicam	B-CHEMICAL
,	O
each	O
treatment	O
for	O
7	O
consecutive	O
days	O
,	O
according	O
to	O
a	O
randomized	O
,	O
double	O
-	O
blind	O
,	O
crossover	O
design	O
.	O

Before	O
dosing	O
and	O
24	O
h	O
after	O
the	O
seventh	O
dose	O
of	O
each	O
regimen	O
,	O
heparinized	O
whole	O
blood	O
samples	O
were	O
incubated	O
with	O
lipopolysaccharide	O
(	O
10	O
microgram	O
/	O
ml	O
)	O
for	O
24	O
h	O
at	O
37	O
degrees	O
C	O
,	O
and	O
prostaglandin	B-CHEMICAL
E2	I-CHEMICAL
was	O
measured	O
in	O
plasma	O
as	O
an	O
index	O
of	O
monocyte	O
COX	B-GENE-Y
-	I-GENE-Y
2	I-GENE-Y
activity	O
.	O

The	O
production	O
of	O
thromboxane	B-CHEMICAL
B2	I-CHEMICAL
in	O
whole	O
blood	O
allowed	O
to	O
clot	O
at	O
37	O
degrees	O
C	O
for	O
60	O
min	O
was	O
assessed	O
as	O
an	O
index	O
of	O
platelet	O
COX	B-GENE-Y
-	I-GENE-Y
1	I-GENE-Y
activity	O
.	O

The	O
administration	O
of	O
placebo	O
did	O
not	O
significantly	O
affect	O
plasma	O
prostaglandin	B-CHEMICAL
E2	I-CHEMICAL
(	O
21	O
.	O
3	O
+	O
/	O
-	O
7	O
.	O
5	O
versus	O
19	O
.	O
1	O
+	O
/	O
-	O
4	O
ng	O
/	O
ml	O
,	O
mean	O
+	O
/	O
-	O
S	O
.	O
D	O
.	O
,	O
n	O
=	O
11	O
)	O
or	O
serum	O
thromboxane	B-CHEMICAL
B2	I-CHEMICAL
(	O
426	O
+	O
/	O
-	O
167	O
versus	O
425	O
+	O
/	O
-	O
150	O
ng	O
/	O
ml	O
)	O
levels	O
.	O

In	O
contrast	O
,	O
the	O
administration	O
of	O
7	O
.	O
5	O
and	O
15	O
mg	O
of	O
meloxicam	B-CHEMICAL
caused	O
dose	O
-	O
dependent	O
reductions	O
in	O
monocyte	O
COX	B-GENE-Y
-	I-GENE-Y
2	I-GENE-Y
activity	O
by	O
51	O
%	O
and	O
70	O
%	O
,	O
respectively	O
,	O
and	O
in	O
platelet	O
COX	B-GENE-Y
-	I-GENE-Y
1	I-GENE-Y
activity	O
by	O
25	O
%	O
and	O
35	O
%	O
,	O
respectively	O
.	O

Although	O
the	O
IC50	O
value	O
of	O
meloxicam	B-CHEMICAL
for	O
inhibition	O
of	O
COX	B-GENE-Y
-	I-GENE-Y
1	I-GENE-Y
was	O
10	O
-	O
fold	O
higher	O
than	O
the	O
IC50	O
value	O
of	O
COX	B-GENE-Y
-	I-GENE-Y
2	I-GENE-Y
in	O
vitro	O
,	O
this	O
biochemical	O
selectivity	O
was	O
inadequate	O
to	O
clearly	O
separate	O
the	O
effects	O
of	O
meloxicam	B-CHEMICAL
on	O
the	O
two	O
isozymes	O
after	O
oral	O
dosing	O
as	O
a	O
function	O
of	O
the	O
daily	O
dose	O
and	O
interindividual	O
variation	O
in	O
steady	O
-	O
state	O
plasma	O
levels	O
.	O

Modulation	O
of	O
dialysate	O
levels	O
of	O
dopamine	B-CHEMICAL
,	O
noradrenaline	B-CHEMICAL
,	O
and	O
serotonin	B-CHEMICAL
(	O
5	B-CHEMICAL
-	I-CHEMICAL
HT	I-CHEMICAL
)	O
in	O
the	O
frontal	O
cortex	O
of	O
freely	O
-	O
moving	O
rats	O
by	O
(	B-CHEMICAL
-	I-CHEMICAL
)	I-CHEMICAL
-	I-CHEMICAL
pindolol	I-CHEMICAL
alone	O
and	O
in	O
association	O
with	O
5	B-CHEMICAL
-	I-CHEMICAL
HT	I-CHEMICAL
reuptake	O
inhibitors	O
:	O
comparative	O
roles	O
of	O
beta	O
-	O
adrenergic	O
,	O
5	B-GENE-Y
-	I-GENE-Y
HT1A	I-GENE-Y
,	I-GENE-Y
and	O
5	B-GENE-Y
-	I-GENE-Y
HT1B	I-GENE-Y
receptors	O
.	O

(	B-CHEMICAL
-	I-CHEMICAL
)	I-CHEMICAL
-	I-CHEMICAL
Pindolol	I-CHEMICAL
,	O
which	O
possesses	O
significant	O
affinity	O
for	O
5	B-GENE-Y
-	I-GENE-Y
HT1A	I-GENE-Y
,	O
5	B-GENE-Y
-	I-GENE-Y
HT1B	I-GENE-Y
,	O
and	O
beta	B-GENE-N
1	I-GENE-N
/	I-GENE-N
2	I-GENE-N
-	I-GENE-N
adrenergic	I-GENE-N
receptors	I-GENE-N
(	B-GENE-N
AR	I-GENE-N
)	I-GENE-N
s	I-GENE-N
,	O
dose	O
-	O
dependently	O
increased	O
extracellular	O
levels	O
of	O
dopamine	B-CHEMICAL
(	O
DA	B-CHEMICAL
)	O
and	O
noradrenaline	B-CHEMICAL
(	O
NAD	B-CHEMICAL
)	O
versus	O
5	B-CHEMICAL
-	I-CHEMICAL
HT	I-CHEMICAL
,	O
in	O
dialysates	O
of	O
the	O
frontal	O
cortex	O
(	O
FCX	O
)	O
,	O
but	O
not	O
accumbens	O
and	O
striatum	O
,	O
of	O
freely	O
-	O
moving	O
rats	O
.	O

In	O
distinction	O
,	O
the	O
preferential	O
beta	B-GENE-Y
1	I-GENE-Y
-	I-GENE-Y
AR	I-GENE-Y
antagonist	O
,	O
betaxolol	B-CHEMICAL
,	O
and	O
the	O
preferential	O
beta	B-GENE-Y
2	I-GENE-Y
-	I-GENE-Y
AR	I-GENE-Y
antagonist	O
,	O
ICI118	B-CHEMICAL
,	I-CHEMICAL
551	I-CHEMICAL
,	O
did	O
not	O
increase	O
basal	O
levels	O
of	O
DA	B-CHEMICAL
,	O
NAD	B-CHEMICAL
,	O
or	O
5	B-CHEMICAL
-	I-CHEMICAL
HT	I-CHEMICAL
.	O

Further	O
,	O
they	O
both	O
dose	O
-	O
dependently	O
and	O
markedly	O
blunted	O
the	O
influence	O
of	O
(	B-CHEMICAL
-	I-CHEMICAL
)	I-CHEMICAL
-	I-CHEMICAL
pindolol	I-CHEMICAL
upon	O
DA	B-CHEMICAL
and	O
NAD	B-CHEMICAL
levels	O
.	O

The	O
selective	O
5	B-GENE-Y
-	I-GENE-Y
HT1A	I-GENE-Y
receptor	O
antagonist	O
,	O
WAY100	B-CHEMICAL
,	I-CHEMICAL
635	I-CHEMICAL
,	O
slightly	O
attenuated	O
the	O
(	B-CHEMICAL
-	I-CHEMICAL
)	I-CHEMICAL
-	I-CHEMICAL
pindolol	I-CHEMICAL
-	O
induced	O
increase	O
in	O
DA	B-CHEMICAL
and	O
NAD	B-CHEMICAL
levels	O
,	O
while	O
the	O
selective	O
5	B-GENE-Y
-	I-GENE-Y
HT1B	I-GENE-Y
antagonist	O
,	O
SB224	B-CHEMICAL
,	I-CHEMICAL
289	I-CHEMICAL
,	O
was	O
ineffective	O
.	O

These	O
data	O
suggest	O
that	O
(	B-CHEMICAL
-	I-CHEMICAL
)	I-CHEMICAL
-	I-CHEMICAL
pindolol	I-CHEMICAL
facilitates	O
frontocortical	O
dopaminergic	O
(	O
and	O
adrenergic	O
)	O
transmission	O
primarily	O
by	O
activation	O
of	O
beta	B-GENE-N
1	I-GENE-N
/	I-GENE-N
2	I-GENE-N
-	I-GENE-N
ARs	I-GENE-N
and	O
,	O
to	O
a	O
lesser	O
degree	O
,	O
by	O
stimulation	O
of	O
5	B-GENE-Y
-	I-GENE-Y
HT1A	I-GENE-Y
receptors	O
,	O
whereas	O
5	B-GENE-Y
-	I-GENE-Y
HT1B	I-GENE-Y
receptors	O
are	O
not	O
involved	O
.	O

(	B-CHEMICAL
-	I-CHEMICAL
)	I-CHEMICAL
-	I-CHEMICAL
Pindolol	I-CHEMICAL
potentiated	O
the	O
increase	O
in	O
FCX	O
levels	O
of	O
5	B-CHEMICAL
-	I-CHEMICAL
HT	I-CHEMICAL
elicited	O
by	O
the	O
5	B-CHEMICAL
-	I-CHEMICAL
HT	I-CHEMICAL
reuptake	O
inhibitors	O
,	O
fluoxetine	B-CHEMICAL
and	O
duloxetine	B-CHEMICAL
,	O
and	O
also	O
enhanced	O
their	O
ability	O
to	O
elevate	O
FCX	O
levels	O
of	O
DA	B-CHEMICAL
-	O
-	O
though	O
not	O
of	O
NAD	B-CHEMICAL
.	O

In	O
contrast	O
to	O
(	B-CHEMICAL
-	I-CHEMICAL
)	I-CHEMICAL
-	I-CHEMICAL
pindolol	I-CHEMICAL
,	O
betaxolol	B-CHEMICAL
and	O
ICI118	B-CHEMICAL
,	I-CHEMICAL
551	I-CHEMICAL
did	O
not	O
affect	O
the	O
actions	O
of	O
fluoxetine	B-CHEMICAL
,	O
whereas	O
both	O
WAY100	B-CHEMICAL
,	I-CHEMICAL
635	I-CHEMICAL
and	O
SB224	B-CHEMICAL
,	I-CHEMICAL
289	I-CHEMICAL
potentiated	O
the	O
increase	O
in	O
levels	O
of	O
5	B-CHEMICAL
-	I-CHEMICAL
HT	I-CHEMICAL
-	O
-	O
but	O
not	O
DA	B-CHEMICAL
or	O
NAD	B-CHEMICAL
levels	O
-	O
-	O
elicited	O
by	O
fluoxetine	B-CHEMICAL
.	O

In	O
conclusion	O
,	O
(	B-CHEMICAL
-	I-CHEMICAL
)	I-CHEMICAL
-	I-CHEMICAL
pindolol	I-CHEMICAL
modulates	O
,	O
both	O
alone	O
and	O
together	O
with	O
5	B-CHEMICAL
-	I-CHEMICAL
HT	I-CHEMICAL
reuptake	O
inhibitors	O
,	O
dopaminergic	O
,	O
adrenergic	O
,	O
and	O
serotonergic	O
transmission	O
in	O
the	O
FCX	O
via	O
a	O
complex	O
pattern	O
of	O
actions	O
at	O
beta	B-GENE-N
1	I-GENE-N
/	I-GENE-N
2	I-GENE-N
-	I-GENE-N
ARs	I-GENE-N
,	O
5	B-GENE-Y
-	I-GENE-Y
HT1A	I-GENE-Y
,	O
and	O
5	B-GENE-Y
-	I-GENE-Y
HT1B	I-GENE-Y
receptors	O
.	O

These	O
findings	O
have	O
important	O
implications	O
for	O
clinical	O
studies	O
of	O
the	O
influence	O
of	O
(	B-CHEMICAL
-	I-CHEMICAL
)	I-CHEMICAL
-	I-CHEMICAL
pindolol	I-CHEMICAL
upon	O
the	O
actions	O
of	O
antidepressant	O
agents	O
.	O

Entacapone	B-CHEMICAL
.	O

A	O
review	O
of	O
its	O
use	O
in	O
Parkinson	O
'	O
s	O
disease	O
.	O

UNLABELLED	O
:	O
Entacapone	B-CHEMICAL
is	O
a	O
potent	O
and	O
specific	O
peripheral	O
catechol	B-GENE-Y
-	I-GENE-Y
O	I-GENE-Y
-	I-GENE-Y
methyltransferase	I-GENE-Y
(	O
COMT	B-GENE-Y
)	O
inhibitor	O
.	O

It	O
has	O
been	O
shown	O
to	O
improve	O
the	O
clinical	O
benefits	O
of	O
levodopa	B-CHEMICAL
plus	O
an	O
aromatic	B-GENE-Y
L	I-GENE-Y
-	I-GENE-Y
amino	I-GENE-Y
acid	I-GENE-Y
decarboxylase	I-GENE-Y
inhibitor	O
(	O
AADC	B-GENE-Y
)	O
when	O
given	O
to	O
patients	O
with	O
Parkinson	O
'	O
s	O
disease	O
and	O
end	O
-	O
of	O
-	O
dose	O
deterioration	O
in	O
the	O
response	O
to	O
levodopa	B-CHEMICAL
(	O
the	O
'	O
wearing	O
off	O
'	O
phenomenon	O
)	O
.	O

The	O
efficacy	O
of	O
entacapone	B-CHEMICAL
is	O
currently	O
being	O
assessed	O
in	O
patients	O
with	O
stable	O
Parkinson	O
'	O
s	O
disease	O
.	O

In	O
2	O
well	O
conducted	O
trials	O
of	O
6	O
months	O
'	O
duration	O
and	O
smaller	O
short	O
term	O
studies	O
,	O
treatment	O
with	O
entacapone	B-CHEMICAL
(	O
200	O
mg	O
with	O
each	O
dose	O
of	O
levodopa	B-CHEMICAL
/	O
AADC	B-GENE-Y
inhibitor	O
)	O
was	O
associated	O
with	O
significant	O
increases	O
in	O
daily	O
'	O
on	O
'	O
time	O
and	O
decreases	O
in	O
'	O
off	O
'	O
time	O
.	O

Changes	O
in	O
Unified	O
Parkinson	O
'	O
s	O
Disease	O
Rating	O
Scale	O
(	O
UPDRS	O
)	O
scores	O
concurred	O
with	O
changes	O
in	O
'	O
on	O
'	O
and	O
'	O
off	O
'	O
times	O
:	O
entacapone	B-CHEMICAL
improved	O
total	O
,	O
activities	O
of	O
daily	O
living	O
and	O
motor	O
function	O
scores	O
,	O
but	O
it	O
had	O
no	O
effect	O
on	O
mentation	O
scores	O
.	O

Entacapone	B-CHEMICAL
also	O
provided	O
benefits	O
when	O
given	O
with	O
controlled	O
release	O
levodopa	B-CHEMICAL
/	O
AADC	B-GENE-Y
inhibitor	O
or	O
with	O
standard	O
levodopa	B-CHEMICAL
/	O
AADC	B-GENE-Y
inhibitor	O
and	O
selegiline	B-CHEMICAL
in	O
small	O
trials	O
.	O

Dopaminergic	O
events	O
,	O
including	O
dyskinesia	O
and	O
nausea	O
,	O
are	O
among	O
the	O
most	O
common	O
events	O
with	O
entacapone	B-CHEMICAL
,	O
and	O
are	O
related	O
to	O
the	O
drug	O
'	O
s	O
ability	O
to	O
potentiate	O
the	O
effects	O
of	O
levodopa	B-CHEMICAL
.	O

Diarrhoea	O
,	O
abdominal	O
pain	O
,	O
constipation	O
and	O
urine	O
discolouration	O
are	O
the	O
most	O
common	O
nondopaminergic	O
events	O
,	O
although	O
the	O
latter	O
event	O
is	O
the	O
only	O
one	O
to	O
occur	O
consistently	O
more	O
frequently	O
with	O
entacapone	O
than	O
with	O
placebo	O
.	O

However	O
,	O
adverse	O
events	O
of	O
any	O
type	O
infrequently	O
led	O
to	O
study	O
discontinuation	O
.	O

CONCLUSIONS	O
:	O
The	O
efficacy	O
and	O
tolerability	O
of	O
entacapone	O
administered	O
with	O
levodopa	B-CHEMICAL
/	O
AADC	B-GENE-Y
inhibitor	O
have	O
not	O
yet	O
been	O
compared	O
with	O
those	O
of	O
other	O
strategies	O
for	O
the	O
treatment	O
of	O
Parkinson	O
'	O
s	O
disease	O
.	O

However	O
,	O
once	O
the	O
decision	O
to	O
initiate	O
levodopa	B-CHEMICAL
therapy	O
has	O
been	O
made	O
,	O
studies	O
generally	O
support	O
the	O
use	O
of	O
entacapone	O
as	O
an	O
adjunct	O
to	O
levodopa	B-CHEMICAL
in	O
patients	O
with	O
Parkinson	O
'	O
s	O
disease	O
and	O
the	O
'	O
wearing	O
off	O
'	O
phenomenon	O
.	O

5	B-CHEMICAL
-	I-CHEMICAL
hydroxytryptamine	I-CHEMICAL
evokes	O
endothelial	B-GENE-Y
nitric	I-GENE-Y
oxide	I-GENE-Y
synthase	I-GENE-Y
activation	O
in	O
bovine	O
aortic	O
endothelial	O
cell	O
cultures	O
.	O

Activation	O
of	O
endothelial	B-GENE-Y
nitric	I-GENE-Y
oxide	I-GENE-Y
synthase	I-GENE-Y
(	O
eNOS	B-GENE-Y
)	O
results	O
in	O
the	O
production	O
of	O
nitric	B-CHEMICAL
oxide	I-CHEMICAL
(	O
NO	B-CHEMICAL
)	O
that	O
mediates	O
the	O
vasorelaxing	O
properties	O
of	O
endothelial	O
cells	O
.	O

The	O
goal	O
of	O
this	O
project	O
was	O
to	O
address	O
the	O
possibility	O
that	O
5	B-CHEMICAL
-	I-CHEMICAL
hydroxytryptamine	I-CHEMICAL
(	O
5	B-CHEMICAL
-	I-CHEMICAL
HT	I-CHEMICAL
)	O
stimulates	O
eNOS	B-GENE-Y
activity	O
in	O
bovine	O
aortic	O
endothelial	O
cell	O
(	O
BAEC	O
)	O
cultures	O
.	O

Here	O
,	O
we	O
tested	O
the	O
hypothesis	O
that	O
5	B-GENE-N
-	I-GENE-N
HT	I-GENE-N
receptors	I-GENE-N
mediate	O
eNOS	B-GENE-Y
activation	O
by	O
measuring	O
agonist	O
-	O
stimulated	O
[	B-CHEMICAL
3H	I-CHEMICAL
]	I-CHEMICAL
L	I-CHEMICAL
-	I-CHEMICAL
citrulline	I-CHEMICAL
(	O
[	B-CHEMICAL
3H	I-CHEMICAL
]	I-CHEMICAL
L	I-CHEMICAL
-	I-CHEMICAL
Cit	I-CHEMICAL
)	O
formation	O
in	O
BAEC	O
cultures	O
.	O

We	O
found	O
that	O
5	B-CHEMICAL
-	I-CHEMICAL
HT	I-CHEMICAL
stimulated	O
the	O
conversion	O
of	O
[	B-CHEMICAL
3H	I-CHEMICAL
]	I-CHEMICAL
L	I-CHEMICAL
-	I-CHEMICAL
arginine	I-CHEMICAL
(	O
[	B-CHEMICAL
3H	I-CHEMICAL
]	I-CHEMICAL
L	I-CHEMICAL
-	I-CHEMICAL
Arg	I-CHEMICAL
)	O
to	O
[	B-CHEMICAL
3H	I-CHEMICAL
]	I-CHEMICAL
L	I-CHEMICAL
-	I-CHEMICAL
Cit	I-CHEMICAL
,	O
indicating	O
eNOS	B-GENE-Y
activation	O
.	O

The	O
high	O
affinity	O
5	B-GENE-Y
-	I-GENE-Y
HT1B	I-GENE-Y
receptor	O
agonist	O
,	O
5	B-CHEMICAL
-	I-CHEMICAL
nonyloxytryptamine	I-CHEMICAL
(	O
5	O
-	O
NOT	O
)	O
-	O
stimulated	O
[	B-CHEMICAL
3H	I-CHEMICAL
]	I-CHEMICAL
L	I-CHEMICAL
-	I-CHEMICAL
Cit	I-CHEMICAL
turnover	O
responses	O
were	O
concentration	O
-	O
(	O
0	O
.	O
01	O
nM	O
to	O
100	O
microM	O
)	O
and	O
time	O
-	O
dependent	O
.	O

Maximal	O
responses	O
were	O
observed	O
within	O
10	O
min	O
following	O
agonist	O
exposures	O
.	O

These	O
responses	O
were	O
effectively	O
blocked	O
by	O
the	O
5	B-GENE-Y
-	I-GENE-Y
HT1B	I-GENE-Y
receptor	O
antagonist	O
,	O
isamoltane	O
,	O
the	O
5	B-GENE-Y
-	I-GENE-Y
HT1B	I-GENE-Y
/	O
5	B-GENE-N
-	I-GENE-N
HT2	I-GENE-N
receptor	I-GENE-N
antagonist	O
,	O
methiothepin	B-CHEMICAL
,	O
and	O
the	O
eNOS	B-GENE-Y
selective	O
antagonists	O
(	O
0	O
.	O
01	O
-	O
10	O
microM	O
)	O
:	O
L	B-CHEMICAL
-	I-CHEMICAL
Nomega	I-CHEMICAL
-	I-CHEMICAL
monomethyl	I-CHEMICAL
-	I-CHEMICAL
L	I-CHEMICAL
-	I-CHEMICAL
arginine	I-CHEMICAL
(	O
L	B-CHEMICAL
-	I-CHEMICAL
NMMA	I-CHEMICAL
)	O
and	O
L	B-CHEMICAL
-	I-CHEMICAL
N	I-CHEMICAL
omega	I-CHEMICAL
-	I-CHEMICAL
iminoethyl	I-CHEMICAL
-	I-CHEMICAL
L	I-CHEMICAL
-	I-CHEMICAL
ornithine	I-CHEMICAL
(	O
L	B-CHEMICAL
-	I-CHEMICAL
NIO	I-CHEMICAL
)	O
.	O

Pretreatment	O
of	O
BAEC	O
cultures	O
with	O
pertussis	B-GENE-N
toxin	I-GENE-N
(	O
PTX	B-GENE-N
;	O
1	O
-	O
100	O
ng	O
/	O
ml	O
)	O
for	O
16	O
hr	O
resulted	O
in	O
significant	O
inhibition	O
of	O
the	O
agonist	O
-	O
stimulated	O
eNOS	B-GENE-Y
activity	O
,	O
indicating	O
the	O
involvement	O
of	O
Gi	B-GENE-N
proteins	I-GENE-N
.	O

These	O
findings	O
lend	O
evidence	O
of	O
a	O
5	B-GENE-Y
-	I-GENE-Y
HT1B	I-GENE-Y
receptor	O
/	O
eNOS	B-GENE-Y
pathway	O
,	O
accounting	O
in	O
part	O
for	O
the	O
activation	O
of	O
eNOS	B-GENE-Y
by	O
5	B-CHEMICAL
-	I-CHEMICAL
HT	I-CHEMICAL
.	O

Further	O
investigation	O
is	O
needed	O
to	O
determine	O
the	O
role	O
of	O
other	O
vascular	O
5	B-GENE-N
-	I-GENE-N
HT	I-GENE-N
receptors	I-GENE-N
in	O
the	O
stimulation	O
of	O
eNOS	B-GENE-Y
activity	O
.	O

Caffeine	B-CHEMICAL
inhibits	O
the	O
checkpoint	O
kinase	B-GENE-N
ATM	B-GENE-Y
.	O

The	O
basis	O
of	O
many	O
anti	O
-	O
cancer	O
therapies	O
is	O
the	O
use	O
of	O
genotoxic	O
agents	O
that	O
damage	O
DNA	O
and	O
thus	O
kill	O
dividing	O
cells	O
.	O

Agents	O
that	O
cause	O
cells	O
to	O
override	O
the	O
DNA	O
-	O
damage	O
checkpoint	O
are	O
predicted	O
to	O
sensitize	O
cells	O
to	O
killing	O
by	O
genotoxic	O
agents	O
.	O

They	O
have	O
therefore	O
been	O
sought	O
as	O
adjuncts	O
in	O
radiation	O
therapy	O
and	O
chemotherapy	O
.	O

One	O
such	O
compound	O
,	O
caffeine	B-CHEMICAL
,	O
uncouples	O
cell	O
-	O
cycle	O
progression	O
from	O
the	O
replication	O
and	O
repair	O
of	O
DNA	O
[	O
1	O
]	O
[	O
2	O
]	O
.	O

Caffeine	B-CHEMICAL
therefore	O
servers	O
as	O
a	O
model	O
compound	O
in	O
establishing	O
the	O
principle	O
that	O
agents	O
that	O
override	O
DNA	O
-	O
damage	O
checkpoints	O
can	O
be	O
used	O
to	O
sensitize	O
cells	O
to	O
the	O
killing	O
effects	O
of	O
genotoxic	O
drugs	O
[	O
3	O
]	O
.	O

But	O
despite	O
more	O
than	O
20	O
years	O
of	O
use	O
,	O
the	O
molecular	O
mechanisms	O
by	O
which	O
caffeine	O
affects	O
the	O
cell	O
cycle	O
and	O
checkpoint	O
responses	O
have	O
not	O
been	O
identified	O
.	O

We	O
investigated	O
the	O
effects	O
of	O
caffeine	O
on	O
the	O
G2	O
/	O
M	O
DNA	O
-	O
damage	O
checkpoint	O
in	O
human	O
cells	O
.	O

We	O
report	O
that	O
the	O
radiation	O
-	O
induced	O
activation	O
of	O
the	O
kinase	B-GENE-N
Cds1	B-GENE-Y
[	O
4	O
]	O
(	O
also	O
known	O
as	O
Chk2	B-GENE-Y
[	O
5	O
]	O
)	O
is	O
inhibited	O
by	O
caffeine	B-CHEMICAL
in	O
vivo	O
and	O
that	O
ATM	B-GENE-Y
kinase	B-GENE-N
activity	O
is	O
directly	O
inhibited	O
by	O
caffeine	B-CHEMICAL
in	O
vitro	O
.	O

Inhibition	O
of	O
ATM	B-GENE-Y
provides	O
a	O
molecular	O
explanation	O
of	O
the	O
attenuation	O
of	O
DNA	O
-	O
damage	O
checkpoint	O
responses	O
and	O
for	O
the	O
increased	O
radiosensitivity	O
of	O
caffeine	B-CHEMICAL
-	O
treated	O
cells	O
[	O
6	O
]	O
[	O
7	O
]	O
[	O
8	O
]	O
.	O

Serotonin	B-GENE-Y
transporter	I-GENE-Y
production	O
and	O
degradation	O
rates	O
:	O
studies	O
with	O
RTI	B-CHEMICAL
-	I-CHEMICAL
76	I-CHEMICAL
.	O

The	O
objective	O
of	O
this	O
study	O
was	O
to	O
examine	O
the	O
turnover	O
of	O
the	O
serotonin	B-GENE-Y
transporter	I-GENE-Y
(	O
SERT	B-GENE-Y
)	O
by	O
determining	O
its	O
production	O
rate	O
(	O
r	O
)	O
,	O
degradation	O
rate	O
constant	O
(	O
k	O
)	O
and	O
half	O
-	O
life	O
of	O
recovery	O
(	O
t1	O
/	O
2	O
)	O
.	O

The	O
turnover	O
of	O
SERT	B-GENE-Y
was	O
determined	O
from	O
the	O
rate	O
of	O
recovery	O
of	O
binding	O
after	O
administration	O
of	O
RTI	B-CHEMICAL
-	I-CHEMICAL
76	I-CHEMICAL
,	O
an	O
irreversible	O
inhibitor	O
of	O
ligand	O
binding	O
.	O

In	O
preliminary	O
studies	O
,	O
in	O
vitro	O
incubation	O
of	O
rat	O
cerebral	O
cortex	O
with	O
RTI	B-CHEMICAL
-	I-CHEMICAL
76	I-CHEMICAL
produced	O
a	O
wash	O
and	O
temperature	O
resistant	O
inhibition	O
of	O
SERT	B-GENE-Y
binding	O
densities	O
(	O
Bmax	O
)	O
.	O

Citalopram	B-CHEMICAL
protected	O
against	O
the	O
RTI	B-CHEMICAL
-	I-CHEMICAL
76	I-CHEMICAL
-	O
induced	O
inhibition	O
of	O
SERT	B-GENE-Y
binding	O
.	O

Following	O
6	O
h	O
of	O
in	O
vivo	O
intracerebroventricular	O
injections	O
of	O
100	O
nmol	O
of	O
RTI	B-CHEMICAL
-	I-CHEMICAL
76	I-CHEMICAL
,	O
there	O
was	O
a	O
dose	O
-	O
and	O
time	O
-	O
dependent	O
reduction	O
(	O
-	O
60	O
%	O
)	O
of	O
SERT	B-GENE-Y
binding	O
in	O
hippocampus	O
and	O
striatum	O
,	O
without	O
a	O
change	O
in	O
the	O
Kd	O
.	O

SERT	B-GENE-Y
binding	O
densities	O
recovered	O
over	O
several	O
days	O
,	O
reaching	O
control	O
levels	O
by	O
day	O
14	O
.	O

The	O
recovery	O
curve	O
fit	O
the	O
standard	O
model	O
of	O
protein	O
synthesis	O
and	O
degradation	O
.	O

The	O
turnover	O
parameters	O
of	O
SERT	B-GENE-Y
were	O
determined	O
in	O
hippocampus	O
and	O
striatum	O
,	O
regions	O
that	O
receive	O
serotonergic	O
innervation	O
from	O
the	O
dorsal	O
and	O
median	O
midbrain	O
raphe	O
nuclei	O
,	O
respectively	O
.	O

In	O
the	O
hippocampus	O
,	O
the	O
production	O
rate	O
constant	O
was	O
2	O
.	O
36	O
fmol	O
mg	O
protein	O
(	O
-	O
1	O
)	O
h	O
(	O
-	O
1	O
)	O
;	O
the	O
degradation	O
rate	O
constant	O
was	O
0	O
.	O
0077	O
h	O
(	O
-	O
1	O
)	O
;	O
and	O
the	O
half	O
-	O
life	O
of	O
the	O
SERT	B-GENE-Y
recovery	O
was	O
3	O
.	O
4	O
days	O
.	O

The	O
values	O
in	O
the	O
striatum	O
were	O
similar	O
.	O

The	O
decrease	O
and	O
recovery	O
of	O
[	B-CHEMICAL
3H	I-CHEMICAL
]	I-CHEMICAL
-	I-CHEMICAL
5	I-CHEMICAL
-	I-CHEMICAL
HT	I-CHEMICAL
uptake	O
correlated	O
highly	O
(	O
r	O
=	O
0	O
.	O
93	O
)	O
with	O
the	O
recovery	O
of	O
SERT	B-GENE-Y
binding	O
.	O

Cannabis	O
and	O
cannabinoids	O
:	O
pharmacology	O
and	O
rationale	O
for	O
clinical	O
use	O
.	O

It	O
is	O
now	O
known	O
that	O
there	O
are	O
at	O
least	O
two	O
types	O
of	O
cannabinoid	B-GENE-N
receptors	I-GENE-N
.	O

These	O
are	O
CB1	B-GENE-Y
receptors	O
,	O
present	O
mainly	O
on	O
central	O
and	O
peripheral	O
neurones	O
,	O
and	O
CB2	B-GENE-Y
receptors	O
,	O
present	O
mainly	O
on	O
immune	O
cells	O
.	O

Endogenous	O
cannabinoid	B-GENE-N
receptor	I-GENE-N
agonists	O
(	O
'	O
endocannabinoids	O
'	O
)	O
have	O
also	O
been	O
identified	O
.	O

The	O
discovery	O
of	O
this	O
'	O
endogenous	O
cannabinoid	O
system	O
'	O
has	O
led	O
to	O
the	O
development	O
of	O
selective	O
CB1	B-GENE-Y
and	O
CB2	B-GENE-Y
receptor	O
ligands	O
and	O
fueled	O
renewed	O
interest	O
in	O
the	O
clinical	O
potential	O
of	O
cannabinoids	O
.	O

Two	O
cannabinoid	O
CB1	B-GENE-Y
receptor	O
agonists	O
are	O
already	O
used	O
clinically	O
,	O
as	O
antiemetics	O
or	O
as	O
appetite	O
stimulants	O
.	O

These	O
are	O
D	B-CHEMICAL
9	I-CHEMICAL
-	I-CHEMICAL
tetrahydrocannabinol	I-CHEMICAL
(	O
THC	B-CHEMICAL
)	O
and	O
nabilone	B-CHEMICAL
.	O

Other	O
possible	O
uses	O
for	O
CB1	B-GENE-Y
receptor	O
agonists	O
include	O
the	O
suppression	O
of	O
muscle	O
spasm	O
/	O
spasticity	O
associated	O
with	O
multiple	O
sclerosis	O
or	O
spinal	O
cord	O
injury	O
,	O
the	O
relief	O
of	O
chronic	O
pain	O
and	O
the	O
management	O
of	O
glaucoma	O
and	O
bronchial	O
asthma	O
.	O

CB1	B-GENE-Y
receptor	O
antagonists	O
may	O
also	O
have	O
clinical	O
applications	O
,	O
e	O
.	O
g	O
.	O
as	O
appetite	O
suppressants	O
and	O
in	O
the	O
management	O
of	O
schizophrenia	O
or	O
disorders	O
of	O
cognition	O
and	O
memory	O
.	O

So	O
too	O
may	O
CB2	B-GENE-Y
receptor	O
ligands	O
and	O
drugs	O
that	O
activate	O
cannabinoid	B-GENE-N
receptors	I-GENE-N
indirectly	O
by	O
augmenting	O
endocannabinoid	O
levels	O
at	O
cannabinoid	B-GENE-N
receptors	I-GENE-N
.	O

When	O
taken	O
orally	O
,	O
THC	B-CHEMICAL
seems	O
to	O
undergo	O
variable	O
absorption	O
and	O
to	O
have	O
a	O
narrow	O
'	O
therapeutic	O
window	O
'	O
(	O
dose	O
range	O
in	O
which	O
it	O
is	O
effective	O
without	O
producing	O
significant	O
unwanted	O
effects	O
)	O
.	O

This	O
makes	O
it	O
difficult	O
to	O
predict	O
an	O
oral	O
dose	O
that	O
will	O
be	O
both	O
effective	O
and	O
tolerable	O
to	O
a	O
patient	O
and	O
indicates	O
a	O
need	O
for	O
better	O
cannabinoid	O
formulations	O
and	O
modes	O
of	O
administration	O
.	O

For	O
the	O
therapeutic	O
potential	O
of	O
cannabis	O
or	O
CB1	B-GENE-Y
receptor	O
agonists	O
to	O
be	O
fully	O
exploited	O
,	O
it	O
will	O
be	O
important	O
to	O
establish	O
objectively	O
and	O
conclusively	O
(	O
a	O
)	O
whether	O
these	O
agents	O
have	O
efficacy	O
against	O
selected	O
symptoms	O
that	O
is	O
of	O
clinical	O
significance	O
and	O
,	O
if	O
so	O
,	O
whether	O
the	O
benefits	O
outweigh	O
the	O
risks	O
,	O
(	O
b	O
)	O
whether	O
cannabis	O
has	O
therapeutic	O
advantages	O
over	O
individual	O
cannabinoids	O
,	O
(	O
c	O
)	O
whether	O
there	O
is	O
a	O
need	O
for	O
additional	O
drug	O
treatments	O
to	O
manage	O
any	O
of	O
the	O
disorders	O
against	O
which	O
cannabinoids	O
are	O
effective	O
,	O
and	O
(	O
d	O
)	O
whether	O
it	O
will	O
be	O
possible	O
to	O
develop	O
drugs	O
that	O
have	O
reduced	O
psychotropic	O
activity	O
and	O
yet	O
retain	O
the	O
ability	O
to	O
act	O
through	O
CB1	B-GENE-Y
receptors	O
to	O
produce	O
their	O
sought	O
-	O
after	O
effects	O
.	O

Pharmacological	O
properties	O
of	O
angiotensin	B-GENE-N
II	I-GENE-N
receptor	I-GENE-N
antagonists	O
.	O

The	O
availability	O
of	O
selective	O
,	O
potent	O
,	O
orally	O
active	O
and	O
long	O
acting	O
nonpeptide	O
angiotensin	B-GENE-Y
II	I-GENE-Y
type	I-GENE-Y
1	I-GENE-Y
(	I-GENE-Y
AT1	I-GENE-Y
)	I-GENE-Y
receptor	I-GENE-Y
antagonists	O
has	O
provided	O
the	O
opportunity	O
to	O
obtain	O
the	O
benefits	O
of	O
selectively	O
blocking	O
the	O
renin	B-GENE-Y
-	O
angiotensin	B-CHEMICAL
-	O
aldosterone	B-CHEMICAL
system	O
at	O
the	O
level	O
of	O
the	O
AT1	B-GENE-Y
receptor	O
that	O
mediates	O
most	O
,	O
if	O
not	O
all	O
,	O
of	O
the	O
important	O
actions	O
of	O
angiotensin	B-CHEMICAL
II	I-CHEMICAL
,	O
and	O
avoid	O
the	O
nonspecificity	O
of	O
the	O
angiotensin	B-GENE-Y
I	I-GENE-Y
converting	I-GENE-Y
enzyme	I-GENE-Y
inhibitors	O
.	O

Losartan	B-CHEMICAL
was	O
the	O
first	O
,	O
but	O
by	O
no	O
means	O
remained	O
the	O
only	O
,	O
AT1	B-GENE-Y
receptor	O
antagonist	O
.	O

Numerous	O
other	O
'	O
sartans	O
'	O
have	O
emerged	O
in	O
the	O
past	O
several	O
years	O
and	O
successfully	O
completed	O
clinical	O
development	O
.	O

With	O
the	O
exception	O
of	O
eprosartan	B-CHEMICAL
,	O
all	O
others	O
,	O
ie	O
,	O
candesartan	B-CHEMICAL
,	O
irbesartan	B-CHEMICAL
,	O
saprisartan	B-CHEMICAL
,	O
tasosartan	B-CHEMICAL
,	O
telmisartan	B-CHEMICAL
,	O
valsartan	B-CHEMICAL
and	O
zolasartan	B-CHEMICAL
,	O
are	O
based	O
on	O
medications	O
of	O
losartan	O
'	O
s	O
prototypical	O
chemical	O
structure	O
.	O

Among	O
the	O
current	O
AT1	B-GENE-Y
receptor	O
antagonists	O
,	O
the	O
rank	O
order	O
of	O
the	O
relative	O
binding	O
affinities	O
(	O
highest	O
affinity	O
=	O
1	O
)	O
is	O
:	O
candesartan	B-CHEMICAL
1	O
,	O
telmisartan	B-CHEMICAL
10	O
,	O
E3174	B-CHEMICAL
(	O
the	O
active	O
metabolite	O
of	O
losartan	B-CHEMICAL
)	O
10	O
,	O
tasosartan	B-CHEMICAL
20	O
,	O
losartan	B-CHEMICAL
50	O
,	O
eprosartan	B-CHEMICAL
100	O
and	O
the	O
prodrug	O
candesartan	B-CHEMICAL
cilexetil	I-CHEMICAL
280	O
.	O

The	O
mode	O
of	O
(	O
functional	O
)	O
AT1	B-GENE-Y
receptor	O
antagonism	O
has	O
been	O
characterized	O
as	O
surmountable	O
/	O
noncompetitive	O
(	O
losartan	B-CHEMICAL
,	O
tasosartan	B-CHEMICAL
,	O
eprosartan	B-CHEMICAL
)	O
or	O
insurmountable	O
/	O
noncompetitive	O
(	O
candesartan	B-CHEMICAL
,	O
saprisartan	B-CHEMICAL
,	O
zolasartan	B-CHEMICAL
,	O
irbesartan	B-CHEMICAL
,	O
valsartan	B-CHEMICAL
,	O
telmisartan	B-CHEMICAL
,	O
E3174	B-CHEMICAL
)	O
.	O

It	O
is	O
very	O
likely	O
that	O
slow	O
dissociation	O
kinetics	O
from	O
the	O
AT1	B-GENE-Y
receptor	O
underlie	O
insurmountable	O
antagonism	O
.	O

However	O
,	O
competitive	O
or	O
noncompetitive	O
antagonism	O
does	O
not	O
determine	O
the	O
antihypertensive	O
efficacy	O
,	O
but	O
the	O
slow	O
off	O
-	O
rate	O
may	O
extend	O
the	O
occupancy	O
of	O
the	O
AT1	B-GENE-Y
receptor	O
and	O
thereby	O
lengthen	O
the	O
duration	O
of	O
the	O
antihypertensive	O
effect	O
.	O

Comparison	O
of	O
chemotherapy	O
with	O
chemohormonal	O
therapy	O
as	O
first	O
-	O
line	O
therapy	O
for	O
metastatic	O
,	O
hormone	O
-	O
sensitive	O
breast	O
cancer	O
:	O
An	O
Eastern	O
Cooperative	O
Oncology	O
Group	O
study	O
.	O

PURPOSE	O
:	O
Although	O
hormonal	O
therapy	O
represents	O
standard	O
therapy	O
for	O
metastatic	O
hormone	O
-	O
sensitive	O
disease	O
,	O
many	O
patients	O
receive	O
initial	O
chemotherapy	O
because	O
of	O
the	O
location	O
,	O
bulk	O
,	O
or	O
aggressiveness	O
of	O
their	O
disease	O
.	O

It	O
is	O
uncertain	O
whether	O
simultaneous	O
hormonal	O
therapy	O
provides	O
additional	O
benefit	O
compared	O
with	O
chemotherapy	O
alone	O
.	O

Eastern	O
Cooperative	O
Oncology	O
Group	O
trial	O
E3186	O
was	O
initiated	O
to	O
explore	O
this	O
question	O
.	O

PATIENTS	O
AND	O
METHODS	O
:	O
Between	O
January	O
1988	O
and	O
December	O
1992	O
,	O
231	O
patients	O
with	O
estrogen	B-GENE-Y
receptor	I-GENE-Y
(	O
ER	B-GENE-Y
)	O
-	O
positive	O
or	O
ER	B-GENE-Y
-	O
unknown	O
metastatic	O
breast	O
cancer	O
were	O
randomized	O
to	O
receive	O
either	O
chemotherapy	O
(	O
cyclophosphamide	B-CHEMICAL
,	O
doxorubicin	B-CHEMICAL
,	O
and	O
fluorouracil	B-CHEMICAL
inverted	O
question	O
markCAF	O
)	O
or	O
chemohormonal	O
therapy	O
(	O
CAF	O
plus	O
tamoxifen	B-CHEMICAL
and	O
Halotestin	B-CHEMICAL
inverted	O
question	O
markfluoxymesterone	B-CHEMICAL
;	O
Pharmacia	O
-	O
Upjohn	O
,	O
Kalamazoo	O
,	O
MI	O
inverted	O
question	O
markCAFTH	O
)	O
as	O
front	O
-	O
line	O
therapy	O
for	O
metastatic	O
breast	O
cancer	O
.	O

Patients	O
who	O
experienced	O
a	O
complete	O
response	O
to	O
induction	O
therapy	O
either	O
received	O
or	O
did	O
not	O
receive	O
maintenance	O
cyclophosphamide	B-CHEMICAL
,	O
methotrexate	B-CHEMICAL
,	O
fluorouracil	B-CHEMICAL
,	O
prednisone	B-CHEMICAL
,	O
and	O
TH	O
as	O
a	O
secondary	O
randomization	O
.	O

RESULTS	O
:	O
The	O
response	O
rates	O
(	O
complete	O
response	O
and	O
partial	O
response	O
)	O
of	O
patients	O
who	O
received	O
CAF	O
and	O
CAFTH	O
were	O
similar	O
(	O
69	O
.	O
2	O
%	O
v	O
68	O
.	O
9	O
%	O
,	O
respectively	O
;	O
P	O
=	O
.	O
99	O
)	O
.	O

Time	O
to	O
treatment	O
failure	O
(	O
TTF	O
)	O
was	O
slightly	O
longer	O
for	O
patients	O
who	O
received	O
chemohormonal	O
therapy	O
compared	O
with	O
chemotherapy	O
alone	O
patients	O
(	O
13	O
.	O
4	O
months	O
v	O
10	O
.	O
3	O
months	O
,	O
respectively	O
;	O
P	O
=	O
.	O
087	O
)	O
,	O
and	O
TTF	O
was	O
significantly	O
longer	O
in	O
ER	B-GENE-Y
-	O
positive	O
compared	O
with	O
ER	B-GENE-Y
-	O
negative	O
patients	O
(	O
17	O
.	O
4	O
months	O
v	O
10	O
.	O
3	O
months	O
,	O
respectively	O
;	O
P	O
=	O
.	O
048	O
)	O
.	O

However	O
,	O
ER	B-GENE-Y
status	O
had	O
no	O
effect	O
on	O
overall	O
survival	O
(	O
30	O
.	O
0	O
months	O
for	O
CAF	O
v	O
29	O
.	O
3	O
months	O
for	O
CAFTH	O
)	O
.	O

CONCLUSION	O
:	O
In	O
patients	O
with	O
potentially	O
hormone	O
-	O
sensitive	O
metastatic	O
breast	O
cancer	O
,	O
chemohormonal	O
therapy	O
prolongs	O
TTF	O
for	O
ER	B-GENE-Y
-	O
positive	O
patients	O
without	O
improving	O
overall	O
survival	O
.	O

Characterization	O
and	O
partial	O
purification	O
of	O
microsomal	O
NAD	B-GENE-N
(	I-GENE-N
P	I-GENE-N
)	I-GENE-N
H	I-GENE-N
:	I-GENE-N
quinone	I-GENE-N
oxidoreductases	I-GENE-N
.	O

Quinone	B-GENE-N
oxidoreductases	I-GENE-N
are	O
flavoproteins	O
that	O
catalyze	O
two	O
-	O
electron	O
reduction	O
and	O
detoxification	O
of	O
quinones	B-CHEMICAL
.	O

This	O
leads	O
to	O
the	O
protection	O
of	O
cells	O
against	O
toxicity	O
,	O
mutagenicity	O
,	O
and	O
cancer	O
due	O
to	O
exposure	O
to	O
environmental	O
and	O
synthetic	O
quinones	B-CHEMICAL
and	O
its	O
precursors	O
.	O

Two	O
cytosolic	O
forms	O
of	O
quinone	B-GENE-N
oxidoreductases	I-GENE-N
[	B-GENE-Y
NAD	I-GENE-Y
(	I-GENE-Y
P	I-GENE-Y
)	I-GENE-Y
H	I-GENE-Y
:	I-GENE-Y
quinone	I-GENE-Y
oxidoreductase	I-GENE-Y
1	I-GENE-Y
(	O
NQO1	B-GENE-Y
)	O
and	O
NRH	B-GENE-Y
:	I-GENE-Y
quinone	I-GENE-Y
oxidoreductase	I-GENE-Y
2	I-GENE-Y
(	O
NQO2	B-GENE-Y
)	O
]	O
were	O
previously	O
identified	O
,	O
purified	O
,	O
and	O
cloned	O
.	O

A	O
role	O
of	O
cytosolic	O
NQO1	B-GENE-Y
in	O
protection	O
of	O
cells	O
from	O
oxidative	O
stress	O
,	O
cytotoxicity	O
,	O
and	O
mutagenicity	O
of	O
quinones	B-CHEMICAL
was	O
established	O
.	O

Currently	O
,	O
we	O
have	O
characterized	O
and	O
partially	O
purified	O
the	O
NQO	B-GENE-N
activity	O
from	O
rat	O
liver	O
microsomes	O
.	O

This	O
activity	O
was	O
designated	O
as	O
microsomal	O
NQO	B-GENE-N
(	O
mNQO	B-GENE-N
)	O
.	O

The	O
mNQO	B-GENE-N
activity	O
showed	O
significantly	O
higher	O
affinity	O
for	O
NADH	B-CHEMICAL
than	O
NADPH	B-CHEMICAL
as	O
electron	O
donors	O
and	O
catalyzed	O
reduction	O
of	O
2	B-CHEMICAL
,	I-CHEMICAL
6	I-CHEMICAL
-	I-CHEMICAL
dichlorophenolindophenol	I-CHEMICAL
and	O
menadione	B-CHEMICAL
.	O

The	O
mNQO	B-GENE-N
activity	O
was	O
insensitive	O
to	O
dicoumarol	B-CHEMICAL
,	O
a	O
potent	O
inhibitor	O
of	O
cytosolic	O
NQO1	B-GENE-Y
.	O

Western	O
analysis	O
of	O
microsomal	O
proteins	O
revealed	O
29	O
-	O
and	O
18	O
-	O
kDa	O
bands	O
that	O
cross	O
-	O
reacted	O
with	O
polyclonal	O
antibodies	O
raised	O
against	O
cytosolic	O
NQO1	B-GENE-Y
.	O

The	O
mNQO	B-GENE-N
activity	O
was	O
partially	O
purified	O
by	O
solubilization	O
of	O
microsomes	O
with	O
detergent	O
Chaps	O
,	O
ammonium	B-CHEMICAL
sulfate	I-CHEMICAL
fractionation	O
,	O
and	O
DEAE	B-CHEMICAL
-	O
Sephacel	O
column	O
chromatography	O
.	O

The	O
microsomal	O
mNQO	B-GENE-N
proteins	O
are	O
expected	O
to	O
provide	O
additional	O
protection	O
after	O
cytosolic	O
NQOs	B-GENE-N
against	O
quinone	B-CHEMICAL
toxicity	O
and	O
mutagenicity	O
.	O

Opioid	O
activity	O
profiles	O
indicate	O
similarities	O
between	O
the	O
nociceptin	B-GENE-Y
/	O
orphanin	B-GENE-Y
FQ	I-GENE-Y
and	O
opioid	B-GENE-N
receptors	I-GENE-N
.	O

Nociceptin	B-GENE-Y
(	O
orphanin	B-GENE-Y
FQ	I-GENE-Y
)	O
is	O
the	O
recently	O
discovered	O
peptide	O
agonist	O
for	O
the	O
orphan	B-GENE-N
receptor	I-GENE-N
opioid	B-GENE-Y
receptor	I-GENE-Y
-	I-GENE-Y
like	I-GENE-Y
1	I-GENE-Y
(	O
ORL1	B-GENE-Y
)	O
.	O

Despite	O
the	O
high	O
sequence	O
homology	O
between	O
ORL1	B-GENE-Y
and	O
the	O
opioid	B-GENE-N
receptors	I-GENE-N
,	O
most	O
opioids	O
lack	O
affinity	O
for	O
the	O
nociceptin	B-GENE-Y
receptor	I-GENE-Y
.	O

The	O
affinity	O
and	O
functional	O
profile	O
of	O
opioids	O
possessing	O
activity	O
at	O
the	O
nociceptin	B-GENE-Y
receptor	I-GENE-Y
was	O
determined	O
using	O
[	O
3H	O
]	O
nociceptin	O
and	O
nociceptin	O
-	O
stimulated	O
[	B-CHEMICAL
35S	I-CHEMICAL
]	I-CHEMICAL
GTPgammaS	I-CHEMICAL
binding	O
.	O

The	O
mu	B-GENE-Y
-	I-GENE-Y
opioid	I-GENE-Y
receptor	I-GENE-Y
-	O
selective	O
agonist	O
lofentanil	B-CHEMICAL
potently	O
and	O
competitively	O
displaced	O
[	O
3H	O
]	O
nociceptin	O
at	O
rat	O
brain	O
receptors	O
(	O
IC	O
(	O
50	O
)	O
62	O
nM	O
)	O
.	O

Lofentanil	B-CHEMICAL
exhibited	O
full	O
agonism	O
for	O
enhancement	O
of	O
[	B-CHEMICAL
35S	I-CHEMICAL
]	I-CHEMICAL
GTPgammaS	I-CHEMICAL
binding	O
to	O
human	O
recombinant	O
ORL1	B-GENE-Y
receptors	O
(	O
EC	O
(	O
50	O
)	O
50	O
nM	O
)	O
.	O

The	O
related	O
piperidines	B-CHEMICAL
ohmefentanyl	B-CHEMICAL
and	O
sufentanil	B-CHEMICAL
and	O
the	O
nonselective	O
opioid	B-GENE-N
receptor	I-GENE-N
agonist	O
etorphine	B-CHEMICAL
were	O
less	O
potent	O
nociceptin	B-GENE-Y
receptor	I-GENE-Y
agonists	O
.	O

The	O
kappa	O
(	O
1	O
)	O
+	O
kappa	O
(	O
3	O
)	O
-	O
opioid	O
receptor	O
agonist	O
/	O
mu	B-GENE-Y
-	I-GENE-Y
opioid	I-GENE-Y
receptor	I-GENE-Y
antagonist	O
naloxone	B-CHEMICAL
benzoylhydrazone	I-CHEMICAL
was	O
a	O
pure	O
antagonist	O
at	O
both	O
rat	O
brain	O
and	O
human	O
ORL1	B-GENE-N
receptors	O
.	O

The	O
nonselective	O
opioid	B-GENE-N
receptor	I-GENE-N
partial	O
agonist	O
buprenorphine	B-CHEMICAL
and	O
the	O
nonselective	O
opioid	B-GENE-N
receptor	I-GENE-N
antagonist	O
(	B-CHEMICAL
-	I-CHEMICAL
)	I-CHEMICAL
-	I-CHEMICAL
quadazocine	I-CHEMICAL
exhibited	O
pure	O
antagonism	O
at	O
rat	O
brain	O
receptors	O
,	O
but	O
displayed	O
partial	O
agonism	O
at	O
human	B-GENE-Y
ORL1	I-GENE-Y
receptors	O
.	O

Thus	O
,	O
opioids	O
displaying	O
full	O
agonism	O
at	O
the	O
nociceptin	B-GENE-Y
receptor	I-GENE-Y
are	O
also	O
opioid	B-GENE-N
receptor	I-GENE-N
agonists	O
,	O
whereas	O
opioids	O
that	O
are	O
antagonists	O
or	O
partial	O
agonists	O
at	O
the	O
nociceptin	B-GENE-Y
receptor	I-GENE-Y
show	O
antagonism	O
or	O
partial	O
agonism	O
at	O
opioid	B-GENE-N
receptors	I-GENE-N
.	O

In	O
addition	O
,	O
the	O
stereospecificity	O
required	O
at	O
opioid	B-GENE-N
receptors	I-GENE-N
appears	O
to	O
be	O
retained	O
at	O
the	O
nociceptin	B-GENE-Y
receptor	I-GENE-Y
,	O
since	O
(	B-CHEMICAL
+	I-CHEMICAL
)	I-CHEMICAL
-	I-CHEMICAL
quadazocine	I-CHEMICAL
is	O
inactive	O
at	O
both	O
receptors	O
.	O

These	O
findings	O
illustrate	O
the	O
structural	O
and	O
functional	O
homology	O
of	O
the	O
opioid	O
recognition	O
site	O
on	O
these	O
two	O
receptor	O
classes	O
and	O
suggest	O
that	O
opioids	O
may	O
provide	O
leads	O
for	O
the	O
design	O
of	O
nonpeptide	O
nociceptin	B-GENE-Y
receptor	I-GENE-Y
agonists	O
and	O
antagonists	O
lacking	O
affinity	O
for	O
the	O
classical	O
opioid	B-GENE-N
receptors	I-GENE-N
.	O

Effects	O
of	O
long	O
-	O
term	O
administration	O
of	O
UFT	O
plus	O
leucovorin	B-CHEMICAL
on	O
colorectal	O
tumors	O
induced	O
with	O
1	B-CHEMICAL
,	I-CHEMICAL
2	I-CHEMICAL
-	I-CHEMICAL
dimethylhydrazine	I-CHEMICAL
in	O
rats	O
.	O

Thymidylate	B-GENE-Y
synthase	I-GENE-Y
and	O
thymidine	B-GENE-Y
kinase	I-GENE-Y
are	O
key	O
enzymes	O
involved	O
in	O
the	O
de	O
novo	O
and	O
salvage	O
pathways	O
for	O
pyrimidine	B-CHEMICAL
nucleotide	I-CHEMICAL
synthesis	O
,	O
respectively	O
.	O

Thymidylate	B-GENE-Y
synthase	I-GENE-Y
is	O
inhibited	O
by	O
5	B-CHEMICAL
-	I-CHEMICAL
fluorodeoxyuridine	I-CHEMICAL
monophosphate	I-CHEMICAL
,	O
forming	O
an	O
inactive	O
ternary	O
complex	O
with	O
intracellular	O
folate	B-CHEMICAL
.	O

We	O
investigated	O
the	O
effects	O
of	O
1	B-CHEMICAL
-	I-CHEMICAL
(	I-CHEMICAL
2	I-CHEMICAL
-	I-CHEMICAL
tetrahydrofuryl	I-CHEMICAL
)	I-CHEMICAL
-	I-CHEMICAL
5	I-CHEMICAL
-	I-CHEMICAL
FU	I-CHEMICAL
plus	O
uracil	B-CHEMICAL
(	O
UFT	B-CHEMICAL
)	O
with	O
or	O
without	O
leucovorin	B-CHEMICAL
on	O
1	B-CHEMICAL
,	I-CHEMICAL
2	I-CHEMICAL
-	I-CHEMICAL
dimethylhydrazine	I-CHEMICAL
-	O
induced	O
rat	O
colorectal	O
carcinomas	O
.	O

Thirty	O
-	O
week	O
administration	O
of	O
UFT	B-CHEMICAL
with	O
or	O
without	O
leucovorin	B-CHEMICAL
markedly	O
suppressed	O
both	O
colorectal	O
carcinogenesis	O
and	O
tumor	O
growth	O
,	O
resulted	O
in	O
the	O
increase	O
of	O
thymidylate	B-GENE-Y
synthase	I-GENE-Y
inhibition	O
and	O
the	O
decrease	O
of	O
thymidine	B-GENE-Y
kinase	I-GENE-Y
activity	O
in	O
the	O
tumor	O
cells	O
.	O

These	O
results	O
indicate	O
that	O
the	O
combination	O
of	O
UFT	B-CHEMICAL
with	O
leucovorin	B-CHEMICAL
could	O
be	O
useful	O
in	O
the	O
development	O
of	O
pre	O
-	O
and	O
post	O
-	O
operative	O
adjuvant	O
chemotherapy	O
programs	O
.	O

Antizyme	B-GENE-N
inhibitor	I-GENE-N
is	O
rapidly	O
induced	O
in	O
growth	O
-	O
stimulated	O
mouse	O
fibroblasts	O
and	O
releases	O
ornithine	B-GENE-Y
decarboxylase	I-GENE-Y
from	O
antizyme	B-GENE-N
suppression	O
.	O

Ornithine	B-GENE-Y
decarboxylase	I-GENE-Y
(	O
ODC	B-GENE-Y
)	O
catalyses	O
the	O
first	O
step	O
in	O
the	O
synthesis	O
of	O
the	O
polyamines	O
putrescine	B-CHEMICAL
,	O
spermidine	B-CHEMICAL
and	O
spermine	B-CHEMICAL
.	O

The	O
polyamines	O
are	O
essential	O
for	O
cell	O
growth	O
,	O
but	O
at	O
elevated	O
levels	O
they	O
may	O
be	O
tumorigenic	O
,	O
toxic	O
,	O
or	O
may	O
induce	O
apoptosis	O
.	O

Therefore	O
,	O
ODC	B-GENE-Y
activity	O
is	O
highly	O
regulated	O
.	O

It	O
is	O
induced	O
when	O
cells	O
are	O
stimulated	O
to	O
grow	O
,	O
and	O
it	O
is	O
subjected	O
to	O
feedback	O
inhibition	O
by	O
the	O
polyamines	O
.	O

By	O
causing	O
ribosomal	O
frameshifting	O
,	O
polyamines	O
induce	O
the	O
synthesis	O
of	O
antizyme	B-GENE-N
,	O
a	O
23	O
-	O
kDa	O
protein	O
,	O
which	O
binds	O
to	O
ODC	B-GENE-Y
,	O
inhibits	O
its	O
activity	O
and	O
promotes	O
its	O
degradation	O
by	O
the	O
26	B-GENE-N
S	I-GENE-N
proteasome	I-GENE-N
.	O

Antizyme	B-GENE-N
,	O
in	O
turn	O
,	O
is	O
inhibited	O
by	O
antizyme	B-GENE-N
inhibitor	I-GENE-N
(	O
AZI	B-GENE-N
)	O
.	O

We	O
describe	O
the	O
cloning	O
of	O
a	O
mouse	B-GENE-N
AZI	I-GENE-N
cDNA	O
,	O
encoding	O
a	O
protein	O
with	O
high	O
homology	O
to	O
mouse	B-GENE-Y
ODC	I-GENE-Y
.	O

Using	O
purified	O
recombinant	O
proteins	O
,	O
we	O
show	O
that	O
AZI	B-GENE-N
(	O
which	O
has	O
no	O
ODC	B-GENE-Y
activity	O
)	O
can	O
release	O
enzymically	O
active	O
ODC	B-GENE-Y
from	O
antizyme	B-GENE-N
suppression	O
in	O
vitro	O
.	O

We	O
also	O
show	O
that	O
ODC	B-GENE-Y
reactivation	O
takes	O
place	O
in	O
mouse	O
fibroblasts	O
upon	O
transient	O
transfection	O
with	O
an	O
AZI	B-GENE-N
-	O
expressing	O
plasmid	O
construct	O
.	O

Finally	O
we	O
demonstrate	O
that	O
the	O
AZI	B-GENE-N
mRNA	O
content	O
of	O
mouse	O
fibroblasts	O
increases	O
significantly	O
within	O
an	O
hour	O
of	O
growth	O
stimulation	O
,	O
i	O
.	O
e	O
.	O
much	O
earlier	O
than	O
ODC	B-GENE-Y
transcripts	O
.	O

Our	O
results	O
indicate	O
that	O
induction	O
of	O
AZI	B-GENE-N
synthesis	O
may	O
represent	O
a	O
means	O
of	O
rescuing	O
ODC	B-GENE-Y
molecules	O
that	O
have	O
been	O
inactivated	O
and	O
tagged	O
for	O
degradation	O
by	O
antizyme	B-GENE-N
,	O
when	O
culture	O
conditions	O
improve	O
and	O
polyamine	O
production	O
is	O
needed	O
for	O
cell	O
growth	O
and	O
proliferation	O
.	O

Characterization	O
of	O
human	O
recombinant	O
alpha	B-GENE-Y
(	I-GENE-Y
2A	I-GENE-Y
)	I-GENE-Y
-	I-GENE-Y
adrenoceptors	I-GENE-Y
expressed	O
in	O
Chinese	O
hamster	O
lung	O
cells	O
using	O
extracellular	O
acidification	O
rate	O
changes	O
.	O

1	O
.	O

Human	B-GENE-Y
alpha	I-GENE-Y
(	I-GENE-Y
2A	I-GENE-Y
)	I-GENE-Y
-	I-GENE-Y
adrenoceptors	I-GENE-Y
heterologously	O
expressed	O
in	O
Chinese	O
hamster	O
lung	O
(	O
CHL	O
)	O
fibroblasts	O
have	O
been	O
characterized	O
pharmacologically	O
using	O
a	O
cytosensor	O
microphysiometer	O
to	O
measure	O
ligand	O
-	O
induced	O
extracellular	O
acidification	O
rate	O
changes	O
.	O

2	O
.	O

In	O
untransfected	O
CHL	O
cells	O
,	O
noradrenaline	B-CHEMICAL
had	O
no	O
effect	O
at	O
concentrations	O
up	O
to	O
100	O
microM	O
.	O

In	O
alpha	B-GENE-Y
(	I-GENE-Y
2A	I-GENE-Y
)	I-GENE-Y
-	I-GENE-Y
adrenoceptor	I-GENE-Y
transfected	O
cells	O
the	O
rank	O
order	O
of	O
agonist	O
potency	O
was	O
A	B-CHEMICAL
-	I-CHEMICAL
54741	I-CHEMICAL
(	O
mean	O
pEC	O
(	O
50	O
)	O
=	O
8	O
.	O
96	O
)	O
>	O
dexmedetomidine	B-CHEMICAL
(	O
8	O
.	O
88	O
)	O
>	O
UK	B-CHEMICAL
-	I-CHEMICAL
14304	I-CHEMICAL
(	O
8	O
.	O
42	O
)	O
>	O
B	B-CHEMICAL
-	I-CHEMICAL
HT	I-CHEMICAL
920	I-CHEMICAL
(	O
7	O
.	O
05	O
)	O
>	O
noradrenaline	B-CHEMICAL
(	O
6	O
.	O
92	O
)	O
.	O

A	B-CHEMICAL
-	I-CHEMICAL
54741	I-CHEMICAL
,	O
UK	B-CHEMICAL
-	I-CHEMICAL
14304	I-CHEMICAL
and	O
noradrenaline	B-CHEMICAL
had	O
the	O
same	O
maximum	O
response	O
while	O
dexmedetomidine	B-CHEMICAL
and	O
B	B-CHEMICAL
-	I-CHEMICAL
HT	I-CHEMICAL
920	I-CHEMICAL
behaved	O
as	O
partial	O
agonists	O
.	O

3	O
.	O

The	O
selective	O
alpha	B-GENE-N
(	I-GENE-N
2	I-GENE-N
)	I-GENE-N
-	I-GENE-N
adrenoceptor	I-GENE-N
ligand	O
rauwolscine	B-CHEMICAL
antagonized	O
acidification	O
rate	O
changes	O
with	O
an	O
affinity	O
independent	O
of	O
the	O
agonist	O
used	O
;	O
the	O
affinity	O
(	O
mean	O
pK	O
(	O
B	O
)	O
)	O
against	O
noradrenaline	B-CHEMICAL
was	O
8	O
.	O
43	O
.	O

4	O
.	O

The	O
selective	O
alpha	B-GENE-N
(	I-GENE-N
1	I-GENE-N
)	I-GENE-N
-	I-GENE-N
adrenoceptor	I-GENE-N
ligands	O
prazosin	B-CHEMICAL
and	O
doxazosin	B-CHEMICAL
(	O
each	O
3	O
microM	O
)	O
had	O
no	O
effect	O
on	O
noradrenaline	B-CHEMICAL
responses	O
.	O

5	O
.	O

Acidification	O
rate	O
changes	O
induced	O
by	O
each	O
agonist	O
were	O
abolished	O
by	O
pre	O
-	O
treatment	O
of	O
cells	O
with	O
pertussis	B-GENE-N
toxin	I-GENE-N
.	O

6	O
.	O

These	O
data	O
suggest	O
that	O
agonist	O
-	O
induced	O
acidification	O
rate	O
responses	O
in	O
CHL	O
cells	O
transfected	O
with	O
the	O
human	B-GENE-Y
alpha	I-GENE-Y
(	I-GENE-Y
2A	I-GENE-Y
)	I-GENE-Y
-	I-GENE-Y
adrenoceptor	I-GENE-Y
are	O
mediated	O
exclusively	O
by	O
the	O
recombinant	O
protein	O
,	O
via	O
pertussis	B-GENE-N
toxin	I-GENE-N
sensitive	O
G	B-GENE-N
(	I-GENE-N
i	I-GENE-N
/	I-GENE-N
o	I-GENE-N
)	I-GENE-N
proteins	I-GENE-N
.	O

Pharmacological	O
characterization	O
of	O
glucocorticoid	B-GENE-N
receptors	I-GENE-N
in	O
primary	O
human	O
bronchial	O
epithelial	O
cells	O
.	O

Bronchial	O
epithelial	O
cells	O
play	O
an	O
important	O
role	O
in	O
amplifying	O
and	O
perpetuating	O
airway	O
inflammation	O
and	O
may	O
be	O
a	O
target	O
for	O
inhaled	O
steroids	B-CHEMICAL
.	O

We	O
have	O
characterized	O
glucocorticoid	B-GENE-Y
receptors	I-GENE-Y
in	O
primary	O
human	O
bronchial	O
epithelial	O
cells	O
.	O

Northern	O
and	O
western	O
blot	O
analyses	O
demonstrated	O
the	O
expression	O
of	O
glucocorticoid	B-GENE-N
receptor	I-GENE-N
mRNA	O
and	O
protein	O
,	O
respectively	O
,	O
in	O
primary	O
bronchial	O
epithelial	O
cells	O
.	O

The	O
activity	O
of	O
these	O
receptors	O
was	O
shown	O
using	O
a	O
radioligand	O
binding	O
assay	O
.	O

High	O
-	O
affinity	O
binding	O
with	O
pharmacological	O
specificity	O
was	O
demonstrated	O
for	O
[	B-CHEMICAL
3H	I-CHEMICAL
]	I-CHEMICAL
dexamethasone	I-CHEMICAL
.	O

The	O
equilibrium	O
dissociation	O
constant	O
(	O
Kd	O
)	O
and	O
density	O
of	O
binding	O
sites	O
(	O
Bmax	O
)	O
for	O
[	B-CHEMICAL
3H	I-CHEMICAL
]	I-CHEMICAL
dexamethasone	I-CHEMICAL
determined	O
from	O
saturation	O
isotherms	O
were	O
4	O
.	O
4	O
nM	O
x	O
/	O
divided	O
by	O
0	O
.	O
95	O
(	O
SEM	O
)	O
and	O
30	O
.	O
1	O
fmol	O
/	O
mg	O
protein	O
+	O
/	O
-	O
6	O
.	O
4	O
(	O
SEM	O
)	O
.	O

Glucocorticoid	B-GENE-Y
receptors	I-GENE-Y
were	O
activated	O
by	O
dexamethasone	B-CHEMICAL
as	O
assessed	O
using	O
a	O
glucocorticoid	O
-	O
responsive	O
reporter	O
plasmid	O
,	O
pTAT3	O
-	O
CAT	O
.	O

Transfection	O
of	O
primary	O
human	O
bronchial	O
epithelial	O
cells	O
with	O
this	O
reporter	O
plasmid	O
resulted	O
in	O
35	O
-	O
fold	O
activation	O
of	O
transcription	O
following	O
dexamethasone	B-CHEMICAL
stimulation	O
(	O
10	O
(	O
-	O
6	O
)	O
M	O
)	O
.	O

The	O
glucocorticoid	B-GENE-Y
receptor	I-GENE-Y
antagonist	O
RU	B-CHEMICAL
-	I-CHEMICAL
486	I-CHEMICAL
(	O
mifepristone	B-CHEMICAL
)	O
significantly	O
counteracted	O
the	O
effect	O
of	O
dexamethasone	B-CHEMICAL
on	O
glucocorticoid	B-GENE-Y
receptor	I-GENE-Y
activation	O
,	O
indicating	O
that	O
the	O
dexamethasone	B-CHEMICAL
effect	O
is	O
specific	O
and	O
is	O
mediated	O
through	O
the	O
glucocorticoid	B-GENE-Y
receptor	I-GENE-Y
.	O

In	O
summary	O
,	O
our	O
study	O
demonstrated	O
that	O
primary	O
cultures	O
of	O
human	O
bronchial	O
epithelial	O
cells	O
possess	O
glucocorticoid	B-GENE-Y
receptors	I-GENE-Y
that	O
function	O
as	O
a	O
ligand	O
-	O
activated	O
transcriptional	O
regulator	O
.	O

The	O
presence	O
of	O
glucocorticoid	B-GENE-Y
receptors	I-GENE-Y
confers	O
their	O
responsiveness	O
to	O
glucocorticoids	O
and	O
indicates	O
that	O
the	O
airway	O
epithelium	O
may	O
be	O
a	O
target	O
for	O
the	O
anti	O
-	O
inflammatory	O
effects	O
of	O
inhaled	O
steroids	B-CHEMICAL
.	O

Molecular	O
characterization	O
of	O
the	O
surface	O
of	O
apoptotic	O
neutrophils	O
:	O
implications	O
for	O
functional	O
downregulation	O
and	O
recognition	O
by	O
phagocytes	O
.	O

We	O
have	O
used	O
a	O
panel	O
of	O
monoclonal	O
antibodies	O
and	O
lectins	B-GENE-N
to	O
examine	O
the	O
profile	O
of	O
surface	O
molecule	O
expression	O
on	O
human	O
neutrophils	O
that	O
have	O
undergone	O
spontaneous	O
apoptosis	O
during	O
in	O
vitro	O
culture	O
.	O

Neutrophil	O
apoptosis	O
was	O
found	O
to	O
be	O
accompanied	O
by	O
down	O
-	O
regulation	O
of	O
the	O
immunoglobulin	B-GENE-N
superfamily	O
members	O
PECAM	B-GENE-Y
-	I-GENE-Y
1	I-GENE-Y
(	O
CD31	B-GENE-Y
)	O
,	O
ICAM	B-GENE-Y
-	I-GENE-Y
3	I-GENE-Y
(	O
CD50	B-GENE-Y
)	O
,	O
CD66acde	B-GENE-N
,	O
and	O
CD66b	B-GENE-Y
and	O
the	O
integrin	B-GENE-N
-	O
associated	O
proteins	O
CD63	B-GENE-Y
and	O
urokinase	B-GENE-Y
plasminogen	I-GENE-Y
activator	I-GENE-Y
receptor	I-GENE-Y
(	O
CD87	B-GENE-Y
)	O
that	O
may	O
alter	O
the	O
potential	O
for	O
adhesive	O
interactions	O
.	O

Cellular	O
interactions	O
may	O
be	O
further	O
influenced	O
by	O
the	O
reduction	O
of	O
the	O
expression	O
of	O
surface	O
carbohydrate	B-CHEMICAL
moieties	O
,	O
including	O
sialic	B-CHEMICAL
acid	I-CHEMICAL
.	O

Reduced	O
expression	O
of	O
FcgammaRII	B-GENE-N
(	O
CD32	B-GENE-Y
)	O
,	O
complement	B-GENE-Y
receptor	I-GENE-Y
type	I-GENE-Y
1	I-GENE-Y
(	O
CD35	B-GENE-Y
)	O
and	O
receptors	O
for	O
pro	O
-	O
inflammatory	O
mediators	O
C5a	B-GENE-Y
(	O
CD88	B-GENE-Y
)	O
and	O
TNFalpha	B-GENE-Y
(	O
CD120b	B-GENE-Y
)	O
associated	O
with	O
apoptosis	O
might	O
limit	O
neutrophil	O
responsiveness	O
to	O
stimuli	O
that	O
trigger	O
degranulation	O
responses	O
.	O

Although	O
many	O
of	O
the	O
receptors	O
we	O
have	O
examined	O
are	O
expressed	O
at	O
reduced	O
levels	O
on	O
apoptotic	O
neutrophils	O
,	O
we	O
found	O
that	O
there	O
was	O
differential	O
loss	O
of	O
certain	O
receptors	O
(	O
e	O
.	O
g	O
.	O
CD16	B-GENE-Y
,	O
CD15	B-GENE-Y
and	O
CD120b	B-GENE-Y
)	O
and	O
increased	O
expression	O
of	O
aminopeptidase	B-GENE-Y
-	I-GENE-Y
N	I-GENE-Y
(	O
CD13	B-GENE-Y
)	O
.	O

Together	O
with	O
our	O
previous	O
data	O
showing	O
that	O
expression	O
of	O
certain	O
molecules	O
e	O
.	O
g	O
.	O
LFA	B-GENE-Y
-	I-GENE-Y
3	I-GENE-Y
(	O
CD58	B-GENE-Y
)	O
is	O
not	O
altered	O
during	O
neutrophil	O
apoptosis	O
,	O
these	O
data	O
are	O
suggestive	O
of	O
specific	O
changes	O
in	O
receptor	O
mobilisation	O
and	O
shedding	O
associated	O
with	O
apoptosis	O
.	O

Although	O
reduced	O
expression	O
of	O
CD63	B-GENE-Y
(	O
azurophilic	O
granules	O
)	O
and	O
CR1	B-GENE-Y
(	O
specific	O
granules	O
)	O
indicates	O
that	O
granule	O
mobilisation	O
does	O
not	O
accompany	O
apoptosis	O
,	O
a	O
monoclonal	O
antibody	O
(	O
BOB78	O
)	O
,	O
that	O
recognises	O
a	O
90	O
kDa	O
antigen	O
localised	O
in	O
intracellular	O
granules	O
,	O
defines	O
a	O
subpopulation	O
of	O
apoptotic	O
neutrophils	O
that	O
exhibit	O
nuclear	O
degradation	O
yet	O
retain	O
intact	O
plasma	O
membranes	O
.	O

BOB78	O
positive	O
neutrophils	O
were	O
found	O
to	O
bind	O
biotinylated	O
thrombospondin	B-GENE-Y
,	O
suggesting	O
that	O
this	O
mAb	O
defines	O
surface	O
molecular	O
changes	O
associated	O
with	O
exposure	O
of	O
thrombospondin	B-GENE-Y
binding	O
moieties	O
.	O

A	O
positron	O
emission	O
tomography	O
study	O
of	O
quetiapine	B-CHEMICAL
in	O
schizophrenia	O
:	O
a	O
preliminary	O
finding	O
of	O
an	O
antipsychotic	O
effect	O
with	O
only	O
transiently	O
high	O
dopamine	B-GENE-Y
D2	I-GENE-Y
receptor	I-GENE-Y
occupancy	O
.	O

BACKGROUND	O
:	O
Quetiapine	B-CHEMICAL
is	O
a	O
new	O
atypical	O
antipsychotic	O
medication	O
.	O

As	O
such	O
,	O
relatively	O
little	O
has	O
been	O
published	O
regarding	O
its	O
in	O
vivo	O
effects	O
at	O
the	O
dopamine	B-GENE-Y
type	I-GENE-Y
2	I-GENE-Y
(	O
D2	B-GENE-Y
)	O
and	O
serotonin	B-GENE-Y
type	I-GENE-Y
2a	I-GENE-Y
(	I-GENE-Y
5	I-GENE-Y
-	I-GENE-Y
HT2a	I-GENE-Y
)	I-GENE-Y
receptor	I-GENE-Y
systems	O
.	O

The	O
following	O
study	O
was	O
undertaken	O
to	O
explore	O
these	O
effects	O
across	O
the	O
clinical	O
dose	O
range	O
and	O
relate	O
this	O
information	O
to	O
its	O
clinical	O
profile	O
.	O

METHODS	O
:	O
Twelve	O
patients	O
with	O
schizophrenia	O
were	O
randomly	O
assigned	O
to	O
doses	O
of	O
150	O
to	O
600	O
mg	O
/	O
d	O
(	O
n	O
=	O
3	O
,	O
at	O
150	O
,	O
300	O
,	O
450	O
,	O
and	O
600	O
mg	O
/	O
d	O
)	O
of	O
quetiapine	B-CHEMICAL
.	O

After	O
3	O
weeks	O
of	O
treatment	O
,	O
D2	B-GENE-Y
and	O
5	B-GENE-Y
-	I-GENE-Y
HT2a	I-GENE-Y
occupancy	O
were	O
measured	O
using	O
positron	O
emission	O
tomography	O
(	O
PET	O
)	O
imaging	O
,	O
12	O
to	O
14	O
hours	O
after	O
the	O
last	O
dose	O
.	O

Clinical	O
efficacy	O
and	O
adverse	O
effect	O
ratings	O
were	O
obtained	O
at	O
baseline	O
,	O
at	O
the	O
time	O
of	O
PET	O
scanning	O
,	O
and	O
at	O
12	O
weeks	O
.	O

Two	O
additional	O
patients	O
were	O
included	O
to	O
examine	O
the	O
effects	O
of	O
the	O
drug	O
2	O
to	O
3	O
hours	O
after	O
last	O
dose	O
.	O

RESULTS	O
:	O
Quetiapine	B-CHEMICAL
was	O
an	O
effective	O
antipsychotic	O
and	O
improved	O
the	O
extrapyramidal	O
symptoms	O
and	O
prolactin	B-GENE-Y
level	O
elevation	O
noted	O
at	O
baseline	O
.	O

It	O
achieved	O
these	O
results	O
with	O
minimal	O
(	O
0	O
%	O
-	O
27	O
%	O
)	O
D2	B-GENE-Y
occupancy	O
12	O
hours	O
after	O
the	O
last	O
dose	O
.	O

Study	O
of	O
the	O
additional	O
subjects	O
revealed	O
that	O
quetiapine	B-CHEMICAL
does	O
give	O
rise	O
to	O
transiently	O
high	O
(	O
58	O
%	O
-	O
64	O
%	O
)	O
D2	B-GENE-Y
occupancy	O
2	O
to	O
3	O
hours	O
after	O
a	O
single	O
dose	O
that	O
then	O
decreases	O
to	O
minimal	O
levels	O
in	O
12	O
hours	O
.	O

CONCLUSIONS	O
:	O
Quetiapine	B-CHEMICAL
shows	O
a	O
transiently	O
high	O
D2	B-GENE-Y
occupancy	O
,	O
which	O
decreases	O
to	O
very	O
low	O
levels	O
by	O
the	O
end	O
of	O
the	O
dosing	O
interval	O
.	O

Quetiapine	O
'	O
s	O
low	O
D2	B-GENE-Y
occupancy	O
can	O
explain	O
its	O
freedom	O
from	O
extrapyramidal	O
symptoms	O
and	O
prolactin	O
level	O
elevation	O
.	O

The	O
data	O
suggest	O
that	O
transient	O
D2	B-GENE-Y
occupancy	O
may	O
be	O
sufficient	O
for	O
its	O
antipsychotic	O
effect	O
.	O

Future	O
studies	O
controlling	O
for	O
nonpharmacological	O
effects	O
as	O
well	O
as	O
activities	O
on	O
other	O
receptors	O
will	O
be	O
necessary	O
to	O
confirm	O
this	O
suggestion	O
.	O

Correlations	O
of	O
receptor	O
binding	O
and	O
metabolic	O
and	O
mitogenic	O
potencies	O
of	O
insulin	B-GENE-Y
analogs	O
designed	O
for	O
clinical	O
use	O
.	O

In	O
recent	O
years	O
,	O
analogs	O
of	O
human	B-GENE-Y
insulin	I-GENE-Y
have	O
been	O
engineered	O
with	O
the	O
aim	O
of	O
improving	O
therapy	O
for	O
people	O
with	O
diabetes	O
.	O

To	O
ensure	O
that	O
the	O
safety	O
profile	O
of	O
the	O
human	O
hormone	O
is	O
not	O
compromised	O
by	O
the	O
molecular	O
modifications	O
,	O
the	O
toxico	O
-	O
pharmacological	O
properties	O
of	O
insulin	B-GENE-Y
analogs	O
should	O
be	O
carefully	O
monitored	O
.	O

In	O
this	O
study	O
,	O
we	O
compared	O
the	O
insulin	B-GENE-Y
and	O
IGF	B-GENE-Y
-	I-GENE-Y
I	I-GENE-Y
receptor	I-GENE-Y
binding	O
properties	O
and	O
metabolic	O
and	O
mitogenic	O
potencies	O
of	O
insulin	B-GENE-Y
aspart	O
(	O
B28Asp	O
human	B-GENE-Y
insulin	I-GENE-Y
)	O
,	O
insulin	B-GENE-Y
lispro	O
(	O
B28Lys	O
,	O
B29Pro	O
human	B-GENE-Y
insulin	I-GENE-Y
)	O
,	O
insulin	B-GENE-Y
glargine	O
(	O
A21Gly	O
,	O
B31Arg	O
,	O
B32Arg	O
human	B-GENE-Y
insulin	I-GENE-Y
)	O
,	O
insulin	B-GENE-Y
detemir	O
(	O
NN304	O
)	O
[	O
B29Lys	O
(	O
epsilon	B-CHEMICAL
-	I-CHEMICAL
tetradecanoyl	I-CHEMICAL
)	O
,	O
desB30	O
human	O
insulin	B-GENE-Y
]	O
,	O
and	O
reference	O
insulin	B-GENE-Y
analogs	O
.	O

Receptor	O
affinities	O
were	O
measured	O
using	O
purified	O
human	O
receptors	O
,	O
insulin	B-GENE-Y
receptor	I-GENE-Y
dissociation	O
rates	O
were	O
determined	O
using	O
Chinese	O
hamster	O
ovary	O
cells	O
overexpressing	O
the	O
human	B-GENE-Y
insulin	I-GENE-Y
receptor	I-GENE-Y
,	O
metabolic	O
potencies	O
were	O
evaluated	O
using	O
primary	O
mouse	O
adipocytes	O
,	O
and	O
mitogenic	O
potencies	O
were	O
determined	O
in	O
human	O
osteosarcoma	O
cells	O
.	O

Metabolic	O
potencies	O
correlated	O
well	O
with	O
insulin	B-GENE-Y
receptor	I-GENE-Y
affinities	O
.	O

Mitogenic	O
potencies	O
in	O
general	O
correlated	O
better	O
with	O
IGF	B-GENE-Y
-	I-GENE-Y
I	I-GENE-Y
receptor	I-GENE-Y
affinities	O
than	O
with	O
insulin	B-GENE-Y
receptor	I-GENE-Y
off	O
-	O
rates	O
.	O

The	O
2	O
rapid	O
-	O
acting	O
insulin	B-GENE-Y
analogs	O
aspart	O
and	O
lispro	O
resembled	O
human	B-GENE-Y
insulin	I-GENE-Y
on	O
all	O
parameters	O
,	O
except	O
for	O
a	O
slightly	O
elevated	O
IGF	B-GENE-Y
-	I-GENE-Y
I	I-GENE-Y
receptor	I-GENE-Y
affinity	O
of	O
lispro	O
.	O

In	O
contrast	O
,	O
the	O
2	O
long	O
-	O
acting	O
insulin	B-GENE-Y
analogs	O
,	O
glargine	O
and	O
detemir	O
,	O
differed	O
significantly	O
from	O
human	B-GENE-Y
insulin	I-GENE-Y
.	O

The	O
combination	O
of	O
the	O
B31B32diArg	O
and	O
A21Gly	O
substitutions	O
provided	O
insulin	B-GENE-Y
glargine	O
with	O
a	O
6	O
-	O
to	O
8	O
-	O
fold	O
increased	O
IGF	B-GENE-Y
-	I-GENE-Y
I	I-GENE-Y
receptor	I-GENE-Y
affinity	O
and	O
mitogenic	O
potency	O
compared	O
with	O
human	B-GENE-Y
insulin	I-GENE-Y
.	O

The	O
attachment	O
of	O
a	O
fatty	B-CHEMICAL
acid	I-CHEMICAL
chain	O
to	O
LysB29	O
provided	O
insulin	B-GENE-Y
detemir	O
with	O
reduced	O
receptor	O
affinities	O
and	O
metabolic	O
and	O
mitogenic	O
potencies	O
but	O
did	O
not	O
change	O
the	O
balance	O
between	O
mitogenic	O
and	O
metabolic	O
potencies	O
.	O

The	O
safety	O
implications	O
of	O
the	O
increased	O
growth	O
-	O
stimulating	O
potential	O
of	O
insulin	B-GENE-Y
glargine	O
are	O
unclear	O
.	O

The	O
reduced	O
in	O
vitro	O
potency	O
of	O
insulin	B-GENE-Y
detemir	O
might	O
explain	O
why	O
this	O
analog	O
is	O
not	O
as	O
effective	O
on	O
a	O
molar	O
basis	O
as	O
human	B-GENE-Y
insulin	I-GENE-Y
in	O
humans	O
.	O

TWIK	B-GENE-Y
-	I-GENE-Y
2	I-GENE-Y
,	O
an	O
inactivating	O
2P	B-GENE-Y
domain	I-GENE-Y
K	I-GENE-Y
+	I-GENE-Y
channel	I-GENE-Y
.	O

We	O
cloned	O
human	O
and	O
rat	O
TWIK	B-GENE-N
-	I-GENE-N
2	I-GENE-N
and	O
expressed	O
this	O
novel	O
2P	B-GENE-N
domain	I-GENE-N
K	I-GENE-N
(	I-GENE-N
+	I-GENE-N
)	I-GENE-N
channel	I-GENE-N
in	O
transiently	O
transfected	O
COS	O
cells	O
.	O

TWIK	B-GENE-Y
-	I-GENE-Y
2	I-GENE-Y
is	O
highly	O
expressed	O
in	O
the	O
gastrointestinal	O
tract	O
,	O
the	O
vasculature	O
,	O
and	O
the	O
immune	O
system	O
.	O

Rat	B-GENE-Y
TWIK	I-GENE-Y
-	I-GENE-Y
2	I-GENE-Y
currents	O
are	O
about	O
15	O
times	O
larger	O
than	O
human	B-GENE-Y
TWIK	I-GENE-Y
-	I-GENE-Y
2	I-GENE-Y
currents	O
,	O
but	O
both	O
exhibit	O
outward	O
rectification	O
in	O
a	O
physiological	O
K	B-CHEMICAL
(	I-CHEMICAL
+	I-CHEMICAL
)	I-CHEMICAL
gradient	O
and	O
mild	O
inward	O
rectification	O
in	O
symmetrical	O
K	B-CHEMICAL
(	I-CHEMICAL
+	I-CHEMICAL
)	I-CHEMICAL
conditions	O
.	O

TWIK	B-GENE-Y
-	I-GENE-Y
2	I-GENE-Y
currents	O
are	O
inactivating	O
at	O
depolarized	O
potentials	O
,	O
and	O
the	O
kinetic	O
of	O
inactivation	O
is	O
highly	O
temperature	O
-	O
sensitive	O
.	O

TWIK	B-GENE-Y
-	I-GENE-Y
2	I-GENE-Y
shows	O
an	O
extremely	O
low	O
conductance	O
,	O
which	O
prevents	O
the	O
visualization	O
of	O
discrete	O
single	O
channel	O
events	O
.	O

The	O
inactivation	O
and	O
rectification	O
are	O
intrinsic	O
properties	O
of	O
TWIK	B-GENE-Y
-	I-GENE-Y
2	I-GENE-Y
channels	O
.	O

In	O
a	O
physiological	O
K	B-CHEMICAL
(	I-CHEMICAL
+	I-CHEMICAL
)	I-CHEMICAL
gradient	O
,	O
TWIK	B-GENE-Y
-	I-GENE-Y
2	I-GENE-Y
is	O
half	O
inhibited	O
by	O
0	O
.	O
1	O
mm	O
Ba	B-CHEMICAL
(	I-CHEMICAL
2	I-CHEMICAL
+	I-CHEMICAL
)	I-CHEMICAL
,	O
quinine	B-CHEMICAL
,	O
and	O
quinidine	B-CHEMICAL
.	O

Finally	O
,	O
cysteine	B-CHEMICAL
53	O
in	O
the	O
M1P1	B-GENE-N
external	I-GENE-N
loop	I-GENE-N
is	O
required	O
for	O
functional	O
expression	O
of	O
TWIK	B-GENE-Y
-	I-GENE-Y
2	I-GENE-Y
but	O
is	O
not	O
critical	O
for	O
subunit	O
self	O
-	O
assembly	O
.	O

TWIK	B-GENE-Y
-	I-GENE-Y
2	I-GENE-Y
is	O
the	O
first	O
reported	O
2P	B-GENE-Y
domain	I-GENE-Y
K	I-GENE-Y
(	I-GENE-Y
+	I-GENE-Y
)	I-GENE-Y
channel	I-GENE-Y
that	O
inactivates	O
.	O

The	O
base	O
-	O
line	O
,	O
transient	O
,	O
and	O
delayed	O
activities	O
of	O
TWIK	B-GENE-Y
-	I-GENE-Y
2	I-GENE-Y
suggest	O
that	O
this	O
novel	O
2P	B-GENE-Y
domain	I-GENE-Y
K	I-GENE-Y
(	I-GENE-Y
+	I-GENE-Y
)	I-GENE-Y
channel	I-GENE-Y
may	O
play	O
an	O
important	O
functional	O
role	O
in	O
cell	O
electrogenesis	O
.	O

Addition	O
of	O
eicosapentaenoic	B-CHEMICAL
acid	I-CHEMICAL
to	O
gamma	B-CHEMICAL
-	I-CHEMICAL
linolenic	I-CHEMICAL
acid	I-CHEMICAL
-	O
supplemented	O
diets	O
prevents	O
serum	O
arachidonic	B-CHEMICAL
acid	I-CHEMICAL
accumulation	O
in	O
humans	O
.	O

Previous	O
studies	O
reveal	O
that	O
supplementation	O
of	O
human	O
diets	O
with	O
gamma	B-CHEMICAL
-	I-CHEMICAL
linolenic	I-CHEMICAL
acid	I-CHEMICAL
(	O
GLA	B-CHEMICAL
)	O
reduces	O
the	O
generation	O
of	O
lipid	O
mediators	O
of	O
inflammation	O
and	O
attenuates	O
clinical	O
symptoms	O
of	O
chronic	O
inflammatory	O
disorders	O
such	O
as	O
rheumatoid	O
arthritis	O
.	O

However	O
,	O
we	O
have	O
shown	O
that	O
supplementation	O
with	O
this	O
same	O
fatty	B-CHEMICAL
acid	I-CHEMICAL
also	O
causes	O
a	O
marked	O
increase	O
in	O
serum	O
arachidonate	B-CHEMICAL
(	O
AA	B-CHEMICAL
)	O
levels	O
,	O
a	O
potentially	O
harmful	O
side	O
effect	O
.	O

The	O
objective	O
of	O
this	O
study	O
was	O
to	O
design	O
a	O
supplementation	O
strategy	O
that	O
maintained	O
the	O
capacity	O
of	O
GLA	B-CHEMICAL
to	O
reduce	O
lipid	O
mediators	O
without	O
causing	O
elevations	O
in	O
serum	O
AA	B-CHEMICAL
levels	O
.	O

Initial	O
in	O
vitro	O
studies	O
utilizing	O
HEP	O
-	O
G2	O
liver	O
cells	O
revealed	O
that	O
addition	O
of	O
eicosapentaenoic	B-CHEMICAL
acid	I-CHEMICAL
(	O
EPA	B-CHEMICAL
)	O
blocked	O
Delta	B-GENE-Y
-	I-GENE-Y
5	I-GENE-Y
-	I-GENE-Y
desaturase	I-GENE-Y
activity	O
,	O
the	O
terminal	O
enzymatic	O
step	O
in	O
AA	B-CHEMICAL
synthesis	O
.	O

To	O
test	O
the	O
in	O
vivo	O
effects	O
of	O
a	O
GLA	B-CHEMICAL
and	O
EPA	B-CHEMICAL
combination	O
in	O
humans	O
,	O
adult	O
volunteers	O
consuming	O
controlled	O
diets	O
supplemented	O
these	O
diets	O
with	O
3	O
.	O
0	O
g	O
/	O
d	O
of	O
GLA	B-CHEMICAL
and	O
EPA	B-CHEMICAL
.	O

This	O
supplementation	O
strategy	O
significantly	O
increased	O
serum	O
levels	O
of	O
EPA	B-CHEMICAL
,	O
but	O
did	O
not	O
increase	O
AA	B-CHEMICAL
levels	O
.	O

EPA	B-CHEMICAL
and	O
the	O
elongation	O
product	O
of	O
GLA	B-CHEMICAL
,	O
dihomo	B-CHEMICAL
-	I-CHEMICAL
gamma	I-CHEMICAL
-	I-CHEMICAL
linolenic	I-CHEMICAL
acid	I-CHEMICAL
(	O
DGLA	B-CHEMICAL
)	O
levels	O
in	O
neutrophil	O
glycerolipids	O
increased	O
significantly	O
during	O
the	O
3	O
-	O
wk	O
supplementation	O
period	O
.	O

Neutrophils	O
isolated	O
from	O
volunteers	O
fed	O
diets	O
supplemented	O
with	O
GLA	B-CHEMICAL
and	O
EPA	B-CHEMICAL
released	O
similar	O
quantities	O
of	O
AA	B-CHEMICAL
,	O
but	O
synthesized	O
significantly	O
lower	O
quantities	O
of	O
leukotrienes	B-CHEMICAL
compared	O
with	O
their	O
neutrophils	O
before	O
supplementation	O
.	O

This	O
study	O
revealed	O
that	O
a	O
GLA	B-CHEMICAL
and	O
EPA	B-CHEMICAL
supplement	O
combination	O
may	O
be	O
utilized	O
to	O
reduce	O
the	O
synthesis	O
of	O
proinflammatory	O
AA	B-CHEMICAL
metabolites	O
,	O
and	O
importantly	O
,	O
not	O
induce	O
potentially	O
harmful	O
increases	O
in	O
serum	O
AA	B-CHEMICAL
levels	O
.	O

Effects	O
of	O
a	O
K	B-GENE-N
(	I-GENE-N
+	I-GENE-N
)	I-GENE-N
channel	I-GENE-N
opener	O
to	O
reduce	O
transmural	O
dispersion	O
of	O
repolarization	O
and	O
prevent	O
torsade	O
de	O
pointes	O
in	O
LQT1	O
,	O
LQT2	O
,	O
and	O
LQT3	O
models	O
of	O
the	O
long	O
-	O
QT	O
syndrome	O
.	O

BACKGROUND	O
:	O
This	O
study	O
examines	O
the	O
effects	O
of	O
nicorandil	B-CHEMICAL
,	O
a	O
K	B-GENE-N
(	I-GENE-N
+	I-GENE-N
)	I-GENE-N
channel	I-GENE-N
opener	O
,	O
on	O
transmural	O
dispersion	O
of	O
repolarization	O
(	O
TDR	O
)	O
and	O
induction	O
of	O
torsade	O
de	O
pointes	O
(	O
TdP	O
)	O
under	O
conditions	O
mimicking	O
the	O
LQT1	O
,	O
LQT2	O
,	O
and	O
LQT3	O
forms	O
of	O
the	O
congenital	O
long	O
-	O
QT	O
syndrome	O
(	O
LQTS	O
)	O
.	O

METHODS	O
AND	O
RESULTS	O
:	O
Transmembrane	O
action	O
potentials	O
of	O
epicardial	O
,	O
M	O
,	O
and	O
endocardial	O
cells	O
were	O
recorded	O
simultaneously	O
from	O
an	O
arterially	O
perfused	O
wedge	O
of	O
canine	O
left	O
ventricle	O
together	O
with	O
a	O
transmural	O
ECG	O
.	O

Chromanol	O
293B	O
(	O
30	O
micromol	O
/	O
L	O
)	O
was	O
used	O
to	O
block	O
I	B-GENE-N
(	I-GENE-N
Ks	I-GENE-N
)	I-GENE-N
(	O
LQT1	O
model	O
)	O
.	O

Isoproterenol	B-CHEMICAL
(	O
50	O
to	O
100	O
nmol	O
/	O
L	O
)	O
was	O
used	O
to	O
mimic	O
an	O
increase	O
in	O
beta	O
-	O
adrenergic	O
tone	O
,	O
d	B-CHEMICAL
-	I-CHEMICAL
sotalol	I-CHEMICAL
(	O
100	O
micromol	O
/	O
L	O
)	O
to	O
block	O
I	B-GENE-N
(	I-GENE-N
Kr	I-GENE-N
)	I-GENE-N
(	O
LQT2	O
model	O
)	O
,	O
and	O
ATX	B-GENE-Y
-	I-GENE-Y
II	I-GENE-Y
(	O
20	O
nmol	O
/	O
L	O
)	O
to	O
augment	O
late	O
I	O
(	O
Na	B-CHEMICAL
)	O
(	O
LQT3	O
model	O
)	O
.	O

Isoproterenol	B-CHEMICAL
+	O
chromanol	B-CHEMICAL
293B	I-CHEMICAL
,	O
d	B-CHEMICAL
-	I-CHEMICAL
sotalol	I-CHEMICAL
,	O
and	O
ATX	B-GENE-Y
-	I-GENE-Y
II	I-GENE-Y
produced	O
preferential	O
prolongation	O
of	O
the	O
action	O
potential	O
duration	O
at	O
90	O
%	O
repolarization	O
(	O
APD	O
(	O
90	O
)	O
)	O
of	O
the	O
M	O
cell	O
,	O
an	O
increase	O
of	O
TDR	O
,	O
and	O
spontaneous	O
as	O
well	O
as	O
stimulation	O
-	O
induced	O
TdP	O
(	O
LQT1	O
,	O
3	O
/	O
6	O
;	O
LQT2	O
,	O
3	O
/	O
6	O
;	O
LQT3	O
,	O
5	O
/	O
6	O
)	O
.	O

Nicorandil	B-CHEMICAL
(	O
2	O
to	O
20	O
micromol	O
/	O
L	O
)	O
abbreviated	O
the	O
QT	O
interval	O
and	O
APD	O
(	O
90	O
)	O
of	O
the	O
3	O
cell	O
types	O
in	O
the	O
3	O
models	O
.	O

High	O
concentrations	O
(	O
10	O
to	O
20	O
micromol	O
/	O
L	O
)	O
completely	O
reversed	O
the	O
effects	O
of	O
293B	O
+	O
/	O
-	O
isoproterenol	B-CHEMICAL
and	O
those	O
of	O
d	B-CHEMICAL
-	I-CHEMICAL
sotalol	I-CHEMICAL
to	O
increase	O
APD	O
(	O
90	O
)	O
and	O
TDR	O
and	O
to	O
induce	O
TdP	O
in	O
LQT1	O
and	O
LQT2	O
models	O
.	O

Nicorandil	B-CHEMICAL
20	O
micromol	O
/	O
L	O
reversed	O
only	O
50	O
%	O
of	O
the	O
effect	O
of	O
ATX	B-GENE-Y
-	I-GENE-Y
II	I-GENE-Y
and	O
failed	O
to	O
completely	O
suppress	O
TdP	O
in	O
the	O
LQT3	O
model	O
(	O
5	O
/	O
6	O
to	O
3	O
/	O
6	O
)	O
.	O

CONCLUSIONS	O
:	O
Our	O
data	O
suggest	O
that	O
K	B-GENE-N
(	I-GENE-N
+	I-GENE-N
)	I-GENE-N
channel	I-GENE-N
openers	O
may	O
be	O
capable	O
of	O
abbreviating	O
the	O
long	O
QT	O
interval	O
,	O
reducing	O
TDR	O
,	O
and	O
preventing	O
spontaneous	O
and	O
stimulation	O
-	O
induced	O
TdP	O
when	O
congenital	O
or	O
acquired	O
LQTS	O
is	O
secondary	O
to	O
reduced	O
I	B-GENE-N
(	I-GENE-N
Kr	I-GENE-N
)	I-GENE-N
or	O
I	B-GENE-N
(	I-GENE-N
Ks	I-GENE-N
)	I-GENE-N
but	O
less	O
so	O
when	O
it	O
is	O
due	O
to	O
augmented	O
late	O
I	O
(	O
Na	B-CHEMICAL
)	O
.	O

Peroxisome	B-GENE-Y
proliferator	I-GENE-Y
-	I-GENE-Y
activated	I-GENE-Y
receptor	I-GENE-Y
alpha	I-GENE-Y
(	O
PPARalpha	B-GENE-Y
)	O
activators	O
,	O
bezafibrate	B-CHEMICAL
and	O
Wy	B-CHEMICAL
-	I-CHEMICAL
14	I-CHEMICAL
,	I-CHEMICAL
643	I-CHEMICAL
,	O
increase	O
uncoupling	B-GENE-Y
protein	I-GENE-Y
-	I-GENE-Y
3	I-GENE-Y
mRNA	O
levels	O
without	O
modifying	O
the	O
mitochondrial	O
membrane	O
potential	O
in	O
primary	O
culture	O
of	O
rat	O
preadipocytes	O
.	O

Uncoupling	B-GENE-N
proteins	I-GENE-N
(	O
UCPs	B-GENE-N
)	O
are	O
inner	O
mitochondrial	O
membrane	O
transporters	O
which	O
act	O
as	O
pores	O
for	O
H	B-CHEMICAL
(	I-CHEMICAL
+	I-CHEMICAL
)	I-CHEMICAL
ions	O
,	O
dissipating	O
the	O
electrochemical	O
gradient	O
that	O
develops	O
during	O
mitochondrial	O
respiration	O
at	O
the	O
expense	O
of	O
ATP	O
synthesis	O
.	O

We	O
have	O
studied	O
the	O
effects	O
of	O
two	O
fibrates	O
,	O
bezafibrate	B-CHEMICAL
and	O
Wy	B-CHEMICAL
-	I-CHEMICAL
14	I-CHEMICAL
,	I-CHEMICAL
643	I-CHEMICAL
,	O
on	O
UCP	B-GENE-Y
-	I-GENE-Y
3	I-GENE-Y
and	O
UCP	B-GENE-Y
-	I-GENE-Y
2	I-GENE-Y
mRNA	O
levels	O
in	O
primary	O
monolayer	O
cultures	O
of	O
rat	O
adipocytes	O
and	O
undifferentiated	O
preadipocytes	O
.	O

Treatment	O
with	O
both	O
PPARalpha	B-GENE-Y
activators	O
for	O
24	O
h	O
up	O
-	O
regulated	O
UCP	B-GENE-Y
-	I-GENE-Y
3	I-GENE-Y
mRNA	O
levels	O
.	O

Thus	O
,	O
bezafibrate	B-CHEMICAL
treatment	O
resulted	O
in	O
an	O
8	O
-	O
fold	O
induction	O
in	O
UCP	B-GENE-Y
-	I-GENE-Y
3	I-GENE-Y
mRNA	O
levels	O
in	O
preadipocytes	O
compared	O
with	O
the	O
3	O
.	O
5	O
-	O
fold	O
induction	O
observed	O
in	O
adipocytes	O
.	O

Differences	O
in	O
the	O
induction	O
of	O
UCP	B-GENE-Y
-	I-GENE-Y
3	I-GENE-Y
between	O
these	O
cells	O
correlated	O
well	O
with	O
the	O
higher	O
expression	O
of	O
PPARalpha	B-GENE-Y
and	O
RXRalpha	B-GENE-Y
mRNA	O
values	O
in	O
preadipocytes	O
compared	O
to	O
adipocytes	O
.	O

Wy	O
-	O
14	O
,	O
643	O
caused	O
similar	O
effects	O
on	O
UCP	B-GENE-Y
-	I-GENE-Y
3	I-GENE-Y
mRNA	O
expression	O
.	O

In	O
contrast	O
to	O
UCP	B-GENE-Y
-	I-GENE-Y
3	I-GENE-Y
,	O
UCP	B-GENE-Y
-	I-GENE-Y
2	I-GENE-Y
mRNA	O
levels	O
were	O
only	O
slightly	O
modified	O
by	O
bezafibrate	B-CHEMICAL
in	O
adipocytes	O
.	O

The	O
induction	O
in	O
UCP	B-GENE-Y
-	I-GENE-Y
3	I-GENE-Y
expression	O
was	O
not	O
accompanied	O
by	O
changes	O
in	O
the	O
mitochondrial	O
membrane	O
potential	O
of	O
rat	O
primary	O
preadipocytes	O
after	O
bezafibrate	B-CHEMICAL
or	O
Wy	B-CHEMICAL
-	I-CHEMICAL
14	I-CHEMICAL
,	I-CHEMICAL
643	I-CHEMICAL
treatment	O
.	O

Since	O
it	O
has	O
been	O
proposed	O
that	O
UCP	B-GENE-Y
-	I-GENE-Y
3	I-GENE-Y
could	O
be	O
involved	O
in	O
the	O
regulation	O
of	O
the	O
use	O
of	O
fatty	O
acids	O
as	O
fuel	O
substrates	O
,	O
the	O
UCP	B-GENE-Y
-	I-GENE-Y
3	I-GENE-Y
induction	O
achieved	O
after	O
bezafibrate	B-CHEMICAL
and	O
Wy	B-CHEMICAL
-	I-CHEMICAL
14	I-CHEMICAL
,	I-CHEMICAL
643	I-CHEMICAL
treatment	O
may	O
indicate	O
a	O
higher	O
oxidation	O
of	O
fatty	B-CHEMICAL
acids	I-CHEMICAL
,	O
limiting	O
their	O
availability	O
to	O
be	O
stored	O
as	O
triglycerides	B-CHEMICAL
.	O

This	O
change	O
may	O
result	O
in	O
a	O
reduced	O
rate	O
of	O
conversion	O
of	O
preadipocytes	O
to	O
adipocytes	O
,	O
which	O
directly	O
affects	O
fat	O
depots	O
.	O

Schisandrin	B-CHEMICAL
B	I-CHEMICAL
protects	O
against	O
menadione	B-CHEMICAL
-	O
induced	O
hepatotoxicity	O
by	O
enhancing	O
DT	B-GENE-Y
-	I-GENE-Y
diaphorase	I-GENE-Y
activity	O
.	O

Pretreating	O
mice	O
with	O
schisandrin	B-CHEMICAL
B	I-CHEMICAL
(	O
Sch	B-CHEMICAL
B	I-CHEMICAL
)	O
,	O
a	O
dibenzocyclooctadiene	O
derivative	O
isolated	O
from	O
the	O
fruit	O
of	O
Schisandra	O
chinensis	O
,	O
at	O
a	O
daily	O
dose	O
of	O
1	O
mmol	O
/	O
kg	O
for	O
3	O
days	O
protected	O
against	O
menadione	B-CHEMICAL
-	O
induced	O
hepatic	O
oxidative	O
damage	O
in	O
mice	O
,	O
as	O
evidenced	O
by	O
decreases	O
in	O
plasma	O
alanine	B-GENE-N
aminotransferase	I-GENE-N
activity	O
(	O
78	O
%	O
)	O
and	O
hepatic	O
malondialdehyde	B-CHEMICAL
level	O
(	O
70	O
%	O
)	O
,	O
when	O
compared	O
with	O
the	O
menadione	B-CHEMICAL
intoxicated	O
control	O
.	O

In	O
order	O
to	O
define	O
the	O
biochemical	O
mechanism	O
involved	O
in	O
the	O
hepatoprotection	O
afforded	O
by	O
Sch	B-CHEMICAL
B	I-CHEMICAL
pretreatment	O
,	O
we	O
examined	O
the	O
activity	O
of	O
DT	B-GENE-Y
-	I-GENE-Y
diaphorase	I-GENE-Y
(	O
DTD	B-GENE-Y
)	O
in	O
hepatocytes	O
isolated	O
from	O
Sch	B-CHEMICAL
B	I-CHEMICAL
pretreated	O
rats	O
.	O

Hepatocytes	O
isolated	O
from	O
Sch	B-CHEMICAL
B	I-CHEMICAL
pretreated	O
(	O
a	O
daily	O
dose	O
of	O
1	O
mmol	O
/	O
kg	O
for	O
3	O
days	O
)	O
rats	O
showed	O
a	O
significant	O
increase	O
(	O
25	O
%	O
)	O
in	O
DTD	B-GENE-Y
activity	O
.	O

The	O
increase	O
in	O
DTD	B-GENE-Y
activity	O
was	O
associated	O
with	O
the	O
enhanced	O
rate	O
of	O
menadione	B-CHEMICAL
elimination	O
in	O
the	O
hepatocyte	O
culture	O
.	O

The	O
ensemble	O
of	O
results	O
suggests	O
that	O
the	O
ability	O
of	O
Sch	B-CHEMICAL
B	I-CHEMICAL
pretreatment	O
to	O
enhance	O
hepatocellular	O
DTD	B-GENE-Y
activity	O
may	O
at	O
least	O
in	O
part	O
be	O
attributed	O
to	O
the	O
protection	O
against	O
menadione	B-CHEMICAL
hepatotoxicity	O
.	O

Interactive	O
and	O
delayed	O
effects	O
of	O
pyridostigmine	B-CHEMICAL
and	O
physical	O
stress	O
on	O
biochemical	O
and	O
histological	O
changes	O
in	O
peripheral	O
tissues	O
of	O
mice	O
.	O

Gulf	O
War	O
veterans	O
were	O
taking	O
pyridostigmine	B-CHEMICAL
orally	O
against	O
possible	O
exposure	O
to	O
nerve	O
agents	O
as	O
well	O
as	O
being	O
under	O
physical	O
stress	O
.	O

This	O
study	O
was	O
designed	O
to	O
investigate	O
the	O
delayed	O
effects	O
of	O
pyridostigmine	B-CHEMICAL
and	O
treadmill	O
exercise	O
on	O
cholinesterase	B-GENE-Y
activity	O
,	O
lipid	O
peroxidation	O
and	O
histology	O
of	O
peripheral	O
tissues	O
of	O
mice	O
.	O

Male	O
NIH	O
Swiss	O
mice	O
were	O
divided	O
into	O
four	O
groups	O
of	O
15	O
animals	O
each	O
and	O
treated	O
as	O
follows	O
:	O
sedentary	O
control	O
;	O
exercise	O
training	O
for	O
10	O
weeks	O
;	O
pyridostigmine	B-CHEMICAL
(	O
1	O
.	O
2	O
mg	O
kg	O
(	O
-	O
1	O
)	O
,	O
p	O
.	O
o	O
.	O
)	O
for	O
2	O
weeks	O
during	O
weeks	O
5	O
and	O
6	O
;	O
and	O
pyridostigmine	B-CHEMICAL
plus	O
exercise	O
training	O
.	O

The	O
mice	O
were	O
sacrificed	O
24	O
h	O
after	O
the	O
last	O
exercise	O
,	O
and	O
blood	O
,	O
triceps	O
muscle	O
and	O
sciatic	O
nerve	O
were	O
isolated	O
and	O
analyzed	O
.	O

The	O
group	O
treated	O
with	O
pyridostigmine	B-CHEMICAL
alone	O
showed	O
decreased	O
plasma	O
butyrylcholinesterase	B-GENE-Y
(	O
BChE	B-GENE-Y
)	O
activity	O
(	O
87	O
%	O
of	O
control	O
)	O
,	O
whereas	O
pyridostigmine	B-CHEMICAL
plus	O
exercise	O
significantly	O
decreased	O
the	O
BChE	B-GENE-Y
activity	O
(	O
79	O
%	O
of	O
control	O
)	O
,	O
indicating	O
an	O
interactive	O
effect	O
of	O
the	O
combination	O
.	O

Acetylcholinesterase	B-GENE-Y
(	O
AChE	B-GENE-Y
)	O
activity	O
did	O
not	O
alter	O
significantly	O
in	O
red	O
blood	O
cells	O
,	O
platelets	O
or	O
sciatic	O
nerve	O
with	O
either	O
of	O
the	O
treatments	O
.	O

However	O
,	O
AChE	B-GENE-Y
activity	O
in	O
triceps	O
muscle	O
decreased	O
significantly	O
(	O
78	O
%	O
of	O
control	O
)	O
in	O
the	O
group	O
treated	O
with	O
pyridostigmine	B-CHEMICAL
plus	O
exercise	O
.	O

Creatine	B-GENE-N
phosphokinase	I-GENE-N
activity	O
in	O
plasma	O
increased	O
slightly	O
(	O
compared	O
to	O
control	O
,	O
pyridostigmine	B-CHEMICAL
or	O
exercise	O
group	O
)	O
in	O
mice	O
treated	O
with	O
pyridostigmine	B-CHEMICAL
plus	O
exercise	O
,	O
which	O
may	O
be	O
indicative	O
of	O
perturbation	O
in	O
the	O
integrity	O
of	O
the	O
skeletal	O
muscle	O
due	O
to	O
combination	O
.	O

However	O
,	O
there	O
were	O
no	O
obvious	O
histological	O
abnormalities	O
in	O
the	O
triceps	O
muscle	O
detected	O
between	O
experimental	O
and	O
control	O
groups	O
.	O

Interaction	O
of	O
pyridostigmine	B-CHEMICAL
and	O
exercise	O
significantly	O
increased	O
the	O
concentration	O
of	O
the	O
end	O
product	O
of	O
lipid	O
peroxidation	O
(	O
malondialdehyde	B-CHEMICAL
)	O
(	O
124	O
%	O
of	O
control	O
)	O
in	O
triceps	O
muscle	O
,	O
indicating	O
an	O
oxidative	O
stress	O
response	O
of	O
the	O
combination	O
.	O

These	O
results	O
indicate	O
that	O
physical	O
stress	O
enhanced	O
the	O
delayed	O
toxic	O
effects	O
of	O
a	O
subchronic	O
oral	O
dose	O
of	O
pyridostigmine	B-CHEMICAL
primarily	O
in	O
the	O
skeletal	O
muscle	O
of	O
mice	O
.	O

Effect	O
of	O
hormonal	O
agents	O
on	O
monocyte	B-GENE-Y
chemotactic	I-GENE-Y
protein	I-GENE-Y
-	I-GENE-Y
1	I-GENE-Y
expression	O
by	O
endometrial	O
epithelial	O
cells	O
of	O
women	O
with	O
endometriosis	O
.	O

OBJECTIVE	O
:	O
To	O
assess	O
whether	O
hormonal	O
agents	O
used	O
in	O
the	O
medical	O
treatment	O
of	O
endometriosis	O
,	O
such	O
as	O
danazol	B-CHEMICAL
and	O
GnRH	B-GENE-Y
agonist	O
,	O
exert	O
direct	O
regulatory	O
action	O
on	O
monocyte	B-GENE-Y
chemotactic	I-GENE-Y
protein	I-GENE-Y
-	I-GENE-Y
1	I-GENE-Y
(	O
MCP	B-GENE-Y
-	I-GENE-Y
1	I-GENE-Y
)	O
expression	O
by	O
endometrial	O
epithelial	O
cells	O
.	O

DESIGN	O
:	O
Primary	O
cultures	O
of	O
epithelial	O
cells	O
isolated	O
from	O
human	O
endometrium	O
were	O
exposed	O
to	O
different	O
concentrations	O
of	O
cytokines	B-GENE-N
and	O
steroid	B-CHEMICAL
hormone	O
analogs	O
.	O

Expression	O
of	O
MCP	B-GENE-Y
-	I-GENE-Y
1	I-GENE-Y
was	O
analyzed	O
at	O
the	O
levels	O
of	O
protein	O
and	O
messenger	O
RNA	O
.	O

SETTING	O
:	O
Gynecology	O
clinic	O
and	O
laboratory	O
of	O
endocrinology	O
of	O
reproduction	O
.	O

PATIENT	O
(	O
S	O
)	O
:	O
Women	O
presenting	O
for	O
infertility	O
or	O
pelvic	O
pain	O
in	O
whom	O
endometriosis	O
was	O
diagnosed	O
by	O
using	O
laparoscopy	O
.	O

INTERVENTION	O
(	O
S	O
)	O
:	O
Endometrial	O
tissue	O
biopsy	O
performed	O
at	O
laparoscopy	O
.	O

MAIN	O
OUTCOME	O
MEASURE	O
(	O
S	O
)	O
:	O
Secretion	O
of	O
MCP	B-GENE-Y
-	I-GENE-Y
1	I-GENE-Y
protein	O
was	O
measured	O
by	O
using	O
enzyme	O
-	O
linked	O
immunosorbent	O
assay	O
,	O
and	O
mRNA	O
steady	O
-	O
state	O
levels	O
were	O
measured	O
by	O
performing	O
Northern	O
blot	O
analysis	O
.	O

RESULT	O
(	O
S	O
)	O
:	O
Buserelin	B-CHEMICAL
acetate	I-CHEMICAL
,	O
a	O
GnRH	B-GENE-Y
agonist	O
(	O
0	O
.	O
1	O
-	O
10	O
ng	O
/	O
mL	O
)	O
,	O
had	O
no	O
significant	O
effect	O
on	O
MCP	B-GENE-Y
-	I-GENE-Y
1	I-GENE-Y
expression	O
,	O
whereas	O
danazol	B-CHEMICAL
(	O
10	O
(	O
-	O
7	O
)	O
-	O
10	O
(	O
-	O
5	O
)	O
M	O
)	O
,	O
a	O
testosterone	B-CHEMICAL
analog	O
,	O
and	O
dexamethasone	B-CHEMICAL
,	O
an	O
anti	O
-	O
inflammatory	O
glucocorticoid	O
hormone	O
(	O
10	O
(	O
-	O
12	O
)	O
-	O
10	O
(	O
-	O
6	O
)	O
M	O
)	O
,	O
showed	O
a	O
direct	O
and	O
a	O
dose	O
-	O
dependent	O
inhibitory	O
effect	O
on	O
MCP	B-GENE-Y
-	I-GENE-Y
1	I-GENE-Y
expression	O
.	O

This	O
effect	O
occurred	O
at	O
the	O
level	O
of	O
protein	O
and	O
mRNA	O
.	O

CONCLUSION	O
(	O
S	O
)	O
:	O
The	O
findings	O
of	O
the	O
study	O
may	O
affect	O
understanding	O
of	O
the	O
mechanisms	O
by	O
which	O
hormonal	O
treatments	O
act	O
on	O
endometriosis	O
and	O
influence	O
its	O
clinical	O
manifestations	O
.	O

Pharmacological	O
modulation	O
of	O
nerve	B-GENE-Y
growth	I-GENE-Y
factor	I-GENE-Y
synthesis	O
:	O
a	O
mechanistic	O
comparison	O
of	O
vitamin	B-GENE-Y
D	I-GENE-Y
receptor	I-GENE-Y
and	O
beta	B-GENE-Y
(	I-GENE-Y
2	I-GENE-Y
)	I-GENE-Y
-	I-GENE-Y
adrenoceptor	I-GENE-Y
agonists	O
.	O

Increasing	O
nerve	B-GENE-Y
growth	I-GENE-Y
factor	I-GENE-Y
(	O
NGF	B-GENE-Y
)	O
in	O
the	O
PNS	O
is	O
a	O
rational	O
strategy	O
for	O
treating	O
certain	O
neurodegenerative	O
disorders	O
.	O

The	O
present	O
studies	O
were	O
undertaken	O
to	O
compare	O
two	O
compounds	O
,	O
a	O
vitamin	B-CHEMICAL
D	I-CHEMICAL
(	I-CHEMICAL
3	I-CHEMICAL
)	I-CHEMICAL
analogue	O
(	O
CB1093	B-CHEMICAL
)	O
with	O
minimal	O
calcaemic	O
effects	O
,	O
and	O
clenbuterol	B-CHEMICAL
,	O
a	O
long	O
-	O
acting	O
beta	B-GENE-Y
(	I-GENE-Y
2	I-GENE-Y
)	I-GENE-Y
-	I-GENE-Y
adrenoceptor	I-GENE-Y
agonist	O
,	O
both	O
of	O
which	O
induce	O
NGF	B-GENE-Y
synthesis	O
in	O
vivo	O
.	O

Clenbuterol	B-CHEMICAL
caused	O
significant	O
increases	O
in	O
both	O
NGF	B-GENE-Y
mRNA	O
and	O
protein	O
in	O
3T3	O
cells	O
;	O
with	O
maxima	O
at	O
10	O
nM	O
and	O
at	O
8	O
-	O
12	O
h	O
exposure	O
.	O

Effects	O
of	O
clenbuterol	B-CHEMICAL
on	O
NGF	B-GENE-Y
mRNA	O
were	O
antagonized	O
by	O
propranolol	B-CHEMICAL
.	O

Mobility	O
shift	O
assays	O
on	O
whole	O
cell	O
extracts	O
showed	O
that	O
clenbuterol	B-CHEMICAL
increased	O
AP1	B-GENE-Y
binding	O
in	O
3T3	O
cells	O
prior	O
to	O
increasing	O
NGF	B-GENE-Y
synthesis	O
.	O

Clenbuterol	B-CHEMICAL
was	O
without	O
effect	O
on	O
NGF	B-GENE-Y
mRNA	O
levels	O
in	O
L929	O
cells	O
,	O
whereas	O
CB1093	B-CHEMICAL
caused	O
significant	O
increases	O
in	O
both	O
NGF	B-GENE-Y
mRNA	O
and	O
protein	O
levels	O
in	O
both	O
3T3	O
and	O
L929	O
cells	O
.	O

Stimulation	O
was	O
almost	O
maximal	O
at	O
24	O
h	O
exposure	O
and	O
was	O
sustained	O
for	O
at	O
least	O
72	O
h	O
.	O

The	O
magnitude	O
of	O
the	O
increase	O
was	O
much	O
greater	O
in	O
L929	O
(	O
700	O
%	O
increase	O
)	O
than	O
in	O
3T3	O
cells	O
(	O
80	O
%	O
)	O
.	O

Binding	O
to	O
the	O
vitamin	B-GENE-Y
D	I-GENE-Y
nuclear	I-GENE-Y
receptor	I-GENE-Y
(	O
VDR	B-GENE-Y
)	O
,	O
which	O
acts	O
as	O
a	O
transcription	O
factor	O
itself	O
,	O
was	O
increased	O
as	O
early	O
as	O
30	O
min	O
after	O
exposure	O
to	O
of	O
CB1093	B-CHEMICAL
and	O
maintained	O
up	O
to	O
24	O
h	O
.	O

Increased	O
VDR	B-GENE-Y
binding	O
preceded	O
increased	O
NGF	B-GENE-Y
mRNA	O
.	O

A	O
150	O
%	O
increase	O
in	O
AP	B-GENE-Y
-	I-GENE-Y
1	I-GENE-Y
binding	O
was	O
also	O
evident	O
.	O

This	O
study	O
demonstrates	O
that	O
CB1093	B-CHEMICAL
and	O
clenbuterol	B-CHEMICAL
stimulate	O
NGF	B-GENE-Y
levels	O
in	O
vitro	O
and	O
that	O
AP	B-GENE-Y
-	I-GENE-Y
1	I-GENE-Y
binding	O
could	O
be	O
a	O
commonality	O
between	O
the	O
mechanism	O
of	O
NGF	B-GENE-Y
induction	O
of	O
these	O
two	O
compounds	O
.	O

Protective	O
effect	O
of	O
halothane	B-CHEMICAL
anesthesia	O
on	O
retinal	O
light	O
damage	O
:	O
inhibition	O
of	O
metabolic	O
rhodopsin	B-GENE-N
regeneration	O
.	O

PURPOSE	O
:	O
To	O
determine	O
whether	O
the	O
volatile	O
anesthetic	O
halothane	B-CHEMICAL
protects	O
against	O
light	O
-	O
induced	O
photoreceptor	B-GENE-N
degeneration	O
in	O
the	O
rodent	O
retina	O
.	O

METHODS	O
:	O
Albino	O
mice	O
and	O
rats	O
were	O
anesthetized	O
with	O
halothane	B-CHEMICAL
and	O
exposed	O
to	O
high	O
levels	O
of	O
white	O
or	O
blue	O
light	O
.	O

Nonanesthetized	O
animals	O
served	O
as	O
controls	O
.	O

Retinal	O
morphology	O
was	O
assessed	O
by	O
light	O
microscopy	O
,	O
and	O
apoptosis	O
of	O
photoreceptor	B-GENE-N
cells	O
was	O
verified	O
by	O
detection	O
of	O
fragmented	O
genomic	O
DNA	O
and	O
in	O
situ	O
staining	O
of	O
apoptotic	O
nuclei	O
(	O
TUNEL	O
assay	O
)	O
.	O

Rhodopsin	B-GENE-N
regeneration	O
after	O
bleaching	O
was	O
determined	O
by	O
measuring	O
rhodopsin	B-GENE-N
levels	O
in	O
retinas	O
of	O
mice	O
or	O
rats	O
at	O
different	O
time	O
points	O
in	O
darkness	O
.	O

RESULTS	O
:	O
Halothane	B-CHEMICAL
anesthesia	O
reversibly	O
inhibited	O
metabolic	O
rhodopsin	B-GENE-N
regeneration	O
and	O
thus	O
prevented	O
rhodopsin	B-GENE-N
from	O
absorbing	O
high	O
numbers	O
of	O
photons	O
during	O
light	O
exposure	O
.	O

Consequently	O
,	O
photoreceptors	B-GENE-N
of	O
mice	O
and	O
rats	O
anesthetized	O
with	O
halothane	B-CHEMICAL
were	O
completely	O
protected	O
against	O
degeneration	O
induced	O
by	O
white	O
light	O
.	O

In	O
remarkable	O
contrast	O
,	O
however	O
,	O
halothane	B-CHEMICAL
anesthesia	O
did	O
not	O
protect	O
against	O
blue	O
-	O
light	O
-	O
induced	O
photoreceptor	O
cell	O
death	O
.	O

CONCLUSIONS	O
:	O
After	O
the	O
initial	O
bleach	O
,	O
halothane	B-CHEMICAL
impeded	O
photon	O
absorption	O
by	O
rhodopsin	B-GENE-N
by	O
inhibiting	O
metabolic	O
rhodopsin	B-GENE-N
regeneration	O
.	O

Apparently	O
,	O
the	O
rhodopsin	B-GENE-N
-	O
mediated	O
uptake	O
of	O
the	O
critical	O
number	O
of	O
photons	O
to	O
initiate	O
white	O
light	O
-	O
induced	O
retinal	O
degeneration	O
was	O
prevented	O
.	O

In	O
contrast	O
,	O
halothane	B-CHEMICAL
did	O
not	O
protect	O
the	O
retina	O
against	O
blue	O
light	O
.	O

Blue	O
light	O
can	O
efficiently	O
restore	O
functional	O
rhodopsin	B-GENE-N
from	O
bleaching	O
intermediates	O
through	O
a	O
process	O
termed	O
photoreversal	O
of	O
bleaching	O
.	O

This	O
process	O
does	O
not	O
depend	O
on	O
the	O
visual	O
cycle	O
via	O
the	O
pigment	O
epithelium	O
but	O
nevertheless	O
enables	O
rhodopsin	B-GENE-N
molecules	O
to	O
absorb	O
the	O
critical	O
number	O
of	O
photons	O
required	O
to	O
induce	O
retinal	O
degeneration	O
.	O

Comparison	O
of	O
antidepressant	O
activity	O
in	O
4	O
-	O
and	O
40	O
-	O
week	O
-	O
old	O
male	O
mice	O
in	O
the	O
forced	O
swimming	O
test	O
:	O
involvement	O
of	O
5	B-GENE-Y
-	I-GENE-Y
HT1A	I-GENE-Y
and	O
5	B-GENE-Y
-	I-GENE-Y
HT1B	I-GENE-Y
receptors	O
in	O
old	O
mice	O
.	O

RATIONALE	O
:	O
A	O
recent	O
study	O
suggested	O
that	O
selective	O
serotonin	B-CHEMICAL
reuptake	O
inhibitors	O
were	O
inactive	O
in	O
40	O
-	O
week	O
-	O
old	O
male	O
mice	O
in	O
the	O
mouse	O
forced	O
swimming	O
test	O
,	O
possibly	O
because	O
of	O
alteration	O
of	O
5	B-GENE-N
-	I-GENE-N
HT1	I-GENE-N
receptors	O
.	O

OBJECTIVES	O
:	O
The	O
present	O
study	O
was	O
aimed	O
at	O
investigating	O
the	O
action	O
of	O
various	O
antidepressant	O
drugs	O
in	O
4	O
-	O
and	O
40	O
-	O
week	O
-	O
old	O
male	O
mice	O
using	O
the	O
mouse	O
forced	O
swimming	O
test	O
and	O
determining	O
the	O
involvement	O
of	O
5	B-GENE-Y
-	I-GENE-Y
HT1A	I-GENE-Y
and	O
5	B-GENE-Y
-	I-GENE-Y
HT1B	I-GENE-Y
receptors	O
mediating	O
the	O
effects	O
.	O

METHODS	O
:	O
Different	O
classes	O
of	O
antidepressants	O
[	O
imipramine	B-CHEMICAL
(	O
tricyclic	B-CHEMICAL
)	O
,	O
maprotiline	B-CHEMICAL
(	O
noradrenline	B-CHEMICAL
reuptake	O
inhibitor	O
)	O
,	O
venlafaxine	B-CHEMICAL
(	O
mixed	O
serotonin	B-CHEMICAL
and	O
noradrenaline	B-CHEMICAL
reuptake	O
inhibitors	O
)	O
,	O
fluvoxamine	B-CHEMICAL
and	O
sertraline	B-CHEMICAL
(	O
selective	O
serotonin	B-CHEMICAL
reuptake	O
inhibitor	O
)	O
]	O
were	O
tested	O
in	O
the	O
same	O
randomised	O
experimental	O
session	O
,	O
alone	O
and	O
in	O
combination	O
with	O
5	B-GENE-Y
-	I-GENE-Y
HT1A	I-GENE-Y
and	O
5	B-GENE-Y
-	I-GENE-Y
HT1B	I-GENE-Y
receptor	O
agonists	O
[	O
buspirone	B-CHEMICAL
(	O
partial	O
5	B-GENE-Y
-	I-GENE-Y
HT1A	I-GENE-Y
agonist	O
)	O
,	O
anpirtoline	B-CHEMICAL
(	O
5	B-GENE-Y
-	I-GENE-Y
HT1B	I-GENE-Y
agonist	O
)	O
]	O
in	O
the	O
mouse	O
forced	O
swimming	O
test	O
.	O

RESULTS	O
:	O
All	O
antidepressants	O
were	O
found	O
to	O
be	O
active	O
in	O
the	O
mouse	O
forced	O
swimming	O
test	O
in	O
4	O
-	O
week	O
-	O
old	O
mice	O
and	O
40	O
-	O
week	O
-	O
old	O
mice	O
,	O
with	O
the	O
exception	O
of	O
fluvoxamine	B-CHEMICAL
in	O
the	O
40	O
-	O
week	O
-	O
old	O
mice	O
.	O

The	O
anti	O
-	O
immobility	O
effect	O
after	O
antidepressant	O
administration	O
was	O
higher	O
in	O
4	O
-	O
week	O
-	O
old	O
male	O
mice	O
than	O
in	O
40	O
-	O
week	O
-	O
old	O
male	O
mice	O
.	O

Venlafaxine	B-CHEMICAL
is	O
the	O
most	O
active	O
antidepressant	O
drug	O
in	O
40	O
-	O
week	O
-	O
old	O
mice	O
.	O

Prior	O
administration	O
of	O
buspirone	B-CHEMICAL
(	O
0	O
.	O
06	O
mg	O
/	O
kg	O
,	O
i	O
.	O
p	O
.	O
)	O
or	O
anpirtoline	B-CHEMICAL
(	O
1	O
mg	O
/	O
kg	O
,	O
i	O
.	O
p	O
.	O
)	O
enhanced	O
the	O
antidepressant	O
-	O
like	O
effects	O
in	O
4	O
-	O
week	O
-	O
old	O
mice	O
(	O
except	O
in	O
the	O
case	O
of	O
sertraline	B-CHEMICAL
,	O
8	O
mg	O
/	O
kg	O
)	O
.	O

In	O
elderly	O
mice	O
,	O
only	O
prior	O
administration	O
of	O
buspirone	B-CHEMICAL
enhanced	O
the	O
antidepressant	O
-	O
like	O
effects	O
of	O
fluvoxamine	B-CHEMICAL
.	O

A	O
neurochemical	O
study	O
showed	O
that	O
significantly	O
higher	O
serotonin	B-CHEMICAL
and	O
dopamine	B-CHEMICAL
concentrations	O
were	O
found	O
in	O
40	O
-	O
week	O
-	O
old	O
control	O
mice	O
brains	O
than	O
4	O
-	O
week	O
-	O
old	O
control	O
mice	O
brains	O
but	O
that	O
the	O
noradrenaline	B-CHEMICAL
concentration	O
is	O
higher	O
in	O
4	O
-	O
week	O
-	O
old	O
mice	O
.	O

CONCLUSION	O
:	O
Tricyclic	B-CHEMICAL
,	O
noradrenaline	B-CHEMICAL
reuptake	O
inhibitors	O
and	O
serotonin	B-CHEMICAL
reuptake	O
inhibitors	O
are	O
more	O
active	O
in	O
4	O
-	O
week	O
-	O
old	O
mice	O
than	O
40	O
-	O
week	O
-	O
old	O
mice	O
.	O

Our	O
results	O
suggested	O
that	O
5	B-GENE-Y
-	I-GENE-Y
HT1B	I-GENE-Y
receptors	O
may	O
be	O
more	O
altered	O
than	O
5	B-GENE-Y
-	I-GENE-Y
HT1A	I-GENE-Y
receptors	O
in	O
40	O
-	O
week	O
-	O
old	O
mice	O
.	O

Cytochrome	B-GENE-N
P450	I-GENE-N
4A	I-GENE-N
,	O
peroxisomal	O
enzymes	O
and	O
nicotinamide	B-CHEMICAL
cofactors	O
in	O
koala	O
liver	O
.	O

We	O
have	O
examined	O
hepatic	O
levels	O
of	O
microsomal	O
lauric	B-GENE-N
acid	I-GENE-N
hydroxylase	I-GENE-N
activity	O
and	O
cyanide	O
-	O
insensitive	O
palmitoyl	O
coenzyme	O
A	O
oxidative	O
activity	O
in	O
koala	O
(	O
Phascolarctos	O
cinereus	O
)	O
and	O
tammar	O
wallaby	O
(	O
Macropus	O
eugenii	O
)	O
and	O
compared	O
our	O
results	O
to	O
those	O
determined	O
in	O
rat	O
.	O

Microsomal	O
lauric	B-CHEMICAL
acid	I-CHEMICAL
hydroxylation	O
was	O
significantly	O
higher	O
in	O
koala	O
than	O
in	O
tammar	O
wallaby	O
or	O
rat	O
.	O

However	O
,	O
cyanide	O
-	O
insensitive	O
palmitoyl	O
-	O
CoA	O
oxidation	O
was	O
absent	O
in	O
the	O
koala	O
.	O

We	O
have	O
also	O
determined	O
the	O
hepatic	O
nicotinamide	B-CHEMICAL
cofactors	O
in	O
these	O
species	O
.	O

Hepatic	O
nicotinamide	B-CHEMICAL
-	I-CHEMICAL
adenine	I-CHEMICAL
dinucleotide	I-CHEMICAL
(	O
NAD	B-CHEMICAL
)	O
and	O
the	O
ratio	O
of	O
NAD	B-CHEMICAL
/	O
nicotinamide	B-CHEMICAL
-	I-CHEMICAL
adenine	I-CHEMICAL
dinucleotide	I-CHEMICAL
phosphate	I-CHEMICAL
(	O
NADP	B-CHEMICAL
)	O
were	O
higher	O
in	O
koala	O
than	O
in	O
tammar	O
wallaby	O
and	O
rat	O
liver	O
.	O

Reverse	O
transcription	O
of	O
koala	O
liver	O
mRNA	O
,	O
followed	O
by	O
polymerase	O
chain	O
reaction	O
using	O
primers	O
based	O
on	O
highly	O
conserved	O
areas	O
in	O
the	O
CYP4A	B-GENE-N
family	O
led	O
to	O
the	O
cloning	O
of	O
a	O
partial	O
,	O
near	O
full	O
length	O
,	O
cDNA	O
clone	O
with	O
approximately	O
70	O
%	O
nucleotide	B-CHEMICAL
and	O
deduced	O
amino	B-CHEMICAL
acid	I-CHEMICAL
sequence	O
identity	O
to	O
human	B-GENE-Y
CYP4A11	I-GENE-Y
.	O

The	O
CYP	B-GENE-N
has	O
been	O
named	O
CYP4A15	B-GENE-Y
.	O

Gemcitabine	B-CHEMICAL
and	O
Pemetrexed	B-CHEMICAL
disodium	I-CHEMICAL
in	O
treating	O
breast	O
cancer	O
.	O

Pemetrexed	B-CHEMICAL
disodium	I-CHEMICAL
(	O
Alimta	B-CHEMICAL
,	O
LY231514	B-CHEMICAL
)	O
is	O
a	O
novel	O
,	O
multitargeted	O
antifolate	O
that	O
inhibits	O
thymidylate	B-GENE-Y
synthase	I-GENE-Y
,	O
dihydrofolate	B-GENE-Y
reductase	I-GENE-Y
,	O
and	O
glycinamide	B-GENE-Y
ribonucleotide	I-GENE-Y
formyl	I-GENE-Y
transferase	I-GENE-Y
.	O

This	O
agent	O
is	O
broadly	O
active	O
in	O
a	O
wide	O
variety	O
of	O
solid	O
tumors	O
,	O
including	O
breast	O
cancer	O
.	O

Pemetrexed	B-CHEMICAL
disodium	I-CHEMICAL
has	O
also	O
shown	O
clinically	O
relevant	O
activity	O
in	O
combination	O
with	O
gemcitabine	B-CHEMICAL
(	O
Gemzar	B-CHEMICAL
)	O
.	O

This	O
combination	O
is	O
being	O
evaluated	O
for	O
the	O
treatment	O
of	O
metastatic	O
breast	O
cancer	O
.	O

Distal	O
bowel	O
selectivity	O
in	O
the	O
chemoprevention	O
of	O
experimental	O
colon	O
carcinogenesis	O
by	O
the	O
non	O
-	O
steroidal	B-CHEMICAL
anti	O
-	O
inflammatory	O
drug	O
nabumetone	B-CHEMICAL
.	O

Use	O
of	O
non	O
-	O
steroidal	B-CHEMICAL
anti	O
-	O
inflammatory	O
drugs	O
(	O
NSAIDs	O
)	O
for	O
chemoprevention	O
of	O
colon	O
cancer	O
has	O
been	O
hindered	O
by	O
their	O
potential	O
gastro	O
-	O
intestinal	O
toxicity	O
.	O

Nabumetone	B-CHEMICAL
,	O
which	O
is	O
approximately	O
10	O
to	O
36	O
times	O
safer	O
than	O
conventional	O
NSAIDs	O
,	O
was	O
evaluated	O
in	O
2	O
models	O
of	O
experimental	O
colon	O
carcinogenesis	O
.	O

In	O
azoxymethane	B-CHEMICAL
(	O
AOM	B-CHEMICAL
)	O
-	O
treated	O
Fisher	O
344	O
rats	O
,	O
nabumetone	B-CHEMICAL
caused	O
dose	O
-	O
dependent	O
inhibition	O
of	O
aberrant	O
crypt	O
foci	O
(	O
ACF	O
)	O
,	O
with	O
750	O
and	O
1	O
,	O
500	O
ppm	O
resulting	O
in	O
15	O
%	O
and	O
37	O
%	O
reductions	O
,	O
respectively	O
(	O
p	O
<	O
0	O
.	O
05	O
)	O
.	O

Moreover	O
,	O
complex	O
ACF	O
were	O
reduced	O
by	O
48	O
%	O
in	O
the	O
latter	O
group	O
.	O

MIN	O
mice	O
studies	O
confirmed	O
the	O
chemopreventive	O
efficacy	O
of	O
nabumetone	B-CHEMICAL
,	O
with	O
900	O
ppm	O
suppressing	O
approximately	O
half	O
of	O
the	O
intestinal	O
tumors	O
.	O

Interestingly	O
,	O
inhibition	O
of	O
intermediate	O
biomarkers	O
in	O
both	O
models	O
was	O
markedly	O
greater	O
in	O
the	O
distal	O
than	O
the	O
proximal	O
bowel	O
.	O

To	O
mechanistically	O
evaluate	O
this	O
regional	O
selectivity	O
,	O
we	O
assessed	O
cyclo	B-GENE-N
-	I-GENE-N
oxygenase	I-GENE-N
-	I-GENE-N
2	I-GENE-N
(	O
COX	B-GENE-N
-	I-GENE-N
2	I-GENE-N
)	O
expression	O
in	O
the	O
uninvolved	O
mucosa	O
and	O
demonstrated	O
a	O
3	O
-	O
to	O
4	O
-	O
fold	O
excess	O
in	O
the	O
distal	O
relative	O
to	O
the	O
proximal	O
bowel	O
in	O
both	O
MIN	O
mice	O
and	O
AOM	B-CHEMICAL
-	O
treated	O
rats	O
.	O

We	O
then	O
investigated	O
another	O
putative	O
NSAID	O
target	O
,	O
peroxisome	B-GENE-N
proliferator	I-GENE-N
-	I-GENE-N
activated	I-GENE-N
receptor	I-GENE-N
-	I-GENE-N
delta	I-GENE-N
(	O
PPAR	B-GENE-N
-	I-GENE-N
delta	I-GENE-N
)	O
and	O
demonstrated	O
up	O
-	O
regulation	O
during	O
AOM	O
-	O
induced	O
colonic	O
tumorigenesis	O
.	O

Furthermore	O
,	O
in	O
pre	O
-	O
neoplastic	O
mucosa	O
,	O
there	O
was	O
a	O
3	O
-	O
fold	O
excess	O
of	O
PPAR	B-GENE-N
-	I-GENE-N
delta	I-GENE-N
in	O
the	O
distal	O
colon	O
.	O

We	O
demonstrate	O
that	O
nabumetone	B-CHEMICAL
is	O
an	O
effective	O
protective	O
agent	O
in	O
both	O
experimental	O
models	O
of	O
colon	O
carcinogenesis	O
.	O

The	O
striking	O
distal	O
predilection	O
of	O
nabumetone	B-CHEMICAL
may	O
be	O
,	O
at	O
least	O
partially	O
,	O
explained	O
by	O
distal	O
bowel	O
over	O
-	O
expression	O
of	O
COX	B-GENE-N
-	I-GENE-N
2	I-GENE-N
and	O
PPAR	B-GENE-N
-	I-GENE-N
delta	I-GENE-N
.	O

Nuclear	O
diacylglycerol	B-GENE-Y
kinase	I-GENE-Y
-	I-GENE-Y
theta	I-GENE-Y
is	O
activated	O
in	O
response	O
to	O
alpha	B-GENE-Y
-	I-GENE-Y
thrombin	I-GENE-Y
.	O

Currently	O
,	O
there	O
is	O
substantial	O
evidence	O
that	O
nuclear	O
lipid	O
metabolism	O
plays	O
a	O
critical	O
role	O
in	O
a	O
number	O
of	O
signal	O
transduction	O
cascades	O
.	O

Previous	O
work	O
from	O
our	O
laboratory	O
showed	O
that	O
stimulation	O
of	O
quiescent	O
fibroblasts	O
with	O
alpha	B-GENE-Y
-	I-GENE-Y
thrombin	I-GENE-Y
leads	O
to	O
the	O
production	O
of	O
two	O
lipid	O
second	O
messengers	O
in	O
the	O
nucleus	O
:	O
an	O
increase	O
in	O
nuclear	O
diacylglycerol	B-CHEMICAL
mass	O
and	O
an	O
activation	O
of	O
phospholipase	O
D	O
,	O
which	O
catalyzes	O
the	O
hydrolysis	O
of	O
phosphatidylcholine	B-CHEMICAL
to	O
generate	O
phosphatidic	B-CHEMICAL
acid	I-CHEMICAL
.	O

Diacylglycerol	B-GENE-N
kinase	I-GENE-N
(	O
DGK	B-GENE-N
)	O
catalyzes	O
the	O
conversion	O
of	O
diacylglycerol	B-CHEMICAL
to	O
phosphatidic	B-CHEMICAL
acid	I-CHEMICAL
,	O
making	O
it	O
an	O
attractive	O
candidate	O
for	O
a	O
signal	O
transduction	O
component	O
.	O

There	O
is	O
substantial	O
evidence	O
that	O
this	O
activity	O
is	O
indeed	O
regulated	O
in	O
a	O
number	O
of	O
signaling	O
cascades	O
(	O
reviewed	O
by	O
van	O
Blitterswijk	O
,	O
W	O
.	O
J	O
.	O
,	O
and	O
Houssa	O
,	O
B	O
.	O
(	O
1999	O
)	O
Chem	O
.	O
Phys	O
.	O
Lipids	O
98	O
,	O
95	O
-	O
108	O
)	O
.	O

In	O
this	O
report	O
,	O
we	O
show	O
that	O
the	O
addition	O
of	O
alpha	B-GENE-Y
-	I-GENE-Y
thrombin	I-GENE-Y
to	O
quiescent	O
IIC9	O
fibroblasts	O
results	O
in	O
an	O
increase	O
in	O
nuclear	O
DGK	B-GENE-N
activity	O
.	O

The	O
examination	O
of	O
nuclei	O
isolated	O
from	O
quiescent	O
IIC9	O
cells	O
indicates	O
that	O
DGK	B-GENE-Y
-	I-GENE-Y
theta	I-GENE-Y
and	O
DGK	B-GENE-Y
-	I-GENE-Y
delta	I-GENE-Y
are	O
both	O
present	O
.	O

We	O
took	O
advantage	O
of	O
the	O
previous	O
observations	O
that	O
phosphatidylserine	B-CHEMICAL
inhibits	O
DGK	B-GENE-Y
-	I-GENE-Y
delta	I-GENE-Y
(	O
reviewed	O
by	O
Sakane	O
,	O
F	O
.	O
,	O
Imai	O
,	O
S	O
.	O
,	O
Kai	O
,	O
M	O
.	O
,	O
Wada	O
,	O
I	O
.	O
,	O
and	O
Kanoh	O
,	O
H	O
.	O
(	O
1996	O
)	O
J	O
.	O
Biol	O
.	O
Chem	O
.	O
271	O
,	O
8394	O
-	O
8401	O
)	O
,	O
and	O
constitutively	O
active	O
RhoA	B-GENE-Y
inhibits	O
DGK	B-GENE-Y
-	I-GENE-Y
theta	I-GENE-Y
(	O
reviewed	O
by	O
Houssa	O
,	O
B	O
.	O
,	O
de	O
Widt	O
,	O
J	O
.	O
,	O
Kranenburg	O
,	O
O	O
.	O
,	O
Moolenaar	O
,	O
W	O
.	O
H	O
.	O
,	O
and	O
van	O
Blitterswijk	O
,	O
W	O
.	O
J	O
.	O
(	O
1999	O
)	O
J	O
.	O
Biol	O
.	O
Chem	O
.	O
274	O
,	O
6820	O
-	O
6822	O
)	O
to	O
identify	O
the	O
activity	O
induced	O
by	O
alpha	B-GENE-Y
-	I-GENE-Y
thrombin	I-GENE-Y
.	O

Constitutively	O
active	O
RhoA	B-GENE-Y
inhibited	O
the	O
nuclear	O
stimulated	O
activity	O
,	O
whereas	O
phosphatidylserine	B-CHEMICAL
did	O
not	O
have	O
an	O
inhibitory	O
effect	O
.	O

In	O
addition	O
,	O
a	O
monoclonal	O
anti	O
-	O
DGK	B-GENE-Y
-	I-GENE-Y
theta	I-GENE-Y
antibody	O
inhibited	O
the	O
alpha	B-GENE-Y
-	I-GENE-Y
thrombin	I-GENE-Y
-	O
stimulated	O
nuclear	O
activity	O
in	O
vitro	O
.	O

These	O
results	O
demonstrate	O
that	O
DGK	B-GENE-Y
-	I-GENE-Y
theta	I-GENE-Y
is	O
the	O
isoform	O
responsive	O
to	O
alpha	B-GENE-Y
-	I-GENE-Y
thrombin	I-GENE-Y
stimulation	O
.	O

Western	O
blot	O
and	O
immunofluorescence	O
microscopy	O
analyses	O
showed	O
that	O
alpha	B-GENE-Y
-	I-GENE-Y
thrombin	I-GENE-Y
induced	O
the	O
translocation	O
of	O
DGK	B-GENE-Y
-	I-GENE-Y
theta	I-GENE-Y
to	O
the	O
nucleus	O
,	O
implicating	O
that	O
this	O
translocation	O
is	O
at	O
least	O
partly	O
responsible	O
for	O
the	O
increased	O
nuclear	O
activity	O
.	O

Taken	O
together	O
,	O
these	O
data	O
are	O
the	O
first	O
to	O
demonstrate	O
an	O
agonist	O
-	O
induced	O
activity	O
of	O
nuclear	O
DGK	B-GENE-Y
-	I-GENE-Y
theta	I-GENE-Y
activity	O
and	O
a	O
nuclear	O
localization	O
of	O
DGK	B-GENE-Y
-	I-GENE-Y
delta	I-GENE-Y
.	O

Pharmacokinetic	O
analysis	O
by	O
high	O
-	O
performance	O
liquid	O
chromatography	O
of	O
intravenous	O
nordihydroguaiaretic	B-CHEMICAL
acid	I-CHEMICAL
in	O
the	O
mouse	O
.	O

Nordihydroguaiaretic	B-CHEMICAL
acid	I-CHEMICAL
(	O
NDGA	B-CHEMICAL
)	O
has	O
been	O
shown	O
to	O
inhibit	O
both	O
5	B-GENE-Y
-	I-GENE-Y
lipoxygenase	I-GENE-Y
and	O
ornithine	B-GENE-Y
decarboxylase	I-GENE-Y
and	O
is	O
active	O
against	O
several	O
cancer	O
cell	O
lines	O
and	O
at	O
least	O
one	O
mouse	O
tumor	O
model	O
.	O

Despite	O
these	O
findings	O
,	O
there	O
have	O
been	O
no	O
reports	O
on	O
the	O
pharmacokinetics	O
of	O
NDGA	B-CHEMICAL
.	O

A	O
reverse	O
-	O
phase	O
high	O
-	O
performance	O
liquid	O
chromatography	O
(	O
HPLC	O
)	O
method	O
was	O
developed	O
to	O
detect	O
NDGA	B-CHEMICAL
in	O
mouse	O
plasma	O
.	O

The	O
limit	O
of	O
detection	O
of	O
this	O
method	O
was	O
0	O
.	O
5	O
microg	O
/	O
ml	O
.	O

Administration	O
of	O
NDGA	B-CHEMICAL
(	O
50	O
mg	O
/	O
kg	O
,	O
i	O
.	O
v	O
.	O
)	O
to	O
mice	O
resulted	O
in	O
a	O
peak	O
plasma	O
concentration	O
of	O
14	O
.	O
7	O
microg	O
/	O
ml	O
.	O

The	O
terminal	O
half	O
-	O
life	O
of	O
NDGA	B-CHEMICAL
was	O
135	O
.	O
0	O
min	O
with	O
a	O
clearance	O
of	O
201	O
.	O
9	O
ml	O
/	O
min	O
x	O
kg	O
.	O

Vasoconstrictive	O
drugs	O
increase	O
carbonic	B-GENE-Y
anhydrase	I-GENE-Y
I	I-GENE-Y
in	O
vascular	O
smooth	O
muscle	O
while	O
vasodilating	O
drugs	O
reduce	O
the	O
activity	O
of	O
this	O
isozyme	O
by	O
a	O
direct	O
mechanism	O
of	O
action	O
.	O

Carbonic	B-GENE-N
anhydrase	I-GENE-N
(	O
CA	B-GENE-N
)	O
is	O
a	O
zinc	B-CHEMICAL
enzyme	O
that	O
catalyses	O
the	O
reversible	O
hydration	O
reaction	O
of	O
CO2	B-CHEMICAL
and	O
plays	O
a	O
major	O
role	O
in	O
the	O
acid	O
-	O
base	O
balance	O
.	O

We	O
have	O
previously	O
shown	O
that	O
certain	O
vasoconstrictive	O
therapeutic	O
agents	O
increase	O
CA	B-GENE-Y
I	I-GENE-Y
activity	O
whereas	O
vasodilating	O
drugs	O
reduce	O
the	O
activity	O
of	O
this	O
isozyme	O
by	O
a	O
direct	O
mechanism	O
of	O
action	O
.	O

In	O
this	O
paper	O
we	O
studied	O
the	O
effect	O
of	O
other	O
vasoconstrictive	O
and	O
vasodilating	O
agents	O
on	O
CA	B-GENE-Y
I	I-GENE-Y
activity	O
in	O
order	O
to	O
elucidate	O
the	O
involvement	O
of	O
vascular	O
smooth	O
muscle	O
CA	B-GENE-Y
I	I-GENE-Y
in	O
vasoconstrictive	O
and	O
vasodilating	O
processes	O
.	O

We	O
studied	O
the	O
in	O
vitro	O
effects	O
of	O
noradrenaline	B-CHEMICAL
,	O
prostaglandin	B-CHEMICAL
F2	I-CHEMICAL
alpha	I-CHEMICAL
,	O
thromboxane	B-CHEMICAL
A2	I-CHEMICAL
,	O
leukotriene	B-CHEMICAL
B4	I-CHEMICAL
,	O
angiotensin	B-CHEMICAL
II	I-CHEMICAL
,	O
vasopressin	B-CHEMICAL
,	O
indomethacin	B-CHEMICAL
,	O
prazosin	B-CHEMICAL
,	O
hydralazine	B-CHEMICAL
,	O
clonidine	B-CHEMICAL
,	O
reserpine	B-CHEMICAL
,	O
prostaglandin	B-CHEMICAL
I2	I-CHEMICAL
,	O
indapamide	B-CHEMICAL
,	O
furosemide	B-CHEMICAL
,	O
amlodipine	B-CHEMICAL
,	O
verapamil	B-CHEMICAL
and	O
irbesartan	B-CHEMICAL
on	O
purified	O
human	B-GENE-Y
red	I-GENE-Y
blood	I-GENE-Y
cell	I-GENE-Y
CA	I-GENE-Y
I	I-GENE-Y
and	O
vascular	O
smooth	O
muscle	O
CA	B-GENE-Y
I	I-GENE-Y
isolated	O
from	O
rabbits	O
.	O

In	O
vivo	O
,	O
we	O
selected	O
six	O
groups	O
of	O
five	O
rabbits	O
each	O
,	O
which	O
were	O
administered	O
the	O
following	O
substances	O
in	O
acute	O
experiments	O
:	O
orciprenaline	B-CHEMICAL
(	O
group	O
1	O
)	O
,	O
desmopressin	B-CHEMICAL
(	O
group	O
2	O
)	O
,	O
verapamil	B-CHEMICAL
(	O
group	O
3	O
)	O
,	O
irbesartan	B-CHEMICAL
(	O
group	O
4	O
)	O
,	O
acetazolamide	B-CHEMICAL
(	O
group	O
5	O
)	O
and	O
placebo	O
(	O
control	O
group	O
)	O
.	O

Vascular	O
smooth	O
muscle	O
CA	B-GENE-Y
I	I-GENE-Y
activity	O
and	O
systolic	O
blood	O
pressure	O
were	O
determined	O
and	O
compared	O
with	O
those	O
of	O
the	O
control	O
group	O
.	O

In	O
vitro	O
results	O
showed	O
that	O
all	O
the	O
vasoconstrictive	O
agents	O
studied	O
increased	O
purified	O
and	O
human	B-GENE-Y
erythrocyte	I-GENE-Y
CA	I-GENE-Y
I	I-GENE-Y
activity	O
as	O
well	O
as	O
vascular	O
smooth	O
muscle	O
CA	B-GENE-Y
I	I-GENE-Y
,	O
while	O
vasodilating	O
substances	O
reduced	O
the	O
activity	O
of	O
isozyme	O
by	O
a	O
direct	O
mechanism	O
of	O
action	O
.	O

The	O
same	O
results	O
obtained	O
in	O
vivo	O
showed	O
that	O
activation	O
of	O
vascular	O
smooth	O
muscle	O
CA	B-GENE-Y
I	I-GENE-Y
increased	O
blood	O
pressure	O
while	O
its	O
inhibition	O
reduced	O
blood	O
pressure	O
.	O

The	O
results	O
of	O
this	O
study	O
suggest	O
that	O
pHi	O
changes	O
,	O
induced	O
by	O
activating	O
or	O
inhibiting	O
CA	B-GENE-Y
I	I-GENE-Y
in	O
vascular	O
smooth	O
muscle	O
,	O
might	O
be	O
responsible	O
for	O
changes	O
in	O
vascular	O
tonus	O
.	O

Neuroparalysis	O
and	O
oxime	B-CHEMICAL
efficacy	O
in	O
organophosphate	B-CHEMICAL
poisoning	O
:	O
a	O
study	O
of	O
butyrylcholinesterase	B-GENE-Y
.	O

The	O
temporal	O
profile	O
of	O
butyrylcholinesterase	B-GENE-Y
(	O
BuChE	B-GENE-Y
)	O
and	O
in	O
vitro	O
pralidoxime	B-CHEMICAL
-	O
reactivated	O
BuChE	B-GENE-Y
was	O
studied	O
in	O
a	O
cohort	O
of	O
25	O
organophosphate	B-CHEMICAL
-	O
poisoned	O
patients	O
to	O
examine	O
their	O
relationship	O
to	O
the	O
development	O
of	O
intermediate	O
syndrome	O
and	O
to	O
understand	O
reasons	O
for	O
lack	O
of	O
efficacy	O
of	O
oxime	B-CHEMICAL
treatment	O
.	O

The	O
clinical	O
severity	O
of	O
poisoning	O
(	O
assessed	O
by	O
the	O
Namba	O
Scale	O
)	O
correlated	O
significantly	O
with	O
the	O
severity	O
of	O
intermediate	O
syndrome	O
.	O

BuChE	B-GENE-Y
activity	O
increased	O
significantly	O
over	O
time	O
and	O
showed	O
significant	O
relationship	O
to	O
muscle	O
power	O
.	O

The	O
temporal	O
profile	O
of	O
the	O
enzyme	O
was	O
correlated	O
to	O
the	O
clinical	O
severity	O
of	O
poisoning	O
.	O

Reactivation	O
potentials	O
of	O
BuChE	B-GENE-Y
(	O
the	O
difference	O
between	O
oxime	B-CHEMICAL
-	O
reactivated	O
and	O
-	O
unreactivated	O
enzyme	O
activity	O
)	O
declined	O
significantly	O
with	O
time	O
after	O
organophosphate	B-CHEMICAL
ingestion	O
.	O

The	O
reactivation	O
potential	O
of	O
the	O
enzyme	O
at	O
admission	O
decreased	O
significantly	O
with	O
increasing	O
severity	O
of	O
poisoning	O
and	O
was	O
lower	O
in	O
patients	O
who	O
developed	O
intermediate	O
syndrome	O
.	O

Patients	O
who	O
received	O
oxime	B-CHEMICAL
prior	O
to	O
hospitalization	O
had	O
a	O
higher	O
rate	O
of	O
intermediate	O
syndrome	O
and	O
lower	O
levels	O
of	O
BuChE	B-GENE-Y
at	O
admission	O
than	O
those	O
who	O
had	O
not	O
.	O

The	O
study	O
suggests	O
that	O
(	O
i	O
)	O
BuChE	B-GENE-Y
reflects	O
the	O
clinical	O
course	O
of	O
poisoning	O
,	O
confirming	O
earlier	O
studies	O
;	O
(	O
ii	O
)	O
intermediate	O
syndrome	O
may	O
be	O
associated	O
with	O
a	O
persistent	O
inhibition	O
of	O
BuChE	B-GENE-Y
;	O
and	O
(	O
iii	O
)	O
the	O
lack	O
of	O
oxime	B-CHEMICAL
efficacy	O
in	O
our	O
patients	O
maybe	O
due	O
to	O
their	O
severity	O
of	O
poisoning	O
and	O
the	O
timing	O
of	O
oxime	B-CHEMICAL
treatment	O
.	O

Potent	O
alpha	B-GENE-Y
(	I-GENE-Y
2A	I-GENE-Y
)	I-GENE-Y
-	I-GENE-Y
adrenoceptor	I-GENE-Y
-	O
mediated	O
vasoconstriction	O
by	O
brimonidine	B-CHEMICAL
in	O
porcine	O
ciliary	O
arteries	O
.	O

PURPOSE	O
:	O
An	O
investigation	O
into	O
whether	O
alpha	B-GENE-N
(	I-GENE-N
2	I-GENE-N
)	I-GENE-N
-	I-GENE-N
adrenoceptor	I-GENE-N
agonists	O
induce	O
contractions	O
in	O
the	O
porcine	O
ciliary	O
arteries	O
and	O
to	O
characterize	O
the	O
functional	O
receptor	O
subtype	O
mediating	O
these	O
responses	O
.	O

METHODS	O
:	O
Isolated	O
arteries	O
from	O
the	O
intraocular	O
part	O
of	O
the	O
porcine	O
ciliary	O
artery	O
were	O
suspended	O
in	O
microvascular	O
myographs	O
for	O
isometric	O
tension	O
recording	O
.	O

The	O
segments	O
were	O
contracted	O
with	O
the	O
alpha	B-GENE-N
(	I-GENE-N
2	I-GENE-N
)	I-GENE-N
-	I-GENE-N
adrenoceptor	I-GENE-N
agonists	O
brimonidine	B-CHEMICAL
,	O
apraclonidine	B-CHEMICAL
,	O
and	O
oxymetazoline	B-CHEMICAL
.	O

To	O
determine	O
which	O
subtypes	O
of	O
the	O
alpha	B-GENE-N
(	I-GENE-N
2	I-GENE-N
)	I-GENE-N
-	I-GENE-N
adrenoceptor	I-GENE-N
mediate	O
this	O
contraction	O
,	O
antagonists	O
subselective	O
for	O
the	O
different	O
alpha	B-GENE-N
(	I-GENE-N
2	I-GENE-N
)	I-GENE-N
-	I-GENE-N
adrenoceptors	I-GENE-N
were	O
added	O
to	O
the	O
vessel	O
bath	O
before	O
concentration	O
-	O
response	O
curves	O
for	O
brimonidine	B-CHEMICAL
were	O
obtained	O
.	O

The	O
following	O
alpha	B-GENE-N
(	I-GENE-N
2	I-GENE-N
)	I-GENE-N
-	I-GENE-N
adrenoceptor	I-GENE-N
antagonists	O
were	O
applied	O
:	O
BRL44408	B-CHEMICAL
(	O
alpha	B-GENE-Y
(	I-GENE-Y
2A	I-GENE-Y
)	I-GENE-Y
-	O
selective	O
)	O
,	O
ARC239	B-CHEMICAL
(	O
alpha	B-GENE-Y
(	I-GENE-Y
2B	I-GENE-Y
)	I-GENE-Y
-	O
and	O
alpha	B-GENE-Y
(	I-GENE-Y
2C	I-GENE-Y
)	I-GENE-Y
-	O
selective	O
)	O
,	O
and	O
prazosin	B-CHEMICAL
(	O
alpha	B-GENE-Y
(	I-GENE-Y
2B	I-GENE-Y
)	I-GENE-Y
-	O
and	O
alpha	B-GENE-Y
(	I-GENE-Y
2C	I-GENE-Y
)	I-GENE-Y
-	O
selective	O
)	O
.	O

RESULTS	O
:	O
The	O
alpha	B-GENE-N
(	I-GENE-N
2	I-GENE-N
)	I-GENE-N
-	I-GENE-N
adrenoceptor	I-GENE-N
agonists	O
induced	O
vasoconstriction	O
in	O
the	O
porcine	O
ciliary	O
artery	O
with	O
the	O
following	O
potency	O
order	O
(	O
EC	O
(	O
50	O
)	O
)	O
expressed	O
in	O
nanomolar	O
:	O
brimonidine	B-CHEMICAL
2	O
.	O
11	O
,	O
oxymetazoline	B-CHEMICAL
5	O
.	O
26	O
,	O
and	O
apraclonidine	B-CHEMICAL
13	O
.	O
0	O
.	O

As	O
a	O
reference	O
,	O
noradrenaline	B-CHEMICAL
was	O
tested	O
,	O
and	O
its	O
EC	O
(	O
50	O
)	O
was	O
determined	O
to	O
be	O
247	O
nM	O
in	O
the	O
ciliary	O
artery	O
.	O

In	O
the	O
porcine	O
ciliary	O
arteries	O
BRL44408	B-CHEMICAL
,	O
ARC239	B-CHEMICAL
,	O
and	O
prazosin	B-CHEMICAL
caused	O
concentration	O
-	O
dependent	O
and	O
parallel	O
rightward	O
shifts	O
of	O
the	O
concentration	O
-	O
response	O
curves	O
for	O
brimonidine	B-CHEMICAL
.	O

Schild	O
analyses	O
for	O
the	O
antagonists	O
against	O
brimonidine	B-CHEMICAL
yielded	O
regression	O
lines	O
with	O
slopes	O
of	O
unity	O
and	O
functional	O
antagonist	O
potencies	O
(	O
pK	O
(	O
B	O
)	O
)	O
for	O
BRL44408	B-CHEMICAL
(	O
7	O
.	O
8	O
)	O
,	O
ARC	B-CHEMICAL
239	I-CHEMICAL
(	O
5	O
.	O
8	O
)	O
and	O
for	O
prazosin	B-CHEMICAL
(	O
6	O
.	O
0	O
)	O
suggesting	O
the	O
presence	O
of	O
functional	O
alpha	B-GENE-Y
(	I-GENE-Y
2A	I-GENE-Y
)	I-GENE-Y
-	I-GENE-Y
adrenoceptors	I-GENE-Y
.	O

Moreover	O
,	O
there	O
was	O
a	O
good	O
correlation	O
of	O
pK	O
(	O
B	O
)	O
with	O
ligand	O
-	O
binding	O
affinity	O
(	O
pK	O
(	O
i	O
)	O
)	O
of	O
the	O
alpha	B-GENE-Y
(	I-GENE-Y
2A	I-GENE-Y
)	I-GENE-Y
-	I-GENE-Y
adrenoceptor	I-GENE-Y
in	O
the	O
porcine	O
eye	O
tissue	O
.	O

CONCLUSIONS	O
:	O
The	O
alpha	B-GENE-N
(	I-GENE-N
2	I-GENE-N
)	I-GENE-N
-	I-GENE-N
adrenoceptor	I-GENE-N
agonists	O
brimonidine	B-CHEMICAL
,	O
apraclonidine	B-CHEMICAL
,	O
and	O
oxymetazoline	B-CHEMICAL
are	O
potent	O
vasoconstrictors	O
in	O
the	O
porcine	O
ciliary	O
artery	O
.	O

In	O
the	O
present	O
work	O
,	O
it	O
was	O
shown	O
for	O
the	O
first	O
time	O
that	O
the	O
alpha	B-GENE-Y
(	I-GENE-Y
2A	I-GENE-Y
)	I-GENE-Y
-	I-GENE-Y
adrenoceptor	I-GENE-Y
subtype	O
mediates	O
this	O
contraction	O
.	O

Gemcitabine	B-CHEMICAL
and	O
pemetrexed	B-CHEMICAL
disodium	I-CHEMICAL
combinations	O
in	O
vitro	O
and	O
in	O
vivo	O
.	O

Pemetrexed	B-CHEMICAL
disodium	I-CHEMICAL
(	O
ALIMTA	B-CHEMICAL
)	O
is	O
a	O
novel	O
antimetabolite	O
that	O
inhibits	O
at	O
least	O
three	O
folate	B-CHEMICAL
-	O
dependent	O
enzymes	O
,	O
thymidylate	B-GENE-Y
synthase	I-GENE-Y
,	O
dihydrofolate	B-GENE-Y
reductase	I-GENE-Y
,	O
and	O
glycinamide	B-GENE-Y
ribonucleotide	I-GENE-Y
formyltransferase	I-GENE-Y
.	O

Pemetrexed	B-CHEMICAL
disodium	I-CHEMICAL
is	O
broadly	O
active	O
in	O
a	O
wide	O
variety	O
of	O
solid	O
tumours	O
,	O
including	O
non	O
-	O
small	O
cell	O
lung	O
,	O
breast	O
,	O
bladder	O
,	O
head	O
and	O
neck	O
and	O
ovarian	O
cancers	O
.	O

Gemcitabine	B-CHEMICAL
is	O
a	O
broadly	O
active	O
pyrimidine	B-CHEMICAL
nucleoside	I-CHEMICAL
antimetabolite	O
,	O
which	O
is	O
approved	O
for	O
the	O
treatment	O
of	O
pancreatic	O
and	O
non	O
-	O
small	O
cell	O
lung	O
cancers	O
.	O

Three	O
preclinical	O
studies	O
have	O
been	O
reported	O
that	O
show	O
cytotoxic	O
synergy	O
between	O
gemcitabine	B-CHEMICAL
and	O
pemetrexed	B-CHEMICAL
.	O

Clinical	O
activity	O
with	O
this	O
combination	O
has	O
been	O
observed	O
in	O
a	O
phase	O
I	O
study	O
,	O
with	O
partial	O
responses	O
in	O
three	O
of	O
five	O
patients	O
previously	O
treated	O
for	O
non	O
-	O
small	O
cell	O
lung	O
cancer	O
.	O

An	O
international	O
phase	O
II	O
study	O
of	O
this	O
combination	O
in	O
non	O
-	O
small	O
cell	O
lung	O
cancer	O
is	O
ongoing	O
.	O

Tetrahydrofolate	B-CHEMICAL
biosynthesis	O
in	O
plants	O
:	O
molecular	O
and	O
functional	O
characterization	O
of	O
dihydrofolate	B-GENE-Y
synthetase	I-GENE-Y
and	O
three	O
isoforms	O
of	O
folylpolyglutamate	B-GENE-N
synthetase	I-GENE-N
in	O
Arabidopsis	O
thaliana	O
.	O

Tetrahydrofolate	B-CHEMICAL
coenzymes	O
involved	O
in	O
one	O
-	O
carbon	B-CHEMICAL
(	O
C1	B-CHEMICAL
)	O
metabolism	O
are	O
polyglutamylated	O
.	O

In	O
organisms	O
that	O
synthesize	O
tetrahydrofolate	B-CHEMICAL
de	O
novo	O
,	O
dihydrofolate	B-GENE-Y
synthetase	I-GENE-Y
(	O
DHFS	B-GENE-Y
)	O
and	O
folylpolyglutamate	B-GENE-N
synthetase	I-GENE-N
(	O
FPGS	B-GENE-N
)	O
catalyze	O
the	O
attachment	O
of	O
glutamate	B-CHEMICAL
residues	O
to	O
the	O
folate	B-CHEMICAL
molecule	O
.	O

In	O
this	O
study	O
we	O
isolated	O
cDNAs	O
coding	O
a	O
DHFS	B-GENE-Y
and	O
three	O
isoforms	O
of	O
FPGS	B-GENE-N
from	O
Arabidopsis	O
thaliana	O
.	O

The	O
function	O
of	O
each	O
enzyme	O
was	O
demonstrated	O
by	O
complementation	O
of	O
yeast	O
mutants	O
deficient	O
in	O
DHFS	B-GENE-Y
or	O
FPGS	B-GENE-Y
activity	O
,	O
and	O
by	O
measuring	O
in	O
vitro	O
glutamate	B-CHEMICAL
incorporation	O
into	O
dihydrofolate	B-CHEMICAL
or	O
tetrahydrofolate	B-CHEMICAL
.	O

DHFS	B-GENE-Y
is	O
present	O
exclusively	O
in	O
the	O
mitochondria	O
,	O
making	O
this	O
compartment	O
the	O
sole	O
site	O
of	O
synthesis	O
of	O
dihydrofolate	B-CHEMICAL
in	O
the	O
plant	O
cell	O
.	O

In	O
contrast	O
,	O
FPGS	B-GENE-N
is	O
present	O
as	O
distinct	O
isoforms	O
in	O
the	O
mitochondria	O
,	O
the	O
cytosol	O
,	O
and	O
the	O
chloroplast	O
.	O

Each	O
isoform	O
is	O
encoded	O
by	O
a	O
separate	O
gene	O
,	O
a	O
situation	O
that	O
is	O
unique	O
among	O
eukaryotes	O
.	O

The	O
compartmentation	O
of	O
FPGS	B-GENE-N
isoforms	O
is	O
in	O
agreement	O
with	O
the	O
predominance	O
of	O
gamma	B-CHEMICAL
-	I-CHEMICAL
glutamyl	I-CHEMICAL
-	I-CHEMICAL
conjugated	I-CHEMICAL
tetrahydrofolate	I-CHEMICAL
derivatives	O
and	O
the	O
presence	O
of	O
serine	B-GENE-N
hydroxymethyltransferase	I-GENE-N
and	O
C1	B-GENE-N
-	I-GENE-N
tetrahydrofolate	I-GENE-N
interconverting	I-GENE-N
enzymes	I-GENE-N
in	O
the	O
cytosol	O
,	O
the	O
mitochondria	O
,	O
and	O
the	O
plastids	O
.	O

Thus	O
,	O
the	O
combination	O
of	O
FPGS	B-GENE-N
with	O
these	O
folate	B-CHEMICAL
-	O
mediated	O
reactions	O
can	O
supply	O
each	O
compartment	O
with	O
the	O
polyglutamylated	O
folate	B-CHEMICAL
coenzymes	O
required	O
for	O
the	O
reactions	O
of	O
C1	B-CHEMICAL
metabolism	O
.	O

Also	O
,	O
the	O
multicompartmentation	O
of	O
FPGS	B-GENE-N
in	O
the	O
plant	O
cell	O
suggests	O
that	O
the	O
transported	O
forms	O
of	O
folate	B-CHEMICAL
are	O
unconjugated	O
.	O

Rabeprazole	B-CHEMICAL
:	O
an	O
update	O
of	O
its	O
use	O
in	O
acid	O
-	O
related	O
disorders	O
.	O

UNLABELLED	O
:	O
Rabeprazole	B-CHEMICAL
is	O
an	O
inhibitor	O
of	O
the	O
gastric	B-GENE-N
proton	I-GENE-N
pump	I-GENE-N
.	O

It	O
causes	O
dose	O
-	O
dependent	O
inhibition	O
of	O
acid	O
secretion	O
.	O

In	O
8	O
-	O
week	O
studies	O
,	O
among	O
patients	O
with	O
gastro	O
-	O
oesophageal	O
reflux	O
disease	O
(	O
GORD	O
)	O
,	O
rabeprazole	B-CHEMICAL
20	O
mg	O
/	O
day	O
or	O
10mg	O
twice	O
daily	O
was	O
as	O
effective	O
as	O
omeprazole	B-CHEMICAL
and	O
superior	O
to	O
ranitidine	B-CHEMICAL
in	O
the	O
healing	O
of	O
GORD	O
.	O

Symptom	O
relief	O
with	O
rabeprazole	B-CHEMICAL
was	O
superior	O
to	O
that	O
provided	O
by	O
placebo	O
and	O
ranitidine	B-CHEMICAL
and	O
similar	O
to	O
omeprazole	B-CHEMICAL
.	O

In	O
long	O
-	O
term	O
trials	O
rabeprazole	B-CHEMICAL
10	O
mg	O
/	O
day	O
was	O
similar	O
to	O
omeprazole	B-CHEMICAL
20	O
mg	O
/	O
day	O
in	O
a	O
2	O
-	O
year	O
study	O
and	O
superior	O
to	O
placebo	O
in	O
1	O
-	O
year	O
studies	O
,	O
in	O
both	O
the	O
maintenance	O
of	O
healing	O
and	O
prevention	O
of	O
symptoms	O
in	O
patients	O
with	O
healed	O
GORD	O
.	O

In	O
nonerosive	O
GORD	O
,	O
4	O
-	O
week	O
studies	O
have	O
shown	O
rabeprazole	B-CHEMICAL
to	O
be	O
more	O
effective	O
than	O
placebo	O
in	O
relieving	O
heartburn	O
and	O
various	O
other	O
gastrointestinal	O
symptoms	O
.	O

Data	O
among	O
patients	O
with	O
Barrett	O
'	O
s	O
oesophagus	O
suggest	O
rabeprazole	B-CHEMICAL
20	O
mg	O
/	O
day	O
may	O
be	O
more	O
effective	O
than	O
placebo	O
in	O
maintaining	O
healing	O
of	O
associated	O
oesophagitis	O
after	O
1	O
year	O
of	O
treatment	O
.	O

One	O
-	O
week	O
triple	O
Helicobacter	O
pylori	O
eradication	O
therapy	O
with	O
rabeprazole	B-CHEMICAL
plus	O
clarithromycin	B-CHEMICAL
and	O
amoxicillin	B-CHEMICAL
achieved	O
eradication	O
rates	O
of	O
>	O
or	O
=	O
85	O
%	O
.	O

Rabeprazole	B-CHEMICAL
is	O
as	O
effective	O
as	O
omeprazole	B-CHEMICAL
and	O
lansoprazole	B-CHEMICAL
when	O
included	O
as	O
part	O
of	O
a	O
triple	O
-	O
therapy	O
regimen	O
for	O
the	O
eradication	O
of	O
H	O
.	O
pylori	O
.	O

Eradication	O
rates	O
of	O
>	O
90	O
%	O
were	O
achieved	O
when	O
rabeprazole	B-CHEMICAL
20	O
to	O
40	O
mg	O
/	O
day	O
was	O
included	O
as	O
part	O
of	O
a	O
quadruple	O
eradication	O
regimen	O
.	O

As	O
monotherapy	O
for	O
peptic	O
ulcer	O
healing	O
and	O
symptom	O
relief	O
,	O
4	O
-	O
to	O
8	O
-	O
week	O
studies	O
have	O
shown	O
rabeprazole	B-CHEMICAL
10	O
to	O
40	O
mg	O
/	O
day	O
to	O
be	O
superior	O
to	O
placebo	O
and	O
ranitidine	B-CHEMICAL
and	O
have	O
similar	O
efficacy	O
to	O
omeprazole	B-CHEMICAL
.	O

Preliminary	O
1	O
-	O
year	O
data	O
among	O
16	O
patients	O
with	O
Zollinger	O
-	O
Ellison	O
syndrome	O
suggest	O
rabeprazole	B-CHEMICAL
60	O
to	O
120	O
mg	O
/	O
day	O
can	O
resolve	O
and	O
prevent	O
the	O
recurrence	O
of	O
symptoms	O
and	O
endoscopic	O
lesions	O
associated	O
with	O
this	O
condition	O
.	O

In	O
clinical	O
trials	O
of	O
up	O
to	O
2	O
years	O
'	O
duration	O
the	O
tolerability	O
of	O
rabeprazole	B-CHEMICAL
is	O
similar	O
to	O
that	O
of	O
placebo	O
,	O
ranitidine	B-CHEMICAL
and	O
omeprazole	B-CHEMICAL
.	O

Common	O
adverse	O
events	O
assigned	O
to	O
rabeprazole	B-CHEMICAL
have	O
been	O
diarrhoea	O
,	O
headache	O
,	O
rhinitis	O
,	O
nausea	O
,	O
pharyngitis	O
and	O
abdominal	O
pain	O
.	O

Histological	O
changes	O
and	O
increases	O
in	O
serum	O
gastrin	B-GENE-Y
levels	O
were	O
unremarkable	O
and	O
typical	O
of	O
proton	B-GENE-N
pump	I-GENE-N
inhibitors	O
.	O

No	O
dosage	O
adjustment	O
is	O
necessary	O
in	O
renal	O
and	O
mild	O
to	O
moderate	O
hepatic	O
impairment	O
.	O

CONCLUSION	O
:	O
Rabeprazole	B-CHEMICAL
is	O
a	O
well	O
tolerated	O
proton	B-GENE-N
pump	I-GENE-N
inhibitor	O
.	O

It	O
has	O
proven	O
efficacy	O
in	O
healing	O
,	O
symptom	O
relief	O
and	O
prevention	O
of	O
relapse	O
of	O
peptic	O
ulcers	O
and	O
GORD	O
and	O
can	O
form	O
part	O
of	O
effective	O
H	O
.	O
pylori	O
eradication	O
regimens	O
.	O

It	O
is	O
an	O
important	O
alternative	O
to	O
H	O
(	O
2	O
)	O
antagonists	O
and	O
an	O
additional	O
treatment	O
option	O
to	O
other	O
proton	B-GENE-N
pump	I-GENE-N
inhibitors	O
in	O
the	O
management	O
of	O
acid	O
-	O
related	O
disorders	O
.	O

Angiotensin	B-CHEMICAL
II	I-CHEMICAL
suppression	O
in	O
humans	O
by	O
the	O
orally	O
active	O
renin	B-GENE-Y
inhibitor	O
Aliskiren	B-CHEMICAL
(	O
SPP100	B-CHEMICAL
)	O
:	O
comparison	O
with	O
enalapril	B-CHEMICAL
.	O

Renin	B-GENE-Y
is	O
the	O
main	O
determinant	O
of	O
angiotensin	B-CHEMICAL
(	I-CHEMICAL
Ang	I-CHEMICAL
)	I-CHEMICAL
II	I-CHEMICAL
levels	O
.	O

It	O
,	O
therefore	O
,	O
always	O
appeared	O
desirable	O
to	O
reduce	O
Ang	B-CHEMICAL
II	I-CHEMICAL
levels	O
by	O
direct	O
inhibition	O
of	O
renin	B-GENE-Y
.	O

So	O
far	O
,	O
specific	O
renin	B-GENE-Y
inhibitors	O
lacked	O
potency	O
and	O
/	O
or	O
oral	O
availability	O
.	O

We	O
tested	O
the	O
new	O
orally	O
active	O
nonpeptidic	O
renin	B-GENE-Y
inhibitor	O
SPP100	B-CHEMICAL
(	O
Aliskiren	B-CHEMICAL
,	O
an	O
octanamide	B-CHEMICAL
with	O
a	O
50	O
%	O
inhibitory	O
concentration	O
[	O
IC50	O
]	O
in	O
the	O
low	O
nanomolar	O
range	O
)	O
in	O
18	O
healthy	O
volunteers	O
on	O
a	O
constant	O
100	O
mmol	O
/	O
d	O
sodium	B-CHEMICAL
diet	O
using	O
a	O
double	O
-	O
blind	O
,	O
3	O
-	O
way	O
crossover	O
protocol	O
.	O

In	O
3	O
periods	O
of	O
8	O
days	O
,	O
separated	O
by	O
wash	O
-	O
outs	O
of	O
6	O
days	O
,	O
each	O
volunteer	O
received	O
2	O
dosage	O
levels	O
of	O
Aliskiren	B-CHEMICAL
(	O
low	O
before	O
high	O
;	O
40	O
and	O
80	O
or	O
160	O
and	O
640	O
mg	O
/	O
d	O
)	O
and	O
randomized	O
placebo	O
or	O
20	O
mg	O
enalapril	B-CHEMICAL
.	O

Aliskiren	B-CHEMICAL
was	O
well	O
tolerated	O
.	O

Not	O
surprisingly	O
,	O
blood	O
pressure	O
and	O
heart	O
rate	O
remained	O
unchanged	O
in	O
these	O
normotensive	O
subjects	O
.	O

There	O
was	O
a	O
dose	O
-	O
dependent	O
decrease	O
in	O
plasma	O
renin	B-GENE-Y
activity	O
,	O
Ang	B-CHEMICAL
I	I-CHEMICAL
,	O
and	O
Ang	B-CHEMICAL
II	I-CHEMICAL
following	O
single	O
doses	O
of	O
Aliskiren	B-CHEMICAL
starting	O
with	O
40	O
mg	O
.	O

Inhibition	O
was	O
still	O
marked	O
and	O
significant	O
after	O
repeated	O
dosing	O
with	O
maximal	O
decreases	O
in	O
Ang	B-CHEMICAL
II	I-CHEMICAL
levels	O
by	O
89	O
%	O
and	O
75	O
%	O
on	O
Days	O
1	O
and	O
8	O
,	O
respectively	O
,	O
when	O
the	O
highest	O
dose	O
of	O
Aliskiren	B-CHEMICAL
was	O
compared	O
with	O
placebo	O
.	O

At	O
the	O
same	O
time	O
,	O
mean	O
plasma	O
active	O
renin	B-GENE-Y
was	O
increased	O
16	O
-	O
and	O
34	O
-	O
fold	O
at	O
the	O
highest	O
dose	O
of	O
Aliskiren	B-CHEMICAL
.	O

Plasma	O
drug	O
levels	O
of	O
Aliskiren	B-CHEMICAL
were	O
dose	O
-	O
dependent	O
with	O
maximal	O
concentrations	O
reached	O
between	O
3	O
to	O
6	O
hours	O
after	O
administration	O
;	O
steady	O
state	O
was	O
reached	O
between	O
5	O
and	O
8	O
days	O
after	O
multiple	O
dosing	O
.	O

Less	O
than	O
1	O
%	O
of	O
dose	O
was	O
excreted	O
in	O
the	O
urine	O
.	O

Plasma	O
and	O
urinary	O
aldosterone	B-CHEMICAL
levels	O
were	O
decreased	O
after	O
doses	O
of	O
Aliskiren	B-CHEMICAL
>	O
or	O
=	O
80	O
mg	O
and	O
after	O
enalapril	B-CHEMICAL
.	O

Aliskiren	B-CHEMICAL
at	O
160	O
and	O
640	O
mg	O
enhanced	O
natriuresis	O
on	O
Day	O
1	O
by	O
+	O
45	O
%	O
and	O
+	O
62	O
%	O
,	O
respectively	O
,	O
compared	O
with	O
placebo	O
(	O
100	O
%	O
,	O
ie	O
,	O
87	O
+	O
/	O
-	O
11	O
mmol	O
/	O
24h	O
)	O
and	O
enalapril	B-CHEMICAL
(	O
+	O
54	O
%	O
)	O
;	O
kaliuresis	O
remained	O
unchanged	O
.	O

In	O
conclusion	O
,	O
the	O
renin	B-GENE-Y
inhibitor	O
Aliskiren	B-CHEMICAL
dose	O
-	O
dependently	O
decreases	O
Ang	B-CHEMICAL
II	I-CHEMICAL
levels	O
in	O
humans	O
following	O
oral	O
administration	O
.	O

The	O
effect	O
is	O
long	O
-	O
lasting	O
and	O
,	O
at	O
a	O
dose	O
of	O
160	O
mg	O
,	O
is	O
equivalent	O
to	O
that	O
of	O
20	O
mg	O
enalapril	B-CHEMICAL
.	O

Aliskiren	B-CHEMICAL
has	O
the	O
potential	O
to	O
become	O
the	O
first	O
orally	O
active	O
renin	B-GENE-Y
inhibitor	O
that	O
provides	O
a	O
true	O
alternative	O
to	O
ACE	B-GENE-Y
-	O
inhibitors	O
and	O
Ang	B-GENE-N
II	I-GENE-N
receptor	I-GENE-N
antagonists	O
in	O
therapy	O
for	O
hypertension	O
and	O
other	O
cardiovascular	O
and	O
renal	O
diseases	O
.	O

Heterogeneity	O
of	O
persistent	O
hyperinsulinaemic	O
hypoglycaemia	O
.	O

A	O
series	O
of	O
175	O
cases	O
.	O

UNLABELLED	O
:	O
Hyperinsulinism	O
is	O
a	O
heterogeneous	O
disorder	O
characterised	O
by	O
severe	O
hypoglycaemia	O
due	O
to	O
an	O
inappropriate	O
oversecretion	O
of	O
insulin	B-GENE-Y
.	O

In	O
a	O
personal	O
series	O
of	O
175	O
patients	O
investigated	O
for	O
hyperinsulinaemic	O
hypoglycaemia	O
over	O
the	O
last	O
20	O
years	O
,	O
we	O
review	O
clinical	O
presentations	O
,	O
molecular	O
studies	O
and	O
therapeutic	O
management	O
of	O
hyperinsulinism	O
.	O

There	O
were	O
98	O
neonatal	O
-	O
onset	O
patients	O
,	O
including	O
86	O
permanent	O
hyperinsulinism	O
and	O
12	O
transient	O
forms	O
,	O
68	O
with	O
infancy	O
-	O
onset	O
and	O
nine	O
with	O
childhood	O
-	O
onset	O
.	O

Hyperammonaemia	O
was	O
found	O
in	O
12	O
out	O
of	O
69	O
patients	O
tested	O
,	O
4	O
neonates	O
and	O
8	O
infants	O
.	O

Neonates	O
were	O
clinically	O
more	O
severely	O
affected	O
than	O
infants	O
.	O

Diagnosis	O
of	O
infancy	O
-	O
onset	O
hyperinsulinism	O
was	O
often	O
delayed	O
because	O
of	O
less	O
profound	O
hypoglycaemia	O
and	O
better	O
tolerance	O
to	O
hypoglycaemia	O
.	O

Neonates	O
required	O
higher	O
rates	O
of	O
i	O
.	O
v	O
.	O
glucose	B-CHEMICAL
than	O
infants	O
to	O
maintain	O
normal	O
plasma	O
glucose	B-CHEMICAL
levels	O
(	O
16	O
mg	O
/	O
kg	O
per	O
min	O
versus	O
12	O
mg	O
/	O
kg	O
per	O
min	O
)	O
.	O

Only	O
16	O
%	O
of	O
neonates	O
were	O
diazoxide	B-CHEMICAL
-	O
sensitive	O
compared	O
to	O
66	O
%	O
of	O
the	O
infants	O
.	O

Neonates	O
with	O
hyperammonaemia	O
or	O
transient	O
hyperinsulinism	O
were	O
diazoxide	B-CHEMICAL
-	O
sensitive	O
.	O

Most	O
neonates	O
were	O
pancreatectomised	O
whereas	O
65	O
%	O
of	O
the	O
infants	O
were	O
treated	O
medically	O
.	O

Among	O
surgically	O
-	O
treated	O
patients	O
,	O
47	O
%	O
had	O
a	O
focal	O
adenomatous	O
hyperplasia	O
(	O
31	O
neonates	O
and	O
13	O
infants	O
)	O
and	O
53	O
%	O
a	O
diffuse	O
form	O
of	O
hyperinsulinism	O
(	O
39	O
neonates	O
and	O
11	O
infants	O
)	O
.	O

Diazoxide	B-CHEMICAL
-	O
responsiveness	O
in	O
the	O
focal	O
and	O
diffuse	O
forms	O
did	O
not	O
differ	O
in	O
both	O
neonates	O
and	O
infants	O
;	O
it	O
depended	O
only	O
upon	O
the	O
age	O
of	O
onset	O
of	O
hypoglycaemia	O
.	O

One	O
or	O
two	O
mutations	O
,	O
SUR1	B-GENE-Y
or	O
KIR6	B-GENE-Y
.	I-GENE-Y
2	I-GENE-Y
,	O
were	O
found	O
in	O
41	O
of	O
73	O
neonates	O
who	O
were	O
investigated	O
and	O
in	O
13	O
/	O
38	O
infants	O
using	O
polymerase	O
chain	O
reaction	O
-	O
single	O
strand	O
conformational	O
polymorphism	O
analysis	O
of	O
both	O
genes	O
.	O

Almost	O
all	O
patients	O
with	O
SUR1	B-GENE-Y
(	O
38	O
/	O
41	O
)	O
or	O
KIR6	B-GENE-Y
.	I-GENE-Y
2	I-GENE-Y
(	O
5	O
/	O
7	O
)	O
mutations	O
were	O
resistant	O
to	O
diazoxide	B-CHEMICAL
.	O

Ten	O
patients	O
with	O
hyperinsulinism	O
-	O
hyperammonaemia	O
syndrome	O
had	O
a	O
mutation	O
in	O
the	O
glutamate	B-GENE-N
dehydrogenase	I-GENE-N
gene	O
(	O
three	O
neonates	O
and	O
seven	O
infants	O
)	O
after	O
reverse	O
transcriptase	O
-	O
polymerase	O
chain	O
reaction	O
and	O
sequence	O
analysis	O
of	O
cDNA	O
.	O

No	O
mutation	O
was	O
found	O
by	O
polymerase	O
chain	O
reaction	O
-	O
single	O
strand	O
conformational	O
polymorphism	O
in	O
the	O
glucokinase	B-GENE-Y
gene	O
.	O

Eight	O
of	O
nine	O
patients	O
with	O
childhood	O
onset	O
hyperinsulinism	O
were	O
treated	O
surgically	O
and	O
histological	O
examination	O
confirmed	O
an	O
adenoma	O
in	O
each	O
case	O
.	O

CONCLUSION	O
:	O
the	O
clinical	O
severity	O
of	O
hyperinsulinism	O
varies	O
mainly	O
with	O
age	O
at	O
onset	O
of	O
hypoglycaemia	O
.	O

The	O
heterogeneity	O
of	O
hyperinsulinism	O
has	O
major	O
consequences	O
in	O
terms	O
of	O
therapeutic	O
outcome	O
and	O
genetic	O
counselling	O
.	O

Donepezil	B-CHEMICAL
hydrochloride	I-CHEMICAL
:	O
a	O
treatment	O
drug	O
for	O
Alzheimer	O
'	O
s	O
disease	O
.	O

The	O
role	O
of	O
the	O
cholinergic	O
system	O
with	O
respect	O
to	O
cognitive	O
deficits	O
characteristic	O
of	O
Alzheimer	O
'	O
s	O
disease	O
(	O
AD	O
)	O
has	O
led	O
to	O
a	O
number	O
of	O
studies	O
focusing	O
on	O
the	O
development	O
of	O
acetylcholinesterase	B-GENE-Y
(	O
AChE	B-GENE-Y
)	O
inhibitors	O
as	O
a	O
drug	O
for	O
treating	O
this	O
disease	O
.	O

The	O
earliest	O
known	O
AChE	B-GENE-Y
inhibitors	O
,	O
namely	O
,	O
physostigmine	B-CHEMICAL
and	O
tacrine	B-CHEMICAL
,	O
performed	O
poorly	O
in	O
clinical	O
trials	O
(	O
e	O
.	O
g	O
.	O
,	O
poor	O
oral	O
activity	O
,	O
brain	O
penetration	O
,	O
and	O
hepatotoxic	O
liability	O
)	O
.	O

Studies	O
were	O
then	O
focused	O
on	O
finding	O
a	O
new	O
type	O
of	O
acetylcholinesterase	O
inhibitor	O
that	O
would	O
overcome	O
the	O
disadvantages	O
of	O
these	O
two	O
compounds	O
.	O

Donepezil	B-CHEMICAL
hydrochloride	I-CHEMICAL
inaugurates	O
a	O
new	O
class	O
of	O
AChE	B-GENE-Y
inhibitors	O
with	O
longer	O
and	O
more	O
selective	O
action	O
and	O
with	O
manageable	O
adverse	O
effects	O
.	O

Alefacept	B-GENE-Y
,	O
an	O
immunomodulatory	O
recombinant	O
LFA	B-GENE-Y
-	I-GENE-Y
3	I-GENE-Y
/	O
IgG1	B-GENE-Y
fusion	O
protein	O
,	O
induces	O
CD16	B-GENE-N
signaling	O
and	O
CD2	B-GENE-Y
/	O
CD16	B-GENE-N
-	O
dependent	O
apoptosis	O
of	O
CD2	O
(	O
+	O
)	O
cells	O
.	O

Alefacept	B-GENE-Y
,	O
an	O
immunomodulatory	O
recombinant	O
fusion	O
protein	O
composed	O
of	O
the	O
first	O
extracellular	O
domain	O
of	O
LFA	B-GENE-Y
-	I-GENE-Y
3	I-GENE-Y
fused	O
to	O
the	O
human	B-GENE-N
IgG1	I-GENE-N
hinge	I-GENE-N
,	I-GENE-N
C	I-GENE-N
(	I-GENE-N
H	I-GENE-N
)	I-GENE-N
2	I-GENE-N
,	I-GENE-N
and	I-GENE-N
C	I-GENE-N
(	I-GENE-N
H	I-GENE-N
)	I-GENE-N
3	I-GENE-N
domains	I-GENE-N
,	O
has	O
recently	O
been	O
shown	O
in	O
phase	O
II	O
and	O
III	O
clinical	O
trials	O
to	O
safely	O
reduce	O
disease	O
expression	O
in	O
patients	O
with	O
chronic	O
plaque	O
psoriasis	O
.	O

Alefacept	B-GENE-Y
modulates	O
the	O
function	O
of	O
and	O
selectively	O
induces	O
apoptosis	O
of	O
CD2	O
(	O
+	O
)	O
human	O
memory	O
-	O
effector	O
T	O
cells	O
in	O
vivo	O
.	O

We	O
have	O
sought	O
to	O
gain	O
further	O
understanding	O
of	O
the	O
mechanisms	O
of	O
action	O
that	O
influence	O
the	O
biological	O
activity	O
of	O
alefacept	B-GENE-Y
and	O
may	O
contribute	O
to	O
its	O
efficacy	O
and	O
patient	O
responsiveness	O
.	O

Specifically	O
evaluated	O
is	O
the	O
ability	O
of	O
alefacept	B-GENE-Y
to	O
activate	O
intracellular	O
signals	O
mediated	O
via	O
CD2	B-GENE-Y
and	O
/	O
or	O
Fc	B-GENE-N
gamma	I-GENE-N
RIII	I-GENE-N
(	O
CD16	B-GENE-N
)	O
.	O

Experimentation	O
using	O
isoforms	O
of	O
alefacept	B-GENE-Y
engineered	O
to	O
have	O
amino	B-CHEMICAL
acid	I-CHEMICAL
substitutions	O
in	O
the	O
IgG1	B-GENE-N
C	I-GENE-N
(	I-GENE-N
H	I-GENE-N
)	I-GENE-N
2	I-GENE-N
domain	I-GENE-N
that	O
impact	O
Fc	B-GENE-N
gamma	I-GENE-N
R	I-GENE-N
binding	O
indicate	O
that	O
alefacept	B-GENE-Y
mediates	O
cognate	O
interactions	O
between	O
cells	O
expressing	O
human	B-GENE-Y
CD2	I-GENE-Y
and	O
CD16	B-GENE-N
to	O
activate	O
cells	O
,	O
e	O
.	O
g	O
.	O
,	O
increase	O
extracellular	B-GENE-N
signal	I-GENE-N
-	I-GENE-N
regulated	I-GENE-N
kinase	I-GENE-N
phosphorylation	O
,	O
up	O
-	O
regulate	O
cell	O
surface	O
expression	O
of	O
the	O
activation	O
marker	O
CD25	B-GENE-Y
,	O
and	O
induce	O
release	O
of	O
granzyme	B-GENE-Y
B	I-GENE-Y
.	O

In	O
the	O
systems	O
used	O
,	O
this	O
signaling	O
is	O
shown	O
to	O
require	O
binding	O
to	O
CD2	B-GENE-Y
and	O
CD16	B-GENE-N
and	O
be	O
mediated	O
through	O
CD16	B-GENE-N
,	O
but	O
not	O
CD2	B-GENE-Y
.	O

Experimentation	O
using	O
human	B-GENE-Y
CD2	I-GENE-Y
-	O
transgenic	O
mice	O
and	O
isoforms	O
of	O
alefacept	B-GENE-Y
confirmed	O
the	O
requirement	O
for	O
Fc	B-GENE-N
gamma	I-GENE-N
R	I-GENE-N
binding	O
for	O
detection	O
of	O
the	O
pharmacological	O
effects	O
of	O
alefacept	O
in	O
vivo	O
.	O

Thus	O
alefacept	B-GENE-Y
acts	O
as	O
an	O
effector	O
molecule	O
,	O
mediating	O
cognate	O
interactions	O
to	O
activate	O
Fc	O
gamma	O
R	O
(	O
+	O
)	O
cells	O
(	O
e	O
.	O
g	O
.	O
,	O
NK	O
cells	O
)	O
to	O
induce	O
apoptosis	O
of	O
sensitive	O
CD2	O
(	O
+	O
)	O
target	O
cells	O
.	O

Thalidomide	B-CHEMICAL
in	O
multiple	O
myeloma	O
.	O

Thalidomide	B-CHEMICAL
-	O
-	O
removed	O
from	O
widespread	O
clinical	O
use	O
by	O
1962	O
because	O
of	O
severe	O
teratogenicity	O
-	O
-	O
has	O
anti	O
-	O
angiogenic	O
and	O
immunomodulatory	O
effects	O
,	O
including	O
the	O
inhibition	O
of	O
TNF	B-GENE-Y
alpha	I-GENE-Y
.	O

It	O
has	O
returned	O
to	O
practice	O
as	O
an	O
effective	O
oral	O
agent	O
in	O
the	O
management	O
of	O
various	O
disease	O
states	O
including	O
erythema	O
nodosum	O
leprosum	O
,	O
for	O
which	O
it	O
was	O
FDA	O
-	O
approved	O
in	O
1998	O
,	O
and	O
more	O
recently	O
certain	O
malignancies	O
,	O
including	O
multiple	O
myeloma	O
.	O

Whilst	O
the	O
mechanism	O
of	O
action	O
of	O
thalidomide	B-CHEMICAL
remains	O
incompletely	O
understood	O
,	O
considerable	O
insight	O
has	O
been	O
generated	O
by	O
extensive	O
preclinical	O
studies	O
in	O
multiple	O
myeloma	O
.	O

Moreover	O
,	O
clinical	O
trials	O
both	O
as	O
a	O
single	O
agent	O
and	O
in	O
combination	O
have	O
confirmed	O
benefit	O
in	O
relapsed	O
and	O
refractory	O
disease	O
.	O

Thalidomide	O
'	O
s	O
role	O
in	O
treating	O
newly	O
diagnosed	O
patients	O
is	O
currently	O
under	O
study	O
and	O
it	O
is	O
now	O
established	O
as	O
an	O
important	O
therapeutic	O
option	O
in	O
the	O
treatment	O
of	O
multiple	O
myeloma	O
.	O

[	O
Leflunomide	B-CHEMICAL
-	O
-	O
a	O
new	O
drug	O
for	O
pharmacological	O
immunomodulation	O
]	O
.	O

The	O
novel	O
immunomodulatory	O
agent	O
leflunomide	B-CHEMICAL
exhibits	O
a	O
strong	O
anti	O
-	O
inflammatory	O
action	O
.	O

This	O
isoxazole	B-CHEMICAL
derivative	O
is	O
chemically	O
unrelated	O
to	O
any	O
hitherto	O
applied	O
immunosuppressants	O
.	O

As	O
a	O
prodrug	O
leflunomide	B-CHEMICAL
is	O
completely	O
converted	O
to	O
its	O
active	O
metabolite	O
A	B-CHEMICAL
77	I-CHEMICAL
1726	I-CHEMICAL
(	O
M1	O
)	O
which	O
blocks	O
the	O
dihydroorotate	B-GENE-Y
dehydrogenase	I-GENE-Y
,	O
a	O
key	O
enzyme	O
of	O
the	O
pyrimidine	B-CHEMICAL
de	O
novo	O
synthesis	O
.	O

Drug	O
-	O
related	O
adverse	O
effects	O
are	O
mild	O
,	O
dose	O
-	O
related	O
and	O
reversible	O
,	O
characterising	O
leflunomide	B-CHEMICAL
as	O
a	O
safe	O
immunosuppressant	O
.	O

While	O
up	O
to	O
now	O
leflunomide	B-CHEMICAL
has	O
just	O
been	O
approved	O
for	O
therapy	O
of	O
rheumatoid	O
arthritis	O
,	O
its	O
mechanism	O
of	O
action	O
affects	O
multiple	O
inflammatory	O
pathways	O
,	O
thereby	O
suggesting	O
it	O
to	O
be	O
a	O
potent	O
therapeutic	O
agent	O
in	O
autoimmune	O
diseases	O
,	O
graft	O
rejection	O
,	O
and	O
tumour	O
therapy	O
.	O

First	O
dermatological	O
experience	O
has	O
been	O
gained	O
in	O
psoriasis	O
and	O
bullous	O
pemphigoid	O
.	O

The	O
role	O
of	O
leflunomide	B-CHEMICAL
in	O
the	O
dermatologist	O
'	O
s	O
therapeutic	O
armamentarium	O
will	O
evolve	O
during	O
the	O
next	O
years	O
.	O

Existing	O
and	O
emerging	O
endocrine	O
therapies	O
for	O
breast	O
cancer	O
.	O

Endocrine	O
therapy	O
is	O
first	O
-	O
line	O
therapy	O
for	O
patients	O
with	O
estrogen	B-GENE-Y
receptor	I-GENE-Y
-	O
positive	O
or	O
progesterone	B-GENE-Y
receptor	I-GENE-Y
-	O
positive	O
metastatic	O
breast	O
cancer	O
.	O

Commonly	O
used	O
endocrine	O
therapies	O
are	O
tamoxifen	B-CHEMICAL
,	O
megestrol	B-CHEMICAL
acetate	I-CHEMICAL
,	O
and	O
aromatase	B-GENE-Y
inhibitors	O
.	O

Although	O
tamoxifen	B-CHEMICAL
and	O
megestrol	B-CHEMICAL
acetate	I-CHEMICAL
have	O
a	O
favorable	O
therapeutic	O
profile	O
,	O
there	O
are	O
risks	O
associated	O
with	O
these	O
agents	O
.	O

With	O
tamoxifen	B-CHEMICAL
,	O
the	O
partial	O
agonist	O
property	O
can	O
lead	O
to	O
thromboembolic	O
events	O
.	O

An	O
important	O
adverse	O
event	O
of	O
megestrol	B-CHEMICAL
acetate	I-CHEMICAL
is	O
weight	O
gain	O
and	O
fluid	O
retention	O
in	O
some	O
patients	O
.	O

The	O
aromatase	B-GENE-Y
inhibitors	O
are	O
currently	O
used	O
as	O
second	O
-	O
line	O
therapy	O
after	O
tamoxifen	B-CHEMICAL
failure	O
.	O

A	O
recent	O
study	O
showed	O
that	O
anastrozole	B-CHEMICAL
,	O
an	O
aromatase	B-GENE-Y
inhibitor	O
,	O
is	O
as	O
effective	O
or	O
even	O
superior	O
to	O
tamoxifen	B-CHEMICAL
when	O
used	O
as	O
a	O
first	O
-	O
line	O
therapy	O
.	O

However	O
,	O
not	O
all	O
patients	O
will	O
respond	O
to	O
currently	O
available	O
therapies	O
.	O

A	O
new	O
class	O
of	O
drug	O
,	O
the	O
estrogen	B-GENE-Y
receptor	I-GENE-Y
downregulators	O
,	O
has	O
been	O
developed	O
.	O

Fulvestrant	B-CHEMICAL
,	O
the	O
first	O
agent	O
in	O
this	O
new	O
class	O
,	O
not	O
only	O
induces	O
the	O
degradation	O
of	O
the	O
estrogen	B-GENE-Y
receptor	I-GENE-Y
but	O
also	O
is	O
an	O
estrogen	B-CHEMICAL
antagonist	O
;	O
further	O
,	O
its	O
lack	O
of	O
agonist	O
activity	O
provides	O
a	O
better	O
safety	O
profile	O
.	O

Two	O
phase	O
III	O
trials	O
have	O
proven	O
that	O
fulvestrant	B-CHEMICAL
is	O
at	O
least	O
as	O
effective	O
as	O
anastrozole	B-CHEMICAL
in	O
postmenopausal	O
women	O
with	O
advanced	O
breast	O
cancer	O
.	O

Fulvestrant	B-CHEMICAL
is	O
an	O
effective	O
and	O
safe	O
endocrine	O
therapy	O
for	O
postmenopausal	O
women	O
who	O
have	O
failed	O
prior	O
endocrine	O
therapy	O
.	O

Microarray	O
and	O
biochemical	O
analysis	O
of	O
lovastatin	B-CHEMICAL
-	O
induced	O
apoptosis	O
of	O
squamous	O
cell	O
carcinomas	O
.	O

We	O
recently	O
identified	O
3	B-GENE-Y
-	I-GENE-Y
hydroxy	I-GENE-Y
-	I-GENE-Y
3	I-GENE-Y
-	I-GENE-Y
methylglutaryl	I-GENE-Y
coenzyme	I-GENE-Y
A	I-GENE-Y
(	I-GENE-Y
HMG	I-GENE-Y
-	I-GENE-Y
CoA	I-GENE-Y
)	I-GENE-Y
reductase	I-GENE-Y
,	O
the	O
rate	O
-	O
limiting	O
enzyme	O
of	O
the	O
mevalonate	O
pathway	O
,	O
as	O
a	O
potential	O
therapeutic	O
target	O
of	O
the	O
head	O
and	O
neck	O
squamous	O
cell	O
carcinomas	O
(	O
HNSCC	O
)	O
and	O
cervical	O
carcinomas	O
(	O
CC	O
)	O
.	O

The	O
products	O
of	O
this	O
complex	O
biochemical	O
pathway	O
,	O
including	O
de	O
novo	O
cholesterol	B-CHEMICAL
,	O
are	O
vital	O
for	O
a	O
variety	O
of	O
key	O
cellular	O
functions	O
affecting	O
membrane	O
integrity	O
,	O
cell	O
signaling	O
,	O
protein	O
synthesis	O
,	O
and	O
cell	O
cycle	O
progression	O
.	O

Lovastatin	B-CHEMICAL
,	O
a	O
specific	O
inhibitor	O
of	O
HMG	B-GENE-Y
-	I-GENE-Y
CoA	I-GENE-Y
reductase	I-GENE-Y
,	O
induces	O
a	O
pronounced	O
apoptotic	O
response	O
in	O
a	O
specific	O
subset	O
of	O
tumor	O
types	O
,	O
including	O
HNSCC	O
and	O
CC	O
.	O

The	O
mediators	O
of	O
this	O
response	O
are	O
not	O
well	O
established	O
.	O

Identification	O
of	O
differentially	O
expressed	O
genes	O
represents	O
a	O
feasible	O
approach	O
to	O
delineate	O
these	O
mediators	O
as	O
lovastatin	B-CHEMICAL
has	O
the	O
potential	O
to	O
modulate	O
transcription	O
indirectly	O
by	O
perturbing	O
levels	O
of	O
sterols	O
and	O
other	O
mevalonate	B-CHEMICAL
metabolites	O
.	O

Expression	O
analysis	O
following	O
treatment	O
of	O
the	O
HNSCC	O
cell	O
lines	O
SCC9	O
or	O
SCC25	O
with	O
10	O
microM	O
lovastatin	B-CHEMICAL
for	O
1	O
day	O
showed	O
that	O
less	O
than	O
2	O
%	O
(	O
9	O
cDNAs	O
)	O
of	O
the	O
588	O
cDNAs	O
on	O
this	O
microarray	O
were	O
affected	O
in	O
both	O
cell	O
lines	O
.	O

These	O
included	O
diazepam	B-GENE-Y
-	I-GENE-Y
binding	I-GENE-Y
inhibitor	I-GENE-Y
/	O
acyl	B-GENE-Y
-	I-GENE-Y
CoA	I-GENE-Y
-	I-GENE-Y
binding	I-GENE-Y
protein	I-GENE-Y
,	I-GENE-Y
the	O
activated	B-GENE-Y
transcription	I-GENE-Y
factor	I-GENE-Y
4	I-GENE-Y
and	O
rhoA	B-GENE-Y
.	O

Because	O
the	O
biosynthesis	O
of	O
mevalonate	B-CHEMICAL
leads	O
to	O
its	O
incorporation	O
into	O
more	O
than	O
a	O
dozen	O
classes	O
of	O
end	O
products	O
,	O
their	O
role	O
in	O
lovastatin	B-CHEMICAL
-	O
induced	O
apoptosis	O
was	O
also	O
evaluated	O
.	O

Addition	O
of	O
the	O
metabolites	O
of	O
all	O
the	O
major	O
branches	O
of	O
the	O
mevalonate	B-CHEMICAL
pathway	O
indicated	O
that	O
only	O
the	O
nonsterol	O
moiety	O
,	O
geranylgeranyl	B-CHEMICAL
pyrophosphate	I-CHEMICAL
(	O
GGPP	B-CHEMICAL
)	O
,	O
significantly	O
inhibited	O
the	O
apoptotic	O
effects	O
of	O
lovastatin	B-CHEMICAL
in	O
HNSCC	O
and	O
CC	O
cells	O
.	O

Because	O
rhoA	B-GENE-Y
requires	O
GGPP	B-CHEMICAL
for	O
its	O
function	O
,	O
this	O
links	O
the	O
microarray	O
and	O
biochemical	O
data	O
and	O
identifies	O
rhoA	B-GENE-Y
as	O
a	O
potential	O
mediator	O
of	O
the	O
anticancer	O
properties	O
of	O
lovastatin	B-CHEMICAL
.	O

Our	O
data	O
suggest	O
that	O
the	O
depletion	O
of	O
nonsterol	O
mevalonate	O
metabolites	O
,	O
particularly	O
GGPP	B-CHEMICAL
,	O
can	O
be	O
potential	O
mediators	O
of	O
lovastatin	B-CHEMICAL
-	O
induced	O
apoptosis	O
of	O
HNSCC	O
and	O
CC	O
cells	O
.	O

Regulation	O
of	O
norepinephrine	B-GENE-Y
transporter	I-GENE-Y
abundance	O
by	O
catecholamines	B-CHEMICAL
and	O
desipramine	B-CHEMICAL
in	O
vivo	O
.	O

The	O
norepinephrine	B-GENE-Y
transporter	I-GENE-Y
(	O
NET	B-GENE-Y
)	O
regulates	O
adrenoreceptor	B-GENE-N
signaling	O
by	O
controlling	O
the	O
availability	O
of	O
synaptic	O
norepinephrine	B-CHEMICAL
(	O
NE	B-CHEMICAL
)	O
,	O
and	O
it	O
is	O
a	O
direct	O
target	O
for	O
some	O
classes	O
of	O
antidepressant	O
drugs	O
.	O

NET	B-GENE-Y
levels	O
are	O
normal	O
in	O
dopamine	B-GENE-Y
beta	I-GENE-Y
-	I-GENE-Y
hydroxylase	I-GENE-Y
knockout	O
(	O
Dbh	B-GENE-Y
-	O
/	O
-	O
)	O
mice	O
that	O
lack	O
NE	B-CHEMICAL
,	O
demonstrating	O
that	O
the	O
NET	B-GENE-Y
does	O
not	O
require	O
endogenous	O
NE	B-CHEMICAL
for	O
appropriate	O
regulation	O
under	O
physiological	O
conditions	O
.	O

In	O
contrast	O
,	O
tyrosine	B-GENE-Y
hydroxylase	I-GENE-Y
knockout	O
(	O
Th	B-GENE-Y
-	O
/	O
-	O
)	O
mice	O
that	O
lack	O
both	O
NE	B-CHEMICAL
and	O
dopamine	B-CHEMICAL
(	O
DA	B-CHEMICAL
)	O
have	O
reduced	O
levels	O
of	O
NET	B-GENE-Y
,	O
suggesting	O
that	O
it	O
is	O
down	O
-	O
regulated	O
by	O
a	O
complete	O
absence	O
of	O
catecholamines	B-CHEMICAL
and	O
not	O
NE	B-CHEMICAL
per	O
se	O
.	O

Chronic	O
treatment	O
with	O
the	O
NET	B-GENE-Y
inhibitor	O
,	O
desipramine	B-CHEMICAL
(	O
DMI	O
)	O
,	O
reduced	O
NET	B-GENE-Y
levels	O
in	O
both	O
control	O
and	O
Dbh	B-GENE-Y
-	O
/	O
-	O
mice	O
,	O
demonstrating	O
that	O
NE	B-CHEMICAL
is	O
not	O
required	O
for	O
the	O
regulation	O
of	O
NET	B-GENE-Y
by	O
antidepressant	O
drugs	O
.	O

There	O
are	O
some	O
qualitative	O
and	O
quantitative	O
differences	O
in	O
the	O
down	O
-	O
regulation	O
of	O
the	O
NET	B-GENE-Y
by	O
catecholamine	O
depletion	O
and	O
DMI	O
treatment	O
,	O
suggesting	O
that	O
different	O
mechanisms	O
may	O
be	O
involved	O
.	O

Nicotinic	B-GENE-N
acetylcholine	I-GENE-N
receptor	I-GENE-N
regulation	O
of	O
spinal	O
norepinephrine	B-CHEMICAL
release	O
.	O

BACKGROUND	O
:	O
Neuronal	B-GENE-N
nicotinic	I-GENE-N
acetylcholine	I-GENE-N
receptor	I-GENE-N
(	O
nAChR	B-GENE-N
)	O
agonists	O
produce	O
antinociception	O
in	O
animals	O
.	O

nAChRs	B-GENE-N
exist	O
almost	O
exclusively	O
on	O
presynaptic	O
terminals	O
in	O
the	O
central	O
nervous	O
system	O
and	O
stimulate	O
neurotransmitter	O
release	O
.	O

This	O
study	O
tested	O
whether	O
nAChR	B-GENE-N
agonists	O
stimulate	O
spinal	O
release	O
of	O
the	O
neurotransmitter	O
norepinephrine	B-CHEMICAL
either	O
by	O
direct	O
actions	O
on	O
noradrenergic	O
terminals	O
or	O
indirectly	O
by	O
stimulating	O
release	O
of	O
other	O
neurotransmitters	O
to	O
induce	O
norepinephrine	B-CHEMICAL
release	O
.	O

METHODS	O
:	O
Adult	O
male	O
rats	O
were	O
anesthetized	O
and	O
microdialysis	O
probes	O
inserted	O
in	O
the	O
L2	O
-	O
L4	O
dermatomes	O
of	O
the	O
spinal	O
cord	O
.	O

Probes	O
were	O
perfused	O
with	O
artificial	O
cerebrospinal	O
fluid	O
containing	O
nicotine	O
,	O
the	O
specific	O
alpha	B-GENE-Y
(	I-GENE-Y
4	I-GENE-Y
)	I-GENE-Y
beta	I-GENE-Y
(	I-GENE-Y
2	I-GENE-Y
*	I-GENE-Y
)	I-GENE-Y
nAChR	I-GENE-Y
agonist	O
metanicotine	B-CHEMICAL
,	O
or	O
nicotine	B-CHEMICAL
plus	O
nAChR	B-GENE-N
antagonists	O
and	O
norepinephrine	B-CHEMICAL
measured	O
in	O
the	O
microdialysates	O
.	O

The	O
effects	O
of	O
specific	O
glutamate	B-GENE-N
receptor	I-GENE-N
antagonists	O
and	O
nitric	B-GENE-N
oxide	I-GENE-N
synthase	I-GENE-N
inhibitors	O
were	O
also	O
examined	O
.	O

To	O
determine	O
direct	O
effects	O
on	O
noradrenergic	O
terminals	O
,	O
synaptosomes	O
were	O
prepared	O
from	O
spinal	O
cord	O
and	O
incubated	O
with	O
nAChR	B-GENE-N
agonists	O
and	O
antagonists	O
.	O

RESULTS	O
:	O
Both	O
nicotine	B-CHEMICAL
and	O
metanicotine	B-CHEMICAL
induced	O
norepinephrine	B-CHEMICAL
release	O
in	O
spinal	O
microdialsyates	O
,	O
an	O
effect	O
reduced	O
by	O
nicotinic	O
antagonists	O
but	O
not	O
glutamate	B-CHEMICAL
antagonists	O
or	O
nitric	B-GENE-N
oxide	I-GENE-N
synthase	I-GENE-N
inhibitors	O
.	O

Both	O
of	O
the	O
nicotinic	O
agonists	O
stimulated	O
norepinephrine	B-CHEMICAL
release	O
in	O
synaptosomes	O
,	O
and	O
the	O
effect	O
of	O
metanicotine	B-CHEMICAL
was	O
blocked	O
at	O
lower	O
concentrations	O
of	O
alpha	B-GENE-Y
(	I-GENE-Y
4	I-GENE-Y
)	I-GENE-Y
beta	I-GENE-Y
(	I-GENE-Y
2	I-GENE-Y
*	I-GENE-Y
)	I-GENE-Y
-	O
than	O
alpha	B-GENE-Y
(	I-GENE-Y
7	I-GENE-Y
*	I-GENE-Y
)	I-GENE-Y
-	O
preferring	O
nAChR	B-GENE-N
antagonists	O
.	O

CONCLUSION	O
:	O
These	O
results	O
suggest	O
that	O
one	O
mechanism	O
by	O
which	O
nAChR	B-GENE-N
agonists	O
act	O
for	O
analgesia	O
is	O
to	O
stimulate	O
spinal	O
norepinephrine	B-CHEMICAL
release	O
.	O

They	O
do	O
so	O
by	O
actions	O
on	O
alpha	B-GENE-Y
(	I-GENE-Y
4	I-GENE-Y
)	I-GENE-Y
beta	I-GENE-Y
(	I-GENE-Y
2	I-GENE-Y
*	I-GENE-Y
)	I-GENE-Y
nAChRs	I-GENE-Y
,	O
and	O
perhaps	O
other	O
subtypes	O
,	O
most	O
likely	O
located	O
on	O
noradrenergic	O
terminals	O
,	O
rather	O
than	O
by	O
indirectly	O
stimulating	O
norepinephrine	B-CHEMICAL
release	O
through	O
glutamate	B-CHEMICAL
release	O
or	O
nitric	B-CHEMICAL
oxide	I-CHEMICAL
synthesis	O
.	O

The	O
pharmacology	O
of	O
cilostazol	B-CHEMICAL
.	O

Cilostazol	B-CHEMICAL
(	B-CHEMICAL
6	I-CHEMICAL
-	I-CHEMICAL
[	I-CHEMICAL
4	I-CHEMICAL
-	I-CHEMICAL
(	I-CHEMICAL
1	I-CHEMICAL
-	I-CHEMICAL
cyclohexyl	I-CHEMICAL
-	I-CHEMICAL
1H	I-CHEMICAL
-	I-CHEMICAL
tetrazol	I-CHEMICAL
-	I-CHEMICAL
5	I-CHEMICAL
-	I-CHEMICAL
yl	I-CHEMICAL
)	I-CHEMICAL
butoxy	I-CHEMICAL
]	I-CHEMICAL
-	I-CHEMICAL
3	I-CHEMICAL
,	I-CHEMICAL
4	I-CHEMICAL
-	I-CHEMICAL
dihydro	I-CHEMICAL
-	I-CHEMICAL
2	I-CHEMICAL
(	I-CHEMICAL
1H	I-CHEMICAL
)	I-CHEMICAL
-	I-CHEMICAL
quinolinone	I-CHEMICAL
;	O
OPC	B-CHEMICAL
-	I-CHEMICAL
13013	I-CHEMICAL
)	O
is	O
a	O
2	B-CHEMICAL
-	I-CHEMICAL
oxo	I-CHEMICAL
-	I-CHEMICAL
quinoline	I-CHEMICAL
derivative	O
with	O
antithrombotic	O
,	O
vasodilator	O
,	O
antimitogenic	O
and	O
cardiotonic	O
properties	O
.	O

The	O
compound	O
is	O
a	O
potent	O
inhibitor	O
of	O
phosphodiesterase	B-GENE-Y
(	I-GENE-Y
PDE	I-GENE-Y
)	I-GENE-Y
3A	I-GENE-Y
,	O
the	O
isoform	O
of	O
PDE	B-GENE-N
3	I-GENE-N
in	O
the	O
cardiovascular	O
system	O
(	O
IC50	O
:	O
0	O
.	O
2	O
microM	O
)	O
.	O

In	O
addition	O
,	O
there	O
is	O
inhibition	O
of	O
adenosine	B-CHEMICAL
uptake	O
,	O
eventually	O
resulting	O
in	O
changes	O
in	O
cAMP	B-CHEMICAL
levels	O
,	O
dependent	O
on	O
the	O
type	O
of	O
adenosine	B-GENE-N
receptors	I-GENE-N
(	I-GENE-N
A1	I-GENE-N
or	I-GENE-N
A2	I-GENE-N
)	I-GENE-N
.	O

Cilostazol	B-CHEMICAL
inhibits	O
platelet	O
aggregation	O
and	O
has	O
considerable	O
antithrombotic	O
effects	O
in	O
vivo	O
.	O

The	O
compound	O
relaxes	O
vascular	O
smooth	O
muscle	O
and	O
inhibits	O
mitogenesis	O
and	O
migration	O
of	O
vascular	O
smooth	O
muscle	O
cells	O
.	O

In	O
the	O
heart	O
,	O
cilostazol	B-CHEMICAL
causes	O
positive	O
inotropic	O
and	O
chronotropic	O
effects	O
.	O

Most	O
,	O
if	O
not	O
all	O
,	O
of	O
these	O
actions	O
are	O
cAMP	B-CHEMICAL
-	O
mediated	O
,	O
including	O
the	O
modification	O
of	O
cAMP	B-CHEMICAL
-	O
controlled	O
gene	O
expression	O
.	O

Cilostazol	B-CHEMICAL
decreases	O
levels	O
of	O
serum	O
triglycerides	O
and	O
causes	O
some	O
increase	O
in	O
HDL	B-GENE-N
-	O
cholesterol	B-CHEMICAL
levels	O
.	O

The	O
compound	O
has	O
a	O
number	O
of	O
additional	O
effects	O
which	O
might	O
contribute	O
to	O
its	O
overall	O
clinical	O
efficacy	O
.	O

Cilostazol	B-CHEMICAL
undergoes	O
intensive	O
and	O
finally	O
complete	O
hepatic	O
metabolism	O
via	O
the	O
cytochrome	B-GENE-N
P450	I-GENE-N
systems	O
.	O

This	O
might	O
result	O
in	O
some	O
drug	O
interaction	O
,	O
i	O
.	O
e	O
.	O
with	O
erythromycin	B-CHEMICAL
and	O
omeprazole	B-CHEMICAL
.	O

The	O
half	O
-	O
life	O
is	O
approximately	O
10	O
h	O
,	O
resulting	O
in	O
about	O
2	O
-	O
fold	O
accumulation	O
of	O
the	O
drug	O
during	O
repeated	O
administration	O
.	O

Identification	O
of	O
interaction	O
sites	O
of	O
cyclic	O
nucleotide	B-CHEMICAL
phosphodiesterase	B-GENE-Y
type	I-GENE-Y
3A	I-GENE-Y
with	O
milrinone	B-CHEMICAL
and	O
cilostazol	B-CHEMICAL
using	O
molecular	O
modeling	O
and	O
site	O
-	O
directed	O
mutagenesis	O
.	O

To	O
identify	O
amino	B-CHEMICAL
acid	I-CHEMICAL
residues	O
involved	O
in	O
PDE3	B-GENE-Y
-	O
selective	O
inhibitor	O
binding	O
,	O
we	O
selected	O
eight	O
presumed	O
interacting	O
residues	O
in	O
the	O
substrate	O
-	O
binding	O
pocket	O
of	O
PDE3A	B-GENE-Y
using	O
a	O
model	O
created	O
on	O
basis	O
of	O
homology	O
to	O
the	O
PDE4B	B-GENE-Y
crystal	O
structure	O
.	O

We	O
changed	O
the	O
residues	O
to	O
alanine	B-CHEMICAL
using	O
site	O
-	O
directed	O
mutagenesis	O
technique	O
,	O
expressed	O
the	O
mutants	O
in	O
a	O
baculovirus	O
/	O
Sf9	O
cell	O
system	O
,	O
and	O
analyzed	O
the	O
kinetic	O
characteristics	O
of	O
inhibition	O
of	O
the	O
mutant	O
enzymes	O
by	O
milrinone	B-CHEMICAL
and	O
cilostazol	B-CHEMICAL
,	O
specific	O
inhibitors	O
of	O
PDE3	B-GENE-Y
.	O

The	O
mutants	O
displayed	O
differential	O
sensitivity	O
to	O
the	O
inhibitors	O
.	O

Mutants	O
Y751A	B-GENE-N
,	O
D950A	B-GENE-N
,	O
and	O
F1004A	B-GENE-N
had	O
reduced	O
sensitivity	O
to	O
milrinone	B-CHEMICAL
(	O
K	O
(	O
i	O
)	O
changed	O
from	O
0	O
.	O
66	O
microM	O
for	O
the	O
recombinant	O
PDE3A	B-GENE-Y
to	O
7	O
.	O
5	O
to	O
156	O
microM	O
for	O
the	O
mutants	O
)	O
,	O
and	O
diminished	O
sensitivity	O
to	O
cilostazol	B-CHEMICAL
(	O
K	O
(	O
i	O
)	O
of	O
the	O
mutants	O
were	O
18	O
-	O
to	O
371	O
-	O
fold	O
higher	O
than	O
that	O
of	O
the	O
recombinant	O
PDE3A	B-GENE-Y
)	O
.	O

In	O
contrast	O
,	O
the	O
mutants	O
T844A	B-GENE-N
,	O
F972A	B-GENE-N
and	O
Q975A	B-GENE-N
showed	O
increased	O
K	O
(	O
i	O
)	O
for	O
cilostazol	B-CHEMICAL
but	O
no	O
difference	O
for	O
milrinone	B-CHEMICAL
from	O
the	O
recombinant	O
PDE3A	B-GENE-Y
.	O

Molecular	O
models	O
show	O
that	O
the	O
PDE3	B-GENE-Y
inhibitors	O
cilostazol	B-CHEMICAL
and	O
milrinone	B-CHEMICAL
share	O
some	O
of	O
common	O
residues	O
but	O
interact	O
with	O
distinct	O
residues	O
at	O
the	O
active	O
site	O
,	O
suggesting	O
that	O
selective	O
inhibitors	O
can	O
be	O
designed	O
with	O
flexible	O
size	O
against	O
PDE3	B-GENE-Y
active	O
site	O
.	O

Our	O
study	O
implies	O
that	O
highly	O
conserved	O
residuals	O
Y751	O
,	O
D950	O
and	O
F1004	O
in	O
the	O
PDE	B-GENE-Y
families	O
are	O
key	O
residues	O
for	O
binding	O
of	O
both	O
substrate	O
and	O
inhibitors	O
,	O
and	O
nonconserved	O
T844	O
may	O
be	O
responsible	O
for	O
the	O
cilostazol	B-CHEMICAL
selectivity	O
of	O
PDE3A	B-GENE-Y
.	O

Detailed	O
knowledge	O
of	O
the	O
structure	O
of	O
inhibitory	O
sites	O
should	O
contribute	O
to	O
development	O
of	O
more	O
potent	O
and	O
specific	O
inhibitory	O
drugs	O
.	O

Enzymatic	O
catalysis	O
in	O
crystals	O
of	O
Escherichia	B-GENE-Y
coli	I-GENE-Y
maltodextrin	I-GENE-Y
phosphorylase	I-GENE-Y
.	O

The	O
bacterial	O
enzyme	O
maltodextrin	B-GENE-N
phosphorylase	I-GENE-N
(	O
MalP	B-GENE-N
)	O
catalyses	O
the	O
phosphorolysis	O
of	O
an	O
alpha	O
-	O
1	O
,	O
4	O
-	O
glycosidic	O
bond	O
in	O
maltodextrins	O
,	O
removing	O
the	O
non	O
-	O
reducing	O
glucosyl	B-CHEMICAL
residues	O
of	O
linear	O
oligosaccharides	O
as	O
glucose	B-CHEMICAL
-	I-CHEMICAL
1	I-CHEMICAL
-	I-CHEMICAL
phosphate	I-CHEMICAL
(	O
Glc1P	B-CHEMICAL
)	O
.	O

In	O
contrast	O
to	O
the	O
well	O
-	O
studied	O
muscle	O
glycogen	B-GENE-Y
phosphorylase	I-GENE-Y
(	O
GP	B-GENE-Y
)	O
,	O
MalP	B-GENE-Y
exhibits	O
no	O
allosteric	O
properties	O
and	O
has	O
a	O
higher	O
affinity	O
for	O
linear	O
oligosaccharides	O
than	O
GP	B-GENE-Y
.	O

We	O
have	O
used	O
MalP	B-GENE-Y
as	O
a	O
model	O
system	O
to	O
study	O
catalysis	O
in	O
the	O
crystal	O
in	O
the	O
direction	O
of	O
maltodextrin	O
synthesis	O
.	O

The	O
2	O
.	O
0A	O
crystal	O
structure	O
of	O
the	O
MalP	B-GENE-Y
/	O
Glc1P	B-CHEMICAL
binary	O
complex	O
shows	O
that	O
the	O
Glc1P	B-CHEMICAL
substrate	O
adopts	O
a	O
conformation	O
seen	O
previously	O
with	O
both	O
inactive	O
and	O
active	O
forms	O
of	O
mammalian	B-GENE-N
GP	I-GENE-N
,	O
with	O
the	O
phosphate	B-CHEMICAL
group	O
not	O
in	O
close	O
contact	O
with	O
the	O
5	B-CHEMICAL
'	I-CHEMICAL
-	I-CHEMICAL
phosphate	I-CHEMICAL
group	O
of	O
the	O
essential	O
pyridoxal	B-CHEMICAL
phosphate	I-CHEMICAL
(	O
PLP	B-CHEMICAL
)	O
cofactor	O
.	O

In	O
the	O
active	O
MalP	B-GENE-Y
enzyme	O
,	O
the	O
residue	O
Arg569	O
stabilizes	O
the	O
negative	O
-	O
charged	O
Glc1P	B-CHEMICAL
,	O
whereas	O
in	O
the	O
inactive	O
form	O
of	O
GP	B-GENE-Y
this	O
key	O
residue	O
is	O
held	O
away	O
from	O
the	O
catalytic	O
site	O
by	O
loop	O
280s	O
and	O
an	O
allosteric	O
transition	O
of	O
the	O
mammalian	O
enzyme	O
is	O
required	O
for	O
activation	O
.	O

The	O
comparison	O
between	O
MalP	B-GENE-Y
structures	O
shows	O
that	O
His377	O
,	O
through	O
a	O
hydrogen	O
bond	O
with	O
the	O
6	B-CHEMICAL
-	I-CHEMICAL
hydroxyl	I-CHEMICAL
group	O
of	O
Glc1P	B-CHEMICAL
substrate	O
,	O
triggers	O
a	O
conformational	O
change	O
of	O
the	O
380s	O
loop	O
.	O

This	O
mobile	O
region	O
folds	O
over	O
the	O
catalytic	O
site	O
and	O
contributes	O
to	O
the	O
specific	O
recognition	O
of	O
the	O
oligosaccharide	O
and	O
to	O
the	O
synergism	O
between	O
substrates	O
in	O
promoting	O
the	O
formation	O
of	O
the	O
MalP	B-GENE-Y
ternary	O
complex	O
.	O

The	O
structures	O
solved	O
after	O
the	O
diffusion	O
of	O
oligosaccharides	O
(	O
either	O
maltotetraose	B-CHEMICAL
,	O
G4	O
or	O
maltopentaose	B-CHEMICAL
,	O
G5	O
)	O
into	O
MalP	B-GENE-Y
/	O
Glc1P	B-CHEMICAL
crystals	O
show	O
the	O
formation	O
of	O
phosphate	B-CHEMICAL
and	O
elongation	O
of	O
the	O
oligosaccharide	O
chain	O
.	O

These	O
structures	O
,	O
refined	O
at	O
1	O
.	O
8A	O
and	O
at	O
2	O
.	O
2A	O
,	O
confirm	O
that	O
only	O
when	O
an	O
oligosaccharide	O
is	O
bound	O
to	O
the	O
catalytic	O
site	O
will	O
Glc1P	B-CHEMICAL
bend	O
its	O
phosphate	B-CHEMICAL
group	O
down	O
so	O
it	O
can	O
contact	O
the	O
PLP	B-CHEMICAL
5	B-CHEMICAL
'	I-CHEMICAL
phosphate	I-CHEMICAL
group	O
and	O
promote	O
catalysis	O
.	O

The	O
relatively	O
large	O
oligosaccharide	O
substrates	O
can	O
diffuse	O
quickly	O
into	O
the	O
MalP	B-GENE-Y
/	O
Glc1P	B-CHEMICAL
crystals	O
and	O
the	O
enzymatic	O
reaction	O
can	O
occur	O
without	O
significant	O
crystal	O
damage	O
.	O

These	O
structures	O
obtained	O
before	O
and	O
after	O
catalysis	O
have	O
been	O
used	O
as	O
frames	O
of	O
a	O
molecular	O
movie	O
.	O

This	O
movie	O
reveals	O
the	O
relative	O
positions	O
of	O
substrates	O
in	O
the	O
catalytic	O
channel	O
and	O
shows	O
a	O
minimal	O
movement	O
of	O
the	O
protein	O
,	O
involving	O
mainly	O
Arg569	O
,	O
which	O
tracks	O
the	O
substrate	O
phosphate	B-CHEMICAL
group	O
.	O

The	O
pharmacokinetics	O
of	O
fondaparinux	B-CHEMICAL
sodium	I-CHEMICAL
in	O
healthy	O
volunteers	O
.	O

OBJECTIVE	O
:	O
Fondaparinux	B-CHEMICAL
sodium	I-CHEMICAL
is	O
the	O
first	O
in	O
a	O
new	O
class	O
of	O
synthetic	O
factor	B-GENE-Y
Xa	I-GENE-Y
inhibitors	O
that	O
binds	O
reversibly	O
with	O
high	O
affinity	O
to	O
antithrombin	B-GENE-Y
III	I-GENE-Y
.	O

It	O
has	O
been	O
investigated	O
for	O
the	O
prevention	O
and	O
treatment	O
of	O
arterial	O
and	O
venous	O
thrombotic	O
disorders	O
and	O
approved	O
for	O
use	O
at	O
a	O
dose	O
of	O
2	O
.	O
5mg	O
once	O
daily	O
in	O
the	O
prevention	O
of	O
venous	O
thromboembolism	O
in	O
major	O
orthopaedic	O
surgery	O
.	O

The	O
pharmacokinetics	O
of	O
fondaparinux	B-CHEMICAL
sodium	I-CHEMICAL
were	O
determined	O
in	O
eight	O
studies	O
in	O
young	O
and	O
elderly	O
healthy	O
volunteers	O
.	O

RESULTS	O
:	O
After	O
a	O
2	O
.	O
5mg	O
subcutaneous	O
dose	O
to	O
young	O
volunteers	O
,	O
absolute	O
bioavailability	O
was	O
100	O
%	O
and	O
absorption	O
was	O
rapid	O
and	O
complete	O
[	O
peak	O
plasma	O
concentration	O
(	O
C	O
(	O
max	O
)	O
)	O
0	O
.	O
34	O
mg	O
/	O
L	O
occurred	O
at	O
approximately	O
2	O
hours	O
]	O
.	O

Within	O
-	O
and	O
total	O
-	O
subject	O
variability	O
estimates	O
were	O
small	O
:	O
5	O
.	O
5	O
and	O
11	O
.	O
6	O
%	O
,	O
respectively	O
,	O
for	O
C	O
(	O
max	O
)	O
and	O
4	O
.	O
4	O
and	O
17	O
.	O
5	O
%	O
for	O
area	O
under	O
the	O
concentration	O
-	O
time	O
curve	O
(	O
AUC	O
)	O
.	O

Steady	O
state	O
was	O
obtained	O
after	O
the	O
third	O
or	O
fourth	O
once	O
-	O
daily	O
dose	O
,	O
with	O
a	O
1	O
.	O
3	O
-	O
fold	O
increase	O
in	O
C	O
(	O
max	O
)	O
and	O
AUC	O
.	O

Distribution	O
volume	O
(	O
7	O
to	O
11L	O
)	O
was	O
limited	O
to	O
blood	O
volume	O
.	O

There	O
was	O
no	O
evidence	O
of	O
metabolism	O
.	O

Fondaparinux	B-CHEMICAL
sodium	I-CHEMICAL
was	O
almost	O
completely	O
excreted	O
in	O
urine	O
as	O
unchanged	O
compound	O
(	O
64	O
to	O
77	O
%	O
of	O
the	O
dose	O
was	O
recovered	O
at	O
72	O
hours	O
after	O
administration	O
)	O
.	O

Plasma	O
clearance	O
was	O
5	O
.	O
1	O
to	O
7	O
.	O
9	O
ml	O
/	O
min	O
,	O
renal	O
clearance	O
4	O
.	O
0	O
to	O
7	O
.	O
9	O
ml	O
/	O
min	O
,	O
and	O
the	O
terminal	O
half	O
-	O
life	O
was	O
17	O
hours	O
in	O
young	O
volunteers	O
and	O
21	O
hours	O
in	O
elderly	O
volunteers	O
.	O

Pharmacokinetics	O
of	O
fondaparinux	B-CHEMICAL
sodium	I-CHEMICAL
were	O
linear	O
in	O
the	O
range	O
2	O
to	O
8mg	O
subcutaneously	O
and	O
2	O
to	O
20mg	O
intravenously	O
.	O

Pharmacokinetics	O
observed	O
in	O
healthy	O
elderly	O
volunteers	O
were	O
consistent	O
with	O
findings	O
in	O
young	O
male	O
volunteers	O
.	O

CONCLUSION	O
:	O
The	O
favourable	O
pharmacokinetic	O
profile	O
of	O
fondaparinux	B-CHEMICAL
sodium	I-CHEMICAL
is	O
likely	O
to	O
play	O
an	O
important	O
role	O
in	O
the	O
major	O
advance	O
that	O
the	O
drug	O
represents	O
in	O
the	O
prevention	O
and	O
treatment	O
of	O
thrombotic	O
disorders	O
.	O

Molecular	O
analysis	O
of	O
PCCB	B-GENE-Y
gene	O
in	O
Korean	O
patients	O
with	O
propionic	B-CHEMICAL
acidemia	O
.	O

Propionic	O
acidemia	O
(	O
PA	O
)	O
is	O
an	O
autosomal	O
recessive	O
inborn	O
error	O
in	O
the	O
catabolism	O
of	O
methionine	B-CHEMICAL
,	O
isoleucine	B-CHEMICAL
,	O
threonine	B-CHEMICAL
,	O
and	O
valine	B-CHEMICAL
,	O
odd	B-CHEMICAL
-	I-CHEMICAL
numbered	I-CHEMICAL
chain	I-CHEMICAL
length	I-CHEMICAL
fatty	I-CHEMICAL
acids	I-CHEMICAL
and	O
cholesterol	B-CHEMICAL
.	O

Clinical	O
symptoms	O
are	O
very	O
heterogeneous	O
and	O
present	O
as	O
a	O
severe	O
neonatal	O
-	O
onset	O
or	O
a	O
late	O
-	O
onset	O
form	O
.	O

It	O
is	O
caused	O
by	O
a	O
deficiency	O
of	O
propionyl	B-GENE-N
-	I-GENE-N
CoA	I-GENE-N
carboxylase	I-GENE-N
(	O
PCC	B-GENE-N
,	O
EC	B-GENE-Y
6	I-GENE-Y
.	I-GENE-Y
4	I-GENE-Y
.	I-GENE-Y
1	I-GENE-Y
.	I-GENE-Y
3	I-GENE-Y
)	O
,	O
a	O
biotin	B-CHEMICAL
-	O
dependent	O
enzyme	O
that	O
catalyzes	O
the	O
carboxylation	O
of	O
propionyl	B-CHEMICAL
-	I-CHEMICAL
CoA	I-CHEMICAL
to	O
D	B-CHEMICAL
-	I-CHEMICAL
methylmalonyl	I-CHEMICAL
-	I-CHEMICAL
CoA	I-CHEMICAL
.	O

PCC	B-GENE-N
is	O
a	O
heteropolymeric	O
enzyme	O
composed	O
of	O
alpha	O
-	O
and	O
beta	O
-	O
subunits	O
.	O

A	O
greater	O
heterogeneity	O
is	O
observed	O
in	O
the	O
PCCA	B-GENE-Y
gene	O
,	O
while	O
for	O
the	O
PCCB	B-GENE-Y
gene	O
,	O
a	O
limited	O
number	O
of	O
mutations	O
is	O
responsible	O
for	O
the	O
majority	O
of	O
the	O
alleles	O
characterized	O
in	O
both	O
Caucasian	O
and	O
Oriental	O
populations	O
.	O

We	O
identified	O
eight	O
Korean	O
patients	O
with	O
PA	O
by	O
organic	O
acid	O
analysis	O
confirmed	O
in	O
five	O
patients	O
by	O
the	O
PCC	B-GENE-N
enzyme	O
assay	O
in	O
the	O
lymphoblasts	O
.	O

Two	O
neonatal	O
-	O
onset	O
patients	O
showed	O
undetectable	O
PCC	B-GENE-N
activities	O
while	O
three	O
cases	O
with	O
residual	O
enzyme	O
activities	O
had	O
relatively	O
late	O
manifestations	O
.	O

In	O
the	O
molecular	O
analysis	O
,	O
we	O
identified	O
five	O
novel	O
mutations	O
,	O
Y439C	B-GENE-N
,	O
1527del3	O
,	O
1357insT	O
,	O
IVS12	B-GENE-N
-	I-GENE-N
8T	I-GENE-N
-	I-GENE-N
-	I-GENE-N
>	I-GENE-N
A	I-GENE-N
,	O
and	O
31del10	O
,	O
and	O
one	O
known	O
mutation	O
,	O
T428I	B-GENE-N
in	O
PCCB	B-GENE-Y
gene	O
.	O

Alleleic	O
frequency	O
of	O
T428I	B-GENE-N
in	O
Korean	O
patients	O
with	O
PA	O
was	O
56	O
.	O
3	O
%	O
in	O
this	O
study	O
.	O

Two	O
neonatal	O
-	O
onset	O
patients	O
with	O
null	O
enzyme	O
activities	O
were	O
homozygotes	O
with	O
1527del3	O
and	O
T428I	B-GENE-N
,	O
respectively	O
.	O

This	O
finding	O
implies	O
that	O
T428I	B-GENE-N
and	O
1527del3	O
mutation	O
could	O
be	O
responsible	O
for	O
their	O
severe	O
clinical	O
courses	O
and	O
null	O
enzyme	O
activities	O
.	O

The	O
mRNA	O
of	O
PCCB	B-GENE-Y
gene	O
in	O
T428I	B-GENE-N
and	O
1527del3	O
homozygotes	O
were	O
normal	O
but	O
in	O
Western	O
blot	O
analysis	O
,	O
the	O
betaPCC	B-GENE-Y
-	O
subunit	O
was	O
only	O
absent	O
in	O
1527del3	O
homozygote	O
patient	O
suggesting	O
different	O
molecular	O
pathology	O
.	O

Atypical	O
antipsychotic	O
drugs	O
,	O
quetiapine	B-CHEMICAL
,	O
iloperidone	B-CHEMICAL
,	O
and	O
melperone	B-CHEMICAL
,	O
preferentially	O
increase	O
dopamine	B-CHEMICAL
and	O
acetylcholine	B-CHEMICAL
release	O
in	O
rat	O
medial	O
prefrontal	O
cortex	O
:	O
role	O
of	O
5	B-GENE-Y
-	I-GENE-Y
HT1A	I-GENE-Y
receptor	O
agonism	O
.	O

Preferential	O
increases	O
in	O
both	O
cortical	O
dopamine	B-CHEMICAL
(	O
DA	B-CHEMICAL
)	O
and	O
acetylcholine	B-CHEMICAL
(	O
ACh	B-CHEMICAL
)	O
release	O
have	O
been	O
proposed	O
to	O
distinguish	O
the	O
atypical	O
antipsychotic	O
drugs	O
(	O
APDs	O
)	O
clozapine	B-CHEMICAL
,	O
olanzapine	B-CHEMICAL
,	O
risperidone	B-CHEMICAL
and	O
ziprasidone	B-CHEMICAL
from	O
typical	O
APDs	O
such	O
as	O
haloperidol	B-CHEMICAL
.	O

Although	O
only	O
clozapine	B-CHEMICAL
and	O
ziprasidone	B-CHEMICAL
are	O
directly	O
acting	O
5	B-GENE-Y
-	I-GENE-Y
HT	I-GENE-Y
(	I-GENE-Y
1A	I-GENE-Y
)	I-GENE-Y
agonists	O
,	O
WAY100635	B-CHEMICAL
,	O
a	O
selective	O
5	B-GENE-Y
-	I-GENE-Y
HT	I-GENE-Y
(	I-GENE-Y
1A	I-GENE-Y
)	I-GENE-Y
antagonist	O
,	O
partially	O
attenuates	O
these	O
atypical	O
APD	O
-	O
induced	O
increases	O
in	O
cortical	O
DA	B-CHEMICAL
release	O
that	O
may	O
be	O
due	O
to	O
combined	O
5	B-GENE-Y
-	I-GENE-Y
HT	I-GENE-Y
(	I-GENE-Y
2A	I-GENE-Y
)	I-GENE-Y
and	O
D	B-GENE-Y
(	I-GENE-Y
2	I-GENE-Y
)	I-GENE-Y
blockade	O
.	O

However	O
,	O
WAY100635	B-CHEMICAL
does	O
not	O
attenuate	O
clozapine	B-CHEMICAL
-	O
induced	O
cortical	O
ACh	B-CHEMICAL
release	O
.	O

The	O
present	O
study	O
determined	O
whether	O
quetiapine	B-CHEMICAL
,	O
iloperidone	B-CHEMICAL
and	O
melperone	B-CHEMICAL
,	O
5	B-GENE-Y
-	I-GENE-Y
HT	I-GENE-Y
(	I-GENE-Y
2A	I-GENE-Y
)	I-GENE-Y
/	O
D	B-GENE-Y
(	I-GENE-Y
2	I-GENE-Y
)	I-GENE-Y
antagonist	O
atypical	O
APDs	O
,	O
also	O
increase	O
cortical	O
DA	B-CHEMICAL
and	O
ACh	B-CHEMICAL
release	O
,	O
and	O
whether	O
these	O
effects	O
are	O
related	O
to	O
5	B-GENE-Y
-	I-GENE-Y
HT	I-GENE-Y
(	I-GENE-Y
1A	I-GENE-Y
)	I-GENE-Y
agonism	O
.	O

Quetiapine	B-CHEMICAL
(	O
30	O
mg	O
/	O
kg	O
)	O
,	O
iloperidone	B-CHEMICAL
(	O
1	O
-	O
10	O
mg	O
/	O
kg	O
)	O
,	O
and	O
melperone	B-CHEMICAL
(	O
3	O
-	O
10	O
mg	O
/	O
kg	O
)	O
increased	O
DA	B-CHEMICAL
and	O
ACh	B-CHEMICAL
release	O
in	O
the	O
medial	O
prefrontal	O
cortex	O
(	O
mPFC	O
)	O
.	O

Iloperidone	B-CHEMICAL
(	O
10	O
mg	O
/	O
kg	O
)	O
and	O
melperone	B-CHEMICAL
(	O
10	O
mg	O
/	O
kg	O
)	O
,	O
but	O
not	O
quetiapine	B-CHEMICAL
(	O
30	O
mg	O
/	O
kg	O
)	O
,	O
produced	O
an	O
equivalent	O
or	O
a	O
smaller	O
increase	O
in	O
DA	B-CHEMICAL
release	O
in	O
the	O
nucleus	O
accumbens	O
(	O
NAC	O
)	O
,	O
respectively	O
,	O
compared	O
to	O
the	O
mPFC	O
,	O
whereas	O
none	O
of	O
them	O
increased	O
ACh	B-CHEMICAL
release	O
in	O
the	O
NAC	O
.	O

WAY100635	B-CHEMICAL
(	O
0	O
.	O
2	O
mg	O
/	O
kg	O
)	O
,	O
which	O
alone	O
did	O
not	O
affect	O
DA	B-CHEMICAL
or	O
ACh	B-CHEMICAL
release	O
,	O
partially	O
attenuated	O
quetiapine	B-CHEMICAL
(	O
30	O
mg	O
/	O
kg	O
)	O
-	O
,	O
iloperidone	B-CHEMICAL
(	O
10	O
mg	O
/	O
kg	O
)	O
-	O
and	O
melperone	B-CHEMICAL
(	O
10	O
mg	O
/	O
kg	O
)	O
-	O
induced	O
DA	B-CHEMICAL
release	O
in	O
the	O
mPFC	O
.	O

WAY100635	B-CHEMICAL
also	O
partially	O
attenuated	O
quetiapine	B-CHEMICAL
(	O
30	O
mg	O
/	O
kg	O
)	O
-	O
induced	O
ACh	B-CHEMICAL
release	O
in	O
the	O
mPFC	O
,	O
but	O
not	O
that	O
induced	O
by	O
iloperidone	B-CHEMICAL
(	O
10	O
mg	O
/	O
kg	O
)	O
or	O
melperone	B-CHEMICAL
(	O
10	O
mg	O
/	O
kg	O
)	O
.	O

These	O
results	O
indicate	O
that	O
quetiapine	B-CHEMICAL
,	O
iloperidone	B-CHEMICAL
and	O
melperone	B-CHEMICAL
preferentially	O
increase	O
DA	B-CHEMICAL
release	O
in	O
the	O
mPFC	O
,	O
compared	O
to	O
the	O
NAC	O
via	O
a	O
5	B-GENE-Y
-	I-GENE-Y
HT	I-GENE-Y
(	I-GENE-Y
1A	I-GENE-Y
)	I-GENE-Y
-	O
related	O
mechanism	O
.	O

However	O
,	O
5	B-GENE-Y
-	I-GENE-Y
HT	I-GENE-Y
(	I-GENE-Y
1A	I-GENE-Y
)	I-GENE-Y
agonism	O
may	O
be	O
important	O
only	O
for	O
quetiapine	B-CHEMICAL
-	O
induced	O
ACh	B-CHEMICAL
release	O
.	O

Effects	O
of	O
age	O
and	O
sex	O
on	O
the	O
disposition	O
of	O
retigabine	B-CHEMICAL
.	O

BACKGROUND	O
:	O
The	O
novel	O
antiepileptic	O
drug	O
retigabine	B-CHEMICAL
is	O
the	O
first	O
selective	O
M	B-GENE-N
-	I-GENE-N
current	I-GENE-N
potassium	I-GENE-N
channel	I-GENE-N
opener	O
for	O
KCNQ2	B-GENE-N
/	I-GENE-N
3	I-GENE-N
and	O
KCNQ3	B-GENE-N
/	I-GENE-N
5	I-GENE-N
channels	O
.	O

Retigabine	B-CHEMICAL
undergoes	O
phase	O
II	O
metabolism	O
(	O
N	B-CHEMICAL
-	O
glucuronidation	O
,	O
acetylation	O
)	O
exclusively	O
and	O
renal	O
excretion	O
.	O

OBJECTIVE	O
:	O
Our	O
objective	O
was	O
to	O
evaluate	O
the	O
effects	O
of	O
age	O
and	O
sex	O
on	O
the	O
pharmacokinetics	O
of	O
retigabine	B-CHEMICAL
.	O

METHODS	O
:	O
Healthy	O
young	O
(	O
age	O
range	O
,	O
18	O
-	O
40	O
years	O
)	O
and	O
elderly	O
(	O
age	O
range	O
,	O
66	O
-	O
81	O
years	O
)	O
white	O
subjects	O
(	O
12	O
men	O
and	O
12	O
women	O
in	O
each	O
group	O
)	O
received	O
a	O
single	O
200	O
-	O
mg	O
oral	O
dose	O
of	O
retigabine	B-CHEMICAL
.	O

After	O
dosing	O
,	O
blood	O
was	O
collected	O
over	O
a	O
72	O
-	O
hour	O
period	O
to	O
determine	O
plasma	O
concentrations	O
of	O
retigabine	B-CHEMICAL
and	O
its	O
acetylated	O
metabolite	O
,	O
AWD21	B-CHEMICAL
-	I-CHEMICAL
360	I-CHEMICAL
.	O

Pharmacokinetics	O
was	O
compared	O
for	O
age	O
group	O
and	O
sex	O
by	O
ANOVA	O
.	O

RESULTS	O
:	O
In	O
young	O
men	O
,	O
retigabine	B-CHEMICAL
was	O
rapidly	O
absorbed	O
,	O
with	O
the	O
maximum	O
concentration	O
occurring	O
within	O
2	O
hours	O
,	O
and	O
was	O
eliminated	O
with	O
an	O
apparent	O
clearance	O
of	O
0	O
.	O
67	O
L	O
x	O
h	O
(	O
-	O
1	O
)	O
x	O
kg	O
(	O
-	O
1	O
)	O
and	O
a	O
mean	O
terminal	O
half	O
-	O
life	O
of	O
8	O
.	O
5	O
hours	O
.	O

Subjects	O
were	O
similarly	O
exposed	O
to	O
AWD21	B-CHEMICAL
-	I-CHEMICAL
360	I-CHEMICAL
.	O

Compared	O
with	O
young	O
men	O
,	O
young	O
women	O
had	O
higher	O
retigabine	B-CHEMICAL
maximum	O
concentration	O
(	O
56	O
%	O
)	O
and	O
exposure	O
(	O
20	O
%	O
)	O
but	O
similar	O
clearance	O
(	O
0	O
.	O
68	O
L	O
x	O
h	O
(	O
-	O
1	O
)	O
x	O
kg	O
(	O
-	O
1	O
)	O
)	O
;	O
these	O
differences	O
were	O
related	O
to	O
differences	O
in	O
body	O
weight	O
.	O

Although	O
maximum	O
concentration	O
was	O
similar	O
in	O
elderly	O
subjects	O
,	O
retigabine	B-CHEMICAL
elimination	O
was	O
slower	O
(	O
30	O
%	O
lower	O
apparent	O
clearance	O
normalized	O
for	O
weight	O
)	O
,	O
resulting	O
in	O
higher	O
exposure	O
(	O
42	O
%	O
)	O
and	O
a	O
longer	O
half	O
-	O
life	O
(	O
30	O
%	O
)	O
.	O

Because	O
phase	O
II	O
metabolism	O
is	O
scarcely	O
affected	O
by	O
age	O
,	O
these	O
differences	O
may	O
be	O
related	O
to	O
the	O
known	O
decline	O
of	O
renal	O
function	O
with	O
age	O
.	O

CONCLUSIONS	O
:	O
Although	O
there	O
are	O
no	O
substantial	O
sex	O
-	O
related	O
differences	O
in	O
the	O
disposition	O
of	O
retigabine	B-CHEMICAL
,	O
a	O
relevant	O
decrease	O
in	O
clearance	O
resulting	O
in	O
higher	O
exposure	O
occurs	O
in	O
elderly	O
patients	O
.	O

The	O
results	O
suggest	O
that	O
decline	O
of	O
renal	O
function	O
with	O
age	O
may	O
account	O
for	O
some	O
of	O
the	O
observed	O
changes	O
.	O

Selective	O
cyclooxygenase	B-GENE-Y
-	I-GENE-Y
2	I-GENE-Y
inhibition	O
does	O
not	O
affect	O
the	O
healing	O
of	O
cutaneous	O
full	O
-	O
thickness	O
incisional	O
wounds	O
in	O
SKH	O
-	O
1	O
mice	O
.	O

BACKGROUND	O
:	O
The	O
inducible	O
cyclooxygenase	B-GENE-Y
-	I-GENE-Y
2	I-GENE-Y
(	O
COX	B-GENE-Y
-	I-GENE-Y
2	I-GENE-Y
)	O
enzyme	O
is	O
upregulated	O
in	O
inflammatory	O
diseases	O
,	O
as	O
well	O
as	O
in	O
epithelial	O
cancers	O
,	O
and	O
has	O
an	O
established	O
role	O
in	O
angiogenesis	O
and	O
tissue	O
repair	O
.	O

OBJECTIVE	O
:	O
Because	O
of	O
these	O
physiological	O
effects	O
and	O
the	O
widespread	O
use	O
of	O
the	O
selective	O
COX	B-GENE-Y
-	I-GENE-Y
2	I-GENE-Y
inhibitor	O
,	O
celecoxib	B-CHEMICAL
,	O
we	O
wanted	O
to	O
determine	O
if	O
inhibition	O
of	O
COX	B-GENE-Y
-	I-GENE-Y
2	I-GENE-Y
would	O
affect	O
incisional	O
skin	O
wound	O
healing	O
.	O

METHODS	O
:	O
Using	O
a	O
cutaneous	O
full	O
-	O
thickness	O
,	O
sutured	O
,	O
incisional	O
wound	O
model	O
in	O
hairless	O
SKH	O
-	O
1	O
mice	O
,	O
we	O
evaluated	O
the	O
role	O
of	O
COX	B-GENE-Y
-	I-GENE-Y
2	I-GENE-Y
in	O
the	O
wound	O
healing	O
process	O
by	O
comparing	O
the	O
effects	O
of	O
a	O
nonselective	O
COX	B-GENE-N
inhibitor	O
,	O
diclofenac	B-CHEMICAL
,	O
with	O
a	O
selective	O
COX	B-GENE-Y
-	I-GENE-Y
2	I-GENE-Y
inhibitor	O
,	O
SC	O
-	O
791	O
.	O

Healing	O
was	O
monitored	O
for	O
up	O
to	O
28	O
days	O
postincision	O
histologically	O
and	O
for	O
recovery	O
of	O
wound	O
strength	O
.	O

RESULTS	O
:	O
COX	B-GENE-Y
-	I-GENE-Y
2	I-GENE-Y
expression	O
was	O
observed	O
over	O
the	O
first	O
week	O
of	O
healing	O
,	O
peaking	O
at	O
day	O
3	O
and	O
was	O
not	O
affected	O
by	O
treatment	O
with	O
the	O
selective	O
COX	B-GENE-Y
-	I-GENE-Y
2	I-GENE-Y
or	O
nonselective	O
COX	B-GENE-N
inhibitors	O
.	O

Infiltrating	O
macrophages	O
,	O
as	O
well	O
as	O
keratinocytes	O
and	O
dermal	O
fibroblasts	O
at	O
the	O
wound	O
site	O
,	O
expressed	O
COX	B-GENE-Y
-	I-GENE-Y
2	I-GENE-Y
.	O

Neither	O
selective	O
COX	B-GENE-Y
-	I-GENE-Y
2	I-GENE-Y
,	O
nor	O
nonselective	O
COX	B-GENE-N
inhibition	O
had	O
a	O
significant	O
effect	O
on	O
the	O
macroscopic	O
or	O
microscopic	O
morphology	O
of	O
the	O
wounds	O
,	O
whereas	O
dexamethasone	B-CHEMICAL
treatment	O
resulted	O
in	O
epidermal	O
and	O
granulation	O
tissue	O
atrophy	O
.	O

In	O
addition	O
,	O
neither	O
selective	O
COX	B-GENE-Y
-	I-GENE-Y
2	I-GENE-Y
,	O
nor	O
nonselective	O
COX	B-GENE-N
inhibition	O
altered	O
keratinocyte	O
proliferation	O
and	O
differentiation	O
,	O
dermal	O
angiogenesis	O
or	O
the	O
recovery	O
of	O
wound	O
tensile	O
strength	O
,	O
whereas	O
dexamethasone	B-CHEMICAL
reduced	O
the	O
tensile	O
strength	O
of	O
the	O
wounds	O
by	O
30	O
-	O
38	O
%	O
throughout	O
the	O
healing	O
period	O
.	O

CONCLUSIONS	O
:	O
These	O
data	O
indicate	O
that	O
selective	O
COX	B-GENE-Y
-	I-GENE-Y
2	I-GENE-Y
inhibition	O
does	O
not	O
affect	O
the	O
healing	O
of	O
surgical	O
skin	O
wounds	O
.	O

Synthesis	O
and	O
in	O
vivo	O
evaluation	O
of	O
novel	O
radiotracers	O
for	O
the	O
in	O
vivo	O
imaging	O
of	O
the	O
norepinephrine	B-GENE-Y
transporter	I-GENE-Y
.	O

The	O
(	B-CHEMICAL
R	I-CHEMICAL
,	I-CHEMICAL
R	I-CHEMICAL
)	I-CHEMICAL
and	I-CHEMICAL
(	I-CHEMICAL
S	I-CHEMICAL
,	I-CHEMICAL
S	I-CHEMICAL
)	I-CHEMICAL
enantiomers	I-CHEMICAL
of	I-CHEMICAL
2	I-CHEMICAL
-	I-CHEMICAL
[	I-CHEMICAL
(	I-CHEMICAL
2	I-CHEMICAL
-	I-CHEMICAL
methoxyphenoxy	I-CHEMICAL
)	I-CHEMICAL
phenylmethyl	I-CHEMICAL
]	I-CHEMICAL
morpholine	I-CHEMICAL
(	O
MeNER	B-CHEMICAL
)	O
have	O
been	O
radiolabelled	O
with	O
carbon	B-CHEMICAL
-	I-CHEMICAL
11	I-CHEMICAL
in	O
good	O
yield	O
and	O
at	O
high	O
specific	O
activity	O
.	O

These	O
radiotracers	O
are	O
close	O
analogues	O
of	O
reboxetine	B-CHEMICAL
,	O
a	O
potent	O
and	O
selective	O
ligand	O
for	O
the	O
norepinephrine	B-GENE-Y
transporter	I-GENE-Y
(	O
NET	B-GENE-Y
)	O
.	O

They	O
were	O
examined	O
as	O
potential	O
ligands	O
for	O
imaging	O
NET	B-GENE-Y
in	O
vivo	O
by	O
positron	O
emission	O
tomography	O
(	O
PET	O
)	O
.	O

The	O
in	O
vivo	O
brain	O
distribution	O
of	O
both	O
[	O
(	B-CHEMICAL
11	I-CHEMICAL
)	I-CHEMICAL
C	I-CHEMICAL
]	O
-	O
labeled	O
enantiomers	O
were	O
evaluated	O
in	O
rats	O
.	O

Following	O
tail	O
-	O
vein	O
injection	O
of	O
the	O
(	O
R	O
,	O
R	O
)	O
-	O
enantiomer	O
regional	O
brain	O
uptake	O
and	O
washout	O
of	O
radioactivity	O
was	O
homogeneous	O
at	O
all	O
time	O
points	O
examined	O
(	O
5	O
-	O
60	O
min	O
)	O
.	O

In	O
contrast	O
,	O
administration	O
of	O
the	O
(	O
S	O
,	O
S	O
)	O
-	O
enantiomer	O
produced	O
a	O
heterogeneous	O
distribution	O
of	O
radioactivity	O
in	O
brain	O
with	O
highest	O
uptake	O
in	O
the	O
hypothalamus	O
,	O
a	O
NET	B-GENE-Y
rich	O
region	O
,	O
and	O
lowest	O
uptake	O
in	O
the	O
striatum	O
,	O
a	O
brain	O
region	O
devoid	O
of	O
NET	B-GENE-Y
.	O

Hypothalamus	O
to	O
striatum	O
ratios	O
of	O
2	O
.	O
5	O
to	O
one	O
were	O
achieved	O
at	O
60	O
min	O
post	O
injection	O
of	O
(	B-CHEMICAL
S	I-CHEMICAL
,	I-CHEMICAL
S	I-CHEMICAL
)	I-CHEMICAL
-	I-CHEMICAL
[	I-CHEMICAL
(	I-CHEMICAL
11	I-CHEMICAL
)	I-CHEMICAL
C	I-CHEMICAL
]	I-CHEMICAL
-	I-CHEMICAL
MeNER	I-CHEMICAL
.	O

Pre	O
-	O
injection	O
of	O
the	O
norepinephrine	B-CHEMICAL
reuptake	O
inhibitors	O
,	O
reboxetine	B-CHEMICAL
or	O
desipramine	B-CHEMICAL
,	O
reduced	O
hypothalamus	O
to	O
striatum	O
ratios	O
to	O
near	O
unity	O
while	O
reuptake	O
inhibitors	O
of	O
dopamine	B-CHEMICAL
and	O
serotonin	B-CHEMICAL
had	O
no	O
significant	O
effect	O
on	O
binding	O
.	O

In	O
vitro	O
autoradiography	O
studies	O
(	O
rat	O
brain	O
slices	O
)	O
with	O
(	B-CHEMICAL
S	I-CHEMICAL
,	I-CHEMICAL
S	I-CHEMICAL
)	I-CHEMICAL
-	I-CHEMICAL
[	I-CHEMICAL
(	I-CHEMICAL
11	I-CHEMICAL
)	I-CHEMICAL
C	I-CHEMICAL
]	I-CHEMICAL
-	I-CHEMICAL
MeNER	I-CHEMICAL
produced	O
a	O
regional	O
distribution	O
pattern	O
that	O
was	O
consistent	O
with	O
the	O
reported	O
distribution	O
of	O
NET	B-GENE-Y
.	O

(	B-CHEMICAL
S	I-CHEMICAL
,	I-CHEMICAL
S	I-CHEMICAL
)	I-CHEMICAL
-	I-CHEMICAL
[	I-CHEMICAL
(	I-CHEMICAL
11	I-CHEMICAL
)	I-CHEMICAL
C	I-CHEMICAL
]	I-CHEMICAL
-	I-CHEMICAL
MeNER	I-CHEMICAL
has	O
the	O
potential	O
to	O
be	O
the	O
first	O
successful	O
PET	O
ligand	O
to	O
image	O
NET	B-GENE-Y
.	O

Histamine	B-GENE-Y
H1	I-GENE-Y
-	I-GENE-Y
receptor	I-GENE-Y
antagonists	O
,	O
promethazine	B-CHEMICAL
and	O
homochlorcyclizine	B-CHEMICAL
,	O
increase	O
the	O
steady	O
-	O
state	O
plasma	O
concentrations	O
of	O
haloperidol	B-CHEMICAL
and	O
reduced	O
haloperidol	B-CHEMICAL
.	O

The	O
effects	O
of	O
histamine	B-GENE-Y
H1	I-GENE-Y
-	I-GENE-Y
receptor	I-GENE-Y
antagonists	O
,	O
promethazine	B-CHEMICAL
and	O
homochlorcyclizine	B-CHEMICAL
,	O
both	O
of	O
which	O
are	O
inhibitors	O
of	O
CYP2D6	B-GENE-Y
,	O
on	O
the	O
steady	O
-	O
state	O
plasma	O
concentrations	O
(	O
Css	O
)	O
of	O
haloperidol	B-CHEMICAL
and	O
reduced	O
haloperidol	B-CHEMICAL
were	O
studied	O
in	O
23	O
schizophrenic	O
inpatients	O
receiving	O
haloperidol	B-CHEMICAL
,	O
12	O
to	O
36	O
mg	O
/	O
d	O
,	O
for	O
2	O
to	O
29	O
weeks	O
.	O

Promethazine	B-CHEMICAL
,	O
150	O
mg	O
/	O
d	O
,	O
in	O
11	O
patients	O
and	O
homochlorcyclizine	B-CHEMICAL
,	O
60	O
mg	O
/	O
d	O
,	O
in	O
the	O
others	O
were	O
coadministered	O
for	O
at	O
least	O
1	O
week	O
.	O

Blood	O
sampling	O
was	O
performed	O
before	O
and	O
during	O
coadministration	O
of	O
promethazine	B-CHEMICAL
or	O
homochlorcyclizine	B-CHEMICAL
and	O
1	O
week	O
after	O
the	O
discontinuation	O
,	O
together	O
with	O
clinical	O
assessments	O
by	O
Brief	O
Psychiatric	O
Rating	O
Scale	O
(	O
BPRS	O
)	O
and	O
Udvalg	O
for	O
kliniske	O
undersogelser	O
(	O
UKU	O
)	O
side	O
effect	O
rating	O
scale	O
.	O

The	O
Css	O
(	O
mean	O
+	O
/	O
-	O
SD	O
)	O
of	O
haloperidol	B-CHEMICAL
and	O
reduced	O
haloperidol	B-CHEMICAL
during	O
promethazine	B-CHEMICAL
coadministration	O
(	O
27	O
.	O
6	O
+	O
/	O
-	O
24	O
.	O
9	O
and	O
8	O
.	O
6	O
+	O
/	O
-	O
13	O
.	O
2	O
ng	O
/	O
mL	O
)	O
were	O
significantly	O
higher	O
than	O
those	O
before	O
the	O
coadministration	O
(	O
12	O
.	O
7	O
+	O
/	O
-	O
10	O
.	O
8	O
and	O
5	O
.	O
0	O
+	O
/	O
-	O
6	O
.	O
0	O
ng	O
/	O
mL	O
;	O
P	O
<	O
0	O
.	O
01	O
)	O
or	O
1	O
week	O
after	O
the	O
discontinuation	O
(	O
15	O
.	O
6	O
+	O
/	O
-	O
14	O
.	O
8	O
and	O
5	O
.	O
8	O
+	O
/	O
-	O
7	O
.	O
9	O
ng	O
/	O
mL	O
;	O
P	O
<	O
0	O
.	O
05	O
)	O
.	O

The	O
Css	O
of	O
haloperidol	B-CHEMICAL
and	O
reduced	O
haloperidol	B-CHEMICAL
during	O
homochlorcyclizine	B-CHEMICAL
coadministration	O
(	O
14	O
.	O
9	O
+	O
/	O
-	O
8	O
.	O
1	O
and	O
6	O
.	O
4	O
+	O
/	O
-	O
5	O
.	O
4	O
ng	O
/	O
mL	O
)	O
were	O
also	O
significantly	O
higher	O
than	O
those	O
before	O
the	O
coadministration	O
(	O
10	O
.	O
9	O
+	O
/	O
-	O
7	O
.	O
2	O
and	O
3	O
.	O
8	O
+	O
/	O
-	O
3	O
.	O
6	O
ng	O
/	O
mL	O
;	O
P	O
<	O
0	O
.	O
01	O
)	O
or	O
1	O
week	O
after	O
the	O
discontinuation	O
(	O
12	O
.	O
9	O
+	O
/	O
-	O
7	O
.	O
4	O
and	O
4	O
.	O
8	O
+	O
/	O
-	O
4	O
.	O
1	O
ng	O
/	O
mL	O
;	O
P	O
<	O
0	O
.	O
05	O
)	O
.	O

No	O
change	O
in	O
BPRS	O
or	O
UKU	O
score	O
was	O
found	O
throughout	O
the	O
study	O
.	O

Thus	O
,	O
the	O
current	O
study	O
suggests	O
that	O
coadministration	O
of	O
clinical	O
doses	O
of	O
promethazine	B-CHEMICAL
and	O
homochlorcyclizine	B-CHEMICAL
increases	O
the	O
Css	O
of	O
haloperidol	B-CHEMICAL
and	O
reduced	O
haloperidol	B-CHEMICAL
via	O
the	O
inhibitory	O
effects	O
on	O
the	O
CYP2D6	B-GENE-Y
-	O
catalyzed	O
metabolism	O
of	O
haloperidol	B-CHEMICAL
and	O
reduced	O
haloperidol	B-CHEMICAL
.	O

Yeast	B-GENE-Y
epiarginase	I-GENE-Y
regulation	O
,	O
an	O
enzyme	O
-	O
enzyme	O
activity	O
control	O
:	O
identification	O
of	O
residues	O
of	O
ornithine	B-GENE-Y
carbamoyltransferase	I-GENE-Y
and	O
arginase	B-GENE-Y
responsible	O
for	O
enzyme	O
catalytic	O
and	O
regulatory	O
activities	O
.	O

In	O
the	O
presence	O
of	O
ornithine	B-CHEMICAL
and	O
arginine	B-CHEMICAL
,	O
ornithine	B-GENE-Y
carbamoyltransferase	I-GENE-Y
(	O
OTCase	B-GENE-Y
)	O
and	O
arginase	B-GENE-Y
form	O
a	O
one	O
-	O
to	O
-	O
one	O
enzyme	O
complex	O
in	O
which	O
the	O
activity	O
of	O
OTCase	B-GENE-Y
is	O
inhibited	O
whereas	O
arginase	B-GENE-Y
remains	O
catalytically	O
active	O
.	O

The	O
mechanism	O
by	O
which	O
these	O
nonallosteric	O
enzymes	O
form	O
a	O
stable	O
complex	O
triggered	O
by	O
the	O
binding	O
of	O
their	O
respective	O
substrates	O
raises	O
the	O
question	O
of	O
how	O
such	O
a	O
cooperative	O
association	O
is	O
induced	O
.	O

Analyses	O
of	O
mutations	O
in	O
both	O
enzymes	O
identify	O
residues	O
that	O
are	O
required	O
for	O
their	O
association	O
,	O
some	O
of	O
them	O
being	O
important	O
for	O
catalysis	O
.	O

In	O
arginase	B-GENE-Y
,	O
two	O
cysteines	B-CHEMICAL
at	O
the	O
C	B-CHEMICAL
terminus	O
of	O
the	O
protein	O
are	O
crucial	O
for	O
its	O
epiarginase	B-GENE-Y
function	O
but	O
not	O
for	O
its	O
catalytic	O
activity	O
and	O
trimeric	O
structure	O
.	O

In	O
OTCase	B-GENE-Y
,	O
mutations	O
of	O
putative	O
ornithine	B-CHEMICAL
binding	O
residues	O
,	O
Asp	B-CHEMICAL
-	O
182	O
,	O
Asn	B-CHEMICAL
-	O
184	O
,	O
Asn	B-CHEMICAL
-	O
185	O
,	O
Cys	B-CHEMICAL
-	O
289	O
,	O
and	O
Glu	B-CHEMICAL
-	O
256	O
greatly	O
reduced	O
the	O
affinity	O
for	O
ornithine	B-CHEMICAL
and	O
impaired	O
the	O
interaction	O
with	O
arginase	B-GENE-Y
.	O

The	O
four	O
lysine	B-CHEMICAL
residues	O
located	O
in	O
the	O
SMG	O
loop	O
,	O
Lys	B-CHEMICAL
-	O
260	O
,	O
Lys	B-CHEMICAL
-	O
263	O
,	O
Lys	B-CHEMICAL
-	O
265	O
,	O
and	O
Lys	B-CHEMICAL
-	O
268	O
,	O
also	O
play	O
an	O
important	O
role	O
in	O
mediating	O
the	O
sensitivity	O
of	O
OTCase	B-GENE-Y
to	O
ornithine	B-CHEMICAL
and	O
to	O
arginase	B-GENE-Y
and	O
appear	O
to	O
be	O
involved	O
in	O
transducing	O
and	O
enhancing	O
the	O
signal	O
given	O
by	O
ornithine	B-CHEMICAL
for	O
the	O
closure	O
of	O
the	O
catalytic	O
domain	O
.	O

[	O
Study	O
on	O
the	O
effect	O
of	O
cysteinyl	B-CHEMICAL
leukotriene	I-CHEMICAL
antagonist	O
,	O
pranlukast	B-CHEMICAL
hydrate	I-CHEMICAL
,	O
on	O
adhesive	O
interaction	O
between	O
eosinophils	O
and	O
pulmonary	O
endothelial	O
cells	O
]	O
.	O

It	O
has	O
been	O
reported	O
that	O
cysteinyl	B-CHEMICAL
leukotriene	I-CHEMICAL
(	O
CysLT	B-CHEMICAL
)	O
antagonists	O
reduce	O
the	O
accumulation	O
of	O
eosinophils	O
in	O
the	O
asthmatic	O
airway	O
.	O

However	O
,	O
the	O
exact	O
mechanism	O
of	O
this	O
action	O
remains	O
to	O
be	O
established	O
.	O

In	O
the	O
present	O
study	O
,	O
we	O
examined	O
whether	O
a	O
CysLT	B-CHEMICAL
antagonist	O
modifies	O
the	O
adhesive	O
interaction	O
between	O
blood	O
eosinophils	O
and	O
endothelial	O
cells	O
.	O

Pranlukast	B-CHEMICAL
hydrate	I-CHEMICAL
,	O
a	O
CysLT	B-CHEMICAL
antagonist	O
,	O
blocked	O
the	O
chemotactic	O
response	O
and	O
adhesion	O
of	O
eosinophils	O
induced	O
by	O
LTD4	B-CHEMICAL
.	O

On	O
the	O
other	O
hand	O
,	O
pranlukast	B-CHEMICAL
did	O
not	O
modify	O
the	O
eosinophil	O
spontaneous	O
adhesion	O
to	O
the	O
resting	O
or	O
IL	B-GENE-Y
-	I-GENE-Y
4	I-GENE-Y
plus	O
TNF	B-GENE-Y
-	I-GENE-Y
alpha	I-GENE-Y
-	O
stimulated	O
pulmonary	O
endothelial	O
cells	O
.	O

Similarly	O
,	O
pranlukast	B-CHEMICAL
did	O
not	O
modulate	O
IL	B-GENE-Y
-	I-GENE-Y
5	I-GENE-Y
-	O
or	O
FMLP	O
-	O
activated	O
eosinophil	O
adhesion	O
to	O
the	O
resting	O
endothelial	O
cells	O
.	O

Finally	O
,	O
pranlukast	B-CHEMICAL
did	O
not	O
modify	O
the	O
expression	O
of	O
adhesion	O
molecules	O
on	O
endothelial	O
cells	O
stimulated	O
with	O
endothelial	O
activating	O
cytokines	O
.	O

These	O
results	O
suggest	O
that	O
the	O
inhibitory	O
action	O
of	O
CysLT	B-CHEMICAL
antagonist	O
on	O
eosinophil	O
accumulation	O
in	O
the	O
asthmatic	O
airways	O
involves	O
mechanisms	O
other	O
than	O
the	O
adhesive	O
interaction	O
between	O
eosinophils	O
and	O
endothelial	O
cells	O
.	O

Comparison	O
of	O
in	O
vitro	O
P	B-GENE-N
-	I-GENE-N
glycoprotein	I-GENE-N
screening	O
assays	O
:	O
recommendations	O
for	O
their	O
use	O
in	O
drug	O
discovery	O
.	O

The	O
ATP	B-GENE-N
-	I-GENE-N
dependent	I-GENE-N
drug	I-GENE-N
efflux	I-GENE-N
pump	I-GENE-N
P	B-GENE-N
-	I-GENE-N
glycoprotein	I-GENE-N
(	O
P	B-GENE-N
-	I-GENE-N
gp	I-GENE-N
)	O
affects	O
the	O
absorption	O
and	O
disposition	O
of	O
many	O
compounds	O
.	O

P	B-GENE-N
-	I-GENE-N
gp	I-GENE-N
may	O
also	O
play	O
role	O
in	O
clinically	O
significant	O
drug	O
-	O
drug	O
interactions	O
.	O

Therefore	O
,	O
it	O
is	O
important	O
to	O
find	O
potential	O
substrates	O
or	O
inhibitors	O
of	O
P	B-GENE-N
-	I-GENE-N
gp	I-GENE-N
early	O
in	O
the	O
drug	O
discovery	O
process	O
.	O

To	O
identify	O
compounds	O
that	O
interact	O
with	O
this	O
transporter	O
,	O
several	O
P	B-GENE-N
-	I-GENE-N
gp	I-GENE-N
assays	O
were	O
validated	O
and	O
compared	O
by	O
testing	O
a	O
set	O
of	O
28	O
reference	O
compounds	O
,	O
including	O
inhibitors	O
of	O
cytochrome	B-GENE-Y
P450	I-GENE-Y
3A4	I-GENE-Y
(	O
CYP3A4	B-GENE-Y
)	O
.	O

The	O
assays	O
included	O
in	O
silico	B-CHEMICAL
predictions	O
,	O
inhibition	O
assays	O
(	O
based	O
on	O
cellular	O
uptake	O
of	O
rhodamine	B-CHEMICAL
-	I-CHEMICAL
123	I-CHEMICAL
or	O
calcein	B-CHEMICAL
AM	I-CHEMICAL
)	O
,	O
and	O
functional	O
assays	O
(	O
ATPase	B-GENE-N
activity	O
assay	O
and	O
transcellular	O
transport	O
assay	O
,	O
the	O
latter	O
for	O
a	O
subset	O
of	O
compounds	O
)	O
.	O

In	O
addition	O
,	O
species	O
differences	O
were	O
studied	O
in	O
an	O
indirect	O
fluorescence	O
indicator	O
screening	O
assay	O
and	O
test	O
systems	O
expressing	O
porcine	O
,	O
mouse	O
,	O
or	O
human	O
P	B-GENE-N
-	I-GENE-N
gp	I-GENE-N
.	O

Our	O
results	O
suggest	O
that	O
several	O
P	B-GENE-N
-	I-GENE-N
gp	I-GENE-N
assays	O
should	O
be	O
used	O
in	O
combination	O
to	O
classify	O
compounds	O
as	O
substrates	O
or	O
inhibitors	O
of	O
P	B-GENE-N
-	I-GENE-N
gp	I-GENE-N
.	O

Recommendations	O
are	O
given	O
on	O
screening	O
strategies	O
which	O
can	O
be	O
applied	O
to	O
different	O
phases	O
of	O
the	O
drug	O
discovery	O
and	O
development	O
process	O
.	O

Incorporation	O
of	O
trifluoroisoleucine	B-CHEMICAL
into	O
proteins	O
in	O
vivo	O
.	O

Two	O
fluorinated	O
derivatives	O
of	O
isoleucine	B-CHEMICAL
:	O
d	B-CHEMICAL
,	I-CHEMICAL
l	I-CHEMICAL
-	I-CHEMICAL
2	I-CHEMICAL
-	I-CHEMICAL
amino	I-CHEMICAL
-	I-CHEMICAL
3	I-CHEMICAL
-	I-CHEMICAL
trifluoromethyl	I-CHEMICAL
pentanoic	I-CHEMICAL
acid	I-CHEMICAL
(	O
3TFI	B-CHEMICAL
,	O
2	O
)	O
and	O
d	B-CHEMICAL
,	I-CHEMICAL
l	I-CHEMICAL
-	I-CHEMICAL
2	I-CHEMICAL
-	I-CHEMICAL
amino	I-CHEMICAL
-	I-CHEMICAL
5	I-CHEMICAL
,	I-CHEMICAL
5	I-CHEMICAL
,	I-CHEMICAL
5	I-CHEMICAL
-	I-CHEMICAL
trifluoro	I-CHEMICAL
-	I-CHEMICAL
3	I-CHEMICAL
-	I-CHEMICAL
methyl	I-CHEMICAL
pentanoic	I-CHEMICAL
acid	I-CHEMICAL
(	O
5TFI	B-CHEMICAL
,	O
3	O
)	O
were	O
prepared	O
.	O

5TFI	B-CHEMICAL
was	O
incorporated	O
into	O
a	O
model	O
target	O
protein	O
,	O
murine	B-GENE-Y
dihydrofolate	I-GENE-Y
reductase	I-GENE-Y
(	O
mDHFR	B-GENE-Y
)	O
,	O
in	O
an	O
isoleucine	B-CHEMICAL
auxotrophic	O
Escherichia	O
coli	O
host	O
strain	O
suspended	O
in	O
5TFI	B-CHEMICAL
-	O
supplemented	O
minimal	O
medium	O
depleted	O
of	O
isoleucine	B-CHEMICAL
.	O

Incorporation	O
of	O
5TFI	B-CHEMICAL
was	O
confirmed	O
by	O
tryptic	O
peptide	O
analysis	O
and	O
matrix	O
-	O
assisted	O
laser	O
desorption	O
ionization	O
mass	O
spectrometry	O
(	O
MALDI	O
-	O
MS	O
)	O
of	O
the	O
protein	O
product	O
.	O

Amino	B-CHEMICAL
acid	I-CHEMICAL
analysis	O
showed	O
that	O
more	O
than	O
93	O
%	O
of	O
the	O
encoded	O
isoleucine	B-CHEMICAL
residues	O
were	O
replaced	O
by	O
5TFI	B-CHEMICAL
.	O

Measurement	O
of	O
the	O
rate	O
of	O
activation	O
of	O
5TFI	B-CHEMICAL
by	O
the	O
E	B-GENE-Y
.	I-GENE-Y
coli	I-GENE-Y
isoleucyl	I-GENE-Y
-	I-GENE-Y
tRNA	I-GENE-Y
synthetase	I-GENE-Y
(	O
IleRS	B-GENE-Y
)	O
yielded	O
a	O
specificity	O
constant	O
(	O
k	O
(	O
cat	O
)	O
/	O
K	O
(	O
m	O
)	O
)	O
134	O
-	O
fold	O
lower	O
than	O
that	O
for	O
isoleucine	B-CHEMICAL
.	O

5TFI	B-CHEMICAL
was	O
successfully	O
introduced	O
into	O
the	O
cytokine	B-GENE-N
murine	B-GENE-Y
interleukin	I-GENE-Y
-	I-GENE-Y
2	I-GENE-Y
(	O
mIL	B-GENE-Y
-	I-GENE-Y
2	I-GENE-Y
)	O
at	O
the	O
encoded	O
isoleucine	B-CHEMICAL
positions	O
.	O

The	O
concentration	O
of	O
fluorinated	O
protein	O
that	O
elicits	O
50	O
%	O
of	O
the	O
maximal	O
proliferative	O
response	O
is	O
3	O
.	O
87	O
ng	O
/	O
mL	O
,	O
about	O
30	O
%	O
higher	O
than	O
that	O
of	O
wild	O
-	O
type	O
mIL	B-GENE-Y
-	I-GENE-Y
2	I-GENE-Y
(	O
EC	O
(	O
50	O
)	O
=	O
2	O
.	O
70	O
ng	O
/	O
mL	O
)	O
.	O

The	O
maximal	O
responses	O
are	O
equivalent	O
for	O
the	O
fluorinated	O
and	O
wild	O
-	O
type	O
cytokines	B-GENE-N
,	O
indicating	O
that	O
fluorinated	O
proteins	O
can	O
fold	O
into	O
stable	O
and	O
functional	O
structures	O
.	O

3TFI	B-CHEMICAL
yielded	O
no	O
evidence	O
for	O
in	O
vivo	O
incorporation	O
into	O
recombinant	O
proteins	O
,	O
and	O
no	O
evidence	O
for	O
activation	O
by	O
IleRS	B-GENE-Y
in	O
vitro	O
.	O

Analysis	O
of	O
plasmin	B-GENE-Y
binding	O
and	O
urokinase	B-GENE-Y
activation	O
of	O
plasminogen	B-GENE-Y
bound	O
to	O
the	O
Heymann	B-GENE-Y
nephritis	I-GENE-Y
autoantigen	I-GENE-Y
,	O
gp330	B-GENE-Y
.	O

Previously	O
,	O
we	O
demonstrated	O
that	O
the	O
Heymann	B-GENE-Y
nephritis	I-GENE-Y
autoantigen	I-GENE-Y
,	O
gp330	B-GENE-Y
,	O
can	O
serve	O
as	O
a	O
receptor	O
site	O
for	O
plasminogen	B-GENE-Y
.	O

This	O
binding	O
was	O
not	O
significantly	O
inhibited	O
by	O
the	O
lysine	B-CHEMICAL
analogue	O
epsilon	B-CHEMICAL
-	I-CHEMICAL
amino	I-CHEMICAL
caproic	I-CHEMICAL
acid	I-CHEMICAL
(	O
EACA	B-CHEMICAL
)	O
,	O
indicating	O
that	O
plasminogen	B-GENE-Y
binding	O
was	O
not	O
just	O
through	O
lysine	B-CHEMICAL
binding	O
sites	O
as	O
suggested	O
for	O
other	O
plasminogen	B-GENE-Y
binding	O
sites	O
.	O

We	O
now	O
report	O
that	O
once	O
plasminogen	B-GENE-Y
is	O
bound	O
to	O
gp330	B-GENE-Y
,	O
it	O
can	O
be	O
converted	O
to	O
its	O
active	O
form	O
of	O
plasmin	B-GENE-Y
by	O
urokinase	B-GENE-Y
.	O

This	O
conversion	O
of	O
plasminogen	B-GENE-Y
to	O
plasmin	B-GENE-Y
proceeds	O
at	O
a	O
faster	O
rate	O
when	O
plasminogen	B-GENE-Y
is	O
first	O
prebound	O
to	O
gp330	B-GENE-Y
.	O

Although	O
there	O
is	O
a	O
proportional	O
increase	O
in	O
the	O
Vmax	O
of	O
the	O
urokinase	B-GENE-Y
-	O
catalyzed	O
reaction	O
with	O
increasing	O
gp330	B-GENE-Y
concentrations	O
,	O
no	O
change	O
in	O
Km	O
was	O
observed	O
.	O

Once	O
activated	O
,	O
plasmin	B-GENE-Y
remains	O
bound	O
to	O
gp330	B-GENE-Y
in	O
an	O
active	O
state	O
capable	O
of	O
cleaving	O
the	O
chromogenic	O
tripeptide	O
,	O
S	O
-	O
2251	O
.	O

The	O
binding	O
of	O
plasmin	B-GENE-Y
to	O
gp330	B-GENE-Y
did	O
not	O
significantly	O
change	O
its	O
enzymatic	O
activity	O
;	O
however	O
,	O
gp330	B-GENE-Y
did	O
have	O
a	O
stabilizing	O
effect	O
on	O
plasmin	B-GENE-Y
activity	O
at	O
37	O
degrees	O
C	O
.	O

While	O
bound	O
to	O
gp330	B-GENE-Y
,	O
plasmin	B-GENE-Y
is	O
protected	O
from	O
inactivation	O
by	O
its	O
natural	O
inhibitor	O
alpha	B-GENE-Y
2	I-GENE-Y
-	I-GENE-Y
antiplasmin	I-GENE-Y
.	O

The	O
binding	O
of	O
plasmin	B-GENE-Y
to	O
gp330	B-GENE-Y
as	O
analyzed	O
by	O
ELISA	O
was	O
shown	O
to	O
be	O
time	O
dependent	O
,	O
reversible	O
,	O
saturable	O
,	O
and	O
specific	O
for	O
gp330	B-GENE-Y
.	O

Inhibition	O
of	O
binding	O
of	O
both	O
plasminogen	B-GENE-Y
and	O
plasmin	B-GENE-Y
to	O
gp330	B-GENE-Y
by	O
benzamidine	B-CHEMICAL
was	O
similar	O
,	O
although	O
EACA	B-CHEMICAL
inhibited	O
the	O
binding	O
of	O
plasmin	B-GENE-Y
to	O
gp330	B-GENE-Y
slightly	O
more	O
than	O
the	O
binding	O
of	O
plasminogen	B-GENE-Y
to	O
gp330	B-GENE-Y
.	O

These	O
results	O
indicate	O
that	O
the	O
binding	O
of	O
plasminogen	B-GENE-Y
to	O
gp330	B-GENE-Y
serves	O
as	O
an	O
effective	O
means	O
of	O
increasing	O
the	O
rate	O
of	O
plasmin	B-GENE-Y
production	O
on	O
the	O
glomerular	O
and	O
tubular	O
epithelial	O
cell	O
surface	O
while	O
protecting	O
the	O
active	O
plasmin	B-GENE-Y
from	O
natural	O
inhibitors	O
.	O

Functional	O
characterization	O
of	O
alpha	B-GENE-N
-	I-GENE-N
adrenoceptors	I-GENE-N
mediating	O
pupillary	O
dilation	O
in	O
rats	O
.	O

Previously	O
,	O
we	O
reported	O
that	O
the	O
alpha	B-GENE-Y
(	I-GENE-Y
1A	I-GENE-Y
)	I-GENE-Y
-	I-GENE-Y
adrenoceptor	I-GENE-Y
,	O
but	O
not	O
the	O
alpha	B-GENE-Y
(	I-GENE-Y
1D	I-GENE-Y
)	I-GENE-Y
-	I-GENE-Y
adrenoceptor	I-GENE-Y
,	O
mediates	O
pupillary	O
dilation	O
elicited	O
by	O
sympathetic	O
nerve	O
stimulation	O
in	O
rats	O
.	O

This	O
study	O
was	O
undertaken	O
to	O
further	O
characterize	O
the	O
alpha	B-GENE-N
-	I-GENE-N
adrenoceptor	I-GENE-N
subtypes	O
mediating	O
pupillary	O
dilation	O
in	O
response	O
to	O
both	O
neural	O
and	O
agonist	O
activation	O
.	O

Pupillary	O
dilator	O
response	O
curves	O
were	O
generated	O
by	O
intravenous	O
injection	O
of	O
norepinephrine	B-CHEMICAL
in	O
pentobarbital	B-CHEMICAL
-	O
anesthetized	O
rats	O
.	O

Involvement	O
of	O
alpha	B-GENE-N
(	I-GENE-N
1	I-GENE-N
)	I-GENE-N
-	I-GENE-N
adrenoceptors	I-GENE-N
was	O
established	O
as	O
mydriatic	O
responses	O
were	O
inhibited	O
by	O
systemic	O
administration	O
of	O
nonselective	O
alpha	B-GENE-N
-	I-GENE-N
adrenoceptor	I-GENE-N
antagonists	O
,	O
phentolamine	B-CHEMICAL
(	O
0	O
.	O
3	O
-	O
3	O
mg	O
/	O
kg	O
)	O
and	O
phenoxybenzamine	B-CHEMICAL
(	O
0	O
.	O
03	O
-	O
0	O
.	O
3	O
mg	O
/	O
kg	O
)	O
,	O
as	O
well	O
as	O
by	O
the	O
selective	O
alpha	B-GENE-N
(	I-GENE-N
1	I-GENE-N
)	I-GENE-N
-	I-GENE-N
adrenoceptor	I-GENE-N
antagonist	O
,	O
prazosin	B-CHEMICAL
(	O
0	O
.	O
3	O
mg	O
/	O
kg	O
)	O
.	O

The	O
alpha	B-GENE-N
(	I-GENE-N
2	I-GENE-N
)	I-GENE-N
-	I-GENE-N
adrenoceptor	I-GENE-N
antagonist	O
,	O
rauwolscine	B-CHEMICAL
(	O
0	O
.	O
5	O
mg	O
/	O
kg	O
)	O
,	O
was	O
without	O
antagonistic	O
effects	O
.	O

alpha	B-GENE-Y
(	I-GENE-Y
1A	I-GENE-Y
)	I-GENE-Y
-	I-GENE-Y
Adrenoceptor	I-GENE-Y
selective	O
antagonists	O
,	O
2	B-CHEMICAL
-	I-CHEMICAL
(	I-CHEMICAL
[	I-CHEMICAL
2	I-CHEMICAL
,	I-CHEMICAL
6	I-CHEMICAL
-	I-CHEMICAL
dimethoxyphenoxyethyl	I-CHEMICAL
]	I-CHEMICAL
aminomethyl	I-CHEMICAL
)	I-CHEMICAL
-	I-CHEMICAL
1	I-CHEMICAL
,	I-CHEMICAL
4	I-CHEMICAL
-	I-CHEMICAL
benzodioxane	I-CHEMICAL
(	O
WB	B-CHEMICAL
-	I-CHEMICAL
4101	I-CHEMICAL
;	O
0	O
.	O
1	O
-	O
1	O
mg	O
/	O
kg	O
)	O
and	O
5	B-CHEMICAL
-	I-CHEMICAL
methylurapidil	I-CHEMICAL
(	O
0	O
.	O
1	O
-	O
1	O
mg	O
/	O
kg	O
)	O
,	O
the	O
alpha	B-GENE-Y
(	I-GENE-Y
1B	I-GENE-Y
)	I-GENE-Y
-	I-GENE-Y
adrenoceptor	I-GENE-Y
selective	O
antagonist	O
,	O
4	B-CHEMICAL
-	I-CHEMICAL
amino	I-CHEMICAL
-	I-CHEMICAL
2	I-CHEMICAL
-	I-CHEMICAL
[	I-CHEMICAL
4	I-CHEMICAL
-	I-CHEMICAL
[	I-CHEMICAL
1	I-CHEMICAL
-	I-CHEMICAL
(	I-CHEMICAL
benzyloxycarbonyl	I-CHEMICAL
)	I-CHEMICAL
-	I-CHEMICAL
2	I-CHEMICAL
(	I-CHEMICAL
S	I-CHEMICAL
)	I-CHEMICAL
-	I-CHEMICAL
[	I-CHEMICAL
[	I-CHEMICAL
(	I-CHEMICAL
1	I-CHEMICAL
,	I-CHEMICAL
1	I-CHEMICAL
-	I-CHEMICAL
dimethylethyl	I-CHEMICAL
)	I-CHEMICAL
amino	I-CHEMICAL
]	I-CHEMICAL
carbonyl	I-CHEMICAL
]	I-CHEMICAL
-	I-CHEMICAL
piperazinyl	I-CHEMICAL
]	I-CHEMICAL
-	I-CHEMICAL
6	I-CHEMICAL
,	I-CHEMICAL
7	I-CHEMICAL
-	I-CHEMICAL
dimethoxyquinazoline	I-CHEMICAL
(	O
L	B-CHEMICAL
-	I-CHEMICAL
765314	I-CHEMICAL
;	O
0	O
.	O
3	O
-	O
1	O
mg	O
/	O
kg	O
)	O
,	O
as	O
well	O
as	O
the	O
alpha	B-GENE-Y
(	I-GENE-Y
1D	I-GENE-Y
)	I-GENE-Y
-	I-GENE-Y
adrenoceptor	I-GENE-Y
selective	O
antagonist	O
,	O
8	B-CHEMICAL
-	I-CHEMICAL
[	I-CHEMICAL
2	I-CHEMICAL
-	I-CHEMICAL
[	I-CHEMICAL
4	I-CHEMICAL
-	I-CHEMICAL
(	I-CHEMICAL
2	I-CHEMICAL
-	I-CHEMICAL
methoxyphenyl	I-CHEMICAL
)	I-CHEMICAL
-	I-CHEMICAL
1	I-CHEMICAL
-	I-CHEMICAL
piperazinyl	I-CHEMICAL
]	I-CHEMICAL
ethyl	I-CHEMICAL
]	I-CHEMICAL
-	I-CHEMICAL
8	I-CHEMICAL
-	I-CHEMICAL
azaspiro	I-CHEMICAL
[	I-CHEMICAL
4	I-CHEMICAL
.	I-CHEMICAL
5	I-CHEMICAL
]	I-CHEMICAL
decane	I-CHEMICAL
-	I-CHEMICAL
7	I-CHEMICAL
,	I-CHEMICAL
9	I-CHEMICAL
-	I-CHEMICAL
dione	I-CHEMICAL
(	O
BMY	B-CHEMICAL
-	I-CHEMICAL
7378	I-CHEMICAL
;	O
1	O
mg	O
/	O
kg	O
)	O
,	O
were	O
used	O
to	O
delineate	O
the	O
adrenoceptor	B-GENE-N
subtypes	O
involved	O
.	O

Mydriatic	O
responses	O
to	O
norepinephrine	B-CHEMICAL
were	O
significantly	O
antagonized	O
by	O
intravenous	O
administration	O
of	O
both	O
WB	B-CHEMICAL
-	I-CHEMICAL
4101	I-CHEMICAL
and	O
5	B-CHEMICAL
-	I-CHEMICAL
methylurapidil	I-CHEMICAL
,	O
but	O
neither	O
by	O
L	B-CHEMICAL
-	I-CHEMICAL
765314	I-CHEMICAL
nor	O
by	O
BMY	B-CHEMICAL
-	I-CHEMICAL
7378	I-CHEMICAL
.	O

L	B-CHEMICAL
-	I-CHEMICAL
765314	I-CHEMICAL
(	O
0	O
.	O
3	O
-	O
3	O
mg	O
/	O
kg	O
,	O
i	O
.	O
v	O
.	O
)	O
was	O
also	O
ineffective	O
in	O
inhibiting	O
the	O
mydriasis	O
evoked	O
by	O
cervical	O
sympathetic	O
nerve	O
stimulation	O
.	O

These	O
results	O
suggest	O
that	O
alpha	B-GENE-Y
(	I-GENE-Y
1B	I-GENE-Y
)	I-GENE-Y
-	I-GENE-Y
adrenoceptors	I-GENE-Y
do	O
not	O
mediate	O
sympathetic	O
mydriasis	O
in	O
rats	O
,	O
and	O
that	O
the	O
alpha	B-GENE-Y
(	I-GENE-Y
1A	I-GENE-Y
)	I-GENE-Y
-	I-GENE-Y
adrenoceptor	I-GENE-Y
is	O
the	O
exclusive	O
subtype	O
mediating	O
mydriatic	O
responses	O
in	O
this	O
species	O
.	O

Colon	O
cancer	O
cells	O
with	O
high	O
invasive	O
potential	O
are	O
susceptible	O
to	O
induction	O
of	O
apoptosis	O
by	O
a	O
selective	O
COX	B-GENE-Y
-	I-GENE-Y
2	I-GENE-Y
inhibitor	O
.	O

Cyclooxygenase	B-GENE-Y
-	I-GENE-Y
2	I-GENE-Y
(	O
COX	B-GENE-Y
-	I-GENE-Y
2	I-GENE-Y
)	O
expression	O
has	O
been	O
shown	O
to	O
correlate	O
with	O
the	O
invasiveness	O
of	O
colon	O
cancer	O
cells	O
.	O

To	O
further	O
investigate	O
this	O
positive	O
correlation	O
and	O
its	O
possible	O
therapeutic	O
implications	O
,	O
a	O
selective	O
COX	B-GENE-Y
-	I-GENE-Y
2	I-GENE-Y
inhibitor	O
,	O
etodolac	B-CHEMICAL
,	O
was	O
tested	O
on	O
three	O
variants	O
of	O
HT	O
-	O
29	O
colon	O
cancer	O
cell	O
lines	O
,	O
HT	O
-	O
29	O
/	O
Inv1	O
,	O
HT	O
-	O
29	O
/	O
Inv2	O
and	O
HT	O
-	O
29	O
/	O
Inv3	O
,	O
with	O
graded	O
increases	O
of	O
in	O
vitro	O
Matrigel	O
invasive	O
potential	O
and	O
COX	B-GENE-Y
-	I-GENE-Y
2	I-GENE-Y
expression	O
levels	O
.	O

HT	O
-	O
29	O
variants	O
with	O
higher	O
invasive	O
potential	O
were	O
found	O
to	O
be	O
more	O
sensitive	O
to	O
etodolac	B-CHEMICAL
by	O
in	O
vitro	O
growth	O
inhibition	O
assays	O
,	O
the	O
estimated	O
LD	O
(	O
50	O
)	O
being	O
0	O
.	O
5	O
mM	O
for	O
highly	O
invasive	O
HT	O
-	O
29	O
/	O
Inv2	O
and	O
HT	O
-	O
29	O
/	O
Inv3	O
cells	O
,	O
0	O
.	O
6	O
mM	O
for	O
slightly	O
less	O
invasive	O
HT	O
-	O
29	O
/	O
Inv1	O
,	O
and	O
1	O
.	O
8	O
mM	O
for	O
the	O
parental	O
HT	O
-	O
29	O
.	O

Treatment	O
of	O
the	O
highly	O
invasive	O
HT	O
-	O
29	O
/	O
Inv2	O
and	O
Inv3	O
variants	O
with	O
as	O
little	O
as	O
0	O
.	O
1	O
mM	O
etodolac	B-CHEMICAL
in	O
the	O
growth	O
medium	O
produced	O
signs	O
of	O
apoptosis	O
,	O
as	O
detected	O
by	O
DNA	O
fragmentation	O
and	O
TUNEL	O
(	O
terminal	O
deoxynucleotidyl	O
transferase	O
dUTP	B-CHEMICAL
-	O
biotin	B-CHEMICAL
nick	O
end	O
labeling	O
)	O
assay	O
.	O

In	O
vivo	O
experiments	O
in	O
SCID	O
mice	O
showed	O
that	O
etolodac	B-CHEMICAL
inhibited	O
the	O
growth	O
of	O
subcutaneous	O
tumors	O
induced	O
by	O
HT	O
-	O
29	O
/	O
Inv3	O
cells	O
significantly	O
more	O
than	O
those	O
by	O
the	O
parental	O
HT	O
-	O
29	O
cells	O
.	O

These	O
results	O
suggest	O
that	O
COX	B-GENE-Y
-	I-GENE-Y
2	I-GENE-Y
inhibitors	O
have	O
a	O
potential	O
role	O
in	O
prevention	O
of	O
tumor	O
invasion	O
in	O
colon	O
cancer	O
patients	O
.	O

Pharmacological	O
characterization	O
of	O
unique	O
prazosin	B-CHEMICAL
-	O
binding	O
sites	O
in	O
human	O
kidney	O
.	O

In	O
human	O
kidney	O
,	O
we	O
found	O
unique	O
prazosin	B-CHEMICAL
-	O
binding	O
sites	O
that	O
were	O
insensitive	O
to	O
phentolamine	B-CHEMICAL
and	O
were	O
thus	O
unlikely	O
to	O
be	O
alpha	B-GENE-N
(	I-GENE-N
1	I-GENE-N
)	I-GENE-N
-	I-GENE-N
adrenoceptors	I-GENE-N
.	O

As	O
the	O
binding	O
of	O
[	B-CHEMICAL
(	I-CHEMICAL
3	I-CHEMICAL
)	I-CHEMICAL
H	I-CHEMICAL
]	I-CHEMICAL
prazosin	I-CHEMICAL
to	O
phentolamine	B-CHEMICAL
-	O
insensitive	O
sites	O
was	O
prevented	O
by	O
100	O
microM	O
guanabenz	B-CHEMICAL
,	O
the	O
insensitive	O
sites	O
were	O
evaluated	O
by	O
subtracting	O
[	B-CHEMICAL
(	I-CHEMICAL
3	I-CHEMICAL
)	I-CHEMICAL
H	I-CHEMICAL
]	I-CHEMICAL
prazosin	I-CHEMICAL
binding	O
in	O
the	O
presence	O
of	O
100	O
microM	O
guanabenz	B-CHEMICAL
from	O
that	O
in	O
the	O
presence	O
of	O
10	O
microM	O
phentolamine	B-CHEMICAL
.	O

[	B-CHEMICAL
(	I-CHEMICAL
3	I-CHEMICAL
)	I-CHEMICAL
H	I-CHEMICAL
]	I-CHEMICAL
Prazosin	I-CHEMICAL
bound	O
to	O
the	O
phentolamine	B-CHEMICAL
-	O
insensitive	O
sites	O
monophasically	O
with	O
a	O
high	O
affinity	O
(	O
pK	O
(	O
d	O
)	O
;	O
9	O
.	O
1	O
+	O
/	O
-	O
0	O
.	O
08	O
,	O
n	O
=	O
8	O
)	O
,	O
and	O
the	O
B	O
(	O
max	O
)	O
value	O
(	O
814	O
+	O
/	O
-	O
204	O
fmol	O
mg	O
(	O
-	O
1	O
)	O
protein	O
,	O
n	O
=	O
8	O
)	O
was	O
more	O
than	O
ten	O
times	O
that	O
of	O
the	O
phentolamine	B-CHEMICAL
-	O
sensitive	O
alpha	B-GENE-N
(	I-GENE-N
1	I-GENE-N
)	I-GENE-N
-	I-GENE-N
adrenoceptor	I-GENE-N
(	O
pK	O
(	O
d	O
)	O
=	O
9	O
.	O
9	O
+	O
/	O
-	O
0	O
.	O
13	O
,	O
B	O
(	O
max	O
)	O
=	O
66	O
+	O
/	O
-	O
23	O
fmol	O
mg	O
(	O
-	O
1	O
)	O
protein	O
,	O
n	O
=	O
7	O
)	O
.	O

The	O
phentolamine	B-CHEMICAL
-	O
insensitive	O
sites	O
in	O
human	O
kidney	O
were	O
highly	O
sensitive	O
to	O
other	O
quinazoline	B-CHEMICAL
derivatives	O
such	O
as	O
terazosin	B-CHEMICAL
and	O
doxazosin	B-CHEMICAL
.	O

However	O
,	O
other	O
alpha	B-GENE-N
(	I-GENE-N
1	I-GENE-N
)	I-GENE-N
-	I-GENE-N
adrenoceptor	I-GENE-N
antagonists	O
(	O
tamsulosin	B-CHEMICAL
,	O
WB4101	B-CHEMICAL
and	O
corynanthine	B-CHEMICAL
)	O
did	O
not	O
inhibit	O
the	O
binding	O
at	O
a	O
range	O
of	O
concentrations	O
that	O
generally	O
exhibit	O
alpha	B-GENE-N
(	I-GENE-N
1	I-GENE-N
)	I-GENE-N
-	I-GENE-N
adrenoceptor	I-GENE-N
antagonism	O
,	O
and	O
noradrenaline	B-CHEMICAL
,	O
rauwolscine	B-CHEMICAL
and	O
propranolol	B-CHEMICAL
were	O
without	O
effect	O
on	O
the	O
[	B-CHEMICAL
(	I-CHEMICAL
3	I-CHEMICAL
)	I-CHEMICAL
H	I-CHEMICAL
]	I-CHEMICAL
prazosin	I-CHEMICAL
binding	O
.	O

On	O
the	O
other	O
hand	O
,	O
ligands	O
for	O
the	O
renal	O
Na	B-GENE-N
(	I-GENE-N
+	I-GENE-N
)	I-GENE-N
-	I-GENE-N
transporter	I-GENE-N
(	O
amiloride	B-CHEMICAL
and	O
triamterene	B-CHEMICAL
)	O
and	O
for	O
imidazoline	B-CHEMICAL
recognition	O
sites	O
(	O
guanabenz	B-CHEMICAL
,	O
guanfacine	B-CHEMICAL
and	O
agmatine	B-CHEMICAL
)	O
displaced	O
the	O
binding	O
of	O
[	B-CHEMICAL
(	I-CHEMICAL
3	I-CHEMICAL
)	I-CHEMICAL
H	I-CHEMICAL
]	I-CHEMICAL
prazosin	I-CHEMICAL
to	O
phentolamine	B-CHEMICAL
-	O
insensitive	O
sites	O
at	O
micromolar	O
concentrations	O
.	O

Photoaffinity	O
labeling	O
with	O
[	B-CHEMICAL
(	I-CHEMICAL
125	I-CHEMICAL
)	I-CHEMICAL
I	I-CHEMICAL
]	I-CHEMICAL
iodoarylazidoprazosin	I-CHEMICAL
showed	O
phentolamine	B-CHEMICAL
-	O
insensitive	O
labeling	O
at	O
around	O
100	O
kDa	O
,	O
a	O
molecular	O
size	O
larger	O
than	O
that	O
of	O
human	B-GENE-N
alpha	I-GENE-N
(	I-GENE-N
1a	I-GENE-N
)	I-GENE-N
-	I-GENE-N
and	I-GENE-N
alpha	I-GENE-N
(	I-GENE-N
1b	I-GENE-N
)	I-GENE-N
-	I-GENE-N
adrenoceptors	I-GENE-N
expressed	O
in	O
293	O
cells	O
(	O
50	O
-	O
60	O
and	O
70	O
-	O
80	O
kDa	O
,	O
respectively	O
)	O
on	O
electrophoresis	O
.	O

In	O
contrast	O
,	O
there	O
was	O
no	O
detectable	O
phentolamine	B-CHEMICAL
-	O
insensitive	O
binding	O
site	O
but	O
were	O
phentolamine	B-CHEMICAL
-	O
sensitive	O
alpha	B-GENE-N
(	I-GENE-N
1	I-GENE-N
)	I-GENE-N
-	I-GENE-N
adrenoceptors	I-GENE-N
in	O
human	O
liver	O
(	O
pK	O
(	O
d	O
)	O
=	O
10	O
.	O
0	O
+	O
/	O
-	O
0	O
.	O
06	O
,	O
B	O
(	O
max	O
)	O
=	O
44	O
+	O
/	O
-	O
6	O
fmol	O
mg	O
(	O
-	O
1	O
)	O
protein	O
,	O
n	O
=	O
3	O
)	O
.	O

Phentolamine	B-CHEMICAL
-	O
insensitive	O
prazosin	B-CHEMICAL
binding	O
sites	O
were	O
also	O
detected	O
in	O
rabbit	O
kidney	O
(	O
approximately	O
50	O
%	O
of	O
specific	O
binding	O
sites	O
)	O
but	O
were	O
minor	O
in	O
rat	O
kidney	O
(	O
less	O
than	O
20	O
%	O
)	O
.	O

In	O
conclusion	O
,	O
there	O
are	O
unique	O
prazosin	B-CHEMICAL
-	O
binding	O
sites	O
in	O
human	O
kidney	O
,	O
the	O
pharmacological	O
profiles	O
of	O
which	O
were	O
distinct	O
from	O
those	O
of	O
known	O
adrenoceptors	O
.	O

chi	O
-	O
Conopeptide	O
MrIA	O
partially	O
overlaps	O
desipramine	B-GENE-N
and	I-GENE-N
cocaine	I-GENE-N
binding	I-GENE-N
sites	I-GENE-N
on	O
the	O
human	B-GENE-Y
norepinephrine	I-GENE-Y
transporter	I-GENE-Y
.	O

The	O
interactions	O
of	O
chi	O
-	O
conopeptide	O
MrIA	O
with	O
the	O
human	B-GENE-Y
norepinephrine	I-GENE-Y
transporter	I-GENE-Y
(	O
hNET	B-GENE-Y
)	O
were	O
investigated	O
by	O
determining	O
the	O
effects	O
of	O
hNET	B-GENE-Y
point	O
mutations	O
on	O
the	O
inhibitory	O
potency	O
of	O
MrIA	O
.	O

The	O
mutants	O
were	O
produced	O
by	O
site	O
-	O
directed	O
mutagenesis	O
and	O
expressed	O
in	O
COS	O
-	O
7	O
cells	O
.	O

The	O
potency	O
of	O
MrIA	O
was	O
greater	O
for	O
inhibition	O
of	O
uptake	O
by	O
hNET	B-GENE-Y
of	O
[	B-CHEMICAL
3H	I-CHEMICAL
]	I-CHEMICAL
norepinephrine	I-CHEMICAL
(	O
Ki	O
1	O
.	O
89	O
microM	O
)	O
than	O
[	B-CHEMICAL
3H	I-CHEMICAL
]	I-CHEMICAL
dopamine	I-CHEMICAL
(	O
Ki	O
4	O
.	O
33	O
microM	O
)	O
,	O
and	O
the	O
human	B-GENE-Y
dopamine	I-GENE-Y
transporter	I-GENE-Y
and	O
serotonin	B-GENE-Y
transporter	I-GENE-Y
were	O
not	O
inhibited	O
by	O
MrIA	O
(	O
to	O
7	O
microM	O
)	O
.	O

Of	O
18	O
mutations	O
where	O
hNET	B-GENE-Y
amino	B-CHEMICAL
acid	I-CHEMICAL
residues	O
were	O
exchanged	O
with	O
those	O
of	O
the	O
human	B-GENE-Y
dopamine	I-GENE-Y
transporter	I-GENE-Y
,	O
MrIA	O
had	O
increased	O
potency	O
for	O
inhibition	O
of	O
[	B-CHEMICAL
3H	I-CHEMICAL
]	I-CHEMICAL
norepinephrine	I-CHEMICAL
uptake	O
for	O
three	O
mutations	O
(	O
in	O
predicted	O
extracellular	O
loops	O
3	O
and	O
4	O
and	O
transmembrane	O
domain	O
(	O
TMD	O
)	O
8	O
)	O
and	O
decreased	O
potency	O
for	O
one	O
mutation	O
(	O
in	O
TMD6	O
and	O
intracellular	O
loop	O
(	O
IL	O
)	O
3	O
)	O
.	O

Of	O
the	O
12	O
additional	O
mutations	O
in	O
TMDs	O
2	O
,	O
4	O
,	O
5	O
,	O
and	O
11	O
and	O
IL1	O
,	O
three	O
mutations	O
(	O
in	O
TMD2	O
and	O
IL1	O
)	O
had	O
reduced	O
MrIA	O
inhibitory	O
potency	O
.	O

All	O
of	O
the	O
other	O
mutations	O
tested	O
had	O
no	O
influence	O
on	O
MrIA	O
potency	O
.	O

A	O
comparison	O
of	O
the	O
results	O
with	O
previous	O
data	O
for	O
desipramine	B-CHEMICAL
and	O
cocaine	O
inhibition	O
of	O
norepinephrine	B-CHEMICAL
uptake	O
by	O
the	O
mutant	O
hNETs	B-GENE-Y
reveals	O
that	O
MrIA	O
binding	O
to	O
hNET	B-GENE-Y
occurs	O
at	O
a	O
site	O
that	O
is	O
distinct	O
from	O
but	O
overlaps	O
with	O
the	O
binding	O
sites	O
for	O
tricyclic	B-CHEMICAL
antidepressants	O
and	O
cocaine	B-CHEMICAL
.	O

The	O
primary	O
structure	O
of	O
porcine	B-GENE-Y
aminoacylase	I-GENE-Y
1	I-GENE-Y
deduced	O
from	O
cDNA	O
sequence	O
.	O

A	O
cDNA	O
encoding	O
the	O
complete	O
amino	B-CHEMICAL
acid	I-CHEMICAL
sequence	O
of	O
aminoacylase	B-GENE-Y
1	I-GENE-Y
(	O
N	B-GENE-Y
-	I-GENE-Y
acylamino	I-GENE-Y
acid	I-GENE-Y
aminohydrolase	I-GENE-Y
,	O
ACY	B-GENE-Y
-	I-GENE-Y
1	I-GENE-Y
)	O
[	O
EC	B-GENE-Y
3	I-GENE-Y
.	I-GENE-Y
5	I-GENE-Y
.	I-GENE-Y
1	I-GENE-Y
.	I-GENE-Y
14	I-GENE-Y
]	O
,	O
a	O
dimeric	O
metalloprotein	B-GENE-N
having	O
two	O
Zn2	B-CHEMICAL
+	I-CHEMICAL
in	O
the	O
molecule	O
,	O
which	O
catalyzes	O
the	O
deacylation	O
of	O
N	B-CHEMICAL
-	I-CHEMICAL
acylated	I-CHEMICAL
L	I-CHEMICAL
-	I-CHEMICAL
amino	I-CHEMICAL
acids	I-CHEMICAL
except	O
L	B-CHEMICAL
-	I-CHEMICAL
aspartic	I-CHEMICAL
acid	I-CHEMICAL
,	O
has	O
been	O
isolated	O
from	O
porcine	O
kidney	O
lambda	O
gt10	O
cDNA	O
library	O
and	O
sequenced	O
.	O

From	O
sequence	O
analysis	O
of	O
the	O
cDNA	O
and	O
the	O
N	B-CHEMICAL
-	O
and	O
C	B-CHEMICAL
-	O
terminal	O
amino	B-CHEMICAL
acid	I-CHEMICAL
analyses	O
of	O
the	O
purified	O
protein	O
,	O
it	O
is	O
deduced	O
that	O
porcine	B-GENE-Y
kidney	I-GENE-Y
ACY	I-GENE-Y
-	I-GENE-Y
1	I-GENE-Y
consists	O
of	O
two	O
identical	O
subunits	O
(	O
M	O
(	O
r	O
)	O
45	O
,	O
260	O
)	O
,	O
each	O
of	O
which	O
consists	O
of	O
a	O
single	O
chain	O
of	O
406	O
amino	B-CHEMICAL
acids	I-CHEMICAL
with	O
acetylalanine	B-CHEMICAL
at	O
the	O
N	B-CHEMICAL
-	O
terminus	O
.	O

A	O
cDNA	O
encoding	O
porcine	B-GENE-Y
liver	I-GENE-Y
ACY	I-GENE-Y
-	I-GENE-Y
1	I-GENE-Y
was	O
also	O
cloned	O
.	O

The	O
amino	B-CHEMICAL
acid	I-CHEMICAL
sequence	O
deduced	O
from	O
the	O
nucleotide	B-CHEMICAL
sequence	O
of	O
the	O
cDNA	O
from	O
porcine	O
liver	O
was	O
identical	O
to	O
that	O
deduced	O
for	O
porcine	B-GENE-Y
kidney	I-GENE-Y
ACY	I-GENE-Y
-	I-GENE-Y
1	I-GENE-Y
.	O

Northern	O
blot	O
analysis	O
suggested	O
that	O
ACY	B-GENE-Y
-	I-GENE-Y
1	I-GENE-Y
is	O
more	O
highly	O
expressed	O
in	O
kidney	O
than	O
in	O
liver	O
.	O

Comparison	O
of	O
the	O
amino	B-CHEMICAL
acid	I-CHEMICAL
sequence	O
of	O
porcine	B-GENE-Y
ACY	I-GENE-Y
-	I-GENE-Y
1	I-GENE-Y
with	O
those	O
of	O
other	O
Zn2	B-GENE-N
+	I-GENE-N
-	I-GENE-N
binding	I-GENE-N
metalloenzymes	I-GENE-N
showed	O
no	O
significant	O
homologies	O
in	O
either	O
the	O
overall	O
sequence	O
or	O
the	O
consensus	O
sequences	O
for	O
the	O
metal	O
binding	O
sites	O
.	O

This	O
indicates	O
that	O
ACY	B-GENE-Y
-	I-GENE-Y
1	I-GENE-Y
is	O
a	O
new	O
type	O
of	O
metalloprotein	B-GENE-N
.	O

Beta	B-GENE-Y
1	I-GENE-Y
-	I-GENE-Y
adrenergic	I-GENE-Y
receptor	I-GENE-Y
polymorphisms	O
and	O
antihypertensive	O
response	O
to	O
metoprolol	B-CHEMICAL
.	O

OBJECTIVES	O
:	O
Marked	O
interpatient	O
variability	O
exists	O
in	O
blood	O
pressure	O
response	O
to	O
beta	O
-	O
blocker	O
monotherapy	O
.	O

We	O
tested	O
the	O
hypothesis	O
that	O
2	O
common	O
polymorphisms	O
in	O
the	O
gene	O
for	O
beta	B-GENE-Y
(	I-GENE-Y
1	I-GENE-Y
)	I-GENE-Y
-	I-GENE-Y
adrenergic	I-GENE-Y
receptor	I-GENE-Y
are	O
associated	O
with	O
antihypertensive	O
response	O
to	O
metoprolol	B-CHEMICAL
in	O
patients	O
with	O
uncomplicated	O
hypertension	O
.	O

METHODS	O
:	O
Forty	O
hypertensive	O
men	O
and	O
women	O
aged	O
35	O
to	O
65	O
years	O
were	O
studied	O
.	O

Baseline	O
studies	O
included	O
24	O
-	O
hour	O
ambulatory	O
blood	O
pressure	O
monitoring	O
.	O

Patients	O
took	O
50	O
mg	O
metoprolol	B-CHEMICAL
twice	O
daily	O
with	O
weekly	O
titration	O
to	O
response	O
or	O
200	O
mg	O
twice	O
daily	O
.	O

After	O
a	O
minimum	O
of	O
4	O
weeks	O
at	O
stable	O
dose	O
,	O
treatment	O
phase	O
24	O
-	O
hour	O
ambulatory	O
blood	O
pressure	O
monitoring	O
was	O
repeated	O
.	O

The	O
codon	O
49	O
and	O
389	O
genotypes	O
for	O
beta	B-GENE-Y
(	I-GENE-Y
1	I-GENE-Y
)	I-GENE-Y
-	I-GENE-Y
adrenergic	I-GENE-Y
receptor	I-GENE-Y
were	O
determined	O
by	O
polymerase	O
chain	O
reaction	O
with	O
restriction	O
fragment	O
length	O
polymorphism	O
.	O

Multilinear	O
regression	O
was	O
performed	O
to	O
determine	O
the	O
impact	O
of	O
genotype	O
and	O
other	O
variables	O
on	O
blood	O
pressure	O
response	O
to	O
metoprolol	B-CHEMICAL
.	O

RESULTS	O
:	O
Patients	O
homozygous	O
for	O
Arg	B-CHEMICAL
at	O
codon	O
389	O
had	O
a	O
nearly	O
3	O
-	O
fold	O
greater	O
reduction	O
in	O
daytime	O
diastolic	O
blood	O
pressure	O
(	O
-	O
13	O
.	O
3	O
%	O
+	O
/	O
-	O
8	O
.	O
4	O
%	O
versus	O
-	O
4	O
.	O
5	O
%	O
+	O
/	O
-	O
8	O
.	O
2	O
%	O
,	O
P	O
=	O
.	O
0018	O
)	O
compared	O
with	O
those	O
who	O
carried	O
the	O
variant	O
allele	O
.	O

The	O
haplotype	O
pair	O
(	O
diplotype	O
)	O
for	O
beta	B-GENE-Y
(	I-GENE-Y
1	I-GENE-Y
)	I-GENE-Y
-	I-GENE-Y
adrenergic	I-GENE-Y
receptor	I-GENE-Y
was	O
also	O
a	O
significant	O
predictor	O
of	O
response	O
,	O
with	O
patients	O
having	O
the	O
Ser49Arg389	B-GENE-N
/	O
Ser49Arg389	B-GENE-N
diplotype	O
demonstrating	O
a	O
decline	O
in	O
blood	O
pressure	O
of	O
14	O
.	O
7	O
mm	O
Hg	O
versus	O
0	O
.	O
5	O
mm	O
Hg	O
in	O
patients	O
with	O
the	O
Gly49Arg389	B-GENE-N
/	O
Ser49Gly389	B-GENE-N
diplotype	O
.	O

In	O
multiregression	O
analysis	O
,	O
baseline	O
daytime	O
diastolic	O
blood	O
pressure	O
,	O
codon	O
389	O
genotype	O
,	O
and	O
codon	O
49	O
genotype	O
were	O
significant	O
predictors	O
of	O
blood	O
pressure	O
after	O
treatment	O
.	O

CONCLUSIONS	O
:	O
Our	O
data	O
suggest	O
that	O
beta	B-GENE-Y
(	I-GENE-Y
1	I-GENE-Y
)	I-GENE-Y
-	I-GENE-Y
adrenergic	I-GENE-Y
receptor	I-GENE-Y
polymorphisms	O
are	O
important	O
determinants	O
of	O
antihypertensive	O
response	O
to	O
metoprolol	B-CHEMICAL
.	O

In	O
the	O
future	O
,	O
codon	O
49	O
and	O
389	O
genotypes	O
or	O
beta	B-GENE-Y
(	I-GENE-Y
1	I-GENE-Y
)	I-GENE-Y
-	I-GENE-Y
adrenergic	I-GENE-Y
receptor	I-GENE-Y
haplotypes	O
might	O
be	O
used	O
to	O
predict	O
the	O
diastolic	O
blood	O
pressure	O
response	O
to	O
metoprolol	B-CHEMICAL
in	O
patients	O
with	O
hypertension	O
.	O

Interaction	O
of	O
rofecoxib	B-CHEMICAL
and	O
celecoxib	B-CHEMICAL
with	O
warfarin	B-CHEMICAL
.	O

The	O
interaction	O
of	O
celecoxib	B-CHEMICAL
and	O
rofecoxib	B-CHEMICAL
with	O
warfarin	B-CHEMICAL
was	O
studied	O
.	O

Patients	O
stable	O
on	O
warfarin	B-CHEMICAL
therapy	O
and	O
concurrently	O
taking	O
a	O
cyclooxygenase	B-GENE-Y
-	I-GENE-Y
2	I-GENE-Y
(	O
COX	B-GENE-Y
-	I-GENE-Y
2	I-GENE-Y
)	O
inhibitor	O
comparator	O
(	O
traditional	O
nonsteroidal	O
antiinflammatory	O
medications	O
,	O
salsalate	B-CHEMICAL
,	O
or	O
acetaminophen	B-CHEMICAL
)	O
randomly	O
received	O
celecoxib	B-CHEMICAL
200	O
mg	O
/	O
day	O
or	O
rofecoxib	B-CHEMICAL
25	O
mg	O
/	O
day	O
for	O
three	O
weeks	O
.	O

After	O
a	O
one	O
-	O
week	O
washout	O
period	O
,	O
the	O
patients	O
were	O
crossed	O
over	O
to	O
treatment	O
with	O
the	O
opposite	O
COX	B-GENE-Y
-	I-GENE-Y
2	I-GENE-Y
inhibitor	O
for	O
three	O
more	O
weeks	O
.	O

The	O
International	O
Normalized	O
Ratio	O
(	O
INR	O
)	O
was	O
measured	O
at	O
baseline	O
and	O
at	O
weeks	O
1	O
,	O
2	O
,	O
and	O
3	O
of	O
therapy	O
with	O
each	O
COX	B-GENE-Y
-	I-GENE-Y
2	I-GENE-Y
inhibitor	O
by	O
testing	O
blood	O
samples	O
obtained	O
by	O
finger	O
stick	O
.	O

Data	O
for	O
16	O
patients	O
were	O
analyzed	O
.	O

The	O
INR	O
increased	O
by	O
13	O
%	O
,	O
6	O
%	O
,	O
and	O
5	O
%	O
on	O
average	O
in	O
patients	O
taking	O
celecoxib	B-CHEMICAL
at	O
weeks	O
1	O
,	O
2	O
,	O
and	O
3	O
,	O
respectively	O
,	O
and	O
by	O
5	O
%	O
,	O
9	O
%	O
,	O
and	O
5	O
%	O
in	O
patients	O
taking	O
rofecoxib	B-CHEMICAL
.	O

Changes	O
in	O
the	O
INR	O
were	O
statistically	O
significant	O
at	O
week	O
1	O
for	O
celecoxib	B-CHEMICAL
and	O
at	O
week	O
2	O
for	O
rofecoxib	B-CHEMICAL
.	O

Of	O
the	O
12	O
subjects	O
who	O
had	O
a	O
clinically	O
significant	O
>	O
or	O
=	O
15	O
%	O
change	O
in	O
the	O
INR	O
while	O
receiving	O
either	O
COX	B-GENE-Y
-	I-GENE-Y
2	I-GENE-Y
inhibitor	O
,	O
4	O
showed	O
this	O
change	O
for	O
both	O
agents	O
.	O

Adverse	O
drug	O
reactions	O
were	O
similar	O
for	O
each	O
COX	B-GENE-Y
-	I-GENE-Y
2	I-GENE-Y
inhibitor	O
,	O
but	O
the	O
rate	O
of	O
edema	O
requiring	O
medical	O
intervention	O
was	O
higher	O
in	O
the	O
rofecoxib	B-CHEMICAL
group	O
.	O

Significant	O
increases	O
in	O
the	O
INR	O
were	O
observed	O
in	O
patients	O
who	O
were	O
stable	O
on	O
warfarin	B-CHEMICAL
therapy	O
after	O
the	O
addition	O
of	O
therapy	O
with	O
rofecoxib	B-CHEMICAL
or	O
celecoxib	B-CHEMICAL
.	O

AT1	B-GENE-Y
antagonism	O
by	O
eprosartan	B-CHEMICAL
lowers	O
heart	O
rate	O
variability	O
and	O
baroreflex	O
gain	O
.	O

INTRODUCTION	O
:	O
Blockade	O
of	O
the	O
renin	B-GENE-Y
-	O
angiotensin	B-CHEMICAL
system	O
(	O
RAS	O
)	O
by	O
ACE	B-GENE-Y
inhibitors	O
has	O
been	O
demonstrated	O
to	O
reduce	O
total	O
mortality	O
in	O
cardiovascular	O
diseases	O
.	O

This	O
advantage	O
was	O
attributed	O
in	O
part	O
to	O
changes	O
of	O
autonomic	O
cardiovascular	O
control	O
,	O
exemplified	O
by	O
an	O
increase	O
of	O
heart	O
rate	O
variability	O
(	O
HRV	O
)	O
and	O
baroreflex	O
gain	O
(	O
BRG	O
)	O
.	O

We	O
sought	O
to	O
assess	O
the	O
effects	O
of	O
the	O
angiotensin	B-GENE-Y
type	I-GENE-Y
1	I-GENE-Y
(	I-GENE-Y
AT1	I-GENE-Y
)	I-GENE-Y
receptor	I-GENE-Y
blocker	O
eprosartan	B-CHEMICAL
on	O
HRV	O
and	O
BRG	O
.	O

MATERIALS	O
AND	O
METHODS	O
:	O
In	O
a	O
double	O
-	O
blind	O
randomized	O
cross	O
-	O
over	O
design	O
25	O
young	O
males	O
took	O
eprosartan	B-CHEMICAL
(	O
600	O
mg	O
/	O
day	O
)	O
and	O
placebo	O
each	O
for	O
a	O
period	O
of	O
7	O
days	O
with	O
a	O
wash	O
-	O
out	O
period	O
of	O
at	O
least	O
4	O
weeks	O
in	O
between	O
.	O

At	O
the	O
end	O
of	O
the	O
intake	O
phases	O
simultaneous	O
recordings	O
of	O
arterial	O
blood	O
pressure	O
(	O
AP	O
;	O
Finapres	O
)	O
and	O
electrocardiogram	O
(	O
ECG	O
)	O
were	O
taken	O
.	O

Power	O
spectra	O
of	O
HRV	O
and	O
arterial	O
blood	O
pressure	O
variability	O
(	O
APV	O
)	O
were	O
calculated	O
by	O
fast	O
Fourier	O
transform	O
(	O
FFT	O
)	O
and	O
served	O
to	O
calculate	O
BRG	O
.	O

Ang	B-GENE-Y
-	I-GENE-Y
II	I-GENE-Y
levels	O
were	O
measured	O
by	O
radioimmunoassay	O
.	O

RESULTS	O
:	O
Eprosartan	B-CHEMICAL
tended	O
to	O
lower	O
mean	O
AP	O
,	O
it	O
slightly	O
increased	O
heart	O
rate	O
(	O
HR	O
)	O
(	O
p	O
<	O
0	O
.	O
05	O
)	O
,	O
and	O
markedly	O
increased	O
circulating	O
Ang	B-CHEMICAL
-	I-CHEMICAL
II	I-CHEMICAL
levels	O
(	O
p	O
<	O
0	O
.	O
01	O
)	O
.	O

Eprosartan	B-CHEMICAL
diminished	O
the	O
total	O
power	O
of	O
HRV	O
(	O
p	O
<	O
0	O
.	O
05	O
)	O
and	O
the	O
BRG	O
(	O
p	O
<	O
0	O
.	O
01	O
)	O
.	O

The	O
low	O
/	O
high	O
frequency	O
(	O
LF	O
/	O
HF	O
)	O
ratio	O
of	O
HRV	O
and	O
the	O
APV	O
were	O
not	O
altered	O
.	O

CONCLUSIONS	O
:	O
AT1	B-GENE-Y
antagonism	O
by	O
eprosartan	B-CHEMICAL
lowers	O
heart	O
rate	O
variability	O
and	O
baroreflex	O
gain	O
.	O

We	O
speculate	O
that	O
these	O
findings	O
are	O
due	O
to	O
the	O
marked	O
increase	O
in	O
circulating	O
angiotensin	B-CHEMICAL
II	I-CHEMICAL
(	O
Ang	B-CHEMICAL
II	I-CHEMICAL
)	O
.	O

Further	O
studies	O
are	O
needed	O
to	O
clarify	O
whether	O
angiotensin	B-GENE-Y
type	I-GENE-Y
1	I-GENE-Y
(	O
AT1	B-GENE-Y
)	O
blockers	O
with	O
potential	O
actions	O
inside	O
the	O
blood	O
-	O
brain	O
barrier	O
(	O
BBB	O
)	O
may	O
have	O
different	O
effects	O
on	O
HRV	O
and	O
BRG	O
.	O

Further	O
characterization	O
of	O
alpha	O
N	B-CHEMICAL
-	I-CHEMICAL
acetyl	I-CHEMICAL
beta	O
-	O
endorphin	O
-	O
(	O
1	O
-	O
31	O
)	O
regulatory	O
activity	O
,	O
I	O
:	O
Effect	O
on	O
opioid	O
-	O
and	O
alpha	O
2	O
-	O
mediated	O
supraspinal	O
antinociception	O
in	O
mice	O
.	O

Picomol	O
doses	O
of	O
the	O
acetylated	O
derivative	O
of	O
beta	O
-	O
endorphin	O
-	O
(	O
1	O
-	O
31	O
)	O
,	O
injected	O
intracerebroventricularly	O
(	O
icv	O
)	O
in	O
mice	O
,	O
reduced	O
the	O
analgesic	O
activity	O
of	O
morphine	B-CHEMICAL
,	O
etorphine	B-CHEMICAL
and	O
beta	O
-	O
endorphin	O
-	O
(	O
1	O
-	O
31	O
)	O
,	O
while	O
the	O
efficiency	O
of	O
DAGO	B-CHEMICAL
and	O
DADLE	B-CHEMICAL
in	O
producing	O
analgesia	O
was	O
enhanced	O
.	O

The	O
effects	O
of	O
the	O
delta	O
agonists	O
DPDPE	B-CHEMICAL
and	O
[	B-CHEMICAL
D	I-CHEMICAL
-	I-CHEMICAL
Ala2	I-CHEMICAL
]	I-CHEMICAL
-	I-CHEMICAL
Deltorphin	I-CHEMICAL
II	I-CHEMICAL
were	O
not	O
altered	O
by	O
this	O
treatment	O
.	O

After	O
alpha	O
N	B-CHEMICAL
-	I-CHEMICAL
acetyl	I-CHEMICAL
beta	O
-	O
endorphin	O
-	O
(	O
1	O
-	O
31	O
)	O
injection	O
,	O
morphine	B-CHEMICAL
antagonized	O
the	O
analgesia	O
of	O
DAGO	B-CHEMICAL
.	O

The	O
regulatory	O
effect	O
of	O
alpha	O
N	B-CHEMICAL
-	I-CHEMICAL
acetyl	I-CHEMICAL
beta	O
-	O
endorphin	O
-	O
(	O
1	O
-	O
31	O
)	O
was	O
exhibited	O
when	O
giving	O
the	O
peptide	O
both	O
before	O
(	O
up	O
to	O
24	O
h	O
)	O
and	O
after	O
the	O
opioids	O
.	O

Naloxone	B-CHEMICAL
did	O
not	O
prevent	O
or	O
reverse	O
that	O
modulatory	O
activity	O
;	O
moreover	O
,	O
pretreatment	O
with	O
the	O
acetylated	O
peptide	O
did	O
not	O
change	O
the	O
pA2	O
value	O
displayed	O
by	O
the	O
antagonist	O
at	O
the	O
mu	B-GENE-Y
receptor	I-GENE-Y
.	O

The	O
antinociceptive	O
activity	O
of	O
the	O
alpha	B-GENE-N
2	I-GENE-N
-	I-GENE-N
adrenoceptor	I-GENE-N
agonist	O
clonidine	B-CHEMICAL
was	O
also	O
increased	O
in	O
mice	O
treated	O
with	O
alpha	O
N	B-CHEMICAL
-	I-CHEMICAL
acetyl	I-CHEMICAL
beta	O
-	O
endorphin	O
-	O
(	O
1	O
-	O
31	O
)	O
.	O

The	O
reducing	O
activity	O
of	O
alpha	O
N	B-CHEMICAL
-	I-CHEMICAL
acetyl	I-CHEMICAL
beta	O
-	O
endorphin	O
-	O
(	O
1	O
-	O
31	O
)	O
upon	O
morphine	B-CHEMICAL
-	O
and	O
beta	O
-	O
endorphin	O
-	O
induced	O
analgesia	O
was	O
not	O
exhibited	O
in	O
mice	O
undergoing	O
treatment	O
with	O
pertussis	O
toxin	O
or	O
N	B-CHEMICAL
-	I-CHEMICAL
ethylmaleimide	I-CHEMICAL
,	O
agents	O
known	O
to	O
impair	O
the	O
function	O
of	O
Gi	B-GENE-N
/	O
Go	B-GENE-N
transducer	O
proteins	O
.	O

However	O
,	O
the	O
enhancing	O
activity	O
displayed	O
by	O
this	O
peptide	O
upon	O
DAGO	B-CHEMICAL
-	O
DADLE	B-CHEMICAL
and	O
clonidine	B-CHEMICAL
-	O
evoked	O
antinociception	O
was	O
still	O
manifested	O
.	O

These	O
results	O
confirm	O
and	O
strengthen	O
the	O
idea	O
of	O
alpha	O
N	B-CHEMICAL
-	I-CHEMICAL
acetyl	I-CHEMICAL
beta	O
-	O
endorphin	O
-	O
(	O
1	O
-	O
31	O
)	O
acting	O
as	O
a	O
non	O
-	O
competitive	O
regulator	O
of	O
mu	B-GENE-Y
opioid	I-GENE-Y
-	O
and	O
alpha	B-GENE-N
2	I-GENE-N
-	I-GENE-N
adrenoceptor	I-GENE-N
-	O
mediated	O
supraspinal	O
antinociception	O
.	O

A	O
neural	O
substrate	O
acted	O
on	O
by	O
both	O
receptors	O
(	O
likely	O
Gi	B-GENE-N
/	O
Go	B-GENE-N
transducer	O
proteins	O
)	O
appears	O
to	O
be	O
involved	O
in	O
the	O
effects	O
of	O
that	O
neuropeptide	O
.	O

Effects	O
of	O
loperamide	B-CHEMICAL
on	O
the	O
human	O
hypothalamo	O
-	O
pituitary	O
-	O
adrenal	O
axis	O
in	O
vivo	O
and	O
in	O
vitro	O
.	O

Loperamide	B-CHEMICAL
,	O
an	O
opiate	O
agonist	O
of	O
high	O
specificity	O
for	O
mu	O
-	O
receptors	O
,	O
was	O
recently	O
reported	O
to	O
suppress	O
ACTH	B-GENE-Y
and	O
cortisol	B-CHEMICAL
levels	O
in	O
normal	O
subjects	O
,	O
but	O
not	O
in	O
patients	O
with	O
proven	O
ACTH	B-GENE-Y
-	O
dependent	O
Cushing	O
'	O
s	O
disease	O
.	O

However	O
,	O
there	O
is	O
little	O
information	O
on	O
the	O
site	O
of	O
action	O
of	O
loperamide	B-CHEMICAL
in	O
the	O
hypothalamo	O
-	O
pituitary	O
-	O
adrenal	O
axis	O
of	O
man	O
.	O

We	O
investigated	O
the	O
effect	O
of	O
loperamide	B-CHEMICAL
on	O
pituitary	O
hormone	O
secretion	O
in	O
vivo	O
and	O
in	O
vitro	O
.	O

In	O
seven	O
normal	O
subjects	O
,	O
basal	O
ACTH	B-GENE-Y
plasma	O
levels	O
were	O
significantly	O
suppressed	O
3	O
h	O
after	O
loperamide	B-CHEMICAL
administration	O
(	O
16	O
mg	O
,	O
orally	O
)	O
from	O
5	O
+	O
/	O
-	O
1	O
to	O
2	O
+	O
/	O
-	O
0	O
pmol	O
/	O
L	O
(	O
P	O
less	O
than	O
0	O
.	O
0001	O
)	O
.	O

After	O
the	O
combined	O
pituitary	O
stimulation	O
test	O
(	O
100	O
micrograms	O
human	B-GENE-Y
CRH	I-GENE-Y
,	O
100	O
micrograms	O
GnRH	B-CHEMICAL
,	O
100	O
micrograms	O
GH	B-CHEMICAL
-	I-CHEMICAL
releasing	I-CHEMICAL
hormone	I-CHEMICAL
,	O
and	O
200	O
micrograms	O
TRH	B-CHEMICAL
)	O
,	O
the	O
ACTH	B-GENE-Y
peak	O
(	O
maximum	O
increase	O
at	O
30	O
min	O
)	O
was	O
significantly	O
blunted	O
by	O
loperamide	B-CHEMICAL
from	O
9	O
+	O
/	O
-	O
1	O
to	O
4	O
+	O
/	O
-	O
1	O
pmol	O
/	O
L	O
(	O
P	O
less	O
than	O
0	O
.	O
001	O
)	O
and	O
the	O
area	O
under	O
the	O
curve	O
of	O
ACTH	B-GENE-Y
from	O
0	O
-	O
120	O
min	O
was	O
reduced	O
from	O
35	O
+	O
/	O
-	O
5	O
to	O
23	O
+	O
/	O
-	O
4	O
pmol	O
/	O
L	O
.	O
2	O
h	O
(	O
P	O
less	O
than	O
0	O
.	O
05	O
)	O
.	O

In	O
the	O
insulin	B-GENE-Y
-	O
hypoglycemia	O
test	O
(	O
0	O
.	O
15	O
IU	O
/	O
kg	O
BW	O
)	O
,	O
neither	O
the	O
ACTH	B-GENE-Y
peak	O
nor	O
the	O
area	O
under	O
the	O
curve	O
of	O
ACTH	B-GENE-Y
was	O
affected	O
by	O
loperamide	B-CHEMICAL
.	O

In	O
six	O
patients	O
with	O
Cushing	O
'	O
s	O
disease	O
and	O
one	O
patient	O
with	O
secondary	O
adrenal	O
insufficiency	O
due	O
to	O
hypothalamic	O
failure	O
,	O
neither	O
basal	O
ACTH	B-GENE-Y
and	O
cortisol	B-CHEMICAL
levels	O
nor	O
CRH	B-GENE-Y
-	O
stimulated	O
levels	O
were	O
influenced	O
by	O
loperamide	B-CHEMICAL
.	O

In	O
four	O
cultured	O
human	O
corticotropic	O
adenomas	O
,	O
loperamide	B-CHEMICAL
was	O
not	O
able	O
to	O
reduce	O
basal	O
and	O
CRH	B-GENE-Y
-	O
induced	O
ACTH	B-GENE-Y
secretion	O
.	O

In	O
summary	O
,	O
loperamide	B-CHEMICAL
is	O
able	O
to	O
reduce	O
basal	O
and	O
CRH	B-GENE-Y
-	O
induced	O
ACTH	B-GENE-Y
and	O
cortisol	B-CHEMICAL
levels	O
in	O
normal	O
subjects	O
,	O
but	O
not	O
in	O
patients	O
with	O
Cushing	O
'	O
s	O
disease	O
or	O
secondary	O
adrenal	O
failure	O
of	O
hypothalamic	O
origin	O
.	O

Loperamide	B-CHEMICAL
has	O
no	O
significant	O
effect	O
on	O
insulin	B-GENE-Y
-	O
hypoglycemia	O
-	O
induced	O
ACTH	B-GENE-Y
and	O
cortisol	B-CHEMICAL
levels	O
and	O
,	O
therefore	O
,	O
no	O
effect	O
on	O
stress	O
-	O
induced	O
elevation	O
of	O
cortisol	O
levels	O
.	O

Loperamide	B-CHEMICAL
might	O
act	O
at	O
a	O
suprapituitary	O
site	O
in	O
man	O
in	O
vivo	O
,	O
but	O
,	O
nevertheless	O
,	O
a	O
pituitary	O
site	O
cannot	O
be	O
excluded	O
.	O

Effects	O
of	O
nedocromil	B-CHEMICAL
sodium	I-CHEMICAL
on	O
the	O
binding	O
of	O
N	B-CHEMICAL
-	I-CHEMICAL
formyl	I-CHEMICAL
-	I-CHEMICAL
methionyl	I-CHEMICAL
-	I-CHEMICAL
leucyl	I-CHEMICAL
-	I-CHEMICAL
phenylalanine	I-CHEMICAL
in	O
human	O
neutrophils	O
.	O

In	O
the	O
present	O
study	O
the	O
inhibition	O
by	O
nedocromil	B-CHEMICAL
sodium	I-CHEMICAL
of	O
the	O
specific	O
receptor	O
binding	O
of	O
FMLP	O
was	O
evaluated	O
in	O
human	O
neutrophils	O
(	O
PMNs	O
)	O
using	O
a	O
FMLP	O
-	O
(	O
3H	O
)	O
binding	O
assay	O
.	O

The	O
time	O
course	O
of	O
the	O
binding	O
was	O
markedly	O
influenced	O
by	O
nedocromil	B-CHEMICAL
sodium	I-CHEMICAL
used	O
at	O
a	O
concentration	O
of	O
300	O
microM	O
.	O

No	O
significant	O
inhibition	O
was	O
obtained	O
when	O
the	O
cells	O
were	O
treated	O
with	O
nedocromil	B-CHEMICAL
sodium	I-CHEMICAL
3	O
microM	O
or	O
with	O
sodium	B-CHEMICAL
cromoglycate	O
300	O
microM	O
.	O

FMLP	O
binding	O
is	O
essentially	O
eliminated	O
by	O
the	O
highest	O
dose	O
of	O
nedocromil	B-CHEMICAL
sodium	I-CHEMICAL
.	O

The	O
biologic	O
meaning	O
of	O
this	O
effect	O
in	O
asthmatic	O
patients	O
should	O
be	O
further	O
evaluated	O
.	O

Effects	O
of	O
nedocromil	B-CHEMICAL
sodium	I-CHEMICAL
and	O
WEB	B-CHEMICAL
2086	I-CHEMICAL
on	O
chemoattractant	O
-	O
stimulated	O
neutrophil	O
migration	O
through	O
cellular	O
and	O
noncellular	O
barriers	O
.	O

Nedocromil	B-CHEMICAL
sodium	I-CHEMICAL
(	O
Tilade	B-CHEMICAL
)	O
is	O
an	O
effective	O
therapeutic	O
agent	O
against	O
asthma	O
and	O
has	O
been	O
shown	O
to	O
exhibit	O
antiinflammatory	O
activity	O
in	O
vitro	O
;	O
however	O
,	O
its	O
mode	O
of	O
action	O
is	O
yet	O
to	O
be	O
described	O
fully	O
.	O

Using	O
an	O
in	O
vitro	O
assay	O
designed	O
to	O
mimic	O
the	O
extravasation	O
of	O
neutrophils	O
from	O
the	O
peripheral	O
circulation	O
through	O
cellular	O
barriers	O
to	O
sites	O
of	O
inflammation	O
,	O
the	O
effect	O
of	O
nedocromil	B-CHEMICAL
sodium	I-CHEMICAL
on	O
chemoattractant	O
-	O
stimulated	O
neutrophil	O
migration	O
was	O
examined	O
.	O

We	O
also	O
examined	O
the	O
effects	O
of	O
WEB	B-CHEMICAL
2086	I-CHEMICAL
,	O
a	O
platelet	B-GENE-Y
-	I-GENE-Y
activating	I-GENE-Y
factor	I-GENE-Y
(	I-GENE-Y
PAF	I-GENE-Y
)	I-GENE-Y
receptor	I-GENE-Y
antagonist	O
,	O
in	O
parallel	O
.	O

Neutrophils	O
and	O
the	O
cellular	O
barrier	O
were	O
pretreated	O
and	O
/	O
or	O
co	O
-	O
incubated	O
with	O
nedocromil	O
or	O
WEB	B-CHEMICAL
2086	I-CHEMICAL
and	O
the	O
effects	O
on	O
neutrophil	O
chemotaxis	O
measured	O
.	O

In	O
all	O
treatments	O
,	O
nedocromil	B-CHEMICAL
did	O
not	O
significantly	O
affect	O
chemotaxis	O
through	O
cellular	O
or	O
noncellular	O
barriers	O
to	O
N	B-CHEMICAL
-	I-CHEMICAL
formyl	I-CHEMICAL
-	I-CHEMICAL
methionyl	I-CHEMICAL
-	I-CHEMICAL
leucyl	I-CHEMICAL
-	I-CHEMICAL
phenylalanine	I-CHEMICAL
(	O
FMLP	B-CHEMICAL
)	O
,	O
leukotriene	B-CHEMICAL
B4	I-CHEMICAL
(	O
LTB4	B-CHEMICAL
)	O
,	O
or	O
PAF	B-CHEMICAL
.	O

In	O
contrast	O
,	O
WEB	B-CHEMICAL
2086	I-CHEMICAL
inhibited	O
PAF	B-CHEMICAL
-	O
induced	O
neutrophil	O
migration	O
through	O
both	O
naked	O
filters	O
and	O
endothelial	O
and	O
epithelial	O
monolayers	O
cultured	O
on	O
these	O
filters	O
.	O

We	O
conclude	O
that	O
while	O
nedocromil	B-CHEMICAL
has	O
been	O
shown	O
to	O
have	O
inhibitory	O
effects	O
on	O
neutrophils	O
and	O
is	O
an	O
effective	O
therapeutic	O
agent	O
for	O
asthma	O
and	O
inflammatory	O
conditions	O
,	O
its	O
activity	O
is	O
not	O
primarily	O
mediated	O
by	O
inhibition	O
of	O
neutrophil	O
chemotaxis	O
.	O

Platelet	B-GENE-Y
-	I-GENE-Y
activating	I-GENE-Y
factor	I-GENE-Y
antagonists	O
may	O
partially	O
be	O
effective	O
in	O
asthma	O
through	O
inhibitory	O
effects	O
on	O
neutrophil	O
chemotaxis	O
.	O

Ocular	O
beta	O
-	O
blockers	O
in	O
glaucoma	O
management	O
.	O

Clinical	O
pharmacological	O
aspects	O
.	O

Topical	O
beta	O
-	O
blockers	O
reduce	O
the	O
intraocular	O
pressure	O
(	O
IOP	O
)	O
by	O
blockade	O
of	O
sympathetic	O
nerve	O
endings	O
in	O
the	O
ciliary	O
epithelium	O
causing	O
a	O
fall	O
in	O
aqueous	O
humour	O
production	O
.	O

Two	O
types	O
of	O
topical	O
beta	O
-	O
blockers	O
are	O
available	O
for	O
use	O
in	O
glaucoma	O
:	O
nonselective	O
,	O
which	O
block	O
both	O
beta	B-GENE-N
1	I-GENE-N
-	I-GENE-N
and	I-GENE-N
beta	I-GENE-N
2	I-GENE-N
-	I-GENE-N
adrenoceptors	I-GENE-N
;	O
and	O
cardioselective	O
,	O
which	O
block	O
only	O
beta	B-GENE-Y
1	I-GENE-Y
-	I-GENE-Y
receptors	I-GENE-Y
.	O

Of	O
the	O
beta	O
-	O
Blockers	O
commercially	O
available	O
,	O
timolol	B-CHEMICAL
,	O
levobunolol	B-CHEMICAL
,	O
metipranolol	B-CHEMICAL
and	O
carteolol	B-CHEMICAL
are	O
nonselective	O
,	O
and	O
betaxolol	B-CHEMICAL
is	O
cardioselective	O
.	O

Twice	O
-	O
daily	O
timolol	B-CHEMICAL
is	O
probably	O
the	O
most	O
effective	O
agent	O
in	O
lowering	O
IOP	O
,	O
although	O
levobunolol	B-CHEMICAL
is	O
equally	O
effective	O
and	O
can	O
be	O
used	O
once	O
daily	O
with	O
little	O
difference	O
in	O
effect	O
.	O

Carteolol	B-CHEMICAL
is	O
used	O
twice	O
daily	O
and	O
any	O
theoretical	O
advantage	O
in	O
diminished	O
side	O
effects	O
conferred	O
by	O
its	O
partial	O
beta	O
-	O
agonist	O
activity	O
compared	O
with	O
timolol	B-CHEMICAL
has	O
not	O
been	O
fully	O
substantiated	O
.	O

Metipranolol	B-CHEMICAL
is	O
effective	O
twice	O
daily	O
and	O
does	O
not	O
have	O
partial	O
beta	O
-	O
agonist	O
activity	O
.	O

Betaxolol	B-CHEMICAL
has	O
an	O
effect	O
comparable	O
to	O
timolol	B-CHEMICAL
in	O
lowering	O
IOP	O
,	O
but	O
is	O
less	O
effective	O
in	O
some	O
patients	O
.	O

beta	O
-	O
Blockers	O
can	O
be	O
used	O
with	O
other	O
antiglaucoma	O
medications	O
,	O
but	O
their	O
combined	O
action	O
with	O
epinephrine	B-CHEMICAL
(	O
adrenaline	B-CHEMICAL
)	O
is	O
suspect	O
,	O
particularly	O
in	O
the	O
case	O
of	O
the	O
nonselective	O
beta	O
-	O
blockers	O
,	O
and	O
the	O
effect	O
should	O
be	O
assessed	O
in	O
patients	O
on	O
an	O
individual	O
basis	O
.	O

Local	O
stinging	O
can	O
be	O
a	O
problem	O
in	O
some	O
patients	O
with	O
betaxolol	B-CHEMICAL
.	O

The	O
most	O
serious	O
side	O
effects	O
of	O
beta	O
-	O
blockers	O
are	O
the	O
exacerbation	O
of	O
chronic	O
obstructive	O
airways	O
disease	O
with	O
nonselective	O
agents	O
and	O
the	O
precipitation	O
of	O
bronchospasm	O
in	O
some	O
patients	O
.	O

Betaxolol	B-CHEMICAL
seems	O
relatively	O
free	O
of	O
adverse	O
respiratory	O
effects	O
,	O
although	O
this	O
may	O
be	O
dose	O
-	O
related	O
and	O
extreme	O
caution	O
should	O
still	O
be	O
exercised	O
in	O
patients	O
with	O
any	O
history	O
of	O
respiratory	O
illness	O
.	O

Because	O
of	O
the	O
lower	O
risk	O
of	O
precipitating	O
side	O
effects	O
,	O
betaxolol	B-CHEMICAL
is	O
probably	O
the	O
beta	O
-	O
blocker	O
of	O
first	O
choice	O
for	O
use	O
in	O
glaucoma	O
;	O
timolol	B-CHEMICAL
or	O
levobunolol	B-CHEMICAL
are	O
reserved	O
for	O
patients	O
who	O
do	O
not	O
respond	O
satisfactorily	O
to	O
betaxolol	B-CHEMICAL
and	O
are	O
quite	O
free	O
of	O
respiratory	O
disease	O
.	O

5	B-GENE-Y
-	I-GENE-Y
Lipoxygenase	I-GENE-Y
inhibitors	O
for	O
the	O
treatment	O
of	O
inflammatory	O
bowel	O
disease	O
.	O

The	O
unique	O
role	O
of	O
the	O
enzyme	O
5	B-GENE-Y
-	I-GENE-Y
lipoxygenase	I-GENE-Y
(	O
5	B-GENE-Y
-	I-GENE-Y
LO	I-GENE-Y
)	O
in	O
the	O
production	O
of	O
leukotrienes	B-CHEMICAL
(	O
LTs	B-CHEMICAL
)	O
makes	O
it	O
a	O
likely	O
target	O
for	O
biochemical	O
manipulation	O
.	O

The	O
rationale	O
for	O
using	O
5	B-GENE-Y
-	I-GENE-Y
LO	I-GENE-Y
inhibitors	O
for	O
the	O
treatment	O
of	O
inflammatory	O
bowel	O
disease	O
(	O
IBD	O
)	O
is	O
based	O
on	O
the	O
increased	O
generation	O
of	O
LTs	B-CHEMICAL
in	O
the	O
inflamed	O
mucosa	O
,	O
LTB4	B-CHEMICAL
being	O
the	O
most	O
potent	O
chemotactic	O
and	O
chemokinetic	O
metabolite	O
of	O
arachidonic	B-CHEMICAL
acid	I-CHEMICAL
.	O

Furthermore	O
,	O
conventional	O
drugs	O
,	O
such	O
as	O
corticosteroids	O
,	O
sulphasalazine	B-CHEMICAL
,	O
and	O
5	B-CHEMICAL
-	I-CHEMICAL
aminosalicylic	I-CHEMICAL
acid	I-CHEMICAL
,	O
inhibit	O
LT	B-CHEMICAL
production	O
and	O
specific	O
5	B-GENE-Y
-	I-GENE-Y
LO	I-GENE-Y
inhibition	O
accelerates	O
healing	O
in	O
animal	O
models	O
of	O
acute	O
colitis	O
.	O

The	O
compounds	O
identified	O
as	O
5	B-GENE-Y
-	I-GENE-Y
LO	I-GENE-Y
inhibitors	O
can	O
be	O
divided	O
into	O
antioxidants	O
,	O
substrate	O
-	O
analogous	O
,	O
and	O
a	O
large	O
miscellaneous	O
group	O
of	O
inhibitors	O
,	O
where	O
hydroxamic	B-CHEMICAL
acids	I-CHEMICAL
are	O
potent	O
and	O
more	O
selective	O
inhibitors	O
of	O
5	B-GENE-Y
-	I-GENE-Y
LO	I-GENE-Y
.	O

The	O
benzothiophene	B-CHEMICAL
hydroxyurea	I-CHEMICAL
,	O
zileuton	B-CHEMICAL
,	O
is	O
the	O
first	O
selective	O
5	B-GENE-Y
-	I-GENE-Y
LO	I-GENE-Y
inhibitor	O
evaluated	O
for	O
the	O
treatment	O
of	O
patients	O
with	O
IBD	O
.	O

An	O
800	O
-	O
mg	O
oral	O
dose	O
of	O
zileuton	B-CHEMICAL
was	O
shown	O
to	O
reduce	O
LTB4	B-CHEMICAL
,	O
but	O
not	O
prostaglandin	B-CHEMICAL
E2	I-CHEMICAL
,	O
concentrations	O
by	O
75	O
-	O
85	O
%	O
in	O
rectal	O
dialysates	O
from	O
patients	O
with	O
active	O
ulcerative	O
colitis	O
.	O

The	O
clinical	O
efficacy	O
of	O
zileuton	B-CHEMICAL
800	O
mg	O
b	O
.	O
i	O
.	O
d	O
.	O
has	O
also	O
been	O
tested	O
in	O
a	O
randomized	O
,	O
double	O
-	O
blind	O
,	O
placebo	O
-	O
controlled	O
trial	O
in	O
similar	O
patients	O
.	O

Zileuton	B-CHEMICAL
significantly	O
improved	O
the	O
symptom	O
scores	O
and	O
the	O
histology	O
score	O
,	O
but	O
not	O
the	O
sigmoidoscopy	O
score	O
,	O
compared	O
to	O
pretreatment	O
conditions	O
and	O
with	O
response	O
to	O
placebo	O
,	O
the	O
beneficial	O
effects	O
being	O
most	O
pronounced	O
in	O
patients	O
not	O
receiving	O
concomitant	O
sulphasalazine	B-CHEMICAL
treatment	O
.	O

The	O
mean	O
inhibition	O
of	O
LTB4	B-CHEMICAL
in	O
the	O
target	O
tissue	O
of	O
inflammation	O
was	O
70	O
%	O
.	O

The	O
proof	O
that	O
any	O
putative	O
5	B-GENE-Y
-	I-GENE-Y
LO	I-GENE-Y
inhibitor	O
is	O
blocking	O
LT	B-CHEMICAL
production	O
is	O
an	O
important	O
stage	O
in	O
assessing	O
any	O
such	O
drug	O
.	O

The	O
main	O
disadvantage	O
of	O
existing	O
new	O
LT	B-CHEMICAL
inhibitors	O
relates	O
to	O
the	O
high	O
potency	O
of	O
LTs	B-CHEMICAL
,	O
and	O
unless	O
a	O
higher	O
level	O
of	O
inhibition	O
can	O
be	O
achieved	O
,	O
endogenous	O
LTs	B-CHEMICAL
may	O
still	O
be	O
present	O
in	O
sufficient	O
amounts	O
to	O
produce	O
their	O
effects	O
.	O

Platelet	B-GENE-Y
-	I-GENE-Y
derived	I-GENE-Y
growth	I-GENE-Y
factor	I-GENE-Y
(	I-GENE-Y
PDGF	I-GENE-Y
)	I-GENE-Y
receptor	I-GENE-Y
-	I-GENE-Y
alpha	I-GENE-Y
-	O
activated	O
c	B-GENE-Y
-	I-GENE-Y
Jun	I-GENE-Y
NH2	I-GENE-Y
-	I-GENE-Y
terminal	I-GENE-Y
kinase	I-GENE-Y
-	I-GENE-Y
1	I-GENE-Y
is	O
critical	O
for	O
PDGF	B-GENE-N
-	O
induced	O
p21WAF1	B-GENE-N
/	I-GENE-N
CIP1	I-GENE-N
promoter	I-GENE-N
activity	O
independent	O
of	O
p53	B-GENE-Y
.	O

Platelet	B-GENE-N
-	I-GENE-N
derived	I-GENE-N
growth	I-GENE-N
factor	I-GENE-N
(	O
PDGF	B-GENE-N
)	O
is	O
a	O
potent	O
mitogen	O
for	O
mesenchymal	O
cells	O
.	O

PDGF	B-GENE-Y
AA	I-GENE-Y
functions	O
as	O
a	O
"	O
competent	O
factor	O
"	O
that	O
stimulates	O
cell	O
cycle	O
entry	O
but	O
requires	O
additional	O
(	O
progression	O
)	O
factors	O
in	O
serum	O
to	O
transit	O
the	O
cell	O
cycle	O
beyond	O
the	O
G1	O
/	O
S	O
checkpoint	O
.	O

Unlike	O
PDGF	B-GENE-Y
AA	I-GENE-Y
,	O
PDGF	B-GENE-Y
B	I-GENE-Y
-	O
chain	O
(	O
c	O
-	O
sis	O
)	O
homodimer	O
(	O
PDGF	B-GENE-Y
BB	I-GENE-Y
)	O
and	O
its	O
viral	O
counterpart	O
v	O
-	O
sis	O
can	O
serve	O
as	O
both	O
competent	O
and	O
progression	O
factors	O
.	O

PDGF	B-GENE-Y
BB	I-GENE-Y
activates	O
alpha	O
-	O
and	O
beta	O
-	O
receptor	O
subunits	O
(	O
alpha	B-GENE-Y
-	I-GENE-Y
PDGFR	I-GENE-Y
and	O
beta	B-GENE-Y
-	I-GENE-Y
PDGFR	I-GENE-Y
)	O
and	O
induces	O
phenotypic	O
transformation	O
in	O
NIH	O
3T3	O
cells	O
,	O
whereas	O
PDGF	B-GENE-Y
AA	I-GENE-Y
activates	O
alpha	B-GENE-Y
-	I-GENE-Y
PDGFR	I-GENE-Y
only	O
and	O
fails	O
to	O
induce	O
transformation	O
.	O

We	O
showed	O
previously	O
that	O
alpha	B-GENE-Y
-	I-GENE-Y
PDGFR	I-GENE-Y
antagonizes	O
beta	B-GENE-Y
-	I-GENE-Y
PDGFR	I-GENE-Y
-	O
mediated	O
transformation	O
through	O
activation	O
of	O
stress	B-GENE-Y
-	I-GENE-Y
activated	I-GENE-Y
protein	I-GENE-Y
kinase	I-GENE-Y
-	I-GENE-Y
1	I-GENE-Y
/	O
c	B-GENE-Y
-	I-GENE-Y
Jun	I-GENE-Y
NH2	I-GENE-Y
-	I-GENE-Y
terminal	I-GENE-Y
kinase	I-GENE-Y
-	I-GENE-Y
1	I-GENE-Y
,	O
whereas	O
both	O
alpha	B-GENE-Y
-	I-GENE-Y
PDGFR	I-GENE-Y
and	O
beta	B-GENE-Y
-	I-GENE-Y
PDGFR	I-GENE-Y
induce	O
mitogenic	O
signals	O
.	O

These	O
studies	O
revealed	O
a	O
striking	O
feature	O
of	O
PDGF	B-GENE-N
signaling	O
;	O
the	O
specificity	O
and	O
the	O
strength	O
of	O
the	O
PDGF	B-GENE-N
growth	O
signal	O
is	O
modulated	O
by	O
alpha	B-GENE-Y
-	I-GENE-Y
PDGFR	I-GENE-Y
-	O
mediated	O
simultaneous	O
activation	O
of	O
growth	O
stimulatory	O
and	O
inhibitory	O
signals	O
,	O
whereas	O
beta	B-GENE-Y
-	I-GENE-Y
PDGFR	I-GENE-Y
mainly	O
induces	O
a	O
growth	O
-	O
promoting	O
signal	O
.	O

Here	O
we	O
demonstrate	O
that	O
PDGF	B-GENE-Y
BB	I-GENE-Y
activation	O
of	O
beta	B-GENE-Y
-	I-GENE-Y
PDGFR	I-GENE-Y
alone	O
results	O
in	O
more	O
efficient	O
cell	O
cycle	O
transition	O
from	O
G1	O
to	O
S	O
phase	O
than	O
PDGF	B-GENE-Y
BB	I-GENE-Y
activation	O
of	O
both	O
alpha	B-GENE-Y
-	I-GENE-Y
PDGFR	I-GENE-Y
and	O
beta	B-GENE-Y
-	I-GENE-Y
PDGFR	I-GENE-Y
.	O

PDGF	B-GENE-Y
AA	I-GENE-Y
activation	O
of	O
alpha	B-GENE-Y
-	I-GENE-Y
PDGFR	I-GENE-Y
or	O
PDGF	B-GENE-Y
BB	I-GENE-Y
activation	O
of	O
both	O
alpha	B-GENE-N
-	I-GENE-N
and	I-GENE-N
beta	I-GENE-N
-	I-GENE-N
PDGFRs	I-GENE-N
up	O
-	O
regulates	O
expression	O
of	O
p21WAF1	B-GENE-Y
/	O
CIP1	B-GENE-Y
,	O
an	O
inhibitor	O
of	O
cell	O
cycle	O
-	O
dependent	O
kinases	B-GENE-N
and	O
a	O
downstream	O
mediator	O
of	O
the	O
tumor	O
suppressor	O
gene	O
product	O
p53	B-GENE-Y
.	O

However	O
,	O
beta	B-GENE-Y
-	I-GENE-Y
PDGFR	I-GENE-Y
activation	O
alone	O
fails	O
to	O
induce	O
p21WAF1	B-GENE-Y
/	O
CIP1	B-GENE-Y
expression	O
.	O

We	O
also	O
demonstrate	O
that	O
alpha	B-GENE-Y
-	I-GENE-Y
PDGFR	I-GENE-Y
-	O
activated	O
JNK	B-GENE-Y
-	I-GENE-Y
1	I-GENE-Y
is	O
a	O
critical	O
signaling	O
component	O
for	O
PDGF	B-GENE-N
induction	O
of	O
p21WAF1	B-GENE-N
/	I-GENE-N
CIP1	I-GENE-N
promoter	O
activity	O
.	O

The	O
ability	O
of	O
PDGF	B-GENE-N
/	O
JNK	B-GENE-Y
-	I-GENE-Y
1	I-GENE-Y
to	O
induce	O
p21WAF1	B-GENE-N
/	I-GENE-N
CIP1	I-GENE-N
promoter	I-GENE-N
activity	O
is	O
independent	O
of	O
p53	B-GENE-Y
,	O
although	O
the	O
overall	O
p21WAF1	B-GENE-N
/	I-GENE-N
CIP1	I-GENE-N
promoter	I-GENE-N
activities	O
are	O
greatly	O
reduced	O
in	O
the	O
absence	O
of	O
p53	B-GENE-Y
.	O

These	O
results	O
provide	O
a	O
molecular	O
basis	O
for	O
differential	O
regulation	O
of	O
the	O
cell	O
cycle	O
and	O
transformation	O
by	O
alpha	B-GENE-N
-	I-GENE-N
and	I-GENE-N
beta	I-GENE-N
-	I-GENE-N
PDGFRs	I-GENE-N
.	O

Searching	O
for	O
preventive	O
measures	O
of	O
cardiovascular	O
events	O
in	O
aged	O
Japanese	O
taxi	O
drivers	O
-	O
-	O
the	O
daily	O
rhythm	O
of	O
cardiovascular	O
risk	O
factors	O
during	O
a	O
night	O
duty	O
day	O
.	O

Previous	O
studies	O
have	O
shown	O
that	O
Japanese	O
taxi	O
drivers	O
are	O
exposed	O
to	O
more	O
risk	O
factors	O
and	O
have	O
a	O
higher	O
mortality	O
rate	O
due	O
to	O
cardiovascular	O
disease	O
than	O
other	O
occupational	O
groups	O
.	O

We	O
investigated	O
the	O
effect	O
of	O
night	O
taxi	O
driving	O
with	O
a	O
view	O
to	O
preventing	O
acute	O
events	O
of	O
cardiovascular	O
disease	O
among	O
aged	O
taxi	O
drivers	O
.	O

Twenty	O
-	O
nine	O
taxi	O
drivers	O
(	O
41	O
-	O
67	O
years	O
old	O
)	O
were	O
examined	O
for	O
urine	O
normetanephrine	B-CHEMICAL
/	O
creatinine	B-CHEMICAL
,	O
von	B-GENE-Y
Willebrand	I-GENE-Y
factor	I-GENE-Y
,	O
anti	B-GENE-Y
-	I-GENE-Y
thrombin	I-GENE-Y
III	I-GENE-Y
,	O
t	B-GENE-Y
-	I-GENE-Y
plasminogen	I-GENE-Y
activator	I-GENE-Y
-	O
plasminogen	B-GENE-Y
activator	I-GENE-Y
inhibitor	I-GENE-Y
1	I-GENE-Y
-	O
complex	O
,	O
hematocrit	O
,	O
blood	O
glucose	B-CHEMICAL
and	O
blood	O
pressure	O
in	O
the	O
morning	O
and	O
at	O
midnight	O
during	O
a	O
duty	O
day	O
and	O
in	O
the	O
following	O
morning	O
.	O

At	O
the	O
same	O
time	O
,	O
the	O
blood	O
pressure	O
and	O
blood	O
glucose	B-CHEMICAL
of	O
46	O
taxi	O
drivers	O
(	O
43	O
-	O
67	O
years	O
old	O
)	O
in	O
the	O
morning	O
after	O
a	O
night	O
duty	O
with	O
little	O
sleep	O
and	O
in	O
the	O
morning	O
after	O
daytime	O
work	O
and	O
subsequent	O
night	O
sleep	O
were	O
compared	O
.	O

The	O
results	O
obtained	O
indicate	O
that	O
the	O
aggravation	O
of	O
sympathetic	O
nervous	O
system	O
functions	O
with	O
disturbed	O
circadian	O
rhythms	O
,	O
increased	O
blood	O
coagulation	O
and	O
blood	O
concentration	O
,	O
endothelial	O
injury	O
and	O
the	O
elevation	O
of	O
blood	O
glucose	O
at	O
midnight	O
or	O
the	O
next	O
morning	O
were	O
induced	O
by	O
their	O
night	O
work	O
.	O

These	O
conditions	O
are	O
supposed	O
to	O
favour	O
acute	O
vascular	O
events	O
in	O
aged	O
taxi	O
drivers	O
.	O

Preventive	O
measures	O
considered	O
include	O
social	O
support	O
for	O
anticoagulant	O
food	O
and	O
water	O
intake	O
,	O
short	O
exercise	O
and	O
walking	O
as	O
well	O
as	O
taking	O
a	O
rest	O
and	O
a	O
nap	O
during	O
night	O
work	O
.	O

The	O
human	B-GENE-Y
ribonucleotide	I-GENE-Y
reductase	I-GENE-Y
subunit	I-GENE-Y
hRRM2	I-GENE-Y
complements	O
p53R2	B-GENE-Y
in	O
response	O
to	O
UV	O
-	O
induced	O
DNA	O
repair	O
in	O
cells	O
with	O
mutant	O
p53	B-GENE-Y
.	O

Ribonucleotide	B-GENE-N
reductase	I-GENE-N
(	O
RR	B-GENE-N
)	O
is	O
responsible	O
for	O
the	O
de	O
novo	O
conversion	O
of	O
the	O
ribonucleoside	B-CHEMICAL
diphosphates	I-CHEMICAL
to	O
deoxyribonucleoside	B-CHEMICAL
diphosphates	I-CHEMICAL
,	O
which	O
are	O
essential	O
for	O
DNA	O
synthesis	O
and	O
repair	O
.	O

RR	B-GENE-N
consists	O
of	O
two	O
subunits	O
,	O
hRRM1	B-GENE-Y
and	O
hRRM2	B-GENE-Y
.	O

p53R2	B-GENE-Y
is	O
a	O
new	O
RR	B-GENE-N
family	O
member	O
.	O

Because	O
the	O
majority	O
of	O
human	O
tumors	O
possess	O
mutant	O
p53	B-GENE-Y
,	O
it	O
is	O
important	O
to	O
know	O
the	O
molecular	O
mechanism	O
by	O
which	O
mutant	O
p53	B-GENE-Y
regulates	O
RR	B-GENE-N
and	O
to	O
what	O
extent	O
.	O

In	O
this	O
study	O
,	O
we	O
investigated	O
the	O
expression	O
and	O
function	O
of	O
p53R2	B-GENE-Y
and	O
hRRM2	B-GENE-Y
after	O
UV	O
treatment	O
in	O
human	O
prostate	O
cancer	O
PC3	O
cells	O
,	O
which	O
possess	O
mutant	O
p53	B-GENE-Y
with	O
a	O
truncated	O
COOH	B-CHEMICAL
-	O
terminal	O
,	O
and	O
in	O
human	O
oropharyngeal	O
cancer	O
KB	O
cells	O
,	O
which	O
possess	O
wild	O
-	O
type	O
p53	B-GENE-Y
.	O

p53R2	B-GENE-Y
(	O
analyzed	O
by	O
Western	O
blot	O
and	O
standardized	O
relative	O
to	O
Coomassie	O
Blue	O
-	O
stained	O
band	O
)	O
was	O
down	O
-	O
regulated	O
in	O
PC3	O
cells	O
and	O
up	O
-	O
regulated	O
in	O
KB	O
cells	O
after	O
UV	O
exposure	O
.	O

In	O
contrast	O
,	O
hRRM2	B-GENE-Y
was	O
up	O
-	O
regulated	O
by	O
UV	O
in	O
both	O
PC3	O
cells	O
and	O
KB	O
cells	O
.	O

hRRM2	B-GENE-Y
and	O
p53R2	B-GENE-Y
mRNA	O
levels	O
were	O
assessed	O
by	O
Northern	O
blot	O
,	O
and	O
the	O
results	O
paralleled	O
that	O
of	O
the	O
Western	O
blot	O
.	O

Coimmunoprecipitation	O
assays	O
using	O
agarose	O
-	O
conjugated	O
goat	O
antihuman	O
RRM1	B-GENE-Y
antibody	O
confirmed	O
that	O
the	O
p53R2	B-GENE-Y
binding	O
to	O
hRRM1	B-GENE-Y
decreased	O
in	O
PC3	O
cells	O
but	O
increased	O
in	O
KB	O
cells	O
after	O
UV	O
treatment	O
.	O

hRRM2	B-GENE-Y
binding	O
to	O
hRRM1	B-GENE-N
increased	O
in	O
both	O
cell	O
lines	O
under	O
the	O
same	O
conditions	O
.	O

These	O
results	O
suggest	O
that	O
PC3	O
cells	O
are	O
deficient	O
in	O
both	O
transcription	O
of	O
p53R2	B-GENE-Y
and	O
binding	O
to	O
hRRM1	B-GENE-Y
in	O
response	O
to	O
UV	O
irradiation	O
.	O

Confocal	O
microscopy	O
further	O
confirmed	O
that	O
these	O
findings	O
were	O
not	O
due	O
to	O
translocation	O
of	O
hRRM2	B-GENE-Y
and	O
p53R2	B-GENE-Y
from	O
the	O
cytoplasm	O
to	O
the	O
nucleus	O
.	O

RR	B-GENE-N
activity	O
was	O
measured	O
following	O
UV	O
treatment	O
and	O
shown	O
to	O
increase	O
in	O
PC3	O
cells	O
.	O

It	O
was	O
unchanged	O
in	O
proportional	O
of	O
KB	O
cells	O
.	O

The	O
RR	B-GENE-N
activity	O
is	O
consistent	O
with	O
the	O
expression	O
of	O
hRRM2	B-GENE-N
seen	O
in	O
the	O
Western	O
blots	O
.	O

Thus	O
,	O
we	O
hypothesize	O
that	O
hRRM2	B-GENE-Y
complements	O
p53R2	B-GENE-Y
to	O
form	O
RR	B-GENE-N
holoenzyme	O
and	O
maintain	O
RR	B-GENE-N
activity	O
in	O
PC3	O
cells	O
after	O
UV	O
treatment	O
.	O

To	O
further	O
confirm	O
this	O
hypothesis	O
,	O
we	O
examined	O
the	O
effect	O
of	O
RRM2	B-GENE-Y
inhibitors	O
on	O
cells	O
exposed	O
to	O
UV	O
.	O

In	O
PC3	O
cells	O
,	O
hydroxyurea	B-CHEMICAL
inhibited	O
hRRM2	B-GENE-Y
and	O
resulted	O
in	O
increased	O
sensitivity	O
to	O
UV	O
irradiation	O
.	O

We	O
also	O
examined	O
the	O
effect	O
of	O
UV	O
treatment	O
on	O
the	O
colony	O
-	O
forming	O
ability	O
of	O
cells	O
transfected	O
with	O
hRRM2	B-GENE-Y
as	O
well	O
as	O
p53R2	B-GENE-Y
sense	O
or	O
antisense	O
expression	O
vectors	O
.	O

Expression	O
of	O
antisense	O
hRRM2	B-GENE-Y
in	O
PC3	O
cells	O
led	O
to	O
decreased	O
hRRM2	B-GENE-Y
expression	O
and	O
resulted	O
in	O
greater	O
sensitivity	O
to	O
UV	O
than	O
observed	O
in	O
wild	O
-	O
type	O
PC3	O
cells	O
.	O

Taken	O
together	O
,	O
we	O
conclude	O
that	O
UV	O
-	O
induced	O
activation	O
of	O
p53R2	B-GENE-Y
transcription	O
and	O
binding	O
of	O
p53R2	B-GENE-N
to	O
hRRM1	B-GENE-Y
to	O
form	O
RR	B-GENE-N
holoenzyme	O
are	O
impaired	O
in	O
the	O
p53	B-GENE-Y
-	O
mutant	O
cell	O
line	O
PC3	O
.	O

Minocycline	B-CHEMICAL
reduces	O
cell	O
death	O
and	O
improves	O
functional	O
recovery	O
after	O
traumatic	O
spinal	O
cord	O
injury	O
in	O
the	O
rat	O
.	O

We	O
examined	O
the	O
effects	O
of	O
minocycline	B-CHEMICAL
,	O
an	O
anti	O
-	O
inflammatory	O
drug	O
,	O
on	O
functional	O
recovery	O
following	O
spinal	O
cord	O
injury	O
(	O
SCI	O
)	O
.	O

Rats	O
received	O
a	O
mild	O
,	O
weight	O
-	O
drop	O
contusion	O
injury	O
to	O
the	O
spinal	O
cord	O
and	O
were	O
treated	O
with	O
the	O
vehicle	O
or	O
minocycline	B-CHEMICAL
at	O
a	O
dose	O
of	O
90	O
mg	O
/	O
kg	O
immediately	O
after	O
SCI	O
and	O
then	O
twice	O
at	O
a	O
dose	O
of	O
45	O
mg	O
/	O
kg	O
every	O
12	O
h	O
.	O

Injecting	O
minocycline	B-CHEMICAL
after	O
SCI	O
improved	O
hind	O
limb	O
motor	O
function	O
as	O
determined	O
by	O
the	O
Basso	O
-	O
Beattie	O
-	O
Bresnahan	O
(	O
BBB	O
)	O
locomotor	O
open	O
field	O
behavioral	O
rating	O
test	O
.	O

Twenty	O
four	O
to	O
38	O
days	O
after	O
SCI	O
,	O
BBB	O
scores	O
were	O
significantly	O
higher	O
in	O
minocycline	B-CHEMICAL
-	O
treated	O
rats	O
as	O
compared	O
with	O
those	O
in	O
vehicle	O
-	O
treated	O
rats	O
.	O

Morphological	O
analysis	O
showed	O
that	O
lesion	O
size	O
increased	O
progressively	O
in	O
both	O
vehicle	O
-	O
treated	O
and	O
minocycline	B-CHEMICAL
-	O
treated	O
spinal	O
cords	O
.	O

However	O
,	O
in	O
response	O
to	O
treatment	O
with	O
minocycline	B-CHEMICAL
,	O
the	O
lesion	O
size	O
was	O
significantly	O
reduced	O
at	O
21	O
-	O
38	O
days	O
after	O
SCI	O
when	O
compared	O
to	O
the	O
vehicle	O
control	O
.	O

Minocycline	B-CHEMICAL
treatment	O
significantly	O
reduced	O
the	O
number	O
of	O
terminal	O
deoxynucleotidyl	O
transferase	O
(	O
TdT	O
)	O
-	O
mediated	O
deoxyuridine	B-CHEMICAL
triphosphate	I-CHEMICAL
-	I-CHEMICAL
biotin	I-CHEMICAL
nick	O
end	O
labeling	O
(	O
TUNEL	O
)	O
-	O
positive	O
cells	O
24	O
h	O
after	O
SCI	O
as	O
compared	O
to	O
that	O
of	O
the	O
vehicle	O
control	O
.	O

DNA	O
gel	O
electrophoresis	O
also	O
revealed	O
a	O
marked	O
decrease	O
in	O
DNA	O
laddering	O
in	O
response	O
to	O
treatment	O
with	O
minocycline	B-CHEMICAL
.	O

In	O
addition	O
,	O
minocycline	B-CHEMICAL
treatment	O
significantly	O
reduced	O
the	O
specific	O
caspase	B-GENE-Y
-	I-GENE-Y
3	I-GENE-Y
activity	O
after	O
SCI	O
as	O
compared	O
to	O
that	O
of	O
vehicle	O
control	O
.	O

Furthermore	O
,	O
RT	O
-	O
PCR	O
analyses	O
revealed	O
that	O
minocycline	B-CHEMICAL
treatment	O
increased	O
expression	O
of	O
interleukin	B-GENE-Y
-	I-GENE-Y
10	I-GENE-Y
mRNA	O
but	O
decreased	O
tumor	B-GENE-Y
necrosis	I-GENE-Y
factor	I-GENE-Y
-	I-GENE-Y
alpha	I-GENE-Y
expression	O
.	O

These	O
data	O
suggest	O
that	O
,	O
after	O
SCI	O
,	O
minocycline	B-CHEMICAL
treatment	O
modulated	O
expression	O
of	O
cytokines	B-GENE-N
,	O
attenuated	O
cell	O
death	O
and	O
the	O
size	O
of	O
lesions	O
,	O
and	O
improved	O
functional	O
recovery	O
in	O
the	O
injured	O
rat	O
.	O

This	O
approach	O
may	O
provide	O
a	O
therapeutic	O
intervention	O
enabling	O
us	O
to	O
reduce	O
cell	O
death	O
and	O
improve	O
functional	O
recovery	O
after	O
SCI	O
.	O

Innovative	O
approach	O
for	O
improvement	O
of	O
an	O
antibiotic	O
-	O
overproducing	O
industrial	O
strain	O
of	O
Streptomyces	O
albus	O
.	O

Working	O
with	O
a	O
Streptomyces	O
albus	O
strain	O
that	O
had	O
previously	O
been	O
bred	O
to	O
produce	O
industrial	O
amounts	O
(	O
10	O
mg	O
/	O
ml	O
)	O
of	O
salinomycin	B-CHEMICAL
,	O
we	O
demonstrated	O
the	O
efficacy	O
of	O
introducing	O
drug	O
resistance	O
-	O
producing	O
mutations	O
for	O
further	O
strain	O
improvement	O
.	O

Mutants	O
with	O
enhanced	O
salinomycin	B-CHEMICAL
production	O
were	O
detected	O
at	O
a	O
high	O
incidence	O
(	O
7	O
to	O
12	O
%	O
)	O
among	O
spontaneous	O
isolates	O
resistant	O
to	O
streptomycin	B-CHEMICAL
(	O
Str	O
(	O
r	O
)	O
)	O
,	O
gentamicin	B-CHEMICAL
,	O
or	O
rifampin	B-CHEMICAL
(	O
Rif	O
(	O
r	O
)	O
)	O
.	O

Finally	O
,	O
we	O
successfully	O
demonstrated	O
improvement	O
of	O
the	O
salinomycin	B-CHEMICAL
productivity	O
of	O
the	O
industrial	O
strain	O
by	O
2	O
.	O
3	O
-	O
fold	O
by	O
introducing	O
a	O
triple	O
mutation	O
.	O

The	O
Str	O
(	O
r	O
)	O
mutant	O
was	O
shown	O
to	O
have	O
a	O
point	O
mutation	O
within	O
the	O
rpsL	B-GENE-Y
gene	O
(	O
encoding	O
ribosomal	B-GENE-Y
protein	I-GENE-Y
S12	I-GENE-Y
)	O
.	O

Likewise	O
,	O
the	O
Rif	O
(	O
r	O
)	O
mutant	O
possessed	O
a	O
mutation	O
in	O
the	O
rpoB	B-GENE-Y
gene	O
(	O
encoding	O
the	O
RNA	B-GENE-N
polymerase	I-GENE-N
beta	I-GENE-N
subunit	O
)	O
.	O

Increased	O
productivity	O
of	O
salinomycin	B-CHEMICAL
in	O
the	O
Str	O
(	O
r	O
)	O
mutant	O
(	O
containing	O
the	O
K88R	B-GENE-N
mutation	O
in	O
the	O
S12	B-GENE-Y
protein	O
)	O
may	O
be	O
a	O
result	O
of	O
an	O
aberrant	O
protein	O
synthesis	O
mechanism	O
.	O

This	O
aberration	O
may	O
manifest	O
itself	O
as	O
enhanced	O
translation	O
activity	O
in	O
stationary	O
-	O
phase	O
cells	O
,	O
as	O
we	O
have	O
observed	O
with	O
the	O
poly	O
(	O
U	O
)	O
-	O
directed	O
cell	O
-	O
free	O
translation	O
system	O
.	O

The	O
K88R	B-GENE-N
mutant	O
ribosome	O
was	O
characterized	O
by	O
increased	O
70S	B-GENE-N
complex	I-GENE-N
stability	O
in	O
low	O
Mg	B-CHEMICAL
(	I-CHEMICAL
2	I-CHEMICAL
+	I-CHEMICAL
)	I-CHEMICAL
concentrations	O
.	O

We	O
conclude	O
that	O
this	O
aberrant	O
protein	O
synthesis	O
ability	O
in	O
the	O
Str	O
(	O
r	O
)	O
mutant	O
,	O
which	O
is	O
a	O
result	O
of	O
increased	O
stability	O
of	O
the	O
70S	B-GENE-N
complex	I-GENE-N
,	O
is	O
responsible	O
for	O
the	O
remarkable	O
salinomycin	B-CHEMICAL
production	O
enhancement	O
obtained	O
.	O

[	O
The	O
effects	O
of	O
nandrolone	B-CHEMICAL
phenylpropionate	I-CHEMICAL
on	O
androgen	B-GENE-Y
receptor	I-GENE-Y
of	O
liver	O
and	O
sexual	O
glands	O
in	O
burned	O
rats	O
]	O
.	O

OBJECTIVE	O
:	O
To	O
assess	O
the	O
effects	O
of	O
nandrolone	B-CHEMICAL
phenylpropionate	I-CHEMICAL
(	O
NP	B-CHEMICAL
)	O
on	O
androgen	B-GENE-Y
receptor	I-GENE-Y
(	O
AR	B-GENE-Y
)	O
of	O
liver	O
and	O
sexual	O
glands	O
in	O
burned	O
rats	O
for	O
supporting	O
the	O
clinical	O
application	O
of	O
anabolic	O
steroids	O
.	O

METHODS	O
:	O
Thirty	O
-	O
two	O
Wistar	O
rats	O
with	O
a	O
deep	O
second	O
-	O
degree	O
cutaneous	O
burn	O
of	O
20	O
%	O
total	O
body	O
surface	O
area	O
were	O
randomly	O
divided	O
into	O
two	O
groups	O
to	O
receive	O
either	O
5	O
mg	O
/	O
kg	O
NP	B-CHEMICAL
(	O
NP	B-CHEMICAL
group	O
)	O
or	O
normal	O
saline	O
as	O
placebo	O
(	O
control	O
group	O
)	O
every	O
other	O
day	O
.	O

The	O
mean	O
integrated	O
optical	O
density	O
(	O
mIOD	O
)	O
of	O
androgen	B-GENE-Y
receptor	I-GENE-Y
(	O
AR	B-GENE-Y
)	O
in	O
liver	O
,	O
testis	O
,	O
ovary	O
tissues	O
were	O
measured	O
by	O
immunohistochemistry	O
ENVISION	O
and	O
LSAB	O
respectively	O
on	O
the	O
4th	O
,	O
7th	O
,	O
14th	O
and	O
21st	O
days	O
after	O
scalding	O
.	O

RESULTS	O
:	O
The	O
density	O
of	O
AR	B-GENE-Y
in	O
liver	O
tissue	O
in	O
NP	B-CHEMICAL
group	O
was	O
higher	O
than	O
that	O
in	O
control	O
group	O
(	O
P	O
<	O
0	O
.	O
05	O
)	O
.	O

The	O
density	O
of	O
AR	B-GENE-Y
in	O
testis	O
and	O
ovary	O
tissues	O
showed	O
no	O
significant	O
difference	O
between	O
NP	B-CHEMICAL
group	O
and	O
control	O
group	O
at	O
every	O
time	O
-	O
point	O
(	O
P	O
>	O
0	O
.	O
05	O
)	O
.	O

The	O
side	O
-	O
effect	O
of	O
NP	B-CHEMICAL
at	O
this	O
dose	O
level	O
on	O
sexual	O
glands	O
seemed	O
limited	O
.	O

CONCLUSION	O
:	O
Nandrolone	B-CHEMICAL
phenylpropionate	I-CHEMICAL
up	O
-	O
regulated	O
the	O
density	O
of	O
AR	B-GENE-Y
in	O
liver	O
tissue	O
,	O
whereas	O
it	O
had	O
no	O
significant	O
effects	O
on	O
the	O
density	O
of	O
AR	B-GENE-Y
in	O
testis	O
and	O
ovary	O
tissues	O
.	O

NP	B-CHEMICAL
was	O
used	O
with	O
safety	O
at	O
this	O
dose	O
level	O
in	O
rats	O
.	O

Serotonin	B-GENE-Y
5	I-GENE-Y
-	I-GENE-Y
HT	I-GENE-Y
(	I-GENE-Y
2B	I-GENE-Y
)	I-GENE-Y
receptor	I-GENE-Y
loss	O
of	O
function	O
mutation	O
in	O
a	O
patient	O
with	O
fenfluramine	B-CHEMICAL
-	O
associated	O
primary	O
pulmonary	O
hypertension	O
.	O

OBJECTIVE	O
:	O
Appetite	O
-	O
suppressant	O
drug	O
fenfluramine	O
is	O
implicated	O
in	O
primary	O
pulmonary	O
hypertension	O
(	O
PPH	O
)	O
but	O
the	O
molecular	O
pathways	O
that	O
mediate	O
this	O
effect	O
are	O
unknown	O
.	O

A	O
mouse	O
model	O
incriminates	O
the	O
serotonin	B-GENE-Y
5	I-GENE-Y
-	I-GENE-Y
HT	I-GENE-Y
(	I-GENE-Y
2B	I-GENE-Y
)	I-GENE-Y
receptor	I-GENE-Y
but	O
contrasts	O
with	O
other	O
models	O
where	O
this	O
receptor	O
has	O
been	O
shown	O
to	O
mediate	O
pulmonary	O
arterial	O
relaxation	O
via	O
nitric	B-CHEMICAL
oxide	I-CHEMICAL
production	O
.	O

METHODS	O
:	O
We	O
analyzed	O
the	O
human	B-GENE-Y
5	I-GENE-Y
-	I-GENE-Y
HT	I-GENE-Y
(	I-GENE-Y
2B	I-GENE-Y
)	I-GENE-Y
gene	O
in	O
10	O
patients	O
with	O
appetite	O
-	O
suppressant	O
drug	O
-	O
associated	O
PPH	O
.	O

RESULTS	O
:	O
A	O
mutation	O
causing	O
premature	O
truncation	O
of	O
the	O
protein	O
product	O
was	O
found	O
in	O
one	O
patient	O
.	O

The	O
mutation	O
was	O
not	O
found	O
in	O
80	O
control	O
subjects	O
and	O
no	O
5	B-GENE-Y
-	I-GENE-Y
HT	I-GENE-Y
(	I-GENE-Y
2B	I-GENE-Y
)	I-GENE-Y
mutation	O
was	O
found	O
in	O
18	O
PPH	O
patients	O
not	O
associated	O
with	O
appetite	O
-	O
suppressants	O
.	O

Functional	O
analysis	O
of	O
the	O
transfected	O
receptor	O
expressed	O
either	O
transiently	O
in	O
COS	O
cells	O
or	O
stably	O
in	O
CHO	B-CHEMICAL
cells	O
demonstrated	O
that	O
the	O
mutated	O
receptor	O
fails	O
to	O
activate	O
the	O
second	O
messenger	O
inositol	B-CHEMICAL
-	I-CHEMICAL
phosphates	I-CHEMICAL
cascade	O
and	O
subsequent	O
intracellular	O
calcium	B-CHEMICAL
release	O
,	O
in	O
spite	O
of	O
normal	O
expression	O
at	O
the	O
cell	O
membrane	O
.	O

The	O
mutated	O
receptor	O
had	O
no	O
constitutive	O
activity	O
,	O
and	O
produced	O
no	O
dominant	O
negative	O
effect	O
on	O
the	O
wild	O
-	O
type	O
receptor	O
.	O

CONCLUSION	O
:	O
Loss	O
of	O
serotonin	B-CHEMICAL
5	B-GENE-Y
-	I-GENE-Y
HT	I-GENE-Y
(	I-GENE-Y
2B	I-GENE-Y
)	I-GENE-Y
receptor	I-GENE-Y
function	O
may	O
predispose	O
to	O
fenfluramine	B-CHEMICAL
-	O
associated	O
PPH	O
in	O
man	O
.	O

The	O
antileukemia	O
drug	O
2	B-CHEMICAL
-	I-CHEMICAL
chloro	I-CHEMICAL
-	I-CHEMICAL
2	I-CHEMICAL
'	I-CHEMICAL
-	I-CHEMICAL
deoxyadenosine	I-CHEMICAL
:	O
an	O
intrinsic	O
transcriptional	O
antagonist	O
.	O

The	O
nucleoside	O
analog	O
2	B-CHEMICAL
-	I-CHEMICAL
chloro	I-CHEMICAL
-	I-CHEMICAL
2	I-CHEMICAL
'	I-CHEMICAL
-	I-CHEMICAL
deoxyadenosine	I-CHEMICAL
(	O
CldAdo	B-CHEMICAL
;	O
cladribine	B-CHEMICAL
)	O
is	O
effective	O
in	O
the	O
treatment	O
of	O
hairy	O
cell	O
leukemia	O
and	O
chronic	O
lymphocytic	O
leukemia	O
.	O

CldAdo	B-CHEMICAL
is	O
phosphorylated	O
and	O
incorporated	O
into	O
cellular	O
DNA	O
but	O
is	O
not	O
an	O
absolute	O
chain	O
terminator	O
.	O

We	O
demonstrated	O
by	O
in	O
vitro	O
gel	O
-	O
shift	O
assays	O
that	O
binding	O
interactions	O
of	O
the	O
human	B-GENE-Y
TATA	I-GENE-Y
box	I-GENE-Y
-	I-GENE-Y
binding	I-GENE-Y
protein	I-GENE-Y
(	O
TBP	B-GENE-Y
)	O
were	O
disrupted	O
on	O
2	B-CHEMICAL
-	I-CHEMICAL
chlorodeoxyadenosine	I-CHEMICAL
monophosphate	I-CHEMICAL
(	O
CldAMP	B-CHEMICAL
)	O
-	O
substituted	O
TATA	B-GENE-N
box	I-GENE-N
consensus	I-GENE-N
sequences	I-GENE-N
.	O

We	O
hypothesized	O
that	O
human	B-GENE-N
RNA	I-GENE-N
polymerase	I-GENE-N
II	I-GENE-N
(	O
pol	B-GENE-N
II	I-GENE-N
)	O
transcriptional	O
processes	O
would	O
therefore	O
be	O
affected	O
by	O
2	B-CHEMICAL
-	I-CHEMICAL
chlorodeoxyadenosine	I-CHEMICAL
triphosphate	I-CHEMICAL
(	O
CldATP	B-CHEMICAL
)	O
incorporation	O
into	O
a	O
promoter	O
TATA	B-GENE-N
element	I-GENE-N
.	O

Double	O
-	O
stranded	O
DNA	O
templates	O
containing	O
the	O
adenovirus	O
major	O
late	O
promoter	O
and	O
coding	O
sequences	O
were	O
enzymatically	O
synthesized	O
as	O
control	O
or	O
with	O
site	O
-	O
specific	O
CldAMP	B-CHEMICAL
residues	O
,	O
incubated	O
with	O
HeLa	O
extract	O
,	O
and	O
the	O
synthesis	O
of	O
radiolabeled	O
44	O
-	O
base	O
transcripts	O
was	O
assessed	O
.	O

With	O
increasing	O
amounts	O
of	O
HeLa	O
extract	O
,	O
CldAMP	B-CHEMICAL
substitution	O
for	O
dAMP	B-CHEMICAL
within	O
the	O
TATA	B-GENE-N
box	I-GENE-N
decreased	O
in	O
vitro	O
pol	B-GENE-N
II	I-GENE-N
transcription	O
by	O
approximately	O
35	O
%	O
compared	O
with	O
control	O
substrates	O
.	O

Time	O
-	O
course	O
studies	O
showed	O
that	O
transcript	O
production	O
increased	O
in	O
a	O
linear	O
fashion	O
on	O
control	O
substrates	O
.	O

In	O
contrast	O
,	O
transcription	O
on	O
CldAMP	B-CHEMICAL
-	O
substituted	O
TATA	B-GENE-N
sequences	I-GENE-N
reached	O
a	O
plateau	O
after	O
20	O
min	O
.	O

Furthermore	O
,	O
CldAMP	B-CHEMICAL
-	O
substituted	O
promoter	O
sequences	O
trapped	O
or	O
sequestered	O
TBP	O
,	O
preventing	O
its	O
dissociation	O
from	O
DNA	O
and	O
subsequent	O
binding	O
to	O
additional	O
TATA	B-GENE-N
elements	I-GENE-N
to	O
reinitiate	O
transcription	O
.	O

CldAdo	B-CHEMICAL
thus	O
represents	O
the	O
first	O
example	O
of	O
a	O
nucleoside	O
analog	O
that	O
acts	O
as	O
a	O
transcriptional	O
antagonist	O
.	O

CldATP	B-CHEMICAL
incorporation	O
into	O
gene	O
regulatory	O
sequences	O
may	O
provide	O
a	O
novel	O
strategy	O
to	O
modulate	O
specific	O
protein	O
/	O
DNA	O
interactions	O
.	O

Blockade	O
of	O
beta	B-GENE-Y
1	I-GENE-Y
-	O
and	O
desensitization	O
of	O
beta	B-GENE-Y
2	I-GENE-Y
-	I-GENE-Y
adrenoceptors	I-GENE-Y
reduce	O
isoprenaline	B-CHEMICAL
-	O
induced	O
cardiac	O
fibrosis	O
.	O

The	O
aim	O
of	O
the	O
present	O
study	O
was	O
to	O
analyse	O
the	O
role	O
of	O
beta	B-GENE-N
(	I-GENE-N
1	I-GENE-N
)	I-GENE-N
-	I-GENE-N
and	I-GENE-N
beta	I-GENE-N
(	I-GENE-N
2	I-GENE-N
)	I-GENE-N
-	I-GENE-N
adrenoceptors	I-GENE-N
in	O
the	O
catecholamine	B-CHEMICAL
-	O
induced	O
myocardial	O
remodeling	O
,	O
especially	O
the	O
interstitial	O
fibrosis	O
.	O

Wistar	O
rats	O
were	O
subjected	O
to	O
a	O
2	O
-	O
week	O
chronic	O
isoprenaline	B-CHEMICAL
administration	O
(	O
30	O
microg	O
/	O
kg	O
/	O
h	O
)	O
.	O

Rats	O
received	O
a	O
concomitant	O
treatment	O
with	O
the	O
selective	O
beta	B-GENE-Y
(	I-GENE-Y
1	I-GENE-Y
)	I-GENE-Y
-	I-GENE-Y
adrenoceptor	I-GENE-Y
antagonist	O
,	O
bisoprolol	B-CHEMICAL
(	O
50	O
mg	O
/	O
kg	O
/	O
day	O
p	O
.	O
o	O
.	O
)	O
or	O
were	O
chronically	O
pretreated	O
with	O
the	O
selective	O
beta	B-GENE-Y
(	I-GENE-Y
2	I-GENE-Y
)	I-GENE-Y
-	I-GENE-Y
adrenoceptor	I-GENE-Y
agonist	O
salbutamol	B-CHEMICAL
(	O
40	O
microg	O
/	O
kg	O
/	O
h	O
)	O
for	O
1	O
week	O
to	O
induce	O
beta	B-GENE-Y
(	I-GENE-Y
2	I-GENE-Y
)	I-GENE-Y
-	I-GENE-Y
adrenoceptor	I-GENE-Y
desensitization	O
.	O

The	O
pretreatment	O
with	O
salbutamol	B-CHEMICAL
induced	O
a	O
59	O
%	O
down	O
-	O
regulation	O
of	O
left	O
ventricular	O
beta	B-GENE-Y
(	I-GENE-Y
2	I-GENE-Y
)	I-GENE-Y
-	I-GENE-Y
adrenoceptors	I-GENE-Y
compared	O
to	O
control	O
.	O

The	O
extent	O
of	O
the	O
isoprenaline	B-CHEMICAL
-	O
induced	O
left	O
ventricular	O
fibrosis	O
was	O
significantly	O
reduced	O
in	O
both	O
the	O
bisoprolol	B-CHEMICAL
and	O
salbutamol	B-CHEMICAL
groups	O
compared	O
with	O
the	O
control	O
isoprenaline	B-CHEMICAL
-	O
treated	O
group	O
especially	O
in	O
the	O
apical	O
region	O
(	O
1	O
.	O
7	O
+	O
/	O
-	O
0	O
.	O
6	O
%	O
and	O
1	O
.	O
4	O
+	O
/	O
-	O
0	O
.	O
3	O
%	O
versus	O
6	O
.	O
0	O
+	O
/	O
-	O
1	O
.	O
3	O
%	O
,	O
respectively	O
,	O
P	O
<	O
0	O
.	O
005	O
)	O
.	O

beta	B-GENE-Y
(	I-GENE-Y
1	I-GENE-Y
)	I-GENE-Y
-	I-GENE-Y
adrenoceptor	I-GENE-Y
blockade	O
and	O
beta	B-GENE-Y
(	I-GENE-Y
2	I-GENE-Y
)	I-GENE-Y
-	I-GENE-Y
adrenoceptors	I-GENE-Y
down	O
-	O
regulation	O
provided	O
similar	O
protection	O
against	O
isoprenaline	B-CHEMICAL
-	O
induced	O
cardiac	O
interstitial	O
fibrosis	O
suggesting	O
that	O
both	O
beta	B-GENE-N
-	I-GENE-N
adrenoceptors	I-GENE-N
are	O
involved	O
in	O
such	O
cardiac	O
remodeling	O
process	O
.	O

Characterization	O
of	O
the	O
mouse	B-GENE-N
cold	I-GENE-N
-	I-GENE-N
menthol	I-GENE-N
receptor	I-GENE-N
TRPM8	B-GENE-Y
and	O
vanilloid	B-GENE-Y
receptor	I-GENE-Y
type	I-GENE-Y
-	I-GENE-Y
1	I-GENE-Y
VR1	B-GENE-Y
using	O
a	O
fluorometric	O
imaging	O
plate	O
reader	O
(	O
FLIPR	O
)	O
assay	O
.	O

1	O
.	O

TRPM8	B-GENE-Y
(	O
CMR1	B-GENE-Y
)	O
is	O
a	O
Ca	B-GENE-N
(	I-GENE-N
2	I-GENE-N
+	I-GENE-N
)	I-GENE-N
-	I-GENE-N
permeable	I-GENE-N
channel	I-GENE-N
,	O
which	O
can	O
be	O
activated	O
by	O
low	O
temperatures	O
,	O
menthol	B-CHEMICAL
,	O
eucalyptol	B-CHEMICAL
and	O
icilin	B-CHEMICAL
.	O

It	O
belongs	O
to	O
the	O
transient	B-GENE-N
receptor	I-GENE-N
potential	I-GENE-N
(	I-GENE-N
TRP	I-GENE-N
)	I-GENE-N
family	I-GENE-N
,	O
and	O
therefore	O
is	O
related	O
to	O
vanilloid	B-GENE-Y
receptor	I-GENE-Y
type	I-GENE-Y
-	I-GENE-Y
1	I-GENE-Y
(	O
VR1	B-GENE-Y
,	O
TRPV1	B-GENE-Y
)	O
.	O

We	O
tested	O
whether	O
substances	O
which	O
are	O
structurally	O
related	O
to	O
menthol	B-CHEMICAL
,	O
or	O
which	O
produce	O
a	O
cooling	O
sensation	O
,	O
could	O
activate	O
TRPM8	B-GENE-Y
,	O
and	O
compared	O
the	O
responses	O
of	O
TRPM8	B-GENE-Y
and	O
VR1	B-GENE-Y
to	O
these	O
ligands	O
.	O

2	O
.	O

The	O
effects	O
of	O
70	O
odorants	O
and	O
menthol	B-CHEMICAL
-	O
related	O
substances	O
on	O
recombinant	O
mouse	B-GENE-Y
TRPM8	I-GENE-Y
(	O
mTRPM8	B-GENE-Y
)	O
,	O
expressed	O
in	O
HEK293	O
cells	O
,	O
were	O
examined	O
using	O
a	O
FLIPR	O
assay	O
.	O

In	O
all	O
,	O
10	O
substances	O
(	O
linalool	B-CHEMICAL
,	O
geraniol	B-CHEMICAL
,	O
hydroxycitronellal	B-CHEMICAL
,	O
WS	B-CHEMICAL
-	I-CHEMICAL
3	I-CHEMICAL
,	O
WS	B-CHEMICAL
-	I-CHEMICAL
23	I-CHEMICAL
,	O
FrescolatMGA	B-CHEMICAL
,	O
FrescolatML	B-CHEMICAL
,	O
PMD38	B-CHEMICAL
,	O
CoolactP	B-CHEMICAL
and	O
Cooling	B-CHEMICAL
Agent	I-CHEMICAL
10	I-CHEMICAL
)	O
were	O
found	O
to	O
be	O
agonists	O
.	O

3	O
.	O

The	O
EC	O
(	O
50	O
)	O
values	O
of	O
the	O
agonists	O
defined	O
their	O
relative	O
potencies	O
:	O
icilin	B-CHEMICAL
(	O
0	O
.	O
2	O
+	O
/	O
-	O
0	O
.	O
1	O
microM	O
)	O
>	O
FrescolatML	B-CHEMICAL
(	O
3	O
.	O
3	O
+	O
/	O
-	O
1	O
.	O
5	O
microM	O
)	O
>	O
WS	B-CHEMICAL
-	I-CHEMICAL
3	I-CHEMICAL
(	O
3	O
.	O
7	O
+	O
/	O
-	O
1	O
.	O
7	O
microM	O
)	O
>	O
(	B-CHEMICAL
-	I-CHEMICAL
)	I-CHEMICAL
menthol	I-CHEMICAL
(	O
4	O
.	O
1	O
+	O
/	O
-	O
1	O
.	O
3	O
microM	O
)	O
>	O
frescolatMAG	B-CHEMICAL
(	O
4	O
.	O
8	O
+	O
/	O
-	O
1	O
.	O
1	O
microM	O
)	O
>	O
cooling	B-CHEMICAL
agent	I-CHEMICAL
10	I-CHEMICAL
(	O
6	O
+	O
/	O
-	O
2	O
.	O
2	O
microM	O
)	O
>	O
(	B-CHEMICAL
+	I-CHEMICAL
)	I-CHEMICAL
menthol	I-CHEMICAL
(	O
14	O
.	O
4	O
+	O
/	O
-	O
1	O
.	O
3	O
microM	O
)	O
>	O
PMD38	B-CHEMICAL
(	O
31	O
+	O
/	O
-	O
1	O
.	O
1	O
microM	O
)	O
>	O
WS	B-CHEMICAL
-	I-CHEMICAL
23	I-CHEMICAL
(	O
44	O
+	O
/	O
-	O
7	O
.	O
3	O
microM	O
)	O
>	O
Coolact	B-CHEMICAL
P	I-CHEMICAL
(	O
66	O
+	O
/	O
-	O
20	O
microM	O
)	O
>	O
geraniol	B-CHEMICAL
(	O
5	O
.	O
9	O
+	O
/	O
-	O
1	O
.	O
6	O
mM	O
)	O
>	O
linalool	B-CHEMICAL
(	O
6	O
.	O
7	O
+	O
/	O
-	O
2	O
.	O
0	O
mM	O
)	O
>	O
eucalyptol	B-CHEMICAL
(	O
7	O
.	O
7	O
+	O
/	O
-	O
2	O
.	O
0	O
mM	O
)	O
>	O
hydroxycitronellal	B-CHEMICAL
(	O
19	O
.	O
6	O
+	O
/	O
-	O
2	O
.	O
2	O
mM	O
)	O
.	O

4	O
.	O

Known	O
VR1	B-GENE-Y
antagonists	O
(	O
BCTC	B-CHEMICAL
,	O
thio	B-CHEMICAL
-	I-CHEMICAL
BCTC	I-CHEMICAL
and	O
capsazepine	B-CHEMICAL
)	O
were	O
also	O
able	O
to	O
block	O
the	O
response	O
of	O
TRPM8	B-GENE-Y
to	O
menthol	B-CHEMICAL
(	O
IC	O
(	O
50	O
)	O
:	O
0	O
.	O
8	O
+	O
/	O
-	O
1	O
.	O
0	O
,	O
3	O
.	O
5	O
+	O
/	O
-	O
1	O
.	O
1	O
and	O
18	O
+	O
/	O
-	O
1	O
.	O
1	O
microM	O
,	O
respectively	O
)	O
.	O

5	O
.	O

The	O
Ca	B-CHEMICAL
(	I-CHEMICAL
2	I-CHEMICAL
+	I-CHEMICAL
)	I-CHEMICAL
response	O
of	O
hVR1	B-GENE-Y
-	O
transfected	O
HEK293	O
cells	O
to	O
the	O
endogenous	O
VR1	B-GENE-Y
agonist	O
N	B-CHEMICAL
-	I-CHEMICAL
arachidonoyl	I-CHEMICAL
-	I-CHEMICAL
dopamine	I-CHEMICAL
was	O
potentiated	O
by	O
low	O
pH	O
.	O

In	O
contrast	O
,	O
menthol	B-CHEMICAL
-	O
and	O
icilin	B-CHEMICAL
-	O
activated	O
TRPM8	B-GENE-Y
currents	O
were	O
suppressed	O
by	O
low	O
pH	O
.	O

6	O
.	O

In	O
conclusion	O
,	O
in	O
the	O
present	O
study	O
,	O
we	O
identified	O
10	O
new	O
agonists	O
and	O
three	O
antagonists	O
of	O
TRPM8	B-GENE-Y
.	O

We	O
found	O
that	O
,	O
in	O
contrast	O
to	O
VR1	B-GENE-Y
,	O
TRPM8	B-GENE-Y
is	O
inhibited	O
rather	O
than	O
potentiated	O
by	O
protons	O
.	O

Inhibitory	O
effects	O
of	O
the	O
monoamine	B-GENE-N
oxidase	I-GENE-N
inhibitor	O
tranylcypromine	B-CHEMICAL
on	O
the	O
cytochrome	B-GENE-N
P450	I-GENE-N
enzymes	O
CYP2C19	B-GENE-Y
,	O
CYP2C9	B-GENE-Y
,	O
and	O
CYP2D6	B-GENE-Y
.	O

1	O
.	O

The	O
inhibitory	O
effects	O
of	O
tranylcypromine	B-CHEMICAL
,	O
a	O
nonselective	O
irreversible	O
inhibitor	O
of	O
monoamine	B-GENE-N
oxidase	I-GENE-N
(	O
MAO	B-GENE-N
)	O
,	O
on	O
three	O
cytochrome	B-GENE-N
P450	I-GENE-N
(	O
CYP	B-GENE-N
)	O
enzymes	O
,	O
namely	O
CYP2C9	B-GENE-Y
,	O
CYP2C19	B-GENE-Y
,	O
and	O
CYP2D6	B-GENE-Y
,	O
have	O
been	O
evaluated	O
in	O
vitro	O
.	O

2	O
.	O

The	O
studies	O
were	O
conducted	O
using	O
cDNA	O
-	O
expressed	O
human	B-GENE-N
CYP	I-GENE-N
enzymes	O
and	O
probe	O
substrates	O
.	O

3	O
.	O

A	O
range	O
of	O
substrate	O
concentrations	O
was	O
coincubated	O
with	O
a	O
range	O
of	O
tranylcypromine	B-CHEMICAL
concentrations	O
in	O
the	O
presence	O
of	O
each	O
of	O
the	O
CYP	B-GENE-N
enzymes	O
at	O
37	O
degrees	O
C	O
for	O
a	O
predetermined	O
period	O
of	O
time	O
.	O

Product	O
concentrations	O
were	O
quantified	O
by	O
HPLC	O
with	O
UV	O
detection	O
.	O

4	O
.	O

The	O
results	O
demonstrated	O
that	O
tranylcypromine	B-CHEMICAL
is	O
a	O
competitive	O
inhibitor	O
of	O
CYP2C19	B-GENE-Y
(	O
Ki	O
=	O
32	O
microM	O
)	O
and	O
CYP2D6	B-GENE-Y
(	O
Ki	O
=	O
367	O
microM	O
)	O
and	O
a	O
noncompetitive	O
inhibitor	O
of	O
CYP2C9	B-GENE-Y
(	O
Ki	O
=	O
56	O
microM	O
)	O
.	O

5	O
.	O

None	O
of	O
these	O
inhibitory	O
effects	O
are	O
considered	O
clinically	O
significant	O
at	O
usual	O
therapeutic	O
doses	O
.	O

However	O
,	O
in	O
certain	O
situations	O
such	O
as	O
high	O
dose	O
tranylcypromine	B-CHEMICAL
therapy	O
,	O
or	O
in	O
poor	O
metabolizers	O
of	O
CYP2C19	B-GENE-Y
substrates	O
,	O
clinically	O
significant	O
interactions	O
might	O
occur	O
,	O
particularly	O
when	O
tranylcypromine	B-CHEMICAL
is	O
coadministered	O
with	O
drugs	O
with	O
a	O
narrow	O
therapeutic	O
index	O
.	O

Organization	O
and	O
expression	O
of	O
the	O
SLC36	B-GENE-N
cluster	I-GENE-N
of	I-GENE-N
amino	I-GENE-N
acid	I-GENE-N
transporter	I-GENE-N
genes	O
.	O

Three	O
closely	O
related	O
genes	O
encoding	O
amino	B-CHEMICAL
acid	I-CHEMICAL
transport	O
proteins	O
are	O
clustered	O
on	O
5q32	O
in	O
humans	O
,	O
and	O
Chromosome	O
(	O
Chr	O
)	O
11	O
in	O
mice	O
.	O

The	O
human	B-GENE-Y
SLC36A1	I-GENE-Y
gene	O
,	O
which	O
encodes	O
the	O
lysosomal	B-GENE-Y
amino	I-GENE-Y
acid	I-GENE-Y
transporter	I-GENE-Y
LYAAT1	I-GENE-Y
/	O
PAT1	B-GENE-Y
,	O
generates	O
multiple	O
alternative	O
mRNAs	O
,	O
some	O
of	O
which	O
encode	O
truncated	O
proteins	O
.	O

SLC36A1	B-GENE-Y
is	O
expressed	O
in	O
numerous	O
tissues	O
,	O
whereas	O
expression	O
of	O
SLC36A2	B-GENE-Y
,	O
which	O
encodes	O
the	O
glycine	B-GENE-N
transporter	I-GENE-N
tramdorinl	B-GENE-Y
/	O
PAT2	B-GENE-Y
,	O
is	O
most	O
abundant	O
in	O
kidney	O
and	O
muscle	O
.	O

Expression	O
of	O
a	O
third	O
gene	O
,	O
SLC36A3	B-GENE-Y
,	O
is	O
restricted	O
to	O
testis	O
.	O

Mouse	B-GENE-Y
Slc36a2	I-GENE-Y
also	O
is	O
expressed	O
in	O
bone	O
and	O
fat	O
tissue	O
.	O

Polymorphisms	O
in	O
human	B-GENE-Y
SLC36A2	I-GENE-Y
exclude	O
it	O
as	O
a	O
candidate	O
locus	O
for	O
a	O
peripheral	O
neuropathy	O
that	O
has	O
been	O
mapped	O
to	O
5q31	O
-	O
33	O
.	O

SLC36A2	B-GENE-Y
is	O
a	O
candidate	O
gene	O
for	O
5q	O
-	O
myelodysplastic	O
syndrome	O
,	O
on	O
the	O
basis	O
of	O
its	O
chromosomal	O
location	O
and	O
its	O
expression	O
in	O
bone	O
.	O

ATR	B-GENE-Y
regulates	O
a	O
G2	O
-	O
phase	O
cell	O
-	O
cycle	O
checkpoint	O
in	O
Arabidopsis	O
thaliana	O
.	O

Ataxia	B-GENE-Y
telangiectasia	I-GENE-Y
-	I-GENE-Y
mutated	I-GENE-Y
and	I-GENE-Y
Rad3	I-GENE-Y
-	I-GENE-Y
related	I-GENE-Y
(	O
ATR	B-GENE-Y
)	O
plays	O
a	O
central	O
role	O
in	O
cell	O
-	O
cycle	O
regulation	O
,	O
transmitting	O
DNA	O
damage	O
signals	O
to	O
downstream	O
effectors	O
of	O
cell	O
-	O
cycle	O
progression	O
.	O

In	O
animals	O
,	O
ATR	B-GENE-Y
is	O
an	O
essential	O
gene	O
.	O

Here	O
,	O
we	O
find	O
that	O
Arabidopsis	O
(	O
Arabidopsis	O
thaliana	O
)	O
atr	B-GENE-Y
-	O
/	O
-	O
mutants	O
were	O
viable	O
,	O
fertile	O
,	O
and	O
phenotypically	O
wild	O
-	O
type	O
in	O
the	O
absence	O
of	O
exogenous	O
DNA	O
damaging	O
agents	O
but	O
exhibit	O
altered	O
expression	O
of	O
AtRNR1	B-GENE-Y
(	O
ribonucleotide	B-GENE-Y
reductase	I-GENE-Y
large	I-GENE-Y
subunit	I-GENE-Y
)	O
and	O
alteration	O
of	O
some	O
damage	O
-	O
induced	O
cell	O
-	O
cycle	O
checkpoints	O
.	O
atr	B-GENE-Y
mutants	O
were	O
hypersensitive	O
to	O
hydroxyurea	B-CHEMICAL
(	O
HU	B-CHEMICAL
)	O
,	O
aphidicolin	B-CHEMICAL
,	O
and	O
UV	O
-	O
B	O
light	O
but	O
only	O
mildly	O
sensitive	O
to	O
gamma	O
-	O
radiation	O
.	O

G2	O
arrest	O
was	O
observed	O
in	O
response	O
to	O
gamma	O
-	O
irradiation	O
in	O
both	O
wild	O
-	O
type	O
and	O
atr	B-GENE-Y
plants	O
,	O
albeit	O
with	O
slightly	O
different	O
kinetics	O
,	O
suggesting	O
that	O
ATR	B-GENE-Y
plays	O
a	O
secondary	O
role	O
in	O
response	O
to	O
double	O
-	O
strand	O
breaks	O
.	O

G2	O
arrest	O
also	O
was	O
observed	O
in	O
wild	O
-	O
type	O
plants	O
in	O
response	O
to	O
aphidicolin	B-CHEMICAL
but	O
was	O
defective	O
in	O
atr	B-GENE-Y
mutants	O
,	O
resulting	O
in	O
compaction	O
of	O
nuclei	O
and	O
subsequent	O
cell	O
death	O
.	O

By	O
contrast	O
,	O
HU	O
-	O
treated	O
wild	O
-	O
type	O
and	O
atr	B-GENE-Y
plants	O
arrested	O
in	O
G1	O
and	O
showed	O
no	O
obvious	O
signs	O
of	O
cell	O
death	O
.	O

We	O
propose	O
that	O
,	O
in	O
plants	O
,	O
HU	O
invokes	O
a	O
novel	O
checkpoint	O
responsive	O
to	O
low	O
levels	O
of	O
deoxynucleotide	B-CHEMICAL
triphosphates	I-CHEMICAL
.	O

These	O
results	O
demonstrate	O
the	O
important	O
role	O
of	O
cell	O
-	O
cycle	O
checkpoints	O
in	O
the	O
ability	O
of	O
plant	O
cells	O
to	O
sense	O
and	O
cope	O
with	O
problems	O
associated	O
with	O
DNA	O
replication	O
.	O

Selective	O
activation	O
of	O
thyroid	B-CHEMICAL
hormone	I-CHEMICAL
signaling	O
pathways	O
by	O
GC	O
-	O
1	O
:	O
a	O
new	O
approach	O
to	O
controlling	O
cholesterol	B-CHEMICAL
and	O
body	O
weight	O
.	O

The	O
current	O
report	O
describes	O
progress	O
in	O
development	O
of	O
a	O
selective	O
thyroid	B-GENE-N
hormone	I-GENE-N
receptor	I-GENE-N
modulator	O
,	O
GC	O
-	O
1	O
.	O

This	O
compound	O
binds	O
selectively	O
to	O
the	O
beta	B-GENE-Y
-	I-GENE-Y
isoform	I-GENE-Y
of	I-GENE-Y
the	I-GENE-Y
thyroid	I-GENE-Y
hormone	I-GENE-Y
receptor	I-GENE-Y
,	O
and	O
its	O
uptake	O
into	O
the	O
heart	O
is	O
relatively	O
low	O
.	O

Studies	O
in	O
rats	O
,	O
mice	O
and	O
monkeys	O
show	O
that	O
GC	O
-	O
1	O
lowers	O
cholesterol	B-CHEMICAL
with	O
600	O
-	O
to	O
1400	O
-	O
fold	O
more	O
potency	O
and	O
approximately	O
two	O
-	O
to	O
threefold	O
more	O
efficacy	O
than	O
atorvastatin	B-CHEMICAL
,	O
a	O
compound	O
that	O
blocks	O
HMG	B-GENE-Y
-	I-GENE-Y
CoA	I-GENE-Y
reductase	I-GENE-Y
.	O

GC	O
-	O
1	O
also	O
decreases	O
plasma	O
levels	O
of	O
triglyceride	B-CHEMICAL
and	O
lipoprotein	B-GENE-N
(	I-GENE-N
a	I-GENE-N
)	I-GENE-N
,	O
and	O
induces	O
loss	O
of	O
fat	O
.	O

These	O
effects	O
can	O
be	O
observed	O
under	O
conditions	O
where	O
there	O
is	O
either	O
no	O
or	O
minimal	O
effect	O
on	O
heart	O
rate	O
,	O
and	O
no	O
detectable	O
loss	O
of	O
muscle	O
.	O

Although	O
more	O
study	O
is	O
required	O
,	O
compounds	O
of	O
this	O
class	O
deserve	O
further	O
investigation	O
for	O
treating	O
lipid	O
disorders	O
and	O
obesity	O
.	O

Flt3	B-GENE-Y
receptor	I-GENE-Y
tyrosine	I-GENE-Y
kinase	I-GENE-Y
as	O
a	O
drug	O
target	O
in	O
leukemia	O
.	O

The	O
hematopoietic	B-GENE-N
class	I-GENE-N
III	I-GENE-N
receptor	I-GENE-N
tyrosine	I-GENE-N
kinase	I-GENE-N
(	I-GENE-N
RTK	I-GENE-N
)	I-GENE-N
Flt3	I-GENE-N
(	O
Flk2	B-GENE-Y
,	O
STK1	B-GENE-Y
)	O
has	O
recently	O
received	O
much	O
attention	O
as	O
a	O
potential	O
drug	O
target	O
.	O

Activation	O
of	O
Flt3	B-GENE-Y
by	O
different	O
types	O
of	O
mutations	O
plays	O
an	O
important	O
role	O
for	O
proliferation	O
,	O
resistance	O
to	O
apoptosis	O
,	O
and	O
prevention	O
of	O
differentiation	O
of	O
leukemic	O
blasts	O
in	O
acute	O
myeloid	O
leukemia	O
(	O
AML	O
)	O
.	O

At	O
least	O
one	O
type	O
of	O
such	O
mutations	O
-	O
an	O
internal	O
tandem	O
duplication	O
in	O
the	O
Flt3	B-GENE-N
juxtamembrane	I-GENE-N
domain	I-GENE-N
(	O
Flt3	B-GENE-N
-	I-GENE-N
ITD	I-GENE-N
)	O
-	O
has	O
been	O
associated	O
with	O
an	O
unfavorable	O
prognosis	O
.	O

Signal	O
transduction	O
of	O
Flt3	B-GENE-Y
involves	O
activation	O
of	O
several	O
conserved	O
pathways	O
,	O
including	O
the	O
RAS	B-GENE-N
/	O
MAP	B-GENE-N
-	I-GENE-N
Kinase	I-GENE-N
and	O
the	O
phosphoinositide	B-GENE-N
-	I-GENE-N
3	I-GENE-N
-	I-GENE-N
kinase	I-GENE-N
/	O
Akt	B-GENE-N
signaling	O
cascades	O
.	O

Transforming	O
versions	O
of	O
Flt3	B-GENE-Y
exhibit	O
altered	O
signaling	O
,	O
for	O
example	O
a	O
very	O
pronounced	O
activation	O
of	O
STAT5	B-GENE-Y
,	O
ultimately	O
resulting	O
in	O
alternate	O
profiles	O
of	O
gene	O
expression	O
and	O
cell	O
transformation	O
.	O

Selective	O
inhibitors	O
of	O
Flt3	B-GENE-Y
tyrosine	B-GENE-N
kinase	I-GENE-N
activity	O
have	O
the	O
potential	O
to	O
suppress	O
aberrant	O
Flt3	B-GENE-Y
signaling	O
.	O

Although	O
highly	O
homologous	O
to	O
other	O
class	B-GENE-N
III	I-GENE-N
RTKs	I-GENE-N
,	O
Flt3	B-GENE-Y
is	O
resistant	O
to	O
the	O
phenylaminopyrimidine	B-CHEMICAL
STI571	B-CHEMICAL
(	O
Gleevec	B-CHEMICAL
,	O
Imatinib	B-CHEMICAL
)	O
,	O
a	O
potent	O
inhibitor	O
of	O
other	O
RTKs	B-GENE-N
in	O
the	O
family	O
,	O
such	O
as	O
the	O
PDGFbeta	B-GENE-Y
-	I-GENE-Y
receptor	I-GENE-Y
or	O
c	B-GENE-Y
-	I-GENE-Y
Kit	I-GENE-Y
.	O

STI571	B-CHEMICAL
binding	O
to	O
Flt3	B-GENE-Y
is	O
prevented	O
by	O
the	O
phenylalanine	B-CHEMICAL
691	O
side	O
-	O
chain	O
in	O
the	O
ATP	B-CHEMICAL
binding	O
center	O
and	O
mutating	O
this	O
site	O
to	O
threonine	B-CHEMICAL
renders	O
the	O
corresponding	O
Flt3	B-GENE-Y
mutant	O
sensitive	O
to	O
STI571	B-CHEMICAL
.	O

Compounds	O
of	O
several	O
other	O
structural	O
families	O
,	O
including	O
the	O
quinoxaline	B-CHEMICAL
AG1296	B-CHEMICAL
,	O
the	O
bis	B-CHEMICAL
(	I-CHEMICAL
1H	I-CHEMICAL
-	I-CHEMICAL
2	I-CHEMICAL
-	I-CHEMICAL
indolyl	I-CHEMICAL
)	I-CHEMICAL
-	I-CHEMICAL
1	I-CHEMICAL
-	I-CHEMICAL
methanone	I-CHEMICAL
D	B-CHEMICAL
-	I-CHEMICAL
65476	I-CHEMICAL
,	O
the	O
indolinones	B-CHEMICAL
SU5416	B-CHEMICAL
and	O
SU11248	B-CHEMICAL
,	O
the	O
indolocarbazoles	B-CHEMICAL
PKC412	B-CHEMICAL
and	O
CEP	B-CHEMICAL
-	I-CHEMICAL
701	I-CHEMICAL
,	O
and	O
the	O
piperazonyl	B-CHEMICAL
quinazoline	I-CHEMICAL
CT53518	B-CHEMICAL
,	O
are	O
potent	O
inhibitors	O
of	O
Flt3	B-GENE-Y
kinase	B-GENE-N
.	O

They	O
exhibit	O
different	O
selectivity	O
profiles	O
,	O
both	O
with	O
respect	O
to	O
other	O
kinases	O
and	O
among	O
wildtype	O
Flt3	B-GENE-Y
and	O
its	O
activated	O
versions	O
.	O

These	O
compounds	O
hold	O
promise	O
as	O
novel	O
drugs	O
against	O
AML	O
and	O
as	O
probes	O
for	O
understanding	O
activation	O
mechanisms	O
and	O
signaling	O
pathways	O
in	O
the	O
class	B-GENE-N
III	I-GENE-N
RTK	I-GENE-N
family	O
.	O

Novel	O
mechanism	O
of	O
action	O
for	O
hydralazine	B-CHEMICAL
:	O
induction	O
of	O
hypoxia	B-GENE-Y
-	I-GENE-Y
inducible	I-GENE-Y
factor	I-GENE-Y
-	I-GENE-Y
1alpha	I-GENE-Y
,	O
vascular	B-GENE-Y
endothelial	I-GENE-Y
growth	I-GENE-Y
factor	I-GENE-Y
,	O
and	O
angiogenesis	O
by	O
inhibition	O
of	O
prolyl	B-GENE-N
hydroxylases	I-GENE-N
.	O

The	O
vasodilator	O
hydralazine	B-CHEMICAL
,	O
used	O
clinically	O
in	O
cardiovascular	O
therapy	O
,	O
relaxes	O
arterial	O
smooth	O
muscle	O
by	O
inhibiting	O
accumulation	O
of	O
intracellular	O
free	O
Ca2	B-CHEMICAL
+	I-CHEMICAL
via	O
an	O
unidentified	O
primary	O
target	O
.	O

Collagen	B-GENE-N
prolyl	I-GENE-N
hydroxylase	I-GENE-N
is	O
a	O
known	O
target	O
of	O
hydralazine	B-CHEMICAL
.	O

We	O
therefore	O
investigated	O
whether	O
inhibition	O
of	O
other	O
members	O
of	O
this	O
enzyme	O
family	O
,	O
namely	O
the	O
hypoxia	B-GENE-N
-	I-GENE-N
inducible	I-GENE-N
factor	I-GENE-N
(	O
HIF	B-GENE-N
)	O
-	O
regulating	O
O2	B-CHEMICAL
-	O
dependent	O
prolyl	B-GENE-N
hydroxylase	I-GENE-N
domain	I-GENE-N
(	O
PHD	B-GENE-N
)	O
enzymes	O
,	O
could	O
represent	O
a	O
novel	O
mechanism	O
of	O
action	O
.	O

Hydralazine	B-CHEMICAL
induced	O
rapid	O
and	O
transient	O
expression	O
of	O
HIF	B-GENE-Y
-	I-GENE-Y
1alpha	I-GENE-Y
and	O
downstream	O
targets	O
of	O
HIF	B-GENE-N
(	O
endothelin	B-GENE-Y
-	I-GENE-Y
1	I-GENE-Y
,	O
adrenomedullin	B-GENE-Y
,	O
haem	B-GENE-Y
oxygenase	I-GENE-Y
1	I-GENE-Y
,	O
and	O
vascular	B-GENE-Y
endothelial	I-GENE-Y
growth	I-GENE-Y
factor	I-GENE-Y
[	O
VEGF	B-GENE-Y
]	O
)	O
in	O
endothelial	O
and	O
smooth	O
muscle	O
cells	O
and	O
induced	O
endothelial	O
cell	O
-	O
specific	O
proliferation	O
.	O

Hydralazine	B-CHEMICAL
dose	O
-	O
dependently	O
inhibited	O
PHD	B-GENE-N
activity	O
and	O
induced	O
nonhydroxylated	O
HIF	B-GENE-Y
-	I-GENE-Y
1alpha	I-GENE-Y
,	O
evidence	O
for	O
HIF	B-GENE-N
stabilization	O
specifically	O
by	O
inhibition	O
of	O
PHD	B-GENE-N
enzyme	O
activity	O
.	O

In	O
vivo	O
,	O
hydralazine	B-CHEMICAL
induced	O
HIF	B-GENE-Y
-	I-GENE-Y
1alpha	I-GENE-Y
and	O
VEGF	B-GENE-Y
protein	O
in	O
tissue	O
extracts	O
and	O
elevated	O
plasma	O
VEGF	B-GENE-Y
levels	O
.	O

In	O
sponge	O
angiogenesis	O
assays	O
,	O
hydralazine	B-CHEMICAL
increased	O
stromal	O
cell	O
infiltration	O
and	O
blood	O
vessel	O
density	O
versus	O
control	O
animals	O
.	O

Thus	O
,	O
hydralazine	B-CHEMICAL
activates	O
the	O
HIF	B-GENE-N
pathway	O
through	O
inhibition	O
of	O
PHD	B-GENE-N
activity	O
and	O
initiates	O
a	O
pro	O
-	O
angiogenic	O
phenotype	O
.	O

This	O
represents	O
a	O
novel	O
mechanism	O
of	O
action	O
for	O
hydralazine	B-CHEMICAL
and	O
presents	O
HIF	B-GENE-N
as	O
a	O
potential	O
target	O
for	O
treatment	O
of	O
ischemic	O
disease	O
.	O

Determination	O
of	O
expression	O
of	O
cyclooxygenase	B-GENE-N
-	I-GENE-N
1	I-GENE-N
and	I-GENE-N
-	I-GENE-N
2	I-GENE-N
isozymes	O
in	O
canine	O
tissues	O
and	O
their	O
differential	O
sensitivity	O
to	O
nonsteroidal	O
anti	O
-	O
inflammatory	O
drugs	O
.	O

OBJECTIVE	O
:	O
To	O
evaluate	O
cyclooxygenase	B-GENE-N
isozyme	O
distribution	O
in	O
tissues	O
from	O
dogs	O
and	O
determine	O
the	O
differential	O
sensitivity	O
of	O
canine	B-GENE-N
cyclooxygenase	I-GENE-N
(	I-GENE-N
COX	I-GENE-N
)	I-GENE-N
-	I-GENE-N
1	I-GENE-N
and	I-GENE-N
-	I-GENE-N
2	I-GENE-N
isozymes	O
to	O
nonsteroidal	O
anti	O
-	O
inflammatory	O
drugs	O
(	O
NSAIDs	O
)	O
.	O

SAMPLE	O
POPULATION	O
:	O
Canine	O
tissue	O
samples	O
(	O
stomach	O
,	O
duodenum	O
,	O
ileum	O
,	O
jejunum	O
,	O
colon	O
,	O
spleen	O
,	O
cerebral	O
cortex	O
,	O
lung	O
,	O
ovary	O
,	O
kidney	O
,	O
and	O
liver	O
)	O
were	O
obtained	O
from	O
2	O
dogs	O
for	O
northern	O
and	O
western	O
blot	O
analyses	O
,	O
and	O
blood	O
for	O
whole	O
blood	O
COX	B-GENE-N
assays	O
was	O
obtained	O
from	O
15	O
dogs	O
.	O

PROCEDURE	O
:	O
11	O
NSAIDs	O
were	O
evaluated	O
to	O
determine	O
their	O
COX	B-GENE-Y
-	I-GENE-Y
2	I-GENE-Y
selectivity	O
in	O
whole	O
blood	O
assays	O
.	O

The	O
concentrations	O
of	O
the	O
drug	O
needed	O
to	O
inhibit	O
50	O
%	O
of	O
enzyme	O
activity	O
(	O
IC50	O
)	O
were	O
then	O
calculated	O
for	O
comparison	O
.	O

Expression	O
and	O
tissue	O
distribution	O
of	O
COX	B-GENE-N
isozymes	O
were	O
determined	O
by	O
northern	O
and	O
western	O
blot	O
analysis	O
.	O

RESULTS	O
:	O
Aspirin	B-CHEMICAL
,	O
diclofenac	B-CHEMICAL
,	O
indomethacin	B-CHEMICAL
,	O
ketoprofen	B-CHEMICAL
,	O
meclofenamic	B-CHEMICAL
acid	I-CHEMICAL
,	O
and	O
piroxicam	B-CHEMICAL
had	O
little	O
selectivity	O
toward	O
COX	B-GENE-N
isozymes	O
,	O
whereas	O
NS398	B-CHEMICAL
,	O
carprofen	B-CHEMICAL
,	O
tolfenamic	B-CHEMICAL
acid	I-CHEMICAL
,	O
nimesulide	B-CHEMICAL
,	O
and	O
etodolac	B-CHEMICAL
had	O
more	O
than	O
5	O
times	O
greater	O
preference	O
for	O
inhibiting	O
COX	B-GENE-Y
-	I-GENE-Y
2	I-GENE-Y
than	O
COX	B-GENE-Y
-	I-GENE-Y
1	I-GENE-Y
.	O

All	O
canine	O
tissues	O
examined	O
,	O
including	O
those	O
from	O
the	O
gastrointestinal	O
tract	O
,	O
coexpressed	O
COX	B-GENE-N
-	I-GENE-N
1	I-GENE-N
and	I-GENE-N
-	I-GENE-N
2	I-GENE-N
mRNA	O
,	O
although	O
protein	O
expression	O
was	O
observed	O
only	O
for	O
COX	B-GENE-Y
-	I-GENE-Y
1	I-GENE-Y
.	O

CONCLUSIONS	O
AND	O
CLINICAL	O
RELEVANCE	O
:	O
Canine	B-GENE-Y
COX	I-GENE-Y
-	I-GENE-Y
2	I-GENE-Y
was	O
selectively	O
inhibited	O
by	O
etodolac	B-CHEMICAL
,	O
nimesulide	B-CHEMICAL
,	O
and	O
NS398	B-CHEMICAL
;	O
tolfenamic	B-CHEMICAL
acid	I-CHEMICAL
and	O
carprofen	B-CHEMICAL
also	O
appeared	O
to	O
be	O
preferential	O
COX	B-GENE-Y
-	I-GENE-Y
2	I-GENE-Y
inhibitors	O
in	O
dogs	O
.	O

The	O
roles	O
of	O
COX	B-GENE-Y
-	I-GENE-Y
1	I-GENE-Y
as	O
a	O
constitutive	O
housekeeping	O
enzyme	O
and	O
COX	B-GENE-Y
-	I-GENE-Y
2	I-GENE-Y
as	O
a	O
proinflammatory	O
inducible	O
enzyme	O
(	O
as	O
determined	O
in	O
humans	O
)	O
appear	O
to	O
apply	O
to	O
dogs	O
;	O
therefore	O
,	O
COX	B-GENE-Y
-	I-GENE-Y
2	I-GENE-Y
-	O
selective	O
inhibitors	O
should	O
prove	O
useful	O
in	O
reducing	O
the	O
adverse	O
effects	O
associated	O
with	O
nonselective	O
NSAIDs	O
.	O

Ketoconazole	B-CHEMICAL
binds	O
to	O
the	O
human	B-GENE-Y
androgen	I-GENE-Y
receptor	I-GENE-Y
.	O

Ketoconazole	B-CHEMICAL
,	O
an	O
imidazole	B-CHEMICAL
anti	O
-	O
fungal	O
agent	O
,	O
has	O
often	O
produced	O
features	O
of	O
androgen	B-CHEMICAL
deficiency	O
including	O
decreased	O
libido	O
,	O
gynecomastia	O
,	O
impotence	O
,	O
oligospermia	O
,	O
and	O
decreased	O
testosterone	B-CHEMICAL
levels	O
,	O
in	O
men	O
being	O
treated	O
for	O
chronic	O
mycotic	O
infections	O
.	O

Based	O
on	O
these	O
potent	O
effects	O
on	O
gonadal	O
function	O
in	O
vivo	O
as	O
well	O
as	O
previous	O
work	O
in	O
vitro	O
demonstrating	O
affinity	O
of	O
ketoconazole	B-CHEMICAL
for	O
receptor	O
proteins	O
for	O
glucocorticoids	O
and	O
1	B-CHEMICAL
,	I-CHEMICAL
25	I-CHEMICAL
(	I-CHEMICAL
OH	I-CHEMICAL
)	I-CHEMICAL
2	I-CHEMICAL
vitamin	I-CHEMICAL
D3	I-CHEMICAL
and	O
for	O
sex	B-GENE-Y
steroid	I-GENE-Y
binding	I-GENE-Y
globulin	I-GENE-Y
(	O
SSBG	B-GENE-Y
)	O
,	O
the	O
binding	O
of	O
ketoconazole	B-CHEMICAL
to	O
human	B-GENE-Y
androgen	I-GENE-Y
receptors	I-GENE-Y
(	O
AR	B-GENE-Y
)	O
in	O
vitro	O
was	O
also	O
examined	O
.	O

Ketoconazole	B-CHEMICAL
competition	O
with	O
[	B-CHEMICAL
3H	I-CHEMICAL
]	I-CHEMICAL
methyltrienolone	I-CHEMICAL
(	O
R1881	B-CHEMICAL
)	O
for	O
androgen	B-CHEMICAL
binding	O
sites	O
in	O
dispersed	O
,	O
intact	O
cultured	O
human	O
skin	O
fibroblasts	O
was	O
determined	O
at	O
22	O
degrees	O
C	O
.	O

Fifty	O
percent	O
displacement	O
of	O
[	B-CHEMICAL
3H	I-CHEMICAL
]	I-CHEMICAL
R1881	I-CHEMICAL
binding	O
to	O
AR	B-GENE-Y
was	O
achieved	O
by	O
6	O
.	O
4	O
+	O
/	O
-	O
1	O
.	O
8	O
(	O
SE	O
)	O
x	O
10	O
(	O
-	O
5	O
)	O
M	O
ketoconazole	B-CHEMICAL
.	O

Additional	O
binding	O
studies	O
performed	O
with	O
ketoconazole	B-CHEMICAL
in	O
the	O
presence	O
of	O
increasing	O
amounts	O
of	O
[	B-CHEMICAL
3H	I-CHEMICAL
]	I-CHEMICAL
R1881	I-CHEMICAL
showed	O
that	O
the	O
interaction	O
of	O
ketoconazole	B-CHEMICAL
with	O
AR	B-GENE-Y
was	O
competitive	O
when	O
the	O
data	O
were	O
analyzed	O
by	O
the	O
Scatchard	O
method	O
.	O

It	O
should	O
be	O
noted	O
,	O
however	O
,	O
that	O
the	O
dose	O
of	O
ketoconazole	B-CHEMICAL
required	O
for	O
50	O
%	O
occupancy	O
of	O
the	O
androgen	B-GENE-Y
receptor	I-GENE-Y
is	O
not	O
likely	O
to	O
be	O
achieved	O
in	O
vivo	O
,	O
at	O
least	O
in	O
plasma	O
.	O

Finally	O
,	O
androgen	B-CHEMICAL
binding	O
studies	O
performed	O
with	O
other	O
imidazoles	B-CHEMICAL
,	O
such	O
as	O
clotrimazole	B-CHEMICAL
,	O
miconazole	B-CHEMICAL
,	O
and	O
fluconozole	B-CHEMICAL
,	O
revealed	O
that	O
in	O
this	O
class	O
of	O
compounds	O
only	O
ketoconazole	B-CHEMICAL
appears	O
to	O
interact	O
with	O
the	O
androgen	B-GENE-Y
receptor	I-GENE-Y
.	O

Ketoconazole	B-CHEMICAL
appears	O
to	O
be	O
the	O
first	O
example	O
of	O
a	O
non	O
-	O
steroidal	B-CHEMICAL
compound	O
which	O
binds	O
competitively	O
to	O
both	O
SSBG	B-GENE-Y
and	O
multiple	O
steroid	B-GENE-N
hormone	I-GENE-N
receptors	I-GENE-N
,	O
suggesting	O
that	O
the	O
ligand	O
binding	O
sites	O
of	O
these	O
proteins	O
share	O
some	O
features	O
in	O
common	O
.	O

P2	B-GENE-N
receptor	I-GENE-N
mRNA	O
expression	O
profiles	O
in	O
human	O
lymphocytes	O
,	O
monocytes	O
and	O
CD34	O
+	O
stem	O
and	O
progenitor	O
cells	O
.	O

BACKGROUND	O
:	O
Extracellular	O
nucleotides	B-CHEMICAL
(	O
ATP	B-CHEMICAL
,	O
ADP	B-CHEMICAL
,	O
UTP	B-CHEMICAL
and	O
UDP	B-CHEMICAL
)	O
exert	O
a	O
wide	O
range	O
of	O
biological	O
effects	O
in	O
blood	O
cells	O
mediated	O
by	O
multiple	O
ionotropic	O
P2X	B-GENE-N
receptors	O
and	O
G	B-GENE-N
protein	I-GENE-N
-	I-GENE-N
coupled	I-GENE-N
P2Y	I-GENE-N
receptors	I-GENE-N
.	O

Although	O
pharmacological	O
experiments	O
have	O
suggested	O
the	O
presence	O
of	O
several	O
P2	B-GENE-N
receptor	I-GENE-N
subtypes	O
on	O
monocytes	O
and	O
lymphocytes	O
,	O
some	O
results	O
are	O
contradictory	O
.	O

Few	O
physiological	O
functions	O
have	O
been	O
firmly	O
established	O
to	O
a	O
specific	O
receptor	O
subtype	O
,	O
partly	O
because	O
of	O
a	O
lack	O
of	O
truly	O
selective	O
agonists	O
and	O
antagonists	O
.	O

This	O
stimulated	O
us	O
to	O
investigate	O
the	O
expression	O
of	O
P2X	B-GENE-N
and	O
P2Y	B-GENE-N
receptors	O
in	O
human	O
lymphocytes	O
and	O
monocytes	O
with	O
a	O
newly	O
established	O
quantitative	O
mRNA	O
assay	O
for	O
P2	B-GENE-N
receptors	I-GENE-N
.	O

In	O
addition	O
,	O
we	O
describe	O
for	O
the	O
first	O
time	O
the	O
expression	O
of	O
P2	B-GENE-N
receptors	I-GENE-N
in	O
CD34	O
+	O
stem	O
and	O
progenitor	O
cells	O
implicating	O
a	O
potential	O
role	O
of	O
P2	B-GENE-N
receptors	I-GENE-N
in	O
hematopoietic	O
lineage	O
and	O
progenitor	O
/	O
stem	O
cell	O
function	O
.	O

RESULTS	O
:	O
Using	O
a	O
quantitative	O
mRNA	O
assay	O
,	O
we	O
assessed	O
the	O
hypothesis	O
that	O
there	O
are	O
specific	O
P2	B-GENE-N
receptor	I-GENE-N
profiles	O
in	O
inflammatory	O
cells	O
.	O

The	O
P2X4	B-GENE-Y
receptor	O
had	O
the	O
highest	O
expression	O
in	O
lymphocytes	O
and	O
monocytes	O
.	O

Among	O
the	O
P2Y	B-GENE-N
receptors	O
,	O
P2Y12	B-GENE-Y
and	O
P2Y2	B-GENE-Y
had	O
highest	O
expression	O
in	O
lymphocytes	O
,	O
while	O
the	O
P2Y2	B-GENE-Y
and	O
P2Y13	B-GENE-Y
had	O
highest	O
expression	O
in	O
monocytes	O
.	O

Several	O
P2	B-GENE-N
receptors	I-GENE-N
were	O
expressed	O
(	O
P2Y2	B-GENE-Y
,	O
P2Y1	B-GENE-Y
,	O
P2Y12	B-GENE-Y
,	O
P2Y13	B-GENE-Y
,	O
P2Y11	B-GENE-Y
,	O
P2X1	B-GENE-Y
,	O
P2X4	B-GENE-Y
)	O
in	O
CD34	O
+	O
stem	O
and	O
progenitor	O
cells	O
.	O

CONCLUSIONS	O
:	O
The	O
most	O
interesting	O
findings	O
were	O
the	O
high	O
mRNA	O
expression	O
of	O
P2Y12	B-GENE-Y
receptors	O
in	O
lymphocytes	O
potentially	O
explaining	O
the	O
anti	O
-	O
inflammatory	O
effects	O
of	O
clopidogrel	B-CHEMICAL
,	O
P2Y13	B-GENE-Y
receptors	O
in	O
monocytes	O
and	O
a	O
previously	O
unrecognised	O
expression	O
of	O
P2X4	B-GENE-Y
in	O
lymphocytes	O
and	O
monocytes	O
.	O

In	O
addition	O
,	O
for	O
the	O
first	O
time	O
P2	B-GENE-N
receptor	I-GENE-N
mRNA	O
expression	O
patterns	O
was	O
studied	O
in	O
CD34	O
+	O
stem	O
and	O
progenitor	O
cells	O
.	O

Several	O
P2	B-GENE-N
receptors	I-GENE-N
were	O
expressed	O
(	O
P2Y2	B-GENE-Y
,	O
P2Y1	B-GENE-Y
,	O
P2Y12	B-GENE-Y
,	O
P2Y13	B-GENE-Y
,	O
P2Y11	B-GENE-Y
,	O
P2X1	B-GENE-Y
,	O
P2X4	B-GENE-Y
)	O
,	O
indicating	O
a	O
role	O
in	O
differentiation	O
and	O
proliferation	O
.	O

Thus	O
,	O
it	O
is	O
possible	O
that	O
specific	O
antibodies	O
to	O
P2	B-GENE-N
receptors	I-GENE-N
could	O
be	O
used	O
to	O
identify	O
progenitors	O
for	O
monocytes	O
,	O
lymphocytes	O
and	O
megakaryocytes	O
.	O

Direct	O
multiplex	O
assay	O
of	O
lysosomal	O
enzymes	O
in	O
dried	O
blood	O
spots	O
for	O
newborn	O
screening	O
.	O

BACKGROUND	O
:	O
Newborn	O
screening	O
for	O
deficiency	O
in	O
the	O
lysosomal	O
enzymes	O
that	O
cause	O
Fabry	O
,	O
Gaucher	O
,	O
Krabbe	O
,	O
Niemann	O
-	O
Pick	O
A	O
/	O
B	O
,	O
and	O
Pompe	O
diseases	O
is	O
warranted	O
because	O
treatment	O
for	O
these	O
syndromes	O
is	O
now	O
available	O
or	O
anticipated	O
in	O
the	O
near	O
feature	O
.	O

We	O
describe	O
a	O
multiplex	O
screening	O
method	O
for	O
all	O
five	O
lysosomal	O
enzymes	O
that	O
uses	O
newborn	O
-	O
screening	O
cards	O
containing	O
dried	O
blood	O
spots	O
as	O
the	O
enzyme	O
source	O
.	O

METHODS	O
:	O
We	O
used	O
a	O
cassette	O
of	O
substrates	O
and	O
internal	O
standards	O
to	O
directly	O
quantify	O
the	O
enzymatic	O
activities	O
,	O
and	O
tandem	O
mass	O
spectrometry	O
for	O
enzymatic	O
product	O
detection	O
.	O

Rehydrated	O
dried	O
blood	O
spots	O
were	O
incubated	O
with	O
the	O
enzyme	O
substrates	O
.	O

We	O
used	O
liquid	O
-	O
liquid	O
extraction	O
followed	O
by	O
solid	O
-	O
phase	O
extraction	O
with	O
silica	O
gel	O
to	O
remove	O
buffer	O
components	O
.	O

Acarbose	B-CHEMICAL
served	O
as	O
inhibitor	O
of	O
an	O
interfering	O
acid	B-GENE-Y
alpha	I-GENE-Y
-	I-GENE-Y
glucosidase	I-GENE-Y
present	O
in	O
neutrophils	O
,	O
which	O
allowed	O
the	O
lysosomal	O
enzyme	O
implicated	O
in	O
Pompe	O
disease	O
to	O
be	O
selectively	O
analyzed	O
.	O

RESULTS	O
:	O
We	O
analyzed	O
dried	O
blood	O
spots	O
from	O
5	O
patients	O
with	O
Gaucher	O
,	O
5	O
with	O
Niemann	O
-	O
Pick	O
A	O
/	O
B	O
,	O
11	O
with	O
Pompe	O
,	O
5	O
with	O
Fabry	O
,	O
and	O
12	O
with	O
Krabbe	O
disease	O
,	O
and	O
in	O
all	O
cases	O
the	O
enzyme	O
activities	O
were	O
below	O
the	O
minimum	O
activities	O
measured	O
in	O
a	O
collection	O
of	O
heterozygous	O
carriers	O
and	O
healthy	O
noncarrier	O
individuals	O
.	O

The	O
enzyme	O
activities	O
measured	O
in	O
5	O
-	O
9	O
heterozygous	O
carriers	O
were	O
approximately	O
one	O
-	O
half	O
those	O
measured	O
with	O
15	O
-	O
32	O
healthy	O
individuals	O
,	O
but	O
there	O
was	O
partial	O
overlap	O
of	O
each	O
condition	O
between	O
the	O
data	O
sets	O
for	O
carriers	O
and	O
healthy	O
individuals	O
.	O

CONCLUSION	O
:	O
For	O
all	O
five	O
diseases	O
,	O
the	O
affected	O
individuals	O
were	O
detected	O
.	O

The	O
assay	O
can	O
be	O
readily	O
automated	O
,	O
and	O
the	O
anticipated	O
reagent	O
and	O
supply	O
costs	O
are	O
well	O
within	O
the	O
budget	O
limits	O
of	O
newborn	O
-	O
screening	O
centers	O
.	O

A	O
disorder	O
to	O
order	O
transition	O
accompanies	O
catalysis	O
in	O
retinaldehyde	B-GENE-Y
dehydrogenase	I-GENE-Y
type	I-GENE-Y
II	I-GENE-Y
.	O

Retinaldehyde	B-GENE-Y
dehydrogenase	I-GENE-Y
II	I-GENE-Y
(	O
RalDH2	B-GENE-Y
)	O
converts	O
retinal	O
to	O
the	O
transcriptional	O
regulator	O
retinoic	O
acid	O
in	O
the	O
developing	O
embryo	O
.	O

The	O
x	O
-	O
ray	O
structure	O
of	O
the	O
enzyme	O
revealed	O
an	O
important	O
structural	O
difference	O
between	O
this	O
protein	O
and	O
other	O
aldehyde	B-GENE-N
dehydrogenases	I-GENE-N
of	O
the	O
same	O
enzyme	O
superfamily	O
;	O
a	O
20	O
-	O
amino	B-CHEMICAL
acid	I-CHEMICAL
span	O
in	O
the	O
substrate	O
access	O
channel	O
in	O
retinaldehyde	B-GENE-Y
dehydrogenase	I-GENE-Y
II	I-GENE-Y
is	O
disordered	O
,	O
whereas	O
in	O
other	O
aldehyde	B-GENE-N
dehydrogenases	I-GENE-N
this	O
region	O
forms	O
a	O
well	O
defined	O
wall	O
of	O
the	O
substrate	O
access	O
channel	O
.	O

We	O
asked	O
whether	O
this	O
disordered	O
loop	O
might	O
order	O
during	O
the	O
course	O
of	O
catalysis	O
and	O
provide	O
a	O
means	O
for	O
an	O
enzyme	O
that	O
requires	O
a	O
large	O
substrate	O
access	O
channel	O
to	O
restrict	O
access	O
to	O
the	O
catalytic	O
machinery	O
by	O
smaller	O
compounds	O
that	O
might	O
potentially	O
enter	O
the	O
active	O
site	O
and	O
be	O
metabolized	O
.	O

Our	O
experiments	O
,	O
a	O
combination	O
of	O
kinetic	O
,	O
spectroscopic	O
,	O
and	O
crystallographic	O
techniques	O
,	O
suggest	O
that	O
a	O
disorder	O
to	O
order	O
transition	O
is	O
linked	O
to	O
catalytic	O
activity	O
.	O

Effects	O
of	O
carvedilol	B-CHEMICAL
on	O
plasma	B-GENE-Y
B	I-GENE-Y
-	I-GENE-Y
type	I-GENE-Y
natriuretic	I-GENE-Y
peptide	I-GENE-Y
concentration	O
and	O
symptoms	O
in	O
patients	O
with	O
heart	O
failure	O
and	O
preserved	O
ejection	O
fraction	O
.	O

Although	O
the	O
benefits	O
of	O
carvedilol	B-CHEMICAL
in	O
patients	O
with	O
heart	O
failure	O
and	O
depressed	O
ejection	O
fraction	O
(	O
EF	O
)	O
have	O
been	O
elucidated	O
,	O
those	O
in	O
patients	O
with	O
preserved	O
EF	O
are	O
not	O
understood	O
.	O

We	O
enrolled	O
40	O
patients	O
with	O
mild	O
or	O
moderate	O
heart	O
failure	O
and	O
EF	O
>	O
/	O
=	O
45	O
%	O
.	O

They	O
were	O
randomly	O
assigned	O
to	O
carvedilol	B-CHEMICAL
(	O
n	O
=	O
19	O
)	O
or	O
conventional	O
therapy	O
(	O
n	O
=	O
21	O
)	O
.	O

After	O
12	O
months	O
of	O
treatment	O
,	O
carvedilol	B-CHEMICAL
significantly	O
improved	O
all	O
end	O
points	O
(	O
plasma	O
concentration	O
of	O
B	B-GENE-Y
-	I-GENE-Y
type	I-GENE-Y
natriuretic	I-GENE-Y
peptide	I-GENE-Y
[	O
BNP	B-GENE-Y
]	O
from	O
175	O
(	O
35	O
to	O
209	O
)	O
to	O
106	O
(	O
52	O
to	O
160	O
)	O
pg	O
/	O
ml	O
,	O
mean	O
(	O
95	O
%	O
confidence	O
interval	O
)	O
p	O
<	O
0	O
.	O
01	O
;	O
New	O
York	O
Heart	O
Association	O
functional	O
class	O
from	O
2	O
.	O
37	O
(	O
2	O
.	O
13	O
to	O
2	O
.	O
61	O
)	O
to	O
1	O
.	O
56	O
(	O
1	O
.	O
21	O
to	O
1	O
.	O
91	O
)	O
,	O
p	O
<	O
0	O
.	O
01	O
;	O
exercise	O
capacity	O
estimated	O
with	O
the	O
Specific	O
Activity	O
Scale	O
from	O
4	O
.	O
75	O
(	O
4	O
.	O
50	O
to	O
5	O
.	O
00	O
)	O
to	O
5	O
.	O
68	O
(	O
5	O
.	O
22	O
to	O
6	O
.	O
14	O
)	O
METs	O
,	O
p	O
<	O
0	O
.	O
02	O
)	O
,	O
whereas	O
conventional	O
therapy	O
did	O
not	O
(	O
plasma	B-GENE-Y
BNP	I-GENE-Y
concentration	O
from	O
150	O
(	O
114	O
to	O
186	O
)	O
to	O
174	O
(	O
100	O
to	O
248	O
)	O
pg	O
/	O
ml	O
;	O
New	O
York	O
Heart	O
Association	O
functional	O
class	O
from	O
2	O
.	O
29	O
(	O
2	O
.	O
08	O
to	O
2	O
.	O
50	O
)	O
to	O
2	O
.	O
11	O
(	O
1	O
.	O
73	O
to	O
2	O
.	O
49	O
)	O
;	O
exercise	O
capacity	O
from	O
4	O
.	O
57	O
(	O
4	O
.	O
34	O
to	O
4	O
.	O
80	O
)	O
to	O
4	O
.	O
72	O
(	O
4	O
.	O
41	O
to	O
5	O
.	O
03	O
)	O
METs	O
)	O
.	O

Univariate	O
regression	O
analyses	O
showed	O
that	O
only	O
the	O
use	O
of	O
carvedilol	B-CHEMICAL
was	O
correlated	O
with	O
the	O
decrease	O
in	O
plasma	B-GENE-Y
BNP	I-GENE-Y
concentration	O
(	O
p	O
<	O
0	O
.	O
03	O
)	O
.	O

Multivariate	O
analyses	O
demonstrated	O
that	O
an	O
ischemic	O
cause	O
of	O
heart	O
failure	O
(	O
p	O
<	O
0	O
.	O
02	O
)	O
,	O
high	O
plasma	O
concentration	O
of	O
BNP	B-GENE-Y
(	O
p	O
<	O
0	O
.	O
02	O
)	O
,	O
left	O
ventricular	O
dilation	O
(	O
p	O
<	O
0	O
.	O
03	O
)	O
,	O
and	O
use	O
of	O
carvedilol	B-CHEMICAL
(	O
p	O
<	O
0	O
.	O
04	O
)	O
at	O
baseline	O
were	O
predictive	O
of	O
a	O
decrease	O
in	O
plasma	O
concentration	O
of	O
BNP	B-GENE-Y
.	O

In	O
conclusion	O
,	O
carvedilol	B-CHEMICAL
potentially	O
decreased	O
neurohumoral	O
activation	O
,	O
decreased	O
symptoms	O
,	O
and	O
increased	O
exercise	O
capacity	O
in	O
patients	O
with	O
heart	O
failure	O
and	O
preserved	O
EF	O
.	O

Psychopharmacology	O
of	O
anticonvulsants	O
:	O
levetiracetam	B-CHEMICAL
as	O
a	O
synaptic	B-GENE-N
vesicle	I-GENE-N
protein	I-GENE-N
modulator	O
.	O

ISSUE	O
:	O
A	O
novel	O
mechanism	O
of	O
action	O
has	O
recently	O
been	O
described	O
for	O
levetiracetam	B-CHEMICAL
,	O
a	O
member	O
of	O
a	O
new	O
class	O
of	O
anticonvulsants	O
.	O

Levetiracetam	B-CHEMICAL
binds	O
selectively	O
and	O
with	O
high	O
affinity	O
to	O
a	O
synaptic	B-GENE-N
vesicle	I-GENE-N
protein	I-GENE-N
known	O
as	O
SV2A	B-GENE-Y
,	O
thought	O
to	O
be	O
involved	O
with	O
synaptic	O
vesicle	O
exocytosis	O
and	O
presynaptic	O
neurotransmitter	O
release	O
.	O

Terbinafine	B-CHEMICAL
:	O
mode	O
of	O
action	O
and	O
properties	O
of	O
the	O
squalene	B-GENE-Y
epoxidase	I-GENE-Y
inhibition	O
.	O

Terbinafine	B-CHEMICAL
(	O
Lamisil	B-CHEMICAL
)	O
has	O
primarily	O
fungicidal	O
action	O
against	O
many	O
fungi	O
as	O
a	O
result	O
of	O
its	O
specific	O
mechanism	O
of	O
squalene	B-GENE-Y
epoxidase	I-GENE-Y
inhibition	O
.	O

Treated	O
fungi	O
accumulate	O
squalene	B-CHEMICAL
while	O
becoming	O
deficient	O
in	O
ergosterol	B-CHEMICAL
,	O
an	O
essential	O
component	O
of	O
fungal	O
cell	O
membranes	O
.	O

The	O
cidal	O
action	O
is	O
closely	O
associated	O
with	O
the	O
development	O
of	O
high	O
intracellular	O
squalene	B-CHEMICAL
concentrations	O
,	O
which	O
are	O
believed	O
to	O
interfere	O
with	O
fungal	O
membrane	O
function	O
and	O
cell	O
wall	O
synthesis	O
.	O

In	O
the	O
case	O
of	O
Candida	O
albicans	O
,	O
growth	O
inhibition	O
with	O
terbinafine	B-CHEMICAL
appears	O
to	O
result	O
from	O
the	O
ergosterol	B-CHEMICAL
deficiency	O
.	O

The	O
filamentous	O
form	O
of	O
this	O
fungus	O
is	O
more	O
susceptible	O
than	O
the	O
yeast	O
form	O
.	O

Measurement	O
of	O
ergosterol	B-CHEMICAL
biosynthesis	O
by	O
incorporation	O
of	O
radiolabelled	O
precursors	O
indicates	O
a	O
correlation	O
between	O
inhibition	O
of	O
growth	O
and	O
ergosterol	B-CHEMICAL
biosynthesis	O
in	O
a	O
range	O
of	O
pathogenic	O
fungi	O
.	O

Terbinafine	B-CHEMICAL
is	O
a	O
potent	O
non	O
-	O
competitive	O
inhibitor	O
of	O
squalene	B-GENE-Y
epoxidase	I-GENE-Y
from	O
Candida	O
(	O
Ki	O
=	O
30	O
nM	O
)	O
.	O

In	O
contrast	O
,	O
inhibition	O
of	O
rat	B-GENE-Y
liver	I-GENE-Y
squalene	I-GENE-Y
epoxidase	I-GENE-Y
only	O
occurs	O
at	O
higher	O
drug	O
concentrations	O
(	O
Ki	O
=	O
77	O
microM	O
)	O
,	O
and	O
is	O
competitive	O
with	O
squalene	B-CHEMICAL
.	O

Thus	O
,	O
terbinafine	B-CHEMICAL
has	O
no	O
effect	O
on	O
cholesterol	B-CHEMICAL
biosynthesis	O
in	O
vivo	O
.	O

Squalene	B-GENE-Y
epoxidase	I-GENE-Y
is	O
not	O
an	O
enzyme	O
of	O
the	O
cytochrome	B-GENE-N
P	I-GENE-N
-	I-GENE-N
450	I-GENE-N
type	O
,	O
thereby	O
avoiding	O
potential	O
inhibition	O
of	O
this	O
class	O
of	O
enzymes	O
.	O

[	O
A	O
case	O
report	O
of	O
metastatic	O
pancreatic	O
cancer	O
that	O
responded	O
remarkably	O
to	O
the	O
combination	O
of	O
thalidomide	B-CHEMICAL
,	O
celecoxib	B-CHEMICAL
and	O
irinotecan	B-CHEMICAL
]	O
.	O

The	O
prognosis	O
of	O
pancreatic	O
cancer	O
with	O
metastases	O
or	O
recurrence	O
is	O
quite	O
poor	O
.	O

Chemotherapy	O
has	O
not	O
resulted	O
in	O
a	O
significant	O
survival	O
benefit	O
;	O
median	O
survival	O
is	O
3	O
-	O
6	O
months	O
.	O

Various	O
chemotherapeutic	O
agents	O
have	O
been	O
evaluated	O
and	O
the	O
standard	O
chemotherapy	O
of	O
pancreatic	O
cancer	O
is	O
gemcitabine	B-CHEMICAL
.	O

The	O
response	O
rate	O
,	O
however	O
,	O
is	O
low	O
at	O
13	O
%	O
.	O

Thalidomide	B-CHEMICAL
and	O
celecoxib	B-CHEMICAL
have	O
different	O
mechanisms	O
of	O
action	O
and	O
activity	O
in	O
various	O
malignant	O
tumors	O
.	O

Both	O
have	O
been	O
evaluated	O
and	O
shown	O
to	O
demonstrate	O
activity	O
against	O
solid	O
tumors	O
.	O

Thalidomide	B-CHEMICAL
decreased	O
the	O
stability	O
of	O
TNF	B-GENE-Y
-	O
mRNA	O
and	O
COX	B-GENE-Y
-	I-GENE-Y
2	I-GENE-Y
mRNA	O
.	O

COX	B-GENE-Y
-	I-GENE-Y
2	I-GENE-Y
is	O
a	O
bifunctional	O
enzyme	O
possessing	O
both	O
cyclooxygenase	B-GENE-N
and	O
peroxidase	B-GENE-N
activities	O
.	O

Although	O
celecoxib	B-CHEMICAL
inhibits	O
PG	O
biosynthesis	O
,	O
most	O
do	O
not	O
affect	O
the	O
peroxidase	B-GENE-N
activity	O
of	O
COX	B-GENE-N
,	O
which	O
can	O
generate	O
proximate	O
carcinogens	O
.	O

Because	O
thalidomide	B-CHEMICAL
does	O
not	O
completely	O
inhibit	O
COX	B-GENE-Y
-	I-GENE-Y
2	I-GENE-Y
expression	O
or	O
PG	O
biosynthesis	O
,	O
a	O
therapeutic	O
strategy	O
combining	O
celecoxib	B-CHEMICAL
with	O
thalidomide	B-CHEMICAL
might	O
be	O
more	O
effective	O
than	O
using	O
either	O
agent	O
alone	O
.	O

Differences	O
in	O
the	O
mechanism	O
of	O
action	O
of	O
gemcitabine	B-CHEMICAL
and	O
irinotecan	B-CHEMICAL
suggest	O
that	O
a	O
change	O
of	O
gemcitabine	B-CHEMICAL
to	O
irinotecan	B-CHEMICAL
could	O
provide	O
clinically	O
efficacious	O
outcomes	O
.	O

In	O
order	O
to	O
accomplish	O
new	O
treatment	O
strategies	O
,	O
we	O
have	O
been	O
using	O
thalidomide	B-CHEMICAL
,	O
celecoxib	B-CHEMICAL
and	O
irinotecan	B-CHEMICAL
in	O
low	O
-	O
doses	O
.	O

We	O
believe	O
this	O
combination	O
represents	O
a	O
viable	O
treatment	O
for	O
patients	O
of	O
pancreatic	O
cancer	O
with	O
recurrence	O
or	O
metastases	O
.	O

Effect	O
of	O
pitavastatin	B-CHEMICAL
on	O
apolipoprotein	B-GENE-Y
A	I-GENE-Y
-	I-GENE-Y
I	I-GENE-Y
production	O
in	O
HepG2	O
cell	O
.	O

There	O
are	O
few	O
reports	O
describing	O
the	O
mechanism	O
of	O
HDL	B-GENE-N
-	O
elevating	O
action	O
of	O
HMG	B-GENE-Y
-	I-GENE-Y
CoA	I-GENE-Y
reductase	I-GENE-Y
inhibitors	O
(	O
statins	O
)	O
.	O

As	O
it	O
is	O
considered	O
that	O
the	O
key	O
step	O
of	O
HDL	B-GENE-N
production	O
is	O
the	O
secretion	O
of	O
apolipoprotein	B-GENE-Y
A	I-GENE-Y
-	I-GENE-Y
I	I-GENE-Y
(	O
apoA	B-GENE-Y
-	I-GENE-Y
I	I-GENE-Y
)	O
,	O
we	O
investigated	O
the	O
effect	O
of	O
statins	O
on	O
apoA	B-GENE-Y
-	I-GENE-Y
I	I-GENE-Y
synthesis	O
and	O
secretion	O
by	O
HepG2	O
cell	O
to	O
elucidate	O
the	O
mechanism	O
of	O
the	O
action	O
.	O

Each	O
statin	O
induced	O
apoA	B-GENE-Y
-	I-GENE-Y
I	I-GENE-Y
expression	O
(	O
mRNA	O
and	O
protein	O
)	O
dose	O
-	O
dependently	O
:	O
the	O
rank	O
order	O
of	O
the	O
apoA	B-GENE-Y
-	I-GENE-Y
I	I-GENE-Y
induction	O
pitavastatin	B-CHEMICAL
(	O
3	O
microM	O
)	O
>	O
simvastatin	B-CHEMICAL
(	O
10	O
microM	O
)	O
>	O
atorvastatin	B-CHEMICAL
(	O
30	O
microM	O
)	O
.	O

The	O
induction	O
of	O
apoA	B-GENE-Y
-	I-GENE-Y
I	I-GENE-Y
by	O
statins	O
disappeared	O
with	O
addition	O
of	O
mevalonate	B-CHEMICAL
,	O
which	O
indicates	O
that	O
the	O
effect	O
is	O
HMG	B-GENE-Y
-	I-GENE-Y
CoA	I-GENE-Y
reductase	I-GENE-Y
inhibition	O
-	O
dependent	O
.	O

Based	O
on	O
HMG	B-GENE-Y
-	I-GENE-Y
CoA	I-GENE-Y
reductase	I-GENE-Y
inhibition	O
,	O
pitavastatin	B-CHEMICAL
-	O
induced	O
apoA	B-GENE-Y
-	I-GENE-Y
I	I-GENE-Y
more	O
efficiently	O
than	O
simvastatin	B-CHEMICAL
and	O
atorvastatin	B-CHEMICAL
.	O

Further	O
study	O
revealed	O
that	O
pitavastatin	B-CHEMICAL
increased	O
ABCA1	B-GENE-Y
mRNA	O
in	O
HMG	B-GENE-Y
-	I-GENE-Y
CoA	I-GENE-Y
reductase	I-GENE-Y
-	O
dependent	O
manner	O
and	O
that	O
Rho	B-GENE-N
and	O
Rho	B-GENE-N
kinase	I-GENE-N
inhibitor	O
(	O
C3T	O
and	O
Y27632	B-CHEMICAL
)	O
increased	O
apoA	B-GENE-Y
-	I-GENE-Y
I	I-GENE-Y
production	O
in	O
the	O
HepG2	O
cells	O
.	O

These	O
results	O
suggest	O
that	O
pitavastatin	B-CHEMICAL
efficiently	O
increases	O
apoA	B-GENE-Y
-	I-GENE-Y
I	I-GENE-Y
in	O
the	O
culture	O
medium	O
of	O
HepG2	O
cells	O
by	O
promoting	O
apoA	B-GENE-Y
-	I-GENE-Y
I	I-GENE-Y
production	O
through	O
inhibition	O
of	O
HMG	B-GENE-Y
-	I-GENE-Y
CoA	I-GENE-Y
reductase	I-GENE-Y
and	O
suppression	O
of	O
Rho	B-GENE-N
activity	O
and	O
by	O
protecting	O
apoA	B-GENE-Y
-	I-GENE-Y
I	I-GENE-Y
from	O
catabolism	O
through	O
ABCA1	B-GENE-Y
induction	O
and	O
lipidation	O
of	O
apoA	B-GENE-Y
-	I-GENE-Y
I	I-GENE-Y
.	O

A	O
multitargeted	O
,	O
metronomic	O
,	O
and	O
maximum	O
-	O
tolerated	O
dose	O
"	O
chemo	O
-	O
switch	O
"	O
regimen	O
is	O
antiangiogenic	O
,	O
producing	O
objective	O
responses	O
and	O
survival	O
benefit	O
in	O
a	O
mouse	O
model	O
of	O
cancer	O
.	O

PURPOSE	O
:	O
A	O
transgenic	O
mouse	O
model	O
has	O
revealed	O
parameters	O
of	O
the	O
angiogenic	O
switch	O
during	O
multistep	O
tumorigenesis	O
of	O
pancreatic	O
islets	O
,	O
and	O
demonstrated	O
efficacy	O
of	O
antiangiogenic	O
therapies	O
.	O

Pericytes	O
have	O
been	O
revealed	O
as	O
functionally	O
important	O
for	O
tumor	O
neovasculature	O
,	O
using	O
kinase	O
inhibitors	O
targeting	O
their	O
platelet	B-GENE-Y
-	I-GENE-Y
derived	I-GENE-Y
growth	I-GENE-Y
factor	I-GENE-Y
receptors	I-GENE-Y
(	O
PDGFRs	B-GENE-Y
)	O
.	O

Additionally	O
,	O
vascular	B-GENE-N
endothelial	I-GENE-N
growth	I-GENE-N
factor	I-GENE-N
receptor	I-GENE-N
(	O
VEGFR	B-GENE-N
)	O
inhibitors	O
and	O
metronomic	O
chemotherapy	O
show	O
modest	O
benefit	O
against	O
early	O
-	O
but	O
not	O
late	O
-	O
stage	O
disease	O
.	O

MATERIALS	O
AND	O
METHODS	O
:	O
Seeking	O
to	O
improve	O
efficacy	O
against	O
otherwise	O
intractable	O
end	O
-	O
stage	O
pancreatic	O
islet	O
tumors	O
,	O
two	O
receptor	B-GENE-N
tyrosine	I-GENE-N
kinase	I-GENE-N
inhibitors	O
,	O
imatinib	B-CHEMICAL
and	O
SU11248	B-CHEMICAL
,	O
were	O
used	O
to	O
disrupt	O
PDGFR	B-GENE-Y
-	O
mediated	O
pericyte	O
support	O
of	O
tumor	O
endothelial	O
cells	O
in	O
concert	O
with	O
maximum	O
-	O
tolerated	O
dose	O
(	O
MTD	O
)	O
or	O
metronomic	O
chemotherapy	O
and	O
/	O
or	O
VEGFR	B-GENE-N
inhibition	O
.	O

RESULTS	O
:	O
Imatinib	B-CHEMICAL
,	O
despite	O
equivocal	O
efficacy	O
as	O
monotherapy	O
,	O
reduced	O
pericyte	O
coverage	O
of	O
tumor	O
vessels	O
and	O
enhanced	O
efficacy	O
in	O
combination	O
with	O
metronomic	O
chemotherapy	O
or	O
VEGFR	B-GENE-N
inhibition	O
.	O

A	O
regimen	O
involving	O
all	O
three	O
was	O
even	O
better	O
.	O

MTD	O
using	O
cyclophosphamide	B-CHEMICAL
caused	O
transitory	O
regression	O
,	O
but	O
then	O
rapid	O
regrowth	O
,	O
in	O
contrast	O
to	O
metronomic	O
cyclophosphamide	B-CHEMICAL
plus	O
imatinib	B-CHEMICAL
,	O
which	O
produced	O
stable	O
disease	O
.	O

The	O
MTD	O
regimen	O
elicited	O
apoptosis	O
of	O
tumor	O
cells	O
but	O
not	O
endothelial	O
cells	O
,	O
whereas	O
the	O
other	O
regimens	O
increased	O
endothelial	O
cell	O
apoptosis	O
concordant	O
with	O
efficacy	O
.	O

A	O
"	O
chemo	O
-	O
switch	O
"	O
protocol	O
,	O
involving	O
sequential	O
MTD	O
and	O
then	O
metronomic	O
chemotherapy	O
,	O
overlaid	O
with	O
multitargeted	O
inhibition	O
of	O
PDGFR	B-GENE-Y
and	O
VEGFR	B-GENE-N
,	O
gave	O
complete	O
responses	O
and	O
unprecedented	O
survival	O
advantage	O
in	O
this	O
model	O
.	O

CONCLUSION	O
:	O
This	O
study	O
demonstrates	O
a	O
potentially	O
tractable	O
clinical	O
strategy	O
in	O
a	O
stringent	O
preclinical	O
model	O
,	O
wherein	O
standard	O
-	O
of	O
-	O
care	O
chemotherapy	O
is	O
followed	O
by	O
a	O
novel	O
maintenance	O
regimen	O
:	O
PDFGR	B-GENE-Y
is	O
targeted	O
to	O
disrupt	O
pericyte	O
support	O
,	O
while	O
metronomic	O
chemotherapy	O
and	O
/	O
or	O
VEGFR	B-GENE-N
inhibitors	O
target	O
consequently	O
sensitized	O
endothelial	O
cells	O
,	O
collectively	O
destabilizing	O
pre	O
-	O
existing	O
tumor	O
vasculature	O
and	O
inhibiting	O
ongoing	O
angiogenesis	O
.	O

Preferential	O
and	O
non	O
-	O
selective	O
cyclooxygenase	B-GENE-N
inhibitors	O
reduce	O
inflammation	O
during	O
lipopolysaccharide	O
-	O
induced	O
synovitis	O
.	O

Synovitis	O
in	O
horses	O
is	O
frequently	O
treated	O
by	O
administration	O
of	O
non	O
-	O
steroidal	B-CHEMICAL
anti	O
-	O
inflammatory	O
drugs	O
(	O
NSAIDs	O
)	O
,	O
which	O
inhibit	O
cyclooxygenase	B-GENE-N
isoforms	O
(	O
COX	B-GENE-Y
-	I-GENE-Y
1	I-GENE-Y
and	O
COX	B-GENE-Y
-	I-GENE-Y
2	I-GENE-Y
)	O
.	O

Constitutively	O
expressed	O
COX	B-GENE-Y
-	I-GENE-Y
1	I-GENE-Y
is	O
involved	O
in	O
physiologic	O
functions	O
such	O
as	O
maintenance	O
of	O
gastric	O
mucosal	O
integrity	O
,	O
whereas	O
COX	B-GENE-Y
-	I-GENE-Y
2	I-GENE-Y
is	O
up	O
-	O
regulated	O
at	O
sites	O
of	O
inflammation	O
.	O

Thus	O
,	O
COX	B-GENE-Y
-	I-GENE-Y
2	I-GENE-Y
inhibitors	O
reduce	O
inflammation	O
with	O
reduced	O
gastrointestinal	O
side	O
effects	O
as	O
compared	O
to	O
non	O
-	O
selective	O
COX	B-GENE-Y
inhibitors	O
.	O

The	O
objective	O
of	O
the	O
present	O
study	O
was	O
to	O
compare	O
the	O
anti	O
-	O
inflammatory	O
effects	O
of	O
the	O
preferential	O
COX	B-GENE-Y
-	I-GENE-Y
2	I-GENE-Y
inhibitor	O
etodolac	O
with	O
the	O
non	O
-	O
selective	O
COX	B-GENE-N
inhibitor	O
phenylbutazone	B-CHEMICAL
in	O
horses	O
with	O
lipopolysaccharide	O
(	O
LPS	O
)	O
-	O
induced	O
synovitis	O
.	O

Three	O
groups	O
of	O
horses	O
(	O
n	O
=	O
6	O
)	O
received	O
no	O
treatment	O
,	O
phenylbutazone	B-CHEMICAL
(	O
4	O
.	O
4	O
mg	O
/	O
kg	O
,	O
IV	O
,	O
q12h	O
)	O
,	O
or	O
etodolac	B-CHEMICAL
(	O
23	O
mg	O
/	O
kg	O
,	O
IV	O
,	O
q12h	O
)	O
,	O
respectively	O
,	O
2	O
-	O
h	O
following	O
injection	O
of	O
LPS	O
into	O
one	O
middle	O
carpal	O
joint	O
.	O

Synovial	O
fluid	O
was	O
analyzed	O
for	O
white	O
blood	O
cell	O
(	O
WBC	O
)	O
count	O
,	O
and	O
TXB2	B-CHEMICAL
and	O
PGE2	B-CHEMICAL
levels	O
.	O

Phenylbutazone	B-CHEMICAL
and	O
etodolac	B-CHEMICAL
significantly	O
reduced	O
WBC	O
count	O
6	O
and	O
24	O
-	O
h	O
following	O
injection	O
of	O
LPS	O
compared	O
to	O
untreated	O
horses	O
.	O

In	O
addition	O
,	O
both	O
drugs	O
significantly	O
reduced	O
PGE2	B-CHEMICAL
levels	O
(	O
P	O
<	O
0	O
.	O
05	O
)	O
6	O
-	O
h	O
following	O
LPS	O
injection	O
,	O
whereas	O
the	O
probable	O
COX	B-GENE-Y
-	I-GENE-Y
1	I-GENE-Y
prostanoid	B-CHEMICAL
TXB2	B-CHEMICAL
was	O
significantly	O
reduced	O
by	O
phenylbutazone	B-CHEMICAL
(	O
P	O
<	O
0	O
.	O
05	O
)	O
,	O
but	O
not	O
etodolac	B-CHEMICAL
.	O

Etodolac	B-CHEMICAL
may	O
serve	O
as	O
a	O
more	O
selective	O
anti	O
-	O
inflammatory	O
agent	O
than	O
phenylbutazone	B-CHEMICAL
for	O
treatment	O
of	O
equine	O
synovitis	O
.	O

Genetic	O
polymorphisms	O
predisposing	O
to	O
hyperhomocysteinemia	O
in	O
cardiac	O
transplant	O
patients	O
.	O

Genetic	O
determinants	O
for	O
high	O
homocysteine	B-CHEMICAL
(	O
Hcy	B-CHEMICAL
)	O
levels	O
are	O
now	O
well	O
known	O
.	O

We	O
studied	O
several	O
single	O
nucleotide	O
polymorphisms	O
(	O
SNP	O
)	O
in	O
Hcy	B-CHEMICAL
-	O
regulating	O
genes	O
[	O
methylenetetrahydrofolate	B-GENE-Y
reductase	I-GENE-Y
(	O
MTHFR	B-GENE-Y
)	O
C677T	B-GENE-N
and	O
A1298C	B-GENE-N
;	O
methionine	B-GENE-Y
synthase	I-GENE-Y
(	O
MS	B-GENE-Y
)	O
A2756G	B-GENE-N
;	O
methionine	B-GENE-Y
synthase	I-GENE-Y
reductase	I-GENE-Y
(	O
MTRR	B-GENE-Y
)	O
A66G	B-GENE-N
]	O
in	O
relation	O
to	O
total	O
plasma	O
Hcy	B-CHEMICAL
levels	O
,	O
transplant	O
coronary	O
artery	O
disease	O
and	O
thromboembolic	O
episodes	O
in	O
84	O
heart	O
transplant	O
patients	O
,	O
and	O
we	O
compared	O
the	O
incidence	O
of	O
these	O
polymorphisms	O
with	O
those	O
in	O
a	O
healthy	O
adult	O
controls	O
.	O

At	O
least	O
one	O
copy	O
of	O
the	O
G	O
allele	O
of	O
the	O
MTRR	B-GENE-Y
A66G	B-GENE-N
SNP	O
was	O
found	O
in	O
a	O
significantly	O
greater	O
proportion	O
of	O
cardiac	O
transplant	O
(	O
CTX	O
)	O
recipients	O
compared	O
with	O
controls	O
(	O
94	O
.	O
0	O
%	O
vs	O
.	O
79	O
.	O
9	O
%	O
respectively	O
)	O
.	O

None	O
of	O
the	O
SNP	O
analyzed	O
were	O
correlated	O
with	O
total	O
Hcy	B-CHEMICAL
plasma	O
levels	O
or	O
the	O
presence	O
of	O
transplant	O
coronary	O
artery	O
disease	O
.	O

However	O
,	O
MS	B-GENE-Y
A2756G	B-GENE-N
was	O
significantly	O
associated	O
with	O
cobalamin	B-CHEMICAL
levels	O
(	O
AA	O
genotype	O
:	O
290	O
+	O
/	O
-	O
122	O
pmol	O
/	O
l	O
;	O
AG	O
:	O
381	O
+	O
/	O
-	O
151	O
pmol	O
/	O
l	O
and	O
GG	O
:	O
415	O
+	O
/	O
-	O
100	O
pmol	O
/	O
l	O
)	O
,	O
as	O
was	O
MTRR	B-GENE-Y
A66G	B-GENE-N
(	O
AA	O
:	O
478	O
+	O
/	O
-	O
219	O
pmol	O
/	O
l	O
,	O
AG	O
:	O
306	O
+	O
/	O
-	O
124	O
pmol	O
/	O
l	O
and	O
GG	O
:	O
306	O
+	O
/	O
-	O
123	O
pmol	O
/	O
l	O
)	O
.	O

MTRR	B-GENE-Y
A66G	B-GENE-N
was	O
also	O
correlated	O
with	O
serum	O
folate	O
.	O

No	O
association	O
was	O
found	O
with	O
thromboembolic	O
events	O
.	O

In	O
conclusion	O
,	O
there	O
was	O
a	O
significant	O
difference	O
in	O
the	O
frequency	O
of	O
the	O
G	O
allele	O
genotype	O
of	O
the	O
MTRR	B-GENE-Y
A66G	B-GENE-N
in	O
CTX	O
patients	O
versus	O
controls	O
.	O

Differences	O
in	O
cobalamin	B-CHEMICAL
and	O
folate	O
levels	O
with	O
the	O
MTRR	B-GENE-Y
A66G	B-GENE-N
and	O
MS	B-GENE-Y
A2756G	B-GENE-N
polymorphisms	O
were	O
noted	O
.	O

Thus	O
,	O
SNP	O
in	O
Hcy	B-CHEMICAL
-	O
regulating	O
genes	O
may	O
be	O
important	O
determinants	O
of	O
vitamin	O
metabolism	O
in	O
CTX	O
,	O
raising	O
the	O
question	O
of	O
increased	O
vitamin	O
requirements	O
to	O
minimize	O
increased	O
plasma	O
Hcy	B-CHEMICAL
in	O
this	O
high	O
-	O
risk	O
group	O
.	O

Effect	O
of	O
bosentan	B-CHEMICAL
(	O
ETA	B-GENE-Y
/	O
ETB	B-GENE-Y
receptor	O
antagonist	O
)	O
on	O
metabolic	O
changes	O
during	O
stress	O
and	O
diabetes	O
.	O

Elevated	O
plasma	O
ET	B-GENE-Y
-	I-GENE-Y
1	I-GENE-Y
levels	O
have	O
been	O
reported	O
in	O
several	O
conditions	O
such	O
as	O
stress	O
and	O
diabetes	O
.	O

ET	B-GENE-Y
-	I-GENE-Y
1	I-GENE-Y
is	O
found	O
to	O
cause	O
insulin	B-GENE-Y
resistance	O
and	O
to	O
stimulate	O
liver	O
glycogenolysis	O
.	O

The	O
question	O
arises	O
whether	O
ET	B-GENE-Y
-	I-GENE-Y
1	I-GENE-Y
has	O
a	O
role	O
in	O
the	O
metabolic	O
changes	O
occurring	O
in	O
such	O
conditions	O
.	O

To	O
test	O
this	O
,	O
we	O
studied	O
the	O
possible	O
effect	O
of	O
the	O
endothelin	B-GENE-N
receptor	I-GENE-N
antagonist	O
,	O
bosentan	B-CHEMICAL
(	O
50	O
and	O
100	O
mg	O
kg	O
(	O
-	O
1	O
)	O
)	O
on	O
serum	O
glucose	B-CHEMICAL
and	O
insulin	B-GENE-N
levels	O
as	O
well	O
as	O
on	O
liver	O
glycogen	O
contents	O
in	O
normoglycemic	O
stressed	O
animals	O
.	O

In	O
addition	O
,	O
the	O
effect	O
of	O
bosentan	B-CHEMICAL
on	O
serum	O
glucose	B-CHEMICAL
and	O
insulin	B-GENE-N
levels	O
in	O
both	O
mild	O
and	O
severely	O
diabetic	O
rats	O
and	O
its	O
effect	O
on	O
insulin	B-GENE-N
-	O
induced	O
hypoglycemia	O
were	O
also	O
determined	O
.	O

Restraining	O
water	O
immersion	O
stress	O
was	O
used	O
as	O
a	O
model	O
for	O
severe	O
stress	O
reported	O
to	O
elevate	O
plasma	O
ET	B-GENE-Y
-	I-GENE-Y
1	I-GENE-Y
level	O
.	O

Mild	O
diabetes	O
was	O
induced	O
in	O
rats	O
by	O
intraperitoneal	O
injection	O
of	O
a	O
low	O
dose	O
of	O
streptozotocin	B-CHEMICAL
(	O
38	O
mg	O
kg	O
(	O
-	O
1	O
)	O
)	O
while	O
severe	O
diabetes	O
was	O
induced	O
by	O
intraperitoneal	O
injection	O
of	O
a	O
higher	O
dose	O
of	O
streptozotocin	B-CHEMICAL
(	O
45	O
mg	O
kg	O
(	O
-	O
1	O
)	O
)	O
.	O

Bosentan	B-CHEMICAL
partially	O
prevented	O
stress	O
-	O
induced	O
both	O
hyperglycemia	O
and	O
decrease	O
in	O
glycogen	O
content	O
while	O
it	O
completely	O
blocked	O
the	O
stress	O
-	O
induced	O
decrease	O
in	O
insulin	B-GENE-N
level	O
in	O
normoglycemic	O
stressed	O
rats	O
.	O

Bosentan	B-CHEMICAL
also	O
decreased	O
serum	O
glucose	B-CHEMICAL
level	O
without	O
any	O
effect	O
on	O
insulin	B-GENE-N
secretion	O
in	O
mild	O
diabetic	O
rats	O
and	O
potentiated	O
the	O
hypoglycemic	O
action	O
of	O
insulin	B-GENE-N
.	O

Modification	O
of	O
radiation	O
damage	O
to	O
mitochondrial	O
system	O
in	O
vivo	O
by	O
Podophyllum	O
hexandrum	O
:	O
mechanistic	O
aspects	O
.	O

The	O
present	O
study	O
was	O
undertaken	O
to	O
investigate	O
whether	O
RP	O
-	O
1	O
treatment	O
protected	O
mitochondrial	O
system	O
against	O
radiation	O
damage	O
and	O
also	O
to	O
unravel	O
the	O
mechanism	O
associated	O
with	O
this	O
process	O
.	O

Radioprotection	O
of	O
mitochondrial	O
system	O
by	O
Podophyllum	O
hexandrum	O
(	O
RP	O
-	O
1	O
)	O
was	O
investigated	O
to	O
understand	O
its	O
mechanism	O
of	O
action	O
.	O

Levels	O
of	O
superoxide	B-CHEMICAL
anion	O
(	O
O2	B-CHEMICAL
-	I-CHEMICAL
)	O
,	O
reduced	O
or	O
oxidized	O
glutathione	B-CHEMICAL
(	O
GSH	B-CHEMICAL
or	O
GSSG	B-CHEMICAL
)	O
,	O
thiobarbituric	B-CHEMICAL
acid	I-CHEMICAL
reactive	O
substance	O
(	O
TBARS	O
)	O
,	O
protein	O
carbonyl	O
(	O
PC	O
)	O
,	O
ATP	B-CHEMICAL
,	O
NADH	B-GENE-N
-	I-GENE-N
ubiquinone	I-GENE-N
oxidoreductase	I-GENE-N
(	O
complex	B-GENE-N
-	I-GENE-N
I	I-GENE-N
)	O
,	O
NADH	B-GENE-N
-	I-GENE-N
cytochrome	I-GENE-N
c	I-GENE-N
oxidoreductase	I-GENE-N
(	O
complex	B-GENE-N
I	I-GENE-N
/	I-GENE-N
II	I-GENE-N
)	O
,	O
succinate	B-GENE-N
-	I-GENE-N
cytochrome	I-GENE-N
c	I-GENE-N
oxidoreductase	I-GENE-N
(	O
complex	B-GENE-N
II	I-GENE-N
/	I-GENE-N
III	I-GENE-N
)	O
and	O
mitochondrial	O
membrane	O
potential	O
(	O
MMP	O
)	O
were	O
studied	O
in	O
mitochondria	O
isolated	O
from	O
liver	O
of	O
mice	O
belonging	O
to	O
various	O
treatment	O
groups	O
.	O

Whole	O
body	O
y	O
-	O
irradiation	O
(	O
10	O
Gy	O
)	O
significantly	O
(	O
p	O
<	O
0	O
.	O
01	O
)	O
increased	O
the	O
formation	O
of	O
O2	B-CHEMICAL
-	I-CHEMICAL
,	O
PC	O
,	O
and	O
TBARS	O
,	O
upto	O
24	O
h	O
as	O
compared	O
to	O
untreated	O
control	O
.	O

RP	O
-	O
1	O
treatment	O
(	O
200	O
mg	O
/	O
kg	O
b	O
.	O
w	O
.	O
)	O
to	O
mice	O
2	O
h	O
before	O
irradiation	O
reduced	O
the	O
radiation	O
-	O
induced	O
O2	B-CHEMICAL
-	I-CHEMICAL
generation	O
within	O
4	O
h	O
and	O
formation	O
of	O
TBARS	O
and	O
PC	O
upto	O
24	O
h	O
significantly	O
(	O
p	O
<	O
0	O
.	O
01	O
)	O
.	O

Singularly	O
irradiation	O
or	O
RP	O
-	O
1	O
treatment	O
significantly	O
(	O
p	O
<	O
0	O
.	O
01	O
)	O
increased	O
the	O
levels	O
of	O
glutathione	B-CHEMICAL
within	O
an	O
hour	O
,	O
as	O
compared	O
to	O
untreated	O
control	O
.	O

Pre	O
-	O
irradiation	O
administration	O
of	O
RP	O
-	O
1	O
enhanced	O
levels	O
of	O
GSH	B-CHEMICAL
induced	O
increase	O
in	O
complex	B-GENE-N
I	I-GENE-N
(	O
upto	O
16	O
h	O
)	O
,	O
complex	B-GENE-N
I	I-GENE-N
/	I-GENE-N
III	I-GENE-N
(	O
4	O
h	O
)	O
complex	B-GENE-N
II	I-GENE-N
/	I-GENE-N
III	I-GENE-N
activity	O
(	O
upto	O
24	O
h	O
;	O
p	O
<	O
0	O
.	O
01	O
)	O
and	O
inhibited	O
the	O
radiation	O
-	O
induced	O
decrease	O
in	O
MMP	O
significantly	O
(	O
24	O
h	O
;	O
p	O
<	O
0	O
.	O
01	O
)	O
.	O

The	O
present	O
study	O
indicates	O
that	O
RP	O
-	O
1	O
itself	O
modulates	O
several	O
mitichondrial	O
perameters	O
due	O
to	O
its	O
influence	O
on	O
the	O
biochemical	O
milieu	O
within	O
and	O
outside	O
the	O
cells	O
.	O

However	O
,	O
RP	O
-	O
1	O
treatment	O
before	O
irradiation	O
modulates	O
radiation	O
induced	O
perturbations	O
such	O
as	O
the	O
increase	O
in	O
electron	O
transport	O
chain	O
enzyme	O
activity	O
,	O
formation	O
of	O
O2	B-CHEMICAL
-	I-CHEMICAL
,	O
TBARS	O
and	O
PC	O
to	O
offer	O
radioprotection	O
.	O

Effects	O
of	O
minocycline	B-CHEMICAL
on	O
Fas	B-GENE-Y
-	O
mediated	O
fulminant	O
hepatitis	O
in	O
mice	O
.	O

1	O
.	O

Minocycline	B-CHEMICAL
has	O
anti	O
-	O
inflammatory	O
and	O
antiapoptotic	O
effects	O
on	O
cartilage	O
,	O
neurons	O
and	O
periodontal	O
tissues	O
,	O
and	O
both	O
properties	O
are	O
central	O
to	O
the	O
pharmaceutical	O
treatment	O
of	O
liver	O
diseases	O
.	O

We	O
investigated	O
the	O
effects	O
of	O
minocycline	B-CHEMICAL
on	O
fulminant	O
hepatitis	O
in	O
C57BL	O
/	O
6J	O
mice	O
induced	O
by	O
lethal	O
challenge	O
of	O
the	O
activating	O
anti	O
-	O
Fas	B-GENE-Y
antibody	O
,	O
Jo2	O
.	O

2	O
.	O

Intraperitoneal	O
injection	O
of	O
Jo2	O
(	O
0	O
.	O
6	O
microg	O
g	O
(	O
-	O
1	O
)	O
)	O
to	O
mice	O
resulted	O
in	O
fulminant	O
hepatitis	O
,	O
as	O
evidenced	O
by	O
increase	O
of	O
serum	B-GENE-N
alanine	I-GENE-N
/	I-GENE-N
aspartate	I-GENE-N
transaminase	I-GENE-N
activities	O
and	O
histopathological	O
alterations	O
in	O
liver	O
sections	O
,	O
as	O
well	O
as	O
animal	O
death	O
.	O

Nevertheless	O
,	O
mice	O
pretreated	O
with	O
three	O
doses	O
of	O
minocycline	B-CHEMICAL
(	O
5	O
mg	O
kg	O
(	O
-	O
1	O
)	O
)	O
resisted	O
this	O
lethal	O
effect	O
significantly	O
.	O

Minocycline	B-CHEMICAL
treatment	O
improved	O
the	O
survival	O
kinetics	O
,	O
although	O
to	O
a	O
lesser	O
extent	O
,	O
when	O
mice	O
were	O
challenged	O
simultaneously	O
with	O
Jo2	O
or	O
even	O
treated	O
30	O
min	O
after	O
the	O
lethal	O
challenge	O
.	O

3	O
.	O

Jo2	O
-	O
induced	O
activation	O
of	O
caspase	B-GENE-N
-	I-GENE-N
3	I-GENE-N
or	I-GENE-N
-	I-GENE-N
9	I-GENE-N
in	O
liver	O
tissues	O
was	O
inhibited	O
by	O
minocycline	B-CHEMICAL
pretreatment	O
,	O
and	O
yet	O
the	O
direct	O
addition	O
of	O
minocycline	B-CHEMICAL
to	O
liver	O
extracts	O
from	O
Jo2	O
-	O
challenged	O
mice	O
failed	O
to	O
block	O
caspase	B-GENE-N
activation	O
in	O
vitro	O
.	O

Moreover	O
,	O
minocycline	B-CHEMICAL
efficiently	O
suppressed	O
the	O
release	O
of	O
cytochrome	B-GENE-Y
c	I-GENE-Y
from	O
mitochondria	O
of	O
the	O
liver	O
tissues	O
from	O
Jo2	O
-	O
challenged	O
mice	O
.	O

In	O
contrast	O
,	O
caspase	B-GENE-Y
-	I-GENE-Y
8	I-GENE-Y
activation	O
and	O
Bid	B-GENE-Y
truncation	O
triggered	O
by	O
Jo2	O
were	O
not	O
diminished	O
by	O
minocycline	B-CHEMICAL
pretreatment	O
in	O
mouse	O
livers	O
.	O

4	O
.	O

Our	O
results	O
suggest	O
that	O
easing	O
of	O
Fas	B-GENE-Y
-	O
triggered	O
fulminant	O
hepatitis	O
by	O
minocycline	B-CHEMICAL
may	O
involve	O
a	O
mitochondrial	O
apoptotic	O
pathway	O
,	O
probably	O
through	O
preventing	O
cytochrome	B-GENE-Y
c	I-GENE-Y
release	O
and	O
thereby	O
blocking	O
downstream	O
caspase	B-GENE-N
activation	O
.	O

Role	O
of	O
hydrogen	B-CHEMICAL
sulfide	I-CHEMICAL
in	O
acute	O
pancreatitis	O
and	O
associated	O
lung	O
injury	O
.	O

Hydrogen	B-CHEMICAL
sulfide	I-CHEMICAL
(	O
H2S	B-CHEMICAL
)	O
is	O
a	O
naturally	O
occurring	O
gas	O
with	O
potent	O
vasodilator	O
activity	O
.	O

Cystathionine	B-GENE-Y
-	I-GENE-Y
gamma	I-GENE-Y
-	I-GENE-Y
lyase	I-GENE-Y
(	O
CSE	B-GENE-Y
)	O
and	O
cystathionine	B-GENE-Y
-	I-GENE-Y
beta	I-GENE-Y
-	I-GENE-Y
synthase	I-GENE-Y
(	O
CBS	B-GENE-Y
)	O
utilize	O
L	B-CHEMICAL
-	I-CHEMICAL
cysteine	I-CHEMICAL
as	O
substrate	O
to	O
form	O
H2S	B-CHEMICAL
.	O

Of	O
these	O
two	O
enzymes	O
,	O
cystathionine	B-GENE-Y
-	I-GENE-Y
gamma	I-GENE-Y
-	I-GENE-Y
lyase	I-GENE-Y
(	O
CSE	B-GENE-Y
)	O
is	O
believed	O
to	O
be	O
the	O
key	O
enzyme	O
that	O
forms	O
H2S	B-CHEMICAL
in	O
the	O
cardiovascular	O
system	O
.	O

Whilst	O
H2S	B-CHEMICAL
has	O
been	O
reported	O
to	O
relax	O
precontracted	O
rat	O
arteries	O
in	O
vitro	O
and	O
to	O
lower	O
blood	O
pressure	O
in	O
the	O
rat	O
,	O
its	O
effect	O
in	O
an	O
inflammatory	O
condition	O
such	O
as	O
acute	O
pancreatitis	O
has	O
not	O
previously	O
been	O
reported	O
.	O

In	O
this	O
paper	O
,	O
we	O
report	O
the	O
presence	O
of	O
H2S	B-CHEMICAL
synthesizing	O
enzyme	O
activity	O
and	O
CSE	B-GENE-Y
(	O
as	O
determined	O
by	O
mRNA	O
signal	O
)	O
in	O
the	O
pancreas	O
.	O

Also	O
,	O
prophylactic	O
,	O
as	O
well	O
as	O
therapeutic	O
,	O
treatment	O
with	O
the	O
CSE	B-GENE-Y
inhibitor	O
,	O
DL	B-CHEMICAL
-	I-CHEMICAL
propargylglycine	I-CHEMICAL
(	O
PAG	B-CHEMICAL
)	O
,	O
significantly	O
reduced	O
the	O
severity	O
of	O
caerulein	B-CHEMICAL
-	O
induced	O
pancreatitis	O
and	O
associated	O
lung	O
injury	O
,	O
as	O
determined	O
by	O
1	O
)	O
hyperamylasemia	O
[	O
plasma	O
amylase	B-GENE-N
(	O
U	O
/	O
L	O
)	O
(	O
control	O
,	O
1204	O
+	O
/	O
-	O
59	O
)	O
;	O
prophylactic	O
treatment	O
:	O
placebo	O
,	O
10635	O
+	O
/	O
-	O
305	O
;	O
PAG	B-CHEMICAL
,	O
7904	O
+	O
/	O
-	O
495	O
;	O
therapeutic	O
treatment	O
:	O
placebo	O
,	O
10427	O
+	O
/	O
-	O
470	O
;	O
PAG	B-CHEMICAL
,	O
7811	O
+	O
/	O
-	O
428	O
;	O
P	O
<	O
0	O
.	O
05	O
PAG	B-CHEMICAL
c	O
.	O
f	O
.	O
placebo	O
;	O
n	O
=	O
24	O
animals	O
in	O
each	O
group	O
]	O
;	O
2	O
)	O
neutrophil	O
sequestration	O
in	O
the	O
pancreas	O
[	O
pancreatic	O
myeloperoxidase	B-GENE-Y
oxidase	I-GENE-Y
(	O
MPO	B-GENE-Y
)	O
activity	O
(	O
fold	O
increase	O
over	O
control	O
)	O
(	O
prophylactic	O
treatment	O
:	O
placebo	O
,	O
5	O
.	O
78	O
+	O
/	O
-	O
0	O
.	O
63	O
;	O
PAG	B-CHEMICAL
,	O
2	O
.	O
97	O
+	O
/	O
-	O
0	O
.	O
39	O
;	O
therapeutic	O
treatment	O
:	O
placebo	O
,	O
5	O
.	O
48	O
+	O
/	O
-	O
0	O
.	O
52	O
;	O
PAG	B-CHEMICAL
,	O
3	O
.	O
03	O
+	O
/	O
-	O
0	O
.	O
47	O
;	O
P	O
<	O
0	O
.	O
05	O
PAG	B-CHEMICAL
c	O
.	O
f	O
.	O
placebo	O
;	O
n	O
=	O
24	O
animals	O
in	O
each	O
group	O
)	O
]	O
;	O
3	O
)	O
pancreatic	O
acinar	O
cell	O
injury	O
/	O
necrosis	O
;	O
4	O
)	O
lung	O
MPO	O
activity	O
(	O
fold	O
increase	O
over	O
control	O
)	O
[	O
prophylactic	O
treatment	O
:	O
placebo	O
,	O
1	O
.	O
99	O
+	O
/	O
-	O
0	O
.	O
16	O
;	O
PAG	B-CHEMICAL
,	O
1	O
.	O
34	O
+	O
/	O
-	O
0	O
.	O
14	O
;	O
therapeutic	O
treatment	O
:	O
placebo	O
,	O
2	O
.	O
03	O
+	O
/	O
-	O
0	O
.	O
12	O
;	O
PAG	B-CHEMICAL
,	O
1	O
.	O
41	O
+	O
/	O
-	O
0	O
.	O
97	O
;	O
P	O
<	O
0	O
.	O
05	O
PAG	B-CHEMICAL
c	O
.	O
f	O
.	O
placebo	O
;	O
n	O
=	O
24	O
animals	O
in	O
each	O
group	O
]	O
;	O
and	O
5	O
)	O
histological	O
evidence	O
of	O
lung	O
injury	O
.	O

These	O
effects	O
of	O
CSE	B-GENE-Y
blockade	O
suggest	O
an	O
important	O
proinflammatory	O
role	O
of	O
H2S	B-CHEMICAL
in	O
regulating	O
the	O
severity	O
of	O
pancreatitis	O
and	O
associated	O
lung	O
injury	O
and	O
raise	O
the	O
possibility	O
that	O
H2S	B-CHEMICAL
may	O
exert	O
similar	O
activity	O
in	O
other	O
forms	O
of	O
inflammation	O
.	O

Atypical	O
and	O
typical	O
antipsychotic	O
drug	O
interactions	O
with	O
the	O
dopamine	B-GENE-Y
D2	I-GENE-Y
receptor	I-GENE-Y
.	O

A	O
model	O
of	O
the	O
dopamine	B-GENE-Y
D2	I-GENE-Y
receptor	I-GENE-Y
was	O
used	O
to	O
study	O
the	O
receptor	O
interactions	O
of	O
dopamine	B-CHEMICAL
,	O
the	O
typical	O
antipsychotics	O
haloperidol	B-CHEMICAL
and	O
loxapine	B-CHEMICAL
,	O
and	O
the	O
atypical	O
antipsychotics	O
clozapine	B-CHEMICAL
and	O
melperone	B-CHEMICAL
.	O

The	O
atypical	O
antipsychotics	O
interacted	O
with	O
the	O
halogen	B-CHEMICAL
atom	O
of	O
the	O
ring	O
system	O
in	O
the	O
direction	O
of	O
the	O
transmembrane	O
helices	O
(	O
TMHs	O
)	O
2	O
,	O
3	O
and	O
7	O
,	O
while	O
the	O
typical	O
had	O
the	O
corresponding	O
halogen	B-CHEMICAL
atom	O
in	O
the	O
direction	O
of	O
TMH5	O
.	O

Molecular	O
dynamics	O
simulations	O
indicated	O
that	O
the	O
average	O
helical	O
displacement	O
upon	O
binding	O
increased	O
in	O
the	O
order	O
:	O
typical	O
<	O
atypical	O
<	O
dopamine	B-CHEMICAL
.	O

Upon	O
binding	O
,	O
the	O
atypical	O
induced	O
larger	O
displacements	O
into	O
TMH5	O
than	O
did	O
the	O
typical	O
.	O

The	O
typical	O
had	O
stronger	O
non	O
-	O
bonded	O
interactions	O
with	O
the	O
receptor	O
than	O
had	O
the	O
atypical	O
,	O
which	O
is	O
in	O
agreement	O
with	O
the	O
experimental	O
observation	O
that	O
the	O
atypical	O
antipsychotic	O
drugs	O
dissociate	O
faster	O
from	O
the	O
receptor	O
than	O
the	O
typical	O
antipsychotic	O
drugs	O
.	O

Pharmacokinetics	O
,	O
pharmacodynamics	O
,	O
and	O
safety	O
of	O
exenatide	O
in	O
patients	O
with	O
type	O
2	O
diabetes	O
mellitus	O
.	O

PURPOSE	O
:	O
The	O
pharmacology	O
and	O
tolerability	O
of	O
exenatide	O
in	O
patients	O
with	O
type	O
2	O
diabetes	O
mellitus	O
were	O
studied	O
.	O

METHODS	O
:	O
Two	O
randomized	O
,	O
single	O
-	O
blind	O
,	O
placebo	O
-	O
controlled	O
studies	O
were	O
conducted	O
.	O

Treatment	O
with	O
oral	O
antidiabetic	O
agents	O
was	O
stopped	O
14	O
days	O
before	O
study	O
initiation	O
.	O

In	O
the	O
first	O
study	O
(	O
study	O
A	O
)	O
,	O
eight	O
subjects	O
received	O
placebo	O
,	O
0	O
.	O
1	O
-	O
,	O
0	O
.	O
2	O
-	O
,	O
0	O
.	O
3	O
-	O
,	O
and	O
either	O
0	O
.	O
4	O
-	O
microg	O
/	O
kg	O
exenatide	O
or	O
placebo	O
five	O
minutes	O
before	O
a	O
meal	O
combined	O
with	O
liquid	O
acetaminophen	B-CHEMICAL
(	O
to	O
assess	O
the	O
rate	O
of	O
gastric	O
emptying	O
)	O
on	O
days	O
1	O
,	O
3	O
,	O
5	O
,	O
7	O
,	O
and	O
9	O
.	O

In	O
the	O
second	O
study	O
(	O
study	O
B	O
)	O
,	O
subjects	O
received	O
a	O
single	O
s	O
.	O
c	O
.	O
dose	O
of	O
exenatide	O
or	O
placebo	O
on	O
consecutive	O
days	O
.	O

Part	O
1	O
of	O
study	O
B	O
used	O
exenatide	O
doses	O
of	O
0	O
.	O
01	O
and	O
0	O
.	O
1	O
microg	O
/	O
kg	O
;	O
0	O
.	O
02	O
-	O
,	O
0	O
.	O
05	O
-	O
,	O
and	O
0	O
.	O
1	O
-	O
microg	O
/	O
kg	O
doses	O
were	O
given	O
in	O
part	O
2	O
.	O

After	O
an	O
overnight	O
fast	O
,	O
the	O
study	O
drug	O
was	O
injected	O
15	O
minutes	O
before	O
a	O
meal	O
(	O
part	O
1	O
)	O
and	O
before	O
a	O
meal	O
and	O
acetaminophen	B-CHEMICAL
(	O
part	O
2	O
)	O
.	O

Parts	O
1	O
and	O
2	O
of	O
study	O
B	O
enrolled	O
six	O
and	O
eight	O
patients	O
,	O
respectively	O
.	O

RESULTS	O
:	O
In	O
both	O
studies	O
,	O
plasma	O
exenatide	O
pharmacokinetic	O
profiles	O
appeared	O
dose	O
proportional	O
.	O

Exenatide	O
doses	O
of	O
0	O
.	O
02	O
-	O
0	O
.	O
2	O
microg	O
/	O
kg	O
dose	O
-	O
dependently	O
lowered	O
postprandial	O
glucose	B-CHEMICAL
excursions	O
.	O

Exenatide	O
suppressed	O
postprandial	O
plasma	O
glucagon	B-GENE-Y
and	O
slowed	O
gastric	O
emptying	O
.	O

There	O
were	O
no	O
serious	O
adverse	O
events	O
and	O
no	O
patient	O
withdrawals	O
related	O
to	O
treatment	O
.	O

Nausea	O
and	O
vomiting	O
were	O
the	O
most	O
common	O
adverse	O
events	O
and	O
were	O
mild	O
to	O
moderate	O
in	O
severity	O
at	O
doses	O
ranging	O
from	O
0	O
.	O
02	O
to	O
0	O
.	O
2	O
microg	O
/	O
kg	O
.	O

CONCLUSION	O
:	O
Administration	O
of	O
preprandial	O
exenatide	O
by	O
s	O
.	O
c	O
.	O
injection	O
resulted	O
in	O
dose	O
-	O
proportional	O
exenatide	O
pharmacokinetics	O
and	O
antidiabetic	O
pharmacodynamic	O
activity	O
.	O

At	O
doses	O
ranging	O
from	O
0	O
.	O
02	O
to	O
0	O
.	O
2	O
microg	O
/	O
kg	O
,	O
exenatide	O
dose	O
-	O
dependently	O
reduced	O
postprandial	O
plasma	O
glucose	B-CHEMICAL
excursion	O
by	O
insulinotropism	O
,	O
suppression	O
of	O
plasma	O
glucagon	B-GENE-Y
,	O
and	O
slowing	O
of	O
gastric	O
emptying	O
.	O

Sterol	B-GENE-N
transporters	I-GENE-N
:	O
targets	O
of	O
natural	O
sterols	B-CHEMICAL
and	O
new	O
lipid	O
lowering	O
drugs	O
.	O

Recent	O
insights	O
in	O
the	O
role	O
of	O
ATP	B-GENE-N
-	I-GENE-N
binding	I-GENE-N
cassette	I-GENE-N
(	I-GENE-N
ABC	I-GENE-N
)	I-GENE-N
transporters	I-GENE-N
ABCG5	B-GENE-Y
and	O
ABCG8	B-GENE-Y
,	O
the	O
discovery	O
of	O
ezetimibe	B-CHEMICAL
,	O
the	O
first	O
approved	O
direct	O
cholesterol	B-CHEMICAL
absorption	O
inhibitor	O
,	O
as	O
well	O
as	O
the	O
identification	O
of	O
Niemann	B-GENE-Y
-	I-GENE-Y
Pick	I-GENE-Y
C1	I-GENE-Y
Like	I-GENE-Y
1	I-GENE-Y
(	O
NPC1L1	B-GENE-Y
)	O
protein	O
as	O
sterol	B-CHEMICAL
transporter	O
in	O
the	O
gut	O
,	O
focused	O
attention	O
on	O
sterol	B-CHEMICAL
transport	O
processes	O
in	O
the	O
small	O
intestine	O
and	O
the	O
liver	O
.	O

The	O
identification	O
of	O
defective	O
structures	O
in	O
the	O
ABCG5	B-GENE-Y
or	O
ABCG8	B-GENE-Y
transporters	O
in	O
patients	O
with	O
the	O
rare	O
disease	O
of	O
sitosterolemia	O
elucidated	O
their	O
role	O
as	O
sterol	B-GENE-N
efflux	I-GENE-N
pumps	I-GENE-N
regulating	O
at	O
least	O
in	O
parts	O
the	O
intestinal	O
sterol	B-CHEMICAL
absorption	O
and	O
the	O
hepatic	O
sterol	B-CHEMICAL
output	O
.	O

ABCG5	B-GENE-Y
and	O
ABCG8	B-GENE-Y
themselves	O
are	O
regulated	O
by	O
cholesterol	B-CHEMICAL
via	O
liver	B-GENE-N
X	I-GENE-N
receptors	I-GENE-N
(	O
LXRs	B-GENE-N
)	O
,	O
which	O
are	O
also	O
activated	O
by	O
oxysterols	O
and	O
some	O
derivatives	O
of	O
plant	O
sterols	B-CHEMICAL
.	O

NPC1L1	B-GENE-Y
could	O
recently	O
be	O
identified	O
as	O
a	O
major	O
sterol	B-GENE-N
transporter	I-GENE-N
for	O
the	O
intestinal	O
uptake	O
of	O
cholesterol	B-CHEMICAL
as	O
well	O
as	O
plant	O
sterols	B-CHEMICAL
.	O

Studies	O
in	O
NPC1L1	B-GENE-Y
knockout	O
mice	O
indicate	O
that	O
this	O
transporter	O
is	O
essential	O
for	O
the	O
intestinal	O
uptake	O
of	O
sterols	B-CHEMICAL
and	O
that	O
NPC1L1	B-GENE-Y
might	O
also	O
be	O
involved	O
in	O
the	O
mechanism	O
of	O
action	O
of	O
ezetimibe	B-CHEMICAL
.	O

However	O
,	O
studies	O
with	O
photoreactive	O
cholesterol	B-CHEMICAL
as	O
well	O
as	O
with	O
photoreactive	O
ezetimibe	B-CHEMICAL
analogues	O
suggest	O
that	O
other	O
processes	O
might	O
also	O
be	O
involved	O
in	O
the	O
mechanism	O
of	O
action	O
of	O
ezetimibe	B-CHEMICAL
.	O

[	O
Change	O
of	O
dopamine	B-GENE-Y
transporter	I-GENE-Y
activity	O
(	O
DAT	B-GENE-Y
)	O
during	O
the	O
action	O
of	O
bupropion	B-CHEMICAL
(	O
in	O
depression	O
)	O
]	O
.	O

Bupropion	B-CHEMICAL
has	O
an	O
antidepressant	O
effect	O
through	O
blocking	O
the	O
dopamine	B-GENE-Y
transporter	I-GENE-Y
.	O

By	O
99mTc	O
-	O
TRODAT	O
-	O
SPECT	O
,	O
we	O
measured	O
the	O
baseline	O
DAT	B-GENE-Y
activity	O
of	O
depressed	O
patients	O
.	O

After	O
3	O
weeks	O
'	O
bupropion	B-CHEMICAL
treatment	O
we	O
studied	O
the	O
change	O
in	O
DAT	B-GENE-Y
activity	O
,	O
which	O
corresponds	O
to	O
the	O
occupancy	O
of	O
bupropion	B-CHEMICAL
.	O

The	O
average	O
occupancy	O
of	O
bupropion	B-CHEMICAL
on	O
DAT	B-GENE-Y
was	O
similar	O
to	O
the	O
international	O
findings	O
at	O
20	O
.	O
84	O
%	O
in	O
9	O
depressed	O
patients	O
.	O

A	O
phase	O
-	O
1	O
trial	O
of	O
bexarotene	B-CHEMICAL
and	O
denileukin	O
diftitox	O
in	O
patients	O
with	O
relapsed	O
or	O
refractory	O
cutaneous	O
T	O
-	O
cell	O
lymphoma	O
.	O

Denileukin	O
diftitox	O
,	O
a	O
genetically	O
engineered	O
fusion	O
protein	O
combining	O
the	O
enzymatically	O
active	O
domains	O
of	O
diphtheria	O
toxin	O
and	O
the	O
full	O
-	O
length	O
sequence	O
for	O
interleukin	B-GENE-Y
-	I-GENE-Y
2	I-GENE-Y
(	O
IL	B-GENE-Y
-	I-GENE-Y
2	I-GENE-Y
)	O
,	O
efficiently	O
targets	O
lymphoma	O
cells	O
expressing	O
the	O
high	O
-	O
affinity	O
IL	B-GENE-N
-	I-GENE-N
2	I-GENE-N
receptor	I-GENE-N
(	O
IL	B-GENE-N
-	I-GENE-N
2R	I-GENE-N
)	O
consisting	O
of	O
the	O
alpha	O
/	O
p55	B-GENE-Y
/	O
CD25	B-GENE-Y
,	O
beta	O
/	O
p75	B-GENE-Y
/	O
CD122	B-GENE-Y
,	O
and	O
gamma	O
/	O
p64	B-GENE-Y
/	O
CD132	B-GENE-Y
chains	O
.	O

In	O
vitro	O
studies	O
demonstrated	O
that	O
the	O
retinoid	B-GENE-N
X	I-GENE-N
receptor	I-GENE-N
(	O
RXR	B-GENE-N
)	O
retinoid	O
,	O
bexarotene	B-CHEMICAL
,	O
at	O
biologically	O
relevant	O
concentrations	O
of	O
10	O
(	O
-	O
6	O
)	O
M	O
to	O
10	O
(	O
-	O
8	O
)	O
M	O
,	O
upregulated	O
both	O
the	O
p55	B-GENE-Y
and	O
p75	B-GENE-Y
subunits	O
of	O
the	O
IL	B-GENE-N
-	I-GENE-N
2R	I-GENE-N
and	O
enhanced	O
5	O
-	O
to	O
10	O
-	O
fold	O
the	O
susceptibility	O
of	O
T	O
-	O
cell	O
leukemia	O
cells	O
to	O
denileukin	O
diftitox	O
.	O

To	O
determine	O
whether	O
this	O
biomodulatory	O
effect	O
could	O
be	O
recapitulated	O
in	O
vivo	O
,	O
we	O
treated	O
14	O
patients	O
with	O
relapsed	O
or	O
refractory	O
cutaneous	O
T	O
-	O
cell	O
lymphoma	O
with	O
escalating	O
doses	O
of	O
bexarotene	B-CHEMICAL
(	O
75	O
mg	O
/	O
day	O
-	O
300	O
mg	O
/	O
day	O
)	O
and	O
denileukin	O
diftitox	O
(	O
18	O
mcg	O
/	O
kg	O
per	O
day	O
x	O
3	O
days	O
every	O
21	O
days	O
)	O
in	O
a	O
phase	O
1	O
trial	O
.	O

Overall	O
response	O
was	O
67	O
%	O
(	O
4	O
complete	O
responses	O
,	O
4	O
partial	O
responses	O
)	O
.	O

Modulation	O
of	O
IL	B-GENE-N
-	I-GENE-N
2R	I-GENE-N
expression	O
was	O
observed	O
at	O
or	O
above	O
a	O
bexarotene	B-CHEMICAL
dose	O
of	O
150	O
mg	O
/	O
day	O
.	O

Four	O
patients	O
experienced	O
grade	O
2	O
or	O
3	O
leukopenia	O
,	O
and	O
2	O
had	O
grade	O
4	O
lymphopenia	O
.	O

Our	O
results	O
demonstrate	O
that	O
the	O
combination	O
of	O
denileukin	O
diftitox	O
and	O
bexarotene	B-CHEMICAL
is	O
well	O
tolerated	O
and	O
that	O
even	O
low	O
doses	O
(	O
150	O
mg	O
/	O
day	O
)	O
of	O
bexarotene	B-CHEMICAL
are	O
capable	O
of	O
in	O
vivo	O
upregulation	O
of	O
CD25	B-GENE-Y
expression	O
on	O
circulating	O
leukemia	O
cells	O
.	O

Crystal	O
structure	O
of	O
prostate	B-GENE-Y
-	I-GENE-Y
specific	I-GENE-Y
membrane	I-GENE-Y
antigen	I-GENE-Y
,	O
a	O
tumor	O
marker	O
and	O
peptidase	B-GENE-N
.	O

Prostate	B-GENE-Y
-	I-GENE-Y
specific	I-GENE-Y
membrane	I-GENE-Y
antigen	I-GENE-Y
(	O
PSMA	B-GENE-Y
)	O
is	O
highly	O
expressed	O
in	O
prostate	O
cancer	O
cells	O
and	O
nonprostatic	O
solid	O
tumor	O
neovasculature	O
and	O
is	O
a	O
target	O
for	O
anticancer	O
imaging	O
and	O
therapeutic	O
agents	O
.	O

PSMA	B-GENE-Y
acts	O
as	O
a	O
glutamate	B-GENE-N
carboxypeptidase	I-GENE-N
(	O
GCPII	B-GENE-Y
)	O
on	O
small	O
molecule	O
substrates	O
,	O
including	O
folate	B-CHEMICAL
,	O
the	O
anticancer	O
drug	O
methotrexate	B-CHEMICAL
,	O
and	O
the	O
neuropeptide	O
N	B-CHEMICAL
-	I-CHEMICAL
acetyl	I-CHEMICAL
-	I-CHEMICAL
l	I-CHEMICAL
-	I-CHEMICAL
aspartyl	I-CHEMICAL
-	I-CHEMICAL
l	I-CHEMICAL
-	I-CHEMICAL
glutamate	I-CHEMICAL
.	O

Here	O
we	O
present	O
the	O
3	O
.	O
5	O
-	O
A	O
crystal	O
structure	O
of	O
the	O
PSMA	B-GENE-N
ectodomain	I-GENE-N
,	O
which	O
reveals	O
a	O
homodimer	O
with	O
structural	O
similarity	O
to	O
transferrin	B-GENE-N
receptor	I-GENE-N
,	O
a	O
receptor	O
for	O
iron	B-CHEMICAL
-	O
loaded	O
transferrin	B-GENE-Y
that	O
lacks	O
protease	B-GENE-N
activity	O
.	O

Unlike	O
transferrin	B-GENE-N
receptor	I-GENE-N
,	O
the	O
protease	B-GENE-N
domain	I-GENE-N
of	O
PSMA	B-GENE-Y
contains	O
a	O
binuclear	O
zinc	B-CHEMICAL
site	O
,	O
catalytic	O
residues	O
,	O
and	O
a	O
proposed	O
substrate	O
-	O
binding	O
arginine	B-CHEMICAL
patch	O
.	O

Elucidation	O
of	O
the	O
PSMA	B-GENE-Y
structure	O
combined	O
with	O
docking	O
studies	O
and	O
a	O
proposed	O
catalytic	O
mechanism	O
provides	O
insight	O
into	O
the	O
recognition	O
of	O
inhibitors	O
and	O
the	O
natural	O
substrate	O
N	B-CHEMICAL
-	I-CHEMICAL
acetyl	I-CHEMICAL
-	I-CHEMICAL
l	I-CHEMICAL
-	I-CHEMICAL
aspartyl	I-CHEMICAL
-	I-CHEMICAL
l	I-CHEMICAL
-	I-CHEMICAL
glutamate	I-CHEMICAL
.	O

The	O
PSMA	B-GENE-Y
structure	O
will	O
facilitate	O
development	O
of	O
chemotherapeutics	O
,	O
cancer	O
-	O
imaging	O
agents	O
,	O
and	O
agents	O
for	O
treatment	O
of	O
neurological	O
disorders	O
.	O

Conversion	O
of	O
5	B-GENE-N
-	I-GENE-N
aminolevulinate	I-GENE-N
synthase	I-GENE-N
into	O
a	O
more	O
active	O
enzyme	O
by	O
linking	O
the	O
two	O
subunits	O
:	O
spectroscopic	O
and	O
kinetic	O
properties	O
.	O

The	O
two	O
active	O
sites	O
of	O
dimeric	O
5	B-GENE-N
-	I-GENE-N
aminolevulinate	I-GENE-N
synthase	I-GENE-N
(	O
ALAS	B-GENE-N
)	O
,	O
a	O
pyridoxal	B-CHEMICAL
5	I-CHEMICAL
'	I-CHEMICAL
-	I-CHEMICAL
phosphate	I-CHEMICAL
(	O
PLP	B-CHEMICAL
)	O
-	O
dependent	O
enzyme	O
,	O
are	O
located	O
on	O
the	O
subunit	O
interface	O
with	O
contribution	O
of	O
essential	O
amino	B-CHEMICAL
acids	I-CHEMICAL
from	O
each	O
subunit	O
.	O

Linking	O
the	O
two	O
subunits	O
into	O
a	O
single	O
polypeptide	O
chain	O
dimer	O
(	O
2XALAS	B-GENE-N
)	O
yielded	O
an	O
enzyme	O
with	O
an	O
approximate	O
sevenfold	O
greater	O
turnover	O
number	O
than	O
that	O
of	O
wild	O
-	O
type	O
ALAS	B-GENE-N
.	O

Spectroscopic	O
and	O
kinetic	O
properties	O
of	O
2XALAS	B-GENE-N
were	O
investigated	O
to	O
explore	O
the	O
differences	O
in	O
the	O
coenzyme	O
structure	O
and	O
kinetic	O
mechanism	O
relative	O
to	O
those	O
of	O
wild	O
-	O
type	O
ALAS	B-GENE-N
that	O
confer	O
a	O
more	O
active	O
enzyme	O
.	O

The	O
absorption	O
spectra	O
of	O
both	O
ALAS	B-GENE-N
and	O
2XALAS	B-GENE-N
had	O
maxima	O
at	O
410	O
and	O
330	O
nm	O
,	O
with	O
a	O
greater	O
A	O
(	O
410	O
)	O
/	O
A	O
(	O
330	O
)	O
ratio	O
at	O
pH	O
approximately	O
7	O
.	O
5	O
for	O
2XALAS	B-GENE-N
.	O

The	O
330	O
nm	O
absorption	O
band	O
showed	O
an	O
intense	O
fluorescence	O
at	O
385	O
nm	O
but	O
not	O
at	O
510	O
nm	O
,	O
indicating	O
that	O
the	O
330	O
nm	O
absorption	O
species	O
is	O
the	O
substituted	O
aldamine	B-CHEMICAL
rather	O
than	O
the	O
enolimine	B-CHEMICAL
form	O
of	O
the	O
Schiff	B-CHEMICAL
base	I-CHEMICAL
.	O

The	O
385	O
nm	O
emission	O
intensity	O
increased	O
with	O
increasing	O
pH	O
with	O
a	O
single	O
pK	O
of	O
approximately	O
8	O
.	O
5	O
for	O
both	O
enzymes	O
,	O
and	O
thus	O
the	O
410	O
and	O
330	O
nm	O
absorption	O
species	O
were	O
attributed	O
to	O
the	O
ketoenamine	B-CHEMICAL
and	O
substituted	O
aldamine	B-CHEMICAL
,	O
respectively	O
.	O

Transient	O
kinetic	O
analysis	O
of	O
the	O
formation	O
and	O
decay	O
of	O
the	O
quinonoid	B-CHEMICAL
intermediate	O
EQ	O
(	O
2	O
)	O
indicated	O
that	O
,	O
although	O
their	O
rates	O
were	O
similar	O
in	O
ALAS	B-GENE-N
and	O
2XALAS	B-GENE-N
,	O
accumulation	O
of	O
this	O
intermediate	O
was	O
greater	O
in	O
the	O
2XALAS	B-GENE-N
-	O
catalyzed	O
reaction	O
.	O

Collectively	O
,	O
these	O
results	O
suggest	O
that	O
ketoenamine	B-CHEMICAL
is	O
the	O
active	O
form	O
of	O
the	O
coenzyme	O
and	O
forms	O
a	O
more	O
prominent	O
coenzyme	O
structure	O
in	O
2XALAS	B-GENE-N
than	O
in	O
ALAS	B-GENE-N
at	O
pH	O
approximately	O
7	O
.	O
5	O
.	O

Regulation	O
of	O
the	O
expression	O
of	O
peptidylarginine	B-GENE-Y
deiminase	I-GENE-Y
type	I-GENE-Y
II	I-GENE-Y
gene	O
(	O
PADI2	B-GENE-Y
)	O
in	O
human	O
keratinocytes	O
involves	O
Sp1	B-GENE-Y
and	O
Sp3	B-GENE-Y
transcription	O
factors	O
.	O

Peptidylarginine	B-GENE-N
deiminases	I-GENE-N
(	O
PAD	B-GENE-N
)	O
convert	O
protein	O
-	O
bound	O
arginine	B-CHEMICAL
residues	O
into	O
citrulline	B-CHEMICAL
residues	O
in	O
a	O
Ca	B-CHEMICAL
(	I-CHEMICAL
2	I-CHEMICAL
+	I-CHEMICAL
)	I-CHEMICAL
ion	O
-	O
dependent	O
manner	O
.	O

Among	O
the	O
five	O
isoforms	O
(	O
PAD1	B-GENE-N
,	I-GENE-N
2	I-GENE-N
,	I-GENE-N
3	I-GENE-N
,	I-GENE-N
4	I-GENE-N
,	I-GENE-N
and	I-GENE-N
6	I-GENE-N
)	O
existing	O
in	O
rodents	O
and	O
humans	O
,	O
PAD2	B-GENE-Y
is	O
the	O
most	O
widely	O
expressed	O
in	O
both	O
species	O
,	O
tissues	O
,	O
and	O
organs	O
.	O

In	O
order	O
to	O
study	O
the	O
mechanisms	O
regulating	O
the	O
expression	O
of	O
the	O
human	B-GENE-Y
PAD2	I-GENE-Y
gene	O
,	O
PADI2	B-GENE-Y
,	O
we	O
characterized	O
its	O
promoter	O
region	O
using	O
transfected	O
human	O
keratinocytes	O
.	O

A	O
series	O
of	O
reporter	O
gene	O
constructions	O
derived	O
from	O
the	O
2	O
kb	O
region	O
upstream	O
of	O
the	O
transcription	B-GENE-N
initiation	I-GENE-N
site	I-GENE-N
defined	O
a	O
minimal	O
promoter	O
sequence	O
from	O
nucleotides	O
-	O
132	O
to	O
-	O
41	O
.	O

This	O
PADI2	B-GENE-Y
region	O
is	O
GC	O
-	O
rich	O
and	O
lacks	O
canonical	O
TATA	B-GENE-N
and	O
CAAT	B-GENE-N
boxes	I-GENE-N
.	O

Investigation	O
of	O
cis	B-GENE-N
-	I-GENE-N
acting	I-GENE-N
elements	I-GENE-N
in	O
the	O
region	O
,	O
further	O
deletion	O
analyses	O
and	O
electrophoretic	O
mobility	O
shift	O
assays	O
using	O
specific	O
antibodies	O
revealed	O
four	O
Sp1	B-GENE-N
-	I-GENE-N
binding	I-GENE-N
sites	I-GENE-N
and	O
identified	O
Sp1	B-GENE-Y
and	O
Sp3	B-GENE-Y
as	O
binding	O
factors	O
important	O
for	O
the	O
promoter	O
activity	O
.	O

These	O
results	O
suggest	O
that	O
Sp1	B-GENE-Y
/	O
Sp3	B-GENE-Y
cooperation	O
may	O
provide	O
a	O
mechanism	O
to	O
control	O
the	O
transcription	O
of	O
PADI2	B-GENE-Y
.	O

Activator	B-GENE-Y
of	I-GENE-Y
G	I-GENE-Y
protein	I-GENE-Y
signaling	I-GENE-Y
3	I-GENE-Y
regulates	O
opiate	O
activation	O
of	O
protein	B-GENE-N
kinase	I-GENE-N
A	I-GENE-N
signaling	O
and	O
relapse	O
of	O
heroin	B-CHEMICAL
-	O
seeking	O
behavior	O
.	O

The	O
nucleus	O
accumbens	O
(	O
NAc	O
)	O
is	O
central	O
to	O
heroin	B-CHEMICAL
addiction	O
.	O

Activation	O
of	O
opiate	B-GENE-N
receptors	I-GENE-N
in	O
the	O
NAc	O
dissociates	O
G	B-GENE-N
(	I-GENE-N
i	I-GENE-N
/	I-GENE-N
o	I-GENE-N
)	I-GENE-N
into	I-GENE-N
alpha	I-GENE-N
and	I-GENE-N
betagamma	I-GENE-N
subunits	O
.	O

Galpha	B-GENE-N
(	I-GENE-N
i	I-GENE-N
)	I-GENE-N
inhibits	O
cAMP	B-CHEMICAL
production	O
,	O
but	O
betagamma	O
regulates	O
several	O
molecular	O
pathways	O
,	O
including	O
protein	B-GENE-N
kinase	I-GENE-N
A	I-GENE-N
(	O
PKA	B-GENE-N
)	O
.	O

We	O
show	O
in	O
NAc	O
/	O
striatal	O
neurons	O
that	O
opiates	O
paradoxically	O
activate	O
PKA	B-GENE-N
signaling	O
by	O
means	O
of	O
betagamma	O
dimers	O
.	O

Activation	O
requires	O
Galpha	B-GENE-Y
(	I-GENE-Y
i3	I-GENE-Y
)	I-GENE-Y
and	O
an	O
activator	B-GENE-Y
of	I-GENE-Y
G	I-GENE-Y
protein	I-GENE-Y
signaling	I-GENE-Y
3	I-GENE-Y
(	O
AGS3	B-GENE-Y
)	O
.	O

AGS3	B-GENE-Y
competes	O
with	O
betagamma	O
for	O
binding	O
to	O
Galpha	B-GENE-Y
(	I-GENE-Y
i3	I-GENE-Y
)	I-GENE-Y
-	O
GDP	O
and	O
enhances	O
the	O
action	O
of	O
unbound	O
betagamma	O
.	O

AGS3	B-GENE-Y
and	O
Galpha	B-GENE-Y
(	I-GENE-Y
i3	I-GENE-Y
)	I-GENE-Y
knockdown	O
prevents	O
opiate	O
activation	O
of	O
PKA	B-GENE-N
signaling	O
.	O

In	O
rats	O
self	O
-	O
administering	O
heroin	B-CHEMICAL
,	O
AGS3	B-GENE-Y
antisense	O
in	O
the	O
NAc	O
core	O
,	O
but	O
not	O
shell	O
,	O
eliminates	O
reinstatement	O
of	O
heroin	B-CHEMICAL
-	O
seeking	O
behavior	O
,	O
a	O
model	O
of	O
human	O
relapse	O
.	O

Thus	O
,	O
Galpha	B-GENE-N
(	I-GENE-N
i3	I-GENE-N
)	I-GENE-N
/	I-GENE-N
betagamma	I-GENE-N
/	O
AGS3	B-GENE-Y
appears	O
to	O
mediate	O
mu	B-GENE-Y
opiate	I-GENE-Y
receptor	I-GENE-Y
activation	O
of	O
PKA	B-GENE-N
signaling	O
as	O
well	O
as	O
heroin	B-CHEMICAL
-	O
seeking	O
behavior	O
.	O

2	B-CHEMICAL
-	I-CHEMICAL
[	I-CHEMICAL
4	I-CHEMICAL
-	I-CHEMICAL
(	I-CHEMICAL
3	I-CHEMICAL
,	I-CHEMICAL
4	I-CHEMICAL
-	I-CHEMICAL
Dimethylphenyl	I-CHEMICAL
)	I-CHEMICAL
piperazin	I-CHEMICAL
-	I-CHEMICAL
1	I-CHEMICAL
-	I-CHEMICAL
ylmethyl	I-CHEMICAL
]	I-CHEMICAL
-	I-CHEMICAL
1H	I-CHEMICAL
benzoimidazole	I-CHEMICAL
(	O
A	B-CHEMICAL
-	I-CHEMICAL
381393	I-CHEMICAL
)	O
,	O
a	O
selective	O
dopamine	B-GENE-Y
D4	I-GENE-Y
receptor	I-GENE-Y
antagonist	O
.	O

2	B-CHEMICAL
-	I-CHEMICAL
[	I-CHEMICAL
4	I-CHEMICAL
-	I-CHEMICAL
(	I-CHEMICAL
3	I-CHEMICAL
,	I-CHEMICAL
4	I-CHEMICAL
-	I-CHEMICAL
Dimethylphenlyl	I-CHEMICAL
)	I-CHEMICAL
piperazin	I-CHEMICAL
-	I-CHEMICAL
1	I-CHEMICAL
-	I-CHEMICAL
ylmethyl	I-CHEMICAL
]	I-CHEMICAL
-	I-CHEMICAL
1H	I-CHEMICAL
benzoimidazole	I-CHEMICAL
(	O
A	B-CHEMICAL
-	I-CHEMICAL
381393	I-CHEMICAL
)	O
was	O
identified	O
as	O
a	O
potent	O
dopamine	B-GENE-Y
D4	I-GENE-Y
receptor	I-GENE-Y
antagonist	O
with	O
excellent	O
receptor	O
selectivity	O
.	O

[	B-CHEMICAL
3H	I-CHEMICAL
]	I-CHEMICAL
-	I-CHEMICAL
spiperone	I-CHEMICAL
competition	O
binding	O
assays	O
showed	O
that	O
A	B-CHEMICAL
-	I-CHEMICAL
381393	I-CHEMICAL
potently	O
bound	O
to	O
membrane	O
from	O
cells	O
expressing	O
recombinant	O
human	B-GENE-N
dopamine	I-GENE-N
D4	I-GENE-N
.	I-GENE-N
4	I-GENE-N
receptor	I-GENE-N
(	O
Ki	O
=	O
1	O
.	O
5	O
nM	O
)	O
,	O
which	O
was	O
20	O
-	O
fold	O
higher	O
than	O
that	O
of	O
clozapine	B-CHEMICAL
(	O
Ki	O
=	O
30	O
.	O
4	O
nM	O
)	O
.	O

A	B-CHEMICAL
-	I-CHEMICAL
381393	I-CHEMICAL
exhibited	O
highly	O
selective	O
binding	O
for	O
the	O
dopamine	B-GENE-N
D4	I-GENE-N
.	I-GENE-N
4	I-GENE-N
receptor	I-GENE-N
(	O
>	O
2700	O
-	O
fold	O
)	O
when	O
compared	O
to	O
D1	B-GENE-N
,	I-GENE-N
D2	I-GENE-N
,	I-GENE-N
D3	I-GENE-N
and	I-GENE-N
D5	I-GENE-N
dopamine	I-GENE-N
receptors	I-GENE-N
.	O

Furthermore	O
,	O
in	O
comparison	O
to	O
clozapine	B-CHEMICAL
and	O
L	B-CHEMICAL
-	I-CHEMICAL
745870	I-CHEMICAL
,	O
A	B-CHEMICAL
-	I-CHEMICAL
381393	I-CHEMICAL
exhibits	O
better	O
receptor	O
selectivity	O
,	O
showing	O
no	O
affinity	O
up	O
to	O
10	O
microM	O
for	O
a	O
panel	O
of	O
more	O
than	O
70	O
receptors	O
and	O
channels	O
,	O
with	O
the	O
exception	O
of	O
moderate	O
affinity	O
for	O
5	B-GENE-Y
-	I-GENE-Y
HT2A	I-GENE-Y
(	O
Ki	O
=	O
370	O
nM	O
)	O
.	O

A	B-CHEMICAL
-	I-CHEMICAL
381393	I-CHEMICAL
potently	O
inhibited	O
the	O
functional	O
activity	O
of	O
agonist	O
-	O
induced	O
GTP	B-CHEMICAL
-	O
gamma	O
-	O
S	O
binding	O
assay	O
and	O
1	O
microM	O
dopamine	B-CHEMICAL
induced	O
-	O
Ca2	B-CHEMICAL
+	I-CHEMICAL
flux	O
in	O
human	B-GENE-N
dopamine	I-GENE-N
D4	I-GENE-N
.	I-GENE-N
4	I-GENE-N
receptor	I-GENE-N
expressing	O
cells	O
,	O
but	O
not	O
in	O
human	B-GENE-N
dopamine	I-GENE-N
D2L	I-GENE-N
or	I-GENE-N
D3	I-GENE-N
receptor	I-GENE-N
cells	O
.	O

In	O
contrast	O
to	O
L	B-CHEMICAL
-	I-CHEMICAL
745870	I-CHEMICAL
,	O
A	B-CHEMICAL
-	I-CHEMICAL
381393	I-CHEMICAL
did	O
not	O
exhibit	O
any	O
significant	O
intrinsic	O
activity	O
in	O
a	O
D4	B-GENE-N
.	I-GENE-N
4	I-GENE-N
receptor	I-GENE-N
.	O

In	O
vivo	O
,	O
A	B-CHEMICAL
-	I-CHEMICAL
381393	I-CHEMICAL
has	O
good	O
brain	O
penetration	O
after	O
subcutaneous	O
administration	O
.	O

A	B-CHEMICAL
-	I-CHEMICAL
381393	I-CHEMICAL
inhibited	O
penile	O
erection	O
induced	O
by	O
the	O
selective	O
D4	O
agonist	O
PD168077	B-CHEMICAL
in	O
conscious	O
rats	O
.	O

Thus	O
,	O
A	B-CHEMICAL
-	I-CHEMICAL
381393	I-CHEMICAL
is	O
a	O
novel	O
selective	O
D4	O
antagonist	O
that	O
will	O
enhance	O
the	O
ability	O
to	O
study	O
dopamine	B-GENE-N
D4	I-GENE-N
receptors	I-GENE-N
both	O
in	O
vitro	O
and	O
in	O
vivo	O
.	O

Review	O
article	O
:	O
5	B-CHEMICAL
-	I-CHEMICAL
hydroxytryptamine	I-CHEMICAL
agonists	O
and	O
antagonists	O
in	O
the	O
modulation	O
of	O
gastrointestinal	O
motility	O
and	O
sensation	O
:	O
clinical	O
implications	O
.	O

Serotonin	B-CHEMICAL
(	O
5	B-CHEMICAL
-	I-CHEMICAL
hydroxytryptamine	I-CHEMICAL
;	O
5	B-CHEMICAL
-	I-CHEMICAL
HT	I-CHEMICAL
)	O
is	O
found	O
in	O
the	O
enteric	O
nervous	O
system	O
where	O
it	O
has	O
been	O
implicated	O
in	O
controlling	O
gastrointestinal	O
motor	O
function	O
.	O

A	O
number	O
of	O
receptor	O
or	O
recognition	O
sites	O
have	O
been	O
identified	O
in	O
the	O
gut	O
,	O
but	O
recently	O
most	O
attention	O
has	O
focused	O
on	O
the	O
5	B-GENE-Y
-	I-GENE-Y
HT3	I-GENE-Y
and	O
5	B-GENE-Y
-	I-GENE-Y
HT4	I-GENE-Y
receptors	O
.	O

The	O
functional	O
role	O
of	O
the	O
5	B-GENE-Y
-	I-GENE-Y
HT3	I-GENE-Y
receptor	O
remains	O
incompletely	O
understood	O
,	O
but	O
it	O
is	O
probably	O
involved	O
in	O
the	O
modulation	O
of	O
colonic	O
motility	O
and	O
visceral	O
pain	O
in	O
the	O
gut	O
.	O

A	O
number	O
of	O
selective	O
5	B-GENE-Y
-	I-GENE-Y
HT3	I-GENE-Y
antagonists	O
have	O
been	O
developed	O
including	O
ondansetron	B-CHEMICAL
,	O
granisetron	B-CHEMICAL
,	O
tropisetron	B-CHEMICAL
renzapride	B-CHEMICAL
and	O
zacopride	B-CHEMICAL
.	O

While	O
the	O
substituted	O
benzamide	B-CHEMICAL
prokinetics	O
(	O
for	O
example	O
,	O
metoclopramide	B-CHEMICAL
,	O
cisapride	B-CHEMICAL
)	O
also	O
block	O
5	B-GENE-Y
-	I-GENE-Y
HT3	I-GENE-Y
receptors	O
in	O
high	O
concentrations	O
,	O
their	O
prokinetic	O
action	O
is	O
believed	O
to	O
be	O
on	O
the	O
basis	O
of	O
their	O
agonist	O
effects	O
on	O
the	O
putative	O
5	B-GENE-Y
-	I-GENE-Y
HT4	I-GENE-Y
receptor	O
.	O

Some	O
5	B-GENE-Y
-	I-GENE-Y
HT3	I-GENE-Y
antagonists	O
have	O
5	B-GENE-Y
-	I-GENE-Y
HT4	I-GENE-Y
agonist	O
activity	O
(	O
for	O
example	O
,	O
renzapride	B-CHEMICAL
,	O
zacopride	B-CHEMICAL
)	O
and	O
others	O
do	O
not	O
(	O
for	O
example	O
,	O
ondansetron	B-CHEMICAL
,	O
granisetron	B-CHEMICAL
)	O
,	O
while	O
tropisetron	B-CHEMICAL
in	O
high	O
concentrations	O
is	O
a	O
5	B-GENE-Y
-	I-GENE-Y
HT4	I-GENE-Y
antagonist	O
.	O

Based	O
on	O
the	O
pharmacological	O
data	O
,	O
it	O
has	O
been	O
suggested	O
that	O
specific	O
5	B-CHEMICAL
-	I-CHEMICAL
HT	I-CHEMICAL
antagonists	O
and	O
agonists	O
may	O
prove	O
to	O
be	O
beneficial	O
in	O
a	O
number	O
of	O
gastrointestinal	O
disorders	O
including	O
the	O
irritable	O
bowel	O
syndrome	O
,	O
functional	O
dyspepsia	O
,	O
non	O
-	O
cardiac	O
chest	O
pain	O
,	O
gastrooesophageal	O
reflux	O
and	O
refractory	O
nausea	O
.	O

In	O
this	O
review	O
,	O
the	O
rationale	O
for	O
the	O
use	O
of	O
these	O
compounds	O
is	O
discussed	O
,	O
and	O
the	O
available	O
experimental	O
evidence	O
is	O
summarized	O
.	O

Niacin	B-CHEMICAL
mediates	O
lipolysis	O
in	O
adipose	O
tissue	O
through	O
its	O
G	B-GENE-Y
-	I-GENE-Y
protein	I-GENE-Y
coupled	I-GENE-Y
receptor	I-GENE-Y
HM74A	I-GENE-Y
.	O

A	O
G	B-GENE-N
-	I-GENE-N
protein	I-GENE-N
coupled	I-GENE-N
receptor	I-GENE-N
to	O
niacin	B-CHEMICAL
(	O
nicotinic	B-CHEMICAL
acid	I-CHEMICAL
)	O
was	O
identified	O
recently	O
but	O
the	O
physiological	O
/	O
pharmacological	O
role	O
of	O
the	O
receptor	O
remains	O
poorly	O
defined	O
.	O

We	O
present	O
our	O
studies	O
to	O
demonstrate	O
that	O
HM74A	B-GENE-N
,	O
but	O
not	O
HM74	B-GENE-N
,	O
binds	O
niacin	B-CHEMICAL
at	O
high	O
affinities	O
and	O
effectively	O
mediates	O
Gi	B-GENE-N
signaling	O
events	O
in	O
human	O
embryonic	O
kidney	O
HEK293	O
cells	O
as	O
well	O
as	O
in	O
3T3L1	O
adipocytes	O
expressing	O
HM74A	B-GENE-N
.	O

Furthermore	O
,	O
HM74A	B-GENE-Y
,	O
but	O
not	O
HM74	B-GENE-Y
,	O
expressed	O
in	O
differentiated	O
3T3L1	O
adipocytes	O
effectively	O
mediated	O
inhibition	O
of	O
lipolysis	O
by	O
niacin	B-CHEMICAL
.	O

Our	O
results	O
provided	O
direct	O
evidence	O
indicating	O
that	O
HM74A	B-GENE-Y
,	O
but	O
not	O
HM74	B-GENE-Y
,	O
was	O
sufficient	O
to	O
mediate	O
anti	O
-	O
lipolytic	O
effect	O
of	O
niacin	B-CHEMICAL
in	O
adipose	O
tissue	O
.	O

Islet	O
cell	O
antibodies	O
in	O
normal	O
French	O
schoolchildren	O
.	O

Islet	O
-	O
cell	O
antibodies	O
have	O
been	O
reported	O
to	O
be	O
of	O
predictive	O
value	O
for	O
the	O
future	O
development	O
of	O
Type	O
1	O
(	O
insulin	B-GENE-Y
-	O
dependent	O
)	O
diabetes	O
in	O
first	O
degree	O
relatives	O
of	O
diabetic	O
patients	O
with	O
the	O
risk	O
increasing	O
in	O
these	O
subjects	O
with	O
the	O
islet	O
-	O
cell	O
antibodies	O
titre	O
.	O

However	O
,	O
very	O
little	O
is	O
known	O
about	O
islet	O
-	O
cell	O
antibodies	O
in	O
background	O
populations	O
.	O

Sera	O
(	O
n	O
=	O
8363	O
)	O
from	O
schoolchildren	O
(	O
6	O
-	O
17	O
years	O
)	O
in	O
the	O
French	O
background	O
population	O
were	O
screened	O
for	O
the	O
presence	O
of	O
islet	O
-	O
cell	O
antibodies	O
by	O
the	O
indirect	O
immunofluorescence	O
technique	O
.	O

Islet	O
-	O
cell	O
antibodies	O
greater	O
than	O
4	O
.	O
5	O
Juvenile	O
Diabetes	O
Foundation	O
units	O
were	O
found	O
in	O
150	O
sera	O
(	O
prevalence	O
rate	O
1	O
.	O
8	O
%	O
;	O
95	O
%	O
confidence	O
interval	O
1	O
.	O
5	O
-	O
2	O
.	O
1	O
%	O
)	O
.	O

Only	O
17	O
sera	O
demonstrated	O
islet	O
-	O
cell	O
antibody	O
titre	O
greater	O
than	O
or	O
equal	O
to	O
24	O
JDF	O
units	O
.	O

No	O
particular	O
feature	O
was	O
found	O
to	O
be	O
significantly	O
different	O
between	O
islet	O
-	O
cell	O
antibody	O
-	O
positive	O
and	O
islet	O
-	O
cell	O
antibody	O
-	O
negative	O
children	O
(	O
age	O
,	O
family	O
history	O
of	O
diabetes	O
,	O
fasting	O
plasma	O
glucose	B-CHEMICAL
,	O
insulin	O
autoantibodies	O
)	O
.	O

A	O
second	O
blood	O
sample	O
was	O
obtained	O
from	O
80	O
of	O
150	O
islet	O
-	O
cell	O
antibody	O
positive	O
children	O
after	O
a	O
mean	O
interval	O
of	O
8	O
months	O
.	O

Only	O
11	O
sera	O
became	O
less	O
than	O
4	O
.	O
5	O
JDF	O
units	O
with	O
islet	O
-	O
cell	O
antibody	O
titres	O
being	O
stable	O
in	O
the	O
remaining	O
sera	O
,	O
including	O
the	O
high	O
-	O
titre	O
positive	O
sera	O
(	O
greater	O
than	O
or	O
equal	O
to	O
24	O
JDF	O
units	O
)	O
.	O

HLA	B-GENE-Y
-	I-GENE-Y
DQB	I-GENE-Y
typing	O
was	O
performed	O
by	O
restriction	O
mapping	O
techniques	O
in	O
80	O
islet	O
-	O
cell	O
antibody	O
-	O
positive	O
,	O
in	O
93	O
islet	O
-	O
cell	O
antibody	O
-	O
negative	O
and	O
in	O
213	O
Type	O
1	O
diabetic	O
children	O
.	O

The	O
distribution	O
of	O
the	O
susceptibility	O
alleles	O
(	O
DQB1	B-GENE-Y
-	O
Asp57	O
-	O
negative	O
)	O
was	O
not	O
significantly	O
different	O
between	O
islet	O
-	O
cell	O
antibody	O
-	O
positive	O
and	O
islet	O
-	O
cell	O
antibody	O
-	O
negative	O
children	O
.	O
(	O
ABSTRACT	O
TRUNCATED	O
AT	O
250	O
WORDS	O
)	O

Effect	O
of	O
gene	O
disruptions	O
of	O
the	O
TCA	B-CHEMICAL
cycle	O
on	O
production	O
of	O
succinic	B-CHEMICAL
acid	I-CHEMICAL
in	O
Saccharomyces	O
cerevisiae	O
.	O

Succinate	B-CHEMICAL
is	O
the	O
main	O
taste	O
component	O
produced	O
by	O
yeasts	O
during	O
sake	O
(	O
Japanese	O
rice	O
wine	O
)	O
fermentation	O
.	O

The	O
pathway	O
leading	O
to	O
accumulation	O
of	O
succinate	B-CHEMICAL
was	O
examined	O
in	O
liquid	O
culture	O
in	O
the	O
presence	O
of	O
a	O
high	O
concentration	O
(	O
15	O
%	O
)	O
of	O
glucose	B-CHEMICAL
under	O
aerobic	O
and	O
anaerobic	O
conditions	O
using	O
a	O
series	O
of	O
Saccharomyces	O
cerevisiae	O
strains	O
in	O
which	O
various	O
genes	O
that	O
encode	O
the	O
expression	O
of	O
enzymes	O
required	O
in	O
TCA	B-CHEMICAL
cycle	O
were	O
disrupted	O
.	O

When	O
cultured	O
in	O
YPD	O
medium	O
containing	O
15	O
%	O
glucose	B-CHEMICAL
under	O
aerobic	O
conditions	O
,	O
the	O
KGD1	B-GENE-Y
(	O
alpha	B-GENE-Y
-	I-GENE-Y
ketoglutarate	I-GENE-Y
dehydrogenase	I-GENE-Y
)	O
gene	O
disrupted	O
mutant	O
produced	O
a	O
lower	O
level	O
of	O
succinate	B-CHEMICAL
than	O
the	O
wild	O
-	O
type	O
strain	O
,	O
while	O
the	O
SDH1	B-GENE-Y
(	O
succinate	B-GENE-Y
dehydrogenase	I-GENE-Y
)	O
gene	O
-	O
disrupted	O
mutant	O
produced	O
an	O
increased	O
level	O
of	O
succinate	B-CHEMICAL
.	O

On	O
the	O
other	O
hand	O
,	O
the	O
FUM1	B-GENE-Y
(	O
fumarase	B-GENE-Y
)	O
gene	O
disrupted	O
mutant	O
produced	O
significantly	O
higher	O
levels	O
of	O
fumarate	B-CHEMICAL
but	O
did	O
not	O
form	O
malate	B-CHEMICAL
at	O
all	O
.	O

These	O
results	O
indicate	O
that	O
succinate	B-CHEMICAL
,	O
fumarate	B-CHEMICAL
and	O
malate	B-CHEMICAL
are	O
mainly	O
synthesized	O
through	O
the	O
TCA	B-CHEMICAL
cycle	O
(	O
oxidative	O
direction	O
)	O
even	O
in	O
the	O
presence	O
of	O
glucose	B-CHEMICAL
at	O
a	O
concentration	O
as	O
high	O
as	O
15	O
%	O
.	O

When	O
the	O
growth	O
condition	O
was	O
shifted	O
from	O
aerobic	O
to	O
anaerobic	O
,	O
the	O
increased	O
level	O
of	O
succinate	B-CHEMICAL
in	O
SDH1	B-GENE-Y
disruptants	O
was	O
no	O
longer	O
observed	O
,	O
whereas	O
the	O
decreased	O
level	O
of	O
succinate	B-CHEMICAL
in	O
the	O
KGD1	B-GENE-Y
diruptant	O
was	O
still	O
observed	O
.	O

A	O
double	O
mutant	O
of	O
the	O
two	O
fumarate	B-GENE-N
reductase	I-GENE-N
isozyme	O
genes	O
(	O
OSM1	B-GENE-Y
and	O
FRDS	B-GENE-Y
)	O
showed	O
a	O
succinate	B-CHEMICAL
productivity	O
of	O
50	O
%	O
as	O
compared	O
to	O
the	O
parent	O
when	O
cells	O
were	O
incubated	O
in	O
glucose	B-CHEMICAL
-	O
buffered	O
solution	O
.	O

These	O
results	O
indicate	O
that	O
succinate	B-CHEMICAL
could	O
be	O
synthesized	O
through	O
two	O
pathways	O
,	O
namely	O
,	O
alpha	B-CHEMICAL
-	I-CHEMICAL
ketoglutarate	I-CHEMICAL
oxidation	O
via	O
the	O
TCA	B-CHEMICAL
cycle	O
and	O
fumarate	B-CHEMICAL
reduction	O
under	O
anaerobic	O
conditions	O
.	O

The	O
unexpected	O
side	O
effects	O
of	O
new	O
nonsteroidal	O
anti	O
-	O
inflammatory	O
drugs	O
.	O

Conventional	O
nonselective	O
NSAIDs	O
are	O
classically	O
associated	O
with	O
a	O
risk	O
of	O
gastrointestinal	O
disorders	O
.	O

These	O
drugs	O
have	O
a	O
broad	O
range	O
of	O
relative	O
selectivity	O
towards	O
the	O
COX	B-GENE-N
family	O
,	O
mainly	O
towards	O
two	O
isoforms	O
of	O
these	O
enzymes	O
:	O
COX	B-GENE-N
-	I-GENE-N
1	I-GENE-N
and	I-GENE-N
-	I-GENE-N
2	I-GENE-N
.	O

As	O
examples	O
,	O
ketorolac	B-CHEMICAL
,	O
flurbiprofen	B-CHEMICAL
,	O
ketoprofen	B-CHEMICAL
and	O
indomethacin	B-CHEMICAL
have	O
increased	O
COX	B-GENE-Y
-	I-GENE-Y
1	I-GENE-Y
selectivity	O
when	O
compared	O
with	O
naproxen	B-CHEMICAL
and	O
ibuprofen	B-CHEMICAL
.	O

Association	O
of	O
MTRRA66G	B-GENE-Y
polymorphism	O
(	O
but	O
not	O
of	O
MTHFR	B-GENE-Y
C677T	B-GENE-N
and	O
A1298C	B-GENE-N
,	O
MTRA2756G	B-GENE-Y
,	O
TCN	B-GENE-N
C776G	B-GENE-N
)	O
with	O
homocysteine	B-CHEMICAL
and	O
coronary	O
artery	O
disease	O
in	O
the	O
French	O
population	O
.	O

Methylenetetrahydrofolate	B-GENE-Y
reductase	I-GENE-Y
polymorphism	O
(	O
MTHFR	B-GENE-Y
C677T	B-GENE-N
)	O
is	O
an	O
established	O
determinant	O
of	O
homocysteine	B-CHEMICAL
plasma	O
level	O
(	O
t	O
-	O
Hcys	B-CHEMICAL
)	O
while	O
its	O
association	O
with	O
coronary	O
artery	O
disease	O
(	O
CAD	O
)	O
seems	O
to	O
be	O
more	O
limited	O
.	O

In	O
contrast	O
,	O
the	O
association	O
of	O
the	O
substitutions	O
A2756G	B-GENE-N
of	O
methionine	B-GENE-Y
synthase	I-GENE-Y
(	O
MTR	B-GENE-Y
)	O
,	O
A66G	B-GENE-N
of	O
methionine	B-GENE-Y
synthase	I-GENE-Y
reductase	I-GENE-Y
(	O
MTRR	B-GENE-Y
)	O
and	O
C776G	B-GENE-N
of	O
transcobalamin	B-GENE-N
(	O
TCN	B-GENE-N
)	O
to	O
both	O
t	O
-	O
Hcys	B-CHEMICAL
and	O
CAD	O
needs	O
to	O
be	O
evaluated	O
further	O
.	O

The	O
objective	O
was	O
to	O
evaluate	O
the	O
association	O
of	O
these	O
polymorphisms	O
with	O
t	O
-	O
Hcys	B-CHEMICAL
and	O
CAD	O
in	O
a	O
French	O
population	O
.	O

We	O
investigated	O
the	O
individual	O
and	O
combined	O
effects	O
of	O
these	O
polymorphisms	O
and	O
of	O
vitamin	B-CHEMICAL
B12	I-CHEMICAL
and	O
folates	B-CHEMICAL
with	O
t	O
-	O
Hcys	O
in	O
530	O
CAD	O
patients	O
and	O
248	O
matched	O
healthy	O
controls	O
.	O

t	O
-	O
Hcys	B-CHEMICAL
was	O
higher	O
in	O
the	O
CAD	O
group	O
than	O
in	O
controls	O
(	O
11	O
.	O
8	O
vs	O
10	O
.	O
4	O
microM	O
,	O
P	O
<	O
0	O
.	O
0001	O
)	O
and	O
in	O
carriers	O
of	O
MTRRAA	B-GENE-Y
and	O
MTHFR	B-GENE-Y
677TT	O
than	O
in	O
those	O
carrying	O
the	O
most	O
frequent	O
allele	O
of	O
both	O
polymorphisms	O
(	O
13	O
.	O
8	O
vs	O
11	O
.	O
4	O
microM	O
,	O
P	O
=	O
0	O
.	O
0102	O
and	O
12	O
.	O
5	O
vs	O
11	O
.	O
0	O
mM	O
,	O
P	O
=	O
0	O
.	O
0065	O
respectively	O
)	O
.	O

The	O
frequency	O
of	O
MTRR	B-GENE-Y
A	O
allele	O
was	O
higher	O
in	O
CAD	O
patients	O
than	O
in	O
controls	O
(	O
0	O
.	O
48	O
[	O
95	O
%	O
CI	O
:	O
0	O
.	O
44	O
-	O
0	O
.	O
52	O
]	O
vs	O
0	O
.	O
38	O
[	O
95	O
%	O
CI	O
:	O
0	O
.	O
32	O
-	O
0	O
.	O
44	O
]	O
,	O
P	O
=	O
0	O
.	O
0081	O
)	O
while	O
no	O
difference	O
was	O
observed	O
for	O
MTHFR	B-GENE-Y
677T	O
frequency	O
.	O

In	O
multivariate	O
analysis	O
,	O
t	O
-	O
Hcys	B-CHEMICAL
>	O
median	O
and	O
MTRRAA	B-GENE-Y
genotype	O
were	O
two	O
significant	O
independent	O
predictors	O
of	O
CAD	O
with	O
respective	O
odds	O
ratios	O
of	O
3	O
.	O
1	O
(	O
95	O
%	O
CI	O
:	O
1	O
.	O
8	O
-	O
5	O
.	O
1	O
,	O
P	O
<	O
0	O
.	O
0001	O
)	O
and	O
4	O
.	O
5	O
(	O
95	O
%	O
CI	O
:	O
1	O
.	O
5	O
-	O
13	O
.	O
1	O
,	O
P	O
=	O
0	O
.	O
0051	O
)	O
.	O

In	O
conclusion	O
,	O
in	O
contrast	O
to	O
North	O
Europe	O
studies	O
,	O
MTRRAA	B-GENE-Y
genotype	O
is	O
a	O
genetic	O
determinant	O
of	O
moderate	O
hyperhomocysteinemia	O
associated	O
with	O
CAD	O
in	O
a	O
French	O
population	O
without	O
vitamin	O
fortification	O
.	O

Vitamin	B-CHEMICAL
E	I-CHEMICAL
supplementation	O
alters	O
HDL	B-GENE-N
-	O
cholesterol	B-CHEMICAL
concentration	O
and	O
paraoxonase	B-GENE-Y
activity	O
in	O
rabbits	O
fed	O
high	O
-	O
cholesterol	B-CHEMICAL
diet	O
:	O
comparison	O
with	O
probucol	B-CHEMICAL
.	O

Vitamin	B-CHEMICAL
E	I-CHEMICAL
and	O
probucol	B-CHEMICAL
are	O
well	O
-	O
known	O
antioxidants	O
that	O
prevent	O
cells	O
from	O
the	O
oxidative	O
stress	O
,	O
which	O
is	O
a	O
risk	O
factor	O
of	O
atherosclerosis	O
.	O

Male	O
rabbits	O
were	O
fed	O
either	O
0	O
.	O
03	O
%	O
vitamin	B-CHEMICAL
E	I-CHEMICAL
or	O
0	O
.	O
05	O
%	O
probucol	B-CHEMICAL
in	O
a	O
0	O
.	O
5	O
%	O
high	O
-	O
cholesterol	B-CHEMICAL
(	O
HC	O
)	O
diet	O
for	O
8	O
weeks	O
.	O

Vitamin	B-CHEMICAL
E	I-CHEMICAL
and	O
probucol	B-CHEMICAL
significantly	O
suppressed	O
an	O
increase	O
in	O
plasma	O
total	O
-	O
cholesterol	B-CHEMICAL
(	O
total	O
-	O
C	O
)	O
and	O
low	B-GENE-N
-	I-GENE-N
density	I-GENE-N
lipoprotein	I-GENE-N
cholesterol	B-CHEMICAL
compared	O
to	O
HC	O
-	O
control	O
group	O
.	O

However	O
,	O
plasma	O
high	B-GENE-N
-	I-GENE-N
density	I-GENE-N
lipoprotein	I-GENE-N
-	O
cholesterol	B-CHEMICAL
(	O
HDL	B-GENE-N
-	O
C	O
)	O
and	O
HDL	B-GENE-N
-	O
C	O
/	O
total	O
-	O
C	O
ratio	O
levels	O
and	O
plasma	O
paraoxonase	B-GENE-Y
activity	O
were	O
only	O
significantly	O
higher	O
in	O
vitamin	B-CHEMICAL
E	I-CHEMICAL
group	O
after	O
8	O
weeks	O
.	O

Hepatic	O
ACAT	B-GENE-Y
activity	O
was	O
significantly	O
lower	O
in	O
both	O
vitamin	B-CHEMICAL
E	I-CHEMICAL
and	O
probucol	B-CHEMICAL
groups	O
than	O
in	O
HC	O
-	O
control	O
group	O
,	O
while	O
HMG	B-GENE-Y
-	I-GENE-Y
CoA	I-GENE-Y
reductase	I-GENE-Y
activity	O
was	O
the	O
highest	O
only	O
in	O
the	O
probucol	B-CHEMICAL
group	O
.	O

Total	O
fecal	O
sterol	B-CHEMICAL
content	O
was	O
significantly	O
higher	O
in	O
probucol	B-CHEMICAL
and	O
vitamin	B-CHEMICAL
E	I-CHEMICAL
groups	O
than	O
in	O
the	O
two	O
control	O
groups	O
.	O

Some	O
atherogenic	O
signs	O
were	O
discovered	O
in	O
the	O
aortic	O
fatty	O
streak	O
of	O
HC	O
-	O
control	O
group	O
,	O
yet	O
not	O
in	O
other	O
groups	O
.	O

Hepatic	O
mRNA	O
expressions	O
of	O
apo	B-GENE-Y
B	I-GENE-Y
-	I-GENE-Y
100	I-GENE-Y
and	O
apo	B-GENE-Y
C	I-GENE-Y
-	I-GENE-Y
III	I-GENE-Y
were	O
significantly	O
lower	O
in	O
probucol	B-CHEMICAL
group	O
than	O
in	O
other	O
groups	O
.	O

Vitamin	B-CHEMICAL
E	I-CHEMICAL
supplementation	O
was	O
found	O
to	O
alter	O
the	O
plasma	O
HDL	B-GENE-N
-	O
C	O
-	O
related	O
factors	O
;	O
meanwhile	O
,	O
probucol	B-CHEMICAL
supplementation	O
was	O
very	O
effective	O
in	O
enhancing	O
cholesterol	B-CHEMICAL
metabolism	O
,	O
except	O
for	O
a	O
negative	O
effect	O
that	O
reduced	O
plasma	O
HDL	B-GENE-N
-	O
C	O
concentration	O
.	O

Molecular	O
cloning	O
and	O
radioligand	O
binding	O
characterization	O
of	O
the	O
chemokine	B-GENE-N
receptor	I-GENE-N
CCR5	I-GENE-N
from	O
rhesus	O
macaque	O
and	O
human	O
.	O

The	O
aim	O
of	O
this	O
study	O
was	O
to	O
determine	O
if	O
macaque	O
represents	O
a	O
suitable	O
species	O
for	O
the	O
pre	O
-	O
clinical	O
evaluation	O
of	O
novel	O
CCR5	B-GENE-Y
antagonists	O
,	O
such	O
as	O
maraviroc	B-CHEMICAL
(	O
UK	B-CHEMICAL
-	I-CHEMICAL
427	I-CHEMICAL
,	I-CHEMICAL
857	I-CHEMICAL
)	O
.	O

To	O
do	O
this	O
we	O
cloned	O
and	O
expressed	O
CCR5	B-GENE-Y
from	O
rhesus	O
macaque	O
and	O
compared	O
the	O
binding	O
properties	O
of	O
[	O
125I	B-CHEMICAL
]	O
-	O
MIP	O
-	O
1beta	O
and	O
[	B-CHEMICAL
3H	I-CHEMICAL
]	I-CHEMICAL
-	I-CHEMICAL
maraviroc	I-CHEMICAL
with	O
human	B-GENE-Y
recombinant	I-GENE-Y
CCR5	I-GENE-Y
.	O

[	O
125I	B-CHEMICAL
]	O
-	O
MIP	O
-	O
1beta	O
bound	O
with	O
similar	O
high	O
affinity	O
to	O
CCR5	B-GENE-N
from	O
macaque	O
(	O
K	O
(	O
d	O
)	O
=	O
0	O
.	O
24	O
+	O
/	O
-	O
0	O
.	O
05	O
nM	O
)	O
and	O
human	O
(	O
K	O
(	O
d	O
)	O
=	O
0	O
.	O
23	O
+	O
/	O
-	O
0	O
.	O
05	O
nM	O
)	O
and	O
with	O
similar	O
kinetic	O
properties	O
.	O

In	O
competition	O
binding	O
studies	O
the	O
affinity	O
of	O
a	O
range	O
of	O
human	O
chemokines	O
for	O
macaque	B-GENE-Y
CCR5	I-GENE-Y
was	O
also	O
similar	O
to	O
human	B-GENE-Y
CCR5	I-GENE-Y
.	O

Maraviroc	B-CHEMICAL
inhibited	O
binding	O
of	O
[	O
125I	B-CHEMICAL
]	O
-	O
MIP	O
-	O
1beta	O
to	O
CCR5	B-GENE-N
from	O
macaque	O
and	O
human	O
with	O
similar	O
potency	O
(	O
IC50	O
=	O
17	O
.	O
50	O
+	O
/	O
-	O
1	O
.	O
24	O
nM	O
and	O
7	O
.	O
18	O
+	O
/	O
-	O
0	O
.	O
93	O
nM	O
,	O
respectively	O
)	O
and	O
antagonised	O
MIP	O
-	O
1beta	O
induced	O
intracellular	O
calcium	B-CHEMICAL
release	O
mediated	O
through	O
CCR5	B-GENE-N
from	O
macaque	O
and	O
human	O
with	O
similar	O
potency	O
(	O
IC50	O
=	O
17	O
.	O
50	O
+	O
/	O
-	O
3	O
.	O
30	O
nM	O
and	O
12	O
.	O
07	O
+	O
/	O
-	O
1	O
.	O
89	O
,	O
respectively	O
)	O
.	O

[	B-CHEMICAL
3H	I-CHEMICAL
]	I-CHEMICAL
-	I-CHEMICAL
maraviroc	I-CHEMICAL
bound	O
with	O
high	O
affinity	O
to	O
CCR5	B-GENE-N
from	O
macaque	O
(	O
K	O
(	O
d	O
)	O
=	O
1	O
.	O
36	O
+	O
/	O
-	O
0	O
.	O
07	O
nM	O
)	O
and	O
human	O
(	O
K	O
(	O
d	O
)	O
=	O
0	O
.	O
86	O
+	O
/	O
-	O
0	O
.	O
08	O
nM	O
)	O
,	O
but	O
was	O
found	O
to	O
dissociate	O
approximately	O
10	O
-	O
fold	O
more	O
quickly	O
from	O
macaque	B-GENE-Y
CCR5	I-GENE-Y
.	O

However	O
,	O
as	O
with	O
the	O
human	O
receptor	O
,	O
maraviroc	B-CHEMICAL
was	O
shown	O
to	O
be	O
a	O
high	O
affinity	O
,	O
potent	O
functional	O
antagonist	O
of	O
macaque	B-GENE-Y
CCR5	I-GENE-Y
thereby	O
indicating	O
that	O
the	O
macaque	O
should	O
be	O
a	O
suitable	O
species	O
in	O
which	O
to	O
evaluate	O
the	O
pharmacology	O
,	O
safety	O
and	O
potential	O
mechanism	O
-	O
related	O
toxicology	O
of	O
novel	O
CCR5	B-GENE-Y
antagonists	O
.	O

A	O
novel	O
function	O
of	O
differentiation	O
revealed	O
by	O
cDNA	O
microarray	O
profiling	O
of	O
p75NTR	B-GENE-Y
-	O
regulated	O
gene	O
expression	O
.	O

The	O
expression	O
of	O
the	O
p75	B-GENE-Y
neurotrophin	I-GENE-Y
receptor	I-GENE-Y
(	O
p75NTR	B-GENE-Y
)	O
is	O
diminished	O
in	O
epithelial	O
cells	O
during	O
progression	O
of	O
prostate	O
cancer	O
in	O
vivo	O
and	O
in	O
vitro	O
.	O

Previous	O
studies	O
have	O
demonstrated	O
a	O
role	O
for	O
p75NTR	B-GENE-Y
as	O
a	O
tumor	O
suppressor	O
in	O
prostate	O
growth	O
.	O

To	O
better	O
understand	O
the	O
molecular	O
mechanism	O
of	O
p75	B-GENE-Y
(	I-GENE-Y
NTR	I-GENE-Y
)	I-GENE-Y
on	O
tumor	O
suppression	O
,	O
we	O
utilized	O
a	O
complementary	O
deoxyribonucleic	B-CHEMICAL
acid	I-CHEMICAL
microarray	O
composed	O
of	O
approximately	O
6	O
,	O
000	O
human	O
cancer	O
-	O
related	O
genes	O
to	O
determine	O
the	O
gene	O
expression	O
pattern	O
altered	O
by	O
re	O
-	O
introduction	O
of	O
p75NTR	B-GENE-Y
into	O
PC	O
-	O
3	O
prostate	O
tumor	O
cells	O
.	O

Comparison	O
of	O
the	O
transcripts	O
in	O
the	O
neo	O
and	O
p75NTR	B-GENE-Y
-	O
transfected	O
cells	O
revealed	O
52	O
differentially	O
expressed	O
genes	O
,	O
of	O
which	O
21	O
were	O
up	O
-	O
regulated	O
and	O
31	O
were	O
down	O
-	O
regulated	O
in	O
the	O
presence	O
of	O
p75NTR	B-GENE-Y
.	O

Based	O
on	O
the	O
known	O
biological	O
functions	O
of	O
the	O
p75NTR	B-GENE-Y
-	O
regulated	O
genes	O
,	O
we	O
observed	O
that	O
p75NTR	B-GENE-Y
modulated	O
the	O
expression	O
of	O
genes	O
that	O
are	O
critically	O
involved	O
in	O
the	O
regulation	O
of	O
differentiation	O
as	O
well	O
as	O
cell	O
adhesion	O
,	O
signal	O
transduction	O
,	O
apoptosis	O
,	O
tumor	O
cell	O
invasion	O
,	O
and	O
metastasis	O
.	O

Several	O
differentially	O
expressed	O
genes	O
identified	O
by	O
microarray	O
were	O
selected	O
for	O
confirmation	O
using	O
quantitative	O
real	O
-	O
time	O
polymerase	O
chain	O
reaction	O
.	O

Immunoblot	O
analysis	O
further	O
confirmed	O
increased	O
cellular	B-GENE-Y
retinoic	I-GENE-Y
acid	I-GENE-Y
-	I-GENE-Y
binding	I-GENE-Y
protein	I-GENE-Y
I	I-GENE-Y
(	O
CRABPI	B-GENE-Y
)	O
and	O
IGFBP5	B-GENE-Y
protein	O
levels	O
and	O
decreased	O
level	O
of	O
PLAUR	B-GENE-Y
protein	O
with	O
increasing	O
p75NTR	B-GENE-Y
protein	O
expression	O
.	O

As	O
CRABPI	B-GENE-Y
was	O
elevated	O
far	O
more	O
than	O
any	O
other	O
genes	O
,	O
we	O
observed	O
that	O
the	O
retinoids	B-CHEMICAL
,	O
all	B-CHEMICAL
-	I-CHEMICAL
trans	I-CHEMICAL
retinoic	I-CHEMICAL
acid	I-CHEMICAL
and	O
9	B-CHEMICAL
-	I-CHEMICAL
cis	I-CHEMICAL
retinoic	I-CHEMICAL
acid	I-CHEMICAL
,	O
that	O
bind	O
CRABPI	B-GENE-Y
,	O
promoted	O
nitroblue	B-CHEMICAL
tetrazolium	I-CHEMICAL
-	O
associated	O
functional	O
cell	O
differentiation	O
in	O
p75NTR	B-GENE-Y
PC	O
-	O
3	O
cells	O
,	O
but	O
not	O
in	O
neo	O
control	O
PC	O
-	O
3	O
cells	O
.	O

Subsequent	O
examination	O
of	O
the	O
retinoic	B-GENE-N
acid	I-GENE-N
receptors	I-GENE-N
(	B-GENE-N
RARs	I-GENE-N
)	O
expression	O
levels	O
demonstrated	O
an	O
absence	O
of	O
RAR	B-GENE-Y
-	I-GENE-Y
beta	I-GENE-Y
in	O
the	O
neo	O
control	O
cells	O
and	O
re	O
-	O
expression	O
in	O
the	O
p75NTR	B-GENE-Y
expressing	O
cells	O
,	O
consistent	O
with	O
previous	O
findings	O
where	O
RAR	B-GENE-Y
-	I-GENE-Y
beta	I-GENE-Y
is	O
believed	O
to	O
play	O
a	O
critical	O
role	O
as	O
a	O
tumor	O
suppressor	O
gene	O
that	O
is	O
lost	O
during	O
de	O
-	O
differentiation	O
of	O
prostate	O
epithelial	O
cells	O
.	O

Whereas	O
the	O
RAR	B-GENE-N
-	I-GENE-N
alpha	I-GENE-N
and	I-GENE-N
-	I-GENE-N
gamma	I-GENE-N
protein	O
levels	O
remained	O
unchanged	O
,	O
retinoid	B-GENE-N
X	I-GENE-N
receptor	I-GENE-N
(	I-GENE-N
RXR	I-GENE-N
)	I-GENE-N
-	I-GENE-N
alpha	I-GENE-N
and	I-GENE-N
-	I-GENE-N
beta	I-GENE-N
also	O
exhibited	O
increasing	O
protein	O
levels	O
with	O
re	O
-	O
expression	O
of	O
the	O
p75NTR	B-GENE-Y
protein	O
.	O

Moreover	O
,	O
the	O
ability	O
of	O
p75NTR	B-GENE-Y
siRNA	O
to	O
knockdown	O
levels	O
of	O
RAR	B-GENE-Y
-	I-GENE-Y
beta	I-GENE-Y
,	O
RXR	B-GENE-Y
-	I-GENE-Y
alpha	I-GENE-Y
,	O
and	O
RXR	B-GENE-Y
-	I-GENE-Y
beta	I-GENE-Y
supports	O
the	O
specificity	O
of	O
the	O
functional	O
involvement	O
of	O
p75NTR	B-GENE-Y
in	O
differentiation	O
.	O

Hence	O
,	O
re	O
-	O
expression	O
of	O
the	O
p75NTR	B-GENE-Y
appears	O
to	O
partially	O
reverse	O
de	O
-	O
differentiation	O
of	O
prostate	O
cancer	O
cells	O
by	O
up	O
-	O
regulating	O
the	O
expression	O
of	O
CRABPI	B-GENE-Y
for	O
localized	O
sequestration	O
of	O
retinoids	B-CHEMICAL
that	O
are	O
available	O
to	O
newly	O
up	O
-	O
regulated	O
RAR	B-GENE-Y
-	I-GENE-Y
beta	I-GENE-Y
,	O
RXR	B-GENE-Y
-	I-GENE-Y
alpha	I-GENE-Y
,	O
and	O
RXR	B-GENE-Y
-	I-GENE-Y
beta	I-GENE-Y
.	O

GPR109A	B-GENE-Y
(	O
PUMA	B-GENE-Y
-	I-GENE-Y
G	I-GENE-Y
/	O
HM74A	B-GENE-Y
)	O
mediates	O
nicotinic	B-CHEMICAL
acid	I-CHEMICAL
-	O
induced	O
flushing	O
.	O

Nicotinic	B-CHEMICAL
acid	I-CHEMICAL
(	O
niacin	B-CHEMICAL
)	O
has	O
long	O
been	O
used	O
as	O
an	O
antidyslipidemic	O
drug	O
.	O

Its	O
special	O
profile	O
of	O
actions	O
,	O
especially	O
the	O
rise	O
in	O
HDL	B-GENE-N
-	O
cholesterol	B-CHEMICAL
levels	O
induced	O
by	O
nicotinic	B-CHEMICAL
acid	I-CHEMICAL
,	O
is	O
unique	O
among	O
the	O
currently	O
available	O
pharmacological	O
tools	O
to	O
treat	O
lipid	O
disorders	O
.	O

Recently	O
,	O
a	O
G	B-GENE-N
-	I-GENE-N
protein	I-GENE-N
-	I-GENE-N
coupled	I-GENE-N
receptor	I-GENE-N
,	O
termed	O
GPR109A	B-GENE-Y
(	O
HM74A	B-GENE-Y
in	O
humans	O
,	O
PUMA	B-GENE-Y
-	I-GENE-Y
G	I-GENE-Y
in	O
mice	O
)	O
,	O
was	O
described	O
and	O
shown	O
to	O
mediate	O
the	O
nicotinic	B-CHEMICAL
acid	I-CHEMICAL
-	O
induced	O
antilipolytic	O
effects	O
in	O
adipocytes	O
.	O

One	O
of	O
the	O
major	O
problems	O
of	O
the	O
pharmacotherapeutical	O
use	O
of	O
nicotinic	B-CHEMICAL
acid	I-CHEMICAL
is	O
a	O
strong	O
flushing	O
response	O
.	O

This	O
side	O
effect	O
,	O
although	O
harmless	O
,	O
strongly	O
affects	O
patient	O
compliance	O
.	O

In	O
the	O
present	O
study	O
,	O
we	O
show	O
that	O
mice	O
lacking	O
PUMA	B-GENE-Y
-	I-GENE-Y
G	I-GENE-Y
did	O
not	O
show	O
nicotinic	B-CHEMICAL
acid	I-CHEMICAL
-	O
induced	O
flushing	O
.	O

In	O
addition	O
,	O
flushing	O
in	O
response	O
to	O
nicotinic	B-CHEMICAL
acid	I-CHEMICAL
was	O
also	O
abrogated	O
in	O
the	O
absence	O
of	O
cyclooxygenase	B-GENE-Y
type	I-GENE-Y
1	I-GENE-Y
,	O
and	O
mice	O
lacking	O
prostaglandin	B-GENE-N
D	I-GENE-N
(	I-GENE-N
2	I-GENE-N
)	I-GENE-N
(	I-GENE-N
PGD	I-GENE-N
(	I-GENE-N
2	I-GENE-N
)	I-GENE-N
)	I-GENE-N
and	I-GENE-N
prostaglandin	I-GENE-N
E	I-GENE-N
(	I-GENE-N
2	I-GENE-N
)	I-GENE-N
(	I-GENE-N
PGE	I-GENE-N
(	I-GENE-N
2	I-GENE-N
)	I-GENE-N
)	I-GENE-N
receptors	I-GENE-N
had	O
reduced	O
flushing	O
responses	O
.	O

The	O
mouse	O
orthologue	O
of	O
GPR109A	B-GENE-Y
,	O
PUMA	B-GENE-Y
-	I-GENE-Y
G	I-GENE-Y
,	O
is	O
highly	O
expressed	O
in	O
macrophages	O
and	O
other	O
immune	O
cells	O
,	O
and	O
transplantation	O
of	O
wild	O
-	O
type	O
bone	O
marrow	O
into	O
irradiated	O
PUMA	B-GENE-Y
-	I-GENE-Y
G	I-GENE-Y
-	O
deficient	O
mice	O
restored	O
the	O
nicotinic	B-CHEMICAL
acid	I-CHEMICAL
-	O
induced	O
flushing	O
response	O
.	O

Our	O
data	O
clearly	O
indicate	O
that	O
GPR109A	B-GENE-Y
mediates	O
nicotinic	B-CHEMICAL
acid	I-CHEMICAL
-	O
induced	O
flushing	O
and	O
that	O
this	O
effect	O
involves	O
release	O
of	O
PGE	B-CHEMICAL
(	I-CHEMICAL
2	I-CHEMICAL
)	I-CHEMICAL
and	O
PGD	B-CHEMICAL
(	I-CHEMICAL
2	I-CHEMICAL
)	I-CHEMICAL
,	O
most	O
likely	O
from	O
immune	O
cells	O
of	O
the	O
skin	O
.	O

The	O
Arg389Gly	B-GENE-N
beta1	B-GENE-Y
-	I-GENE-Y
adrenoceptor	I-GENE-Y
polymorphism	O
and	O
catecholamine	B-CHEMICAL
effects	O
on	O
plasma	O
-	O
renin	B-GENE-Y
activity	O
.	O

OBJECTIVES	O
:	O
The	O
purpose	O
of	O
this	O
research	O
was	O
to	O
find	O
out	O
whether	O
,	O
in	O
humans	O
,	O
dobutamine	B-CHEMICAL
-	O
induced	O
hemodynamic	O
effects	O
and	O
increase	O
in	O
plasma	O
-	O
renin	B-GENE-Y
activity	O
(	O
PRA	O
)	O
might	O
be	O
beta1	B-GENE-Y
-	I-GENE-Y
adrenoceptor	I-GENE-Y
(	O
beta1AR	B-GENE-Y
)	O
genotype	O
-	O
dependent	O
.	O

BACKGROUND	O
:	O
In	O
vitro	O
Arg389Gly	B-GENE-N
-	O
beta1AR	B-GENE-Y
polymorphism	O
exhibits	O
decreased	O
receptor	O
signaling	O
.	O

METHODS	O
:	O
We	O
studied	O
10	O
male	O
homozygous	O
Arg389	O
-	O
beta1AR	B-GENE-Y
subjects	O
and	O
8	O
male	O
homozygous	O
Gly389beta1AR	B-GENE-Y
subjects	O
;	O
to	O
avoid	O
influences	O
of	O
codon	O
49	O
polymorphism	O
,	O
all	O
were	O
homozygous	O
Ser49	O
-	O
beta1AR	B-GENE-Y
.	O

Subjects	O
were	O
infused	O
with	O
dobutamine	B-CHEMICAL
(	O
1	O
to	O
6	O
microg	O
/	O
kg	O
/	O
min	O
)	O
with	O
or	O
without	O
bisoprolol	B-CHEMICAL
(	O
10	O
mg	O
orally	O
)	O
pretreatment	O
,	O
and	O
PRA	O
,	O
heart	O
rate	O
,	O
contractility	O
,	O
and	O
blood	O
pressure	O
were	O
assessed	O
.	O

RESULTS	O
:	O
With	O
regard	O
to	O
PRA	O
,	O
dobutamine	B-CHEMICAL
increased	O
PRA	O
more	O
potently	O
in	O
Arg389	O
-	O
beta1AR	B-GENE-Y
versus	O
Gly389	O
-	O
beta1AR	B-GENE-Y
subjects	O
.	O

Bisoprolol	B-CHEMICAL
markedly	O
suppressed	O
the	O
dobutamine	B-CHEMICAL
-	O
induced	O
PRA	O
increase	O
in	O
Arg389	O
-	O
but	O
only	O
marginally	O
in	O
Gly389	O
-	O
beta1AR	B-GENE-Y
subjects	O
.	O

With	O
regard	O
to	O
hemodynamics	O
,	O
dobutamine	B-CHEMICAL
caused	O
larger	O
heart	O
rate	O
and	O
contractility	O
increases	O
and	O
diastolic	O
blood	O
pressure	O
decreases	O
in	O
Arg389	O
-	O
versus	O
Gly389	O
-	O
beta1AR	B-GENE-Y
subjects	O
.	O

Bisoprolol	B-CHEMICAL
reduced	O
dobutamine	B-CHEMICAL
-	O
induced	O
heart	O
rate	O
and	O
contractility	O
increases	O
and	O
diastolic	O
blood	O
pressure	O
decreases	O
more	O
potently	O
in	O
Arg389	O
-	O
versus	O
Gly389	O
-	O
beta1AR	B-GENE-Y
subjects	O
.	O

CONCLUSIONS	O
:	O
Codon	O
389	O
beta1AR	B-GENE-Y
polymorphism	O
is	O
a	O
determinant	O
not	O
only	O
of	O
hemodynamic	O
effects	O
but	O
also	O
of	O
PRA	O
.	O

Thus	O
,	O
beta1AR	B-GENE-Y
polymorphisms	O
may	O
be	O
useful	O
for	O
predicting	O
therapeutic	O
responses	O
to	O
betaAR	B-GENE-N
-	O
blocker	O
treatment	O
.	O

Valproic	B-CHEMICAL
acid	I-CHEMICAL
selectively	O
inhibits	O
conversion	O
of	O
arachidonic	B-CHEMICAL
acid	I-CHEMICAL
to	O
arachidonoyl	B-CHEMICAL
-	I-CHEMICAL
CoA	I-CHEMICAL
by	O
brain	B-GENE-N
microsomal	I-GENE-N
long	I-GENE-N
-	I-GENE-N
chain	I-GENE-N
fatty	I-GENE-N
acyl	I-GENE-N
-	I-GENE-N
CoA	I-GENE-N
synthetases	I-GENE-N
:	O
relevance	O
to	O
bipolar	O
disorder	O
.	O

RATIONALE	O
:	O
Several	O
drugs	O
used	O
to	O
treat	O
bipolar	O
disorder	O
(	O
lithium	B-CHEMICAL
and	O
carbamazepine	B-CHEMICAL
)	O
,	O
when	O
administered	O
chronically	O
to	O
rats	O
,	O
reduce	O
the	O
turnover	O
of	O
arachidonic	B-CHEMICAL
acid	I-CHEMICAL
,	O
but	O
not	O
docosahexaenoic	B-CHEMICAL
acid	I-CHEMICAL
,	O
in	O
brain	O
phospholipids	O
by	O
decreasing	O
the	O
activity	O
of	O
an	O
arachidonic	B-CHEMICAL
acid	I-CHEMICAL
-	O
selective	O
phospholipase	B-GENE-N
A	I-GENE-N
(	I-GENE-N
2	I-GENE-N
)	I-GENE-N
.	O

Although	O
chronic	O
valproic	B-CHEMICAL
acid	I-CHEMICAL
produces	O
similar	O
effects	O
on	O
brain	O
arachidonic	B-CHEMICAL
acid	I-CHEMICAL
and	O
docosahexaenoic	B-CHEMICAL
acid	I-CHEMICAL
turnover	O
,	O
it	O
does	O
not	O
alter	O
phospholipase	B-GENE-N
A	I-GENE-N
(	I-GENE-N
2	I-GENE-N
)	I-GENE-N
activity	O
,	O
suggesting	O
that	O
it	O
targets	O
a	O
different	O
enzyme	O
in	O
the	O
turnover	O
pathway	O
.	O

MATERIALS	O
AND	O
METHODS	O
/	O
RESULTS	O
:	O
By	O
isolating	O
rat	B-GENE-N
brain	I-GENE-N
microsomal	I-GENE-N
long	I-GENE-N
-	I-GENE-N
chain	I-GENE-N
fatty	I-GENE-N
acyl	I-GENE-N
-	I-GENE-N
CoA	I-GENE-N
synthetases	I-GENE-N
(	O
Acsl	B-GENE-N
)	O
,	O
we	O
show	O
in	O
vitro	O
that	O
valproic	B-CHEMICAL
acid	I-CHEMICAL
is	O
a	O
non	O
-	O
competitive	O
inhibitor	O
of	O
Acsl	B-GENE-N
,	O
as	O
it	O
reduces	O
the	O
maximal	O
velocity	O
of	O
the	O
reaction	O
without	O
changing	O
the	O
affinity	O
of	O
the	O
substrate	O
for	O
the	O
enzyme	O
.	O

While	O
valproic	B-CHEMICAL
acid	I-CHEMICAL
inhibited	O
the	O
synthesis	O
of	O
arachidonoyl	B-CHEMICAL
-	I-CHEMICAL
CoA	I-CHEMICAL
,	O
palmitoyl	B-CHEMICAL
-	I-CHEMICAL
CoA	I-CHEMICAL
,	O
and	O
docosahexaenoyl	B-CHEMICAL
-	I-CHEMICAL
CoA	I-CHEMICAL
,	O
the	O
K	O
(	O
i	O
)	O
for	O
inhibition	O
of	O
arachidonoyl	B-CHEMICAL
-	I-CHEMICAL
CoA	I-CHEMICAL
synthesis	O
(	O
14	O
.	O
1	O
mM	O
)	O
was	O
approximately	O
one	O
fifth	O
the	O
K	O
(	O
i	O
)	O
for	O
inhibiting	O
palmitoyl	B-CHEMICAL
-	I-CHEMICAL
CoA	I-CHEMICAL
(	O
85	O
.	O
4	O
mM	O
)	O
and	O
docosahexaenoyl	B-CHEMICAL
-	I-CHEMICAL
CoA	I-CHEMICAL
(	O
78	O
.	O
2	O
mM	O
)	O
synthesis	O
.	O

As	O
chronic	O
administration	O
of	O
valproic	B-CHEMICAL
acid	I-CHEMICAL
in	O
bipolar	O
disorder	O
achieves	O
whole	O
-	O
brain	O
levels	O
of	O
1	O
.	O
0	O
to	O
1	O
.	O
5	O
mM	O
,	O
inhibition	O
of	O
arachidonoyl	B-CHEMICAL
-	I-CHEMICAL
CoA	I-CHEMICAL
formation	O
can	O
occur	O
at	O
brain	O
concentrations	O
that	O
are	O
therapeutically	O
relevant	O
to	O
this	O
disease	O
.	O

Furthermore	O
,	O
brain	B-GENE-N
microsomal	I-GENE-N
Acsl	I-GENE-N
did	O
not	O
produce	O
valproyl	B-CHEMICAL
-	I-CHEMICAL
CoA	I-CHEMICAL
.	O

CONCLUSIONS	O
:	O
This	O
study	O
shows	O
that	O
valproic	B-CHEMICAL
acid	I-CHEMICAL
acts	O
as	O
a	O
non	O
-	O
competitive	O
inhibitor	O
of	O
brain	B-GENE-N
microsomal	I-GENE-N
Acsl	I-GENE-N
,	O
and	O
that	O
inhibition	O
is	O
substrate	O
-	O
selective	O
.	O

The	O
study	O
supports	O
the	O
hypothesis	O
that	O
valproic	B-CHEMICAL
acid	I-CHEMICAL
acts	O
in	O
bipolar	O
disorder	O
by	O
reducing	O
the	O
brain	O
arachidonic	B-CHEMICAL
acid	I-CHEMICAL
cascade	O
,	O
by	O
inhibiting	O
arachidonoyl	B-CHEMICAL
-	I-CHEMICAL
CoA	I-CHEMICAL
formation	O
.	O

From	O
an	O
inborn	O
error	O
patient	O
to	O
a	O
search	O
for	O
regulatory	O
meaning	O
:	O
a	O
biotin	B-CHEMICAL
conducted	O
voyage	O
.	O

This	O
article	O
summarizes	O
some	O
findings	O
of	O
a	O
research	O
that	O
I	O
have	O
pursued	O
for	O
the	O
past	O
25	O
years	O
,	O
whose	O
roots	O
are	O
immersed	O
in	O
the	O
field	O
of	O
inherited	O
metabolic	O
disorders	O
,	O
and	O
deal	O
with	O
different	O
aspects	O
of	O
the	O
vitamin	O
biotin	B-CHEMICAL
,	O
starting	O
with	O
a	O
patient	O
with	O
multiple	O
carboxylase	B-GENE-N
deficiency	O
(	O
MCD	O
)	O
.	O

Several	O
of	O
MCD	O
clinical	O
manifestations	O
resemble	O
those	O
of	O
infant	O
malnutrition	O
;	O
we	O
demonstrated	O
that	O
about	O
one	O
-	O
third	O
of	O
infants	O
with	O
this	O
common	O
nutritional	O
disorder	O
were	O
indeed	O
biotin	B-CHEMICAL
-	O
deficient	O
,	O
and	O
that	O
this	O
deficiency	O
is	O
metabolically	O
significant	O
,	O
by	O
studying	O
urine	O
instead	O
of	O
blood	O
,	O
studying	O
urinary	O
organic	O
acids	O
by	O
gas	O
chromatography	O
-	O
mass	O
spectrometry	O
.	O

Remarkably	O
,	O
the	O
metabolic	O
abnormalities	O
became	O
apparent	O
only	O
after	O
protein	O
feeding	O
was	O
started	O
,	O
suggesting	O
that	O
this	O
phenomenon	O
may	O
contribute	O
to	O
the	O
worsening	O
of	O
malnourished	O
individuals	O
when	O
they	O
are	O
abruptly	O
fed	O
.	O

Afterwards	O
,	O
we	O
studied	O
biotin	B-CHEMICAL
deficiency	O
at	O
the	O
tissue	O
level	O
.	O

Carboxylase	B-GENE-N
activities	O
and	O
masses	O
were	O
significantly	O
reduced	O
in	O
liver	O
,	O
kidney	O
,	O
muscle	O
,	O
adipose	O
tissue	O
,	O
intestine	O
,	O
and	O
spleen	O
,	O
but	O
brain	O
and	O
heart	O
were	O
spared	O
;	O
their	O
mRNAs	O
remained	O
unchanged	O
.	O

On	O
the	O
other	O
hand	O
,	O
holocarboxylase	B-GENE-Y
synthetase	I-GENE-Y
(	O
HCS	B-GENE-Y
)	O
mRNA	O
levels	O
were	O
markedly	O
low	O
in	O
the	O
deficient	O
animals	O
,	O
and	O
increased	O
upon	O
biotin	B-CHEMICAL
injection	O
.	O

Over	O
2000	O
human	O
genes	O
have	O
been	O
identified	O
that	O
depend	O
on	O
biotin	B-CHEMICAL
for	O
expression	O
.	O

To	O
probe	O
into	O
the	O
"	O
logic	O
"	O
of	O
this	O
enigma	O
,	O
we	O
have	O
started	O
comparative	O
studies	O
among	O
evolutionarily	O
distant	O
organisms	O
,	O
such	O
as	O
mouse	O
and	O
Saccharomyces	O
cerevisiae	O
,	O
and	O
we	O
are	O
now	O
looking	O
for	O
biotin	B-CHEMICAL
effects	O
on	O
specific	O
genes	O
and	O
proteins	O
,	O
such	O
as	O
HCS	B-CHEMICAL
and	O
hexokinases	B-GENE-N
,	O
and	O
on	O
their	O
proteomes	O
.	O

Involvement	O
of	O
COX	B-GENE-Y
-	I-GENE-Y
1	I-GENE-Y
and	O
up	O
-	O
regulated	O
prostaglandin	B-GENE-Y
E	I-GENE-Y
synthases	I-GENE-Y
in	O
phosphatidylserine	B-CHEMICAL
liposome	O
-	O
induced	O
prostaglandin	B-CHEMICAL
E2	I-CHEMICAL
production	O
by	O
microglia	O
.	O

After	O
engulfment	O
of	O
apoptotic	O
cells	O
through	O
phosphatidylserine	B-CHEMICAL
(	O
PS	O
)	O
-	O
mediated	O
recognition	O
,	O
microglia	O
secrete	O
prostaglandin	B-CHEMICAL
E2	I-CHEMICAL
(	O
PGE2	B-CHEMICAL
)	O
,	O
a	O
potent	O
anti	O
-	O
inflammatory	O
molecule	O
in	O
the	O
central	O
nervous	O
system	O
.	O

Despite	O
the	O
clinical	O
significance	O
,	O
the	O
mechanism	O
underlying	O
PGE2	B-CHEMICAL
production	O
by	O
phagocytosis	O
of	O
apoptotic	O
cells	O
is	O
poorly	O
understood	O
.	O

In	O
the	O
present	O
study	O
,	O
we	O
used	O
PS	O
liposomes	O
to	O
elucidate	O
the	O
phagocytic	O
pathway	O
for	O
PGE2	B-CHEMICAL
production	O
in	O
microglia	O
,	O
because	O
PS	O
liposomes	O
mimic	O
the	O
effects	O
of	O
apoptotic	O
cells	O
on	O
microglia	O
/	O
macrophages	O
.	O

The	O
level	O
of	O
PGE2	B-CHEMICAL
in	O
the	O
culture	O
medium	O
of	O
primary	O
cultured	O
rat	O
microglia	O
was	O
significantly	O
increased	O
by	O
PS	O
liposomes	O
treatment	O
but	O
not	O
by	O
phosphatidylcholine	B-CHEMICAL
liposomes	O
treatment	O
.	O

The	O
specific	O
ligand	O
for	O
class	B-GENE-N
B	I-GENE-N
scavenger	I-GENE-N
receptor	I-GENE-N
(	O
SR	B-GENE-N
-	I-GENE-N
B	I-GENE-N
)	O
,	O
high	B-GENE-N
density	I-GENE-N
lipoprotein	I-GENE-N
,	O
significantly	O
suppressed	O
PS	O
liposome	O
-	O
induced	O
PGE2	B-CHEMICAL
production	O
.	O

PS	O
liposomes	O
were	O
immediately	O
phagocytosed	O
by	O
microglia	O
and	O
sorted	O
to	O
endosomes	O
/	O
lysosomes	O
.	O

Cyclooxygenase	B-GENE-N
(	B-GENE-Y
COX	I-GENE-Y
)	I-GENE-Y
-	I-GENE-Y
2	I-GENE-Y
and	O
membrane	O
-	O
bound	O
prostaglandin	B-GENE-Y
E	I-GENE-Y
synthase	I-GENE-Y
-	I-GENE-Y
1	I-GENE-Y
(	O
mPGES	B-GENE-Y
-	I-GENE-Y
1	I-GENE-Y
)	O
were	O
induced	O
by	O
treatment	O
with	O
lipopolysaccharide	O
(	O
LPS	O
)	O
but	O
not	O
with	O
PS	O
liposomes	O
.	O

On	O
the	O
other	O
hand	O
,	O
mPGES	B-GENE-Y
-	I-GENE-Y
2	I-GENE-Y
and	O
cytosolic	B-GENE-Y
PGES	I-GENE-Y
(	O
cPGES	B-GENE-Y
)	O
that	O
are	O
functionally	O
coupled	O
with	O
COX	B-GENE-Y
-	I-GENE-Y
1	I-GENE-Y
were	O
upregulated	O
after	O
treatment	O
with	O
PS	O
liposomes	O
or	O
LPS	O
.	O

Furthermore	O
,	O
PS	O
liposome	O
-	O
induced	O
PGE2	B-CHEMICAL
production	O
was	O
significantly	O
suppressed	O
by	O
indomethacin	B-CHEMICAL
,	O
a	O
preferential	O
COX	B-GENE-Y
-	I-GENE-Y
1	I-GENE-Y
inhibitor	O
,	O
but	O
not	O
by	O
NS	B-CHEMICAL
-	I-CHEMICAL
398	I-CHEMICAL
,	O
a	O
selective	O
COX	B-GENE-Y
-	I-GENE-Y
2	I-GENE-Y
inhibitor	O
.	O

PS	O
liposomes	O
induced	O
activation	O
of	O
p44	B-GENE-Y
/	O
p42	B-GENE-Y
extracellular	B-GENE-N
signal	I-GENE-N
-	I-GENE-N
regulated	I-GENE-N
kinase	I-GENE-N
(	O
ERK	B-GENE-N
)	O
but	O
not	O
p38	B-GENE-N
mitogen	B-GENE-N
-	I-GENE-N
activated	I-GENE-N
protein	I-GENE-N
kinase	I-GENE-N
in	O
SR	B-GENE-Y
-	I-GENE-Y
BI	I-GENE-Y
independent	O
manner	O
.	O

These	O
observations	O
strongly	O
suggest	O
that	O
the	O
up	O
-	O
regulation	O
of	O
terminal	O
PGESs	B-GENE-Y
that	O
are	O
preferentially	O
coupled	O
with	O
COX	B-GENE-Y
-	I-GENE-Y
1	I-GENE-Y
,	O
especially	O
mPGES	B-GENE-Y
-	I-GENE-Y
2	I-GENE-Y
,	O
plays	O
the	O
pivotal	O
role	O
in	O
PS	O
liposome	O
-	O
induced	O
PGE2	B-CHEMICAL
production	O
by	O
microglia	O
.	O

Although	O
SR	B-GENE-Y
-	I-GENE-Y
BI	I-GENE-Y
plays	O
an	O
essential	O
role	O
in	O
PS	O
liposome	O
-	O
induced	O
PGE2	B-CHEMICAL
production	O
,	O
other	O
PS	B-GENE-N
-	I-GENE-N
recognizing	I-GENE-N
receptors	I-GENE-N
,	O
possibly	O
PS	B-GENE-N
-	I-GENE-N
specific	I-GENE-N
receptor	I-GENE-N
,	O
could	O
also	O
promote	O
PGE2	B-CHEMICAL
production	O
by	O
transducing	O
intracellular	O
signals	O
including	O
p44	B-GENE-Y
/	O
p42	B-GENE-Y
ERK	B-GENE-N
after	O
PS	O
liposomes	O
treatment	O
.	O

Sorafenib	B-CHEMICAL
:	O
scientific	O
rationales	O
for	O
single	O
-	O
agent	O
and	O
combination	O
therapy	O
in	O
clear	O
-	O
cell	O
renal	O
cell	O
carcinoma	O
.	O

Clear	O
-	O
cell	O
renal	O
cell	O
carcinoma	O
(	O
RCC	O
)	O
is	O
characterized	O
by	O
the	O
loss	O
of	O
von	B-GENE-Y
Hippel	I-GENE-Y
-	I-GENE-Y
Lindau	I-GENE-Y
disease	I-GENE-Y
protein	I-GENE-Y
and	O
the	O
resultant	O
dysregulation	O
of	O
the	O
vascular	B-GENE-Y
endothelial	I-GENE-Y
growth	I-GENE-Y
factor	I-GENE-Y
(	O
VEGF	B-GENE-Y
)	O
/	O
VEGF	B-GENE-N
receptor	I-GENE-N
(	O
VEGFR	B-GENE-N
)	O
,	O
platelet	B-GENE-Y
-	I-GENE-Y
derived	I-GENE-Y
growth	I-GENE-Y
factor	I-GENE-Y
-	I-GENE-Y
beta	I-GENE-Y
(	O
PDGF	B-GENE-Y
-	I-GENE-Y
beta	I-GENE-Y
)	O
/	O
PDGF	B-GENE-Y
receptor	I-GENE-Y
-	I-GENE-Y
beta	I-GENE-Y
(	O
PDGFR	B-GENE-Y
-	I-GENE-Y
beta	I-GENE-Y
)	O
,	O
and	O
transforming	B-GENE-Y
growth	I-GENE-Y
factor	I-GENE-Y
-	I-GENE-Y
alpha	I-GENE-Y
(	O
TGF	B-GENE-Y
-	I-GENE-Y
alpha	I-GENE-Y
)	O
/	O
epidermal	B-GENE-Y
growth	I-GENE-Y
factor	I-GENE-Y
receptor	I-GENE-Y
(	O
EGFR	B-GENE-Y
)	O
/	O
Raf	B-GENE-Y
pathways	O
,	O
which	O
contribute	O
to	O
angiogenesis	O
,	O
lymphangiogenesis	O
,	O
and	O
tumor	O
cell	O
growth	O
and	O
survival	O
.	O

Significant	O
advances	O
in	O
the	O
treatment	O
of	O
clear	O
-	O
cell	O
RCC	O
have	O
been	O
derived	O
from	O
agents	O
that	O
target	O
these	O
pathways	O
,	O
including	O
the	O
multiple	O
-	O
kinase	B-GENE-N
inhibitors	O
(	O
MKIs	O
)	O
sorafenib	B-CHEMICAL
,	O
sunitinib	B-CHEMICAL
,	O
and	O
AG013736	B-CHEMICAL
,	O
which	O
target	O
multiple	O
VEGFRs	B-GENE-N
as	O
well	O
as	O
PDGFR	B-GENE-Y
-	I-GENE-Y
beta	I-GENE-Y
.	O

Sorafenib	B-CHEMICAL
has	O
the	O
added	O
advantage	O
of	O
inhibiting	O
multiple	O
different	O
Raf	B-GENE-Y
isoforms	O
,	O
which	O
enables	O
it	O
to	O
target	O
TGF	B-GENE-Y
-	I-GENE-Y
alpha	I-GENE-Y
/	O
EGFR	B-GENE-Y
signaling	O
and	O
may	O
also	O
enhance	O
its	O
inhibition	O
of	O
VEGFR	B-GENE-N
and	O
PDGFR	B-GENE-Y
-	I-GENE-Y
beta	I-GENE-Y
.	O

This	O
review	O
will	O
examine	O
the	O
recent	O
advances	O
in	O
our	O
understanding	O
of	O
the	O
biology	O
of	O
clear	O
-	O
cell	O
RCC	O
and	O
show	O
how	O
those	O
advances	O
have	O
helped	O
delineate	O
new	O
targets	O
of	O
opportunity	O
for	O
treatment	O
.	O

It	O
will	O
also	O
present	O
the	O
early	O
clinical	O
results	O
of	O
agents	O
that	O
target	O
the	O
pathways	O
dysregulated	O
in	O
clear	O
-	O
cell	O
RCC	O
,	O
with	O
special	O
emphasis	O
on	O
sorafenib	B-CHEMICAL
and	O
the	O
other	O
active	O
MKIs	O
,	O
and	O
will	O
describe	O
the	O
scientific	O
rationales	O
for	O
ongoing	O
and	O
future	O
sorafenib	B-CHEMICAL
-	O
based	O
combination	O
therapy	O
trials	O
in	O
RCC	O
.	O

A	O
case	O
of	O
adult	O
-	O
onset	O
type	O
II	O
citrullinemia	O
-	O
-	O
deterioration	O
of	O
clinical	O
course	O
after	O
infusion	O
of	O
hyperosmotic	O
and	O
high	O
sugar	O
solutions	O
.	O

BACKGROUND	O
:	O
Adult	O
-	O
onset	O
type	O
II	O
citrullinemia	O
(	O
CTLN2	O
)	O
is	O
an	O
autosomal	O
recessive	O
disorder	O
caused	O
by	O
mutations	O
of	O
SLC25A13	B-GENE-Y
gene	O
encoding	O
citrin	B-GENE-Y
and	O
is	O
characterized	O
by	O
recurrent	O
encephalopathy	O
with	O
hyperammonemia	O
.	O

Factors	O
affecting	O
disease	O
progression	O
remain	O
unknown	O
.	O

We	O
report	O
a	O
case	O
with	O
CTLN2	O
,	O
whose	O
clinical	O
course	O
was	O
rapidly	O
worsened	O
by	O
the	O
administration	O
of	O
Glyceol	O
,	O
a	O
hyperosmotic	O
diuretic	O
solution	O
consisting	O
of	O
10	O
%	O
glycerol	B-CHEMICAL
and	O
5	O
%	O
fructose	B-CHEMICAL
in	O
saline	O
.	O

CASE	O
REPORT	O
:	O
A	O
34	O
-	O
year	O
-	O
old	O
man	O
was	O
admitted	O
in	O
coma	O
after	O
repeated	O
episodes	O
of	O
altered	O
consciousness	O
.	O

His	O
plasma	O
ammonia	B-CHEMICAL
level	O
was	O
markedly	O
elevated	O
without	O
any	O
evidence	O
of	O
liver	O
diseases	O
.	O

Brain	O
MRI	O
revealed	O
high	O
signal	O
intensities	O
at	O
the	O
bilateral	O
cingulate	O
gyri	O
and	O
insular	O
cortices	O
,	O
suggesting	O
hepatic	O
encephalopathy	O
.	O

We	O
administered	O
Glyceol	O
.	O
intravenously	O
to	O
alleviate	O
brain	O
edema	O
,	O
however	O
,	O
he	O
developed	O
intractable	O
seizures	O
along	O
with	O
steep	O
increase	O
in	O
plasma	O
ammonia	B-CHEMICAL
levels	O
(	O
from	O
808	O
to	O
2210	O
microg	O
/	O
dL	O
)	O
and	O
died	O
.	O

The	O
diagnosis	O
of	O
CTLN2	O
was	O
confirmed	O
by	O
elevations	O
of	O
plasma	O
citrulline	B-CHEMICAL
level	O
(	O
384	O
.	O
3	O
nmol	O
/	O
mL	O
;	O
normal	O
17	O
-	O
43	O
nmol	O
/	O
mL	O
)	O
and	O
serum	O
pancreatic	B-GENE-Y
secretory	I-GENE-Y
trypsin	I-GENE-Y
inhibitor	I-GENE-Y
(	O
PSTI	B-GENE-Y
)	O
(	O
110	O
ng	O
/	O
mL	O
;	O
normal	O
4	O
.	O
6	O
-	O
12	O
.	O
2	O
ng	O
/	O
mL	O
)	O
,	O
decrease	O
in	O
hepatic	O
argininosuccinate	B-GENE-Y
synthetase	I-GENE-Y
activity	O
(	O
5	O
.	O
5	O
%	O
of	O
control	O
)	O
,	O
lack	O
of	O
hepatic	O
citrin	B-GENE-Y
protein	O
expression	O
and	O
mutations	O
in	O
SLC25A13	B-GENE-Y
gene	O
(	O
compound	O
heterozygote	O
with	O
S225X	B-GENE-N
and	O
Ex1	B-GENE-N
-	I-GENE-N
1G	I-GENE-N
>	I-GENE-N
A	I-GENE-N
)	O
.	O

CONCLUSIONS	O
:	O
Physicians	O
should	O
take	O
CTLN2	O
into	O
consideration	O
as	O
a	O
differential	O
diagnosis	O
in	O
Asian	O
patients	O
with	O
a	O
history	O
of	O
repeated	O
unconsciousness	O
with	O
hyperammonemia	O
and	O
use	O
D	B-CHEMICAL
-	I-CHEMICAL
mannitol	I-CHEMICAL
but	O
not	O
glycerol	B-CHEMICAL
to	O
treat	O
brain	O
edema	O
in	O
patients	O
with	O
CTLN2	O
.	O

Inhibition	O
of	O
gentamicin	B-CHEMICAL
binding	O
to	O
rat	O
renal	O
brush	O
-	O
border	O
membrane	O
by	O
megalin	B-GENE-Y
ligands	O
and	O
basic	O
peptides	O
.	O

Our	O
previous	O
studies	O
showed	O
that	O
coadministration	O
of	O
cytochrome	B-GENE-Y
c	I-GENE-Y
and	O
a	O
20	O
-	O
residue	O
basic	O
peptide	O
,	O
N	O
-	O
WASP181	O
-	O
200	O
(	O
NISHTKEKKKGKAKKKRLTK	B-GENE-N
,	O
pI	O
=	O
10	O
.	O
87	O
)	O
inhibits	O
renal	O
accumulation	O
of	O
gentamicin	B-CHEMICAL
.	O

In	O
this	O
study	O
,	O
we	O
examined	O
effects	O
of	O
ligands	O
of	O
megalin	B-GENE-Y
,	O
an	O
endocytic	O
receptor	O
involved	O
in	O
renal	O
uptake	O
of	O
gentamicin	B-CHEMICAL
,	O
and	O
basic	O
peptides	O
including	O
N	O
-	O
WASP180	O
-	O
200	O
and	O
its	O
mutant	O
peptides	O
on	O
gentamicin	B-CHEMICAL
binding	O
to	O
isolated	O
rat	O
renal	O
brush	O
-	O
border	O
membrane	O
(	O
BBM	O
)	O
.	O

Gentamicin	B-CHEMICAL
binding	O
to	O
BBM	O
was	O
inhibited	O
by	O
megalin	B-GENE-Y
ligands	O
,	O
basic	O
peptide	O
fragments	O
of	O
cytochrome	B-GENE-Y
c	I-GENE-Y
,	O
and	O
N	O
-	O
WASP181	O
-	O
200	O
in	O
a	O
concentration	O
-	O
dependent	O
manner	O
.	O

Klotz	O
plot	O
analysis	O
showed	O
that	O
N	O
-	O
WASP181	O
-	O
200	O
inhibited	O
the	O
binding	O
of	O
gentamicin	B-CHEMICAL
in	O
a	O
competitive	O
manner	O
.	O

By	O
substituting	O
glycines	B-CHEMICAL
for	O
lysines	B-CHEMICAL
in	O
N	O
-	O
WASP181	O
-	O
200	O
at	O
positions	O
9	O
and	O
15	O
,	O
the	O
inhibitory	O
effect	O
on	O
gentamicin	B-CHEMICAL
binding	O
to	O
BBM	O
was	O
reduced	O
,	O
which	O
may	O
be	O
related	O
to	O
a	O
decrease	O
in	O
the	O
alpha	B-GENE-N
-	I-GENE-N
helix	I-GENE-N
content	O
in	O
the	O
peptide	O
.	O

Gentamicin	B-CHEMICAL
binding	O
to	O
BBM	O
treated	O
with	O
trypsin	B-GENE-N
,	O
in	O
which	O
megalin	B-GENE-Y
completely	O
disappeared	O
,	O
was	O
significantly	O
but	O
not	O
completely	O
decreased	O
compared	O
with	O
the	O
native	O
BBM	O
.	O

In	O
addition	O
,	O
treatment	O
of	O
BBM	O
with	O
trypsin	B-GENE-N
led	O
to	O
a	O
decrease	O
in	O
the	O
inhibitory	O
effect	O
of	O
N	O
-	O
WASP181	O
-	O
200	O
on	O
gentamicin	B-CHEMICAL
binding	O
.	O

These	O
observations	O
support	O
that	O
megalin	B-GENE-Y
ligands	O
and	O
basic	O
peptides	O
including	O
N	O
-	O
WASP181	O
-	O
200	O
decrease	O
renal	O
accumulation	O
of	O
gentamicin	B-CHEMICAL
by	O
inhibiting	O
its	O
binding	O
to	O
BBM	O
of	O
proximal	O
tubule	O
cells	O
,	O
partly	O
interacting	O
with	O
megalin	B-GENE-Y
.	O

In	O
addition	O
,	O
the	O
alpha	B-GENE-N
-	I-GENE-N
helix	I-GENE-N
conformation	O
may	O
play	O
an	O
important	O
role	O
in	O
the	O
inhibitory	O
effect	O
of	O
N	O
-	O
WASP181	O
-	O
200	O
on	O
the	O
binding	O
of	O
gentamicin	B-CHEMICAL
to	O
BBM	O
.	O

Thymidylate	B-GENE-Y
synthase	I-GENE-Y
expression	O
pattern	O
,	O
expression	O
level	O
and	O
single	O
nucleotide	B-CHEMICAL
polymorphism	O
are	O
predictors	O
for	O
disease	O
-	O
free	O
survival	O
in	O
patients	O
of	O
colorectal	O
cancer	O
treated	O
with	O
5	B-CHEMICAL
-	I-CHEMICAL
fluorouracil	I-CHEMICAL
.	O

Several	O
variables	O
associated	O
to	O
thymidylate	B-GENE-Y
synthase	I-GENE-Y
(	O
TS	B-GENE-Y
)	O
,	O
the	O
biological	O
target	O
of	O
5	B-CHEMICAL
-	I-CHEMICAL
fluorouracil	I-CHEMICAL
(	O
5FU	B-CHEMICAL
)	O
have	O
been	O
studied	O
for	O
their	O
possible	O
role	O
as	O
predictors	O
of	O
the	O
clinical	O
outcome	O
and	O
response	O
to	O
chemotherapy	O
in	O
colorectal	O
cancer	O
(	O
CRC	O
)	O
patients	O
.	O

The	O
level	O
of	O
protein	O
expression	O
and	O
the	O
number	O
of	O
variable	O
tandem	O
-	O
repeats	O
of	O
a	O
28	O
-	O
bp	O
sequence	O
within	O
the	O
gene	O
promoter	O
have	O
been	O
proposed	O
as	O
predictive	O
and	O
/	O
or	O
prognostic	O
factors	O
with	O
variable	O
agreement	O
,	O
while	O
consensus	O
seems	O
to	O
be	O
achieved	O
with	O
respect	O
to	O
the	O
value	O
of	O
a	O
single	O
nucleotide	B-CHEMICAL
polymorphism	O
(	O
SNP	O
)	O
described	O
within	O
this	O
same	O
region	O
.	O

More	O
recently	O
,	O
an	O
association	O
between	O
TS	O
expression	O
pattern	O
and	O
survival	O
has	O
been	O
disclosed	O
.	O

Paraffin	O
-	O
embedded	O
sections	O
from	O
140	O
CRC	O
patients	O
were	O
analyzed	O
by	O
immuno	O
-	O
histochemistry	O
(	O
Mab	O
TS106	O
)	O
for	O
TS	B-GENE-Y
levels	O
and	O
expression	O
pattern	O
.	O

Also	O
,	O
VNTR	O
and	O
SNP	O
were	O
determined	O
by	O
polymerase	O
-	O
chain	O
reaction	O
(	O
PCR	O
)	O
and	O
restriction	O
-	O
length	O
-	O
fragment	O
polymorphism	O
(	O
RFLP	O
)	O
in	O
123	O
and	O
112	O
patients	O
,	O
respectively	O
.	O

Cytoplasmic	O
expression	O
pattern	O
tended	O
to	O
be	O
associated	O
to	O
C	O
SNP	O
(	O
p	O
=	O
0	O
.	O
06	O
)	O
.	O

Low	O
TS	B-GENE-Y
expression	O
levels	O
,	O
cytoplasmic	O
expression	O
pattern	O
and	O
C	O
SNP	O
arose	O
as	O
variables	O
associated	O
to	O
longer	O
progression	O
-	O
free	O
survival	O
(	O
PFS	O
)	O
in	O
patients	O
treated	O
with	O
5FU	B-CHEMICAL
.	O

Accordingly	O
,	O
patients	O
having	O
at	O
least	O
two	O
favourable	O
or	O
unfavourable	O
variables	O
were	O
classified	O
respectively	O
as	O
'	O
low	O
risk	O
'	O
and	O
'	O
high	O
risk	O
'	O
,	O
the	O
former	O
showing	O
significantly	O
longer	O
PFS	O
(	O
p	O
=	O
0	O
.	O
0299	O
)	O
.	O

The	O
possibility	O
for	O
designing	O
a	O
selection	O
method	O
for	O
subsequent	O
therapies	O
is	O
suggested	O
on	O
the	O
basis	O
of	O
a	O
probable	O
combined	O
effect	O
of	O
the	O
above	O
mentioned	O
parameters	O
but	O
further	O
studies	O
in	O
larger	O
populations	O
are	O
needed	O
to	O
confirm	O
these	O
results	O
.	O

Leishmania	O
donovani	O
singly	O
deficient	O
in	O
HGPRT	B-GENE-Y
,	O
APRT	B-GENE-Y
or	O
XPRT	B-GENE-Y
are	O
viable	O
in	O
vitro	O
and	O
within	O
mammalian	O
macrophages	O
.	O

Leishmania	O
species	O
express	O
three	O
phosphoribosyltransferase	B-GENE-N
enzymes	O
,	O
hypoxanthine	B-GENE-Y
-	I-GENE-Y
guanine	I-GENE-Y
phosphoribosyltransferase	I-GENE-Y
(	O
HGPRT	B-GENE-Y
)	O
,	O
adenine	B-GENE-Y
phosphoribosyltransferase	I-GENE-Y
(	O
APRT	B-GENE-Y
)	O
,	O
and	O
xanthine	B-GENE-Y
phosphoribosyltransferase	I-GENE-Y
(	O
XPRT	B-GENE-Y
)	O
,	O
which	O
enable	O
this	O
genus	O
to	O
acquire	O
purine	B-CHEMICAL
nutrients	O
from	O
their	O
hosts	O
.	O

To	O
test	O
whether	O
any	O
of	O
these	O
enzymes	O
is	O
essential	O
for	O
viability	O
,	O
transformation	O
into	O
amastigotes	O
,	O
and	O
infectivity	O
and	O
proliferation	O
within	O
mammalian	O
macrophages	O
,	O
Deltahgprt	O
,	O
Deltaaprt	O
,	O
and	O
Deltaxprt	O
null	O
mutants	O
were	O
created	O
by	O
targeted	O
gene	O
replacement	O
within	O
a	O
virulent	O
background	O
of	O
Leishmania	O
donovani	O
.	O

Each	O
of	O
the	O
three	O
knockout	O
strains	O
was	O
viable	O
as	O
promastigotes	O
and	O
axenic	O
amastigotes	O
and	O
capable	O
of	O
maintaining	O
an	O
infection	O
in	O
bone	O
marrow	O
-	O
derived	O
murine	O
macrophages	O
.	O

These	O
data	O
support	O
the	O
hypothesis	O
that	O
none	O
of	O
the	O
three	O
phosphoribosyltransferases	B-GENE-N
is	O
essential	O
for	O
purine	B-CHEMICAL
salvage	O
or	O
viability	O
by	O
itself	O
and	O
that	O
purine	B-CHEMICAL
salvage	O
occurs	O
through	O
multiple	O
anabolic	O
routes	O
in	O
both	O
parasite	O
life	O
cycle	O
stages	O
.	O

In	O
addition	O
these	O
studies	O
revealed	O
the	O
presence	O
of	O
an	O
adenine	B-GENE-Y
aminohydrolase	I-GENE-Y
enzyme	O
in	O
L	O
.	O
donovani	O
axenic	O
amastigotes	O
,	O
an	O
activity	O
previously	O
thought	O
to	O
be	O
restricted	O
to	O
promastigotes	O
.	O

Loss	O
of	O
a	O
primordial	O
identity	O
element	O
for	O
a	O
mammalian	O
mitochondrial	O
aminoacylation	O
system	O
.	O

In	O
mammalian	O
mitochondria	O
the	O
translational	O
machinery	O
is	O
of	O
dual	O
origin	O
with	O
tRNAs	O
encoded	O
by	O
a	O
simplified	O
and	O
rapidly	O
evolving	O
mitochondrial	O
(	O
mt	O
)	O
genome	O
and	O
aminoacyl	B-GENE-N
-	I-GENE-N
tRNA	I-GENE-N
synthetases	I-GENE-N
(	O
aaRS	B-GENE-N
)	O
coded	O
by	O
the	O
nuclear	O
genome	O
,	O
and	O
imported	O
.	O

Mt	O
-	O
tRNAs	O
are	O
atypical	O
with	O
biased	O
sequences	O
,	O
size	O
variations	O
in	O
loops	O
and	O
stems	O
,	O
and	O
absence	O
of	O
residues	O
forming	O
classical	O
tertiary	O
interactions	O
,	O
whereas	O
synthetases	B-GENE-N
appear	O
typical	O
.	O

This	O
raises	O
questions	O
about	O
identity	O
elements	O
in	O
mt	O
-	O
tRNAs	O
and	O
adaptation	O
of	O
their	O
cognate	O
mt	B-GENE-N
-	I-GENE-N
aaRSs	I-GENE-N
.	O

We	O
have	O
explored	O
here	O
the	O
human	O
mt	O
-	O
aspartate	B-CHEMICAL
system	O
in	O
which	O
a	O
prokaryotic	B-GENE-N
-	I-GENE-N
type	I-GENE-N
AspRS	I-GENE-N
,	O
highly	O
similar	O
to	O
the	O
Escherichia	O
coli	O
enzyme	O
,	O
recognizes	O
a	O
bizarre	O
tRNA	O
(	O
Asp	O
)	O
.	O

Analysis	O
of	O
human	B-GENE-N
mt	I-GENE-N
-	I-GENE-N
tRNA	I-GENE-N
(	I-GENE-N
Asp	I-GENE-N
)	I-GENE-N
transcripts	I-GENE-N
confirms	O
the	O
identity	O
role	O
of	O
the	O
GUC	O
anticodon	O
as	O
in	O
other	O
aspartylation	O
systems	O
but	O
reveals	O
the	O
non	O
-	O
involvement	O
of	O
position	O
73	O
.	O

This	O
position	O
is	O
otherwise	O
known	O
as	O
the	O
site	O
of	O
a	O
universally	O
conserved	O
major	O
aspartate	B-CHEMICAL
identity	O
element	O
,	O
G73	B-GENE-N
,	O
also	O
known	O
as	O
a	O
primordial	O
identity	O
signal	O
.	O

In	O
mt	O
-	O
tRNA	O
(	O
Asp	O
)	O
,	O
position	O
73	O
can	O
be	O
occupied	O
by	O
any	O
of	O
the	O
four	O
nucleotides	B-CHEMICAL
without	O
affecting	O
aspartylation	O
.	O

Sequence	O
alignments	O
of	O
various	O
AspRSs	B-GENE-N
allowed	O
placing	O
Gly	B-CHEMICAL
-	O
269	O
at	O
a	O
position	O
occupied	O
by	O
Asp	B-CHEMICAL
-	O
220	O
,	O
the	O
residue	O
contacting	O
G73	B-GENE-N
in	O
the	O
crystallographic	O
structure	O
of	O
E	B-GENE-Y
.	I-GENE-Y
coli	I-GENE-Y
AspRS	I-GENE-Y
-	O
tRNA	O
(	O
Asp	O
)	O
complex	O
.	O

Replacing	O
this	O
glycine	B-CHEMICAL
by	O
an	O
aspartate	B-CHEMICAL
renders	O
human	B-GENE-Y
mt	I-GENE-Y
-	I-GENE-Y
AspRS	I-GENE-Y
more	O
discriminative	O
to	O
G73	B-GENE-N
.	O

Restriction	O
in	O
the	O
aspartylation	O
identity	O
set	O
,	O
driven	O
by	O
a	O
rapid	O
mutagenic	O
rate	O
of	O
the	O
mt	O
-	O
genome	O
,	O
suggests	O
a	O
reverse	O
evolution	O
of	O
the	O
mt	O
-	O
tRNA	O
(	O
Asp	O
)	O
identity	O
elements	O
in	O
regard	O
to	O
its	O
bacterial	O
ancestor	O
.	O

Metabolic	O
syndrome	O
:	O
adenosine	B-GENE-N
monophosphate	I-GENE-N
-	I-GENE-N
activated	I-GENE-N
protein	I-GENE-N
kinase	I-GENE-N
and	O
malonyl	B-CHEMICAL
coenzyme	I-CHEMICAL
A	I-CHEMICAL
.	O

The	O
metabolic	O
syndrome	O
can	O
be	O
defined	O
as	O
a	O
state	O
of	O
metabolic	O
dysregulation	O
characterized	O
by	O
insulin	B-GENE-Y
resistance	O
,	O
central	O
obesity	O
,	O
and	O
a	O
predisposition	O
to	O
type	O
2	O
diabetes	O
,	O
dyslipidemia	O
,	O
premature	O
atherosclerosis	O
,	O
and	O
other	O
diseases	O
.	O

An	O
increasing	O
body	O
of	O
evidence	O
has	O
linked	O
the	O
metabolic	O
syndrome	O
to	O
abnormalities	O
in	O
lipid	O
metabolism	O
that	O
ultimately	O
lead	O
to	O
cellular	O
dysfunction	O
.	O

We	O
review	O
here	O
the	O
hypothesis	O
that	O
,	O
in	O
many	O
instances	O
,	O
the	O
cause	O
of	O
these	O
lipid	O
abnormalities	O
could	O
be	O
a	O
dysregulation	O
of	O
the	O
adenosine	B-GENE-N
monophosphate	I-GENE-N
-	I-GENE-N
activated	I-GENE-N
protein	I-GENE-N
kinase	I-GENE-N
(	O
AMPK	B-GENE-N
)	O
/	O
malonyl	B-CHEMICAL
coenzyme	I-CHEMICAL
A	I-CHEMICAL
(	O
CoA	O
)	O
fuel	O
-	O
sensing	O
and	O
signaling	O
mechanism	O
.	O

Such	O
dysregulation	O
could	O
be	O
reflected	O
by	O
isolated	O
increases	O
in	O
malonyl	B-CHEMICAL
CoA	I-CHEMICAL
or	O
by	O
concurrent	O
changes	O
in	O
malonyl	B-CHEMICAL
CoA	I-CHEMICAL
and	O
AMPK	B-GENE-N
,	O
both	O
of	O
which	O
would	O
alter	O
intracellular	O
fatty	O
acid	O
partitioning	O
.	O

The	O
possibility	O
is	O
also	O
raised	O
that	O
pharmacological	O
agents	O
and	O
other	O
factors	O
that	O
activate	O
AMPK	B-GENE-N
and	O
/	O
or	O
decrease	O
malonyl	B-CHEMICAL
CoA	I-CHEMICAL
could	O
be	O
therapeutic	O
targets	O
.	O

Chronic	O
effect	O
of	O
[	B-CHEMICAL
D	I-CHEMICAL
-	I-CHEMICAL
Pen2	I-CHEMICAL
,	I-CHEMICAL
D	I-CHEMICAL
-	I-CHEMICAL
Pen5	I-CHEMICAL
]	I-CHEMICAL
enkephalin	I-CHEMICAL
on	O
rat	B-GENE-N
brain	I-GENE-N
opioid	I-GENE-N
receptors	I-GENE-N
.	O

In	O
previous	O
studies	O
,	O
we	O
have	O
demonstrated	O
that	O
chronic	O
etorphine	B-CHEMICAL
or	O
[	B-CHEMICAL
D	I-CHEMICAL
-	I-CHEMICAL
Ala2	I-CHEMICAL
,	I-CHEMICAL
D	I-CHEMICAL
-	I-CHEMICAL
Leu5	I-CHEMICAL
]	I-CHEMICAL
enkephalin	I-CHEMICAL
(	O
DADLE	B-CHEMICAL
)	O
treatment	O
of	O
rats	O
results	O
in	O
the	O
reduction	O
of	O
mu	B-GENE-N
-	I-GENE-N
and	I-GENE-N
delta	I-GENE-N
-	I-GENE-N
opioid	I-GENE-N
receptor	I-GENE-N
binding	O
activities	O
as	O
tolerance	O
develops	O
.	O

As	O
both	O
etorphine	B-CHEMICAL
and	O
DADLE	B-CHEMICAL
are	O
relatively	O
non	O
-	O
specific	O
opioid	O
ligands	O
,	O
interacting	O
with	O
both	O
mu	B-GENE-N
-	I-GENE-N
and	I-GENE-N
delta	I-GENE-N
-	I-GENE-N
receptors	I-GENE-N
,	O
these	O
studies	O
could	O
not	O
determine	O
whether	O
down	O
-	O
regulation	O
of	O
a	O
specific	O
receptor	O
type	O
occurs	O
.	O

Therefore	O
,	O
in	O
the	O
present	O
studies	O
,	O
animals	O
were	O
rendered	O
tolerant	O
to	O
the	O
delta	B-GENE-Y
-	I-GENE-Y
opioid	I-GENE-Y
receptor	I-GENE-Y
-	O
selective	O
agonist	O
[	B-CHEMICAL
D	I-CHEMICAL
-	I-CHEMICAL
Pen2	I-CHEMICAL
,	I-CHEMICAL
D	I-CHEMICAL
-	I-CHEMICAL
Pen5	I-CHEMICAL
]	I-CHEMICAL
enkephalin	I-CHEMICAL
(	O
DPDPE	B-CHEMICAL
)	O
,	O
and	O
receptor	O
binding	O
activities	O
were	O
measured	O
.	O

Treating	O
Sprague	O
-	O
Dawley	O
rats	O
with	O
increasing	O
doses	O
of	O
DPDPE	B-CHEMICAL
(	O
80	O
-	O
160	O
-	O
240	O
-	O
320	O
micrograms	O
/	O
kg	O
)	O
i	O
.	O
c	O
.	O
v	O
.	O
for	O
1	O
to	O
4	O
days	O
resulted	O
in	O
a	O
time	O
-	O
dependent	O
increase	O
in	O
the	O
AD50	O
of	O
DPDPE	B-CHEMICAL
to	O
elicit	O
an	O
antinociceptive	O
response	O
.	O

When	O
delta	B-GENE-Y
-	I-GENE-Y
receptor	I-GENE-Y
binding	O
was	O
determined	O
by	O
using	O
[	B-CHEMICAL
3H	I-CHEMICAL
]	I-CHEMICAL
DPDPE	I-CHEMICAL
,	O
a	O
40	O
-	O
50	O
%	O
decrease	O
in	O
binding	O
in	O
the	O
midbrain	O
and	O
cortex	O
,	O
and	O
25	O
-	O
35	O
%	O
decrease	O
in	O
binding	O
in	O
the	O
striatum	O
were	O
observed	O
after	O
3	O
or	O
4	O
days	O
of	O
DPDPE	B-CHEMICAL
treatment	O
.	O

Scatchard	O
analysis	O
of	O
the	O
[	B-CHEMICAL
3H	I-CHEMICAL
]	I-CHEMICAL
DPDPE	I-CHEMICAL
saturation	O
binding	O
data	O
revealed	O
a	O
decrease	O
in	O
Bmax	O
values	O
and	O
no	O
significant	O
change	O
in	O
Kd	O
values	O
.	O

To	O
our	O
surprise	O
,	O
when	O
mu	B-GENE-Y
-	I-GENE-Y
receptor	I-GENE-Y
binding	O
was	O
determined	O
by	O
using	O
[	B-CHEMICAL
3H	I-CHEMICAL
]	I-CHEMICAL
Tyr	I-CHEMICAL
-	I-CHEMICAL
D	I-CHEMICAL
-	I-CHEMICAL
Ala	I-CHEMICAL
-	I-CHEMICAL
Gly	I-CHEMICAL
-	I-CHEMICAL
MePhe	I-CHEMICAL
-	I-CHEMICAL
Gly	I-CHEMICAL
-	I-CHEMICAL
ol	I-CHEMICAL
(	O
DAMGO	B-CHEMICAL
)	O
,	O
a	O
10	O
-	O
15	O
%	O
decrease	O
in	O
binding	O
was	O
also	O
observed	O
in	O
the	O
midbrain	O
and	O
cortex	O
after	O
4	O
days	O
of	O
DPDPE	B-CHEMICAL
treatment	O
.	O

Our	O
conclusion	O
is	O
that	O
chronic	O
DPDPE	B-CHEMICAL
treatment	O
preferentially	O
reduces	O
delta	B-GENE-Y
-	I-GENE-Y
opioid	I-GENE-Y
receptor	I-GENE-Y
binding	O
activity	O
.	O

Its	O
minor	O
effect	O
on	O
the	O
mu	B-GENE-Y
-	I-GENE-Y
opioid	I-GENE-Y
receptor	I-GENE-Y
maybe	O
due	O
to	O
an	O
interaction	O
between	O
delta	B-GENE-Y
cx	I-GENE-Y
and	O
mu	B-GENE-Y
cx	I-GENE-Y
binding	O
sites	O
.	O

[	O
Preclinical	O
pharmacology	O
of	O
amoxapine	B-CHEMICAL
and	O
amitriptyline	B-CHEMICAL
.	O
Implications	O
of	O
serotoninergic	O
and	O
opiodergic	O
systems	O
in	O
their	O
central	O
effect	O
in	O
rats	O
]	O
.	O

The	O
effects	O
of	O
two	O
antidepressant	O
drugs	O
,	O
amoxapine	B-CHEMICAL
and	O
amitriptyline	B-CHEMICAL
,	O
that	O
belong	O
to	O
distinct	O
chemical	O
classes	O
,	O
have	O
been	O
examined	O
on	O
various	O
biochemical	O
parameters	O
related	O
to	O
serotoninergic	O
and	O
opioidergic	O
neurotransmission	O
in	O
the	O
rat	O
brain	O
and	O
spinal	O
cord	O
.	O

In	O
vitro	O
binding	O
studies	O
showed	O
that	O
both	O
amoxapine	B-CHEMICAL
and	O
amitriptyline	B-CHEMICAL
interact	O
in	O
the	O
nanomolar	O
range	O
with	O
5	B-GENE-N
-	I-GENE-N
HT2	I-GENE-N
receptors	O
labelled	O
by	O
[	B-CHEMICAL
3H	I-CHEMICAL
]	I-CHEMICAL
ketanserin	I-CHEMICAL
in	O
cortical	O
membranes	O
.	O

By	O
contrast	O
,	O
neither	O
amoxapine	B-CHEMICAL
nor	O
amitriptyline	B-CHEMICAL
can	O
be	O
considered	O
as	O
possible	O
ligands	O
of	O
5	B-GENE-Y
-	I-GENE-Y
HT1A	I-GENE-Y
and	O
5	B-GENE-Y
-	I-GENE-Y
HT1B	I-GENE-Y
receptors	O
because	O
their	O
affinities	O
for	O
these	O
sites	O
are	O
in	O
the	O
micromolar	O
range	O
(	O
or	O
even	O
worse	O
)	O
.	O

Interestingly	O
,	O
amoxapine	B-CHEMICAL
binds	O
with	O
a	O
good	O
affinity	O
(	O
IC50	O
=	O
0	O
.	O
30	O
microM	O
)	O
to	O
5	B-GENE-N
-	I-GENE-N
HT3	I-GENE-N
receptors	O
labelled	O
by	O
[	B-CHEMICAL
3H	I-CHEMICAL
]	I-CHEMICAL
zacopride	I-CHEMICAL
in	O
cortical	O
membranes	O
.	O

Complementary	O
experiments	O
using	O
the	O
5	B-GENE-N
-	I-GENE-N
HT3	I-GENE-N
-	O
dependent	O
Bezold	O
-	O
Jarisch	O
reflex	O
confirmed	O
that	O
amoxapine	B-CHEMICAL
really	O
acts	O
in	O
vivo	O
as	O
a	O
5	B-GENE-N
-	I-GENE-N
HT3	I-GENE-N
antagonist	O
(	O
IC50	O
=	O
50	O
micrograms	O
/	O
kg	O
i	O
.	O
v	O
.	O
)	O
,	O
whereas	O
amitriptyline	B-CHEMICAL
is	O
essentially	O
inactive	O
on	O
5	B-GENE-N
-	I-GENE-N
HT3	I-GENE-N
receptors	O
.	O

The	O
second	O
part	O
of	O
this	O
study	O
consisted	O
of	O
looking	O
for	O
possible	O
changes	O
in	O
central	O
5	B-GENE-N
-	I-GENE-N
HT	I-GENE-N
receptors	I-GENE-N
24	O
h	O
after	O
either	O
a	O
single	O
or	O
a	O
repeated	O
(	O
for	O
14	O
days	O
)	O
treatment	O
with	O
amoxapine	B-CHEMICAL
(	O
10	O
mg	O
/	O
kg	O
i	O
.	O
p	O
.	O
each	O
day	O
)	O
or	O
amitriptyline	B-CHEMICAL
(	O
10	O
mg	O
/	O
kg	O
i	O
.	O
p	O
.	O
)	O
.	O

A	O
marked	O
decrease	O
in	O
the	O
density	O
of	O
5	B-GENE-N
-	I-GENE-N
HT2	I-GENE-N
receptors	O
was	O
found	O
in	O
the	O
cerebral	O
cortex	O
in	O
both	O
treatment	O
groups	O
.	O

By	O
contrast	O
,	O
neither	O
5	B-GENE-Y
-	I-GENE-Y
HT1A	I-GENE-Y
nor	O
5	B-GENE-Y
-	I-GENE-Y
HT1B	I-GENE-Y
receptors	O
were	O
significantly	O
affected	O
in	O
any	O
brain	O
region	O
studied	O
.	O

Finally	O
we	O
explored	O
whether	O
acute	O
and	O
/	O
or	O
chronic	O
administration	O
of	O
amoxapine	B-CHEMICAL
or	O
amitriptyline	B-CHEMICAL
affected	O
the	O
levels	O
of	O
opioid	O
peptides	O
and	O
the	O
mu	B-GENE-N
and	I-GENE-N
delta	I-GENE-N
classes	I-GENE-N
of	I-GENE-N
opioid	I-GENE-N
receptors	I-GENE-N
in	O
various	O
regions	O
of	O
the	O
brain	O
and	O
the	O
spinal	O
cord	O
.	O
(	O
ABSTRACT	O
TRUNCATED	O
AT	O
250	O
WORDS	O
)	O

Desvenlafaxine	B-CHEMICAL
succinate	I-CHEMICAL
:	O
A	O
new	O
serotonin	B-CHEMICAL
and	O
norepinephrine	B-CHEMICAL
reuptake	O
inhibitor	O
.	O

The	O
purpose	O
of	O
this	O
study	O
was	O
to	O
characterize	O
a	O
new	O
chemical	O
entity	O
,	O
desvenlafaxine	B-CHEMICAL
succinate	I-CHEMICAL
(	O
DVS	B-CHEMICAL
)	O
.	O

DVS	B-CHEMICAL
is	O
a	O
novel	O
salt	O
form	O
of	O
the	O
isolated	O
major	O
active	O
metabolite	O
of	O
venlafaxine	B-CHEMICAL
.	O

Competitive	O
radioligand	O
binding	O
assays	O
were	O
performed	O
using	O
cells	O
expressing	O
either	O
the	O
human	B-GENE-Y
serotonin	I-GENE-Y
(	I-GENE-Y
5	I-GENE-Y
-	I-GENE-Y
HT	I-GENE-Y
)	I-GENE-Y
transporter	I-GENE-Y
(	O
hSERT	B-GENE-Y
)	O
or	O
norepinephrine	B-GENE-Y
(	I-GENE-Y
NE	I-GENE-Y
)	I-GENE-Y
transporter	I-GENE-Y
(	O
hNET	B-GENE-Y
)	O
with	O
K	O
(	O
i	O
)	O
values	O
for	O
DVS	B-CHEMICAL
of	O
40	O
.	O
2	O
+	O
/	O
-	O
1	O
.	O
6	O
and	O
558	O
.	O
4	O
+	O
/	O
-	O
121	O
.	O
6	O
nM	O
,	O
respectively	O
.	O

DVS	B-CHEMICAL
showed	O
weak	O
binding	O
affinity	O
(	O
62	O
%	O
inhibition	O
at	O
100	O
microM	O
)	O
at	O
the	O
human	B-GENE-Y
dopamine	I-GENE-Y
(	I-GENE-Y
DA	I-GENE-Y
)	I-GENE-Y
transporter	I-GENE-Y
.	O

Inhibition	O
of	O
[	B-CHEMICAL
3H	I-CHEMICAL
]	I-CHEMICAL
5	I-CHEMICAL
-	I-CHEMICAL
HT	I-CHEMICAL
or	O
[	B-CHEMICAL
3H	I-CHEMICAL
]	I-CHEMICAL
NE	I-CHEMICAL
uptake	O
by	O
DVS	B-CHEMICAL
for	O
the	O
hSERT	B-GENE-Y
or	O
hNET	B-GENE-Y
produced	O
IC50	O
values	O
of	O
47	O
.	O
3	O
+	O
/	O
-	O
19	O
.	O
4	O
and	O
531	O
.	O
3	O
+	O
/	O
-	O
113	O
.	O
0	O
nM	O
,	O
respectively	O
.	O

DVS	B-CHEMICAL
(	O
10	O
microM	O
)	O
,	O
examined	O
at	O
a	O
large	O
number	O
of	O
nontransporter	O
targets	O
,	O
showed	O
no	O
significant	O
activity	O
.	O

DVS	B-CHEMICAL
(	O
30	O
mg	O
/	O
kg	O
orally	O
)	O
rapidly	O
penetrated	O
the	O
male	O
rat	O
brain	O
and	O
hypothalamus	O
.	O

DVS	B-CHEMICAL
(	O
30	O
mg	O
/	O
kg	O
orally	O
)	O
significantly	O
increased	O
extracellular	O
NE	B-CHEMICAL
levels	O
compared	O
with	O
baseline	O
in	O
the	O
male	O
rat	O
hypothalamus	O
but	O
had	O
no	O
effect	O
on	O
DA	B-CHEMICAL
levels	O
using	O
microdialysis	O
.	O

To	O
mimic	O
chronic	O
selective	O
serotonin	B-CHEMICAL
reuptake	O
inhibitor	O
treatment	O
and	O
to	O
block	O
the	O
inhibitory	O
5	B-GENE-Y
-	I-GENE-Y
HT	I-GENE-Y
(	I-GENE-Y
1A	I-GENE-Y
)	I-GENE-Y
autoreceptors	O
,	O
a	O
5	B-GENE-Y
-	I-GENE-Y
HT	I-GENE-Y
(	I-GENE-Y
1A	I-GENE-Y
)	I-GENE-Y
antagonist	O
,	O
N	B-CHEMICAL
-	I-CHEMICAL
[	I-CHEMICAL
2	I-CHEMICAL
-	I-CHEMICAL
[	I-CHEMICAL
4	I-CHEMICAL
-	I-CHEMICAL
(	I-CHEMICAL
2	I-CHEMICAL
-	I-CHEMICAL
methoxyphenyl	I-CHEMICAL
)	I-CHEMICAL
-	I-CHEMICAL
1	I-CHEMICAL
-	I-CHEMICAL
piperazinyl	I-CHEMICAL
]	I-CHEMICAL
ethyl	I-CHEMICAL
]	I-CHEMICAL
-	I-CHEMICAL
N	I-CHEMICAL
-	I-CHEMICAL
2	I-CHEMICAL
-	I-CHEMICAL
pyridinylcyclo	I-CHEMICAL
hexanecarboxamide	I-CHEMICAL
maleate	I-CHEMICAL
salt	I-CHEMICAL
(	O
WAY	B-CHEMICAL
-	I-CHEMICAL
100635	I-CHEMICAL
)	O
(	O
0	O
.	O
3	O
mg	O
/	O
kg	O
s	O
.	O
c	O
.	O
)	O
,	O
was	O
administered	O
with	O
DVS	B-CHEMICAL
(	O
30	O
mg	O
/	O
kg	O
orally	O
)	O
.	O

5	B-CHEMICAL
-	I-CHEMICAL
HT	I-CHEMICAL
increased	O
78	O
%	O
compared	O
with	O
baseline	O
with	O
no	O
additional	O
increase	O
in	O
NE	B-CHEMICAL
or	O
DA	B-CHEMICAL
levels	O
.	O

In	O
conclusion	O
,	O
DVS	B-CHEMICAL
is	O
a	O
new	O
5	B-CHEMICAL
-	I-CHEMICAL
HT	I-CHEMICAL
and	O
NE	B-CHEMICAL
reuptake	O
inhibitor	O
in	O
vitro	O
and	O
in	O
vivo	O
that	O
demonstrates	O
good	O
brain	O
-	O
to	O
-	O
plasma	O
ratios	O
,	O
suggesting	O
utility	O
in	O
a	O
variety	O
of	O
central	O
nervous	O
system	O
-	O
related	O
disorders	O
.	O

How	O
may	O
anticancer	O
chemotherapy	O
with	O
fluorouracil	B-CHEMICAL
be	O
individualised	O
?	O

Fluorouracil	B-CHEMICAL
is	O
used	O
clinically	O
against	O
various	O
solid	O
tumours	O
.	O

Both	O
fluorouracil	B-CHEMICAL
toxicity	O
and	O
pharmacokinetics	O
vary	O
highly	O
within	O
and	O
between	O
individuals	O
.	O

The	O
reasons	O
why	O
doses	O
are	O
not	O
individualised	O
routinely	O
are	O
difficulties	O
in	O
defining	O
,	O
predicting	O
and	O
achieving	O
an	O
optimal	O
fluorouracil	B-CHEMICAL
exposure	O
or	O
dose	O
because	O
of	O
a	O
narrow	O
therapeutic	O
index	O
,	O
nonlinear	O
pharmacokinetics	O
,	O
variabilities	O
in	O
administration	O
rates	O
and	O
metabolism	O
,	O
and	O
in	O
targets	O
like	O
thymidylate	B-GENE-Y
synthase	I-GENE-Y
.	O

To	O
individualise	O
fluorouracil	B-CHEMICAL
administration	O
before	O
the	O
first	O
dose	O
,	O
assessment	O
of	O
the	O
individual	O
dihydropyrimidine	B-GENE-Y
dehydrogenase	I-GENE-Y
(	O
DPD	B-GENE-Y
)	O
activity	O
may	O
be	O
useful	O
,	O
because	O
this	O
genetically	O
highly	O
polymorphic	O
enzyme	O
controls	O
approximately	O
80	O
%	O
of	O
fluorouracil	B-CHEMICAL
elimination	O
.	O

A	O
complete	O
or	O
partial	O
loss	O
of	O
DPD	B-GENE-Y
activity	O
in	O
0	O
.	O
1	O
and	O
3	O
-	O
5	O
%	O
of	O
Caucasians	O
,	O
respectively	O
,	O
leads	O
to	O
increased	O
fluorouracil	B-CHEMICAL
exposure	O
and	O
toxicity	O
.	O

Several	O
methods	O
to	O
assess	O
DPD	B-GENE-Y
activity	O
in	O
patients	O
have	O
been	O
proposed	O
(	O
genotyping	O
,	O
various	O
phenotyping	O
methods	O
)	O
,	O
but	O
each	O
of	O
them	O
has	O
limitations	O
,	O
as	O
has	O
the	O
fluorouracil	B-CHEMICAL
test	O
dose	O
approach	O
.	O

To	O
adapt	O
exposure	O
towards	O
fluorouracil	B-CHEMICAL
a	O
priori	O
,	O
a	O
combination	O
of	O
genotyping	O
and	O
phenotyping	O
may	O
yield	O
better	O
prediction	O
of	O
toxicity	O
than	O
one	O
method	O
alone	O
.	O

A	O
prerequisite	O
for	O
dose	O
adaptation	O
is	O
the	O
definition	O
of	O
fluorouracil	B-CHEMICAL
exposure	O
ranges	O
with	O
sufficient	O
therapeutic	O
activity	O
,	O
but	O
without	O
serious	O
toxicity	O
.	O

While	O
an	O
increased	O
risk	O
of	O
leukopenia	O
,	O
diarrhoea	O
,	O
stomatitis	O
,	O
and	O
hand	O
-	O
foot	O
syndrome	O
during	O
continuous	O
5	O
-	O
day	O
infusions	O
was	O
related	O
to	O
fluorouracil	B-CHEMICAL
exposures	O
above	O
an	O
area	O
under	O
the	O
plasma	O
concentration	O
-	O
time	O
curve	O
(	O
AUC	O
)	O
threshold	O
of	O
25	O
-	O
30	O
mg	O
.	O
h	O
/	O
L	O
,	O
tumour	O
response	O
was	O
higher	O
when	O
an	O
AUC	O
of	O
approximately	O
30	O
mg	O
.	O
h	O
/	O
L	O
was	O
achieved	O
,	O
illustrating	O
the	O
extremely	O
narrow	O
therapeutic	O
window	O
of	O
fluorouracil	B-CHEMICAL
.	O

Pharmacokinetic	O
target	O
values	O
are	O
less	O
clear	O
for	O
other	O
regimens	O
,	O
including	O
chronomodulated	O
regimens	O
,	O
which	O
yielded	O
a	O
superior	O
clinically	O
efficacy	O
and	O
tolerability	O
in	O
several	O
trials	O
.	O

However	O
,	O
the	O
monitoring	O
of	O
fluorouracil	B-CHEMICAL
plasma	O
concentrations	O
seems	O
principally	O
useful	O
for	O
individual	O
a	O
posteriori	O
dose	O
adjustment	O
.	O

Whether	O
an	O
adaptation	O
of	O
the	O
fluorouracil	B-CHEMICAL
starting	O
dose	O
to	O
the	O
results	O
of	O
two	O
DPD	B-GENE-Y
activity	O
tests	O
before	O
fluorouracil	B-CHEMICAL
administration	O
a	O
priori	O
,	O
and	O
the	O
adaptation	O
of	O
doses	O
to	O
fluorouracil	B-CHEMICAL
exposure	O
a	O
posteriori	O
is	O
a	O
reasonable	O
approach	O
to	O
better	O
prevent	O
toxicity	O
and	O
increase	O
efficacy	O
,	O
remains	O
to	O
be	O
evaluated	O
in	O
randomised	O
clinical	O
studies	O
comparing	O
these	O
strategies	O
to	O
routine	O
clinical	O
safety	O
monitoring	O
.	O

Expression	O
of	O
basic	B-GENE-Y
fibroblast	I-GENE-Y
growth	I-GENE-Y
factor	I-GENE-Y
correlates	O
with	O
resistance	O
to	O
paclitaxel	B-CHEMICAL
in	O
human	O
patient	O
tumors	O
.	O

BACKGROUND	O
:	O
Preclinical	O
results	O
indicate	O
acidic	B-GENE-Y
fibroblast	I-GENE-Y
growth	I-GENE-Y
factor	I-GENE-Y
(	O
aFGF	B-GENE-Y
)	O
and	O
basic	B-GENE-Y
FGF	I-GENE-Y
(	O
bFGF	B-GENE-Y
)	O
present	O
in	O
solid	O
tumors	O
as	O
a	O
cause	O
of	O
broad	O
-	O
spectrum	O
chemoresistance	O
,	O
whereas	O
earlier	O
clinical	O
studies	O
suggest	O
that	O
bFGF	B-GENE-Y
expression	O
is	O
associated	O
with	O
opposing	O
outcomes	O
in	O
patients	O
.	O

We	O
investigated	O
the	O
relationship	O
between	O
FGF	B-GENE-N
expression	O
and	O
paclitaxel	B-CHEMICAL
activity	O
in	O
tumors	O
from	O
bladder	O
,	O
breast	O
,	O
head	O
and	O
neck	O
,	O
ovarian	O
,	O
and	O
prostate	O
cancer	O
patients	O
.	O

MATERIALS	O
AND	O
METHODS	O
:	O
Tumors	O
(	O
n	O
=	O
96	O
)	O
were	O
maintained	O
in	O
three	O
-	O
dimensional	O
histocultures	O
,	O
retaining	O
tumor	O
-	O
stromal	O
interaction	O
.	O

Bladder	O
tumors	O
were	O
treated	O
with	O
paclitaxel	B-CHEMICAL
for	O
2	O
h	O
,	O
and	O
the	O
other	O
tumors	O
for	O
24	O
h	O
.	O

Antiproliferative	O
and	O
proapoptotic	O
effects	O
of	O
paclitaxel	B-CHEMICAL
were	O
quantified	O
and	O
correlated	O
with	O
expression	O
of	O
aFGF	B-GENE-Y
,	O
bFGF	B-GENE-Y
,	O
P	B-GENE-N
-	I-GENE-N
glycoprotein	I-GENE-N
(	O
Pgp	B-GENE-N
)	O
,	O
p53	B-GENE-Y
,	O
and	O
bcl	B-GENE-Y
-	I-GENE-Y
2	I-GENE-Y
.	O

RESULTS	O
:	O
Fifty	O
-	O
one	O
percent	O
(	O
49	O
/	O
96	O
)	O
and	O
63	O
%	O
(	O
61	O
/	O
96	O
)	O
of	O
tumors	O
showed	O
aFGF	B-GENE-Y
and	O
bFGF	B-GENE-Y
staining	O
,	O
respectively	O
.	O

aFGF	B-GENE-Y
expression	O
was	O
positively	O
correlated	O
with	O
tumor	O
stage	O
(	O
p	O
<	O
0	O
.	O
01	O
)	O
,	O
and	O
bFGF	B-GENE-Y
expression	O
with	O
tumor	O
grade	O
and	O
Pgp	B-GENE-N
expression	O
(	O
p	O
<	O
0	O
.	O
05	O
)	O
.	O

Paclitaxel	B-CHEMICAL
inhibited	O
antiproliferation	O
in	O
86	O
%	O
of	O
tumors	O
(	O
83	O
/	O
96	O
)	O
,	O
with	O
an	O
average	O
inhibition	O
of	O
46	O
+	O
/	O
-	O
19	O
%	O
(	O
mean	O
+	O
/	O
-	O
SD	O
)	O
in	O
the	O
responding	O
tumors	O
.	O

Paclitaxel	B-CHEMICAL
also	O
induced	O
apoptosis	O
in	O
96	O
%	O
of	O
tumors	O
(	O
92	O
/	O
96	O
)	O
,	O
with	O
an	O
average	O
apoptotic	O
index	O
of	O
12	O
+	O
/	O
-	O
7	O
%	O
in	O
the	O
responding	O
tumors	O
.	O

aFGF	B-GENE-Y
expression	O
did	O
not	O
correlate	O
with	O
tumor	O
sensitivity	O
to	O
paclitaxel	B-CHEMICAL
,	O
whereas	O
bFGF	B-GENE-Y
expression	O
showed	O
an	O
inverse	O
correlation	O
(	O
p	O
<	O
0	O
.	O
01	O
)	O
.	O

bFGF	B-GENE-Y
expression	O
was	O
a	O
stronger	O
predictor	O
of	O
paclitaxel	B-CHEMICAL
resistance	O
compared	O
to	O
Pgp	B-GENE-N
,	O
p53	B-GENE-Y
,	O
or	O
Bcl	B-GENE-Y
-	I-GENE-Y
2	I-GENE-Y
.	O

CONCLUSION	O
:	O
These	O
results	O
support	O
a	O
role	O
of	O
bFGF	B-GENE-Y
in	O
paclitaxel	B-CHEMICAL
resistance	O
in	O
human	O
patient	O
tumors	O
.	O

Thyroid	B-GENE-N
hormone	I-GENE-N
receptor	I-GENE-N
expression	O
in	O
the	O
obligatory	O
paedomorphic	O
salamander	O
Necturus	O
maculosus	O
.	O

Amphibian	O
metamorphosis	O
is	O
under	O
the	O
strict	O
control	O
of	O
thyroid	B-CHEMICAL
hormones	I-CHEMICAL
(	O
TH	B-CHEMICAL
)	O
.	O

These	O
hormones	O
induce	O
metamorphosis	O
by	O
controlling	O
gene	O
expression	O
through	O
binding	O
to	O
thyroid	B-GENE-N
hormone	I-GENE-N
receptors	I-GENE-N
(	O
TRs	B-GENE-N
)	O
.	O

Necturus	O
maculosus	O
is	O
considered	O
to	O
be	O
an	O
obligatory	O
paedomorphic	O
Amphibian	O
since	O
metamorphosis	O
never	O
occurs	O
spontaneously	O
and	O
cannot	O
be	O
induced	O
by	O
pharmacological	O
means	O
.	O

Since	O
metamorphosis	O
depends	O
on	O
the	O
acquisition	O
of	O
response	O
of	O
tadpole	O
tissues	O
to	O
thyroid	B-CHEMICAL
hormone	I-CHEMICAL
,	O
we	O
aimed	O
to	O
determine	O
TR	B-GENE-N
gene	O
expression	O
patterns	O
in	O
Necturus	O
maculosus	O
as	O
well	O
as	O
the	O
expression	O
of	O
two	O
TH	B-CHEMICAL
-	O
related	O
genes	O
:	O
Cytosolic	B-GENE-N
Thyroid	I-GENE-N
Hormone	I-GENE-N
-	I-GENE-N
Binding	I-GENE-N
Protein	I-GENE-N
(	O
CTHBP	B-GENE-N
)	O
-	O
M2	B-GENE-N
-	I-GENE-N
pyruvate	I-GENE-N
kinase	I-GENE-N
,	O
a	O
gene	O
encoding	O
a	O
cytosolic	B-GENE-N
TH	I-GENE-N
binding	I-GENE-N
protein	I-GENE-N
and	O
stromelysin	B-GENE-Y
3	I-GENE-Y
,	O
a	O
direct	O
TH	O
target	O
gene	O
in	O
Xenopus	O
laevis	O
.	O

Tissue	O
samples	O
were	O
obtained	O
from	O
specimens	O
of	O
Necturus	O
maculosus	O
.	O

We	O
performed	O
in	O
situ	O
hybridization	O
using	O
non	O
-	O
cross	O
-	O
hybridizing	O
RNA	O
probes	O
obtained	O
from	O
the	O
cloned	O
Necturus	B-GENE-Y
TRalpha	I-GENE-Y
and	O
TRbeta	B-GENE-Y
genes	O
.	O

We	O
found	O
clear	O
expression	O
of	O
Necturus	B-GENE-Y
TRalpha	I-GENE-Y
gene	O
in	O
several	O
tissues	O
including	O
the	O
central	O
nervous	O
system	O
,	O
epithelial	O
cells	O
of	O
digestive	O
and	O
urinary	O
organs	O
,	O
as	O
well	O
as	O
myocardium	O
and	O
skeletal	O
muscle	O
.	O

TRbeta	B-GENE-Y
was	O
also	O
expressed	O
in	O
the	O
brain	O
.	O

In	O
other	O
tissues	O
,	O
hybridization	O
signals	O
were	O
too	O
low	O
to	O
draw	O
reliable	O
conclusions	O
about	O
their	O
precise	O
distribution	O
.	O

In	O
addition	O
,	O
we	O
observed	O
that	O
the	O
expression	O
of	O
CTHBP	B-GENE-N
and	O
ST3	B-GENE-Y
is	O
largely	O
distinct	O
from	O
that	O
of	O
TRs	O
.	O

The	O
fact	O
that	O
we	O
observed	O
a	O
clear	O
expression	O
of	O
TRalpha	B-GENE-Y
and	O
TRbeta	B-GENE-Y
which	O
are	O
evolutionary	O
conserved	O
,	O
suggests	O
that	O
Necturus	O
tissues	O
express	O
TRs	B-GENE-N
.	O

Our	O
results	O
thus	O
indicate	O
that	O
,	O
in	O
contrast	O
to	O
previously	O
held	O
hypotheses	O
,	O
Necturus	O
tissues	O
are	O
TH	B-CHEMICAL
responsive	O
.	O

Regulation	O
of	O
retinal	O
dehydrogenases	O
and	O
retinoic	B-CHEMICAL
acid	I-CHEMICAL
synthesis	O
by	O
cholesterol	B-CHEMICAL
metabolites	O
.	O

Retinoic	B-CHEMICAL
acid	I-CHEMICAL
(	O
RA	B-CHEMICAL
)	O
constitutes	O
the	O
major	O
active	O
ingredient	O
of	O
vitamin	B-CHEMICAL
A	I-CHEMICAL
and	O
is	O
required	O
for	O
various	O
biological	O
processes	O
.	O

The	O
tissue	O
RA	B-CHEMICAL
level	O
is	O
maintained	O
through	O
a	O
cascade	O
of	O
metabolic	O
reactions	O
where	O
retinal	B-GENE-N
dehydrogenases	I-GENE-N
(	O
RALDHs	B-GENE-N
)	O
catalyze	O
the	O
terminal	O
reaction	O
of	O
RA	B-CHEMICAL
biosynthesis	O
from	O
retinal	B-CHEMICAL
,	O
a	O
rate	O
-	O
limiting	O
step	O
.	O

We	O
showed	O
that	O
dietary	O
supplement	O
of	O
cholesterol	B-CHEMICAL
enhanced	O
the	O
expression	O
of	O
RALDH1	B-GENE-N
and	I-GENE-N
2	I-GENE-N
genes	O
and	O
the	O
cellular	O
RA	B-CHEMICAL
content	O
in	O
vital	O
organs	O
such	O
as	O
brain	O
,	O
kidney	O
,	O
liver	O
and	O
heart	O
.	O

Consistently	O
,	O
the	O
cholesterol	B-CHEMICAL
-	O
lowering	O
agent	O
(	O
pravastatin	B-CHEMICAL
sodium	I-CHEMICAL
)	O
downregulated	O
the	O
expression	O
of	O
RALDH1	B-GENE-N
and	I-GENE-N
2	I-GENE-N
genes	O
in	O
several	O
organs	O
especially	O
the	O
liver	O
and	O
in	O
cultured	O
liver	O
cells	O
.	O

Further	O
,	O
cholesterol	B-CHEMICAL
metabolites	O
,	O
predominantly	O
the	O
oxysterols	B-CHEMICAL
,	O
the	O
natural	O
ligands	O
for	O
liver	B-GENE-N
X	I-GENE-N
receptor	I-GENE-N
(	O
LXR	B-GENE-N
)	O
,	O
induced	O
these	O
genes	O
via	O
upregulation	O
of	O
sterol	B-GENE-Y
regulatory	I-GENE-Y
element	I-GENE-Y
binding	I-GENE-Y
protein	I-GENE-Y
-	I-GENE-Y
1c	I-GENE-Y
(	O
SREBP	B-GENE-Y
-	I-GENE-Y
1c	I-GENE-Y
)	O
that	O
bound	O
to	O
the	O
regulatory	O
regions	O
of	O
these	O
genes	O
.	O

Knockdown	O
of	O
LXRalpha	B-GENE-N
/	I-GENE-N
beta	I-GENE-N
or	O
SREBP	B-GENE-Y
-	I-GENE-Y
1c	I-GENE-Y
downregulated	O
the	O
expression	O
of	O
RALDH	B-GENE-N
genes	O
,	O
which	O
could	O
be	O
rescued	O
by	O
re	O
-	O
expressing	O
SREBP	B-GENE-Y
-	I-GENE-Y
1c	I-GENE-Y
,	O
suggesting	O
SREBP	B-GENE-Y
-	I-GENE-Y
1c	I-GENE-Y
as	O
a	O
direct	O
positive	O
regulator	O
for	O
these	O
genes	O
.	O

This	O
study	O
uncovered	O
a	O
novel	O
crosstalk	O
between	O
cholesterol	B-CHEMICAL
and	O
RA	B-CHEMICAL
biosynthesis	O
.	O

Reelin	B-GENE-Y
down	O
-	O
regulation	O
in	O
mice	O
and	O
psychosis	O
endophenotypes	O
.	O

Reelin	B-GENE-Y
,	O
a	O
large	O
glycoprotein	O
secreted	O
by	O
telencephalic	O
GABAergic	O
neurons	O
,	O
plays	O
an	O
important	O
role	O
in	O
neuronal	O
guidance	O
embryonically	O
and	O
in	O
synaptic	O
plasticity	O
postnatally	O
.	O

The	O
reeler	O
heterozygous	O
mouse	O
(	O
+	O
/	O
rl	O
)	O
appears	O
superficially	O
normal	O
but	O
has	O
been	O
of	O
interest	O
as	O
an	O
animal	O
model	O
for	O
psychosis	O
since	O
the	O
discovery	O
that	O
reelin	B-GENE-Y
is	O
50	O
%	O
down	O
-	O
regulated	O
in	O
postmortem	O
psychotic	O
brain	O
.	O

Brain	O
abnormalities	O
in	O
+	O
/	O
rl	O
are	O
similar	O
to	O
psychotic	O
brain	O
and	O
include	O
a	O
reduction	O
in	O
glutamic	B-GENE-Y
acid	I-GENE-Y
de	I-GENE-Y
carboxylase	I-GENE-Y
67	I-GENE-Y
(	O
GAD67	B-GENE-Y
)	O
,	O
dendritic	O
arbors	O
and	O
spine	O
density	O
in	O
cortex	O
and	O
hippocampus	O
,	O
and	O
abnormalities	O
in	O
synaptic	O
function	O
including	O
long	O
-	O
term	O
potentiation	O
(	O
LTP	O
)	O
.	O

In	O
spite	O
of	O
these	O
abnormalities	O
,	O
behavioral	O
abnormalities	O
in	O
+	O
/	O
rl	O
are	O
subtle	O
and	O
controversial	O
.	O

Recent	O
findings	O
indicate	O
that	O
the	O
reelin	B-GENE-N
(	I-GENE-N
RELN	I-GENE-N
)	I-GENE-N
and	I-GENE-N
GAD67	I-GENE-N
promoters	I-GENE-N
are	O
hypermethylated	O
in	O
GABAergic	O
neurons	O
of	O
psychotic	O
postmortem	O
brain	O
and	O
that	O
DNA	B-GENE-Y
methyltransferase	I-GENE-Y
1	I-GENE-Y
(	O
DNMT1	B-GENE-Y
)	O
is	O
up	O
-	O
regulated	O
.	O

Hypermethlyation	O
of	O
RELN	B-GENE-N
and	I-GENE-N
GAD67	I-GENE-N
promoters	I-GENE-N
can	O
be	O
induced	O
by	O
treating	O
mice	O
with	O
methionine	B-CHEMICAL
,	O
and	O
these	O
mice	O
display	O
brain	O
and	O
behavioral	O
abnormalities	O
similar	O
to	O
+	O
/	O
rl	O
.	O

Thus	O
,	O
an	O
animal	O
model	O
that	O
combines	O
genetic	O
heterozygocity	O
with	O
epigenesis	O
holds	O
promise	O
for	O
understanding	O
the	O
role	O
of	O
Reelin	B-GENE-Y
down	O
-	O
regulation	O
in	O
psychosis	O
.	O

Functional	O
and	O
bioenergetic	O
consequences	O
of	O
AT1	B-GENE-Y
antagonist	O
olmesartan	B-CHEMICAL
medoxomil	I-CHEMICAL
in	O
hearts	O
with	O
postinfarction	O
LV	O
remodeling	O
.	O

The	O
structural	O
left	O
ventricular	O
(	O
LV	O
)	O
remodeling	O
and	O
contractile	O
dysfunction	O
of	O
hearts	O
with	O
postinfarction	O
LV	O
remodeling	O
are	O
benefited	O
by	O
angiotensin	B-GENE-Y
II	I-GENE-Y
type	I-GENE-Y
1	I-GENE-Y
receptor	I-GENE-Y
(	O
AT1	B-GENE-Y
)	O
blocker	O
.	O

However	O
,	O
the	O
myocardial	O
bioenergetic	O
consequences	O
of	O
AT1	B-GENE-Y
blocker	O
in	O
these	O
hearts	O
are	O
not	O
known	O
.	O

To	O
investigate	O
,	O
we	O
used	O
a	O
porcine	O
model	O
of	O
postinfarction	O
LV	O
remodeling	O
produced	O
by	O
ligation	O
of	O
the	O
left	O
circumflex	O
coronary	O
artery	O
.	O

After	O
infarction	O
,	O
7	O
pigs	O
received	O
olmesartan	B-CHEMICAL
medoxomil	I-CHEMICAL
(	O
2	O
mg	O
/	O
kg	O
)	O
for	O
comparison	O
against	O
9	O
untreated	O
and	O
10	O
normal	O
pigs	O
.	O

Measurements	O
of	O
hemodynamics	O
,	O
myocardial	O
perfusion	O
,	O
and	O
myocardial	O
bioenergetics	O
were	O
taken	O
7	O
weeks	O
postinfarction	O
.	O

The	O
treated	O
group	O
had	O
an	O
LV	O
-	O
to	O
-	O
body	O
weight	O
ratio	O
significantly	O
lower	O
than	O
the	O
untreated	O
group	O
(	O
2	O
.	O
69	O
+	O
/	O
-	O
0	O
.	O
70	O
,	O
2	O
.	O
96	O
+	O
/	O
-	O
0	O
.	O
51	O
,	O
3	O
.	O
66	O
+	O
/	O
-	O
0	O
.	O
60	O
g	O
/	O
kg	O
for	O
control	O
,	O
treated	O
,	O
and	O
untreated	O
groups	O
,	O
respectively	O
)	O
.	O

The	O
untreated	O
group	O
had	O
a	O
mean	O
aortic	O
pressure	O
significantly	O
higher	O
than	O
the	O
control	O
(	O
73	O
+	O
/	O
-	O
16	O
,	O
86	O
+	O
/	O
-	O
14	O
,	O
and	O
94	O
+	O
/	O
-	O
20	O
mm	O
Hg	O
,	O
respectively	O
)	O
.	O

The	O
subendocardial	O
phosphocreatine	B-CHEMICAL
-	O
to	O
-	O
ATP	B-CHEMICAL
ratios	O
of	O
the	O
treated	O
group	O
were	O
significantly	O
higher	O
than	O
that	O
of	O
the	O
untreated	O
group	O
.	O

The	O
untreated	O
group	O
,	O
but	O
not	O
the	O
treated	O
group	O
,	O
had	O
significant	O
reductions	O
in	O
mitochondrial	O
F0F1	B-GENE-N
-	I-GENE-N
ATPase	I-GENE-N
subunits	O
compared	O
with	O
controls	O
.	O

Congestive	O
heart	O
failure	O
as	O
evidenced	O
by	O
significant	O
ascites	O
(	O
100	O
to	O
2000	O
mL	O
)	O
developed	O
in	O
4	O
of	O
the	O
9	O
untreated	O
animals	O
,	O
but	O
was	O
absent	O
in	O
the	O
treated	O
group	O
.	O

Animals	O
with	O
heart	O
failure	O
demonstrated	O
reductions	O
in	O
both	O
mitochondrial	O
F0F1	B-GENE-N
-	I-GENE-N
ATPase	I-GENE-N
expression	O
and	O
myocardial	O
high	O
-	O
energy	O
phosphate	B-CHEMICAL
levels	O
.	O

Thus	O
,	O
severe	O
LV	O
dysfunction	O
and	O
accompanying	O
abnormal	O
myocardial	O
bioenergetic	O
phenotype	O
were	O
prevented	O
by	O
the	O
AT1	B-GENE-Y
antagonist	O
olmesartan	B-CHEMICAL
medoxomil	I-CHEMICAL
.	O

Regulation	O
of	O
retinoic	B-GENE-N
acid	I-GENE-N
receptors	I-GENE-N
alpha	I-GENE-N
,	I-GENE-N
beta	I-GENE-N
and	O
retinoid	B-GENE-Y
X	I-GENE-Y
receptor	I-GENE-Y
alpha	I-GENE-Y
after	O
sciatic	O
nerve	O
injury	O
.	O

Cell	O
culture	O
experiments	O
indicated	O
that	O
activation	O
of	O
the	O
retinoic	B-CHEMICAL
acid	I-CHEMICAL
signaling	O
system	O
is	O
involved	O
in	O
axonal	O
regeneration	O
.	O

This	O
hypothesis	O
was	O
tested	O
with	O
sciatic	O
nerve	O
injury	O
in	O
the	O
rat	O
.	O

Since	O
the	O
effect	O
of	O
retinoic	B-CHEMICAL
acid	I-CHEMICAL
is	O
mediated	O
via	O
retinoic	B-GENE-N
acid	I-GENE-N
receptors	I-GENE-N
and	O
retinoid	B-GENE-N
X	I-GENE-N
receptors	I-GENE-N
,	O
we	O
investigated	O
mRNA	O
and	O
protein	O
expression	O
of	O
these	O
receptors	O
during	O
injury	O
-	O
induced	O
degeneration	O
and	O
regeneration	O
.	O

Seven	O
days	O
after	O
crush	O
injury	O
,	O
transcript	O
concentrations	O
of	O
all	O
retinoic	B-GENE-N
acid	I-GENE-N
receptors	I-GENE-N
and	O
of	O
retinoid	B-GENE-Y
X	I-GENE-Y
receptor	I-GENE-Y
alpha	I-GENE-Y
were	O
significantly	O
higher	O
than	O
in	O
non	O
-	O
lesioned	O
nerves	O
.	O

Protein	O
levels	O
of	O
retinoic	B-GENE-Y
acid	I-GENE-Y
receptor	I-GENE-Y
alpha	I-GENE-Y
,	O
retinoic	B-GENE-Y
acid	I-GENE-Y
receptor	I-GENE-Y
beta	I-GENE-Y
and	O
retinoid	B-GENE-Y
X	I-GENE-Y
receptor	I-GENE-Y
alpha	I-GENE-Y
were	O
upregulated	O
4	O
,	O
7	O
and	O
14	O
days	O
after	O
injury	O
.	O

In	O
degenerating	O
nerves	O
a	O
significant	O
increase	O
of	O
retinoic	B-GENE-Y
acid	I-GENE-Y
receptor	I-GENE-Y
alpha	I-GENE-Y
was	O
detected	O
7	O
and	O
14	O
days	O
,	O
and	O
of	O
retinoic	B-GENE-Y
acid	I-GENE-Y
receptor	I-GENE-Y
beta	I-GENE-Y
14	O
and	O
21	O
days	O
after	O
complete	O
transection	O
.	O

Immunohistochemical	O
staining	O
of	O
retinoid	B-GENE-N
receptors	I-GENE-N
revealed	O
their	O
expression	O
in	O
Schwann	O
cells	O
and	O
macrophages	O
.	O

In	O
addition	O
,	O
we	O
observed	O
that	O
retinoic	B-GENE-Y
acid	I-GENE-Y
receptor	I-GENE-Y
alpha	I-GENE-Y
and	O
retinoid	B-GENE-Y
X	I-GENE-Y
receptor	I-GENE-Y
alpha	I-GENE-Y
appeared	O
in	O
the	O
cell	O
nuclei	O
of	O
macrophages	O
during	O
the	O
lesion	O
-	O
induced	O
inflammatory	O
reaction	O
,	O
and	O
that	O
retinoid	B-GENE-Y
X	I-GENE-Y
receptor	I-GENE-Y
alpha	I-GENE-Y
-	O
staining	O
co	O
-	O
localized	O
with	O
some	O
regenerating	O
axons	O
.	O

Experiments	O
with	O
Schwann	O
cell	O
primary	O
cultures	O
revealed	O
an	O
effect	O
of	O
retinoic	B-CHEMICAL
acid	I-CHEMICAL
on	O
the	O
expression	O
of	O
the	O
neuregulin	B-GENE-N
receptor	I-GENE-N
ErbB3	B-GENE-Y
,	O
suggesting	O
that	O
one	O
function	O
of	O
retinoic	B-CHEMICAL
acid	I-CHEMICAL
consists	O
in	O
the	O
regulation	O
of	O
neuroglial	O
interactions	O
after	O
peripheral	O
nerve	O
injury	O
.	O

Cellular	O
effects	O
of	O
imatinib	B-CHEMICAL
on	O
medullary	O
thyroid	O
cancer	O
cells	O
harboring	O
multiple	O
endocrine	O
neoplasia	O
Type	O
2A	O
and	O
2B	O
associated	O
RET	B-GENE-Y
mutations	O
.	O

BACKGROUND	O
:	O
Activating	O
mutations	O
in	O
the	O
RET	B-GENE-Y
gene	O
,	O
which	O
encodes	O
a	O
tyrosine	B-GENE-N
kinase	I-GENE-N
receptor	I-GENE-N
,	O
often	O
cause	O
medullary	O
thyroid	O
carcinoma	O
(	O
MTC	O
)	O
.	O

Surgical	O
resection	O
is	O
the	O
only	O
curative	O
treatment	O
;	O
no	O
effective	O
systemic	O
treatment	O
is	O
available	O
.	O

We	O
evaluated	O
imatinib	B-CHEMICAL
,	O
a	O
tyrosine	B-GENE-N
kinase	I-GENE-N
inhibitor	O
currently	O
used	O
to	O
treat	O
chronic	O
myelogenous	O
leukemia	O
and	O
gastrointestinal	O
stromal	O
tumors	O
,	O
as	O
a	O
potential	O
drug	O
for	O
systemic	O
treatment	O
of	O
MTC	O
,	O
in	O
2	O
MTC	O
-	O
derived	O
cell	O
lines	O
expressing	O
multiple	O
endocrine	O
neoplasia	O
-	O
associated	O
mutant	O
RET	B-GENE-N
receptors	I-GENE-N
.	O

METHODS	O
:	O
We	O
determined	O
RET	B-GENE-Y
expression	O
and	O
Y1062	B-GENE-N
phosphorylation	O
using	O
Western	O
blot	O
analysis	O
and	O
quantitative	O
polymerase	O
chain	O
reaction	O
.	O

We	O
determined	O
the	O
effects	O
on	O
cell	O
proliferation	O
by	O
a	O
3	B-CHEMICAL
-	I-CHEMICAL
[	I-CHEMICAL
4	I-CHEMICAL
,	I-CHEMICAL
5	I-CHEMICAL
-	I-CHEMICAL
dimethylthiazol	I-CHEMICAL
-	I-CHEMICAL
2	I-CHEMICAL
-	I-CHEMICAL
yl	I-CHEMICAL
]	I-CHEMICAL
-	I-CHEMICAL
2	I-CHEMICAL
,	I-CHEMICAL
5	I-CHEMICAL
-	I-CHEMICAL
diphenyltetrazolium	I-CHEMICAL
bromide	I-CHEMICAL
assay	O
,	O
and	O
we	O
used	O
fluorescence	O
-	O
activated	O
cell	O
sorter	O
analysis	O
with	O
annexin	O
V	O
/	O
propidium	B-CHEMICAL
iodide	I-CHEMICAL
staining	O
to	O
study	O
imatinib	B-CHEMICAL
-	O
induced	O
cell	O
-	O
cycle	O
arrest	O
,	O
apoptosis	O
,	O
and	O
cell	O
death	O
.	O

RESULTS	O
:	O
Imatinib	B-CHEMICAL
inhibited	O
RET	B-GENE-Y
Y1062	B-GENE-N
phosphorylation	O
in	O
a	O
dose	O
-	O
dependent	O
manner	O
after	O
1	O
.	O
5	O
hours	O
of	O
exposure	O
.	O

After	O
16	O
hours	O
both	O
RET	B-GENE-Y
Y1062	B-GENE-N
phosphorylation	O
and	O
protein	O
expression	O
levels	O
were	O
affected	O
.	O

Dose	O
-	O
dependent	O
decreases	O
in	O
cell	O
proliferation	O
of	O
both	O
cell	O
lines	O
after	O
exposure	O
to	O
imatinib	B-CHEMICAL
with	O
inhibitory	O
concentration	O
of	O
50	O
%	O
levels	O
of	O
23	O
+	O
/	O
-	O
2	O
micromol	O
/	O
L	O
and	O
25	O
+	O
/	O
-	O
4	O
micromol	O
/	O
L	O
were	O
seen	O
.	O

These	O
values	O
are	O
high	O
,	O
compared	O
with	O
those	O
for	O
chronic	O
myelogenous	O
leukemia	O
and	O
gastrointestinal	O
stromal	O
tumors	O
.	O

We	O
further	O
could	O
show	O
that	O
imatinib	B-CHEMICAL
induced	O
cell	O
-	O
cycle	O
arrest	O
,	O
and	O
apoptotic	O
and	O
nonapoptotic	O
cell	O
death	O
.	O

CONCLUSIONS	O
:	O
Imatinib	B-CHEMICAL
inhibits	O
RET	B-GENE-Y
-	O
mediated	O
MTC	O
cell	O
growth	O
affecting	O
RET	B-GENE-Y
protein	O
levels	O
in	O
vitro	O
in	O
a	O
dose	O
-	O
dependent	O
manner	O
.	O

The	O
concentration	O
of	O
imatinib	B-CHEMICAL
necessary	O
to	O
inhibit	O
RET	B-GENE-Y
in	O
vitro	O
,	O
however	O
,	O
makes	O
it	O
impossible	O
to	O
conclude	O
that	O
imatinib	B-CHEMICAL
monotherapy	O
will	O
be	O
a	O
good	O
option	O
for	O
systemic	O
therapy	O
of	O
MTC	O
.	O

Cell	O
biology	O
of	O
molybdenum	B-CHEMICAL
.	O

The	O
transition	O
element	O
molybdenum	B-CHEMICAL
(	O
Mo	B-CHEMICAL
)	O
is	O
of	O
essential	O
importance	O
for	O
(	O
nearly	O
)	O
all	O
biological	O
systems	O
as	O
it	O
is	O
required	O
by	O
enzymes	O
catalyzing	O
diverse	O
key	O
reactions	O
in	O
the	O
global	O
carbon	B-CHEMICAL
,	O
sulfur	B-CHEMICAL
and	O
nitrogen	B-CHEMICAL
metabolism	O
.	O

The	O
metal	O
itself	O
is	O
biologically	O
inactive	O
unless	O
it	O
is	O
complexed	O
by	O
a	O
special	O
cofactor	O
.	O

With	O
the	O
exception	O
of	O
bacterial	B-GENE-N
nitrogenase	I-GENE-N
,	O
where	O
Mo	B-CHEMICAL
is	O
a	O
constituent	O
of	O
the	O
FeMo	B-CHEMICAL
-	O
cofactor	O
,	O
Mo	B-CHEMICAL
is	O
bound	O
to	O
a	O
pterin	B-CHEMICAL
,	O
thus	O
forming	O
the	O
molybdenum	B-CHEMICAL
cofactor	O
(	O
Moco	O
)	O
which	O
is	O
the	O
active	O
compound	O
at	O
the	O
catalytic	O
site	O
of	O
all	O
other	O
Mo	B-CHEMICAL
-	O
enzymes	O
.	O

In	O
eukaryotes	O
,	O
the	O
most	O
prominent	O
Mo	B-CHEMICAL
-	O
enzymes	O
are	O
(	O
1	O
)	O
sulfite	B-GENE-Y
oxidase	I-GENE-Y
,	O
which	O
catalyzes	O
the	O
final	O
step	O
in	O
the	O
degradation	O
of	O
sulfur	B-CHEMICAL
-	O
containing	O
amino	B-CHEMICAL
acids	I-CHEMICAL
and	O
is	O
involved	O
in	O
detoxifying	O
excess	O
sulfite	B-CHEMICAL
,	O
(	O
2	O
)	O
xanthine	B-GENE-Y
dehydrogenase	I-GENE-Y
,	O
which	O
is	O
involved	O
in	O
purine	B-CHEMICAL
catabolism	O
and	O
reactive	O
oxygen	B-CHEMICAL
production	O
,	O
(	O
3	O
)	O
aldehyde	B-GENE-Y
oxidase	I-GENE-Y
,	O
which	O
oxidizes	O
a	O
variety	O
of	O
aldehydes	B-CHEMICAL
and	O
is	O
essential	O
for	O
the	O
biosynthesis	O
of	O
the	O
phytohormone	O
abscisic	B-CHEMICAL
acid	I-CHEMICAL
,	O
and	O
in	O
autotrophic	O
organisms	O
also	O
(	O
4	O
)	O
nitrate	B-GENE-N
reductase	I-GENE-N
,	O
which	O
catalyzes	O
the	O
key	O
step	O
in	O
inorganic	O
nitrogen	B-CHEMICAL
assimilation	O
.	O

All	O
Mo	B-CHEMICAL
-	O
enzymes	O
,	O
except	O
plant	B-GENE-N
sulfite	I-GENE-N
oxidase	I-GENE-N
,	O
need	O
at	O
least	O
one	O
more	O
redox	O
active	O
center	O
,	O
many	O
of	O
them	O
involving	O
iron	B-CHEMICAL
in	O
electron	O
transfer	O
.	O

The	O
biosynthesis	O
of	O
Moco	O
involves	O
the	O
complex	O
interaction	O
of	O
six	O
proteins	O
and	O
is	O
a	O
process	O
of	O
four	O
steps	O
,	O
which	O
also	O
includes	O
iron	O
as	O
well	O
as	O
copper	B-CHEMICAL
in	O
an	O
indispensable	O
way	O
.	O

Moco	O
as	O
released	O
after	O
synthesis	O
is	O
likely	O
to	O
be	O
distributed	O
to	O
the	O
apoproteins	O
of	O
Mo	B-CHEMICAL
-	O
enzymes	O
by	O
putative	O
Moco	O
-	O
carrier	O
proteins	O
.	O

Xanthine	B-GENE-Y
dehydrogenase	I-GENE-Y
and	O
aldehyde	B-GENE-Y
oxidase	I-GENE-Y
,	O
but	O
not	O
sulfite	B-GENE-Y
oxidase	I-GENE-Y
and	O
nitrate	B-GENE-N
reductase	I-GENE-N
,	O
require	O
the	O
post	O
-	O
translational	O
sulfuration	O
of	O
their	O
Mo	B-CHEMICAL
-	O
site	O
for	O
becoming	O
active	O
.	O

This	O
final	O
maturation	O
step	O
is	O
catalyzed	O
by	O
a	O
Moco	B-GENE-Y
-	I-GENE-Y
sulfurase	I-GENE-Y
enzyme	O
,	O
which	O
mobilizes	O
sulfur	B-CHEMICAL
from	O
l	B-CHEMICAL
-	I-CHEMICAL
cysteine	I-CHEMICAL
in	O
a	O
pyridoxal	B-CHEMICAL
phosphate	I-CHEMICAL
-	O
dependent	O
manner	O
as	O
typical	O
for	O
cysteine	B-GENE-N
desulfurases	I-GENE-N
.	O

[	O
Retinoid	B-CHEMICAL
therapy	O
for	O
autoimmune	O
diseases	O
]	O
.	O

Retinoid	B-CHEMICAL
is	O
a	O
collective	O
term	O
for	O
compounds	O
which	O
bind	O
to	O
and	O
activate	O
retinoic	B-GENE-N
acid	I-GENE-N
receptors	I-GENE-N
(	O
RARalpha	B-GENE-N
,	I-GENE-N
beta	I-GENE-N
,	I-GENE-N
gamma	I-GENE-N
and	O
RXRalpha	B-GENE-N
,	I-GENE-N
beta	I-GENE-N
,	I-GENE-N
gamma	I-GENE-N
)	O
,	O
members	O
of	O
nuclear	B-GENE-N
hormone	I-GENE-N
receptor	I-GENE-N
superfamily	O
.	O

The	O
most	O
important	O
endogeneous	O
retinoid	B-CHEMICAL
is	O
all	B-CHEMICAL
-	I-CHEMICAL
trans	I-CHEMICAL
-	I-CHEMICAL
retinoic	I-CHEMICAL
acid	I-CHEMICAL
(	O
ATRA	B-CHEMICAL
)	O
which	O
is	O
an	O
RARalpha	B-GENE-N
,	I-GENE-N
beta	I-GENE-N
and	I-GENE-N
gamma	I-GENE-N
ligand	O
.	O

ATRA	B-CHEMICAL
and	O
its	O
mimics	O
have	O
been	O
in	O
clinical	O
use	O
for	O
treatment	O
of	O
acute	O
promyelocytic	O
leukemia	O
(	O
APL	O
)	O
and	O
some	O
skin	O
diseases	O
.	O

Many	O
synthetic	O
retinoids	O
have	O
been	O
developed	O
and	O
attempts	O
to	O
improve	O
their	O
medicinal	O
properties	O
have	O
been	O
made	O
.	O

Among	O
them	O
,	O
tamibarotene	B-CHEMICAL
(	O
Am80	B-CHEMICAL
)	O
is	O
an	O
RARalpha	B-GENE-Y
-	O
and	O
RARbeta	B-GENE-Y
-	O
specific	O
(	O
but	O
RARgamma	B-GENE-Y
-	O
and	O
RXRs	B-GENE-N
-	O
nonbinding	O
)	O
synthetic	O
retinoid	B-CHEMICAL
that	O
is	O
effective	O
in	O
the	O
treatment	O
of	O
psoriasis	O
patients	O
and	O
relapsed	O
APL	O
.	O

Experimentally	O
,	O
this	O
compound	O
is	O
also	O
active	O
in	O
animal	O
models	O
of	O
rheumatoid	O
arthritis	O
and	O
experimental	O
autoimmune	O
encephalomyelitis	O
.	O

On	O
this	O
background	O
,	O
possible	O
application	O
of	O
retinoids	B-CHEMICAL
for	O
the	O
treatment	O
of	O
autoimmune	O
diseases	O
was	O
discussed	O
.	O

In	O
particular	O
,	O
Th1	O
dominant	O
autoimmune	O
diseases	O
may	O
be	O
the	O
targets	O
of	O
the	O
retinoids	B-CHEMICAL
.	O

Simvastatin	B-CHEMICAL
regulates	O
non	O
-	O
neuronal	O
cholinergic	O
activity	O
in	O
T	O
lymphocytes	O
via	O
CD11a	B-GENE-Y
-	O
mediated	O
pathways	O
.	O

Lymphocyte	B-GENE-Y
function	I-GENE-Y
associated	I-GENE-Y
antigen	I-GENE-Y
-	I-GENE-Y
1	I-GENE-Y
(	O
LFA	B-GENE-Y
-	I-GENE-Y
1	I-GENE-Y
;	O
CD11a	B-GENE-Y
/	O
CD18	B-GENE-Y
)	O
is	O
an	O
important	O
mediator	O
of	O
leukocyte	O
migration	O
and	O
T	O
cell	O
activation	O
.	O

We	O
previously	O
showed	O
that	O
antithymocyte	B-GENE-N
globulin	I-GENE-N
stimulates	O
an	O
independent	O
,	O
non	O
-	O
neuronal	O
cholinergic	O
system	O
in	O
T	O
cells	O
via	O
LFA	B-GENE-Y
-	I-GENE-Y
1	I-GENE-Y
-	O
mediated	O
pathways	O
,	O
as	O
evidenced	O
by	O
increases	O
in	O
acetylcholine	B-CHEMICAL
(	O
ACh	B-CHEMICAL
)	O
synthesis	O
and	O
choline	B-GENE-Y
acetyltransferase	I-GENE-Y
(	O
ChAT	B-GENE-Y
)	O
mRNA	O
expression	O
.	O

The	O
cholesterol	B-CHEMICAL
-	O
lowering	O
drug	O
simvastatin	B-CHEMICAL
inhibits	O
LFA	B-GENE-Y
-	I-GENE-Y
1	I-GENE-Y
signaling	O
by	O
binding	O
to	O
an	O
allosteric	O
site	O
on	O
CD11a	B-GENE-Y
(	O
LFA	B-GENE-Y
-	I-GENE-Y
1	I-GENE-Y
alpha	I-GENE-Y
chain	I-GENE-Y
)	O
,	O
which	O
leads	O
to	O
immunomodulation	O
.	O

In	O
the	O
present	O
study	O
,	O
we	O
investigated	O
whether	O
simvastatin	B-CHEMICAL
modulates	O
lymphocytic	O
cholinergic	O
activity	O
in	O
T	O
cells	O
.	O

We	O
found	O
that	O
anti	O
-	O
CD11a	B-GENE-N
monoclonal	O
antibody	O
(	O
mAb	O
)	O
increased	O
ChAT	B-GENE-N
activity	O
,	O
ACh	B-CHEMICAL
synthesis	O
and	O
release	O
,	O
and	O
expression	O
of	O
ChAT	B-GENE-Y
and	O
M5	B-GENE-Y
muscarinic	I-GENE-Y
ACh	I-GENE-Y
receptor	I-GENE-Y
mRNA	O
in	O
MOLT	O
-	O
3	O
cells	O
,	O
a	O
human	O
leukemic	O
T	O
cell	O
line	O
.	O

Simvastatin	B-CHEMICAL
abolished	O
these	O
anti	O
-	O
CD11a	B-GENE-Y
mAb	O
-	O
induced	O
increases	O
in	O
lymphocytic	O
cholinergic	O
activity	O
in	O
a	O
manner	O
independent	O
of	O
its	O
cholesterol	B-CHEMICAL
-	O
lowering	O
activity	O
.	O

These	O
results	O
indicate	O
that	O
LFA	B-GENE-Y
-	I-GENE-Y
1	I-GENE-Y
contributes	O
to	O
the	O
regulation	O
of	O
lymphocytic	O
cholinergic	O
activity	O
via	O
CD11a	B-GENE-Y
-	O
mediated	O
pathways	O
,	O
and	O
suggest	O
that	O
simvastatin	B-CHEMICAL
exerts	O
its	O
immunosuppressive	O
effects	O
in	O
part	O
via	O
modification	O
of	O
lymphocytic	O
cholinergic	O
activity	O
.	O

More	O
than	O
cool	O
:	O
promiscuous	O
relationships	O
of	O
menthol	B-CHEMICAL
and	O
other	O
sensory	O
compounds	O
.	O

Several	O
temperature	B-GENE-N
-	I-GENE-N
activated	I-GENE-N
transient	I-GENE-N
receptor	I-GENE-N
potential	I-GENE-N
(	I-GENE-N
thermoTRP	I-GENE-N
)	I-GENE-N
ion	I-GENE-N
channels	I-GENE-N
are	O
the	O
molecular	O
receptors	O
of	O
natural	O
compounds	O
that	O
evoke	O
thermal	O
and	O
pain	O
sensations	O
.	O

Menthol	B-CHEMICAL
,	O
popularly	O
known	O
for	O
its	O
cooling	O
effect	O
,	O
activates	O
TRPM8	B-GENE-Y
-	O
-	O
a	O
cold	O
-	O
activated	O
thermoTRP	B-GENE-N
ion	I-GENE-N
channel	I-GENE-N
.	O

However	O
,	O
human	O
physiological	O
studies	O
demonstrate	O
a	O
paradoxical	O
role	O
of	O
menthol	B-CHEMICAL
in	O
modulation	O
of	O
warm	O
sensation	O
,	O
and	O
here	O
,	O
we	O
show	O
that	O
menthol	B-CHEMICAL
also	O
activates	O
heat	O
-	O
activated	O
TRPV3	B-GENE-Y
.	O

We	O
further	O
show	O
that	O
menthol	B-CHEMICAL
inhibits	O
TRPA1	B-GENE-Y
,	O
potentially	O
explaining	O
the	O
use	O
of	O
menthol	B-CHEMICAL
as	O
an	O
analgesic	O
.	O

Similar	O
to	O
menthol	B-CHEMICAL
,	O
both	O
camphor	B-CHEMICAL
and	O
cinnamaldehyde	B-CHEMICAL
(	O
initially	O
reported	O
to	O
be	O
specific	O
activators	O
of	O
TRPV3	B-GENE-Y
and	O
TRPA1	B-GENE-Y
,	O
respectively	O
)	O
also	O
modulate	O
other	O
thermoTRPs	B-GENE-N
.	O

Therefore	O
,	O
we	O
find	O
that	O
many	O
"	O
sensory	O
compounds	O
"	O
presumed	O
to	O
be	O
specific	O
have	O
a	O
promiscuous	O
relationship	O
with	O
thermoTRPs	B-GENE-N
.	O

Effect	O
of	O
keratinocyte	B-GENE-Y
growth	I-GENE-Y
factor	I-GENE-Y
on	O
cell	O
viability	O
in	O
primary	O
cultured	O
human	O
prostate	O
cancer	O
stromal	O
cells	O
.	O

In	O
normal	O
prostate	O
,	O
keratinocyte	B-GENE-Y
growth	I-GENE-Y
factor	I-GENE-Y
(	O
KGF	B-GENE-Y
)	O
,	O
also	O
known	O
as	O
fibroblast	B-GENE-Y
growth	I-GENE-Y
factor	I-GENE-Y
-	I-GENE-Y
7	I-GENE-Y
(	O
FGF	B-GENE-Y
-	I-GENE-Y
7	I-GENE-Y
)	O
serves	O
as	O
a	O
paracrine	O
growth	O
factor	O
synthesized	O
in	O
stromal	O
cells	O
that	O
acts	O
on	O
epithelial	O
cells	O
through	O
its	O
receptor	O
,	O
KGFR	B-GENE-Y
.	O

KGF	B-GENE-Y
and	O
KGFR	B-GENE-Y
were	O
found	O
in	O
human	O
cancer	O
epithelial	O
cells	O
as	O
well	O
as	O
stromal	O
cells	O
.	O

Since	O
KGF	B-GENE-Y
expressed	O
in	O
epithelial	O
cells	O
of	O
benign	O
prostatic	O
hyperplasia	O
(	O
BPH	O
)	O
and	O
in	O
prostate	O
cancer	O
,	O
it	O
has	O
been	O
suggested	O
that	O
KGF	B-GENE-Y
might	O
act	O
as	O
an	O
autocrine	O
factor	O
in	O
BPH	O
and	O
prostate	O
cancer	O
.	O

To	O
investigate	O
the	O
roles	O
of	O
KGF	B-GENE-Y
in	O
cancerous	O
stroma	O
,	O
primary	O
cultured	O
human	O
prostate	O
cancer	O
stromal	O
cells	O
(	O
PCSCs	O
)	O
were	O
isolated	O
and	O
evaluated	O
.	O

These	O
PCSCs	O
possessed	O
estrogen	B-GENE-Y
receptors	I-GENE-Y
and	O
KGFR	B-GENE-Y
,	O
but	O
not	O
androgen	B-GENE-Y
receptor	I-GENE-Y
as	O
determined	O
by	O
RT	O
-	O
PCR	O
and	O
Western	O
blot	O
,	O
respectively	O
.	O

KGF	B-GENE-Y
exhibited	O
mitogenic	O
and	O
anti	O
-	O
apoptotic	O
effects	O
that	O
correlated	O
with	O
induction	O
of	O
cyclin	B-GENE-Y
-	I-GENE-Y
D1	I-GENE-Y
,	O
Bcl	B-GENE-Y
-	I-GENE-Y
2	I-GENE-Y
,	O
Bcl	B-GENE-Y
-	I-GENE-Y
xL	I-GENE-Y
and	O
phospho	B-GENE-N
-	I-GENE-N
Akt	I-GENE-N
expression	O
in	O
PCSCs	O
,	O
where	O
treatment	O
with	O
KGF	B-GENE-Y
antiserum	O
abolished	O
cell	O
proliferation	O
and	O
anti	O
-	O
apoptotic	O
protein	O
expression	O
.	O

PCSCs	O
exposed	O
to	O
KGF	B-GENE-Y
for	O
various	O
time	O
periods	O
resulted	O
in	O
phosphorylation	O
of	O
Akt	B-GENE-N
and	O
subsequent	O
up	O
-	O
regulation	O
of	O
Bcl	B-GENE-Y
-	I-GENE-Y
2	I-GENE-Y
.	O

KGF	B-GENE-Y
modulated	O
dynamic	O
protein	O
expression	O
indicated	O
that	O
KGF	B-GENE-Y
triggered	O
cell	O
cycle	O
machinery	O
and	O
then	O
activated	O
anti	O
-	O
apoptotic	O
actions	O
in	O
PCSCs	O
.	O

Cell	O
proliferation	O
analysis	O
indicated	O
that	O
tamoxifen	B-CHEMICAL
or	O
ICI	B-CHEMICAL
182	I-CHEMICAL
,	I-CHEMICAL
780	I-CHEMICAL
reduced	O
cell	O
viability	O
in	O
a	O
dose	O
-	O
dependent	O
manner	O
;	O
however	O
,	O
KGF	B-GENE-Y
prevented	O
this	O
inhibition	O
,	O
which	O
further	O
demonstrated	O
KGF	B-GENE-Y
triggered	O
anti	O
-	O
apoptotic	O
machinery	O
through	O
activating	O
Bcl	B-GENE-Y
-	I-GENE-Y
2	I-GENE-Y
and	O
phospho	B-GENE-N
-	I-GENE-N
Akt	I-GENE-N
expression	O
.	O

In	O
summary	O
,	O
KGF	B-GENE-Y
has	O
an	O
autocrine	O
effect	O
and	O
serves	O
as	O
a	O
survival	O
factor	O
in	O
primary	O
cultured	O
human	O
prostate	O
cancer	O
stromal	O
cells	O
.	O

The	O
glutamate	B-GENE-N
-	I-GENE-N
aspartate	I-GENE-N
transporter	I-GENE-N
GLAST	B-GENE-N
mediates	O
glutamate	B-CHEMICAL
uptake	O
at	O
inner	O
hair	O
cell	O
afferent	O
synapses	O
in	O
the	O
mammalian	O
cochlea	O
.	O

Ribbon	O
synapses	O
formed	O
between	O
inner	O
hair	O
cells	O
(	O
IHCs	O
)	O
and	O
afferent	O
dendrites	O
in	O
the	O
mammalian	O
cochlea	O
can	O
sustain	O
high	O
rates	O
of	O
release	O
,	O
placing	O
strong	O
demands	O
on	O
glutamate	B-CHEMICAL
clearance	O
mechanisms	O
.	O

To	O
investigate	O
the	O
role	O
of	O
transporters	O
in	O
glutamate	B-CHEMICAL
removal	O
at	O
these	O
synapses	O
,	O
we	O
made	O
whole	O
-	O
cell	O
recordings	O
from	O
IHCs	O
,	O
afferent	O
dendrites	O
,	O
and	O
glial	O
cells	O
adjacent	O
to	O
IHCs	O
[	O
inner	O
phalangeal	O
cells	O
(	O
IPCs	O
)	O
]	O
in	O
whole	O
-	O
mount	O
preparations	O
of	O
rat	O
organ	O
of	O
Corti	O
.	O

Focal	O
application	O
of	O
the	O
transporter	O
substrate	O
D	B-CHEMICAL
-	I-CHEMICAL
aspartate	I-CHEMICAL
elicited	O
inward	O
currents	O
in	O
IPCs	O
,	O
which	O
were	O
larger	O
in	O
the	O
presence	O
of	O
anions	O
that	O
permeate	O
the	O
transporter	O
-	O
associated	O
anion	B-GENE-N
channel	I-GENE-N
and	O
blocked	O
by	O
the	O
transporter	O
antagonist	O
D	B-CHEMICAL
,	I-CHEMICAL
L	I-CHEMICAL
-	I-CHEMICAL
threo	I-CHEMICAL
-	I-CHEMICAL
beta	I-CHEMICAL
-	I-CHEMICAL
benzyloxyaspartate	I-CHEMICAL
.	O

These	O
currents	O
were	O
produced	O
by	O
glutamate	B-GENE-Y
-	I-GENE-Y
aspartate	I-GENE-Y
transporters	I-GENE-Y
(	O
GLAST	B-GENE-Y
)	O
(	O
excitatory	B-GENE-Y
amino	I-GENE-Y
acid	I-GENE-Y
transporter	I-GENE-Y
1	I-GENE-Y
)	O
because	O
they	O
were	O
weakly	O
inhibited	O
by	O
dihydrokainate	B-CHEMICAL
,	O
an	O
antagonist	O
of	O
glutamate	B-GENE-Y
transporter	I-GENE-Y
-	I-GENE-Y
1	I-GENE-Y
(	O
excitatory	B-GENE-Y
amino	I-GENE-Y
acid	I-GENE-Y
transporter	I-GENE-Y
2	I-GENE-Y
)	O
and	O
were	O
absent	O
from	O
IPCs	O
in	O
GLAST	B-GENE-Y
-	O
/	O
-	O
cochleas	O
.	O

Furthermore	O
,	O
D	B-CHEMICAL
-	I-CHEMICAL
aspartate	I-CHEMICAL
-	O
induced	O
currents	O
in	O
outside	O
-	O
out	O
patches	O
from	O
IPCs	O
exhibited	O
larger	O
steady	O
-	O
state	O
currents	O
than	O
responses	O
elicited	O
by	O
L	B-CHEMICAL
-	I-CHEMICAL
glutamate	I-CHEMICAL
,	O
a	O
prominent	O
feature	O
of	O
GLAST	B-GENE-Y
,	O
and	O
examination	O
of	O
cochlea	O
from	O
GLAST	B-GENE-Y
-	O
Discosoma	O
red	O
(	O
DsRed	O
)	O
promoter	O
reporter	O
mice	O
revealed	O
that	O
DsRed	O
expression	O
was	O
restricted	O
to	O
IPCs	O
and	O
other	O
supporting	O
cells	O
surrounding	O
IHCs	O
.	O

Saturation	O
of	O
transporters	O
by	O
photolysis	O
of	O
caged	O
D	B-CHEMICAL
-	I-CHEMICAL
aspartate	I-CHEMICAL
failed	O
to	O
elicit	O
transporter	O
currents	O
in	O
IHCs	O
,	O
as	O
did	O
local	O
application	O
of	O
D	B-CHEMICAL
-	I-CHEMICAL
aspartate	I-CHEMICAL
to	O
afferent	O
terminals	O
,	O
indicating	O
that	O
neither	O
presynaptic	O
nor	O
postsynaptic	O
membranes	O
are	O
major	O
sites	O
for	O
glutamate	B-CHEMICAL
removal	O
.	O

These	O
data	O
indicate	O
that	O
GLAST	B-GENE-Y
in	O
supporting	O
cells	O
is	O
responsible	O
for	O
transmitter	O
uptake	O
at	O
IHC	O
afferent	O
synapses	O
.	O

The	O
alpha	B-GENE-N
-	I-GENE-N
and	I-GENE-N
beta	I-GENE-N
-	I-GENE-N
adrenoceptor	I-GENE-N
blocking	O
activities	O
of	O
labetalol	B-CHEMICAL
and	O
its	O
RR	O
-	O
SR	O
(	O
50	O
:	O
50	O
)	O
stereoisomers	O
.	O

1	O
.	O

We	O
compared	O
the	O
alpha	B-GENE-N
1	I-GENE-N
-	I-GENE-N
,	I-GENE-N
alpha	I-GENE-N
2	I-GENE-N
-	I-GENE-N
and	I-GENE-N
beta	I-GENE-N
1	I-GENE-N
-	I-GENE-N
adrenoceptor	I-GENE-N
blocking	O
potencies	O
of	O
labetalol	B-CHEMICAL
with	O
those	O
of	O
its	O
two	O
stereoisomers	O
(	O
RR	O
and	O
SR	O
)	O
in	O
pithed	O
rats	O
and	O
in	O
homogenized	O
rat	O
cerebral	O
cortex	O
and	O
heart	O
.	O

2	O
.	O

In	O
pithed	O
rats	O
,	O
labetalol	B-CHEMICAL
and	O
the	O
RR	O
-	O
SR	O
combination	O
were	O
given	O
orally	O
either	O
at	O
doses	O
of	O
25	O
and	O
50	O
mg	O
kg	O
-	O
1	O
body	O
wt	O
.	O
or	O
intravenously	O
at	O
doses	O
of	O
1	O
and	O
5	O
mg	O
kg	O
-	O
1	O
body	O
wt	O
.	O

Prazosin	B-CHEMICAL
4	O
and	O
20	O
micrograms	O
kg	O
-	O
1	O
body	O
wt	O
.	O
and	O
propranolol	B-CHEMICAL
1	O
and	O
5	O
mg	O
kg	O
-	O
1	O
body	O
wt	O
.	O
,	O
were	O
given	O
intravenously	O
for	O
comparison	O
studies	O
of	O
potency	O
at	O
alpha	B-GENE-N
1	I-GENE-N
-	I-GENE-N
and	I-GENE-N
beta	I-GENE-N
1	I-GENE-N
-	I-GENE-N
adrenoceptors	I-GENE-N
,	O
respectively	O
.	O

Effects	O
were	O
studied	O
before	O
and	O
after	O
i	O
.	O
v	O
.	O
administration	O
of	O
either	O
phenylephrine	B-CHEMICAL
(	O
at	O
doses	O
which	O
increased	O
the	O
mean	O
arterial	O
pressure	O
by	O
approximately	O
80	O
mmHg	O
)	O
or	O
isoprenaline	B-CHEMICAL
(	O
at	O
doses	O
that	O
increased	O
heart	O
rate	O
by	O
approximately	O
100	O
beats	O
min	O
-	O
1	O
)	O
.	O

3	O
.	O

In	O
pithed	O
rats	O
,	O
labetalol	B-CHEMICAL
and	O
the	O
RR	O
-	O
SR	O
combination	O
antagonized	O
,	O
in	O
a	O
dose	O
-	O
dependent	O
manner	O
,	O
the	O
pressor	O
effect	O
of	O
phenylephrine	B-CHEMICAL
(	O
P	O
less	O
than	O
0	O
.	O
05	O
)	O
and	O
the	O
chronotropic	O
effect	O
of	O
isoprenaline	B-CHEMICAL
(	O
P	O
less	O
than	O
0	O
.	O
05	O
)	O
.	O

Following	O
both	O
oral	O
and	O
intravenous	O
dosing	O
,	O
the	O
RR	O
-	O
SR	O
combination	O
was	O
twice	O
potent	O
as	O
labetalol	B-CHEMICAL
in	O
terms	O
of	O
alpha	B-GENE-N
1	I-GENE-N
-	I-GENE-N
and	I-GENE-N
beta	I-GENE-N
1	I-GENE-N
-	I-GENE-N
adrenoceptor	I-GENE-N
antagonism	O
at	O
equivalent	O
doses	O
.	O

4	O
.	O

Labetalol	B-CHEMICAL
and	O
the	O
enantiomers	O
lacked	O
affinity	O
at	O
alpha	B-GENE-N
2	I-GENE-N
-	I-GENE-N
adrenoceptors	I-GENE-N
while	O
at	O
alpha	B-GENE-N
1	I-GENE-N
-	I-GENE-N
adrenoceptors	I-GENE-N
the	O
order	O
of	O
potency	O
was	O
prazosin	B-CHEMICAL
much	O
greater	O
than	O
RR	O
-	O
SR	O
greater	O
than	O
labetalol	B-CHEMICAL
.	O

At	O
beta	B-GENE-Y
1	I-GENE-Y
-	I-GENE-Y
adrenoceptors	I-GENE-Y
,	O
the	O
affinity	O
of	O
the	O
compound	O
RR	O
-	O
SR	O
was	O
about	O
3	O
times	O
that	O
of	O
labetalol	B-CHEMICAL
.	O
5	O
.	O

As	O
labetalol	B-CHEMICAL
is	O
a	O
mixture	O
of	O
active	O
(	O
RR	O
and	O
SR	O
)	O
and	O
inactive	O
(	O
SS	O
and	O
SR	O
)	O
enantiomers	O
(	O
in	O
terms	O
of	O
alpha	B-GENE-N
and	I-GENE-N
beta	I-GENE-N
receptor	I-GENE-N
actions	O
)	O
,	O
the	O
combination	O
of	O
RR	O
and	O
SR	O
may	O
be	O
a	O
valuable	O
substitute	O
for	O
labetalol	B-CHEMICAL
in	O
the	O
treatment	O
of	O
systemic	O
hypertension	O
.	O

Although	O
the	O
potential	O
for	O
non	O
-	O
specific	O
side	O
effects	O
(	O
common	O
to	O
all	O
four	O
enantiomers	O
)	O
could	O
be	O
expected	O
to	O
be	O
diminished	O
,	O
recent	O
reports	O
by	O
postmarketing	O
surveillance	O
indicate	O
that	O
the	O
RR	O
isomer	O
(	O
dilevalol	B-CHEMICAL
)	O
can	O
induce	O
liver	O
toxicity	O
.	O

Interestingly	O
,	O
labetalol	B-CHEMICAL
is	O
devoid	O
of	O
this	O
effect	O
;	O
whether	O
the	O
combination	O
of	O
RR	O
and	O
SR	O
enantiomers	O
could	O
be	O
of	O
clinical	O
importance	O
warrants	O
further	O
investigation	O
.	O

Overexpression	O
of	O
proline	B-GENE-Y
oxidase	I-GENE-Y
induces	O
proline	B-CHEMICAL
-	O
dependent	O
and	O
mitochondria	O
-	O
mediated	O
apoptosis	O
.	O

Proline	B-GENE-Y
oxidase	I-GENE-Y
(	O
POX	B-GENE-Y
)	O
,	O
a	O
mitochondrial	O
inner	O
-	O
membrane	O
protein	O
,	O
catalyzes	O
the	O
rate	O
-	O
limiting	O
oxidation	O
of	O
proline	B-CHEMICAL
to	O
pyrroline	B-CHEMICAL
-	I-CHEMICAL
5	I-CHEMICAL
-	I-CHEMICAL
carboxylate	I-CHEMICAL
(	O
P5C	B-CHEMICAL
)	O
.	O

Previously	O
we	O
showed	O
that	O
overexpression	O
of	O
POX	B-GENE-Y
is	O
associated	O
with	O
generation	O
of	O
reactive	O
oxygen	B-CHEMICAL
species	O
(	O
ROS	O
)	O
and	O
apoptosis	O
in	O
POX	B-GENE-Y
-	O
inducible	O
colorectal	O
cancer	O
cells	O
,	O
DLD	O
-	O
1	O
.	O
POX	B-GENE-Y
.	O

We	O
also	O
showed	O
expression	O
of	O
mitochondrial	O
MnSOD	B-GENE-Y
partially	O
blunts	O
POX	B-GENE-Y
-	O
induced	O
ROS	O
generation	O
and	O
apoptosis	O
.	O

To	O
further	O
investigate	O
the	O
molecular	O
basis	O
of	O
POX	B-GENE-Y
-	O
induced	O
apoptosis	O
,	O
we	O
utilized	O
the	O
DLD	O
-	O
1	O
.	O
POX	B-GENE-Y
cells	O
to	O
show	O
that	O
cells	O
overproducing	O
POX	B-GENE-Y
exhibit	O
an	O
L	B-CHEMICAL
-	I-CHEMICAL
proline	I-CHEMICAL
-	O
dependent	O
apoptotic	O
response	O
.	O

The	O
apoptotic	O
effect	O
is	O
specific	O
for	O
L	B-CHEMICAL
-	I-CHEMICAL
proline	I-CHEMICAL
,	O
detectable	O
at	O
0	O
.	O
2	O
mM	O
,	O
maximal	O
at	O
1	O
mM	O
,	O
and	O
occurs	O
during	O
48	O
-	O
72	O
h	O
following	O
the	O
addition	O
of	O
L	B-CHEMICAL
-	I-CHEMICAL
proline	I-CHEMICAL
to	O
cells	O
with	O
maximally	O
induced	O
POX	B-GENE-Y
.	O

The	O
apoptotic	O
response	O
is	O
mitochondria	O
-	O
mediated	O
with	O
release	O
of	O
cytochrome	B-GENE-Y
c	I-GENE-Y
,	O
activation	O
of	O
caspase	B-GENE-Y
-	I-GENE-Y
9	I-GENE-Y
,	O
chromatin	O
condensation	O
/	O
DNA	O
fragmentation	O
,	O
and	O
cell	O
shrinkage	O
.	O

We	O
conclude	O
that	O
in	O
the	O
presence	O
of	O
proline	B-CHEMICAL
,	O
high	O
POX	B-GENE-Y
activity	O
is	O
sufficient	O
to	O
induce	O
mitochondria	O
-	O
mediated	O
apoptosis	O
.	O

The	O
effects	O
of	O
norepinephrine	B-GENE-Y
transporter	I-GENE-Y
inactivation	O
on	O
locomotor	O
activity	O
in	O
mice	O
.	O

BACKGROUND	O
:	O
Acute	O
administration	O
of	O
different	O
classes	O
of	O
antidepressants	O
can	O
enhance	O
or	O
reduce	O
spontaneous	O
locomotor	O
activity	O
in	O
a	O
novel	O
environment	O
,	O
but	O
the	O
effects	O
of	O
chronic	O
antidepressant	O
treatment	O
on	O
spontaneous	O
locomotor	O
activity	O
in	O
novel	O
and	O
familiar	O
environments	O
are	O
less	O
well	O
characterized	O
.	O

Because	O
norepinephrine	B-CHEMICAL
is	O
an	O
important	O
regulator	O
of	O
spontaneous	O
locomotor	O
activity	O
,	O
we	O
speculated	O
that	O
norepinephrine	B-GENE-Y
transporter	I-GENE-Y
blockade	O
contributes	O
to	O
the	O
effects	O
of	O
some	O
antidepressants	O
on	O
spontaneous	O
locomotor	O
activity	O
.	O

METHODS	O
:	O
Antidepressant	O
drugs	O
(	O
reboxetine	B-CHEMICAL
,	O
desipramine	B-CHEMICAL
,	O
imipramine	B-CHEMICAL
,	O
venlafaxine	B-CHEMICAL
,	O
bupropion	B-CHEMICAL
)	O
were	O
administered	O
acutely	O
(	O
intraperitoneal	O
)	O
or	O
chronically	O
(	O
via	O
osmotic	O
minipump	O
)	O
to	O
control	O
and	O
norepinephrine	B-GENE-Y
transporter	I-GENE-Y
knockout	O
mice	O
,	O
and	O
spontaneous	O
locomotor	O
activity	O
in	O
novel	O
or	O
familiar	O
environments	O
was	O
recorded	O
.	O

RESULTS	O
:	O
Acute	O
treatment	O
with	O
most	O
norepinephrine	B-GENE-Y
transporter	I-GENE-Y
-	O
blocking	O
antidepressants	O
decreased	O
spontaneous	O
locomotor	O
activity	O
in	O
a	O
novel	O
environment	O
,	O
whereas	O
chronic	O
treatment	O
decreased	O
spontaneous	O
locomotor	O
activity	O
in	O
both	O
novel	O
and	O
familiar	O
environments	O
.	O

The	O
exception	O
was	O
bupropion	B-CHEMICAL
,	O
a	O
dual	O
norepinephrine	B-GENE-Y
transporter	I-GENE-Y
/	O
dopamine	B-GENE-Y
transporter	I-GENE-Y
blocker	O
,	O
which	O
tended	O
to	O
increase	O
spontaneous	O
locomotor	O
activity	O
.	O

Coadministration	O
of	O
reboxetine	B-CHEMICAL
and	O
the	O
dopamine	B-GENE-Y
transporter	I-GENE-Y
blocker	O
GBR	B-CHEMICAL
12909	I-CHEMICAL
also	O
increased	O
spontaneous	O
locomotor	O
activity	O
.	O

Norepinephrine	B-GENE-Y
transporter	I-GENE-Y
knockout	O
mice	O
had	O
low	O
basal	O
spontaneous	O
locomotor	O
activity	O
,	O
which	O
was	O
increased	O
by	O
bupropion	B-CHEMICAL
,	O
whereas	O
reboxetine	B-CHEMICAL
had	O
no	O
effect	O
in	O
norepinephrine	B-GENE-Y
transporter	I-GENE-Y
knockout	O
mice	O
.	O

CONCLUSIONS	O
:	O
Acute	O
or	O
chronic	O
inactivation	O
of	O
the	O
norepinephrine	B-GENE-Y
transporter	I-GENE-Y
decreases	O
spontaneous	O
locomotor	O
activity	O
in	O
novel	O
and	O
familiar	O
environments	O
unless	O
coupled	O
with	O
dopamine	B-GENE-Y
transporter	I-GENE-Y
blockade	O
.	O

Treatment	O
of	O
Postmenopausal	O
Breast	O
Cancer	O
with	O
Selective	O
Estrogen	B-GENE-Y
Receptor	I-GENE-Y
Modulators	O
(	O
SERMs	O
)	O
.	O

Endocrine	O
therapy	O
that	O
targets	O
the	O
estrogen	B-GENE-Y
receptor	I-GENE-Y
(	O
ER	B-GENE-Y
)	O
is	O
a	O
standard	O
of	O
care	O
for	O
the	O
treatment	O
of	O
postmenopausal	O
women	O
with	O
ER	B-GENE-Y
-	O
positive	O
breast	O
cancer	O
.	O

The	O
selective	O
ER	B-GENE-Y
modulator	O
(	O
SERM	O
)	O
tamoxifen	B-CHEMICAL
has	O
been	O
in	O
use	O
for	O
the	O
treatment	O
of	O
advanced	O
breast	O
cancer	O
for	O
more	O
than	O
30	O
years	O
and	O
is	O
currently	O
a	O
treatment	O
option	O
for	O
all	O
stages	O
of	O
ER	B-GENE-Y
-	O
positive	O
disease	O
.	O

Tamoxifen	B-CHEMICAL
blocks	O
the	O
action	O
of	O
estrogen	B-CHEMICAL
by	O
binding	O
to	O
the	O
ER	B-GENE-Y
,	O
and	O
possesses	O
both	O
ER	B-GENE-Y
-	O
agonist	O
and	O
antagonist	O
properties	O
.	O

Unfortunately	O
,	O
long	O
-	O
term	O
use	O
of	O
tamoxifen	B-CHEMICAL
is	O
associated	O
with	O
several	O
important	O
concerns	O
including	O
an	O
increased	O
risk	O
of	O
endometrial	O
cancer	O
and	O
thromboembolic	O
complications	O
.	O

In	O
addition	O
,	O
many	O
patients	O
who	O
initially	O
respond	O
to	O
tamoxifen	B-CHEMICAL
eventually	O
relapse	O
with	O
resistant	O
disease	O
.	O

New	O
treatment	O
approaches	O
are	O
therefore	O
required	O
.	O

A	O
number	O
of	O
alternative	O
SERMs	O
have	O
been	O
tested	O
as	O
substitutes	O
for	O
tamoxifen	B-CHEMICAL
.	O

These	O
include	O
;	O
toremifene	B-CHEMICAL
,	O
droloxifene	B-CHEMICAL
,	O
idoxifene	B-CHEMICAL
,	O
and	O
keoxifene	B-CHEMICAL
.	O

Unfortunately	O
,	O
the	O
SERMs	O
have	O
not	O
proved	O
to	O
be	O
more	O
effective	O
than	O
tamoxifen	B-CHEMICAL
for	O
the	O
treatment	O
of	O
advanced	O
breast	O
cancer	O
and	O
have	O
shown	O
a	O
high	O
level	O
of	O
cross	O
-	O
resistance	O
with	O
tamoxifen	B-CHEMICAL
.	O

The	O
subsequent	O
development	O
of	O
the	O
aromatase	B-GENE-Y
inhibitors	O
(	O
AIs	O
)	O
is	O
an	O
important	O
therapeutic	O
advance	O
by	O
creating	O
a	O
"	O
no	O
estrogen	B-CHEMICAL
"	O
environment	O
.	O

Another	O
approach	O
is	O
the	O
development	O
of	O
pure	O
antiestrogens	O
.	O

Fulvestrant	B-CHEMICAL
is	O
a	O
novel	O
ER	B-GENE-Y
antagonist	O
that	O
destroys	O
the	O
ER	B-GENE-Y
and	O
its	O
signaling	O
pathway	O
and	O
is	O
not	O
associated	O
with	O
tamoxifen	B-CHEMICAL
-	O
like	O
agonist	O
effects	O
.	O

It	O
produces	O
high	O
response	O
rates	O
compared	O
with	O
other	O
SERMs	O
and	O
is	O
not	O
cross	O
-	O
resistant	O
to	O
tamoxifen	B-CHEMICAL
or	O
aromatase	B-GENE-Y
inhibitors	O
and	O
is	O
equally	O
as	O
effective	O
as	O
the	O
AI	O
anastrozole	B-CHEMICAL
in	O
the	O
treatment	O
of	O
postmenopausal	O
women	O
with	O
advanced	O
breast	O
cancer	O
who	O
have	O
progressed	O
on	O
prior	O
adjuvant	O
tamoxifen	B-CHEMICAL
therapy	O
.	O

This	O
review	O
article	O
discusses	O
the	O
significant	O
and	O
continuing	O
value	O
of	O
SERMs	O
for	O
the	O
treatment	O
of	O
postmenopausal	O
ER	B-GENE-Y
-	O
positive	O
breast	O
cancer	O
.	O

A	O
46	O
-	O
amino	B-CHEMICAL
acid	I-CHEMICAL
segment	O
in	O
phosphodiesterase	B-GENE-Y
-	I-GENE-Y
5	I-GENE-Y
GAF	B-GENE-N
-	I-GENE-N
B	I-GENE-N
domain	I-GENE-N
provides	O
for	O
high	O
vardenafil	B-CHEMICAL
potency	O
over	O
sildenafil	B-CHEMICAL
and	O
tadalafil	B-CHEMICAL
and	O
is	O
involved	O
in	O
phosphodiesterase	B-GENE-Y
-	I-GENE-Y
5	I-GENE-Y
dimerization	O
.	O

Phosphodiesterase	B-GENE-Y
-	I-GENE-Y
5	I-GENE-Y
(	O
PDE5	B-GENE-Y
)	O
contains	O
a	O
catalytic	O
domain	O
(	O
C	O
domain	O
)	O
that	O
hydrolyzes	O
cGMP	B-CHEMICAL
and	O
a	O
regulatory	O
domain	O
(	O
R	O
domain	O
)	O
that	O
contains	O
two	O
mammalian	B-GENE-N
cGMP	I-GENE-N
-	I-GENE-N
binding	I-GENE-N
phosphodiesterase	I-GENE-N
,	O
Anabaena	B-GENE-Y
adenylyl	I-GENE-Y
cyclases	I-GENE-Y
,	O
Escherichia	B-GENE-Y
coli	I-GENE-Y
FhlAs	I-GENE-Y
(	B-GENE-N
GAFs	I-GENE-N
)	I-GENE-N
(	I-GENE-N
A	I-GENE-N
and	I-GENE-N
B	I-GENE-N
)	I-GENE-N
and	O
a	O
phosphorylation	O
site	O
for	O
cyclic	B-GENE-N
nucleotide	I-GENE-N
-	I-GENE-N
dependent	I-GENE-N
protein	I-GENE-N
kinases	I-GENE-N
(	O
cNPKs	B-GENE-N
)	O
.	O

Binding	O
of	O
cGMP	B-CHEMICAL
to	O
GAF	B-GENE-N
-	I-GENE-N
A	I-GENE-N
increases	O
cNPK	B-GENE-N
phosphorylation	O
of	O
PDE5	B-GENE-Y
and	O
improves	O
catalytic	O
site	O
affinity	O
for	O
cGMP	B-CHEMICAL
or	O
inhibitors	O
.	O

GAF	B-GENE-N
-	I-GENE-N
B	I-GENE-N
contributes	O
to	O
dimerization	O
of	O
PDE5	B-GENE-Y
,	O
inhibition	O
of	O
cGMP	B-CHEMICAL
binding	O
to	O
GAF	B-GENE-N
-	I-GENE-N
A	I-GENE-N
,	O
and	O
sequestration	O
of	O
the	O
phosphorylation	O
site	O
.	O

To	O
probe	O
potential	O
PDE5	B-GENE-N
R	I-GENE-N
domain	I-GENE-N
effects	O
on	O
catalytic	O
site	O
affinity	O
for	O
certain	O
inhibitors	O
,	O
four	O
N	B-CHEMICAL
-	O
terminal	O
truncation	O
mutants	O
were	O
generated	O
:	O
PDE5Delta1	B-GENE-Y
-	I-GENE-Y
321	I-GENE-Y
contained	O
GAF	B-GENE-N
-	I-GENE-N
B	I-GENE-N
domain	I-GENE-N
,	O
C	O
domain	O
,	O
and	O
the	O
sequence	O
between	O
GAF	B-GENE-N
-	I-GENE-N
A	I-GENE-N
and	I-GENE-N
-	I-GENE-N
B	I-GENE-N
;	O
PDE5Delta1	B-GENE-Y
-	I-GENE-Y
419	I-GENE-Y
contained	O
GAF	B-GENE-N
-	I-GENE-N
B	I-GENE-N
and	I-GENE-N
C	I-GENE-N
domain	I-GENE-N
;	O
PDE5Delta1	B-GENE-Y
-	I-GENE-Y
465	I-GENE-Y
contained	O
the	O
C	O
domain	O
and	O
the	O
C	B-CHEMICAL
-	O
terminal	O
portion	O
of	O
GAF	B-GENE-N
-	I-GENE-N
B	I-GENE-N
;	O
and	O
PDE5Delta1	B-GENE-Y
-	I-GENE-Y
534	I-GENE-Y
contained	O
only	O
C	O
domain	O
.	O

Truncated	O
proteins	O
with	O
a	O
complete	O
GAF	B-GENE-N
-	I-GENE-N
B	I-GENE-N
were	O
dimers	O
,	O
but	O
those	O
lacking	O
the	O
N	B-CHEMICAL
-	O
terminal	O
46	O
amino	B-CHEMICAL
acids	I-CHEMICAL
of	O
GAF	B-GENE-N
-	I-GENE-N
B	I-GENE-N
were	O
monomers	O
,	O
indicating	O
that	O
these	O
residues	O
are	O
vital	O
for	O
GAF	B-GENE-N
-	I-GENE-N
B	I-GENE-N
-	O
mediated	O
PDE5	B-GENE-Y
dimerization	O
.	O

K	O
(	O
m	O
)	O
values	O
of	O
the	O
mutants	O
for	O
cGMP	B-CHEMICAL
were	O
similar	O
to	O
that	O
of	O
full	O
-	O
length	O
PDE5	B-GENE-Y
.	O

All	O
PDE5	B-GENE-Y
constructs	O
had	O
similar	O
affinities	O
for	O
3	B-CHEMICAL
-	I-CHEMICAL
isobutyl	I-CHEMICAL
-	I-CHEMICAL
1	I-CHEMICAL
-	I-CHEMICAL
methylxanthine	I-CHEMICAL
,	O
sildenafil	B-CHEMICAL
,	O
tadalafil	B-CHEMICAL
,	O
and	O
UK	B-CHEMICAL
-	I-CHEMICAL
122764	I-CHEMICAL
,	O
but	O
mutants	O
containing	O
a	O
complete	O
GAF	B-GENE-N
-	I-GENE-N
B	I-GENE-N
had	O
7	O
-	O
to	O
18	O
-	O
fold	O
higher	O
affinity	O
for	O
vardenafil	B-CHEMICAL
-	O
based	O
compounds	O
compared	O
with	O
those	O
lacking	O
a	O
complete	O
GAF	B-GENE-N
-	I-GENE-N
B	I-GENE-N
.	O

This	O
indicated	O
that	O
the	O
N	B-CHEMICAL
-	O
terminal	O
46	O
amino	B-CHEMICAL
acids	I-CHEMICAL
in	O
GAF	B-GENE-N
-	I-GENE-N
B	I-GENE-N
are	O
required	O
for	O
high	O
vardenafil	B-CHEMICAL
potency	O
.	O

This	O
is	O
the	O
first	O
evidence	O
that	O
PDE5	B-GENE-N
R	I-GENE-N
domain	I-GENE-N
,	O
and	O
GAF	B-GENE-N
-	I-GENE-N
B	I-GENE-N
in	O
particular	O
,	O
influences	O
affinity	O
and	O
selectivity	O
of	O
the	O
catalytic	O
site	O
for	O
certain	O
classes	O
of	O
inhibitors	O
.	O

Telmisartan	B-CHEMICAL
downregulates	O
angiotensin	B-GENE-Y
II	I-GENE-Y
type	I-GENE-Y
1	I-GENE-Y
receptor	I-GENE-Y
through	O
activation	O
of	O
peroxisome	B-GENE-Y
proliferator	I-GENE-Y
-	I-GENE-Y
activated	I-GENE-Y
receptor	I-GENE-Y
gamma	I-GENE-Y
.	O

OBJECTIVE	O
:	O
Telmisartan	B-CHEMICAL
,	O
an	O
angiotensin	B-GENE-Y
II	I-GENE-Y
type	I-GENE-Y
1	I-GENE-Y
receptor	I-GENE-Y
(	O
AT1R	B-GENE-Y
)	O
antagonist	O
,	O
was	O
found	O
to	O
have	O
a	O
unique	O
property	O
:	O
it	O
is	O
a	O
partial	O
agonist	O
of	O
peroxisome	B-GENE-Y
proliferator	I-GENE-Y
-	I-GENE-Y
activated	I-GENE-Y
receptor	I-GENE-Y
gamma	I-GENE-Y
(	O
PPARgamma	B-GENE-Y
)	O
.	O

Since	O
previous	O
studies	O
have	O
demonstrated	O
that	O
PPARgamma	B-GENE-Y
activators	O
suppressed	O
AT1R	B-GENE-Y
expression	O
,	O
we	O
examined	O
whether	O
telmisartan	B-CHEMICAL
affects	O
AT1R	B-GENE-Y
expression	O
in	O
vascular	O
smooth	O
muscle	O
cells	O
.	O

METHODS	O
:	O
Vascular	O
smooth	O
muscle	O
cells	O
were	O
derived	O
from	O
the	O
thoracic	O
aorta	O
of	O
Wistar	O
-	O
Kyoto	O
rat	O
.	O

Northern	O
and	O
Western	O
blotting	O
analysis	O
were	O
used	O
to	O
examine	O
AT1R	B-GENE-Y
mRNA	O
and	O
protein	O
expression	O
,	O
respectively	O
.	O

The	O
DEAE	O
-	O
dextran	O
method	O
was	O
used	O
for	O
transfection	O
,	O
and	O
the	O
promoter	O
activity	O
of	O
AT1R	B-GENE-Y
was	O
examined	O
by	O
luciferase	O
assay	O
.	O

RESULTS	O
:	O
Telmisartan	B-CHEMICAL
decreased	O
the	O
expression	O
of	O
AT1R	B-GENE-Y
at	O
the	O
mRNA	O
and	O
protein	O
levels	O
in	O
a	O
dose	O
-	O
and	O
time	O
-	O
dependent	O
manner	O
.	O

Decreased	O
AT1R	B-GENE-N
promoter	I-GENE-N
activity	O
with	O
unchanged	O
mRNA	O
stability	O
suggested	O
that	O
telmisartan	B-CHEMICAL
suppressed	O
AT1R	B-GENE-Y
gene	O
expression	O
at	O
the	O
transcriptional	O
level	O
.	O

However	O
,	O
the	O
expression	O
of	O
AT1R	B-GENE-Y
was	O
not	O
suppressed	O
by	O
other	O
AT1R	B-GENE-Y
antagonists	O
such	O
as	O
candesartan	B-CHEMICAL
or	O
olmesartan	B-CHEMICAL
.	O

Since	O
the	O
suppression	O
of	O
AT1R	B-GENE-Y
expression	O
was	O
prevented	O
by	O
pretreatment	O
with	O
GW9662	B-CHEMICAL
,	O
a	O
PPARgamma	B-GENE-Y
antagonist	O
,	O
PPARgamma	B-GENE-Y
should	O
have	O
participated	O
in	O
the	O
process	O
.	O

The	O
deletion	O
and	O
mutation	O
analysis	O
of	O
the	O
AT1R	B-GENE-Y
gene	O
promoter	O
indicated	O
that	O
a	O
GC	B-GENE-N
box	I-GENE-N
located	O
in	O
the	O
proximal	O
promoter	O
region	O
is	O
responsible	O
for	O
the	O
telmisartan	B-CHEMICAL
-	O
induced	O
downregulation	O
.	O

CONCLUSION	O
:	O
Our	O
data	O
provides	O
a	O
novel	O
insight	O
into	O
an	O
effect	O
of	O
telmisartan	B-CHEMICAL
:	O
telmisartan	B-CHEMICAL
inhibits	O
AT1R	B-GENE-Y
gene	O
expression	O
through	O
PPARgamma	B-GENE-Y
activation	O
.	O

The	O
dual	O
inhibition	O
of	O
angiotensin	B-GENE-Y
II	I-GENE-Y
function	O
by	O
telmisartan	O
-	O
AT1R	B-GENE-Y
blockade	O
and	O
downregulation	O
-	O
would	O
contribute	O
to	O
more	O
complete	O
inhibition	O
of	O
the	O
renin	B-GENE-Y
-	O
angiotensin	B-GENE-Y
system	O
.	O

Secretion	O
of	O
L	B-CHEMICAL
-	I-CHEMICAL
glutamate	I-CHEMICAL
from	O
osteoclasts	O
through	O
transcytosis	O
.	O

Osteoclasts	O
are	O
involved	O
in	O
the	O
catabolism	O
of	O
the	O
bone	O
matrix	O
and	O
eliminate	O
the	O
resulting	O
degradation	O
products	O
through	O
transcytosis	O
,	O
but	O
the	O
molecular	O
mechanism	O
and	O
regulation	O
of	O
transcytosis	O
remain	O
poorly	O
understood	O
.	O

Upon	O
differentiation	O
,	O
osteoclasts	O
express	O
vesicular	B-GENE-Y
glutamate	I-GENE-Y
transporter	I-GENE-Y
1	I-GENE-Y
(	O
VGLUT1	B-GENE-Y
)	O
,	O
which	O
is	O
essential	O
for	O
vesicular	O
storage	O
and	O
subsequent	O
exocytosis	O
of	O
glutamate	B-CHEMICAL
in	O
neurons	O
.	O

VGLUT1	B-GENE-Y
is	O
localized	O
in	O
transcytotic	O
vesicles	O
and	O
accumulates	O
L	B-CHEMICAL
-	I-CHEMICAL
glutamate	I-CHEMICAL
.	O

Osteoclasts	O
secrete	O
L	B-CHEMICAL
-	I-CHEMICAL
glutamate	I-CHEMICAL
and	O
the	O
bone	O
degradation	O
products	O
upon	O
stimulation	O
with	O
KCl	B-CHEMICAL
or	O
ATP	B-CHEMICAL
in	O
a	O
Ca2	B-CHEMICAL
+	I-CHEMICAL
-	O
dependent	O
manner	O
.	O

KCl	B-CHEMICAL
-	O
and	O
ATP	B-CHEMICAL
-	O
dependent	O
secretion	O
of	O
L	B-CHEMICAL
-	I-CHEMICAL
glutamate	I-CHEMICAL
was	O
absent	O
in	O
osteoclasts	O
prepared	O
from	O
VGLUT1	B-GENE-Y
-	O
/	O
-	O
knockout	O
mice	O
.	O

Osteoclasts	O
express	O
mGluR8	B-GENE-Y
,	O
a	O
class	B-GENE-N
III	I-GENE-N
metabotropic	I-GENE-N
glutamate	I-GENE-N
receptor	I-GENE-N
.	O

Its	O
stimulation	O
by	O
a	O
specific	O
agonist	O
inhibits	O
secretion	O
of	O
L	B-CHEMICAL
-	I-CHEMICAL
glutamate	I-CHEMICAL
and	O
bone	O
degradation	O
products	O
,	O
whereas	O
its	O
suppression	O
by	O
a	O
specific	O
antagonist	O
stimulates	O
bone	O
resorption	O
.	O

Finally	O
,	O
it	O
was	O
found	O
that	O
VGLUT1	B-GENE-Y
-	O
/	O
-	O
mice	O
develop	O
osteoporosis	O
.	O

Thus	O
,	O
in	O
bone	O
-	O
resorbing	O
osteoclasts	O
,	O
L	B-CHEMICAL
-	I-CHEMICAL
glutamate	I-CHEMICAL
and	O
bone	O
degradation	O
products	O
are	O
secreted	O
through	O
transcytosis	O
and	O
the	O
released	O
L	B-CHEMICAL
-	I-CHEMICAL
glutamate	I-CHEMICAL
is	O
involved	O
in	O
autoregulation	O
of	O
transcytosis	O
.	O

Glutamate	B-CHEMICAL
signaling	O
may	O
play	O
an	O
important	O
role	O
in	O
the	O
bone	O
homeostasis	O
.	O

Synthesis	O
,	O
dihydrofolate	B-GENE-Y
reductase	I-GENE-Y
inhibition	O
,	O
antitumor	O
testing	O
,	O
and	O
molecular	O
modeling	O
study	O
of	O
some	O
new	O
4	B-CHEMICAL
(	I-CHEMICAL
3H	I-CHEMICAL
)	I-CHEMICAL
-	I-CHEMICAL
quinazolinone	I-CHEMICAL
analogs	O
.	O

In	O
order	O
to	O
produce	O
potent	O
new	O
leads	O
for	O
anticancer	O
drugs	O
,	O
a	O
new	O
series	O
of	O
quinazoline	B-CHEMICAL
analogs	O
was	O
designed	O
to	O
resemble	O
methotrexate	B-CHEMICAL
(	O
MTX	B-CHEMICAL
,	O
1	O
)	O
structure	O
features	O
and	O
fitted	O
with	O
functional	O
groups	O
believed	O
to	O
enhance	O
inhibition	O
of	O
mammalian	B-GENE-N
DHFR	I-GENE-N
activity	O
.	O

Molecular	O
modeling	O
studies	O
were	O
used	O
to	O
assess	O
the	O
fit	O
of	O
these	O
compounds	O
within	O
the	O
active	O
site	O
of	O
human	B-GENE-Y
DHFR	I-GENE-Y
.	O

The	O
synthesized	O
compounds	O
were	O
evaluated	O
for	O
their	O
ability	O
to	O
inhibit	O
mammalian	B-GENE-N
DHFR	I-GENE-N
in	O
vitro	O
and	O
for	O
their	O
antitumor	O
activity	O
in	O
a	O
standard	O
in	O
vitro	O
tissue	O
culture	O
assay	O
panel	O
.	O

Compounds	O
28	O
,	O
30	O
,	O
and	O
31	O
were	O
the	O
most	O
active	O
DHFR	B-GENE-Y
inhibitors	O
with	O
IC	O
(	O
50	O
)	O
values	O
of	O
0	O
.	O
5	O
,	O
0	O
.	O
4	O
,	O
and	O
0	O
.	O
4microM	O
,	O
respectively	O
.	O

The	O
most	O
active	O
antitumor	O
agents	O
in	O
this	O
study	O
were	O
compounds	O
19	O
,	O
31	O
,	O
41	O
,	O
and	O
47	O
with	O
median	O
growth	O
inhibitory	O
concentrations	O
(	O
GI	O
(	O
50	O
)	O
)	O
of	O
20	O
.	O
1	O
,	O
23	O
.	O
5	O
,	O
26	O
.	O
7	O
,	O
and	O
9	O
.	O
1microM	O
,	O
respectively	O
.	O

Of	O
this	O
series	O
of	O
compounds	O
,	O
only	O
compound	O
31	O
combined	O
antitumor	O
potency	O
with	O
potent	O
DHFR	B-GENE-Y
inhibition	O
;	O
the	O
other	O
active	O
antitumor	O
compounds	O
(	O
19	O
,	O
41	O
,	O
and	O
47	O
)	O
all	O
had	O
DHFR	B-GENE-Y
IC	O
(	O
50	O
)	O
values	O
above	O
15microM	O
,	O
suggesting	O
that	O
they	O
might	O
exert	O
their	O
antitumor	O
potency	O
through	O
some	O
other	O
mode	O
of	O
action	O
.	O

Alternatively	O
,	O
the	O
compounds	O
could	O
differ	O
significantly	O
in	O
uptake	O
or	O
concentration	O
within	O
mammalian	O
cells	O
.	O

Hyperphagia	O
alters	O
expression	O
of	O
hypothalamic	O
5	B-GENE-Y
-	I-GENE-Y
HT2C	I-GENE-Y
and	O
5	B-GENE-Y
-	I-GENE-Y
HT1B	I-GENE-Y
receptor	O
genes	O
and	O
plasma	O
des	B-GENE-Y
-	I-GENE-Y
acyl	I-GENE-Y
ghrelin	I-GENE-Y
levels	O
in	O
Ay	O
mice	O
.	O

The	O
central	O
melanocortin	B-GENE-Y
(	O
MC	B-GENE-Y
)	O
pathway	O
is	O
suggested	O
to	O
mediate	O
satiety	O
signaling	O
downstream	O
of	O
serotonin	B-GENE-Y
(	I-GENE-Y
5	I-GENE-Y
-	I-GENE-Y
HT	I-GENE-Y
)	I-GENE-Y
2C	I-GENE-Y
receptors	I-GENE-Y
.	O

5	B-GENE-Y
-	I-GENE-Y
HT2C	I-GENE-Y
receptor	O
mutant	O
mice	O
consume	O
more	O
food	O
,	O
which	O
leads	O
to	O
late	O
-	O
onset	O
obesity	O
and	O
impaired	O
glucose	B-CHEMICAL
tolerance	O
.	O

Ay	O
mice	O
with	O
ectopic	O
expression	O
of	O
the	O
agouti	B-GENE-Y
peptide	I-GENE-Y
,	O
which	O
leads	O
to	O
a	O
perturbation	O
of	O
the	O
central	O
MC	B-GENE-Y
pathway	O
,	O
develop	O
obesity	O
and	O
diabetes	O
,	O
associated	O
with	O
low	O
levels	O
of	O
plasma	O
total	O
ghrelin	B-GENE-Y
.	O

Here	O
,	O
we	O
report	O
that	O
5	O
-	O
wk	O
-	O
old	O
Ay	O
mice	O
consumed	O
more	O
food	O
in	O
association	O
with	O
decreases	O
in	O
levels	O
of	O
plasma	O
des	B-GENE-Y
-	I-GENE-Y
acyl	I-GENE-Y
ghrelin	I-GENE-Y
,	O
but	O
not	O
active	O
ghrelin	B-GENE-Y
,	O
and	O
increases	O
in	O
hypothalamic	O
5	B-GENE-Y
-	I-GENE-Y
HT2C	I-GENE-Y
and	O
5	B-GENE-Y
-	I-GENE-Y
HT1B	I-GENE-Y
receptor	O
gene	O
expression	O
compared	O
with	O
wild	O
-	O
type	O
mice	O
matched	O
for	O
age	O
and	O
body	O
weight	O
.	O

These	O
alterations	O
were	O
also	O
observed	O
in	O
8	O
-	O
wk	O
-	O
old	O
obese	O
Ay	O
mice	O
.	O

Restricted	O
feeding	O
significantly	O
decreased	O
hypothalamic	O
5	B-GENE-Y
-	I-GENE-Y
HT2C	I-GENE-Y
and	O
5	B-GENE-Y
-	I-GENE-Y
HT1B	I-GENE-Y
receptor	O
gene	O
expression	O
in	O
association	O
with	O
a	O
reversal	O
of	O
the	O
decreases	O
in	O
plasma	O
des	B-GENE-Y
-	I-GENE-Y
acyl	I-GENE-Y
ghrelin	I-GENE-Y
levels	O
in	O
5	O
-	O
wk	O
-	O
old	O
Ay	O
mice	O
.	O

Moreover	O
,	O
restricted	O
feeding	O
reduced	O
body	O
weight	O
,	O
hyperinsulinemia	O
,	O
and	O
hyperglycemia	O
in	O
association	O
with	O
increases	O
in	O
plasma	O
des	B-GENE-Y
-	I-GENE-Y
acyl	I-GENE-Y
ghrelin	I-GENE-Y
levels	O
in	O
8	O
-	O
wk	O
-	O
old	O
obese	O
Ay	O
mice	O
.	O

Administration	O
of	O
m	B-CHEMICAL
-	I-CHEMICAL
chlorophenylpiperazine	I-CHEMICAL
and	O
fenfluramine	B-CHEMICAL
,	O
both	O
of	O
which	O
induce	O
anorexic	O
effects	O
via	O
5	B-GENE-Y
-	I-GENE-Y
HT2C	I-GENE-Y
receptors	O
and	O
/	O
or	O
5	B-GENE-Y
-	I-GENE-Y
HT1B	I-GENE-Y
receptors	O
,	O
suppressed	O
food	O
intake	O
in	O
5	O
-	O
and	O
8	O
-	O
wk	O
-	O
old	O
Ay	O
mice	O
,	O
whereas	O
the	O
anorexic	O
effects	O
were	O
attenuated	O
in	O
food	O
-	O
restricted	O
Ay	O
mice	O
.	O

These	O
findings	O
suggest	O
that	O
the	O
agouti	B-GENE-Y
peptide	I-GENE-Y
down	O
-	O
regulates	O
hypothalamic	O
5	B-GENE-Y
-	I-GENE-Y
HT2C	I-GENE-Y
and	O
5	B-GENE-Y
-	I-GENE-Y
HT1B	I-GENE-Y
receptor	O
gene	O
expression	O
under	O
restricted	O
feeding	O
conditions	O
,	O
whereas	O
chronic	O
hyperphagia	O
increases	O
the	O
expression	O
of	O
these	O
genes	O
and	O
decreases	O
plasma	O
des	B-GENE-Y
-	I-GENE-Y
acyl	I-GENE-Y
ghrelin	I-GENE-Y
levels	O
in	O
Ay	O
mice	O
.	O

Gonadotropin	B-GENE-Y
-	I-GENE-Y
releasing	I-GENE-Y
hormone	I-GENE-Y
antagonist	O
in	O
the	O
management	O
of	O
prostate	O
cancer	O
.	O

Luteinizing	B-GENE-Y
hormone	I-GENE-Y
-	I-GENE-Y
releasing	I-GENE-Y
hormone	I-GENE-Y
(	O
LHRH	B-GENE-Y
)	O
agonist	O
therapy	O
to	O
induce	O
medical	O
castration	O
has	O
become	O
the	O
most	O
common	O
form	O
of	O
hormonal	O
therapy	O
for	O
advanced	O
and	O
metastatic	O
prostate	O
cancer	O
.	O

When	O
treatment	O
is	O
started	O
,	O
LHRH	B-GENE-Y
agonists	O
initially	O
stimulate	O
the	O
release	O
of	O
LH	B-GENE-N
,	O
causing	O
a	O
surge	O
in	O
serum	O
testosterone	B-CHEMICAL
that	O
can	O
precipitate	O
a	O
"	O
flare	O
"	O
phenomenon	O
or	O
worsening	O
of	O
disease	O
,	O
particularly	O
in	O
patients	O
with	O
bone	O
metastatic	O
disease	O
.	O

Gonadotropin	B-GENE-Y
-	I-GENE-Y
releasing	I-GENE-Y
hormone	I-GENE-Y
(	I-GENE-Y
GnRH	I-GENE-Y
)	I-GENE-Y
receptor	I-GENE-Y
antagonism	O
represents	O
a	O
newer	O
approach	O
to	O
medical	O
castration	O
.	O

Abarelix	O
is	O
a	O
pure	O
GnRH	B-GENE-Y
receptor	I-GENE-Y
antagonist	O
that	O
is	O
devoid	O
of	O
any	O
LHRH	B-GENE-Y
agonist	O
activity	O
.	O

Results	O
from	O
1	O
phase	O
II	O
and	O
3	O
phase	O
III	O
clinical	O
trials	O
demonstrate	O
that	O
abarelix	O
produces	O
medical	O
castration	O
more	O
quickly	O
and	O
without	O
causing	O
testosterone	B-CHEMICAL
surge	O
,	O
as	O
compared	O
with	O
LHRH	B-GENE-Y
agonists	O
with	O
or	O
without	O
a	O
nonsteroidal	O
antagonist	O
.	O

The	O
safety	O
profile	O
in	O
terms	O
of	O
adverse	O
events	O
is	O
comparable	O
between	O
the	O
2	O
types	O
of	O
treatment	O
,	O
but	O
the	O
lack	O
of	O
testosterone	B-CHEMICAL
surge	O
with	O
abarelix	O
might	O
confer	O
a	O
safety	O
advantage	O
by	O
abolishing	O
the	O
risk	O
of	O
a	O
disease	O
flare	O
.	O

Diet	O
and	O
gene	O
expression	O
:	O
delta	B-GENE-N
-	I-GENE-N
5	I-GENE-N
and	I-GENE-N
delta	I-GENE-N
-	I-GENE-N
6	I-GENE-N
desaturases	I-GENE-N
in	O
healthy	O
Chinese	O
and	O
European	O
subjects	O
.	O

AIM	O
:	O
To	O
compare	O
the	O
composition	O
of	O
fatty	B-CHEMICAL
acids	I-CHEMICAL
(	O
FAs	B-CHEMICAL
)	O
in	O
diet	O
,	O
and	O
the	O
expression	O
of	O
delta	B-GENE-Y
-	I-GENE-Y
6	I-GENE-Y
desaturase	I-GENE-Y
(	O
D6D	B-GENE-Y
)	O
and	O
delta	B-GENE-Y
-	I-GENE-Y
5	I-GENE-Y
desaturase	I-GENE-Y
(	O
D5D	B-GENE-Y
)	O
genes	O
in	O
peripheral	O
blood	O
mononuclear	O
cells	O
(	O
PBMCs	O
)	O
between	O
Chinese	O
and	O
Europeans	O
.	O

METHODS	O
:	O
Three	O
-	O
day	O
dietary	O
records	O
from	O
20	O
subjects	O
from	O
Beijing	O
,	O
China	O
(	O
n	O
=	O
10	O
)	O
and	O
Kent	O
,	O
UK	O
(	O
n	O
=	O
10	O
)	O
were	O
analysed	O
.	O

Expression	O
of	O
PBMC	O
D6D	B-GENE-Y
and	O
D5D	B-GENE-Y
genes	O
of	O
the	O
subjects	O
was	O
determined	O
using	O
RT	O
-	O
PCR	O
.	O

RESULTS	O
:	O
The	O
dietary	O
intake	O
of	O
Chinese	O
subjects	O
contained	O
less	O
saturated	B-CHEMICAL
fatty	I-CHEMICAL
acids	I-CHEMICAL
(	O
SFAs	B-CHEMICAL
)	O
and	O
monounsaturated	B-CHEMICAL
fatty	I-CHEMICAL
acids	I-CHEMICAL
(	O
MUFAs	B-CHEMICAL
)	O
,	O
but	O
more	O
essential	B-CHEMICAL
fatty	I-CHEMICAL
acids	I-CHEMICAL
(	O
EFAs	B-CHEMICAL
)	O
than	O
that	O
of	O
Europeans	O
.	O

Levels	O
of	O
expression	O
of	O
PBMC	O
D6D	B-GENE-Y
and	O
D5D	B-GENE-Y
genes	O
of	O
Chinese	O
subjects	O
were	O
significantly	O
lower	O
than	O
those	O
of	O
Europeans	O
.	O

A	O
significant	O
positive	O
correlation	O
was	O
found	O
between	O
dietary	O
intake	O
of	O
total	O
SFAs	O
and	O
total	O
MUFAs	O
and	O
expression	O
of	O
PBMC	O
D6D	B-GENE-Y
and	O
D5D	B-GENE-Y
genes	O
,	O
but	O
a	O
significant	O
negative	O
correlation	O
between	O
dietary	O
intake	O
of	O
linoleic	B-CHEMICAL
acid	I-CHEMICAL
(	O
LA	B-CHEMICAL
)	O
and	O
alpha	B-CHEMICAL
-	I-CHEMICAL
linolenic	I-CHEMICAL
acid	I-CHEMICAL
(	O
LNA	B-CHEMICAL
)	O
and	O
the	O
expression	O
of	O
PBMC	O
D6D	B-GENE-Y
and	O
D5D	B-GENE-Y
genes	O
.	O

CONCLUSION	O
:	O
Intake	O
of	O
high	O
SFAs	B-CHEMICAL
and	O
MUFAs	B-CHEMICAL
appears	O
to	O
increase	O
expression	O
of	O
PBMC	O
D6D	B-GENE-Y
and	O
D5D	B-GENE-Y
genes	O
,	O
whilst	O
high	O
EFAs	B-CHEMICAL
intake	O
appears	O
to	O
decrease	O
expression	O
of	O
PBMC	O
D6D	B-GENE-Y
and	O
D5D	B-GENE-Y
genes	O
.	O

A	O
follow	O
-	O
up	O
study	O
of	O
the	O
expression	O
of	O
D6D	B-GENE-Y
and	O
D5D	B-GENE-Y
genes	O
in	O
Chinese	O
who	O
live	O
in	O
European	O
countries	O
with	O
high	O
SFA	B-CHEMICAL
and	O
MUFA	B-CHEMICAL
diets	O
would	O
be	O
of	O
interest	O
.	O

The	O
evolution	O
of	O
progesterone	B-GENE-Y
receptor	I-GENE-Y
ligands	O
.	O

Progesterone	B-CHEMICAL
is	O
one	O
of	O
the	O
first	O
nuclear	B-GENE-N
receptor	I-GENE-N
hormones	O
to	O
be	O
described	O
functionally	O
and	O
subsequently	O
approached	O
as	O
a	O
drug	O
target	O
.	O

Because	O
progesterone	B-CHEMICAL
(	O
1	O
)	O
affects	O
both	O
menstruation	O
and	O
gestation	O
via	O
the	O
progesterone	B-GENE-Y
receptor	I-GENE-Y
(	O
PR	B-GENE-Y
)	O
,	O
research	O
aimed	O
at	O
modulating	O
its	O
activity	O
is	O
usually	O
surrounded	O
by	O
controversy	O
.	O

However	O
,	O
ligands	O
for	O
PR	B-GENE-Y
were	O
developed	O
into	O
drugs	O
,	O
and	O
their	O
evolution	O
can	O
be	O
crudely	O
divided	O
into	O
three	O
periods	O
:	O
(	O
1	O
)	O
drug	O
-	O
like	O
steroids	B-CHEMICAL
that	O
mimic	O
the	O
gestational	O
properties	O
of	O
progesterone	B-CHEMICAL
;	O
(	O
2	O
)	O
drug	O
-	O
like	O
steroids	B-CHEMICAL
with	O
different	O
properties	O
from	O
progesterone	B-CHEMICAL
and	O
expanded	O
therapeutic	O
applications	O
;	O
and	O
(	O
3	O
)	O
non	O
-	O
steroidal	B-CHEMICAL
PR	B-GENE-Y
ligands	O
with	O
improved	O
selectivity	O
and	O
modulator	O
properties	O
and	O
further	O
expanded	O
therapeutic	O
applications	O
.	O

Although	O
the	O
latter	O
have	O
yet	O
to	O
see	O
widespread	O
clinical	O
applications	O
,	O
their	O
development	O
is	O
founded	O
on	O
a	O
half	O
century	O
of	O
research	O
,	O
and	O
they	O
represent	O
the	O
future	O
for	O
this	O
drug	O
target	O
.	O

Decitabine	B-CHEMICAL
-	O
-	O
bedside	O
to	O
bench	O
.	O

PURPOSE	O
OF	O
THE	O
REVIEW	O
:	O
Epigenetic	O
changes	O
marked	O
by	O
DNA	O
methylation	O
are	O
known	O
to	O
contribute	O
to	O
the	O
malignant	O
transformation	O
of	O
cells	O
by	O
silencing	O
critical	O
genes	O
.	O

Decitabine	B-CHEMICAL
inhibits	O
DNA	B-GENE-N
methyltransferase	I-GENE-N
and	O
has	O
shown	O
therapeutic	O
effects	O
in	O
patients	O
with	O
hematologic	O
malignancies	O
.	O

However	O
,	O
the	O
connection	O
between	O
the	O
clinical	O
activity	O
of	O
decitabine	B-CHEMICAL
and	O
its	O
demethylating	O
activity	O
is	O
not	O
clear	O
.	O

Herein	O
,	O
we	O
summarize	O
the	O
results	O
of	O
recent	O
clinical	O
trials	O
of	O
decitabine	B-CHEMICAL
in	O
hematologic	O
malignancies	O
,	O
and	O
review	O
the	O
translational	O
research	O
into	O
decitabine	O
'	O
s	O
mechanism	O
of	O
clinical	O
activity	O
.	O

RECENT	O
FINDINGS	O
:	O
Low	O
-	O
dose	O
decitabine	B-CHEMICAL
has	O
been	O
studied	O
recently	O
in	O
multiple	O
clinical	O
trials	O
and	O
has	O
been	O
shown	O
to	O
be	O
effective	O
for	O
treatment	O
of	O
myelodysplastic	O
syndromes	O
.	O

Correlative	O
laboratory	O
studies	O
of	O
clinical	O
trials	O
have	O
shown	O
that	O
decitabine	B-CHEMICAL
induces	O
global	O
hypomethylation	O
as	O
well	O
as	O
hypomethylation	O
of	O
gene	O
-	O
specific	O
promoters	O
and	O
activation	O
of	O
gene	O
expression	O
.	O

Past	O
a	O
given	O
threshold	O
,	O
induction	O
of	O
higher	O
degrees	O
of	O
hypomethylation	O
is	O
not	O
directly	O
associated	O
with	O
a	O
better	O
clinical	O
outcome	O
.	O

Moreover	O
,	O
studies	O
have	O
suggested	O
that	O
patients	O
with	O
promoter	O
hypermethylation	O
of	O
p15	B-GENE-Y
(	I-GENE-Y
INK4B	I-GENE-Y
)	I-GENE-Y
at	O
baseline	O
have	O
paradoxically	O
a	O
lower	O
chance	O
of	O
achieving	O
response	O
than	O
those	O
without	O
hypermethylation	O
.	O

Furthermore	O
,	O
several	O
other	O
genes	O
activated	O
by	O
decitabine	B-CHEMICAL
were	O
independent	O
of	O
hypomethylation	O
in	O
the	O
promoter	O
regions	O
.	O

CONCLUSION	O
:	O
While	O
at	O
least	O
part	O
of	O
decitabine	O
'	O
s	O
activity	O
is	O
through	O
induction	O
of	O
hypomethylation	O
and	O
reactivation	O
of	O
critical	O
genes	O
,	O
mechanisms	O
independent	O
from	O
hypomethylation	O
are	O
also	O
important	O
for	O
decitabine	O
'	O
s	O
antitumor	O
activity	O
.	O

[	O
Efalizumab	O
]	O
.	O

Efalizumab	O
(	O
Raptiva	O
,	O
Serono	O
)	O
is	O
a	O
humanised	O
monoclonal	O
antibody	O
(	O
IgG1	B-GENE-Y
)	O
produced	O
by	O
biotechnology	O
.	O

This	O
antibody	O
has	O
a	O
novel	O
place	O
among	O
biotherapies	O
for	O
psoriasis	O
.	O

It	O
is	O
bound	O
to	O
the	O
CD11a	B-GENE-Y
subunit	O
of	O
a	O
surface	O
molecule	O
of	O
the	O
T	O
lymphocyte	O
LFA	B-GENE-N
-	I-GENE-N
1	I-GENE-N
(	O
Leucocyte	B-GENE-N
Function	I-GENE-N
-	I-GENE-N
associated	I-GENE-N
Antigen	I-GENE-N
-	I-GENE-N
1	I-GENE-N
)	O
.	O

This	O
molecule	O
is	O
essential	O
for	O
binding	O
of	O
T	O
lymphocytes	O
to	O
the	O
ICAM	B-GENE-Y
-	I-GENE-Y
1	I-GENE-Y
molecule	O
(	O
Intercellular	B-GENE-Y
Adhesion	I-GENE-Y
Molecule	I-GENE-Y
-	I-GENE-Y
1	I-GENE-Y
)	O
found	O
on	O
antigen	O
-	O
presenting	O
cells	O
,	O
endothelial	O
cells	O
and	O
keratinocytes	O
.	O

Binding	O
of	O
efalizumab	O
to	O
CD11a	B-GENE-Y
prevents	O
binding	O
of	O
LFA	B-GENE-N
-	I-GENE-N
1	I-GENE-N
to	O
ICAM	B-GENE-Y
-	I-GENE-Y
1	I-GENE-Y
,	O
thus	O
inhibiting	O
several	O
steps	O
in	O
the	O
immunological	O
process	O
responsible	O
for	O
formation	O
of	O
psoriatic	O
plaque	O
(	O
activation	O
of	O
naive	O
T	O
lymphocytes	O
to	O
memory	O
T	O
lymphocytes	O
,	O
lymphocyte	O
migration	O
and	O
reactivation	O
of	O
T	O
lymphocytes	O
in	O
skin	O
)	O
.	O

Efalizumab	O
was	O
approved	O
in	O
the	O
United	O
States	O
by	O
the	O
FDA	O
(	O
Food	O
and	O
Drug	O
Administration	O
)	O
in	O
2003	O
for	O
the	O
treatment	O
of	O
moderate	O
-	O
to	O
-	O
severe	O
psoriasis	O
requiring	O
systemic	O
therapy	O
.	O

It	O
may	O
be	O
used	O
as	O
first	O
-	O
line	O
therapy	O
in	O
the	O
United	O
States	O
in	O
this	O
indication	O
.	O

In	O
France	O
,	O
marketing	O
authorisation	O
(	O
MA	O
)	O
was	O
granted	O
more	O
recently	O
in	O
September	O
2005	O
.	O

The	O
indications	O
are	O
moderate	O
-	O
to	O
-	O
severe	O
cutaneous	O
plaque	O
psoriasis	O
in	O
adults	O
in	O
cases	O
of	O
failure	O
,	O
intolerance	O
or	O
contraindication	O
of	O
at	O
least	O
two	O
systemic	O
treatments	O
including	O
phototherapy	O
,	O
methotrexate	B-CHEMICAL
and	O
cyclosporine	B-CHEMICAL
.	O

Current	O
clinical	O
trial	O
data	O
is	O
available	O
for	O
3500	O
patients	O
with	O
plaque	O
psoriasis	O
.	O

A	O
75	O
%	O
improvement	O
in	O
PASI	O
score	O
was	O
seen	O
in	O
between	O
22	O
and	O
39	O
%	O
of	O
patients	O
treated	O
with	O
efalizumab	O
(	O
vs	O
.	O
2	O
to	O
5	O
%	O
for	O
patients	O
on	O
placebo	O
)	O
in	O
a	O
single	O
weekly	O
subcutaneous	O
injection	O
(	O
1	O
mg	O
/	O
kg	O
)	O
.	O

A	O
study	O
in	O
good	O
responders	O
confirms	O
the	O
continuing	O
long	O
-	O
term	O
efficacy	O
of	O
prescription	O
of	O
the	O
drug	O
up	O
to	O
36	O
months	O
(	O
with	O
at	O
least	O
a	O
75	O
%	O
improvement	O
in	O
PASI	O
score	O
in	O
53	O
%	O
of	O
patients	O
)	O
.	O

However	O
,	O
it	O
is	O
not	O
effective	O
against	O
joint	O
involvement	O
in	O
psoriasis	O
.	O

The	O
most	O
common	O
side	O
-	O
effects	O
(	O
incidence	O
>	O
1	O
/	O
100	O
)	O
are	O
influenza	O
-	O
like	O
syndrome	O
,	O
risk	O
of	O
outbreak	O
of	O
cutaneous	O
psoriasis	O
during	O
or	O
after	O
discontinuation	O
of	O
treatment	O
,	O
worsening	O
of	O
arthralgia	O
,	O
minor	O
hypersensitivity	O
reactions	O
,	O
reversible	O
changes	O
in	O
laboratory	O
values	O
(	O
hyperlymphocytosis	O
,	O
elevated	O
alkaline	B-GENE-N
phosphatases	I-GENE-N
and	O
transaminases	B-GENE-N
)	O
.	O

Because	O
of	O
rare	O
cases	O
of	O
thrombocytopenia	O
(	O
incidence	O
<	O
1	O
/	O
100	O
)	O
,	O
reversible	O
on	O
discontinuation	O
of	O
treatment	O
,	O
monthly	O
monitoring	O
of	O
platelet	O
counts	O
is	O
required	O
over	O
the	O
first	O
3	O
months	O
of	O
therapy	O
.	O

There	O
are	O
currently	O
no	O
randomised	O
studies	O
comparing	O
the	O
various	O
systemic	O
treatments	O
(	O
standard	O
therapy	O
and	O
biotherapy	O
)	O
for	O
psoriasis	O
.	O

However	O
,	O
on	O
extrapolation	O
of	O
the	O
available	O
results	O
concerning	O
efficacy	O
(	O
PASI	O
-	O
75	O
after	O
12	O
weeks	O
of	O
treatment	O
)	O
,	O
efalizumab	O
appears	O
to	O
be	O
less	O
efficacious	O
than	O
anti	O
-	O
TNF	B-GENE-Y
alpha	I-GENE-Y
agents	O
.	O

This	O
drug	O
constitutes	O
an	O
additional	O
treatment	O
option	O
and	O
its	O
position	O
in	O
the	O
therapeutic	O
arsenal	B-CHEMICAL
will	O
depend	O
upon	O
its	O
long	O
-	O
term	O
benefit	O
/	O
risk	O
ratio	O
in	O
relation	O
to	O
other	O
biotherapies	O
.	O

Multiple	O
pathways	O
for	O
cationic	O
amino	B-CHEMICAL
acid	I-CHEMICAL
transport	O
in	O
rat	O
seminiferous	O
tubule	O
cells	O
.	O

Arginine	B-CHEMICAL
and	O
ornithine	B-CHEMICAL
are	O
known	O
to	O
be	O
important	O
for	O
various	O
biological	O
processes	O
in	O
the	O
testis	O
,	O
but	O
the	O
delivery	O
of	O
extracellular	O
cationic	O
amino	B-CHEMICAL
acids	I-CHEMICAL
to	O
the	O
seminiferous	O
tubule	O
cells	O
remains	O
poorly	O
understood	O
.	O

We	O
investigated	O
the	O
activity	O
and	O
expression	O
of	O
cationic	B-GENE-N
amino	I-GENE-N
acid	I-GENE-N
transporters	I-GENE-N
in	O
isolated	O
rat	O
Sertoli	O
cells	O
,	O
peritubular	O
cells	O
,	O
pachytene	O
spermatocytes	O
,	O
and	O
early	O
spermatids	O
.	O

We	O
assessed	O
the	O
l	B-CHEMICAL
-	I-CHEMICAL
arginine	I-CHEMICAL
uptake	O
kinetics	O
,	O
Na	B-CHEMICAL
(	I-CHEMICAL
+	I-CHEMICAL
)	I-CHEMICAL
dependence	O
of	O
transport	O
,	O
profiles	O
of	O
cis	O
inhibition	O
of	O
uptake	O
by	O
cationic	O
and	O
neutral	O
amino	B-CHEMICAL
acids	I-CHEMICAL
,	O
and	O
sensitivity	O
to	O
trans	O
stimulation	O
of	O
cationic	B-GENE-N
amino	I-GENE-N
acid	I-GENE-N
transporters	I-GENE-N
,	O
and	O
studied	O
the	O
expression	O
of	O
the	O
genes	O
encoding	O
them	O
by	O
RT	O
-	O
PCR	O
.	O

Our	O
data	O
suggest	O
that	O
l	B-CHEMICAL
-	I-CHEMICAL
arginine	I-CHEMICAL
is	O
taken	O
up	O
by	O
Sertoli	O
cells	O
and	O
peritubular	O
cells	O
,	O
principally	O
via	O
system	O
y	O
(	O
+	O
)	O
L	O
(	O
SLC3A2	B-GENE-Y
/	O
SLC7A6	B-GENE-Y
)	O
and	O
system	O
y	O
(	O
+	O
)	O
(	O
SLC7A1	B-GENE-Y
and	O
SLC7A2	B-GENE-Y
)	O
,	O
with	O
system	O
B	O
(	O
0	O
+	O
)	O
making	O
a	O
minor	O
contribution	O
.	O

By	O
contrast	O
,	O
system	O
B	O
(	O
0	O
+	O
)	O
,	O
associated	O
with	O
system	O
y	O
(	O
+	O
)	O
L	O
(	O
SLC3A2	B-GENE-Y
/	O
SLC7A7	B-GENE-Y
and	O
SLC7A6	B-GENE-Y
)	O
,	O
made	O
a	O
major	O
contribution	O
to	O
the	O
transport	O
of	O
cationic	O
amino	B-CHEMICAL
acids	I-CHEMICAL
in	O
pachytene	O
spermatocytes	O
and	O
early	O
spermatids	O
.	O

Sertoli	O
cells	O
had	O
higher	O
rates	O
of	O
l	B-CHEMICAL
-	I-CHEMICAL
arginine	I-CHEMICAL
transport	O
than	O
the	O
other	O
seminiferous	O
tubule	O
cells	O
.	O

This	O
high	O
efficiency	O
of	O
arginine	B-CHEMICAL
transport	O
in	O
Sertoli	O
cells	O
and	O
the	O
properties	O
of	O
the	O
y	O
(	O
+	O
)	O
L	O
system	O
predominating	O
in	O
these	O
cells	O
strongly	O
suggest	O
that	O
Sertoli	O
cells	O
play	O
a	O
key	O
role	O
in	O
supplying	O
germ	O
cells	O
with	O
l	B-CHEMICAL
-	I-CHEMICAL
arginine	I-CHEMICAL
and	O
other	O
cationic	O
amino	B-CHEMICAL
acids	I-CHEMICAL
.	O

Furthermore	O
,	O
whereas	O
cytokines	B-GENE-N
induce	O
nitric	B-CHEMICAL
oxide	I-CHEMICAL
(	O
NO	B-CHEMICAL
)	O
production	O
in	O
peritubular	O
and	O
Sertoli	O
cells	O
,	O
little	O
or	O
no	O
upregulation	O
of	O
arginine	B-CHEMICAL
transport	O
by	O
cytokines	B-GENE-N
was	O
observed	O
in	O
these	O
cells	O
.	O

Thus	O
,	O
NO	B-CHEMICAL
synthesis	O
does	O
not	O
depend	O
on	O
the	O
stimulation	O
of	O
arginine	B-CHEMICAL
transport	O
in	O
these	O
somatic	O
tubular	O
cells	O
.	O

Transition	O
-	O
state	O
structure	O
of	O
human	B-GENE-Y
5	I-GENE-Y
'	I-GENE-Y
-	I-GENE-Y
methylthioadenosine	I-GENE-Y
phosphorylase	I-GENE-Y
.	O

Kinetic	O
isotope	O
effects	O
(	O
KIEs	O
)	O
and	O
computer	O
modeling	O
using	O
density	O
functional	O
theory	O
were	O
used	O
to	O
approximate	O
the	O
transition	O
state	O
of	O
human	B-GENE-Y
5	I-GENE-Y
'	I-GENE-Y
-	I-GENE-Y
methylthioadenosine	I-GENE-Y
phosphorylase	I-GENE-Y
(	O
MTAP	B-GENE-Y
)	O
.	O

KIEs	O
were	O
measured	O
on	O
the	O
arsenolysis	O
of	O
5	B-CHEMICAL
'	I-CHEMICAL
-	I-CHEMICAL
methylthioadenosine	I-CHEMICAL
(	O
MTA	B-CHEMICAL
)	O
catalyzed	O
by	O
MTAP	B-GENE-Y
and	O
were	O
corrected	O
for	O
the	O
forward	O
commitment	O
to	O
catalysis	O
.	O

Intrinsic	O
KIEs	O
were	O
obtained	O
for	O
[	B-CHEMICAL
1	I-CHEMICAL
'	I-CHEMICAL
-	I-CHEMICAL
(	I-CHEMICAL
3	I-CHEMICAL
)	I-CHEMICAL
H	I-CHEMICAL
]	I-CHEMICAL
,	I-CHEMICAL
[	I-CHEMICAL
1	I-CHEMICAL
'	I-CHEMICAL
-	I-CHEMICAL
(	I-CHEMICAL
14	I-CHEMICAL
)	I-CHEMICAL
C	I-CHEMICAL
]	I-CHEMICAL
,	I-CHEMICAL
[	I-CHEMICAL
2	I-CHEMICAL
'	I-CHEMICAL
-	I-CHEMICAL
(	I-CHEMICAL
3	I-CHEMICAL
)	I-CHEMICAL
H	I-CHEMICAL
]	I-CHEMICAL
,	I-CHEMICAL
[	I-CHEMICAL
4	I-CHEMICAL
'	I-CHEMICAL
-	I-CHEMICAL
(	I-CHEMICAL
3	I-CHEMICAL
)	I-CHEMICAL
H	I-CHEMICAL
]	I-CHEMICAL
,	I-CHEMICAL
[	I-CHEMICAL
5	I-CHEMICAL
'	I-CHEMICAL
-	I-CHEMICAL
(	I-CHEMICAL
3	I-CHEMICAL
)	I-CHEMICAL
H	I-CHEMICAL
(	I-CHEMICAL
2	I-CHEMICAL
)	I-CHEMICAL
]	I-CHEMICAL
,	I-CHEMICAL
[	I-CHEMICAL
9	I-CHEMICAL
-	I-CHEMICAL
(	I-CHEMICAL
15	I-CHEMICAL
)	I-CHEMICAL
N	I-CHEMICAL
]	I-CHEMICAL
,	I-CHEMICAL
and	I-CHEMICAL
[	I-CHEMICAL
Me	I-CHEMICAL
-	I-CHEMICAL
(	I-CHEMICAL
3	I-CHEMICAL
)	I-CHEMICAL
H	I-CHEMICAL
(	I-CHEMICAL
3	I-CHEMICAL
)	I-CHEMICAL
]	I-CHEMICAL
MTAs	I-CHEMICAL
.	O

The	O
primary	O
intrinsic	O
KIEs	O
(	O
1	B-CHEMICAL
'	I-CHEMICAL
-	I-CHEMICAL
(	I-CHEMICAL
14	I-CHEMICAL
)	I-CHEMICAL
C	I-CHEMICAL
and	O
9	B-CHEMICAL
-	I-CHEMICAL
(	I-CHEMICAL
15	I-CHEMICAL
)	I-CHEMICAL
N	I-CHEMICAL
)	O
suggest	O
that	O
MTAP	B-GENE-Y
has	O
a	O
dissociative	O
S	O
(	O
N	O
)	O
1	O
transition	O
state	O
with	O
its	O
cationic	O
center	O
at	O
the	O
anomeric	O
carbon	B-CHEMICAL
and	O
insignificant	O
bond	O
order	O
to	O
the	O
leaving	O
group	O
.	O

The	O
9	B-CHEMICAL
-	I-CHEMICAL
(	I-CHEMICAL
15	I-CHEMICAL
)	I-CHEMICAL
N	I-CHEMICAL
intrinsic	O
KIE	O
of	O
1	O
.	O
039	O
also	O
establishes	O
an	O
anionic	O
character	O
for	O
the	O
adenine	B-CHEMICAL
leaving	O
group	O
,	O
whereas	O
the	O
alpha	O
-	O
primary	O
1	B-CHEMICAL
'	I-CHEMICAL
-	I-CHEMICAL
(	I-CHEMICAL
14	I-CHEMICAL
)	I-CHEMICAL
C	I-CHEMICAL
KIE	O
of	O
1	O
.	O
031	O
indicates	O
significant	O
nucleophilic	O
participation	O
at	O
the	O
transition	O
state	O
.	O

Computational	O
matching	O
of	O
the	O
calculated	O
EIEs	O
to	O
the	O
intrinsic	O
isotope	O
effects	O
places	O
the	O
oxygen	B-CHEMICAL
nucleophile	O
2	O
.	O
0	O
Angstrom	O
from	O
the	O
anomeric	O
carbon	B-CHEMICAL
.	O

The	O
4	B-CHEMICAL
'	I-CHEMICAL
-	I-CHEMICAL
(	I-CHEMICAL
3	I-CHEMICAL
)	I-CHEMICAL
H	I-CHEMICAL
KIE	O
is	O
sensitive	O
to	O
the	O
polarization	O
of	O
the	O
3	B-CHEMICAL
'	I-CHEMICAL
-	I-CHEMICAL
OH	I-CHEMICAL
group	O
.	O

Calculations	O
suggest	O
that	O
a	O
4	B-CHEMICAL
'	I-CHEMICAL
-	I-CHEMICAL
(	I-CHEMICAL
3	I-CHEMICAL
)	I-CHEMICAL
H	I-CHEMICAL
KIE	O
of	O
1	O
.	O
047	O
is	O
consistent	O
with	O
ionization	O
of	O
the	O
3	B-CHEMICAL
'	I-CHEMICAL
-	I-CHEMICAL
OH	I-CHEMICAL
group	O
,	O
indicating	O
formation	O
of	O
a	O
zwitterion	O
at	O
the	O
transition	O
state	O
.	O

The	O
transition	O
state	O
has	O
cationic	O
character	O
at	O
the	O
anomeric	O
carbon	B-CHEMICAL
and	O
is	O
anionic	O
at	O
the	O
3	B-CHEMICAL
'	I-CHEMICAL
-	I-CHEMICAL
OH	I-CHEMICAL
oxygen	B-CHEMICAL
,	O
with	O
an	O
anionic	O
leaving	O
group	O
.	O

The	O
isotope	O
effects	O
predicted	O
a	O
3	O
'	O
-	O
endo	O
conformation	O
for	O
the	O
ribosyl	B-CHEMICAL
zwitterion	I-CHEMICAL
,	O
corresponding	O
to	O
a	O
H1	B-CHEMICAL
'	I-CHEMICAL
-	I-CHEMICAL
C1	I-CHEMICAL
'	I-CHEMICAL
-	I-CHEMICAL
C2	I-CHEMICAL
'	I-CHEMICAL
-	I-CHEMICAL
H2	I-CHEMICAL
'	I-CHEMICAL
torsional	O
angle	O
of	O
33	O
degrees	O
.	O

The	O
[	O
Me	B-CHEMICAL
-	I-CHEMICAL
(	I-CHEMICAL
3	I-CHEMICAL
)	I-CHEMICAL
H	I-CHEMICAL
(	I-CHEMICAL
3	I-CHEMICAL
)	I-CHEMICAL
]	O
and	O
[	O
5	B-CHEMICAL
'	I-CHEMICAL
-	I-CHEMICAL
(	I-CHEMICAL
3	I-CHEMICAL
)	I-CHEMICAL
H	I-CHEMICAL
(	I-CHEMICAL
2	I-CHEMICAL
)	I-CHEMICAL
]	O
KIEs	O
arise	O
predominantly	O
from	O
the	O
negative	O
hyperconjugation	O
of	O
the	O
lone	O
pairs	O
of	O
sulfur	B-CHEMICAL
with	O
the	O
sigma	O
(	O
C	B-CHEMICAL
-	I-CHEMICAL
H	I-CHEMICAL
)	O
antibonding	O
orbitals	O
.	O

Human	B-GENE-Y
MTAP	I-GENE-Y
is	O
characterized	O
by	O
a	O
late	O
S	O
(	O
N	O
)	O
1	O
transition	O
state	O
with	O
significant	O
participation	O
of	O
the	O
phosphate	B-CHEMICAL
nucleophile	O
.	O

Sequestration	O
of	O
retinyl	B-CHEMICAL
esters	I-CHEMICAL
is	O
essential	O
for	O
retinoid	O
signaling	O
in	O
the	O
zebrafish	O
embryo	O
.	O

For	O
vertebrate	O
development	O
,	O
vitamin	B-CHEMICAL
A	I-CHEMICAL
(	O
all	B-CHEMICAL
-	I-CHEMICAL
trans	I-CHEMICAL
retinol	I-CHEMICAL
)	O
is	O
required	O
in	O
quantitative	O
different	O
amounts	O
and	O
spatiotemporal	O
distribution	O
for	O
the	O
production	O
of	O
retinoic	B-CHEMICAL
acid	I-CHEMICAL
,	O
a	O
nuclear	O
hormone	O
receptor	O
ligand	O
,	O
and	O
11	B-CHEMICAL
-	I-CHEMICAL
cis	I-CHEMICAL
retinal	I-CHEMICAL
,	O
the	O
chromophore	O
of	O
visual	O
pigments	O
.	O

We	O
show	O
here	O
for	O
zebrafish	O
that	O
embryonic	O
retinoid	O
homeostasis	O
essentially	O
depends	O
on	O
the	O
activity	O
of	O
a	O
leci	B-GENE-Y
-	I-GENE-Y
thin	I-GENE-Y
:	I-GENE-Y
retinol	I-GENE-Y
acyltransferase	I-GENE-Y
(	O
Lratb	B-GENE-Y
)	O
.	O

During	O
embryogenesis	O
,	O
lratb	B-GENE-Y
is	O
expressed	O
in	O
mostly	O
non	O
-	O
overlapping	O
domains	O
opposite	O
to	O
retinal	B-GENE-Y
dehydrogenase	I-GENE-Y
2	I-GENE-Y
(	O
raldh2	B-GENE-Y
)	O
,	O
the	O
key	O
enzyme	O
for	O
retinoic	B-CHEMICAL
acid	I-CHEMICAL
synthesis	O
.	O

Blocking	O
retinyl	B-CHEMICAL
ester	I-CHEMICAL
formation	O
by	O
a	O
targeted	O
knock	O
down	O
of	O
Lratb	B-GENE-Y
results	O
in	O
significantly	O
increased	O
retinoic	B-CHEMICAL
acid	I-CHEMICAL
levels	O
,	O
which	O
lead	O
to	O
severe	O
embryonic	O
patterning	O
defects	O
.	O

Thus	O
,	O
we	O
provide	O
evidence	O
that	O
a	O
balanced	O
competition	O
between	O
Lratb	B-GENE-Y
and	O
Raldh2	B-GENE-Y
for	O
yolk	O
vitamin	B-CHEMICAL
A	I-CHEMICAL
defines	O
embryonic	O
compartments	O
either	O
for	O
retinyl	B-CHEMICAL
ester	I-CHEMICAL
or	O
retinoic	B-CHEMICAL
acid	I-CHEMICAL
synthesis	O
.	O

This	O
homeostatic	O
mechanism	O
dynamically	O
adjusts	O
embryonic	O
retinoic	B-CHEMICAL
acid	I-CHEMICAL
levels	O
for	O
gene	O
regulation	O
,	O
concomitantly	O
sequestering	O
excess	O
yolk	O
vitamin	B-CHEMICAL
A	I-CHEMICAL
in	O
the	O
form	O
of	O
retinyl	O
esters	O
for	O
the	O
establishment	O
of	O
larval	O
vision	O
later	O
during	O
development	O
.	O

A	O
case	O
of	O
Ehlers	O
Danlos	O
syndrome	O
type	O
VI	O
.	O

Ehlers	O
Danlos	O
type	O
VI	O
is	O
a	O
rare	O
autosomal	O
recessive	O
connective	O
tissue	O
disease	O
involving	O
primarily	O
the	O
skin	O
and	O
joints	O
.	O

The	O
main	O
feature	O
of	O
the	O
condition	O
is	O
neonatal	O
hypotonia	O
and	O
rare	O
complications	O
are	O
ruptures	O
of	O
arteries	O
and	O
the	O
eye	O
globe	O
.	O

A	O
4	O
year	O
old	O
girl	O
with	O
a	O
typical	O
clinical	O
presentation	O
and	O
molecular	O
diagnosis	O
of	O
EDS	O
VI	O
is	O
presented	O
.	O

Sequencing	O
of	O
PLOD1	B-GENE-Y
gene	O
revealed	O
a	O
homozygous	O
deletion	O
in	O
exon	O
13	O
(	O
c	O
.	O
1362delC	O
)	O
,	O
leading	O
to	O
a	O
frameshift	O
and	O
truncation	O
of	O
the	O
lysyl	B-GENE-N
hydroxylase	I-GENE-N
,	O
an	O
enzyme	O
necessary	O
for	O
collagen	B-GENE-N
biosynthesis	O
.	O

Early	O
diagnosis	O
allowed	O
treatment	O
with	O
high	O
doses	O
of	O
ascorbic	B-CHEMICAL
acid	I-CHEMICAL
in	O
order	O
to	O
prevent	O
complications	O
,	O
genetic	O
counseling	O
of	O
the	O
family	O
and	O
prenatal	O
diagnosis	O
of	O
an	O
unaffected	O
embryo	O
.	O

Molecular	O
modeling	O
of	O
purinergic	B-GENE-N
receptor	I-GENE-N
P2Y12	B-GENE-Y
and	O
interaction	O
with	O
its	O
antagonists	O
.	O

Purinergic	B-GENE-N
receptors	I-GENE-N
are	O
a	O
class	O
of	O
cell	O
surface	O
receptors	O
for	O
purines	B-CHEMICAL
that	O
prefer	O
ATP	B-CHEMICAL
or	O
ADP	B-CHEMICAL
over	O
adenosine	B-CHEMICAL
.	O

The	O
surface	O
receptors	O
for	O
extracellular	O
nucleotides	B-CHEMICAL
are	O
called	O
P2	B-GENE-N
receptors	I-GENE-N
.	O

They	O
are	O
activated	O
by	O
both	O
pyrimidine	B-CHEMICAL
and	I-CHEMICAL
purine	I-CHEMICAL
nucleotides	I-CHEMICAL
.	O

ADP	B-CHEMICAL
initiates	O
platelet	O
aggregation	O
by	O
'	O
simultaneous	O
activation	O
of	O
two	O
G	B-GENE-N
protein	I-GENE-N
-	I-GENE-N
coupled	I-GENE-N
receptors	I-GENE-N
,	O
P2Y1	B-GENE-Y
and	O
P2Y12	B-GENE-Y
.	O

P2Y12	B-GENE-Y
has	O
been	O
shown	O
to	O
be	O
the	O
target	O
of	O
the	O
thienopyridine	B-CHEMICAL
drugs	O
,	O
ticlopidine	B-CHEMICAL
and	O
clopidogrel	B-CHEMICAL
.	O

Here	O
,	O
the	O
active	O
sites	O
of	O
P2Y12	B-GENE-Y
for	O
ATP	B-CHEMICAL
as	O
well	O
as	O
ADP	B-CHEMICAL
are	O
predicted	O
by	O
bioinformatics	O
and	O
molecular	O
modeling	O
.	O

First	O
,	O
the	O
three	O
-	O
dimensional	O
(	O
3D	O
)	O
structure	O
of	O
P2Y12	B-GENE-Y
was	O
constructed	O
by	O
InsightII	O
/	O
Homology	O
module	O
using	O
the	O
corresponding	O
bovine	B-GENE-Y
rhodopsin	I-GENE-Y
(	O
PDB	B-GENE-Y
code	I-GENE-Y
:	I-GENE-Y
1HZX	I-GENE-Y
)	O
as	O
the	O
template	O
.	O

Then	O
the	O
primary	O
structures	O
were	O
optimized	O
by	O
energy	O
minimization	O
that	O
has	O
been	O
successfully	O
accepted	O
by	O
the	O
Protein	O
Data	O
Bank	O
(	O
PDB	B-GENE-Y
code	I-GENE-Y
:	I-GENE-Y
1VZ1	I-GENE-Y
)	O
.	O

Second	O
,	O
a	O
simple	O
scoring	O
matrix	O
was	O
built	O
up	O
based	O
on	O
the	O
analysis	O
of	O
13	O
known	O
ATP	B-CHEMICAL
-	O
binding	O
proteins	O
.	O

And	O
the	O
most	O
probable	O
active	O
sites	O
of	O
P2Y12	B-GENE-Y
were	O
predicted	O
using	O
the	O
scoring	O
matrix	O
,	O
which	O
include	O
three	O
distant	O
areas	O
:	O
"	O
head	O
area	O
"	O
(	O
LGTGPLRTFV	B-CHEMICAL
,	O
87	O
-	O
96	O
)	O
,	O
"	O
middle	O
area	O
"	O
(	O
VGLITNGLAM	B-CHEMICAL
,	O
38	O
-	O
47	O
,	O
and	O
LGAKILSVVI	B-CHEMICAL
,	O
139	O
-	O
148	O
)	O
,	O
and	O
"	O
bottom	O
area	O
"	O
(	O
RTRGVGKVPR	B-CHEMICAL
,	O
222	O
-	O
231	O
)	O
.	O

Subsequently	O
the	O
structural	O
model	O
of	O
P2Y12	B-GENE-Y
was	O
docked	O
with	O
ATP	B-CHEMICAL
/	O
ADP	B-CHEMICAL
in	O
comparison	O
with	O
P2Y1	B-GENE-Y
(	O
PDB	B-GENE-Y
code	I-GENE-Y
1ddd	I-GENE-Y
)	O
.	O

As	O
a	O
comparison	O
,	O
we	O
docked	O
its	O
antagonists	O
,	O
such	O
as	O
ticlopidine	B-CHEMICAL
and	O
clopidogrel	B-CHEMICAL
,	O
to	O
the	O
most	O
probable	O
sites	O
and	O
calculated	O
their	O
intermolecular	O
energy	O
.	O

Our	O
results	O
imply	O
that	O
P2Y12	B-GENE-Y
has	O
the	O
potential	O
to	O
be	O
inhibited	O
by	O
ADP	B-CHEMICAL
/	O
ATP	B-CHEMICAL
analogs	O
,	O
and	O
it	O
suggests	O
that	O
P2Y12	B-GENE-Y
acts	O
as	O
a	O
target	O
of	O
new	O
drugs	O
that	O
inhibit	O
platelet	O
aggregation	O
.	O

Cadmium	B-CHEMICAL
induces	O
mitogenic	O
signaling	O
in	O
breast	O
cancer	O
cell	O
by	O
an	O
ERalpha	B-GENE-Y
-	O
dependent	O
mechanism	O
.	O

Breast	O
cancer	O
(	O
BC	O
)	O
is	O
linked	O
to	O
estrogen	O
exposure	O
.	O

Estradiol	B-CHEMICAL
(	O
E2	B-CHEMICAL
)	O
stimulates	O
BC	O
cells	O
proliferation	O
by	O
binding	O
the	O
estrogen	B-GENE-Y
receptor	I-GENE-Y
(	O
ER	B-GENE-Y
)	O
.	O

Hormone	O
-	O
related	O
cancers	O
have	O
been	O
linked	O
to	O
estrogenic	O
environmental	O
contaminants	O
.	O

Cadmium	B-CHEMICAL
(	O
Cd	B-CHEMICAL
)	O
a	O
toxic	O
pollutant	O
,	O
acts	O
as	O
estrogens	O
in	O
BC	O
cells	O
.	O

Purpose	O
of	O
our	O
study	O
was	O
to	O
evaluate	O
whether	O
Cd	B-CHEMICAL
regulates	O
MCF	O
-	O
7	O
cell	O
proliferation	O
by	O
activating	O
ERK1	B-GENE-N
/	I-GENE-N
2	I-GENE-N
,	O
Akt	B-GENE-N
and	O
PDGFRalpha	B-GENE-Y
kinases	B-GENE-N
.	O

Cd	B-CHEMICAL
increased	O
cell	O
proliferation	O
and	O
the	O
ER	B-GENE-Y
-	O
antagonist	O
ICI	O
182	O
,	O
780	O
blunted	O
it	O
.	O

To	O
characterize	O
an	O
ER	B-GENE-Y
-	O
dependent	O
mechanism	O
,	O
ERalpha	B-GENE-N
/	I-GENE-N
beta	I-GENE-N
expression	O
was	O
evaluated	O
.	O

Cd	B-CHEMICAL
decreased	O
ERalpha	B-GENE-Y
expression	O
,	O
but	O
not	O
ERbeta	B-GENE-Y
.	O

Cd	B-CHEMICAL
also	O
increased	O
ERK1	B-GENE-N
/	I-GENE-N
2	I-GENE-N
,	O
Akt	B-GENE-N
and	O
PDGFRalpha	B-GENE-Y
phosphorylation	O
while	O
ICI	O
blocked	O
it	O
.	O

Since	O
stimulation	O
of	O
phosphorylation	O
was	O
slower	O
than	O
expected	O
,	O
c	B-GENE-Y
-	I-GENE-Y
fos	I-GENE-Y
and	O
c	B-GENE-Y
-	I-GENE-Y
jun	I-GENE-Y
proto	O
-	O
oncogenes	O
,	O
and	O
PDGFA	B-GENE-Y
were	O
analyzed	O
.	O

Cd	B-CHEMICAL
rapidly	O
increased	O
c	B-GENE-N
-	I-GENE-N
jun	I-GENE-N
,	O
c	B-GENE-N
-	I-GENE-N
fos	I-GENE-N
and	O
PDGFA	B-GENE-Y
expression	O
.	O

Cells	O
were	O
also	O
co	O
-	O
incubated	O
with	O
the	O
Cd	B-CHEMICAL
and	O
specific	O
kinases	B-GENE-N
inhibitors	O
,	O
which	O
blocked	O
the	O
Cd	B-CHEMICAL
-	O
stimulated	O
proliferation	O
.	O

In	O
conclusion	O
,	O
our	O
results	O
indicate	O
that	O
Cd	B-CHEMICAL
increases	O
BC	O
cell	O
proliferation	O
in	O
vitro	O
by	O
stimulating	O
Akt	B-GENE-N
,	O
ERK1	B-GENE-N
/	I-GENE-N
2	I-GENE-N
and	O
PDGFRalpha	B-GENE-Y
kinases	B-GENE-N
activity	O
likely	O
by	O
activating	O
c	B-GENE-Y
-	I-GENE-Y
fos	I-GENE-Y
,	O
c	B-GENE-Y
-	I-GENE-Y
jun	I-GENE-Y
and	O
PDGFA	B-GENE-Y
by	O
an	O
ERalpha	B-GENE-Y
-	O
dependent	O
mechanism	O
.	O

Gonadotropin	B-CHEMICAL
-	I-CHEMICAL
releasing	I-CHEMICAL
hormone	I-CHEMICAL
functionally	O
antagonizes	O
testosterone	B-CHEMICAL
activation	O
of	O
the	O
human	B-GENE-Y
androgen	I-GENE-Y
receptor	I-GENE-Y
in	O
prostate	O
cells	O
through	O
focal	O
adhesion	O
complexes	O
involving	O
Hic	B-GENE-Y
-	I-GENE-Y
5	I-GENE-Y
.	O

Gonadotropin	B-CHEMICAL
-	I-CHEMICAL
releasing	I-CHEMICAL
hormone	I-CHEMICAL
(	O
GnRH	B-CHEMICAL
)	O
analogs	O
constitute	O
the	O
most	O
widely	O
employed	O
medical	O
treatment	O
for	O
prostatic	O
cancer	O
.	O

The	O
predominant	O
mechanism	O
of	O
action	O
is	O
presumed	O
to	O
be	O
via	O
the	O
inhibition	O
of	O
gonadotropins	O
and	O
resultant	O
decrease	O
in	O
androgen	O
.	O

However	O
,	O
GnRH	B-CHEMICAL
analogs	O
have	O
also	O
been	O
shown	O
to	O
directly	O
inhibit	O
prostate	O
cancer	O
cells	O
both	O
in	O
vitro	O
and	O
in	O
vivo	O
through	O
antiproliferative	O
cell	O
cycle	O
arrest	O
and	O
stimulation	O
of	O
apoptosis	O
.	O

Since	O
the	O
GnRH	B-GENE-Y
receptor	I-GENE-Y
has	O
been	O
shown	O
to	O
affect	O
sex	B-GENE-N
steroid	I-GENE-N
hormone	I-GENE-N
receptor	I-GENE-N
function	O
,	O
we	O
considered	O
that	O
part	O
of	O
GnRH	B-CHEMICAL
analog	O
actions	O
on	O
prostate	O
cells	O
may	O
be	O
mediated	O
through	O
modulation	O
of	O
the	O
human	B-GENE-Y
androgen	I-GENE-Y
receptor	I-GENE-Y
.	O

Using	O
a	O
model	O
HEK293	O
cell	O
line	O
expressing	O
the	O
GnRH	B-GENE-Y
receptor	I-GENE-Y
,	O
we	O
demonstrated	O
a	O
novel	O
signalling	O
pathway	O
of	O
the	O
GnRH	B-GENE-Y
receptor	I-GENE-Y
that	O
induces	O
nuclear	O
translocation	O
of	O
the	O
androgen	B-GENE-Y
receptor	I-GENE-Y
that	O
renders	O
it	O
transcriptionally	O
inactive	O
.	O

This	O
mechanism	O
involves	O
the	O
calcium	B-CHEMICAL
-	O
dependent	O
tyrosine	B-GENE-N
kinase	I-GENE-N
Pyk2	B-GENE-Y
,	O
the	O
non	B-GENE-N
-	I-GENE-N
receptor	I-GENE-N
tyrosine	I-GENE-N
kinase	I-GENE-N
c	B-GENE-Y
-	I-GENE-Y
Src	I-GENE-Y
and	O
the	O
focal	B-GENE-N
adhesion	I-GENE-N
protein	I-GENE-N
/	O
steroid	B-GENE-N
receptor	I-GENE-N
co	I-GENE-N
-	I-GENE-N
factor	I-GENE-N
,	O
Hic	B-GENE-Y
-	I-GENE-Y
5	I-GENE-Y
.	O

In	O
this	O
setting	O
there	O
is	O
a	O
GnRH	B-CHEMICAL
-	O
induced	O
association	O
and	O
nuclear	O
translocation	O
of	O
the	O
androgen	B-GENE-Y
receptor	I-GENE-Y
with	O
Hic	B-GENE-Y
-	I-GENE-Y
5	I-GENE-Y
.	O

GnRH	B-CHEMICAL
-	O
induced	O
Pyk2	B-GENE-Y
activation	O
opposed	O
the	O
association	O
of	O
Hic	B-GENE-Y
-	I-GENE-Y
5	I-GENE-Y
with	O
androgen	B-GENE-Y
receptor	I-GENE-Y
as	O
overexpression	O
of	O
a	O
dominant	O
negative	O
Pyk2	B-GENE-Y
enhanced	O
the	O
GnRH	B-CHEMICAL
-	O
induced	O
nuclear	O
translocation	O
of	O
a	O
green	O
fluorescent	O
protein	O
-	O
tagged	O
human	B-GENE-Y
androgen	I-GENE-Y
receptor	I-GENE-Y
.	O

GnRH	B-CHEMICAL
-	O
induced	O
c	B-GENE-Y
-	I-GENE-Y
Src	I-GENE-Y
activation	O
resulted	O
in	O
the	O
phosphorylation	O
of	O
expressed	O
Hic	B-GENE-Y
-	I-GENE-Y
5	I-GENE-Y
and	O
promoted	O
its	O
association	O
with	O
the	O
human	B-GENE-Y
androgen	I-GENE-Y
receptor	I-GENE-Y
.	O

In	O
contrast	O
to	O
testosterone	B-CHEMICAL
,	O
GnRH	B-CHEMICAL
-	O
induced	O
nuclear	O
translocation	O
did	O
not	O
transcriptionally	O
activate	O
the	O
androgen	B-GENE-Y
receptor	I-GENE-Y
.	O

We	O
then	O
demonstrated	O
that	O
GnRH	B-CHEMICAL
can	O
also	O
stimulate	O
androgen	B-GENE-Y
receptor	I-GENE-Y
mobilization	O
in	O
human	O
prostate	O
PC3	O
,	O
BPH	O
-	O
1	O
and	O
LNCaP	O
cells	O
,	O
and	O
in	O
cultured	O
rat	O
ventral	O
prostate	O
cells	O
through	O
the	O
same	O
mechanism	O
.	O

To	O
determine	O
if	O
GnRH	B-CHEMICAL
could	O
antagonize	O
androgen	O
effects	O
in	O
normal	O
tissue	O
,	O
we	O
examined	O
the	O
effect	O
of	O
GnRH	B-CHEMICAL
on	O
rat	O
ventral	O
prostate	O
organ	O
cultures	O
and	O
demonstrated	O
that	O
GnRH	B-CHEMICAL
can	O
functionally	O
antagonize	O
the	O
actions	O
of	O
testosterone	B-CHEMICAL
on	O
prostate	O
cell	O
proliferation	O
and	O
tissue	O
growth	O
.	O

This	O
antagonism	O
of	O
testosterone	B-CHEMICAL
action	O
by	O
GnRH	B-CHEMICAL
may	O
underlie	O
in	O
part	O
the	O
capacity	O
of	O
GnRH	B-GENE-Y
receptor	I-GENE-Y
activation	O
to	O
inhibit	O
prostate	O
tumor	O
growth	O
.	O

Trace	B-GENE-Y
amine	I-GENE-Y
-	I-GENE-Y
associated	I-GENE-Y
receptor	I-GENE-Y
1	I-GENE-Y
displays	O
species	O
-	O
dependent	O
stereoselectivity	O
for	O
isomers	O
of	O
methamphetamine	B-CHEMICAL
,	O
amphetamine	B-CHEMICAL
,	O
and	O
para	B-CHEMICAL
-	I-CHEMICAL
hydroxyamphetamine	I-CHEMICAL
.	O

The	O
synthetic	O
amines	B-CHEMICAL
methamphetamine	B-CHEMICAL
(	O
METH	B-CHEMICAL
)	O
,	O
amphetamine	B-CHEMICAL
(	O
AMPH	B-CHEMICAL
)	O
,	O
and	O
their	O
metabolite	O
para	B-CHEMICAL
-	I-CHEMICAL
hydroxyamphetamine	I-CHEMICAL
(	O
POHA	B-CHEMICAL
)	O
are	O
chemically	O
and	O
structurally	O
related	O
to	O
the	O
catecholamine	B-CHEMICAL
neurotransmitters	O
and	O
a	O
small	O
group	O
of	O
endogenous	O
biogenic	O
amines	B-CHEMICAL
collectively	O
referred	O
to	O
as	O
the	O
trace	O
amines	B-CHEMICAL
(	O
TAs	O
)	O
.	O

Recently	O
,	O
it	O
was	O
reported	O
that	O
METH	B-CHEMICAL
,	O
AMPH	B-CHEMICAL
,	O
POHA	B-CHEMICAL
,	O
and	O
the	O
TAs	O
para	B-CHEMICAL
-	I-CHEMICAL
tyramine	I-CHEMICAL
(	O
TYR	B-CHEMICAL
)	O
and	O
beta	B-CHEMICAL
-	I-CHEMICAL
phenylethylamine	I-CHEMICAL
(	O
PEA	B-CHEMICAL
)	O
stimulate	O
cAMP	B-CHEMICAL
production	O
in	O
human	O
embryonic	O
kidney	O
(	O
HEK	O
)	O
-	O
293	O
cells	O
expressing	O
rat	B-GENE-Y
trace	I-GENE-Y
amine	I-GENE-Y
-	I-GENE-Y
associated	I-GENE-Y
receptor	I-GENE-Y
1	I-GENE-Y
(	O
rTAAR1	B-GENE-Y
)	O
.	O

The	O
discovery	O
that	O
METH	B-CHEMICAL
and	O
AMPH	B-CHEMICAL
activate	O
the	O
rTAAR1	B-GENE-Y
motivated	O
us	O
to	O
study	O
the	O
effect	O
of	O
these	O
drugs	O
on	O
the	O
mouse	B-GENE-Y
TAAR1	I-GENE-Y
(	O
mTAAR1	B-GENE-Y
)	O
and	O
a	O
human	O
-	O
rat	O
chimera	O
(	O
hrChTAAR1	B-GENE-Y
)	O
.	O

Furthermore	O
,	O
because	O
S	O
-	O
(	O
+	O
)	O
-	O
isomers	O
of	O
METH	B-CHEMICAL
and	O
AMPH	B-CHEMICAL
are	O
reported	O
to	O
be	O
more	O
potent	O
and	O
efficacious	O
in	O
vivo	O
than	O
R	O
-	O
(	O
-	O
)	O
,	O
we	O
determined	O
the	O
enantiomeric	O
selectivity	O
of	O
all	O
three	O
species	O
of	O
TAAR1	B-GENE-Y
.	O

In	O
response	O
to	O
METH	B-CHEMICAL
,	O
AMPH	B-CHEMICAL
,	O
or	O
POHA	B-CHEMICAL
exposure	O
,	O
the	O
accumulation	O
of	O
cAMP	B-CHEMICAL
by	O
HEK	O
-	O
293	O
cells	O
stably	O
expressing	O
different	O
species	O
of	O
TAAR1	B-GENE-Y
was	O
concentration	O
-	O
and	O
isomer	O
-	O
dependent	O
.	O

EC50	O
values	O
for	O
S	B-CHEMICAL
-	I-CHEMICAL
(	I-CHEMICAL
+	I-CHEMICAL
)	I-CHEMICAL
-	I-CHEMICAL
METH	I-CHEMICAL
were	O
0	O
.	O
89	O
,	O
0	O
.	O
92	O
,	O
and	O
4	O
.	O
44	O
microM	O
for	O
rTAAR1	B-GENE-Y
,	O
mTAAR1	B-GENE-Y
,	O
and	O
h	B-GENE-Y
-	I-GENE-Y
rChTAAR1	I-GENE-Y
,	O
respectively	O
.	O

PEA	B-CHEMICAL
was	O
a	O
potent	O
and	O
full	O
agonist	O
at	O
each	O
species	O
of	O
TAAR1	B-GENE-Y
,	O
whereas	O
TYR	B-CHEMICAL
was	O
a	O
full	O
agonist	O
for	O
the	O
rodent	B-GENE-Y
TAAR1s	I-GENE-Y
but	O
was	O
a	O
partial	O
agonist	O
at	O
h	B-GENE-Y
-	I-GENE-Y
rChTAAR1	I-GENE-Y
.	O

Interestingly	O
,	O
both	O
isomers	O
of	O
METH	B-CHEMICAL
were	O
full	O
agonists	O
at	O
mTAAR1	B-GENE-Y
and	O
h	B-GENE-Y
-	I-GENE-Y
rChTAAR1	I-GENE-Y
,	O
whereas	O
both	O
were	O
partial	O
agonists	O
at	O
rTAAR1	B-GENE-Y
.	O

Taken	O
together	O
,	O
these	O
in	O
vitro	O
results	O
suggest	O
that	O
,	O
in	O
vivo	O
,	O
TAAR1	B-GENE-Y
could	O
be	O
a	O
novel	O
mediator	O
of	O
the	O
effects	O
of	O
these	O
drugs	O
.	O

Regulation	O
of	O
pancreatic	O
endocrine	O
cell	O
differentiation	O
by	O
sulphated	O
proteoglycans	O
.	O

AIMS	O
/	O
HYPOTHESIS	O
:	O
Epithelium	O
-	O
mesenchyme	O
interactions	O
play	O
a	O
major	O
role	O
in	O
pancreas	O
development	O
.	O

Recently	O
,	O
we	O
demonstrated	O
that	O
embryonic	O
pancreatic	O
mesenchyme	O
enhanced	O
progenitor	O
cell	O
proliferation	O
but	O
inhibited	O
endocrine	O
cell	O
differentiation	O
.	O

Here	O
,	O
we	O
investigated	O
the	O
role	O
played	O
by	O
sulphated	O
proteoglycans	O
,	O
which	O
are	O
known	O
to	O
be	O
essential	O
to	O
embryonic	O
development	O
,	O
in	O
this	O
inhibitory	O
effect	O
.	O

MATERIALS	O
AND	O
METHODS	O
:	O
We	O
first	O
determined	O
the	O
expression	O
of	O
the	O
genes	O
encoding	O
glypicans	B-GENE-N
,	O
syndecans	B-GENE-N
and	O
the	O
main	O
glycosaminoglycan	O
chain	O
-	O
modifying	O
enzymes	O
in	O
immature	O
embryonic	O
day	O
(	O
E	O
)	O
13	O
.	O
5	O
and	O
more	O
differentiated	O
E17	O
.	O
5	O
rat	O
pancreases	O
.	O

Next	O
,	O
using	O
an	O
in	O
vitro	O
model	O
of	O
pancreas	O
development	O
,	O
we	O
blocked	O
the	O
action	O
of	O
endogenous	O
sulphated	O
proteoglycans	O
by	O
treating	O
embryonic	O
pancreases	O
in	O
culture	O
with	O
chlorate	B-CHEMICAL
,	O
an	O
inhibitor	O
of	O
proteoglycan	O
sulphation	O
,	O
and	O
examined	O
the	O
effects	O
on	O
pancreatic	O
endocrine	O
cell	O
differentiation	O
.	O

RESULTS	O
:	O
We	O
first	O
showed	O
that	O
expression	O
of	O
the	O
genes	O
encoding	O
glypicans	B-GENE-N
1	I-GENE-N
,	I-GENE-N
2	I-GENE-N
,	I-GENE-N
3	I-GENE-N
and	I-GENE-N
5	I-GENE-N
and	O
heparan	B-GENE-Y
sulphate	I-GENE-Y
2	I-GENE-Y
-	I-GENE-Y
sulfotransferase	I-GENE-Y
decreased	O
between	O
E13	O
.	O
5	O
and	O
E17	O
.	O
5	O
.	O

We	O
next	O
found	O
that	O
alteration	O
of	O
proteoglycan	O
action	O
by	O
chlorate	B-CHEMICAL
blocked	O
the	O
inhibitory	O
effect	O
of	O
the	O
mesenchyme	O
on	O
endocrine	O
differentiation	O
.	O

Chlorate	B-CHEMICAL
-	O
treated	O
pancreases	O
exhibited	O
a	O
dramatic	O
increase	O
in	O
beta	O
cell	O
number	O
in	O
a	O
dose	O
-	O
dependent	O
manner	O
(	O
169	O
-	O
and	O
375	O
-	O
fold	O
increase	O
with	O
30	O
mmol	O
/	O
l	O
and	O
40	O
mmol	O
/	O
l	O
chlorate	B-CHEMICAL
,	O
respectively	O
)	O
and	O
in	O
alpha	O
cell	O
development	O
.	O

Insulin	B-GENE-N
-	O
positive	O
cells	O
that	O
developed	O
in	O
the	O
presence	O
of	O
chlorate	B-CHEMICAL
exhibited	O
a	O
phenotype	O
of	O
mature	O
cells	O
with	O
regard	O
to	O
the	O
expression	O
of	O
the	O
following	O
genes	O
:	O
pancreatic	B-GENE-Y
and	I-GENE-Y
duodenal	I-GENE-Y
homeobox	I-GENE-Y
gene	I-GENE-Y
1	I-GENE-Y
(	O
Pdx1	B-GENE-Y
)	O
,	O
proprotein	B-GENE-Y
convertase	I-GENE-Y
subtilisin	I-GENE-Y
/	I-GENE-Y
kexin	I-GENE-Y
type	I-GENE-Y
1	I-GENE-Y
(	O
Pcsk1	B-GENE-Y
;	O
previously	O
known	O
as	O
pro	B-GENE-Y
-	I-GENE-Y
hormone	I-GENE-Y
convertase	I-GENE-Y
1	I-GENE-Y
/	I-GENE-Y
3	I-GENE-Y
)	O
,	O
proprotein	B-GENE-Y
convertase	I-GENE-Y
subtilisin	I-GENE-Y
/	I-GENE-Y
kexin	I-GENE-Y
type	I-GENE-Y
2	I-GENE-Y
(	O
Pcsk2	B-GENE-Y
;	O
previously	O
known	O
as	O
pro	B-GENE-Y
-	I-GENE-Y
hormone	I-GENE-Y
convertase	I-GENE-Y
2	I-GENE-Y
)	O
and	O
solute	B-GENE-Y
carrier	I-GENE-Y
family	I-GENE-Y
2	I-GENE-Y
(	I-GENE-Y
facilitated	I-GENE-Y
glucose	I-GENE-Y
transporter	I-GENE-Y
)	I-GENE-Y
,	I-GENE-Y
member	I-GENE-Y
2	I-GENE-Y
(	O
Slc2a1	B-GENE-Y
;	O
previously	O
known	O
as	O
glucose	B-GENE-Y
transporter	I-GENE-Y
2	I-GENE-Y
)	O
.	O

Finally	O
,	O
we	O
showed	O
that	O
chlorate	B-CHEMICAL
activated	O
endocrine	O
cell	O
development	O
by	O
inducing	O
neurogenin	B-GENE-Y
3	I-GENE-Y
(	O
Neurog3	B-GENE-Y
)	O
expression	O
in	O
early	O
endocrine	O
progenitor	O
cells	O
.	O

CONCLUSIONS	O
/	O
INTERPRETATION	O
:	O
We	O
demonstrated	O
that	O
sulphated	O
proteoglycans	O
control	O
pancreatic	O
endocrine	O
cell	O
differentiation	O
.	O

Understanding	O
the	O
mechanism	O
by	O
which	O
sulphated	O
proteoglycans	O
affect	O
beta	O
cell	O
development	O
could	O
be	O
useful	O
in	O
the	O
generation	O
of	O
beta	O
cells	O
from	O
embryonic	O
stem	O
cells	O
.	O

Carbonic	B-GENE-N
anhydrase	I-GENE-N
inhibitors	O
.	O

DNA	O
cloning	O
,	O
characterization	O
,	O
and	O
inhibition	O
studies	O
of	O
the	O
human	B-GENE-Y
secretory	I-GENE-Y
isoform	I-GENE-Y
VI	I-GENE-Y
,	O
a	O
new	O
target	O
for	O
sulfonamide	B-CHEMICAL
and	O
sulfamate	B-CHEMICAL
inhibitors	O
.	O

The	O
secretory	O
isozyme	O
of	O
human	B-GENE-N
carbonic	I-GENE-N
anhydrase	I-GENE-N
(	O
hCA	B-GENE-N
,	O
EC	B-GENE-N
4	I-GENE-N
.	I-GENE-N
2	I-GENE-N
.	I-GENE-N
1	I-GENE-N
.	I-GENE-N
1	I-GENE-N
)	O
,	O
hCA	B-GENE-Y
VI	I-GENE-Y
,	O
has	O
been	O
cloned	O
,	O
expressed	O
,	O
and	O
purified	O
in	O
a	O
bacterial	O
expression	O
system	O
.	O

The	O
kinetic	O
parameters	O
for	O
the	O
CO2	B-CHEMICAL
hydration	O
reaction	O
proved	O
hCA	B-GENE-Y
VI	I-GENE-Y
to	O
possess	O
a	O
kcat	O
of	O
3	O
.	O
4	O
x	O
10	O
(	O
5	O
)	O
s	O
-	O
1	O
and	O
kcat	O
/	O
KM	O
of	O
4	O
.	O
9	O
x	O
10	O
(	O
7	O
)	O
M	O
-	O
1	O
s	O
-	O
1	O
(	O
at	O
pH	O
7	O
.	O
5	O
and	O
20	O
degrees	O
C	O
)	O
.	O

hCA	B-GENE-Y
VI	I-GENE-Y
has	O
a	O
significant	O
catalytic	O
activity	O
for	O
the	O
physiological	O
reaction	O
on	O
the	O
same	O
order	O
of	O
magnitude	O
as	O
the	O
ubiquitous	O
isoform	O
CA	B-GENE-N
I	I-GENE-N
or	O
the	O
transmembrane	O
,	O
tumor	O
-	O
associated	O
isozyme	O
CA	B-GENE-N
IX	I-GENE-N
.	O

A	O
series	O
of	O
sulfonamides	B-CHEMICAL
and	O
one	O
sulfamate	B-CHEMICAL
have	O
been	O
tested	O
for	O
their	O
interaction	O
with	O
this	O
isozyme	O
.	O

Simple	O
benzenesulfonamides	B-CHEMICAL
were	O
rather	O
ineffective	O
hCA	B-GENE-Y
VI	I-GENE-Y
inhibitors	O
,	O
with	O
inhibition	O
constants	O
in	O
the	O
range	O
of	O
1090	O
-	O
6680	O
nM	O
.	O

Better	O
inhibitors	O
were	O
detected	O
among	O
such	O
derivatives	O
bearing	O
2	B-CHEMICAL
-	I-CHEMICAL
or	I-CHEMICAL
4	I-CHEMICAL
-	I-CHEMICAL
amino	I-CHEMICAL
-	O
,	O
4	B-CHEMICAL
-	I-CHEMICAL
aminomethyl	I-CHEMICAL
-	O
,	O
or	O
4	B-CHEMICAL
-	I-CHEMICAL
hydroxymethyl	I-CHEMICAL
moieties	O
or	O
among	O
halogenated	O
sulfanilamides	B-CHEMICAL
(	O
KI	O
values	O
of	O
608	O
-	O
955	O
nM	O
)	O
.	O

Some	O
clinically	O
used	O
compounds	O
,	O
such	O
as	O
acetazolamide	B-CHEMICAL
,	O
methazolamide	B-CHEMICAL
,	O
ethoxzolamide	B-CHEMICAL
,	O
dichlorophenamide	B-CHEMICAL
,	O
dorzolamide	B-CHEMICAL
,	O
brinzolamide	B-CHEMICAL
,	O
topiramate	B-CHEMICAL
,	O
sulpiride	B-CHEMICAL
,	O
and	O
indisulam	B-CHEMICAL
,	O
or	O
the	O
orphan	O
drug	O
benzolamide	B-CHEMICAL
,	O
showed	O
effective	O
hCA	B-GENE-Y
VI	I-GENE-Y
inhibitory	O
activity	O
,	O
with	O
inhibition	O
constants	O
of	O
0	O
.	O
8	O
-	O
79	O
nM	O
.	O

The	O
best	O
inhibitors	O
were	O
brinzolamide	B-CHEMICAL
and	O
sulpiride	B-CHEMICAL
(	O
KI	O
values	O
of	O
0	O
.	O
8	O
-	O
0	O
.	O
9	O
nM	O
)	O
,	O
the	O
latter	O
compound	O
being	O
also	O
a	O
CA	B-GENE-Y
VI	I-GENE-Y
-	O
selective	O
inhibitor	O
.	O

The	O
metallic	O
taste	O
reported	O
as	O
a	O
side	O
effect	O
after	O
the	O
treatment	O
with	O
systemic	O
sulfonamides	B-CHEMICAL
may	O
be	O
due	O
to	O
the	O
inhibition	O
of	O
the	O
salivary	B-GENE-Y
CA	I-GENE-Y
VI	I-GENE-Y
.	O

Some	O
of	O
the	O
compounds	O
investigated	O
in	O
this	O
study	O
might	O
be	O
used	O
as	O
additives	O
in	O
toothpastes	O
for	O
reducing	O
the	O
acidification	O
produced	O
by	O
the	O
relevant	O
CO2	B-CHEMICAL
hydrase	O
activity	O
of	O
enamel	O
CA	B-GENE-Y
VI	I-GENE-Y
,	O
which	O
leads	O
to	O
the	O
formation	O
of	O
protons	O
and	O
bicarbonate	B-CHEMICAL
and	O
may	O
have	O
a	O
role	O
in	O
cariogenesis	O
.	O

Role	O
of	O
the	O
calcium	B-GENE-N
modulated	I-GENE-N
cyclases	I-GENE-N
in	O
the	O
development	O
of	O
the	O
retinal	B-CHEMICAL
projections	O
.	O

Transmembrane	O
isoforms	O
of	O
adenylate	B-GENE-N
cyclases	I-GENE-N
(	O
AC	B-GENE-N
)	O
integrate	O
a	O
wide	O
variety	O
of	O
extracellular	O
signals	O
from	O
neurotransmitters	O
to	O
morphogens	O
and	O
can	O
also	O
regulate	O
cAMP	B-CHEMICAL
production	O
in	O
response	O
to	O
calcium	B-CHEMICAL
entry	O
.	O

Based	O
on	O
observations	O
in	O
the	O
barrelless	O
mouse	O
strain	O
,	O
the	O
Adcy1	B-GENE-Y
gene	O
(	O
AC1	B-GENE-Y
)	O
was	O
involved	O
in	O
the	O
segregation	O
of	O
binocular	O
retinal	B-CHEMICAL
inputs	O
.	O

To	O
determine	O
the	O
potential	O
role	O
of	O
other	O
AC	B-GENE-N
isoforms	O
we	O
localized	O
the	O
Adcy	B-GENE-N
genes	O
in	O
the	O
visual	O
centres	O
during	O
development	O
,	O
using	O
in	O
situ	O
hybridization	O
.	O

Six	O
different	O
AC	B-GENE-N
subtypes	O
were	O
found	O
in	O
the	O
developing	O
retinal	O
ganglion	O
cell	O
layer	O
(	O
RGC	O
;	O
AC1	B-GENE-Y
,	O
AC2	B-GENE-Y
,	O
AC3	B-GENE-Y
,	O
AC5	B-GENE-Y
,	O
AC8	B-GENE-Y
,	O
and	O
AC9	B-GENE-Y
)	O
,	O
and	O
three	O
AC	B-GENE-N
subtypes	O
were	O
expressed	O
in	O
the	O
central	O
brain	O
targets	O
,	O
the	O
dorsal	O
lateral	O
geniculate	O
nucleus	O
(	O
AC1	B-GENE-Y
and	O
AC8	B-GENE-Y
)	O
,	O
the	O
ventral	O
lateral	O
geniculate	O
nucleus	O
(	O
AC2	B-GENE-Y
and	O
AC8	B-GENE-Y
)	O
and	O
the	O
superior	O
colliculus	O
(	O
AC1	B-GENE-Y
,	O
AC2	B-GENE-Y
,	O
AC8	B-GENE-Y
)	O
.	O

Using	O
a	O
genetic	O
approach	O
we	O
tested	O
the	O
role	O
of	O
the	O
calcium	B-GENE-N
modulated	I-GENE-N
cyclases	I-GENE-N
AC1	B-GENE-Y
,	O
AC5	B-GENE-Y
and	O
AC8	B-GENE-Y
for	O
the	O
segregation	O
retinal	B-CHEMICAL
fibres	O
.	O

Ipsilateral	O
retinal	B-CHEMICAL
axons	O
remained	O
exuberant	O
in	O
the	O
AC1	B-GENE-Y
(	O
-	O
/	O
-	O
)	O
mice	O
,	O
with	O
overlapping	O
retinal	B-CHEMICAL
projections	O
from	O
both	O
eyes	O
in	O
the	O
superior	O
colliculus	O
and	O
the	O
visual	O
thalamus	O
.	O

These	O
abnormalities	O
were	O
similar	O
to	O
those	O
of	O
barrelless	O
mouse	O
mutants	O
.	O

No	O
abnormalities	O
were	O
detectable	O
in	O
the	O
AC5	B-GENE-Y
(	O
-	O
/	O
-	O
)	O
or	O
the	O
AC8	B-GENE-Y
(	O
-	O
/	O
-	O
)	O
mice	O
.	O

Similar	O
abnormalities	O
were	O
noted	O
in	O
the	O
single	O
AC1	B-GENE-Y
(	O
-	O
/	O
-	O
)	O
and	O
the	O
AC1	B-GENE-Y
/	O
AC8	B-GENE-Y
double	O
-	O
knockout	O
mice	O
(	O
DKO	O
)	O
.	O

Thus	O
,	O
only	O
AC1	B-GENE-Y
is	O
required	O
for	O
the	O
maturation	O
of	O
the	O
retinal	B-CHEMICAL
axon	O
terminals	O
whereas	O
AC5	B-GENE-Y
and	O
AC8	B-GENE-Y
are	O
not	O
needed	O
.	O

The	O
specificity	O
of	O
AC1	B-GENE-Y
'	I-GENE-Y
s	I-GENE-Y
action	O
is	O
linked	O
to	O
its	O
cellular	O
localization	O
in	O
the	O
RGCs	O
and	O
to	O
its	O
distinctive	O
functional	O
profile	O
,	O
compared	O
with	O
the	O
other	O
cyclases	B-GENE-N
expressed	O
in	O
the	O
same	O
cells	O
.	O

Pirfenidone	B-CHEMICAL
inhibits	O
TGF	B-GENE-Y
-	I-GENE-Y
beta	I-GENE-Y
expression	O
in	O
malignant	O
glioma	O
cells	O
.	O

Due	O
to	O
its	O
immunosuppressive	O
properties	O
,	O
the	O
cytokine	B-GENE-N
transforming	B-GENE-Y
growth	I-GENE-Y
factor	I-GENE-Y
(	I-GENE-Y
TGF	I-GENE-Y
)	I-GENE-Y
-	I-GENE-Y
beta	I-GENE-Y
has	O
become	O
a	O
promising	O
target	O
in	O
the	O
experimental	O
treatment	O
of	O
human	O
malignant	O
gliomas	O
.	O

Here	O
,	O
we	O
report	O
that	O
the	O
antifibrotic	O
drug	O
5	B-CHEMICAL
-	I-CHEMICAL
methyl	I-CHEMICAL
-	I-CHEMICAL
1	I-CHEMICAL
-	I-CHEMICAL
phenyl	I-CHEMICAL
-	I-CHEMICAL
2	I-CHEMICAL
-	I-CHEMICAL
(	I-CHEMICAL
1H	I-CHEMICAL
)	I-CHEMICAL
-	I-CHEMICAL
pyridone	I-CHEMICAL
(	O
pirfenidone	B-CHEMICAL
,	O
PFD	B-CHEMICAL
)	O
elicits	O
growth	O
-	O
inhibitory	O
effects	O
and	O
reduces	O
TGF	B-GENE-Y
-	I-GENE-Y
beta2	I-GENE-Y
protein	O
levels	O
in	O
human	O
glioma	O
cell	O
lines	O
.	O

This	O
reduction	O
in	O
TGF	B-GENE-Y
-	I-GENE-Y
beta2	I-GENE-Y
is	O
biologically	O
relevant	O
since	O
PFD	B-CHEMICAL
treatment	O
reduces	O
the	O
growth	O
inhibition	O
of	O
TGF	B-GENE-Y
-	I-GENE-Y
beta	I-GENE-Y
-	O
sensitive	O
CCL	O
-	O
64	O
cells	O
mediated	O
by	O
conditioned	O
media	O
of	O
glioma	O
cells	O
.	O

The	O
downregulation	O
of	O
TGF	B-GENE-Y
-	I-GENE-Y
beta	I-GENE-Y
is	O
mediated	O
at	O
multiple	O
levels	O
.	O

PFD	B-CHEMICAL
leads	O
to	O
a	O
reduction	O
of	O
TGF	B-GENE-Y
-	I-GENE-Y
beta2	I-GENE-Y
mRNA	O
levels	O
and	O
of	O
the	O
mature	O
TGF	B-GENE-Y
-	I-GENE-Y
beta2	I-GENE-Y
protein	O
due	O
to	O
decreased	O
expression	O
and	O
direct	O
inhibition	O
of	O
the	O
TGF	B-GENE-Y
-	I-GENE-Y
beta	I-GENE-Y
pro	B-GENE-N
-	I-GENE-N
protein	I-GENE-N
convertase	I-GENE-N
furin	B-GENE-Y
.	O

In	O
addition	O
,	O
PFD	B-CHEMICAL
reduces	O
the	O
protein	O
levels	O
of	O
the	O
matrix	B-GENE-Y
metalloproteinase	I-GENE-Y
(	I-GENE-Y
MMP	I-GENE-Y
)	I-GENE-Y
-	I-GENE-Y
11	I-GENE-Y
,	O
a	O
TGF	B-GENE-Y
-	I-GENE-Y
beta	I-GENE-Y
target	O
gene	O
and	O
furin	B-GENE-Y
substrate	O
involved	O
in	O
carcinogenesis	O
.	O

These	O
data	O
define	O
PFD	B-CHEMICAL
or	O
PFD	B-CHEMICAL
-	O
related	O
agents	O
as	O
promising	O
agents	O
for	O
human	O
cancers	O
associated	O
with	O
enhanced	O
TGF	B-GENE-Y
-	I-GENE-Y
beta	I-GENE-Y
activity	O
.	O

Human	O
and	O
rat	O
bile	B-GENE-N
acid	I-GENE-N
-	I-GENE-N
CoA	I-GENE-N
:	I-GENE-N
amino	I-GENE-N
acid	I-GENE-N
N	I-GENE-N
-	I-GENE-N
acyltransferase	I-GENE-N
are	O
liver	O
-	O
specific	O
peroxisomal	O
enzymes	O
:	O
implications	O
for	O
intracellular	O
bile	B-CHEMICAL
salt	I-CHEMICAL
transport	O
.	O

UNLABELLED	O
:	O
Bile	B-GENE-Y
acid	I-GENE-Y
-	I-GENE-Y
coenzyme	I-GENE-Y
A	I-GENE-Y
:	I-GENE-Y
amino	I-GENE-Y
acid	I-GENE-Y
N	I-GENE-Y
-	I-GENE-Y
acyltransferase	I-GENE-Y
(	O
BAAT	B-GENE-Y
)	O
is	O
the	O
sole	O
enzyme	O
responsible	O
for	O
conjugation	O
of	O
primary	O
and	O
secondary	O
bile	B-CHEMICAL
acids	I-CHEMICAL
to	O
taurine	B-CHEMICAL
and	O
glycine	B-CHEMICAL
.	O

Previous	O
studies	O
indicate	O
a	O
peroxisomal	O
location	O
of	O
BAAT	B-GENE-Y
in	O
peroxisomes	O
with	O
variable	O
amounts	O
up	O
to	O
95	O
%	O
detected	O
in	O
cytosolic	O
fractions	O
.	O

The	O
absence	O
or	O
presence	O
of	O
a	O
cytosolic	O
pool	O
of	O
BAAT	B-GENE-Y
has	O
important	O
implications	O
for	O
the	O
intracellular	O
transport	O
of	O
unconjugated	O
/	O
deconjugated	O
bile	B-CHEMICAL
salts	I-CHEMICAL
.	O

We	O
used	O
immunofluorescence	O
microscopy	O
and	O
digitonin	B-CHEMICAL
permeabilization	O
assays	O
to	O
determine	O
the	O
subcellular	O
location	O
of	O
endogenous	O
BAAT	B-GENE-N
in	O
primary	O
human	O
and	O
rat	O
hepatocytes	O
.	O

In	O
addition	O
,	O
green	O
fluorescent	O
protein	O
(	O
GFP	O
)	O
-	O
tagged	O
rat	B-GENE-Y
Baat	I-GENE-Y
(	O
rBaat	B-GENE-Y
)	O
and	O
human	B-GENE-Y
BAAT	I-GENE-Y
(	O
hBAAT	B-GENE-Y
)	O
were	O
transiently	O
expressed	O
in	O
primary	O
rat	O
hepatocytes	O
and	O
human	O
fibroblasts	O
.	O

Catalase	B-GENE-Y
and	O
recombinant	O
GFP	O
-	O
SKL	B-GENE-N
and	O
DsRed	O
-	O
SKL	B-GENE-N
were	O
used	O
as	O
peroxisomal	O
markers	O
.	O

Endogenous	O
hBAAT	B-GENE-Y
and	O
rBaat	B-GENE-Y
were	O
found	O
to	O
specifically	O
localize	O
to	O
peroxisomes	O
in	O
human	O
and	O
rat	O
hepatocytes	O
,	O
respectively	O
.	O

No	O
significant	O
cytosolic	O
fraction	O
was	O
detected	O
for	O
either	O
protein	O
.	O

GFP	O
-	O
tagged	O
hBAAT	B-GENE-Y
and	O
rBaat	B-GENE-Y
were	O
efficiently	O
sorted	O
to	O
peroxisomes	O
of	O
primary	O
rat	O
hepatocytes	O
.	O

Significant	O
amounts	O
of	O
GFP	B-GENE-N
-	O
tagged	O
hBAAT	B-GENE-Y
or	O
rBaat	B-GENE-Y
were	O
detected	O
in	O
the	O
cytosol	O
only	O
when	O
coexpressed	O
with	O
DsRed	O
-	O
SKL	B-GENE-N
,	O
suggesting	O
that	O
hBAAT	B-GENE-Y
/	O
rBaat	B-GENE-Y
and	O
DsRed	O
-	O
SKL	B-GENE-N
compete	O
for	O
the	O
same	O
peroxisomal	O
import	O
machinery	O
.	O

When	O
expressed	O
in	O
fibroblasts	O
,	O
GFP	O
-	O
tagged	O
hBAAT	B-GENE-Y
localized	O
to	O
the	O
cytosol	O
,	O
confirming	O
earlier	O
observations	O
.	O

CONCLUSION	O
:	O
hBAAT	B-GENE-Y
and	O
rBaat	B-GENE-Y
are	O
peroxisomal	O
enzymes	O
present	O
in	O
undetectable	O
amounts	O
in	O
the	O
cytosol	O
.	O

Unconjugated	O
or	O
deconjugated	O
bile	B-CHEMICAL
salts	I-CHEMICAL
returning	O
to	O
the	O
liver	O
need	O
to	O
shuttle	O
through	O
the	O
peroxisome	O
before	O
reentering	O
the	O
enterohepatic	O
circulation	O
.	O

[	O
Construction	O
of	O
the	O
flavinogenic	O
yeast	O
Candida	O
famata	O
strains	O
with	O
high	O
riboflavin	B-GENE-N
kinase	I-GENE-N
activity	O
using	O
gene	O
engineering	O
]	O
.	O

The	O
recombinant	O
strains	O
of	O
the	O
flavinogenic	O
yeast	O
Candida	O
famata	O
,	O
which	O
contain	O
the	O
DNA	O
fragment	O
consisting	O
of	O
the	O
FMN1	B-GENE-N
gene	O
(	O
encoding	O
the	O
riboflavin	B-GENE-N
kinase	I-GENE-N
,	O
enzyme	O
that	O
converts	O
riboflavin	B-CHEMICAL
to	O
flavinmononucleotide	B-CHEMICAL
)	O
driven	O
by	O
the	O
strong	O
promoters	O
(	O
the	O
regulated	O
RIB1	B-GENE-N
or	O
constitutive	O
TEF1	B-GENE-N
promoter	I-GENE-N
)	O
were	O
isolated	O
.	O

Riboflavin	B-GENE-N
kinase	I-GENE-N
activity	O
in	O
the	O
isolated	O
transformants	O
was	O
tested	O
.	O

The	O
6	O
-	O
8	O
-	O
fold	O
increase	O
of	O
the	O
riboflavin	B-GENE-N
kinase	I-GENE-N
activity	O
was	O
shown	O
in	O
the	O
recombinant	O
strains	O
containing	O
the	O
integrated	O
Debaryomyces	B-GENE-N
hansenii	I-GENE-N
FMN1	I-GENE-N
gene	O
under	O
the	O
strong	O
constitutive	O
TEF1	B-GENE-N
promoter	I-GENE-N
.	O

The	O
recombinant	O
strains	O
can	O
be	O
used	O
for	O
the	O
following	O
construction	O
of	O
flavinmononucleotide	B-CHEMICAL
overproducers	O
.	O

The	O
impact	O
of	O
thyroid	O
activity	O
variations	O
on	O
some	O
oxidizing	O
-	O
stress	O
parameters	O
in	O
rats	O
.	O

The	O
effect	O
of	O
the	O
thyroid	O
activity	O
on	O
the	O
formation	O
of	O
lipid	O
peroxidation	O
and	O
on	O
liver	O
and	O
heart	O
antioxidant	O
enzyme	O
activities	O
was	O
investigated	O
in	O
Wistar	O
rats	O
.	O

Hypothyroidism	O
and	O
hyperthyroidism	O
conditions	O
were	O
induced	O
for	O
five	O
weeks	O
by	O
the	O
administration	O
of	O
0	O
.	O
05	O
%	O
benzythiouracile	B-CHEMICAL
(	O
BTU	B-CHEMICAL
)	O
and	O
L	B-CHEMICAL
-	I-CHEMICAL
thyroxine	I-CHEMICAL
sodium	I-CHEMICAL
salt	I-CHEMICAL
(	O
0	O
.	O
0012	O
%	O
)	O
,	O
in	O
drinking	O
water	O
,	O
respectively	O
.	O

No	O
significant	O
effect	O
was	O
observed	O
on	O
the	O
rates	O
of	O
both	O
lipid	O
peroxidation	O
and	O
the	O
vitamin	B-CHEMICAL
E	I-CHEMICAL
in	O
hepatic	O
and	O
cardiac	O
tissues	O
of	O
hypothyroidism	O
rats	O
compared	O
to	O
the	O
controls	O
,	O
contrary	O
to	O
the	O
hyperthyroidism	O
rats	O
,	O
which	O
expressed	O
a	O
pronounced	O
increase	O
.	O

The	O
increased	O
glutathione	B-GENE-N
peroxidase	I-GENE-N
activity	O
in	O
rats	O
suffering	O
from	O
hyperthyroidism	O
was	O
associated	O
with	O
a	O
fall	O
of	O
the	O
reduced	O
glutathione	B-CHEMICAL
in	O
the	O
homogenate	O
and	O
a	O
marked	O
increase	O
in	O
the	O
glutathione	B-GENE-Y
reductase	I-GENE-Y
activity	O
.	O

An	O
increase	O
in	O
superoxide	B-CHEMICAL
dismutase	O
and	O
catalase	O
activities	O
was	O
also	O
recorded	O
in	O
hyperthyroidism	O
.	O

Our	O
results	O
explain	O
the	O
thyroid	O
activity	O
variation	O
in	O
relation	O
to	O
the	O
lipid	O
peroxidation	O
and	O
the	O
tissular	O
contents	O
of	O
the	O
enzymatic	O
and	O
the	O
non	O
-	O
enzymatic	O
antioxidants	O
.	O

To	O
conclude	O
,	O
our	O
results	O
show	O
the	O
occurrence	O
of	O
a	O
state	O
of	O
oxidizing	O
stress	O
in	O
relation	O
to	O
hyperthyroidism	O
.	O

Mechanism	O
of	O
the	O
irreversible	O
inactivation	O
of	O
mouse	B-GENE-Y
ornithine	I-GENE-Y
decarboxylase	I-GENE-Y
by	O
alpha	B-CHEMICAL
-	I-CHEMICAL
difluoromethylornithine	I-CHEMICAL
.	O

Characterization	O
of	O
sequences	O
at	O
the	O
inhibitor	O
and	O
coenzyme	O
binding	O
sites	O
.	O

Mouse	B-GENE-Y
ornithine	I-GENE-Y
decarboxylase	I-GENE-Y
(	O
ODC	B-GENE-Y
)	O
was	O
expressed	O
in	O
Escherichia	O
coli	O
and	O
the	O
purified	O
recombinant	O
enzyme	O
used	O
for	O
determination	O
of	O
the	O
binding	O
site	O
for	O
pyridoxal	B-CHEMICAL
5	I-CHEMICAL
'	I-CHEMICAL
-	I-CHEMICAL
phosphate	I-CHEMICAL
and	O
of	O
the	O
residues	O
modified	O
in	O
the	O
inactivation	O
of	O
the	O
enzyme	O
by	O
the	O
enzyme	O
-	O
activated	O
irreversible	O
inhibitor	O
,	O
alpha	B-CHEMICAL
-	I-CHEMICAL
difluoromethylornithine	I-CHEMICAL
(	O
DFMO	B-CHEMICAL
)	O
.	O

The	O
pyridoxal	B-CHEMICAL
5	I-CHEMICAL
'	I-CHEMICAL
-	I-CHEMICAL
phosphate	I-CHEMICAL
binding	O
lysine	B-CHEMICAL
in	O
mouse	B-GENE-Y
ODC	I-GENE-Y
was	O
identified	O
as	O
lysine	B-CHEMICAL
69	O
of	O
the	O
mouse	O
sequence	O
by	O
reduction	O
of	O
the	O
purified	O
holoenzyme	O
form	O
with	O
NaB	B-CHEMICAL
[	I-CHEMICAL
3H	I-CHEMICAL
]	I-CHEMICAL
4	I-CHEMICAL
followed	O
by	O
digestion	O
of	O
the	O
carboxymethylated	O
protein	O
with	O
endoproteinase	B-GENE-Y
Lys	I-GENE-Y
-	I-GENE-Y
C	I-GENE-Y
,	O
radioactive	O
peptide	O
mapping	O
using	O
reversed	O
-	O
phase	O
high	O
pressure	O
liquid	O
chromatography	O
and	O
gas	O
-	O
phase	O
peptide	O
sequencing	O
.	O

This	O
lysine	B-CHEMICAL
is	O
contained	O
in	O
the	O
sequence	O
PFYAVKC	B-CHEMICAL
,	O
which	O
is	O
found	O
in	O
all	O
known	O
ODCs	B-GENE-N
from	O
eukaryotes	O
.	O

The	O
preceding	O
amino	B-CHEMICAL
acids	I-CHEMICAL
do	O
not	O
conform	O
to	O
the	O
consensus	O
sequence	O
of	O
SXHK	B-GENE-N
,	O
which	O
contains	O
the	O
pyridoxal	B-CHEMICAL
5	I-CHEMICAL
'	I-CHEMICAL
-	I-CHEMICAL
phosphate	I-CHEMICAL
binding	O
lysine	B-CHEMICAL
in	O
a	O
number	O
of	O
other	O
decarboxylases	B-GENE-N
including	O
ODCs	B-GENE-N
from	O
E	O
.	O
coli	O
.	O

Using	O
a	O
similar	O
procedure	O
to	O
analyze	O
ODC	B-GENE-Y
labeled	O
by	O
reaction	O
with	O
[	B-CHEMICAL
5	I-CHEMICAL
-	I-CHEMICAL
14C	I-CHEMICAL
]	I-CHEMICAL
DFMO	I-CHEMICAL
,	O
it	O
was	O
found	O
that	O
lysine	B-CHEMICAL
69	O
and	O
cysteine	B-CHEMICAL
360	O
formed	O
covalent	O
adducts	O
with	O
the	O
inhibitor	O
.	O

Cysteine	B-CHEMICAL
360	O
,	O
which	O
was	O
the	O
major	O
adduct	O
accounting	O
for	O
about	O
90	O
%	O
of	O
the	O
total	O
labeling	O
,	O
is	O
contained	O
within	O
the	O
sequence	O
-	O
WGPTCDGL	B-CHEMICAL
(	I-CHEMICAL
I	I-CHEMICAL
)	I-CHEMICAL
D	I-CHEMICAL
-	O
,	O
which	O
is	O
present	O
in	O
all	O
known	O
eukaryote	B-GENE-N
ODCs	I-GENE-N
.	O

These	O
results	O
provide	O
strong	O
evidence	O
that	O
these	O
two	O
peptides	O
form	O
essential	O
parts	O
of	O
the	O
catalytic	O
site	O
of	O
ODC	B-GENE-Y
.	O

Analysis	O
by	O
fast	O
atom	O
bombardment	O
-	O
mass	O
spectrometry	O
of	O
tryptic	O
peptides	O
containing	O
the	O
DFMO	B-CHEMICAL
-	O
cysteine	B-CHEMICAL
adduct	O
indicated	O
that	O
the	O
adduct	O
formed	O
in	O
the	O
enzyme	O
was	O
probably	O
the	O
cyclic	B-CHEMICAL
imine	I-CHEMICAL
S	B-CHEMICAL
-	I-CHEMICAL
(	I-CHEMICAL
2	I-CHEMICAL
-	I-CHEMICAL
(	I-CHEMICAL
1	I-CHEMICAL
-	I-CHEMICAL
pyrroline	I-CHEMICAL
)	I-CHEMICAL
methyl	I-CHEMICAL
)	I-CHEMICAL
cysteine	I-CHEMICAL
.	O

This	O
is	O
readily	O
oxidized	O
to	O
S	B-CHEMICAL
-	I-CHEMICAL
(	I-CHEMICAL
(	I-CHEMICAL
2	I-CHEMICAL
-	I-CHEMICAL
pyrrole	I-CHEMICAL
)	I-CHEMICAL
methyl	I-CHEMICAL
)	I-CHEMICAL
cysteine	I-CHEMICAL
or	O
converted	O
to	O
S	B-CHEMICAL
-	I-CHEMICAL
(	I-CHEMICAL
(	I-CHEMICAL
2	I-CHEMICAL
-	I-CHEMICAL
pyrrolidine	I-CHEMICAL
)	I-CHEMICAL
methyl	I-CHEMICAL
)	I-CHEMICAL
cysteine	I-CHEMICAL
by	O
NaBH4	B-CHEMICAL
reduction	O
.	O

This	O
adduct	O
is	O
consistent	O
with	O
spectral	O
evidence	O
showing	O
that	O
inactivation	O
of	O
the	O
enzyme	O
with	O
DFMO	B-CHEMICAL
does	O
not	O
entail	O
the	O
formation	O
of	O
a	O
stable	O
adduct	O
between	O
the	O
pyridoxal	B-CHEMICAL
5	I-CHEMICAL
'	I-CHEMICAL
-	I-CHEMICAL
phosphate	I-CHEMICAL
,	O
the	O
enzyme	O
,	O
and	O
the	O
inhibitor	O
.	O

Pre	O
-	O
steady	O
-	O
state	O
currents	O
in	O
neutral	B-GENE-N
amino	I-GENE-N
acid	I-GENE-N
transporters	I-GENE-N
induced	O
by	O
photolysis	O
of	O
a	O
new	O
caged	O
alanine	B-CHEMICAL
derivative	O
.	O

Na	B-CHEMICAL
+	I-CHEMICAL
-	O
Dependent	O
transmembrane	O
transport	O
of	O
small	O
neutral	O
amino	B-CHEMICAL
acids	I-CHEMICAL
,	O
such	O
as	O
glutamine	B-CHEMICAL
and	O
alanine	B-CHEMICAL
,	O
is	O
mediated	O
,	O
among	O
others	O
,	O
by	O
the	O
neutral	B-GENE-N
amino	I-GENE-N
acid	I-GENE-N
transporters	I-GENE-N
of	O
the	O
solute	B-GENE-N
carrier	I-GENE-N
1	I-GENE-N
[	O
SLC1	B-GENE-N
,	O
alanine	B-GENE-Y
serine	I-GENE-Y
cysteine	I-GENE-Y
transporter	I-GENE-Y
1	I-GENE-Y
(	O
ASCT1	B-GENE-Y
)	O
,	O
and	O
ASCT2	B-GENE-Y
]	O
and	O
SLC38	B-GENE-N
families	O
[	O
sodium	B-GENE-Y
-	I-GENE-Y
coupled	I-GENE-Y
neutral	I-GENE-Y
amino	I-GENE-Y
acid	I-GENE-Y
transporter	I-GENE-Y
1	I-GENE-Y
(	O
SNAT1	B-GENE-Y
)	O
,	O
SNAT2	B-GENE-Y
,	O
and	O
SNAT4	B-GENE-Y
]	O
.	O

Many	O
mechanistic	O
aspects	O
of	O
amino	B-CHEMICAL
acid	I-CHEMICAL
transport	O
by	O
these	O
systems	O
are	O
not	O
well	O
-	O
understood	O
.	O

Here	O
,	O
we	O
describe	O
a	O
new	O
photolabile	O
alanine	B-CHEMICAL
derivative	O
based	O
on	O
protection	O
of	O
alanine	B-CHEMICAL
with	O
the	O
4	B-CHEMICAL
-	I-CHEMICAL
methoxy	I-CHEMICAL
-	I-CHEMICAL
7	I-CHEMICAL
-	I-CHEMICAL
nitroindolinyl	I-CHEMICAL
(	O
MNI	B-CHEMICAL
)	O
caging	O
group	O
,	O
which	O
we	O
use	O
for	O
pre	O
-	O
steady	O
-	O
state	O
kinetic	O
analysis	O
of	O
alanine	O
transport	O
by	O
ASCT2	B-GENE-Y
,	O
SNAT1	B-GENE-Y
,	O
and	O
SNAT2	B-GENE-Y
.	O

MNI	O
-	O
alanine	B-CHEMICAL
has	O
favorable	O
photochemical	O
properties	O
and	O
is	O
stable	O
in	O
aqueous	O
solution	O
.	O

It	O
is	O
also	O
inert	O
with	O
respect	O
to	O
the	O
transport	O
systems	O
studied	O
.	O

Photolytic	O
release	O
of	O
free	O
alanine	B-CHEMICAL
results	O
in	O
the	O
generation	O
of	O
significant	O
transient	O
current	O
components	O
in	O
HEK293	O
cells	O
expressing	O
the	O
ASCT2	B-GENE-Y
,	O
SNAT1	B-GENE-Y
,	O
and	O
SNAT2	B-GENE-Y
proteins	O
.	O

In	O
ASCT2	B-GENE-Y
,	O
these	O
currents	O
show	O
biphasic	O
decay	O
with	O
time	O
constants	O
,	O
tau	O
,	O
in	O
the	O
1	O
-	O
30	O
ms	O
time	O
range	O
.	O

They	O
are	O
fully	O
inhibited	O
in	O
the	O
absence	O
of	O
extracellular	O
Na	B-CHEMICAL
+	I-CHEMICAL
,	O
demonstrating	O
that	O
Na	B-CHEMICAL
+	I-CHEMICAL
binding	O
to	O
the	O
transporter	O
is	O
necessary	O
for	O
induction	O
of	O
the	O
alanine	B-CHEMICAL
-	O
mediated	O
current	O
.	O

For	O
SNAT1	B-GENE-Y
,	O
these	O
transient	O
currents	O
differ	O
in	O
their	O
time	O
course	O
(	O
tau	O
=	O
1	O
.	O
6	O
ms	O
)	O
from	O
previously	O
described	O
pre	O
-	O
steady	O
-	O
state	O
currents	O
generated	O
by	O
applying	O
steps	O
in	O
the	O
membrane	O
potential	O
(	O
tau	O
approximately	O
4	O
-	O
5	O
ms	O
)	O
,	O
indicating	O
that	O
they	O
are	O
associated	O
with	O
a	O
fast	O
,	O
previously	O
undetected	O
,	O
electrogenic	O
partial	O
reaction	O
in	O
the	O
SNAT1	B-GENE-Y
transport	O
cycle	O
.	O

The	O
implications	O
of	O
these	O
results	O
for	O
the	O
mechanisms	O
of	O
transmembrane	O
transport	O
of	O
alanine	B-CHEMICAL
are	O
discussed	O
.	O

The	O
new	O
caged	O
alanine	B-CHEMICAL
derivative	O
will	O
provide	O
a	O
useful	O
tool	O
for	O
future	O
,	O
more	O
detailed	O
studies	O
of	O
neutral	O
amino	B-CHEMICAL
acid	I-CHEMICAL
transport	O
.	O

Histochemical	O
staining	O
and	O
quantification	O
of	O
dihydrolipoamide	B-GENE-Y
dehydrogenase	I-GENE-Y
diaphorase	B-GENE-N
activity	O
using	O
blue	O
native	O
PAGE	O
.	O

Mammalian	B-GENE-Y
mitochondrial	I-GENE-Y
dihydrolipoamide	I-GENE-Y
dehydrogenase	I-GENE-Y
(	O
DLDH	B-GENE-Y
,	O
EC	B-GENE-Y
1	I-GENE-Y
.	I-GENE-Y
8	I-GENE-Y
.	I-GENE-Y
1	I-GENE-Y
.	I-GENE-Y
4	I-GENE-Y
)	O
catalyzes	O
NAD	B-CHEMICAL
(	I-CHEMICAL
+	I-CHEMICAL
)	I-CHEMICAL
-	O
dependent	O
oxidation	O
of	O
dihydrolipoamide	B-CHEMICAL
in	O
vivo	O
and	O
can	O
also	O
act	O
as	O
a	O
diaphorase	B-GENE-N
catalyzing	O
in	O
vitro	O
nicotinamide	B-CHEMICAL
adenine	I-CHEMICAL
dinucleotide	I-CHEMICAL
(	I-CHEMICAL
reduced	I-CHEMICAL
form	I-CHEMICAL
)	I-CHEMICAL
(	O
NADH	B-CHEMICAL
)	O
-	O
dependent	O
reduction	O
of	O
electron	O
-	O
accepting	O
molecules	O
such	O
as	O
ubiquinone	O
and	O
nitroblue	B-CHEMICAL
tetrazolium	I-CHEMICAL
(	O
NBT	B-CHEMICAL
)	O
.	O

In	O
this	O
paper	O
,	O
we	O
report	O
a	O
gel	O
-	O
based	O
method	O
for	O
histochemical	O
staining	O
and	O
quantification	O
of	O
DLDH	B-GENE-Y
diaphorase	B-GENE-N
activity	O
using	O
blue	O
native	O
PAGE	O
(	O
BN	O
-	O
PAGE	O
)	O
.	O

Rat	O
brain	O
mitochondrial	O
extracts	O
,	O
used	O
as	O
the	O
source	O
of	O
DLDH	B-GENE-Y
,	O
were	O
resolved	O
by	O
nongradient	O
BN	O
-	O
PAGE	O
(	O
9	O
%	O
)	O
,	O
which	O
was	O
followed	O
by	O
diaphorase	B-GENE-N
activity	O
staining	O
using	O
NADH	B-CHEMICAL
as	O
the	O
electron	O
donor	O
and	O
NBT	B-CHEMICAL
as	O
the	O
electron	O
acceptor	O
.	O

It	O
was	O
shown	O
that	O
activity	O
staining	O
of	O
DLDH	B-GENE-Y
diaphorase	B-GENE-N
was	O
both	O
protein	O
amount	O
-	O
and	O
time	O
-	O
dependent	O
.	O

Moreover	O
,	O
this	O
in	O
-	O
gel	O
activity	O
-	O
staining	O
method	O
was	O
demonstrated	O
to	O
be	O
in	O
good	O
agreement	O
with	O
the	O
conventional	O
spectrophotometric	O
method	O
that	O
measures	O
DLDH	B-GENE-Y
dehydrogenase	B-GENE-N
activity	O
using	O
dihydrolipoamide	B-CHEMICAL
as	O
the	O
substrate	O
.	O

The	O
method	O
was	O
applied	O
to	O
determine	O
levels	O
of	O
DLDH	B-GENE-Y
diaphorase	B-GENE-N
activity	O
in	O
several	O
rat	O
tissues	O
other	O
than	O
the	O
brain	O
,	O
and	O
the	O
results	O
indicated	O
a	O
similar	O
level	O
of	O
DLDH	B-GENE-Y
diaphorase	B-GENE-N
activity	O
for	O
all	O
the	O
tissues	O
examined	O
.	O

Finally	O
,	O
the	O
effects	O
of	O
thiol	B-CHEMICAL
-	O
reactive	O
reagents	O
such	O
as	O
N	B-CHEMICAL
-	I-CHEMICAL
ethylmaleimide	I-CHEMICAL
(	O
NEM	B-CHEMICAL
)	O
and	O
nitric	B-CHEMICAL
oxide	I-CHEMICAL
donors	O
on	O
DLDH	B-GENE-Y
diaphorase	B-GENE-N
activity	O
were	O
evaluated	O
,	O
demonstrating	O
that	O
,	O
with	O
this	O
method	O
,	O
DLDH	B-GENE-Y
diaphorase	B-GENE-N
activity	O
can	O
be	O
determined	O
without	O
having	O
to	O
remove	O
these	O
thiol	B-CHEMICAL
-	O
reactive	O
reagents	O
that	O
may	O
otherwise	O
interfere	O
with	O
spectrophotometric	O
measurement	O
of	O
DLDH	B-GENE-Y
dehydrogenase	B-GENE-N
activity	O
.	O

The	O
gel	O
-	O
based	O
method	O
can	O
also	O
be	O
used	O
as	O
a	O
means	O
to	O
isolate	O
mitochondrial	O
DLDH	B-GENE-Y
that	O
is	O
to	O
be	O
analyzed	O
by	O
mass	O
spectral	O
techniques	O
in	O
studying	O
DLDH	B-GENE-Y
post	O
-	O
translational	O
modifications	O
.	O

Reticulated	O
platelets	O
and	O
uninhibited	O
COX	B-GENE-Y
-	I-GENE-Y
1	I-GENE-Y
and	O
COX	B-GENE-Y
-	I-GENE-Y
2	I-GENE-Y
decrease	O
the	O
antiplatelet	O
effects	O
of	O
aspirin	B-CHEMICAL
.	O

BACKGROUND	O
:	O
The	O
mechanisms	O
for	O
the	O
variability	O
in	O
antiplatelet	O
effects	O
of	O
aspirin	B-CHEMICAL
are	O
unclear	O
.	O

Immature	O
(	O
reticulated	O
)	O
platelets	O
may	O
modulate	O
the	O
antiplatelet	O
effects	O
of	O
aspirin	B-CHEMICAL
through	O
uninhibited	O
cyclooxygenase	B-GENE-N
(	B-GENE-Y
COX	I-GENE-Y
)	I-GENE-Y
-	I-GENE-Y
1	I-GENE-Y
and	O
COX	B-GENE-Y
-	I-GENE-Y
2	I-GENE-Y
.	O

OBJECTIVES	O
:	O
To	O
evaluate	O
the	O
role	O
of	O
reticulated	O
platelets	O
in	O
the	O
antiplatelet	O
effects	O
of	O
aspirin	B-CHEMICAL
.	O

METHODS	O
:	O
Sixty	O
healthy	O
volunteers	O
had	O
platelet	O
studies	O
performed	O
before	O
and	O
24	O
h	O
after	O
a	O
single	O
325	O
-	O
mg	O
dose	O
of	O
aspirin	B-CHEMICAL
.	O

Platelet	O
studies	O
included	O
light	O
transmission	O
aggregometry	O
;	O
P	B-GENE-Y
-	I-GENE-Y
selectin	I-GENE-Y
and	O
integrin	B-GENE-N
alpha	I-GENE-N
(	I-GENE-N
IIb	I-GENE-N
)	I-GENE-N
beta	I-GENE-N
(	I-GENE-N
3	I-GENE-N
)	I-GENE-N
expression	O
,	O
and	O
serum	O
thromboxane	B-CHEMICAL
B	I-CHEMICAL
(	I-CHEMICAL
2	I-CHEMICAL
)	I-CHEMICAL
(	O
TxB	B-CHEMICAL
(	I-CHEMICAL
2	I-CHEMICAL
)	I-CHEMICAL
)	O
levels	O
.	O

Reticulated	O
platelets	O
and	O
platelet	O
COX	B-GENE-Y
-	I-GENE-Y
2	I-GENE-Y
expression	O
were	O
measured	O
using	O
flow	O
cytometry	O
.	O

RESULTS	O
:	O
Subjects	O
were	O
divided	O
into	O
tertiles	O
based	O
on	O
the	O
percentage	O
of	O
reticulated	O
platelets	O
in	O
whole	O
blood	O
.	O

Baseline	O
platelet	O
aggregation	O
to	O
1	O
microg	O
mL	O
(	O
-	O
1	O
)	O
collagen	B-GENE-N
,	O
and	O
postaspirin	O
aggregations	O
to	O
5	O
microm	O
and	O
20	O
microm	O
ADP	B-CHEMICAL
and	O
collagen	B-GENE-N
,	O
were	O
greater	O
in	O
the	O
upper	O
than	O
in	O
the	O
lower	O
tertile	O
of	O
reticulated	O
platelets	O
.	O

Stimulated	O
P	B-GENE-Y
-	I-GENE-Y
selectin	I-GENE-Y
and	O
integrin	B-GENE-N
alpha	I-GENE-N
(	I-GENE-N
IIb	I-GENE-N
)	I-GENE-N
beta	I-GENE-N
(	I-GENE-N
3	I-GENE-N
)	I-GENE-N
expression	O
were	O
also	O
higher	O
in	O
the	O
upper	O
tertile	O
both	O
before	O
and	O
after	O
aspirin	B-CHEMICAL
.	O

Platelet	O
COX	B-GENE-Y
-	I-GENE-Y
2	I-GENE-Y
expression	O
was	O
detected	O
in	O
12	O
+	O
/	O
-	O
7	O
%	O
(	O
n	O
=	O
10	O
)	O
of	O
platelets	O
in	O
the	O
upper	O
tertile	O
,	O
and	O
in	O
7	O
+	O
/	O
-	O
3	O
%	O
(	O
n	O
=	O
12	O
)	O
of	O
platelets	O
in	O
the	O
lower	O
two	O
tertiles	O
(	O
P	O
=	O
0	O
.	O
03	O
)	O
.	O

Postaspirin	O
serum	O
TxB	O
(	O
2	O
)	O
levels	O
were	O
higher	O
in	O
the	O
upper	O
(	O
5	O
.	O
5	O
+	O
/	O
-	O
4	O
ng	O
mL	O
(	O
-	O
1	O
)	O
)	O
than	O
in	O
the	O
lower	O
tertile	O
(	O
3	O
.	O
2	O
+	O
/	O
-	O
2	O
.	O
5	O
ng	O
mL	O
(	O
-	O
1	O
)	O
,	O
P	O
=	O
0	O
.	O
03	O
)	O
,	O
and	O
decreased	O
even	O
further	O
with	O
ex	O
vivo	O
additional	O
COX	B-GENE-Y
-	I-GENE-Y
1	I-GENE-Y
and	O
COX	B-GENE-Y
-	I-GENE-Y
2	I-GENE-Y
inhibition	O
.	O

The	O
incidence	O
of	O
aspirin	O
resistance	O
(	O
>	O
or	O
=	O
70	O
%	O
platelet	O
aggregation	O
to	O
5	O
microm	O
ADP	O
)	O
was	O
significantly	O
higher	O
in	O
the	O
upper	O
tertile	O
(	O
45	O
%	O
)	O
than	O
in	O
the	O
lower	O
tertile	O
(	O
5	O
%	O
,	O
P	O
<	O
0	O
.	O
0001	O
)	O
.	O

CONCLUSIONS	O
:	O
Reticulated	O
platelets	O
are	O
associated	O
with	O
diminished	O
antiplatelet	O
effects	O
of	O
aspirin	B-CHEMICAL
and	O
increased	O
aspirin	B-CHEMICAL
resistance	O
,	O
possibly	O
because	O
of	O
increased	O
reactivity	O
,	O
and	O
uninhibited	O
COX	B-GENE-Y
-	I-GENE-Y
1	I-GENE-Y
and	O
COX	B-GENE-Y
-	I-GENE-Y
2	I-GENE-Y
activity	O
.	O

Neuroprotection	O
by	O
estrogen	B-CHEMICAL
against	O
MPP	B-CHEMICAL
+	I-CHEMICAL
-	O
induced	O
dopamine	B-CHEMICAL
neuron	O
death	O
is	O
mediated	O
by	O
ERalpha	B-GENE-Y
in	O
primary	O
cultures	O
of	O
mouse	O
mesencephalon	O
.	O

Estrogen	B-CHEMICAL
involvement	O
in	O
neuroprotection	O
is	O
now	O
widely	O
accepted	O
,	O
although	O
the	O
specific	O
molecular	O
and	O
cellular	O
mechanisms	O
of	O
estrogen	B-CHEMICAL
action	O
in	O
neuroprotection	O
remain	O
unclear	O
.	O

This	O
study	O
examines	O
estrogenic	O
effects	O
in	O
a	O
mixed	O
population	O
of	O
cells	O
in	O
attempts	O
to	O
identify	O
the	O
contributing	O
cells	O
that	O
result	O
in	O
estrogen	B-CHEMICAL
-	O
mediated	O
neuroprotection	O
.	O

Utilizing	O
primary	O
mesencephalic	O
neurons	O
,	O
we	O
found	O
expression	O
of	O
both	O
estrogen	B-GENE-Y
receptor	I-GENE-Y
alpha	I-GENE-Y
(	O
ERalpha	B-GENE-Y
)	O
and	O
estrogen	B-GENE-Y
receptor	I-GENE-Y
beta	I-GENE-Y
(	O
ERbeta	B-GENE-Y
)	O
with	O
a	O
predominance	O
of	O
ERalpha	B-GENE-Y
on	O
both	O
dopamine	B-CHEMICAL
neurons	O
and	O
astrocytes	O
.	O

We	O
also	O
found	O
that	O
17beta	B-CHEMICAL
-	I-CHEMICAL
estradiol	I-CHEMICAL
protects	O
dopamine	B-CHEMICAL
neurons	O
from	O
injury	O
induced	O
by	O
the	O
complex	O
I	O
inhibitor	O
,	O
1	B-CHEMICAL
-	I-CHEMICAL
methyl	I-CHEMICAL
-	I-CHEMICAL
4	I-CHEMICAL
-	I-CHEMICAL
phenyl	I-CHEMICAL
pyridinium	I-CHEMICAL
(	O
MPP	B-CHEMICAL
(	I-CHEMICAL
+	I-CHEMICAL
)	I-CHEMICAL
)	O
in	O
a	O
time	O
-	O
and	O
ER	B-GENE-Y
-	O
dependent	O
manner	O
.	O

At	O
least	O
4	O
h	O
of	O
estrogen	B-CHEMICAL
pre	O
-	O
treatment	O
was	O
required	O
to	O
elicit	O
protection	O
,	O
an	O
effect	O
that	O
was	O
blocked	O
by	O
the	O
ER	B-GENE-Y
antagonist	O
,	O
ICI	B-CHEMICAL
182	I-CHEMICAL
,	I-CHEMICAL
780	I-CHEMICAL
.	O

Moreover	O
,	O
ERalpha	B-GENE-Y
mediated	O
the	O
protection	O
afforded	O
by	O
estrogen	B-CHEMICAL
since	O
only	O
the	O
ERalpha	B-GENE-Y
agonist	O
,	O
HPTE	O
,	O
but	O
not	O
the	O
ERbeta	B-GENE-Y
agonist	O
,	O
DPN	B-CHEMICAL
,	O
protected	O
against	O
dopamine	B-CHEMICAL
cell	O
loss	O
.	O

Since	O
glial	O
cells	O
were	O
shown	O
to	O
express	O
significant	O
levels	O
of	O
ERalpha	B-GENE-Y
,	O
we	O
investigated	O
a	O
possible	O
indirect	O
mechanism	O
of	O
estrogen	B-CHEMICAL
-	O
mediated	O
neuroprotection	O
through	O
glial	O
cell	O
interaction	O
.	O

Removal	O
of	O
glial	O
cells	O
from	O
the	O
cultures	O
by	O
application	O
of	O
the	O
mitotic	O
inhibitor	O
,	O
5	B-CHEMICAL
-	I-CHEMICAL
fluoro	I-CHEMICAL
-	I-CHEMICAL
2	I-CHEMICAL
'	I-CHEMICAL
-	I-CHEMICAL
deoxyuridine	I-CHEMICAL
,	O
significantly	O
reduced	O
the	O
neuroprotective	O
effects	O
of	O
estrogen	B-CHEMICAL
.	O

These	O
data	O
indicate	O
that	O
neuroprotection	O
provided	O
by	O
estrogen	B-CHEMICAL
against	O
MPP	B-CHEMICAL
(	I-CHEMICAL
+	I-CHEMICAL
)	I-CHEMICAL
toxicity	O
is	O
mediated	O
by	O
ERalpha	B-GENE-Y
and	O
involves	O
an	O
interplay	O
among	O
at	O
least	O
two	O
cell	O
types	O
.	O

Differential	O
activation	O
of	O
cAMP	B-GENE-N
response	I-GENE-N
element	I-GENE-N
binding	I-GENE-N
protein	I-GENE-N
in	O
discrete	O
nucleus	O
accumbens	O
subregions	O
during	O
early	O
and	O
late	O
cocaine	B-CHEMICAL
sensitization	O
.	O

The	O
present	O
study	O
examined	O
the	O
differential	O
cocaine	B-CHEMICAL
-	O
induced	O
activation	O
of	O
the	O
cyclic	B-GENE-N
adenosine	I-GENE-N
monophosphate	I-GENE-N
(	I-GENE-N
cAMP	I-GENE-N
)	I-GENE-N
response	I-GENE-N
element	I-GENE-N
binding	I-GENE-N
protein	I-GENE-N
(	O
CREB	B-GENE-N
)	O
throughout	O
discrete	O
zones	O
of	O
analysis	O
of	O
the	O
nucleus	O
accumbens	O
(	O
NAc	O
)	O
in	O
rats	O
.	O

CREB	B-GENE-N
-	O
dependent	O
gene	O
transcription	O
,	O
which	O
may	O
underlie	O
long	O
-	O
lasting	O
drug	O
-	O
induced	O
changes	O
in	O
behavior	O
and	O
the	O
subjective	O
effects	O
of	O
cocaine	B-CHEMICAL
,	O
varies	O
depending	O
on	O
the	O
stage	O
of	O
drug	O
exposure	O
or	O
withdrawal	O
and	O
the	O
cell	O
population	O
involved	O
.	O

Using	O
immunohistochemistry	O
,	O
the	O
authors	O
analyzed	O
changes	O
in	O
CREB	B-GENE-N
phosphorylation	O
in	O
the	O
NAc	O
after	O
5	O
days	O
of	O
cocaine	B-CHEMICAL
,	O
a	O
short	O
or	O
long	O
drug	O
-	O
free	O
period	O
,	O
and	O
a	O
subsequent	O
challenge	O
injection	O
.	O

The	O
NAc	O
shell	O
was	O
separated	O
into	O
5	O
zones	O
of	O
analysis	O
previously	O
defined	O
by	O
neurochemistry	O
and	O
connectivity	O
.	O

Repeated	O
cocaine	B-CHEMICAL
resulted	O
in	O
CREB	B-GENE-N
phosphorylation	O
in	O
all	O
analyzed	O
subregions	O
of	O
the	O
NAc	O
excluding	O
the	O
most	O
ventrolateral	O
region	O
of	O
the	O
shell	O
2	O
weeks	O
after	O
cessation	O
of	O
repeated	O
cocaine	B-CHEMICAL
,	O
but	O
rats	O
challenged	O
after	O
2	O
drug	O
-	O
free	O
days	O
yielded	O
a	O
more	O
localized	O
activation	O
of	O
CREB	B-GENE-N
in	O
the	O
3	O
most	O
dorsomedial	O
zones	O
of	O
the	O
shell	O
.	O

The	O
temporal	O
and	O
anatomical	O
determinants	O
of	O
cocaine	B-CHEMICAL
-	O
induced	O
CREB	B-GENE-N
activity	O
may	O
indicate	O
functional	O
differences	O
among	O
NAc	O
shell	O
subregions	O
and	O
suggest	O
the	O
involvement	O
of	O
CREB	B-GENE-N
in	O
early	O
and	O
late	O
cocaine	B-CHEMICAL
effects	O
.	O

Fatal	O
hemorrhage	O
in	O
mice	O
lacking	O
gamma	B-GENE-Y
-	I-GENE-Y
glutamyl	I-GENE-Y
carboxylase	I-GENE-Y
.	O

The	O
carboxylation	O
of	O
glutamic	B-CHEMICAL
acid	I-CHEMICAL
residues	O
to	O
gamma	B-CHEMICAL
-	I-CHEMICAL
carboxyglutamic	I-CHEMICAL
acid	I-CHEMICAL
(	O
Gla	B-CHEMICAL
)	O
by	O
the	O
vitamin	B-GENE-Y
K	I-GENE-Y
-	I-GENE-Y
dependent	I-GENE-Y
gamma	I-GENE-Y
-	I-GENE-Y
glutamyl	I-GENE-Y
carboxylase	I-GENE-Y
(	O
gamma	B-GENE-Y
-	I-GENE-Y
carboxylase	I-GENE-Y
)	O
is	O
an	O
essential	O
posttranslational	O
modification	O
required	O
for	O
the	O
biological	O
activity	O
of	O
a	O
number	O
of	O
proteins	O
,	O
including	O
proteins	O
involved	O
in	O
blood	O
coagulation	O
and	O
its	O
regulation	O
.	O

Heterozygous	O
mice	O
carrying	O
a	O
null	O
mutation	O
at	O
the	O
gamma	B-GENE-Y
-	I-GENE-Y
carboxylase	I-GENE-Y
(	O
Ggcx	B-GENE-Y
)	O
gene	O
exhibit	O
normal	O
development	O
and	O
survival	O
with	O
no	O
evidence	O
of	O
hemorrhage	O
and	O
normal	O
functional	O
activity	O
of	O
the	O
vitamin	B-GENE-N
K	I-GENE-N
-	I-GENE-N
dependent	I-GENE-N
clotting	I-GENE-N
factors	I-GENE-N
IX	I-GENE-N
,	I-GENE-N
X	I-GENE-N
,	O
and	O
prothrombin	B-GENE-Y
.	O

Analysis	O
of	O
a	O
Ggcx	B-GENE-Y
(	O
+	O
/	O
-	O
)	O
intercross	O
revealed	O
a	O
partial	O
developmental	O
block	O
with	O
only	O
50	O
%	O
of	O
expected	O
Ggcx	B-GENE-Y
(	O
-	O
/	O
-	O
)	O
offspring	O
surviving	O
to	O
term	O
,	O
with	O
the	O
latter	O
animals	O
dying	O
uniformly	O
at	O
birth	O
of	O
massive	O
intra	O
-	O
abdominal	O
hemorrhage	O
.	O

This	O
phenotype	O
closely	O
resembles	O
the	O
partial	O
midembryonic	O
loss	O
and	O
postnatal	O
hemorrhage	O
previously	O
reported	O
for	O
both	O
prothrombin	B-GENE-Y
-	O
and	O
factor	B-GENE-Y
V	I-GENE-Y
(	O
F5	B-GENE-Y
)	O
-	O
deficient	O
mice	O
.	O

These	O
data	O
exclude	O
the	O
existence	O
of	O
a	O
redundant	O
carboxylase	B-GENE-N
pathway	O
and	O
suggest	O
that	O
functionally	O
critical	O
substrates	O
for	O
gamma	O
-	O
carboxylation	O
,	O
at	O
least	O
in	O
the	O
developing	O
embryo	O
and	O
neonate	O
,	O
are	O
primarily	O
restricted	O
to	O
components	O
of	O
the	O
blood	O
coagulation	O
cascade	O
.	O

Levels	O
of	O
2	B-CHEMICAL
-	I-CHEMICAL
thiothiazolidine	I-CHEMICAL
-	I-CHEMICAL
4	I-CHEMICAL
-	I-CHEMICAL
carboxylic	I-CHEMICAL
acid	I-CHEMICAL
(	O
TTCA	B-CHEMICAL
)	O
and	O
effect	O
modification	O
of	O
polymorphisms	O
of	O
glutathione	B-CHEMICAL
-	O
related	O
genes	O
in	O
vulcanization	O
workers	O
in	O
the	O
southern	O
Sweden	O
rubber	O
industries	O
.	O

OBJECTIVES	O
:	O
Workers	O
in	O
the	O
rubber	O
industry	O
are	O
exposed	O
to	O
a	O
complex	O
mixture	O
of	O
hazardous	O
substances	O
and	O
have	O
increased	O
risk	O
of	O
developing	O
several	O
diseases	O
.	O

However	O
,	O
there	O
is	O
no	O
up	O
to	O
date	O
survey	O
examining	O
the	O
exposure	O
in	O
the	O
Swedish	O
rubber	O
industry	O
.	O

One	O
of	O
the	O
toxic	O
compounds	O
in	O
the	O
industry	O
is	O
carbon	O
disulfide	O
(	O
CS	O
(	O
2	O
)	O
)	O
,	O
which	O
is	O
biotransformed	O
to	O
2	B-CHEMICAL
-	I-CHEMICAL
thiothiazolidine	I-CHEMICAL
-	I-CHEMICAL
4	I-CHEMICAL
-	I-CHEMICAL
carboxylic	I-CHEMICAL
acid	I-CHEMICAL
(	O
TTCA	B-CHEMICAL
)	O
.	O

TTCA	B-CHEMICAL
is	O
used	O
as	O
a	O
biomarker	O
of	O
CS	O
(	O
2	O
)	O
exposure	O
,	O
but	O
there	O
seem	O
to	O
exist	O
inter	O
-	O
and	O
intraindividual	O
variability	O
;	O
which	O
could	O
partly	O
be	O
due	O
to	O
genetic	O
variation	O
.	O

The	O
aim	O
of	O
the	O
study	O
was	O
to	O
determine	O
TTCA	B-CHEMICAL
levels	O
and	O
the	O
modifying	O
effects	O
of	O
glutathione	B-CHEMICAL
-	O
related	O
genes	O
in	O
a	O
group	O
of	O
Swedish	O
rubber	O
workers	O
.	O

METHODS	O
:	O
Urine	O
was	O
collected	O
from	O
both	O
exposed	O
workers	O
and	O
controls	O
during	O
the	O
last	O
4	O
h	O
of	O
the	O
work	O
shift	O
.	O

The	O
level	O
of	O
TTCA	B-CHEMICAL
in	O
urine	O
was	O
analyzed	O
by	O
liquid	O
chromatograpy	O
tandem	O
mass	O
spectrometry	O
.	O

Genotyping	O
of	O
the	O
single	O
nucleotide	B-CHEMICAL
polymorphisms	O
GCLC	B-GENE-Y
-	O
129	O
,	O
GCLM	B-GENE-Y
-	O
588	O
,	O
GSTA1	B-GENE-Y
-	O
52	O
,	O
GSTP1	B-GENE-Y
-	O
105	O
and	O
GSTP1	B-GENE-Y
-	O
114	O
and	O
deletions	O
of	O
GSTM1	B-GENE-Y
and	O
GSTT1	B-GENE-Y
were	O
performed	O
with	O
real	O
-	O
time	O
PCR	O
or	O
ordinary	O
PCR	O
and	O
subsequent	O
agarose	O
electrophoresis	O
.	O

RESULTS	O
:	O
The	O
highest	O
levels	O
of	O
TTCA	B-CHEMICAL
were	O
found	O
among	O
workers	O
curing	O
with	O
salt	O
bath	O
,	O
hot	O
air	O
,	O
microwaves	O
or	O
fluid	O
-	O
bed	O
,	O
and	O
lower	O
levels	O
were	O
found	O
among	O
workers	O
curing	O
with	O
injection	O
and	O
compression	O
molding	O
.	O

Furthermore	O
,	O
with	O
respect	O
to	O
GSTM1	B-GENE-Y
and	O
GSTT1	B-GENE-Y
there	O
were	O
statistically	O
significant	O
differences	O
in	O
TTCA	B-CHEMICAL
-	O
levels	O
between	O
genotypes	O
among	O
exposed	O
workers	O
but	O
not	O
among	O
controls	O
.	O

The	O
other	O
five	O
polymorphisms	O
had	O
no	O
impact	O
on	O
the	O
TTCA	B-CHEMICAL
levels	O
.	O

CONCLUSIONS	O
:	O
The	O
present	O
study	O
demonstrates	O
relatively	O
high	O
levels	O
of	O
TTCA	B-CHEMICAL
in	O
urine	O
from	O
Swedish	O
rubber	O
workers	O
.	O

Polymorphisms	O
in	O
GSTM1	B-GENE-Y
and	O
GSTT1	B-GENE-Y
modify	O
the	O
levels	O
.	O

H3	B-GENE-Y
histamine	I-GENE-Y
receptor	I-GENE-Y
agonist	O
inhibits	O
biliary	O
growth	O
of	O
BDL	O
rats	O
by	O
downregulation	O
of	O
the	O
cAMP	B-GENE-N
-	I-GENE-N
dependent	I-GENE-N
PKA	I-GENE-N
/	O
ERK1	B-GENE-N
/	I-GENE-N
2	I-GENE-N
/	O
ELK	B-GENE-Y
-	I-GENE-Y
1	I-GENE-Y
pathway	O
.	O

Histamine	B-CHEMICAL
regulates	O
many	O
functions	O
by	O
binding	O
to	O
four	O
histamine	B-GENE-N
G	I-GENE-N
-	I-GENE-N
coupled	I-GENE-N
receptor	I-GENE-N
proteins	I-GENE-N
(	O
H1R	B-GENE-Y
,	O
H2R	B-GENE-Y
,	O
H3R	B-GENE-Y
and	O
H4R	B-GENE-Y
)	O
.	O

As	O
H3R	B-GENE-N
exerts	O
their	O
effects	O
by	O
coupling	O
to	O
Galpha	B-GENE-N
(	I-GENE-N
i	I-GENE-N
/	I-GENE-N
o	I-GENE-N
)	I-GENE-N
proteins	O
reducing	O
adenosine	B-CHEMICAL
3	I-CHEMICAL
'	I-CHEMICAL
,	I-CHEMICAL
5	I-CHEMICAL
'	I-CHEMICAL
-	I-CHEMICAL
monophosphate	I-CHEMICAL
(	O
cAMP	B-CHEMICAL
)	O
levels	O
(	O
a	O
key	O
player	O
in	O
the	O
modulation	O
of	O
cholangiocyte	O
hyperplasia	O
/	O
damage	O
)	O
,	O
we	O
evaluated	O
the	O
role	O
of	O
H3R	B-GENE-Y
in	O
the	O
regulation	O
of	O
biliary	O
growth	O
.	O

We	O
posed	O
the	O
following	O
questions	O
:	O
(	O
1	O
)	O
Do	O
cholangiocytes	O
express	O
H3R	B-GENE-N
?	O

(	O
2	O
)	O
Does	O
in	O
vivo	O
administration	O
of	O
(	B-CHEMICAL
R	I-CHEMICAL
)	I-CHEMICAL
-	I-CHEMICAL
(	I-CHEMICAL
alpha	I-CHEMICAL
)	I-CHEMICAL
-	I-CHEMICAL
(	I-CHEMICAL
-	I-CHEMICAL
)	I-CHEMICAL
-	I-CHEMICAL
methylhistamine	I-CHEMICAL
dihydrobromide	I-CHEMICAL
(	O
RAMH	B-CHEMICAL
)	O
(	O
H3R	B-GENE-Y
agonist	O
)	O
,	O
thioperamide	B-CHEMICAL
maleate	I-CHEMICAL
(	O
H3R	B-GENE-Y
antagonist	O
)	O
or	O
histamine	B-CHEMICAL
,	O
in	O
the	O
absence	O
/	O
presence	O
of	O
thioperamide	B-CHEMICAL
maleate	I-CHEMICAL
,	O
to	O
bile	O
duct	O
ligated	O
(	O
BDL	O
)	O
rats	O
regulate	O
cholangiocyte	O
proliferation	O
?	O
and	O
(	O
3	O
)	O
Does	O
RAMH	B-CHEMICAL
inhibit	O
cholangiocyte	O
proliferation	O
by	O
downregulation	O
of	O
cAMP	B-CHEMICAL
-	O
dependent	O
phosphorylation	O
of	O
protein	B-GENE-N
kinase	I-GENE-N
A	I-GENE-N
(	O
PKA	B-GENE-N
)	O
/	O
extracellular	B-GENE-N
signal	I-GENE-N
-	I-GENE-N
regulated	I-GENE-N
kinase	I-GENE-N
1	I-GENE-N
/	I-GENE-N
2	I-GENE-N
(	O
ERK1	B-GENE-N
/	I-GENE-N
2	I-GENE-N
)	O
/	O
ets	B-GENE-Y
-	I-GENE-Y
like	I-GENE-Y
gene	I-GENE-Y
-	I-GENE-Y
1	I-GENE-Y
(	O
Elk	B-GENE-Y
-	I-GENE-Y
1	I-GENE-Y
)	O
?	O

The	O
expression	O
of	O
H3R	B-GENE-Y
was	O
evaluated	O
in	O
liver	O
sections	O
by	O
immunohistochemistry	O
and	O
immunofluorescence	O
,	O
and	O
by	O
real	O
-	O
time	O
PCR	O
in	O
cholangiocyte	O
RNA	O
from	O
normal	O
and	O
BDL	O
rats	O
.	O

BDL	O
rats	O
(	O
immediately	O
after	O
BDL	O
)	O
were	O
treated	O
daily	O
with	O
RAMH	B-CHEMICAL
,	O
thioperamide	B-CHEMICAL
maleate	I-CHEMICAL
or	O
histamine	B-CHEMICAL
in	O
the	O
absence	O
/	O
presence	O
of	O
thioperamide	B-CHEMICAL
maleate	I-CHEMICAL
for	O
1	O
week	O
.	O

Following	O
in	O
vivo	O
treatment	O
of	O
BDL	O
rats	O
with	O
RAMH	B-CHEMICAL
for	O
1	O
week	O
,	O
and	O
in	O
vitro	O
stimulation	O
of	O
BDL	O
cholangiocytes	O
with	O
RAMH	B-CHEMICAL
,	O
we	O
evaluated	O
cholangiocyte	O
proliferation	O
,	O
cAMP	B-CHEMICAL
levels	O
and	O
PKA	B-GENE-N
,	O
ERK1	B-GENE-N
/	I-GENE-N
2	I-GENE-N
and	O
Elk	B-GENE-Y
-	I-GENE-Y
1	I-GENE-Y
phosphorylation	O
.	O

Cholangiocytes	O
from	O
normal	O
and	O
BDL	O
rats	O
express	O
H3R	B-GENE-Y
.	O

The	O
expression	O
of	O
H3R	B-GENE-Y
mRNA	O
increased	O
in	O
BDL	O
compared	O
to	O
normal	O
cholangiocytes	O
.	O

Histamine	B-CHEMICAL
decreased	O
cholangiocyte	O
growth	O
of	O
BDL	O
rats	O
to	O
a	O
lower	O
extent	O
than	O
that	O
observed	O
in	O
BDL	O
RAMH	B-CHEMICAL
-	O
treated	O
rats	O
;	O
histamine	B-CHEMICAL
-	O
induced	O
inhibition	O
of	O
cholangiocyte	O
growth	O
was	O
partly	O
blocked	O
by	O
thioperamide	B-CHEMICAL
maleate	I-CHEMICAL
.	O

In	O
BDL	O
rats	O
treated	O
with	O
thioperamide	B-CHEMICAL
maleate	I-CHEMICAL
,	O
cholangiocyte	O
hyperplasia	O
was	O
slightly	O
higher	O
than	O
that	O
of	O
BDL	O
rats	O
.	O

In	O
vitro	O
,	O
RAMH	B-CHEMICAL
inhibited	O
the	O
proliferation	O
of	O
BDL	O
cholangiocytes	O
.	O

RAMH	B-CHEMICAL
inhibition	O
of	O
cholangiocyte	O
growth	O
was	O
associated	O
with	O
decreased	O
cAMP	B-CHEMICAL
levels	O
and	O
PKA	B-GENE-N
/	O
ERK1	B-GENE-N
/	I-GENE-N
2	I-GENE-N
/	O
Elk	B-GENE-Y
-	I-GENE-Y
1	I-GENE-Y
phosphorylation	O
.	O

Downregulation	O
of	O
cAMP	B-CHEMICAL
-	O
dependent	O
PKA	B-GENE-N
/	O
ERK1	B-GENE-N
/	I-GENE-N
2	I-GENE-N
/	O
Elk	B-GENE-Y
-	I-GENE-Y
1	I-GENE-Y
phosphorylation	O
(	O
by	O
activation	O
of	O
H3R	B-GENE-Y
)	O
is	O
important	O
in	O
the	O
inhibition	O
of	O
cholangiocyte	O
growth	O
in	O
liver	O
diseases	O
.	O

Structure	O
and	O
kinetics	O
of	O
monofunctional	O
proline	B-GENE-Y
dehydrogenase	I-GENE-Y
from	O
Thermus	O
thermophilus	O
.	O

Proline	B-GENE-Y
dehydrogenase	I-GENE-Y
(	O
PRODH	B-GENE-Y
)	O
and	O
Delta	B-GENE-Y
(	I-GENE-Y
1	I-GENE-Y
)	I-GENE-Y
-	I-GENE-Y
pyrroline	I-GENE-Y
-	I-GENE-Y
5	I-GENE-Y
-	I-GENE-Y
carboxylate	I-GENE-Y
dehydrogenase	I-GENE-Y
(	O
P5CDH	B-GENE-Y
)	O
catalyze	O
the	O
two	O
-	O
step	O
oxidation	O
of	O
proline	B-CHEMICAL
to	O
glutamate	B-CHEMICAL
.	O

They	O
are	O
distinct	O
monofunctional	O
enzymes	O
in	O
all	O
eukaryotes	O
and	O
some	O
bacteria	O
but	O
are	O
fused	O
into	O
bifunctional	O
enzymes	O
known	O
as	O
proline	B-GENE-N
utilization	I-GENE-N
A	I-GENE-N
(	O
PutA	B-GENE-N
)	O
in	O
other	O
bacteria	O
.	O

Here	O
we	O
report	O
the	O
first	O
structure	O
and	O
biochemical	O
data	O
for	O
a	O
monofunctional	O
PRODH	B-GENE-Y
.	O

The	O
2	O
.	O
0	O
-	O
A	O
resolution	O
structure	O
of	O
Thermus	B-GENE-Y
thermophilus	I-GENE-Y
PRODH	I-GENE-Y
reveals	O
a	O
distorted	O
(	B-GENE-N
betaalpha	I-GENE-N
)	I-GENE-N
(	I-GENE-N
8	I-GENE-N
)	I-GENE-N
barrel	I-GENE-N
catalytic	I-GENE-N
core	I-GENE-N
domain	I-GENE-N
and	O
a	O
hydrophobic	B-GENE-N
alpha	I-GENE-N
-	I-GENE-N
helical	I-GENE-N
domain	I-GENE-N
located	O
above	O
the	O
carboxyl	B-CHEMICAL
-	O
terminal	O
ends	O
of	O
the	O
strands	O
of	O
the	O
barrel	O
.	O

Although	O
the	O
catalytic	O
core	O
is	O
similar	O
to	O
that	O
of	O
the	O
PutA	B-GENE-N
PRODH	I-GENE-N
domain	I-GENE-N
,	O
the	O
FAD	O
conformation	O
of	O
T	B-GENE-Y
.	I-GENE-Y
thermophilus	I-GENE-Y
PRODH	I-GENE-Y
is	O
remarkably	O
different	O
and	O
likely	O
reflects	O
unique	O
requirements	O
for	O
membrane	O
association	O
and	O
communication	O
with	O
P5CDH	B-GENE-Y
.	O

Also	O
,	O
the	O
FAD	O
of	O
T	B-GENE-Y
.	I-GENE-Y
thermophilus	I-GENE-Y
PRODH	I-GENE-Y
is	O
highly	O
solvent	O
-	O
exposed	O
compared	O
with	O
PutA	B-GENE-N
due	O
to	O
a	O
4	O
-	O
A	O
shift	O
of	O
helix	O
8	O
.	O

Structure	O
-	O
based	O
sequence	O
analysis	O
of	O
the	O
PutA	B-GENE-N
/	O
PRODH	B-GENE-Y
family	O
led	O
us	O
to	O
identify	O
nine	O
conserved	O
motifs	O
involved	O
in	O
cofactor	O
and	O
substrate	O
recognition	O
.	O

Biochemical	O
studies	O
show	O
that	O
the	O
midpoint	O
potential	O
of	O
the	O
FAD	O
is	O
-	O
75	O
mV	O
and	O
the	O
kinetic	O
parameters	O
for	O
proline	O
are	O
K	O
(	O
m	O
)	O
=	O
27	O
mm	O
and	O
k	O
(	O
cat	O
)	O
=	O
13	O
s	O
(	O
-	O
1	O
)	O
.	O

3	B-CHEMICAL
,	I-CHEMICAL
4	I-CHEMICAL
-	I-CHEMICAL
Dehydro	I-CHEMICAL
-	I-CHEMICAL
l	I-CHEMICAL
-	I-CHEMICAL
proline	I-CHEMICAL
was	O
found	O
to	O
be	O
an	O
efficient	O
substrate	O
,	O
and	O
l	B-CHEMICAL
-	I-CHEMICAL
tetrahydro	I-CHEMICAL
-	I-CHEMICAL
2	I-CHEMICAL
-	I-CHEMICAL
furoic	I-CHEMICAL
acid	I-CHEMICAL
is	O
a	O
competitive	O
inhibitor	O
(	O
K	O
(	O
I	O
)	O
=	O
1	O
.	O
0	O
mm	O
)	O
.	O

Finally	O
,	O
we	O
demonstrate	O
that	O
T	B-GENE-Y
.	I-GENE-Y
thermophilus	I-GENE-Y
PRODH	I-GENE-Y
reacts	O
with	O
O	B-CHEMICAL
(	I-CHEMICAL
2	I-CHEMICAL
)	I-CHEMICAL
producing	O
superoxide	B-CHEMICAL
.	O

This	O
is	O
significant	O
because	O
superoxide	B-CHEMICAL
production	O
underlies	O
the	O
role	O
of	O
human	B-GENE-Y
PRODH	I-GENE-Y
in	O
p53	B-GENE-Y
-	O
mediated	O
apoptosis	O
,	O
implying	O
commonalities	O
between	O
eukaryotic	B-GENE-N
and	I-GENE-N
bacterial	I-GENE-N
monofunctional	I-GENE-N
PRODHs	I-GENE-N
.	O

Creatine	B-CHEMICAL
uptake	O
in	O
brain	O
and	O
skeletal	O
muscle	O
of	O
mice	O
lacking	O
guanidinoacetate	B-GENE-Y
methyltransferase	I-GENE-Y
assessed	O
by	O
magnetic	O
resonance	O
spectroscopy	O
.	O

Creatine	B-CHEMICAL
(	O
Cr	B-CHEMICAL
)	O
levels	O
in	O
skeletal	O
muscle	O
and	O
brain	O
of	O
a	O
mouse	O
model	O
of	O
Cr	B-CHEMICAL
deficiency	O
caused	O
by	O
guanidinoacetate	B-GENE-Y
methyltransferase	I-GENE-Y
absence	O
(	O
GAMT	B-GENE-Y
-	O
/	O
-	O
)	O
were	O
studied	O
after	O
Cr	B-CHEMICAL
supplementation	O
with	O
2	O
g	O
.	O
kg	O
body	O
wt	O
-	O
1	O
.	O
day	O
-	O
1	O
Cr	B-CHEMICAL
for	O
35	O
days	O
.	O

Localized	O
1H	B-CHEMICAL
magnetic	O
resonance	O
spectroscopy	O
(	O
MRS	O
)	O
was	O
performed	O
in	O
brain	O
(	O
cerebellum	O
and	O
thalamus	O
/	O
hippocampus	O
)	O
and	O
in	O
hind	O
leg	O
muscle	O
of	O
GAMT	B-GENE-Y
-	O
/	O
-	O
mice	O
before	O
and	O
after	O
Cr	B-CHEMICAL
supplementation	O
and	O
in	O
control	O
(	O
Con	O
)	O
mice	O
.	O

As	O
expected	O
,	O
a	O
signal	O
for	O
Cr	B-CHEMICAL
was	O
hardly	O
detectable	O
in	O
MR	O
spectra	O
of	O
GAMT	B-GENE-Y
-	O
/	O
-	O
mice	O
before	O
Cr	B-CHEMICAL
supplementation	O
.	O

In	O
the	O
thalamus	O
/	O
hippocampus	O
region	O
of	O
these	O
mice	O
,	O
an	O
increase	O
in	O
N	B-CHEMICAL
-	I-CHEMICAL
acetylasparate	I-CHEMICAL
(	O
NAA	B-CHEMICAL
)	O
was	O
observed	O
.	O

During	O
Cr	B-CHEMICAL
administration	O
,	O
Cr	B-CHEMICAL
levels	O
increased	O
faster	O
in	O
skeletal	O
muscle	O
compared	O
with	O
brain	O
,	O
but	O
this	O
occurred	O
only	O
during	O
the	O
first	O
day	O
of	O
supplementation	O
.	O

Thereafter	O
,	O
Cr	B-CHEMICAL
levels	O
increased	O
by	O
0	O
.	O
8	O
mM	O
/	O
day	O
in	O
all	O
studied	O
locations	O
.	O

After	O
35	O
days	O
of	O
Cr	B-CHEMICAL
supplementation	O
,	O
Cr	B-CHEMICAL
levels	O
in	O
all	O
locations	O
were	O
higher	O
compared	O
with	O
Con	O
mice	O
on	O
a	O
Cr	B-CHEMICAL
-	O
free	O
diet	O
and	O
NAA	B-CHEMICAL
levels	O
normalized	O
.	O

Only	O
because	O
of	O
the	O
repeated	O
MRS	O
measurements	O
performed	O
in	O
this	O
longitudinal	O
Cr	B-CHEMICAL
supplementation	O
study	O
on	O
GAMT	B-GENE-Y
-	O
/	O
-	O
mice	O
were	O
we	O
able	O
to	O
discover	O
the	O
initial	O
faster	O
uptake	O
of	O
Cr	B-CHEMICAL
in	O
skeletal	O
muscle	O
compared	O
with	O
brain	O
,	O
which	O
may	O
represent	O
muscular	O
Cr	B-CHEMICAL
uptake	O
independent	O
of	O
Cr	B-CHEMICAL
transporter	O
expression	O
.	O

Our	O
results	O
can	O
provide	O
the	O
basis	O
for	O
additional	O
experiments	O
to	O
optimize	O
Cr	B-CHEMICAL
supplementation	O
in	O
GAMT	B-GENE-Y
deficiency	O
,	O
as	O
increases	O
in	O
brain	O
Cr	B-CHEMICAL
are	O
slow	O
in	O
patients	O
after	O
Cr	B-CHEMICAL
supplementation	O
.	O

Highly	O
selective	O
phosphodiesterase	B-GENE-N
4	I-GENE-N
inhibitors	O
for	O
the	O
treatment	O
of	O
allergic	O
skin	O
diseases	O
and	O
psoriasis	O
.	O

The	O
phosphodiesterase	B-GENE-N
(	I-GENE-N
PDE	I-GENE-N
)	I-GENE-N
4	I-GENE-N
is	O
the	O
predominant	O
cyclic	B-CHEMICAL
AMP	I-CHEMICAL
degrading	O
enzyme	O
in	O
a	O
variety	O
of	O
inflammatory	O
cells	O
including	O
eosinophils	O
,	O
neutrophils	O
,	O
macrophages	O
,	O
T	O
cells	O
and	O
monocytes	O
.	O

In	O
addition	O
,	O
this	O
enzyme	O
is	O
expressed	O
in	O
non	O
-	O
immune	O
cells	O
such	O
as	O
keratinocytes	O
and	O
fibroblasts	O
.	O

Highly	O
selective	O
PDE4	B-GENE-N
inhibitors	O
are	O
currently	O
under	O
evaluation	O
for	O
the	O
treatment	O
of	O
asthma	O
and	O
/	O
or	O
chronic	O
obstructive	O
pulmonary	O
disease	O
.	O

Due	O
to	O
the	O
broad	O
anti	O
-	O
inflammatory	O
/	O
immuno	O
-	O
modulatory	O
action	O
of	O
PDE4	B-GENE-N
inhibitors	O
,	O
it	O
has	O
been	O
proposed	O
that	O
PDE4	B-GENE-N
inhibitors	O
might	O
also	O
be	O
efficacious	O
for	O
skin	O
disorders	O
such	O
as	O
atopic	O
dermatitis	O
.	O

Consequently	O
,	O
PDE4	B-GENE-N
inhibitors	O
including	O
cilomilast	B-CHEMICAL
and	O
AWD	B-CHEMICAL
12	I-CHEMICAL
-	I-CHEMICAL
281	I-CHEMICAL
have	O
been	O
tested	O
in	O
several	O
models	O
of	O
allergic	O
and	O
irritant	O
skin	O
inflammation	O
.	O

These	O
PDE4	B-GENE-N
inhibitors	O
displayed	O
strong	O
anti	O
-	O
inflammatory	O
action	O
in	O
models	O
of	O
allergic	O
contact	O
dermatitis	O
in	O
mice	O
,	O
in	O
the	O
arachidonic	B-CHEMICAL
acid	I-CHEMICAL
induced	O
skin	O
inflammation	O
in	O
mice	O
and	O
in	O
ovalbumin	B-GENE-Y
sensitised	O
guinea	O
pigs	O
.	O

The	O
determination	O
of	O
cytokines	B-GENE-N
in	O
skin	O
homogenates	O
revealed	O
that	O
both	O
Th1	O
as	O
well	O
as	O
Th2	O
cytokines	B-GENE-N
are	O
suppressed	O
by	O
PDE4	B-GENE-N
inhibitors	O
,	O
indicating	O
an	O
anti	O
-	O
inflammatory	O
activity	O
in	O
both	O
the	O
Th2	O
dominated	O
acute	O
phase	O
as	O
well	O
as	O
the	O
Th1	O
dominated	O
chronic	O
phase	O
of	O
atopic	O
dermatitis	O
.	O

Due	O
to	O
the	O
suppression	O
of	O
Th1	O
cytokines	B-GENE-N
,	O
activity	O
can	O
also	O
be	O
expected	O
in	O
psoriasis	O
.	O

Results	O
of	O
early	O
clinical	O
trials	O
with	O
both	O
topically	O
(	O
cipamfylline	B-CHEMICAL
,	O
CP80	B-CHEMICAL
,	I-CHEMICAL
633	I-CHEMICAL
)	O
and	O
systemically	O
(	O
CC	O
-	O
10004	O
)	O
active	O
PDE4	B-GENE-N
inhibitors	O
demonstrated	O
efficacy	O
in	O
atopic	O
dermatitis	O
and	O
in	O
the	O
case	O
of	O
CC	O
-	O
10004	O
,	O
also	O
in	O
psoriasis	O
.	O

AWD	B-CHEMICAL
12	I-CHEMICAL
-	I-CHEMICAL
281	I-CHEMICAL
(	O
GW	B-CHEMICAL
842470	I-CHEMICAL
)	O
is	O
currently	O
under	O
clinical	O
evaluation	O
for	O
the	O
topical	O
treatment	O
of	O
atopic	O
dermatitis	O
.	O

Results	O
concerning	O
clinical	O
efficacy	O
of	O
this	O
potent	O
and	O
selective	O
PDE4	B-GENE-N
inhibitor	O
are	O
anxiously	O
awaited	O
.	O

Aberrant	O
regulation	O
of	O
argininosuccinate	B-GENE-Y
synthetase	I-GENE-Y
by	O
TNF	B-GENE-Y
-	I-GENE-Y
alpha	I-GENE-Y
in	O
human	O
epithelial	O
ovarian	O
cancer	O
.	O

The	O
pro	O
-	O
inflammatory	O
cytokine	B-GENE-N
,	O
tumour	B-GENE-Y
necrosis	I-GENE-Y
factor	I-GENE-Y
-	I-GENE-Y
alpha	I-GENE-Y
,	O
TNF	B-GENE-Y
-	I-GENE-Y
alpha	I-GENE-Y
,	O
is	O
dysregulated	O
in	O
malignant	O
compared	O
with	O
normal	O
ovarian	O
surface	O
epithelium	O
(	O
OSE	O
)	O
.	O

Several	O
epidemiological	O
studies	O
have	O
associated	O
inflammation	O
with	O
ovarian	O
tumorigenesis	O
,	O
with	O
TNF	B-GENE-Y
-	I-GENE-Y
alpha	I-GENE-Y
playing	O
a	O
key	O
role	O
in	O
modulating	O
invasion	O
,	O
angiogenesis	O
and	O
metastasis	O
.	O

Here	O
,	O
we	O
show	O
that	O
TNF	B-GENE-Y
-	I-GENE-Y
alpha	I-GENE-Y
also	O
induces	O
expression	O
of	O
arate	O
-	O
limiting	O
enzyme	O
in	O
arginine	B-CHEMICAL
synthesis	O
,	O
argininosuccinate	B-GENE-Y
synthetase	I-GENE-Y
(	O
AS	B-GENE-Y
)	O
,	O
thereby	O
linking	O
inflammation	O
with	O
several	O
arginine	B-CHEMICAL
-	O
dependent	O
metabolic	O
pathways	O
,	O
implicated	O
in	O
accelerated	O
carcinogenesis	O
and	O
tumour	O
progression	O
.	O

Having	O
identified	O
AS	B-GENE-Y
mRNA	O
induction	O
in	O
TNF	B-GENE-Y
-	I-GENE-Y
alpha	I-GENE-Y
-	O
treated	O
IGROV	O
-	O
1	O
ovarian	O
cancer	O
cells	O
,	O
using	O
RNA	O
-	O
arbitrarily	O
primed	O
-	O
PCR	O
,	O
we	O
then	O
observed	O
differential	O
regulation	O
of	O
AS	B-GENE-Y
mRNA	O
and	O
protein	O
in	O
malignant	O
,	O
compared	O
with	O
normal	O
,	O
OSE	O
cells	O
.	O

A	O
cDNA	O
cancer	O
profiling	O
array	O
with	O
matched	O
normal	O
ovarian	O
and	O
ovarian	O
tumour	O
samples	O
revealed	O
increased	O
expression	O
of	O
AS	B-GENE-Y
mRNA	O
in	O
the	O
latter	O
.	O

Moreover	O
,	O
AS	B-GENE-Y
protein	O
co	O
-	O
localised	O
with	O
TNF	B-GENE-Y
-	I-GENE-Y
alpha	I-GENE-Y
in	O
ovarian	O
cancer	O
cells	O
,	O
with	O
significantly	O
higher	O
levels	O
of	O
AS	B-GENE-Y
in	O
malignant	O
compared	O
with	O
normal	O
ovarian	O
tissue	O
.	O

Increased	O
co	O
-	O
expression	O
of	O
AS	B-GENE-Y
and	O
TNF	B-GENE-Y
-	I-GENE-Y
alpha	I-GENE-Y
mRNA	O
was	O
also	O
observed	O
in	O
2	O
other	O
epithelial	O
tumours	O
,	O
non	O
-	O
small	O
cell	O
lung	O
and	O
stomach	O
cancer	O
,	O
compared	O
with	O
normal	O
corresponding	O
tissues	O
.	O

In	O
summary	O
,	O
high	O
levels	O
of	O
AS	B-GENE-Y
expression	O
,	O
which	O
may	O
be	O
required	O
for	O
several	O
arginine	B-CHEMICAL
-	O
dependent	O
processes	O
in	O
cancer	O
,	O
including	O
the	O
production	O
of	O
nitric	B-CHEMICAL
oxide	I-CHEMICAL
,	O
proline	B-CHEMICAL
,	O
pyrimidines	B-CHEMICAL
and	O
polyamines	B-CHEMICAL
,	O
is	O
regulated	O
by	O
TNF	B-GENE-Y
-	I-GENE-Y
alpha	I-GENE-Y
and	O
may	O
provide	O
an	O
important	O
molecular	O
pathway	O
linking	O
inflammation	O
and	O
metabolism	O
to	O
ovarian	O
tumorigenesis	O
.	O

Mechanism	O
of	O
specific	O
membrane	O
targeting	O
by	O
C2	B-GENE-N
domains	I-GENE-N
:	O
localized	O
pools	O
of	O
target	O
lipids	O
enhance	O
Ca2	B-CHEMICAL
+	I-CHEMICAL
affinity	O
.	O

The	O
C2	B-GENE-N
domain	I-GENE-N
is	O
a	O
ubiquitous	O
,	O
conserved	O
protein	B-GENE-N
signaling	I-GENE-N
motif	I-GENE-N
widely	O
found	O
in	O
eukaryotic	O
signaling	O
proteins	O
.	O

Although	O
considerable	O
functional	O
diversity	O
exists	O
,	O
most	O
C2	B-GENE-N
domains	I-GENE-N
are	O
activated	O
by	O
Ca2	B-CHEMICAL
+	I-CHEMICAL
binding	O
and	O
then	O
dock	O
to	O
a	O
specific	O
cellular	O
membrane	O
.	O

The	O
C2	B-GENE-N
domains	I-GENE-N
of	O
protein	B-GENE-Y
kinase	I-GENE-Y
Calpha	I-GENE-Y
(	O
PKCalpha	B-GENE-Y
)	O
and	O
cytosolic	B-GENE-Y
phospholipase	I-GENE-Y
A2alpha	I-GENE-Y
(	O
cPLA2alpha	B-GENE-Y
)	O
,	O
for	O
example	O
,	O
are	O
known	O
to	O
dock	O
to	O
different	O
membrane	O
surfaces	O
during	O
an	O
intracellular	O
Ca2	B-CHEMICAL
+	I-CHEMICAL
signal	O
.	O

Ca2	B-CHEMICAL
+	I-CHEMICAL
activation	O
targets	O
the	O
PKCalpha	B-GENE-N
C2	I-GENE-N
domain	I-GENE-N
to	O
the	O
plasma	O
membrane	O
and	O
the	O
cPLA2alpha	B-GENE-N
C2	I-GENE-N
domain	I-GENE-N
to	O
the	O
internal	O
membranes	O
,	O
with	O
no	O
detectable	O
spatial	O
overlap	O
.	O

It	O
is	O
crucial	O
to	O
determine	O
how	O
such	O
targeting	O
specificity	O
is	O
achieved	O
at	O
physiological	O
bulk	O
Ca2	B-CHEMICAL
+	I-CHEMICAL
concentrations	O
that	O
during	O
a	O
typical	O
signaling	O
event	O
rarely	O
exceed	O
1	O
muM	O
.	O

For	O
the	O
isolated	O
PKCalpha	B-GENE-N
C2	I-GENE-N
domain	I-GENE-N
in	O
the	O
presence	O
of	O
physiological	O
Ca2	B-CHEMICAL
+	I-CHEMICAL
levels	O
,	O
the	O
target	O
lipids	O
phosphatidylserine	B-CHEMICAL
(	O
PS	B-CHEMICAL
)	O
and	O
phosphatidylinositol	B-CHEMICAL
-	I-CHEMICAL
4	I-CHEMICAL
,	I-CHEMICAL
5	I-CHEMICAL
-	I-CHEMICAL
bisphosphate	I-CHEMICAL
(	O
PIP2	B-CHEMICAL
)	O
are	O
together	O
sufficient	O
to	O
recruit	O
the	O
PKCalpha	B-GENE-N
C2	I-GENE-N
domain	I-GENE-N
to	O
a	O
lipid	O
mixture	O
mimicking	O
the	O
plasma	O
membrane	O
inner	O
leaflet	O
.	O

For	O
the	O
cPLA2alpha	B-GENE-N
C2	I-GENE-N
domain	I-GENE-N
,	O
the	O
target	O
lipid	O
phosphatidylcholine	B-CHEMICAL
(	O
PC	B-CHEMICAL
)	O
appears	O
to	O
be	O
sufficient	O
to	O
drive	O
membrane	O
targeting	O
to	O
an	O
internal	O
membrane	O
mimic	O
at	O
physiological	O
Ca2	B-CHEMICAL
+	I-CHEMICAL
levels	O
,	O
although	O
the	O
results	O
do	O
not	O
rule	O
out	O
a	O
second	O
,	O
unknown	O
target	O
molecule	O
.	O

Stopped	O
-	O
flow	O
kinetic	O
studies	O
provide	O
additional	O
information	O
about	O
the	O
fundamental	O
molecular	O
events	O
that	O
occur	O
during	O
Ca2	B-CHEMICAL
+	I-CHEMICAL
-	O
activated	O
membrane	O
docking	O
.	O

In	O
principle	O
,	O
C2	B-GENE-N
domain	I-GENE-N
-	O
directed	O
intracellular	O
targeting	O
,	O
which	O
requires	O
coincidence	O
detection	O
of	O
multiple	O
signals	O
(	O
Ca2	B-CHEMICAL
+	I-CHEMICAL
and	O
one	O
or	O
more	O
target	O
lipids	O
)	O
,	O
can	O
exhibit	O
two	O
different	O
mechanisms	O
:	O
messenger	O
-	O
activated	O
target	O
affinity	O
(	O
MATA	O
)	O
and	O
target	O
-	O
activated	O
messenger	O
affinity	O
(	O
TAMA	O
)	O
.	O

The	O
C2	B-GENE-N
domains	I-GENE-N
studied	O
here	O
both	O
utilize	O
the	O
TAMA	O
mechanism	O
,	O
in	O
which	O
the	O
C2	B-GENE-N
domain	I-GENE-N
Ca2	B-CHEMICAL
+	I-CHEMICAL
affinity	O
is	O
too	O
low	O
to	O
be	O
activated	O
by	O
physiological	O
Ca2	B-CHEMICAL
+	I-CHEMICAL
signals	O
in	O
most	O
regions	O
of	O
the	O
cell	O
.	O

Only	O
when	O
the	O
C2	B-GENE-N
domain	I-GENE-N
nears	O
its	O
target	O
membrane	O
,	O
which	O
provides	O
a	O
high	O
local	O
concentration	O
of	O
target	O
lipid	O
,	O
is	O
the	O
effective	O
Ca2	B-CHEMICAL
+	I-CHEMICAL
affinity	O
increased	O
by	O
the	O
coupled	O
binding	O
equilibrium	O
to	O
a	O
level	O
that	O
enables	O
substantial	O
Ca2	B-CHEMICAL
+	I-CHEMICAL
activation	O
and	O
target	O
docking	O
.	O

Overall	O
,	O
the	O
findings	O
emphasize	O
the	O
importance	O
of	O
using	O
physiological	O
ligand	O
concentrations	O
in	O
targeting	O
studies	O
because	O
super	O
-	O
physiological	O
concentrations	O
can	O
drive	O
docking	O
interactions	O
even	O
when	O
an	O
important	O
targeting	O
molecule	O
is	O
missing	O
.	O

Quantification	O
and	O
regulation	O
of	O
the	O
subcellular	O
distribution	O
of	O
bile	B-GENE-Y
acid	I-GENE-Y
coenzyme	I-GENE-Y
A	I-GENE-Y
:	I-GENE-Y
amino	I-GENE-Y
acid	I-GENE-Y
N	I-GENE-Y
-	I-GENE-Y
acyltransferase	I-GENE-Y
activity	O
in	O
rat	O
liver	O
.	O

Bile	B-GENE-Y
acid	I-GENE-Y
coenzyme	I-GENE-Y
A	I-GENE-Y
:	I-GENE-Y
amino	I-GENE-Y
acid	I-GENE-Y
N	I-GENE-Y
-	I-GENE-Y
acyltransferase	I-GENE-Y
(	O
BAT	B-GENE-Y
)	O
is	O
responsible	O
for	O
the	O
amidation	O
of	O
bile	B-CHEMICAL
acids	I-CHEMICAL
with	O
the	O
amino	B-CHEMICAL
acids	I-CHEMICAL
glycine	B-CHEMICAL
and	O
taurine	B-CHEMICAL
.	O

To	O
quantify	O
total	O
BAT	B-GENE-Y
activity	O
in	O
liver	O
subcellular	O
organelles	O
,	O
livers	O
from	O
young	O
adult	O
male	O
and	O
female	O
Sprague	O
-	O
Dawley	O
rats	O
were	O
fractionated	O
into	O
multiple	O
subcellular	O
compartments	O
.	O

In	O
male	O
and	O
female	O
rats	O
,	O
65	O
-	O
75	O
%	O
of	O
total	O
liver	O
BAT	B-GENE-Y
activity	O
was	O
found	O
in	O
the	O
cytosol	O
,	O
15	O
-	O
17	O
%	O
was	O
found	O
in	O
the	O
peroxisomes	O
,	O
and	O
5	O
-	O
10	O
%	O
was	O
found	O
in	O
the	O
heavy	O
mitochondrial	O
fraction	O
.	O

After	O
clofibrate	O
treatment	O
,	O
male	O
rats	O
displayed	O
an	O
increase	O
in	O
peroxisomal	O
BAT	B-GENE-Y
specific	O
activity	O
and	O
a	O
decrease	O
in	O
cytosolic	O
BAT	B-GENE-Y
specific	O
activity	O
,	O
whereas	O
females	O
showed	O
an	O
opposite	O
response	O
.	O

However	O
,	O
there	O
was	O
no	O
overall	O
change	O
in	O
BAT	B-GENE-Y
specific	O
activity	O
in	O
whole	O
liver	O
homogenate	O
.	O

Treatment	O
with	O
rosiglitazone	B-CHEMICAL
or	O
cholestyramine	B-CHEMICAL
had	O
no	O
effect	O
on	O
BAT	B-GENE-Y
activity	O
in	O
any	O
subcellular	O
compartment	O
.	O

These	O
experiments	O
indicate	O
that	O
the	O
majority	O
of	O
BAT	B-GENE-Y
activity	O
in	O
the	O
rat	O
liver	O
resides	O
in	O
the	O
cytosol	O
.	O

Approximately	O
15	O
%	O
of	O
BAT	B-GENE-Y
activity	O
is	O
present	O
in	O
the	O
peroxisomal	O
matrix	O
.	O

These	O
data	O
support	O
the	O
novel	O
finding	O
that	O
clofibrate	B-CHEMICAL
treatment	O
does	O
not	O
directly	O
regulate	O
BAT	B-GENE-Y
activity	O
but	O
does	O
alter	O
the	O
subcellular	O
localization	O
of	O
BAT	B-GENE-Y
.	O

Mesenchymal	O
cells	O
regulate	O
the	O
response	O
of	O
acute	O
lymphoblastic	O
leukemia	O
cells	O
to	O
asparaginase	B-GENE-N
.	O

Because	O
of	O
their	O
low	O
asparagine	B-GENE-Y
synthetase	I-GENE-Y
(	O
ASNS	B-GENE-Y
)	O
expression	O
and	O
asparagine	B-CHEMICAL
biosynthesis	O
,	O
acute	O
lymphoblastic	O
leukemia	O
(	O
ALL	O
)	O
cells	O
are	O
exquisitely	O
sensitive	O
to	O
asparagine	B-CHEMICAL
depletion	O
.	O

Consequently	O
,	O
asparaginase	B-GENE-N
is	O
a	O
major	O
component	O
of	O
ALL	O
therapy	O
,	O
but	O
the	O
mechanisms	O
regulating	O
the	O
susceptibility	O
of	O
leukemic	O
cells	O
to	O
this	O
agent	O
are	O
unclear	O
.	O

In	O
288	O
children	O
with	O
ALL	O
,	O
cellular	O
ASNS	B-GENE-Y
expression	O
was	O
more	O
likely	O
to	O
be	O
high	O
in	O
T	O
-	O
lineage	O
ALL	O
and	O
low	O
in	O
B	O
-	O
lineage	O
ALL	O
with	O
TEL	B-GENE-Y
-	O
AML1	B-GENE-Y
or	O
hyperdiploidy	O
.	O

However	O
,	O
ASNS	B-GENE-Y
expression	O
levels	O
in	O
bone	O
marrow	O
-	O
derived	O
mesenchymal	O
cells	O
(	O
MSCs	O
)	O
,	O
which	O
form	O
the	O
microenvironment	O
where	O
leukemic	O
cells	O
grow	O
,	O
were	O
on	O
average	O
20	O
times	O
higher	O
than	O
those	O
in	O
ALL	O
cells	O
.	O

MSCs	O
protected	O
ALL	O
cells	O
from	O
asparaginase	B-GENE-N
cytotoxicity	O
in	O
coculture	O
experiments	O
.	O

This	O
protective	O
effect	O
correlated	O
with	O
levels	O
of	O
ASNS	B-GENE-Y
expression	O
:	O
downregulation	O
by	O
RNA	O
interference	O
decreased	O
the	O
capacity	O
of	O
MSCs	O
to	O
protect	O
ALL	O
cells	O
from	O
asparaginase	B-GENE-N
,	O
whereas	O
enforced	O
ASNS	B-GENE-Y
expression	O
conferred	O
enhanced	O
protection	O
.	O

Asparagine	B-CHEMICAL
secretion	O
by	O
MSCs	O
was	O
directly	O
related	O
to	O
their	O
ASNS	B-GENE-Y
expression	O
levels	O
,	O
suggesting	O
a	O
mechanism	O
-	O
increased	O
concentrations	O
of	O
asparagine	B-CHEMICAL
in	O
the	O
leukemic	O
cell	O
microenvironment	O
-	O
for	O
the	O
protective	O
effects	O
we	O
observed	O
.	O

These	O
results	O
provide	O
what	O
we	O
believe	O
to	O
be	O
a	O
new	O
basis	O
for	O
understanding	O
asparaginase	B-GENE-N
resistance	O
in	O
ALL	O
and	O
indicate	O
that	O
MSC	O
niches	O
in	O
the	O
bone	O
marrow	O
can	O
form	O
a	O
safe	O
haven	O
for	O
leukemic	O
cells	O
.	O

Toxicity	O
of	O
beta	B-GENE-Y
-	I-GENE-Y
amyloid	I-GENE-Y
in	O
HEK293	O
cells	O
expressing	O
NR1	B-GENE-Y
/	O
NR2A	B-GENE-Y
or	O
NR1	B-GENE-Y
/	O
NR2B	B-GENE-Y
N	B-GENE-N
-	I-GENE-N
methyl	I-GENE-N
-	I-GENE-N
D	I-GENE-N
-	I-GENE-N
aspartate	I-GENE-N
receptor	I-GENE-N
subunits	O
.	O

Neurotoxicity	O
induced	O
by	O
beta	B-GENE-Y
-	I-GENE-Y
amyloid	I-GENE-Y
peptide	I-GENE-Y
(	O
Abeta	B-GENE-Y
)	O
involves	O
glutamate	B-CHEMICAL
toxicity	O
,	O
resulting	O
from	O
overactivation	O
of	O
N	B-GENE-N
-	I-GENE-N
methyl	I-GENE-N
-	I-GENE-N
D	I-GENE-N
-	I-GENE-N
aspartate	I-GENE-N
(	I-GENE-N
NMDA	I-GENE-N
)	I-GENE-N
receptors	I-GENE-N
and	O
elevation	O
of	O
intracellular	O
calcium	B-CHEMICAL
.	O

However	O
,	O
the	O
heterogeneity	O
of	O
the	O
NMDA	B-GENE-N
receptors	I-GENE-N
,	O
frequently	O
composed	O
of	O
NR1	B-GENE-Y
and	O
NR2A	B-GENE-N
-	I-GENE-N
D	I-GENE-N
subunits	O
,	O
has	O
been	O
less	O
studied	O
.	O

Thus	O
,	O
we	O
determined	O
the	O
contribution	O
of	O
NMDA	B-GENE-N
receptor	I-GENE-N
subtypes	O
on	O
Abeta	B-GENE-Y
(	I-GENE-Y
1	I-GENE-Y
-	I-GENE-Y
40	I-GENE-Y
)	I-GENE-Y
toxicity	O
in	O
HEK293	O
cells	O
transiently	O
expressing	O
NR1	B-GENE-Y
/	O
NR2A	B-GENE-Y
or	O
NR1	B-GENE-Y
/	O
NR2B	B-GENE-Y
subunits	O
.	O

Analysis	O
of	O
lactate	B-GENE-N
dehydrogenase	I-GENE-N
(	O
LDH	B-GENE-N
)	O
release	O
and	O
trypan	B-CHEMICAL
blue	I-CHEMICAL
exclusion	O
revealed	O
an	O
increase	O
in	O
Abeta	B-GENE-Y
(	I-GENE-Y
1	I-GENE-Y
-	I-GENE-Y
40	I-GENE-Y
)	I-GENE-Y
toxicity	O
upon	O
NR1	B-GENE-Y
/	O
NR2A	B-GENE-Y
expression	O
,	O
compared	O
to	O
NR1	B-GENE-Y
/	O
NR2B	B-GENE-Y
,	O
indicating	O
loss	O
of	O
plasma	O
membrane	O
integrity	O
.	O

Furthermore	O
,	O
Abeta	B-GENE-Y
(	I-GENE-Y
1	I-GENE-Y
-	I-GENE-Y
40	I-GENE-Y
)	I-GENE-Y
decreased	O
intracellular	O
ATP	B-CHEMICAL
in	O
cells	O
expressing	O
NR1	B-GENE-Y
/	O
NR2A	B-GENE-Y
.	O

MK	B-CHEMICAL
-	I-CHEMICAL
801	I-CHEMICAL
(	O
(	B-CHEMICAL
+	I-CHEMICAL
)	I-CHEMICAL
-	I-CHEMICAL
5	I-CHEMICAL
-	I-CHEMICAL
methyl	I-CHEMICAL
-	I-CHEMICAL
10	I-CHEMICAL
,	I-CHEMICAL
11	I-CHEMICAL
-	I-CHEMICAL
dihydro	I-CHEMICAL
-	I-CHEMICAL
5H	I-CHEMICAL
-	I-CHEMICAL
dibenzo	I-CHEMICAL
[	I-CHEMICAL
a	I-CHEMICAL
,	I-CHEMICAL
d	I-CHEMICAL
]	I-CHEMICAL
cyclohepten	I-CHEMICAL
-	I-CHEMICAL
5	I-CHEMICAL
,	I-CHEMICAL
10	I-CHEMICAL
-	I-CHEMICAL
imine	I-CHEMICAL
maleate	I-CHEMICAL
)	O
,	O
a	O
noncompetitive	O
NMDA	B-GENE-N
receptor	I-GENE-N
antagonist	O
,	O
partially	O
prevented	O
the	O
decrease	O
in	O
cell	O
viability	O
and	O
the	O
energy	O
impairment	O
.	O

These	O
differences	O
were	O
not	O
accounted	O
for	O
by	O
the	O
activation	O
of	O
caspases	B-GENE-N
2	I-GENE-N
,	I-GENE-N
3	I-GENE-N
,	I-GENE-N
8	I-GENE-N
and	I-GENE-N
9	I-GENE-N
or	O
calpains	O
or	O
by	O
DNA	O
fragmentation	O
,	O
excluding	O
the	O
hypothesis	O
of	O
apoptosis	O
.	O

Functional	O
NR1	B-GENE-Y
/	O
NR2A	B-GENE-Y
and	O
NR1	B-GENE-Y
/	O
NR2B	B-GENE-Y
receptor	O
subtypes	O
were	O
further	O
evidenced	O
by	O
single	O
-	O
cell	O
calcium	B-CHEMICAL
imaging	O
.	O

Stimulation	O
of	O
NR1	B-GENE-Y
/	O
NR2A	B-GENE-Y
receptors	O
with	O
NMDA	B-CHEMICAL
/	O
glycine	B-CHEMICAL
revealed	O
an	O
increase	O
in	O
intracellular	O
calcium	B-CHEMICAL
in	O
cells	O
pre	O
-	O
exposed	O
to	O
Abeta	B-GENE-Y
(	I-GENE-Y
1	I-GENE-Y
-	I-GENE-Y
40	I-GENE-Y
)	I-GENE-Y
.	O

Opposite	O
effects	O
were	O
observed	O
upon	O
activation	O
of	O
NR1	B-GENE-Y
/	O
NR2B	B-GENE-Y
receptors	O
.	O

These	O
results	O
suggest	O
that	O
NR1	B-GENE-Y
/	O
NR2A	B-GENE-Y
-	O
composed	O
NMDA	B-GENE-N
receptors	I-GENE-N
mediate	O
necrotic	O
cell	O
death	O
in	O
HEK293	O
cells	O
exposed	O
to	O
Abeta	B-GENE-Y
(	I-GENE-Y
1	I-GENE-Y
-	I-GENE-Y
40	I-GENE-Y
)	I-GENE-Y
through	O
changes	O
in	O
calcium	B-CHEMICAL
homeostasis	O
.	O

Competition	O
between	O
24	O
:	O
5n	O
-	O
3	O
and	O
ALA	O
for	O
Delta	B-GENE-Y
6	I-GENE-Y
desaturase	I-GENE-Y
may	O
limit	O
the	O
accumulation	O
of	O
DHA	O
in	O
HepG2	O
cell	O
membranes	O
.	O

The	O
use	O
of	O
Delta	B-GENE-Y
6	I-GENE-Y
desaturase	I-GENE-Y
(	O
D6D	B-GENE-Y
)	O
twice	O
in	O
the	O
conversion	O
of	O
alpha	B-CHEMICAL
-	I-CHEMICAL
linolenic	I-CHEMICAL
acid	I-CHEMICAL
(	O
ALA	B-CHEMICAL
;	O
18	O
:	O
3n	O
-	O
3	O
)	O
to	O
docosahexaenoic	B-CHEMICAL
acid	I-CHEMICAL
(	O
DHA	B-CHEMICAL
;	O
22	O
:	O
6n	O
-	O
3	O
)	O
suggests	O
that	O
this	O
enzyme	O
may	O
play	O
a	O
key	O
regulatory	O
role	O
in	O
the	O
synthesis	O
and	O
accumulation	O
of	O
DHA	B-CHEMICAL
from	O
ALA	B-CHEMICAL
.	O

We	O
examined	O
this	O
using	O
an	O
in	O
vitro	O
model	O
of	O
fatty	B-CHEMICAL
acid	I-CHEMICAL
metabolism	O
to	O
measure	O
the	O
accumulation	O
of	O
the	O
long	O
-	O
chain	O
metabolites	O
of	O
ALA	B-CHEMICAL
in	O
HepG2	O
cell	O
phospholipids	O
.	O

The	O
accumulation	O
of	O
ALA	B-CHEMICAL
,	O
eicosapentaenoic	B-CHEMICAL
acid	I-CHEMICAL
(	O
20	O
:	O
5n	O
-	O
3	O
)	O
,	O
docosapentaenoic	B-CHEMICAL
acid	I-CHEMICAL
(	O
22	O
:	O
5n	O
-	O
3	O
)	O
,	O
and	O
24	O
:	O
5n	O
-	O
3	O
in	O
cell	O
phospholipids	O
was	O
linearly	O
related	O
to	O
the	O
concentration	O
of	O
supplemented	O
ALA	B-CHEMICAL
over	O
the	O
range	O
tested	O
(	O
1	O
.	O
8	O
-	O
72	O
microM	O
)	O
.	O

The	O
accumulation	O
of	O
the	O
post	O
-	O
D6D	B-GENE-Y
products	O
of	O
22	O
:	O
5n	O
-	O
3	O
,	O
24	O
:	O
6n	O
-	O
3	O
and	O
DHA	B-CHEMICAL
,	O
in	O
cell	O
phospholipids	O
was	O
saturated	O
at	O
concentrations	O
of	O
>	O
18	O
microM	O
ALA	B-CHEMICAL
.	O

Supplementation	O
of	O
HepG2	O
cells	O
with	O
preformed	O
DHA	B-CHEMICAL
revealed	O
that	O
,	O
although	O
the	O
accumulation	O
of	O
DHA	B-CHEMICAL
in	O
cell	O
phospholipids	O
approached	O
saturation	O
,	O
the	O
level	O
of	O
DHA	B-CHEMICAL
in	O
cell	O
phospholipids	O
was	O
significantly	O
greater	O
compared	O
with	O
the	O
accumulation	O
of	O
DHA	B-CHEMICAL
from	O
ALA	B-CHEMICAL
,	O
indicating	O
that	O
the	O
accumulation	O
of	O
DHA	B-CHEMICAL
from	O
ALA	B-CHEMICAL
was	O
not	O
limited	O
by	O
incorporation	O
.	O

The	O
parallel	O
pattern	O
of	O
accumulation	O
of	O
24	O
:	O
6n	O
-	O
3	O
and	O
DHA	B-CHEMICAL
in	O
response	O
to	O
increasing	O
concentrations	O
of	O
ALA	B-CHEMICAL
suggests	O
that	O
the	O
competition	O
between	O
24	O
:	O
5n	O
-	O
3	O
and	O
ALA	B-CHEMICAL
for	O
D6D	B-GENE-Y
may	O
contribute	O
to	O
the	O
limited	O
accumulation	O
of	O
DHA	B-CHEMICAL
in	O
cell	O
membranes	O
.	O

Plasma	O
S	O
/	O
R	O
ratio	O
of	O
warfarin	B-CHEMICAL
co	O
-	O
varies	O
with	O
VKORC1	B-GENE-Y
haplotype	O
.	O

We	O
recently	O
reported	O
that	O
the	O
low	O
-	O
dose	O
VKORC1	B-GENE-Y
*	O
2	O
haplotype	O
is	O
an	O
important	O
genetic	O
determinant	O
for	O
warfarin	B-CHEMICAL
dose	O
requirement	O
and	O
is	O
associated	O
with	O
difficulties	O
to	O
attain	O
stable	O
therapeutic	O
prothrombin	B-GENE-Y
time	O
-	O
-	O
International	O
Normalized	O
Ratio	O
in	O
patients	O
undergoing	O
anticoagulation	O
therapy	O
.	O

The	O
aim	O
of	O
this	O
study	O
was	O
to	O
investigate	O
whether	O
patients	O
with	O
VKORC1	B-GENE-Y
*	O
2	O
compared	O
with	O
patients	O
carrying	O
high	O
-	O
dose	O
haplotypes	O
VKORC1	B-GENE-Y
*	O
3	O
or	O
VKORC1	B-GENE-Y
*	O
4	O
had	O
different	O
warfarin	B-CHEMICAL
S	I-CHEMICAL
/	I-CHEMICAL
R	I-CHEMICAL
ratios	O
in	O
their	O
plasma	O
,	O
and	O
whether	O
that	O
was	O
related	O
to	O
CYP2C9	B-GENE-Y
variants	O
CYP2C9	B-GENE-Y
*	O
2	O
and	O
CYP2C9	B-GENE-Y
*	O
3	O
or	O
other	O
factors	O
.	O

Samples	O
from	O
patients	O
previously	O
haplotyped	O
for	O
VKORC1	B-GENE-Y
and	O
measured	O
for	O
plasma	O
warfarin	B-CHEMICAL
concentration	O
were	O
genotyped	O
for	O
the	O
CYP2C9	B-GENE-Y
variants	O
CYP2C9	B-GENE-Y
*	O
2	O
and	O
CYP2C9	B-GENE-Y
*	O
3	O
.	O

Nonparametric	O
statistical	O
analysis	O
was	O
performed	O
to	O
elucidate	O
whether	O
there	O
was	O
any	O
significant	O
difference	O
in	O
the	O
warfarin	B-CHEMICAL
S	I-CHEMICAL
/	I-CHEMICAL
R	I-CHEMICAL
ratio	O
between	O
the	O
two	O
patient	O
groups	O
.	O

Our	O
result	O
shows	O
that	O
there	O
is	O
a	O
significant	O
difference	O
(	O
P	O
<	O
0	O
.	O
01	O
)	O
in	O
warfarin	B-CHEMICAL
S	I-CHEMICAL
/	I-CHEMICAL
R	I-CHEMICAL
ratios	O
between	O
VKORC1	B-GENE-Y
*	O
2	O
and	O
VKORC1	B-GENE-Y
*	O
3	O
or	O
VKORC1	B-GENE-Y
*	O
4	O
patients	O
.	O

This	O
difference	O
did	O
not	O
originate	O
from	O
CYP2C9	B-GENE-Y
variants	O
CYP2C9	B-GENE-Y
*	O
2	O
and	O
CYP2C9	B-GENE-Y
*	O
3	O
.	O

We	O
speculate	O
that	O
VKORC1	B-GENE-Y
haplotypes	O
possibly	O
are	O
linked	O
to	O
some	O
unidentified	O
factors	O
involved	O
in	O
the	O
metabolic	O
clearance	O
of	O
warfarin	B-CHEMICAL
enantiomers	O
.	O

Dose	O
-	O
dependent	O
variations	O
in	O
(	B-CHEMICAL
S	I-CHEMICAL
)	I-CHEMICAL
-	I-CHEMICAL
warfarin	I-CHEMICAL
and	O
(	B-CHEMICAL
R	I-CHEMICAL
)	I-CHEMICAL
-	I-CHEMICAL
warfarin	I-CHEMICAL
clearance	O
in	O
these	O
patients	O
can	O
also	O
be	O
a	O
probable	O
explanation	O
for	O
the	O
difference	O
in	O
warfarin	B-CHEMICAL
S	I-CHEMICAL
/	I-CHEMICAL
R	I-CHEMICAL
ratios	O
.	O

Dopamine	B-GENE-Y
D1	I-GENE-Y
receptor	I-GENE-Y
agonist	O
and	O
D2	B-GENE-Y
receptor	I-GENE-Y
antagonist	O
effects	O
of	O
the	O
natural	O
product	O
(	B-CHEMICAL
-	I-CHEMICAL
)	I-CHEMICAL
-	I-CHEMICAL
stepholidine	I-CHEMICAL
:	O
molecular	O
modeling	O
and	O
dynamics	O
simulations	O
.	O

(	B-CHEMICAL
-	I-CHEMICAL
)	I-CHEMICAL
-	I-CHEMICAL
Stepholidine	I-CHEMICAL
(	O
SPD	B-CHEMICAL
)	O
,	O
an	O
active	O
ingredient	O
of	O
the	O
Chinese	O
herb	O
Stephania	O
,	O
is	O
the	O
first	O
compound	O
found	O
to	O
have	O
dual	O
function	O
as	O
a	O
dopamine	B-GENE-Y
receptor	I-GENE-Y
D1	I-GENE-Y
agonist	O
and	O
D2	B-GENE-Y
antagonist	O
.	O

Insights	O
into	O
dynamical	O
behaviors	O
of	O
D1	B-GENE-N
and	I-GENE-N
D2	I-GENE-N
receptors	I-GENE-N
and	O
their	O
interaction	O
modes	O
with	O
SPD	B-CHEMICAL
are	O
crucial	O
in	O
understanding	O
the	O
structural	O
and	O
functional	O
characteristics	O
of	O
dopamine	B-GENE-N
receptors	I-GENE-N
.	O

In	O
this	O
study	O
a	O
computational	O
approach	O
,	O
integrating	O
protein	O
structure	O
prediction	O
,	O
automated	O
molecular	O
docking	O
,	O
and	O
molecular	O
dynamics	O
simulations	O
were	O
employed	O
to	O
investigate	O
the	O
dual	O
action	O
mechanism	O
of	O
SPD	B-CHEMICAL
on	O
the	O
D1	B-GENE-N
and	I-GENE-N
D2	I-GENE-N
receptors	I-GENE-N
,	O
with	O
the	O
eventual	O
aim	O
to	O
develop	O
new	O
drugs	O
for	O
treating	O
diseases	O
affecting	O
the	O
central	O
nervous	O
system	O
such	O
as	O
schizophrenia	O
.	O

The	O
dynamics	O
simulations	O
revealed	O
the	O
surface	O
features	O
of	O
the	O
electrostatic	O
potentials	O
and	O
the	O
conformational	O
"	O
open	O
-	O
closed	O
"	O
process	O
of	O
the	O
binding	O
entrances	O
of	O
two	O
dopamine	B-GENE-N
receptors	I-GENE-N
.	O

Potential	O
binding	O
conformations	O
of	O
D1	B-GENE-N
and	I-GENE-N
D2	I-GENE-N
receptors	I-GENE-N
were	O
obtained	O
,	O
and	O
the	O
D1	B-GENE-Y
-	O
SPD	B-CHEMICAL
and	O
D2	B-GENE-Y
-	O
SPD	B-CHEMICAL
complexes	O
were	O
generated	O
,	O
which	O
are	O
in	O
good	O
agreement	O
with	O
most	O
of	O
experimental	O
data	O
.	O

The	O
D1	B-GENE-Y
-	O
SPD	B-CHEMICAL
structure	O
shows	O
that	O
the	O
K	O
-	O
167	O
_	O
EL	O
-	O
2	O
-	O
E	O
-	O
302	O
_	O
EL	O
-	O
3	O
(	O
EL	O
-	O
2	O
:	O
extracellular	O
loop	O
2	O
;	O
EL	O
-	O
3	O
:	O
extracellular	O
loop	O
3	O
)	O
salt	O
bridge	O
plays	O
an	O
important	O
role	O
for	O
both	O
the	O
conformational	O
change	O
of	O
the	O
extracellular	O
domain	O
and	O
the	O
binding	O
of	O
SPD	B-CHEMICAL
.	O

Based	O
on	O
our	O
modeling	O
and	O
simulations	O
,	O
we	O
proposed	O
a	O
mechanism	O
of	O
the	O
dual	O
action	O
of	O
SPD	B-CHEMICAL
and	O
a	O
subsequent	O
signal	O
transduction	O
model	O
.	O

Further	O
mutagenesis	O
and	O
biophysical	O
experiments	O
are	O
needed	O
to	O
test	O
and	O
improve	O
our	O
proposed	O
dual	O
action	O
mechanism	O
of	O
SPD	B-CHEMICAL
and	O
signal	O
transduction	O
model	O
.	O

GLP	B-GENE-Y
-	I-GENE-Y
1	I-GENE-Y
receptor	I-GENE-Y
expression	O
in	O
human	O
tumors	O
and	O
human	O
normal	O
tissues	O
:	O
potential	O
for	O
in	O
vivo	O
targeting	O
.	O

UNLABELLED	O
:	O
Peptide	B-GENE-N
hormone	I-GENE-N
receptors	I-GENE-N
overexpressed	O
in	O
human	O
tumors	O
,	O
such	O
as	O
somatostatin	B-GENE-N
receptors	I-GENE-N
,	O
can	O
be	O
used	O
for	O
in	O
vivo	O
targeting	O
for	O
diagnostic	O
and	O
therapeutic	O
purposes	O
.	O

A	O
novel	O
promising	O
candidate	O
in	O
this	O
field	O
is	O
the	O
GLP	B-GENE-Y
-	I-GENE-Y
1	I-GENE-Y
receptor	I-GENE-Y
,	O
which	O
was	O
recently	O
shown	O
to	O
be	O
massively	O
overexpressed	O
in	O
gut	O
and	O
lung	O
neuroendocrine	O
tumors	O
-	O
-	O
in	O
particular	O
,	O
in	O
insulinomas	O
.	O

Anticipating	O
a	O
major	O
development	O
of	O
GLP	B-GENE-Y
-	I-GENE-Y
1	I-GENE-Y
receptor	I-GENE-Y
targeting	O
in	O
nuclear	O
medicine	O
,	O
our	O
aim	O
was	O
to	O
evaluate	O
in	O
vitro	O
the	O
GLP	B-GENE-Y
-	I-GENE-Y
1	I-GENE-Y
receptor	I-GENE-Y
expression	O
in	O
a	O
large	O
variety	O
of	O
other	O
tumors	O
and	O
to	O
compare	O
it	O
with	O
that	O
in	O
nonneoplastic	O
tissues	O
.	O

METHODS	O
:	O
The	O
GLP	B-GENE-Y
-	I-GENE-Y
1	I-GENE-Y
receptor	I-GENE-Y
protein	O
expression	O
was	O
qualitatively	O
and	O
quantitatively	O
investigated	O
in	O
a	O
broad	O
spectrum	O
of	O
human	O
tumors	O
(	O
n	O
=	O
419	O
)	O
and	O
nonneoplastic	O
human	O
tissues	O
(	O
n	O
=	O
209	O
)	O
with	O
receptor	O
autoradiography	O
using	O
(	O
125	O
)	O
I	O
-	O
GLP	B-GENE-Y
-	I-GENE-Y
1	I-GENE-Y
(	I-GENE-Y
7	I-GENE-Y
-	I-GENE-Y
36	I-GENE-Y
)	I-GENE-Y
amide	O
.	O

Pharmacologic	O
competition	O
experiments	O
were	O
performed	O
to	O
provide	O
proof	O
of	O
specificity	O
of	O
the	O
procedure	O
.	O

RESULTS	O
:	O
GLP	B-GENE-Y
-	I-GENE-Y
1	I-GENE-Y
receptors	I-GENE-Y
were	O
expressed	O
in	O
various	O
endocrine	O
tumors	O
,	O
with	O
particularly	O
high	O
amounts	O
in	O
pheochromocytomas	O
,	O
as	O
well	O
as	O
in	O
brain	O
tumors	O
and	O
embryonic	O
tumors	O
but	O
not	O
in	O
carcinomas	O
or	O
lymphomas	O
.	O

In	O
nonneoplastic	O
tissues	O
,	O
GLP	B-GENE-Y
-	I-GENE-Y
1	I-GENE-Y
receptors	I-GENE-Y
were	O
present	O
in	O
generally	O
low	O
amounts	O
in	O
specific	O
tissue	O
compartments	O
of	O
several	O
organs	O
-	O
-	O
namely	O
,	O
pancreas	O
,	O
intestine	O
,	O
lung	O
,	O
kidney	O
,	O
breast	O
,	O
and	O
brain	O
;	O
no	O
receptors	O
were	O
identified	O
in	O
lymph	O
nodes	O
,	O
spleen	O
,	O
liver	O
,	O
or	O
the	O
adrenal	O
gland	O
.	O

The	O
rank	O
order	O
of	O
potencies	O
for	O
receptor	O
binding	O
-	O
-	O
namely	O
,	O
GLP	B-GENE-Y
-	I-GENE-Y
1	I-GENE-Y
(	I-GENE-Y
7	I-GENE-Y
-	I-GENE-Y
36	I-GENE-Y
)	I-GENE-Y
amide	O
=	O
exendin	B-GENE-Y
-	I-GENE-Y
4	I-GENE-Y
>	O
>	O
GLP	B-GENE-Y
-	I-GENE-Y
2	I-GENE-Y
=	O
glucagon	B-GENE-Y
(	I-GENE-Y
1	I-GENE-Y
-	I-GENE-Y
29	I-GENE-Y
)	I-GENE-Y
-	O
-	O
provided	O
proof	O
of	O
specific	O
GLP	B-GENE-Y
-	I-GENE-Y
1	I-GENE-Y
receptor	I-GENE-Y
identification	O
.	O

CONCLUSION	O
:	O
The	O
GLP	B-GENE-Y
-	I-GENE-Y
1	I-GENE-Y
receptors	I-GENE-Y
may	O
represent	O
a	O
novel	O
molecular	O
target	O
for	O
in	O
vivo	O
scintigraphy	O
and	O
targeted	O
radiotherapy	O
for	O
a	O
variety	O
of	O
GLP	B-GENE-Y
-	I-GENE-Y
1	I-GENE-Y
receptor	I-GENE-Y
-	O
expressing	O
tumors	O
.	O

For	O
GLP	B-GENE-Y
-	I-GENE-Y
1	I-GENE-Y
receptor	I-GENE-Y
scintigraphy	O
,	O
a	O
low	O
-	O
background	O
signal	O
can	O
be	O
expected	O
,	O
on	O
the	O
basis	O
of	O
the	O
low	O
receptor	O
expression	O
in	O
the	O
normal	O
tissues	O
surrounding	O
tumors	O
.	O

A	O
novel	O
variant	O
L263F	B-GENE-N
in	O
human	B-GENE-Y
inosine	I-GENE-Y
5	I-GENE-Y
'	I-GENE-Y
-	I-GENE-Y
monophosphate	I-GENE-Y
dehydrogenase	I-GENE-Y
2	I-GENE-Y
is	O
associated	O
with	O
diminished	O
enzyme	O
activity	O
.	O

BACKGROUND	O
AND	O
OBJECTIVE	O
:	O
Inosine	B-GENE-Y
5	I-GENE-Y
'	I-GENE-Y
-	I-GENE-Y
monophosphate	I-GENE-Y
dehydrogenase	I-GENE-Y
2	I-GENE-Y
is	O
required	O
for	O
purine	O
synthesis	O
in	O
activated	O
lymphocytes	O
.	O

Variants	O
in	O
the	O
IMPDH2	B-GENE-Y
gene	O
may	O
account	O
for	O
the	O
large	O
inter	O
-	O
individual	O
variability	O
in	O
baseline	O
enzyme	O
activity	O
,	O
immunosuppressive	O
efficacy	O
and	O
side	O
effects	O
in	O
transplant	O
recipients	O
receiving	O
mycophenolic	B-CHEMICAL
acid	I-CHEMICAL
.	O

Therefore	O
,	O
the	O
objective	O
of	O
this	O
study	O
was	O
to	O
identify	O
and	O
functionally	O
characterize	O
IMPDH2	B-GENE-Y
variants	O
.	O

METHODS	O
:	O
DNA	O
samples	O
from	O
152	O
solid	O
organ	O
transplant	O
patients	O
were	O
screened	O
at	O
exons	O
and	O
exon	O
/	O
intron	O
junctions	O
of	O
the	O
IMPDH2	B-GENE-Y
genes	O
by	O
PCR	O
amplification	O
followed	O
by	O
bidirectional	O
direct	O
DNA	O
sequencing	O
.	O

Genetic	O
variant	O
was	O
constructed	O
by	O
site	O
-	O
directed	O
mutagenesis	O
and	O
transformed	O
to	O
an	O
inosine	B-GENE-Y
5	I-GENE-Y
'	I-GENE-Y
-	I-GENE-Y
monophosphate	I-GENE-Y
dehydrogenase	I-GENE-Y
-	O
deficient	O
strain	O
of	O
Escherichia	O
coli	O
h712	O
.	O

Proteins	O
were	O
purified	O
to	O
homogeneity	O
and	O
the	O
enzymatic	O
activity	O
was	O
measured	O
by	O
reduced	O
nicotinamide	B-CHEMICAL
adenine	I-CHEMICAL
dinucleotide	I-CHEMICAL
production	O
.	O

RESULTS	O
:	O
Nine	O
genetic	O
variants	O
were	O
identified	O
in	O
the	O
IMPDH2	B-GENE-Y
gene	O
,	O
with	O
frequencies	O
of	O
the	O
rarer	O
alleles	O
ranging	O
from	O
0	O
.	O
5	O
to	O
10	O
.	O
2	O
%	O
.	O

A	O
novel	O
nonsynonymous	O
variant	O
L263F	B-GENE-N
was	O
identified	O
,	O
and	O
the	O
kinetic	O
assay	O
demonstrated	O
that	O
the	O
inosine	B-GENE-N
5	I-GENE-N
'	I-GENE-N
-	I-GENE-N
monophosphate	I-GENE-N
dehydrogenase	I-GENE-N
activity	O
of	O
L263F	B-GENE-N
variant	O
was	O
decreased	O
to	O
10	O
%	O
of	O
the	O
wild	O
-	O
type	O
.	O

The	O
Ki	O
for	O
mycophenolic	B-CHEMICAL
acid	I-CHEMICAL
inhibition	O
of	O
the	O
L263F	B-GENE-N
variant	O
was	O
comparable	O
with	O
the	O
wild	O
-	O
type	O
,	O
and	O
the	O
variant	O
Km	O
for	O
inosine	B-CHEMICAL
5	I-CHEMICAL
'	I-CHEMICAL
-	I-CHEMICAL
monophosphate	I-CHEMICAL
and	O
nicotinamide	B-CHEMICAL
adenine	I-CHEMICAL
dinucleotide	I-CHEMICAL
did	O
not	O
change	O
significantly	O
.	O

CONCLUSIONS	O
:	O
IMPDH2	B-GENE-Y
has	O
low	O
genetic	O
diversity	O
,	O
but	O
the	O
nonsynonymous	O
variant	O
L263F	B-GENE-N
has	O
a	O
significant	O
impact	O
on	O
inosine	B-GENE-N
5	I-GENE-N
'	I-GENE-N
-	I-GENE-N
monophosphate	I-GENE-N
dehydrogenase	I-GENE-N
activity	O
.	O

This	O
novel	O
functional	O
variant	O
may	O
be	O
one	O
of	O
the	O
factors	O
contributing	O
to	O
the	O
inter	O
-	O
individual	O
difference	O
of	O
baseline	O
inosine	B-GENE-N
5	I-GENE-N
'	I-GENE-N
-	I-GENE-N
monophosphate	I-GENE-N
dehydrogenase	I-GENE-N
activity	O
as	O
well	O
as	O
drug	O
efficacy	O
and	O
adverse	O
events	O
in	O
transplant	O
patients	O
.	O

[	O
Effects	O
of	O
Panax	O
notoginseng	O
saponins	B-CHEMICAL
on	O
mRNA	O
expressions	O
of	O
interleukin	B-GENE-Y
-	I-GENE-Y
1	I-GENE-Y
beta	I-GENE-Y
,	O
its	O
correlative	O
factors	O
and	O
cysteinyl	B-GENE-N
-	I-GENE-N
aspartate	I-GENE-N
specific	I-GENE-N
protease	I-GENE-N
after	O
cerebral	O
ischemia	O
-	O
reperfusion	O
in	O
rats	O
]	O
.	O

OBJECTIVE	O
:	O
To	O
investigate	O
the	O
effects	O
of	O
Panax	O
notoginseng	O
saponins	B-CHEMICAL
(	O
PNS	O
)	O
on	O
mRNA	O
expressions	O
of	O
interleukin	B-GENE-Y
-	I-GENE-Y
1	I-GENE-Y
beta	I-GENE-Y
(	O
IL	B-GENE-Y
-	I-GENE-Y
1	I-GENE-Y
beta	I-GENE-Y
)	O
,	O
interleukin	B-GENE-Y
-	I-GENE-Y
1	I-GENE-Y
receptor	I-GENE-Y
type	I-GENE-Y
I	I-GENE-Y
(	O
IL	B-GENE-Y
-	I-GENE-Y
1RI	I-GENE-Y
)	O
,	O
interleukin	B-GENE-Y
-	I-GENE-Y
1	I-GENE-Y
receptor	I-GENE-Y
antagonist	I-GENE-Y
(	O
IL	B-GENE-Y
-	I-GENE-Y
1ra	I-GENE-Y
)	O
,	O
intercellular	B-GENE-Y
adhesion	I-GENE-Y
molecule	I-GENE-Y
-	I-GENE-Y
1	I-GENE-Y
(	O
ICAM	B-GENE-Y
-	I-GENE-Y
1	I-GENE-Y
)	O
,	O
cysteinyl	B-GENE-Y
-	I-GENE-Y
aspartate	I-GENE-Y
specific	I-GENE-Y
protease	I-GENE-Y
-	I-GENE-Y
1	I-GENE-Y
(	O
caspase	B-GENE-Y
-	I-GENE-Y
1	I-GENE-Y
)	O
,	O
caspase	B-GENE-Y
-	I-GENE-Y
3	I-GENE-Y
and	O
caspase	B-GENE-Y
-	I-GENE-Y
8	I-GENE-Y
after	O
cerebral	O
ischemia	O
-	O
reperfusion	O
in	O
rats	O
.	O

METHODS	O
:	O
Focal	O
cerebral	O
ischemia	O
reperfusion	O
in	O
rats	O
was	O
induced	O
by	O
the	O
method	O
of	O
nylon	O
monofilament	O
via	O
the	O
internal	O
carotid	O
artery	O
.	O

PNS	O
was	O
administered	O
intraperitoneally	O
respectively	O
five	O
minutes	O
before	O
cerebral	O
ischemia	O
and	O
twelve	O
hours	O
after	O
cerebral	O
ischemia	O
.	O

After	O
cerebral	O
ischemia	O
for	O
two	O
hours	O
followed	O
by	O
reperfusion	O
for	O
twenty	O
two	O
hours	O
,	O
the	O
mRNA	O
expressions	O
of	O
IL	B-GENE-Y
-	I-GENE-Y
1	I-GENE-Y
beta	I-GENE-Y
,	O
IL	B-GENE-Y
-	I-GENE-Y
1RI	I-GENE-Y
,	O
IL	B-GENE-Y
-	I-GENE-Y
1ra	I-GENE-Y
,	O
ICAM	B-GENE-Y
-	I-GENE-Y
1	I-GENE-Y
,	O
caspase	B-GENE-Y
-	I-GENE-Y
1	I-GENE-Y
,	O
caspase	B-GENE-Y
-	I-GENE-Y
3	I-GENE-Y
and	O
caspase	B-GENE-Y
-	I-GENE-Y
8	I-GENE-Y
in	O
brain	O
tissue	O
were	O
determined	O
by	O
reverse	O
transcription	O
polymerase	O
chain	O
reaction	O
assay	O
.	O

RESULTS	O
:	O
After	O
cerebral	O
ischemia	O
for	O
two	O
hours	O
followed	O
by	O
reperfusion	O
for	O
twenty	O
two	O
hours	O
,	O
the	O
mRNA	O
expression	O
levels	O
of	O
IL	B-GENE-Y
-	I-GENE-Y
1	I-GENE-Y
beta	I-GENE-Y
,	O
IL	B-GENE-Y
-	I-GENE-Y
1RI	I-GENE-Y
,	O
IL	B-GENE-Y
-	I-GENE-Y
1ra	I-GENE-Y
,	O
ICAM	B-GENE-Y
-	I-GENE-Y
1	I-GENE-Y
,	O
caspase	B-GENE-Y
-	I-GENE-Y
1	I-GENE-Y
,	O
caspase	B-GENE-Y
-	I-GENE-Y
3	I-GENE-Y
and	O
caspase	B-GENE-Y
-	I-GENE-Y
8	I-GENE-Y
in	O
brain	O
tissue	O
in	O
the	O
untreated	O
group	O
were	O
obviously	O
elevated	O
as	O
compared	O
to	O
those	O
in	O
the	O
sham	O
-	O
operation	O
group	O
(	O
P	O
<	O
0	O
.	O
05	O
or	O
P	O
<	O
0	O
.	O
01	O
)	O
.	O

The	O
mRNA	O
expression	O
levels	O
of	O
IL	B-GENE-Y
-	I-GENE-Y
1	I-GENE-Y
beta	I-GENE-Y
,	O
IL	B-GENE-Y
-	I-GENE-Y
1RI	I-GENE-Y
,	O
IL	B-GENE-Y
-	I-GENE-Y
1ra	I-GENE-Y
in	O
brain	O
tissue	O
in	O
the	O
PNS	O
group	O
were	O
lower	O
than	O
those	O
in	O
the	O
untreated	O
group	O
,	O
but	O
higher	O
than	O
those	O
in	O
the	O
sham	O
-	O
operation	O
group	O
,	O
and	O
without	O
statistical	O
differences	O
as	O
compared	O
to	O
those	O
in	O
the	O
sham	O
-	O
operation	O
group	O
and	O
in	O
the	O
untreated	O
group	O
(	O
P	O
>	O
0	O
.	O
05	O
)	O
.	O

The	O
mRNA	O
expression	O
level	O
of	O
caspase	B-GENE-Y
-	I-GENE-Y
3	I-GENE-Y
in	O
brain	O
tissue	O
in	O
the	O
PNS	O
group	O
was	O
significantly	O
lower	O
than	O
that	O
in	O
the	O
untreated	O
group	O
(	O
P	O
<	O
0	O
.	O
05	O
)	O
,	O
but	O
PNS	O
had	O
no	O
effect	O
on	O
the	O
mRNA	O
expression	O
levels	O
of	O
ICAM	B-GENE-Y
-	I-GENE-Y
1	I-GENE-Y
,	O
caspase	B-GENE-Y
-	I-GENE-Y
1	I-GENE-Y
and	O
caspase	B-GENE-Y
-	I-GENE-Y
8	I-GENE-Y
in	O
brain	O
tissue	O
.	O

CONCLUSION	O
:	O
PNS	O
can	O
inhibit	O
the	O
mRNA	O
expression	O
of	O
caspase	B-GENE-Y
-	I-GENE-Y
3	I-GENE-Y
,	O
slightly	O
inhibit	O
the	O
mRNA	O
expressions	O
of	O
IL	B-GENE-Y
-	I-GENE-Y
1	I-GENE-Y
beta	I-GENE-Y
and	O
its	O
correlative	O
inflammatory	O
factors	O
in	O
brain	O
tissue	O
.	O

The	O
protective	O
effects	O
of	O
PNS	O
on	O
cerebral	O
injury	O
induced	O
by	O
ischemia	O
-	O
reperfusion	O
may	O
be	O
related	O
to	O
inhibiting	O
the	O
mRNA	O
expressions	O
of	O
caspase	B-GENE-Y
-	I-GENE-Y
3	I-GENE-Y
,	O
IL	B-GENE-Y
-	I-GENE-Y
1	I-GENE-Y
beta	I-GENE-Y
and	O
its	O
correlative	O
inflammatory	O
factors	O
in	O
brain	O
tissue	O
.	O

Downregulation	O
of	O
glutaredoxin	B-GENE-N
but	O
not	O
glutathione	B-CHEMICAL
loss	O
leads	O
to	O
mitochondrial	O
dysfunction	O
in	O
female	O
mice	O
CNS	O
:	O
implications	O
in	O
excitotoxicity	O
.	O

Oxidative	O
stress	O
,	O
excitotoxicity	O
and	O
mitochondrial	O
dysfunction	O
play	O
synergistic	O
roles	O
in	O
neurodegeneration	O
.	O

Maintenance	O
of	O
thiol	B-CHEMICAL
homeostasis	O
is	O
important	O
for	O
normal	O
mitochondrial	O
function	O
and	O
dysregulation	O
of	O
protein	O
thiol	B-CHEMICAL
homeostasis	O
by	O
oxidative	O
stress	O
leads	O
to	O
mitochondrial	O
dysfunction	O
and	O
neurodegeneration	O
.	O

We	O
examined	O
the	O
critical	O
roles	O
played	O
by	O
the	O
antioxidant	O
,	O
non	O
-	O
protein	O
thiol	B-CHEMICAL
,	O
glutathione	B-CHEMICAL
and	O
related	O
enzyme	O
,	O
glutaredoxin	B-GENE-N
in	O
maintaining	O
mitochondrial	O
function	O
during	O
excitotoxicity	O
caused	O
by	O
beta	B-CHEMICAL
-	I-CHEMICAL
N	I-CHEMICAL
-	I-CHEMICAL
oxalyl	I-CHEMICAL
amino	I-CHEMICAL
-	I-CHEMICAL
L	I-CHEMICAL
-	I-CHEMICAL
alanine	I-CHEMICAL
(	O
L	B-CHEMICAL
-	I-CHEMICAL
BOAA	I-CHEMICAL
)	O
,	O
the	O
causative	O
factor	O
of	O
neurolathyrism	O
,	O
a	O
motor	O
neuron	O
disease	O
involving	O
the	O
pyramidal	O
system	O
.	O

L	B-CHEMICAL
-	I-CHEMICAL
BOAA	I-CHEMICAL
causes	O
loss	O
of	O
GSH	B-CHEMICAL
and	O
inhibition	O
of	O
mitochondrial	B-GENE-N
complex	I-GENE-N
I	I-GENE-N
in	O
lumbosacral	O
cord	O
of	O
male	O
mice	O
through	O
oxidation	O
of	O
thiol	B-CHEMICAL
groups	O
,	O
while	O
female	O
mice	O
are	O
resistant	O
.	O

Reducing	O
GSH	B-CHEMICAL
levels	O
in	O
female	O
mice	O
CNS	O
by	O
pretreatment	O
with	O
diethyl	B-CHEMICAL
maleate	I-CHEMICAL
or	O
L	B-CHEMICAL
-	I-CHEMICAL
propargyl	I-CHEMICAL
glycine	I-CHEMICAL
did	O
not	O
result	O
in	O
inhibition	O
of	O
complex	B-GENE-N
I	I-GENE-N
activity	O
,	O
unlike	O
male	O
mice	O
.	O

Further	O
,	O
treatment	O
of	O
female	O
mice	O
depleted	O
of	O
GSH	B-CHEMICAL
with	O
L	B-CHEMICAL
-	I-CHEMICAL
BOAA	I-CHEMICAL
did	O
not	O
induce	O
inhibition	O
of	O
complex	B-GENE-N
I	I-GENE-N
indicating	O
that	O
GSH	B-CHEMICAL
levels	O
were	O
not	O
critical	O
for	O
maintaining	O
complex	B-GENE-N
I	I-GENE-N
activity	O
in	O
female	O
mice	O
unlike	O
their	O
male	O
counterpart	O
.	O

Glutaredoxin	B-GENE-N
,	O
a	O
thiol	B-GENE-N
disulfide	I-GENE-N
oxidoreductase	I-GENE-N
helps	O
maintain	O
redox	O
status	O
of	O
proteins	O
and	O
downregulation	O
of	O
glutaredoxin	B-GENE-N
results	O
in	O
loss	O
of	O
mitochondrial	B-GENE-N
complex	I-GENE-N
I	I-GENE-N
activity	O
.	O

Female	O
mice	O
express	O
higher	O
levels	O
of	O
glutaredoxin	B-GENE-N
in	O
certain	O
CNS	O
regions	O
and	O
downregulation	O
of	O
glutaredoxin	B-GENE-N
using	O
antisense	O
oligonucleotides	O
sensitizes	O
them	O
to	O
L	B-CHEMICAL
-	I-CHEMICAL
BOAA	I-CHEMICAL
toxicity	O
seen	O
as	O
mitochondrial	B-GENE-N
complex	I-GENE-N
I	I-GENE-N
loss	O
.	O

Ovariectomy	O
downregulates	O
glutaredoxin	B-GENE-N
and	O
renders	O
female	O
mice	O
vulnerable	O
to	O
L	B-CHEMICAL
-	I-CHEMICAL
BOAA	I-CHEMICAL
toxicity	O
as	O
evidenced	O
by	O
activation	O
of	O
AP1	B-GENE-Y
,	O
loss	O
of	O
GSH	B-CHEMICAL
and	O
complex	B-GENE-N
I	I-GENE-N
activity	O
indicating	O
the	O
important	O
role	O
of	O
glutaredoxin	B-GENE-N
in	O
neuroprotection	O
.	O

Estrogen	B-CHEMICAL
protects	O
against	O
mitochondrial	O
dysfunction	O
caused	O
by	O
excitotoxicity	O
by	O
maintaining	O
cellular	O
redox	O
status	O
through	O
higher	O
constitutive	O
expression	O
of	O
glutaredoxin	B-GENE-N
in	O
the	O
CNS	O
.	O

Therapeutic	O
interventions	O
designed	O
to	O
upregulate	O
glutaredoxin	B-GENE-N
may	O
offer	O
neuroprotection	O
against	O
excitotoxicity	O
in	O
motor	O
neurons	O
.	O

The	O
calponin	B-GENE-N
homology	I-GENE-N
domain	I-GENE-N
of	O
Vav1	B-GENE-Y
associates	O
with	O
calmodulin	B-GENE-Y
and	O
is	O
prerequisite	O
to	O
T	B-GENE-N
cell	I-GENE-N
antigen	I-GENE-N
receptor	I-GENE-N
-	O
induced	O
calcium	B-CHEMICAL
release	O
in	O
Jurkat	O
T	O
lymphocytes	O
.	O

Vav1	B-GENE-Y
is	O
a	O
guanine	B-GENE-N
nucleotide	I-GENE-N
exchange	I-GENE-N
factor	I-GENE-N
that	O
is	O
expressed	O
specifically	O
in	O
hematopoietic	O
cells	O
and	O
plays	O
important	O
roles	O
in	O
T	O
cell	O
development	O
and	O
activation	O
.	O

Vav1	B-GENE-Y
consists	O
of	O
multiple	O
structural	O
domains	O
so	O
as	O
to	O
facilitate	O
both	O
its	O
guanine	B-CHEMICAL
nucleotide	I-CHEMICAL
exchange	O
activity	O
and	O
scaffold	O
function	O
following	O
T	B-GENE-N
cell	I-GENE-N
antigen	I-GENE-N
receptor	I-GENE-N
(	O
TCR	B-GENE-N
)	O
engagement	O
.	O

Previous	O
studies	O
demonstrated	O
that	O
the	O
calponin	B-GENE-N
homology	I-GENE-N
(	I-GENE-N
CH	I-GENE-N
)	I-GENE-N
domain	I-GENE-N
of	O
Vav1	B-GENE-Y
is	O
required	O
for	O
TCR	B-GENE-Y
-	O
stimulated	O
calcium	B-CHEMICAL
mobilization	O
and	O
thus	O
downstream	O
activation	O
of	O
nuclear	B-GENE-N
factor	I-GENE-N
of	I-GENE-N
activated	I-GENE-N
T	I-GENE-N
cells	I-GENE-N
.	O

However	O
,	O
it	O
remained	O
obscure	O
how	O
Vav1	B-GENE-Y
functions	O
in	O
regulating	O
calcium	B-CHEMICAL
flux	O
.	O

In	O
an	O
effort	O
to	O
explore	O
molecules	O
interacting	O
with	O
Vav1	B-GENE-Y
,	O
we	O
found	O
that	O
calmodulin	B-GENE-Y
bound	O
to	O
Vav1	B-GENE-Y
in	O
a	O
calcium	B-CHEMICAL
-	O
dependent	O
and	O
TCR	B-GENE-N
activation	O
-	O
independent	O
manner	O
.	O

The	O
binding	O
site	O
was	O
mapped	O
to	O
the	O
CH	B-GENE-N
domain	I-GENE-N
of	O
Vav1	B-GENE-Y
.	O

Reconstitution	O
of	O
vav1	B-GENE-Y
-	O
null	O
Jurkat	O
T	O
cells	O
(	O
J	O
.	O
Vav1	B-GENE-Y
)	O
with	O
CH	B-GENE-N
-	O
deleted	O
Vav1	B-GENE-Y
exhibited	O
a	O
severe	O
deficiency	O
in	O
calcium	B-CHEMICAL
release	O
to	O
the	O
same	O
extent	O
as	O
that	O
of	O
Jurkat	O
cells	O
treated	O
with	O
the	O
calmodulin	B-GENE-Y
inhibitor	O
or	O
J	O
.	O
Vav1	B-GENE-Y
cells	O
.	O

The	O
defect	O
persisted	O
even	O
when	O
phospholipase	B-GENE-Y
-	I-GENE-Y
Cgamma1	I-GENE-Y
was	O
fully	O
activated	O
,	O
indicating	O
a	O
prerequisite	O
role	O
of	O
Vav1	B-GENE-N
CH	I-GENE-N
domain	I-GENE-N
in	O
calcium	B-CHEMICAL
signaling	O
.	O

The	O
results	O
suggest	O
that	O
Vav1	B-GENE-Y
and	O
calmodulin	B-GENE-Y
function	O
cooperatively	O
to	O
potentiate	O
TCR	B-GENE-N
-	O
induced	O
calcium	B-CHEMICAL
release	O
.	O

This	O
study	O
unveiled	O
a	O
mechanism	O
by	O
which	O
the	O
Vav1	B-GENE-N
CH	I-GENE-N
domain	I-GENE-N
is	O
involved	O
in	O
calcium	B-CHEMICAL
signaling	O
and	O
provides	O
insight	O
into	O
our	O
understanding	O
of	O
the	O
role	O
of	O
Vav1	B-GENE-Y
in	O
T	O
cell	O
activation	O
.	O

The	O
transporters	O
GlyT2	B-GENE-Y
and	O
VIAAT	B-GENE-Y
cooperate	O
to	O
determine	O
the	O
vesicular	O
glycinergic	O
phenotype	O
.	O

The	O
mechanisms	O
that	O
specify	O
the	O
vesicular	O
phenotype	O
of	O
inhibitory	O
interneurons	O
in	O
vertebrates	O
are	O
poorly	O
understood	O
because	O
the	O
two	O
main	O
inhibitory	O
transmitters	O
,	O
glycine	B-CHEMICAL
and	O
GABA	B-CHEMICAL
,	O
share	O
the	O
same	O
vesicular	B-GENE-Y
inhibitory	I-GENE-Y
amino	I-GENE-Y
acid	I-GENE-Y
transporter	I-GENE-Y
(	O
VIAAT	B-GENE-Y
)	O
and	O
are	O
both	O
present	O
in	O
neurons	O
during	O
postnatal	O
development	O
.	O

We	O
have	O
expressed	O
VIAAT	B-GENE-Y
and	O
the	O
plasmalemmal	B-GENE-N
transporters	I-GENE-N
for	O
glycine	B-CHEMICAL
and	O
GABA	B-CHEMICAL
in	O
a	O
neuroendocrine	O
cell	O
line	O
and	O
measured	O
the	O
quantal	O
release	O
of	O
glycine	B-CHEMICAL
and	O
GABA	B-CHEMICAL
using	O
a	O
novel	O
double	O
-	O
sniffer	O
patch	O
-	O
clamp	O
technique	O
.	O

We	O
found	O
that	O
glycine	B-CHEMICAL
is	O
released	O
from	O
vesicles	O
when	O
VIAAT	B-GENE-Y
is	O
coexpressed	O
with	O
either	O
the	O
neuronal	B-GENE-N
transporter	I-GENE-N
GlyT2	B-GENE-Y
or	O
the	O
glial	B-GENE-N
transporter	I-GENE-N
GlyT1	B-GENE-Y
.	O

However	O
,	O
GlyT2	B-GENE-Y
was	O
more	O
effective	O
than	O
GlyT1	B-GENE-Y
,	O
probably	O
because	O
GlyT2	B-GENE-Y
is	O
unable	O
to	O
operate	O
in	O
the	O
reverse	O
mode	O
,	O
which	O
gives	O
it	O
an	O
advantage	O
in	O
maintaining	O
the	O
high	O
cytosolic	O
glycine	B-CHEMICAL
concentration	O
required	O
for	O
efficient	O
vesicular	O
loading	O
by	O
VIAAT	B-GENE-Y
.	O

The	O
vesicular	O
inhibitory	O
phenotype	O
was	O
gradually	O
altered	O
from	O
glycinergic	O
to	O
GABAergic	O
through	O
mixed	O
events	O
when	O
GABA	B-CHEMICAL
is	O
introduced	O
into	O
the	O
secretory	O
cell	O
and	O
competes	O
for	O
uptake	O
by	O
VIAAT	B-GENE-Y
.	O

Interestingly	O
,	O
the	O
VIAAT	B-GENE-N
ortholog	O
from	O
Caenorhabditis	O
elegans	O
(	O
UNC	O
-	O
47	O
)	O
,	O
a	O
species	O
lacking	O
glycine	B-CHEMICAL
transmission	O
,	O
also	O
supports	O
glycine	B-CHEMICAL
exocytosis	O
in	O
the	O
presence	O
of	O
GlyT2	B-GENE-N
,	O
and	O
a	O
point	O
mutation	O
of	O
UNC	O
-	O
47	O
that	O
abolishes	O
GABA	B-CHEMICAL
transmission	O
in	O
the	O
worm	O
confers	O
glycine	O
specificity	O
.	O

Together	O
,	O
these	O
results	O
suggest	O
that	O
an	O
increased	O
cytosolic	O
availability	O
of	O
glycine	B-CHEMICAL
in	O
VIAAT	B-GENE-Y
-	O
containing	O
terminals	O
was	O
crucial	O
for	O
the	O
emergence	O
of	O
glycinergic	O
transmission	O
in	O
vertebrates	O
.	O

Biochemical	O
assessments	O
of	O
total	O
antioxidant	O
status	O
in	O
active	O
and	O
nonactive	O
female	O
adults	O
with	O
intellectual	O
disability	O
.	O

Long	O
-	O
term	O
physical	O
activity	O
is	O
known	O
to	O
increase	O
the	O
antioxidant	O
defense	O
(	O
AOD	O
)	O
system	O
,	O
whereas	O
sedentary	O
lifestyle	O
is	O
associated	O
with	O
oxidative	O
stress	O
(	O
OS	O
)	O
.	O

The	O
underlying	O
molecular	O
mechanisms	O
are	O
incompletely	O
understood	O
.	O

The	O
aim	O
of	O
this	O
prospective	O
,	O
nonrandomized	O
study	O
was	O
to	O
evaluate	O
and	O
compare	O
the	O
relationship	O
between	O
long	O
-	O
term	O
physical	O
activity	O
and	O
inactivity	O
and	O
plasma	O
antioxidant	O
status	O
in	O
female	O
adults	O
with	O
intellectual	O
disability	O
(	O
ID	O
)	O
that	O
were	O
diagnosed	O
after	O
birth	O
.	O

A	O
total	O
of	O
21	O
adults	O
with	O
ID	O
were	O
examined	O
.	O

The	O
following	O
AOD	O
was	O
examined	O
:	O
superoxide	B-GENE-N
dismutase	I-GENE-N
(	O
SOD	B-GENE-N
)	O
,	O
catalase	B-GENE-Y
(	O
CAT	B-GENE-Y
)	O
,	O
glutathione	B-GENE-N
peroxidase	I-GENE-N
(	O
GPX	B-GENE-N
)	O
,	O
vitamin	B-CHEMICAL
E	I-CHEMICAL
,	O
and	O
vitamin	B-CHEMICAL
A	I-CHEMICAL
.	O

Inactive	O
persons	O
with	O
ID	O
had	O
significantly	O
lower	O
SOD	B-GENE-N
(	O
p	O
<	O
0	O
.	O
05	O
)	O
,	O
CAT	B-GENE-Y
(	O
p	O
<	O
0	O
.	O
05	O
)	O
,	O
and	O
GPX	B-GENE-N
(	O
p	O
<	O
0	O
.	O
05	O
)	O
.	O

All	O
plasma	O
vitamin	O
levels	O
were	O
significantly	O
higher	O
in	O
physically	O
active	O
subjects	O
(	O
vitamin	B-CHEMICAL
A	I-CHEMICAL
:	O
1	O
.	O
42	O
+	O
/	O
-	O
0	O
.	O
05	O
mmol	O
/	O
l	O
,	O
vitamin	B-CHEMICAL
E	I-CHEMICAL
:	O
31	O
.	O
32	O
+	O
/	O
-	O
2	O
.	O
62	O
mmol	O
/	O
l	O
)	O
than	O
in	O
sedentary	O
control	O
subjects	O
(	O
vitamin	B-CHEMICAL
A	I-CHEMICAL
:	O
1	O
.	O
02	O
+	O
/	O
-	O
0	O
.	O
03	O
mmol	O
/	O
l	O
,	O
vitamin	B-CHEMICAL
E	I-CHEMICAL
:	O
18	O
.	O
88	O
+	O
/	O
-	O
2	O
.	O
23	O
mmol	O
/	O
l	O
)	O
p	O
<	O
0	O
.	O
01	O
.	O

These	O
results	O
suggest	O
that	O
regular	O
physical	O
activity	O
is	O
associated	O
with	O
preserved	O
AODs	O
in	O
adults	O
with	O
ID	O
.	O

As	O
opposed	O
to	O
a	O
physically	O
active	O
lifestyle	O
,	O
an	O
inactive	O
results	O
in	O
low	O
levels	O
of	O
antioxidants	O
.	O

Na	B-CHEMICAL
+	I-CHEMICAL
/	O
Cl	B-CHEMICAL
-	I-CHEMICAL
dipole	O
couples	O
agonist	O
binding	O
to	O
kainate	B-GENE-N
receptor	I-GENE-N
activation	O
.	O

Kainate	B-GENE-N
-	I-GENE-N
selective	I-GENE-N
ionotropic	I-GENE-N
glutamate	I-GENE-N
receptors	I-GENE-N
(	O
GluRs	B-GENE-N
)	O
require	O
external	O
Na	B-CHEMICAL
+	I-CHEMICAL
and	O
Cl	B-CHEMICAL
-	I-CHEMICAL
as	O
well	O
as	O
the	O
neurotransmitter	O
L	B-CHEMICAL
-	I-CHEMICAL
glutamate	I-CHEMICAL
for	O
activation	O
.	O

Although	O
,	O
external	O
anions	O
and	O
cations	O
apparently	O
coactivate	O
kainate	B-GENE-N
receptors	I-GENE-N
(	O
KARs	B-GENE-N
)	O
in	O
an	O
identical	O
manner	O
,	O
it	O
has	O
yet	O
to	O
be	O
established	O
how	O
ions	O
of	O
opposite	O
charge	O
achieve	O
this	O
.	O

An	O
additional	O
complication	O
is	O
that	O
KARs	B-GENE-N
are	O
subject	O
to	O
other	O
forms	O
of	O
cation	O
modulation	O
via	O
extracellular	O
acidification	O
(	O
i	O
.	O
e	O
.	O
,	O
protons	O
)	O
and	O
divalent	O
ions	O
.	O

Consequently	O
,	O
other	O
cation	O
species	O
may	O
compete	O
with	O
Na	B-CHEMICAL
+	I-CHEMICAL
to	O
regulate	O
the	O
time	O
KARs	B-GENE-N
remain	O
in	O
the	O
open	O
state	O
.	O

Here	O
we	O
designed	O
experiments	O
to	O
unravel	O
how	O
external	O
ions	O
regulate	O
GluR6	B-GENE-N
KARs	B-GENE-N
.	O

We	O
show	O
that	O
GluR6	B-GENE-Y
kinetics	O
are	O
unaffected	O
by	O
alterations	O
in	O
physiological	O
pH	O
but	O
that	O
divalent	O
and	O
alkali	O
metal	O
ions	O
compete	O
to	O
determine	O
the	O
time	O
course	O
of	O
KAR	B-GENE-N
channel	I-GENE-N
activity	O
.	O

Additionally	O
,	O
Na	B-CHEMICAL
+	I-CHEMICAL
and	O
Cl	B-CHEMICAL
-	I-CHEMICAL
ions	O
coactivate	O
GluR6	B-GENE-Y
receptors	O
by	O
establishing	O
a	O
dipole	O
,	O
accounting	O
for	O
their	O
common	O
effect	O
on	O
KARs	B-GENE-N
.	O

Using	O
charged	O
amino	B-CHEMICAL
acids	I-CHEMICAL
as	O
tethered	O
ions	O
,	O
we	O
further	O
demonstrate	O
that	O
the	O
docking	O
order	O
is	O
fixed	O
with	O
cations	O
binding	O
first	O
,	O
followed	O
by	O
anions	O
.	O

Together	O
,	O
our	O
findings	O
identify	O
the	O
dipole	O
as	O
a	O
novel	O
gating	O
feature	O
that	O
couples	O
neurotransmitter	O
binding	O
to	O
KAR	B-GENE-N
activation	O
.	O

Nicotine	B-CHEMICAL
receptor	O
gene	O
CHRNA4	B-GENE-Y
modulates	O
early	O
event	O
-	O
related	O
potentials	O
in	O
auditory	O
and	O
visual	O
oddball	O
target	O
detection	O
tasks	O
.	O

The	O
present	O
study	O
seeks	O
to	O
identify	O
effects	O
of	O
a	O
common	O
genetic	O
polymorphism	O
in	O
the	O
human	B-GENE-N
nicotinic	I-GENE-N
alpha4beta2	I-GENE-N
receptor	I-GENE-N
on	O
components	O
of	O
the	O
cognitive	O
event	O
-	O
related	O
potentials	O
in	O
auditory	O
and	O
visual	O
modalities	O
.	O

The	O
same	O
sense	O
thymine	B-CHEMICAL
-	O
to	O
-	O
cytosine	B-CHEMICAL
polymorphism	O
(	O
c	O
.	O
1629T	B-GENE-N
-	I-GENE-N
C	I-GENE-N
;	O
Ser543Ser	B-GENE-N
)	O
was	O
shown	O
to	O
preferentially	O
modulate	O
early	O
components	O
in	O
both	O
modalities	O
.	O

Specifically	O
,	O
the	O
auditory	O
N1	O
component	O
amplitude	O
was	O
higher	O
for	O
T	O
allele	O
homozygotes	O
than	O
for	O
C	O
allele	O
carriers	O
.	O

The	O
visual	O
P1	O
component	O
revealed	O
the	O
same	O
pattern	O
of	O
significant	O
polymorphic	O
modulation	O
,	O
but	O
the	O
later	O
N1	O
amplitude	O
differences	O
were	O
only	O
marginally	O
significant	O
.	O

There	O
was	O
no	O
reliable	O
indication	O
of	O
interactions	O
between	O
genotype	O
and	O
task	O
factors	O
.	O

Parallel	O
modulation	O
of	O
early	O
latency	O
modality	O
-	O
specific	O
event	O
-	O
related	O
potential	O
(	O
ERP	O
)	O
components	O
in	O
vision	O
and	O
audition	O
may	O
indicate	O
that	O
the	O
CHRNA4	B-GENE-Y
polymorphism	O
affects	O
factors	O
that	O
are	O
common	O
to	O
top	O
-	O
down	O
modulation	O
of	O
sensory	O
processing	O
across	O
modalities	O
.	O

Phenserine	B-CHEMICAL
.	O

Phenserine	B-CHEMICAL
,	O
a	O
derivative	O
of	O
physostigmine	B-CHEMICAL
,	O
was	O
first	O
described	O
as	O
an	O
inhibitor	O
of	O
acetylcholinesterase	B-GENE-N
(	O
AChE	B-GENE-N
)	O
and	O
was	O
shown	O
to	O
improve	O
cognition	O
in	O
various	O
experimental	O
paradigms	O
in	O
rodents	O
and	O
dogs	O
.	O

It	O
was	O
clinically	O
tested	O
for	O
Alzheimer	O
'	O
s	O
disease	O
,	O
with	O
moderate	O
success	O
in	O
initial	O
Phase	O
II	O
studies	O
.	O

Phenserine	B-CHEMICAL
deserves	O
attention	O
for	O
an	O
additional	O
quality	O
of	O
action	O
:	O
in	O
addition	O
to	O
inhibiting	O
AChE	B-GENE-Y
,	O
it	O
modulates	O
the	O
amount	O
of	O
beta	B-GENE-Y
-	I-GENE-Y
amyloid	I-GENE-Y
precursor	I-GENE-Y
protein	I-GENE-Y
(	O
APP	B-GENE-Y
)	O
in	O
neuronal	O
cell	O
culture	O
by	O
reducing	O
APP	B-GENE-Y
translation	O
.	O

This	O
effect	O
probably	O
involves	O
interaction	O
of	O
phenserine	B-CHEMICAL
with	O
a	O
regulatory	O
element	O
in	O
the	O
5	O
'	O
-	O
untranslated	O
region	O
of	O
the	O
APP	B-GENE-Y
gene	O
that	O
controls	O
APP	B-GENE-Y
expression	O
.	O

Phenserine	B-CHEMICAL
apparently	O
reduces	O
translational	O
efficiency	O
of	O
APP	B-GENE-Y
mRNA	O
into	O
protein	O
,	O
a	O
process	O
that	O
may	O
involve	O
an	O
interaction	O
with	O
iron	B-CHEMICAL
and	O
/	O
or	O
an	O
iron	B-CHEMICAL
-	O
responsive	O
element	O
.	O

As	O
a	O
consequence	O
,	O
phenserine	B-CHEMICAL
reduces	O
beta	B-GENE-Y
-	I-GENE-Y
amyloid	I-GENE-Y
peptide	O
(	O
Abeta	B-GENE-Y
)	O
formation	O
in	O
vitro	O
and	O
in	O
vivo	O
.	O

Phenserine	B-CHEMICAL
is	O
also	O
unique	O
because	O
of	O
differing	O
actions	O
of	O
its	O
enantiomers	O
:	O
(	B-CHEMICAL
-	I-CHEMICAL
)	I-CHEMICAL
-	I-CHEMICAL
phenserine	I-CHEMICAL
is	O
the	O
active	O
enantiomer	O
for	O
inhibition	O
of	O
AChE	B-GENE-Y
,	O
whereas	O
(	B-CHEMICAL
+	I-CHEMICAL
)	I-CHEMICAL
-	I-CHEMICAL
phenserine	I-CHEMICAL
(	O
'	O
posiphen	B-CHEMICAL
'	O
)	O
has	O
weak	O
activity	O
as	O
an	O
AChE	B-GENE-Y
inhibitor	O
and	O
can	O
be	O
dosed	O
much	O
higher	O
.	O

Both	O
enantiomers	O
are	O
equipotent	O
in	O
downregulating	O
APP	B-GENE-Y
expression	O
.	O

(	B-CHEMICAL
+	I-CHEMICAL
)	I-CHEMICAL
-	I-CHEMICAL
Posiphen	I-CHEMICAL
may	O
be	O
a	O
promising	O
drug	O
,	O
either	O
alone	O
or	O
in	O
combination	O
with	O
(	B-CHEMICAL
-	I-CHEMICAL
)	I-CHEMICAL
-	I-CHEMICAL
phenserine	I-CHEMICAL
,	O
to	O
attenuate	O
the	O
progression	O
of	O
Alzheimer	O
'	O
s	O
disease	O
.	O

Alpha1	B-GENE-N
-	I-GENE-N
adrenoceptors	I-GENE-N
are	O
required	O
for	O
normal	O
male	O
sexual	O
function	O
.	O

BACKGROUND	O
AND	O
PURPOSE	O
:	O
Alpha	B-GENE-N
(	I-GENE-N
1	I-GENE-N
)	I-GENE-N
-	I-GENE-N
adrenoceptor	I-GENE-N
antagonists	O
are	O
extensively	O
used	O
in	O
the	O
treatment	O
of	O
hypertension	O
and	O
lower	O
urinary	O
tract	O
symptoms	O
associated	O
with	O
benign	O
prostatic	O
hyperplasia	O
.	O

Among	O
the	O
side	O
effects	O
,	O
ejaculatory	O
dysfunction	O
occurs	O
more	O
frequently	O
with	O
drugs	O
that	O
are	O
relatively	O
selective	O
for	O
alpha	B-GENE-Y
(	I-GENE-Y
1A	I-GENE-Y
)	I-GENE-Y
-	I-GENE-Y
adrenoceptors	I-GENE-Y
compared	O
with	O
other	O
drugs	O
of	O
this	O
class	O
.	O

This	O
suggests	O
that	O
alpha	B-GENE-Y
(	I-GENE-Y
1A	I-GENE-Y
)	I-GENE-Y
-	I-GENE-Y
adrenoceptors	I-GENE-Y
may	O
contribute	O
to	O
ejaculation	O
.	O

However	O
,	O
this	O
has	O
not	O
been	O
studied	O
at	O
the	O
molecular	O
level	O
.	O

EXPERIMENTAL	O
APPROACH	O
:	O
The	O
physiological	O
contribution	O
of	O
each	O
alpha	B-GENE-N
(	I-GENE-N
1	I-GENE-N
)	I-GENE-N
-	I-GENE-N
adrenoceptor	I-GENE-N
subtype	O
was	O
characterized	O
using	O
alpha	B-GENE-N
(	I-GENE-N
1	I-GENE-N
)	I-GENE-N
-	I-GENE-N
adrenoceptor	I-GENE-N
subtype	O
-	O
selective	O
knockout	O
(	O
KO	O
)	O
mice	O
(	O
alpha	B-GENE-N
(	I-GENE-N
1A	I-GENE-N
)	I-GENE-N
-	I-GENE-N
,	I-GENE-N
alpha	I-GENE-N
(	I-GENE-N
1B	I-GENE-N
)	I-GENE-N
-	I-GENE-N
and	I-GENE-N
alpha	I-GENE-N
(	I-GENE-N
1D	I-GENE-N
)	I-GENE-N
-	I-GENE-N
AR	I-GENE-N
KO	O
mice	O
)	O
since	O
the	O
subtype	O
-	O
specific	O
drugs	O
available	O
are	O
only	O
moderately	O
selective	O
.	O

We	O
analysed	O
the	O
role	O
of	O
alpha	B-GENE-N
(	I-GENE-N
1	I-GENE-N
)	I-GENE-N
-	I-GENE-N
adrenoceptors	I-GENE-N
in	O
the	O
blood	O
pressure	O
and	O
vascular	O
response	O
as	O
well	O
as	O
ejaculation	O
by	O
determining	O
these	O
variables	O
in	O
alpha	B-GENE-N
(	I-GENE-N
1	I-GENE-N
)	I-GENE-N
-	I-GENE-N
adrenoceptor	I-GENE-N
subtype	O
-	O
selective	O
KO	O
mice	O
and	O
in	O
mice	O
with	O
all	O
their	O
alpha	B-GENE-N
(	I-GENE-N
1	I-GENE-N
)	I-GENE-N
-	I-GENE-N
adrenoceptor	I-GENE-N
subtypes	O
deleted	O
(	O
alpha	B-GENE-N
(	I-GENE-N
1	I-GENE-N
)	I-GENE-N
-	I-GENE-N
AR	I-GENE-N
triple	O
-	O
KO	O
mice	O
)	O
.	O

KEY	O
RESULTS	O
:	O
The	O
pregnancy	O
rate	O
was	O
reduced	O
by	O
50	O
%	O
in	O
alpha	B-GENE-Y
(	I-GENE-Y
1A	I-GENE-Y
)	I-GENE-Y
-	I-GENE-Y
adrenoceptor	I-GENE-Y
KO	O
mice	O
,	O
and	O
this	O
reduction	O
was	O
dramatically	O
enhanced	O
in	O
alpha	B-GENE-N
(	I-GENE-N
1	I-GENE-N
)	I-GENE-N
-	I-GENE-N
adrenoceptor	I-GENE-N
triple	O
-	O
KO	O
mice	O
.	O

Contractile	O
tension	O
of	O
the	O
vas	O
deferens	O
in	O
response	O
to	O
noradrenaline	B-CHEMICAL
was	O
markedly	O
decreased	O
in	O
alpha	B-GENE-Y
(	I-GENE-Y
1A	I-GENE-Y
)	I-GENE-Y
-	I-GENE-Y
adrenoceptor	I-GENE-Y
KO	O
mice	O
,	O
and	O
this	O
contraction	O
was	O
completely	O
abolished	O
in	O
alpha	B-GENE-N
(	I-GENE-N
1	I-GENE-N
)	I-GENE-N
-	I-GENE-N
adrenoceptor	I-GENE-N
triple	O
-	O
KO	O
mice	O
.	O

This	O
attenuation	O
of	O
contractility	O
was	O
also	O
observed	O
in	O
the	O
electrically	O
stimulated	O
vas	O
deferens	O
.	O

CONCLUSIONS	O
AND	O
IMPLICATIONS	O
:	O
These	O
results	O
demonstrate	O
that	O
alpha	B-GENE-N
(	I-GENE-N
1	I-GENE-N
)	I-GENE-N
-	I-GENE-N
adrenoceptors	I-GENE-N
,	O
particularly	O
alpha	B-GENE-Y
(	I-GENE-Y
1A	I-GENE-Y
)	I-GENE-Y
-	I-GENE-Y
adrenoceptors	I-GENE-Y
,	O
are	O
required	O
for	O
normal	O
contractility	O
of	O
the	O
vas	O
deferens	O
and	O
consequent	O
sperm	O
ejaculation	O
as	O
well	O
as	O
having	O
a	O
function	O
in	O
fertility	O
.	O

Pharmacological	O
activators	O
of	O
AMP	B-GENE-Y
-	I-GENE-Y
activated	I-GENE-Y
protein	I-GENE-Y
kinase	I-GENE-Y
have	O
different	O
effects	O
on	O
Na	B-CHEMICAL
+	I-CHEMICAL
transport	O
processes	O
across	O
human	O
lung	O
epithelial	O
cells	O
.	O

BACKGROUND	O
AND	O
PURPOSE	O
:	O
AMP	B-GENE-Y
-	I-GENE-Y
activated	I-GENE-Y
protein	I-GENE-Y
kinase	I-GENE-Y
(	O
AMPK	B-GENE-Y
)	O
is	O
activated	O
by	O
metformin	B-CHEMICAL
,	O
phenformin	B-CHEMICAL
,	O
and	O
the	O
AMP	B-CHEMICAL
mimetic	O
,	O
5	B-CHEMICAL
-	I-CHEMICAL
aminoimidazole	I-CHEMICAL
-	I-CHEMICAL
4	I-CHEMICAL
-	I-CHEMICAL
carboxamide	I-CHEMICAL
-	I-CHEMICAL
1	I-CHEMICAL
-	I-CHEMICAL
beta	I-CHEMICAL
-	I-CHEMICAL
D	I-CHEMICAL
-	I-CHEMICAL
ribofuranoside	I-CHEMICAL
(	O
AICAR	B-CHEMICAL
)	O
.	O

We	O
have	O
completed	O
an	O
extensive	O
study	O
of	O
the	O
pharmacological	O
effects	O
of	O
these	O
drugs	O
on	O
AMPK	B-GENE-Y
activation	O
,	O
adenine	B-CHEMICAL
nucleotide	I-CHEMICAL
concentration	O
,	O
transepithelial	O
amiloride	B-CHEMICAL
-	O
sensitive	O
(	O
I	O
(	O
amiloride	B-CHEMICAL
)	O
)	O
and	O
ouabain	B-CHEMICAL
-	O
sensitive	O
basolateral	O
(	O
I	O
(	O
ouabain	B-CHEMICAL
)	O
)	O
short	O
circuit	O
current	O
in	O
H441	O
lung	O
epithelial	O
cells	O
.	O

EXPERIMENTAL	O
APPROACH	O
:	O
H441	O
cells	O
were	O
grown	O
on	O
permeable	O
filters	O
at	O
air	O
interface	O
.	O

I	O
(	O
amiloride	B-CHEMICAL
)	O
,	O
I	O
(	O
ouabain	B-CHEMICAL
)	O
and	O
transepithelial	O
resistance	O
were	O
measured	O
in	O
Ussing	O
chambers	O
.	O

AMPK	B-GENE-Y
activity	O
was	O
measured	O
as	O
the	O
amount	O
of	O
radiolabelled	O
phosphate	B-CHEMICAL
transferred	O
to	O
the	O
SAMS	O
peptide	O
.	O

Adenine	B-CHEMICAL
nucleotide	I-CHEMICAL
concentration	O
was	O
analysed	O
by	O
reverse	O
phase	O
HPLC	O
and	O
NAD	B-CHEMICAL
(	I-CHEMICAL
P	I-CHEMICAL
)	I-CHEMICAL
H	I-CHEMICAL
autofluorescence	O
was	O
measured	O
using	O
confocal	O
microscopy	O
.	O

KEY	O
RESULTS	O
:	O
Phenformin	B-CHEMICAL
,	O
AICAR	B-CHEMICAL
and	O
metformin	B-CHEMICAL
increased	O
AMPK	B-GENE-Y
(	I-GENE-Y
alpha1	I-GENE-Y
)	I-GENE-Y
activity	O
and	O
decreased	O
I	O
(	O
amiloride	B-CHEMICAL
)	O
.	O

The	O
AMPK	B-GENE-Y
inhibitor	O
Compound	O
C	O
prevented	O
the	O
action	O
of	O
metformin	B-CHEMICAL
and	O
AICAR	B-CHEMICAL
but	O
not	O
phenformin	B-CHEMICAL
.	O

Phenformin	B-CHEMICAL
and	O
AICAR	B-CHEMICAL
decreased	O
I	O
(	O
ouabain	B-CHEMICAL
)	O
across	O
H441	O
monolayers	O
and	O
decreased	O
monolayer	O
resistance	O
.	O

The	O
decrease	O
in	O
I	O
(	O
amiloride	B-CHEMICAL
)	O
was	O
closely	O
related	O
to	O
I	O
(	O
ouabain	B-CHEMICAL
)	O
with	O
phenformin	B-CHEMICAL
,	O
but	O
not	O
in	O
AICAR	B-CHEMICAL
treated	O
monolayers	O
.	O

Metformin	B-CHEMICAL
and	O
phenformin	B-CHEMICAL
increased	O
the	O
cellular	O
AMP	B-CHEMICAL
:	O
ATP	B-CHEMICAL
ratio	O
but	O
only	O
phenformin	B-CHEMICAL
and	O
AICAR	B-CHEMICAL
decreased	O
cellular	O
ATP	B-CHEMICAL
.	O

CONCLUSIONS	O
AND	O
IMPLICATIONS	O
:	O
Activation	O
of	O
alpha1	B-GENE-Y
-	I-GENE-Y
AMPK	I-GENE-Y
is	O
associated	O
with	O
inhibition	O
of	O
apical	O
amiloride	B-GENE-N
-	I-GENE-N
sensitive	I-GENE-N
Na	I-GENE-N
(	I-GENE-N
+	I-GENE-N
)	I-GENE-N
channels	I-GENE-N
(	O
ENaC	B-GENE-N
)	O
,	O
which	O
has	O
important	O
implications	O
for	O
the	O
clinical	O
use	O
of	O
metformin	B-CHEMICAL
.	O

Additional	O
pharmacological	O
effects	O
evoked	O
by	O
AICAR	B-CHEMICAL
and	O
phenformin	B-CHEMICAL
on	O
I	O
(	O
ouabain	B-CHEMICAL
)	O
,	O
with	O
potential	O
secondary	O
effects	O
on	O
apical	O
Na	B-CHEMICAL
+	I-CHEMICAL
conductance	O
,	O
ENaC	B-GENE-N
activity	O
and	O
monolayer	O
resistance	O
,	O
have	O
important	O
consequences	O
for	O
their	O
use	O
as	O
pharmacological	O
activators	O
of	O
AMPK	B-GENE-Y
in	O
cell	O
systems	O
where	O
Na	B-GENE-N
+	I-GENE-N
K	I-GENE-N
+	I-GENE-N
ATPase	I-GENE-N
is	O
an	O
important	O
component	O
.	O

Neuroprotective	O
effect	O
of	O
nimesulide	B-CHEMICAL
,	O
a	O
preferential	O
COX	B-GENE-Y
-	I-GENE-Y
2	I-GENE-Y
inhibitor	O
,	O
against	O
pentylenetetrazol	B-CHEMICAL
(	O
PTZ	B-CHEMICAL
)	O
-	O
induced	O
chemical	O
kindling	O
and	O
associated	O
biochemical	O
parameters	O
in	O
mice	O
.	O

Brain	O
cyclooxygenases	B-GENE-N
(	O
COX	B-GENE-N
)	O
,	O
the	O
rate	O
-	O
limiting	O
enzyme	O
in	O
prostaglandin	B-CHEMICAL
synthesis	O
,	O
is	O
rapidly	O
and	O
transiently	O
induced	O
by	O
convulsions	O
in	O
hippocampal	O
and	O
cortical	O
neurons	O
.	O

Previous	O
studies	O
have	O
explored	O
the	O
protective	O
effect	O
of	O
naproxen	B-CHEMICAL
(	O
non	O
-	O
selective	O
COX	B-GENE-N
-	O
inhibitor	O
)	O
or	O
rofecoxib	B-CHEMICAL
(	O
selective	O
COX	B-GENE-Y
-	I-GENE-Y
2	I-GENE-Y
inhibitor	O
)	O
against	O
chemical	O
kindling	O
in	O
mice	O
.	O

With	O
this	O
background	O
,	O
the	O
present	O
study	O
was	O
designed	O
to	O
explore	O
the	O
possible	O
effect	O
of	O
nimesulide	B-CHEMICAL
(	O
a	O
preferential	O
COX	B-GENE-Y
-	I-GENE-Y
2	I-GENE-Y
inhibitor	O
)	O
against	O
pentylenetetrazol	B-CHEMICAL
(	O
PTZ	B-CHEMICAL
)	O
-	O
induced	O
kindling	O
epilepsy	O
in	O
mice	O
.	O

To	O
induce	O
kindling	O
,	O
PTZ	B-CHEMICAL
was	O
injected	O
in	O
a	O
subconvulsive	O
dose	O
(	O
40	O
mg	O
/	O
kg	O
,	O
i	O
.	O
p	O
.	O
)	O
every	O
other	O
day	O
for	O
15	O
days	O
.	O

Nimesulide	B-CHEMICAL
(	O
2	O
.	O
5	O
or	O
5	O
mg	O
/	O
kg	O
,	O
p	O
.	O
o	O
.	O
)	O
was	O
administered	O
each	O
day	O
45	O
min	O
before	O
either	O
PTZ	B-CHEMICAL
or	O
vehicle	O
challenge	O
.	O

The	O
intensity	O
of	O
kindling	O
was	O
assessed	O
immediately	O
after	O
PTZ	B-CHEMICAL
administration	O
according	O
to	O
a	O
prevalidated	O
scoring	O
scale	O
.	O

On	O
16th	O
day	O
i	O
.	O
e	O
.	O
24	O
h	O
after	O
the	O
last	O
dose	O
of	O
PTZ	B-CHEMICAL
,	O
animals	O
were	O
sacrificed	O
and	O
various	O
biochemical	O
parameters	O
were	O
assessed	O
in	O
the	O
whole	O
brain	O
.	O

Compared	O
with	O
normal	O
control	O
group	O
,	O
PTZ	B-CHEMICAL
-	O
kindled	O
mice	O
had	O
significantly	O
higher	O
levels	O
of	O
malondialdehyde	B-CHEMICAL
,	O
nitrite	B-CHEMICAL
,	O
myeloperoxidase	B-GENE-Y
but	O
had	O
lower	O
levels	O
of	O
reduced	O
glutathione	B-CHEMICAL
in	O
the	O
whole	O
brain	O
homogenate	O
.	O

Chronic	O
treatment	O
with	O
nimesulide	B-CHEMICAL
(	O
2	O
.	O
5	O
or	O
5	O
mg	O
/	O
kg	O
,	O
p	O
.	O
o	O
.	O
)	O
for	O
15	O
days	O
showed	O
significant	O
decrease	O
in	O
kindling	O
score	O
and	O
could	O
play	O
a	O
role	O
in	O
controlling	O
the	O
accompanying	O
biochemical	O
alterations	O
due	O
to	O
PTZ	B-CHEMICAL
.	O

These	O
results	O
suggested	O
that	O
nimesulide	B-CHEMICAL
,	O
a	O
preferential	O
COX	B-GENE-Y
-	I-GENE-Y
2	I-GENE-Y
inhibitor	O
offered	O
neuroprotection	O
against	O
PTZ	B-CHEMICAL
-	O
induced	O
kindling	O
in	O
mice	O
.	O

Glutathione	B-GENE-N
S	I-GENE-N
-	I-GENE-N
transferase	I-GENE-N
polymorphisms	O
,	O
cruciferous	O
vegetable	O
intake	O
and	O
cancer	O
risk	O
in	O
the	O
Central	O
and	O
Eastern	O
European	O
Kidney	O
Cancer	O
Study	O
.	O

High	O
consumption	O
of	O
cruciferous	O
vegetables	O
has	O
been	O
associated	O
with	O
reduced	O
kidney	O
cancer	O
risk	O
in	O
many	O
studies	O
.	O

Isothiocyanates	B-CHEMICAL
,	O
thought	O
to	O
be	O
responsible	O
for	O
the	O
chemopreventive	O
properties	O
of	O
this	O
food	O
group	O
,	O
are	O
conjugated	O
to	O
glutathione	B-CHEMICAL
by	O
glutathione	B-GENE-N
S	I-GENE-N
-	I-GENE-N
transferases	I-GENE-N
(	O
GSTs	B-GENE-N
)	O
before	O
urinary	O
excretion	O
.	O

Modification	O
of	O
this	O
relationship	O
by	O
host	O
genetic	O
factors	O
is	O
unknown	O
.	O

We	O
investigated	O
cruciferous	O
vegetable	O
intake	O
in	O
1097	O
cases	O
and	O
1555	O
controls	O
enrolled	O
in	O
a	O
multicentric	O
case	O
-	O
control	O
study	O
from	O
the	O
Czech	O
Republic	O
,	O
Poland	O
,	O
Romania	O
and	O
Russia	O
.	O

To	O
assess	O
possible	O
gene	O
-	O
diet	O
interactions	O
,	O
genotyped	O
cases	O
(	O
N	O
=	O
925	O
)	O
and	O
controls	O
(	O
N	O
=	O
1247	O
)	O
for	O
selected	O
functional	O
or	O
non	O
-	O
synonymous	O
polymorphisms	O
including	O
the	O
GSTM1	B-GENE-Y
deletion	O
,	O
GSTM3	B-GENE-Y
3	O
bp	O
deletion	O
(	O
IVS6	O
+	O
22	O
-	O
AGG	O
)	O
and	O
V224I	B-GENE-N
G	B-GENE-N
>	I-GENE-N
A	I-GENE-N
substitution	O
,	O
GSTT1	B-GENE-Y
deletion	O
and	O
the	O
GSTP1	B-GENE-Y
I105V	B-GENE-N
A	B-GENE-N
>	I-GENE-N
G	I-GENE-N
substitution	O
.	O

The	O
odds	O
ratio	O
(	O
OR	O
)	O
for	O
low	O
(	O
less	O
than	O
once	O
per	O
month	O
)	O
versus	O
high	O
(	O
at	O
least	O
once	O
per	O
week	O
)	O
intake	O
of	O
cruciferous	O
vegetables	O
was	O
1	O
.	O
29	O
[	O
95	O
%	O
confidence	O
interval	O
(	O
CI	O
)	O
:	O
1	O
.	O
02	O
-	O
1	O
.	O
62	O
;	O
P	O
-	O
trend	O
=	O
0	O
.	O
03	O
]	O
.	O

When	O
low	O
intake	O
of	O
cruciferous	O
vegetables	O
(	O
less	O
than	O
once	O
per	O
month	O
)	O
was	O
stratified	O
by	O
GST	B-GENE-N
genotype	O
,	O
higher	O
kidney	O
cancer	O
risks	O
were	O
observed	O
among	O
individuals	O
with	O
the	O
GSTT1	B-GENE-Y
null	O
(	O
OR	O
=	O
1	O
.	O
86	O
;	O
95	O
%	O
CI	O
:	O
1	O
.	O
07	O
-	O
3	O
.	O
23	O
;	O
P	O
-	O
interaction	O
=	O
0	O
.	O
05	O
)	O
or	O
with	O
both	O
GSTM1	B-GENE-N
/	I-GENE-N
T1	I-GENE-N
null	O
genotypes	O
(	O
OR	O
=	O
2	O
.	O
49	O
;	O
95	O
%	O
CI	O
:	O
1	O
.	O
08	O
-	O
5	O
.	O
77	O
;	O
P	O
-	O
interaction	O
=	O
0	O
.	O
05	O
)	O
.	O

These	O
data	O
provide	O
additional	O
evidence	O
for	O
the	O
role	O
of	O
cruciferous	O
vegetables	O
in	O
cancer	O
prevention	O
among	O
individuals	O
with	O
common	O
,	O
functional	O
genetic	O
polymorphisms	O
.	O

Regulated	O
function	O
of	O
the	O
prolyl	B-GENE-N
-	I-GENE-N
4	I-GENE-N
-	I-GENE-N
hydroxylase	I-GENE-N
domain	I-GENE-N
(	I-GENE-N
PHD	I-GENE-N
)	I-GENE-N
oxygen	I-GENE-N
sensor	I-GENE-N
proteins	I-GENE-N
.	O

Cellular	O
oxygen	B-CHEMICAL
is	O
sensed	O
by	O
prolyl	B-GENE-N
-	I-GENE-N
4	I-GENE-N
-	I-GENE-N
hydroxylase	I-GENE-N
domain	I-GENE-N
(	I-GENE-N
PHD	I-GENE-N
)	I-GENE-N
proteins	I-GENE-N
that	O
hydroxylate	B-CHEMICAL
hypoxia	B-GENE-N
-	I-GENE-N
inducible	I-GENE-N
factor	I-GENE-N
(	I-GENE-N
HIF	I-GENE-N
)	I-GENE-N
alpha	I-GENE-N
subunits	O
.	O

Under	O
normoxic	O
conditions	O
,	O
hydroxylated	O
HIFalpha	B-GENE-N
is	O
bound	O
by	O
the	O
von	O
Hippel	O
-	O
Lindau	O
(	O
pVHL	O
)	O
tumor	O
suppressor	O
,	O
leading	O
to	O
ubiquitinylation	O
and	O
proteasomal	O
degradation	O
.	O

Under	O
hypoxic	O
conditions	O
,	O
hydroxylation	O
becomes	O
reduced	O
,	O
leading	O
to	O
HIFalpha	B-GENE-N
stabilization	O
.	O

The	O
authors	O
recently	O
showed	O
that	O
changes	O
in	O
PHD	B-GENE-N
abundance	O
and	O
activity	O
can	O
regulate	O
HIFalpha	B-GENE-N
stability	O
under	O
normoxic	O
as	O
well	O
as	O
under	O
hypoxic	O
conditions	O
.	O

Thus	O
,	O
the	O
PHD	B-GENE-N
oxygen	B-CHEMICAL
sensors	O
themselves	O
represent	O
effectors	O
of	O
cellular	O
signalling	O
pathways	O
as	O
well	O
as	O
potential	O
drug	O
targets	O
.	O

Here	O
,	O
a	O
cell	O
-	O
free	O
in	O
vitro	O
microtiter	O
plate	O
-	O
based	O
peptide	O
hydroxylation	O
assay	O
was	O
used	O
to	O
investigate	O
the	O
influence	O
of	O
ferrous	B-CHEMICAL
iron	I-CHEMICAL
,	O
Krebs	O
cycle	O
intermediates	O
,	O
transition	O
metals	O
,	O
and	O
vitamin	B-CHEMICAL
C	I-CHEMICAL
and	O
other	O
antioxidants	O
on	O
the	O
activity	O
of	O
purified	O
PHD1	B-GENE-N
to	I-GENE-N
3	I-GENE-N
.	O

PHD	B-GENE-N
activity	O
depends	O
not	O
only	O
on	O
oxygen	B-CHEMICAL
availability	O
but	O
is	O
also	O
regulated	O
by	O
iron	B-CHEMICAL
,	O
vitamin	B-CHEMICAL
C	I-CHEMICAL
,	O
and	O
Krebs	O
cycle	O
intermediates	O
,	O
suggesting	O
a	O
physiological	O
relevance	O
of	O
their	O
cellular	O
concentrations	O
.	O

Copper	B-CHEMICAL
but	O
not	O
iron	B-CHEMICAL
,	O
cobalt	B-CHEMICAL
,	O
or	O
nickel	B-CHEMICAL
salts	O
catalyzed	O
vitamin	B-CHEMICAL
C	I-CHEMICAL
oxidation	O
.	O

While	O
vitamin	B-CHEMICAL
C	I-CHEMICAL
is	O
essential	O
for	O
PHD	B-GENE-N
activity	O
in	O
vitro	O
,	O
N	B-CHEMICAL
-	I-CHEMICAL
acetyl	I-CHEMICAL
-	I-CHEMICAL
L	I-CHEMICAL
-	I-CHEMICAL
cysteine	I-CHEMICAL
had	O
no	O
effect	O
,	O
and	O
gallic	B-CHEMICAL
acid	I-CHEMICAL
or	O
n	B-CHEMICAL
-	I-CHEMICAL
propyl	I-CHEMICAL
gallate	I-CHEMICAL
efficiently	O
inhibited	O
the	O
activity	O
of	O
all	O
three	O
PHDs	B-GENE-N
,	O
demonstrating	O
different	O
functions	O
of	O
these	O
antioxidants	O
.	O

Crystal	O
structure	O
of	O
a	O
human	O
membrane	O
protein	O
involved	O
in	O
cysteinyl	B-CHEMICAL
leukotriene	I-CHEMICAL
biosynthesis	O
.	O

The	O
cysteinyl	B-CHEMICAL
leukotrienes	I-CHEMICAL
,	O
namely	O
leukotriene	B-CHEMICAL
(	I-CHEMICAL
LT	I-CHEMICAL
)	I-CHEMICAL
C4	I-CHEMICAL
and	O
its	O
metabolites	O
LTD4	B-CHEMICAL
and	O
LTE4	B-CHEMICAL
,	O
the	O
components	O
of	O
slow	O
-	O
reacting	O
substance	O
of	O
anaphylaxis	O
,	O
are	O
lipid	O
mediators	O
of	O
smooth	O
muscle	O
constriction	O
and	O
inflammation	O
,	O
particularly	O
implicated	O
in	O
bronchial	O
asthma	O
.	O

LTC4	B-GENE-Y
synthase	I-GENE-Y
(	O
LTC4S	B-GENE-Y
)	O
,	O
the	O
pivotal	O
enzyme	O
for	O
the	O
biosynthesis	O
of	O
LTC4	B-CHEMICAL
(	O
ref	O
.	O
10	O
)	O
,	O
is	O
an	O
18	O
-	O
kDa	O
integral	O
nuclear	O
membrane	O
protein	O
that	O
belongs	O
to	O
a	O
superfamily	O
of	O
membrane	O
-	O
associated	O
proteins	O
in	O
eicosanoid	B-CHEMICAL
and	O
glutathione	B-CHEMICAL
metabolism	O
that	O
includes	O
5	B-GENE-Y
-	I-GENE-Y
lipoxygenase	I-GENE-Y
-	I-GENE-Y
activating	I-GENE-Y
protein	I-GENE-Y
,	O
microsomal	B-GENE-N
glutathione	I-GENE-N
S	I-GENE-N
-	I-GENE-N
transferases	I-GENE-N
(	O
MGSTs	B-GENE-N
)	O
,	O
and	O
microsomal	B-GENE-Y
prostaglandin	I-GENE-Y
E	I-GENE-Y
synthase	I-GENE-Y
1	I-GENE-Y
(	O
ref	O
.	O
13	O
)	O
.	O

LTC4S	B-GENE-Y
conjugates	O
glutathione	B-CHEMICAL
to	O
LTA4	B-CHEMICAL
,	O
the	O
endogenous	O
substrate	O
derived	O
from	O
arachidonic	B-CHEMICAL
acid	I-CHEMICAL
through	O
the	O
5	B-GENE-Y
-	I-GENE-Y
lipoxygenase	I-GENE-Y
pathway	O
.	O

In	O
contrast	O
with	O
MGST2	B-GENE-Y
and	O
MGST3	B-GENE-Y
(	O
refs	O
15	O
,	O
16	O
)	O
,	O
LTC4S	B-GENE-Y
does	O
not	O
conjugate	O
glutathione	B-CHEMICAL
to	O
xenobiotics	O
.	O

Here	O
we	O
show	O
the	O
atomic	O
structure	O
of	O
human	B-GENE-Y
LTC4S	I-GENE-Y
in	O
a	O
complex	O
with	O
glutathione	B-CHEMICAL
at	O
3	O
.	O
3	O
A	O
resolution	O
by	O
X	O
-	O
ray	O
crystallography	O
and	O
provide	O
insights	O
into	O
the	O
high	O
substrate	O
specificity	O
for	O
glutathione	B-CHEMICAL
and	O
LTA4	B-CHEMICAL
that	O
distinguishes	O
LTC4S	B-GENE-Y
from	O
other	O
MGSTs	B-GENE-N
.	O

The	O
LTC4S	B-GENE-Y
monomer	O
has	O
four	O
transmembrane	O
alpha	O
-	O
helices	O
and	O
forms	O
a	O
threefold	O
symmetric	O
trimer	O
as	O
a	O
unit	O
with	O
functional	O
domains	O
across	O
each	O
interface	O
.	O

Glutathione	B-CHEMICAL
resides	O
in	O
a	O
U	O
-	O
shaped	O
conformation	O
within	O
an	O
interface	O
between	O
adjacent	O
monomers	O
,	O
and	O
this	O
binding	O
is	O
stabilized	O
by	O
a	O
loop	O
structure	O
at	O
the	O
top	O
of	O
the	O
interface	O
.	O

LTA4	B-CHEMICAL
would	O
fit	O
into	O
the	O
interface	O
so	O
that	O
Arg	B-CHEMICAL
104	O
of	O
one	O
monomer	O
activates	O
glutathione	B-CHEMICAL
to	O
provide	O
the	O
thiolate	B-CHEMICAL
anion	O
that	O
attacks	O
C6	B-CHEMICAL
of	O
LTA4	B-CHEMICAL
to	O
form	O
a	O
thioether	B-CHEMICAL
bond	O
,	O
and	O
Arg	B-CHEMICAL
31	O
in	O
the	O
neighbouring	O
monomer	O
donates	O
a	O
proton	O
to	O
form	O
a	O
hydroxyl	B-CHEMICAL
group	O
at	O
C5	O
,	O
resulting	O
in	O
5	B-CHEMICAL
(	I-CHEMICAL
S	I-CHEMICAL
)	I-CHEMICAL
-	I-CHEMICAL
hydroxy	I-CHEMICAL
-	I-CHEMICAL
6	I-CHEMICAL
(	I-CHEMICAL
R	I-CHEMICAL
)	I-CHEMICAL
-	I-CHEMICAL
S	I-CHEMICAL
-	I-CHEMICAL
glutathionyl	I-CHEMICAL
-	I-CHEMICAL
7	I-CHEMICAL
,	I-CHEMICAL
9	I-CHEMICAL
-	I-CHEMICAL
trans	I-CHEMICAL
-	I-CHEMICAL
11	I-CHEMICAL
,	I-CHEMICAL
14	I-CHEMICAL
-	I-CHEMICAL
cis	I-CHEMICAL
-	I-CHEMICAL
eicosatetraenoic	I-CHEMICAL
acid	I-CHEMICAL
(	O
LTC4	B-CHEMICAL
)	O
.	O

These	O
findings	O
provide	O
a	O
structural	O
basis	O
for	O
the	O
development	O
of	O
LTC4S	B-GENE-Y
inhibitors	O
for	O
a	O
proinflammatory	O
pathway	O
mediated	O
by	O
three	O
cysteinyl	B-CHEMICAL
leukotriene	I-CHEMICAL
ligands	O
whose	O
stability	O
and	O
potency	O
are	O
different	O
and	O
by	O
multiple	O
cysteinyl	B-GENE-N
leukotriene	I-GENE-N
receptors	I-GENE-N
whose	O
functions	O
may	O
be	O
non	O
-	O
redundant	O
.	O

FCGR2A	B-GENE-Y
and	O
FCGR3A	B-GENE-Y
polymorphisms	O
associated	O
with	O
clinical	O
outcome	O
of	O
epidermal	B-GENE-Y
growth	I-GENE-Y
factor	I-GENE-Y
receptor	I-GENE-Y
expressing	O
metastatic	O
colorectal	O
cancer	O
patients	O
treated	O
with	O
single	O
-	O
agent	O
cetuximab	O
.	O

PURPOSE	O
:	O
Cetuximab	O
,	O
a	O
chimeric	O
immunoglobulin	B-GENE-Y
G	I-GENE-Y
1	I-GENE-Y
(	O
IgG1	B-GENE-Y
)	O
anti	O
-	O
epidermal	B-GENE-Y
growth	I-GENE-Y
factor	I-GENE-Y
receptor	I-GENE-Y
(	O
EGFR	B-GENE-Y
)	O
monoclonal	O
antibody	O
(	O
mAb	O
)	O
,	O
has	O
shown	O
efficacy	O
in	O
10	O
%	O
of	O
patients	O
with	O
metastatic	O
colorectal	O
cancer	O
(	O
CRC	O
)	O
.	O

Recent	O
studies	O
demonstrate	O
antibody	O
-	O
dependent	O
cell	O
-	O
mediated	O
cytotoxicity	O
(	O
ADCC	O
)	O
is	O
one	O
of	O
the	O
modes	O
of	O
action	O
for	O
rituximab	O
and	O
trastuzumab	O
.	O

Fragment	O
c	O
(	O
Fc	O
)	O
portion	O
of	O
IgG1	B-GENE-Y
mAb	O
has	O
shown	O
to	O
induce	O
ADCC	O
.	O

Fragment	B-GENE-N
c	I-GENE-N
gamma	I-GENE-N
receptors	I-GENE-N
(	O
FcgammaR	B-GENE-N
)	O
play	O
an	O
important	O
role	O
in	O
initiating	O
ADCC	O
.	O

Studies	O
have	O
shown	O
that	O
two	O
IgG	B-GENE-N
FcgammaR	B-GENE-N
polymorphisms	O
(	O
FCGR2A	B-GENE-Y
-	O
H131R	B-GENE-N
and	O
FCGR3A	B-GENE-Y
-	O
V158F	B-GENE-N
)	O
independently	O
predict	O
response	O
to	O
rituximab	O
in	O
patients	O
with	O
follicular	O
lymphoma	O
.	O

We	O
tested	O
the	O
hypothesis	O
of	O
whether	O
these	O
two	O
polymorphisms	O
are	O
associated	O
with	O
clinical	O
outcome	O
in	O
metastatic	O
CRC	O
patients	O
treated	O
with	O
single	O
-	O
agent	O
cetuximab	O
.	O

PATIENTS	O
AND	O
METHODS	O
:	O
Thirty	O
-	O
nine	O
metastatic	O
CRC	O
patients	O
were	O
enrolled	O
onto	O
the	O
ImClone0144	O
trial	O
.	O

Using	O
an	O
allele	O
-	O
specific	O
polymerase	O
chain	O
reaction	O
(	O
PCR	O
)	O
-	O
based	O
method	O
,	O
gene	O
polymorphisms	O
of	O
FCGA2A	B-GENE-Y
-	O
H131R	B-GENE-N
and	O
FCGA3A	B-GENE-Y
-	O
V158F	B-GENE-N
were	O
assessed	O
from	O
genomic	O
DNA	O
extracted	O
from	O
peripheral	O
blood	O
samples	O
.	O

RESULTS	O
:	O
FCGR2A	B-GENE-Y
-	O
H131R	B-GENE-N
and	O
FCGR3A	B-GENE-Y
-	O
V158F	B-GENE-N
polymorphisms	O
were	O
independently	O
associated	O
with	O
progression	O
-	O
free	O
survival	O
(	O
PFS	O
;	O
P	O
=	O
.	O
037	O
and	O
.	O
055	O
,	O
respectively	O
;	O
log	O
-	O
rank	O
test	O
)	O
.	O

Combined	O
analysis	O
of	O
these	O
two	O
polymorphisms	O
showed	O
that	O
patients	O
with	O
the	O
favorable	O
genotypes	O
(	O
FCGR2A	B-GENE-Y
,	O
any	O
histidine	B-CHEMICAL
allele	O
,	O
and	O
FCGR3A	B-GENE-Y
,	O
any	O
phenylalanine	B-CHEMICAL
allele	O
)	O
showed	O
a	O
median	O
PFS	O
of	O
3	O
.	O
7	O
months	O
(	O
95	O
%	O
CI	O
,	O
2	O
.	O
4	O
to	O
4	O
.	O
4	O
months	O
)	O
,	O
whereas	O
patients	O
with	O
any	O
two	O
unfavorable	O
genotypes	O
(	O
FCGR2A	B-GENE-Y
arginine	B-CHEMICAL
/	O
arginine	B-CHEMICAL
or	O
valine	B-CHEMICAL
/	O
valine	B-CHEMICAL
)	O
had	O
a	O
PFS	O
of	O
1	O
.	O
1	O
months	O
(	O
95	O
%	O
CI	O
,	O
1	O
.	O
0	O
to	O
1	O
.	O
4	O
months	O
;	O
P	O
=	O
.	O
004	O
;	O
log	O
-	O
rank	O
test	O
)	O
.	O

CONCLUSION	O
:	O
Our	O
preliminary	O
data	O
suggest	O
that	O
these	O
two	O
polymorphisms	O
may	O
be	O
useful	O
molecular	O
markers	O
to	O
predict	O
clinical	O
outcome	O
in	O
metastatic	O
CRC	O
patients	O
treated	O
with	O
cetuximab	O
and	O
that	O
they	O
may	O
indicate	O
a	O
role	O
of	O
ADCC	O
of	O
cetuximab	O
.	O

Phenelzine	B-CHEMICAL
causes	O
an	O
increase	O
in	O
brain	O
ornithine	O
that	O
is	O
prevented	O
by	O
prior	O
monoamine	B-GENE-N
oxidase	I-GENE-N
inhibition	O
.	O

Phenelzine	B-CHEMICAL
(	O
PLZ	B-CHEMICAL
)	O
,	O
a	O
nonselective	O
irreversible	O
inhibitor	O
of	O
monoamine	B-GENE-N
oxidase	I-GENE-N
(	O
MAO	B-GENE-N
)	O
,	O
also	O
inhibits	O
GABA	B-GENE-Y
-	I-GENE-Y
transaminase	I-GENE-Y
(	O
GABA	B-GENE-Y
-	I-GENE-Y
T	I-GENE-Y
)	O
,	O
markedly	O
increasing	O
brain	O
GABA	B-CHEMICAL
levels	O
.	O

PLZ	B-CHEMICAL
is	O
also	O
a	O
substrate	O
for	O
MAO	B-GENE-N
,	O
and	O
studies	O
suggest	O
that	O
a	O
metabolite	O
formed	O
by	O
the	O
action	O
of	O
this	O
enzyme	O
on	O
PLZ	B-CHEMICAL
may	O
be	O
responsible	O
for	O
the	O
increase	O
in	O
GABA	B-CHEMICAL
observed	O
.	O

We	O
have	O
recently	O
found	O
that	O
PLZ	B-CHEMICAL
also	O
elevates	O
brain	O
ornithine	B-CHEMICAL
(	O
ORN	B-CHEMICAL
)	O
,	O
an	O
amino	B-CHEMICAL
acid	I-CHEMICAL
precursor	O
to	O
both	O
glutamate	B-CHEMICAL
(	O
and	O
GABA	B-CHEMICAL
)	O
and	O
the	O
polyamines	B-CHEMICAL
,	O
and	O
have	O
conducted	O
dose	O
-	O
and	O
time	O
-	O
response	O
studies	O
on	O
this	O
effect	O
.	O

Rats	O
were	O
treated	O
with	O
vehicle	O
or	O
PLZ	B-CHEMICAL
doses	O
(	O
7	O
.	O
5	O
,	O
15	O
or	O
30	O
mg	O
/	O
kg	O
i	O
.	O
p	O
.	O
)	O
,	O
and	O
brains	O
were	O
collected	O
3	O
h	O
later	O
.	O

In	O
the	O
time	O
-	O
response	O
study	O
,	O
animals	O
were	O
treated	O
with	O
vehicle	O
or	O
PLZ	B-CHEMICAL
(	O
15	O
mg	O
/	O
kg	O
i	O
.	O
p	O
.	O
)	O
and	O
brains	O
were	O
collected	O
1	O
-	O
24	O
h	O
later	O
.	O

To	O
determine	O
whether	O
a	O
metabolite	O
formed	O
by	O
the	O
action	O
of	O
MAO	B-GENE-N
on	O
PLZ	B-CHEMICAL
may	O
be	O
responsible	O
for	O
the	O
elevation	O
in	O
brain	O
ORN	B-CHEMICAL
observed	O
,	O
animals	O
were	O
pretreated	O
with	O
vehicle	O
or	O
the	O
MAO	B-GENE-N
inhibitor	O
tranylcypromine	B-CHEMICAL
(	O
TCP	B-CHEMICAL
)	O
before	O
vehicle	O
or	O
PLZ	B-CHEMICAL
(	O
15	O
mg	O
/	O
kg	O
)	O
,	O
and	O
brains	O
collected	O
3	O
h	O
later	O
.	O

ORN	B-CHEMICAL
levels	O
(	O
measured	O
by	O
an	O
HPLC	O
procedure	O
)	O
were	O
dose	O
-	O
and	O
time	O
-	O
dependently	O
increased	O
in	O
PLZ	B-CHEMICAL
-	O
treated	O
animals	O
,	O
with	O
levels	O
reaching	O
approximately	O
650	O
%	O
of	O
control	O
at	O
6	O
and	O
12	O
h	O
.	O

Pretreatment	O
with	O
TCP	B-CHEMICAL
completely	O
abolished	O
the	O
PLZ	B-CHEMICAL
-	O
induced	O
increase	O
in	O
brain	O
ORN	B-CHEMICAL
,	O
suggesting	O
,	O
as	O
with	O
GABA	B-CHEMICAL
,	O
that	O
a	O
metabolite	O
of	O
PLZ	B-CHEMICAL
formed	O
by	O
the	O
action	O
of	O
MAO	B-GENE-N
is	O
responsible	O
for	O
the	O
elevation	O
of	O
brain	O
ORN	B-CHEMICAL
observed	O
.	O

The	O
possible	O
contribution	O
of	O
increased	O
ORN	B-CHEMICAL
to	O
therapeutic	O
and	O
/	O
or	O
neuroprotective	O
properties	O
of	O
PLZ	B-CHEMICAL
is	O
discussed	O
.	O

Endothelial	O
nitric	B-CHEMICAL
oxide	I-CHEMICAL
production	O
is	O
tightly	O
coupled	O
to	O
the	O
citrulline	B-CHEMICAL
-	I-CHEMICAL
NO	I-CHEMICAL
cycle	O
.	O

Nitric	B-CHEMICAL
oxide	I-CHEMICAL
(	O
NO	B-CHEMICAL
)	O
is	O
an	O
important	O
vasorelaxant	O
produced	O
along	O
with	O
L	B-CHEMICAL
-	I-CHEMICAL
citrulline	I-CHEMICAL
from	O
L	B-CHEMICAL
-	I-CHEMICAL
arginine	I-CHEMICAL
in	O
a	O
reaction	O
catalyzed	O
by	O
endothelial	B-GENE-Y
nitric	I-GENE-Y
oxide	I-GENE-Y
synthase	I-GENE-Y
(	O
eNOS	B-GENE-Y
)	O
.	O

Previous	O
studies	O
suggested	O
that	O
the	O
recycling	O
of	O
L	B-CHEMICAL
-	I-CHEMICAL
citrulline	I-CHEMICAL
to	O
L	B-CHEMICAL
-	I-CHEMICAL
arginine	I-CHEMICAL
is	O
essential	O
for	O
NO	B-CHEMICAL
production	O
in	O
endothelial	O
cells	O
.	O

However	O
,	O
there	O
is	O
no	O
direct	O
evidence	O
demonstrating	O
the	O
degree	O
to	O
which	O
the	O
recycling	O
of	O
L	B-CHEMICAL
-	I-CHEMICAL
citrulline	I-CHEMICAL
to	O
L	B-CHEMICAL
-	I-CHEMICAL
arginine	I-CHEMICAL
is	O
coupled	O
to	O
NO	B-CHEMICAL
production	O
.	O

We	O
hypothesized	O
that	O
the	O
amount	O
of	O
NO	B-CHEMICAL
formed	O
would	O
be	O
significantly	O
higher	O
than	O
the	O
amount	O
of	O
L	B-CHEMICAL
-	I-CHEMICAL
citrulline	I-CHEMICAL
formed	O
due	O
to	O
the	O
efficiency	O
of	O
L	B-CHEMICAL
-	I-CHEMICAL
citrulline	I-CHEMICAL
recycling	O
via	O
the	O
citrulline	B-CHEMICAL
-	O
NO	B-CHEMICAL
cycle	O
.	O

To	O
test	O
this	O
hypothesis	O
,	O
endothelial	O
cells	O
were	O
incubated	O
with	O
[	B-CHEMICAL
14C	I-CHEMICAL
]	I-CHEMICAL
-	I-CHEMICAL
L	I-CHEMICAL
-	I-CHEMICAL
arginine	I-CHEMICAL
and	O
stimulated	O
by	O
various	O
agents	O
to	O
produce	O
NO	B-CHEMICAL
.	O

The	O
extent	O
of	O
NO	B-CHEMICAL
and	O
[	B-CHEMICAL
14C	I-CHEMICAL
]	I-CHEMICAL
-	I-CHEMICAL
L	I-CHEMICAL
-	I-CHEMICAL
citrulline	I-CHEMICAL
formation	O
were	O
simultaneously	O
determined	O
.	O

NO	B-CHEMICAL
production	O
exceeded	O
apparent	O
L	B-CHEMICAL
-	I-CHEMICAL
citrulline	I-CHEMICAL
formation	O
of	O
the	O
order	O
of	O
8	O
to	O
1	O
,	O
under	O
both	O
basal	O
and	O
stimulated	O
conditions	O
.	O

As	O
further	O
support	O
,	O
alpha	B-CHEMICAL
-	I-CHEMICAL
methyl	I-CHEMICAL
-	I-CHEMICAL
DL	I-CHEMICAL
-	I-CHEMICAL
aspartate	I-CHEMICAL
,	O
an	O
inhibitor	O
of	O
argininosuccinate	B-GENE-Y
synthase	I-GENE-Y
(	O
AS	B-GENE-Y
)	O
,	O
a	O
component	O
of	O
the	O
citrulline	B-CHEMICAL
-	O
NO	B-CHEMICAL
cycle	O
,	O
inhibited	O
NO	B-CHEMICAL
production	O
in	O
a	O
dose	O
-	O
dependent	O
manner	O
.	O

The	O
results	O
of	O
this	O
study	O
provide	O
evidence	O
for	O
the	O
essential	O
and	O
efficient	O
coupling	O
of	O
L	B-CHEMICAL
-	I-CHEMICAL
citrulline	I-CHEMICAL
recycling	O
,	O
via	O
the	O
citrulline	B-CHEMICAL
-	O
NO	B-CHEMICAL
cycle	O
,	O
to	O
endothelial	O
NO	B-CHEMICAL
production	O
.	O

The	O
use	O
of	O
escitalopram	B-CHEMICAL
beyond	O
major	O
depression	O
:	O
pharmacological	O
aspects	O
,	O
efficacy	O
and	O
tolerability	O
in	O
anxiety	O
disorders	O
.	O

Escitalopram	B-CHEMICAL
,	O
the	O
active	O
(	B-CHEMICAL
S	I-CHEMICAL
)	I-CHEMICAL
-	I-CHEMICAL
enantiomer	I-CHEMICAL
of	I-CHEMICAL
citalopram	I-CHEMICAL
,	O
has	O
been	O
approved	O
in	O
many	O
countries	O
throughout	O
the	O
world	O
for	O
the	O
treatment	O
of	O
depression	O
and	O
anxiety	O
disorders	O
.	O

It	O
is	O
more	O
potent	O
and	O
selective	O
than	O
citalopram	B-CHEMICAL
in	O
inhibiting	O
serotonin	B-CHEMICAL
re	O
-	O
uptake	O
in	O
the	O
CNS	O
,	O
and	O
less	O
potent	O
than	O
various	O
other	O
selective	O
serotonin	B-CHEMICAL
re	O
-	O
uptake	O
inhibitors	O
in	O
relation	O
to	O
other	O
transporter	O
proteins	O
and	O
receptors	O
:	O
in	O
particular	O
,	O
it	O
is	O
six	O
times	O
less	O
potent	O
than	O
citalopram	B-CHEMICAL
in	O
binding	O
to	O
the	O
histamine	B-GENE-Y
H1	I-GENE-Y
and	O
muscarinic	B-GENE-N
receptors	I-GENE-N
.	O

Escitalopram	B-CHEMICAL
has	O
favourable	O
pharmacokinetics	O
:	O
it	O
is	O
rapidly	O
absorbed	O
,	O
has	O
a	O
bioavailability	O
of	O
80	O
%	O
and	O
is	O
not	O
affected	O
by	O
food	O
intake	O
.	O

It	O
has	O
little	O
potential	O
for	O
drug	O
interactions	O
:	O
it	O
has	O
low	O
protein	O
binding	O
and	O
,	O
as	O
it	O
is	O
metabolised	O
by	O
three	O
CYP	B-GENE-N
isozymes	O
,	O
any	O
impairment	O
in	O
the	O
activity	O
of	O
one	O
is	O
unlikely	O
to	O
have	O
a	O
significant	O
effect	O
on	O
metabolic	O
clearance	O
.	O

Caution	O
is	O
necessary	O
only	O
when	O
it	O
is	O
coadministered	O
with	O
drugs	O
metabolised	O
by	O
CYP2D6	B-GENE-Y
,	O
such	O
as	O
metoprolol	B-CHEMICAL
,	O
or	O
administered	O
to	O
the	O
elderly	O
or	O
patients	O
with	O
severe	O
hepatic	O
or	O
renal	O
impairment	O
.	O

The	O
multiple	O
-	O
dose	O
pharmacokinetics	O
of	O
oral	O
escitalopram	B-CHEMICAL
are	O
proportional	O
at	O
a	O
range	O
of	O
doses	O
including	O
its	O
therapeutic	O
doses	O
.	O

Escitalopram	B-CHEMICAL
is	O
approved	O
for	O
the	O
treatment	O
of	O
a	O
number	O
of	O
anxiety	O
disorders	O
.	O

It	O
seems	O
to	O
be	O
well	O
tolerated	O
and	O
induces	O
few	O
or	O
no	O
discontinuation	O
symptoms	O
,	O
and	O
may	O
be	O
considered	O
a	O
first	O
-	O
line	O
agent	O
for	O
the	O
pharmacotherapy	O
of	O
obsessive	O
-	O
compulsive	O
disorder	O
,	O
generalised	O
anxiety	O
disorder	O
,	O
panic	O
disorder	O
and	O
social	O
phobia	O
.	O

Further	O
studies	O
are	O
needed	O
to	O
define	O
its	O
activity	O
in	O
impulse	O
control	O
disorders	O
.	O

Inhibition	O
of	O
platelet	O
aggregation	O
by	O
AZD6140	B-CHEMICAL
,	O
a	O
reversible	O
oral	O
P2Y12	B-GENE-Y
receptor	O
antagonist	O
,	O
compared	O
with	O
clopidogrel	B-CHEMICAL
in	O
patients	O
with	O
acute	O
coronary	O
syndromes	O
.	O

OBJECTIVES	O
:	O
In	O
a	O
substudy	O
of	O
DISPERSE	O
(	O
Dose	O
confIrmation	O
Study	O
assessing	O
anti	O
-	O
Platelet	O
Effects	O
of	O
AZD6140	B-CHEMICAL
vs	O
.	O
clopidogRel	O
in	O
non	O
-	O
ST	O
-	O
segment	O
Elevation	O
myocardial	O
infarction	O
)	O
-	O
2	O
,	O
we	O
compared	O
the	O
antiplatelet	O
effects	O
of	O
AZD6140	B-CHEMICAL
and	O
clopidogrel	B-CHEMICAL
and	O
assessed	O
the	O
effects	O
of	O
AZD6140	B-CHEMICAL
in	O
clopidogrel	B-CHEMICAL
-	O
pretreated	O
patients	O
.	O

BACKGROUND	O
:	O
Clopidogrel	B-CHEMICAL
,	O
in	O
combination	O
with	O
aspirin	O
,	O
reduces	O
cardiovascular	O
events	O
in	O
patients	O
with	O
acute	O
coronary	O
syndromes	O
(	O
ACS	O
)	O
.	O

However	O
,	O
patients	O
with	O
poor	O
inhibition	O
of	O
platelet	O
aggregation	O
with	O
clopidogrel	B-CHEMICAL
may	O
be	O
less	O
well	O
protected	O
.	O

AZD6140	B-CHEMICAL
is	O
a	O
reversible	O
oral	O
P2Y	B-GENE-Y
(	I-GENE-Y
12	I-GENE-Y
)	I-GENE-Y
receptor	O
antagonist	O
that	O
has	O
been	O
studied	O
in	O
ACS	O
patients	O
in	O
comparison	O
with	O
clopidogrel	B-CHEMICAL
(	O
DISPERSE	O
-	O
2	O
study	O
)	O
.	O

METHODS	O
:	O
Patients	O
were	O
randomized	O
to	O
receive	O
either	O
AZD6140	B-CHEMICAL
90	O
mg	O
twice	O
a	O
day	O
,	O
AZD6140	B-CHEMICAL
180	O
mg	O
twice	O
a	O
day	O
,	O
or	O
clopidogrel	B-CHEMICAL
75	O
mg	O
once	O
a	O
day	O
for	O
up	O
to	O
12	O
weeks	O
in	O
a	O
double	O
-	O
blind	O
,	O
double	O
-	O
dummy	O
design	O
.	O

One	O
-	O
half	O
the	O
patients	O
allocated	O
AZD6140	B-CHEMICAL
received	O
a	O
270	O
-	O
mg	O
loading	O
dose	O
.	O

Patients	O
randomized	O
to	O
receive	O
clopidogrel	B-CHEMICAL
were	O
given	O
a	O
300	O
-	O
mg	O
loading	O
dose	O
unless	O
they	O
had	O
already	O
been	O
treated	O
with	O
clopidogrel	B-CHEMICAL
.	O

Adenosine	B-CHEMICAL
diphosphate	I-CHEMICAL
-	O
induced	O
platelet	O
aggregation	O
was	O
assessed	O
by	O
optical	O
aggregometry	O
on	O
day	O
1	O
and	O
at	O
4	O
-	O
week	O
intervals	O
.	O

RESULTS	O
:	O
AZD6140	B-CHEMICAL
inhibited	O
platelet	O
aggregation	O
in	O
a	O
dose	O
-	O
dependent	O
fashion	O
and	O
both	O
doses	O
achieved	O
greater	O
levels	O
of	O
inhibition	O
than	O
clopidogrel	B-CHEMICAL
(	O
e	O
.	O
g	O
.	O
,	O
4	O
weeks	O
,	O
4	O
-	O
h	O
postdose	O
[	O
mean	O
(	O
+	O
/	O
-	O
SD	O
)	O
]	O
:	O
clopidogrel	B-CHEMICAL
64	O
%	O
[	O
+	O
/	O
-	O
22	O
%	O
]	O
,	O
AZD6140	B-CHEMICAL
90	O
mg	O
79	O
%	O
[	O
+	O
/	O
-	O
22	O
%	O
]	O
,	O
AZD6140	B-CHEMICAL
180	O
mg	O
95	O
%	O
[	O
+	O
/	O
-	O
8	O
%	O
]	O
.	O

AZD6140	B-CHEMICAL
also	O
produced	O
further	O
suppression	O
of	O
platelet	O
aggregation	O
in	O
patients	O
previously	O
treated	O
with	O
clopidogrel	B-CHEMICAL
.	O

CONCLUSIONS	O
:	O
AZD6140	B-CHEMICAL
exhibited	O
greater	O
mean	O
inhibition	O
of	O
platelet	O
aggregation	O
than	O
a	O
standard	O
regimen	O
of	O
clopidogrel	B-CHEMICAL
in	O
ACS	O
patients	O
.	O

In	O
addition	O
,	O
AZD6140	B-CHEMICAL
further	O
suppressed	O
platelet	O
aggregation	O
in	O
clopidogrel	O
pretreated	O
patients	O
.	O

The	O
preparation	O
and	O
human	B-GENE-N
muscarinic	I-GENE-N
receptor	I-GENE-N
profiling	O
of	O
oxybutynin	B-CHEMICAL
and	O
N	B-CHEMICAL
-	I-CHEMICAL
desethyloxybutynin	I-CHEMICAL
enantiomers	O
.	O

Oxybutynin	B-CHEMICAL
(	O
1	O
)	O
is	O
a	O
non	O
-	O
selective	O
muscarinic	B-GENE-N
receptor	I-GENE-N
antagonist	O
that	O
is	O
used	O
clinically	O
for	O
the	O
treatment	O
of	O
urinary	O
incontinence	O
.	O

The	O
major	O
metabolite	O
of	O
oxybutynin	B-CHEMICAL
in	O
humans	O
is	O
desethyloxybutynin	B-CHEMICAL
(	O
2	O
)	O
.	O

We	O
have	O
prepared	O
the	O
enantiomers	O
of	O
1	O
and	O
2	O
and	O
evaluated	O
their	O
ability	O
to	O
displace	O
N	B-CHEMICAL
-	I-CHEMICAL
CT	I-CHEMICAL
(	I-CHEMICAL
3	I-CHEMICAL
)	I-CHEMICAL
-	I-CHEMICAL
scopolamine	I-CHEMICAL
chloride	I-CHEMICAL
(	O
(	B-CHEMICAL
3	I-CHEMICAL
)	I-CHEMICAL
H	I-CHEMICAL
-	I-CHEMICAL
NMS	I-CHEMICAL
)	O
binding	O
on	O
human	B-GENE-N
cloned	I-GENE-N
muscarinic	I-GENE-N
m1	I-GENE-N
-	I-GENE-N
5	I-GENE-N
receptors	I-GENE-N
.	O

Compounds	O
1	O
and	O
2	O
potently	O
displaced	O
(	B-CHEMICAL
3	I-CHEMICAL
)	I-CHEMICAL
H	I-CHEMICAL
-	I-CHEMICAL
NMS	I-CHEMICAL
binding	O
at	O
m1	B-GENE-N
,	I-GENE-N
m3	I-GENE-N
and	I-GENE-N
m4	I-GENE-N
receptors	I-GENE-N
,	O
but	O
were	O
less	O
potent	O
at	O
the	O
m2	B-GENE-Y
and	O
m5	B-GENE-Y
subtypes	O
.	O

However	O
,	O
metabolite	O
2	O
was	O
more	O
potent	O
than	O
the	O
parent	O
compound	O
1	O
in	O
the	O
binding	O
assay	O
.	O

In	O
general	O
the	O
R	O
enantiomers	O
were	O
more	O
potent	O
than	O
their	O
respective	O
S	O
enantiomers	O
.	O

Therefore	O
,	O
we	O
suggest	O
that	O
the	O
cholinergic	O
side	O
effects	O
associated	O
with	O
2	O
may	O
be	O
due	O
to	O
its	O
greater	O
apparent	O
potency	O
with	O
m1	B-GENE-N
and	I-GENE-N
m3	I-GENE-N
receptors	I-GENE-N
,	O
especially	O
of	O
its	O
R	O
-	O
enantiomer	O
,	O
when	O
compared	O
with	O
parent	O
drug	O
1	O
.	O

Degradation	O
of	O
submandibular	O
gland	O
AQP5	B-GENE-Y
by	O
parasympathetic	O
denervation	O
of	O
chorda	O
tympani	O
and	O
its	O
recovery	O
by	O
cevimeline	B-CHEMICAL
,	O
an	O
M3	B-GENE-Y
muscarinic	I-GENE-Y
receptor	I-GENE-Y
agonist	O
.	O

By	O
chorda	O
tympani	O
denervation	O
(	O
CTD	O
,	O
parasympathectomy	O
)	O
,	O
the	O
aquaporin	B-GENE-Y
5	I-GENE-Y
(	O
AQP5	B-GENE-Y
)	O
,	O
but	O
not	O
AQP1	B-GENE-Y
,	O
protein	O
level	O
in	O
the	O
rat	O
submandibular	O
gland	O
(	O
SMG	O
)	O
was	O
significantly	O
decreased	O
,	O
dropping	O
to	O
37	O
%	O
of	O
that	O
of	O
the	O
contralateral	O
gland	O
at	O
4	O
wk	O
.	O

The	O
protein	O
levels	O
of	O
AQP5	B-GENE-Y
and	O
AQP1	B-GENE-Y
were	O
not	O
significantly	O
affected	O
by	O
denervation	O
of	O
the	O
cervical	O
sympathetic	O
trunk	O
(	O
sympathectomy	O
)	O
.	O

Administration	O
of	O
cevimeline	B-CHEMICAL
hydrochloride	I-CHEMICAL
,	O
an	O
M3	B-GENE-Y
muscarinic	I-GENE-Y
receptor	I-GENE-Y
agonist	O
(	O
10	O
mg	O
/	O
kg	O
for	O
7	O
days	O
po	O
)	O
,	O
but	O
not	O
pilocarpine	B-CHEMICAL
(	O
0	O
.	O
3	O
mg	O
/	O
kg	O
for	O
7	O
days	O
po	O
)	O
,	O
recovered	O
the	O
AQP5	B-GENE-Y
protein	O
level	O
reduced	O
by	O
CTD	O
and	O
increased	O
the	O
AQP1	B-GENE-Y
protein	O
level	O
above	O
the	O
control	O
one	O
.	O

The	O
mRNA	O
level	O
of	O
AQP5	B-GENE-Y
was	O
scarcely	O
affected	O
by	O
CTD	O
and	O
cevimeline	B-CHEMICAL
hydrochloride	I-CHEMICAL
administration	O
.	O

Administration	O
of	O
chloroquine	B-CHEMICAL
(	O
50	O
mg	O
/	O
kg	O
for	O
7	O
days	O
po	O
)	O
,	O
a	O
denaturant	O
of	O
lysosomes	O
,	O
increased	O
the	O
AQP5	B-GENE-Y
protein	O
level	O
reduced	O
by	O
CTD	O
.	O

An	O
extract	O
obtained	O
from	O
the	O
submandibular	O
lysosomal	O
fraction	O
degraded	O
the	O
AQP5	B-GENE-Y
protein	O
in	O
the	O
total	O
membrane	O
fraction	O
in	O
vitro	O
.	O

These	O
results	O
suggest	O
the	O
possible	O
regulation	O
of	O
the	O
AQP5	B-GENE-Y
protein	O
level	O
in	O
the	O
SMG	O
by	O
the	O
parasympathetic	O
nerves	O
/	O
M3	B-GENE-Y
muscarinic	I-GENE-Y
receptor	I-GENE-Y
agonist	O
and	O
imply	O
the	O
involvement	O
of	O
lysosomal	O
enzymes	O
,	O
but	O
not	O
a	O
transcriptional	O
mechanism	O
,	O
in	O
this	O
regulation	O
.	O

Multicenter	O
trial	O
of	O
everolimus	B-CHEMICAL
in	O
pediatric	O
renal	O
transplant	O
recipients	O
:	O
results	O
at	O
three	O
year	O
.	O

There	O
are	O
few	O
prospective	O
clinical	O
trials	O
of	O
mTOR	B-CHEMICAL
inhibitors	O
(	O
or	O
proliferation	O
signal	O
inhibitors	O
)	O
combined	O
with	O
CNI	O
inhibitors	O
in	O
de	O
novo	O
pediatric	O
renal	O
transplantation	O
.	O

Results	O
reported	O
here	O
are	O
from	O
a	O
multicenter	O
,	O
open	O
-	O
label	O
study	O
in	O
de	O
novo	O
pediatric	O
renal	O
transplant	O
patients	O
(	O
<	O
or	O
=	O
16	O
yr	O
)	O
,	O
in	O
which	O
patients	O
received	O
everolimus	O
with	O
cyclosporine	O
and	O
corticosteroids	O
for	O
one	O
yr	O
,	O
then	O
entered	O
an	O
extension	O
study	O
for	O
a	O
further	O
two	O
yr	O
.	O

Nineteen	O
patients	O
completed	O
the	O
one	O
-	O
yr	O
study	O
,	O
of	O
whom	O
three	O
discontinued	O
study	O
medication	O
.	O

Fifteen	O
of	O
the	O
remaining	O
16	O
patients	O
entered	O
the	O
extension	O
study	O
,	O
eight	O
of	O
whom	O
were	O
aged	O
<	O
10	O
yr	O
(	O
Group	O
1	O
)	O
and	O
seven	O
were	O
aged	O
10	O
-	O
16	O
yr	O
(	O
Group	O
2	O
)	O
.	O

Mean	O
daily	O
dose	O
of	O
everolimus	O
during	O
the	O
first	O
36	O
months	O
was	O
1	O
.	O
53	O
mg	O
/	O
m	O
(	O
2	O
)	O
BSA	O
.	O

Biopsy	O
-	O
proven	O
acute	O
rejection	O
occurred	O
in	O
three	O
patients	O
in	O
Group	O
2	O
and	O
in	O
one	O
patient	O
in	O
Group	O
1	O
.	O

Biopsy	O
-	O
proven	O
chronic	O
allograft	O
rejection	O
was	O
reported	O
in	O
four	O
patients	O
(	O
two	O
in	O
each	O
age	O
group	O
)	O
.	O

Graft	O
survival	O
at	O
one	O
yr	O
was	O
100	O
%	O
;	O
one	O
patient	O
in	O
Group	O
2	O
lost	O
their	O
graft	O
subsequently	O
during	O
the	O
extension	O
.	O

For	O
patients	O
entering	O
the	O
extension	O
,	O
patient	O
survival	O
at	O
three	O
yr	O
was	O
100	O
%	O
.	O

There	O
were	O
three	O
cases	O
of	O
viral	O
infection	O
,	O
including	O
one	O
case	O
of	O
cytomegalovirus	O
infection	O
.	O

At	O
three	O
yr	O
,	O
mean	O
total	O
cholesterol	O
was	O
5	O
.	O
5	O
+	O
/	O
-	O
0	O
.	O
8	O
mm	O
/	O
L	O
(	O
213	O
+	O
/	O
-	O
31	O
mg	O
/	O
dL	O
)	O
and	O
four	O
patients	O
received	O
statin	O
therapy	O
.	O

Mean	O
serum	O
creatinine	O
at	O
36	O
months	O
was	O
96	O
+	O
/	O
-	O
36	O
microm	O
/	O
L	O
(	O
1	O
.	O
1	O
+	O
/	O
-	O
0	O
.	O
4	O
mg	O
/	O
dL	O
)	O
.	O

This	O
is	O
the	O
first	O
long	O
-	O
term	O
prospective	O
study	O
to	O
demonstrate	O
that	O
a	O
regimen	O
of	O
everolimus	O
,	O
cyclosporine	O
,	O
and	O
corticosteroids	O
provides	O
good	O
efficacy	O
,	O
tolerability	O
,	O
and	O
safety	O
in	O
de	O
novo	O
pediatric	O
renal	O
transplant	O
patients	O
.	O

Differential	O
pharmacokinetics	O
and	O
pharmacodynamics	O
of	O
methylphenidate	B-CHEMICAL
enantiomers	O
:	O
does	O
chirality	O
matter	O
?	O

d	B-CHEMICAL
,	I-CHEMICAL
l	I-CHEMICAL
-	I-CHEMICAL
threo	I-CHEMICAL
-	I-CHEMICAL
methylphenidate	I-CHEMICAL
(	O
MPH	B-CHEMICAL
)	O
is	O
an	O
effective	O
first	O
-	O
line	O
treatment	O
for	O
the	O
symptoms	O
associated	O
with	O
attention	O
-	O
deficit	O
/	O
hyperactivity	O
disorder	O
.	O
threo	B-CHEMICAL
-	I-CHEMICAL
methylphenidate	I-CHEMICAL
inhibits	O
the	O
dopamine	B-GENE-Y
transporter	I-GENE-Y
and	O
the	O
norepinephrine	B-GENE-Y
transporter	I-GENE-Y
,	O
resulting	O
in	O
elevations	O
of	O
these	O
monoamines	B-CHEMICAL
after	O
impulse	O
release	O
.	O

Although	O
MPH	B-CHEMICAL
has	O
long	O
been	O
administered	O
as	O
a	O
racemic	O
mixture	O
of	O
the	O
2	O
enantiomers	O
,	O
d	B-CHEMICAL
-	I-CHEMICAL
MPH	I-CHEMICAL
and	O
l	B-CHEMICAL
-	I-CHEMICAL
MPH	I-CHEMICAL
,	O
converging	O
lines	O
of	O
evidence	O
drawn	O
from	O
investigations	O
using	O
in	O
vitro	O
systems	O
,	O
animal	O
models	O
,	O
and	O
humans	O
indicate	O
that	O
it	O
is	O
predominantly	O
,	O
if	O
not	O
exclusively	O
,	O
d	B-CHEMICAL
-	I-CHEMICAL
MPH	I-CHEMICAL
that	O
mediates	O
the	O
pharmacological	O
/	O
therapeutic	O
actions	O
of	O
MPH	B-CHEMICAL
.	O

In	O
both	O
rodent	O
and	O
primate	O
animal	O
models	O
,	O
the	O
binding	O
of	O
radiolabeled	O
d	B-CHEMICAL
-	I-CHEMICAL
MPH	I-CHEMICAL
to	O
dopamine	B-GENE-N
transporter	I-GENE-N
was	O
found	O
to	O
be	O
selective	O
,	O
saturable	O
,	O
and	O
reversible	O
,	O
whereas	O
binding	O
of	O
l	B-CHEMICAL
-	I-CHEMICAL
MPH	I-CHEMICAL
was	O
diffuse	O
and	O
nonspecific	O
.	O

The	O
behavioral	O
effects	O
of	O
the	O
enantiomers	O
of	O
MPH	B-CHEMICAL
have	O
been	O
tested	O
in	O
several	O
animal	O
models	O
,	O
and	O
results	O
indicate	O
these	O
observed	O
behavioral	O
changes	O
are	O
likewise	O
mediated	O
by	O
d	B-CHEMICAL
-	I-CHEMICAL
MPH	I-CHEMICAL
,	O
whereas	O
l	B-CHEMICAL
-	I-CHEMICAL
MPH	I-CHEMICAL
has	O
little	O
or	O
no	O
effect	O
.	O
The	O
contribution	O
of	O
the	O
l	O
-	O
isomer	O
to	O
the	O
overall	O
pharmacological	O
profile	O
of	O
the	O
racemate	O
remains	O
unclear	O
,	O
owing	O
to	O
several	O
studies	O
suggesting	O
that	O
l	B-CHEMICAL
-	I-CHEMICAL
MPH	I-CHEMICAL
may	O
not	O
be	O
merely	O
an	O
inert	O
isomeric	O
ballast	O
.	O

For	O
example	O
,	O
behavioral	O
studies	O
conducted	O
in	O
rats	O
demonstrate	O
an	O
attenuation	O
of	O
the	O
effect	O
of	O
d	B-CHEMICAL
-	I-CHEMICAL
MPH	I-CHEMICAL
in	O
animals	O
pretreated	O
with	O
l	B-CHEMICAL
-	I-CHEMICAL
MPH	I-CHEMICAL
,	O
suggesting	O
that	O
l	B-CHEMICAL
-	I-CHEMICAL
MPH	I-CHEMICAL
may	O
interfere	O
with	O
the	O
action	O
of	O
the	O
active	O
enantiomer	O
.	O

The	O
importance	O
of	O
MPH	B-CHEMICAL
chirality	O
to	O
central	O
nervous	O
system	O
MPH	B-GENE-N
receptor	I-GENE-N
targeting	O
has	O
culminated	O
in	O
human	O
imaging	O
studies	O
revealing	O
that	O
d	B-CHEMICAL
-	I-CHEMICAL
MPH	I-CHEMICAL
binds	O
specifically	O
to	O
striatal	O
structures	O
,	O
whereas	O
l	B-CHEMICAL
-	I-CHEMICAL
MPH	I-CHEMICAL
binding	O
is	O
nonspecific	O
.	O

Taken	O
together	O
,	O
data	O
from	O
in	O
vitro	O
,	O
animal	O
,	O
and	O
human	O
studies	O
support	O
the	O
premise	O
that	O
the	O
d	B-CHEMICAL
-	I-CHEMICAL
enantiomer	I-CHEMICAL
of	I-CHEMICAL
MPH	I-CHEMICAL
mediates	O
the	O
neurophysiological	O
actions	O
of	O
MPH	B-CHEMICAL
and	O
therefore	O
likely	O
mediates	O
its	O
clinical	O
efficacy	O
.	O

Identification	O
of	O
N	B-CHEMICAL
-	O
terminal	O
receptor	O
activity	O
-	O
modifying	O
protein	O
residues	O
important	O
for	O
calcitonin	B-GENE-N
gene	I-GENE-N
-	I-GENE-N
related	I-GENE-N
peptide	I-GENE-N
,	O
adrenomedullin	B-GENE-Y
,	O
and	O
amylin	B-GENE-N
receptor	I-GENE-N
function	O
.	O

Calcitonin	B-GENE-N
-	I-GENE-N
family	I-GENE-N
receptors	I-GENE-N
comprise	O
calcitonin	B-GENE-Y
receptor	I-GENE-Y
-	I-GENE-Y
like	I-GENE-Y
receptor	I-GENE-Y
(	O
CL	B-GENE-Y
)	O
or	O
calcitonin	B-GENE-Y
receptor	I-GENE-Y
and	O
receptor	B-GENE-N
activity	I-GENE-N
-	I-GENE-N
modifying	I-GENE-N
protein	I-GENE-N
(	O
RAMP	B-GENE-N
)	O
pairings	O
.	O

Calcitonin	B-GENE-Y
gene	I-GENE-Y
-	I-GENE-Y
related	I-GENE-Y
peptide	I-GENE-Y
(	I-GENE-Y
CGRP	I-GENE-Y
)	I-GENE-Y
receptors	I-GENE-Y
are	O
CL	B-GENE-Y
/	O
RAMP1	B-GENE-Y
,	O
whereas	O
adrenomedullin	B-GENE-N
(	I-GENE-N
AM	I-GENE-N
)	I-GENE-N
receptors	I-GENE-N
are	O
CL	B-GENE-Y
/	O
RAMP2	B-GENE-Y
(	O
AM1	B-GENE-Y
receptor	I-GENE-Y
)	O
or	O
CL	B-GENE-Y
/	O
RAMP3	B-GENE-Y
(	O
AM2	B-GENE-Y
receptor	I-GENE-Y
)	O
.	O

Amylin	B-GENE-N
(	I-GENE-N
Amy	I-GENE-N
)	I-GENE-N
receptors	I-GENE-N
are	O
RAMP	B-GENE-N
hetero	O
-	O
oligomers	O
with	O
the	O
calcitonin	B-GENE-Y
receptor	I-GENE-Y
(	O
AMY1	B-GENE-Y
,	O
AMY2	B-GENE-Y
,	O
and	O
AMY3	B-GENE-Y
,	O
respectively	O
)	O
.	O

How	O
RAMPs	B-GENE-N
change	O
G	B-GENE-N
protein	I-GENE-N
-	I-GENE-N
coupled	I-GENE-N
receptor	I-GENE-N
pharmacology	O
is	O
not	O
fully	O
understood	O
.	O

We	O
exploited	O
sequence	O
differences	O
between	O
RAMP1	B-GENE-Y
and	O
RAMP3	B-GENE-Y
to	O
identify	O
individual	O
residues	O
capable	O
of	O
altering	O
receptor	O
pharmacology	O
.	O

Alignment	O
of	O
human	B-GENE-N
RAMPs	I-GENE-N
revealed	O
eight	O
residues	O
that	O
are	O
conserved	O
in	O
RAMP2	B-GENE-Y
and	O
RAMP3	B-GENE-Y
but	O
are	O
different	O
in	O
RAMP1	B-GENE-Y
.	O

We	O
hypothesized	O
that	O
residues	O
in	O
RAMP2	B-GENE-Y
and	O
RAMP3	B-GENE-Y
,	O
but	O
not	O
RAMP1	B-GENE-Y
,	O
are	O
responsible	O
for	O
making	O
CL	B-GENE-Y
/	O
RAMP2	B-GENE-Y
and	O
CL	B-GENE-Y
/	O
RAMP3	B-GENE-Y
AM	B-GENE-N
receptors	I-GENE-N
.	O

Using	O
site	O
-	O
directed	O
mutagenesis	O
,	O
we	O
introduced	O
individual	O
RAMP3	B-GENE-Y
residues	O
into	O
RAMP1	B-GENE-Y
and	O
vice	O
versa	O
in	O
these	O
eight	O
positions	O
.	O

Mutant	O
or	O
wild	O
-	O
type	O
RAMPs	B-GENE-N
were	O
transfected	O
into	O
Cos7	O
cells	O
with	O
CL	B-GENE-Y
or	O
the	O
insert	O
-	O
negative	O
form	O
of	O
the	O
calcitonin	B-GENE-Y
receptor	I-GENE-Y
[	O
CT	B-GENE-Y
(	I-GENE-Y
a	I-GENE-Y
)	I-GENE-Y
]	O
.	O

Agonist	O
-	O
stimulated	O
cAMP	O
production	O
and	O
cell	O
-	O
surface	O
expression	O
of	O
constructs	O
were	O
measured	O
.	O

Position	O
74	O
in	O
RAMP1	B-GENE-Y
and	O
RAMP3	B-GENE-Y
was	O
critical	O
for	O
determining	O
AM	B-GENE-Y
potency	O
and	O
affinity	O
,	O
and	O
Phe93	O
in	O
RAMP1	B-GENE-Y
was	O
an	O
important	O
contributor	O
to	O
alphaCGRP	B-GENE-Y
potency	O
at	O
CGRP	B-GENE-Y
receptors	I-GENE-Y
.	O

Mutant	O
RAMP	B-GENE-N
/	O
CT	B-GENE-Y
(	I-GENE-Y
a	I-GENE-Y
)	I-GENE-Y
receptor	I-GENE-Y
complexes	O
displayed	O
different	O
phenotypes	O
.	O

It	O
is	O
noteworthy	O
that	O
RAMP1	B-GENE-Y
S103N	B-GENE-N
and	O
W74E	B-GENE-N
mutations	O
led	O
to	O
enhanced	O
rAmy	B-GENE-Y
potency	O
,	O
probably	O
related	O
to	O
increased	O
cell	O
-	O
surface	O
expression	O
of	O
these	O
complexes	O
.	O

This	O
differs	O
from	O
the	O
effect	O
on	O
CL	B-GENE-Y
-	O
based	O
receptors	O
where	O
expression	O
was	O
unchanged	O
.	O

Targeted	O
substitution	O
has	O
emphasized	O
the	O
importance	O
of	O
position	O
74	O
in	O
RAMP1	B-GENE-Y
/	O
RAMP3	B-GENE-Y
as	O
a	O
key	O
determinant	O
of	O
AM	B-GENE-Y
pharmacology	O
.	O

Nitrosoureas	O
inhibit	O
the	O
stathmin	B-GENE-Y
-	O
mediated	O
migration	O
and	O
invasion	O
of	O
malignant	O
glioma	O
cells	O
.	O

Malignant	O
gliomas	O
are	O
the	O
most	O
common	O
primary	O
intrinsic	O
brain	O
tumors	O
and	O
are	O
highly	O
lethal	O
.	O

The	O
widespread	O
migration	O
and	O
invasion	O
of	O
neoplastic	O
cells	O
from	O
the	O
initial	O
site	O
of	O
tumor	O
formation	O
into	O
the	O
surrounding	O
brain	O
render	O
these	O
lesions	O
refractory	O
to	O
definitive	O
surgical	O
treatment	O
.	O

Stathmin	B-GENE-Y
,	O
a	O
microtubule	B-GENE-N
-	O
destabilizing	O
protein	O
that	O
mediates	O
cell	O
cycle	O
progression	O
,	O
can	O
also	O
regulate	O
directed	O
cell	O
movement	O
.	O

Nitrosoureas	O
,	O
traditionally	O
viewed	O
as	O
DNA	O
alkylating	O
agents	O
,	O
can	O
also	O
covalently	O
modify	O
proteins	O
such	O
as	O
stathmin	B-GENE-Y
.	O

We	O
therefore	O
sought	O
to	O
establish	O
a	O
role	O
for	O
stathmin	B-GENE-Y
in	O
malignant	O
glioma	O
cell	O
motility	O
,	O
migration	O
,	O
and	O
invasion	O
and	O
determine	O
the	O
effects	O
of	O
nitrosoureas	B-CHEMICAL
on	O
these	O
cell	O
movement	O
-	O
related	O
processes	O
.	O

Scratch	O
wound	O
-	O
healing	O
recovery	O
,	O
Boyden	O
chamber	O
migration	O
,	O
Matrigel	O
invasion	O
,	O
and	O
organotypic	O
slice	O
invasion	O
assays	O
were	O
performed	O
before	O
and	O
after	O
the	O
down	O
-	O
regulation	O
of	O
cellular	O
stathmin	B-GENE-Y
levels	O
and	O
in	O
the	O
absence	O
and	O
presence	O
of	O
sublethal	O
nitrosourea	B-CHEMICAL
(	O
[	B-CHEMICAL
1	I-CHEMICAL
-	I-CHEMICAL
(	I-CHEMICAL
2	I-CHEMICAL
-	I-CHEMICAL
chloroethyl	I-CHEMICAL
)	I-CHEMICAL
-	I-CHEMICAL
3	I-CHEMICAL
-	I-CHEMICAL
cyclohexyl	I-CHEMICAL
-	I-CHEMICAL
l	I-CHEMICAL
-	I-CHEMICAL
nitrosourea	I-CHEMICAL
]	I-CHEMICAL
;	O
CCNU	B-CHEMICAL
)	O
concentrations	O
.	O

We	O
show	O
that	O
decreases	O
in	O
stathmin	B-GENE-Y
expression	O
lead	O
to	O
significant	O
decreases	O
in	O
malignant	O
glioma	O
cell	O
motility	O
,	O
migration	O
,	O
and	O
invasion	O
.	O

CCNU	B-CHEMICAL
,	O
at	O
a	O
concentration	O
of	O
10	O
micromol	O
/	O
L	O
,	O
causes	O
similar	O
significant	O
decreases	O
,	O
even	O
in	O
the	O
absence	O
of	O
any	O
effects	O
on	O
cell	O
viability	O
.	O

The	O
direct	O
inhibition	O
of	O
stathmin	B-GENE-Y
by	O
CCNU	B-CHEMICAL
is	O
likely	O
a	O
contributing	O
factor	O
.	O

These	O
findings	O
suggest	O
that	O
the	O
inhibition	O
of	O
stathmin	O
expression	O
and	O
function	O
may	O
be	O
useful	O
in	O
limiting	O
the	O
spread	O
of	O
malignant	O
gliomas	O
within	O
the	O
brain	O
,	O
and	O
that	O
nitrosoureas	B-CHEMICAL
may	O
have	O
therapeutic	O
benefits	O
in	O
addition	O
to	O
their	O
antiproliferative	O
effects	O
.	O

Interaction	O
with	O
the	O
hERG	B-GENE-Y
channel	O
and	O
cytotoxicity	O
of	O
amiodarone	B-CHEMICAL
and	O
amiodarone	B-CHEMICAL
analogues	O
.	O

BACKGROUND	O
AND	O
PURPOSE	O
:	O
Amiodarone	B-CHEMICAL
(	O
2	B-CHEMICAL
-	I-CHEMICAL
n	I-CHEMICAL
-	I-CHEMICAL
butyl	I-CHEMICAL
-	I-CHEMICAL
3	I-CHEMICAL
-	I-CHEMICAL
[	I-CHEMICAL
3	I-CHEMICAL
,	I-CHEMICAL
5	I-CHEMICAL
diiodo	I-CHEMICAL
-	I-CHEMICAL
4	I-CHEMICAL
-	I-CHEMICAL
diethylaminoethoxybenzoyl	I-CHEMICAL
]	I-CHEMICAL
-	I-CHEMICAL
benzofuran	I-CHEMICAL
,	O
B2	B-CHEMICAL
-	I-CHEMICAL
O	I-CHEMICAL
-	I-CHEMICAL
CH	I-CHEMICAL
(	I-CHEMICAL
2	I-CHEMICAL
)	I-CHEMICAL
CH	I-CHEMICAL
(	I-CHEMICAL
2	I-CHEMICAL
)	I-CHEMICAL
-	I-CHEMICAL
N	I-CHEMICAL
-	I-CHEMICAL
diethyl	I-CHEMICAL
)	O
is	O
an	O
effective	O
class	O
III	O
antiarrhythmic	O
drug	O
demonstrating	O
potentially	O
life	O
-	O
threatening	O
organ	O
toxicity	O
.	O

The	O
principal	O
aim	O
of	O
the	O
study	O
was	O
to	O
find	O
amiodarone	B-CHEMICAL
analogues	O
that	O
retained	O
human	B-GENE-Y
ether	I-GENE-Y
-	I-GENE-Y
a	I-GENE-Y
-	I-GENE-Y
go	I-GENE-Y
-	I-GENE-Y
go	I-GENE-Y
-	I-GENE-Y
related	I-GENE-Y
protein	I-GENE-Y
(	I-GENE-Y
hERG	I-GENE-Y
)	I-GENE-Y
channel	I-GENE-Y
inhibition	O
but	O
with	O
reduced	O
cytotoxicity	O
.	O

EXPERIMENTAL	O
APPROACH	O
:	O
We	O
synthesized	O
amiodarone	B-CHEMICAL
analogues	O
with	O
or	O
without	O
a	O
positively	O
ionizable	O
nitrogen	B-CHEMICAL
in	O
the	O
phenolic	B-CHEMICAL
side	O
chain	O
.	O

The	O
cytotoxic	O
properties	O
of	O
the	O
compounds	O
were	O
evaluated	O
using	O
HepG2	O
(	O
a	O
hepatocyte	O
cell	O
line	O
)	O
and	O
A549	O
cells	O
(	O
a	O
pneumocyte	O
line	O
)	O
.	O

Interactions	O
of	O
all	O
compounds	O
with	O
the	O
hERG	B-GENE-Y
channel	O
were	O
measured	O
using	O
pharmacological	O
and	O
in	O
silico	O
methods	O
.	O

KEY	O
RESULTS	O
:	O
Compared	O
with	O
amiodarone	B-CHEMICAL
,	O
which	O
displayed	O
only	O
a	O
weak	O
cytotoxicity	O
,	O
the	O
mono	O
-	O
and	O
bis	O
-	O
desethylated	O
metabolites	O
,	O
the	O
further	O
degraded	O
alcohol	B-CHEMICAL
(	O
B2	B-CHEMICAL
-	I-CHEMICAL
O	I-CHEMICAL
-	I-CHEMICAL
CH	I-CHEMICAL
(	I-CHEMICAL
2	I-CHEMICAL
)	I-CHEMICAL
-	I-CHEMICAL
CH	I-CHEMICAL
(	I-CHEMICAL
2	I-CHEMICAL
)	I-CHEMICAL
-	I-CHEMICAL
OH	I-CHEMICAL
)	O
,	O
the	O
corresponding	O
acid	O
(	O
B2	B-CHEMICAL
-	I-CHEMICAL
O	I-CHEMICAL
-	I-CHEMICAL
CH	I-CHEMICAL
(	I-CHEMICAL
2	I-CHEMICAL
)	I-CHEMICAL
-	I-CHEMICAL
COOH	I-CHEMICAL
)	O
and	O
,	O
finally	O
,	O
the	O
newly	O
synthesized	O
B2	B-CHEMICAL
-	I-CHEMICAL
O	I-CHEMICAL
-	I-CHEMICAL
CH	I-CHEMICAL
(	I-CHEMICAL
2	I-CHEMICAL
)	I-CHEMICAL
-	I-CHEMICAL
CH	I-CHEMICAL
(	I-CHEMICAL
2	I-CHEMICAL
)	I-CHEMICAL
-	I-CHEMICAL
N	I-CHEMICAL
-	I-CHEMICAL
pyrrolidine	I-CHEMICAL
were	O
equally	O
or	O
more	O
toxic	O
.	O

Conversely	O
,	O
structural	O
analogues	O
such	O
as	O
the	O
B2	B-CHEMICAL
-	I-CHEMICAL
O	I-CHEMICAL
-	I-CHEMICAL
CH	I-CHEMICAL
(	I-CHEMICAL
2	I-CHEMICAL
)	I-CHEMICAL
-	I-CHEMICAL
CH	I-CHEMICAL
(	I-CHEMICAL
2	I-CHEMICAL
)	I-CHEMICAL
-	I-CHEMICAL
N	I-CHEMICAL
-	I-CHEMICAL
diisopropyl	I-CHEMICAL
and	O
the	O
B2	B-CHEMICAL
-	I-CHEMICAL
O	I-CHEMICAL
-	I-CHEMICAL
CH	I-CHEMICAL
(	I-CHEMICAL
2	I-CHEMICAL
)	I-CHEMICAL
-	I-CHEMICAL
CH	I-CHEMICAL
(	I-CHEMICAL
2	I-CHEMICAL
)	I-CHEMICAL
-	I-CHEMICAL
N	I-CHEMICAL
-	I-CHEMICAL
piperidine	I-CHEMICAL
were	O
significantly	O
less	O
toxic	O
than	O
amiodarone	B-CHEMICAL
.	O

Cytotoxicity	O
was	O
associated	O
with	O
a	O
drop	O
in	O
the	O
mitochondrial	O
membrane	O
potential	O
,	O
suggesting	O
mitochondrial	O
involvement	O
.	O

Pharmacological	O
and	O
in	O
silico	O
investigations	O
concerning	O
the	O
interactions	O
of	O
these	O
compounds	O
with	O
the	O
hERG	B-GENE-Y
channel	O
revealed	O
that	O
compounds	O
carrying	O
a	O
basic	O
nitrogen	B-CHEMICAL
in	O
the	O
side	O
chain	O
display	O
a	O
much	O
higher	O
affinity	O
than	O
those	O
lacking	O
such	O
a	O
group	O
.	O

Specifically	O
,	O
B2	B-CHEMICAL
-	I-CHEMICAL
O	I-CHEMICAL
-	I-CHEMICAL
CH	I-CHEMICAL
(	I-CHEMICAL
2	I-CHEMICAL
)	I-CHEMICAL
-	I-CHEMICAL
CH	I-CHEMICAL
(	I-CHEMICAL
2	I-CHEMICAL
)	I-CHEMICAL
-	I-CHEMICAL
N	I-CHEMICAL
-	I-CHEMICAL
piperidine	I-CHEMICAL
and	O
B2	B-CHEMICAL
-	I-CHEMICAL
O	I-CHEMICAL
-	I-CHEMICAL
CH	I-CHEMICAL
(	I-CHEMICAL
2	I-CHEMICAL
)	I-CHEMICAL
-	I-CHEMICAL
CH	I-CHEMICAL
(	I-CHEMICAL
2	I-CHEMICAL
)	I-CHEMICAL
-	I-CHEMICAL
N	I-CHEMICAL
-	I-CHEMICAL
pyrrolidine	I-CHEMICAL
revealed	O
a	O
higher	O
affinity	O
towards	O
hERG	B-GENE-Y
channels	O
than	O
amiodarone	B-CHEMICAL
.	O

CONCLUSIONS	O
AND	O
IMPLICATIONS	O
:	O
Amiodarone	B-CHEMICAL
analogues	O
with	O
better	O
hERG	B-GENE-Y
channel	O
inhibition	O
and	O
cytotoxicity	O
profiles	O
than	O
the	O
parent	O
compound	O
have	O
been	O
identified	O
,	O
demonstrating	O
that	O
cytotoxicity	O
and	O
hERG	B-GENE-Y
channel	O
interaction	O
are	O
mechanistically	O
distinct	O
and	O
separable	O
properties	O
of	O
the	O
compounds	O
.	O

Interaction	O
of	O
human	B-GENE-Y
alpha	I-GENE-Y
-	I-GENE-Y
lactalbumin	I-GENE-Y
with	O
fatty	B-CHEMICAL
acids	I-CHEMICAL
:	O
determination	O
of	O
binding	O
parameters	O
.	O

The	O
interaction	O
of	O
holo	O
-	O
and	O
apo	O
-	O
forms	O
of	O
human	B-GENE-Y
alpha	I-GENE-Y
-	I-GENE-Y
lactalbumin	I-GENE-Y
with	O
fatty	B-CHEMICAL
acids	I-CHEMICAL
was	O
studied	O
by	O
a	O
partition	O
equilibrium	O
method	O
.	O

Apo	B-GENE-Y
-	I-GENE-Y
alpha	I-GENE-Y
-	I-GENE-Y
lactalbumin	I-GENE-Y
,	O
obtained	O
by	O
treatment	O
with	O
EDTA	B-CHEMICAL
,	O
displays	O
one	O
binding	O
site	O
for	O
fatty	B-CHEMICAL
acids	I-CHEMICAL
,	O
the	O
association	O
constants	O
for	O
oleic	B-CHEMICAL
and	I-CHEMICAL
palmitic	I-CHEMICAL
acids	I-CHEMICAL
being	O
1	O
.	O
9	O
.	O
10	O
(	O
6	O
)	O
and	O
4	O
.	O
2	O
.	O
10	O
(	O
5	O
)	O
M	O
(	O
-	O
1	O
)	O
,	O
respectively	O
.	O

However	O
,	O
holo	B-GENE-Y
-	I-GENE-Y
alpha	I-GENE-Y
-	I-GENE-Y
lactalbumin	I-GENE-Y
was	O
unable	O
to	O
bind	O
fatty	B-CHEMICAL
acids	I-CHEMICAL
as	O
measured	O
by	O
this	O
technique	O
.	O

Likewise	O
,	O
no	O
fatty	B-CHEMICAL
acids	I-CHEMICAL
bound	O
to	O
holo	B-GENE-Y
-	I-GENE-Y
alpha	I-GENE-Y
-	I-GENE-Y
lactalbumin	I-GENE-Y
,	O
isolated	O
using	O
nondenaturing	O
conditions	O
,	O
were	O
detected	O
by	O
gas	O
chromatography	O
.	O

These	O
results	O
demonstrate	O
that	O
the	O
conformational	O
change	O
induced	O
in	O
alpha	B-GENE-Y
-	I-GENE-Y
lactalbumin	I-GENE-Y
by	O
the	O
removal	O
of	O
calcium	B-CHEMICAL
enables	O
the	O
protein	O
to	O
interact	O
with	O
fatty	O
acids	O
.	O

Peptide	O
and	O
non	O
-	O
peptide	O
agonists	O
and	O
antagonists	O
for	O
the	O
vasopressin	B-CHEMICAL
and	O
oxytocin	B-CHEMICAL
V1a	B-GENE-Y
,	O
V1b	B-GENE-Y
,	O
V2	B-GENE-Y
and	O
OT	B-GENE-Y
receptors	I-GENE-Y
:	O
research	O
tools	O
and	O
potential	O
therapeutic	O
agents	O
.	O

Oxytocin	B-CHEMICAL
(	O
OT	B-CHEMICAL
)	O
and	O
vasopressin	B-CHEMICAL
(	O
AVP	B-CHEMICAL
)	O
mediate	O
their	O
biological	O
actions	O
by	O
acting	O
on	O
four	O
known	O
receptors	O
:	O
The	O
OT	B-CHEMICAL
(	O
uterine	O
)	O
and	O
the	O
AVP	B-CHEMICAL
V	B-GENE-Y
(	I-GENE-Y
1a	I-GENE-Y
)	I-GENE-Y
(	O
vasopressor	O
)	O
,	O
V	B-GENE-Y
(	I-GENE-Y
1b	I-GENE-Y
)	I-GENE-Y
(	O
pituitary	O
)	O
,	O
V	B-GENE-Y
(	I-GENE-Y
2	I-GENE-Y
)	I-GENE-Y
(	O
renal	O
)	O
receptors	O
and	O
a	O
fifth	O
putative	O
AVP	B-CHEMICAL
V	B-GENE-N
(	I-GENE-N
1c	I-GENE-N
)	I-GENE-N
?	O

(	O
vasodilating	O
)	O
receptor	O
.	O

This	O
presentation	O
will	O
summarize	O
some	O
highlights	O
of	O
the	O
recent	O
progress	O
,	O
in	O
the	O
design	O
and	O
synthesis	O
of	O
selective	O
peptide	O
agonists	O
,	O
antagonists	O
,	O
radioiodinated	O
ligands	O
,	O
fluorescent	O
ligands	O
and	O
bivalent	O
ligands	O
for	O
these	O
receptors	O
.	O

Here	O
we	O
present	O
published	O
and	O
unpublished	O
pharmacological	O
data	O
on	O
the	O
most	O
widely	O
used	O
agonists	O
,	O
antagonists	O
and	O
labelled	O
ligands	O
.	O

The	O
pharmacological	O
properties	O
of	O
promising	O
new	O
selective	O
OT	B-CHEMICAL
antagonists	O
and	O
V	B-GENE-Y
(	I-GENE-Y
1b	I-GENE-Y
)	I-GENE-Y
agonists	O
are	O
also	O
presented	O
.	O

This	O
review	O
should	O
serve	O
as	O
a	O
useful	O
guide	O
for	O
the	O
selection	O
of	O
the	O
most	O
appropriate	O
ligand	O
for	O
a	O
given	O
study	O
.	O

The	O
current	O
status	O
of	O
non	O
-	O
peptide	O
OT	B-CHEMICAL
and	O
AVP	B-CHEMICAL
antagonists	O
and	O
agonists	O
is	O
also	O
summarized	O
.	O

The	O
relative	O
merits	O
of	O
peptide	O
and	O
non	O
-	O
peptide	O
AVP	B-CHEMICAL
and	O
OT	B-CHEMICAL
agonists	O
and	O
antagonists	O
as	O
:	O
(	O
1	O
)	O
research	O
tools	O
and	O
(	O
2	O
)	O
therapeutic	O
agents	O
will	O
be	O
evaluated	O
.	O

Many	O
of	O
the	O
receptor	O
selective	O
peptide	O
agonists	O
and	O
antagonists	O
from	O
this	O
and	O
other	O
laboratories	O
are	O
far	O
more	O
widely	O
used	O
as	O
pharmacological	O
tools	O
for	O
studies	O
on	O
the	O
peripheral	O
and	O
central	O
effects	O
of	O
OT	B-CHEMICAL
and	O
AVP	B-CHEMICAL
than	O
their	O
non	O
-	O
peptide	O
counterparts	O
.	O

In	O
addition	O
to	O
OT	B-CHEMICAL
and	O
to	O
a	O
lesser	O
extent	O
AVP	B-CHEMICAL
(	O
pitressin	O
)	O
,	O
a	O
number	O
of	O
OT	B-CHEMICAL
and	O
AVP	B-CHEMICAL
analogues	O
;	O
such	O
as	O
carbetocin	B-CHEMICAL
(	O
OT	B-CHEMICAL
agonist	O
)	O
dDAVP	B-GENE-Y
(	O
desmopressin	B-CHEMICAL
,	O
V	B-GENE-Y
(	I-GENE-Y
2	I-GENE-Y
)	I-GENE-Y
agonist	O
)	O
,	O
terlipressin	B-CHEMICAL
(	O
V	B-GENE-Y
(	I-GENE-Y
1a	I-GENE-Y
)	I-GENE-Y
agonist	O
)	O
,	O
felypressin	B-CHEMICAL
(	O
V	B-GENE-Y
(	I-GENE-Y
1a	I-GENE-Y
)	I-GENE-Y
agonist	O
)	O
and	O
atosiban	B-CHEMICAL
(	O
Tractocile	B-CHEMICAL
OT	B-CHEMICAL
antagonist	O
)	O
are	O
also	O
in	O
clinical	O
use	O
.	O

Despite	O
much	O
early	O
promise	O
,	O
no	O
non	O
-	O
peptide	O
V	B-GENE-Y
(	I-GENE-Y
1a	I-GENE-Y
)	I-GENE-Y
or	O
OT	B-GENE-Y
antagonists	O
are	O
currently	O
in	O
clinical	O
trials	O
.	O

While	O
a	O
number	O
of	O
orally	O
active	O
non	O
-	O
peptide	O
V	B-GENE-Y
(	I-GENE-Y
2	I-GENE-Y
)	I-GENE-Y
antagonists	O
(	O
Vaptans	O
)	O
;	O
notably	O
,	O
Tolvaptan	B-CHEMICAL
,	O
Lixivaptan	B-CHEMICAL
and	O
Satavaptan	B-CHEMICAL
,	O
are	O
currently	O
in	O
Phase	O
III	O
clinical	O
trials	O
;	O
to	O
date	O
,	O
only	O
the	O
mixed	O
V	B-GENE-Y
(	I-GENE-Y
2	I-GENE-Y
)	I-GENE-Y
/	O
V	B-GENE-Y
(	I-GENE-Y
1a	I-GENE-Y
)	I-GENE-Y
,	O
antagonist	O
Conivaptan	B-CHEMICAL
(	O
Vaprisol	B-CHEMICAL
)	O
,	O
has	O
been	O
approved	O
by	O
the	O
US	O
FDA	O
for	O
clinical	O
use	O
(	O
by	O
i	O
.	O
v	O
.	O
administration	O
)	O
,	O
for	O
the	O
treatment	O
of	O
euvolemic	O
and	O
hypervolemic	O
hyponatremia	O
in	O
hospitalized	O
patients	O
.	O

Promising	O
new	O
non	O
-	O
peptide	O
V	B-GENE-Y
(	I-GENE-Y
1b	I-GENE-Y
)	I-GENE-Y
and	O
OT	B-CHEMICAL
antagonists	O
,	O
as	O
well	O
as	O
non	O
-	O
peptide	O
V	B-GENE-Y
(	I-GENE-Y
2	I-GENE-Y
)	I-GENE-Y
and	O
OT	B-CHEMICAL
agonists	O
are	O
now	O
in	O
pre	O
-	O
clinical	O
development	O
.	O

Mechanisms	O
of	O
lipid	O
-	O
lowering	O
agents	O
.	O

Lipid	O
-	O
lowering	O
agents	O
are	O
used	O
with	O
the	O
purpose	O
of	O
ameliorating	O
hyperlipoproteinemias	O
,	O
in	O
order	O
to	O
prevent	O
arterial	O
disease	O
.	O

Lipid	O
-	O
lowering	O
drugs	O
can	O
be	O
classified	O
into	O
absorbable	O
agents	O
and	O
into	O
nonabsorbable	O
compounds	O
,	O
acting	O
within	O
the	O
gastrointestinal	O
lumen	O
.	O

Absorbable	O
drugs	O
(	O
fibric	B-CHEMICAL
acids	I-CHEMICAL
,	O
nicotinic	B-CHEMICAL
acid	I-CHEMICAL
,	O
probucol	B-CHEMICAL
,	O
HMG	B-GENE-Y
-	I-GENE-Y
CoA	I-GENE-Y
reductase	I-GENE-Y
inhibitors	O
)	O
reduce	O
plasma	B-GENE-N
very	I-GENE-N
-	I-GENE-N
low	I-GENE-N
-	I-GENE-N
density	I-GENE-N
lipoproteins	I-GENE-N
(	O
VLDL	B-GENE-N
)	O
and	O
/	O
or	O
low	B-GENE-N
-	I-GENE-N
density	I-GENE-N
lipoproteins	I-GENE-N
(	O
LDL	B-GENE-N
)	O
by	O
a	O
variety	O
of	O
mechanisms	O
.	O

Fibric	B-CHEMICAL
acids	I-CHEMICAL
,	O
in	O
particular	O
,	O
act	O
by	O
stimulating	O
the	O
catabolism	O
of	O
VLDL	B-GENE-N
and	O
also	O
,	O
as	O
a	O
consequence	O
,	O
improving	O
LDL	B-GENE-N
delipidation	O
,	O
thus	O
favoring	O
receptor	O
uptake	O
.	O

Nicotinic	B-CHEMICAL
acid	I-CHEMICAL
and	O
acipimox	O
interfere	O
with	O
the	O
biosynthesis	O
of	O
LDL	B-GENE-N
and	O
can	O
also	O
improve	O
the	O
clearance	O
of	O
VLDL	B-GENE-N
/	O
LDL	B-GENE-N
.	O

Probucol	B-CHEMICAL
acts	O
by	O
a	O
newly	O
described	O
mechanism	O
,	O
i	O
.	O
e	O
.	O
accelerating	O
reverse	O
transport	O
of	O
cholesteryl	B-CHEMICAL
esters	I-CHEMICAL
from	O
high	B-GENE-N
-	I-GENE-N
density	I-GENE-N
lipoproteins	I-GENE-N
to	O
lower	B-GENE-N
-	I-GENE-N
density	I-GENE-N
lipoproteins	I-GENE-N
.	O

Finally	O
,	O
HMG	B-GENE-Y
-	I-GENE-Y
CoA	I-GENE-Y
reductase	I-GENE-Y
inhibitors	O
,	O
interfering	O
with	O
the	O
biosynthesis	O
of	O
cholesterol	B-CHEMICAL
,	O
can	O
induce	O
an	O
increased	O
expression	O
of	O
liver	O
high	O
-	O
affinity	O
lipoprotein	B-GENE-N
receptors	I-GENE-N
.	O

Nonabsorbable	O
agents	O
(	O
anion	O
-	O
exchange	O
resins	O
,	O
neomycin	B-CHEMICAL
,	O
beta	B-CHEMICAL
-	I-CHEMICAL
sitosterol	I-CHEMICAL
)	O
interrupt	O
the	O
recirculation	O
of	O
bile	B-CHEMICAL
acids	I-CHEMICAL
and	O
/	O
or	O
reduce	O
the	O
absorption	O
of	O
cholesterol	B-CHEMICAL
with	O
the	O
gut	O
.	O

They	O
display	O
a	O
selective	O
activity	O
on	O
hypercholesterolemia	O
,	O
again	O
by	O
increasing	O
LDL	B-GENE-N
receptor	I-GENE-N
expression	O
.	O

The	O
choice	O
of	O
one	O
or	O
more	O
lipid	O
-	O
lowering	O
agents	O
will	O
depend	O
upon	O
the	O
patient	O
'	O
s	O
phenotype	O
,	O
determining	O
responsiveness	O
to	O
the	O
pharmacological	O
treatment	O
.	O

Lapatinib	B-CHEMICAL
:	O
a	O
dual	O
inhibitor	O
of	O
human	B-GENE-Y
epidermal	I-GENE-Y
growth	I-GENE-Y
factor	I-GENE-Y
receptor	I-GENE-Y
tyrosine	B-GENE-N
kinases	I-GENE-N
.	O

BACKGROUND	O
:	O
Lapatinib	B-CHEMICAL
,	O
the	O
first	O
dual	O
inhibitor	O
of	O
epidermal	B-GENE-Y
growth	I-GENE-Y
factor	I-GENE-Y
receptor	I-GENE-Y
(	O
EGFR	B-GENE-Y
)	O
and	O
human	B-GENE-Y
epidermal	I-GENE-Y
growth	I-GENE-Y
factor	I-GENE-Y
receptor	I-GENE-Y
2	I-GENE-Y
(	O
HER2	B-GENE-Y
)	O
tyrosine	B-GENE-N
kinases	I-GENE-N
,	O
was	O
approved	O
by	O
the	O
US	O
Food	O
and	O
Drug	O
Administration	O
(	O
FDA	O
)	O
in	O
2007	O
.	O

It	O
is	O
indicated	O
for	O
use	O
in	O
combination	O
with	O
capecitabine	B-CHEMICAL
for	O
the	O
treatment	O
of	O
patients	O
with	O
advanced	O
breast	O
cancer	O
or	O
metastatic	O
breast	O
cancer	O
(	O
MBC	O
)	O
whose	O
tumors	O
overexpress	O
HER2	B-GENE-Y
(	O
ErbB2	B-GENE-Y
)	O
and	O
who	O
have	O
received	O
previous	O
treatment	O
that	O
included	O
an	O
anthracycline	B-CHEMICAL
,	O
a	O
taxane	B-CHEMICAL
,	O
and	O
trastuzumab	O
.	O

OBJECTIVE	O
:	O
This	O
review	O
summarizes	O
the	O
pharmacology	O
,	O
pharmacokinetics	O
,	O
clinical	O
efficacy	O
,	O
and	O
safety	O
profile	O
of	O
lapatinib	B-CHEMICAL
,	O
and	O
its	O
current	O
and	O
potential	O
role	O
in	O
the	O
treatment	O
of	O
breast	O
cancer	O
and	O
other	O
malignancies	O
.	O

METHODS	O
:	O
Relevant	O
English	O
-	O
language	O
publications	O
were	O
identified	O
through	O
searches	O
of	O
MEDLINE	O
(	O
1966	O
-	O
May	O
2008	O
)	O
,	O
the	O
American	O
Society	O
of	O
Clinical	O
Oncology	O
abstracts	O
database	O
(	O
2000	O
-	O
2007	O
)	O
,	O
abstracts	O
from	O
the	O
San	O
Antonio	O
Breast	O
Cancer	O
Symposium	O
(	O
2005	O
-	O
2007	O
)	O
,	O
and	O
the	O
FDA	O
Web	O
site	O
(	O
January	O
2008	O
)	O
.	O

Search	O
terms	O
included	O
lapatinib	B-CHEMICAL
,	O
GW572016	B-CHEMICAL
,	O
HER2	B-GENE-Y
,	O
EGFR	B-GENE-Y
,	O
receptor	B-GENE-N
tyrosine	I-GENE-N
kinase	I-GENE-N
,	O
dual	O
-	O
receptor	O
blockade	O
,	O
adverse	O
events	O
,	O
and	O
clinical	O
trials	O
.	O

RESULTS	O
:	O
The	O
T	O
(	O
max	O
)	O
of	O
lapatinib	B-CHEMICAL
after	O
oral	O
administration	O
is	O
3	O
to	O
4	O
hours	O
.	O

Dividing	O
the	O
dose	O
or	O
administering	O
it	O
with	O
food	O
,	O
particularly	O
a	O
high	O
-	O
fat	O
meal	O
,	O
increases	O
the	O
AUC	O
>	O
2	O
-	O
fold	O
.	O

Lapatinib	B-CHEMICAL
is	O
metabolized	O
primarily	O
by	O
the	O
cytochrome	B-GENE-Y
P450	I-GENE-Y
3A4	I-GENE-Y
isozyme	O
,	O
with	O
1	O
metabolite	O
remaining	O
active	O
against	O
EGFR	B-GENE-Y
but	O
not	O
HER2	B-GENE-Y
.	O

Due	O
to	O
drug	O
accumulation	O
,	O
the	O
t	O
(	O
1	O
/	O
2	O
)	O
of	O
lapatinib	B-CHEMICAL
is	O
24	O
hours	O
with	O
continuous	O
dosing	O
.	O

In	O
a	O
Phase	O
III	O
trial	O
comparing	O
lapatinib	B-CHEMICAL
and	O
capecitabine	B-CHEMICAL
with	O
capecitabine	B-CHEMICAL
alone	O
in	O
women	O
with	O
HER2	B-GENE-Y
-	O
positive	O
,	O
locally	O
advanced	O
breast	O
cancer	O
or	O
MBC	O
that	O
had	O
progressed	O
after	O
treatment	O
with	O
an	O
anthracycline	B-CHEMICAL
,	O
a	O
taxane	B-CHEMICAL
,	O
and	O
trastuzumab	O
,	O
the	O
combination	O
of	O
lapatinib	B-CHEMICAL
and	O
capecitabine	B-CHEMICAL
was	O
associated	O
with	O
a	O
numeric	O
improvement	O
in	O
response	O
rate	O
compared	O
with	O
capecitabine	B-CHEMICAL
alone	O
(	O
22	O
%	O
vs	O
14	O
%	O
,	O
respectively	O
;	O
P	O
=	O
NS	O
)	O
and	O
a	O
significant	O
increase	O
in	O
time	O
to	O
progression	O
(	O
6	O
.	O
2	O
vs	O
4	O
.	O
3	O
months	O
;	O
hazard	O
ratio	O
=	O
0	O
.	O
57	O
;	O
95	O
%	O
CI	O
,	O
0	O
.	O
43	O
-	O
0	O
.	O
77	O
;	O
P	O
<	O
0	O
.	O
001	O
)	O
.	O

Lapatinib	B-CHEMICAL
has	O
been	O
reported	O
to	O
have	O
antitumor	O
activity	O
in	O
Phase	O
II	O
trials	O
when	O
used	O
as	O
first	O
-	O
line	O
therapy	O
for	O
MBC	O
,	O
in	O
patients	O
with	O
inflammatory	O
breast	O
cancer	O
,	O
and	O
in	O
patients	O
with	O
central	O
nervous	O
system	O
metastases	O
.	O

Phase	O
II	O
trials	O
in	O
other	O
solid	O
tumor	O
types	O
found	O
modest	O
activity	O
.	O

The	O
approved	O
dosing	O
of	O
lapatinib	B-CHEMICAL
is	O
1	O
,	O
250	O
mg	O
PO	O
QD	O
given	O
continuously	O
in	O
combination	O
with	O
capecitabine	B-CHEMICAL
2	O
,	O
000	O
mg	O
/	O
m	O
(	O
2	O
)	O
daily	O
administered	O
in	O
2	O
divided	O
doses	O
on	O
days	O
1	O
to	O
14	O
of	O
a	O
21	O
-	O
day	O
cycle	O
.	O

The	O
most	O
common	O
clinical	O
toxicities	O
of	O
all	O
grades	O
associated	O
with	O
lapatinib	B-CHEMICAL
used	O
in	O
combination	O
with	O
capecitabine	B-CHEMICAL
in	O
the	O
pivotal	O
clinical	O
trial	O
were	O
diarrhea	O
(	O
65	O
%	O
)	O
,	O
hand	O
-	O
foot	O
syndrome	O
(	O
53	O
%	O
)	O
,	O
nausea	O
(	O
44	O
%	O
)	O
,	O
rash	O
(	O
29	O
%	O
)	O
,	O
and	O
fatigue	O
(	O
24	O
%	O
)	O
.	O

Cardiac	O
toxicity	O
appears	O
to	O
be	O
less	O
frequent	O
with	O
lapatinib	B-CHEMICAL
than	O
with	O
trastuzumab	O
.	O

CONCLUSIONS	O
:	O
Lapatinib	B-CHEMICAL
is	O
a	O
dual	O
inhibitor	O
of	O
the	O
EGFR	B-GENE-Y
and	O
HER2	B-GENE-Y
tyrosine	B-GENE-N
kinases	I-GENE-N
.	O

It	O
is	O
approved	O
by	O
the	O
FDA	O
for	O
use	O
in	O
combination	O
with	O
capecitabine	B-CHEMICAL
for	O
the	O
treatment	O
of	O
HER2	B-GENE-Y
-	O
positive	O
MBC	O
that	O
has	O
progressed	O
with	O
standard	O
treatment	O
.	O

In	O
clinical	O
trials	O
,	O
this	O
combination	O
was	O
associated	O
with	O
a	O
significant	O
improvement	O
in	O
the	O
time	O
to	O
progression	O
in	O
patients	O
with	O
MBC	O
.	O

Lapatinib	O
'	O
s	O
efficacy	O
in	O
other	O
malignancies	O
that	O
overexpress	O
EGFR	B-GENE-Y
and	O
/	O
or	O
HER2	B-GENE-Y
is	O
under	O
evaluation	O
.	O

N2	B-CHEMICAL
-	I-CHEMICAL
acetylphenelzine	I-CHEMICAL
:	O
effects	O
on	O
rat	O
brain	O
GABA	B-CHEMICAL
,	O
alanine	B-CHEMICAL
and	O
biogenic	O
amines	B-CHEMICAL
.	O

The	O
neurochemical	O
properties	O
of	O
N2	B-CHEMICAL
-	I-CHEMICAL
acetylphenelzine	I-CHEMICAL
were	O
compared	O
with	O
those	O
of	O
phenelzine	B-CHEMICAL
in	O
a	O
rat	O
model	O
.	O

N2	B-CHEMICAL
-	I-CHEMICAL
Acetylphenelzine	I-CHEMICAL
is	O
a	O
relatively	O
potent	O
inhibitor	O
of	O
monoamine	B-GENE-N
oxidase	I-GENE-N
-	I-GENE-N
A	I-GENE-N
and	I-GENE-N
-	I-GENE-N
B	I-GENE-N
and	O
causes	O
increases	O
in	O
whole	O
-	O
brain	O
levels	O
of	O
noradrenaline	B-CHEMICAL
and	O
5	B-CHEMICAL
-	I-CHEMICAL
hydroxytryptamine	I-CHEMICAL
,	O
and	O
decreases	O
in	O
homovanillic	B-CHEMICAL
acid	I-CHEMICAL
,	O
5	B-CHEMICAL
-	I-CHEMICAL
hydroxyindole	I-CHEMICAL
-	I-CHEMICAL
3	I-CHEMICAL
-	I-CHEMICAL
acetic	I-CHEMICAL
acid	I-CHEMICAL
,	O
and	O
3	B-CHEMICAL
,	I-CHEMICAL
4	I-CHEMICAL
-	I-CHEMICAL
dihydroxyphenylacetic	I-CHEMICAL
acetic	I-CHEMICAL
after	O
acute	O
i	O
.	O
p	O
.	O
administration	O
of	O
the	O
drug	O
.	O

Phenelzine	B-CHEMICAL
is	O
a	O
more	O
potent	O
monoamine	B-GENE-N
oxidase	I-GENE-N
inhibitor	O
than	O
is	O
N2	B-CHEMICAL
-	I-CHEMICAL
acetylphenelzine	I-CHEMICAL
.	O

The	O
most	O
marked	O
difference	O
in	O
the	O
profile	O
was	O
that	O
N2	B-CHEMICAL
-	I-CHEMICAL
acetylphenelzine	I-CHEMICAL
had	O
no	O
effect	O
on	O
whole	O
brain	O
levels	O
of	O
the	O
amino	B-CHEMICAL
acid	I-CHEMICAL
neurotransmitters	O
alanine	B-CHEMICAL
and	O
gamma	B-CHEMICAL
-	I-CHEMICAL
aminobutyric	I-CHEMICAL
acid	I-CHEMICAL
,	O
whereas	O
phenelzine	B-CHEMICAL
caused	O
dramatic	O
increases	O
.	O

Acetylation	O
of	O
phenelzine	B-CHEMICAL
at	O
the	O
N2	B-CHEMICAL
position	O
presumably	O
interferes	O
with	O
the	O
inhibition	O
of	O
the	O
transaminase	B-GENE-N
enzymes	O
for	O
gamma	B-CHEMICAL
-	I-CHEMICAL
aminobutyric	I-CHEMICAL
acid	I-CHEMICAL
and	O
alanine	B-CHEMICAL
.	O

Dopamine	B-GENE-Y
D3	I-GENE-Y
receptor	I-GENE-Y
-	O
preferring	O
agonists	O
increase	O
dendrite	O
arborization	O
of	O
mesencephalic	O
dopaminergic	O
neurons	O
via	O
extracellular	B-GENE-N
signal	I-GENE-N
-	I-GENE-N
regulated	I-GENE-N
kinase	I-GENE-N
phosphorylation	O
.	O

Clinical	O
improvements	O
in	O
Parkinson	O
'	O
s	O
disease	O
produced	O
by	O
dopamine	B-GENE-Y
D3	I-GENE-Y
receptor	I-GENE-Y
-	O
preferring	O
agonists	O
have	O
been	O
related	O
to	O
their	O
neuroprotective	O
actions	O
and	O
,	O
more	O
recently	O
,	O
to	O
their	O
neuroregenerative	O
properties	O
.	O

However	O
,	O
it	O
is	O
unclear	O
whether	O
dopamine	B-CHEMICAL
agonists	O
produce	O
their	O
neurotrophic	O
effects	O
by	O
acting	O
directly	O
on	O
receptors	O
expressed	O
by	O
the	O
mesencephalic	O
dopaminergic	O
neurons	O
or	O
indirectly	O
on	O
receptors	O
expressed	O
by	O
astrocytes	O
,	O
via	O
release	O
of	O
neurotrophic	B-GENE-N
factors	I-GENE-N
.	O

In	O
this	O
study	O
,	O
we	O
investigated	O
the	O
effects	O
of	O
the	O
dopamine	B-GENE-Y
D3	I-GENE-Y
receptor	I-GENE-Y
-	O
preferring	O
agonists	O
quinpirole	B-CHEMICAL
and	O
7	B-CHEMICAL
-	I-CHEMICAL
hydroxy	I-CHEMICAL
-	I-CHEMICAL
N	I-CHEMICAL
,	I-CHEMICAL
N	I-CHEMICAL
-	I-CHEMICAL
di	I-CHEMICAL
-	I-CHEMICAL
propyl	I-CHEMICAL
-	I-CHEMICAL
2	I-CHEMICAL
-	I-CHEMICAL
aminotetralin	I-CHEMICAL
(	O
7	B-CHEMICAL
-	I-CHEMICAL
OH	I-CHEMICAL
-	I-CHEMICAL
DPAT	I-CHEMICAL
)	O
,	O
as	O
well	O
as	O
of	O
the	O
indirect	O
agonist	O
amphetamine	B-CHEMICAL
,	O
on	O
dopaminergic	O
neurons	O
identified	O
by	O
tyrosine	B-GENE-Y
hydroxylase	I-GENE-Y
immunoreactivity	O
(	O
TH	B-GENE-Y
-	O
IR	O
)	O
.	O

Experiments	O
were	O
performed	O
on	O
neuronal	O
-	O
enriched	O
primary	O
cultures	O
containing	O
less	O
than	O
0	O
.	O
5	O
%	O
of	O
astrocytes	O
prepared	O
from	O
the	O
mouse	O
embryo	O
mesencephalon	O
.	O

After	O
3	O
days	O
of	O
incubation	O
,	O
both	O
quinpirole	B-CHEMICAL
(	O
1	O
-	O
10	O
microm	O
)	O
and	O
7	B-CHEMICAL
-	I-CHEMICAL
OH	I-CHEMICAL
-	I-CHEMICAL
DPAT	I-CHEMICAL
(	O
5	O
-	O
500	O
nm	O
)	O
dose	O
-	O
dependently	O
increased	O
the	O
maximal	O
dendrite	O
length	O
(	O
P	O
<	O
0	O
.	O
001	O
)	O
,	O
number	O
of	O
primary	O
dendrites	O
(	O
P	O
<	O
0	O
.	O
01	O
)	O
and	O
[	B-CHEMICAL
3H	I-CHEMICAL
]	I-CHEMICAL
dopamine	I-CHEMICAL
uptake	O
(	O
P	O
<	O
0	O
.	O
01	O
)	O
of	O
TH	B-GENE-Y
-	O
IR	O
-	O
positive	O
mesencephalic	O
neurons	O
.	O

Similar	O
effects	O
were	O
observed	O
with	O
10	O
microm	O
amphetamine	B-CHEMICAL
.	O

All	O
neurotrophic	O
effects	O
were	O
blocked	O
by	O
the	O
unselective	O
D2	B-GENE-N
/	I-GENE-N
D3	I-GENE-N
receptor	I-GENE-N
antagonist	O
sulpiride	B-CHEMICAL
(	O
5	O
microm	O
)	O
and	O
by	O
the	O
selective	O
D3	B-GENE-Y
receptor	I-GENE-Y
antagonist	O
SB	B-CHEMICAL
-	I-CHEMICAL
277011	I-CHEMICAL
-	I-CHEMICAL
A	I-CHEMICAL
at	O
a	O
low	O
dose	O
(	O
50	O
nm	O
)	O
.	O

Quinpirole	B-CHEMICAL
and	O
7	B-CHEMICAL
-	I-CHEMICAL
OH	I-CHEMICAL
-	I-CHEMICAL
DPAT	I-CHEMICAL
also	O
increased	O
the	O
phosphorylation	O
of	O
extracellular	B-GENE-N
signal	I-GENE-N
-	I-GENE-N
regulated	I-GENE-N
kinase	I-GENE-N
(	O
ERK	B-GENE-N
)	O
within	O
minutes	O
,	O
an	O
effect	O
blocked	O
by	O
pretreatment	O
with	O
SB	B-CHEMICAL
-	I-CHEMICAL
277011	I-CHEMICAL
-	I-CHEMICAL
A	I-CHEMICAL
.	O

Inhibition	O
of	O
the	O
D2	B-GENE-N
/	I-GENE-N
D3	I-GENE-N
receptor	I-GENE-N
signalling	O
pathway	O
to	O
ERK	B-GENE-N
was	O
obtained	O
with	O
PD98059	B-CHEMICAL
,	O
GF109203	B-CHEMICAL
or	O
LY294002	B-CHEMICAL
,	O
resulting	O
in	O
blockade	O
of	O
neurotrophic	O
effects	O
.	O

These	O
data	O
suggest	O
that	O
dopamine	B-CHEMICAL
agonists	O
increase	O
dendritic	O
arborizations	O
of	O
mesencephalic	O
dopaminergic	O
neurons	O
via	O
a	O
direct	O
effect	O
on	O
D2	B-GENE-N
/	I-GENE-N
D3	I-GENE-N
receptors	I-GENE-N
,	O
preferentially	O
involving	O
D3	B-GENE-Y
receptor	I-GENE-Y
-	O
dependent	O
neurotransmission	O
.	O

Molecular	O
pharmacology	O
of	O
human	B-GENE-Y
Cav3	I-GENE-Y
.	I-GENE-Y
2	I-GENE-Y
T	B-GENE-N
-	I-GENE-N
type	I-GENE-N
Ca2	I-GENE-N
+	I-GENE-N
channels	I-GENE-N
:	O
block	O
by	O
antihypertensives	O
,	O
antiarrhythmics	O
,	O
and	O
their	O
analogs	O
.	O

Antihypertensive	O
drugs	O
of	O
the	O
"	O
calcium	B-GENE-N
channel	I-GENE-N
blocker	O
"	O
or	O
"	O
calcium	B-CHEMICAL
antagonist	O
"	O
class	O
have	O
been	O
used	O
to	O
establish	O
the	O
physiological	O
role	O
of	O
L	B-GENE-N
-	I-GENE-N
type	I-GENE-N
Ca	I-GENE-N
(	I-GENE-N
2	I-GENE-N
+	I-GENE-N
)	I-GENE-N
channels	I-GENE-N
in	O
vascular	O
smooth	O
muscle	O
.	O

In	O
contrast	O
,	O
there	O
has	O
been	O
limited	O
progress	O
on	O
the	O
pharmacology	O
T	B-GENE-N
-	I-GENE-N
type	I-GENE-N
Ca	I-GENE-N
(	I-GENE-N
2	I-GENE-N
+	I-GENE-N
)	I-GENE-N
channels	I-GENE-N
.	O

T	B-GENE-N
-	I-GENE-N
type	I-GENE-N
channels	I-GENE-N
play	O
a	O
role	O
in	O
cardiac	O
pacemaking	O
,	O
aldosterone	B-CHEMICAL
secretion	O
,	O
and	O
renal	O
hemodynamics	O
,	O
leading	O
to	O
the	O
hypothesis	O
that	O
mixed	O
T	O
-	O
and	O
L	O
-	O
type	O
blockers	O
may	O
have	O
therapeutic	O
advantages	O
over	O
selective	O
L	O
-	O
type	O
blockers	O
.	O

The	O
goal	O
of	O
this	O
study	O
was	O
to	O
identify	O
compounds	O
that	O
block	O
the	O
Ca	B-GENE-Y
(	I-GENE-Y
v	I-GENE-Y
)	I-GENE-Y
3	I-GENE-Y
.	I-GENE-Y
2	I-GENE-Y
T	B-GENE-N
-	I-GENE-N
type	I-GENE-N
channel	I-GENE-N
with	O
high	O
affinity	O
,	O
focusing	O
on	O
two	O
classes	O
of	O
compounds	O
:	O
phenylalkylamines	B-CHEMICAL
(	O
e	O
.	O
g	O
.	O
,	O
mibefradil	B-CHEMICAL
)	O
and	O
dihydropyridines	B-CHEMICAL
(	O
e	O
.	O
g	O
.	O
,	O
efonidipine	B-CHEMICAL
)	O
.	O

Compounds	O
were	O
tested	O
using	O
a	O
validated	O
Ca	B-CHEMICAL
(	I-CHEMICAL
2	I-CHEMICAL
+	I-CHEMICAL
)	I-CHEMICAL
influx	O
assay	O
into	O
a	O
cell	O
line	O
expressing	O
recombinant	O
Ca	B-GENE-Y
(	I-GENE-Y
v	I-GENE-Y
)	I-GENE-Y
3	I-GENE-Y
.	I-GENE-Y
2	I-GENE-Y
channels	O
.	O

This	O
study	O
identified	O
four	O
clinically	O
approved	O
antihypertensive	O
drugs	O
(	O
efonidipine	B-CHEMICAL
,	O
felodipine	B-CHEMICAL
,	O
isradipine	B-CHEMICAL
,	O
and	O
nitrendipine	B-CHEMICAL
)	O
as	O
potent	O
T	B-GENE-N
-	I-GENE-N
channel	I-GENE-N
blockers	O
(	O
IC	O
(	O
50	O
)	O
<	O
3	O
microM	O
)	O
.	O

In	O
contrast	O
,	O
other	O
widely	O
prescribed	O
dihydropyridines	B-CHEMICAL
,	O
such	O
as	O
amlodipine	B-CHEMICAL
and	O
nifedipine	B-CHEMICAL
,	O
were	O
10	O
-	O
fold	O
less	O
potent	O
,	O
making	O
them	O
a	O
more	O
appropriate	O
choice	O
in	O
research	O
studies	O
on	O
the	O
role	O
of	O
L	O
-	O
type	O
currents	O
.	O

In	O
summary	O
,	O
the	O
present	O
results	O
support	O
the	O
notion	O
that	O
many	O
available	O
antihypertensive	O
drugs	O
block	O
a	O
substantial	O
fraction	O
of	O
T	O
-	O
current	O
at	O
therapeutically	O
relevant	O
concentrations	O
,	O
contributing	O
to	O
their	O
mechanism	O
of	O
action	O
.	O

The	O
role	O
of	O
combination	O
medical	O
therapy	O
in	O
benign	O
prostatic	O
hyperplasia	O
.	O

To	O
review	O
key	O
trials	O
of	O
monotherapy	O
and	O
combination	O
therapy	O
of	O
alpha	B-GENE-N
(	I-GENE-N
1	I-GENE-N
)	I-GENE-N
-	I-GENE-N
adrenergic	I-GENE-N
receptor	I-GENE-N
antagonists	O
(	O
alpha	O
(	O
1	O
)	O
-	O
ARAs	O
)	O
,	O
5alpha	B-GENE-N
-	I-GENE-N
reductase	I-GENE-N
inhibitors	O
(	O
5alphaRIs	O
)	O
and	O
anti	O
-	O
muscarinic	O
agents	O
in	O
the	O
treatment	O
of	O
lower	O
urinary	O
tract	O
symptoms	O
(	O
LUTS	O
)	O
associated	O
with	O
benign	O
prostatic	O
hyperplasia	O
(	O
BPH	O
)	O
.	O

To	O
assess	O
the	O
safety	O
and	O
efficacy	O
of	O
combination	O
therapies	O
for	O
LUTS	O
associated	O
with	O
BPH	O
,	O
a	O
search	O
of	O
the	O
MEDLINE	O
and	O
Cochrane	O
databases	O
(	O
1976	O
-	O
2008	O
)	O
was	O
conducted	O
for	O
relevant	O
trials	O
and	O
reviews	O
using	O
the	O
terms	O
benign	O
prostatic	O
hyperplasia	O
,	O
lower	O
urinary	O
tract	O
symptoms	O
,	O
alpha	B-GENE-N
(	I-GENE-N
1	I-GENE-N
)	I-GENE-N
-	I-GENE-N
adrenergic	I-GENE-N
receptor	I-GENE-N
antagonists	O
,	O
5alpha	B-GENE-N
-	I-GENE-N
reductase	I-GENE-N
inhibitors	O
,	O
anti	O
-	O
muscarinics	O
,	O
anticholinergics	O
,	O
combination	O
therapy	O
,	O
alfuzosin	B-CHEMICAL
,	O
doxazosin	B-CHEMICAL
,	O
tamsulosin	B-CHEMICAL
,	O
terazosin	B-CHEMICAL
,	O
dutasteride	B-CHEMICAL
,	O
finasteride	B-CHEMICAL
,	O
tolterodine	B-CHEMICAL
,	O
flavoxate	B-CHEMICAL
,	O
propiverine	B-CHEMICAL
,	O
oxybutynin	B-CHEMICAL
,	O
erectile	O
dysfunction	O
,	O
sildenafil	B-CHEMICAL
,	O
vardenafil	B-CHEMICAL
and	O
tadalafil	B-CHEMICAL
.	O

Data	O
from	O
the	O
Medical	O
Therapy	O
of	O
Prostatic	O
Symptoms	O
(	O
MTOPS	O
)	O
study	O
indicated	O
a	O
role	O
for	O
long	O
-	O
term	O
use	O
of	O
alpha	O
(	O
1	O
)	O
-	O
ARAs	O
and	O
5alphaRIs	O
in	O
combination	O
.	O

In	O
the	O
MTOPS	O
study	O
,	O
combination	O
therapy	O
with	O
the	O
alpha	O
(	O
1	O
)	O
-	O
ARA	O
doxazosin	B-CHEMICAL
and	O
the	O
5alphaRI	O
finasteride	B-CHEMICAL
was	O
significantly	O
more	O
effective	O
than	O
either	O
component	O
alone	O
in	O
reducing	O
symptoms	O
(	O
P	O
=	O
0	O
.	O
006	O
vs	O
doxazosin	B-CHEMICAL
monotherapy	O
;	O
P	O
<	O
0	O
.	O
001	O
vs	O
finasteride	O
monotherapy	O
)	O
and	O
in	O
lowering	O
the	O
rate	O
of	O
clinical	O
progression	O
(	O
P	O
<	O
0	O
.	O
001	O
vs	O
either	O
monotherapy	O
)	O
.	O

These	O
findings	O
were	O
confirmed	O
by	O
the	O
2	O
-	O
year	O
preliminary	O
results	O
of	O
the	O
Combination	O
of	O
Avodart	B-CHEMICAL
and	O
Tamsulosin	B-CHEMICAL
study	O
.	O

In	O
this	O
study	O
,	O
combination	O
therapy	O
of	O
the	O
alpha	O
(	O
1	O
)	O
-	O
ARA	O
tamsulosin	B-CHEMICAL
and	O
the	O
5alphaRI	O
dutasteride	B-CHEMICAL
resulted	O
in	O
a	O
significantly	O
greater	O
decrease	O
in	O
International	O
Prostate	O
Symptom	O
Score	O
(	O
IPSS	O
)	O
when	O
compared	O
with	O
either	O
monotherapy	O
.	O

Several	O
recent	O
trials	O
have	O
studied	O
the	O
efficacy	O
of	O
combining	O
alpha	O
(	O
1	O
)	O
-	O
ARAs	O
and	O
anti	O
-	O
muscarinic	O
agents	O
in	O
the	O
treatment	O
of	O
BPH	O
.	O

These	O
studies	O
have	O
found	O
this	O
combination	O
to	O
result	O
in	O
statistically	O
significant	O
benefits	O
in	O
quality	O
of	O
life	O
scores	O
,	O
patient	O
satisfaction	O
,	O
urinary	O
frequency	O
,	O
storage	O
symptoms	O
and	O
IPSS	O
scores	O
.	O

Studies	O
have	O
not	O
shown	O
an	O
increased	O
risk	O
of	O
urinary	O
retention	O
associated	O
with	O
the	O
use	O
of	O
anti	O
-	O
muscarinics	O
in	O
a	O
highly	O
select	O
cohort	O
of	O
men	O
with	O
BPH	O
.	O

The	O
available	O
data	O
suggest	O
that	O
combination	O
therapy	O
can	O
be	O
beneficial	O
in	O
the	O
treatment	O
of	O
BPH	O
and	O
associated	O
LUTS	O
.	O

The	O
greatest	O
efficacy	O
for	O
the	O
alpha	O
(	O
1	O
)	O
-	O
ARA	O
and	O
5alphaRI	O
combination	O
was	O
shown	O
in	O
patients	O
with	O
larger	O
prostate	O
size	O
and	O
more	O
severe	O
symptoms	O
.	O

The	O
combination	O
of	O
alpha	O
(	O
1	O
)	O
-	O
ARAs	O
and	O
5alphaRIs	O
appears	O
to	O
prevent	O
disease	O
progression	O
in	O
these	O
patients	O
.	O

The	O
combination	O
of	O
alpha	O
(	O
1	O
)	O
-	O
ARAs	O
with	O
anti	O
-	O
muscarinic	O
agents	O
is	O
useful	O
for	O
relieving	O
symptoms	O
of	O
bladder	O
outlet	O
obstruction	O
and	O
detrusor	O
overactivity	O
.	O

Theoretic	O
concerns	O
regarding	O
the	O
risk	O
of	O
acute	O
urinary	O
retention	O
have	O
been	O
refuted	O
in	O
several	O
recent	O
clinical	O
trials	O
;	O
however	O
,	O
it	O
must	O
be	O
noted	O
that	O
the	O
patients	O
in	O
these	O
trials	O
were	O
a	O
highly	O
select	O
cohort	O
of	O
men	O
.	O

Men	O
with	O
overactive	O
bladder	O
and	O
BPH	O
who	O
are	O
not	O
receiving	O
adequate	O
alleviation	O
of	O
symptoms	O
from	O
the	O
first	O
-	O
line	O
alpha	O
(	O
1	O
)	O
-	O
ARAs	O
may	O
benefit	O
from	O
the	O
addition	O
of	O
an	O
anti	O
-	O
muscarinic	O
agent	O
.	O

Pharmacological	O
characterization	O
of	O
pannexin	B-GENE-Y
-	I-GENE-Y
1	I-GENE-Y
currents	O
expressed	O
in	O
mammalian	O
cells	O
.	O

Pannexin	B-GENE-Y
(	I-GENE-Y
Panx	I-GENE-Y
)	I-GENE-Y
1	I-GENE-Y
is	O
a	O
widely	O
expressed	O
protein	O
that	O
shares	O
structural	O
,	O
but	O
not	O
amino	B-CHEMICAL
acid	I-CHEMICAL
,	O
homology	O
with	O
gap	O
junction	O
proteins	O
,	O
the	O
connexins	B-GENE-N
.	O

Panx1	B-GENE-Y
does	O
not	O
form	O
gap	O
junctions	O
in	O
mammalian	O
cells	O
,	O
but	O
it	O
may	O
function	O
as	O
a	O
plasma	B-GENE-N
membrane	I-GENE-N
hemichannel	I-GENE-N
.	O

Little	O
is	O
known	O
of	O
the	O
pharmacological	O
properties	O
of	O
panx1	B-GENE-Y
expression	O
in	O
mammalian	O
cells	O
.	O

Here	O
,	O
we	O
identify	O
three	O
variants	O
in	O
the	O
human	B-GENE-Y
PANX1	I-GENE-Y
gene	O
.	O

We	O
expressed	O
these	O
variants	O
and	O
mouse	B-GENE-Y
Panx1	I-GENE-Y
in	O
mammalian	O
cells	O
and	O
compared	O
Panx1	B-GENE-Y
-	O
induced	O
currents	O
.	O

All	O
human	B-GENE-Y
Panx1	I-GENE-Y
variants	O
and	O
the	O
mouse	B-GENE-Y
Panx1	I-GENE-Y
showed	O
identical	O
protein	O
expression	O
levels	O
,	O
localization	O
patterns	O
,	O
and	O
functional	O
properties	O
,	O
although	O
the	O
frequency	O
of	O
functional	O
expression	O
was	O
species	O
-	O
dependent	O
.	O

Panx1	B-GENE-Y
currents	O
were	O
independent	O
of	O
changes	O
in	O
extracellular	O
or	O
intracellular	O
calcium	O
or	O
phospholipase	B-GENE-N
C	I-GENE-N
transduction	O
.	O

We	O
found	O
compounds	O
that	O
inhibited	O
Panx1	B-GENE-Y
currents	O
with	O
a	O
rank	O
order	O
of	O
potency	O
:	O
carbenoxolone	B-CHEMICAL
>	O
disodium	B-CHEMICAL
4	I-CHEMICAL
,	I-CHEMICAL
4	I-CHEMICAL
'	I-CHEMICAL
-	I-CHEMICAL
diisothiocyanatostilbene	I-CHEMICAL
-	I-CHEMICAL
2	I-CHEMICAL
,	I-CHEMICAL
2	I-CHEMICAL
'	I-CHEMICAL
-	I-CHEMICAL
disulfonate	I-CHEMICAL
(	O
DIDS	B-CHEMICAL
)	O
approximately	O
disodium	B-CHEMICAL
4	I-CHEMICAL
-	I-CHEMICAL
acetamido	I-CHEMICAL
-	I-CHEMICAL
4	I-CHEMICAL
'	I-CHEMICAL
-	I-CHEMICAL
isothiocyanato	I-CHEMICAL
-	I-CHEMICAL
stilben	I-CHEMICAL
-	I-CHEMICAL
2	I-CHEMICAL
,	I-CHEMICAL
2	I-CHEMICAL
'	I-CHEMICAL
-	I-CHEMICAL
disulfonate	I-CHEMICAL
approximately	O
5	B-CHEMICAL
-	I-CHEMICAL
nitro	I-CHEMICAL
-	I-CHEMICAL
2	I-CHEMICAL
-	I-CHEMICAL
(	I-CHEMICAL
3	I-CHEMICAL
-	I-CHEMICAL
phenylpropylamino	I-CHEMICAL
)	I-CHEMICAL
benzoic	I-CHEMICAL
acid	I-CHEMICAL
>	O
indanyloxyacetic	B-CHEMICAL
acid	I-CHEMICAL
94	I-CHEMICAL
>	O
>	O
probenecid	B-CHEMICAL
>	O
>	O
flufenamic	B-CHEMICAL
acid	I-CHEMICAL
=	O
niflumic	B-CHEMICAL
acid	I-CHEMICAL
.	O

Triphosphate	B-CHEMICAL
nucleotides	I-CHEMICAL
(	O
ATP	B-CHEMICAL
,	O
GTP	B-CHEMICAL
,	O
and	O
UTP	B-CHEMICAL
)	O
rapidly	O
and	O
reversibly	O
inhibited	O
Panx1	B-GENE-Y
currents	O
via	O
mechanism	O
(	O
s	O
)	O
independent	O
of	O
purine	B-GENE-N
receptors	I-GENE-N
.	O

When	O
Panx1	B-GENE-Y
was	O
coexpressed	O
with	O
purinergic	B-GENE-Y
P2X	I-GENE-Y
(	I-GENE-Y
7	I-GENE-Y
)	I-GENE-Y
receptor	I-GENE-Y
(	O
P2X	B-GENE-Y
(	I-GENE-Y
7	I-GENE-Y
)	I-GENE-Y
R	I-GENE-Y
)	O
,	O
DIDS	B-CHEMICAL
was	O
found	O
to	O
act	O
as	O
a	O
P2X	B-GENE-Y
(	I-GENE-Y
7	I-GENE-Y
)	I-GENE-Y
R	I-GENE-Y
antagonist	O
to	O
inhibit	O
ATP	B-CHEMICAL
-	O
evoked	O
currents	O
,	O
but	O
none	O
of	O
the	O
other	O
compounds	O
inhibited	O
P2X	B-GENE-Y
(	I-GENE-Y
7	I-GENE-Y
)	I-GENE-Y
R	I-GENE-Y
currents	O
.	O

This	O
is	O
the	O
first	O
detailed	O
pharmacological	O
characterization	O
of	O
Panx1	B-GENE-Y
-	O
mediated	O
currents	O
in	O
mammalian	O
cells	O
and	O
sheds	O
new	O
,	O
although	O
contradictory	O
,	O
light	O
on	O
the	O
hypothesis	O
that	O
Panx1	B-GENE-Y
acts	O
as	O
a	O
hemichannel	O
to	O
allow	O
passage	O
of	O
large	O
molecules	O
in	O
response	O
to	O
P2X	B-GENE-Y
(	I-GENE-Y
7	I-GENE-Y
)	I-GENE-Y
R	I-GENE-Y
activation	O
.	O

Captopril	B-CHEMICAL
attenuates	O
matrix	B-GENE-N
metalloproteinase	I-GENE-N
-	I-GENE-N
2	I-GENE-N
and	I-GENE-N
-	I-GENE-N
9	I-GENE-N
in	O
monocrotaline	B-CHEMICAL
-	O
induced	O
right	O
ventricular	O
hypertrophy	O
in	O
rats	O
.	O

Little	O
is	O
known	O
about	O
the	O
influence	O
of	O
angiotensin	B-GENE-Y
converting	I-GENE-Y
enzyme	I-GENE-Y
(	O
ACE	B-GENE-Y
)	O
inhibitors	O
on	O
matrix	B-GENE-N
metalloproteinase	I-GENE-N
(	O
MMP	B-GENE-N
)	O
in	O
right	O
ventricular	O
remodeling	O
.	O

We	O
investigated	O
the	O
effect	O
of	O
captopril	B-CHEMICAL
,	O
an	O
ACE	B-GENE-Y
inhibitor	O
,	O
on	O
MMP	B-GENE-Y
-	I-GENE-Y
2	I-GENE-Y
and	O
MMP	B-GENE-Y
-	I-GENE-Y
9	I-GENE-Y
in	O
monocrotaline	B-CHEMICAL
-	O
induced	O
right	O
ventricular	O
hypertrophy	O
.	O

Six	O
-	O
week	O
-	O
old	O
male	O
Wistar	O
rats	O
were	O
injected	O
intraperitoneally	O
with	O
monocrotaline	B-CHEMICAL
(	O
60	O
mg	O
/	O
kg	O
)	O
or	O
saline	O
.	O

The	O
rats	O
were	O
administrated	O
captopril	B-CHEMICAL
(	O
30	O
mg	O
/	O
kg	O
per	O
day	O
)	O
or	O
a	O
vehicle	O
orally	O
for	O
24	O
days	O
from	O
the	O
day	O
of	O
monocrotaline	B-CHEMICAL
injection	O
.	O

At	O
day	O
25	O
,	O
echocardiography	O
was	O
performed	O
and	O
hearts	O
were	O
excised	O
.	O

Expressions	O
and	O
activities	O
of	O
MMP	B-GENE-Y
-	I-GENE-Y
2	I-GENE-Y
and	O
MMP	B-GENE-Y
-	I-GENE-Y
9	I-GENE-Y
were	O
measured	O
by	O
Western	O
blotting	O
and	O
by	O
gelatin	O
zymography	O
,	O
respectively	O
.	O

In	O
monocrotaline	B-CHEMICAL
-	O
injected	O
rats	O
,	O
right	O
ventricular	O
weight	O
/	O
tail	O
length	O
ratio	O
increased	O
significantly	O
.	O

Histological	O
analysis	O
revealed	O
cardiomyocyte	O
hypertrophy	O
and	O
fibrosis	O
in	O
right	O
ventricular	O
sections	O
.	O

Echocardiography	O
showed	O
right	O
ventricular	O
dysfunction	O
compared	O
with	O
saline	O
-	O
injected	O
rats	O
.	O

The	O
right	O
ventricular	O
hypertrophy	O
,	O
fibrosis	O
,	O
and	O
dysfunction	O
were	O
inhibited	O
by	O
captopril	B-CHEMICAL
.	O

However	O
,	O
captopril	B-CHEMICAL
did	O
not	O
attenuate	O
an	O
increase	O
in	O
pulmonary	O
artery	O
pressure	O
.	O

MMP	B-GENE-Y
-	I-GENE-Y
2	I-GENE-Y
and	O
MMP	B-GENE-Y
-	I-GENE-Y
9	I-GENE-Y
expressions	O
and	O
activities	O
in	O
right	O
ventricles	O
increased	O
significantly	O
in	O
monocrotaline	B-CHEMICAL
-	O
injected	O
rats	O
and	O
captopril	B-CHEMICAL
inhibited	O
them	O
.	O

These	O
findings	O
indicate	O
that	O
captopril	B-CHEMICAL
attenuates	O
the	O
development	O
of	O
monocrotaline	B-CHEMICAL
-	O
induced	O
right	O
ventricular	O
hypertrophy	O
in	O
association	O
with	O
inhibition	O
of	O
MMP	B-GENE-Y
-	I-GENE-Y
2	I-GENE-Y
and	O
MMP	B-GENE-Y
-	I-GENE-Y
9	I-GENE-Y
in	O
rats	O
.	O

Carbonic	B-GENE-N
anhydrase	I-GENE-N
inhibitors	O
.	O

Comparison	O
of	O
chlorthalidone	B-CHEMICAL
,	O
indapamide	B-CHEMICAL
,	O
trichloromethiazide	B-CHEMICAL
,	O
and	O
furosemide	B-CHEMICAL
X	O
-	O
ray	O
crystal	O
structures	O
in	O
adducts	O
with	O
isozyme	O
II	O
,	O
when	O
several	O
water	O
molecules	O
make	O
the	O
difference	O
.	O

Thiazide	B-CHEMICAL
and	O
high	O
ceiling	O
diuretics	O
were	O
recently	O
shown	O
to	O
inhibit	O
all	O
mammalian	O
isoforms	O
of	O
carbonic	B-GENE-N
anhydrase	I-GENE-N
(	O
CA	B-GENE-N
,	O
EC	B-GENE-Y
4	I-GENE-Y
.	I-GENE-Y
2	I-GENE-Y
.	I-GENE-Y
1	I-GENE-Y
.	I-GENE-Y
1	I-GENE-Y
)	O
with	O
a	O
very	O
different	O
profile	O
as	O
compared	O
to	O
classical	O
inhibitors	O
,	O
such	O
as	O
acetazolamide	B-CHEMICAL
,	O
methazolamide	B-CHEMICAL
,	O
and	O
ethoxzolamide	B-CHEMICAL
.	O

Some	O
of	O
these	O
structurally	O
related	O
compounds	O
have	O
a	O
very	O
different	O
behavior	O
against	O
the	O
widespread	O
isozyme	O
CA	B-GENE-Y
II	I-GENE-Y
,	O
with	O
chlorthalidone	B-CHEMICAL
,	O
trichloromethiazide	B-CHEMICAL
,	O
and	O
furosemide	B-CHEMICAL
being	O
efficient	O
inhibitors	O
against	O
CA	B-GENE-Y
II	I-GENE-Y
(	O
K	O
(	O
I	O
)	O
s	O
of	O
65	O
-	O
138	O
nM	O
)	O
,	O
whereas	O
indapamide	B-CHEMICAL
is	O
a	O
much	O
weaker	O
one	O
(	O
K	O
(	O
I	O
)	O
of	O
2520	O
nM	O
)	O
.	O

Furthermore	O
,	O
some	O
of	O
these	O
diuretics	O
are	O
quite	O
efficient	O
(	O
low	O
nanomolar	O
)	O
inhibitors	O
of	O
other	O
isoforms	O
,	O
for	O
example	O
,	O
chlorthalidone	B-CHEMICAL
against	O
hCA	B-GENE-N
VB	I-GENE-N
,	I-GENE-N
VII	I-GENE-N
,	I-GENE-N
IX	I-GENE-N
,	I-GENE-N
and	I-GENE-N
XIII	I-GENE-N
;	O
indapamide	B-CHEMICAL
against	O
CA	B-GENE-N
VII	I-GENE-N
,	I-GENE-N
IX	I-GENE-N
,	I-GENE-N
XII	I-GENE-N
,	I-GENE-N
and	I-GENE-N
XIII	I-GENE-N
,	O
trichloromethiazide	B-CHEMICAL
against	O
CA	B-GENE-N
VII	I-GENE-N
and	I-GENE-N
IX	I-GENE-N
,	O
and	O
furosemide	B-CHEMICAL
against	O
CA	B-GENE-N
I	I-GENE-N
and	I-GENE-N
XIV	I-GENE-N
.	O

Examining	O
the	O
four	O
X	O
-	O
ray	O
crystal	O
structures	O
of	O
their	O
CA	B-GENE-Y
II	I-GENE-Y
adducts	O
,	O
we	O
observed	O
several	O
(	O
2	O
-	O
3	O
)	O
active	O
site	O
water	O
molecules	O
interacting	O
with	O
the	O
chlorthalidone	B-CHEMICAL
,	O
trichloromethiazide	B-CHEMICAL
,	O
and	O
furosemide	B-CHEMICAL
scaffolds	O
which	O
may	O
be	O
responsible	O
for	O
this	O
important	O
difference	O
of	O
activity	O
.	O

Indeed	O
,	O
indapamide	B-CHEMICAL
bound	O
to	O
CA	B-GENE-Y
II	I-GENE-Y
has	O
no	O
interactions	O
with	O
active	O
site	O
water	O
molecules	O
.	O

Chlorthalidone	B-CHEMICAL
bound	O
within	O
the	O
CA	B-GENE-Y
II	I-GENE-Y
active	O
site	O
is	O
in	O
an	O
enolic	O
(	O
lactimic	O
)	O
tautomeric	O
form	O
,	O
with	O
the	O
enolic	O
OH	B-CHEMICAL
also	O
participating	O
in	O
two	O
strong	O
hydrogen	B-CHEMICAL
bonds	O
with	O
Asn67	O
and	O
a	O
water	O
molecule	O
.	O

The	O
newly	O
evidenced	O
binding	O
modes	O
of	O
these	O
diuretics	O
may	O
be	O
exploited	O
for	O
designing	O
better	O
CA	B-GENE-Y
II	I-GENE-Y
inhibitors	O
as	O
well	O
as	O
compounds	O
with	O
selectivity	O
/	O
affinity	O
for	O
various	O
isoforms	O
with	O
medicinal	O
chemistry	O
applications	O
.	O

Sergliflozin	B-CHEMICAL
etabonate	I-CHEMICAL
,	O
a	O
selective	O
SGLT2	B-GENE-Y
inhibitor	O
,	O
improves	O
glycemic	O
control	O
in	O
streptozotocin	B-CHEMICAL
-	O
induced	O
diabetic	O
rats	O
and	O
Zucker	O
fatty	O
rats	O
.	O

The	O
low	O
-	O
affinity	O
sodium	B-GENE-N
glucose	I-GENE-N
cotransporter	I-GENE-N
(	O
SGLT2	B-GENE-Y
)	O
is	O
responsible	O
for	O
most	O
of	O
the	O
glucose	B-CHEMICAL
reabsorption	O
in	O
the	O
kidney	O
and	O
has	O
been	O
highlighted	O
as	O
a	O
novel	O
therapeutic	O
target	O
for	O
the	O
treatment	O
of	O
diabetes	O
.	O

We	O
discovered	O
sergliflozin	B-CHEMICAL
etabonate	I-CHEMICAL
,	O
a	O
novel	O
selective	O
SGLT2	B-GENE-Y
inhibitor	O
,	O
and	O
found	O
that	O
selective	O
inhibition	O
of	O
SGLT2	B-GENE-Y
increased	O
urinary	O
glucose	B-CHEMICAL
excretion	O
and	O
consequently	O
decreased	O
plasma	O
glucose	B-CHEMICAL
levels	O
.	O

In	O
this	O
report	O
,	O
we	O
examined	O
the	O
antihyperglycemic	O
effects	O
of	O
sergliflozin	B-CHEMICAL
etabonate	I-CHEMICAL
in	O
normal	O
and	O
diabetic	O
rats	O
in	O
comparison	O
with	O
those	O
of	O
a	O
sulfonylurea	B-CHEMICAL
(	O
gliclazide	B-CHEMICAL
)	O
and	O
an	O
alpha	B-GENE-Y
-	I-GENE-Y
glucosidase	I-GENE-Y
inhibitor	O
(	O
voglibose	B-CHEMICAL
)	O
.	O

Sergliflozin	B-CHEMICAL
etabonate	I-CHEMICAL
increased	O
urinary	O
glucose	B-CHEMICAL
excretion	O
in	O
a	O
dose	O
-	O
dependent	O
manner	O
,	O
and	O
inhibited	O
the	O
increase	O
in	O
plasma	O
glucose	B-CHEMICAL
after	O
sucrose	B-CHEMICAL
loading	O
independently	O
of	O
insulin	B-GENE-N
secretion	O
in	O
normal	O
rats	O
.	O

Sergliflozin	B-CHEMICAL
etabonate	I-CHEMICAL
also	O
improved	O
postprandial	O
hyperglycemia	O
in	O
neonatal	O
streptozotocin	B-CHEMICAL
-	O
induced	O
diabetic	O
rats	O
;	O
whereas	O
gliclazide	B-CHEMICAL
did	O
not	O
improve	O
it	O
.	O

In	O
rats	O
with	O
mild	O
or	O
moderate	O
streptozotocin	B-CHEMICAL
-	O
induced	O
diabetes	O
,	O
the	O
degree	O
of	O
the	O
antihyperglycemic	O
effects	O
of	O
sergliflozin	B-CHEMICAL
etabonate	I-CHEMICAL
correlated	O
with	O
the	O
severity	O
of	O
the	O
diabetic	O
condition	O
.	O

Sergliflozin	B-CHEMICAL
etabonate	I-CHEMICAL
did	O
not	O
affect	O
the	O
plasma	O
glucose	B-CHEMICAL
level	O
of	O
normal	O
rats	O
as	O
seen	O
with	O
gliclazide	B-CHEMICAL
.	O

Chronic	O
treatment	O
with	O
sergliflozin	B-CHEMICAL
etabonate	I-CHEMICAL
reduced	O
the	O
levels	O
of	O
glycated	B-GENE-N
hemoglobin	I-GENE-N
and	O
fasting	O
plasma	O
glucose	B-CHEMICAL
,	O
and	O
improved	O
the	O
glycemic	O
response	O
after	O
glucose	B-CHEMICAL
loading	O
in	O
Zucker	O
fatty	O
rats	O
.	O

In	O
addition	O
,	O
sergliflozin	B-CHEMICAL
etabonate	I-CHEMICAL
did	O
not	O
affect	O
the	O
body	O
weight	O
or	O
food	O
intake	O
.	O

These	O
data	O
indicate	O
that	O
sergliflozin	B-CHEMICAL
etabonate	I-CHEMICAL
could	O
improve	O
glycemic	O
control	O
without	O
its	O
use	O
resulting	O
in	O
insulin	B-GENE-N
secretion	O
,	O
hypoglycemia	O
,	O
and	O
body	O
weight	O
gain	O
,	O
and	O
may	O
provide	O
a	O
unique	O
approach	O
to	O
the	O
treatment	O
of	O
diabetes	O
.	O

D1	B-GENE-N
-	I-GENE-N
like	I-GENE-N
receptors	I-GENE-N
inhibit	O
insulin	B-GENE-Y
-	O
induced	O
vascular	O
smooth	O
muscle	O
cell	O
proliferation	O
via	O
down	O
-	O
regulation	O
of	O
insulin	B-GENE-Y
receptor	I-GENE-Y
expression	O
.	O

OBJECTIVE	O
:	O
Vascular	O
smooth	O
muscle	O
cell	O
(	O
VSMC	O
)	O
proliferation	O
is	O
central	O
to	O
the	O
development	O
of	O
vascular	O
diseases	O
,	O
including	O
hypertension	O
,	O
which	O
is	O
regulated	O
by	O
numerous	O
hormones	O
and	O
humoral	O
factors	O
.	O

Our	O
previous	O
study	O
showed	O
that	O
the	O
stimulatory	O
effect	O
of	O
norepinephrine	B-CHEMICAL
on	O
VSMC	O
proliferation	O
is	O
inhibited	O
by	O
D1	B-GENE-N
-	I-GENE-N
like	I-GENE-N
receptors	I-GENE-N
and	O
the	O
D3	B-GENE-Y
dopamine	I-GENE-Y
receptor	I-GENE-Y
,	O
a	O
member	O
of	O
the	O
D2	B-GENE-N
-	I-GENE-N
like	I-GENE-N
receptor	I-GENE-N
family	O
.	O

Insulin	B-GENE-Y
is	O
a	O
proliferative	O
hormone	O
but	O
it	O
is	O
not	O
known	O
if	O
there	O
is	O
any	O
interaction	O
between	O
insulin	B-GENE-Y
and	O
D1	B-GENE-N
-	I-GENE-N
like	I-GENE-N
receptors	I-GENE-N
.	O

We	O
hypothesized	O
that	O
Dl	B-GENE-N
-	I-GENE-N
like	I-GENE-N
receptors	I-GENE-N
may	O
have	O
an	O
inhibitory	O
effect	O
on	O
the	O
insulin	B-GENE-Y
-	O
induced	O
VSMC	O
proliferation	O
;	O
aberrant	O
insulin	B-GENE-Y
and	O
Dl	B-GENE-N
-	I-GENE-N
like	I-GENE-N
receptor	I-GENE-N
functions	O
could	O
be	O
involved	O
in	O
the	O
pathogenesis	O
of	O
essential	O
hypertension	O
.	O

METHODS	O
:	O
VSMC	O
proliferation	O
was	O
determined	O
by	O
[	B-CHEMICAL
H	I-CHEMICAL
]	I-CHEMICAL
-	I-CHEMICAL
thymidine	I-CHEMICAL
incorporation	O
;	O
insulin	B-GENE-Y
receptor	I-GENE-Y
mRNA	O
and	O
protein	O
expressions	O
were	O
determined	O
by	O
RT	O
-	O
PCR	O
,	O
immunoblotting	O
,	O
and	O
immunohistochemistry	O
.	O

RESULTS	O
:	O
Insulin	B-GENE-Y
increased	O
VSMC	O
proliferation	O
in	O
immortalized	O
aortic	O
A10	O
cells	O
,	O
determined	O
by	O
[	B-CHEMICAL
H	I-CHEMICAL
]	I-CHEMICAL
-	I-CHEMICAL
thymidine	I-CHEMICAL
incorporation	O
.	O

Although	O
the	O
D1	B-GENE-N
-	I-GENE-N
like	I-GENE-N
receptor	I-GENE-N
,	O
by	O
itself	O
,	O
had	O
no	O
effect	O
on	O
VSMC	O
proliferation	O
,	O
stimulation	O
with	O
fenoldopam	B-CHEMICAL
,	O
a	O
D1	B-GENE-N
-	I-GENE-N
like	I-GENE-N
receptor	I-GENE-N
agonist	O
,	O
inhibited	O
the	O
stimulatory	O
effect	O
of	O
insulin	B-GENE-Y
.	O

The	O
inhibitory	O
effect	O
of	O
fenoldopam	B-CHEMICAL
on	O
insulin	B-GENE-Y
-	O
mediated	O
VSMC	O
proliferation	O
was	O
receptor	O
specific	O
,	O
because	O
its	O
effect	O
could	O
be	O
blocked	O
by	O
SCH23390	B-CHEMICAL
,	O
a	O
D1	B-GENE-N
-	I-GENE-N
like	I-GENE-N
receptor	I-GENE-N
antagonist	O
.	O

Fenoldopam	B-CHEMICAL
also	O
inhibited	O
insulin	B-GENE-Y
receptor	I-GENE-Y
mRNA	O
and	O
protein	O
expression	O
,	O
which	O
was	O
time	O
dependent	O
and	O
concentration	O
dependent	O
.	O

A	O
PKC	B-GENE-N
or	O
MAP	B-GENE-N
kinase	I-GENE-N
inhibitor	O
blocked	O
the	O
inhibitory	O
effect	O
of	O
fenoldopam	B-CHEMICAL
on	O
insulin	B-GENE-Y
receptor	I-GENE-Y
expression	O
,	O
indicating	O
that	O
PKC	B-GENE-N
and	O
MAP	B-GENE-N
kinase	I-GENE-N
were	O
involved	O
in	O
the	O
signaling	O
pathway	O
.	O

CONCLUSION	O
:	O
The	O
inhibitory	O
effect	O
of	O
D1	B-GENE-N
-	I-GENE-N
like	I-GENE-N
receptors	I-GENE-N
on	O
insulin	B-GENE-Y
-	O
mediated	O
VSMC	O
proliferation	O
may	O
play	O
an	O
important	O
role	O
in	O
the	O
regulation	O
of	O
blood	O
pressure	O
.	O

Successful	O
liver	O
transplantation	O
for	O
Budd	O
-	O
Chiari	O
syndrome	O
in	O
a	O
patient	O
with	O
paroxysmal	O
nocturnal	O
hemoglobinuria	O
treated	O
with	O
the	O
anti	O
-	O
complement	O
antibody	O
eculizumab	O
.	O

Paroxysmal	O
nocturnal	O
hemoglobinuria	O
(	O
PNH	O
)	O
is	O
a	O
rare	O
,	O
acquired	O
hemolytic	O
anemia	O
caused	O
by	O
somatic	O
mutations	O
in	O
the	O
phosphatidylinositol	B-GENE-Y
glycan	I-GENE-Y
-	I-GENE-Y
complementation	I-GENE-Y
class	I-GENE-Y
A	I-GENE-Y
gene	O
and	O
the	O
resulting	O
absence	O
of	O
a	O
key	O
complement	O
regulatory	O
protein	O
,	O
CD59	B-GENE-Y
.	O

Affected	O
red	O
blood	O
cells	O
in	O
patients	O
with	O
PNH	O
undergo	O
intravascular	O
complement	O
-	O
mediated	O
lysis	O
with	O
resulting	O
anemia	O
,	O
hemoglobinuria	O
,	O
and	O
venous	O
thromboses	O
.	O

Hepatic	O
venous	O
outflow	O
thrombosis	O
[	O
Budd	O
-	O
Chiari	O
syndrome	O
(	O
BCS	O
)	O
]	O
is	O
especially	O
common	O
in	O
PNH	O
patients	O
and	O
often	O
fatal	O
.	O

The	O
few	O
case	O
reports	O
of	O
outcomes	O
in	O
patients	O
undergoing	O
liver	O
transplant	O
for	O
BCS	O
secondary	O
to	O
PNH	O
detail	O
instances	O
of	O
recurrent	O
BCS	O
as	O
well	O
as	O
early	O
thrombotic	O
portal	O
vein	O
occlusion	O
and	O
hepatic	O
artery	O
thrombosis	O
requiring	O
retransplantation	O
.	O

PNH	O
is	O
therefore	O
generally	O
considered	O
a	O
contraindication	O
to	O
liver	O
transplantation	O
.	O

Here	O
we	O
present	O
the	O
first	O
report	O
of	O
a	O
patient	O
with	O
PNH	O
and	O
BCS	O
undergoing	O
successful	O
liver	O
transplantation	O
while	O
receiving	O
eculizumab	O
,	O
a	O
humanized	O
monoclonal	O
antibody	O
that	O
blocks	O
the	O
activation	O
of	O
the	O
terminal	O
complement	O
at	O
C5	B-GENE-Y
.	O

Screening	O
of	O
acetylcholinesterase	B-GENE-Y
inhibitors	O
by	O
CE	O
after	O
enzymatic	O
reaction	O
at	O
capillary	O
inlet	O
.	O

In	O
this	O
study	O
the	O
development	O
of	O
a	O
procedure	O
based	O
on	O
capillary	O
electrophoresis	O
after	O
enzymatic	O
reaction	O
at	O
capillary	O
inlet	O
methodology	O
for	O
the	O
screening	O
and	O
in	O
vitro	O
evaluation	O
of	O
the	O
biological	O
activity	O
of	O
acetylcholinesterase	B-GENE-Y
(	O
AChE	B-GENE-Y
)	O
inhibitors	O
is	O
presented	O
.	O

The	O
progress	O
of	O
the	O
enzymatic	O
reaction	O
of	O
the	O
hydrolysis	O
of	O
acetylthiocholine	B-CHEMICAL
at	O
pH	O
8	O
in	O
the	O
presence	O
of	O
AChE	B-GENE-Y
and	O
the	O
inhibitor	O
studied	O
is	O
determined	O
by	O
measuring	O
at	O
230	O
nm	O
the	O
peak	O
area	O
of	O
the	O
reaction	O
product	O
thiocholine	B-CHEMICAL
(	O
TCh	O
)	O
.	O

In	O
the	O
method	O
employed	O
the	O
capillary	O
was	O
first	O
filled	O
with	O
30	O
mM	O
borate	B-CHEMICAL
-	O
phosphate	B-CHEMICAL
buffer	O
(	O
pH	O
8	O
.	O
0	O
)	O
and	O
subsequently	O
,	O
plugs	O
of	O
:	O
(	O
i	O
)	O
water	O
,	O
(	O
ii	O
)	O
AChE	B-GENE-Y
solution	O
,	O
(	O
iii	O
)	O
substrate	O
solution	O
with	O
or	O
without	O
inhibitor	O
,	O
(	O
iv	O
)	O
AChE	B-GENE-Y
solution	O
,	O
and	O
(	O
v	O
)	O
water	O
,	O
were	O
hydrodynamically	O
injected	O
into	O
the	O
capillary	O
,	O
and	O
were	O
allowed	O
to	O
stand	O
(	O
and	O
react	O
)	O
during	O
a	O
waiting	O
period	O
of	O
2	O
min	O
.	O

The	O
applicability	O
of	O
the	O
proposed	O
methodology	O
to	O
estimate	O
different	O
kinetic	O
parameters	O
of	O
interest	O
such	O
as	O
inhibition	O
constants	O
K	O
(	O
i	O
)	O
,	O
identification	O
of	O
inhibitory	O
action	O
mechanism	O
and	O
IC	O
(	O
50	O
)	O
,	O
is	O
evaluated	O
using	O
compounds	O
with	O
known	O
activity	O
,	O
tacrine	B-CHEMICAL
edrophonium	B-CHEMICAL
,	O
and	O
neostigmine	B-CHEMICAL
.	O

The	O
results	O
obtained	O
are	O
compared	O
with	O
bibliographic	O
values	O
and	O
confirm	O
the	O
effectiveness	O
of	O
the	O
methodology	O
proposed	O
.	O

Finally	O
a	O
method	O
for	O
AChE	B-GENE-Y
Inhibitor	O
screening	O
is	O
proposed	O
.	O

Dopamine	B-GENE-N
D2	I-GENE-N
/	I-GENE-N
3	I-GENE-N
receptor	I-GENE-N
binding	O
potential	O
and	O
occupancy	O
in	O
midbrain	O
and	O
temporal	O
cortex	O
by	O
haloperidol	B-CHEMICAL
,	O
olanzapine	B-CHEMICAL
and	O
clozapine	B-CHEMICAL
.	O

AIMS	O
:	O
Aberrant	O
dopamine	B-CHEMICAL
transmission	O
in	O
extrastriatal	O
brain	O
regions	O
has	O
been	O
repeatedly	O
illustrated	O
among	O
patients	O
with	O
schizophrenia	O
.	O

Differences	O
between	O
typical	O
and	O
second	O
-	O
generation	O
antipsychotics	O
in	O
dopamine	B-GENE-Y
D	I-GENE-Y
(	I-GENE-Y
2	I-GENE-Y
)	I-GENE-Y
receptor	I-GENE-Y
modulation	O
within	O
various	O
brain	O
areas	O
remain	O
a	O
topic	O
for	O
debate	O
.	O

The	O
aim	O
of	O
the	O
present	O
study	O
was	O
therefore	O
to	O
investigate	O
dopamine	B-GENE-N
D	I-GENE-N
(	I-GENE-N
2	I-GENE-N
/	I-GENE-N
3	I-GENE-N
)	I-GENE-N
receptor	I-GENE-N
apparent	O
binding	O
potential	O
(	O
BP	O
(	O
app	O
)	O
)	O
and	O
occupancy	O
in	O
midbrain	O
and	O
temporal	O
cortex	O
among	O
clozapine	B-CHEMICAL
-	O
,	O
olanzapine	B-CHEMICAL
-	O
and	O
haloperidol	B-CHEMICAL
-	O
treated	O
schizophrenia	O
patients	O
.	O

METHODS	O
:	O
Dopamine	B-GENE-N
D	I-GENE-N
(	I-GENE-N
2	I-GENE-N
/	I-GENE-N
3	I-GENE-N
)	I-GENE-N
binding	O
was	O
studied	O
on	O
single	O
-	O
photon	O
emission	O
computed	O
tomography	O
ligand	O
[	B-CHEMICAL
(	I-CHEMICAL
123	I-CHEMICAL
)	I-CHEMICAL
I	I-CHEMICAL
]	I-CHEMICAL
epidepride	I-CHEMICAL
in	O
13	O
schizophrenia	O
patients	O
treated	O
with	O
medication	O
(	O
two	O
with	O
haloperidol	B-CHEMICAL
,	O
four	O
with	O
olanzapine	B-CHEMICAL
and	O
seven	O
with	O
clozapine	B-CHEMICAL
)	O
,	O
six	O
drug	O
-	O
naive	O
patients	O
and	O
seven	O
healthy	O
controls	O
.	O

RESULTS	O
:	O
Statistically	O
significant	O
differences	O
in	O
midbrain	O
dopamine	B-GENE-N
D	I-GENE-N
(	I-GENE-N
2	I-GENE-N
/	I-GENE-N
3	I-GENE-N
)	I-GENE-N
receptor	I-GENE-N
BP	O
(	O
app	O
)	O
(	O
P	O
=	O
0	O
.	O
015	O
)	O
and	O
occupancy	O
(	O
P	O
=	O
0	O
.	O
016	O
)	O
were	O
observed	O
between	O
the	O
clozapine	B-CHEMICAL
,	O
olanzapine	B-CHEMICAL
and	O
haloperidol	B-CHEMICAL
groups	O
.	O

The	O
lowest	O
occupancy	O
was	O
found	O
in	O
clozapine	B-CHEMICAL
-	O
treated	O
patients	O
(	O
5	O
%	O
)	O
,	O
followed	O
by	O
olanzapine	B-CHEMICAL
-	O
treated	O
patients	O
(	O
28	O
%	O
)	O
,	O
compared	O
to	O
haloperidol	B-CHEMICAL
-	O
treated	O
patients	O
(	O
40	O
%	O
)	O
.	O

No	O
significant	O
differences	O
were	O
observed	O
in	O
the	O
temporal	O
poles	O
.	O

Occupancy	O
changed	O
substantially	O
depending	O
on	O
the	O
comparison	O
group	O
used	O
(	O
either	O
drug	O
-	O
naive	O
vs	O
healthy	O
controls	O
)	O
in	O
the	O
examined	O
brain	O
areas	O
(	O
P	O
=	O
0	O
.	O
001	O
)	O
,	O
showing	O
an	O
overestimation	O
with	O
all	O
antipsychotics	O
when	O
the	O
healthy	O
control	O
group	O
was	O
used	O
.	O

CONCLUSION	O
:	O
Both	O
typical	O
and	O
second	O
-	O
generation	O
antipsychotics	O
occupy	O
cortical	O
dopamine	B-GENE-N
D	I-GENE-N
(	I-GENE-N
2	I-GENE-N
/	I-GENE-N
3	I-GENE-N
)	I-GENE-N
receptors	I-GENE-N
,	O
thus	O
mediating	O
therapeutic	O
efficacy	O
.	O

Observed	O
differences	O
in	O
midbrain	O
dopamine	B-GENE-N
D	I-GENE-N
(	I-GENE-N
2	I-GENE-N
/	I-GENE-N
3	I-GENE-N
)	I-GENE-N
occupancy	O
between	O
classical	O
antipsychotics	O
and	O
second	O
-	O
generation	O
antipsychotics	O
may	O
have	O
clinical	O
relevance	O
by	O
modulating	O
altered	O
nigrostriatal	O
dopamine	B-CHEMICAL
neurotransmission	O
during	O
the	O
acute	O
phase	O
of	O
schizophrenia	O
.	O

Medical	O
treatment	O
of	O
acute	O
poisoning	O
with	O
organophosphorus	B-CHEMICAL
and	O
carbamate	B-CHEMICAL
pesticides	O
.	O

Organophosphorus	B-CHEMICAL
compounds	O
(	O
OPs	O
)	O
are	O
used	O
as	O
pesticides	O
and	O
developed	O
as	O
warfare	O
nerve	O
agents	O
such	O
as	O
tabun	B-CHEMICAL
,	O
soman	B-CHEMICAL
,	O
sarin	B-CHEMICAL
,	O
VX	O
and	O
others	O
.	O

Exposure	O
to	O
even	O
small	O
amounts	O
of	O
an	O
OP	B-CHEMICAL
can	O
be	O
fatal	O
and	O
death	O
is	O
usually	O
caused	O
by	O
respiratory	O
failure	O
.	O

The	O
mechanism	O
of	O
OP	B-CHEMICAL
poisoning	O
involves	O
inhibition	O
of	O
acetylcholinesterase	B-GENE-Y
(	O
AChE	B-GENE-Y
)	O
leading	O
to	O
inactivation	O
of	O
the	O
enzyme	O
which	O
has	O
an	O
important	O
role	O
in	O
neurotransmission	O
.	O

AChE	B-GENE-Y
inhibition	O
results	O
in	O
the	O
accumulation	O
of	O
acetylcholine	B-CHEMICAL
at	O
cholinergic	O
receptor	O
sites	O
,	O
producing	O
continuous	O
stimulation	O
of	O
cholinergic	O
fibers	O
throughout	O
the	O
nervous	O
systems	O
.	O

During	O
more	O
than	O
five	O
decades	O
,	O
pyridinium	B-CHEMICAL
oximes	I-CHEMICAL
have	O
been	O
developed	O
as	O
therapeutic	O
agents	O
used	O
in	O
the	O
medical	O
treatment	O
of	O
poisoning	O
with	O
OP	B-CHEMICAL
.	O

They	O
act	O
by	O
reactivation	O
of	O
AChE	B-GENE-Y
inhibited	O
by	O
OP	B-CHEMICAL
.	O

However	O
,	O
they	O
differ	O
in	O
their	O
activity	O
in	O
poisoning	O
with	O
pesticides	O
and	O
warfare	O
nerve	O
agents	O
and	O
there	O
is	O
still	O
no	O
universal	O
broad	O
-	O
spectrum	O
oxime	B-CHEMICAL
capable	O
of	O
protecting	O
against	O
all	O
known	O
OP	B-CHEMICAL
.	O

In	O
spite	O
of	O
enormous	O
efforts	O
devoted	O
to	O
development	O
of	O
new	O
pyridinium	B-CHEMICAL
oximes	I-CHEMICAL
as	O
potential	O
antidotes	O
against	O
poisoning	O
with	O
OP	B-CHEMICAL
only	O
four	O
compounds	O
so	O
far	O
have	O
found	O
its	O
application	O
in	O
human	O
medicine	O
.	O

Presently	O
,	O
a	O
combination	O
of	O
an	O
antimuscarinic	O
agent	O
,	O
e	O
.	O
g	O
.	O
atropine	B-CHEMICAL
,	O
AChE	B-GENE-Y
reactivator	O
such	O
as	O
one	O
of	O
the	O
recommended	O
pyridinium	B-CHEMICAL
oximes	I-CHEMICAL
(	O
pralidoxime	B-CHEMICAL
,	O
trimedoxime	B-CHEMICAL
,	O
obidoxime	B-CHEMICAL
and	O
HI	B-CHEMICAL
-	I-CHEMICAL
6	I-CHEMICAL
)	O
and	O
diazepam	B-CHEMICAL
are	O
used	O
for	O
the	O
treatment	O
of	O
OP	B-CHEMICAL
poisoning	O
in	O
humans	O
.	O

In	O
this	O
article	O
the	O
available	O
data	O
related	O
to	O
medical	O
treatment	O
of	O
poisoning	O
with	O
OP	B-CHEMICAL
pesticides	O
are	O
reviewed	O
and	O
the	O
current	O
recommendations	O
are	O
presented	O
.	O

Preclinical	O
properties	O
of	O
18F	B-CHEMICAL
-	I-CHEMICAL
AV	I-CHEMICAL
-	I-CHEMICAL
45	I-CHEMICAL
:	O
a	O
PET	O
agent	O
for	O
Abeta	B-GENE-Y
plaques	O
in	O
the	O
brain	O
.	O

UNLABELLED	O
:	O
beta	B-GENE-Y
-	I-GENE-Y
amyloid	I-GENE-Y
plaques	O
(	O
Abeta	B-GENE-Y
plaques	O
)	O
in	O
the	O
brain	O
,	O
containing	O
predominantly	O
fibrillary	O
Abeta	B-GENE-Y
peptide	O
aggregates	O
,	O
represent	O
a	O
defining	O
pathologic	O
feature	O
of	O
Alzheimer	O
disease	O
(	O
AD	O
)	O
.	O

Imaging	O
agents	O
targeting	O
the	O
Abeta	B-GENE-Y
plaques	O
in	O
the	O
living	O
human	O
brain	O
are	O
potentially	O
valuable	O
as	O
biomarkers	O
of	O
pathogenesis	O
processes	O
in	O
AD	O
.	O

(	B-CHEMICAL
E	I-CHEMICAL
)	I-CHEMICAL
-	I-CHEMICAL
4	I-CHEMICAL
-	I-CHEMICAL
(	I-CHEMICAL
2	I-CHEMICAL
-	I-CHEMICAL
(	I-CHEMICAL
6	I-CHEMICAL
-	I-CHEMICAL
(	I-CHEMICAL
2	I-CHEMICAL
-	I-CHEMICAL
(	I-CHEMICAL
2	I-CHEMICAL
-	I-CHEMICAL
(	I-CHEMICAL
2	I-CHEMICAL
-	I-CHEMICAL
(	I-CHEMICAL
18	I-CHEMICAL
)	I-CHEMICAL
F	I-CHEMICAL
-	I-CHEMICAL
fluoroethoxy	I-CHEMICAL
)	I-CHEMICAL
ethoxy	I-CHEMICAL
)	I-CHEMICAL
ethoxy	I-CHEMICAL
)	I-CHEMICAL
pyridin	I-CHEMICAL
-	I-CHEMICAL
3	I-CHEMICAL
-	I-CHEMICAL
yl	I-CHEMICAL
)	I-CHEMICAL
vinyl	I-CHEMICAL
)	I-CHEMICAL
-	I-CHEMICAL
N	I-CHEMICAL
-	I-CHEMICAL
methy	I-CHEMICAL
l	I-CHEMICAL
benzenamine	I-CHEMICAL
(	O
(	B-CHEMICAL
18	I-CHEMICAL
)	I-CHEMICAL
F	I-CHEMICAL
-	I-CHEMICAL
AV	I-CHEMICAL
-	I-CHEMICAL
45	I-CHEMICAL
)	O
is	O
such	O
as	O
an	O
agent	O
currently	O
in	O
phase	O
III	O
clinical	O
studies	O
for	O
PET	O
of	O
Abeta	B-GENE-Y
plaques	O
in	O
the	O
brain	O
.	O

METHODS	O
:	O
In	O
vitro	O
binding	O
of	O
(	B-CHEMICAL
18	I-CHEMICAL
)	I-CHEMICAL
F	I-CHEMICAL
-	I-CHEMICAL
AV	I-CHEMICAL
-	I-CHEMICAL
45	I-CHEMICAL
to	O
Abeta	B-GENE-Y
plaques	O
in	O
the	O
postmortem	O
AD	O
brain	O
tissue	O
was	O
evaluated	O
by	O
in	O
vitro	O
binding	O
assay	O
and	O
autoradiography	O
.	O

In	O
vivo	O
biodistribution	O
of	O
(	B-CHEMICAL
18	I-CHEMICAL
)	I-CHEMICAL
F	I-CHEMICAL
-	I-CHEMICAL
AV	I-CHEMICAL
-	I-CHEMICAL
45	I-CHEMICAL
in	O
mice	O
and	O
ex	O
vivo	O
autoradiography	O
of	O
AD	O
transgenic	O
mice	O
(	O
APPswe	B-GENE-Y
/	O
PSEN1	B-GENE-Y
)	O
with	O
Abeta	B-GENE-Y
aggregates	O
in	O
the	O
brain	O
were	O
performed	O
.	O

Small	O
-	O
animal	O
PET	O
of	O
a	O
monkey	O
brain	O
after	O
an	O
intravenous	O
injection	O
of	O
(	B-CHEMICAL
18	I-CHEMICAL
)	I-CHEMICAL
F	I-CHEMICAL
-	I-CHEMICAL
AV	I-CHEMICAL
-	I-CHEMICAL
45	I-CHEMICAL
was	O
evaluated	O
.	O

RESULTS	O
:	O
(	B-CHEMICAL
18	I-CHEMICAL
)	I-CHEMICAL
F	I-CHEMICAL
-	I-CHEMICAL
AV	I-CHEMICAL
-	I-CHEMICAL
45	I-CHEMICAL
displayed	O
a	O
high	O
binding	O
affinity	O
and	O
specificity	O
to	O
Abeta	B-GENE-Y
plaques	O
(	O
K	O
(	O
d	O
)	O
,	O
3	O
.	O
72	O
+	O
/	O
-	O
0	O
.	O
30	O
nM	O
)	O
.	O

In	O
vitro	O
autoradiography	O
of	O
postmortem	O
human	O
brain	O
sections	O
showed	O
substantial	O
plaque	O
labeling	O
in	O
AD	O
brains	O
and	O
not	O
in	O
the	O
control	O
brains	O
.	O

Initial	O
high	O
brain	O
uptake	O
and	O
rapid	O
washout	O
from	O
the	O
brain	O
of	O
healthy	O
mice	O
and	O
monkey	O
were	O
observed	O
.	O

Metabolites	O
produced	O
in	O
the	O
blood	O
of	O
healthy	O
mice	O
after	O
an	O
intravenous	O
injection	O
were	O
identified	O
.	O

(	B-CHEMICAL
18	I-CHEMICAL
)	I-CHEMICAL
F	I-CHEMICAL
-	I-CHEMICAL
AV	I-CHEMICAL
-	I-CHEMICAL
45	I-CHEMICAL
displayed	O
excellent	O
binding	O
affinity	O
to	O
Abeta	B-GENE-Y
plaques	O
in	O
the	O
AD	O
brain	O
by	O
ex	O
vivo	O
autoradiography	O
in	O
transgenic	O
AD	O
model	O
mice	O
.	O

The	O
results	O
lend	O
support	O
that	O
(	B-CHEMICAL
18	I-CHEMICAL
)	I-CHEMICAL
F	I-CHEMICAL
-	I-CHEMICAL
AV	I-CHEMICAL
-	I-CHEMICAL
45	I-CHEMICAL
may	O
be	O
a	O
useful	O
PET	O
agent	O
for	O
detecting	O
Abeta	B-GENE-Y
plaques	O
in	O
the	O
living	O
human	O
brain	O
.	O

Palonosetron	B-CHEMICAL
:	O
in	O
the	O
prevention	O
of	O
nausea	O
and	O
vomiting	O
.	O

Palonosetron	B-CHEMICAL
is	O
a	O
second	O
-	O
generation	O
serotonin	B-GENE-N
5	I-GENE-N
-	I-GENE-N
HT3	I-GENE-N
receptor	I-GENE-N
antagonist	O
,	O
with	O
a	O
distinct	O
pharmacological	O
profile	O
that	O
differs	O
from	O
first	O
-	O
generation	O
5	B-GENE-N
-	I-GENE-N
HT3	I-GENE-N
receptor	I-GENE-N
antagonists	O
.	O

Intravenous	O
palonosetron	B-CHEMICAL
is	O
widely	O
indicated	O
for	O
the	O
prevention	O
of	O
chemotherapy	O
-	O
induced	O
nausea	O
and	O
vomiting	O
(	O
CINV	O
)	O
in	O
the	O
acute	O
and	O
delayed	O
phases	O
following	O
moderately	O
emetogenic	O
chemotherapy	O
(	O
MEC	O
)	O
and	O
the	O
prevention	O
of	O
CINV	O
in	O
the	O
acute	O
phase	O
following	O
highly	O
emetogenic	O
chemotherapy	O
(	O
HEC	O
)	O
.	O

In	O
the	O
US	O
,	O
oral	O
palonosetron	B-CHEMICAL
is	O
approved	O
for	O
the	O
prevention	O
of	O
CINV	O
in	O
the	O
acute	O
phase	O
following	O
MEC	O
(	O
although	O
this	O
formulation	O
is	O
not	O
currently	O
available	O
)	O
,	O
and	O
intravenous	O
palonosetron	B-CHEMICAL
is	O
indicated	O
for	O
the	O
prevention	O
of	O
postoperative	O
nausea	O
and	O
vomiting	O
(	O
PONV	O
)	O
in	O
the	O
first	O
24	O
hours	O
following	O
surgery	O
.	O

All	O
indications	O
are	O
currently	O
limited	O
to	O
adult	O
patients	O
.	O

Intravenous	O
palonosetron	B-CHEMICAL
was	O
noninferior	O
to	O
intravenous	O
ondansetron	B-CHEMICAL
(	O
with	O
statistically	O
greater	O
efficacy	O
than	O
ondansetron	B-CHEMICAL
)	O
or	O
dolasetron	B-CHEMICAL
in	O
preventing	O
CINV	O
following	O
MEC	O
,	O
or	O
to	O
intravenous	O
ondansetron	B-CHEMICAL
or	O
granisetron	B-CHEMICAL
in	O
preventing	O
CINV	O
following	O
HEC	O
,	O
in	O
the	O
acute	O
phase	O
.	O

Statistically	O
greater	O
efficacy	O
was	O
seen	O
with	O
intravenous	O
palonosetron	B-CHEMICAL
than	O
ondansetron	B-CHEMICAL
or	O
dolasetron	B-CHEMICAL
in	O
preventing	O
CINV	O
following	O
MEC	O
in	O
the	O
delayed	O
phase	O
.	O

Oral	O
palonosetron	B-CHEMICAL
was	O
noninferior	O
to	O
intravenous	O
palonosetron	B-CHEMICAL
in	O
preventing	O
CINV	O
in	O
the	O
acute	O
phase	O
in	O
patients	O
receiving	O
MEC	O
.	O

Intravenous	O
palonosetron	B-CHEMICAL
was	O
superior	O
to	O
placebo	O
in	O
preventing	O
PONV	O
in	O
the	O
first	O
24	O
hours	O
following	O
surgery	O
.	O

Palonosetron	B-CHEMICAL
was	O
generally	O
well	O
tolerated	O
in	O
clinical	O
trials	O
.	O

Intravenous	O
palonosetron	B-CHEMICAL
is	O
a	O
valuable	O
option	O
in	O
the	O
prevention	O
of	O
acute	O
-	O
and	O
delayed	O
-	O
phase	O
CINV	O
in	O
adult	O
patients	O
receiving	O
MEC	O
,	O
and	O
of	O
acute	O
-	O
phase	O
CINV	O
in	O
patients	O
receiving	O
HEC	O
.	O

Oral	O
palonosetron	B-CHEMICAL
is	O
likely	O
to	O
be	O
a	O
useful	O
addition	O
to	O
oral	O
formulations	O
of	O
other	O
5	B-GENE-N
-	I-GENE-N
HT3	I-GENE-N
receptor	I-GENE-N
antagonists	O
in	O
preventing	O
CINV	O
in	O
patients	O
receiving	O
MEC	O
.	O

Intravenous	O
palonosetron	B-CHEMICAL
is	O
a	O
useful	O
alternative	O
to	O
currently	O
recommended	O
agents	O
in	O
PONV	O
prevention	O
.	O

Structural	O
features	O
of	O
low	O
-	O
molecular	O
-	O
weight	O
heparins	O
affecting	O
their	O
affinity	O
to	O
antithrombin	O
.	O

As	O
part	O
of	O
a	O
more	O
extensive	O
investigation	O
on	O
structural	O
features	O
of	O
different	O
low	O
-	O
molecular	O
-	O
weight	O
heparins	O
(	O
LMWHs	O
)	O
that	O
can	O
affect	O
their	O
biological	O
activities	O
,	O
Enoxaparin	O
,	O
Tinzaparin	O
and	O
Dalteparin	O
were	O
characterised	O
with	O
regards	O
to	O
the	O
distribution	O
of	O
different	O
chain	O
length	O
oligosaccharides	O
as	O
determined	O
by	O
size	O
-	O
exclusion	O
(	O
SE	O
)	O
chromatography	O
,	O
as	O
well	O
as	O
their	O
structure	O
as	O
defined	O
by	O
2D	O
-	O
NMR	O
spectra	O
(	O
HSQC	O
)	O
.	O

The	O
three	O
LMWHs	O
were	O
also	O
fractionated	O
into	O
high	O
affinity	O
(	O
HA	O
)	O
and	O
no	O
affinity	O
(	O
NA	O
)	O
pools	O
with	O
regards	O
to	O
their	O
ability	O
to	O
bind	O
antithrombin	O
(	O
AT	O
)	O
.	O

The	O
HA	O
fractions	O
were	O
further	O
subfractionated	O
and	O
characterised	O
.	O

For	O
the	O
parent	O
LMWHs	O
and	O
selected	O
fractions	O
,	O
molecular	O
weight	O
parameters	O
were	O
measured	O
using	O
a	O
SE	O
chromatographic	O
system	O
with	O
a	O
triple	O
detector	O
(	O
TDA	O
)	O
to	O
obtain	O
absolute	O
molecular	O
weights	O
.	O

The	O
SE	O
chromatograms	O
clearly	O
indicate	O
that	O
Enoxaparin	O
is	O
consistently	O
richer	O
in	O
shorter	O
oligosaccharides	O
than	O
Tinzaparin	O
and	O
Dalteparin	O
.	O

Besides	O
providing	O
the	O
content	O
of	O
terminal	O
groups	O
and	O
individual	O
glucosamine	B-CHEMICAL
and	O
uronic	B-CHEMICAL
acid	I-CHEMICAL
residues	O
with	O
different	O
sulfate	B-CHEMICAL
substituents	O
,	O
the	O
HSQC	O
-	O
NMR	O
spectra	O
permitted	O
us	O
to	O
evaluate	O
and	O
correlate	O
the	O
content	O
of	O
the	O
pentasaccharide	B-CHEMICAL
,	O
AT	O
-	O
binding	O
sequence	O
A	B-GENE-N
-	I-GENE-N
G	I-GENE-N
-	I-GENE-N
A	I-GENE-N
*	I-GENE-N
-	I-GENE-N
I	I-GENE-N
-	I-GENE-N
A	I-GENE-N
(	O
AT	O
-	O
bs	O
)	O
through	O
quantification	O
of	O
signals	O
of	O
the	O
disaccharide	B-CHEMICAL
sequence	O
G	O
-	O
A	O
*	O
.	O

Whereas	O
the	O
percent	O
content	O
of	O
HA	O
species	O
is	O
approximately	O
the	O
same	O
for	O
the	O
three	O
LMWHs	O
,	O
substantial	O
differences	O
were	O
observed	O
for	O
the	O
chain	O
distribution	O
of	O
AT	O
-	O
bs	O
as	O
a	O
function	O
of	O
length	O
,	O
with	O
the	O
AT	O
-	O
bs	O
being	O
preferentially	O
contained	O
in	O
the	O
longest	O
chains	O
of	O
each	O
LMWH	O
.	O

The	O
above	O
information	O
will	O
be	O
useful	O
in	O
establishing	O
structure	O
-	O
activity	O
relationships	O
currently	O
under	O
way	O
.	O

This	O
study	O
is	O
therefore	O
critical	O
for	O
establishing	O
correlations	O
between	O
structural	O
features	O
of	O
LMWHs	O
and	O
their	O
AT	O
-	O
mediated	O
anticoagulant	O
activity	O
.	O

Abarelix	B-CHEMICAL
and	O
other	O
gonadotrophin	B-CHEMICAL
-	I-CHEMICAL
releasing	I-CHEMICAL
hormone	I-CHEMICAL
antagonists	O
in	O
prostate	O
cancer	O
.	O

Hormonal	O
therapy	O
is	O
the	O
main	O
recommended	O
treatment	O
for	O
locally	O
advanced	O
and	O
metastatic	O
prostate	O
cancer	O
.	O

Luteinizing	B-GENE-Y
hormone	I-GENE-Y
-	I-GENE-Y
releasing	I-GENE-Y
hormone	I-GENE-Y
(	O
LHRH	B-GENE-Y
)	O
agonists	O
,	O
such	O
as	O
buserelin	B-CHEMICAL
,	O
goserelin	B-CHEMICAL
,	O
leuprorelin	B-CHEMICAL
and	O
triptorelin	B-CHEMICAL
,	O
stimulate	O
the	O
pituitary	O
'	O
s	O
gonadotrophin	B-GENE-Y
-	I-GENE-Y
releasing	I-GENE-Y
hormone	I-GENE-Y
(	I-GENE-Y
GnRH	I-GENE-Y
)	I-GENE-Y
receptor	I-GENE-Y
,	O
ultimately	O
leading	O
to	O
its	O
de	O
-	O
sensitization	O
and	O
subsequent	O
reduction	O
of	O
LH	B-GENE-N
and	O
testosterone	B-CHEMICAL
levels	O
.	O

However	O
,	O
this	O
reduction	O
is	O
accompanied	O
by	O
a	O
well	O
described	O
increase	O
or	O
'	O
surge	O
'	O
in	O
LH	B-GENE-N
and	O
testosterone	B-CHEMICAL
levels	O
,	O
necessitating	O
the	O
concomitant	O
administration	O
of	O
an	O
antiandrogen	O
to	O
combat	O
the	O
potential	O
effects	O
of	O
transient	O
acceleration	O
in	O
cancer	O
activity	O
.	O

Two	O
pure	O
GnRH	B-CHEMICAL
antagonists	O
have	O
been	O
developed	O
,	O
abarelix	B-CHEMICAL
and	O
degarelix	B-CHEMICAL
,	O
that	O
are	O
devoid	O
of	O
any	O
agonist	O
effect	O
on	O
the	O
GnRH	B-GENE-Y
receptor	I-GENE-Y
and	O
consequently	O
do	O
not	O
result	O
in	O
testosterone	B-CHEMICAL
flare	O
.	O

Abarelix	B-CHEMICAL
was	O
the	O
first	O
GnRH	B-CHEMICAL
antagonist	O
to	O
be	O
developed	O
and	O
was	O
approved	O
by	O
the	O
USA	O
Food	O
and	O
Drug	O
Administration	O
in	O
2004	O
for	O
the	O
initiation	O
of	O
hormonal	O
castration	O
in	O
advanced	O
or	O
metastasizing	O
hormone	O
-	O
dependent	O
prostate	O
carcinoma	O
,	O
when	O
rapid	O
androgen	B-CHEMICAL
suppression	O
is	O
necessary	O
.	O

Clinical	O
data	O
on	O
both	O
abarelix	B-CHEMICAL
and	O
degarelix	B-CHEMICAL
show	O
that	O
they	O
can	O
produce	O
rapid	O
and	O
sustained	O
decreases	O
in	O
testosterone	B-CHEMICAL
to	O
castrate	O
levels	O
without	O
the	O
need	O
for	O
co	O
-	O
administration	O
of	O
an	O
antiandrogen	O
,	O
and	O
with	O
a	O
very	O
low	O
complication	O
rate	O
in	O
the	O
short	O
term	O
.	O

Fulvestrant	B-CHEMICAL
:	O
a	O
unique	O
antiendocrine	O
agent	O
for	O
estrogen	B-CHEMICAL
-	O
sensitive	O
breast	O
cancer	O
.	O

IMPORTANCE	O
OF	O
THE	O
FIELD	O
:	O
The	O
role	O
of	O
estrogen	B-CHEMICAL
deprivation	O
for	O
the	O
treatment	O
of	O
breast	O
cancer	O
has	O
been	O
understood	O
since	O
the	O
1800s	O
.	O

Pharmacologic	O
advances	O
in	O
the	O
field	O
in	O
the	O
past	O
decades	O
,	O
including	O
tamoxifen	B-CHEMICAL
and	O
the	O
aromatase	B-GENE-Y
inhibitors	O
,	O
have	O
contributed	O
significantly	O
to	O
the	O
reduced	O
mortality	O
of	O
estrogen	B-CHEMICAL
-	O
sensitive	O
breast	O
cancer	O
.	O

However	O
,	O
this	O
subtype	O
of	O
breast	O
cancer	O
still	O
presents	O
with	O
relapses	O
and	O
,	O
once	O
metastatic	O
,	O
progression	O
to	O
hormone	O
-	O
refractory	O
state	O
and	O
loss	O
of	O
disease	O
control	O
remain	O
an	O
expected	O
disease	O
course	O
.	O

Fulvestrant	B-CHEMICAL
,	O
a	O
pure	O
estrogen	B-GENE-Y
receptor	I-GENE-Y
downregulator	O
,	O
is	O
a	O
new	O
addition	O
to	O
the	O
antiestrogen	O
therapeutic	O
armamentarium	O
since	O
its	O
FDA	O
approval	O
in	O
2002	O
.	O

Its	O
unique	O
mechanism	O
of	O
action	O
offers	O
potential	O
advantages	O
over	O
other	O
estrogen	B-CHEMICAL
targeted	O
therapies	O
.	O

AREAS	O
COVERED	O
IN	O
THIS	O
REVIEW	O
:	O
Published	O
scientific	O
literature	O
,	O
including	O
presented	O
abstracts	O
,	O
on	O
fulvestrant	B-CHEMICAL
from	O
1985	O
to	O
the	O
present	O
were	O
reviewed	O
with	O
selected	O
publications	O
included	O
.	O

WHAT	O
THE	O
READER	O
WILL	O
GAIN	O
:	O
This	O
review	O
addresses	O
current	O
issues	O
and	O
therapies	O
for	O
estrogen	B-CHEMICAL
-	O
sensitive	O
breast	O
cancer	O
,	O
highlights	O
the	O
role	O
of	O
fulvestrant	B-CHEMICAL
in	O
current	O
treatment	O
guidelines	O
and	O
outlines	O
some	O
of	O
the	O
ongoing	O
investigations	O
of	O
this	O
compound	O
.	O

TAKE	O
HOME	O
MESSAGE	O
:	O
Fulvestrant	B-CHEMICAL
is	O
an	O
effective	O
and	O
well	O
-	O
tolerated	O
drug	O
for	O
treatment	O
of	O
metastatic	O
estrogen	B-CHEMICAL
-	O
sensitive	O
breast	O
cancer	O
.	O

Work	O
is	O
underway	O
to	O
enhance	O
its	O
clinical	O
benefit	O
to	O
patients	O
as	O
a	O
single	O
agent	O
and	O
in	O
combination	O
with	O
other	O
therapies	O
.	O

Alpha	B-GENE-Y
-	I-GENE-Y
2B	I-GENE-Y
adrenergic	I-GENE-Y
receptor	I-GENE-Y
mediated	O
hemodynamic	O
profile	O
of	O
etomidate	B-CHEMICAL
.	O

Etomidate	B-CHEMICAL
has	O
been	O
used	O
since	O
1972	O
as	O
an	O
inductor	O
and	O
in	O
maintaining	O
anesthesia	O
.	O

There	O
are	O
multiple	O
mechanisms	O
that	O
account	O
for	O
the	O
biologic	O
effects	O
of	O
etomidate	B-CHEMICAL
.	O

One	O
of	O
the	O
most	O
prominent	O
features	O
of	O
this	O
drug	O
is	O
that	O
it	O
provides	O
anesthesia	O
without	O
gross	O
changes	O
in	O
hemodynamic	O
parameters	O
.	O

This	O
feature	O
allows	O
using	O
etomidate	B-CHEMICAL
in	O
patients	O
with	O
considerable	O
cardiopulmonary	O
compromise	O
avoiding	O
the	O
characteristic	O
hypotension	O
produced	O
by	O
other	O
anesthetics	O
.	O

The	O
mechanism	O
that	O
provides	O
the	O
basis	O
for	O
its	O
cardiovascular	O
stability	O
is	O
the	O
capacity	O
to	O
bind	O
and	O
stimulate	O
peripheral	O
alpha	B-GENE-Y
-	I-GENE-Y
2B	I-GENE-Y
adrenergic	I-GENE-Y
receptors	I-GENE-Y
with	O
a	O
subsequent	O
vasoconstriction	O
.	O

Alterations	O
in	O
the	O
function	O
or	O
number	O
of	O
these	O
receptors	O
may	O
account	O
for	O
abnormal	O
responses	O
during	O
etomidate	B-CHEMICAL
induction	O
.	O

N	B-CHEMICAL
-	I-CHEMICAL
carbamylglutamate	I-CHEMICAL
treatment	O
for	O
acute	O
neonatal	O
hyperammonemia	O
in	O
isovaleric	O
acidemia	O
.	O

Hyperammonemia	O
occurs	O
mainly	O
in	O
patients	O
with	O
branched	O
-	O
chain	O
organic	O
acidemias	O
such	O
as	O
propionic	O
,	O
methylmalonic	O
,	O
and	O
isovaleric	O
acidemias	O
.	O

Its	O
pathophysiological	O
process	O
is	O
mainly	O
via	O
the	O
competitive	O
inhibition	O
of	O
N	B-GENE-Y
-	I-GENE-Y
acetylglutamate	I-GENE-Y
synthetase	I-GENE-Y
.	O

Oral	O
carglumic	B-CHEMICAL
acid	I-CHEMICAL
(	O
N	B-CHEMICAL
-	I-CHEMICAL
carbamylglutamate	I-CHEMICAL
)	O
administration	O
can	O
correct	O
hyperammonemia	O
in	O
neonates	O
with	O
propionic	O
and	O
methylmalonic	O
acidemias	O
,	O
thus	O
avoiding	O
dialysis	O
therapy	O
.	O

Isovaleric	O
acidemia	O
is	O
an	O
autosomal	O
recessive	O
disease	O
of	O
leucine	B-CHEMICAL
metabolism	O
due	O
to	O
deficiency	O
of	O
isovaleryl	B-GENE-Y
-	I-GENE-Y
CoA	I-GENE-Y
dehydrogenase	I-GENE-Y
.	O

For	O
the	O
first	O
time	O
,	O
we	O
report	O
a	O
neonate	O
with	O
isovaleric	O
acidemia	O
,	O
whose	O
plasma	O
ammonia	B-CHEMICAL
concentration	O
dropped	O
dramatically	O
after	O
one	O
oral	O
load	O
of	O
carglumic	B-CHEMICAL
acid	I-CHEMICAL
.	O

This	O
experience	O
suggests	O
that	O
carglumic	B-CHEMICAL
acid	I-CHEMICAL
could	O
be	O
considered	O
for	O
acute	O
hyperammonemia	O
resulting	O
from	O
isovaleric	O
acidemia	O
.	O

However	O
,	O
trials	O
with	O
more	O
patients	O
are	O
needed	O
.	O

Stoichiometry	O
of	O
estramustine	B-CHEMICAL
phosphate	I-CHEMICAL
binding	O
to	O
MAP2	B-GENE-Y
measured	O
by	O
the	O
disassembly	O
of	O
chick	B-GENE-Y
brain	I-GENE-Y
MAP2	I-GENE-Y
:	O
tubulin	B-GENE-N
microtubules	O
.	O

The	O
concentration	O
of	O
estramustine	B-CHEMICAL
phosphate	I-CHEMICAL
required	O
to	O
inhibit	O
the	O
assembly	O
or	O
to	O
induce	O
the	O
disassembly	O
of	O
chick	B-GENE-Y
brain	I-GENE-Y
MAP2	I-GENE-Y
:	O
tubulin	B-GENE-N
microtubules	O
is	O
markedly	O
dependent	O
upon	O
the	O
microtubule	O
protein	O
concentration	O
.	O

Analysis	O
of	O
this	O
relationship	O
shows	O
that	O
estramustine	B-CHEMICAL
phosphate	I-CHEMICAL
and	O
tubulin	B-GENE-N
compete	O
for	O
common	O
MAP2	B-GENE-Y
sites	O
,	O
that	O
MAP2	B-GENE-Y
can	O
bind	O
5	O
-	O
6	O
moles	O
.	O
mole	O
-	O
1	O
estramustine	B-CHEMICAL
phosphate	I-CHEMICAL
,	O
and	O
that	O
the	O
Kd	O
of	O
these	O
sites	O
is	O
congruent	O
to	O
20	O
microM	O
estramustine	B-CHEMICAL
phosphate	I-CHEMICAL
.	O

It	O
is	O
proposed	O
that	O
two	O
molecules	O
of	O
estramustine	B-CHEMICAL
phosphate	I-CHEMICAL
interact	O
with	O
each	O
of	O
the	O
three	O
tubulin	O
-	O
binding	O
sites	O
of	O
MAP2	B-GENE-Y
and	O
inhibit	O
the	O
MAP2	B-GENE-Y
:	O
tubulin	B-GENE-N
interaction	O
by	O
neutralising	O
two	O
highly	O
conserved	O
basic	O
residues	O
.	O

Activity	O
of	O
XL184	B-CHEMICAL
(	O
Cabozantinib	B-CHEMICAL
)	O
,	O
an	O
oral	O
tyrosine	B-GENE-N
kinase	I-GENE-N
inhibitor	O
,	O
in	O
patients	O
with	O
medullary	O
thyroid	O
cancer	O
.	O

PURPOSE	O
:	O
XL184	B-CHEMICAL
(	O
cabozantinib	B-CHEMICAL
)	O
is	O
a	O
potent	O
inhibitor	O
of	O
MET	B-GENE-Y
,	O
vascular	B-GENE-Y
endothelial	I-GENE-Y
growth	I-GENE-Y
factor	I-GENE-Y
receptor	I-GENE-Y
2	I-GENE-Y
(	O
VEGFR2	B-GENE-Y
)	O
,	O
and	O
RET	B-GENE-Y
,	O
with	O
robust	O
antiangiogenic	O
,	O
antitumor	O
,	O
and	O
anti	O
-	O
invasive	O
effects	O
in	O
preclinical	O
models	O
.	O

Early	O
observations	O
of	O
clinical	O
benefit	O
in	O
a	O
phase	O
I	O
study	O
of	O
cabozantinib	B-CHEMICAL
,	O
which	O
included	O
patients	O
with	O
medullary	O
thyroid	O
cancer	O
(	O
MTC	O
)	O
,	O
led	O
to	O
expansion	O
of	O
an	O
MTC	O
-	O
enriched	O
cohort	O
,	O
which	O
is	O
the	O
focus	O
of	O
this	O
article	O
.	O

PATIENTS	O
AND	O
METHODS	O
:	O
A	O
phase	O
I	O
dose	O
-	O
escalation	O
study	O
of	O
oral	O
cabozantinib	B-CHEMICAL
was	O
conducted	O
in	O
patients	O
with	O
advanced	O
solid	O
tumors	O
.	O

Primary	O
end	O
points	O
included	O
evaluation	O
of	O
safety	O
,	O
pharmacokinetics	O
,	O
and	O
maximum	O
-	O
tolerated	O
dose	O
(	O
MTD	O
)	O
determination	O
.	O

Additional	O
end	O
points	O
included	O
RECIST	O
(	O
Response	O
Evaluation	O
Criteria	O
in	O
Solid	O
Tumors	O
)	O
response	O
,	O
pharmacodynamics	O
,	O
RET	B-GENE-Y
mutational	O
status	O
,	O
and	O
biomarker	O
analyses	O
.	O

RESULTS	O
:	O
Eighty	O
-	O
five	O
patients	O
were	O
enrolled	O
,	O
including	O
37	O
with	O
MTC	O
.	O

The	O
MTD	O
was	O
175	O
mg	O
daily	O
.	O

Dose	O
-	O
limiting	O
toxicities	O
were	O
grade	O
3	O
palmar	O
plantar	O
erythrodysesthesia	O
(	O
PPE	O
)	O
,	O
mucositis	O
,	O
and	O
AST	B-GENE-N
,	O
ALT	B-GENE-N
,	O
and	O
lipase	B-GENE-N
elevations	O
and	O
grade	O
2	O
mucositis	O
that	O
resulted	O
in	O
dose	O
interruption	O
and	O
reduction	O
.	O

Ten	O
(	O
29	O
%	O
)	O
of	O
35	O
patients	O
with	O
MTC	O
with	O
measurable	O
disease	O
had	O
a	O
confirmed	O
partial	O
response	O
.	O

Overall	O
,	O
18	O
patients	O
experienced	O
tumor	O
shrinkage	O
of	O
30	O
%	O
or	O
more	O
,	O
including	O
17	O
(	O
49	O
%	O
)	O
of	O
35	O
patients	O
with	O
MTC	O
with	O
measurable	O
disease	O
.	O

Additionally	O
,	O
15	O
(	O
41	O
%	O
)	O
of	O
37	O
patients	O
with	O
MTC	O
had	O
stable	O
disease	O
(	O
SD	O
)	O
for	O
at	O
least	O
6	O
months	O
,	O
resulting	O
in	O
SD	O
for	O
6	O
months	O
or	O
longer	O
or	O
confirmed	O
partial	O
response	O
in	O
68	O
%	O
of	O
patients	O
with	O
MTC	O
.	O

CONCLUSION	O
:	O
Cabozantinib	B-CHEMICAL
has	O
an	O
acceptable	O
safety	O
profile	O
and	O
is	O
active	O
in	O
MTC	O
.	O

Cabozantinib	B-CHEMICAL
may	O
provide	O
clinical	O
benefit	O
by	O
simultaneously	O
targeting	O
multiple	O
pathways	O
of	O
importance	O
in	O
MTC	O
,	O
including	O
MET	B-GENE-Y
,	O
VEGFR2	B-GENE-Y
,	O
and	O
RET	B-GENE-Y
.	O

A	O
global	O
phase	O
III	O
pivotal	O
study	O
in	O
MTC	O
is	O
ongoing	O
(	O
ClinicalTrials	O
.	O
gov	O
number	O
NCT00215605	O
)	O
.	O

Toxic	O
effects	O
of	O
chromium	B-CHEMICAL
on	O
tannery	O
workers	O
at	O
Sialkot	O
(	O
Pakistan	O
)	O
.	O

Chromium	B-CHEMICAL
is	O
widely	O
used	O
in	O
the	O
leather	O
industry	O
,	O
and	O
tannery	O
workers	O
are	O
under	O
constant	O
threat	O
of	O
adverse	O
health	O
effects	O
due	O
to	O
its	O
excessive	O
exposure	O
.	O

Our	O
objective	O
was	O
to	O
find	O
out	O
the	O
toxic	O
effects	O
of	O
chromium	B-CHEMICAL
on	O
tannery	O
workers	O
at	O
Sialkot	O
,	O
Pakistan	O
.	O

A	O
total	O
of	O
240	O
males	O
consisting	O
of	O
120	O
workers	O
from	O
tanneries	O
at	O
Sialkot	O
and	O
equal	O
number	O
of	O
controls	O
were	O
included	O
.	O

Blood	O
complete	O
counts	O
,	O
high	O
-	O
sensitive	O
C	B-GENE-Y
-	I-GENE-Y
reactive	I-GENE-Y
protein	I-GENE-Y
,	O
malondialdehyde	B-CHEMICAL
and	O
routine	O
biochemical	O
tests	O
were	O
carried	O
out	O
by	O
routine	O
procedures	O
.	O

Chromium	B-CHEMICAL
levels	O
in	O
blood	O
(	O
BCr	O
)	O
and	O
urine	O
were	O
analyzed	O
using	O
graphite	B-CHEMICAL
furnace	O
atomic	O
absorption	O
spectrophotometer	O
Perkin	O
Elmer	O
analyst	O
-	O
200	O
.	O

Results	O
revealed	O
that	O
all	O
the	O
workers	O
were	O
male	O
with	O
average	O
age	O
of	O
33	O
years	O
and	O
15	O
(	O
13	O
%	O
)	O
had	O
skin	O
rashes	O
,	O
14	O
(	O
12	O
%	O
)	O
had	O
chronic	O
bronchitis	O
,	O
10	O
(	O
8	O
%	O
)	O
had	O
gastritis	O
and	O
4	O
(	O
3	O
%	O
)	O
conjunctivitis	O
.	O

The	O
tannery	O
workers	O
had	O
significantly	O
raised	O
median	O
(	O
interquartile	O
range	O
)	O
of	O
BCr	O
569	O
(	O
377	O
-	O
726	O
)	O
nmol	O
/	O
L	O
as	O
compared	O
to	O
318	O
(	O
245	O
-	O
397	O
)	O
nmol	O
/	O
L	O
in	O
the	O
control	O
(	O
p	O
<	O
0	O
.	O
001	O
)	O
.	O

Sixty	O
-	O
five	O
(	O
54	O
%	O
)	O
workers	O
had	O
BCr	O
levels	O
above	O
the	O
upper	O
limit	O
set	O
by	O
Agency	O
for	O
Toxic	O
Substance	O
and	O
Drug	O
Registry	O
.	O

The	O
urinary	O
chromium	B-CHEMICAL
excretion	O
was	O
significantly	O
high	O
in	O
workers	O
131	O
(	O
46	O
-	O
312	O
)	O
nmol	O
/	O
L	O
as	O
compared	O
to	O
13	O
(	O
3	O
-	O
26	O
)	O
nmol	O
/	O
L	O
in	O
controls	O
(	O
p	O
<	O
0	O
.	O
01	O
)	O
.	O

The	O
workers	O
had	O
hematological	O
,	O
hepatic	O
and	O
renal	O
function	O
impairment	O
because	O
of	O
oxidative	O
stress	O
on	O
body	O
systems	O
.	O

It	O
is	O
concluded	O
that	O
about	O
half	O
of	O
the	O
workers	O
had	O
excessive	O
exposure	O
to	O
chromium	B-CHEMICAL
in	O
the	O
tanneries	O
at	O
Sialkot	O
.	O

They	O
had	O
significantly	O
raised	O
chromium	B-CHEMICAL
levels	O
in	O
their	O
biological	O
fluids	O
and	O
adverse	O
health	O
effects	O
due	O
to	O
enhanced	O
oxidative	O
stress	O
and	O
inflammatory	O
changes	O
.	O

Protective	O
effect	O
of	O
vitamin	B-CHEMICAL
E	I-CHEMICAL
and	O
epicatechin	B-CHEMICAL
against	O
nicotine	B-CHEMICAL
-	O
induced	O
oxidative	O
stress	O
in	O
rats	O
.	O

Nicotine	B-CHEMICAL
is	O
a	O
major	O
pharmacologically	O
active	O
and	O
addictive	O
component	O
of	O
tobacco	O
smoke	O
,	O
which	O
is	O
regarded	O
to	O
be	O
a	O
primary	O
risk	O
factor	O
in	O
the	O
development	O
of	O
cardiovascular	O
and	O
pulmonary	O
diseases	O
.	O

Epicatechin	B-CHEMICAL
is	O
one	O
of	O
the	O
most	O
potent	O
antioxidants	O
present	O
in	O
the	O
human	O
diet	O
.	O

Particularly	O
high	O
levels	O
of	O
this	O
compound	O
are	O
found	O
in	O
tea	O
,	O
apples	O
and	O
chocolate	O
.	O

It	O
has	O
been	O
reported	O
that	O
tea	O
extracts	O
and	O
/	O
or	O
its	O
constituents	O
have	O
antibacterial	O
,	O
antiviral	O
,	O
antioxidative	O
,	O
antitumor	O
and	O
antimutagenic	O
activities	O
.	O

Vitamin	B-CHEMICAL
E	I-CHEMICAL
is	O
a	O
major	O
lipid	O
-	O
soluble	O
antioxidant	O
vitamin	O
and	O
free	O
radical	O
scavenger	O
,	O
presents	O
as	O
an	O
integral	O
component	O
of	O
cellular	O
membranes	O
and	O
has	O
important	O
biological	O
functions	O
.	O

The	O
primary	O
mechanism	O
by	O
which	O
vitamin	B-CHEMICAL
E	I-CHEMICAL
is	O
proposed	O
to	O
prevent	O
cancer	O
is	O
through	O
their	O
antioxidant	O
properties	O
.	O

The	O
goal	O
of	O
this	O
study	O
is	O
to	O
evaluate	O
the	O
effect	O
of	O
epicatechin	B-CHEMICAL
alone	O
or	O
combined	O
with	O
vitamin	B-CHEMICAL
E	I-CHEMICAL
in	O
inhibiting	O
the	O
oxidative	O
stress	O
induced	O
by	O
nicotine	B-CHEMICAL
in	O
rats	O
.	O

Results	O
obtained	O
indicated	O
that	O
there	O
was	O
a	O
significant	O
elevation	O
in	O
the	O
levels	O
of	O
malondialdhyde	B-CHEMICAL
(	O
MDA	B-CHEMICAL
)	O
in	O
nicotine	B-CHEMICAL
injected	O
rats	O
.	O

The	O
combined	O
treatment	O
(	O
epicatechin	B-CHEMICAL
+	O
Vit	B-CHEMICAL
E	I-CHEMICAL
)	O
group	O
showed	O
a	O
potential	O
reduction	O
of	O
these	O
parameters	O
more	O
than	O
individual	O
treatment	O
.	O

The	O
activities	O
of	O
superoxide	B-GENE-N
dismutase	I-GENE-N
,	O
catalase	B-GENE-Y
and	O
glutathione	B-GENE-N
peroxidase	I-GENE-N
were	O
found	O
significantly	O
higher	O
in	O
combined	O
treated	O
than	O
untreated	O
rats	O
.	O

In	O
nicotine	B-CHEMICAL
group	O
,	O
a	O
negative	O
significant	O
correlation	O
between	O
reduced	O
glutathione	B-CHEMICAL
and	O
MDA	B-CHEMICAL
(	O
r	O
=	O
-	O
0	O
.	O
92	O
)	O
was	O
observed	O
.	O

In	O
conclusion	O
,	O
these	O
results	O
suggested	O
that	O
the	O
supplementation	O
of	O
diet	O
with	O
epicatechin	B-CHEMICAL
and	O
vitamin	B-CHEMICAL
E	I-CHEMICAL
provided	O
antioxidant	O
defense	O
with	O
strong	O
chemopreventive	O
activity	O
against	O
nicotine	B-CHEMICAL
-	O
induced	O
carcinogenesis	O
.	O

Conditional	O
activation	O
of	O
Pik3ca	B-GENE-Y
(	O
H1047R	B-GENE-N
)	O
in	O
a	O
knock	O
-	O
in	O
mouse	O
model	O
promotes	O
mammary	O
tumorigenesis	O
and	O
emergence	O
of	O
mutations	O
.	O

Oncogenic	O
mutations	O
in	O
PIK3CA	B-GENE-Y
,	O
which	O
encodes	O
the	O
phosphoinositide	B-GENE-Y
-	I-GENE-Y
3	I-GENE-Y
-	I-GENE-Y
kinase	I-GENE-Y
(	I-GENE-Y
PI3K	I-GENE-Y
)	I-GENE-Y
catalytic	I-GENE-Y
subunit	I-GENE-Y
p110	I-GENE-Y
,	O
occur	O
in	O
	O
25	O
%	O
of	O
human	O
breast	O
cancers	O
.	O

In	O
this	O
study	O
,	O
we	O
report	O
the	O
development	O
of	O
a	O
knock	O
-	O
in	O
mouse	O
model	O
for	O
breast	O
cancer	O
where	O
the	O
endogenous	O
Pik3ca	B-GENE-Y
allele	O
was	O
modified	O
to	O
allow	O
tissue	O
-	O
specific	O
conditional	O
expression	O
of	O
a	O
frequently	O
found	O
Pik3ca	B-GENE-Y
(	O
H1047R	B-GENE-N
)	O
(	O
Pik3ca	B-GENE-Y
(	O
e20H1047R	B-GENE-N
)	O
)	O
mutant	O
allele	O
.	O

We	O
found	O
that	O
activation	O
of	O
the	O
latent	O
Pik3ca	B-GENE-Y
(	O
H1047R	B-GENE-N
)	O
allele	O
resulted	O
in	O
breast	O
tumors	O
with	O
multiple	O
histological	O
types	O
.	O

Whole	O
-	O
exome	O
analysis	O
of	O
the	O
Pik3ca	B-GENE-Y
(	O
H1047R	B-GENE-N
)	O
-	O
driven	O
mammary	O
tumors	O
identified	O
multiple	O
mutations	O
,	O
including	O
Trp53	B-GENE-Y
mutations	O
that	O
appeared	O
spontaneously	O
during	O
the	O
development	O
of	O
adenocarinoma	O
and	O
spindle	O
cell	O
tumors	O
.	O

Further	O
,	O
we	O
used	O
this	O
model	O
to	O
test	O
the	O
efficacy	O
of	O
GDC	B-CHEMICAL
-	I-CHEMICAL
0941	I-CHEMICAL
,	O
a	O
PI3K	B-GENE-N
inhibitor	O
,	O
in	O
clinical	O
development	O
,	O
and	O
showed	O
that	O
the	O
tumors	O
respond	O
to	O
PI3K	B-GENE-N
inhibition	O
.	O

Quercetin	B-CHEMICAL
reduces	O
high	O
-	O
fat	O
diet	O
-	O
induced	O
fat	O
accumulation	O
in	O
the	O
liver	O
by	O
regulating	O
lipid	O
metabolism	O
genes	O
.	O

To	O
understand	O
the	O
molecular	O
mechanisms	O
underlying	O
the	O
influence	O
of	O
quercetin	B-CHEMICAL
on	O
the	O
physiological	O
effects	O
of	O
hyperlipidemia	O
,	O
we	O
investigated	O
its	O
role	O
in	O
the	O
prevention	O
of	O
high	O
-	O
fat	O
diet	O
(	O
HFD	O
)	O
-	O
induced	O
obesity	O
and	O
found	O
that	O
it	O
regulated	O
hepatic	O
gene	O
expression	O
related	O
to	O
lipid	O
metabolism	O
.	O

Quercetin	B-CHEMICAL
supplementation	O
in	O
mice	O
significantly	O
reduced	O
the	O
HFD	O
-	O
induced	O
gains	O
in	O
body	O
weight	O
,	O
liver	O
weight	O
,	O
and	O
white	O
adipose	O
tissue	O
weight	O
compared	O
with	O
the	O
mice	O
fed	O
only	O
with	O
HFD	O
.	O

It	O
also	O
significantly	O
reduced	O
HFD	O
-	O
induced	O
increases	O
in	O
serum	O
lipids	O
,	O
including	O
cholesterol	B-CHEMICAL
,	O
triglyceride	B-CHEMICAL
,	O
and	O
thiobarbituric	B-CHEMICAL
acid	I-CHEMICAL
-	O
reactive	O
substance	O
(	O
TBARS	O
)	O
.	O

Consistent	O
with	O
the	O
reduced	O
liver	O
weight	O
and	O
white	O
adipose	O
tissue	O
weight	O
,	O
hepatic	O
lipid	O
accumulation	O
and	O
the	O
size	O
of	O
lipid	O
droplets	O
in	O
the	O
epididymal	O
fat	O
pads	O
were	O
also	O
reduced	O
by	O
quercetin	B-CHEMICAL
supplementation	O
.	O

To	O
further	O
investigate	O
how	O
quercetin	B-CHEMICAL
may	O
reduce	O
obesity	O
,	O
we	O
analyzed	O
lipid	O
metabolism	O
-	O
related	O
genes	O
in	O
the	O
liver	O
.	O

Quercetin	B-CHEMICAL
supplementation	O
altered	O
expression	O
profiles	O
of	O
several	O
lipid	O
metabolism	O
-	O
related	O
genes	O
,	O
including	O
Fnta	B-GENE-Y
,	O
Pon1	B-GENE-Y
,	O
Pparg	B-GENE-Y
,	O
Aldh1b1	B-GENE-Y
,	O
Apoa4	B-GENE-Y
,	O
Abcg5	B-GENE-Y
,	O
Gpam	B-GENE-Y
,	O
Acaca	B-GENE-Y
,	O
Cd36	B-GENE-Y
,	O
Fdft1	B-GENE-Y
,	O
and	O
Fasn	B-GENE-Y
,	O
relative	O
to	O
those	O
in	O
HFD	O
control	O
mice	O
.	O

The	O
expression	O
patterns	O
of	O
these	O
genes	O
observed	O
by	O
quantitative	O
reverse	O
transcriptase	O
-	O
polymerase	O
chain	O
reaction	O
were	O
confirmed	O
by	O
immunoblot	O
assays	O
.	O

Collectively	O
,	O
our	O
results	O
indicate	O
that	O
quercetin	B-CHEMICAL
prevents	O
HFD	O
-	O
induced	O
obesity	O
in	O
C57B1	O
/	O
6	O
mice	O
,	O
and	O
its	O
anti	O
-	O
obesity	O
effects	O
may	O
be	O
related	O
to	O
the	O
regulation	O
of	O
lipogenesis	O
at	O
the	O
level	O
of	O
transcription	O
.	O

In	O
vivo	O
and	O
in	O
vitro	O
models	O
for	O
the	O
therapeutic	O
targeting	O
of	O
Wnt	B-GENE-N
signaling	O
using	O
a	O
Tet	O
-	O
ON89	O
-	O
catenin	O
system	O
.	O

Although	O
significant	O
progress	O
has	O
been	O
made	O
in	O
understanding	O
the	O
importance	O
of	O
Wnt	B-GENE-N
signaling	O
in	O
the	O
initiation	O
of	O
colorectal	O
cancer	O
,	O
less	O
is	O
known	O
about	O
responses	O
that	O
accompany	O
the	O
reversal	O
of	O
oncogenic	O
Wnt	B-GENE-N
signaling	O
.	O

The	O
aim	O
of	O
this	O
study	O
was	O
to	O
analyze	O
in	O
vivo	O
and	O
in	O
vitro	O
responses	O
to	O
an	O
'	O
ideal	O
'	O
Wnt	B-GENE-N
pathway	O
inhibitor	O
as	O
a	O
model	O
for	O
the	O
therapeutic	O
targeting	O
of	O
the	O
pathway	O
.	O

A	O
tetracycline	B-CHEMICAL
-	O
inducible	O
transgenic	O
mouse	O
model	O
expressing	O
truncated	O
	B-GENE-Y
-	I-GENE-Y
catenin	I-GENE-Y
(	O
N89	B-GENE-Y
-	I-GENE-Y
catenin	I-GENE-Y
)	O
that	O
exhibited	O
a	O
strong	O
intestinal	O
hyperplasia	O
was	O
analyzed	O
during	O
the	O
removal	O
of	O
oncogenic	O
	B-GENE-Y
-	I-GENE-Y
catenin	I-GENE-Y
expression	O
both	O
in	O
3D	O
'	O
crypt	O
culture	O
'	O
and	O
in	O
vivo	O
.	O

Oncogenic	O
Wnt	B-GENE-N
signaling	O
was	O
rapidly	O
and	O
completely	O
reversed	O
.	O

The	O
strongest	O
inhibition	O
of	O
Wnt	B-GENE-N
target	O
gene	O
expression	O
occurred	O
within	O
24	O
h	O
of	O
doxycycline	O
removal	O
at	O
which	O
time	O
the	O
target	O
genes	O
Ascl2	B-GENE-Y
,	O
Axin2	B-GENE-Y
and	O
C	B-GENE-Y
-	I-GENE-Y
myc	I-GENE-Y
were	O
downregulated	O
to	O
levels	O
below	O
that	O
in	O
the	O
control	O
intestine	O
.	O

In	O
vitro	O
,	O
the	O
small	O
molecule	O
Wnt	B-GENE-N
inhibitor	O
CCT036477	O
induced	O
a	O
response	O
within	O
4	O
h	O
of	O
treatment	O
.	O

By	O
7	O
days	O
following	O
doxycycline	B-CHEMICAL
withdrawal	O
,	O
gene	O
expression	O
,	O
cell	O
proliferation	O
and	O
tissue	O
morphology	O
were	O
undistinguishable	O
from	O
control	O
animals	O
.	O
In	O
conclusion	O
,	O
these	O
results	O
demonstrate	O
that	O
the	O
reversal	O
of	O
Wnt	B-GENE-N
signaling	O
by	O
inhibitors	O
should	O
ideally	O
be	O
studied	O
within	O
hours	O
of	O
treatment	O
.	O

The	O
reversible	O
system	O
described	O
,	O
involving	O
medium	O
throughput	O
in	O
vitro	O
approaches	O
and	O
rapid	O
in	O
vivo	O
responses	O
,	O
should	O
allow	O
the	O
rapid	O
advance	O
of	O
early	O
stage	O
compounds	O
into	O
efficacy	O
models	O
that	O
are	O
more	O
usually	O
considered	O
later	O
in	O
the	O
drug	O
discovery	O
pipeline	O
.	O

Discovery	O
and	O
structural	O
characterization	O
of	O
a	O
phospholamban	B-GENE-Y
-	O
binding	O
cyclic	O
peptide	O
and	O
design	O
of	O
novel	O
inhibitors	O
of	O
phospholamban	B-GENE-Y
.	O

The	O
interplay	O
between	O
cardiac	O
sarcoplasmic	O
Ca	B-GENE-N
(	I-GENE-N
2	I-GENE-N
+	I-GENE-N
)	I-GENE-N
ATPase	I-GENE-N
and	O
phospholamban	B-GENE-Y
is	O
a	O
key	O
regulating	O
factor	O
of	O
contraction	O
and	O
relaxation	O
in	O
the	O
cardiac	O
muscle	O
.	O

In	O
heart	O
failure	O
,	O
aberrations	O
in	O
the	O
inhibition	O
of	O
sarcoplasmic	O
Ca	B-GENE-N
(	I-GENE-N
2	I-GENE-N
+	I-GENE-N
)	I-GENE-N
ATPase	I-GENE-N
by	O
phospholamban	B-GENE-Y
are	O
associated	O
with	O
anomalies	O
in	O
cardiac	O
functions	O
.	O

In	O
experimental	O
heart	O
failure	O
models	O
,	O
modulation	O
of	O
the	O
interaction	O
between	O
these	O
two	O
proteins	O
has	O
been	O
shown	O
to	O
be	O
a	O
potential	O
therapeutic	O
approach	O
.	O

The	O
aim	O
of	O
our	O
research	O
was	O
to	O
find	O
molecules	O
able	O
to	O
interfere	O
with	O
the	O
inhibitory	O
activity	O
of	O
phospholamban	B-GENE-Y
on	O
sarcoplasmic	O
Ca	B-GENE-N
(	I-GENE-N
2	I-GENE-N
+	I-GENE-N
)	I-GENE-N
ATPase	I-GENE-N
.	O

For	O
this	O
purpose	O
,	O
a	O
portion	O
of	O
phospholamban	B-GENE-Y
was	O
synthesized	O
and	O
used	O
as	O
target	O
for	O
a	O
phage	O
-	O
display	O
peptide	O
library	O
screening	O
.	O

The	O
cyclic	O
peptide	O
C	B-GENE-N
-	I-GENE-N
Y	I-GENE-N
-	I-GENE-N
W	I-GENE-N
-	I-GENE-N
E	I-GENE-N
-	I-GENE-N
L	I-GENE-N
-	I-GENE-N
E	I-GENE-N
-	I-GENE-N
W	I-GENE-N
-	I-GENE-N
L	I-GENE-N
-	I-GENE-N
P	I-GENE-N
-	I-GENE-N
C	I-GENE-N
-	I-GENE-N
A	I-GENE-N
was	O
found	O
to	O
bind	O
to	O
phospholamban	B-GENE-Y
(	I-GENE-Y
1	I-GENE-Y
-	I-GENE-Y
36	I-GENE-Y
)	I-GENE-Y
with	O
high	O
specificity	O
.	O

Its	O
functional	O
activity	O
was	O
tested	O
in	O
Ca	B-CHEMICAL
(	I-CHEMICAL
2	I-CHEMICAL
+	I-CHEMICAL
)	I-CHEMICAL
uptake	O
assays	O
utilizing	O
preparations	O
from	O
cardiac	O
sarcoplasmic	O
reticulum	O
.	O

By	O
synthesizing	O
and	O
testing	O
a	O
series	O
of	O
alanine	B-CHEMICAL
point	O
-	O
mutated	O
cyclic	B-GENE-N
peptides	I-GENE-N
,	O
we	O
identified	O
which	O
amino	B-CHEMICAL
acid	I-CHEMICAL
was	O
important	O
for	O
the	O
inhibition	O
of	O
the	O
phospholamban	B-GENE-Y
function	O
.	O

The	O
structures	O
of	O
active	O
and	O
inactive	O
alanine	B-CHEMICAL
-	O
mutated	O
cyclic	B-GENE-N
peptides	I-GENE-N
,	O
and	O
of	O
phospholamban	B-GENE-Y
(	I-GENE-Y
1	I-GENE-Y
-	I-GENE-Y
36	I-GENE-Y
)	I-GENE-Y
,	O
were	O
determined	O
by	O
NMR	O
.	O

This	O
structure	O
-	O
activity	O
analysis	O
allowed	O
building	O
a	O
model	O
of	O
phospholamban	B-GENE-Y
-	O
cyclic	O
peptide	O
complex	O
.	O

Thereafter	O
,	O
a	O
simple	O
pharmacophore	O
was	O
defined	O
and	O
used	O
for	O
the	O
design	O
of	O
small	O
molecules	O
.	O

Finally	O
,	O
examples	O
of	O
such	O
molecules	O
were	O
synthesized	O
and	O
characterized	O
as	O
phospholamban	B-GENE-Y
inhibitors	O
.	O

Macrophage	O
cathepsin	B-GENE-Y
K	I-GENE-Y
promotes	O
prostate	O
tumor	O
progression	O
in	O
bone	O
.	O

Bone	O
marrow	O
macrophages	O
(	O
BMMs	O
)	O
share	O
common	O
progenitors	O
with	O
osteoclasts	O
and	O
are	O
critical	O
components	O
of	O
bone	O
-	O
tumor	O
microenvironment	O
;	O
however	O
,	O
their	O
function	O
in	O
prostate	O
tumor	O
growth	O
in	O
the	O
skeleton	O
has	O
not	O
been	O
explored	O
.	O

BMMs	O
are	O
the	O
major	O
source	O
of	O
inflammatory	O
factors	O
and	O
proteases	B-GENE-N
,	O
including	O
cysteine	B-GENE-N
protease	I-GENE-N
cathepsin	B-GENE-Y
K	I-GENE-Y
(	O
CTSK	B-GENE-Y
)	O
.	O

In	O
this	O
study	O
,	O
utilizing	O
mice	O
deficient	O
in	O
CTSK	B-GENE-Y
,	O
we	O
demonstrate	O
the	O
critical	O
involvement	O
of	O
this	O
potent	O
collagenase	B-GENE-N
in	O
tumor	O
progression	O
in	O
bone	O
.	O

We	O
present	O
the	O
evidence	O
that	O
tumor	O
growth	O
and	O
progression	O
in	O
the	O
bone	O
are	O
impaired	O
in	O
the	O
absence	O
of	O
CTSK	B-GENE-Y
.	O

Most	O
importantly	O
,	O
we	O
show	O
for	O
the	O
first	O
time	O
that	O
BMM	O
-	O
supplied	O
CTSK	B-GENE-Y
may	O
be	O
involved	O
in	O
CCL2	B-GENE-Y
-	O
and	O
COX	B-GENE-Y
-	I-GENE-Y
2	I-GENE-Y
-	O
driven	O
pathways	O
that	O
contribute	O
to	O
tumor	O
progression	O
in	O
bone	O
.	O

Together	O
,	O
our	O
data	O
unravel	O
novel	O
roles	O
for	O
CTSK	B-GENE-Y
in	O
macrophage	O
-	O
regulated	O
processes	O
,	O
and	O
provide	O
evidence	O
for	O
close	O
interplay	O
between	O
inflammatory	O
,	O
osteolytic	O
and	O
tumor	O
cell	O
-	O
driven	O
events	O
in	O
the	O
bone	O
-	O
tumor	O
microenvironment	O
.	O

Effect	O
of	O
tetrabrombisphenol	B-CHEMICAL
A	I-CHEMICAL
on	O
induction	O
of	O
apoptosis	O
in	O
the	O
testes	O
and	O
changes	O
in	O
expression	O
of	O
selected	O
testicular	O
genes	O
in	O
CD1	O
mice	O
.	O

Tetrabromobisphenol	B-CHEMICAL
A	I-CHEMICAL
(	O
TBBPA	B-CHEMICAL
)	O
is	O
a	O
substance	O
widely	O
used	O
in	O
industry	O
as	O
a	O
flame	O
retardant	O
.	O

TBBPA	B-CHEMICAL
was	O
found	O
in	O
the	O
environment	O
and	O
was	O
detected	O
even	O
in	O
the	O
human	O
body	O
.	O

The	O
effect	O
of	O
this	O
chemical	O
was	O
observed	O
in	O
different	O
cell	O
lines	O
in	O
vitro	O
and	O
it	O
is	O
supposed	O
that	O
TBBPA	B-CHEMICAL
may	O
affect	O
various	O
hormonal	O
systems	O
in	O
vivo	O
.	O

In	O
this	O
study	O
we	O
examined	O
the	O
effect	O
of	O
TBBPA	B-CHEMICAL
on	O
the	O
reproductive	O
parameters	O
of	O
two	O
generations	O
of	O
outbred	O
mice	O
in	O
vivo	O
.	O

Experimental	O
and	O
control	O
animals	O
of	O
F1	O
generation	O
were	O
bred	O
in	O
various	O
conditions	O
to	O
enable	O
evaluation	O
of	O
the	O
possible	O
trans	O
-	O
generational	O
effect	O
.	O

An	O
increased	O
incidence	O
of	O
apoptosis	O
in	O
the	O
testes	O
and	O
changes	O
in	O
the	O
morphometry	O
of	O
seminiferous	O
tubules	O
was	O
detected	O
in	O
the	O
experimental	O
animals	O
.	O

In	O
addition	O
,	O
changes	O
in	O
the	O
expression	O
pattern	O
of	O
selected	O
genes	O
encoding	O
proteins	O
that	O
play	O
an	O
important	O
role	O
during	O
spermatogenesis	O
were	O
observed	O
.	O

In	O
contrast	O
,	O
sperm	O
quality	O
and	O
reproduction	O
were	O
not	O
affected	O
by	O
TBBPA	B-CHEMICAL
.	O

Inhibitory	O
effect	O
of	O
synthetic	O
progestins	B-CHEMICAL
,	O
4	B-CHEMICAL
-	I-CHEMICAL
MA	I-CHEMICAL
and	O
cyanoketone	B-CHEMICAL
on	O
human	B-GENE-N
placental	I-GENE-N
3	I-GENE-N
beta	I-GENE-N
-	I-GENE-N
hydroxysteroid	I-GENE-N
dehydrogenase	I-GENE-N
/	I-GENE-N
5	I-GENE-N
-	I-GENE-N
-	I-GENE-N
-	I-GENE-N
-	I-GENE-N
4	I-GENE-N
-	I-GENE-N
ene	I-GENE-N
-	I-GENE-N
isomerase	I-GENE-N
activity	O
.	O

Human	B-GENE-N
placental	I-GENE-N
3	I-GENE-N
beta	I-GENE-N
-	I-GENE-N
hydroxysteroid	I-GENE-N
dehydrogenase	I-GENE-N
/	I-GENE-N
5	I-GENE-N
-	I-GENE-N
-	I-GENE-N
-	I-GENE-N
-	I-GENE-N
4	I-GENE-N
-	I-GENE-N
ene	I-GENE-N
isomerase	I-GENE-N
(	O
3	B-GENE-N
beta	I-GENE-N
-	I-GENE-N
HSD	I-GENE-N
)	O
purified	O
from	O
human	O
placenta	O
transforms	O
C	O
-	O
21	O
(	O
pregnenolone	B-CHEMICAL
and	O
17	B-CHEMICAL
alpha	I-CHEMICAL
-	I-CHEMICAL
hydroxy	I-CHEMICAL
pregnenolone	I-CHEMICAL
)	O
as	O
well	O
as	O
C	O
-	O
19	O
(	O
dehydroepiandrosterone	B-CHEMICAL
and	O
androst	B-CHEMICAL
-	I-CHEMICAL
5	I-CHEMICAL
-	I-CHEMICAL
ene	I-CHEMICAL
-	I-CHEMICAL
3	I-CHEMICAL
beta	I-CHEMICAL
,	I-CHEMICAL
17	I-CHEMICAL
beta	I-CHEMICAL
-	I-CHEMICAL
diol	I-CHEMICAL
)	O
steroids	O
into	O
the	O
corresponding	O
3	B-CHEMICAL
-	I-CHEMICAL
keto	I-CHEMICAL
-	I-CHEMICAL
4	I-CHEMICAL
-	I-CHEMICAL
ene	I-CHEMICAL
-	I-CHEMICAL
steroids	I-CHEMICAL
and	O
is	O
thus	O
involved	O
in	O
the	O
biosynthesis	O
of	O
all	O
classes	O
of	O
hormonal	O
steroids	O
.	O

Trilostane	B-CHEMICAL
,	O
epostane	B-CHEMICAL
and	O
cyanoketone	B-CHEMICAL
are	O
potent	O
inhibitors	O
of	O
3	B-GENE-N
beta	I-GENE-N
-	I-GENE-N
HSD	I-GENE-N
with	O
Ki	O
values	O
of	O
approximately	O
50	O
nM	O
.	O

4	B-CHEMICAL
-	I-CHEMICAL
MA	I-CHEMICAL
,	O
a	O
well	O
known	O
5	B-GENE-N
alpha	I-GENE-N
-	I-GENE-N
reductase	I-GENE-N
inhibitor	O
,	O
is	O
also	O
a	O
potent	O
inhibitor	O
of	O
3	B-GENE-N
beta	I-GENE-N
-	I-GENE-N
HSD	I-GENE-N
with	O
a	O
Ki	O
value	O
of	O
56	O
nM	O
.	O

Synthetic	O
progestin	B-CHEMICAL
compounds	O
such	O
as	O
promegestone	B-CHEMICAL
and	O
RU2323	B-CHEMICAL
show	O
relatively	O
strong	O
inhibitory	O
effects	O
with	O
Ki	O
values	O
of	O
110	O
and	O
190	O
nM	O
,	O
respectively	O
.	O

Cyproterone	B-CHEMICAL
acetate	I-CHEMICAL
,	O
a	O
progestin	B-CHEMICAL
used	O
in	O
the	O
treatment	O
of	O
hirsutism	O
,	O
acne	O
and	O
prostate	O
cancer	O
as	O
well	O
as	O
norgestrel	B-CHEMICAL
and	O
norethindrone	B-CHEMICAL
that	O
are	O
widely	O
used	O
as	O
oral	O
contraceptives	O
also	O
inhibit	O
3	B-GENE-N
beta	I-GENE-N
-	I-GENE-N
HSD	I-GENE-N
activity	O
at	O
Ki	O
values	O
of	O
1	O
.	O
5	O
,	O
1	O
.	O
7	O
and	O
2	O
.	O
5	O
microM	O
,	O
respectively	O
.	O

Enhanced	O
mGlu5	B-GENE-Y
-	I-GENE-Y
receptor	I-GENE-Y
dependent	O
long	O
-	O
term	O
depression	O
at	O
the	O
Schaffer	O
collateral	O
-	O
CA1	O
synapse	O
of	O
congenitally	O
learned	O
helpless	O
rats	O
.	O

Alterations	O
of	O
the	O
glutamatergic	O
system	O
have	O
been	O
implicated	O
in	O
the	O
pathophysiology	O
and	O
treatment	O
of	O
major	O
depression	O
.	O

In	O
order	O
to	O
investigate	O
the	O
expression	O
and	O
function	O
of	O
mGlu5	B-GENE-Y
receptors	I-GENE-Y
in	O
an	O
animal	O
model	O
for	O
treatment	O
-	O
resistant	O
depression	O
we	O
used	O
rats	O
bred	O
for	O
congenital	O
learned	O
helplessness	O
(	O
cLH	O
)	O
and	O
the	O
control	O
strain	O
,	O
bred	O
for	O
resistance	O
against	O
inescapable	O
stress	O
,	O
congenitally	O
.	O
not	O
learned	O
helpless	O
rats	O
(	O
cNLH	O
)	O
.	O

Western	O
blot	O
analysis	O
showed	O
an	O
increased	O
expression	O
of	O
mGlu5	B-GENE-Y
(	O
but	O
not	O
mGlu1a	B-GENE-Y
)	O
receptors	O
in	O
the	O
hippocampus	O
of	O
cLH	O
rats	O
,	O
as	O
compared	O
with	O
control	O
cNLH	O
rats	O
.	O

We	O
also	O
examined	O
mGlu1	B-GENE-N
/	I-GENE-N
5	I-GENE-N
receptor	O
signaling	O
by	O
in	O
vivo	O
measurement	O
of	O
DHPG	B-CHEMICAL
-	O
stimulated	O
polyphosphoinositides	B-CHEMICAL
hydrolysis	O
.	O

Stimulation	O
of	O
(	B-CHEMICAL
3	I-CHEMICAL
)	I-CHEMICAL
H	I-CHEMICAL
-	I-CHEMICAL
inositolmonophosphate	I-CHEMICAL
formation	O
induced	O
by	O
i	O
.	O
c	O
.	O
v	O
.	O
injection	O
of	O
DHPG	B-CHEMICAL
was	O
enhanced	O
by	O
about	O
50	O
%	O
in	O
the	O
hippocampus	O
of	O
cLH	O
rats	O
.	O

Correspondingly	O
,	O
DHPG	B-CHEMICAL
-	O
induced	O
long	O
-	O
term	O
depression	O
(	O
LTD	O
)	O
at	O
Schaffer	O
collateral	O
/	O
CA1	O
pyramidal	O
cell	O
synapses	O
was	O
amplified	O
in	O
hippocampal	O
slices	O
of	O
cLH	O
rats	O
,	O
whereas	O
LTD	O
induced	O
by	O
low	O
frequency	O
stimulation	O
of	O
the	O
Schaffer	O
collaterals	O
did	O
not	O
change	O
.	O

Moreover	O
,	O
these	O
effects	O
were	O
associated	O
with	O
decreased	O
basal	O
dendritic	O
spine	O
density	O
of	O
CA1	O
pyramidal	O
cell	O
in	O
cLH	O
rats	O
.	O

These	O
data	O
raise	O
the	O
attractive	O
possibility	O
that	O
changes	O
in	O
the	O
expression	O
and	O
function	O
of	O
mGlu5	B-GENE-Y
receptors	I-GENE-Y
in	O
the	O
hippocampus	O
might	O
underlie	O
the	O
changes	O
in	O
synaptic	O
plasticity	O
associated	O
with	O
the	O
depressive	O
-	O
like	O
phenotype	O
of	O
cLH	O
rats	O
.	O

However	O
,	O
chronic	O
treatment	O
of	O
cLH	O
rats	O
with	O
MPEP	B-CHEMICAL
did	O
not	O
reverse	O
learned	O
helplessness	O
,	O
indicating	O
that	O
the	O
enhanced	O
mGlu5	B-GENE-Y
receptor	I-GENE-Y
function	O
is	O
not	O
the	O
only	O
player	O
in	O
the	O
behavioral	O
phenotype	O
of	O
this	O
genetic	O
model	O
of	O
depression	O
.	O

This	O
article	O
is	O
part	O
of	O
a	O
Special	O
Issue	O
entitled	O
'	O
Metabotropic	B-GENE-N
Glutamate	I-GENE-N
Receptors	I-GENE-N
'	O
.	O

Deep	O
brain	O
stimulation	O
,	O
histone	B-GENE-N
deacetylase	I-GENE-N
inhibitors	O
and	O
glutamatergic	O
drugs	O
rescue	O
resistance	O
to	O
fear	O
extinction	O
in	O
a	O
genetic	O
mouse	O
model	O
.	O

Anxiety	O
disorders	O
are	O
characterized	O
by	O
persistent	O
,	O
excessive	O
fear	O
.	O

Therapeutic	O
interventions	O
that	O
reverse	O
deficits	O
in	O
fear	O
extinction	O
represent	O
a	O
tractable	O
approach	O
to	O
treating	O
these	O
disorders	O
.	O

We	O
previously	O
reported	O
that	O
129S1	O
/	O
SvImJ	O
(	O
S1	O
)	O
mice	O
show	O
no	O
extinction	O
learning	O
following	O
normal	O
fear	O
conditioning	O
.	O

We	O
now	O
demonstrate	O
that	O
weak	O
fear	O
conditioning	O
does	O
permit	O
fear	O
reduction	O
during	O
massed	O
extinction	O
training	O
in	O
S1	O
mice	O
,	O
but	O
reveals	O
specific	O
deficiency	O
in	O
extinction	O
memory	O
consolidation	O
/	O
retrieval	O
.	O

Rescue	O
of	O
this	O
impaired	O
extinction	O
consolidation	O
/	O
retrieval	O
was	O
achieved	O
with	O
d	B-CHEMICAL
-	I-CHEMICAL
cycloserine	I-CHEMICAL
(	O
N	B-CHEMICAL
-	I-CHEMICAL
methly	I-CHEMICAL
-	I-CHEMICAL
d	I-CHEMICAL
-	I-CHEMICAL
aspartate	I-CHEMICAL
partial	O
agonist	O
)	O
or	O
MS	B-CHEMICAL
-	I-CHEMICAL
275	I-CHEMICAL
(	O
histone	B-GENE-N
deacetylase	I-GENE-N
(	O
HDAC	B-GENE-N
)	O
inhibitor	O
)	O
,	O
applied	O
after	O
extinction	O
training	O
.	O

We	O
next	O
examined	O
the	O
ability	O
of	O
different	O
drugs	O
and	O
non	O
-	O
pharmacological	O
manipulations	O
to	O
rescue	O
the	O
extreme	O
fear	O
extinction	O
deficit	O
in	O
S1	O
following	O
normal	O
fear	O
conditioning	O
with	O
the	O
ultimate	O
aim	O
to	O
produce	O
low	O
fear	O
levels	O
in	O
extinction	O
retrieval	O
tests	O
.	O

Results	O
showed	O
that	O
deep	O
brain	O
stimulation	O
(	O
DBS	O
)	O
by	O
applying	O
high	O
frequency	O
stimulation	O
to	O
the	O
nucleus	O
accumbens	O
(	O
ventral	O
striatum	O
)	O
during	O
extinction	O
training	O
,	O
indeed	O
significantly	O
reduced	O
fear	O
during	O
extinction	O
retrieval	O
compared	O
to	O
sham	O
stimulation	O
controls	O
.	O

Rescue	O
of	O
both	O
impaired	O
extinction	O
acquisition	O
and	O
deficient	O
extinction	O
consolidation	O
/	O
retrieval	O
was	O
achieved	O
with	O
prior	O
extinction	O
training	O
administration	O
of	O
valproic	B-CHEMICAL
acid	I-CHEMICAL
(	O
a	O
GABAergic	O
enhancer	O
and	O
HDAC	B-GENE-N
inhibitor	O
)	O
or	O
AMN082	B-CHEMICAL
[	O
metabotropic	B-GENE-Y
glutamate	I-GENE-Y
receptor	I-GENE-Y
7	I-GENE-Y
(	O
mGlu7	B-GENE-Y
)	O
agonist	O
]	O
,	O
while	O
MS	B-CHEMICAL
-	I-CHEMICAL
275	I-CHEMICAL
or	O
PEPA	B-CHEMICAL
(	O
AMPA	B-GENE-N
receptor	I-GENE-N
potentiator	O
)	O
failed	O
to	O
affect	O
extinction	O
acquisition	O
in	O
S1	O
mice	O
.	O

Collectively	O
,	O
these	O
data	O
identify	O
potential	O
beneficial	O
effects	O
of	O
DBS	O
and	O
various	O
drug	O
treatments	O
,	O
including	O
those	O
with	O
HDAC	B-GENE-N
inhibiting	O
or	O
mGlu7	B-GENE-Y
agonism	O
properties	O
,	O
as	O
adjuncts	O
to	O
overcome	O
treatment	O
resistance	O
in	O
exposure	O
-	O
based	O
therapies	O
.	O

This	O
article	O
is	O
part	O
of	O
a	O
Special	O
Issue	O
entitled	O
'	O
Cognitive	O
Enhancers	O
'	O
.	O

Nicotine	B-CHEMICAL
facilitates	O
memory	O
consolidation	O
in	O
perceptual	O
learning	O
.	O

Perceptual	O
learning	O
is	O
a	O
special	O
type	O
of	O
non	O
-	O
declarative	O
learning	O
that	O
involves	O
experience	O
-	O
dependent	O
plasticity	O
in	O
sensory	O
cortices	O
.	O

The	O
cholinergic	O
system	O
is	O
known	O
to	O
modulate	O
declarative	O
learning	O
.	O

In	O
particular	O
,	O
reduced	O
levels	O
or	O
efficacy	O
of	O
the	O
neurotransmitter	O
acetylcholine	B-CHEMICAL
were	O
found	O
to	O
facilitate	O
declarative	O
memory	O
consolidation	O
.	O

However	O
,	O
little	O
is	O
known	O
about	O
the	O
role	O
of	O
the	O
cholinergic	O
system	O
in	O
memory	O
consolidation	O
of	O
non	O
-	O
declarative	O
learning	O
.	O

Here	O
we	O
compared	O
two	O
groups	O
of	O
non	O
-	O
smoking	O
men	O
who	O
learned	O
a	O
visual	O
texture	O
discrimination	O
task	O
(	O
TDT	O
)	O
.	O

One	O
group	O
received	O
chewing	O
tobacco	O
containing	O
nicotine	B-CHEMICAL
for	O
1	O
h	O
directly	O
following	O
the	O
TDT	O
training	O
.	O

The	O
other	O
group	O
received	O
a	O
similar	O
tasting	O
control	O
substance	O
without	O
nicotine	B-CHEMICAL
.	O

Electroencephalographic	O
recordings	O
during	O
substance	O
consumption	O
showed	O
reduced	O
alpha	O
activity	O
and	O
P300	B-GENE-Y
latencies	O
in	O
the	O
nicotine	B-CHEMICAL
group	O
compared	O
to	O
the	O
control	O
group	O
.	O

When	O
re	O
-	O
tested	O
on	O
the	O
TDT	O
the	O
following	O
day	O
,	O
both	O
groups	O
responded	O
more	O
accurately	O
and	O
more	O
rapidly	O
than	O
during	O
training	O
.	O

These	O
improvements	O
were	O
specific	O
to	O
the	O
retinal	O
location	O
and	O
orientation	O
of	O
the	O
texture	O
elements	O
of	O
the	O
TDT	O
suggesting	O
that	O
learning	O
involved	O
early	O
visual	O
cortex	O
.	O

A	O
group	O
comparison	O
showed	O
that	O
learning	O
effects	O
were	O
more	O
pronounced	O
in	O
the	O
nicotine	B-CHEMICAL
group	O
than	O
in	O
the	O
control	O
group	O
.	O

These	O
findings	O
suggest	O
that	O
oral	O
consumption	O
of	O
nicotine	B-CHEMICAL
enhances	O
the	O
efficacy	O
of	O
nicotinic	B-GENE-N
acetylcholine	I-GENE-N
receptors	I-GENE-N
.	O

Our	O
findings	O
further	O
suggest	O
that	O
enhanced	O
efficacy	O
of	O
the	O
cholinergic	O
system	O
facilitates	O
memory	O
consolidation	O
in	O
perceptual	O
learning	O
(	O
and	O
possibly	O
other	O
types	O
of	O
non	O
-	O
declarative	O
learning	O
)	O
.	O

In	O
that	O
regard	O
acetylcholine	B-CHEMICAL
seems	O
to	O
affect	O
consolidation	O
processes	O
in	O
perceptual	O
learning	O
in	O
a	O
different	O
manner	O
than	O
in	O
declarative	O
learning	O
.	O

Alternatively	O
,	O
our	O
findings	O
might	O
reflect	O
dose	O
-	O
dependent	O
cholinergic	O
modulation	O
of	O
memory	O
consolidation	O
.	O

This	O
article	O
is	O
part	O
of	O
a	O
Special	O
Issue	O
entitled	O
'	O
Cognitive	O
Enhancers	O
'	O
.	O

Increased	O
expression	O
of	O
P450scc	B-GENE-Y
and	O
CYP17	B-GENE-Y
in	O
development	O
of	O
endogenous	O
hyperandrogenism	O
in	O
a	O
rat	O
model	O
of	O
PCOS	O
.	O

The	O
objective	O
of	O
the	O
present	O
study	O
was	O
to	O
characterize	O
the	O
effect	O
of	O
insulin	B-GENE-N
plus	O
hCG	B-GENE-N
on	O
the	O
expression	O
of	O
steroidogenic	O
enzymes	O
(	O
P450scc	B-GENE-Y
and	O
CYP17	B-GENE-Y
)	O
in	O
polycystic	O
ovaries	O
of	O
rats	O
.	O

Changes	O
in	O
estrous	O
cycle	O
,	O
ovarian	O
morphology	O
,	O
hormonal	O
levels	O
,	O
and	O
protein	O
levels	O
by	O
immunohistochemistry	O
and	O
western	O
-	O
blot	O
were	O
determined	O
.	O

Rats	O
treated	O
with	O
insulin	B-GENE-N
plus	O
hCG	B-GENE-N
displayed	O
abnormal	O
estrous	O
cycles	O
with	O
increasing	O
androgen	B-CHEMICAL
biosynthesis	O
.	O

Meanwhile	O
,	O
insulin	B-GENE-N
plus	O
hCG	B-GENE-N
resulted	O
in	O
multiple	O
large	O
cysts	O
with	O
diminished	O
granulosa	O
layers	O
and	O
increased	O
thecal	O
layers	O
and	O
stromal	O
-	O
interstitial	O
tissue	O
.	O

Moreover	O
,	O
there	O
was	O
an	O
increase	O
in	O
the	O
expression	O
of	O
P450scc	B-GENE-Y
and	O
CYP17	B-GENE-Y
in	O
thecal	O
and	O
stromal	O
cells	O
in	O
our	O
PCOS	O
rat	O
model	O
compared	O
with	O
control	O
rats	O
.	O

These	O
results	O
indicate	O
that	O
administration	O
of	O
insulin	B-GENE-N
with	O
hCG	B-GENE-N
can	O
synergistically	O
result	O
in	O
endogenous	O
hyperandrogenism	O
which	O
may	O
partially	O
upregulate	O
the	O
expression	O
of	O
steroidogenic	O
enzymes	O
in	O
ovarian	O
tissue	O
.	O

Can	O
the	O
chemical	O
reactivity	O
of	O
an	O
ultimate	O
carcinogen	O
be	O
related	O
to	O
its	O
carcinogenicity	O
?	O

An	O
application	O
to	O
propylene	B-CHEMICAL
oxide	I-CHEMICAL
.	O

In	O
this	O
article	O
we	O
report	O
calculations	O
of	O
the	O
activation	O
free	O
energy	O
for	O
a	O
chemical	O
reaction	O
between	O
propylene	B-CHEMICAL
oxide	I-CHEMICAL
and	O
DNA	O
,	O
in	O
particular	O
with	O
the	O
guanine	B-CHEMICAL
at	O
the	O
N7	O
position	O
.	O

Calculations	O
were	O
performed	O
using	O
Hartree	O
-	O
Fock	O
and	O
MP2	O
methods	O
in	O
conjunction	O
with	O
flexible	O
basis	O
sets	O
.	O

The	O
effects	O
of	O
solvation	O
were	O
considered	O
using	O
the	O
Langevin	O
dipoles	O
and	O
solvent	O
reaction	O
field	O
methods	O
.	O

The	O
calculated	O
activation	O
free	O
energies	O
are	O
in	O
good	O
agreement	O
with	O
the	O
experimental	O
value	O
of	O
25	O
.	O
36	O
kcal	O
/	O
mol	O
.	O

Moreover	O
,	O
the	O
reactivities	O
of	O
a	O
series	O
of	O
ultimate	O
carcinogens	O
of	O
the	O
epoxy	B-CHEMICAL
type	O
toward	O
DNA	O
are	O
shown	O
to	O
be	O
related	O
to	O
their	O
carcinogenicities	O
.	O

Higher	O
reactivity	O
is	O
generally	O
associated	O
with	O
higher	O
carcinogenicity	O
,	O
although	O
transport	O
properties	O
,	O
reactions	O
with	O
ultimate	O
carcinogen	O
scavengers	O
,	O
and	O
the	O
DNA	O
correction	O
mechanism	O
are	O
also	O
very	O
important	O
.	O

It	O
is	O
very	O
likely	O
that	O
the	O
window	O
of	O
reactivity	O
rather	O
than	O
a	O
high	O
reactivity	O
value	O
is	O
the	O
relevant	O
measure	O
of	O
carcinogenicity	O
,	O
since	O
highly	O
reactive	O
ultimate	O
carcinogens	O
interact	O
with	O
water	O
and	O
proteins	O
before	O
they	O
reach	O
DNA	O
.	O

A	O
significant	O
dose	O
-	O
dependent	O
relationship	O
between	O
mercury	B-CHEMICAL
exposure	O
from	O
dental	O
amalgams	O
and	O
kidney	O
integrity	O
biomarkers	O
:	O
A	O
further	O
assessment	O
of	O
the	O
Casa	O
Pia	O
children	O
'	O
s	O
dental	O
amalgam	O
trial	O
.	O

Dental	O
amalgams	O
are	O
a	O
commonly	O
used	O
dental	O
restorative	O
material	O
.	O

Amalgams	O
are	O
about	O
50	O
%	O
mercury	B-CHEMICAL
(	O
Hg	B-CHEMICAL
)	O
,	O
and	O
Hg	B-CHEMICAL
is	O
known	O
to	O
significantly	O
accumulate	O
in	O
the	O
kidney	O
.	O

It	O
was	O
hypothesized	O
that	O
because	O
Hg	B-CHEMICAL
accumulates	O
in	O
the	O
proximal	O
tubules	O
(	O
PTs	O
)	O
,	O
glutathione	B-GENE-N
-	I-GENE-N
S	I-GENE-N
-	I-GENE-N
transferases	I-GENE-N
(	I-GENE-N
GST	I-GENE-N
)	I-GENE-N
-	I-GENE-N
	I-GENE-N
(	O
suggestive	O
of	O
kidney	O
damage	O
at	O
the	O
level	O
of	O
PT	O
)	O
would	O
be	O
expected	O
to	O
be	O
more	O
related	O
to	O
Hg	B-CHEMICAL
exposure	O
than	O
GST	B-GENE-Y
-	I-GENE-Y
	I-GENE-Y
(	O
suggestive	O
of	O
kidney	O
damage	O
at	O
the	O
level	O
of	O
the	O
distal	O
tubules	O
)	O
.	O

Urinary	O
biomarkers	O
of	O
kidney	O
integrity	O
were	O
examined	O
in	O
children	O
of	O
8	O
-	O
18	O
years	O
old	O
,	O
with	O
and	O
without	O
dental	O
amalgam	O
fillings	O
,	O
from	O
a	O
completed	O
clinical	O
trial	O
(	O
parent	O
study	O
)	O
.	O

Our	O
study	O
determined	O
whether	O
there	O
was	O
a	O
significant	O
dose	O
-	O
dependent	O
correlation	O
between	O
increasing	O
Hg	B-CHEMICAL
exposure	O
from	O
dental	O
amalgams	O
and	O
GST	B-GENE-N
-	I-GENE-N
	I-GENE-N
and	O
GST	B-GENE-Y
-	I-GENE-Y
	I-GENE-Y
as	O
biomarkers	O
of	O
kidney	O
integrity	O
.	O

Overall	O
,	O
the	O
present	O
study	O
,	O
using	O
a	O
different	O
and	O
more	O
sensitive	O
statistical	O
model	O
than	O
the	O
parent	O
study	O
,	O
revealed	O
a	O
statistically	O
significant	O
dose	O
-	O
dependent	O
correlation	O
between	O
cumulative	O
exposure	O
to	O
Hg	B-CHEMICAL
from	O
dental	O
amalgams	O
and	O
urinary	O
levels	O
of	O
GST	B-GENE-N
-	I-GENE-N
	I-GENE-N
,	O
after	O
covariate	O
adjustment	O
;	O
where	O
as	O
,	O
a	O
nonsignificant	O
relationship	O
was	O
observed	O
with	O
urinary	O
levels	O
of	O
GST	B-GENE-Y
-	I-GENE-Y
	I-GENE-Y
.	O

Furthermore	O
,	O
it	O
was	O
observed	O
that	O
urinary	O
GST	B-GENE-N
-	I-GENE-N
	I-GENE-N
levels	O
increased	O
by	O
about	O
10	O
%	O
over	O
the	O
8	O
-	O
year	O
course	O
of	O
the	O
study	O
among	O
individuals	O
with	O
an	O
average	O
exposure	O
to	O
amalgams	O
among	O
the	O
study	O
subjects	O
from	O
the	O
amalgam	O
group	O
,	O
in	O
comparison	O
with	O
study	O
subjects	O
with	O
no	O
exposure	O
to	O
dental	O
amalgams	O
.	O

The	O
results	O
of	O
our	O
study	O
suggest	O
that	O
dental	O
amalgams	O
contribute	O
to	O
ongoing	O
kidney	O
damage	O
at	O
the	O
level	O
of	O
the	O
PTs	O
in	O
a	O
dose	O
-	O
dependent	O
fashion	O
.	O

Liver	O
glycogen	O
loading	O
dampens	O
glycogen	O
synthesis	O
seen	O
in	O
response	O
to	O
either	O
hyperinsulinemia	O
or	O
intraportal	O
glucose	B-CHEMICAL
infusion	O
.	O

The	O
purpose	O
of	O
this	O
study	O
was	O
to	O
determine	O
the	O
effect	O
of	O
liver	O
glycogen	O
loading	O
on	O
net	O
hepatic	O
glycogen	O
synthesis	O
during	O
hyperinsulinemia	O
or	O
hepatic	O
portal	O
vein	O
glucose	B-CHEMICAL
infusion	O
in	O
vivo	O
.	O

Liver	O
glycogen	O
levels	O
were	O
supercompensated	O
(	O
SCGly	O
)	O
in	O
two	O
groups	O
(	O
using	O
intraportal	O
fructose	B-CHEMICAL
infusion	O
)	O
but	O
not	O
in	O
two	O
others	O
(	O
Gly	O
)	O
during	O
hyperglycemic	O
-	O
normoinsulinemia	O
.	O

Following	O
a	O
2	O
-	O
h	O
control	O
period	O
during	O
which	O
fructose	B-CHEMICAL
infusion	O
was	O
stopped	O
,	O
there	O
was	O
a	O
2	O
-	O
h	O
experimental	O
period	O
in	O
which	O
the	O
response	O
to	O
hyperglycemia	O
plus	O
either	O
4	O
	O
basal	O
insulin	B-GENE-Y
(	O
INS	B-GENE-Y
)	O
or	O
portal	O
vein	O
glucose	B-CHEMICAL
infusion	O
(	O
PoG	O
)	O
was	O
measured	O
.	O

Increased	O
hepatic	O
glycogen	O
reduced	O
the	O
percent	O
of	O
glucose	B-CHEMICAL
taken	O
up	O
by	O
the	O
liver	O
that	O
was	O
deposited	O
in	O
glycogen	O
(	O
74	O
	O
3	O
vs	O
.	O
53	O
	O
5	O
%	O
in	O
Gly	O
+	O
INS	B-GENE-Y
and	O
SCGly	O
+	O
INS	B-GENE-Y
,	O
respectively	O
,	O
and	O
72	O
	O
3	O
vs	O
.	O
50	O
	O
6	O
%	O
in	O
Gly	O
+	O
PoG	O
and	O
SCGly	O
+	O
PoG	O
,	O
respectively	O
)	O
.	O

The	O
reduction	O
in	O
liver	O
glycogen	O
synthesis	O
in	O
SCGly	O
+	O
INS	B-GENE-Y
was	O
accompanied	O
by	O
a	O
decrease	O
in	O
both	O
insulin	B-GENE-Y
signaling	O
and	O
an	O
increase	O
in	O
AMPK	B-GENE-N
activation	O
,	O
whereas	O
only	O
the	O
latter	O
was	O
observed	O
in	O
SCGly	O
+	O
PoG	O
.	O

These	O
data	O
indicate	O
that	O
liver	O
glycogen	O
loading	O
impairs	O
glycogen	O
synthesis	O
regardless	O
of	O
the	O
signal	O
used	O
to	O
stimulate	O
it	O
.	O

Quantitation	O
of	O
UGT1A1	B-GENE-Y
in	O
human	O
liver	O
microsomes	O
using	O
stable	O
isotope	O
-	O
labelled	O
peptides	O
and	O
mass	O
spectrometry	O
based	O
proteomic	O
approaches	O
.	O

1	O
.	O

UDP	B-GENE-N
-	I-GENE-N
glucuronosyltransferases	I-GENE-N
(	O
UGTs	B-GENE-N
)	O
are	O
a	O
group	O
of	O
drug	O
-	O
metabolizing	O
enzymes	O
that	O
catalyse	O
the	O
conjugation	O
of	O
endogeonous	O
compounds	O
and	O
xenobiotics	O
to	O
yield	O
hydrophilic	O
glucuronides	O
which	O
subsequently	O
undergo	O
excretion	O
.	O

This	O
report	O
describes	O
an	O
approach	O
for	O
the	O
identification	O
and	O
accurate	O
quantitation	O
of	O
human	B-GENE-Y
UGT1A1	I-GENE-Y
in	O
complex	O
biological	O
matrices	O
using	O
liquid	O
chromatography	O
/	O
mass	O
spectrometry	O
/	O
mass	O
spectrometry	O
(	O
LC	O
-	O
MS	O
/	O
MS	O
)	O
analysis	O
of	O
protein	O
digests	O
.	O

2	O
.	O

A	O
stable	O
isotope	O
-	O
labelled	O
(	O
SIL	O
)	O
peptide	O
of	O
a	O
unique	O
peptide	O
spanning	O
residues	O
54	O
-	O
69	O
in	O
exon	O
1	O
of	O
the	O
human	B-GENE-Y
UGT1A1	I-GENE-Y
protein	O
with	O
the	O
sequence	O
RIYLSADPALVVIEHG	B-GENE-N
was	O
synthesized	O
.	O

The	O
peptide	O
sequence	O
synthesized	O
was	O
in	O
the	O
reverse	O
order	O
of	O
the	O
human	O
peptide	O
with	O
the	O
stable	O
isotope	O
-	O
labels	O
in	O
the	O
amino	B-CHEMICAL
acid	I-CHEMICAL
arginine	B-CHEMICAL
(	O
(	B-CHEMICAL
13	I-CHEMICAL
)	I-CHEMICAL
C6	I-CHEMICAL
(	I-CHEMICAL
15	I-CHEMICAL
)	I-CHEMICAL
N4	I-CHEMICAL
)	O
resulting	O
in	O
an	O
increase	O
in	O
the	O
mass	O
of	O
the	O
SIL	O
peptide	O
of	O
10	O
amu	O
,	O
from	O
1753	O
to	O
1763	O
.	O

The	O
SIL	O
peptide	O
was	O
quantitated	O
by	O
injecting	O
increasing	O
concentrations	O
of	O
the	O
peptide	O
into	O
the	O
LC	O
-	O
MS	O
to	O
obtain	O
a	O
standard	O
curve	O
.	O

3	O
.	O

The	O
labelled	O
peptide	O
along	O
with	O
precursor	O
ion	O
monitoring	O
was	O
used	O
to	O
quantify	O
the	O
levels	O
of	O
UGT1A1	B-GENE-Y
in	O
commercial	O
recombinant	O
preparations	O
(	O
supersomes	O
)	O
and	O
individual	O
human	O
liver	O
microsomal	O
samples	O
and	O
pooled	O
human	O
liver	O
micrsomes	O
obtained	O
from	O
BD	O
Biosciences	O
.	O

4	O
.	O

Glucuronidation	O
activity	O
studies	O
were	O
performed	O
,	O
which	O
demonstrated	O
a	O
positive	O
correlation	O
between	O
enzyme	O
activity	O
levels	O
and	O
the	O
UGT1A1	B-GENE-Y
content	O
in	O
the	O
liver	O
microsomes	O
obtained	O
from	O
individual	O
human	O
donors	O
.	O

Toxicity	O
profile	O
of	O
small	O
-	O
molecule	O
IAP	B-GENE-N
antagonist	O
GDC	B-CHEMICAL
-	I-CHEMICAL
0152	I-CHEMICAL
is	O
linked	O
to	O
TNF	B-GENE-Y
-	I-GENE-Y
	I-GENE-Y
pharmacology	O
.	O

Inhibitor	B-GENE-N
-	I-GENE-N
of	I-GENE-N
-	I-GENE-N
apoptosis	I-GENE-N
(	O
IAP	B-GENE-N
)	O
proteins	O
suppress	O
apoptosis	O
and	O
are	O
overexpressed	O
in	O
a	O
variety	O
of	O
cancers	O
.	O

Small	O
-	O
molecule	O
IAP	B-GENE-N
antagonists	O
are	O
currently	O
being	O
tested	O
in	O
clinical	O
trials	O
as	O
novel	O
cancer	O
therapeutics	O
.	O

GDC	B-CHEMICAL
-	I-CHEMICAL
0152	I-CHEMICAL
is	O
a	O
small	O
-	O
molecule	O
drug	O
that	O
triggers	O
tumor	O
cell	O
apoptosis	O
by	O
selectively	O
antagonizing	O
IAPs	B-GENE-N
.	O

GDC	B-CHEMICAL
-	I-CHEMICAL
0152	I-CHEMICAL
induces	O
NF	B-GENE-N
-	I-GENE-N
B	I-GENE-N
transcriptional	O
activity	O
leading	O
to	O
expression	O
of	O
several	O
chemokines	B-GENE-N
and	O
cytokines	B-GENE-N
,	O
of	O
which	O
tumor	B-GENE-Y
necrosis	I-GENE-Y
factor	I-GENE-Y
alpha	I-GENE-Y
(	O
TNF	B-GENE-Y
-	I-GENE-Y
	I-GENE-Y
)	O
is	O
the	O
most	O
important	O
for	O
single	O
-	O
agent	O
tumor	O
activity	O
.	O

TNF	B-GENE-Y
-	I-GENE-Y
	I-GENE-Y
is	O
a	O
pleiotropic	O
cytokine	B-GENE-N
that	O
drives	O
a	O
variety	O
of	O
cellular	O
responses	O
,	O
comprising	O
inflammation	O
,	O
proliferation	O
,	O
and	O
cell	O
survival	O
or	O
death	O
depending	O
on	O
the	O
cellular	O
context	O
.	O

As	O
malignant	O
and	O
normal	O
cells	O
produce	O
TNF	B-GENE-Y
-	I-GENE-Y
	I-GENE-Y
upon	O
IAP	B-GENE-N
antagonism	O
,	O
increased	O
TNF	B-GENE-Y
-	I-GENE-Y
	I-GENE-Y
could	O
drive	O
both	O
efficacy	O
and	O
toxicity	O
.	O

The	O
toxicity	O
profile	O
of	O
GDC	B-CHEMICAL
-	I-CHEMICAL
0152	I-CHEMICAL
in	O
dogs	O
and	O
rats	O
was	O
characterized	O
after	O
iv	O
dose	O
administration	O
once	O
every	O
2	O
weeks	O
for	O
four	O
doses	O
.	O

Findings	O
in	O
both	O
species	O
consisted	O
of	O
a	O
dose	O
-	O
related	O
,	O
acute	O
,	O
systemic	O
inflammatory	O
response	O
,	O
and	O
hepatic	O
injury	O
.	O

Laboratory	O
findings	O
included	O
elevated	O
plasma	O
cytokines	B-GENE-N
,	O
an	O
inflammatory	O
leukogram	O
,	O
and	O
increased	O
liver	B-GENE-N
transaminases	I-GENE-N
with	O
histopathological	O
findings	O
of	O
inflammatory	O
infiltrates	O
and	O
apoptosis	O
/	O
necrosis	O
in	O
multiple	O
tissues	O
;	O
a	O
toxicology	O
profile	O
consistent	O
with	O
TNF	B-GENE-Y
-	I-GENE-Y
	I-GENE-Y
-	O
mediated	O
toxicity	O
.	O

Dogs	O
exhibited	O
more	O
severe	O
findings	O
than	O
rats	O
,	O
and	O
humans	O
did	O
not	O
exhibit	O
these	O
findings	O
,	O
at	O
comparable	O
exposures	O
across	O
species	O
.	O

Furthermore	O
,	O
elevations	O
in	O
blood	O
neutrophil	O
count	O
,	O
serum	O
monocyte	B-GENE-Y
chemoattractant	I-GENE-Y
protein	I-GENE-Y
-	I-GENE-Y
1	I-GENE-Y
,	O
and	O
other	O
markers	O
of	O
inflammation	O
corresponded	O
to	O
GDC	B-CHEMICAL
-	I-CHEMICAL
0152	I-CHEMICAL
exposure	O
and	O
toxicity	O
and	O
thus	O
may	O
have	O
utility	O
as	O
safety	O
biomarkers	O
.	O

Tub	B-GENE-Y
has	O
a	O
key	O
role	O
in	O
insulin	B-GENE-N
and	O
leptin	B-GENE-Y
signaling	O
and	O
action	O
in	O
vivo	O
in	O
hypothalamic	O
nuclei	O
.	O

Mutation	O
of	O
tub	B-GENE-Y
gene	O
in	O
mice	O
induces	O
obesity	O
,	O
suggesting	O
that	O
tub	B-GENE-Y
could	O
be	O
an	O
important	O
regulator	O
of	O
energy	O
balance	O
.	O

In	O
the	O
current	O
study	O
,	O
we	O
investigated	O
whether	O
insulin	B-GENE-N
,	O
leptin	B-GENE-Y
,	O
and	O
obesity	O
can	O
modulate	O
Tub	B-GENE-Y
in	O
vivo	O
in	O
hypothalamic	O
nuclei	O
,	O
and	O
we	O
investigated	O
possible	O
consequences	O
on	O
energy	O
balance	O
,	O
neuropeptide	O
expression	O
,	O
and	O
hepatic	O
glucose	B-CHEMICAL
metabolism	O
.	O

Food	O
intake	O
,	O
metabolic	O
characteristics	O
,	O
signaling	O
proteins	O
,	O
and	O
neuropeptide	O
expression	O
were	O
measured	O
in	O
response	O
to	O
fasting	O
and	O
refeeding	O
,	O
intracerebroventricular	O
insulin	B-GENE-N
and	O
leptin	B-GENE-Y
,	O
and	O
Tub	B-GENE-Y
antisense	O
oligonucleotide	O
(	O
ASO	O
)	O
.	O

Tub	B-GENE-Y
tyrosine	B-CHEMICAL
phosphorylation	O
(	O
Tub	O
-	O
p	O
-	O
tyr	B-CHEMICAL
)	O
is	O
modulated	O
by	O
nutritional	O
status	O
.	O

Tub	B-GENE-Y
is	O
a	O
substrate	O
of	O
insulin	B-GENE-Y
receptor	I-GENE-Y
tyrosine	I-GENE-Y
kinase	I-GENE-Y
(	O
IRTK	B-GENE-Y
)	O
and	O
leptin	B-GENE-Y
receptor	I-GENE-Y
(	O
LEPR	B-GENE-Y
)	O
-	O
Janus	B-GENE-Y
kinase	I-GENE-Y
2	I-GENE-Y
(	O
JAK2	B-GENE-Y
)	O
in	O
hypothalamic	O
nuclei	O
.	O

After	O
leptin	B-GENE-Y
or	O
insulin	B-GENE-N
stimulation	O
,	O
Tub	B-GENE-Y
translocates	O
to	O
the	O
nucleus	O
.	O

Inhibition	O
of	O
Tub	B-GENE-Y
expression	O
in	O
hypothalamus	O
by	O
ASO	O
increased	O
food	O
intake	O
,	O
fasting	O
blood	O
glucose	B-CHEMICAL
,	O
and	O
hepatic	O
glucose	B-CHEMICAL
output	O
,	O
decreased	O
O	B-CHEMICAL
(	I-CHEMICAL
2	I-CHEMICAL
)	I-CHEMICAL
consumption	O
,	O
and	O
blunted	O
the	O
effect	O
of	O
insulin	B-GENE-N
or	O
leptin	B-GENE-Y
on	O
proopiomelanocortin	B-GENE-Y
,	O
thyroid	B-GENE-Y
-	I-GENE-Y
releasing	I-GENE-Y
hormone	I-GENE-Y
,	O
melanin	B-GENE-Y
-	I-GENE-Y
concentrating	I-GENE-Y
hormone	I-GENE-Y
,	O
and	O
orexin	B-GENE-Y
expression	O
.	O

In	O
hypothalamus	O
of	O
mice	O
administered	O
a	O
high	O
-	O
fat	O
diet	O
,	O
there	O
is	O
a	O
reduction	O
in	O
leptin	B-GENE-Y
and	O
insulin	B-GENE-N
-	O
induced	O
Tub	B-GENE-Y
-	O
p	O
-	O
tyr	B-CHEMICAL
and	O
nuclear	O
translocation	O
,	O
which	O
is	O
reversed	O
by	O
reducing	O
protein	B-GENE-Y
tyrosine	I-GENE-Y
phosphatase	I-GENE-Y
1B	I-GENE-Y
expression	O
.	O

These	O
results	O
indicate	O
that	O
Tub	B-GENE-Y
has	O
a	O
key	O
role	O
in	O
the	O
control	O
of	O
insulin	B-GENE-N
and	O
leptin	B-GENE-Y
effects	O
on	O
food	O
intake	O
,	O
and	O
the	O
modulation	O
of	O
Tub	B-GENE-Y
may	O
contribute	O
to	O
insulin	B-GENE-N
and	O
leptin	B-GENE-Y
resistance	O
in	O
DIO	O
mice	O
.	O

The	O
PARP	B-GENE-N
inhibitor	O
PJ34	B-CHEMICAL
modifies	O
proliferation	O
,	O
NIS	B-GENE-Y
expression	O
and	O
epigenetic	O
marks	O
in	O
thyroid	O
cancer	O
cell	O
lines	O
.	O

Since	O
PARP	B-GENE-Y
-	I-GENE-Y
1	I-GENE-Y
is	O
supposed	O
to	O
be	O
part	O
of	O
a	O
multimeric	O
repressor	O
of	O
sodium	B-GENE-Y
iodide	I-GENE-Y
symporter	I-GENE-Y
(	O
NIS	B-GENE-Y
)	O
expression	O
,	O
in	O
this	O
study	O
the	O
effect	O
of	O
the	O
PARP	B-GENE-N
inhibitor	O
PJ34	B-CHEMICAL
on	O
several	O
properties	O
of	O
thyroid	O
cancer	O
cell	O
lines	O
was	O
investigated	O
.	O

In	O
TPC1	O
,	O
BCPAP	O
,	O
FRO	O
,	O
WRO	O
cell	O
lines	O
PJ34	B-CHEMICAL
induced	O
a	O
strong	O
increase	O
in	O
NIS	B-GENE-Y
mRNA	O
levels	O
.	O

In	O
BCPAP	O
and	O
TPC1	O
cells	O
also	O
significant	O
increase	O
of	O
radio	B-CHEMICAL
-	I-CHEMICAL
iodine	I-CHEMICAL
uptake	O
was	O
induced	O
.	O

Accordingly	O
,	O
in	O
transfection	O
experiments	O
performed	O
in	O
TPC1	O
cells	O
,	O
treatment	O
with	O
PJ34	B-CHEMICAL
increased	O
NIS	B-GENE-N
promoter	I-GENE-N
activity	O
without	O
affecting	O
PARP	B-GENE-Y
-	I-GENE-Y
1	I-GENE-Y
binding	O
to	O
the	O
promoter	O
sequence	O
.	O

We	O
also	O
investigated	O
the	O
epigenetic	O
status	O
of	O
NIS	B-GENE-N
promoter	I-GENE-N
after	O
PJ34	B-CHEMICAL
treatment	O
in	O
TPC1	O
cell	O
line	O
:	O
in	O
addition	O
to	O
an	O
increase	O
of	O
histone	B-GENE-N
modification	I-GENE-N
activation	I-GENE-N
marks	I-GENE-N
(	O
H3K9K14ac	B-GENE-N
,	O
H3K4me3	B-GENE-N
)	O
,	O
surprisingly	O
we	O
observed	O
also	O
an	O
increase	O
of	O
H3K27me3	O
,	O
a	O
classical	O
repressive	O
mark	O
.	O

Our	O
data	O
demonstrate	O
that	O
in	O
various	O
thyroid	O
cancer	O
cell	O
lines	O
PARP	B-GENE-N
inhibition	O
increases	O
NIS	B-GENE-Y
gene	O
expression	O
through	O
a	O
particular	O
modulation	O
of	O
transcriptional	O
regulatory	O
mechanisms	O
.	O

Therefore	O
,	O
we	O
suggest	O
that	O
PARP	B-GENE-N
inhibitors	O
may	O
deserve	O
future	O
investigations	O
as	O
tools	O
for	O
medical	O
treatment	O
of	O
thyroid	O
cancer	O
.	O

Comparative	O
antioxidant	O
effects	O
of	O
lycopene	O
,	O
apo	B-CHEMICAL
-	I-CHEMICAL
10	I-CHEMICAL
'	I-CHEMICAL
-	I-CHEMICAL
lycopenoic	I-CHEMICAL
acid	I-CHEMICAL
and	O
apo	B-CHEMICAL
-	I-CHEMICAL
14	I-CHEMICAL
'	I-CHEMICAL
-	I-CHEMICAL
lycopenoic	I-CHEMICAL
acid	I-CHEMICAL
in	O
human	O
macrophages	O
exposed	O
to	O
H2O2	B-CHEMICAL
and	O
cigarette	O
smoke	O
extract	O
.	O

Much	O
of	O
the	O
beneficial	O
effects	O
of	O
tomato	O
lycopene	B-CHEMICAL
in	O
the	O
prevention	O
of	O
chronic	O
diseases	O
has	O
been	O
attributed	O
to	O
its	O
antioxidant	O
properties	O
,	O
which	O
could	O
be	O
mediated	O
by	O
its	O
metabolites	O
and	O
/	O
or	O
oxidation	O
products	O
.	O

However	O
,	O
the	O
biological	O
functions	O
of	O
these	O
lycopene	B-CHEMICAL
derivatives	O
remain	O
still	O
unknown	O
.	O

In	O
the	O
present	O
study	O
,	O
we	O
evaluated	O
and	O
compared	O
the	O
antioxidant	O
efficacy	O
of	O
the	O
lycopene	B-CHEMICAL
eccentric	O
cleavage	O
products	O
apo	B-CHEMICAL
-	I-CHEMICAL
10	I-CHEMICAL
'	I-CHEMICAL
-	I-CHEMICAL
lycopenoic	I-CHEMICAL
acid	I-CHEMICAL
and	O
apo	B-CHEMICAL
-	I-CHEMICAL
14	I-CHEMICAL
'	I-CHEMICAL
-	I-CHEMICAL
lycopenoic	I-CHEMICAL
acid	I-CHEMICAL
in	O
counteracting	O
the	O
oxidative	O
effects	O
of	O
H	B-CHEMICAL
(	I-CHEMICAL
2	I-CHEMICAL
)	I-CHEMICAL
O	I-CHEMICAL
(	I-CHEMICAL
2	I-CHEMICAL
)	I-CHEMICAL
and	O
cigarette	O
smoke	O
extract	O
(	O
CSE	O
)	O
in	O
THP	O
-	O
1	O
macrophages	O
.	O

Both	O
apo	B-CHEMICAL
-	I-CHEMICAL
10	I-CHEMICAL
'	I-CHEMICAL
-	I-CHEMICAL
lycopenoic	I-CHEMICAL
acid	I-CHEMICAL
and	O
apo	B-CHEMICAL
-	I-CHEMICAL
14	I-CHEMICAL
'	I-CHEMICAL
-	I-CHEMICAL
lycopenoic	I-CHEMICAL
acid	I-CHEMICAL
were	O
able	O
to	O
inhibit	O
spontaneous	O
and	O
H	B-CHEMICAL
(	I-CHEMICAL
2	I-CHEMICAL
)	I-CHEMICAL
O	I-CHEMICAL
(	I-CHEMICAL
2	I-CHEMICAL
)	I-CHEMICAL
-	O
induced	O
ROS	O
production	O
in	O
a	O
dose	O
-	O
dependent	O
manner	O
.	O

Such	O
an	O
effect	O
was	O
accompanied	O
by	O
an	O
inhibition	O
of	O
MAPK	B-GENE-N
phosphorylation	O
,	O
by	O
NF	B-GENE-N
-	I-GENE-N
B	I-GENE-N
inactivation	O
,	O
and	O
by	O
inhibition	O
of	O
hsp	B-GENE-N
-	I-GENE-N
70	I-GENE-N
and	O
hsp	B-GENE-N
-	I-GENE-N
90	I-GENE-N
expressions	O
.	O

Both	O
apo	B-CHEMICAL
-	I-CHEMICAL
lycopenoic	I-CHEMICAL
acids	I-CHEMICAL
also	O
decreased	O
CSE	O
-	O
induced	O
ROS	O
production	O
,	O
8	B-CHEMICAL
-	I-CHEMICAL
OHdG	I-CHEMICAL
formation	O
and	O
reduced	O
the	O
increase	O
in	O
NOX	B-GENE-Y
-	I-GENE-Y
4	I-GENE-Y
and	O
COX	B-GENE-Y
-	I-GENE-Y
2	I-GENE-Y
expressions	O
caused	O
by	O
CSE	O
.	O

However	O
,	O
in	O
both	O
the	O
models	O
of	O
oxidative	O
stress	O
,	O
apo	B-CHEMICAL
-	I-CHEMICAL
14	I-CHEMICAL
'	I-CHEMICAL
-	I-CHEMICAL
lycopenoic	I-CHEMICAL
acid	I-CHEMICAL
was	O
much	O
more	O
potent	O
as	O
an	O
antioxidant	O
than	O
apo	B-CHEMICAL
-	I-CHEMICAL
10	I-CHEMICAL
'	I-CHEMICAL
-	I-CHEMICAL
lycopenoic	I-CHEMICAL
acid	I-CHEMICAL
,	O
showing	O
antioxidant	O
properties	O
similar	O
to	O
lycopene	B-CHEMICAL
.	O

These	O
data	O
strongly	O
suggest	O
that	O
apo	B-CHEMICAL
-	I-CHEMICAL
lycopenoic	I-CHEMICAL
acids	I-CHEMICAL
,	O
and	O
particularly	O
apo	B-CHEMICAL
-	I-CHEMICAL
14	I-CHEMICAL
'	I-CHEMICAL
-	I-CHEMICAL
lycopenoic	I-CHEMICAL
acid	I-CHEMICAL
,	O
may	O
mediate	O
some	O
of	O
the	O
antioxidant	O
functions	O
of	O
lycopene	O
in	O
cells	O
.	O

Plants	O
as	O
a	O
source	O
of	O
butyrylcholinesterase	B-GENE-Y
variants	O
designed	O
for	O
enhanced	O
cocaine	B-GENE-N
hydrolase	I-GENE-N
activity	O
.	O

Cocaine	B-CHEMICAL
addiction	O
affects	O
millions	O
of	O
people	O
with	O
disastrous	O
personal	O
and	O
social	O
consequences	O
.	O

Cocaine	B-CHEMICAL
is	O
one	O
of	O
the	O
most	O
reinforcing	O
of	O
all	O
drugs	O
of	O
abuse	O
,	O
and	O
even	O
those	O
who	O
undergo	O
rehabilitation	O
and	O
experience	O
long	O
periods	O
of	O
abstinence	O
have	O
more	O
than	O
80	O
%	O
chance	O
of	O
relapse	O
.	O

Yet	O
there	O
is	O
no	O
FDA	O
-	O
approved	O
treatment	O
to	O
decrease	O
the	O
likelihood	O
of	O
relapse	O
in	O
rehabilitated	O
addicts	O
.	O

Recent	O
studies	O
,	O
however	O
,	O
have	O
demonstrated	O
a	O
promising	O
potential	O
treatment	O
option	O
with	O
the	O
help	O
of	O
the	O
serum	O
enzyme	O
butyrylcholinesterase	B-GENE-Y
(	O
BChE	B-GENE-Y
)	O
,	O
which	O
is	O
capable	O
of	O
breaking	O
down	O
naturally	O
occurring	O
(	B-CHEMICAL
-	I-CHEMICAL
)	I-CHEMICAL
-	I-CHEMICAL
cocaine	I-CHEMICAL
before	O
the	O
drug	O
can	O
influence	O
the	O
reward	O
centers	O
of	O
the	O
brain	O
or	O
affect	O
other	O
areas	O
of	O
the	O
body	O
.	O

This	O
activity	O
of	O
wild	O
-	O
type	O
(	O
WT	O
)	O
BChE	B-GENE-Y
,	O
however	O
,	O
is	O
relatively	O
low	O
.	O

This	O
prompted	O
the	O
design	O
of	O
variants	O
of	O
BChE	B-GENE-Y
which	O
exhibit	O
significantly	O
improved	O
catalytic	O
activity	O
against	O
(	B-CHEMICAL
-	I-CHEMICAL
)	I-CHEMICAL
-	I-CHEMICAL
cocaine	I-CHEMICAL
.	O

Plants	O
are	O
a	O
promising	O
means	O
to	O
produce	O
large	O
amounts	O
of	O
these	O
cocaine	B-GENE-N
hydrolase	I-GENE-N
variants	O
of	O
BChE	B-GENE-N
,	O
cheaply	O
,	O
safely	O
with	O
no	O
concerns	O
regarding	O
human	O
pathogens	O
and	O
functionally	O
equivalent	O
to	O
enzymes	O
derived	O
from	O
other	O
sources	O
.	O

Here	O
,	O
in	O
expressing	O
cocaine	B-CHEMICAL
-	O
hydrolyzing	O
mutants	O
of	O
BChE	B-GENE-N
in	O
Nicotiana	O
benthamiana	O
using	O
the	O
MagnICON	O
virus	O
-	O
assisted	O
transient	O
expression	O
system	O
,	O
and	O
in	O
reporting	O
their	O
initial	O
biochemical	O
analysis	O
,	O
we	O
provide	O
proof	O
-	O
of	O
-	O
principle	O
that	O
plants	O
can	O
express	O
engineered	O
BChE	B-GENE-N
proteins	O
with	O
desired	O
properties	O
.	O

Experimental	O
tooth	O
movement	O
-	O
induced	O
osteoclast	O
activation	O
is	O
regulated	O
by	O
sympathetic	O
signaling	O
.	O

Experimental	O
tooth	O
movement	O
(	O
ETM	O
)	O
changes	O
the	O
distribution	O
of	O
sensory	O
nerve	O
fibers	O
in	O
periodontal	O
ligament	O
and	O
the	O
bone	O
architecture	O
through	O
the	O
stimulation	O
of	O
bone	O
remodeling	O
.	O

As	O
the	O
sympathetic	O
nervous	O
system	O
is	O
involved	O
in	O
bone	O
remodeling	O
,	O
we	O
examined	O
whether	O
ETM	O
is	O
controlled	O
by	O
sympathetic	O
signaling	O
or	O
not	O
.	O

In	O
male	O
mice	O
,	O
elastic	O
rubber	O
was	O
inserted	O
between	O
upper	O
left	O
first	O
molar	O
(	O
M1	O
)	O
and	O
second	O
molar	O
(	O
M2	O
)	O
for	O
3	O
or	O
5	O
days	O
.	O

Nerve	O
fibers	O
immunoreactive	O
for	O
not	O
only	O
sensory	O
neuromarkers	O
,	O
such	O
as	O
calcitonin	B-GENE-N
gene	I-GENE-N
-	I-GENE-N
related	I-GENE-N
peptide	I-GENE-N
(	O
CGRP	B-GENE-N
)	O
,	O
but	O
also	O
sympathetic	O
neuromarkers	O
,	O
such	O
as	O
tyrosine	B-GENE-Y
hydroxylase	I-GENE-Y
(	O
TH	B-GENE-Y
)	O
and	O
neuropeptide	B-GENE-Y
Y	I-GENE-Y
(	O
NPY	B-GENE-Y
)	O
were	O
increased	O
in	O
the	O
periodontal	O
ligament	O
during	O
ETM	O
.	O

To	O
elucidate	O
the	O
effect	O
of	O
the	O
sympathetic	O
signal	O
mediated	O
by	O
ETM	O
,	O
mice	O
were	O
intraperitoneally	O
injected	O
with	O
a	O
	O
-	O
antagonist	O
,	O
propranolol	B-CHEMICAL
(	O
PRO	B-CHEMICAL
:	O
20	O
g	O
/	O
g	O
/	O
day	O
)	O
,	O
or	O
a	O
	O
-	O
agonist	O
,	O
isoproterenol	B-CHEMICAL
(	O
ISO	B-CHEMICAL
:	O
5	O
g	O
/	O
g	O
/	O
day	O
)	O
from	O
7	O
days	O
before	O
ETM	O
.	O

PRO	B-CHEMICAL
treatment	O
suppressed	O
the	O
amount	O
of	O
tooth	O
movement	O
by	O
12	O
.	O
9	O
%	O
in	O
3	O
-	O
day	O
ETM	O
and	O
by	O
32	O
.	O
2	O
%	O
in	O
5	O
-	O
day	O
ETM	O
compared	O
with	O
vehicle	O
treatment	O
.	O

On	O
the	O
other	O
hand	O
,	O
ISO	B-CHEMICAL
treatment	O
increased	O
it	O
.	O

Furthermore	O
,	O
ETM	O
remarkably	O
increased	O
the	O
osteoclast	O
number	O
on	O
the	O
bone	O
surface	O
(	O
alveolar	O
socket	O
)	O
(	O
Oc	O
.	O
N	O
/	O
BS	O
)	O
in	O
all	O
drug	O
treatments	O
.	O

PRO	B-CHEMICAL
treatment	O
suppressed	O
Oc	O
.	O
N	O
/	O
BS	O
by	O
39	O
.	O
4	O
%	O
in	O
3	O
-	O
day	O
ETM	O
,	O
while	O
ISO	B-CHEMICAL
treatment	O
increased	O
it	O
by	O
32	O
.	O
1	O
%	O
in	O
3	O
-	O
day	O
ETM	O
compared	O
with	O
vehicle	O
treatment	O
.	O

Chemical	O
sympathectomy	O
using	O
6	B-CHEMICAL
-	I-CHEMICAL
hydroxydopamine	I-CHEMICAL
(	O
6	B-CHEMICAL
-	I-CHEMICAL
OHDA	I-CHEMICAL
:	O
250	O
g	O
/	O
g	O
)	O
showed	O
results	O
similar	O
to	O
those	O
for	O
PRO	B-CHEMICAL
treatment	O
in	O
terms	O
of	O
both	O
the	O
amount	O
of	O
tooth	O
movement	O
and	O
osteoclast	O
parameters	O
.	O

Our	O
data	O
showed	O
that	O
blockade	O
of	O
sympathetic	O
signaling	O
inhibited	O
the	O
tooth	O
movement	O
and	O
osteoclast	O
increase	O
induced	O
by	O
ETM	O
,	O
and	O
stimulation	O
of	O
sympathetic	O
signaling	O
accelerated	O
these	O
responses	O
.	O

These	O
data	O
suggest	O
that	O
the	O
mechano	O
-	O
adaptive	O
response	O
induced	O
by	O
ETM	O
is	O
controlled	O
by	O
sympathetic	O
signaling	O
through	O
osteoclast	O
activation	O
.	O

Resistin	B-GENE-Y
knockout	O
mice	O
exhibit	O
impaired	O
adipocyte	O
glucose	B-GENE-Y
-	I-GENE-Y
dependent	I-GENE-Y
insulinotropic	I-GENE-Y
polypeptide	I-GENE-Y
receptor	I-GENE-Y
(	O
GIPR	B-GENE-Y
)	O
expression	O
.	O

Glucose	B-GENE-Y
-	I-GENE-Y
dependent	I-GENE-Y
insulinotropic	I-GENE-Y
polypeptide	I-GENE-Y
(	O
GIP	B-GENE-Y
)	O
is	O
an	O
incretin	B-GENE-N
hormone	I-GENE-N
that	O
also	O
plays	O
a	O
regulatory	O
role	O
in	O
fat	O
metabolism	O
.	O

In	O
3T3	O
-	O
L1	O
cells	O
,	O
resistin	B-GENE-Y
was	O
demonstrated	O
to	O
be	O
a	O
key	O
mediator	O
of	O
GIP	B-GENE-Y
stimulation	O
of	O
lipoprotein	B-GENE-Y
lipase	I-GENE-Y
(	O
LPL	B-GENE-Y
)	O
activity	O
,	O
involving	O
activation	O
of	O
protein	B-GENE-Y
kinase	I-GENE-Y
B	I-GENE-Y
(	O
PKB	B-GENE-Y
)	O
and	O
reduced	O
phosphorylation	O
of	O
liver	B-GENE-Y
kinase	I-GENE-Y
B1	I-GENE-Y
(	O
LKB1	B-GENE-Y
)	O
and	O
AMP	B-GENE-Y
-	I-GENE-Y
activated	I-GENE-Y
protein	I-GENE-Y
kinase	I-GENE-Y
(	O
AMPK	B-GENE-Y
)	O
.	O

The	O
current	O
study	O
was	O
initiated	O
to	O
determine	O
whether	O
resistin	B-GENE-Y
has	O
additional	O
roles	O
in	O
GIP	B-GENE-Y
-	O
regulated	O
adipocyte	O
functions	O
.	O

Analysis	O
of	O
primary	O
adipocytes	O
isolated	O
from	O
Retn	B-GENE-Y
(	O
-	O
/	O
-	O
)	O
,	O
Retn	B-GENE-Y
(	O
+	O
/	O
-	O
)	O
,	O
and	O
Retn	B-GENE-Y
(	O
+	O
/	O
+	O
)	O
mice	O
found	O
that	O
GIP	B-GENE-Y
stimulated	O
the	O
PKB	B-GENE-Y
/	O
LKB1	B-GENE-Y
/	O
AMPK	B-GENE-Y
/	O
LPL	B-GENE-Y
pathway	O
and	O
fatty	B-CHEMICAL
acid	I-CHEMICAL
uptake	O
only	O
in	O
Retn	B-GENE-Y
(	O
+	O
/	O
+	O
)	O
adipocytes	O
,	O
suggesting	O
that	O
GIP	B-GENE-Y
signaling	O
and	O
/	O
or	O
GIP	B-GENE-Y
responsiveness	O
were	O
compromised	O
in	O
Retn	B-GENE-Y
(	O
+	O
/	O
-	O
)	O
and	O
Retn	B-GENE-Y
(	O
-	O
/	O
-	O
)	O
adipocytes	O
.	O

GIP	B-GENE-Y
receptor	I-GENE-Y
(	O
GIPR	B-GENE-Y
)	O
protein	O
and	O
mRNA	O
were	O
decreased	O
in	O
Retn	B-GENE-Y
(	O
+	O
/	O
-	O
)	O
and	O
Retn	B-GENE-Y
(	O
-	O
/	O
-	O
)	O
adipocytes	O
,	O
but	O
resistin	B-GENE-Y
treatment	O
rescued	O
LPL	O
responsiveness	O
to	O
GIP	B-GENE-Y
.	O

In	O
addition	O
,	O
genes	O
encoding	O
tumor	B-GENE-Y
necrosis	I-GENE-Y
factor	I-GENE-Y
(	O
TNF	B-GENE-Y
)	O
,	O
TNF	B-GENE-Y
receptor	I-GENE-Y
2	I-GENE-Y
(	O
TNFR2	B-GENE-Y
)	O
,	O
and	O
the	O
signaling	O
proteins	O
stress	B-GENE-N
-	I-GENE-N
activated	I-GENE-N
protein	I-GENE-N
kinase	I-GENE-N
(	O
SAPK	B-GENE-N
)	O
/	O
Jun	B-GENE-N
NH	I-GENE-N
(	I-GENE-N
2	I-GENE-N
)	I-GENE-N
-	I-GENE-N
terminal	I-GENE-N
kinase	I-GENE-N
(	O
JNK	B-GENE-N
)	O
,	O
were	O
downregulated	O
,	O
and	O
phosphorylated	O
levels	O
of	O
SAPK	B-GENE-N
/	O
JNK	B-GENE-N
/	O
c	B-GENE-Y
-	I-GENE-Y
Jun	I-GENE-Y
were	O
decreased	O
in	O
Retn	B-GENE-Y
(	O
-	O
/	O
-	O
)	O
mice	O
.	O

Chromatin	O
immunoprecipitation	O
assays	O
were	O
used	O
to	O
identify	O
a	O
12	B-GENE-N
-	I-GENE-N
O	I-GENE-N
-	I-GENE-N
tetradecanoylphorbol	I-GENE-N
-	I-GENE-N
13	I-GENE-N
-	I-GENE-N
acetate	I-GENE-N
(	I-GENE-N
TPA	I-GENE-N
)	I-GENE-N
-	I-GENE-N
response	I-GENE-N
element	I-GENE-N
(	O
TRE	B-GENE-N
-	I-GENE-N
III	I-GENE-N
)	O
responsible	O
for	O
c	B-GENE-Y
-	I-GENE-Y
Jun	I-GENE-Y
-	O
mediated	O
transcriptional	O
activation	O
of	O
Gipr	B-GENE-Y
.	O

Blunted	O
GIP	B-GENE-Y
responsiveness	O
in	O
Retn	B-GENE-Y
(	O
+	O
/	O
-	O
)	O
and	O
Retn	B-GENE-Y
(	O
-	O
/	O
-	O
)	O
adipocytes	O
was	O
therefore	O
largely	O
due	O
to	O
the	O
greatly	O
reduced	O
GIPR	B-GENE-Y
expression	O
associated	O
with	O
decreased	O
c	B-GENE-N
-	I-GENE-N
Jun	I-GENE-N
-	O
mediated	O
transcriptional	O
activation	O
of	O
Gipr	B-GENE-Y
.	O

Cyclooxygenase	B-GENE-Y
(	I-GENE-Y
COX	I-GENE-Y
)	I-GENE-Y
-	I-GENE-Y
1	I-GENE-Y
and	O
COX	B-GENE-Y
-	I-GENE-Y
2	I-GENE-Y
both	O
play	O
an	O
important	O
role	O
in	O
the	O
protection	O
of	O
the	O
duodenal	O
mucosa	O
in	O
cats	O
.	O

Although	O
nonsteroidal	O
anti	O
-	O
inflammatory	O
drugs	O
often	O
cause	O
ulcers	O
in	O
the	O
duodenum	O
in	O
humans	O
,	O
the	O
role	O
of	O
cyclooxygenase	B-GENE-N
(	O
COX	B-GENE-N
)	O
isoforms	O
in	O
the	O
pathogenesis	O
of	O
duodenal	O
ulcers	O
has	O
not	O
been	O
fully	O
elucidated	O
.	O

We	O
examined	O
in	O
cats	O
the	O
1	O
)	O
ulcerogenic	O
effects	O
of	O
selective	O
COX	B-GENE-Y
-	I-GENE-Y
1	I-GENE-Y
(	O
SC	B-CHEMICAL
-	I-CHEMICAL
560	I-CHEMICAL
,	O
ketorolac	B-CHEMICAL
)	O
and	O
COX	B-GENE-Y
-	I-GENE-Y
2	I-GENE-Y
(	O
celecoxib	B-CHEMICAL
,	O
meloxicam	B-CHEMICAL
)	O
inhibitors	O
on	O
the	O
gastrointestinal	O
mucosa	O
,	O
2	O
)	O
effect	O
of	O
feeding	O
and	O
cimetidine	B-CHEMICAL
on	O
the	O
expression	O
of	O
COX	B-GENE-N
isoforms	O
and	O
prostaglandin	B-CHEMICAL
E	I-CHEMICAL
(	I-CHEMICAL
2	I-CHEMICAL
)	I-CHEMICAL
(	O
PGE	B-CHEMICAL
(	I-CHEMICAL
2	I-CHEMICAL
)	I-CHEMICAL
)	O
level	O
in	O
the	O
duodenum	O
,	O
and	O
3	O
)	O
localization	O
of	O
COX	B-GENE-N
isoforms	O
in	O
the	O
duodenum	O
.	O

COX	B-GENE-N
inhibitors	O
were	O
administered	O
after	O
the	O
morning	O
meal	O
in	O
cats	O
once	O
daily	O
for	O
3	O
days	O
.	O

Gastrointestinal	O
lesions	O
were	O
examined	O
on	O
day	O
4	O
.	O

Localization	O
and	O
expression	O
of	O
COX	B-GENE-N
isoforms	O
(	O
by	O
immunohistochemistry	O
,	O
Western	O
blot	O
)	O
and	O
PGE	B-CHEMICAL
(	I-CHEMICAL
2	I-CHEMICAL
)	I-CHEMICAL
level	O
(	O
by	O
enzyme	O
immunoassay	O
)	O
were	O
examined	O
.	O

Results	O
were	O
as	O
follows	O
.	O

First	O
,	O
selective	O
COX	B-GENE-Y
-	I-GENE-Y
1	I-GENE-Y
or	O
COX	B-GENE-Y
-	I-GENE-Y
2	I-GENE-Y
inhibitors	O
alone	O
produced	O
marked	O
ulcers	O
in	O
the	O
duodenum	O
but	O
did	O
not	O
cause	O
obvious	O
lesions	O
in	O
the	O
small	O
intestine	O
.	O

Coadministration	O
of	O
SC	B-CHEMICAL
-	I-CHEMICAL
560	I-CHEMICAL
and	O
celecoxib	B-CHEMICAL
produced	O
marked	O
lesions	O
in	O
the	O
small	O
intestine	O
.	O

Second	O
,	O
feeding	O
increased	O
both	O
the	O
expression	O
of	O
COX	B-GENE-N
isoforms	O
and	O
PGE	B-CHEMICAL
(	I-CHEMICAL
2	I-CHEMICAL
)	I-CHEMICAL
level	O
in	O
the	O
duodenum	O
,	O
and	O
the	O
effects	O
were	O
markedly	O
inhibited	O
by	O
pretreatment	O
with	O
cimetidine	B-CHEMICAL
.	O

Third	O
,	O
COX	B-GENE-Y
-	I-GENE-Y
1	I-GENE-Y
was	O
localized	O
in	O
goblet	O
and	O
Brunner	O
'	O
s	O
gland	O
cells	O
,	O
Meissner	O
'	O
s	O
and	O
Auerbach	O
'	O
s	O
plexus	O
,	O
smooth	O
muscle	O
cells	O
,	O
and	O
arterioles	O
;	O
and	O
COX	B-GENE-Y
-	I-GENE-Y
2	I-GENE-Y
was	O
observed	O
in	O
capillaries	O
,	O
venules	O
,	O
and	O
basal	O
granulated	O
cells	O
.	O

The	O
expression	O
of	O
COX	B-GENE-N
isoforms	O
in	O
the	O
duodenum	O
is	O
up	O
-	O
regulated	O
by	O
feeding	O
,	O
and	O
inhibition	O
of	O
either	O
COX	B-GENE-Y
-	I-GENE-Y
1	I-GENE-Y
or	O
COX	B-GENE-Y
-	I-GENE-Y
2	I-GENE-Y
causes	O
ulcers	O
in	O
the	O
duodenum	O
,	O
suggesting	O
that	O
both	O
isoforms	O
play	O
an	O
important	O
role	O
in	O
the	O
protection	O
of	O
the	O
duodenal	O
mucosa	O
.	O

Reversal	O
of	O
dopamine	B-GENE-Y
D2	I-GENE-Y
agonist	O
-	O
induced	O
inhibition	O
of	O
ventral	O
tegmental	O
area	O
neurons	O
by	O
Gq	B-GENE-N
-	O
linked	O
neurotransmitters	O
is	O
dependent	O
on	O
protein	B-GENE-N
kinase	I-GENE-N
C	I-GENE-N
,	O
G	B-GENE-N
protein	I-GENE-N
-	I-GENE-N
coupled	I-GENE-N
receptor	I-GENE-N
kinase	I-GENE-N
,	O
and	O
dynamin	B-GENE-N
.	O

Dopaminergic	O
neurons	O
of	O
the	O
ventral	O
tegmental	O
area	O
are	O
important	O
components	O
of	O
brain	O
pathways	O
related	O
to	O
addiction	O
.	O

Prolonged	O
exposure	O
of	O
these	O
neurons	O
to	O
moderate	O
concentrations	O
of	O
dopamine	B-CHEMICAL
(	O
DA	O
)	O
decreases	O
their	O
sensitivity	O
to	O
inhibition	O
by	O
DA	O
,	O
a	O
process	O
called	O
DA	O
-	O
inhibition	O
reversal	O
(	O
DIR	O
)	O
.	O

DIR	O
is	O
mediated	O
by	O
phospholipase	B-GENE-N
C	I-GENE-N
and	O
conventional	B-GENE-N
subtype	I-GENE-N
of	I-GENE-N
protein	I-GENE-N
kinase	I-GENE-N
C	I-GENE-N
(	O
cPKC	B-GENE-N
)	O
through	O
concurrent	O
stimulation	O
of	O
D2	B-GENE-Y
and	O
D1	B-GENE-N
-	I-GENE-N
like	I-GENE-N
DA	I-GENE-N
receptors	I-GENE-N
,	O
or	O
by	O
D2	B-GENE-Y
stimulation	O
concurrent	O
with	O
activation	O
of	O
5	B-GENE-N
-	I-GENE-N
HT	I-GENE-N
(	I-GENE-N
2	I-GENE-N
)	I-GENE-N
or	O
neurotensin	B-GENE-N
receptors	I-GENE-N
.	O

In	O
the	O
present	O
study	O
,	O
we	O
further	O
characterized	O
this	O
phenomenon	O
by	O
use	O
of	O
extracellular	O
recordings	O
in	O
brain	O
slices	O
to	O
examine	O
whether	O
DIR	O
is	O
linked	O
to	O
G	B-GENE-Y
protein	I-GENE-Y
-	I-GENE-Y
coupled	I-GENE-Y
receptor	I-GENE-Y
kinase	I-GENE-Y
-	I-GENE-Y
2	I-GENE-Y
(	O
GRK2	B-GENE-Y
)	O
or	O
dynamin	B-GENE-N
by	O
assessing	O
DIR	O
in	O
the	O
presence	O
of	O
antagonists	O
of	O
these	O
enzymes	O
.	O

DIR	O
was	O
blocked	O
by	O
	O
-	O
ARK1	O
inhibitor	O
,	O
which	O
inhibits	O
GRK2	B-GENE-Y
,	O
and	O
by	O
dynasore	O
,	O
which	O
blocks	O
dynamin	B-GENE-N
.	O

Reversal	O
of	O
inhibition	O
by	O
D2	B-GENE-Y
agonist	O
quinpirole	B-CHEMICAL
was	O
produced	O
by	O
serotonin	B-CHEMICAL
(	O
50	O
M	O
)	O
and	O
by	O
neurotensin	B-CHEMICAL
(	O
5	O
-	O
10	O
nM	O
)	O
.	O

Serotonin	B-CHEMICAL
-	O
induced	O
or	O
neurotensin	B-CHEMICAL
-	O
induced	O
reversal	O
was	O
blocked	O
by	O
	O
-	O
ARK1	O
inhibitor	O
,	O
dynasore	O
,	O
or	O
cPKC	B-GENE-N
antagonist	O
5	B-CHEMICAL
,	I-CHEMICAL
6	I-CHEMICAL
,	I-CHEMICAL
7	I-CHEMICAL
,	I-CHEMICAL
13	I-CHEMICAL
-	I-CHEMICAL
tetrahydro	I-CHEMICAL
-	I-CHEMICAL
13	I-CHEMICAL
-	I-CHEMICAL
methyl	I-CHEMICAL
-	I-CHEMICAL
5	I-CHEMICAL
-	I-CHEMICAL
oxo	I-CHEMICAL
-	I-CHEMICAL
12H	I-CHEMICAL
-	I-CHEMICAL
indolo	I-CHEMICAL
[	I-CHEMICAL
2	I-CHEMICAL
,	I-CHEMICAL
3	I-CHEMICAL
-	I-CHEMICAL
a	I-CHEMICAL
]	I-CHEMICAL
pyrrolo	I-CHEMICAL
[	I-CHEMICAL
3	I-CHEMICAL
,	I-CHEMICAL
4c	I-CHEMICAL
]	I-CHEMICAL
carbazole	I-CHEMICAL
-	I-CHEMICAL
12	I-CHEMICAL
-	I-CHEMICAL
propanenitrile	I-CHEMICAL
(	O
G6976	B-CHEMICAL
)	O
.	O

This	O
further	O
characterization	O
of	O
DIR	O
indicates	O
that	O
cPKC	B-GENE-N
,	O
GRK2	B-GENE-Y
,	O
and	O
dynamin	B-GENE-N
play	O
important	O
roles	O
in	O
the	O
desensitization	O
of	O
D2	B-GENE-Y
receptors	O
.	O

As	O
drugs	O
of	O
abuse	O
produce	O
persistent	O
increases	O
in	O
DA	O
concentration	O
in	O
the	O
ventral	O
tegmental	O
area	O
,	O
reduction	O
of	O
D2	B-GENE-Y
receptor	I-GENE-Y
sensitivity	O
as	O
a	O
result	O
of	O
drug	O
abuse	O
may	O
be	O
a	O
critical	O
factor	O
in	O
the	O
processes	O
of	O
addiction	O
.	O

Differential	O
cell	O
-	O
protective	O
function	O
of	O
two	O
resveratrol	B-CHEMICAL
(	B-CHEMICAL
trans	I-CHEMICAL
-	I-CHEMICAL
3	I-CHEMICAL
,	I-CHEMICAL
5	I-CHEMICAL
,	I-CHEMICAL
4	I-CHEMICAL
'	I-CHEMICAL
-	I-CHEMICAL
trihydroxystilbene	I-CHEMICAL
)	I-CHEMICAL
glucosides	I-CHEMICAL
against	O
oxidative	O
stress	O
.	O

Resveratrol	B-CHEMICAL
(	O
trans	B-CHEMICAL
-	I-CHEMICAL
3	I-CHEMICAL
,	I-CHEMICAL
5	I-CHEMICAL
,	I-CHEMICAL
4	I-CHEMICAL
'	I-CHEMICAL
-	I-CHEMICAL
trihydroxystilbene	I-CHEMICAL
;	O
RSV	B-CHEMICAL
)	O
,	O
a	O
natural	O
polyphenol	B-CHEMICAL
,	O
exerts	O
a	O
beneficial	O
effect	O
on	O
health	O
and	O
diseases	O
.	O

RSV	B-CHEMICAL
targets	O
and	O
activates	O
the	O
NAD	B-GENE-Y
(	I-GENE-Y
+	I-GENE-Y
)	I-GENE-Y
-	I-GENE-Y
dependent	I-GENE-Y
protein	I-GENE-Y
deacetylase	I-GENE-Y
SIRT1	I-GENE-Y
;	O
in	O
turn	O
,	O
SIRT1	B-GENE-Y
induces	O
an	O
intracellular	O
antioxidative	O
mechanism	O
by	O
inducing	O
mitochondrial	B-GENE-Y
superoxide	I-GENE-Y
dismutase	I-GENE-Y
(	O
SOD2	B-GENE-Y
)	O
.	O

Most	O
RSV	O
found	O
in	O
plants	O
is	O
glycosylated	O
,	O
and	O
the	O
effect	O
of	O
these	O
glycosylated	O
forms	O
on	O
SIRT1	B-GENE-Y
has	O
not	O
been	O
studied	O
.	O

In	O
this	O
study	O
,	O
we	O
compared	O
the	O
effects	O
of	O
RSV	B-CHEMICAL
and	O
two	O
glycosyl	B-CHEMICAL
RSVs	I-CHEMICAL
,	O
resveratrol	B-CHEMICAL
-	I-CHEMICAL
3	I-CHEMICAL
-	I-CHEMICAL
O	I-CHEMICAL
-	I-CHEMICAL
	I-CHEMICAL
-	I-CHEMICAL
d	I-CHEMICAL
-	I-CHEMICAL
glucoside	I-CHEMICAL
(	O
3G	B-CHEMICAL
-	I-CHEMICAL
RSV	I-CHEMICAL
;	O
polydatin	B-CHEMICAL
/	O
piceid	B-CHEMICAL
)	O
and	O
resveratrol	B-CHEMICAL
-	I-CHEMICAL
4	I-CHEMICAL
'	I-CHEMICAL
-	I-CHEMICAL
O	I-CHEMICAL
-	I-CHEMICAL
	I-CHEMICAL
-	I-CHEMICAL
d	I-CHEMICAL
-	I-CHEMICAL
glucoside	I-CHEMICAL
(	O
4	B-CHEMICAL
'	I-CHEMICAL
G	I-CHEMICAL
-	I-CHEMICAL
RSV	I-CHEMICAL
)	O
,	O
at	O
the	O
cellular	O
level	O
.	O

In	O
oxygen	O
radical	O
absorbance	O
capacity	O
and	O
2	B-CHEMICAL
,	I-CHEMICAL
2	I-CHEMICAL
-	I-CHEMICAL
diphenyl	I-CHEMICAL
-	I-CHEMICAL
1	I-CHEMICAL
-	I-CHEMICAL
picrylhydrazyl	I-CHEMICAL
radical	O
scavenging	O
assays	O
,	O
the	O
antioxidant	O
activity	O
of	O
3G	B-CHEMICAL
-	I-CHEMICAL
RSV	I-CHEMICAL
was	O
comparable	O
to	O
that	O
of	O
RSV	B-CHEMICAL
,	O
whereas	O
the	O
radical	O
-	O
scavenging	O
efficiency	O
of	O
4	B-CHEMICAL
'	I-CHEMICAL
G	I-CHEMICAL
-	I-CHEMICAL
RSV	I-CHEMICAL
was	O
less	O
than	O
50	O
%	O
of	O
that	O
of	O
RSV	B-CHEMICAL
.	O

However	O
,	O
4	B-CHEMICAL
'	I-CHEMICAL
G	I-CHEMICAL
-	I-CHEMICAL
RSV	I-CHEMICAL
,	O
but	O
not	O
3G	B-CHEMICAL
-	I-CHEMICAL
RSV	I-CHEMICAL
,	O
induced	O
SIRT1	B-GENE-Y
-	O
dependent	O
histone	B-GENE-N
H3	I-GENE-N
deacetylation	O
and	O
SOD2	B-GENE-Y
expression	O
in	O
mouse	O
C2C12	O
skeletal	O
myoblasts	O
;	O
as	O
with	O
RSV	B-CHEMICAL
,	O
SIRT1	B-GENE-Y
knockdown	O
blunted	O
these	O
effects	O
.	O

RSV	B-CHEMICAL
and	O
4	B-CHEMICAL
'	I-CHEMICAL
G	I-CHEMICAL
-	I-CHEMICAL
RSV	I-CHEMICAL
,	O
but	O
not	O
3G	B-CHEMICAL
-	I-CHEMICAL
RSV	I-CHEMICAL
,	O
mitigated	O
oxidative	O
stress	O
-	O
induced	O
cell	O
death	O
in	O
C2C12	O
cells	O
and	O
primary	O
neonatal	O
rat	O
cardiomyocytes	O
.	O

RSV	B-CHEMICAL
and	O
4	B-CHEMICAL
'	I-CHEMICAL
G	I-CHEMICAL
-	I-CHEMICAL
RSV	I-CHEMICAL
inhibited	O
C2C12	O
cell	O
proliferation	O
,	O
but	O
3G	B-CHEMICAL
-	I-CHEMICAL
RSV	I-CHEMICAL
did	O
not	O
.	O

RSV	B-CHEMICAL
was	O
found	O
in	O
both	O
the	O
intracellular	O
and	O
extracellular	O
fractions	O
of	O
C2C12	O
cells	O
that	O
had	O
been	O
incubated	O
with	O
4	B-CHEMICAL
'	I-CHEMICAL
G	I-CHEMICAL
-	I-CHEMICAL
RSV	I-CHEMICAL
,	O
indicating	O
that	O
4	B-CHEMICAL
'	I-CHEMICAL
G	I-CHEMICAL
-	I-CHEMICAL
RSV	I-CHEMICAL
was	O
extracellularly	O
deglycosylated	O
to	O
RSV	B-CHEMICAL
,	O
which	O
was	O
then	O
taken	O
up	O
by	O
the	O
cells	O
.	O

C2C12	O
cells	O
did	O
not	O
deglycosylate	O
3G	B-CHEMICAL
-	I-CHEMICAL
RSV	I-CHEMICAL
.	O

Our	O
results	O
point	O
to	O
4	B-CHEMICAL
'	I-CHEMICAL
G	I-CHEMICAL
-	I-CHEMICAL
RSV	I-CHEMICAL
as	O
a	O
useful	O
RSV	B-CHEMICAL
prodrug	O
with	O
high	O
water	O
solubility	O
.	O

These	O
data	O
also	O
show	O
that	O
the	O
in	O
vitro	O
antioxidative	O
activity	O
of	O
these	O
molecules	O
did	O
not	O
correlate	O
with	O
their	O
ability	O
to	O
protect	O
cells	O
from	O
oxidative	O
stress	O
-	O
induced	O
apoptosis	O
.	O

Hydrophobic	O
amino	B-CHEMICAL
acids	I-CHEMICAL
in	O
the	O
hinge	O
region	O
of	O
the	O
5A	B-GENE-Y
apolipoprotein	I-GENE-Y
mimetic	O
peptide	O
are	O
essential	O
for	O
promoting	O
cholesterol	B-CHEMICAL
efflux	O
by	O
the	O
ABCA1	B-GENE-Y
transporter	O
.	O

The	O
bihelical	O
apolipoprotein	B-GENE-Y
mimetic	I-GENE-Y
peptide	I-GENE-Y
5A	I-GENE-Y
effluxes	O
cholesterol	B-CHEMICAL
from	O
cells	O
and	O
reduces	O
inflammation	O
and	O
atherosclerosis	O
in	O
animal	O
models	O
.	O

We	O
investigated	O
how	O
hydrophobic	O
residues	O
in	O
the	O
hinge	O
region	O
between	O
the	O
two	O
helices	O
are	O
important	O
in	O
the	O
structure	O
and	O
function	O
of	O
this	O
peptide	O
.	O

By	O
simulated	O
annealing	O
analysis	O
and	O
molecular	O
dynamics	O
modeling	O
,	O
two	O
hydrophobic	O
amino	B-CHEMICAL
acids	I-CHEMICAL
,	O
F	O
-	O
18	O
and	O
W	O
-	O
21	O
,	O
in	O
the	O
hinge	O
region	O
were	O
predicted	O
to	O
be	O
relatively	O
surface	O
-	O
exposed	O
and	O
to	O
interact	O
with	O
the	O
aqueous	O
solvent	O
.	O

Using	O
a	O
series	O
of	O
5A	O
peptide	O
analogs	O
in	O
which	O
F	O
-	O
18	O
or	O
W	O
-	O
21	O
was	O
changed	O
to	O
either	O
F	O
,	O
W	O
,	O
A	O
,	O
or	O
E	O
,	O
only	O
peptides	O
with	O
hydrophobic	O
amino	B-CHEMICAL
acids	I-CHEMICAL
in	O
these	O
two	O
positions	O
were	O
able	O
to	O
readily	O
bind	O
and	O
solubilize	O
phospholipid	O
vesicles	O
.	O

Compared	O
with	O
active	O
peptides	O
containing	O
F	O
or	O
W	O
,	O
peptides	O
containing	O
E	O
in	O
either	O
of	O
these	O
two	O
positions	O
were	O
more	O
than	O
10	O
-	O
fold	O
less	O
effective	O
in	O
effluxing	O
cholesterol	B-CHEMICAL
by	O
the	O
ABCA1	B-GENE-Y
transporter	O
.	O

Intravenous	O
injection	O
of	O
5A	O
in	O
C57BL	O
/	O
6	O
mice	O
increased	O
plasma	O
-	O
free	O
cholesterol	B-CHEMICAL
(	O
5A	O
:	O
89	O
.	O
9	O
	O
13	O
.	O
6	O
mg	O
/	O
dl	O
;	O
control	O
:	O
38	O
.	O
7	O
	O
4	O
.	O
3	O
mg	O
/	O
dl	O
(	O
mean	O
	O
S	O
.	O
D	O
.	O
)	O
;	O
P	O
<	O
0	O
.	O
05	O
)	O
and	O
triglycerides	B-CHEMICAL
(	O
5A	O
:	O
887	O
.	O
0	O
	O
172	O
.	O
0	O
mg	O
/	O
dl	O
;	O
control	O
:	O
108	O
.	O
9	O
	O
9	O
.	O
9	O
mg	O
/	O
dl	O
;	O
P	O
<	O
0	O
.	O
05	O
)	O
,	O
whereas	O
the	O
EE	O
peptide	O
containing	O
E	O
in	O
both	O
positions	O
had	O
no	O
effect	O
.	O

Finally	O
,	O
5A	O
increased	O
cholesterol	B-CHEMICAL
efflux	O
approximately	O
2	O
.	O
5	O
-	O
fold	O
in	O
vivo	O
from	O
radiolabeled	O
macrophages	O
,	O
whereas	O
the	O
EE	O
peptide	O
was	O
inactive	O
.	O

These	O
results	O
provide	O
a	O
rationale	O
for	O
future	O
design	O
of	O
therapeutic	O
apolipoprotein	B-GENE-N
mimetic	O
peptides	O
and	O
provide	O
new	O
insights	O
into	O
the	O
interaction	O
of	O
hydrophobic	O
residues	O
on	O
apolipoproteins	O
with	O
phospholipids	O
in	O
the	O
lipid	O
microdomain	O
created	O
by	O
the	O
ABCA1	B-GENE-Y
transporter	O
during	O
the	O
cholesterol	B-CHEMICAL
efflux	O
process	O
.	O

Efficacy	O
of	O
the	O
GluK1	B-GENE-Y
/	O
AMPA	B-GENE-N
receptor	I-GENE-N
antagonist	O
LY293558	B-CHEMICAL
against	O
seizures	O
and	O
neuropathology	O
in	O
a	O
soman	O
-	O
exposure	O
model	O
without	O
pretreatment	O
and	O
its	O
pharmacokinetics	O
after	O
intramuscular	O
administration	O
.	O

Control	O
of	O
brain	O
seizures	O
after	O
exposure	O
to	O
nerve	O
agents	O
is	O
imperative	O
for	O
the	O
prevention	O
of	O
brain	O
damage	O
and	O
death	O
.	O

Animal	O
models	O
of	O
nerve	O
agent	O
exposure	O
make	O
use	O
of	O
pretreatments	O
,	O
or	O
medication	O
administered	O
within	O
1	O
minute	O
after	O
exposure	O
,	O
in	O
order	O
to	O
prevent	O
rapid	O
death	O
from	O
peripheral	O
toxic	O
effects	O
and	O
respiratory	O
failure	O
,	O
which	O
then	O
allows	O
the	O
testing	O
of	O
anticonvulsant	O
compounds	O
.	O

However	O
,	O
in	O
a	O
real	O
-	O
case	O
scenario	O
of	O
an	O
unexpected	O
attack	O
with	O
nerve	O
agents	O
,	O
pretreatment	O
would	O
not	O
be	O
possible	O
,	O
and	O
medical	O
assistance	O
may	O
not	O
be	O
available	O
immediately	O
.	O

To	O
determine	O
if	O
control	O
of	O
seizures	O
and	O
survival	O
are	O
still	O
possible	O
without	O
pretreatment	O
or	O
immediate	O
pharmacologic	O
intervention	O
,	O
we	O
studied	O
the	O
anticonvulsant	O
efficacy	O
of	O
the	O
GluK1	B-GENE-Y
(	O
GluR5	B-GENE-Y
)	O
/	O
	B-GENE-N
-	I-GENE-N
amino	I-GENE-N
-	I-GENE-N
3	I-GENE-N
-	I-GENE-N
hydroxy	I-GENE-N
-	I-GENE-N
5	I-GENE-N
-	I-GENE-N
methyl	I-GENE-N
-	I-GENE-N
4	I-GENE-N
-	I-GENE-N
isoxazolepropionic	I-GENE-N
acid	I-GENE-N
(	I-GENE-N
AMPA	I-GENE-N
)	I-GENE-N
receptor	I-GENE-N
antagonist	O
(	B-CHEMICAL
3S	I-CHEMICAL
,	I-CHEMICAL
4aR	I-CHEMICAL
,	I-CHEMICAL
6R	I-CHEMICAL
,	I-CHEMICAL
8aR	I-CHEMICAL
)	I-CHEMICAL
-	I-CHEMICAL
6	I-CHEMICAL
-	I-CHEMICAL
[	I-CHEMICAL
2	I-CHEMICAL
-	I-CHEMICAL
(	I-CHEMICAL
1	I-CHEMICAL
(	I-CHEMICAL
2	I-CHEMICAL
)	I-CHEMICAL
H	I-CHEMICAL
-	I-CHEMICAL
tetrazole	I-CHEMICAL
-	I-CHEMICAL
5	I-CHEMICAL
-	I-CHEMICAL
yl	I-CHEMICAL
)	I-CHEMICAL
ethyl	I-CHEMICAL
]	I-CHEMICAL
decahydroisoquinoline	I-CHEMICAL
-	I-CHEMICAL
3	I-CHEMICAL
-	I-CHEMICAL
carboxylic	I-CHEMICAL
acid	I-CHEMICAL
(	O
LY293558	B-CHEMICAL
)	O
in	O
rats	O
that	O
did	O
not	O
receive	O
any	O
treatment	O
until	O
20	O
minutes	O
after	O
exposure	O
to	O
the	O
nerve	O
agent	O
soman	O
.	O

We	O
injected	O
LY293558	B-CHEMICAL
intramuscularly	O
,	O
as	O
this	O
would	O
be	O
the	O
most	O
likely	O
route	O
of	O
administration	O
to	O
humans	O
.	O

LY293558	B-CHEMICAL
(	O
15	O
mg	O
/	O
kg	O
)	O
,	O
injected	O
along	O
with	O
atropine	O
and	O
the	O
oxime	B-CHEMICAL
HI	B-CHEMICAL
-	I-CHEMICAL
6	I-CHEMICAL
at	O
20	O
minutes	O
after	O
soman	O
exposure	O
,	O
stopped	O
seizures	O
and	O
increased	O
survival	O
rate	O
from	O
64	O
%	O
to	O
100	O
%	O
.	O

LY293558	B-CHEMICAL
also	O
prevented	O
neuronal	O
loss	O
in	O
the	O
amygdala	O
and	O
hippocampus	O
,	O
and	O
reduced	O
neurodegeneration	O
in	O
a	O
number	O
of	O
brain	O
regions	O
studied	O
7	O
days	O
after	O
soman	O
exposure	O
.	O

Analysis	O
of	O
the	O
LY293558	B-CHEMICAL
pharmacokinetics	O
after	O
intramuscular	O
administration	O
showed	O
that	O
this	O
compound	O
readily	O
crosses	O
the	O
blood	O
-	O
brain	O
barrier	O
.	O

There	O
was	O
good	O
correspondence	O
between	O
the	O
time	O
course	O
of	O
seizure	O
suppression	O
by	O
LY293558	B-CHEMICAL
and	O
the	O
brain	O
levels	O
of	O
the	O
compound	O
.	O

Overexpression	O
of	O
H1	B-GENE-Y
calponin	I-GENE-Y
in	O
osteoblast	O
lineage	O
cells	O
leads	O
to	O
a	O
decrease	O
in	O
bone	O
mass	O
by	O
disrupting	O
osteoblast	O
function	O
and	O
promoting	O
osteoclast	O
formation	O
.	O

H1	B-GENE-Y
calponin	I-GENE-Y
(	O
CNN1	B-GENE-Y
)	O
is	O
known	O
as	O
a	O
smooth	O
muscle	O
-	O
specific	O
,	O
actin	B-GENE-N
-	O
binding	O
protein	O
which	O
regulates	O
smooth	O
muscle	O
contractive	O
activity	O
.	O

Although	O
previous	O
studies	O
have	O
shown	O
that	O
CNN1	B-GENE-Y
has	O
effect	O
on	O
bone	O
,	O
the	O
mechanism	O
is	O
not	O
well	O
defined	O
.	O

To	O
investigate	O
the	O
role	O
of	O
CNN1	B-GENE-Y
in	O
maintaining	O
bone	O
homeostasis	O
,	O
we	O
generated	O
transgenic	O
mice	O
overexpressing	O
Cnn1	B-GENE-Y
under	O
the	O
control	O
of	O
the	O
osteoblast	O
-	O
specific	O
3	O
.	O
6	O
-	O
kb	O
Col1a1	B-GENE-N
promoter	I-GENE-N
.	O

Col1a1	B-GENE-Y
-	O
Cnn1	B-GENE-Y
transgenic	O
mice	O
showed	O
delayed	O
bone	O
formation	O
at	O
embryonic	O
stage	O
and	O
decreased	O
bone	O
mass	O
at	O
adult	O
stage	O
.	O

Morphology	O
analyses	O
showed	O
reduced	O
trabecular	O
number	O
,	O
thickness	O
and	O
defects	O
in	O
bone	O
formation	O
.	O

The	O
proliferation	O
and	O
migration	O
of	O
osteoblasts	O
were	O
decreased	O
in	O
Col1a1	B-GENE-Y
-	O
Cnn1	B-GENE-Y
mice	O
due	O
to	O
alterations	O
in	O
cytoskeleton	O
.	O

The	O
early	O
osteoblast	O
differentiation	O
of	O
Col1a1	B-GENE-Y
-	O
Cnn1	B-GENE-Y
mice	O
was	O
increased	O
,	O
but	O
the	O
late	O
stage	O
differentiation	O
and	O
mineralization	O
of	O
osteoblasts	O
derived	O
from	O
Col1a1	B-GENE-Y
-	O
Cnn1	B-GENE-Y
mice	O
were	O
significantly	O
decreased	O
.	O

In	O
addition	O
to	O
impaired	O
bone	O
formation	O
,	O
the	O
decreased	O
bone	O
mass	O
was	O
also	O
associated	O
with	O
enhanced	O
osteoclastogenesis	O
.	O

Tartrate	B-GENE-Y
-	I-GENE-Y
resistant	I-GENE-Y
acid	I-GENE-Y
phosphatase	I-GENE-Y
(	O
TRAP	B-GENE-Y
)	O
staining	O
revealed	O
increased	O
osteoclast	O
numbers	O
in	O
tibias	O
of	O
2	O
-	O
month	O
-	O
old	O
Col1a1	B-GENE-Y
-	O
Cnn1	B-GENE-Y
mice	O
,	O
and	O
increased	O
numbers	O
of	O
osteoclasts	O
co	O
-	O
cultured	O
with	O
Col1a1	B-GENE-Y
-	O
Cnn1	B-GENE-Y
osteoblasts	O
.	O

The	O
ratio	O
of	O
RANKL	B-GENE-Y
to	O
OPG	B-GENE-Y
was	O
significantly	O
increased	O
in	O
Col1a1	B-GENE-Y
-	O
Cnn1	B-GENE-Y
osteoblasts	O
.	O

These	O
findings	O
reveal	O
a	O
novel	O
function	O
of	O
CNN1	B-GENE-Y
in	O
maintaining	O
bone	O
homeostasis	O
by	O
coupling	O
bone	O
formation	O
to	O
bone	O
resorption	O
.	O

Characterisation	O
of	O
acetylcholinesterase	B-GENE-N
release	O
from	O
neuronal	O
cells	O
.	O

Although	O
acetylcholinesterase	B-GENE-Y
(	O
AChE	B-GENE-Y
)	O
is	O
primarily	O
a	O
hydrolytic	O
enzyme	O
,	O
metabolising	O
the	O
neurotransmitter	O
acetylcholine	B-CHEMICAL
in	O
cholinergic	O
synapses	O
,	O
it	O
also	O
has	O
some	O
non	O
-	O
catalytic	O
functions	O
in	O
the	O
brain	O
which	O
are	O
far	O
less	O
well	O
characterised	O
.	O

AChE	B-GENE-Y
was	O
shown	O
to	O
be	O
secreted	O
or	O
shed	O
from	O
the	O
neuronal	O
cell	O
surface	O
like	O
several	O
other	O
membrane	O
proteins	O
,	O
such	O
as	O
the	O
amyloid	B-GENE-Y
precursor	I-GENE-Y
protein	I-GENE-Y
(	O
APP	B-GENE-Y
)	O
.	O

Since	O
AChE	B-GENE-Y
does	O
not	O
possess	O
a	O
transmembrane	B-GENE-N
domain	I-GENE-N
,	O
its	O
anchorage	O
in	O
the	O
membrane	O
is	O
established	O
via	O
the	O
Proline	B-GENE-Y
Rich	I-GENE-Y
Membrane	I-GENE-Y
Anchor	I-GENE-Y
(	O
PRiMA	B-GENE-Y
)	O
,	O
a	O
transmembrane	O
protein	O
.	O

Both	O
the	O
subunit	O
oligomerisation	O
and	O
membrane	O
anchor	O
of	O
AChE	B-GENE-Y
are	O
shared	O
by	O
a	O
related	O
enzyme	O
,	O
butyrylcholinesterase	B-GENE-Y
(	O
BChE	B-GENE-Y
)	O
,	O
the	O
physiological	O
function	O
of	O
which	O
in	O
the	O
brain	O
is	O
unclear	O
.	O

In	O
this	O
work	O
,	O
we	O
have	O
assayed	O
the	O
relative	O
activities	O
of	O
AChE	B-GENE-Y
and	O
BChE	B-GENE-Y
in	O
membrane	O
fractions	O
and	O
culture	O
medium	O
of	O
three	O
different	O
neuronal	O
cell	O
lines	O
,	O
namely	O
the	O
neuroblastoma	O
cell	O
lines	O
SH	O
-	O
SY5Y	O
and	O
NB7	O
and	O
the	O
mouse	O
basal	O
forebrain	O
cell	O
line	O
SN56	O
.	O

In	O
an	O
effort	O
to	O
understand	O
the	O
shedding	O
process	O
of	O
AChE	B-GENE-Y
,	O
we	O
have	O
used	O
several	O
pharmacological	O
treatments	O
,	O
which	O
showed	O
that	O
it	O
is	O
likely	O
to	O
be	O
mediated	O
in	O
part	O
by	O
an	O
EDTA	B-CHEMICAL
-	O
and	O
batimastat	B-CHEMICAL
-	O
sensitive	O
,	O
but	O
GM6001	B-CHEMICAL
-	O
insensitive	O
metalloprotease	B-GENE-N
,	O
with	O
the	O
possible	O
additional	O
involvement	O
of	O
a	O
thiol	B-GENE-N
isomerase	I-GENE-N
.	O

Cellular	O
release	O
of	O
AChE	B-GENE-Y
by	O
SH	O
-	O
SY5Y	O
is	O
significantly	O
enhanced	O
by	O
the	O
muscarinic	B-GENE-N
acetylcholine	I-GENE-N
receptor	I-GENE-N
(	O
mAChR	B-GENE-N
)	O
agonists	O
carbachol	B-CHEMICAL
or	O
muscarine	B-CHEMICAL
,	O
with	O
the	O
effect	O
of	O
carbachol	B-CHEMICAL
blocked	O
by	O
the	O
mAChR	B-GENE-N
antagonist	O
atropine	B-CHEMICAL
.	O

AChE	B-GENE-Y
has	O
been	O
implicated	O
in	O
the	O
pathogenesis	O
of	O
Alzheimer	O
'	O
s	O
disease	O
and	O
it	O
has	O
been	O
shown	O
that	O
it	O
accelerates	O
formation	O
and	O
increases	O
toxicity	O
of	O
amyloid	B-GENE-Y
fibrils	I-GENE-Y
,	O
which	O
have	O
been	O
closely	O
linked	O
to	O
the	O
pathology	O
of	O
AD	O
.	O

In	O
light	O
of	O
this	O
,	O
greater	O
understanding	O
of	O
AChE	B-GENE-Y
and	O
BChE	B-GENE-Y
physiology	O
may	O
also	O
benefit	O
AD	O
research	O
.	O

Circulating	O
very	O
-	O
low	B-GENE-N
-	I-GENE-N
density	I-GENE-N
lipoprotein	I-GENE-N
from	O
subjects	O
with	O
impaired	O
glucose	B-CHEMICAL
tolerance	O
accelerates	O
adrenocortical	O
cortisol	B-CHEMICAL
and	O
aldosterone	B-CHEMICAL
synthesis	O
.	O

Apart	O
from	O
their	O
role	O
in	O
cardiovascular	O
homeostasis	O
and	O
immunomodulation	O
,	O
aldosterone	B-CHEMICAL
and	O
cortisol	B-CHEMICAL
are	O
also	O
implicated	O
in	O
the	O
pathogenesis	O
of	O
insulin	B-GENE-Y
resistance	O
and	O
type	O
2	O
diabetes	O
mellitus	O
(	O
T2DM	O
)	O
.	O

Furthermore	O
,	O
glycoxidative	O
modifications	O
of	O
lipoproteins	O
are	O
increasingly	O
recognized	O
as	O
an	O
etiological	O
factor	O
for	O
increased	O
cardiovascular	O
morbidity	O
and	O
mortality	O
in	O
prediabetic	O
individuals	O
.	O

The	O
causative	O
relationship	O
between	O
in	O
vivo	O
lipoprotein	O
modifications	O
and	O
steroidogenesis	O
in	O
subjects	O
with	O
impaired	O
glucose	B-CHEMICAL
tolerance	O
(	O
IGT	O
)	O
,	O
however	O
,	O
is	O
not	O
well	O
defined	O
.	O

Therefore	O
,	O
we	O
aimed	O
to	O
investigate	O
the	O
impact	O
of	O
in	O
vivo	O
modified	O
lipoproteins	O
on	O
aldosterone	B-CHEMICAL
and	O
cortisol	B-CHEMICAL
release	O
from	O
human	O
adrenocortical	O
H295R	O
cells	O
.	O

Following	O
an	O
oral	O
glucose	B-CHEMICAL
tolerance	O
test	O
,	O
20	O
individuals	O
with	O
normal	O
glucose	B-CHEMICAL
tolerance	O
(	O
NGT	O
)	O
and	O
20	O
IGT	O
subjects	O
were	O
randomly	O
selected	O
from	O
the	O
ongoing	O
PRAEDIAS	O
prevention	O
study	O
in	O
our	O
department	O
.	O

Cells	O
were	O
incubated	O
for	O
24	O
h	O
with	O
lipoproteins	O
isolated	O
from	O
NGT	O
and	O
IGT	O
individuals	O
and	O
aldosterone	B-CHEMICAL
and	O
cortisol	B-CHEMICAL
release	O
was	O
measured	O
in	O
the	O
supernatants	O
.	O

VLDL	B-GENE-N
induced	O
a	O
greater	O
stimulating	O
effect	O
on	O
adrenocortical	O
aldosterone	B-CHEMICAL
and	O
cortisol	B-CHEMICAL
release	O
compared	O
to	O
HDL	B-GENE-N
and	O
LDL	B-GENE-N
.	O

Moreover	O
,	O
IGT	O
-	O
VLDL	B-GENE-N
evoked	O
a	O
significantly	O
higher	O
effect	O
(	O
p	O
<	O
0	O
.	O
05	O
)	O
on	O
hormone	O
release	O
than	O
NGT	O
-	O
VLDL	B-GENE-N
.	O

Incubation	O
of	O
cells	O
with	O
in	O
vitro	O
modified	O
lipoproteins	O
and	O
specific	O
pharmacological	O
inhibitors	O
suggests	O
that	O
VLDL	B-GENE-N
presumably	O
recruits	O
ERK1	B-GENE-N
/	I-GENE-N
2	I-GENE-N
as	O
one	O
of	O
the	O
downstream	O
effectors	O
of	O
Jak	B-GENE-Y
-	I-GENE-Y
2	I-GENE-Y
.	O

In	O
summary	O
,	O
in	O
vivo	O
modified	O
VLDL	B-GENE-N
are	O
able	O
to	O
promote	O
prediabetic	O
hormonal	O
dysregulation	O
by	O
modulating	O
adrenocortical	O
steroidogenesis	O
via	O
Jak	B-GENE-Y
-	I-GENE-Y
2	I-GENE-Y
-	O
ERK	B-GENE-N
dependent	O
pathway	O
.	O

L	B-CHEMICAL
-	I-CHEMICAL
BMAA	I-CHEMICAL
induced	O
ER	O
stress	O
and	O
enhanced	O
caspase	B-GENE-Y
12	I-GENE-Y
cleavage	O
in	O
human	O
neuroblastoma	O
SH	O
-	O
SY5Y	O
cells	O
at	O
low	O
nonexcitotoxic	O
concentrations	O
.	O

The	O
cyanobacterial	O
	B-CHEMICAL
-	I-CHEMICAL
N	I-CHEMICAL
-	I-CHEMICAL
methylamino	I-CHEMICAL
-	I-CHEMICAL
L	I-CHEMICAL
-	I-CHEMICAL
alanine	I-CHEMICAL
(	O
L	B-CHEMICAL
-	I-CHEMICAL
BMAA	I-CHEMICAL
)	O
is	O
described	O
as	O
a	O
low	O
-	O
potency	O
excitotoxin	O
,	O
possibly	O
a	O
factor	O
in	O
the	O
increased	O
incidence	O
of	O
amyotrophic	O
lateral	O
sclerosis	O
(	O
ALS	O
)	O
and	O
Parkinsonism	O
-	O
dementia	O
complex	O
(	O
PDC	O
)	O
in	O
Guam	O
.	O

The	O
latter	O
association	O
is	O
intensively	O
disputed	O
,	O
as	O
L	B-CHEMICAL
-	I-CHEMICAL
BMAA	I-CHEMICAL
concentrations	O
required	O
for	O
toxic	O
effects	O
exceed	O
those	O
assumed	O
to	O
occur	O
via	O
food	O
.	O

The	O
question	O
thus	O
was	O
raised	O
whether	O
L	B-CHEMICAL
-	I-CHEMICAL
BMAA	I-CHEMICAL
leads	O
to	O
neurodegeneration	O
at	O
nonexcitotoxic	O
conditions	O
.	O

Using	O
human	O
SH	O
-	O
SY5Y	O
neuroblastoma	O
cells	O
,	O
L	B-CHEMICAL
-	I-CHEMICAL
BMAA	I-CHEMICAL
-	O
transport	O
,	O
incorporation	O
into	O
proteins	O
,	O
and	O
subsequent	O
impairment	O
of	O
cellular	O
protein	O
homeostasis	O
were	O
investigated	O
.	O

Binding	O
of	O
L	B-CHEMICAL
-	I-CHEMICAL
BMAA	I-CHEMICAL
to	O
intracellular	O
proteins	O
,	O
but	O
no	O
clear	O
protein	O
incorporation	O
was	O
detected	O
in	O
response	O
to	O
(	B-CHEMICAL
14	I-CHEMICAL
)	I-CHEMICAL
C	I-CHEMICAL
-	O
L	B-CHEMICAL
-	I-CHEMICAL
BMAA	I-CHEMICAL
exposures	O
.	O

Nevertheless	O
,	O
low	O
L	B-CHEMICAL
-	I-CHEMICAL
BMAA	I-CHEMICAL
concentrations	O
(	O
	O
0	O
.	O
1mM	O
,	O
48	O
h	O
)	O
increased	O
protein	O
ubiquitination	O
,	O
20S	B-GENE-N
proteasomal	I-GENE-N
and	O
caspase	B-GENE-Y
12	I-GENE-Y
activity	O
,	O
expression	O
of	O
the	O
endoplasmic	O
reticulum	O
(	O
ER	O
)	O
stress	O
marker	O
CHOP	B-GENE-Y
,	O
and	O
enhanced	O
phosphorylation	O
of	O
elf2	B-GENE-Y
in	O
SH	O
-	O
SY5Y	O
cells	O
.	O

In	O
contrast	O
,	O
high	O
L	B-CHEMICAL
-	I-CHEMICAL
BMAA	I-CHEMICAL
concentrations	O
(	O
	O
1mM	O
,	O
48	O
h	O
)	O
increased	O
reactive	O
oxygen	B-CHEMICAL
species	O
and	O
protein	O
oxidization	O
,	O
which	O
were	O
partially	O
ameliorated	O
by	O
coincubation	O
with	O
vitamin	B-CHEMICAL
E	I-CHEMICAL
.	O

L	B-CHEMICAL
-	I-CHEMICAL
BMAA	I-CHEMICAL
-	O
mediated	O
cytotoxicity	O
was	O
observable	O
48	O
h	O
following	O
	O
2mM	O
L	B-CHEMICAL
-	I-CHEMICAL
BMAA	I-CHEMICAL
treatment	O
.	O

Consequently	O
,	O
the	O
data	O
presented	O
here	O
suggest	O
that	O
low	O
L	B-CHEMICAL
-	I-CHEMICAL
BMAA	I-CHEMICAL
concentrations	O
result	O
in	O
a	O
dysregulation	O
of	O
the	O
cellular	O
protein	O
homeostasis	O
with	O
ensuing	O
ER	O
stress	O
that	O
is	O
independent	O
from	O
high	O
-	O
concentration	O
effects	O
such	O
as	O
excitotoxicity	O
and	O
oxidative	O
stress	O
.	O

Thus	O
,	O
the	O
latter	O
could	O
be	O
a	O
contributing	O
factor	O
in	O
the	O
onset	O
and	O
slow	O
progression	O
of	O
ALS	O
/	O
PDC	O
in	O
Guam	O
.	O

Ribavirin	B-CHEMICAL
-	O
induced	O
intracellular	O
GTP	B-CHEMICAL
depletion	O
activates	O
transcription	O
elongation	O
in	O
coagulation	B-GENE-Y
factor	I-GENE-Y
VII	I-GENE-Y
gene	O
expression	O
.	O

Coagulation	B-GENE-Y
FVII	I-GENE-Y
(	O
Factor	B-GENE-Y
VII	I-GENE-Y
)	O
is	O
a	O
vitamin	B-CHEMICAL
K	I-CHEMICAL
-	O
dependent	O
glycoprotein	O
synthesized	O
in	O
hepatocytes	O
.	O

It	O
was	O
reported	O
previously	O
that	O
FVII	B-GENE-Y
gene	O
(	O
F7	B-GENE-Y
)	O
expression	O
was	O
up	O
-	O
regulated	O
by	O
ribavirin	B-CHEMICAL
treatment	O
in	O
hepatitis	O
C	O
virus	O
-	O
infected	O
haemophilia	O
patients	O
;	O
however	O
,	O
its	O
precise	O
mechanism	O
is	O
still	O
unknown	O
.	O

In	O
the	O
present	O
study	O
,	O
we	O
investigated	O
the	O
molecular	O
mechanism	O
of	O
ribavirin	B-CHEMICAL
-	O
induced	O
up	O
-	O
regulation	O
of	O
F7	B-GENE-Y
expression	O
in	O
HepG2	O
(	O
human	O
hepatoma	O
cell	O
line	O
)	O
.	O

We	O
found	O
that	O
intracellular	O
GTP	B-CHEMICAL
depletion	O
by	O
ribavirin	B-CHEMICAL
as	O
well	O
as	O
other	O
IMPDH	B-GENE-N
(	O
inosine	B-GENE-N
-	I-GENE-N
5	I-GENE-N
'	I-GENE-N
-	I-GENE-N
monophosphate	I-GENE-N
dehydrogenase	I-GENE-N
)	O
inhibitors	O
,	O
such	O
as	O
mycophenolic	B-CHEMICAL
acid	I-CHEMICAL
and	O
6	B-CHEMICAL
-	I-CHEMICAL
mercaptopurine	I-CHEMICAL
,	O
up	O
-	O
regulated	O
F7	B-GENE-Y
expression	O
.	O

FVII	B-GENE-Y
mRNA	O
transcription	O
was	O
mainly	O
enhanced	O
by	O
accelerated	O
transcription	O
elongation	O
,	O
which	O
was	O
mediated	O
by	O
the	O
P	B-GENE-N
-	I-GENE-N
TEFb	I-GENE-N
(	O
positive	B-GENE-N
-	I-GENE-N
transcription	I-GENE-N
elongation	I-GENE-N
factor	I-GENE-N
b	I-GENE-N
)	O
complex	O
,	O
rather	O
than	O
by	O
promoter	O
activation	O
.	O

Ribavirin	B-CHEMICAL
unregulated	O
ELL	B-GENE-Y
(	O
eleven	B-GENE-Y
-	I-GENE-Y
nineteen	I-GENE-Y
lysine	I-GENE-Y
-	I-GENE-Y
rich	I-GENE-Y
leukaemia	I-GENE-Y
)	I-GENE-Y
3	I-GENE-Y
mRNA	O
expression	O
before	O
F7	B-GENE-Y
up	O
-	O
regulation	O
.	O

We	O
observed	O
that	O
ribavirin	B-CHEMICAL
enhanced	O
ELL3	B-GENE-Y
recruitment	O
to	O
F7	B-GENE-Y
,	O
whereas	O
knockdown	O
of	O
ELL3	B-GENE-Y
diminished	O
ribavirin	B-CHEMICAL
-	O
induced	O
FVII	B-GENE-Y
mRNA	O
up	O
-	O
regulation	O
.	O

Ribavirin	B-CHEMICAL
also	O
enhanced	O
recruitment	O
of	O
CDK9	B-GENE-Y
(	O
cyclin	B-GENE-Y
-	I-GENE-Y
dependent	I-GENE-Y
kinase	I-GENE-Y
9	I-GENE-Y
)	O
and	O
AFF4	B-GENE-Y
to	O
F7	B-GENE-Y
.	O

These	O
data	O
suggest	O
that	O
ribavirin	B-CHEMICAL
-	O
induced	O
intracellular	O
GTP	B-CHEMICAL
depletion	O
recruits	O
a	O
super	O
elongation	O
complex	O
containing	O
P	B-GENE-N
-	I-GENE-N
TEFb	I-GENE-N
,	O
AFF4	B-GENE-Y
and	O
ELL3	B-GENE-Y
,	O
to	O
F7	B-GENE-Y
,	O
and	O
modulates	O
FVII	B-GENE-Y
mRNA	O
transcription	O
elongation	O
.	O

Collectively	O
,	O
we	O
have	O
elucidated	O
a	O
basal	O
mechanism	O
for	O
ribavirin	B-CHEMICAL
-	O
induced	O
FVII	B-GENE-Y
mRNA	O
up	O
-	O
regulation	O
by	O
acceleration	O
of	O
transcription	O
elongation	O
,	O
which	O
may	O
be	O
crucial	O
in	O
understanding	O
its	O
pleiotropic	O
functions	O
in	O
vivo	O
.	O

Neuropeptide	B-GENE-Y
Y	I-GENE-Y
Y1	I-GENE-Y
receptor	I-GENE-Y
knockdown	O
can	O
modify	O
glutathione	B-GENE-N
peroxidase	I-GENE-N
and	O
c	B-GENE-N
-	I-GENE-N
AMP	I-GENE-N
response	I-GENE-N
element	I-GENE-N
-	I-GENE-N
binding	I-GENE-N
protein	I-GENE-N
in	O
phenylpropanolamine	B-CHEMICAL
-	O
treated	O
rats	O
.	O

It	O
has	O
been	O
reported	O
that	O
antioxidative	O
enzymes	O
,	O
neuropeptide	B-GENE-Y
Y	I-GENE-Y
(	O
NPY	B-GENE-Y
)	O
,	O
and	O
c	B-GENE-N
-	I-GENE-N
AMP	I-GENE-N
response	I-GENE-N
element	I-GENE-N
-	I-GENE-N
binding	I-GENE-N
protein	I-GENE-N
(	O
CREB	B-GENE-N
)	O
are	O
involved	O
in	O
regulating	O
phenylpropanolamine	B-CHEMICAL
(	O
PPA	B-CHEMICAL
)	O
-	O
mediated	O
appetite	O
suppression	O
.	O

Here	O
,	O
we	O
investigated	O
whether	O
Y1	B-GENE-Y
receptor	I-GENE-Y
(	O
Y1R	B-GENE-Y
)	O
might	O
be	O
involved	O
in	O
this	O
regulation	O
.	O

Rats	O
were	O
daily	O
treated	O
with	O
PPA	B-CHEMICAL
for	O
4	O
days	O
.	O

Changes	O
in	O
the	O
contents	O
of	O
NPY	B-GENE-Y
,	O
Y1R	B-GENE-Y
,	O
glutathione	B-GENE-N
peroxidase	I-GENE-N
(	O
GP	B-GENE-N
)	O
,	O
and	O
CREB	B-GENE-N
were	O
assessed	O
and	O
compared	O
.	O

Results	O
showed	O
that	O
Y1R	B-GENE-Y
,	O
GP	B-GENE-N
,	O
and	O
CREB	B-GENE-N
increased	O
,	O
with	O
a	O
maximal	O
increase	O
about	O
100	O
,	O
200	O
,	O
and	O
150	O
%	O
,	O
respectively	O
,	O
on	O
Day	O
2	O
.	O

By	O
contrast	O
,	O
NPY	B-GENE-Y
decreased	O
with	O
a	O
biggest	O
reduction	O
about	O
48	O
%	O
on	O
Day	O
2	O
and	O
the	O
pattern	O
of	O
expression	O
during	O
PPA	B-CHEMICAL
treatment	O
was	O
opposite	O
to	O
those	O
of	O
Y1R	B-GENE-Y
,	O
GP	B-GENE-N
,	O
and	O
CREB	B-GENE-N
.	O

Central	O
knockdown	O
(	O
using	O
antisense	O
)	O
or	O
inhibition	O
(	O
using	O
antagonist	O
)	O
of	O
Y1R	B-GENE-Y
expression	O
modulated	O
the	O
anorectic	O
response	O
of	O
PPA	B-CHEMICAL
and	O
the	O
reciprocal	O
regulation	O
between	O
NPY	B-GENE-Y
and	O
GP	B-GENE-N
(	O
or	O
CREB	B-GENE-N
)	O
,	O
revealing	O
an	O
essential	O
role	O
of	O
Y1R	B-GENE-Y
in	O
regulating	O
NPY	B-GENE-Y
,	O
GP	B-GENE-N
,	O
and	O
CREB	B-GENE-N
.	O

These	O
results	O
suggest	O
that	O
Y1R	B-GENE-Y
participates	O
in	O
the	O
reciprocal	O
regulation	O
of	O
NPY	B-GENE-Y
,	O
GP	B-GENE-N
,	O
and	O
CREB	B-GENE-N
in	O
the	O
hypothalamus	O
during	O
PPA	B-CHEMICAL
treatment	O
in	O
conscious	O
rats	O
.	O

The	O
present	O
results	O
may	O
aid	O
the	O
therapeutic	O
research	O
of	O
PPA	B-CHEMICAL
and	O
related	O
antiobesity	O
drugs	O
.	O

Activation	O
of	O
group	B-GENE-N
I	I-GENE-N
metabotropic	I-GENE-N
glutamate	I-GENE-N
receptors	I-GENE-N
potentiates	O
heteromeric	O
kainate	B-GENE-N
receptors	I-GENE-N
.	O

Kainate	B-GENE-N
receptors	I-GENE-N
(	O
KARs	B-GENE-N
)	O
,	O
a	O
family	O
of	O
ionotropic	B-GENE-N
glutamate	I-GENE-N
receptors	I-GENE-N
,	O
are	O
widely	O
expressed	O
in	O
the	O
central	O
nervous	O
system	O
and	O
are	O
critically	O
involved	O
in	O
synaptic	O
transmission	O
.	O

KAR	B-GENE-N
activation	O
is	O
influenced	O
by	O
metabotropic	B-GENE-N
glutamate	I-GENE-N
receptor	I-GENE-N
(	O
mGlu	B-GENE-N
)	O
signaling	O
,	O
but	O
the	O
underlying	O
mechanisms	O
are	O
not	O
understood	O
.	O

We	O
undertook	O
studies	O
to	O
examine	O
how	O
mGlu	B-GENE-N
modulation	O
affects	O
activation	O
of	O
KARs	B-GENE-N
.	O

Confocal	O
immunohistochemistry	O
of	O
rat	O
hippocampus	O
and	O
cultured	O
rat	O
cortex	O
revealed	O
colocalization	O
of	O
the	O
high	O
-	O
affinity	O
KAR	B-GENE-N
subunits	O
with	O
group	B-GENE-N
I	I-GENE-N
mGlu	I-GENE-N
receptors	I-GENE-N
.	O

In	O
hippocampal	O
and	O
cortical	O
cultures	O
,	O
the	O
calcium	B-CHEMICAL
signal	O
caused	O
by	O
activation	O
of	O
native	O
KARs	B-GENE-N
was	O
potentiated	O
by	O
activation	O
of	O
group	B-GENE-N
I	I-GENE-N
mGlu	I-GENE-N
receptors	I-GENE-N
.	O

In	O
Xenopus	O
laevis	O
oocytes	O
,	O
activation	O
of	O
group	B-GENE-N
I	I-GENE-N
mGlu	I-GENE-N
receptors	I-GENE-N
potentiated	O
heteromeric	O
but	O
not	O
homomeric	O
KAR	B-GENE-N
-	O
mediated	O
currents	O
,	O
with	O
no	O
change	O
in	O
agonist	O
potency	O
.	O

The	O
potentiation	O
of	O
heteromeric	O
KARs	B-GENE-N
by	O
mGlu1	B-GENE-Y
activation	O
was	O
attenuated	O
by	O
GDPS	O
,	O
blocked	O
by	O
an	O
inhibitor	O
of	O
phospholipase	B-GENE-N
C	I-GENE-N
or	O
the	O
calcium	B-CHEMICAL
chelator	O
1	B-CHEMICAL
,	I-CHEMICAL
2	I-CHEMICAL
-	I-CHEMICAL
bis	I-CHEMICAL
(	I-CHEMICAL
o	I-CHEMICAL
-	I-CHEMICAL
aminophenoxy	I-CHEMICAL
)	I-CHEMICAL
ethane	I-CHEMICAL
-	I-CHEMICAL
N	I-CHEMICAL
,	I-CHEMICAL
N	I-CHEMICAL
,	I-CHEMICAL
N	I-CHEMICAL
'	I-CHEMICAL
,	I-CHEMICAL
N	I-CHEMICAL
'	I-CHEMICAL
-	I-CHEMICAL
tetraacetic	I-CHEMICAL
acid	I-CHEMICAL
(	O
BAPTA	B-CHEMICAL
)	O
,	O
prolonged	O
by	O
the	O
phosphatase	B-GENE-N
inhibitor	O
okadaic	B-CHEMICAL
acid	I-CHEMICAL
,	O
but	O
unaffected	O
by	O
the	O
tyrosine	B-GENE-N
kinase	I-GENE-N
inhibitor	O
lavendustin	B-CHEMICAL
A	I-CHEMICAL
.	O

Protein	B-GENE-N
kinase	I-GENE-N
C	I-GENE-N
(	O
PKC	B-GENE-N
)	O
inhibition	O
reduced	O
the	O
potentiation	O
by	O
mGlu1	B-GENE-Y
of	O
GluK2	B-GENE-Y
/	O
GluK5	B-GENE-Y
,	O
and	O
conversely	O
,	O
direct	O
activation	O
of	O
PKC	B-GENE-N
by	O
phorbol	B-CHEMICAL
12	I-CHEMICAL
-	I-CHEMICAL
myristate	I-CHEMICAL
,	I-CHEMICAL
13	I-CHEMICAL
-	I-CHEMICAL
acetate	I-CHEMICAL
potentiated	O
GluK2	B-GENE-Y
/	O
GluK5	B-GENE-Y
.	O

Using	O
site	O
-	O
directed	O
mutagenesis	O
,	O
we	O
identified	O
three	O
serines	B-CHEMICAL
(	O
Ser833	B-CHEMICAL
,	O
Ser836	B-CHEMICAL
,	O
and	O
Ser840	B-CHEMICAL
)	O
within	O
the	O
membrane	O
proximal	O
region	O
of	O
the	O
GluK5	B-GENE-Y
C	B-CHEMICAL
-	O
terminal	O
domain	O
that	O
,	O
in	O
combination	O
,	O
are	O
required	O
for	O
mGlu1	B-GENE-Y
-	O
mediated	O
potentiation	O
of	O
KARs	B-GENE-N
.	O

Together	O
,	O
these	O
data	O
suggest	O
that	O
phosphorylation	O
of	O
key	O
residues	O
in	O
the	O
C	B-CHEMICAL
-	O
terminal	O
domain	O
changes	O
the	O
overall	O
charge	O
of	O
this	O
domain	O
,	O
resulting	O
in	O
potentiated	O
agonist	O
responses	O
.	O

Fingolimod	B-CHEMICAL
protects	O
cultured	O
cortical	O
neurons	O
against	O
excitotoxic	O
death	O
.	O

Fingolimod	B-CHEMICAL
(	O
FTY720	B-CHEMICAL
)	O
,	O
a	O
novel	O
drug	O
approved	O
for	O
the	O
treatment	O
of	O
relapsing	O
-	O
remitting	O
multiple	O
sclerosis	O
,	O
activates	O
different	O
sphingosine	B-GENE-N
-	I-GENE-N
1	I-GENE-N
-	I-GENE-N
phosphate	I-GENE-N
receptor	I-GENE-N
(	O
S1PR	B-GENE-N
)	O
subtypes	O
.	O

Its	O
primary	O
mechanism	O
of	O
action	O
is	O
to	O
reduce	O
the	O
egress	O
of	O
T	O
lymphocytes	O
from	O
secondary	O
lymphoid	O
organs	O
,	O
thus	O
restraining	O
neuroinflammation	O
and	O
autoimmunity	O
.	O

However	O
,	O
recent	O
evidence	O
suggests	O
that	O
the	O
action	O
of	O
FTY720	B-CHEMICAL
involves	O
S1PRs	B-GENE-N
expressed	O
by	O
cells	O
resident	O
in	O
the	O
CNS	O
,	O
including	O
neurons	O
.	O

Here	O
,	O
we	O
examined	O
the	O
effect	O
of	O
FTY720	B-CHEMICAL
,	O
its	O
active	O
metabolite	O
,	O
FTY720	B-CHEMICAL
-	I-CHEMICAL
P	I-CHEMICAL
,	O
and	O
sphingosine	B-CHEMICAL
-	I-CHEMICAL
1	I-CHEMICAL
-	I-CHEMICAL
phosphate	I-CHEMICAL
(	O
S1P	B-CHEMICAL
)	O
on	O
neuronal	O
viability	O
using	O
a	O
classical	O
in	O
vitro	O
model	O
of	O
excitotoxic	O
neuronal	O
death	O
.	O

Mixed	O
cultures	O
of	O
mouse	O
cortical	O
cells	O
were	O
challenged	O
with	O
toxic	O
concentrations	O
of	O
N	B-CHEMICAL
-	I-CHEMICAL
methyl	I-CHEMICAL
-	I-CHEMICAL
d	I-CHEMICAL
-	I-CHEMICAL
aspartate	I-CHEMICAL
(	O
NMDA	B-CHEMICAL
)	O
for	O
10	O
min	O
,	O
and	O
neuronal	O
death	O
was	O
assessed	O
20	O
h	O
later	O
.	O

FTY720	B-CHEMICAL
,	O
FTY720	B-CHEMICAL
-	I-CHEMICAL
P	I-CHEMICAL
,	O
and	O
S1P	B-CHEMICAL
were	O
all	O
neuroprotective	O
when	O
applied	O
18	O
-	O
20	O
h	O
prior	O
to	O
the	O
NMDA	B-CHEMICAL
pulse	O
.	O

Neuroprotection	O
was	O
attenuated	O
by	O
pertussis	B-GENE-N
toxin	I-GENE-N
,	O
and	O
inhibited	O
by	O
the	O
selective	O
type	B-GENE-Y
-	I-GENE-Y
1	I-GENE-Y
S1PR	I-GENE-Y
(	O
S1P1R	B-GENE-Y
)	O
antagonist	O
,	O
W146	B-CHEMICAL
,	O
and	O
by	O
inhibitors	O
of	O
the	O
mitogen	B-GENE-N
associated	I-GENE-N
protein	I-GENE-N
kinase	I-GENE-N
(	O
MAPK	B-GENE-N
)	O
and	O
the	O
phosphatidylinositol	B-GENE-N
-	I-GENE-N
3	I-GENE-N
-	I-GENE-N
kinase	I-GENE-N
(	O
PtdIns	B-GENE-N
-	I-GENE-N
3	I-GENE-N
-	I-GENE-N
K	I-GENE-N
)	O
pathways	O
.	O

Both	O
FTY720	B-CHEMICAL
and	O
FTY720	B-CHEMICAL
-	I-CHEMICAL
P	I-CHEMICAL
retained	O
their	O
protective	O
activity	O
in	O
pure	O
cultures	O
of	O
mouse	O
or	O
rat	O
cortical	O
neurons	O
.	O

These	O
data	O
offer	O
the	O
first	O
direct	O
demonstration	O
that	O
FTY720	B-CHEMICAL
and	O
its	O
active	O
metabolite	O
protect	O
neurons	O
against	O
excitotoxic	O
death	O
.	O

Pharmacokinetics	O
and	O
metabolism	O
of	O
[	B-CHEMICAL
(	I-CHEMICAL
14	I-CHEMICAL
)	I-CHEMICAL
C	I-CHEMICAL
]	I-CHEMICAL
anagliptin	I-CHEMICAL
,	O
a	O
novel	O
dipeptidyl	B-GENE-Y
peptidase	I-GENE-Y
-	I-GENE-Y
4	I-GENE-Y
inhibitor	O
,	O
in	O
humans	O
.	O

1	O
.	O

The	O
disposition	O
of	O
anagliptin	B-CHEMICAL
,	O
an	O
orally	O
active	O
,	O
highly	O
selective	O
dipeptidyl	B-GENE-Y
peptidase	I-GENE-Y
-	I-GENE-Y
4	I-GENE-Y
inhibitor	O
,	O
was	O
investigated	O
after	O
a	O
single	O
oral	O
dose	O
of	O
100	O
mg	O
/	O
1	O
.	O
92	O
MBq	O
[	B-CHEMICAL
(	I-CHEMICAL
14	I-CHEMICAL
)	I-CHEMICAL
C	I-CHEMICAL
]	I-CHEMICAL
anagliptin	I-CHEMICAL
to	O
six	O
healthy	O
men	O
.	O

Almost	O
all	O
the	O
dose	O
(	O
98	O
.	O
2	O
%	O
)	O
was	O
recovered	O
within	O
168	O
h	O
:	O
73	O
.	O
2	O
%	O
in	O
urine	O
and	O
25	O
.	O
0	O
%	O
in	O
faeces	O
.	O

2	O
.	O

Anagliptin	B-CHEMICAL
was	O
rapidly	O
absorbed	O
,	O
with	O
peak	O
plasma	O
concentrations	O
of	O
unchanged	O
drug	O
attained	O
at	O
a	O
mean	O
time	O
of	O
1	O
.	O
8	O
-	O
h	O
postdose	O
.	O

Mean	O
fraction	O
of	O
the	O
dose	O
absorbed	O
was	O
>	O
73	O
%	O
.	O

Unchanged	O
drug	O
and	O
a	O
carboxylate	B-CHEMICAL
metabolite	O
(	O
M1	O
)	O
were	O
the	O
major	O
components	O
in	O
plasma	O
,	O
accounting	O
for	O
66	O
.	O
0	O
and	O
23	O
.	O
4	O
%	O
of	O
total	O
plasma	O
radioactivity	O
area	O
under	O
the	O
curve	O
,	O
respectively	O
.	O

3	O
.	O

Anagliptin	B-CHEMICAL
was	O
incompletely	O
metabolized	O
,	O
with	O
about	O
50	O
%	O
dose	O
eliminated	O
as	O
unchanged	O
drug	O
(	O
46	O
.	O
6	O
%	O
in	O
urine	O
and	O
4	O
.	O
1	O
%	O
in	O
faeces	O
)	O
.	O

Metabolism	O
to	O
M1	O
accounted	O
for	O
29	O
.	O
2	O
%	O
of	O
the	O
dose	O
.	O

No	O
other	O
metabolite	O
accounted	O
for	O
>	O
1	O
%	O
dose	O
in	O
excreta	O
or	O
yielded	O
measurable	O
systemic	O
exposure	O
.	O

Terminal	O
half	O
-	O
life	O
of	O
anagliptin	B-CHEMICAL
and	O
M1	O
was	O
4	O
.	O
37	O
and	O
9	O
.	O
88	O
h	O
,	O
respectively	O
.	O

Renal	O
clearance	O
of	O
unbound	O
anagliptin	B-CHEMICAL
and	O
unbound	O
M1	O
far	O
exceeded	O
glomerular	O
filtration	O
rate	O
,	O
indicating	O
active	O
renal	O
elimination	O
:	O
that	O
might	O
reflect	O
the	O
fact	O
that	O
anagliptin	B-CHEMICAL
may	O
be	O
a	O
substrate	O
of	O
OAT1	B-GENE-Y
,	O
OAT3	B-GENE-Y
,	O
MDR1	B-GENE-Y
and	O
MRP2	B-GENE-Y
,	O
and	O
M1	O
a	O
substrate	O
of	O
OAT3	B-GENE-Y
,	O
BCRP	B-GENE-Y
,	O
MRP2	B-GENE-Y
and	O
MRP4	B-GENE-Y
.	O

Chemical	O
cholecystokinin	B-GENE-N
receptor	I-GENE-N
activation	O
protects	O
against	O
obesity	O
-	O
diabetes	O
in	O
high	O
fat	O
fed	O
mice	O
and	O
has	O
sustainable	O
beneficial	O
effects	O
in	O
genetic	O
ob	O
/	O
ob	O
mice	O
.	O

The	O
current	O
study	O
has	O
determined	O
the	O
ability	O
of	O
(	B-GENE-Y
pGlu	I-GENE-Y
-	I-GENE-Y
Gln	I-GENE-Y
)	I-GENE-Y
-	I-GENE-Y
CCK	I-GENE-Y
-	I-GENE-Y
8	I-GENE-Y
to	O
counter	O
the	O
development	O
of	O
diet	O
-	O
induced	O
obesity	O
-	O
diabetes	O
and	O
examined	O
persistence	O
of	O
beneficial	O
metabolic	O
effects	O
in	O
high	O
fat	O
and	O
ob	O
/	O
ob	O
mice	O
,	O
respectively	O
.	O

Twice	O
daily	O
injection	O
of	O
(	B-GENE-Y
pGlu	I-GENE-Y
-	I-GENE-Y
Gln	I-GENE-Y
)	I-GENE-Y
-	I-GENE-Y
CCK	I-GENE-Y
-	I-GENE-Y
8	I-GENE-Y
in	O
normal	O
mice	O
transferred	O
to	O
a	O
high	O
fat	O
diet	O
reduced	O
energy	O
intake	O
(	O
p	O
<	O
0	O
.	O
001	O
)	O
,	O
body	O
weight	O
(	O
p	O
<	O
0	O
.	O
01	O
)	O
,	O
circulating	O
insulin	B-GENE-N
and	O
LDL	B-GENE-N
-	O
cholesterol	B-CHEMICAL
(	O
p	O
<	O
0	O
.	O
001	O
)	O
and	O
improved	O
insulin	B-GENE-N
sensitivity	O
(	O
p	O
<	O
0	O
.	O
001	O
)	O
as	O
well	O
as	O
oral	O
and	O
intraperitoneal	O
(	O
p	O
<	O
0	O
.	O
001	O
)	O
glucose	B-CHEMICAL
tolerance	O
.	O

Energy	O
intake	O
,	O
body	O
weight	O
,	O
circulating	O
insulin	B-GENE-N
and	O
glucose	B-CHEMICAL
tolerance	O
of	O
(	B-GENE-Y
pGlu	I-GENE-Y
-	I-GENE-Y
Gln	I-GENE-Y
)	I-GENE-Y
-	I-GENE-Y
CCK	I-GENE-Y
-	I-GENE-Y
8	I-GENE-Y
mice	O
were	O
similar	O
to	O
lean	O
controls	O
.	O

In	O
addition	O
,	O
(	B-GENE-Y
pGlu	I-GENE-Y
-	I-GENE-Y
Gln	I-GENE-Y
)	I-GENE-Y
-	I-GENE-Y
CCK	I-GENE-Y
-	I-GENE-Y
8	I-GENE-Y
prevented	O
the	O
effect	O
of	O
high	O
fat	O
feeding	O
on	O
triacylglycerol	B-CHEMICAL
accumulation	O
in	O
liver	O
and	O
muscle	O
.	O

Interestingly	O
,	O
(	B-GENE-Y
pGlu	I-GENE-Y
-	I-GENE-Y
Gln	I-GENE-Y
)	I-GENE-Y
-	I-GENE-Y
CCK	I-GENE-Y
-	I-GENE-Y
8	I-GENE-Y
significantly	O
(	O
p	O
<	O
0	O
.	O
001	O
)	O
elevated	O
pancreatic	O
glucagon	B-GENE-Y
content	O
.	O

Histological	O
examination	O
of	O
the	O
pancreata	O
of	O
(	B-GENE-Y
pGlu	I-GENE-Y
-	I-GENE-Y
Gln	I-GENE-Y
)	I-GENE-Y
-	I-GENE-Y
CCK	I-GENE-Y
-	I-GENE-Y
8	I-GENE-Y
mice	O
revealed	O
no	O
changes	O
in	O
islet	O
number	O
or	O
size	O
,	O
but	O
there	O
was	O
increased	O
turnover	O
of	O
beta	O
-	O
cells	O
with	O
significantly	O
(	O
p	O
<	O
0	O
.	O
001	O
)	O
increased	O
numbers	O
of	O
peripherally	O
located	O
alpha	O
-	O
cells	O
,	O
co	O
-	O
expressing	O
both	O
glucagon	B-GENE-Y
and	O
GLP	B-GENE-Y
-	I-GENE-Y
1	I-GENE-Y
.	O

Beneficial	O
metabolic	O
effects	O
were	O
observed	O
similarly	O
in	O
ob	O
/	O
ob	O
mice	O
treated	O
twice	O
daily	O
with	O
(	B-GENE-Y
pGlu	I-GENE-Y
-	I-GENE-Y
Gln	I-GENE-Y
)	I-GENE-Y
-	I-GENE-Y
CCK	I-GENE-Y
-	I-GENE-Y
8	I-GENE-Y
for	O
18	O
days	O
,	O
including	O
significantly	O
reduced	O
energy	O
intake	O
(	O
p	O
<	O
0	O
.	O
05	O
)	O
,	O
body	O
weight	O
(	O
p	O
<	O
0	O
.	O
05	O
to	O
p	O
<	O
0	O
.	O
01	O
)	O
,	O
circulating	O
glucose	B-CHEMICAL
(	O
p	O
<	O
0	O
.	O
05	O
to	O
p	O
<	O
0	O
.	O
01	O
)	O
and	O
insulin	B-GENE-N
(	O
p	O
<	O
0	O
.	O
05	O
to	O
p	O
<	O
0	O
.	O
001	O
)	O
and	O
improved	O
glucose	B-CHEMICAL
tolerance	O
(	O
p	O
<	O
0	O
.	O
05	O
)	O
and	O
insulin	B-GENE-N
sensitivity	O
(	O
p	O
<	O
0	O
.	O
001	O
)	O
.	O

Notably	O
,	O
these	O
beneficial	O
effects	O
were	O
still	O
evident	O
18	O
days	O
following	O
cessation	O
of	O
treatment	O
.	O

These	O
studies	O
emphasize	O
the	O
potential	O
of	O
(	B-GENE-Y
pGlu	I-GENE-Y
-	I-GENE-Y
Gln	I-GENE-Y
)	I-GENE-Y
-	I-GENE-Y
CCK	I-GENE-Y
-	I-GENE-Y
8	I-GENE-Y
for	O
the	O
treatment	O
of	O
obesity	O
-	O
diabetes	O
.	O

Combination	O
lopinavir	B-CHEMICAL
and	O
ritonavir	B-CHEMICAL
alter	O
exogenous	O
and	O
endogenous	O
bile	B-CHEMICAL
acid	I-CHEMICAL
disposition	O
in	O
sandwich	O
-	O
cultured	O
rat	O
hepatocytes	O
.	O

Inhibition	O
of	O
the	O
bile	B-GENE-Y
salt	I-GENE-Y
export	I-GENE-Y
pump	I-GENE-Y
(	O
BSEP	B-GENE-Y
)	O
can	O
cause	O
intracellular	O
accumulation	O
of	O
bile	B-CHEMICAL
acids	I-CHEMICAL
and	O
is	O
a	O
risk	O
factor	O
for	O
drug	O
-	O
induced	O
liver	O
injury	O
in	O
humans	O
.	O

Antiretroviral	O
protease	B-GENE-N
inhibitors	O
lopinavir	B-CHEMICAL
(	O
LPV	B-CHEMICAL
)	O
and	O
ritonavir	B-CHEMICAL
(	O
RTV	B-CHEMICAL
)	O
are	O
reported	O
BSEP	B-GENE-Y
inhibitors	O
.	O

However	O
,	O
the	O
consequences	O
of	O
LPV	B-CHEMICAL
and	O
RTV	B-CHEMICAL
,	O
alone	O
and	O
combined	O
(	O
LPV	B-CHEMICAL
/	O
r	O
)	O
,	O
on	O
hepatocyte	O
viability	O
,	O
bile	B-CHEMICAL
acid	I-CHEMICAL
transport	O
,	O
and	O
endogenous	O
bile	B-CHEMICAL
acid	I-CHEMICAL
disposition	O
in	O
rat	O
hepatocytes	O
have	O
not	O
been	O
examined	O
.	O

The	O
effect	O
of	O
LPV	B-CHEMICAL
,	O
RTV	B-CHEMICAL
,	O
and	O
LPV	B-CHEMICAL
/	O
r	O
on	O
cellular	O
viability	O
and	O
the	O
disposition	O
of	O
[	B-CHEMICAL
(	I-CHEMICAL
3	I-CHEMICAL
)	I-CHEMICAL
H	I-CHEMICAL
]	I-CHEMICAL
taurocholic	I-CHEMICAL
acid	I-CHEMICAL
(	O
TCA	B-CHEMICAL
)	O
and	O
[	B-CHEMICAL
(	I-CHEMICAL
14	I-CHEMICAL
)	I-CHEMICAL
C	I-CHEMICAL
]	I-CHEMICAL
chenodeoxycholic	I-CHEMICAL
acid	I-CHEMICAL
(	O
CDCA	B-CHEMICAL
)	O
was	O
determined	O
in	O
sandwich	O
-	O
cultured	O
rat	O
hepatocytes	O
(	O
SCRH	O
)	O
and	O
suspended	O
rat	O
hepatocytes	O
.	O

Lactate	B-CHEMICAL
dehydrogenase	O
and	O
ATP	B-CHEMICAL
assays	O
revealed	O
a	O
concentration	O
-	O
dependent	O
effect	O
of	O
LPV	B-CHEMICAL
and	O
RTV	B-CHEMICAL
on	O
cellular	O
viability	O
.	O

LPV	B-CHEMICAL
(	O
5	O
M	O
)	O
,	O
alone	O
and	O
combined	O
with	O
5	O
M	O
RTV	B-CHEMICAL
,	O
significantly	O
decreased	O
[	B-CHEMICAL
(	I-CHEMICAL
3	I-CHEMICAL
)	I-CHEMICAL
H	I-CHEMICAL
]	I-CHEMICAL
TCA	I-CHEMICAL
accumulation	O
in	O
cells	O
+	O
bile	O
of	O
SCRHs	O
compared	O
with	O
control	O
.	O

LPV	B-CHEMICAL
/	O
r	O
significantly	O
increased	O
[	B-CHEMICAL
(	I-CHEMICAL
3	I-CHEMICAL
)	I-CHEMICAL
H	I-CHEMICAL
]	I-CHEMICAL
TCA	I-CHEMICAL
cellular	O
accumulation	O
(	O
7	O
.	O
7	O
	O
0	O
.	O
1	O
pmol	O
/	O
mg	O
of	O
protein	O
)	O
compared	O
with	O
vehicle	O
and	O
5	O
M	O
LPV	B-CHEMICAL
alone	O
(	O
5	O
.	O
1	O
	O
0	O
.	O
7	O
and	O
5	O
.	O
0	O
	O
0	O
.	O
5	O
pmol	O
/	O
mg	O
of	O
protein	O
)	O
.	O

The	O
[	B-CHEMICAL
(	I-CHEMICAL
3	I-CHEMICAL
)	I-CHEMICAL
H	I-CHEMICAL
]	I-CHEMICAL
TCA	I-CHEMICAL
biliary	O
clearance	O
was	O
reduced	O
significantly	O
by	O
LPV	B-CHEMICAL
and	O
RTV	B-CHEMICAL
and	O
further	O
reduced	O
by	O
LPV	B-CHEMICAL
/	O
r	O
.	O

LPV	B-CHEMICAL
and	O
RTV	B-CHEMICAL
did	O
not	O
affect	O
the	O
initial	O
uptake	O
rates	O
of	O
[	B-CHEMICAL
(	I-CHEMICAL
3	I-CHEMICAL
)	I-CHEMICAL
H	I-CHEMICAL
]	I-CHEMICAL
TCA	I-CHEMICAL
or	O
[	B-CHEMICAL
(	I-CHEMICAL
14	I-CHEMICAL
)	I-CHEMICAL
C	I-CHEMICAL
]	I-CHEMICAL
CDCA	I-CHEMICAL
in	O
suspended	O
rat	O
hepatocytes	O
.	O

LPV	B-CHEMICAL
(	O
50	O
M	O
)	O
,	O
RTV	B-CHEMICAL
(	O
5	O
M	O
)	O
,	O
and	O
LPV	B-CHEMICAL
/	O
r	O
(	O
5	O
and	O
50	O
M	O
/	O
5	O
M	O
)	O
significantly	O
decreased	O
the	O
accumulation	O
of	O
total	O
measured	O
endogenous	O
bile	B-CHEMICAL
acids	I-CHEMICAL
(	O
TCA	B-CHEMICAL
,	O
glycocholic	B-CHEMICAL
acid	I-CHEMICAL
,	O
taurochenodeoxycholic	B-CHEMICAL
acid	I-CHEMICAL
,	O
glycochenodeoxycholic	B-CHEMICAL
acid	I-CHEMICAL
,	O
and	O
	B-CHEMICAL
/	I-CHEMICAL
	I-CHEMICAL
-	I-CHEMICAL
tauromuricholic	I-CHEMICAL
acid	I-CHEMICAL
)	O
in	O
SCRH	O
.	O

Quantification	O
of	O
endogenous	O
bile	B-CHEMICAL
acids	I-CHEMICAL
in	O
SCRH	O
may	O
reveal	O
important	O
adaptive	O
responses	O
associated	O
with	O
exposure	O
to	O
known	O
BSEP	B-GENE-Y
inhibitors	O
.	O

Pharmacokinetic	O
study	O
of	O
Growth	B-CHEMICAL
Hormone	I-CHEMICAL
-	I-CHEMICAL
Releasing	I-CHEMICAL
Peptide	I-CHEMICAL
6	I-CHEMICAL
(	O
GHRP	B-CHEMICAL
-	I-CHEMICAL
6	I-CHEMICAL
)	O
in	O
nine	O
male	O
healthy	O
volunteers	O
.	O

GHRP	B-CHEMICAL
-	I-CHEMICAL
6	I-CHEMICAL
is	O
a	O
growth	B-GENE-Y
hormone	I-GENE-Y
secretagogue	O
that	O
also	O
enhances	O
tissue	O
viability	O
in	O
different	O
organs	O
.	O

In	O
the	O
present	O
work	O
,	O
we	O
studied	O
the	O
pharmacokinetics	O
of	O
this	O
short	O
therapeutic	O
hexapeptide	O
(	O
His	B-CHEMICAL
-	I-CHEMICAL
(	I-CHEMICAL
D	I-CHEMICAL
-	I-CHEMICAL
Trp	I-CHEMICAL
)	I-CHEMICAL
-	I-CHEMICAL
Ala	I-CHEMICAL
-	I-CHEMICAL
Trp	I-CHEMICAL
-	I-CHEMICAL
(	I-CHEMICAL
D	I-CHEMICAL
-	I-CHEMICAL
Phe	I-CHEMICAL
)	I-CHEMICAL
-	I-CHEMICAL
Lys	I-CHEMICAL
-	I-CHEMICAL
NH	I-CHEMICAL
(	I-CHEMICAL
2	I-CHEMICAL
,	I-CHEMICAL
)	I-CHEMICAL
MW	O
=	O
872	O
.	O
44	O
Da	O
)	O
in	O
nine	O
male	O
healthy	O
volunteers	O
after	O
a	O
single	O
intravenous	O
bolus	O
administration	O
of	O
100	O
,	O
200	O
and	O
400	O
g	O
/	O
kg	O
of	O
body	O
weight	O
.	O

GHRP	B-CHEMICAL
-	I-CHEMICAL
6	I-CHEMICAL
was	O
quantified	O
in	O
human	O
plasma	O
by	O
a	O
specific	O
LC	O
-	O
MS	O
method	O
,	O
previously	O
developed	O
and	O
validated	O
following	O
FDA	O
guidelines	O
,	O
using	O
(	B-CHEMICAL
13	I-CHEMICAL
)	I-CHEMICAL
C	I-CHEMICAL
(	I-CHEMICAL
3	I-CHEMICAL
)	I-CHEMICAL
Ala	I-CHEMICAL
-	I-CHEMICAL
GHRP	I-CHEMICAL
-	I-CHEMICAL
6	I-CHEMICAL
as	O
internal	O
standard	O
(	O
Gil	O
et	O
al	O
.	O
,	O
2012	O
,	O
J	O
.	O
Pharm	O
.	O
Biomed	O
.	O
Anal	O
.	O
60	O
,	O
19	O
-	O
25	O
)	O
.	O

The	O
Lower	O
Limit	O
of	O
Quantification	O
(	O
5	O
ng	O
/	O
mL	O
)	O
was	O
reached	O
in	O
all	O
subjects	O
at	O
12h	O
post	O
-	O
administration	O
,	O
which	O
was	O
sufficient	O
for	O
modeling	O
a	O
pharmacokinetic	O
profile	O
including	O
over	O
85	O
%	O
of	O
the	O
Area	O
under	O
the	O
Curve	O
(	O
AUC	O
)	O
.	O

Disposition	O
of	O
GHRP	B-CHEMICAL
-	I-CHEMICAL
6	I-CHEMICAL
best	O
fitted	O
a	O
bi	O
-	O
exponential	O
function	O
with	O
R	O
(	O
2	O
)	O
higher	O
than	O
0	O
.	O
99	O
,	O
according	O
to	O
a	O
mathematic	O
modeling	O
and	O
confirmed	O
by	O
an	O
Akaike	O
index	O
(	O
AIC	O
)	O
lower	O
than	O
that	O
of	O
the	O
corresponding	O
one	O
-	O
compartment	O
model	O
for	O
all	O
subjects	O
.	O

Averaging	O
all	O
three	O
dose	O
levels	O
,	O
the	O
distribution	O
and	O
elimination	O
half	O
-	O
life	O
of	O
GHRP	B-CHEMICAL
-	I-CHEMICAL
6	I-CHEMICAL
were	O
7	O
.	O
6	O
	O
1	O
.	O
9	O
min	O
and	O
2	O
.	O
5	O
	O
1	O
.	O
1h	O
,	O
respectively	O
.	O

These	O
values	O
are	O
coherent	O
with	O
existing	O
data	O
for	O
other	O
drugs	O
whose	O
disposition	O
also	O
fits	O
this	O
model	O
.	O

Dose	O
dependence	O
analysis	O
revealed	O
a	O
noticeable	O
trend	O
for	O
AUC	O
to	O
increase	O
proportionally	O
with	O
administered	O
dose	O
.	O

Atypical	O
GHRP	B-CHEMICAL
-	I-CHEMICAL
6	I-CHEMICAL
concentration	O
spikes	O
were	O
observed	O
during	O
the	O
elimination	O
phase	O
in	O
four	O
out	O
of	O
the	O
nine	O
subjects	O
studied	O
.	O

Efficacy	O
of	O
asiatic	B-CHEMICAL
acid	I-CHEMICAL
,	O
a	O
pentacyclic	B-CHEMICAL
triterpene	I-CHEMICAL
on	O
attenuating	O
the	O
key	O
enzymes	O
activities	O
of	O
carbohydrate	B-CHEMICAL
metabolism	O
in	O
streptozotocin	B-CHEMICAL
-	O
induced	O
diabetic	O
rats	O
.	O

Asiatic	B-CHEMICAL
acid	I-CHEMICAL
(	O
AA	O
)	O
,	O
a	O
triterpenoid	B-CHEMICAL
derivative	O
of	O
Centella	O
asiatica	O
,	O
has	O
shown	O
significant	O
biological	O
effects	O
of	O
antioxidant	O
and	O
anti	O
-	O
inflammatory	O
activities	O
.	O

Aim	O
of	O
this	O
investigation	O
was	O
to	O
evaluate	O
the	O
antihyperglycemic	O
effect	O
of	O
AA	O
on	O
the	O
activities	O
of	O
hepatic	O
enzymes	O
of	O
carbohydrate	B-CHEMICAL
metabolism	O
in	O
streptozotocin	B-CHEMICAL
(	O
STZ	B-CHEMICAL
)	O
-	O
induced	O
diabetic	O
rats	O
.	O

To	O
induce	O
diabetes	O
mellitus	O
,	O
rats	O
were	O
injected	O
with	O
streptozotocin	B-CHEMICAL
intraperitoneally	O
at	O
a	O
single	O
dose	O
of	O
40	O
mg	O
/	O
kg	O
b	O
.	O
w	O
.	O

Diabetic	O
rats	O
showed	O
significant	O
(	O
p	O
<	O
0	O
.	O
05	O
)	O
increased	O
in	O
plasma	O
glucose	B-CHEMICAL
,	O
glycosylated	B-GENE-N
hemoglobin	I-GENE-N
and	O
significant	O
(	O
p	O
<	O
0	O
.	O
05	O
)	O
decreased	O
in	O
circulating	O
insulin	B-GENE-N
and	O
hemoglobin	B-GENE-N
.	O

The	O
altered	O
activities	O
of	O
key	O
enzymes	O
such	O
as	O
glucose	B-GENE-Y
-	I-GENE-Y
6	I-GENE-Y
-	I-GENE-Y
phosphatase	I-GENE-Y
and	O
fructose	B-GENE-Y
-	I-GENE-Y
1	I-GENE-Y
,	I-GENE-Y
6	I-GENE-Y
-	I-GENE-Y
bisphosphatase	I-GENE-Y
of	O
carbohydrate	B-CHEMICAL
metabolism	O
significantly	O
(	O
p	O
<	O
0	O
.	O
05	O
)	O
increased	O
whereas	O
hexokinase	B-GENE-N
,	O
pyruvate	B-GENE-N
kinase	I-GENE-N
,	O
glucose	B-GENE-Y
-	I-GENE-Y
6	I-GENE-Y
-	I-GENE-Y
phosphate	I-GENE-Y
dehydrogenase	I-GENE-Y
and	O
glycogen	O
content	O
significantly	O
(	O
p	O
<	O
0	O
.	O
05	O
)	O
decreased	O
in	O
the	O
liver	O
of	O
diabetic	O
rats	O
and	O
also	O
increased	O
activities	O
of	O
aspartate	B-GENE-N
transaminase	I-GENE-N
(	O
AST	B-GENE-N
)	O
,	O
alanine	B-GENE-N
transaminase	I-GENE-N
(	O
ALT	B-GENE-N
)	O
and	O
alkaline	B-GENE-N
phosphatase	I-GENE-N
(	O
ALP	B-GENE-N
)	O
.	O

Oral	O
administration	O
of	O
AA	O
(	O
5	O
,	O
10	O
and	O
20	O
mg	O
/	O
kg	O
b	O
.	O
w	O
.	O
)	O
and	O
glibenclamide	B-CHEMICAL
(	O
600	O
g	O
/	O
kg	O
b	O
.	O
w	O
.	O
)	O
to	O
diabetic	O
rats	O
for	O
45	O
days	O
prevented	O
the	O
above	O
alteration	O
and	O
reverted	O
to	O
near	O
normalcy	O
.	O

Protection	O
of	O
body	O
weight	O
loss	O
of	O
diabetic	O
rats	O
by	O
AA	O
was	O
also	O
observed	O
.	O

No	O
significant	O
effect	O
was	O
observed	O
in	O
normal	O
rats	O
treated	O
with	O
AA	O
(	O
20	O
mg	O
/	O
kg	O
b	O
.	O
w	O
.	O
)	O
.	O

In	O
this	O
search	O
,	O
AA	O
found	O
to	O
be	O
potential	O
bioactive	O
compound	O
to	O
regulate	O
the	O
carbohydrate	B-CHEMICAL
metabolism	O
by	O
modulating	O
the	O
key	O
regulatory	O
enzymes	O
in	O
diabetic	O
rats	O
.	O

These	O
findings	O
merit	O
further	O
research	O
in	O
this	O
field	O
.	O

Ibandronate	B-CHEMICAL
increases	O
the	O
expression	O
of	O
the	O
pro	O
-	O
apoptotic	O
gene	O
FAS	B-GENE-Y
by	O
epigenetic	O
mechanisms	O
in	O
tumor	O
cells	O
.	O

There	O
is	O
growing	O
evidence	O
that	O
aminobisphosphonates	B-CHEMICAL
like	O
ibandronate	B-CHEMICAL
show	O
anticancer	O
activity	O
by	O
an	O
unknown	O
mechanism	O
.	O

Biochemically	O
,	O
they	O
prevent	O
posttranslational	O
isoprenylation	O
of	O
small	O
GTPases	B-GENE-N
,	O
thus	O
inhibiting	O
their	O
activity	O
.	O

In	O
tumor	O
cells	O
,	O
activated	O
RAS	B-GENE-N
-	I-GENE-N
GTPase	I-GENE-N
,	O
the	O
founding	O
member	O
of	O
the	O
gene	O
family	O
,	O
down	O
-	O
regulates	O
the	O
expression	O
of	O
the	O
pro	O
-	O
apoptotic	O
gene	O
FAS	B-GENE-Y
via	O
epigenetic	O
DNA	O
-	O
methylation	O
by	O
DNMT1	B-GENE-Y
.	O

We	O
compared	O
ibandronate	B-CHEMICAL
treatment	O
in	O
neoplastic	O
human	O
U	O
-	O
2	O
osteosarcoma	O
and	O
in	O
mouse	O
CCL	O
-	O
51	O
breast	O
cancer	O
cells	O
as	O
well	O
as	O
in	O
the	O
immortalized	O
non	O
-	O
neoplastic	O
MC3T3	O
-	O
E1	O
osteoblastic	O
cells	O
.	O

Ibandronate	B-CHEMICAL
attenuated	O
cell	O
proliferation	O
in	O
all	O
cell	O
lines	O
tested	O
.	O

In	O
the	O
neoplastic	O
cells	O
we	O
found	O
up	O
-	O
regulation	O
of	O
caspases	B-GENE-N
suggesting	O
apoptosis	O
.	O

Further	O
we	O
found	O
stimulation	O
of	O
FAS	B-GENE-Y
-	O
expression	O
as	O
a	O
result	O
of	O
epigenetic	O
DNA	O
demethylation	O
that	O
was	O
due	O
to	O
down	O
-	O
regulation	O
of	O
DNMT1	B-GENE-Y
,	O
which	O
was	O
rescued	O
by	O
re	O
-	O
isoprenylation	O
by	O
both	O
geranylgeranyl	B-CHEMICAL
-	I-CHEMICAL
pyrophosphate	I-CHEMICAL
and	O
farnesylpyrophosphate	B-CHEMICAL
.	O

In	O
contrast	O
,	O
ibandronate	B-CHEMICAL
did	O
not	O
affect	O
FAS	B-GENE-Y
and	O
DNMT1	B-GENE-Y
expression	O
in	O
MC3T3	O
-	O
E1	O
non	O
-	O
neoplastic	O
cells	O
.	O

Data	O
suggest	O
that	O
bisphosphonates	B-CHEMICAL
via	O
modulation	O
of	O
the	O
activity	O
of	O
small	O
-	O
GTPases	B-GENE-N
induce	O
apoptosis	O
in	O
neoplastic	O
cells	O
by	O
DNA	O
-	O
CpG	B-CHEMICAL
-	O
demethylation	O
and	O
stimulation	O
of	O
FAS	B-GENE-Y
-	O
expression	O
.	O

In	O
conclusion	O
the	O
shown	O
epigenetic	O
mechanism	O
underlying	O
the	O
anti	O
-	O
neoplastic	O
activity	O
of	O
farnesyl	B-GENE-N
-	I-GENE-N
transferase	I-GENE-N
-	O
inhibition	O
,	O
also	O
explains	O
the	O
clinical	O
success	O
of	O
other	O
drugs	O
,	O
which	O
target	O
this	O
pathway	O
.	O

Androgen	B-GENE-Y
receptor	I-GENE-Y
CAG	B-GENE-N
repeat	I-GENE-N
length	O
modifies	O
the	O
effect	O
of	O
2	B-CHEMICAL
,	I-CHEMICAL
3	I-CHEMICAL
,	I-CHEMICAL
7	I-CHEMICAL
,	I-CHEMICAL
8	I-CHEMICAL
-	I-CHEMICAL
tetrachlorodibenzo	I-CHEMICAL
-	I-CHEMICAL
p	I-CHEMICAL
-	I-CHEMICAL
dioxin	I-CHEMICAL
on	O
receptor	O
activity	O
in	O
human	O
prostate	O
cells	O
.	O

Increased	O
incidence	O
of	O
prostate	O
cancer	O
has	O
been	O
reported	O
in	O
men	O
exposed	O
to	O
2	B-CHEMICAL
,	I-CHEMICAL
3	I-CHEMICAL
,	I-CHEMICAL
7	I-CHEMICAL
,	I-CHEMICAL
8	I-CHEMICAL
-	I-CHEMICAL
tetrachlorodibenzo	I-CHEMICAL
-	I-CHEMICAL
p	I-CHEMICAL
-	I-CHEMICAL
dioxin	I-CHEMICAL
(	O
TCDD	B-CHEMICAL
)	O
.	O

TCDD	B-CHEMICAL
acts	O
through	O
the	O
aryl	B-GENE-Y
hydrocarbon	I-GENE-Y
receptor	I-GENE-Y
(	O
AhR	B-GENE-Y
)	O
,	O
which	O
interacts	O
with	O
the	O
androgen	B-GENE-Y
receptor	I-GENE-Y
(	O
AR	B-GENE-Y
)	O
.	O

The	O
AR	B-GENE-Y
gene	O
contains	O
a	O
polymorphic	O
CAG	B-GENE-N
repeat	I-GENE-N
that	O
influences	O
its	O
transcriptional	O
activity	O
.	O

We	O
investigated	O
the	O
influence	O
of	O
TCDD	B-CHEMICAL
on	O
prostate	O
cancer	O
cells	O
(	O
PC	O
-	O
3	O
)	O
and	O
non	O
-	O
tumor	O
prostate	O
cells	O
(	O
PNT1A	O
)	O
on	O
5	B-CHEMICAL
-	I-CHEMICAL
dihydrotestosterone	I-CHEMICAL
-	O
activated	O
ARs	B-GENE-Y
containing	O
CAG	B-GENE-N
repeats	I-GENE-N
within	O
normal	O
length	O
range	O
(	O
16	O
,	O
22	O
,	O
and	O
28	O
)	O
.	O

The	O
AhR	B-GENE-Y
target	O
gene	O
CYP1A1	B-GENE-Y
mRNA	O
expression	O
was	O
induced	O
by	O
TCDD	B-CHEMICAL
,	O
but	O
was	O
not	O
affected	O
by	O
the	O
AR	B-GENE-Y
CAG	B-GENE-N
length	O
.	O

TCDD	B-CHEMICAL
had	O
no	O
effect	O
on	O
AR	B-GENE-Y
activity	O
in	O
PC	O
-	O
3	O
cells	O
,	O
whereas	O
the	O
shortest	O
AR	B-GENE-Y
variant	O
was	O
induced	O
by	O
TCDD	B-CHEMICAL
in	O
PNT1A	O
cells	O
.	O

In	O
conclusion	O
,	O
the	O
CAG	B-GENE-N
length	O
dependent	O
effect	O
of	O
TCDD	B-CHEMICAL
on	O
AR	B-GENE-Y
activity	O
in	O
PNT1A	O
,	O
but	O
not	O
in	O
PC	O
-	O
3	O
cells	O
,	O
indicates	O
as	O
a	O
cell	O
-	O
specific	O
effect	O
of	O
TCDD	B-CHEMICAL
on	O
AR	B-GENE-Y
activity	O
.	O

An	O
improved	O
mass	O
spectrometric	O
method	O
for	O
identification	O
and	O
quantification	O
of	O
phenolic	B-CHEMICAL
compounds	O
in	O
apple	O
fruits	O
.	O

Thirty	O
-	O
nine	O
phenolic	B-CHEMICAL
compounds	O
were	O
analysed	O
using	O
ultra	O
high	O
performance	O
liquid	O
chromatography	O
(	O
UHPLC	O
)	O
coupled	O
with	O
diode	O
array	O
and	O
accurate	O
mass	O
spectrometry	O
detection	O
using	O
electrospray	O
ionisation	O
(	O
DAD	O
/	O
ESI	O
-	O
am	O
-	O
MS	O
)	O
.	O

Instrumental	O
parameters	O
such	O
as	O
scan	O
speed	O
,	O
resolution	O
,	O
and	O
mass	O
accuracy	O
were	O
optimised	O
to	O
establish	O
accurate	O
mass	O
measurements	O
.	O

The	O
method	O
was	O
fully	O
validated	O
in	O
terms	O
of	O
model	O
deviation	O
(	O
r	O
(	O
2	O
)	O
>	O
0	O
.	O
9990	O
)	O
,	O
range	O
(	O
typically	O
10	O
-	O
3500	O
ngg	O
(	O
-	O
1	O
)	O
)	O
,	O
intra	O
/	O
inter	O
-	O
day	O
precision	O
(	O
<	O
6	O
%	O
and	O
<	O
8	O
%	O
,	O
respectively	O
)	O
and	O
accuracy	O
(	O
typically	O
100	O
	O
10	O
%	O
)	O
.	O

The	O
mass	O
accuracy	O
of	O
each	O
selected	O
phenolic	B-CHEMICAL
compound	O
was	O
below	O
1	O
.	O
5	O
ppm	O
.	O

The	O
results	O
confirmed	O
that	O
the	O
UHPLC	O
-	O
DAD	O
/	O
ESI	O
-	O
am	O
-	O
MS	O
method	O
developed	O
here	O
was	O
convenient	O
and	O
reliable	O
for	O
the	O
determination	O
of	O
phenolic	B-CHEMICAL
compounds	O
in	O
apple	O
extracts	O
.	O

Reduced	O
in	O
vitro	O
and	O
in	O
vivo	O
toxicity	O
of	O
siRNA	O
-	O
lipoplexes	O
with	O
addition	O
of	O
polyglutamate	B-CHEMICAL
.	O

We	O
previously	O
designed	O
a	O
new	O
siRNA	O
vector	O
that	O
efficiently	O
silences	O
genes	O
in	O
vitro	O
and	O
in	O
vivo	O
.	O

The	O
vector	O
originality	O
is	O
based	O
on	O
the	O
fact	O
that	O
,	O
in	O
addition	O
to	O
the	O
siRNA	O
molecule	O
,	O
it	O
contains	O
two	O
components	O
:	O
1	O
)	O
a	O
cationic	O
liposome	O
that	O
auto	O
-	O
associates	O
with	O
the	O
siRNA	O
to	O
form	O
particles	O
called	O
"	O
lipoplexes	O
"	O
and	O
,	O
2	O
)	O
an	O
anionic	O
polymer	O
which	O
enhances	O
the	O
lipoplex	O
'	O
s	O
efficiency	O
.	O

This	O
anionic	O
polymer	O
can	O
be	O
a	O
nucleic	O
acid	O
,	O
a	O
polypeptide	O
or	O
a	O
polysaccharide	O
.	O

We	O
show	O
here	O
how	O
the	O
nature	O
of	O
the	O
added	O
anionic	O
polymer	O
into	O
our	O
siRNA	O
delivery	O
system	O
impacts	O
the	O
toxic	O
effects	O
induced	O
by	O
siRNA	O
lipoplexes	O
.	O

We	O
first	O
observed	O
that	O
:	O
(	O
i	O
)	O
siRNA	O
lipoplexes	O
-	O
induced	O
toxicity	O
was	O
cell	O
line	O
dependent	O
,	O
tumoral	O
cell	O
lines	O
being	O
the	O
more	O
sensitive	O
;	O
and	O
(	O
ii	O
)	O
plasmid	O
DNA	O
-	O
containing	O
siRNA	O
lipoplexes	O
were	O
more	O
toxic	O
than	O
polyglutamate	B-CHEMICAL
-	O
containing	O
ones	O
or	O
cationic	O
liposomes	O
.	O

We	O
next	O
determined	O
that	O
the	O
toxicity	O
induced	O
by	O
plasmid	O
-	O
containing	O
lipoplexes	O
is	O
a	O
long	O
-	O
lasting	O
effect	O
that	O
decreased	O
cell	O
survival	O
capacity	O
for	O
several	O
generations	O
.	O

We	O
also	O
found	O
that	O
treated	O
cells	O
underwent	O
death	O
following	O
apoptosis	O
pathway	O
.	O

Systemic	O
injection	O
to	O
mice	O
of	O
siRNA	O
lipoplexes	O
,	O
rather	O
than	O
of	O
cationic	O
liposome	O
,	O
triggered	O
a	O
production	O
of	O
several	O
cytokines	B-GENE-N
in	O
mice	O
and	O
replacement	O
of	O
plasmid	O
by	O
polyglutamate	B-CHEMICAL
reduced	O
the	O
elevation	O
of	O
all	O
assayed	O
cytokines	B-GENE-N
.	O

In	O
order	O
to	O
enhance	O
siRNA	O
lipoplexes	O
efficiency	O
,	O
the	O
addition	O
of	O
polyglutamate	B-CHEMICAL
as	O
anionic	O
polymer	O
should	O
be	O
preferred	O
to	O
plasmid	O
DNA	O
as	O
far	O
as	O
in	O
vitro	O
as	O
well	O
as	O
in	O
vivo	O
toxicity	O
is	O
concerned	O
.	O

Helenalin	B-CHEMICAL
-	O
induced	O
apoptosis	O
is	O
dependent	O
on	O
production	O
of	O
reactive	O
oxygen	B-CHEMICAL
species	O
and	O
independent	O
of	O
induction	O
of	O
endoplasmic	O
reticulum	O
stress	O
in	O
renal	O
cell	O
carcinoma	O
.	O

Helenalin	B-CHEMICAL
,	O
a	O
sesquiterpene	B-CHEMICAL
lactone	I-CHEMICAL
,	O
exhibits	O
anti	O
-	O
inflammatory	O
and	O
anti	O
-	O
tumor	O
activities	O
.	O

Here	O
,	O
we	O
investigated	O
whether	O
helenalin	B-CHEMICAL
could	O
induce	O
apoptosis	O
in	O
human	O
renal	O
carcinoma	O
Caki	O
cells	O
.	O

Helenalin	B-CHEMICAL
increased	O
apoptosis	O
in	O
dose	O
dependent	O
manner	O
in	O
Caki	O
cells	O
,	O
and	O
also	O
induced	O
apoptosis	O
in	O
other	O
carcinoma	O
cells	O
,	O
such	O
as	O
human	O
renal	O
carcinoma	O
ACHN	O
cells	O
,	O
human	O
colon	O
carcinoma	O
HT29	O
and	O
HCT116	O
cells	O
.	O

We	O
found	O
that	O
helenalin	B-CHEMICAL
markedly	O
induced	O
endoplasmic	O
reticulum	O
(	O
ER	O
)	O
stress	O
-	O
related	O
genes	O
,	O
such	O
as	O
regulated	B-GENE-Y
in	I-GENE-Y
development	I-GENE-Y
and	I-GENE-Y
DNA	I-GENE-Y
damage	I-GENE-Y
responses	I-GENE-Y
(	I-GENE-Y
REDD	I-GENE-Y
)	I-GENE-Y
1	I-GENE-Y
,	O
activating	B-GENE-Y
transcription	I-GENE-Y
factor	I-GENE-Y
-	I-GENE-Y
4	I-GENE-Y
(	O
ATF4	B-GENE-Y
)	O
and	O
/	O
or	O
the	O
CCAAT	B-GENE-Y
enhancer	I-GENE-Y
-	I-GENE-Y
binding	I-GENE-Y
protein	I-GENE-Y
-	I-GENE-Y
homologous	I-GENE-Y
protein	I-GENE-Y
(	O
CHOP	B-GENE-Y
)	O
.	O

However	O
,	O
down	O
-	O
regulation	O
of	O
ATF4	B-GENE-Y
and	O
/	O
or	O
CHOP	B-GENE-Y
expression	O
by	O
siRNA	O
had	O
no	O
effect	O
on	O
helenalin	B-CHEMICAL
-	O
induced	O
apoptosis	O
in	O
Caki	O
and	O
HCT116	O
cells	O
.	O

Helenalin	B-CHEMICAL
increased	O
production	O
of	O
intracellular	O
reactive	O
oxygen	B-CHEMICAL
species	O
(	O
ROS	O
)	O
.	O

Furthermore	O
,	O
ROS	O
scavengers	O
,	O
N	B-CHEMICAL
-	I-CHEMICAL
acetylcystine	I-CHEMICAL
(	O
NAC	B-CHEMICAL
)	O
,	O
and	O
glutathione	B-CHEMICAL
ethyl	I-CHEMICAL
ester	I-CHEMICAL
(	O
GEE	B-CHEMICAL
)	O
,	O
reduced	O
helenalin	B-CHEMICAL
-	O
induced	O
apoptosis	O
.	O

Taken	O
together	O
,	O
helenalin	B-CHEMICAL
induced	O
apoptosis	O
via	O
ROS	O
generation	O
in	O
human	O
renal	O
carcinoma	O
Caki	O
cells	O
.	O

Contributions	O
of	O
rat	B-GENE-Y
Ctr1	I-GENE-Y
to	O
the	O
uptake	O
and	O
toxicity	O
of	O
copper	B-CHEMICAL
and	O
platinum	B-CHEMICAL
anticancer	O
drugs	O
in	O
dorsal	O
root	O
ganglion	O
neurons	O
.	O

Dorsal	O
root	O
ganglion	O
(	O
DRG	O
)	O
neurons	O
are	O
affected	O
by	O
platinum	B-CHEMICAL
-	O
induced	O
neurotoxicity	O
and	O
neurodegenerative	O
processes	O
associated	O
with	O
disturbed	O
copper	B-CHEMICAL
homeostasis	O
and	O
transport	O
.	O

This	O
study	O
aimed	O
to	O
understand	O
the	O
role	O
of	O
copper	B-GENE-Y
transporter	I-GENE-Y
1	I-GENE-Y
(	O
Ctr1	B-GENE-Y
)	O
in	O
the	O
uptake	O
and	O
toxicity	O
of	O
copper	B-CHEMICAL
and	O
platinum	B-CHEMICAL
drugs	O
in	O
cultured	O
rat	O
DRG	O
neurons	O
,	O
and	O
the	O
functional	O
activities	O
of	O
rat	B-GENE-Y
Ctr1	I-GENE-Y
(	O
rCtr1	B-GENE-Y
)	O
as	O
a	O
membrane	O
transporter	O
of	O
copper	B-CHEMICAL
and	O
platinum	B-CHEMICAL
drugs	O
.	O

Heterologous	O
expression	O
of	O
rCtr1	B-GENE-Y
in	O
HEK293	O
cells	O
(	O
HEK	O
/	O
rCtr1	B-GENE-Y
cells	O
)	O
increased	O
the	O
uptake	O
and	O
cytotoxicity	O
of	O
copper	B-CHEMICAL
,	O
oxaliplatin	B-CHEMICAL
,	O
cisplatin	B-CHEMICAL
and	O
carboplatin	B-CHEMICAL
,	O
in	O
comparison	O
to	O
isogenic	O
vector	O
-	O
transfected	O
control	O
cells	O
.	O

Cultured	O
rat	O
DRG	O
neurons	O
endogenously	O
expressed	O
rCtr1	B-GENE-Y
protein	O
on	O
their	O
neuronal	O
cell	O
body	O
plasma	O
membranes	O
and	O
cytoplasm	O
,	O
and	O
displayed	O
substantial	O
capacity	O
for	O
taking	O
up	O
copper	B-CHEMICAL
,	O
but	O
were	O
resistant	O
to	O
copper	B-CHEMICAL
toxicity	O
.	O

The	O
uptake	O
of	O
copper	B-CHEMICAL
by	O
both	O
cultured	O
rat	O
DRG	O
neurons	O
and	O
HEK	O
/	O
rCtr1	B-GENE-Y
cells	O
was	O
saturable	O
and	O
inhibited	O
by	O
cold	O
temperature	O
,	O
silver	B-CHEMICAL
and	O
zinc	B-CHEMICAL
,	O
consistent	O
with	O
it	O
being	O
mediated	O
by	O
rCtr1	B-GENE-Y
.	O

Cultured	O
rat	O
DRG	O
neurons	O
accumulated	O
platinum	B-CHEMICAL
during	O
their	O
exposure	O
to	O
oxaliplatin	B-CHEMICAL
and	O
were	O
sensitive	O
to	O
oxaliplatin	B-CHEMICAL
cytotoxicity	O
.	O

The	O
accumulation	O
of	O
platinum	B-CHEMICAL
by	O
both	O
cultured	O
rat	O
DRG	O
neurons	O
and	O
HEK	O
/	O
rCtr1	B-GENE-Y
cells	O
,	O
during	O
oxaliplatin	B-CHEMICAL
exposure	O
,	O
was	O
saturable	O
and	O
temperature	O
dependent	O
,	O
but	O
was	O
inhibited	O
by	O
copper	B-CHEMICAL
only	O
in	O
HEK	O
/	O
rCtr1	B-GENE-Y
cells	O
.	O

In	O
conclusion	O
,	O
rCtr1	B-GENE-Y
can	O
transport	O
copper	B-CHEMICAL
and	O
platinum	B-CHEMICAL
drugs	O
,	O
and	O
sensitizes	O
cells	O
to	O
their	O
cytotoxicities	O
.	O

DRG	O
neurons	O
display	O
substantial	O
capacity	O
for	O
accumulating	O
copper	B-CHEMICAL
via	O
a	O
transport	O
process	O
mediated	O
by	O
rCtr1	B-GENE-Y
,	O
but	O
appear	O
able	O
to	O
resist	O
copper	B-CHEMICAL
toxicity	O
and	O
use	O
alternative	O
mechanisms	O
to	O
take	O
up	O
oxaliplatin	B-CHEMICAL
.	O

Cell	O
cycle	O
regulation	O
by	O
glucosamine	B-CHEMICAL
in	O
human	O
pulmonary	O
epithelial	O
cells	O
.	O

Airway	O
epithelial	O
cells	O
play	O
an	O
important	O
role	O
against	O
intruding	O
pathogens	O
.	O

Glucosamine	B-CHEMICAL
,	O
a	O
commonly	O
used	O
supplemental	O
compound	O
,	O
has	O
recently	O
begun	O
to	O
be	O
regarded	O
as	O
a	O
potential	O
anti	O
-	O
inflammatory	O
molecule	O
.	O

This	O
study	O
aimed	O
to	O
uncover	O
how	O
glucosamine	B-CHEMICAL
impacts	O
on	O
cellular	O
proliferation	O
in	O
human	O
alveolar	O
epithelial	O
cells	O
(	O
A549	O
)	O
and	O
bronchial	O
epithelial	O
cells	O
(	O
HBECs	O
)	O
.	O

With	O
trypan	B-CHEMICAL
blue	I-CHEMICAL
-	O
exclusion	O
assay	O
,	O
we	O
observed	O
that	O
glucosamine	B-CHEMICAL
(	O
10	O
,	O
20	O
,	O
50	O
mM	O
)	O
caused	O
a	O
decrease	O
in	O
cell	O
number	O
at	O
24	O
and	O
48	O
h	O
;	O
with	O
a	O
flow	O
cytometric	O
analysis	O
,	O
we	O
also	O
noted	O
an	O
enhanced	O
cell	O
accumulation	O
within	O
the	O
G	O
(	O
0	O
)	O
/	O
G	O
(	O
1	O
)	O
phase	O
at	O
24	O
h	O
and	O
induction	O
of	O
late	O
apoptosis	O
at	O
24	O
and	O
48	O
h	O
by	O
glucosamine	B-CHEMICAL
(	O
10	O
,	O
20	O
,	O
50	O
mM	O
)	O
in	O
A549	O
cells	O
and	O
HBECs	O
.	O

Examination	O
of	O
phosphorylation	O
in	O
retinoblastoma	B-GENE-Y
(	I-GENE-Y
Rb	I-GENE-Y
)	I-GENE-Y
protein	I-GENE-Y
,	O
we	O
found	O
an	O
inhibitory	O
effect	O
by	O
glucosamine	B-CHEMICAL
at	O
20	O
and	O
50	O
mM	O
.	O

Glucosamine	B-CHEMICAL
at	O
50	O
mM	O
was	O
demonstrated	O
to	O
elevate	O
both	O
the	O
mRNA	O
and	O
protein	O
expression	O
of	O
p53	B-GENE-N
and	O
heme	B-GENE-Y
oxygenase	I-GENE-Y
-	I-GENE-Y
1	I-GENE-Y
(	O
HO	B-GENE-Y
-	I-GENE-Y
1	I-GENE-Y
)	O
,	O
but	O
also	O
caused	O
a	O
reduction	O
in	O
p21	B-GENE-Y
protein	O
expression	O
.	O

In	O
addition	O
,	O
glucosamine	B-CHEMICAL
attenuated	O
p21	B-GENE-Y
protein	O
stability	O
via	O
the	O
proteasomal	O
proteolytic	O
pathway	O
,	O
as	O
well	O
as	O
inducing	O
p21	B-GENE-Y
nuclear	O
accumulation	O
.	O

Altogether	O
,	O
our	O
results	O
suggest	O
that	O
a	O
high	O
dose	O
of	O
glucosamine	B-CHEMICAL
may	O
inhibit	O
cell	O
proliferation	O
through	O
apoptosis	O
and	O
disturb	O
cell	O
cycle	O
progression	O
with	O
a	O
halt	O
at	O
G	O
(	O
0	O
)	O
/	O
G	O
(	O
1	O
)	O
phase	O
,	O
and	O
that	O
this	O
occurs	O
,	O
at	O
least	O
in	O
part	O
,	O
by	O
a	O
reduction	O
in	O
Rb	B-GENE-Y
phosphorylation	O
together	O
with	O
modulation	O
of	O
p21	B-GENE-Y
,	O
p53	B-GENE-N
and	O
HO	B-GENE-Y
-	I-GENE-Y
1	I-GENE-Y
expression	O
,	O
and	O
nuclear	O
p21	B-GENE-Y
accumulation	O
.	O

Characterization	O
of	O
substituted	O
phenylpropylamides	B-CHEMICAL
as	O
highly	O
selective	O
agonists	O
at	O
the	O
melatonin	B-GENE-Y
MT2	I-GENE-Y
receptor	I-GENE-Y
.	O

Melatonin	B-CHEMICAL
is	O
a	O
widely	O
distributed	O
hormone	O
that	O
regulates	O
several	O
major	O
physiological	O
processes	O
,	O
including	O
the	O
circadian	O
rhythm	O
and	O
seasonal	O
adaptation	O
.	O

The	O
two	O
subtypes	O
of	O
mammalian	B-GENE-N
G	I-GENE-N
protein	I-GENE-N
-	I-GENE-N
coupled	I-GENE-N
melatonin	I-GENE-N
receptors	I-GENE-N
are	O
primarily	O
responsible	O
for	O
mediating	O
the	O
actions	O
of	O
melatonin	B-CHEMICAL
.	O

Because	O
synthetic	O
melatonin	B-CHEMICAL
agonists	O
have	O
considerable	O
therapeutic	O
potentials	O
in	O
modulating	O
insomnia	O
and	O
circadian	O
-	O
related	O
sleep	O
disorders	O
,	O
it	O
is	O
highly	O
desirable	O
to	O
develop	O
subtype	O
-	O
selective	O
melatoninergic	O
compounds	O
.	O

The	O
pharmacological	O
potencies	O
of	O
a	O
series	O
of	O
substituted	O
N	B-CHEMICAL
-	I-CHEMICAL
[	I-CHEMICAL
3	I-CHEMICAL
-	I-CHEMICAL
(	I-CHEMICAL
3	I-CHEMICAL
-	I-CHEMICAL
methoxyphenyl	I-CHEMICAL
)	I-CHEMICAL
propyl	I-CHEMICAL
]	I-CHEMICAL
amides	I-CHEMICAL
towards	O
human	B-GENE-Y
melatonin	I-GENE-Y
MT	I-GENE-Y
(	I-GENE-Y
1	I-GENE-Y
)	I-GENE-Y
and	O
MT	B-GENE-Y
(	I-GENE-Y
2	I-GENE-Y
)	I-GENE-Y
receptors	I-GENE-Y
were	O
evaluated	O
by	O
the	O
FLIPR	O
high	O
-	O
throughput	O
screening	O
assay	O
,	O
whilst	O
their	O
subtype	O
-	O
selectivity	O
was	O
subsequently	O
verified	O
with	O
ERK	B-GENE-N
phosphorylation	O
and	O
cAMP	B-CHEMICAL
assays	O
.	O

Structure	O
-	O
activity	O
relationship	O
analysis	O
of	O
highly	O
potent	O
subtype	O
-	O
selective	O
ligands	O
(	O
MT	B-GENE-Y
(	I-GENE-Y
2	I-GENE-Y
)	I-GENE-Y
EC	O
(	O
50	O
)	O
10	O
-	O
90	O
pM	O
)	O
revealed	O
that	O
a	O
benzyloxyl	B-CHEMICAL
substituent	O
incorporated	O
at	O
C6	O
position	O
of	O
the	O
3	B-CHEMICAL
-	I-CHEMICAL
methoxyphenyl	I-CHEMICAL
ring	O
dramatically	O
enhanced	O
the	O
MT	B-GENE-Y
(	I-GENE-Y
2	I-GENE-Y
)	I-GENE-Y
potency	O
and	O
at	O
the	O
same	O
time	O
decreased	O
MT	B-GENE-Y
(	I-GENE-Y
1	I-GENE-Y
)	I-GENE-Y
potency	O
.	O

Incorporation	O
of	O
structural	O
moieties	O
conferring	O
the	O
subtype	O
selectivity	O
produced	O
several	O
extremely	O
potent	O
MT	B-GENE-Y
(	I-GENE-Y
2	I-GENE-Y
)	I-GENE-Y
-	O
selective	O
ligands	O
.	O

The	O
most	O
potent	O
subtype	O
-	O
selective	O
ligand	O
,	O
2q	O
had	O
a	O
substantially	O
higher	O
potency	O
for	O
MT	B-GENE-Y
(	I-GENE-Y
2	I-GENE-Y
)	I-GENE-Y
receptor	I-GENE-Y
than	O
melatonin	B-CHEMICAL
for	O
elevation	O
of	O
[	O
Ca	B-CHEMICAL
(	I-CHEMICAL
2	I-CHEMICAL
+	I-CHEMICAL
)	I-CHEMICAL
]	O
i	O
and	O
inhibition	O
of	O
forskolin	O
-	O
elevated	O
cAMP	O
.	O

Representative	O
MT	B-GENE-Y
(	I-GENE-Y
2	I-GENE-Y
)	I-GENE-Y
-	O
selective	O
ligands	O
also	O
induced	O
ERK	B-GENE-N
phosphorylation	O
in	O
both	O
recombinant	O
and	O
native	O
cell	O
lines	O
,	O
and	O
no	O
cross	O
-	O
reactivity	O
to	O
17	O
other	O
GPCRs	B-GENE-N
could	O
be	O
detected	O
.	O

These	O
ligands	O
represent	O
invaluable	O
tools	O
for	O
delineating	O
the	O
functional	O
roles	O
of	O
distinct	O
melatonin	B-GENE-N
receptor	I-GENE-N
subtypes	O
and	O
are	O
viable	O
candidates	O
for	O
drug	O
development	O
.	O

Proto	B-GENE-N
-	I-GENE-N
oncogene	I-GENE-N
PIM	B-GENE-Y
-	I-GENE-Y
1	I-GENE-Y
is	O
a	O
novel	O
estrogen	B-GENE-Y
receptor	I-GENE-Y
target	O
associating	O
with	O
high	O
grade	O
breast	O
tumors	O
.	O

We	O
searched	O
ER	B-GENE-Y
cistromes	O
of	O
MCF	O
-	O
7	O
breast	O
cancer	O
cells	O
for	O
previously	O
unrecognized	O
ER	B-GENE-Y
targets	O
and	O
identified	O
proto	B-GENE-N
-	I-GENE-N
oncogene	I-GENE-N
PIM	B-GENE-Y
-	I-GENE-Y
1	I-GENE-Y
as	O
a	O
novel	O
potential	O
target	O
gene	O
.	O

We	O
show	O
that	O
the	O
expression	O
of	O
PIM	B-GENE-Y
-	I-GENE-Y
1	I-GENE-Y
is	O
induced	O
in	O
response	O
to	O
estradiol	B-CHEMICAL
in	O
MCF	O
-	O
7	O
cells	O
and	O
that	O
the	O
induction	O
is	O
mediated	O
by	O
ER	B-GENE-Y
-	O
regulated	O
enhancers	O
located	O
distally	O
upstream	O
from	O
the	O
gene	O
.	O

In	O
keeping	O
with	O
the	O
growth	O
-	O
promoting	O
role	O
of	O
the	O
PIM	B-GENE-Y
-	I-GENE-Y
1	I-GENE-Y
,	O
depletion	O
of	O
the	O
PIM	B-GENE-Y
-	I-GENE-Y
1	I-GENE-Y
attenuated	O
the	O
proliferation	O
of	O
the	O
MCF	O
-	O
7	O
cells	O
,	O
which	O
was	O
paralleled	O
with	O
up	O
-	O
regulation	O
of	O
cyclin	B-GENE-N
-	I-GENE-N
dependent	I-GENE-N
protein	I-GENE-N
kinase	I-GENE-N
inhibitor	I-GENE-N
CDKN1A	B-GENE-Y
and	O
CDKN2B	B-GENE-Y
expression	O
.	O

Analysis	O
of	O
PIM	B-GENE-Y
-	I-GENE-Y
1	I-GENE-Y
expression	O
between	O
invasive	O
breast	O
tumors	O
and	O
benign	O
breast	O
tissue	O
samples	O
showed	O
that	O
elevated	O
PIM	B-GENE-Y
-	I-GENE-Y
1	I-GENE-Y
expression	O
is	O
associated	O
with	O
malignancy	O
and	O
a	O
higher	O
tumor	O
grade	O
.	O

In	O
sum	O
,	O
identification	O
of	O
PIM	B-GENE-Y
-	I-GENE-Y
1	I-GENE-Y
as	O
an	O
ER	B-GENE-Y
target	O
gene	O
adds	O
a	O
novel	O
potential	O
mechanism	O
by	O
which	O
estrogens	B-CHEMICAL
can	O
contribute	O
to	O
breast	O
cancer	O
cell	O
proliferation	O
and	O
carcinogenesis	O
.	O

Metabolic	O
pathways	O
of	O
inhaled	O
glucocorticoids	O
by	O
the	O
CYP3A	B-GENE-N
enzymes	O
.	O

Asthma	O
is	O
one	O
of	O
the	O
most	O
prevalent	O
diseases	O
in	O
the	O
world	O
,	O
for	O
which	O
the	O
mainstay	O
treatment	O
has	O
been	O
inhaled	O
glucocorticoids	O
(	O
GCs	O
)	O
.	O

Despite	O
the	O
widespread	O
use	O
of	O
these	O
drugs	O
,	O
approximately	O
30	O
%	O
of	O
asthma	O
sufferers	O
exhibit	O
some	O
degree	O
of	O
steroid	B-CHEMICAL
insensitivity	O
or	O
are	O
refractory	O
to	O
inhaled	O
GCs	O
.	O

One	O
hypothesis	O
to	O
explain	O
this	O
phenomenon	O
is	O
interpatient	O
variability	O
in	O
the	O
clearance	O
of	O
these	O
compounds	O
.	O

The	O
objective	O
of	O
this	O
research	O
is	O
to	O
determine	O
how	O
metabolism	O
of	O
GCs	O
by	O
the	O
CYP3A	B-GENE-N
family	O
of	O
enzymes	O
could	O
affect	O
their	O
effectiveness	O
in	O
asthmatic	O
patients	O
.	O

In	O
this	O
work	O
,	O
the	O
metabolism	O
of	O
four	O
frequently	O
prescribed	O
inhaled	O
GCs	O
,	O
triamcinolone	B-CHEMICAL
acetonide	I-CHEMICAL
,	O
flunisolide	B-CHEMICAL
,	O
budesonide	B-CHEMICAL
,	O
and	O
fluticasone	B-CHEMICAL
propionate	I-CHEMICAL
,	O
by	O
the	O
CYP3A	B-GENE-N
family	O
of	O
enzymes	O
was	O
studied	O
to	O
identify	O
differences	O
in	O
their	O
rates	O
of	O
clearance	O
and	O
to	O
identify	O
their	O
metabolites	O
.	O

Both	O
interenzyme	O
and	O
interdrug	O
variability	O
in	O
rates	O
of	O
metabolism	O
and	O
metabolic	O
fate	O
were	O
observed	O
.	O

CYP3A4	B-GENE-Y
was	O
the	O
most	O
efficient	O
metabolic	O
catalyst	O
for	O
all	O
the	O
compounds	O
,	O
and	O
CYP3A7	B-GENE-Y
had	O
the	O
slowest	O
rates	O
.	O

CYP3A5	B-GENE-Y
,	O
which	O
is	O
particularly	O
relevant	O
to	O
GC	O
metabolism	O
in	O
the	O
lungs	O
,	O
was	O
also	O
shown	O
to	O
efficiently	O
metabolize	O
triamcinolone	B-CHEMICAL
acetonide	I-CHEMICAL
,	O
budesonide	B-CHEMICAL
,	O
and	O
fluticasone	B-CHEMICAL
propionate	I-CHEMICAL
.	O

In	O
contrast	O
,	O
flunisolide	B-CHEMICAL
was	O
only	O
metabolized	O
via	O
CYP3A4	B-GENE-Y
,	O
with	O
no	O
significant	O
turnover	O
by	O
CYP3A5	B-GENE-Y
or	O
CYP3A7	B-GENE-Y
.	O

Common	O
metabolites	O
included	O
6	O
-	O
hydroxylation	O
and	O
	O
(	O
6	O
)	O
-	O
dehydrogenation	O
for	O
triamcinolone	B-CHEMICAL
acetonide	I-CHEMICAL
,	O
budesonide	B-CHEMICAL
,	O
and	O
flunisolide	B-CHEMICAL
.	O

The	O
structure	O
of	O
	B-CHEMICAL
(	I-CHEMICAL
6	I-CHEMICAL
)	I-CHEMICAL
-	I-CHEMICAL
flunisolide	I-CHEMICAL
was	O
unambiguously	O
established	O
by	O
NMR	O
analysis	O
.	O

Metabolism	O
also	O
occurred	O
on	O
the	O
D	O
-	O
ring	O
substituents	O
,	O
including	O
the	O
21	B-CHEMICAL
-	I-CHEMICAL
carboxy	I-CHEMICAL
metabolites	O
for	O
triamcinolone	B-CHEMICAL
acetonide	I-CHEMICAL
and	O
flunisolide	B-CHEMICAL
.	O

The	O
novel	O
metabolite	O
21	B-CHEMICAL
-	I-CHEMICAL
nortriamcinolone	I-CHEMICAL
acetonide	I-CHEMICAL
was	O
also	O
identified	O
by	O
liquid	O
chromatography	O
-	O
mass	O
spectrometry	O
and	O
NMR	O
analysis	O
.	O

Distinct	O
roles	O
of	O
methamphetamine	B-CHEMICAL
in	O
modulating	O
spatial	O
memory	O
consolidation	O
,	O
retrieval	O
,	O
reconsolidation	O
and	O
the	O
accompanying	O
changes	O
of	O
ERK	B-GENE-N
and	O
CREB	B-GENE-N
activation	O
in	O
hippocampus	O
and	O
prefrontal	O
cortex	O
.	O

Drugs	O
of	O
abuse	O
modulated	O
learning	O
and	O
memory	O
in	O
humans	O
yet	O
the	O
underlying	O
mechanism	O
remained	O
unclear	O
.	O

The	O
extracellular	B-GENE-N
signal	I-GENE-N
-	I-GENE-N
regulated	I-GENE-N
kinase	I-GENE-N
(	O
ERK	B-GENE-N
)	O
and	O
the	O
transcription	O
factor	O
cAMP	B-GENE-N
response	I-GENE-N
element	I-GENE-N
-	I-GENE-N
binding	I-GENE-N
protein	I-GENE-N
(	O
CREB	B-GENE-N
)	O
were	O
involved	O
in	O
neuroplastic	O
changes	O
associated	O
with	O
learning	O
and	O
memory	O
.	O

In	O
the	O
current	O
study	O
,	O
we	O
used	O
a	O
Morris	O
water	O
maze	O
to	O
examine	O
the	O
effect	O
of	O
methamphetamine	B-CHEMICAL
(	O
METH	B-CHEMICAL
)	O
on	O
different	O
processes	O
of	O
spatial	O
memory	O
in	O
mice	O
.	O

We	O
then	O
investigated	O
the	O
status	O
of	O
ERK	B-GENE-N
and	O
CREB	B-GENE-N
in	O
the	O
hippocampus	O
and	O
prefrontal	O
cortex	O
(	O
PFC	O
)	O
.	O

We	O
found	O
that	O
1	O
.	O
0	O
mg	O
/	O
kg	O
dose	O
of	O
METH	B-CHEMICAL
facilitated	O
spatial	O
memory	O
consolidation	O
when	O
it	O
was	O
injected	O
immediately	O
after	O
the	O
last	O
learning	O
trial	O
.	O

In	O
contrast	O
,	O
the	O
same	O
dose	O
of	O
METH	B-CHEMICAL
had	O
no	O
effect	O
on	O
spatial	O
memory	O
retrieval	O
when	O
it	O
was	O
injected	O
30	O
min	O
before	O
the	O
test	O
.	O

Furthermore	O
,	O
1	O
.	O
0	O
mg	O
/	O
kg	O
dose	O
of	O
METH	B-CHEMICAL
injected	O
immediately	O
after	O
retrieval	O
had	O
no	O
effect	O
on	O
spatial	O
memory	O
reconsolidation	O
.	O

Activation	O
of	O
both	O
ERK	B-GENE-N
and	O
CREB	B-GENE-N
in	O
the	O
hippocampus	O
was	O
found	O
following	O
memory	O
consolidation	O
but	O
not	O
after	O
retrieval	O
or	O
reconsolidation	O
in	O
METH	B-CHEMICAL
-	O
treated	O
mouse	O
groups	O
.	O

In	O
contrast	O
,	O
activation	O
of	O
both	O
ERK	B-GENE-N
and	O
CREB	B-GENE-N
in	O
the	O
PFC	O
was	O
found	O
following	O
memory	O
retrieval	O
but	O
not	O
other	O
processes	O
in	O
METH	B-CHEMICAL
-	O
treated	O
mouse	O
groups	O
.	O

These	O
results	O
suggested	O
that	O
METH	B-CHEMICAL
facilitated	O
spatial	O
memory	O
consolidation	O
but	O
not	O
retrieval	O
or	O
reconsolidation	O
.	O

Moreover	O
,	O
activation	O
of	O
the	O
ERK	B-GENE-N
and	O
CREB	B-GENE-N
signaling	O
pathway	O
in	O
the	O
hippocampus	O
might	O
be	O
involved	O
in	O
METH	B-CHEMICAL
-	O
induced	O
spatial	O
memory	O
changes	O
.	O

The	O
impact	O
of	O
oxytocin	B-CHEMICAL
administration	O
and	O
maternal	O
love	O
withdrawal	O
on	O
event	O
-	O
related	O
potential	O
(	O
ERP	O
)	O
responses	O
to	O
emotional	O
faces	O
with	O
performance	O
feedback	O
.	O

This	O
is	O
the	O
first	O
experimental	O
study	O
on	O
the	O
effect	O
of	O
oxytocin	B-CHEMICAL
administration	O
on	O
the	O
neural	O
processing	O
of	O
facial	O
stimuli	O
conducted	O
with	O
female	O
participants	O
that	O
uses	O
event	O
-	O
related	O
potentials	O
(	O
ERPs	O
)	O
.	O

Using	O
a	O
double	O
-	O
blind	O
,	O
placebo	O
-	O
controlled	O
within	O
-	O
subjects	O
design	O
,	O
we	O
studied	O
the	O
effects	O
of	O
16	O
IU	O
of	O
intranasal	O
oxytocin	B-CHEMICAL
on	O
ERPs	O
to	O
pictures	O
combining	O
performance	O
feedback	O
with	O
emotional	O
facial	O
expressions	O
in	O
48	O
female	O
undergraduate	O
students	O
.	O

Participants	O
also	O
reported	O
on	O
the	O
amount	O
of	O
love	O
withdrawal	O
they	O
experienced	O
from	O
their	O
mothers	O
.	O

Vertex	O
positive	O
potential	O
(	O
VPP	O
)	O
and	O
late	O
positive	O
potential	O
(	O
LPP	O
)	O
amplitudes	O
were	O
more	O
positive	O
after	O
oxytocin	B-CHEMICAL
compared	O
to	O
placebo	O
administration	O
.	O

This	O
suggests	O
that	O
oxytocin	B-CHEMICAL
increased	O
attention	O
to	O
the	O
feedback	O
stimuli	O
(	O
LPP	O
)	O
and	O
enhanced	O
the	O
processing	O
of	O
emotional	O
faces	O
(	O
VPP	O
)	O
.	O

Oxytocin	B-CHEMICAL
heightened	O
processing	O
of	O
the	O
happy	O
and	O
disgusted	O
faces	O
primarily	O
for	O
those	O
reporting	O
less	O
love	O
withdrawal	O
.	O

Significant	O
associations	O
with	O
LPP	O
amplitude	O
suggest	O
that	O
more	O
maternal	O
love	O
withdrawal	O
relates	O
to	O
the	O
allocation	O
of	O
attention	O
toward	O
the	O
motivationally	O
relevant	O
combination	O
of	O
negative	O
feedback	O
with	O
a	O
disgusted	O
face	O
.	O

Ras	B-GENE-Y
-	I-GENE-Y
dva	I-GENE-Y
is	O
a	O
novel	O
Pit	B-GENE-Y
-	I-GENE-Y
1	I-GENE-Y
-	O
and	O
glucocorticoid	O
-	O
regulated	O
gene	O
in	O
the	O
embryonic	O
anterior	O
pituitary	O
gland	O
.	O

Glucocorticoids	O
play	O
a	O
role	O
in	O
functional	O
differentiation	O
of	O
pituitary	O
somatotrophs	O
and	O
lactotrophs	O
during	O
embryogenesis	O
.	O

Ras	B-GENE-Y
-	I-GENE-Y
dva	I-GENE-Y
was	O
identified	O
as	O
a	O
gene	O
regulated	O
by	O
anterior	B-GENE-Y
neural	I-GENE-Y
fold	I-GENE-Y
protein	I-GENE-Y
-	I-GENE-Y
1	I-GENE-Y
/	I-GENE-Y
homeobox	I-GENE-Y
expressed	O
in	O
embryonic	O
stem	O
cells	O
-	O
1	O
,	O
a	O
transcription	O
factor	O
known	O
to	O
be	O
critical	O
in	O
pituitary	O
development	O
,	O
and	O
has	O
an	O
expression	O
profile	O
in	O
the	O
chicken	O
embryonic	O
pituitary	O
gland	O
that	O
is	O
consistent	O
with	O
in	O
vivo	O
regulation	O
by	O
glucocorticoids	O
.	O

The	O
objective	O
of	O
this	O
study	O
was	O
to	O
characterize	O
expression	O
and	O
regulation	O
of	O
ras	B-GENE-Y
-	I-GENE-Y
dva	I-GENE-Y
mRNA	O
in	O
the	O
developing	O
chicken	O
anterior	O
pituitary	O
.	O

Pituitary	O
ras	B-GENE-Y
-	I-GENE-Y
dva	I-GENE-Y
mRNA	O
levels	O
increased	O
during	O
embryogenesis	O
to	O
a	O
maximum	O
on	O
embryonic	O
day	O
(	O
e	O
)	O
18	O
and	O
then	O
decreased	O
and	O
remained	O
low	O
or	O
undetectable	O
after	O
hatch	O
.	O

Ras	B-GENE-Y
-	I-GENE-Y
dva	I-GENE-Y
expression	O
was	O
highly	O
enriched	O
in	O
the	O
pituitary	O
gland	O
on	O
e18	O
relative	O
to	O
other	O
tissues	O
examined	O
.	O

Glucocorticoid	O
treatment	O
of	O
pituitary	O
cells	O
from	O
mid	O
-	O
and	O
late	O
-	O
stage	O
embryos	O
rapidly	O
increased	O
ras	B-GENE-Y
-	I-GENE-Y
dva	I-GENE-Y
mRNA	O
,	O
suggesting	O
it	O
may	O
be	O
a	O
direct	O
transcriptional	O
target	O
of	O
glucocorticoids	O
.	O

A	O
reporter	O
construct	O
driven	O
by	O
4	O
kb	O
of	O
the	O
chicken	B-GENE-Y
ras	I-GENE-Y
-	I-GENE-Y
dva	I-GENE-Y
5	O
'	O
-	O
flanking	O
region	O
,	O
containing	O
six	O
putative	O
pituitary	B-GENE-N
-	I-GENE-N
specific	I-GENE-N
transcription	I-GENE-N
factor	I-GENE-N
-	I-GENE-N
1	I-GENE-N
(	I-GENE-N
Pit	I-GENE-N
-	I-GENE-N
1	I-GENE-N
)	I-GENE-N
binding	I-GENE-N
sites	I-GENE-N
and	O
two	O
potential	O
glucocorticoid	B-GENE-N
receptor	I-GENE-N
(	I-GENE-N
GR	I-GENE-N
)	I-GENE-N
binding	I-GENE-N
sites	I-GENE-N
,	O
was	O
highly	O
activated	O
in	O
embryonic	O
pituitary	O
cells	O
and	O
up	O
-	O
regulated	O
by	O
corticosterone	B-CHEMICAL
.	O

Mutagenesis	O
of	O
the	O
most	O
proximal	O
Pit	B-GENE-N
-	I-GENE-N
1	I-GENE-N
site	I-GENE-N
decreased	O
promoter	O
activity	O
in	O
chicken	O
e11	O
pituitary	O
cells	O
,	O
indicating	O
regulation	O
of	O
ras	B-GENE-Y
-	I-GENE-Y
dva	I-GENE-Y
by	O
Pit	B-GENE-Y
-	I-GENE-Y
1	I-GENE-Y
.	O

However	O
,	O
mutating	O
putative	O
GR	B-GENE-N
binding	I-GENE-N
sites	I-GENE-N
did	O
not	O
substantially	O
reduce	O
induction	O
of	O
ras	B-GENE-N
-	I-GENE-N
dva	I-GENE-N
promoter	I-GENE-N
activity	O
by	O
corticosterone	B-CHEMICAL
,	O
suggesting	O
additional	O
DNA	B-GENE-N
elements	I-GENE-N
within	O
the	O
5	O
'	O
-	O
flanking	O
region	O
are	O
responsible	O
for	O
glucocorticoid	O
regulation	O
.	O

We	O
have	O
identified	O
ras	B-GENE-Y
-	I-GENE-Y
dva	I-GENE-Y
as	O
a	O
glucocorticoid	O
-	O
regulated	O
gene	O
that	O
is	O
likely	O
expressed	O
in	O
cells	O
of	O
the	O
Pit	B-GENE-Y
-	I-GENE-Y
1	I-GENE-Y
lineage	O
within	O
the	O
developing	O
anterior	O
pituitary	O
gland	O
.	O

Differential	O
modulation	O
of	O
retinal	O
ganglion	O
cell	O
light	O
responses	O
by	O
orthosteric	O
and	O
allosteric	O
metabotropic	B-GENE-Y
glutamate	I-GENE-Y
receptor	I-GENE-Y
8	I-GENE-Y
compounds	O
.	O

To	O
investigate	O
the	O
role	O
of	O
mGluR8	B-GENE-Y
in	O
modulating	O
the	O
synaptic	O
responses	O
of	O
retinal	O
ganglion	O
cells	O
,	O
we	O
used	O
a	O
recently	O
identified	O
positive	O
allosteric	O
modulator	O
of	O
mGluR8	B-GENE-Y
,	O
AZ12216052	B-CHEMICAL
(	O
AZ	O
)	O
and	O
the	O
mGluR8	B-GENE-Y
-	O
specific	O
orthosteric	O
agonist	O
(	B-CHEMICAL
S	I-CHEMICAL
)	I-CHEMICAL
-	I-CHEMICAL
3	I-CHEMICAL
,	I-CHEMICAL
4	I-CHEMICAL
-	I-CHEMICAL
dicarboxyphenylglycine	I-CHEMICAL
(	O
DCPG	B-CHEMICAL
)	O
.	O

These	O
agents	O
were	O
applied	O
to	O
whole	O
-	O
cell	O
voltage	O
-	O
clamped	O
ganglion	O
cells	O
from	O
an	O
isolated	O
,	O
superfused	O
mouse	O
retina	O
preparation	O
.	O

DCPG	B-CHEMICAL
reduced	O
OFF	O
-	O
ganglion	O
cell	O
excitatory	O
currents	O
,	O
whereas	O
AZ	O
enhanced	O
the	O
peak	O
excitatory	O
currents	O
in	O
ON	O
-	O
,	O
OFF	O
-	O
,	O
and	O
ON	O
-	O
OFF	O
-	O
ganglion	O
cells	O
.	O

The	O
effects	O
on	O
ganglion	O
cell	O
inhibitory	O
currents	O
were	O
more	O
varied	O
.	O

The	O
effects	O
of	O
the	O
allosteric	O
modulator	O
were	O
stronger	O
for	O
bright	O
stimuli	O
than	O
for	O
dim	O
stimuli	O
,	O
consistent	O
with	O
receptor	O
stimulation	O
by	O
endogenous	O
glutamate	B-CHEMICAL
being	O
stronger	O
during	O
bright	O
light	O
stimulation	O
and	O
with	O
mGluR8	B-GENE-Y
receptors	O
mainly	O
being	O
localized	O
away	O
from	O
glutamate	B-CHEMICAL
release	O
sites	O
,	O
immuno	O
-	O
labeled	O
with	O
VGLUT1	B-GENE-Y
.	O

The	O
differential	O
sensitivity	O
of	O
ganglion	O
cell	O
light	O
responses	O
to	O
DCPG	B-CHEMICAL
and	O
AZ	O
supports	O
multiple	O
sites	O
where	O
mGluR8	B-GENE-Y
modulates	O
the	O
light	O
responses	O
of	O
ganglion	O
cells	O
.	O

UCCB01	B-CHEMICAL
-	I-CHEMICAL
125	I-CHEMICAL
,	O
a	O
dimeric	O
inhibitor	O
of	O
PSD	O
-	O
95	O
,	O
reduces	O
inflammatory	O
pain	O
without	O
disrupting	O
cognitive	O
or	O
motor	O
performance	O
:	O
comparison	O
with	O
the	O
NMDA	B-GENE-N
receptor	I-GENE-N
antagonist	O
MK	B-CHEMICAL
-	I-CHEMICAL
801	I-CHEMICAL
.	O

Excessive	O
N	B-GENE-N
-	I-GENE-N
Methyl	I-GENE-N
-	I-GENE-N
d	I-GENE-N
-	I-GENE-N
aspartate	I-GENE-N
receptor	I-GENE-N
(	O
NMDAR	B-GENE-N
)	O
-	O
dependent	O
production	O
of	O
nitric	B-CHEMICAL
oxide	I-CHEMICAL
(	O
NO	B-CHEMICAL
)	O
is	O
involved	O
in	O
the	O
development	O
and	O
maintenance	O
of	O
chronic	O
pain	O
states	O
,	O
and	O
is	O
mediated	O
by	O
postsynaptic	B-GENE-Y
density	I-GENE-Y
protein	I-GENE-Y
-	I-GENE-Y
95	I-GENE-Y
(	O
PSD	B-GENE-Y
-	I-GENE-Y
95	I-GENE-Y
)	O
.	O

By	O
binding	O
to	O
both	O
the	O
NMDAR	B-GENE-N
and	O
neuronal	B-GENE-Y
NO	I-GENE-Y
synthase	I-GENE-Y
(	O
nNOS	B-GENE-Y
)	O
,	O
PSD	B-GENE-Y
-	I-GENE-Y
95	I-GENE-Y
mediates	O
a	O
specific	O
coupling	O
between	O
NMDAR	B-GENE-N
activation	O
and	O
NO	B-CHEMICAL
production	O
.	O

NMDAR	B-GENE-N
antagonism	O
shows	O
anti	O
-	O
nociceptive	O
action	O
in	O
humans	O
and	O
animal	O
models	O
of	O
chronic	O
pain	O
but	O
is	O
associated	O
with	O
severe	O
disturbances	O
of	O
cognitive	O
and	O
motor	O
functions	O
.	O

An	O
alternative	O
approach	O
to	O
modulate	O
the	O
NMDAR	B-GENE-N
-	O
related	O
activity	O
is	O
to	O
perturb	O
the	O
NMDAR	B-GENE-N
/	O
PSD	B-GENE-Y
-	I-GENE-Y
95	I-GENE-Y
/	O
nNOS	B-GENE-Y
complex	O
by	O
targeting	O
PSD	B-GENE-N
-	I-GENE-N
95	I-GENE-N
,	O
thereby	O
decreasing	O
NO	B-CHEMICAL
production	O
without	O
interfering	O
with	O
the	O
NMDAR	B-GENE-N
ion	B-GENE-N
channel	I-GENE-N
function	O
.	O

Here	O
,	O
we	O
compared	O
the	O
effects	O
of	O
a	O
dimeric	O
PSD	B-GENE-Y
-	I-GENE-Y
95	I-GENE-Y
inhibitor	O
,	O
UCCB01	B-CHEMICAL
-	I-CHEMICAL
125	I-CHEMICAL
,	O
and	O
the	O
NMDAR	B-GENE-N
antagonist	O
,	O
MK	B-CHEMICAL
-	I-CHEMICAL
801	I-CHEMICAL
,	O
on	O
mechanical	O
hypersensitivity	O
in	O
the	O
complete	O
Freund	O
'	O
s	O
adjuvant	O
(	O
CFA	O
)	O
model	O
of	O
inflammatory	O
pain	O
.	O

To	O
examine	O
side	O
-	O
effect	O
profiles	O
we	O
also	O
compared	O
the	O
effects	O
of	O
UCCB01	B-CHEMICAL
-	I-CHEMICAL
125	I-CHEMICAL
and	O
MK	B-CHEMICAL
-	I-CHEMICAL
801	I-CHEMICAL
in	O
tests	O
of	O
attention	O
,	O
long	O
-	O
term	O
memory	O
,	O
and	O
motor	O
performance	O
.	O

When	O
administered	O
concurrently	O
with	O
CFA	O
,	O
both	O
MK	B-CHEMICAL
-	I-CHEMICAL
801	I-CHEMICAL
and	O
UCCB01	B-CHEMICAL
-	I-CHEMICAL
125	I-CHEMICAL
prevented	O
the	O
development	O
of	O
CFA	O
-	O
induced	O
mechanical	O
hypersensitivity	O
1	O
and	O
24	O
h	O
after	O
treatment	O
.	O

Moreover	O
,	O
UCCB01	B-CHEMICAL
-	I-CHEMICAL
125	I-CHEMICAL
was	O
found	O
to	O
reverse	O
CFA	O
-	O
induced	O
hypersensitivity	O
when	O
administered	O
24	O
h	O
after	O
CFA	O
treatment	O
,	O
an	O
effect	O
lasting	O
for	O
at	O
least	O
3	O
days	O
.	O

At	O
the	O
dose	O
reducing	O
hypersensitivity	O
,	O
MK	B-CHEMICAL
-	I-CHEMICAL
801	I-CHEMICAL
disrupted	O
attention	O
,	O
long	O
-	O
term	O
memory	O
,	O
and	O
motor	O
performance	O
.	O

By	O
contrast	O
,	O
even	O
high	O
doses	O
of	O
UCCB01	B-CHEMICAL
-	I-CHEMICAL
125	I-CHEMICAL
were	O
devoid	O
of	O
side	O
-	O
effects	O
in	O
these	O
tests	O
.	O

The	O
data	O
suggest	O
that	O
PSD	B-GENE-Y
-	I-GENE-Y
95	I-GENE-Y
inhibition	O
is	O
a	O
feasible	O
strategy	O
to	O
prevent	O
both	O
development	O
and	O
maintenance	O
of	O
chronic	O
inflammatory	O
pain	O
,	O
while	O
avoiding	O
NMDAR	B-GENE-N
antagonism	O
-	O
related	O
side	O
-	O
effects	O
.	O

Conformational	O
landscape	O
of	O
diisopropyl	B-CHEMICAL
ketone	I-CHEMICAL
:	O
quantum	O
chemical	O
calculations	O
validated	O
by	O
microwave	O
spectroscopy	O
.	O

We	O
report	O
on	O
the	O
gas	O
-	O
phase	O
structure	O
of	O
the	O
most	O
abundant	O
conformer	O
of	O
diisopropyl	B-CHEMICAL
ketone	I-CHEMICAL
,	O
(	B-CHEMICAL
CH	I-CHEMICAL
(	I-CHEMICAL
3	I-CHEMICAL
)	I-CHEMICAL
)	I-CHEMICAL
(	I-CHEMICAL
2	I-CHEMICAL
)	I-CHEMICAL
HC	I-CHEMICAL
-	I-CHEMICAL
CO	I-CHEMICAL
-	I-CHEMICAL
CH	I-CHEMICAL
(	I-CHEMICAL
CH	I-CHEMICAL
(	I-CHEMICAL
3	I-CHEMICAL
)	I-CHEMICAL
)	I-CHEMICAL
(	I-CHEMICAL
2	I-CHEMICAL
)	I-CHEMICAL
,	O
as	O
observed	O
by	O
molecular	O
beam	O
Fourier	O
transform	O
microwave	O
spectroscopy	O
.	O

The	O
gas	O
-	O
phase	O
structures	O
of	O
five	O
conformers	O
of	O
diisopropyl	B-CHEMICAL
ketone	I-CHEMICAL
were	O
optimized	O
using	O
ab	O
initio	O
calculations	O
at	O
the	O
MP2	O
/	O
6	O
-	O
311	O
+	O
+	O
G	O
(	O
d	O
,	O
p	O
)	O
level	O
of	O
theory	O
.	O

The	O
natures	O
of	O
the	O
stationary	O
points	O
were	O
verified	O
using	O
harmonic	O
frequency	O
calculations	O
.	O

The	O
only	O
conformer	O
observed	O
in	O
the	O
supersonic	O
jet	O
possesses	O
C	O
(	O
2	O
)	O
symmetry	O
and	O
appears	O
as	O
an	O
enantiomeric	O
pair	O
.	O

From	O
the	O
microwave	O
spectrum	O
,	O
a	O
set	O
of	O
three	O
highly	O
accurate	O
rotational	O
constants	O
,	O
five	O
centrifugal	O
distortion	O
constants	O
,	O
and	O
three	O
sextic	O
centrifugal	O
distortion	O
constants	O
were	O
determined	O
.	O

The	O
structure	O
of	O
the	O
observed	O
conformer	O
was	O
optimized	O
again	O
at	O
different	O
levels	O
of	O
theory	O
using	O
the	O
HF	O
,	O
MP2	O
,	O
and	O
B3LYP	O
methods	O
.	O

The	O
theoretical	O
constants	O
of	O
the	O
C	O
(	O
2	O
)	O
conformer	O
were	O
subsequently	O
validated	O
using	O
the	O
experimental	O
constants	O
.	O

To	O
understand	O
the	O
transitions	O
of	O
one	O
conformer	O
to	O
the	O
others	O
,	O
the	O
isopropyl	B-CHEMICAL
groups	O
were	O
rotated	O
against	O
each	O
other	O
.	O

The	O
resulting	O
two	O
-	O
dimensional	O
potential	O
energy	O
surface	O
shows	O
nicely	O
the	O
symmetry	O
of	O
the	O
conformational	O
landscape	O
and	O
also	O
indicates	O
the	O
enantiomeric	O
pairs	O
of	O
the	O
conformers	O
.	O

The	O
barriers	O
to	O
internal	O
rotation	O
of	O
the	O
methyl	B-CHEMICAL
groups	O
were	O
determined	O
to	O
be	O
1052	O
and	O
905	O
cm	O
(	O
-	O
1	O
)	O
at	O
the	O
MP2	O
/	O
6	O
-	O
311	O
+	O
+	O
G	O
(	O
d	O
,	O
p	O
)	O
and	O
the	O
B3LYP	O
/	O
6	O
-	O
311	O
+	O
+	O
G	O
(	O
d	O
,	O
p	O
)	O
levels	O
,	O
respectively	O
.	O

In	O
agreement	O
with	O
the	O
theoretical	O
predictions	O
,	O
no	O
internal	O
rotation	O
patterns	O
could	O
be	O
observed	O
in	O
the	O
microwave	O
spectrum	O
.	O

Control	O
of	O
hypercholesterolemia	O
and	O
atherosclerosis	O
using	O
the	O
cholesterol	B-CHEMICAL
recognition	O
/	O
interaction	O
amino	B-CHEMICAL
acid	I-CHEMICAL
sequence	O
of	O
the	O
translocator	B-GENE-Y
protein	I-GENE-Y
TSPO	I-GENE-Y
.	O

The	O
translocator	B-GENE-Y
protein	I-GENE-Y
(	I-GENE-Y
18	I-GENE-Y
-	I-GENE-Y
kDa	I-GENE-Y
)	I-GENE-Y
TSPO	I-GENE-Y
is	O
an	O
ubiquitous	O
high	O
affinity	O
cholesterol	B-CHEMICAL
-	O
binding	O
protein	O
reported	O
to	O
be	O
present	O
in	O
the	O
endothelial	O
and	O
smooth	O
muscle	O
cells	O
of	O
the	O
blood	O
vessels	O
;	O
its	O
expression	O
dramatically	O
increased	O
in	O
macrophages	O
found	O
in	O
atherosclerotic	O
plaques	O
.	O

A	O
domain	O
in	O
the	O
carboxy	B-CHEMICAL
-	O
terminus	O
of	O
TSPO	B-GENE-Y
was	O
identified	O
and	O
characterized	O
as	O
the	O
cholesterol	B-CHEMICAL
recognition	O
/	O
interaction	O
amino	B-CHEMICAL
acid	I-CHEMICAL
consensus	O
(	O
CRAC	O
)	O
.	O

The	O
ability	O
of	O
the	O
CRAC	O
domain	O
to	O
bind	O
to	O
cholesterol	B-CHEMICAL
led	O
us	O
to	O
hypothesize	O
that	O
this	O
peptide	O
could	O
be	O
used	O
as	O
an	O
hypocholesterolemic	O
,	O
with	O
potential	O
anti	O
-	O
atherogenic	O
properties	O
,	O
agent	O
.	O

We	O
report	O
herein	O
the	O
therapeutic	O
benefit	O
that	O
resulted	O
for	O
the	O
administration	O
of	O
the	O
VLNYYVWR	O
human	O
CRAC	O
sequence	O
to	O
guinea	O
pigs	O
fed	O
with	O
a	O
high	O
cholesterol	B-CHEMICAL
diet	O
and	O
ApoE	B-GENE-Y
knock	O
-	O
out	O
B6	O
.	O
129P2	O
-	O
Apoetm1Unc	O
/	O
J	O
mice	O
.	O

CRAC	O
treatment	O
(	O
3	O
and	O
30mg	O
/	O
kg	O
once	O
daily	O
for	O
6	O
weeks	O
)	O
resulted	O
in	O
reduced	O
circulating	O
cholesterol	B-CHEMICAL
levels	O
in	O
guinea	O
pigs	O
fed	O
with	O
2	O
%	O
high	O
cholesterol	B-CHEMICAL
diet	O
and	O
ApoE	B-GENE-Y
knock	O
-	O
out	O
B6	O
.	O
129P2	O
-	O
Apoetm1Unc	O
/	O
J	O
mice	O
.	O

In	O
high	O
cholesterol	B-CHEMICAL
fed	O
guinea	O
pigs	O
,	O
CRAC	O
treatment	O
administered	O
once	O
daily	O
induced	O
an	O
increase	O
in	O
circulating	O
HDL	O
,	O
decreased	O
total	O
,	O
free	O
and	O
LDL	O
cholesterol	B-CHEMICAL
,	O
and	O
removed	O
atheroma	O
deposits	O
in	O
the	O
aorta	O
in	O
a	O
dose	O
-	O
dependent	O
manner	O
.	O

The	O
treatment	O
also	O
prevented	O
the	O
high	O
cholesterol	B-CHEMICAL
diet	O
-	O
induced	O
increase	O
in	O
serum	O
creatine	B-GENE-N
kinase	I-GENE-N
,	O
total	O
and	O
isoforms	O
,	O
markers	O
of	O
neurological	O
,	O
cardiac	O
and	O
muscular	O
damage	O
.	O

No	O
toxicity	O
was	O
observed	O
.	O

Taken	O
together	O
these	O
results	O
support	O
a	O
role	O
of	O
TSPO	B-GENE-Y
in	O
lipid	O
homeostasis	O
and	O
atherosclerosis	O
and	O
indicate	O
that	O
CRAC	O
may	O
constitute	O
a	O
novel	O
and	O
safe	O
treatment	O
of	O
hypercholesterolemia	O
and	O
atherosclerosis	O
.	O

Effects	O
of	O
bidentate	O
coordination	O
on	O
the	O
molecular	O
properties	O
rapta	B-CHEMICAL
-	I-CHEMICAL
C	I-CHEMICAL
based	O
complex	O
using	O
theoretical	O
approach	O
.	O

In	O
this	O
work	O
several	O
quantum	O
properties	O
including	O
the	O
NEDA	O
and	O
QTAIM	O
are	O
computed	O
on	O
three	O
models	O
of	O
rapta	B-CHEMICAL
-	I-CHEMICAL
C	I-CHEMICAL
complexes	O
using	O
DFT	O
with	O
hybrid	O
functional	O
and	O
basis	O
set	O
with	O
ECP	O
and	O
without	O
ECP	O
.	O

Several	O
interesting	O
correlations	O
within	O
the	O
observed	O
properties	O
and	O
also	O
with	O
the	O
reported	O
experimental	O
behaviors	O
of	O
these	O
complexes	O
including	O
their	O
biological	O
activities	O
are	O
presented	O
.	O

The	O
study	O
shows	O
that	O
the	O
stability	O
of	O
the	O
two	O
complexes	O
with	O
bidentate	O
ligands	O
is	O
associated	O
with	O
their	O
high	O
hydrogen	B-CHEMICAL
bonding	O
stability	O
and	O
existence	O
of	O
stronger	O
non	O
-	O
covalent	O
metal	O
-	O
ligand	O
bonds	O
.	O

The	O
energy	O
decomposition	O
analysis	O
indicated	O
that	O
inter	O
-	O
atomic	O
interactions	O
in	O
the	O
three	O
forms	O
of	O
rapta	B-CHEMICAL
-	I-CHEMICAL
C	I-CHEMICAL
complexes	O
and	O
their	O
stability	O
are	O
governed	O
by	O
the	O
charge	O
transfer	O
term	O
with	O
significant	O
contributions	O
from	O
polarization	O
and	O
electrostatic	O
terms	O
.	O

The	O
higher	O
stability	O
of	O
complex	O
1	O
and	O
2	O
over	O
3	O
comes	O
from	O
the	O
lower	O
exchange	O
repulsion	O
and	O
higher	O
polarization	O
contributions	O
to	O
their	O
stability	O
which	O
agrees	O
perfectly	O
with	O
the	O
experimental	O
observation	O
.	O

Our	O
results	O
provide	O
insight	O
into	O
the	O
nature	O
of	O
intramolecular	O
forces	O
that	O
influence	O
the	O
structural	O
stability	O
of	O
the	O
three	O
complexes	O
.	O

Transcriptional	B-GENE-Y
regulatory	I-GENE-Y
factor	I-GENE-Y
X6	I-GENE-Y
(	O
Rfx6	B-GENE-Y
)	O
increases	O
gastric	B-GENE-Y
inhibitory	I-GENE-Y
polypeptide	I-GENE-Y
(	O
GIP	B-GENE-Y
)	O
expression	O
in	O
enteroendocrine	O
K	O
-	O
cells	O
and	O
is	O
involved	O
in	O
GIP	B-GENE-Y
hypersecretion	O
in	O
high	O
fat	O
diet	O
-	O
induced	O
obesity	O
.	O

Gastric	B-GENE-Y
inhibitory	I-GENE-Y
polypeptide	I-GENE-Y
(	O
GIP	B-GENE-Y
)	O
is	O
an	O
incretin	B-GENE-Y
released	O
from	O
enteroendocrine	O
K	O
-	O
cells	O
in	O
response	O
to	O
nutrient	O
ingestion	O
.	O

GIP	B-GENE-Y
potentiates	O
glucose	B-CHEMICAL
-	O
stimulated	O
insulin	B-GENE-Y
secretion	O
and	O
induces	O
energy	O
accumulation	O
into	O
adipose	O
tissue	O
,	O
resulting	O
in	O
obesity	O
.	O

Plasma	O
GIP	B-GENE-Y
levels	O
are	O
reported	O
to	O
be	O
increased	O
in	O
the	O
obese	O
state	O
.	O

However	O
,	O
the	O
molecular	O
mechanisms	O
of	O
GIP	B-GENE-Y
secretion	O
and	O
high	O
fat	O
diet	O
(	O
HFD	O
)	O
-	O
induced	O
GIP	B-GENE-Y
hypersecretion	O
remain	O
unclear	O
,	O
primarily	O
due	O
to	O
difficulties	O
in	O
separating	O
K	O
-	O
cells	O
from	O
other	O
intestinal	O
epithelial	O
cells	O
in	O
vivo	O
.	O

In	O
this	O
study	O
,	O
GIP	B-GENE-Y
-	O
GFP	B-GENE-N
knock	O
-	O
in	O
mice	O
that	O
enable	O
us	O
to	O
visualize	O
K	O
-	O
cells	O
by	O
enhanced	O
GFP	B-GENE-Y
were	O
established	O
.	O

Microarray	O
analysis	O
of	O
isolated	O
K	O
-	O
cells	O
from	O
these	O
mice	O
revealed	O
that	O
transcriptional	B-GENE-Y
regulatory	I-GENE-Y
factor	I-GENE-Y
X6	I-GENE-Y
(	O
Rfx6	B-GENE-Y
)	O
is	O
expressed	O
exclusively	O
in	O
K	O
-	O
cells	O
.	O

In	O
vitro	O
experiments	O
using	O
the	O
mouse	O
intestinal	O
cell	O
line	O
STC	O
-	O
1	O
showed	O
that	O
knockdown	O
of	O
Rfx6	B-GENE-Y
decreased	O
mRNA	O
expression	O
,	O
cellular	O
content	O
,	O
and	O
secretion	O
of	O
GIP	B-GENE-Y
.	O

Rfx6	B-GENE-Y
bound	O
to	O
the	O
region	O
in	O
the	O
gip	B-GENE-N
promoter	I-GENE-N
that	O
regulates	O
gip	B-GENE-N
promoter	I-GENE-N
activity	O
,	O
and	O
overexpression	O
of	O
Rfx6	B-GENE-Y
increased	O
GIP	B-GENE-Y
mRNA	O
expression	O
.	O

HFD	O
induced	O
obesity	O
and	O
GIP	B-GENE-Y
hypersecretion	O
in	O
GIP	B-GENE-Y
-	O
GFP	B-GENE-N
heterozygous	O
mice	O
in	O
vivo	O
.	O

Immunohistochemical	O
and	O
flow	O
cytometry	O
analysis	O
showed	O
no	O
significant	O
difference	O
in	O
K	O
-	O
cell	O
number	O
between	O
control	O
fat	O
diet	O
-	O
fed	O
(	O
CFD	O
)	O
and	O
HFD	O
-	O
fed	O
mice	O
.	O

However	O
,	O
GIP	B-GENE-Y
content	O
in	O
the	O
upper	O
small	O
intestine	O
and	O
GIP	B-GENE-Y
mRNA	O
expression	O
in	O
K	O
-	O
cells	O
were	O
significantly	O
increased	O
in	O
HFD	O
-	O
fed	O
mice	O
compared	O
with	O
those	O
in	O
CFD	O
-	O
fed	O
mice	O
.	O

Furthermore	O
,	O
expression	O
levels	O
of	O
Rfx6	B-GENE-Y
mRNA	O
were	O
increased	O
in	O
K	O
-	O
cells	O
of	O
HFD	O
-	O
fed	O
mice	O
.	O

These	O
results	O
suggest	O
that	O
Rfx6	B-GENE-Y
increases	O
GIP	B-GENE-Y
expression	O
and	O
content	O
in	O
K	O
-	O
cells	O
and	O
is	O
involved	O
in	O
GIP	B-GENE-Y
hypersecretion	O
in	O
HFD	O
-	O
induced	O
obesity	O
.	O

Diet	O
,	O
physical	O
exercise	O
and	O
Orlistat	B-CHEMICAL
administration	O
increase	O
serum	O
Anti	B-GENE-Y
-	I-GENE-Y
Mllerian	I-GENE-Y
Hormone	I-GENE-Y
(	O
AMH	B-GENE-Y
)	O
levels	O
in	O
women	O
with	O
polycystic	O
ovary	O
syndrome	O
(	O
PCOS	O
)	O
.	O

The	O
present	O
study	O
investigates	O
the	O
combined	O
effect	O
of	O
diet	O
,	O
physical	O
exercise	O
and	O
Orlistat	B-CHEMICAL
for	O
24	O
weeks	O
,	O
on	O
serum	O
Anti	B-GENE-Y
-	I-GENE-Y
Mllerian	I-GENE-Y
Hormone	I-GENE-Y
(	O
AMH	B-GENE-Y
)	O
levels	O
in	O
overweight	O
and	O
obese	O
women	O
with	O
polycystic	O
ovary	O
syndrome	O
(	O
PCOS	O
)	O
and	O
in	O
overweight	O
and	O
obese	O
controls	O
.	O

Sixty	O
-	O
one	O
(	O
61	O
)	O
selected	O
women	O
with	O
PCOS	O
and	O
20	O
overweight	O
and	O
obese	O
controls	O
followed	O
an	O
energy	O
-	O
restricted	O
diet	O
,	O
physical	O
exercise	O
plus	O
Orlistat	B-CHEMICAL
administration	O
(	O
120	O
mg	O
,	O
3	O
times	O
per	O
day	O
)	O
for	O
24	O
weeks	O
.	O

At	O
baseline	O
,	O
week	O
12	O
and	O
week	O
24	O
,	O
serum	O
levels	O
of	O
AMH	B-GENE-Y
,	O
FSH	B-GENE-N
,	O
LH	B-GENE-N
,	O
PRL	B-GENE-Y
,	O
androgens	B-CHEMICAL
,	O
sex	B-GENE-Y
hormone	I-GENE-Y
-	I-GENE-Y
binding	I-GENE-Y
globulin	I-GENE-Y
(	O
SHBG	B-GENE-Y
)	O
,	O
glucose	B-CHEMICAL
,	O
and	O
insulin	B-GENE-Y
were	O
measured	O
and	O
Free	O
Androgen	B-CHEMICAL
Index	O
(	O
FAI	O
)	O
and	O
Insulin	B-GENE-Y
Resistance	O
(	O
IR	O
)	O
indices	O
were	O
calculated	O
.	O

In	O
PCOS	O
women	O
,	O
serum	O
AMH	B-GENE-Y
levels	O
increased	O
after	O
12	O
and	O
24	O
weeks	O
of	O
treatment	O
.	O

After	O
12	O
weeks	O
LH	B-GENE-N
and	O
SHBG	B-GENE-Y
were	O
increased	O
,	O
while	O
Testosterone	B-CHEMICAL
decreased	O
.	O

After	O
12	O
and	O
24	O
weeks	O
,	O
FAI	O
was	O
decreased	O
and	O
all	O
indices	O
of	O
IR	O
were	O
significantly	O
improved	O
.	O

We	O
concluded	O
that	O
in	O
overweight	O
and	O
obese	O
women	O
with	O
PCOS	O
Orlistat	B-CHEMICAL
administration	O
,	O
combined	O
with	O
diet	O
and	O
physical	O
exercise	O
,	O
for	O
24	O
weeks	O
,	O
resulted	O
in	O
significant	O
weight	O
loss	O
,	O
improvement	O
of	O
hyperandrogenism	O
and	O
insulin	B-GENE-Y
sensitivity	O
,	O
and	O
increased	O
serum	O
AMH	B-GENE-Y
levels	O
.	O

Phenolic	O
profiles	O
and	O
antioxidant	O
activity	O
of	O
litchi	O
pulp	O
of	O
different	O
cultivars	O
cultivated	O
in	O
Southern	O
China	O
.	O

The	O
phenolic	O
profiles	O
and	O
antioxidant	O
activity	O
of	O
litchi	O
pulp	O
of	O
13	O
varieties	O
were	O
investigated	O
.	O

The	O
free	O
,	O
bound	O
and	O
total	O
phenolic	O
contents	O
were	O
66	O
.	O
17	O
-	O
226	O
.	O
03	O
,	O
11	O
.	O
18	O
-	O
40	O
.	O
54	O
,	O
and	O
101	O
.	O
51	O
-	O
259	O
.	O
18	O
mg	O
of	O
gallic	B-CHEMICAL
acid	I-CHEMICAL
equivalents	O
/	O
100	O
g	O
,	O
respectively	O
.	O

The	O
free	O
,	O
bound	O
and	O
total	O
flavonoid	B-CHEMICAL
contents	O
were	O
16	O
.	O
68	O
-	O
110	O
.	O
33	O
,	O
10	O
.	O
48	O
-	O
22	O
.	O
75	O
,	O
and	O
39	O
.	O
43	O
-	O
129	O
.	O
86	O
mg	O
of	O
catechin	B-CHEMICAL
equivalents	O
/	O
100	O
g	O
,	O
respectively	O
.	O

Free	O
phenolics	B-CHEMICAL
and	O
flavonoids	B-CHEMICAL
contributed	O
averagely	O
80	O
.	O
1	O
%	O
and	O
75	O
%	O
to	O
their	O
total	O
contents	O
,	O
respectively	O
.	O

Six	O
individual	O
phenolics	B-CHEMICAL
(	O
gallic	B-CHEMICAL
acid	I-CHEMICAL
,	O
chlorogenic	B-CHEMICAL
acid	I-CHEMICAL
,	O
(	B-CHEMICAL
+	I-CHEMICAL
)	I-CHEMICAL
-	I-CHEMICAL
catechin	I-CHEMICAL
,	O
caffeic	B-CHEMICAL
acid	I-CHEMICAL
,	O
(	B-CHEMICAL
-	I-CHEMICAL
)	I-CHEMICAL
-	I-CHEMICAL
epicatechin	I-CHEMICAL
,	O
and	O
rutin	B-CHEMICAL
)	O
were	O
detected	O
in	O
litchi	O
pulp	O
by	O
HPLC	O
.	O

The	O
contents	O
of	O
each	O
compound	O
in	O
free	O
and	O
bound	O
fractions	O
were	O
determined	O
.	O

Significant	O
varietal	O
discrepancy	O
in	O
antioxidant	O
activity	O
was	O
also	O
found	O
by	O
FRAP	O
and	O
DPPH	B-CHEMICAL
scavenging	O
capacity	O
methods	O
.	O

Antioxidant	O
activity	O
was	O
significantly	O
correlated	O
with	O
phenolic	O
and	O
flavonoid	B-CHEMICAL
contents	O
.	O

Thus	O
,	O
phenolics	B-CHEMICAL
and	O
flavonoids	B-CHEMICAL
exist	O
mainly	O
in	O
the	O
free	O
form	O
in	O
litchi	O
pulp	O
.	O

There	O
were	O
significant	O
varietal	O
differences	O
in	O
phytochemical	O
contents	O
and	O
antioxidant	O
activity	O
of	O
litchi	O
pulp	O
.	O

Purification	O
,	O
physicochemical	O
characterisation	O
and	O
anticancer	O
activity	O
of	O
a	O
polysaccharide	O
from	O
Cyclocarya	O
paliurus	O
leaves	O
.	O

A	O
Cyclocarya	O
paliurus	O
(	O
Batal	O
.	O
)	O
Iljinskaja	O
polysaccharide	O
(	O
CPP	O
)	O
was	O
isolated	O
and	O
purified	O
by	O
hot	O
water	O
extraction	O
,	O
ethanol	B-CHEMICAL
precipitation	O
,	O
deproteinisation	O
and	O
anion	O
-	O
exchange	O
chromatography	O
.	O

Its	O
physicochemical	O
properties	O
were	O
characterised	O
by	O
gel	O
permeation	O
chromatography	O
(	O
GPC	O
)	O
,	O
gas	O
chromatography	O
-	O
mass	O
spectrometry	O
(	O
GC	O
-	O
MS	O
)	O
,	O
thermal	O
gravimetric	O
analysis	O
(	O
TGA	O
)	O
,	O
Fourier	O
transform	O
infrared	O
spectrometry	O
(	O
FTIR	O
)	O
,	O
UV	O
-	O
visible	O
spectrophotometry	O
,	O
dynamic	O
light	O
scattering	O
(	O
DLS	O
)	O
and	O
viscometry	O
analysis	O
.	O

The	O
anticancer	O
effect	O
of	O
CPP	O
in	O
human	O
gastric	O
cancer	O
HeLa	O
cells	O
was	O
also	O
evaluated	O
by	O
3	B-CHEMICAL
-	I-CHEMICAL
(	I-CHEMICAL
4	I-CHEMICAL
,	I-CHEMICAL
5	I-CHEMICAL
-	I-CHEMICAL
dimethylthiazol	I-CHEMICAL
-	I-CHEMICAL
2	I-CHEMICAL
-	I-CHEMICAL
yl	I-CHEMICAL
)	I-CHEMICAL
-	I-CHEMICAL
2	I-CHEMICAL
,	I-CHEMICAL
5	I-CHEMICAL
-	I-CHEMICAL
diphenyltetrazolium	I-CHEMICAL
bromide	I-CHEMICAL
(	O
MTT	B-CHEMICAL
)	O
assay	O
.	O

The	O
results	O
showed	O
that	O
the	O
molecular	O
weight	O
of	O
CPP	O
was	O
900	O
kDa	O
,	O
and	O
it	O
contained	O
64	O
.	O
8	O
%	O
total	O
sugar	O
,	O
23	O
.	O
5	O
%	O
uronic	B-CHEMICAL
acid	I-CHEMICAL
,	O
9	O
.	O
26	O
%	O
protein	O
,	O
and	O
six	O
kinds	O
of	O
monosaccharides	B-CHEMICAL
,	O
including	O
glucose	B-CHEMICAL
,	O
rhamnose	B-CHEMICAL
,	O
arabinose	B-CHEMICAL
,	O
xylose	B-CHEMICAL
,	O
mannose	B-CHEMICAL
and	O
galactose	B-CHEMICAL
,	O
with	O
molar	O
percentages	O
of	O
32	O
.	O
7	O
%	O
,	O
9	O
.	O
33	O
%	O
,	O
30	O
.	O
6	O
%	O
,	O
3	O
.	O
48	O
%	O
,	O
10	O
.	O
4	O
%	O
,	O
and	O
13	O
.	O
5	O
%	O
,	O
respectively	O
.	O

Furthermore	O
,	O
the	O
results	O
showed	O
that	O
CPP	O
exhibited	O
a	O
strong	O
inhibition	O
effect	O
on	O
the	O
growth	O
of	O
human	O
gastric	O
cancer	O
HeLa	O
cells	O
.	O

Bioinspired	O
and	O
highly	O
oriented	O
clay	O
nanocomposites	O
with	O
a	O
xyloglucan	O
biopolymer	O
matrix	O
:	O
extending	O
the	O
range	O
of	O
mechanical	O
and	O
barrier	O
properties	O
.	O

The	O
development	O
of	O
clay	O
bionanocomposites	O
requires	O
processing	O
routes	O
with	O
nanostructural	O
control	O
.	O

Moreover	O
,	O
moisture	O
durability	O
is	O
a	O
concern	O
with	O
water	O
-	O
soluble	O
biopolymers	O
.	O

Here	O
,	O
oriented	O
bionanocomposite	O
coatings	O
with	O
strong	O
in	O
-	O
plane	O
orientation	O
of	O
clay	O
platelets	O
are	O
for	O
the	O
first	O
time	O
prepared	O
by	O
continuous	O
water	O
-	O
based	O
processing	O
.	O

Montmorillonite	B-CHEMICAL
(	O
MTM	B-CHEMICAL
)	O
and	O
a	O
"	O
new	O
"	O
unmodified	O
biological	O
polymer	O
(	O
xyloglucan	O
(	O
XG	O
)	O
)	O
are	O
combined	O
.	O

The	O
resulting	O
nanocomposites	O
are	O
characterized	O
by	O
FE	O
-	O
SEM	O
,	O
TEM	O
,	O
and	O
XRD	O
.	O

XG	O
adsorption	O
on	O
MTM	B-CHEMICAL
is	O
measured	O
by	O
quartz	B-CHEMICAL
crystal	O
microbalance	O
analysis	O
.	O

Mechanical	O
and	O
gas	O
barrier	O
properties	O
are	O
measured	O
,	O
also	O
at	O
high	O
relative	O
humidity	O
.	O

The	O
reinforcement	O
effects	O
are	O
modeled	O
.	O

XG	O
dimensions	O
in	O
composites	O
are	O
estimated	O
using	O
atomistic	O
simulations	O
.	O

The	O
nanostructure	O
shows	O
highly	O
oriented	O
and	O
intercalated	O
clay	O
platelets	O
.	O

The	O
reinforcement	O
efficiency	O
and	O
effects	O
on	O
barrier	O
properties	O
are	O
remarkable	O
and	O
are	O
likely	O
to	O
be	O
due	O
to	O
highly	O
oriented	O
and	O
well	O
-	O
dispersed	O
MTM	B-CHEMICAL
and	O
strong	O
XG	O
-	O
MTM	B-CHEMICAL
interactions	O
.	O

Properties	O
are	O
well	O
preserved	O
in	O
humid	O
conditions	O
and	O
the	O
reasons	O
for	O
this	O
are	O
discussed	O
.	O

Lessons	O
from	O
the	O
dissection	O
of	O
the	O
activation	B-GENE-N
functions	I-GENE-N
(	O
AF	B-GENE-N
-	I-GENE-N
1	I-GENE-N
and	O
AF	B-GENE-N
-	I-GENE-N
2	I-GENE-N
)	O
of	O
the	O
estrogen	B-GENE-Y
receptor	I-GENE-Y
alpha	I-GENE-Y
in	O
vivo	O
.	O

Estrogens	B-CHEMICAL
influence	O
most	O
of	O
the	O
physiological	O
processes	O
in	O
mammals	O
,	O
including	O
but	O
not	O
limited	O
to	O
reproduction	O
,	O
cognition	O
,	O
behavior	O
,	O
vascular	O
system	O
,	O
metabolism	O
and	O
bone	O
integrity	O
.	O

Given	O
this	O
widespread	O
role	O
for	O
estrogen	B-CHEMICAL
in	O
human	O
physiology	O
,	O
it	O
is	O
not	O
surprising	O
that	O
estrogen	B-CHEMICAL
influence	O
the	O
pathophysiology	O
of	O
numerous	O
diseases	O
,	O
including	O
cancer	O
(	O
of	O
the	O
reproductive	O
tract	O
as	O
breast	O
,	O
endometrial	O
but	O
also	O
colorectal	O
,	O
prostate	O
,	O
	O
)	O
,	O
as	O
well	O
as	O
neurodegenerative	O
,	O
inflammatory	O
-	O
immune	O
,	O
cardiovascular	O
and	O
metabolic	O
diseases	O
,	O
and	O
osteoporosis	O
.	O

These	O
actions	O
are	O
mediated	O
by	O
the	O
activation	O
of	O
estrogen	B-GENE-N
receptors	I-GENE-N
(	I-GENE-N
ER	I-GENE-N
)	I-GENE-N
alpha	I-GENE-N
(	I-GENE-N
ER	I-GENE-N
)	I-GENE-N
and	I-GENE-N
beta	I-GENE-N
(	O
ER	B-GENE-Y
)	O
,	O
which	O
regulate	O
target	O
gene	O
transcription	O
(	O
genomic	O
action	O
)	O
through	O
two	O
independent	O
activation	B-GENE-N
functions	I-GENE-N
(	B-GENE-N
AF	I-GENE-N
)	I-GENE-N
-	I-GENE-N
1	I-GENE-N
and	O
AF	B-GENE-N
-	I-GENE-N
2	I-GENE-N
,	O
but	O
can	O
also	O
elicit	O
rapid	O
membrane	O
initiated	O
steroid	B-CHEMICAL
signals	O
(	O
MISS	O
)	O
.	O

Targeted	O
ER	B-GENE-Y
gene	O
inactivation	O
has	O
shown	O
that	O
although	O
ER	B-GENE-Y
plays	O
an	O
important	O
role	O
in	O
the	O
central	O
nervous	O
system	O
and	O
in	O
the	O
heart	O
,	O
ER	B-GENE-Y
appears	O
to	O
play	O
a	O
prominent	O
role	O
in	O
most	O
of	O
the	O
other	O
tissues	O
.	O

Pharmacological	O
activation	O
or	O
inhibition	O
of	O
ER	B-GENE-Y
and	O
/	O
or	O
ER	B-GENE-Y
provides	O
already	O
the	O
basis	O
for	O
many	O
therapeutic	O
interventions	O
,	O
from	O
hormone	O
replacement	O
at	O
menopause	O
to	O
prevention	O
of	O
the	O
recurrence	O
of	O
breast	O
cancer	O
.	O

However	O
,	O
the	O
use	O
of	O
these	O
estrogens	B-CHEMICAL
or	O
selective	O
estrogen	B-GENE-Y
receptors	I-GENE-Y
modulators	O
(	O
SERMs	O
)	O
have	O
also	O
induced	O
undesired	O
effects	O
.	O

Thus	O
,	O
an	O
important	O
challenge	O
consists	O
now	O
to	O
uncouple	O
the	O
beneficial	O
actions	O
from	O
other	O
deleterious	O
ones	O
.	O

The	O
in	O
vivo	O
molecular	O
"	O
dissection	O
"	O
of	O
ER	B-GENE-Y
represents	O
both	O
a	O
molecular	O
and	O
integrated	O
approach	O
that	O
already	O
allowed	O
to	O
delineate	O
in	O
mouse	O
the	O
role	O
of	O
the	O
main	O
"	O
subfunctions	O
"	O
of	O
the	O
receptor	O
and	O
that	O
could	O
pave	O
the	O
way	O
to	O
an	O
optimization	O
of	O
the	O
ER	B-GENE-Y
modulation	O
.	O

Inhibitory	O
effect	O
of	O
1	B-CHEMICAL
,	I-CHEMICAL
25	I-CHEMICAL
-	I-CHEMICAL
dihydroxyvitamin	I-CHEMICAL
D	I-CHEMICAL
on	O
excretion	O
of	O
JBP485	B-CHEMICAL
via	O
organic	B-GENE-N
anion	I-GENE-N
transporters	I-GENE-N
in	O
rats	O
.	O

The	O
aim	O
of	O
this	O
study	O
was	O
to	O
investigate	O
the	O
pharmacokinetic	O
mechanism	O
of	O
interaction	O
between	O
JBP485	B-CHEMICAL
and	O
1	B-CHEMICAL
,	I-CHEMICAL
25	I-CHEMICAL
-	I-CHEMICAL
dihydroxyvitamin	I-CHEMICAL
D	I-CHEMICAL
(	I-CHEMICAL
3	I-CHEMICAL
)	I-CHEMICAL
[	O
1	B-CHEMICAL
,	I-CHEMICAL
25	I-CHEMICAL
(	I-CHEMICAL
OH	I-CHEMICAL
)	I-CHEMICAL
(	I-CHEMICAL
2	I-CHEMICAL
)	I-CHEMICAL
D	I-CHEMICAL
(	I-CHEMICAL
3	I-CHEMICAL
)	I-CHEMICAL
]	O
.	O

Rats	O
were	O
injected	O
intraperitoneally	O
with	O
0	O
.	O
64	O
nmol	O
/	O
kg	O
/	O
day	O
1	B-CHEMICAL
,	I-CHEMICAL
25	I-CHEMICAL
(	I-CHEMICAL
OH	I-CHEMICAL
)	I-CHEMICAL
(	I-CHEMICAL
2	I-CHEMICAL
)	I-CHEMICAL
D	I-CHEMICAL
(	I-CHEMICAL
3	I-CHEMICAL
)	I-CHEMICAL
in	O
1	O
ml	O
/	O
kg	O
corn	O
oil	O
for	O
5	O
days	O
.	O

The	O
plasma	O
and	O
urine	O
concentrations	O
of	O
JBP485	B-CHEMICAL
after	O
intravenous	O
administration	O
and	O
the	O
uptake	O
of	O
JBP485	B-CHEMICAL
in	O
kidney	O
slices	O
in	O
vitro	O
were	O
determined	O
by	O
liquid	O
chromatography	O
/	O
tandem	O
mass	O
spectrometry	O
.	O

Quantitative	O
polymerase	O
chain	O
reaction	O
,	O
western	O
blotting	O
,	O
immunohistochemical	O
analysis	O
and	O
immunofluorescence	O
were	O
used	O
to	O
determine	O
the	O
changes	O
in	O
the	O
expression	O
of	O
organic	B-GENE-N
anion	I-GENE-N
transporter	I-GENE-N
(	B-GENE-Y
Oat	I-GENE-Y
)	I-GENE-Y
1	I-GENE-Y
and	O
Oat3	B-GENE-Y
in	O
rat	O
kidney	O
in	O
response	O
to	O
1	B-CHEMICAL
,	I-CHEMICAL
25	I-CHEMICAL
(	I-CHEMICAL
OH	I-CHEMICAL
)	I-CHEMICAL
(	I-CHEMICAL
2	I-CHEMICAL
)	I-CHEMICAL
D	I-CHEMICAL
(	I-CHEMICAL
3	I-CHEMICAL
)	I-CHEMICAL
treatment	O
.	O

The	O
plasma	O
concentrations	O
and	O
AUCs	O
of	O
JBP485	B-CHEMICAL
were	O
significantly	O
increased	O
,	O
while	O
the	O
renal	O
clearance	O
of	O
JBP485	B-CHEMICAL
and	O
uptake	O
of	O
JBP485	B-CHEMICAL
in	O
kidney	O
slices	O
were	O
significantly	O
decreased	O
after	O
1	B-CHEMICAL
,	I-CHEMICAL
25	I-CHEMICAL
(	I-CHEMICAL
OH	I-CHEMICAL
)	I-CHEMICAL
(	I-CHEMICAL
2	I-CHEMICAL
)	I-CHEMICAL
D	I-CHEMICAL
(	I-CHEMICAL
3	I-CHEMICAL
)	I-CHEMICAL
treatment	O
.	O

These	O
results	O
confirmed	O
that	O
1	B-CHEMICAL
,	I-CHEMICAL
25	I-CHEMICAL
(	I-CHEMICAL
OH	I-CHEMICAL
)	I-CHEMICAL
(	I-CHEMICAL
2	I-CHEMICAL
)	I-CHEMICAL
D	I-CHEMICAL
(	I-CHEMICAL
3	I-CHEMICAL
)	I-CHEMICAL
inhibited	O
renal	O
excretion	O
of	O
JBP485	B-CHEMICAL
.	O

Moreover	O
,	O
1	B-CHEMICAL
,	I-CHEMICAL
25	I-CHEMICAL
(	I-CHEMICAL
OH	I-CHEMICAL
)	I-CHEMICAL
(	I-CHEMICAL
2	I-CHEMICAL
)	I-CHEMICAL
D	I-CHEMICAL
(	I-CHEMICAL
3	I-CHEMICAL
)	I-CHEMICAL
decreased	O
expression	O
of	O
Oat1	B-GENE-Y
and	O
Oat3	B-GENE-Y
in	O
rat	O
kidney	O
.	O

Our	O
results	O
are	O
novel	O
in	O
demonstrating	O
an	O
interaction	O
between	O
JBP485	B-CHEMICAL
and	O
1	B-CHEMICAL
,	I-CHEMICAL
25	I-CHEMICAL
(	I-CHEMICAL
OH	I-CHEMICAL
)	I-CHEMICAL
(	I-CHEMICAL
2	I-CHEMICAL
)	I-CHEMICAL
D	I-CHEMICAL
(	I-CHEMICAL
3	I-CHEMICAL
)	I-CHEMICAL
when	O
they	O
are	O
co	O
-	O
administered	O
.	O

The	O
mechanism	O
of	O
interaction	O
between	O
JBP485	B-CHEMICAL
and	O
1	B-CHEMICAL
,	I-CHEMICAL
25	I-CHEMICAL
(	I-CHEMICAL
OH	I-CHEMICAL
)	I-CHEMICAL
(	I-CHEMICAL
2	I-CHEMICAL
)	I-CHEMICAL
D	I-CHEMICAL
(	I-CHEMICAL
3	I-CHEMICAL
)	I-CHEMICAL
could	O
be	O
explained	O
at	O
least	O
in	O
part	O
by	O
inhibitory	O
effect	O
of	O
1	B-CHEMICAL
,	I-CHEMICAL
25	I-CHEMICAL
(	I-CHEMICAL
OH	I-CHEMICAL
)	I-CHEMICAL
(	I-CHEMICAL
2	I-CHEMICAL
)	I-CHEMICAL
D	I-CHEMICAL
(	I-CHEMICAL
3	I-CHEMICAL
)	I-CHEMICAL
on	O
expression	O
of	O
Oats	B-GENE-N
in	O
rat	O
kidney	O
.	O

Nanoparticle	O
toxicity	O
in	O
Daphnia	O
magna	O
reproduction	O
studies	O
:	O
the	O
importance	O
of	O
test	O
design	O
.	O

The	O
increasing	O
use	O
of	O
titanium	B-CHEMICAL
dioxide	I-CHEMICAL
nanoparticles	O
(	O
nTiO	B-CHEMICAL
(	I-CHEMICAL
2	I-CHEMICAL
)	I-CHEMICAL
)	O
inevitably	O
results	O
in	O
their	O
release	O
into	O
the	O
environment	O
,	O
raising	O
concerns	O
about	O
potential	O
adverse	O
effects	O
in	O
wildlife	O
.	O

By	O
following	O
standard	O
test	O
protocols	O
,	O
several	O
studies	O
investigated	O
the	O
ecotoxicity	O
of	O
nTiO	B-CHEMICAL
(	I-CHEMICAL
2	I-CHEMICAL
)	I-CHEMICAL
among	O
others	O
to	O
Daphnia	O
magna	O
.	O

These	O
studies	O
indicated	O
a	O
large	O
variability	O
-	O
several	O
orders	O
of	O
magnitude	O
-	O
in	O
the	O
response	O
variables	O
.	O

However	O
,	O
other	O
factors	O
,	O
like	O
nanoparticle	O
characteristics	O
and	O
test	O
design	O
,	O
potentially	O
triggering	O
these	O
differences	O
,	O
were	O
largely	O
ignored	O
.	O

Therefore	O
,	O
the	O
present	O
study	O
assessed	O
the	O
chronic	O
ecotoxicity	O
of	O
two	O
nTiO	B-CHEMICAL
(	I-CHEMICAL
2	I-CHEMICAL
)	I-CHEMICAL
products	O
with	O
varying	O
crystalline	O
structure	O
(	O
A	O
-	O
100	O
;	O
P25	O
)	O
to	O
D	O
.	O
magna	O
.	O

A	O
semi	O
-	O
static	O
and	O
a	O
flow	O
-	O
through	O
exposure	O
scenario	O
were	O
compared	O
,	O
ensuring	O
that	O
both	O
contained	O
environmentally	O
relevant	O
concentrations	O
of	O
dissolved	O
organic	O
carbon	B-CHEMICAL
.	O

Utilizing	O
the	O
semi	O
-	O
static	O
test	O
design	O
,	O
a	O
concentration	O
as	O
low	O
as	O
0	O
.	O
06	O
mg	O
/	O
L	O
A	O
-	O
100	O
(	O
	O
330	O
nm	O
)	O
significantly	O
reduced	O
the	O
reproduction	O
of	O
daphnia	O
indicating	O
environmental	O
risk	O
.	O

In	O
contrast	O
,	O
no	O
implication	O
in	O
the	O
number	O
of	O
released	O
offspring	O
was	O
observed	O
during	O
the	O
flow	O
-	O
through	O
experiment	O
with	O
A	O
-	O
100	O
(	O
	O
140	O
nm	O
)	O
.	O

Likewise	O
,	O
P25	O
(	O
	O
130	O
nm	O
)	O
did	O
not	O
adversely	O
affect	O
reproduction	O
irrespective	O
of	O
the	O
test	O
design	O
utilized	O
.	O

Given	O
the	O
present	O
study	O
'	O
s	O
results	O
,	O
the	O
particle	O
size	O
,	O
the	O
product	O
composition	O
,	O
i	O
.	O
e	O
.	O
the	O
crystalline	O
structure	O
,	O
and	O
the	O
accumulation	O
of	O
nTiO	B-CHEMICAL
(	I-CHEMICAL
2	I-CHEMICAL
)	I-CHEMICAL
at	O
the	O
bottom	O
of	O
the	O
test	O
vessel	O
-	O
the	O
latter	O
is	O
relevant	O
for	O
a	O
semi	O
-	O
static	O
test	O
design	O
-	O
may	O
be	O
suggested	O
as	O
factors	O
potentially	O
triggering	O
differences	O
in	O
nTiO	B-CHEMICAL
(	I-CHEMICAL
2	I-CHEMICAL
)	I-CHEMICAL
toxicity	O
to	O
D	O
.	O
magna	O
.	O

Hence	O
,	O
these	O
factors	O
should	O
be	O
considered	O
to	O
improve	O
environmental	O
risk	O
assessment	O
of	O
nanoparticles	O
.	O

Magnetic	O
nanoclusters	O
exhibiting	O
protein	O
-	O
activated	O
near	O
-	O
infrared	O
fluorescence	O
.	O

Composite	O
nanoclusters	O
with	O
chemical	O
,	O
magnetic	O
,	O
and	O
biofunctionality	O
offer	O
broad	O
opportunities	O
for	O
targeted	O
cellular	O
imaging	O
.	O

A	O
key	O
challenge	O
is	O
to	O
load	O
a	O
high	O
degree	O
of	O
targeting	O
,	O
imaging	O
,	O
and	O
therapeutic	O
functionality	O
onto	O
stable	O
metal	B-CHEMICAL
-	I-CHEMICAL
oxide	I-CHEMICAL
nanoparticles	O
.	O

Here	O
we	O
report	O
a	O
route	O
for	O
producing	O
magnetic	O
nanoclusters	O
(	O
MNCs	O
)	O
with	O
alkyne	B-CHEMICAL
surface	O
functionality	O
that	O
can	O
be	O
utilized	O
as	O
multimodal	O
imaging	O
probes	O
.	O

We	O
form	O
MNCs	O
composed	O
of	O
magnetic	O
Fe	O
(	O
3	O
)	O
O	O
(	O
4	O
)	O
nanoparticles	O
and	O
poly	O
(	O
acrylic	O
acid	O
-	O
co	O
-	O
propargyl	O
acrylate	O
)	O
by	O
the	O
co	O
-	O
precipitation	O
of	O
iron	O
salts	O
in	O
the	O
presence	O
of	O
copolymer	O
stabilizers	O
.	O

The	O
MNCs	O
were	O
surface	O
-	O
modified	O
with	O
near	O
-	O
infrared	O
(	O
NIR	O
)	O
emitting	O
fluorophore	O
used	O
in	O
photodynamic	O
therapy	O
,	O
an	O
azide	B-CHEMICAL
-	O
modified	O
indocyanine	B-CHEMICAL
green	I-CHEMICAL
.	O

The	O
fluorophores	O
engaged	O
and	O
complexed	O
with	O
bovine	B-GENE-Y
serum	I-GENE-Y
albumin	I-GENE-Y
,	O
forming	O
an	O
extended	O
coverage	O
of	O
serum	O
proteins	O
on	O
the	O
MNCs	O
.	O

These	O
proteins	O
isolated	O
indocyanine	B-CHEMICAL
green	I-CHEMICAL
fluorophores	O
from	O
the	O
aqueous	O
environment	O
and	O
induced	O
an	O
effective	O
"	O
turn	O
-	O
on	O
"	O
of	O
NIR	O
emission	O
.	O

From	O
in	O
situ	O
to	O
in	O
vivo	O
:	O
an	O
in	O
situ	O
click	O
-	O
chemistry	O
-	O
derived	O
carbonic	O
anhydrase	O
II	O
imaging	O
agent	O
for	O
positron	O
emission	O
tomography	O
.	O

CA	O
II	O
makes	O
a	O
good	O
PET	O
:	O
Discovering	O
positron	O
emission	O
tomography	O
(	O
PET	O
)	O
probes	O
with	O
high	O
target	O
affinities	O
is	O
challenging	O
.	O

PET	O
probe	O
discovery	O
using	O
in	O
situ	O
click	O
chemistry	O
uses	O
(	B-CHEMICAL
19	I-CHEMICAL
)	I-CHEMICAL
F	I-CHEMICAL
-	O
bearing	O
fragments	O
as	O
(	B-CHEMICAL
18	I-CHEMICAL
)	I-CHEMICAL
F	I-CHEMICAL
surrogates	O
.	O

This	O
ensures	O
that	O
the	O
lead	O
hits	O
and	O
PET	O
probes	O
have	O
equivalent	O
chemical	O
or	O
biological	O
characteristics	O
,	O
making	O
PET	O
probe	O
discovery	O
predictable	O
and	O
reliable	O
.	O

Dendronized	B-GENE-N
albumin	I-GENE-N
core	I-GENE-N
-	I-GENE-N
shell	I-GENE-N
transporters	I-GENE-N
with	O
high	O
drug	O
loading	O
capacity	O
.	O

We	O
describe	O
the	O
synthesis	O
of	O
a	O
core	O
-	O
shell	O
biohybrid	O
consisting	O
of	O
a	O
human	B-GENE-Y
serum	I-GENE-Y
albumin	I-GENE-Y
(	O
HSA	B-GENE-Y
)	O
core	O
that	O
serves	O
as	O
a	O
reservoir	O
for	O
lipophilic	O
molecules	O
and	O
a	O
cationized	O
shell	O
region	O
consisting	O
of	O
ethynyl	B-CHEMICAL
-	O
G2	O
.	O
0	O
-	O
PAMAM	B-CHEMICAL
or	O
ethynyl	B-CHEMICAL
-	O
G3	O
.	O
0	O
-	O
PAMAM	B-CHEMICAL
dendrons	O
.	O

The	O
binding	O
capacity	O
of	O
lipophilic	O
guests	O
was	O
quantified	O
applying	O
electron	O
paramagnetic	O
resonance	O
(	O
EPR	O
)	O
spectroscopy	O
,	O
and	O
five	O
to	O
six	O
out	O
of	O
seven	O
pockets	O
were	O
still	O
available	O
compared	O
with	O
HSA	B-GENE-Y
.	O

The	O
attachment	O
of	O
ethynyl	B-CHEMICAL
-	O
G2	O
.	O
0	O
-	O
PAMAM	B-CHEMICAL
dendrons	O
to	O
HSA	B-GENE-Y
yielded	O
a	O
nontoxic	O
core	O
-	O
shell	O
macromolecule	O
that	O
was	O
clearly	O
uptaken	O
by	O
A549	O
human	O
epithelial	O
cells	O
due	O
to	O
the	O
presence	O
of	O
the	O
dendritic	O
PAMAM	B-CHEMICAL
shell	O
.	O

Significantly	O
higher	O
loading	O
of	O
doxorubicin	B-CHEMICAL
was	O
observed	O
for	O
dendronized	O
G2	O
-	O
DHSA	O
compared	O
with	O
the	O
native	O
protein	O
due	O
to	O
the	O
availability	O
of	O
binding	O
pockets	O
of	O
the	O
HSA	B-GENE-Y
core	O
,	O
and	O
interaction	O
with	O
the	O
dendritic	O
shell	O
.	O

Dendronized	O
G2	O
-	O
DHSA	O
-	O
doxorubicin	B-CHEMICAL
displayed	O
significant	O
cytotoxicity	O
resulting	O
from	O
high	O
drug	O
loading	O
and	O
high	O
stability	O
under	O
different	O
conditions	O
,	O
thus	O
demonstrating	O
its	O
great	O
potential	O
as	O
a	O
transporter	O
for	O
drug	O
molecules	O
.	O

Impairment	O
of	O
novel	O
object	O
recognition	O
in	O
adulthood	O
after	O
neonatal	O
exposure	O
to	O
diazinon	B-CHEMICAL
.	O

Diazinon	B-CHEMICAL
is	O
an	O
organophosphate	B-CHEMICAL
pesticide	O
that	O
is	O
still	O
heavily	O
used	O
in	O
agriculture	O
,	O
home	O
gardening	O
,	O
and	O
indoor	O
pest	O
control	O
in	O
Japan	O
.	O

The	O
present	O
study	O
investigated	O
the	O
effect	O
of	O
neonatal	O
exposure	O
to	O
diazinon	B-CHEMICAL
on	O
hippocampus	O
-	O
dependent	O
novel	O
object	O
recognition	O
test	O
performance	O
and	O
the	O
expression	O
of	O
the	O
N	B-GENE-N
-	I-GENE-N
methyl	I-GENE-N
-	I-GENE-N
D	I-GENE-N
-	I-GENE-N
aspartate	I-GENE-N
(	I-GENE-N
NMDA	I-GENE-N
)	I-GENE-N
receptor	I-GENE-N
and	O
its	O
signal	O
transduction	O
pathway	O
-	O
related	O
genes	O
in	O
the	O
hippocampi	O
of	O
young	O
adult	O
and	O
adult	O
mice	O
.	O

Male	O
offspring	O
of	O
C3H	O
/	O
HeN	O
mice	O
were	O
subcutaneously	O
treated	O
with	O
0	O
,	O
0	O
.	O
5	O
,	O
or	O
5	O
mg	O
/	O
kg	O
of	O
diazinon	B-CHEMICAL
for	O
4	O
consecutive	O
days	O
beginning	O
on	O
postnatal	O
day	O
(	O
PND	O
)	O
8	O
.	O

Beginning	O
on	O
PND	O
46	O
or	O
PND	O
81	O
,	O
a	O
novel	O
object	O
recognition	O
test	O
was	O
performed	O
on	O
4	O
consecutive	O
days	O
.	O

The	O
hippocampi	O
were	O
collected	O
on	O
PND	O
50	O
or	O
PND	O
85	O
after	O
the	O
completion	O
of	O
the	O
novel	O
object	O
recognition	O
test	O
,	O
and	O
the	O
expression	O
levels	O
of	O
neurotrophins	B-GENE-N
and	O
the	O
NMDA	B-GENE-N
receptor	I-GENE-N
and	O
its	O
signal	O
transduction	O
pathway	O
-	O
related	O
genes	O
were	O
examined	O
using	O
real	O
-	O
time	O
RT	O
-	O
PCR	O
.	O

Diazinon	B-CHEMICAL
-	O
injected	O
mice	O
exhibited	O
a	O
poor	O
ability	O
to	O
discriminate	O
between	O
novel	O
and	O
familiar	O
objects	O
during	O
both	O
the	O
PND	O
49	O
and	O
the	O
PND	O
84	O
tests	O
.	O

The	O
NMDA	B-GENE-N
receptor	I-GENE-N
subunits	I-GENE-N
NR1	I-GENE-N
and	I-GENE-N
NR2B	I-GENE-N
and	O
the	O
related	O
protein	O
kinase	B-GENE-N
calcium	B-GENE-Y
/	I-GENE-Y
calmodulin	I-GENE-Y
-	I-GENE-Y
dependent	I-GENE-Y
protein	I-GENE-Y
kinase	I-GENE-Y
(	I-GENE-Y
CaMK	I-GENE-Y
)	I-GENE-Y
-	I-GENE-Y
IV	I-GENE-Y
and	O
the	O
transcription	O
factor	O
cyclic	B-GENE-Y
AMP	I-GENE-Y
responsive	I-GENE-Y
element	I-GENE-Y
binding	I-GENE-Y
protein	I-GENE-Y
(	I-GENE-Y
CREB	I-GENE-Y
)	I-GENE-Y
-	I-GENE-Y
1	I-GENE-Y
mRNA	O
levels	O
were	O
reduced	O
in	O
the	O
PND	O
50	O
mice	O
.	O

However	O
,	O
no	O
significant	O
changes	O
in	O
the	O
expressions	O
of	O
the	O
NMDA	B-CHEMICAL
subunits	O
and	O
their	O
signal	O
transduction	O
molecules	O
were	O
observed	O
in	O
the	O
hippocampi	O
of	O
the	O
PND	O
85	O
mice	O
.	O

The	O
expression	O
level	O
of	O
nerve	B-GENE-Y
growth	I-GENE-Y
factor	I-GENE-Y
mRNA	O
was	O
significantly	O
reduced	O
in	O
the	O
PND	O
50	O
or	O
85	O
mice	O
.	O

These	O
results	O
indicate	O
that	O
neonatal	O
diazinon	B-CHEMICAL
exposure	O
impaired	O
the	O
hippocampus	O
-	O
dependent	O
novel	O
object	O
recognition	O
ability	O
,	O
accompanied	O
by	O
a	O
modulation	O
in	O
the	O
expressions	O
of	O
the	O
NMDA	B-GENE-N
receptor	I-GENE-N
and	O
neurotrophin	O
in	O
young	O
adult	O
and	O
adult	O
mice	O
.	O

Functional	O
imaging	O
of	O
legumain	B-GENE-Y
in	O
cancer	O
using	O
a	O
new	O
quenched	O
activity	O
-	O
based	O
probe	O
.	O

Legumain	B-GENE-Y
is	O
a	O
lysosomal	O
cysteine	B-GENE-N
protease	I-GENE-N
whose	O
biological	O
function	O
remains	O
poorly	O
defined	O
.	O

Legumain	B-GENE-Y
activity	O
is	O
up	O
-	O
regulated	O
in	O
most	O
human	O
cancers	O
and	O
inflammatory	O
diseases	O
most	O
likely	O
as	O
the	O
result	O
of	O
high	O
expression	O
in	O
populations	O
of	O
activated	O
macrophages	O
.	O

Within	O
the	O
tumor	O
microenvironment	O
,	O
legumain	B-GENE-Y
activity	O
is	O
thought	O
to	O
promote	O
tumorigenesis	O
.	O

To	O
obtain	O
a	O
greater	O
understanding	O
of	O
the	O
role	O
of	O
legumain	B-GENE-Y
activity	O
during	O
cancer	O
progression	O
and	O
inflammation	O
,	O
we	O
developed	O
an	O
activity	O
-	O
based	O
probe	O
that	O
becomes	O
fluorescent	O
only	O
upon	O
binding	O
active	O
legumain	B-GENE-Y
.	O

This	O
probe	O
is	O
highly	O
selective	O
for	O
legumain	B-GENE-Y
,	O
even	O
in	O
the	O
context	O
of	O
whole	O
cells	O
and	O
tissues	O
,	O
and	O
is	O
also	O
a	O
more	O
effective	O
label	O
of	O
legumain	O
than	O
previously	O
reported	O
probes	O
.	O

Here	O
we	O
present	O
the	O
synthesis	O
and	O
application	O
of	O
our	O
probe	O
to	O
the	O
analysis	O
of	O
legumain	B-GENE-Y
activity	O
in	O
primary	O
macrophages	O
and	O
in	O
two	O
mouse	O
models	O
of	O
cancer	O
.	O

We	O
find	O
that	O
legumain	B-GENE-Y
activity	O
is	O
highly	O
correlated	O
with	O
macrophage	O
activation	O
and	O
furthermore	O
that	O
it	O
is	O
an	O
ideal	O
marker	O
for	O
primary	O
tumor	O
inflammation	O
and	O
early	O
stage	O
metastatic	O
lesions	O
.	O

Mutational	O
consequences	O
of	O
dNTP	O
pool	O
imbalances	O
in	O
E	O
.	O
coli	O
.	O

The	O
accuracy	O
of	O
DNA	O
synthesis	O
depends	O
on	O
the	O
accuracy	O
of	O
the	O
polymerase	B-GENE-N
as	O
well	O
as	O
the	O
quality	O
and	O
concentration	O
(	O
s	O
)	O
of	O
the	O
available	O
5	B-CHEMICAL
'	I-CHEMICAL
-	I-CHEMICAL
deoxynucleoside	I-CHEMICAL
-	I-CHEMICAL
triphosphate	I-CHEMICAL
DNA	O
precursors	O
(	O
dNTPs	B-CHEMICAL
)	O
.	O

The	O
relationships	O
between	O
dNTPs	B-CHEMICAL
and	O
error	O
rates	O
have	O
been	O
studied	O
in	O
vitro	O
,	O
but	O
only	O
limited	O
insights	O
exist	O
into	O
these	O
correlations	O
during	O
in	O
vivo	O
replication	O
.	O

We	O
have	O
investigated	O
this	O
issue	O
in	O
the	O
bacterium	O
Escherichia	O
coli	O
by	O
analyzing	O
the	O
mutational	O
properties	O
of	O
dcd	B-GENE-Y
and	O
ndk	B-GENE-Y
strains	O
.	O

These	O
strains	O
,	O
defective	O
in	O
dCTP	B-GENE-Y
deaminase	I-GENE-Y
and	O
nucleoside	B-GENE-Y
diphosphate	I-GENE-Y
kinase	I-GENE-Y
,	O
respectively	O
,	O
are	O
characterized	O
by	O
both	O
disturbances	O
of	O
dNTP	B-CHEMICAL
pools	O
and	O
a	O
mutator	O
phenotype	O
.	O
ndk	B-GENE-Y
strains	O
have	O
been	O
studied	O
before	O
,	O
but	O
were	O
included	O
in	O
this	O
study	O
,	O
as	O
controversies	O
exist	O
regarding	O
the	O
source	O
of	O
its	O
mutator	O
phenotype	O
.	O

We	O
show	O
that	O
dcd	B-GENE-Y
strains	O
suffer	O
from	O
increased	O
intracellular	O
levels	O
of	O
dCTP	B-CHEMICAL
(	O
4	O
-	O
fold	O
)	O
and	O
reduced	O
levels	O
of	O
dGTP	B-CHEMICAL
(	O
2	O
-	O
fold	O
)	O
,	O
while	O
displaying	O
,	O
as	O
measured	O
using	O
a	O
set	O
of	O
lacZ	O
reversion	O
markers	O
in	O
a	O
mismatch	O
-	O
repair	O
defective	O
(	O
mutL	O
)	O
background	O
,	O
a	O
strong	O
mutator	O
effect	O
for	O
G	B-GENE-N
	I-GENE-N
C	I-GENE-N
	I-GENE-N
T	I-GENE-N
	I-GENE-N
A	I-GENE-N
and	O
A	B-GENE-N
	I-GENE-N
T	I-GENE-N
	I-GENE-N
T	I-GENE-N
	I-GENE-N
A	I-GENE-N
transversions	O
(	O
27	O
-	O
and	O
42	O
-	O
fold	O
enhancement	O
,	O
respectively	O
)	O
.	O

In	O
contrast	O
,	O
ndk	B-GENE-Y
strains	O
possess	O
a	O
lowered	O
dATP	B-CHEMICAL
level	O
(	O
4	O
-	O
fold	O
)	O
and	O
modestly	O
enhanced	O
dCTP	B-CHEMICAL
level	O
(	O
2	O
-	O
fold	O
)	O
,	O
while	O
its	O
mutator	O
effect	O
is	O
specific	O
for	O
just	O
the	O
A	B-GENE-N
	I-GENE-N
T	I-GENE-N
	I-GENE-N
T	I-GENE-N
	I-GENE-N
A	I-GENE-N
transversions	O
.	O

The	O
two	O
strains	O
also	O
display	O
differential	O
mutability	O
for	O
rifampicin	B-CHEMICAL
-	O
resistant	O
mutants	O
.	O

Overall	O
,	O
our	O
analysis	O
reveals	O
for	O
both	O
strains	O
a	O
satisfactory	O
correlation	O
between	O
dNTP	B-CHEMICAL
pool	O
alterations	O
and	O
the	O
replication	O
error	O
rates	O
,	O
and	O
also	O
suggests	O
that	O
a	O
minimal	O
explanation	O
for	O
the	O
ndk	B-GENE-Y
mutator	O
does	O
not	O
require	O
assumptions	O
beyond	O
the	O
predicted	O
effect	O
of	O
the	O
dNTP	B-CHEMICAL
pools	O
.	O

MAPK	B-GENE-N
signaling	O
pathways	O
regulate	O
mitochondrial	O
-	O
mediated	O
apoptosis	O
induced	O
by	O
isoorientin	B-CHEMICAL
in	O
human	O
hepatoblastoma	O
cancer	O
cells	O
.	O

Isoorientin	B-CHEMICAL
(	O
ISO	B-CHEMICAL
)	O
(	O
CAS	O
RN	O
:	O
4261	B-CHEMICAL
-	I-CHEMICAL
42	I-CHEMICAL
-	I-CHEMICAL
1	I-CHEMICAL
)	O
is	O
a	O
flavonoid	B-CHEMICAL
compound	O
that	O
can	O
be	O
extracted	O
from	O
several	O
plant	O
species	O
,	O
such	O
as	O
Phyllostachys	O
pubescens	O
,	O
Patrinia	O
,	O
and	O
Drosophyllum	O
lusitanicum	O
.	O

ISO	B-CHEMICAL
is	O
able	O
to	O
induce	O
apoptosis	O
through	O
mitochondrial	O
dysfunction	O
and	O
inhibition	O
of	O
PI3K	B-GENE-N
/	O
Akt	B-GENE-N
signaling	O
pathway	O
in	O
HepG2	O
cells	O
,	O
however	O
,	O
the	O
effects	O
of	O
ISO	B-CHEMICAL
on	O
MAPK	B-GENE-N
signaling	O
pathways	O
remain	O
unknown	O
.	O

The	O
present	O
study	O
investigated	O
the	O
effects	O
of	O
ISO	B-CHEMICAL
on	O
this	O
pathway	O
,	O
and	O
the	O
roles	O
of	O
MAPK	B-GENE-N
kinases	B-GENE-N
on	O
mitochondrial	O
-	O
mediated	O
apoptosis	O
in	O
HepG2	O
cells	O
.	O

The	O
results	O
showed	O
that	O
ISO	B-CHEMICAL
induced	O
cell	O
death	O
in	O
a	O
dose	O
-	O
and	O
time	O
-	O
dependent	O
manner	O
,	O
and	O
induction	O
apoptosis	O
is	O
main	O
cause	O
for	O
ISO	B-CHEMICAL
-	O
induced	O
cytotoxicity	O
in	O
HepG2	O
cells	O
.	O

ISO	B-CHEMICAL
significantly	O
inhibited	O
the	O
levels	O
of	O
ERK1	B-GENE-N
/	I-GENE-N
2	I-GENE-N
kinase	O
and	O
increased	O
the	O
expression	O
of	O
JNK	B-GENE-N
and	O
p38	B-GENE-N
kinases	B-GENE-N
.	O

Furthermore	O
,	O
U0126	B-CHEMICAL
(	O
an	O
ERK1	B-GENE-N
/	I-GENE-N
2	I-GENE-N
inhibitor	O
)	O
significantly	O
enhanced	O
the	O
ISO	B-CHEMICAL
-	O
induced	O
the	O
Bax	B-GENE-Y
/	O
Bcl	B-GENE-Y
-	I-GENE-Y
2	I-GENE-Y
ratio	O
,	O
the	O
release	O
of	O
cytochrome	B-GENE-Y
c	I-GENE-Y
to	O
the	O
cytosol	O
fraction	O
,	O
and	O
the	O
levels	O
of	O
cleaved	O
caspase	B-GENE-Y
-	I-GENE-Y
3	I-GENE-Y
.	O

While	O
SP600125	B-CHEMICAL
(	O
a	O
JNK	B-GENE-N
inhibitor	O
)	O
and	O
SB203580	B-CHEMICAL
(	O
a	O
p38	B-GENE-N
inhibitor	O
)	O
markedly	O
prevented	O
the	O
expression	O
of	O
these	O
proteins	O
induced	O
by	O
ISO	B-CHEMICAL
.	O

Furthermore	O
,	O
the	O
ROS	O
inhibitor	O
(	O
NAC	B-CHEMICAL
)	O
notably	O
promoted	O
the	O
inhibited	O
effect	O
of	O
ISO	B-CHEMICAL
on	O
the	O
ERK1	B-GENE-N
/	I-GENE-N
2	I-GENE-N
kinase	O
.	O

NAC	B-CHEMICAL
also	O
suppressed	O
the	O
p	O
-	O
JNK	B-GENE-N
and	O
p	B-GENE-N
-	I-GENE-N
p38	I-GENE-N
,	O
but	O
failed	O
to	O
reverse	O
the	O
effects	O
of	O
ISO	B-CHEMICAL
.	O

These	O
results	O
demonstrated	O
for	O
the	O
first	O
time	O
that	O
ISO	B-CHEMICAL
induces	O
apoptosis	O
in	O
HepG2	O
cells	O
through	O
inactivating	O
ERK1	B-GENE-N
/	I-GENE-N
2	I-GENE-N
kinase	O
and	O
activating	O
JNK	B-GENE-N
and	O
p38	B-GENE-N
kinases	B-GENE-N
,	O
and	O
ROS	O
stimulated	O
by	O
ISO	B-CHEMICAL
is	O
able	O
to	O
activate	O
the	O
MAPK	B-GENE-N
singaling	O
pathway	O
as	O
the	O
upstream	O
signaling	O
molecules	O
.	O

Initiating	O
event	O
of	O
the	O
mitochondrial	O
-	O
mediated	O
apoptosis	O
induced	O
by	O
ISO	B-CHEMICAL
is	O
MAPK	B-GENE-N
signals	O
.	O

Antithrombotic	O
and	O
profibrinolytic	O
activities	O
of	O
isorhamnetin	B-CHEMICAL
-	I-CHEMICAL
3	I-CHEMICAL
-	I-CHEMICAL
O	I-CHEMICAL
-	I-CHEMICAL
galactoside	I-CHEMICAL
and	O
hyperoside	B-CHEMICAL
.	O

The	O
potential	O
anticoagulant	O
activities	O
of	O
two	O
single	O
compounds	O
,	O
isorhamnetin	B-CHEMICAL
-	I-CHEMICAL
3	I-CHEMICAL
-	I-CHEMICAL
O	I-CHEMICAL
-	I-CHEMICAL
galactoside	I-CHEMICAL
(	O
IMG	B-CHEMICAL
)	O
and	O
hyperoside	B-CHEMICAL
,	O
from	O
Oenanthe	O
javanica	O
,	O
were	O
tested	O
.	O

The	O
anticoagulant	O
activities	O
were	O
investigated	O
by	O
measuring	O
activated	O
partial	O
thromboplastin	B-GENE-Y
time	O
(	O
aPTT	O
)	O
and	O
prothrombin	B-GENE-Y
time	O
(	O
PT	O
)	O
,	O
and	O
the	O
ability	O
to	O
inhibit	O
production	O
of	O
thrombin	B-GENE-Y
and	O
activated	B-GENE-Y
factor	I-GENE-Y
X	I-GENE-Y
(	O
FXa	B-GENE-Y
)	O
was	O
investigated	O
in	O
human	O
umbilical	O
vein	O
endothelial	O
cells	O
(	O
HUVECs	O
)	O
.	O

And	O
,	O
the	O
effects	O
of	O
the	O
compounds	O
on	O
expression	O
of	O
plasminogen	B-GENE-Y
activator	I-GENE-Y
inhibitor	I-GENE-Y
type	I-GENE-Y
1	I-GENE-Y
(	O
PAI	B-GENE-Y
-	I-GENE-Y
1	I-GENE-Y
)	O
and	O
tissue	B-GENE-Y
-	I-GENE-Y
type	I-GENE-Y
plasminogen	I-GENE-Y
activator	I-GENE-Y
(	B-GENE-Y
t	I-GENE-Y
-	I-GENE-Y
PA	I-GENE-Y
)	O
were	O
tested	O
in	O
tumor	B-GENE-Y
necrosis	I-GENE-Y
factor	I-GENE-Y
-	I-GENE-Y
(	I-GENE-Y
TNF	I-GENE-Y
)	I-GENE-Y
-	I-GENE-Y
	I-GENE-Y
activated	O
HUVECs	O
.	O

Treatment	O
with	O
IMG	B-CHEMICAL
and	O
hyperoside	B-CHEMICAL
resulted	O
in	O
significantly	O
prolonged	O
aPTT	O
and	O
PT	O
and	O
inhibition	O
of	O
the	O
activities	O
of	O
thrombin	B-GENE-Y
and	O
FXa	B-GENE-Y
,	O
and	O
IMG	B-CHEMICAL
or	O
hyperoside	B-CHEMICAL
inhibited	O
production	O
of	O
thrombin	B-GENE-Y
and	O
FXa	B-GENE-Y
in	O
HUVECs	O
.	O

In	O
accordance	O
with	O
these	O
anticoagulant	O
activities	O
,	O
both	O
agents	O
elicited	O
anticoagulant	O
effects	O
in	O
mouse	O
.	O

In	O
addition	O
,	O
treatment	O
with	O
IMG	B-CHEMICAL
and	O
hyperoside	B-CHEMICAL
resulted	O
in	O
inhibition	O
of	O
TNF	B-GENE-Y
-	I-GENE-Y
	I-GENE-Y
-	O
induced	O
production	O
of	O
PAI	B-GENE-Y
-	I-GENE-Y
1	I-GENE-Y
,	O
and	O
treatment	O
with	O
IMG	B-CHEMICAL
resulted	O
in	O
significant	O
reduction	O
of	O
the	O
PAI	B-GENE-Y
-	I-GENE-Y
1	I-GENE-Y
to	O
t	B-GENE-Y
-	I-GENE-Y
PA	I-GENE-Y
ratio	O
.	O

The	O
anticoagulant	O
and	O
profibrinolytic	O
effects	O
of	O
IMG	B-CHEMICAL
were	O
greater	O
than	O
those	O
of	O
hyperoside	B-CHEMICAL
,	O
indicating	O
positive	O
regulation	O
of	O
its	O
anticoagulant	O
function	O
by	O
the	O
methoxy	B-CHEMICAL
group	O
of	O
IMG	B-CHEMICAL
.	O

IMG	B-CHEMICAL
and	O
hyperoside	B-CHEMICAL
possess	O
antithrombotic	O
activities	O
and	O
offer	O
bases	O
for	O
development	O
of	O
a	O
novel	O
anticoagulant	O
.	O

Optimization	O
of	O
5	B-CHEMICAL
-	I-CHEMICAL
hydroxytryptamines	I-CHEMICAL
as	O
dual	O
function	O
inhibitors	O
targeting	O
phospholipase	B-GENE-N
A2	I-GENE-N
and	O
leukotriene	B-GENE-Y
A4	I-GENE-Y
hydrolase	I-GENE-Y
.	O

Dual	O
function	O
inhibitors	O
targeting	O
phospholipase	B-GENE-N
A	I-GENE-N
(	I-GENE-N
2	I-GENE-N
)	I-GENE-N
(	O
PLA	B-GENE-N
(	I-GENE-N
2	I-GENE-N
)	I-GENE-N
)	O
and	O
leukotriene	B-GENE-Y
A	I-GENE-Y
(	I-GENE-Y
4	I-GENE-Y
)	I-GENE-Y
hydrolase	I-GENE-Y
(	O
LTA	B-GENE-Y
(	I-GENE-Y
4	I-GENE-Y
)	I-GENE-Y
H	I-GENE-Y
)	O
may	O
balance	O
the	O
arachidonic	B-CHEMICAL
acid	I-CHEMICAL
(	O
AA	O
)	O
metabolic	O
network	O
and	O
be	O
used	O
as	O
new	O
anti	O
-	O
inflammatory	O
drugs	O
.	O

In	O
previous	O
study	O
,	O
we	O
discovered	O
multi	O
-	O
target	O
drugs	O
towards	O
the	O
AA	O
metabolic	O
network	O
,	O
among	O
which	O
a	O
dual	O
-	O
target	O
inhibitor	O
(	O
JMC08	B-CHEMICAL
-	I-CHEMICAL
4	I-CHEMICAL
)	O
for	O
human	B-GENE-Y
nonpancreatic	I-GENE-Y
secretory	I-GENE-Y
phospholipase	I-GENE-Y
A	I-GENE-Y
(	I-GENE-Y
2	I-GENE-Y
)	I-GENE-Y
(	O
hnps	B-GENE-Y
-	I-GENE-Y
PLA	I-GENE-Y
(	I-GENE-Y
2	I-GENE-Y
)	I-GENE-Y
)	O
and	O
human	B-GENE-Y
leukotriene	I-GENE-Y
A	I-GENE-Y
(	I-GENE-Y
4	I-GENE-Y
)	I-GENE-Y
hydrolase	I-GENE-Y
(	O
LTA	B-GENE-Y
(	I-GENE-Y
4	I-GENE-Y
)	I-GENE-Y
H	I-GENE-Y
-	I-GENE-Y
h	I-GENE-Y
)	O
was	O
found	O
.	O

Based	O
on	O
the	O
structure	O
of	O
compound	O
JMC08	B-CHEMICAL
-	I-CHEMICAL
4	I-CHEMICAL
,	O
new	O
dual	O
-	O
target	O
inhibitors	O
were	O
designed	O
assisted	O
by	O
molecular	O
docking	O
.	O

In	O
this	O
report	O
,	O
a	O
series	O
of	O
5	B-CHEMICAL
-	I-CHEMICAL
hydroxytryptamine	I-CHEMICAL
compounds	O
were	O
synthesized	O
;	O
and	O
most	O
of	O
these	O
title	O
compounds	O
showed	O
more	O
potent	O
inhibitory	O
activity	O
than	O
compound	O
JMC08	B-CHEMICAL
-	I-CHEMICAL
4	I-CHEMICAL
in	O
the	O
in	O
vitro	O
bioassay	O
against	O
these	O
two	O
enzymes	O
.	O

The	O
best	O
one	O
inhibited	O
hnps	B-GENE-Y
-	I-GENE-Y
PLA	I-GENE-Y
(	I-GENE-Y
2	I-GENE-Y
)	I-GENE-Y
and	O
LTA	B-GENE-Y
(	I-GENE-Y
4	I-GENE-Y
)	I-GENE-Y
H	I-GENE-Y
-	I-GENE-Y
h	I-GENE-Y
with	O
IC	O
(	O
50	O
)	O
values	O
of	O
9	O
.	O
2	O
	O
0	O
.	O
5	O
M	O
and	O
2	O
.	O
4	O
	O
1	O
.	O
4	O
M	O
,	O
respectively	O
.	O

Apomorphine	B-CHEMICAL
is	O
a	O
bimodal	O
modulator	O
of	O
TRPA1	B-GENE-Y
channels	O
.	O

Apomorphine	B-CHEMICAL
is	O
a	O
non	O
-	O
narcotic	O
derivative	O
of	O
morphine	B-CHEMICAL
,	O
which	O
acts	O
as	O
a	O
dopamine	B-CHEMICAL
agonist	O
and	O
is	O
clinically	O
used	O
to	O
treat	O
"	O
off	O
-	O
states	O
"	O
in	O
patients	O
suffering	O
from	O
Parkinson	O
'	O
s	O
disease	O
.	O

Adverse	O
effects	O
of	O
apomorphine	B-CHEMICAL
treatment	O
include	O
severe	O
emesis	O
and	O
nausea	O
,	O
and	O
ulceration	O
and	O
pain	O
at	O
the	O
injection	O
site	O
.	O

We	O
wanted	O
to	O
test	O
whether	O
sensory	O
transient	B-GENE-N
receptor	I-GENE-N
potential	I-GENE-N
(	I-GENE-N
TRP	I-GENE-N
)	I-GENE-N
channels	I-GENE-N
are	O
a	O
molecular	O
target	O
for	O
apomorphine	B-CHEMICAL
.	O

Here	O
,	O
we	O
show	O
that	O
rTRPV1	B-GENE-Y
,	O
rTRPV2	B-GENE-Y
,	O
rTRPV3	B-GENE-Y
,	O
and	O
mTRPV4	B-GENE-Y
,	O
as	O
well	O
as	O
hTRPM8	B-GENE-Y
,	O
and	O
rTRPM3	B-GENE-Y
,	O
which	O
are	O
expressed	O
in	O
dorsal	O
root	O
ganglion	O
neurons	O
,	O
are	O
insensitive	O
toward	O
apomorphine	B-CHEMICAL
treatment	O
.	O

This	O
also	O
applied	O
to	O
the	O
cellular	O
redox	O
sensor	O
hTRPM2	B-GENE-Y
.	O

On	O
the	O
contrary	O
,	O
human	B-GENE-Y
TRPA1	I-GENE-Y
could	O
be	O
concentration	O
-	O
dependently	O
modulated	O
by	O
apomorphine	B-CHEMICAL
.	O

Whereas	O
the	O
addition	O
of	O
apomorphine	B-CHEMICAL
in	O
the	O
low	O
micromolar	O
range	O
produced	O
an	O
irreversible	O
activation	O
of	O
the	O
channel	O
,	O
application	O
of	O
higher	O
concentrations	O
caused	O
a	O
reversible	O
voltage	O
-	O
dependent	O
inhibition	O
of	O
heterologously	O
expressed	O
TRPA1	B-GENE-Y
channels	O
,	O
resulting	O
from	O
a	O
reduction	O
of	O
single	O
-	O
channel	O
open	O
times	O
.	O

In	O
addition	O
,	O
we	O
provide	O
evidence	O
that	O
apomorphine	B-CHEMICAL
also	O
acts	O
on	O
endogenous	O
TRPA1	B-GENE-N
in	O
cultured	O
dorsal	O
root	O
ganglion	O
neurons	O
from	O
rats	O
and	O
in	O
the	O
enterochromaffin	O
model	O
cell	O
line	O
QGP	O
-	O
1	O
,	O
from	O
which	O
serotonin	B-CHEMICAL
is	O
released	O
upon	O
activation	O
of	O
TRPA1	B-GENE-Y
.	O

Our	O
study	O
shows	O
that	O
human	B-GENE-Y
TRPA1	I-GENE-Y
is	O
a	O
target	O
for	O
apomorphine	B-CHEMICAL
,	O
suggesting	O
that	O
an	O
activation	O
of	O
TRPA1	B-GENE-Y
might	O
contribute	O
to	O
adverse	O
side	O
effects	O
such	O
as	O
nausea	O
and	O
painful	O
injections	O
,	O
which	O
can	O
occur	O
during	O
treatment	O
with	O
apomorphine	B-CHEMICAL
.	O

Human	B-GENE-Y
stearoyl	I-GENE-Y
-	I-GENE-Y
CoA	I-GENE-Y
desaturase	I-GENE-Y
1	I-GENE-Y
(	O
SCD	B-GENE-Y
-	I-GENE-Y
1	I-GENE-Y
)	O
gene	O
expression	O
is	O
negatively	O
regulated	O
by	O
thyroid	B-CHEMICAL
hormone	I-CHEMICAL
without	O
direct	O
binding	O
of	O
thyroid	B-GENE-N
hormone	I-GENE-N
receptor	I-GENE-N
to	O
the	O
gene	O
promoter	O
.	O

Stearoyl	B-GENE-Y
-	I-GENE-Y
CoA	I-GENE-Y
desaturase	I-GENE-Y
-	I-GENE-Y
1	I-GENE-Y
(	O
SCD	B-GENE-Y
-	I-GENE-Y
1	I-GENE-Y
)	O
plays	O
a	O
pivotal	O
role	O
in	O
an	O
increase	O
of	O
triglyceride	B-CHEMICAL
by	O
an	O
excess	O
of	O
dietary	O
carbohydrate	B-CHEMICAL
intake	O
.	O

Dietary	O
carbohydrates	B-CHEMICAL
increase	O
SCD	B-GENE-Y
-	I-GENE-Y
1	I-GENE-Y
gene	O
expression	O
in	O
liver	O
by	O
sterol	B-GENE-Y
response	I-GENE-Y
element	I-GENE-Y
binding	I-GENE-Y
protein	I-GENE-Y
(	I-GENE-Y
SREBP	I-GENE-Y
)	I-GENE-Y
-	I-GENE-Y
1c	I-GENE-Y
-	O
dependent	O
and	O
SREBP	B-GENE-Y
-	I-GENE-Y
1c	I-GENE-Y
-	O
independent	O
pathways	O
.	O

Previous	O
report	O
demonstrated	O
that	O
thyroid	B-CHEMICAL
hormone	I-CHEMICAL
(	O
TH	O
)	O
negatively	O
regulates	O
mouse	B-GENE-N
SCD	I-GENE-N
-	I-GENE-N
1	I-GENE-N
gene	I-GENE-N
promoter	I-GENE-N
before	O
SREBP	B-GENE-Y
-	I-GENE-Y
1c	I-GENE-Y
was	O
revealed	O
.	O

We	O
reported	O
that	O
TH	O
negatively	O
regulates	O
SREBP	B-GENE-Y
-	I-GENE-Y
1c	I-GENE-Y
recently	O
.	O

Therefore	O
,	O
in	O
the	O
current	O
study	O
,	O
we	O
examined	O
whether	O
and	O
how	O
TH	O
regulates	O
human	B-GENE-Y
SCD	I-GENE-Y
-	I-GENE-Y
1	I-GENE-Y
gene	O
expression	O
and	O
evaluated	O
SREBP	B-GENE-Y
-	I-GENE-Y
1c	I-GENE-Y
effect	O
on	O
the	O
negative	O
regulation	O
.	O

Luciferase	O
assays	O
revealed	O
that	O
TH	O
suppresses	O
both	O
mouse	B-GENE-N
and	I-GENE-N
human	I-GENE-N
SCD	I-GENE-N
-	I-GENE-N
1	I-GENE-N
gene	I-GENE-N
promoter	I-GENE-N
activity	O
.	O

In	O
SREBP	B-GENE-Y
-	I-GENE-Y
1	I-GENE-Y
knockdown	O
HepG2	O
cells	O
,	O
TH	O
still	O
suppresses	O
SCD	B-GENE-N
-	I-GENE-N
1	I-GENE-N
gene	I-GENE-N
promoter	I-GENE-N
activity	O
,	O
and	O
it	O
also	O
exerted	O
the	O
negative	O
regulation	O
under	O
cotransfection	O
of	O
a	O
small	O
amount	O
of	O
SREBP	B-GENE-Y
-	I-GENE-Y
1c	I-GENE-Y
.	O

These	O
data	O
indicated	O
that	O
SREBP	B-GENE-Y
-	I-GENE-Y
1c	I-GENE-Y
does	O
not	O
play	O
the	O
decisive	O
role	O
for	O
the	O
negative	O
regulation	O
by	O
TH	O
.	O

The	O
responsible	O
region	O
for	O
the	O
negative	O
regulation	O
in	O
human	B-GENE-N
SCD	I-GENE-N
-	I-GENE-N
1	I-GENE-N
gene	I-GENE-N
promoter	I-GENE-N
turned	O
out	O
to	O
be	O
between	O
-	O
124	O
and	O
-	O
92	O
bp	O
,	O
referred	O
to	O
as	O
site	B-GENE-N
A	I-GENE-N
.	O

Chromatin	O
immunoprecipitation	O
assays	O
demonstrated	O
that	O
TH	B-GENE-Y
receptor	I-GENE-Y
-	I-GENE-Y
	I-GENE-Y
is	O
recruited	O
to	O
the	O
region	O
upon	O
T	O
(	O
3	O
)	O
administration	O
,	O
although	O
TR	B-GENE-Y
-	I-GENE-Y
	I-GENE-Y
does	O
not	O
bind	O
directly	O
to	O
site	B-GENE-N
A	I-GENE-N
.	O

In	O
conclusion	O
,	O
TH	O
negatively	O
regulates	O
human	B-GENE-Y
SCD	I-GENE-Y
-	I-GENE-Y
1	I-GENE-Y
gene	O
expression	O
in	O
without	O
direct	O
binding	O
of	O
the	O
TH	B-GENE-N
receptor	I-GENE-N
to	O
the	O
SCD	B-GENE-N
-	I-GENE-N
1	I-GENE-N
gene	I-GENE-N
promoter	I-GENE-N
.	O

Dissociation	O
of	O
Bcl	B-GENE-Y
-	I-GENE-Y
2	I-GENE-Y
-	O
Beclin1	B-GENE-Y
complex	O
by	O
activated	O
AMPK	B-GENE-Y
enhances	O
cardiac	O
autophagy	O
and	O
protects	O
against	O
cardiomyocyte	O
apoptosis	O
in	O
diabetes	O
.	O

Diabetic	O
cardiomyopathy	O
is	O
associated	O
with	O
suppression	O
of	O
cardiac	O
autophagy	O
,	O
and	O
activation	O
of	O
AMP	B-GENE-Y
-	I-GENE-Y
activated	I-GENE-Y
protein	I-GENE-Y
kinase	I-GENE-Y
(	O
AMPK	B-GENE-Y
)	O
restores	O
cardiac	O
autophagy	O
and	O
prevents	O
cardiomyopathy	O
in	O
diabetic	O
mice	O
,	O
albeit	O
by	O
an	O
unknown	O
mechanism	O
.	O

We	O
hypothesized	O
that	O
AMPK	B-GENE-N
-	O
induced	O
autophagy	O
ameliorates	O
diabetic	O
cardiomyopathy	O
by	O
inhibiting	O
cardiomyocyte	O
apoptosis	O
and	O
examined	O
the	O
effects	O
of	O
AMPK	B-GENE-N
on	O
the	O
interaction	O
between	O
Beclin1	B-GENE-N
and	O
Bcl	B-GENE-N
-	I-GENE-N
2	I-GENE-N
,	O
a	O
switch	O
between	O
autophagy	O
and	O
apoptosis	O
,	O
in	O
diabetic	O
mice	O
and	O
high	O
glucose	B-CHEMICAL
-	O
treated	O
H9c2	O
cardiac	O
myoblast	O
cells	O
.	O

Exposure	O
of	O
H9c2	O
cells	O
to	O
high	O
glucose	B-CHEMICAL
reduced	O
AMPK	B-GENE-Y
activity	O
,	O
inhibited	O
Jun	B-GENE-Y
NH2	I-GENE-Y
-	I-GENE-Y
terminal	I-GENE-Y
kinase	I-GENE-Y
1	I-GENE-Y
(	O
JNK1	B-GENE-Y
)	O
-	O
B	B-GENE-Y
-	I-GENE-Y
cell	I-GENE-Y
lymphoma	I-GENE-Y
2	I-GENE-Y
(	O
Bcl	B-GENE-Y
-	I-GENE-Y
2	I-GENE-Y
)	O
signaling	O
,	O
and	O
promoted	O
Beclin1	B-GENE-Y
binding	O
to	O
Bcl	B-GENE-Y
-	I-GENE-Y
2	I-GENE-Y
.	O

Conversely	O
,	O
activation	O
of	O
AMPK	B-GENE-Y
by	O
metformin	O
stimulated	O
JNK1	B-GENE-Y
-	O
Bcl	B-GENE-Y
-	I-GENE-Y
2	I-GENE-Y
signaling	O
and	O
disrupted	O
the	O
Beclin1	B-GENE-Y
-	O
Bcl	B-GENE-Y
-	I-GENE-Y
2	I-GENE-Y
complex	O
.	O

Activation	O
of	O
AMPK	B-GENE-Y
,	O
which	O
normalized	O
cardiac	O
autophagy	O
,	O
attenuated	O
high	O
glucose	B-CHEMICAL
-	O
induced	O
apoptosis	O
in	O
cultured	O
H9c2	O
cells	O
.	O

This	O
effect	O
was	O
attenuated	O
by	O
inhibition	O
of	O
autophagy	O
.	O

Finally	O
,	O
chronic	O
administration	O
of	O
metformin	B-CHEMICAL
in	O
diabetic	O
mice	O
restored	O
cardiac	O
autophagy	O
by	O
activating	O
JNK1	B-GENE-Y
-	O
Bcl	B-GENE-Y
-	I-GENE-Y
2	I-GENE-Y
pathways	O
and	O
dissociating	O
Beclin1	B-GENE-Y
and	O
Bcl	B-GENE-Y
-	I-GENE-Y
2	I-GENE-Y
.	O

The	O
induction	O
of	O
autophagy	O
protected	O
against	O
cardiac	O
apoptosis	O
and	O
improved	O
cardiac	O
structure	O
and	O
function	O
in	O
diabetic	O
mice	O
.	O

We	O
concluded	O
that	O
dissociation	O
of	O
Bcl	B-GENE-Y
-	I-GENE-Y
2	I-GENE-Y
from	O
Beclin1	B-GENE-Y
may	O
be	O
an	O
important	O
mechanism	O
for	O
preventing	O
diabetic	O
cardiomyopathy	O
via	O
AMPK	B-GENE-N
activation	O
that	O
restores	O
autophagy	O
and	O
protects	O
against	O
cardiac	O
apoptosis	O
.	O

Metformin	B-CHEMICAL
-	O
mediated	O
downregulation	O
of	O
p38	B-GENE-N
mitogen	B-GENE-N
-	I-GENE-N
activated	I-GENE-N
protein	I-GENE-N
kinase	I-GENE-N
-	O
dependent	O
excision	O
repair	O
cross	O
-	O
complementing	O
1	O
decreases	O
DNA	O
repair	O
capacity	O
and	O
sensitizes	O
human	O
lung	O
cancer	O
cells	O
to	O
paclitaxel	B-CHEMICAL
.	O

Metformin	B-CHEMICAL
,	O
an	O
extensively	O
used	O
and	O
well	O
-	O
tolerated	O
drug	O
for	O
treating	O
individuals	O
with	O
type	O
2	O
diabetes	O
,	O
has	O
recently	O
gained	O
significant	O
attention	O
as	O
an	O
anticancer	O
drug	O
.	O

On	O
the	O
other	O
hand	O
,	O
paclitaxel	B-CHEMICAL
(	O
Taxol	B-CHEMICAL
)	O
is	O
a	O
new	O
antineoplastic	O
drug	O
that	O
has	O
shown	O
promise	O
in	O
the	O
treatment	O
of	O
non	O
-	O
small	O
cell	O
lung	O
cancer	O
(	O
NSCLC	O
)	O
.	O

High	O
expression	O
levels	O
of	O
excision	B-GENE-Y
repair	I-GENE-Y
cross	I-GENE-Y
-	I-GENE-Y
complementary	I-GENE-Y
1	I-GENE-Y
(	O
ERCC1	B-GENE-Y
)	O
in	O
cancers	O
have	O
been	O
positively	O
associated	O
with	O
the	O
DNA	O
repair	O
capacity	O
and	O
a	O
poor	O
prognosis	O
in	O
NSCLC	O
patients	O
treated	O
with	O
platinum	B-CHEMICAL
-	O
containing	O
chemotherapy	O
.	O

In	O
this	O
current	O
study	O
,	O
paclitaxel	B-CHEMICAL
was	O
found	O
to	O
increase	O
phosphorylation	O
of	O
mitogen	B-GENE-N
-	I-GENE-N
activated	I-GENE-N
protein	I-GENE-N
kinase	I-GENE-N
(	O
MAPK	O
)	O
kinase	O
3	O
/	O
6	O
(	O
MKK3	B-GENE-N
/	I-GENE-N
6	I-GENE-N
)	O
-	O
p38	B-GENE-N
MAPK	B-GENE-N
as	O
well	O
as	O
protein	O
and	O
mRNA	O
levels	O
of	O
ERCC1	B-GENE-Y
in	O
H1650	O
and	O
H1703	O
cells	O
.	O

Moreover	O
,	O
paclitaxel	B-CHEMICAL
-	O
induced	O
ERCC1	B-GENE-Y
protein	O
and	O
mRNA	O
levels	O
significantly	O
decreased	O
via	O
the	O
downregulation	O
of	O
p38	B-GENE-N
activity	O
by	O
either	O
a	O
p38	B-GENE-N
MAPK	B-GENE-N
inhibitor	O
SB202190	B-CHEMICAL
or	O
p38	B-GENE-N
knockdown	O
with	O
specific	O
small	O
interfering	O
RNA	O
(	O
siRNA	O
)	O
.	O

Specific	O
inhibition	O
of	O
ERCC1	B-GENE-Y
with	O
siRNA	O
was	O
found	O
to	O
enhance	O
the	O
paclitaxel	B-CHEMICAL
-	O
induced	O
cytotoxic	O
effect	O
and	O
growth	O
inhibition	O
.	O

Furthermore	O
,	O
metformin	B-CHEMICAL
was	O
able	O
to	O
not	O
only	O
decrease	O
the	O
paclitaxel	B-CHEMICAL
-	O
induced	O
p38	B-GENE-N
MAPK	B-GENE-N
-	O
mediated	O
ERCC1	B-GENE-Y
expression	O
,	O
but	O
also	O
augment	O
the	O
cytotoxic	O
effect	O
induced	O
by	O
paclitaxel	B-CHEMICAL
.	O

Finally	O
,	O
expression	O
of	O
constitutive	O
activate	O
MKK6	B-GENE-Y
or	O
HA	O
-	O
p38	B-GENE-N
MAPK	B-GENE-N
vectors	O
in	O
lung	O
cancer	O
cells	O
was	O
able	O
to	O
abrogate	O
ERCC1	B-GENE-Y
downregulation	O
by	O
metformin	B-CHEMICAL
and	O
paclitaxel	B-CHEMICAL
as	O
well	O
as	O
cell	O
viability	O
and	O
DNA	O
repair	O
capacity	O
.	O

Overall	O
,	O
our	O
results	O
suggest	O
that	O
inhibition	O
of	O
the	O
p38	B-GENE-N
MAPK	B-GENE-N
signaling	O
by	O
metformin	B-CHEMICAL
coupled	O
with	O
paclitaxel	B-CHEMICAL
therapy	O
in	O
human	O
NSCLC	O
cells	O
may	O
be	O
a	O
clinically	O
useful	O
combination	O
,	O
which	O
however	O
will	O
require	O
further	O
validation	O
.	O

Carboxylesterase	B-GENE-Y
-	I-GENE-Y
2	I-GENE-Y
is	O
a	O
highly	O
sensitive	O
target	O
of	O
the	O
antiobesity	O
agent	O
orlistat	B-CHEMICAL
with	O
profound	O
implications	O
in	O
the	O
activation	O
of	O
anticancer	O
prodrugs	O
.	O

Orlistat	B-CHEMICAL
has	O
been	O
the	O
most	O
used	O
anti	O
-	O
obesity	O
drug	O
and	O
the	O
mechanism	O
of	O
its	O
action	O
is	O
to	O
reduce	O
lipid	O
absorption	O
by	O
inhibiting	O
gastrointestinal	O
lipases	B-GENE-N
.	O

These	O
enzymes	O
,	O
like	O
carboxylesterases	B-GENE-N
(	O
CESs	B-GENE-N
)	O
,	O
structurally	O
belong	O
to	O
the	O
	B-GENE-N
/	I-GENE-N
	I-GENE-N
hydrolase	I-GENE-N
fold	O
superfamily	O
.	O

Lipases	B-GENE-N
and	O
CESs	B-GENE-N
are	O
functionally	O
related	O
as	O
well	O
.	O

Some	O
CESs	B-GENE-N
(	O
e	O
.	O
g	O
.	O
,	O
human	B-GENE-Y
CES1	I-GENE-Y
)	O
have	O
been	O
shown	O
to	O
hydrolyze	O
lipids	O
.	O

This	O
study	O
was	O
designed	O
to	O
test	O
the	O
hypothesis	O
that	O
orlistat	B-CHEMICAL
inhibits	O
CESs	B-GENE-N
with	O
higher	O
potency	O
toward	O
CES1	B-GENE-Y
than	O
CES2	B-GENE-Y
,	O
a	O
carboxylesterase	B-GENE-N
with	O
little	O
lipase	B-GENE-N
activity	O
.	O

Liver	O
microsomes	O
and	O
recombinant	O
CESs	B-GENE-N
were	O
tested	O
for	O
the	O
inhibition	O
of	O
the	O
hydrolysis	O
of	O
standard	O
substrates	O
and	O
the	O
anticancer	O
prodrugs	O
pentyl	B-CHEMICAL
carbamate	I-CHEMICAL
of	O
p	B-CHEMICAL
-	I-CHEMICAL
aminobenzyl	I-CHEMICAL
carbamate	I-CHEMICAL
of	O
doxazolidine	B-CHEMICAL
(	O
PPD	B-CHEMICAL
)	O
and	O
irinotecan	B-CHEMICAL
.	O

Contrary	O
to	O
the	O
hypothesis	O
,	O
orlistat	O
at	O
1	O
nM	O
inhibited	O
CES2	B-GENE-Y
activity	O
by	O
75	O
%	O
but	O
no	O
inhibition	O
on	O
CES1	B-GENE-Y
,	O
placing	O
CES2	B-GENE-Y
one	O
of	O
the	O
most	O
sensitive	O
targets	O
of	O
orlistat	B-CHEMICAL
.	O

The	O
inhibition	O
varied	O
among	O
some	O
CES2	B-GENE-Y
polymorphic	O
variants	O
.	O

Pretreatment	O
with	O
orlistat	B-CHEMICAL
reduced	O
the	O
cell	O
killing	O
activity	O
of	O
PPD	B-CHEMICAL
.	O

Certain	O
mouse	O
but	O
not	O
rat	B-GENE-N
CESs	I-GENE-N
were	O
also	O
highly	O
sensitive	O
.	O

CES2	B-GENE-Y
is	O
responsible	O
for	O
the	O
hydrolysis	O
of	O
many	O
common	O
drugs	O
and	O
abundantly	O
expressed	O
in	O
the	O
gastrointestinal	O
track	O
and	O
liver	O
.	O

Inhibition	O
of	O
this	O
carboxylesterase	B-GENE-N
probably	O
presents	O
a	O
major	O
source	O
for	O
altered	O
therapeutic	O
activity	O
of	O
these	O
medicines	O
if	O
co	O
-	O
administered	O
with	O
orlistat	B-CHEMICAL
.	O

In	O
addition	O
,	O
orlistat	B-CHEMICAL
has	O
been	O
linked	O
to	O
various	O
types	O
of	O
organ	O
toxicities	O
,	O
and	O
this	O
study	O
provides	O
an	O
alternative	O
target	O
potentially	O
involved	O
in	O
these	O
toxicological	O
responses	O
.	O

Regions	O
on	O
adenylyl	B-GENE-Y
cyclase	I-GENE-Y
VII	I-GENE-Y
required	O
for	O
selective	O
regulation	O
by	O
the	O
G13	B-GENE-Y
pathway	O
.	O

Regulation	O
of	O
multiple	O
adenylyl	B-GENE-N
cyclases	I-GENE-N
(	O
AC	B-GENE-N
)	O
provides	O
unique	O
inputs	O
to	O
mediate	O
the	O
synthesis	O
of	O
cAMP	B-CHEMICAL
,	O
a	O
ubiquitous	O
second	O
messenger	O
that	O
controls	O
many	O
aspects	O
of	O
cellular	O
function	O
.	O

On	O
stimulation	O
by	O
G	B-GENE-N
(	I-GENE-N
s	I-GENE-N
)	I-GENE-N
,	O
the	O
activities	O
of	O
ACs	B-GENE-N
can	O
be	O
further	O
selectively	O
modulated	O
by	O
other	O
pathways	O
to	O
ensure	O
precise	O
control	O
of	O
intracellular	O
cAMP	B-CHEMICAL
responses	O
to	O
specific	O
stimuli	O
.	O

Recently	O
,	O
we	O
reported	O
that	O
one	O
of	O
the	O
AC	B-GENE-N
isoforms	O
,	O
AC7	B-GENE-Y
,	O
is	O
uniquely	O
regulated	O
by	O
the	O
G	B-GENE-Y
(	I-GENE-Y
13	I-GENE-Y
)	I-GENE-Y
pathway	O
.	O

To	O
understand	O
more	O
fully	O
the	O
molecular	O
mechanism	O
of	O
this	O
regulation	O
,	O
we	O
compared	O
the	O
regulation	O
of	O
AC7	B-GENE-Y
with	O
that	O
of	O
AC2	B-GENE-Y
in	O
bone	O
marrow	O
-	O
derived	O
macrophages	O
devoid	O
of	O
AC7	B-GENE-Y
.	O

Although	O
both	O
enzymes	O
could	O
fully	O
restore	O
regulation	O
of	O
cAMP	B-CHEMICAL
by	O
G	B-GENE-N
,	O
activation	O
of	O
the	O
G	B-GENE-Y
(	I-GENE-Y
13	I-GENE-Y
)	I-GENE-Y
pathway	O
preferentially	O
synergized	O
with	O
AC7	B-GENE-Y
.	O

Exchange	O
of	O
domains	O
between	O
the	O
two	O
isoforms	O
indicates	O
that	O
the	O
C1b	B-GENE-N
domain	I-GENE-N
and	O
the	O
N	B-CHEMICAL
-	O
terminus	O
of	O
the	O
C1a	B-GENE-N
domain	I-GENE-N
are	O
important	O
for	O
directing	O
selective	O
regulation	O
of	O
AC7	B-GENE-Y
by	O
the	O
G	B-GENE-Y
(	I-GENE-Y
13	I-GENE-Y
)	I-GENE-Y
pathway	O
.	O

A	O
mutagenesis	O
screen	O
identified	O
more	O
specific	O
regions	O
of	O
AC7	B-GENE-Y
that	O
differentially	O
mediate	O
its	O
regulation	O
by	O
distinct	O
pathways	O
.	O

Identification	O
and	O
characterization	O
of	O
a	O
potent	O
activator	O
of	O
p53	B-GENE-Y
-	O
independent	O
cellular	O
senescence	O
via	O
a	O
small	O
-	O
molecule	O
screen	O
for	O
modifiers	O
of	O
the	O
integrated	O
stress	O
response	O
.	O

The	O
Integrated	O
Stress	O
Response	O
(	O
ISR	O
)	O
is	O
a	O
signaling	O
program	O
that	O
enables	O
cellular	O
adaptation	O
to	O
stressful	O
conditions	O
like	O
hypoxia	O
and	O
nutrient	O
deprivation	O
in	O
the	O
tumor	O
microenvironment	O
.	O

An	O
important	O
effector	O
of	O
the	O
ISR	O
is	O
activating	B-GENE-Y
transcription	I-GENE-Y
factor	I-GENE-Y
4	I-GENE-Y
(	O
ATF4	B-GENE-Y
)	O
,	O
a	O
transcription	O
factor	O
that	O
regulates	O
genes	O
involved	O
in	O
redox	O
homeostasis	O
and	O
amino	B-CHEMICAL
acid	I-CHEMICAL
metabolism	O
and	O
transport	O
.	O

Because	O
both	O
inhibition	O
and	O
overactivation	O
of	O
the	O
ISR	O
can	O
induce	O
tumor	O
cell	O
death	O
,	O
modulators	O
of	O
ATF4	B-GENE-Y
expression	O
could	O
prove	O
to	O
be	O
clinically	O
useful	O
.	O

In	O
this	O
study	O
,	O
chemical	O
libraries	O
were	O
screened	O
for	O
modulators	O
of	O
ATF4	B-GENE-Y
expression	O
.	O

We	O
identified	O
one	O
compound	O
,	O
E235	B-CHEMICAL
(	B-CHEMICAL
N	I-CHEMICAL
-	I-CHEMICAL
(	I-CHEMICAL
1	I-CHEMICAL
-	I-CHEMICAL
benzyl	I-CHEMICAL
-	I-CHEMICAL
piperidin	I-CHEMICAL
-	I-CHEMICAL
4	I-CHEMICAL
-	I-CHEMICAL
yl	I-CHEMICAL
)	I-CHEMICAL
-	I-CHEMICAL
2	I-CHEMICAL
-	I-CHEMICAL
(	I-CHEMICAL
4	I-CHEMICAL
-	I-CHEMICAL
fluoro	I-CHEMICAL
-	I-CHEMICAL
phenyl	I-CHEMICAL
)	I-CHEMICAL
-	I-CHEMICAL
benzo	I-CHEMICAL
[	I-CHEMICAL
d	I-CHEMICAL
]	I-CHEMICAL
imidazo	I-CHEMICAL
[	I-CHEMICAL
2	I-CHEMICAL
,	I-CHEMICAL
1	I-CHEMICAL
-	I-CHEMICAL
b	I-CHEMICAL
]	I-CHEMICAL
thiazole	I-CHEMICAL
-	I-CHEMICAL
7	I-CHEMICAL
-	I-CHEMICAL
carboxamide	I-CHEMICAL
)	I-CHEMICAL
,	O
that	O
activated	O
the	O
ISR	O
and	O
dose	O
-	O
dependently	O
increased	O
levels	O
of	O
ATF4	B-GENE-Y
in	O
transformed	O
cells	O
.	O

A	O
dose	O
-	O
dependent	O
decrease	O
in	O
viability	O
was	O
observed	O
in	O
several	O
mouse	O
and	O
human	O
tumor	O
cell	O
lines	O
,	O
and	O
knockdown	O
of	O
ATF4	B-GENE-Y
significantly	O
increased	O
the	O
antiproliferative	O
effects	O
of	O
E235	B-CHEMICAL
.	O

Interestingly	O
,	O
low	O
M	O
doses	O
of	O
E235	B-CHEMICAL
induced	O
senescence	O
in	O
many	O
cell	O
types	O
,	O
including	O
HT1080	O
human	O
fibrosarcoma	O
and	O
B16F10	O
mouse	O
melanoma	O
cells	O
.	O

E235	B-CHEMICAL
-	O
mediated	O
induction	O
of	O
senescence	O
was	O
not	O
dependent	O
on	O
p21	B-GENE-Y
or	O
p53	B-GENE-Y
;	O
however	O
,	O
p21	B-GENE-Y
conferred	O
protection	O
against	O
the	O
growth	O
inhibitory	O
effects	O
of	O
E235	B-CHEMICAL
.	O

Treatment	O
with	O
E235	B-CHEMICAL
resulted	O
in	O
an	O
increase	O
in	O
cells	O
arrested	O
at	O
the	O
G2	O
/	O
M	O
phase	O
with	O
a	O
concurrent	O
decrease	O
in	O
S	O
-	O
phase	O
cells	O
.	O

E235	B-CHEMICAL
also	O
activated	O
DNA	O
damage	O
response	O
signaling	O
,	O
resulting	O
in	O
increased	O
levels	O
of	O
Ser15	B-CHEMICAL
-	O
phosphorylated	B-GENE-Y
p53	I-GENE-Y
,	O
	B-GENE-Y
-	I-GENE-Y
H2AX	I-GENE-Y
,	O
and	O
phosphorylated	B-GENE-Y
checkpoint	I-GENE-Y
kinase	I-GENE-Y
2	I-GENE-Y
(	O
Chk2	B-GENE-Y
)	O
,	O
although	O
E235	B-CHEMICAL
does	O
not	O
appear	O
to	O
cause	O
physical	O
DNA	O
damage	O
.	O

Induction	O
of	O
	B-GENE-Y
-	I-GENE-Y
H2AX	I-GENE-Y
was	O
abrogated	O
in	O
ATF4	B-GENE-Y
knockdown	O
cells	O
.	O

Together	O
,	O
these	O
results	O
suggest	O
that	O
modulation	O
of	O
the	O
ISR	O
pathway	O
with	O
the	O
small	O
molecule	O
E235	B-CHEMICAL
could	O
be	O
a	O
promising	O
antitumor	O
strategy	O
.	O

Tilting	O
the	O
balance	O
between	O
canonical	O
and	O
noncanonical	O
conformations	O
for	O
the	O
H1	B-GENE-N
hypervariable	I-GENE-N
loop	I-GENE-N
of	O
a	O
llama	O
VHH	B-GENE-N
through	O
point	O
mutations	O
.	O

Nanobodies	O
are	O
single	O
-	O
domain	O
antibodies	O
found	O
in	O
camelids	O
.	O

These	O
are	O
the	O
smallest	O
naturally	O
occurring	O
binding	O
domains	O
and	O
derive	O
functionality	O
via	O
three	O
hypervariable	B-GENE-N
loops	I-GENE-N
(	O
H1	B-GENE-N
-	O
H3	B-GENE-N
)	O
that	O
form	O
the	O
binding	O
surface	O
.	O

They	O
are	O
excellent	O
candidates	O
for	O
antibody	O
engineering	O
because	O
of	O
their	O
favorable	O
characteristics	O
like	O
small	O
size	O
,	O
high	O
solubility	O
,	O
and	O
stability	O
.	O

To	O
rationally	O
engineer	O
antibodies	O
with	O
affinity	O
for	O
a	O
specific	O
target	O
,	O
the	O
hypervariable	B-GENE-N
loops	I-GENE-N
can	O
be	O
tailored	O
to	O
obtain	O
the	O
desired	O
binding	O
surface	O
.	O

As	O
a	O
first	O
step	O
toward	O
such	O
a	O
goal	O
,	O
we	O
consider	O
the	O
design	O
of	O
loops	O
with	O
a	O
desired	O
conformation	O
.	O

In	O
this	O
study	O
,	O
we	O
focus	O
on	O
the	O
H1	B-GENE-N
loop	I-GENE-N
of	O
the	O
anti	O
-	O
hCG	B-GENE-N
llama	O
nanobody	O
that	O
exhibits	O
a	O
noncanonical	O
conformation	O
.	O

We	O
aim	O
to	O
"	O
tilt	O
"	O
the	O
stability	O
of	O
the	O
H1	B-GENE-N
loop	I-GENE-N
structure	O
from	O
a	O
noncanonical	O
conformation	O
to	O
a	O
(	O
humanized	O
)	O
type	O
1	O
canonical	O
conformation	O
by	O
studying	O
the	O
effect	O
of	O
selected	O
mutations	O
to	O
the	O
amino	B-CHEMICAL
acid	I-CHEMICAL
sequence	O
of	O
the	O
H1	B-GENE-N
,	O
H2	B-GENE-N
,	O
and	O
proximal	O
residues	O
.	O

We	O
use	O
all	O
-	O
atomistic	O
,	O
explicit	O
-	O
solvent	O
,	O
biased	O
molecular	O
dynamic	O
simulations	O
to	O
simulate	O
the	O
wild	O
-	O
type	O
and	O
mutant	O
loops	O
in	O
a	O
prefolded	O
framework	O
.	O

We	O
thus	O
find	O
mutants	O
with	O
increasing	O
propensity	O
to	O
form	O
a	O
stable	O
type	O
1	O
canonical	O
conformation	O
of	O
the	O
H1	B-GENE-N
loop	I-GENE-N
.	O

Free	O
energy	O
landscapes	O
reveal	O
the	O
existence	O
of	O
conformational	O
isomers	O
of	O
the	O
canonical	O
conformation	O
that	O
may	O
play	O
a	O
role	O
in	O
binding	O
different	O
antigenic	O
surfaces	O
.	O

We	O
also	O
elucidate	O
the	O
approximate	O
mechanism	O
and	O
kinetics	O
of	O
transitions	O
between	O
such	O
conformational	O
isomers	O
by	O
using	O
a	O
Markovian	O
model	O
.	O

We	O
find	O
that	O
a	O
particular	O
three	O
-	O
point	O
mutant	O
has	O
the	O
strongest	O
thermodynamic	O
propensity	O
to	O
form	O
the	O
H1	B-GENE-N
type	O
1	O
canonical	O
structure	O
but	O
also	O
to	O
exhibit	O
transitions	O
between	O
conformational	O
isomers	O
,	O
while	O
a	O
different	O
,	O
more	O
rigid	O
three	O
-	O
point	O
mutant	O
has	O
the	O
strongest	O
propensity	O
to	O
be	O
kinetically	O
trapped	O
in	O
such	O
a	O
canonical	O
structure	O
.	O

Synthesis	O
and	O
NIR	O
optical	O
properties	O
of	O
hollow	O
gold	O
nanospheres	O
with	O
LSPR	O
greater	O
than	O
one	O
micrometer	O
.	O

Optical	O
analysis	O
in	O
the	O
near	O
infrared	O
region	O
is	O
of	O
significant	O
biological	O
importance	O
due	O
to	O
better	O
tissue	O
penetration	O
and	O
reduced	O
autofluorescence	O
.	O

In	O
this	O
work	O
,	O
an	O
improved	O
synthesis	O
of	O
hollow	O
gold	O
nanospheres	O
(	O
HGNs	O
)	O
,	O
which	O
provides	O
a	O
tunable	O
localized	O
surface	O
plasmon	O
resonance	O
(	O
LSPR	O
)	O
from	O
610	O
nm	O
up	O
to	O
1320	O
nm	O
,	O
is	O
demonstrated	O
.	O

The	O
scattering	O
properties	O
of	O
these	O
nanoparticles	O
are	O
shown	O
using	O
surface	O
enhanced	O
Raman	O
scattering	O
(	O
SERS	O
)	O
at	O
1064	O
nm	O
excitation	O
wavelength	O
and	O
are	O
compared	O
to	O
citrate	B-CHEMICAL
reduced	O
gold	O
and	O
silver	B-CHEMICAL
nanoparticles	O
of	O
similar	O
physical	O
sizes	O
and	O
surface	O
properties	O
.	O

After	O
the	O
addition	O
of	O
salts	O
,	O
a	O
strong	O
signal	O
was	O
observed	O
from	O
hollow	O
gold	O
with	O
a	O
LSPR	O
of	O
650	O
nm	O
and	O
a	O
weaker	O
,	O
yet	O
observable	O
,	O
signal	O
from	O
HGNs	O
with	O
a	O
LSPR	O
of	O
775	O
nm	O
.	O

However	O
,	O
no	O
obvious	O
signals	O
were	O
observed	O
in	O
the	O
case	O
of	O
standard	O
citrate	B-CHEMICAL
reduced	O
gold	O
,	O
silver	B-CHEMICAL
or	O
HGNs	O
with	O
a	O
LSPR	O
of	O
1080	O
nm	O
.	O

The	O
absorption	O
properties	O
of	O
HGNs	O
were	O
investigated	O
by	O
monitoring	O
their	O
photothermal	O
activity	O
.	O

In	O
this	O
case	O
,	O
different	O
nanoparticle	O
suspensions	O
including	O
citrate	B-CHEMICAL
reduced	O
gold	O
,	O
silver	B-CHEMICAL
,	O
and	O
HGNs	O
were	O
illuminated	O
by	O
a	O
continuous	O
laser	O
at	O
785	O
nm	O
excitation	O
wavelength	O
and	O
the	O
absorption	O
efficiency	O
of	O
HGNs	O
with	O
a	O
LSPR	O
of	O
775	O
nm	O
was	O
calculated	O
to	O
be	O
0	O
.	O
81	O
%	O
which	O
is	O
more	O
than	O
5	O
times	O
higher	O
than	O
the	O
absorption	O
efficiency	O
of	O
citrate	B-CHEMICAL
reduced	O
gold	O
nanoparticles	O
under	O
similar	O
conditions	O
.	O

Influence	O
of	O
surface	O
groups	O
on	O
poly	B-CHEMICAL
(	I-CHEMICAL
propylene	I-CHEMICAL
imine	I-CHEMICAL
)	I-CHEMICAL
dendrimers	O
antiprion	O
activity	O
.	O

Prion	B-GENE-N
diseases	O
are	O
characterized	O
by	O
the	O
accumulation	O
of	O
PrP	B-GENE-Y
(	I-GENE-Y
Sc	I-GENE-Y
)	I-GENE-Y
,	O
an	O
aberrantly	O
folded	O
isoform	O
of	O
the	O
host	O
protein	O
PrP	B-GENE-Y
(	I-GENE-Y
C	I-GENE-Y
)	I-GENE-Y
.	O

Specific	O
forms	O
of	O
synthetic	O
molecules	O
known	O
as	O
dendrimers	O
are	O
able	O
to	O
eliminate	O
protease	O
-	O
resistant	O
PrP	B-GENE-Y
(	I-GENE-Y
Sc	I-GENE-Y
)	I-GENE-Y
in	O
both	O
an	O
intracellular	O
and	O
in	O
vitro	O
setting	O
.	O

The	O
properties	O
of	O
a	O
dendrimer	O
which	O
govern	O
this	O
ability	O
are	O
unknown	O
.	O

We	O
addressed	O
the	O
issue	O
by	O
comparing	O
the	O
in	O
vitro	O
antiprion	O
ability	O
of	O
numerous	O
modified	O
poly	B-CHEMICAL
(	I-CHEMICAL
propylene	I-CHEMICAL
-	I-CHEMICAL
imine	I-CHEMICAL
)	I-CHEMICAL
dendrimers	O
,	O
which	O
varied	O
in	O
size	O
,	O
structure	O
,	O
charge	O
,	O
and	O
surface	O
group	O
composition	O
.	O

Several	O
of	O
the	O
modified	O
dendrimers	O
,	O
including	O
an	O
anionic	O
glycodendrimer	O
,	O
reduced	O
the	O
level	O
of	O
protease	B-GENE-N
resistant	O
PrP	B-GENE-Y
(	I-GENE-Y
Sc	I-GENE-Y
)	I-GENE-Y
in	O
a	O
prion	O
strain	O
-	O
dependent	O
manner	O
.	O

This	O
led	O
to	O
the	O
formulation	O
of	O
a	O
new	O
working	O
model	O
for	O
dendrimer	O
/	O
prion	O
interactions	O
which	O
proposes	O
dendrimers	O
eliminate	O
PrP	B-GENE-Y
(	I-GENE-Y
Sc	I-GENE-Y
)	I-GENE-Y
by	O
destabilizing	O
the	O
protein	O
and	O
rendering	O
it	O
susceptible	O
to	O
proteolysis	O
.	O

This	O
ability	O
is	O
not	O
dependent	O
on	O
any	O
particular	O
charge	O
of	O
dendrimer	O
,	O
but	O
does	O
require	O
a	O
high	O
density	O
of	O
reactive	O
surface	O
groups	O
.	O

Acid	O
-	O
degradable	O
cationic	O
poly	B-CHEMICAL
(	I-CHEMICAL
ketal	I-CHEMICAL
amidoamine	I-CHEMICAL
)	I-CHEMICAL
for	O
enhanced	O
RNA	O
interference	O
in	O
vitro	O
and	O
in	O
vivo	O
.	O

Efficient	O
delivery	O
of	O
small	O
interfering	O
RNA	O
(	O
siRNA	O
)	O
is	O
one	O
of	O
major	O
challenges	O
in	O
the	O
successful	O
applications	O
of	O
siRNA	O
in	O
clinic	O
.	O

In	O
the	O
present	O
study	O
,	O
we	O
report	O
a	O
new	O
acid	O
-	O
degradable	O
poly	B-CHEMICAL
(	I-CHEMICAL
ketal	I-CHEMICAL
amidoamine	I-CHEMICAL
)	I-CHEMICAL
(	O
PKAA	B-CHEMICAL
)	O
as	O
a	O
siRNA	O
carrier	O
,	O
which	O
has	O
high	O
delivery	O
efficiency	O
and	O
low	O
cytotoxicity	O
.	O

PKAA	B-CHEMICAL
was	O
designed	O
to	O
have	O
acid	O
-	O
cleavable	O
ketal	O
linkages	O
in	O
the	O
backbone	O
of	O
cationic	O
biodegradable	O
poly	B-CHEMICAL
(	I-CHEMICAL
amidoamine	I-CHEMICAL
)	I-CHEMICAL
.	O

PKAA	B-CHEMICAL
efficiently	O
self	O
-	O
assembled	O
with	O
siRNA	O
to	O
form	O
nanocomplexes	O
with	O
a	O
diameter	O
of	O
~	O
200	O
nm	O
and	O
slightly	O
positive	O
charges	O
,	O
which	O
are	O
stable	O
under	O
physiological	O
conditions	O
,	O
but	O
rapidly	O
release	O
siRNA	O
at	O
acidic	O
pH	O
.	O

PKAA	B-CHEMICAL
exhibited	O
sufficient	O
buffering	O
capability	O
and	O
endosomolytic	O
activity	O
due	O
mainly	O
to	O
the	O
presence	O
of	O
secondary	B-CHEMICAL
amine	I-CHEMICAL
groups	O
in	O
its	O
backbone	O
and	O
rapid	O
degradation	O
in	O
acidic	O
endosomes	O
,	O
leading	O
to	O
the	O
enhanced	O
release	O
of	O
siRNA	O
to	O
cytoplasm	O
.	O

Cell	O
culture	O
studies	O
demonstrated	O
that	O
PKAA	B-CHEMICAL
is	O
capable	O
of	O
delivering	O
anti	O
-	O
TNF	B-GENE-Y
(	B-GENE-Y
tumor	I-GENE-Y
necrosis	I-GENE-Y
factor	I-GENE-Y
)	I-GENE-Y
-	I-GENE-Y
	I-GENE-Y
siRNA	O
to	O
lipopolysaccharide	O
(	O
LPS	O
)	O
-	O
stimulated	O
macrophages	O
and	O
significantly	O
inhibits	O
the	O
expression	O
of	O
TNF	B-GENE-Y
-	I-GENE-Y
	I-GENE-Y
.	O

A	O
mouse	O
model	O
of	O
acetaminophen	B-CHEMICAL
(	O
APAP	B-CHEMICAL
)	O
-	O
induced	O
acute	O
liver	O
failure	O
was	O
used	O
to	O
evaluate	O
in	O
vivo	O
siRNA	O
delivery	O
efficacy	O
of	O
PKAA	B-CHEMICAL
.	O

PKAA	B-CHEMICAL
/	O
anti	O
-	O
TNF	B-GENE-Y
-	I-GENE-Y
	I-GENE-Y
siRNA	O
nanocomplexes	O
significantly	O
reduced	O
the	O
ALT	B-GENE-N
(	O
alanine	B-GENE-N
transaminase	I-GENE-N
)	O
and	O
the	O
hepatic	O
cellular	O
damages	O
in	O
APAP	B-CHEMICAL
-	O
intoxicated	O
mice	O
.	O

We	O
anticipate	O
that	O
acid	O
-	O
degradable	O
PKAA	B-CHEMICAL
has	O
great	O
potential	O
as	O
siRNA	O
carriers	O
based	O
on	O
its	O
excellent	O
biocompatibility	O
,	O
pH	O
sensitivity	O
,	O
potential	O
endosomolytic	O
activity	O
,	O
and	O
high	O
delivery	O
efficiency	O
.	O

Wogonin	B-CHEMICAL
inhibits	O
H2O2	B-CHEMICAL
-	O
induced	O
vascular	O
permeability	O
through	O
suppressing	O
the	O
phosphorylation	O
of	O
caveolin	B-GENE-Y
-	I-GENE-Y
1	I-GENE-Y
.	O

Wogonin	B-CHEMICAL
,	O
a	O
naturally	O
occurring	O
monoflavonoid	B-CHEMICAL
extracted	O
from	O
the	O
root	O
of	O
Scutellaria	O
baicalensis	O
Georgi	O
,	O
has	O
been	O
reported	O
for	O
its	O
anti	O
-	O
oxidant	O
activity	O
.	O

However	O
,	O
it	O
is	O
still	O
unclear	O
whether	O
wogonin	B-CHEMICAL
can	O
inhibit	O
oxidant	O
-	O
induced	O
vascular	O
permeability	O
.	O

In	O
this	O
study	O
,	O
we	O
evaluated	O
the	O
effects	O
of	O
wogonin	B-CHEMICAL
on	O
H2O2	B-CHEMICAL
-	O
induced	O
vascular	O
permeability	O
in	O
human	O
umbilical	O
vein	O
endothelial	O
cells	O
(	O
HUVECs	O
)	O
.	O

We	O
found	O
that	O
wogonin	B-CHEMICAL
can	O
suppress	O
the	O
H2O2	B-CHEMICAL
-	O
stimulated	O
actin	B-GENE-N
remodeling	O
and	O
albumin	B-GENE-Y
uptake	O
of	O
HUVECs	O
,	O
as	O
well	O
as	O
transendothelial	O
cell	O
migration	O
of	O
the	O
human	O
breast	O
carcinoma	O
cell	O
MDA	O
-	O
MB	O
-	O
231	O
.	O

The	O
mechanism	O
revealed	O
that	O
wogonin	B-CHEMICAL
inhibited	O
H2O2	B-CHEMICAL
-	O
induced	O
phosphorylation	O
of	O
caveolin	B-GENE-Y
-	I-GENE-Y
1	I-GENE-Y
(	O
cav	B-GENE-Y
-	I-GENE-Y
1	I-GENE-Y
)	O
associating	O
with	O
the	O
suppression	O
of	O
stabilization	O
of	O
VE	B-GENE-Y
-	I-GENE-Y
cadherin	I-GENE-Y
and	O
	B-GENE-Y
-	I-GENE-Y
catenin	I-GENE-Y
.	O

Moreover	O
,	O
wogonin	B-CHEMICAL
repressed	O
anisomycin	B-CHEMICAL
-	O
induced	O
phosphorylation	O
of	O
p38	B-GENE-N
,	O
cav	B-GENE-Y
-	I-GENE-Y
1	I-GENE-Y
and	O
vascular	O
permeability	O
.	O

These	O
results	O
suggested	O
that	O
wogonin	B-CHEMICAL
could	O
inhibit	O
H2O2	B-CHEMICAL
-	O
induced	O
vascular	O
permeability	O
by	O
downregulating	O
the	O
phosphorylation	O
of	O
cav	B-GENE-Y
-	I-GENE-Y
1	I-GENE-Y
,	O
and	O
that	O
it	O
might	O
have	O
a	O
therapeutic	O
potential	O
for	O
the	O
diseases	O
associated	O
with	O
the	O
development	O
of	O
both	O
oxidant	O
and	O
vascular	O
permeability	O
.	O

The	O
discovery	O
of	O
fused	O
oxadiazepines	B-CHEMICAL
as	O
gamma	B-GENE-N
secretase	I-GENE-N
modulators	O
for	O
treatment	O
of	O
Alzheimer	O
'	O
s	O
disease	O
.	O

In	O
an	O
attempt	O
to	O
further	O
improve	O
overall	O
profiles	O
of	O
the	O
oxadiazine	B-CHEMICAL
series	O
of	O
GSMs	O
,	O
in	O
particular	O
the	O
hERG	B-GENE-Y
activity	O
,	O
conformational	O
modifications	O
of	O
the	O
core	O
structure	O
resulted	O
in	O
the	O
identification	O
of	O
fused	O
oxadiazepines	B-CHEMICAL
such	O
as	O
7i	O
which	O
had	O
an	O
improved	O
hERG	B-GENE-Y
inhibition	O
profile	O
and	O
was	O
a	O
highly	O
efficacious	O
GSM	O
in	O
vitro	O
and	O
in	O
vivo	O
in	O
rats	O
.	O

These	O
SAR	O
explorations	O
offer	O
opportunities	O
to	O
identify	O
potential	O
drugs	O
to	O
treat	O
Alzheimer	O
'	O
s	O
disease	O
.	O

Inhibitory	O
effects	O
of	O
a	O
bazedoxifene	B-CHEMICAL
/	O
conjugated	O
equine	O
estrogen	B-CHEMICAL
combination	O
on	O
human	O
breast	O
cancer	O
cells	O
in	O
vitro	O
.	O

Breast	O
cancer	O
incidence	O
is	O
increased	O
in	O
women	O
receiving	O
menopausal	O
hormone	O
therapy	O
with	O
estrogen	B-CHEMICAL
plus	O
progestin	O
but	O
not	O
with	O
estrogen	B-CHEMICAL
alone	O
.	O

The	O
use	O
of	O
a	O
tissue	O
-	O
selective	O
estrogen	B-CHEMICAL
complex	O
(	O
TSEC	O
)	O
has	O
been	O
proposed	O
as	O
a	O
novel	O
menopausal	O
hormone	O
therapy	O
strategy	O
to	O
eliminate	O
the	O
requirement	O
for	O
a	O
progestogen	B-CHEMICAL
.	O

Combination	O
of	O
bazedoxifene	B-CHEMICAL
(	O
BZA	B-CHEMICAL
)	O
with	O
conjugated	O
estrogens	B-CHEMICAL
(	O
CEs	O
)	O
,	O
the	O
first	O
TSEC	O
,	O
has	O
shown	O
beneficial	O
effects	O
.	O

Whether	O
it	O
would	O
exert	O
antiestrogenic	O
effects	O
on	O
breast	O
cancer	O
is	O
not	O
clear	O
.	O

To	O
address	O
this	O
issue	O
,	O
we	O
compared	O
estradiol	B-CHEMICAL
(	O
E	O
(	O
2	O
)	O
)	O
and	O
CE	O
alone	O
on	O
proliferation	O
and	O
apoptosis	O
in	O
MCF	O
-	O
7	O
breast	O
cancer	O
cells	O
.	O

CE	O
stimulated	O
growth	O
of	O
MCF	O
-	O
7	O
cells	O
at	O
a	O
peak	O
concentration	O
10	O
-	O
fold	O
higher	O
than	O
required	O
for	O
E	O
(	O
2	O
)	O
.	O

Both	O
CE	O
and	O
E	O
(	O
2	O
)	O
alone	O
increased	O
DNA	O
synthesis	O
and	O
reduced	O
apoptosis	O
with	O
activation	O
of	O
MAPK	B-GENE-N
,	O
Akt	B-GENE-N
,	O
and	O
p70S6K	B-GENE-N
and	O
up	O
-	O
regulation	O
of	O
antiapoptotic	O
factors	O
survivin	B-GENE-Y
,	O
Bcl	B-GENE-Y
-	I-GENE-Y
2	I-GENE-Y
,	O
and	O
X	B-GENE-Y
-	I-GENE-Y
linked	I-GENE-Y
inhibitor	I-GENE-Y
of	I-GENE-Y
apoptosis	I-GENE-Y
protein	I-GENE-Y
,	O
These	O
effects	O
could	O
be	O
completely	O
blocked	O
by	O
BZA	B-CHEMICAL
.	O

Gene	O
expression	O
studies	O
demonstrated	O
that	O
CE	O
and	O
E	O
(	O
2	O
)	O
were	O
equally	O
potent	O
on	O
expression	O
of	O
cMyc	B-GENE-Y
,	O
pS2	B-GENE-Y
,	O
and	O
WNT1	B-GENE-Y
inducible	I-GENE-Y
signaling	I-GENE-Y
pathway	I-GENE-Y
protein	I-GENE-Y
2	I-GENE-Y
,	O
whereas	O
the	O
stimulatory	O
effects	O
of	O
CE	O
on	O
progesterone	B-GENE-Y
receptor	I-GENE-Y
and	O
amphiregulin	B-GENE-Y
expression	O
were	O
weaker	O
than	O
E	O
(	O
2	O
)	O
.	O

BZA	B-CHEMICAL
effectively	O
blocked	O
each	O
of	O
these	O
effects	O
and	O
showed	O
no	O
estrogen	B-CHEMICAL
agonistic	O
effects	O
when	O
used	O
alone	O
.	O

Our	O
results	O
indicate	O
that	O
the	O
stimulatory	O
effects	O
of	O
E	O
(	O
2	O
)	O
or	O
CE	O
on	O
breast	O
cancer	O
cells	O
could	O
be	O
completely	O
abrogated	O
by	O
BZA	B-CHEMICAL
.	O

These	O
studies	O
imply	O
that	O
the	O
CE	O
/	O
BZA	B-CHEMICAL
,	O
TSEC	O
,	O
exerts	O
antiestrogenic	O
effects	O
on	O
breast	O
cancer	O
cells	O
and	O
might	O
block	O
the	O
growth	O
of	O
occult	O
breast	O
neoplasms	O
in	O
postmenopausal	O
women	O
,	O
resulting	O
in	O
an	O
overall	O
reduction	O
in	O
tumor	O
incidence	O
.	O

Characterization	O
of	O
steroidogenic	O
enzyme	O
expression	O
in	O
aldosterone	B-CHEMICAL
-	O
producing	O
adenoma	O
:	O
a	O
comparison	O
with	O
various	O
human	O
adrenal	O
tumors	O
.	O

We	O
analyzed	O
the	O
expression	O
profiles	O
of	O
several	O
steroidogenic	O
enzymes	O
in	O
normal	O
adrenals	O
,	O
aldosterone	B-CHEMICAL
-	O
producing	O
adenomas	O
(	O
APA	O
)	O
,	O
cortisol	B-CHEMICAL
-	O
producing	O
adenomas	O
combined	O
with	O
Cushing	O
'	O
s	O
syndrome	O
(	O
CPA	O
)	O
or	O
with	O
subclinical	O
Cushing	O
'	O
s	O
syndrome	O
(	O
SCPA	O
)	O
,	O
and	O
nonfunctioning	O
adrenal	O
adenomas	O
(	O
NFA	O
)	O
to	O
clarify	O
the	O
nature	O
and	O
characteristics	O
of	O
steroidogenesis	O
in	O
APA	O
.	O

Clinical	O
data	O
were	O
collected	O
for	O
all	O
subjects	O
.	O

In	O
resected	O
adrenal	O
glands	O
(	O
normal	O
adrenals	O
,	O
APA	O
,	O
CPA	O
,	O
SCPA	O
,	O
and	O
NFA	O
)	O
,	O
the	O
mRNA	O
expression	O
levels	O
of	O
the	O
CYP17	B-GENE-Y
,	O
HSD3B2	B-GENE-Y
,	O
CYP11B1	B-GENE-Y
,	O
and	O
CYP11B2	B-GENE-Y
genes	O
were	O
studied	O
using	O
real	O
-	O
time	O
quantitative	O
PCR	O
and	O
immunohistochemistry	O
.	O

The	O
CYP11B2	B-GENE-Y
mRNA	O
level	O
in	O
APA	O
was	O
significantly	O
higher	O
than	O
that	O
in	O
other	O
groups	O
.	O

The	O
CYP17	B-GENE-Y
/	O
HSD3B2	B-GENE-Y
ratio	O
for	O
mRNA	O
in	O
APA	O
was	O
significantly	O
lower	O
than	O
those	O
in	O
the	O
other	O
groups	O
.	O

Low	O
ratio	O
of	O
CYP17	B-GENE-Y
/	O
HSD3B2	B-GENE-Y
with	O
high	O
expression	O
of	O
CYP11B2	B-GENE-Y
seems	O
to	O
explain	O
steroidogenic	O
characteristics	O
of	O
APA	O
.	O

Live	O
-	O
cell	O
imaging	O
of	O
p53	B-GENE-Y
interactions	O
using	O
a	O
novel	O
Venus	O
-	O
based	O
bimolecular	O
fluorescence	O
complementation	O
system	O
.	O

p53	B-GENE-Y
plays	O
an	O
important	O
role	O
in	O
regulating	O
a	O
wide	O
variety	O
of	O
cellular	O
processes	O
,	O
such	O
as	O
cell	O
cycle	O
arrest	O
and	O
/	O
or	O
apoptosis	O
.	O

Dysfunction	O
of	O
p53	B-GENE-Y
is	O
frequently	O
associated	O
with	O
several	O
pathologies	O
,	O
such	O
as	O
cancer	O
and	O
neurodegenerative	O
diseases	O
.	O

In	O
recent	O
years	O
substantial	O
progress	O
has	O
been	O
made	O
in	O
developing	O
novel	O
p53	B-GENE-Y
-	O
activating	O
molecules	O
.	O

Importantly	O
,	O
modulation	O
of	O
p53	B-GENE-Y
interaction	O
with	O
its	O
main	O
inhibitor	O
,	O
Mdm2	B-GENE-Y
,	O
has	O
been	O
highlighted	O
as	O
a	O
promising	O
therapeutic	O
target	O
.	O

In	O
this	O
regard	O
,	O
bimolecular	O
fluorescence	O
complementation	O
(	O
BiFC	O
)	O
analysis	O
,	O
by	O
providing	O
direct	O
visualization	O
of	O
protein	O
interactions	O
in	O
living	O
cells	O
,	O
offers	O
a	O
straightforward	O
method	O
to	O
identify	O
potential	O
modulators	O
of	O
protein	O
interactions	O
.	O

In	O
this	O
study	O
,	O
we	O
developed	O
a	O
simple	O
and	O
robust	O
Venus	O
-	O
based	O
BiFC	O
system	O
to	O
screen	O
for	O
modulators	O
of	O
p53	B-GENE-N
-	O
p53	B-GENE-N
and	O
p53	B-GENE-N
-	O
Mdm2	B-GENE-N
interactions	O
in	O
live	O
mammalian	O
cells	O
.	O

We	O
used	O
nutlin	B-CHEMICAL
-	I-CHEMICAL
3	I-CHEMICAL
,	O
a	O
well	O
-	O
known	O
disruptor	O
of	O
p53	B-GENE-Y
-	O
Mdm2	B-GENE-Y
interaction	O
,	O
to	O
validate	O
the	O
specificity	O
of	O
the	O
assay	O
.	O

The	O
reduction	O
of	O
BiFC	O
signal	O
mediated	O
by	O
nutlin	B-CHEMICAL
-	I-CHEMICAL
3	I-CHEMICAL
was	O
correlated	O
with	O
an	O
increase	O
in	O
Puma	B-GENE-Y
transactivation	O
,	O
PARP	B-GENE-N
cleavage	O
,	O
and	O
cell	O
death	O
.	O

Finally	O
,	O
this	O
novel	O
BiFC	O
approach	O
was	O
exploited	O
to	O
identify	O
potential	O
modulators	O
of	O
p53	B-GENE-Y
-	O
Mdm2	B-GENE-Y
complex	O
formation	O
among	O
a	O
commercially	O
available	O
chemical	O
library	O
of	O
33	O
protein	B-GENE-N
phosphatase	I-GENE-N
inhibitors	O
.	O

Our	O
results	O
constitute	O
"	O
proof	O
-	O
of	O
-	O
concept	O
"	O
that	O
this	O
model	O
has	O
strong	O
potential	O
as	O
an	O
alternative	O
to	O
traditional	O
target	O
-	O
based	O
drug	O
discovery	O
strategies	O
.	O

Identification	O
of	O
new	O
modulators	O
of	O
p53	B-GENE-Y
-	O
p53	B-GENE-Y
and	O
p53	B-GENE-Y
-	O
Mdm2	B-GENE-Y
interactions	O
will	O
be	O
useful	O
to	O
achieve	O
synergistic	O
drug	O
efficacy	O
with	O
currently	O
used	O
anti	O
-	O
tumor	O
therapies	O
.	O

Salsolinol	B-CHEMICAL
induced	O
apoptotic	O
changes	O
in	O
neural	O
stem	O
cells	O
:	O
amelioration	O
by	O
neurotrophin	B-GENE-N
support	O
.	O

Salsolinol	B-CHEMICAL
(	O
SAL	B-CHEMICAL
)	O
,	O
a	O
catechol	B-CHEMICAL
isoquinoline	I-CHEMICAL
has	O
invited	O
considerable	O
attention	O
due	O
to	O
its	O
structural	O
similarity	O
with	O
dopaminergic	O
neurotoxin	O
1	B-CHEMICAL
-	I-CHEMICAL
methyl	I-CHEMICAL
-	I-CHEMICAL
4	I-CHEMICAL
-	I-CHEMICAL
phenyl	I-CHEMICAL
-	I-CHEMICAL
1	I-CHEMICAL
,	I-CHEMICAL
2	I-CHEMICAL
,	I-CHEMICAL
3	I-CHEMICAL
,	I-CHEMICAL
6	I-CHEMICAL
-	I-CHEMICAL
tetrahydropyridine	I-CHEMICAL
(	O
MPTP	B-CHEMICAL
)	O
.	O

Its	O
high	O
endogenous	O
presence	O
in	O
Parkinsonian	O
brain	O
implicated	O
its	O
possible	O
association	O
with	O
the	O
disease	O
process	O
.	O

SAL	B-CHEMICAL
is	O
also	O
present	O
in	O
alcohol	O
beverages	O
and	O
certain	O
food	O
materials	O
and	O
can	O
get	O
access	O
to	O
brain	O
especially	O
in	O
conditions	O
of	O
immature	O
or	O
impaired	O
BBB	O
.	O

Besides	O
this	O
,	O
the	O
effect	O
of	O
SAL	B-CHEMICAL
on	O
neural	O
stem	O
cells	O
(	O
NSCs	O
)	O
which	O
are	O
potential	O
candidates	O
for	O
adult	O
neurogenesis	O
and	O
transplantation	O
mediated	O
rejuvenating	O
attempts	O
for	O
Parkinson	O
'	O
s	O
disease	O
(	O
PD	O
)	O
brain	O
has	O
not	O
been	O
known	O
so	O
far	O
.	O

NSCs	O
in	O
both	O
the	O
cases	O
have	O
to	O
overcome	O
suppressive	O
cues	O
of	O
diseased	O
brain	O
for	O
their	O
survival	O
and	O
function	O
.	O

In	O
this	O
study	O
we	O
explored	O
the	O
toxicity	O
of	O
SAL	B-CHEMICAL
toward	O
NSCs	O
focusing	O
on	O
apoptosis	O
and	O
status	O
of	O
PI3K	B-GENE-N
survival	O
signaling	O
.	O

NSCs	O
cultured	O
from	O
embryonic	O
day	O
11	O
rat	O
fetal	O
brain	O
including	O
those	O
differentiated	O
to	O
TH	O
(	O
+	O
ve	O
)	O
colonies	O
,	O
when	O
challenged	O
with	O
SAL	B-CHEMICAL
(	O
1	O
-	O
100M	O
)	O
,	O
elicited	O
a	O
concentration	O
and	O
time	O
dependent	O
cell	O
death	O
/	O
loss	O
of	O
mitochondrial	O
viability	O
.	O

10M	O
SAL	B-CHEMICAL
on	O
which	O
significant	O
mitochondrial	O
impairment	O
initiated	O
was	O
further	O
used	O
to	O
study	O
mechanism	O
of	O
toxicity	O
.	O

Morphological	O
impairment	O
,	O
enhanced	O
TUNEL	O
positivity	O
,	O
cleaved	O
caspase	B-GENE-Y
-	I-GENE-Y
3	I-GENE-Y
and	O
decreased	O
Bcl	B-GENE-Y
-	I-GENE-Y
2	I-GENE-Y
:	O
Bax	B-GENE-Y
suggested	O
apoptosis	O
.	O

Sal	B-CHEMICAL
toxicity	O
coincided	O
with	O
reduced	O
pAkt	B-GENE-N
level	O
and	O
its	O
downstream	O
effectors	O
:	O
pCREB	B-GENE-N
,	O
pGSK	B-GENE-Y
-	I-GENE-Y
3	I-GENE-Y
,	O
Bcl	B-GENE-Y
-	I-GENE-Y
2	I-GENE-Y
and	O
neurotrophins	B-GENE-N
GDNF	B-GENE-Y
,	O
BDNF	B-GENE-Y
suggesting	O
repressed	O
PI3K	B-GENE-N
/	O
Akt	B-GENE-N
signaling	O
.	O

Multiple	O
neurotrophic	O
factor	O
support	O
in	O
the	O
form	O
of	O
Olfactory	O
Ensheathing	O
Cell	O
'	O
s	O
Conditioned	O
Media	O
(	O
OEC	O
CM	O
)	O
potentially	O
protected	O
NSCs	O
against	O
SAL	B-CHEMICAL
through	O
activating	O
PI3K	B-GENE-N
/	O
Akt	B-GENE-N
pathway	O
.	O

This	O
was	O
confirmed	O
on	O
adding	O
LY294002	B-CHEMICAL
the	O
PI3K	B-GENE-N
inhibitor	O
which	O
abolished	O
the	O
protection	O
.	O

We	O
inferred	O
that	O
SAL	B-CHEMICAL
exerts	O
substantial	O
toxicity	O
toward	O
NSCs	O
.	O

These	O
findings	O
will	O
lead	O
to	O
better	O
understanding	O
of	O
endogenous	O
threats	O
that	O
might	O
affect	O
the	O
fate	O
of	O
transplanted	O
NSCs	O
and	O
their	O
probable	O
antidotes	O
.	O

Central	O
nervous	O
system	O
damage	O
due	O
to	O
acute	O
paraquat	B-CHEMICAL
poisoning	O
:	O
an	O
experimental	O
study	O
with	O
rat	O
model	O
.	O

Paraquat	B-CHEMICAL
(	O
PQ	O
)	O
is	O
a	O
common	O
herbicide	O
and	O
PQ	O
poisoning	O
is	O
a	O
major	O
medical	O
problem	O
in	O
Asia	O
.	O

However	O
,	O
few	O
studies	O
have	O
focused	O
on	O
the	O
acute	O
neurotoxic	O
changes	O
caused	O
by	O
PQ	O
.	O

Here	O
we	O
report	O
the	O
acute	O
neurotoxicological	O
findings	O
of	O
rats	O
treated	O
with	O
lethal	O
dose	O
of	O
PQ	O
.	O

In	O
substantia	O
nigra	O
(	O
SN	O
)	O
and	O
striatum	O
we	O
found	O
obvious	O
microglia	O
(	O
labeled	O
by	O
Iba	B-GENE-Y
-	I-GENE-Y
1	I-GENE-Y
)	O
activation	O
within	O
one	O
week	O
.	O

In	O
SN	O
and	O
hippocampus	O
,	O
we	O
detected	O
increased	O
oxidative	O
stress	O
in	O
the	O
neurons	O
based	O
on	O
NeuN	O
/	O
8	B-CHEMICAL
-	I-CHEMICAL
OHdG	I-CHEMICAL
immunofluorescence	O
double	O
labeling	O
and	O
laser	O
cofocal	O
microscopy	O
.	O

Moreover	O
,	O
we	O
provided	O
ultrastructural	O
evidences	O
of	O
astrocyte	O
edema	O
and	O
neurons	O
apoptosis	O
in	O
rat	O
brain	O
by	O
electron	O
microscopy	O
.	O

Further	O
studies	O
will	O
be	O
needed	O
with	O
non	O
-	O
lethal	O
dose	O
of	O
PQ	O
to	O
confirm	O
these	O
results	O
and	O
demonstrate	O
the	O
direct	O
CNS	O
toxicity	O
of	O
PQ	O
.	O

(	B-CHEMICAL
-	I-CHEMICAL
)	I-CHEMICAL
Epicatechin	I-CHEMICAL
attenuates	O
mitochondrial	O
damage	O
by	O
enhancing	O
mitochondrial	O
multi	O
-	O
marker	O
enzymes	O
,	O
adenosine	B-CHEMICAL
triphosphate	I-CHEMICAL
and	O
lowering	O
calcium	B-CHEMICAL
in	O
isoproterenol	B-CHEMICAL
induced	O
myocardial	O
infarcted	O
rats	O
.	O

Cardiac	O
mitochondrial	O
damage	O
plays	O
an	O
important	O
role	O
in	O
the	O
pathology	O
of	O
myocardial	O
infarction	O
.	O

The	O
protective	O
effects	O
of	O
(	B-CHEMICAL
-	I-CHEMICAL
)	I-CHEMICAL
epicatechin	I-CHEMICAL
on	O
cardiac	O
mitochondrial	O
damage	O
in	O
isoproterenol	B-CHEMICAL
induced	O
myocardial	O
infarction	O
were	O
evaluated	O
in	O
rats	O
.	O

Rats	O
were	O
pretreated	O
with	O
(	B-CHEMICAL
-	I-CHEMICAL
)	I-CHEMICAL
epicatechin	I-CHEMICAL
(	O
20	O
mg	O
/	O
kg	O
body	O
weight	O
)	O
daily	O
for	O
a	O
period	O
of	O
21	O
days	O
.	O

After	O
the	O
pretreatment	O
period	O
,	O
isoproterenol	B-CHEMICAL
(	O
100	O
mg	O
/	O
kg	O
body	O
weight	O
)	O
was	O
injected	O
subcutaneously	O
into	O
rats	O
twice	O
at	O
an	O
interval	O
of	O
24	O
h	O
to	O
induce	O
myocardial	O
infarction	O
.	O

Isoproterenol	B-CHEMICAL
induced	O
myocardial	O
infarcted	O
rats	O
showed	O
a	O
significant	O
increase	O
in	O
the	O
levels	O
of	O
cardiac	O
diagnostic	O
markers	O
,	O
heart	O
mitochondrial	O
lipid	O
peroxidation	O
,	O
calcium	B-CHEMICAL
,	O
and	O
a	O
significant	O
decrease	O
in	O
the	O
activities	O
/	O
levels	O
of	O
heart	O
mitochondrial	O
glutathione	B-GENE-N
peroxidase	I-GENE-N
,	O
glutathione	B-GENE-Y
reductase	I-GENE-Y
,	O
reduced	B-CHEMICAL
glutathione	I-CHEMICAL
,	O
isocitrate	B-CHEMICAL
,	O
succinate	B-CHEMICAL
,	O
malate	B-CHEMICAL
,	O
	B-CHEMICAL
-	I-CHEMICAL
ketoglutarate	I-CHEMICAL
and	O
NADH	B-GENE-N
-	I-GENE-N
dehydrogenases	I-GENE-N
,	O
cytochrome	B-GENE-N
-	I-GENE-N
C	I-GENE-N
-	I-GENE-N
oxidase	I-GENE-N
and	O
adenosine	B-CHEMICAL
triphosphate	I-CHEMICAL
.	O

(	B-CHEMICAL
-	I-CHEMICAL
)	I-CHEMICAL
Epicatechin	I-CHEMICAL
pretreatment	O
showed	O
significant	O
protective	O
effects	O
on	O
all	O
the	O
biochemical	O
parameters	O
evaluated	O
.	O

The	O
in	O
vitro	O
study	O
revealed	O
the	O
superoxide	B-CHEMICAL
and	O
hydroxyl	B-CHEMICAL
radical	O
scavenging	O
activity	O
of	O
(	B-CHEMICAL
-	I-CHEMICAL
)	I-CHEMICAL
epicatechin	I-CHEMICAL
.	O

The	O
possible	O
mechanisms	O
for	O
the	O
beneficial	O
effects	O
of	O
(	B-CHEMICAL
-	I-CHEMICAL
)	I-CHEMICAL
epicatechin	I-CHEMICAL
on	O
cardiac	O
mitochondria	O
could	O
be	O
attributed	O
to	O
scavenging	O
of	O
free	O
radicals	O
,	O
decreasing	O
calcium	B-CHEMICAL
,	O
increasing	O
multi	O
-	O
enzymes	O
(	O
antioxidant	O
,	O
tricarboxylic	B-CHEMICAL
acid	I-CHEMICAL
cycle	O
and	O
respiratory	O
chain	O
enzymes	O
)	O
,	O
reduced	O
glutathione	B-CHEMICAL
and	O
adenosine	B-CHEMICAL
triphosphate	I-CHEMICAL
.	O

Thus	O
,	O
(	B-CHEMICAL
-	I-CHEMICAL
)	I-CHEMICAL
epicatechin	I-CHEMICAL
attenuated	O
mitochondrial	O
damage	O
in	O
isoproterenol	B-CHEMICAL
induced	O
myocardial	O
infarcted	O
rats	O
.	O

Increased	O
urinary	O
excretion	O
of	O
albumin	B-GENE-N
,	O
hemopexin	B-GENE-Y
,	O
transferrin	B-GENE-Y
and	O
VDBP	B-GENE-Y
correlates	O
with	O
chronic	O
sensitization	O
to	O
gentamicin	B-CHEMICAL
nephrotoxicity	O
in	O
rats	O
.	O

Drug	O
nephrotoxicity	O
is	O
a	O
serious	O
health	O
and	O
economic	O
problem	O
worldwide	O
.	O

Rats	O
can	O
be	O
acutely	O
sensitized	O
to	O
acute	O
kidney	O
injury	O
(	O
AKI	O
)	O
by	O
subnephrotoxic	O
treatments	O
with	O
potentially	O
nephrotoxic	O
drugs	O
.	O

Acquired	O
sensitization	O
to	O
AKI	O
poses	O
a	O
silent	O
risk	O
impossible	O
to	O
diagnose	O
pre	O
-	O
emptively	O
with	O
the	O
technology	O
available	O
at	O
the	O
clinical	O
level	O
.	O

Herein	O
,	O
we	O
hypothesized	O
whether	O
a	O
chronic	O
,	O
subnephrotoxic	O
insult	O
to	O
the	O
kidneys	O
might	O
result	O
in	O
chronically	O
acquired	O
sensitization	O
to	O
AKI	O
,	O
and	O
whether	O
chronic	O
sensitization	O
might	O
be	O
detected	O
through	O
specific	O
urinary	O
markers	O
.	O

To	O
this	O
end	O
,	O
rats	O
were	O
treated	O
with	O
a	O
subtoxic	O
dosage	O
of	O
the	O
experimental	O
nephrotoxin	O
uranyl	O
nitrate	B-CHEMICAL
(	O
UN	O
)	O
in	O
the	O
drinking	O
water	O
for	O
21	O
weeks	O
,	O
or	O
plain	O
water	O
(	O
as	O
control	O
)	O
,	O
and	O
then	O
with	O
low	O
-	O
dose	O
gentamicin	B-CHEMICAL
for	O
7	O
days	O
.	O

Renal	O
function	O
and	O
renal	O
tissue	O
damage	O
were	O
evaluated	O
through	O
the	O
experiment	O
.	O

The	O
mild	O
renal	O
damage	O
caused	O
by	O
gentamicin	B-CHEMICAL
was	O
markedly	O
magnified	O
in	O
rats	O
having	O
received	O
UN	O
chronically	O
,	O
which	O
was	O
evident	O
both	O
at	O
the	O
functional	O
and	O
histological	O
level	O
.	O

Four	O
proteins	O
,	O
namely	O
albumin	B-GENE-N
,	O
hemopexin	B-GENE-Y
,	O
transferrin	B-GENE-Y
and	O
vitamin	B-GENE-Y
D	I-GENE-Y
binding	I-GENE-Y
protein	I-GENE-Y
were	O
increased	O
in	O
the	O
urine	O
in	O
temporal	O
association	O
with	O
the	O
appearance	O
of	O
chronic	O
predisposition	O
.	O

Although	O
further	O
studies	O
are	O
necessary	O
,	O
our	O
results	O
suggest	O
that	O
these	O
proteins	O
might	O
be	O
potentially	O
used	O
as	O
markers	O
of	O
hidden	O
,	O
chronic	O
predisposition	O
to	O
gentamicin	B-CHEMICAL
nephrotoxicity	O
,	O
in	O
order	O
to	O
appropriately	O
and	O
pre	O
-	O
emptively	O
stratify	O
and	O
handle	O
individuals	O
according	O
to	O
their	O
specific	O
risk	O
in	O
the	O
long	O
term	O
,	O
and	O
to	O
conveniently	O
optimize	O
their	O
life	O
conditions	O
or	O
additional	O
clinical	O
procedures	O
or	O
treatments	O
that	O
might	O
trigger	O
the	O
disease	O
.	O

This	O
might	O
reduce	O
AKI	O
incidence	O
and	O
severity	O
and	O
the	O
associated	O
costs	O
.	O

Antioxidant	O
and	O
immunomodulatory	O
activity	O
of	O
selenium	B-CHEMICAL
exopolysaccharide	O
produced	O
by	O
Lactococcus	O
lactis	O
subsp	O
.	O
lactis	O
.	O

Exopolysaccharide	O
(	O
EPS	O
)	O
was	O
isolated	O
and	O
purified	O
from	O
Lactococcus	O
lactis	O
subsp	O
.	O

Lactis	O
culture	O
broth	O
.	O

Selenium	B-CHEMICAL
chloride	I-CHEMICAL
oxide	I-CHEMICAL
(	O
SeCl	B-CHEMICAL
(	I-CHEMICAL
2	I-CHEMICAL
)	I-CHEMICAL
O	I-CHEMICAL
)	O
was	O
added	O
to	O
the	O
EPS	O
to	O
synthesize	O
selenium	B-CHEMICAL
-	O
exopolysaccharide	O
(	O
Se	B-CHEMICAL
-	O
EPS	O
)	O
.	O

The	O
in	O
vitro	O
and	O
in	O
vivo	O
antioxidant	O
and	O
in	O
vivo	O
immunomodulatory	O
activity	O
of	O
EPS	O
and	O
Se	B-CHEMICAL
-	O
EPS	O
were	O
compared	O
.	O

EPS	O
and	O
Se	B-CHEMICAL
-	O
EPS	O
scavenged	O
superoxide	B-CHEMICAL
anions	O
and	O
hydroxyl	B-CHEMICAL
radicals	O
.	O

They	O
also	O
increased	O
catalase	B-GENE-Y
(	O
CAT	B-GENE-Y
)	O
,	O
superoxide	B-GENE-N
dismutase	I-GENE-N
(	O
SOD	B-GENE-N
)	O
and	O
glutathione	B-GENE-N
peroxidase	I-GENE-N
(	O
GSH	B-GENE-N
-	I-GENE-N
Px	I-GENE-N
)	O
activity	O
,	O
while	O
decreasing	O
malondialdehyde	B-CHEMICAL
(	O
MDA	B-CHEMICAL
)	O
levels	O
in	O
serum	O
and	O
in	O
the	O
livers	O
of	O
mice	O
.	O

Se	B-CHEMICAL
-	O
EPS	O
showed	O
stronger	O
in	O
vitro	O
and	O
in	O
vivo	O
antioxidant	O
activity	O
than	O
were	O
shown	O
by	O
EPS	O
.	O

The	O
in	O
vivo	O
immunoenhancement	O
activity	O
of	O
EPS	O
and	O
Se	B-CHEMICAL
-	O
EPS	O
induced	O
by	O
cyclophosphamide	B-CHEMICAL
(	O
CY	O
)	O
treatment	O
in	O
immunosuppressed	O
mice	O
was	O
researched	O
.	O

EPS	O
and	O
Se	B-CHEMICAL
-	O
EPS	O
treatments	O
increased	O
macrophage	O
phagocytosis	O
,	O
spleen	O
and	O
thymus	O
indices	O
and	O
haemolytic	O
complement	O
activity	O
(	O
HC	O
(	O
50	O
)	O
)	O
.	O

Se	B-CHEMICAL
-	O
EPS	O
showed	O
stronger	O
immunomodulatory	O
activity	O
than	O
did	O
EPS	O
.	O

Influence	O
of	O
extraction	O
procedures	O
on	O
phenolic	O
content	O
and	O
antioxidant	O
activity	O
of	O
Cretan	O
barberry	O
herb	O
.	O

The	O
main	O
goal	O
of	O
present	O
study	O
was	O
the	O
development	O
,	O
optimization	O
and	O
application	O
of	O
different	O
extraction	O
protocols	O
,	O
especially	O
those	O
employing	O
green	O
technologies	O
,	O
in	O
order	O
to	O
obtain	O
from	O
Berberis	O
cretica	O
extracts	O
with	O
high	O
antioxidant	O
capacity	O
.	O

For	O
this	O
purpose	O
,	O
the	O
applied	O
methods	O
:	O
maceration	O
,	O
ASE	O
and	O
SFE	O
coupled	O
with	O
ASE	O
were	O
incorporated	O
.	O

The	O
antioxidant	O
assessment	O
was	O
carried	O
out	O
using	O
DPPH	B-CHEMICAL
and	O
total	O
phenolic	O
content	O
(	O
Folin	O
-	O
Ciocalteu	O
)	O
assays	O
.	O

Major	O
constituents	O
were	O
elucidated	O
using	O
HPLC	O
-	O
DAD	O
and	O
UHPLC	O
-	O
HRMS	O
/	O
MS	O
(	O
hybrid	O
IT	O
-	O
Orbital	O
trap	O
spectrometer	O
)	O
equipped	O
with	O
an	O
ESI	O
probe	O
.	O

The	O
chromatographic	O
and	O
spectral	O
data	O
revealed	O
the	O
presence	O
of	O
several	O
simple	O
phenolic	B-CHEMICAL
acids	I-CHEMICAL
,	O
derivatives	O
of	O
both	O
caffeic	B-CHEMICAL
and	I-CHEMICAL
benzoic	I-CHEMICAL
acids	I-CHEMICAL
,	O
and	O
flavonoids	B-CHEMICAL
in	O
the	O
produced	O
extracts	O
.	O

It	O
was	O
clearly	O
evidenced	O
that	O
the	O
extraction	O
method	O
and	O
solvents	O
used	O
affected	O
both	O
the	O
activity	O
and	O
the	O
chemical	O
content	O
of	O
the	O
results	O
,	O
significantly	O
.	O

The	O
most	O
beneficial	O
conditions	O
were	O
calculated	O
for	O
methanol	B-CHEMICAL
and	O
water	O
:	O
ethanol	B-CHEMICAL
(	O
50	O
:	O
50	O
)	O
extracts	O
derived	O
from	O
the	O
combination	O
of	O
SFE	O
and	O
ASE	O
methodologies	O
.	O

Obtained	O
results	O
classify	O
Cretan	O
barberry	O
as	O
a	O
strong	O
antioxidant	O
agent	O
.	O

Shelf	O
-	O
life	O
of	O
infrared	O
dry	O
-	O
roasted	O
almonds	O
.	O

Infrared	O
heating	O
was	O
recently	O
used	O
to	O
develop	O
a	O
more	O
efficient	O
roasting	O
technology	O
than	O
traditional	O
hot	O
air	O
roasting	O
.	O

Therefore	O
,	O
in	O
this	O
study	O
,	O
we	O
evaluated	O
the	O
shelf	O
-	O
life	O
of	O
almonds	O
roasted	O
with	O
three	O
different	O
approaches	O
,	O
namely	O
infrared	O
(	O
IR	O
)	O
,	O
sequential	O
infrared	O
and	O
hot	O
air	O
(	O
SIRHA	O
)	O
and	O
regular	O
hot	O
air	O
(	O
HA	O
)	O
.	O

Nine	O
medium	O
roasted	O
almond	O
samples	O
produced	O
by	O
the	O
aforementioned	O
heating	O
methods	O
were	O
processed	O
at	O
three	O
different	O
temperatures	O
(	O
130	O
,	O
140	O
and	O
150	O
	O
C	O
)	O
,	O
packed	O
in	O
paper	O
bags	O
and	O
then	O
stored	O
at	O
37	O
	O
C	O
for	O
three	O
,	O
six	O
or	O
eight	O
months	O
.	O

Shelf	O
-	O
life	O
of	O
the	O
roasted	O
almonds	O
was	O
determined	O
by	O
measuring	O
the	O
changes	O
in	O
colour	O
,	O
peroxide	B-CHEMICAL
value	O
,	O
moisture	O
content	O
,	O
water	O
activity	O
,	O
volatile	O
components	O
and	O
sensory	O
quality	O
.	O

No	O
significant	O
difference	O
was	O
observed	O
in	O
moisture	O
content	O
and	O
water	O
activity	O
among	O
the	O
almond	O
samples	O
processed	O
with	O
different	O
roasting	O
methods	O
and	O
stored	O
under	O
the	O
same	O
conditions	O
.	O

GC	O
/	O
MS	O
analysis	O
showed	O
that	O
aldehydes	B-CHEMICAL
,	O
alcohols	B-CHEMICAL
,	O
and	O
pyrazines	B-CHEMICAL
were	O
the	O
main	O
volatile	O
components	O
of	O
almonds	O
.	O

Aliphatic	B-CHEMICAL
aldehydes	I-CHEMICAL
such	O
as	O
hexanal	B-CHEMICAL
,	O
(	B-CHEMICAL
E	I-CHEMICAL
)	I-CHEMICAL
-	I-CHEMICAL
2	I-CHEMICAL
-	I-CHEMICAL
octenal	I-CHEMICAL
,	O
and	O
nonanal	B-CHEMICAL
were	O
produced	O
as	O
off	O
-	O
odours	O
during	O
storage	O
.	O

Although	O
the	O
overall	O
quality	O
of	O
roasted	O
almonds	O
produced	O
with	O
SIRHA	O
and	O
HA	O
heating	O
was	O
similar	O
during	O
the	O
first	O
three	O
months	O
of	O
storage	O
,	O
their	O
peroxide	B-CHEMICAL
value	O
and	O
concentration	O
of	O
aliphatic	B-CHEMICAL
aldehydes	I-CHEMICAL
differed	O
significantly	O
for	O
different	O
roasting	O
methods	O
and	O
increased	O
significantly	O
in	O
all	O
roasted	O
samples	O
during	O
storage	O
.	O

We	O
postulate	O
that	O
hexanal	B-CHEMICAL
and	O
nonanal	B-CHEMICAL
might	O
be	O
better	O
indicators	O
of	O
the	O
shelf	O
life	O
of	O
roasted	O
almonds	O
than	O
the	O
current	O
standard	O
,	O
peroxide	B-CHEMICAL
value	O
.	O

Design	O
and	O
synthesis	O
of	O
novel	O
2	B-CHEMICAL
-	I-CHEMICAL
methyl	I-CHEMICAL
-	I-CHEMICAL
4	I-CHEMICAL
,	I-CHEMICAL
5	I-CHEMICAL
-	I-CHEMICAL
substitutedbenzo	I-CHEMICAL
[	I-CHEMICAL
f	I-CHEMICAL
]	I-CHEMICAL
-	I-CHEMICAL
3	I-CHEMICAL
,	I-CHEMICAL
3a	I-CHEMICAL
,	I-CHEMICAL
4	I-CHEMICAL
,	I-CHEMICAL
5	I-CHEMICAL
-	I-CHEMICAL
tetrahydro	I-CHEMICAL
-	I-CHEMICAL
pyrazolo	I-CHEMICAL
[	I-CHEMICAL
1	I-CHEMICAL
,	I-CHEMICAL
5	I-CHEMICAL
-	I-CHEMICAL
d	I-CHEMICAL
]	I-CHEMICAL
[	I-CHEMICAL
1	I-CHEMICAL
,	I-CHEMICAL
4	I-CHEMICAL
]	I-CHEMICAL
oxazepin	I-CHEMICAL
-	I-CHEMICAL
8	I-CHEMICAL
(	I-CHEMICAL
7H	I-CHEMICAL
)	I-CHEMICAL
-	I-CHEMICAL
one	I-CHEMICAL
derivatives	O
as	O
telomerase	B-GENE-N
inhibitors	O
.	O

Eight	O
novel	O
4	B-CHEMICAL
,	I-CHEMICAL
5	I-CHEMICAL
-	I-CHEMICAL
tetrahydropyrazolo	I-CHEMICAL
[	I-CHEMICAL
1	I-CHEMICAL
,	I-CHEMICAL
5	I-CHEMICAL
-	I-CHEMICAL
d	I-CHEMICAL
]	I-CHEMICAL
[	I-CHEMICAL
1	I-CHEMICAL
,	I-CHEMICAL
4	I-CHEMICAL
]	I-CHEMICAL
oxazepine	I-CHEMICAL
derivatives	O
have	O
been	O
synthesized	O
and	O
purified	O
to	O
be	O
screened	O
for	O
anticancer	O
activity	O
.	O

By	O
a	O
modified	O
TRAP	O
assay	O
,	O
some	O
titled	O
compounds	O
were	O
tested	O
against	O
telomerase	B-GENE-N
,	O
and	O
compound	O
4a	O
showed	O
the	O
most	O
potent	O
inhibitory	O
activity	O
with	O
IC	O
(	O
50	O
)	O
value	O
at	O
0	O
.	O
78	O
	O
0	O
.	O
22	O
M	O
.	O

Western	O
blot	O
assays	O
showed	O
that	O
compounds	O
4a	O
and	O
4b	O
could	O
inhibit	O
expression	O
of	O
Cyclin	B-GENE-Y
D1	I-GENE-Y
,	O
TERT	B-GENE-Y
,	O
phospho	B-GENE-N
-	I-GENE-N
AKT	I-GENE-N
and	O
PI3K	B-GENE-N
/	O
AKT	B-GENE-N
pathway	O
.	O

Anti	O
-	O
inflammatory	O
effects	O
of	O
trans	B-CHEMICAL
-	I-CHEMICAL
1	I-CHEMICAL
,	I-CHEMICAL
3	I-CHEMICAL
-	I-CHEMICAL
diphenyl	I-CHEMICAL
-	I-CHEMICAL
2	I-CHEMICAL
,	I-CHEMICAL
3	I-CHEMICAL
-	I-CHEMICAL
epoxypropane	I-CHEMICAL
-	I-CHEMICAL
1	I-CHEMICAL
-	I-CHEMICAL
one	I-CHEMICAL
mediated	O
by	O
suppression	O
of	O
inflammatory	O
mediators	O
in	O
LPS	O
-	O
stimulated	O
RAW	O
264	O
.	O
7	O
macrophages	O
.	O

To	O
assess	O
the	O
potential	O
therapeutic	O
properties	O
of	O
trans	B-CHEMICAL
-	I-CHEMICAL
1	I-CHEMICAL
,	I-CHEMICAL
3	I-CHEMICAL
-	I-CHEMICAL
diphenyl	I-CHEMICAL
-	I-CHEMICAL
2	I-CHEMICAL
,	I-CHEMICAL
3	I-CHEMICAL
-	I-CHEMICAL
epoxypropane	I-CHEMICAL
-	I-CHEMICAL
1	I-CHEMICAL
-	I-CHEMICAL
one	I-CHEMICAL
(	O
DPEP	B-CHEMICAL
)	O
,	O
its	O
anti	O
-	O
inflammatory	O
effects	O
were	O
investigated	O
in	O
lipopolysaccharide	O
(	O
LPS	O
)	O
-	O
stimulated	O
mouse	O
macrophage	O
(	O
RAW	O
264	O
.	O
7	O
)	O
cells	O
.	O

DPEP	B-CHEMICAL
induced	O
dose	O
-	O
dependent	O
reduction	O
of	O
the	O
protein	O
levels	O
of	O
inducible	B-GENE-Y
nitric	I-GENE-Y
oxide	I-GENE-Y
synthase	I-GENE-Y
(	O
iNOS	B-GENE-Y
)	O
and	O
cyclooxygenase	B-GENE-Y
-	I-GENE-Y
2	I-GENE-Y
(	O
COX	B-GENE-Y
-	I-GENE-Y
2	I-GENE-Y
)	O
and	O
concomitant	O
reduction	O
in	O
the	O
production	O
of	O
NO	B-CHEMICAL
and	O
prostaglandin	B-CHEMICAL
E	I-CHEMICAL
(	I-CHEMICAL
2	I-CHEMICAL
)	I-CHEMICAL
(	O
PGE	B-CHEMICAL
(	I-CHEMICAL
2	I-CHEMICAL
)	I-CHEMICAL
)	O
.	O

Additionally	O
,	O
DPEP	B-CHEMICAL
suppressed	O
the	O
production	O
of	O
inflammatory	O
cytokines	B-GENE-N
,	O
including	O
tumor	B-GENE-Y
necrosis	I-GENE-Y
factor	I-GENE-Y
-	I-GENE-Y
	I-GENE-Y
(	O
TNF	B-GENE-Y
-	I-GENE-Y
	I-GENE-Y
)	O
,	O
interleukin	B-GENE-Y
(	I-GENE-Y
IL	I-GENE-Y
)	I-GENE-Y
-	I-GENE-Y
1	I-GENE-Y
,	O
and	O
IL	B-GENE-Y
-	I-GENE-Y
6	I-GENE-Y
.	O

We	O
investigated	O
the	O
mechanism	O
by	O
which	O
DPEP	B-CHEMICAL
inhibits	O
NO	B-CHEMICAL
and	O
PGE	B-CHEMICAL
(	I-CHEMICAL
2	I-CHEMICAL
)	I-CHEMICAL
by	O
examining	O
the	O
level	O
of	O
nuclear	B-GENE-N
factor	I-GENE-N
-	I-GENE-N
B	I-GENE-N
(	O
NF	B-GENE-N
-	I-GENE-N
B	I-GENE-N
)	O
activation	O
within	O
the	O
mitogen	B-GENE-N
-	I-GENE-N
activated	I-GENE-N
protein	I-GENE-N
kinase	I-GENE-N
(	O
MAPK	B-GENE-N
)	O
pathway	O
,	O
which	O
is	O
an	O
inflammation	O
-	O
induced	O
signaling	O
pathway	O
in	O
RAW	O
264	O
.	O
7	O
cells	O
.	O

DPEP	B-CHEMICAL
inhibited	O
LPS	O
-	O
induced	O
phosphorylation	O
of	O
ERK	B-GENE-N
,	O
JNK	B-GENE-N
,	O
and	O
p38	B-GENE-N
.	O

Furthermore	O
,	O
DPEP	B-CHEMICAL
inhibited	O
the	O
LPS	O
-	O
induced	O
phosphorylation	O
of	O
inhibitor	B-GENE-Y
B	I-GENE-Y
(	I-GENE-Y
IB	I-GENE-Y
)	I-GENE-Y
-	I-GENE-Y
	I-GENE-Y
and	O
NF	B-GENE-N
-	I-GENE-N
B	I-GENE-N
p50	B-GENE-Y
.	O

Taken	O
together	O
,	O
the	O
results	O
of	O
this	O
study	O
demonstrate	O
that	O
DPEP	B-CHEMICAL
inhibits	O
LPS	O
-	O
stimulated	O
inflammation	O
by	O
blocking	O
the	O
NF	B-GENE-N
-	I-GENE-N
B	I-GENE-N
and	O
MAPK	B-GENE-N
pathways	O
in	O
macrophages	O
.	O

Radioprotection	O
by	O
two	O
phenolic	B-CHEMICAL
compounds	O
:	O
chlorogenic	B-CHEMICAL
and	I-CHEMICAL
quinic	I-CHEMICAL
acid	I-CHEMICAL
,	O
on	O
X	O
-	O
ray	O
induced	O
DNA	O
damage	O
in	O
human	O
blood	O
lymphocytes	O
in	O
vitro	O
.	O

The	O
present	O
study	O
was	O
designed	O
to	O
determine	O
the	O
radioprotective	O
effect	O
of	O
two	O
phytochemicals	O
,	O
namely	O
,	O
quinic	B-CHEMICAL
acid	I-CHEMICAL
and	O
chlorogenic	B-CHEMICAL
acid	I-CHEMICAL
,	O
against	O
X	O
-	O
ray	O
irradiation	O
-	O
induced	O
genomic	O
instability	O
in	O
non	O
-	O
tumorigenic	O
human	O
blood	O
lymphocytes	O
.	O

The	O
protective	O
ability	O
of	O
two	O
phenolic	B-CHEMICAL
acids	I-CHEMICAL
against	O
radiation	O
-	O
induced	O
DNA	O
damage	O
was	O
assessed	O
using	O
the	O
alkaline	O
comet	O
assay	O
in	O
human	O
blood	O
lymphocytes	O
isolated	O
from	O
two	O
healthy	O
human	O
donors	O
.	O

A	O
Siemens	O
Mevatron	O
MD2	O
(	O
Siemens	O
AG	O
,	O
USA	O
,	O
1994	O
)	O
linear	O
accelerator	O
was	O
used	O
for	O
irradiation	O
.	O

The	O
results	O
of	O
the	O
alkaline	O
comet	O
assay	O
revealed	O
that	O
quinic	B-CHEMICAL
acid	I-CHEMICAL
and	O
chlorogenic	B-CHEMICAL
acid	I-CHEMICAL
decreased	O
the	O
DNA	O
damage	O
induced	O
by	O
X	O
-	O
ray	O
irradiation	O
and	O
provided	O
a	O
significant	O
radioprotective	O
effect	O
.	O

Quinic	B-CHEMICAL
acid	I-CHEMICAL
decreased	O
the	O
presence	O
of	O
irradiation	O
-	O
induced	O
DNA	O
damage	O
by	O
5	O
.	O
99	O
-	O
53	O
.	O
57	O
%	O
and	O
chlorogenic	B-CHEMICAL
acid	I-CHEMICAL
by	O
4	O
.	O
49	O
-	O
48	O
.	O
15	O
%	O
,	O
as	O
determined	O
by	O
the	O
alkaline	O
comet	O
assay	O
.	O

The	O
results	O
show	O
that	O
quinic	B-CHEMICAL
acid	I-CHEMICAL
and	O
chlorogenic	B-CHEMICAL
acid	I-CHEMICAL
may	O
act	O
as	O
radioprotective	O
compounds	O
.	O

Future	O
studies	O
should	O
focus	O
on	O
determining	O
the	O
mechanism	O
by	O
which	O
these	O
phenolic	B-CHEMICAL
acids	I-CHEMICAL
provide	O
radioprotection	O
.	O

DNA	B-GENE-N
polymerase	I-GENE-N
minor	I-GENE-N
groove	I-GENE-N
interactions	O
modulate	O
mutagenic	O
bypass	O
of	O
a	O
templating	O
8	B-CHEMICAL
-	I-CHEMICAL
oxoguanine	I-CHEMICAL
lesion	O
.	O

A	O
major	O
base	O
lesion	O
resulting	O
from	O
oxidative	O
stress	O
is	O
8	B-CHEMICAL
-	I-CHEMICAL
oxo	I-CHEMICAL
-	I-CHEMICAL
7	I-CHEMICAL
,	I-CHEMICAL
8	I-CHEMICAL
-	I-CHEMICAL
dihydro	I-CHEMICAL
-	I-CHEMICAL
2	I-CHEMICAL
'	I-CHEMICAL
-	I-CHEMICAL
deoxyguanosine	I-CHEMICAL
(	O
8	B-CHEMICAL
-	I-CHEMICAL
oxoG	I-CHEMICAL
)	O
that	O
has	O
ambiguous	O
coding	O
potential	O
.	O

Error	O
-	O
free	O
DNA	O
synthesis	O
involves	O
8	B-CHEMICAL
-	I-CHEMICAL
oxoG	I-CHEMICAL
adopting	O
an	O
anti	O
-	O
conformation	O
to	O
base	O
pair	O
with	O
cytosine	B-CHEMICAL
whereas	O
mutagenic	O
bypass	O
involves	O
8	B-CHEMICAL
-	I-CHEMICAL
oxoG	I-CHEMICAL
adopting	O
a	O
syn	O
-	O
conformation	O
to	O
base	O
pair	O
with	O
adenine	B-CHEMICAL
.	O

Left	O
unrepaired	O
the	O
syn	B-CHEMICAL
-	I-CHEMICAL
8	I-CHEMICAL
-	I-CHEMICAL
oxoG	I-CHEMICAL
/	O
dAMP	B-CHEMICAL
base	O
pair	O
results	O
in	O
a	O
G	O
-	O
C	O
to	O
T	O
-	O
A	O
transversion	O
.	O

During	O
base	O
excision	O
repair	O
of	O
this	O
mispair	O
,	O
DNA	B-GENE-Y
polymerase	I-GENE-Y
(	I-GENE-Y
pol	I-GENE-Y
)	I-GENE-Y
	I-GENE-Y
is	O
confronted	O
with	O
gap	O
filling	O
opposite	O
8	B-CHEMICAL
-	I-CHEMICAL
oxoG	I-CHEMICAL
.	O

To	O
determine	O
how	O
pol	B-GENE-Y
	I-GENE-Y
discriminates	O
between	O
anti	B-CHEMICAL
-	I-CHEMICAL
and	I-CHEMICAL
syn	I-CHEMICAL
-	I-CHEMICAL
8	I-CHEMICAL
-	I-CHEMICAL
oxoG	I-CHEMICAL
,	O
we	O
introduced	O
a	O
point	O
mutation	O
(	O
R283K	B-GENE-N
)	O
to	O
alter	O
insertion	O
specificity	O
.	O

Kinetic	O
studies	O
demonstrate	O
that	O
this	O
substitution	O
results	O
in	O
an	O
increased	O
fidelity	O
opposite	O
8	B-CHEMICAL
-	I-CHEMICAL
oxoG	I-CHEMICAL
.	O

Structural	O
studies	O
with	O
R283K	B-GENE-N
pol	B-GENE-Y
	I-GENE-Y
show	O
that	O
the	O
binary	O
DNA	O
complex	O
has	O
8	B-CHEMICAL
-	I-CHEMICAL
oxoG	I-CHEMICAL
in	O
equilibrium	O
between	O
anti	O
-	O
and	O
syn	O
-	O
forms	O
.	O

Ternary	O
complexes	O
with	O
incoming	O
dCTP	B-CHEMICAL
resemble	O
the	O
wild	O
-	O
type	O
enzyme	O
,	O
with	O
templating	O
anti	B-CHEMICAL
-	I-CHEMICAL
8	I-CHEMICAL
-	I-CHEMICAL
oxoG	I-CHEMICAL
base	O
pairing	O
with	O
incoming	O
cytosine	B-CHEMICAL
.	O

In	O
contrast	O
to	O
wild	O
-	O
type	O
pol	B-GENE-Y
	I-GENE-Y
,	O
the	O
ternary	O
complex	O
of	O
the	O
R283K	B-GENE-N
mutant	O
with	O
an	O
incoming	O
dATP	B-CHEMICAL
-	O
analogue	O
and	O
templating	O
8	B-CHEMICAL
-	I-CHEMICAL
oxoG	I-CHEMICAL
resembles	O
a	O
G	O
-	O
A	O
mismatched	O
structure	O
with	O
8	B-CHEMICAL
-	I-CHEMICAL
oxoG	I-CHEMICAL
adopting	O
an	O
anti	O
-	O
conformation	O
.	O

These	O
results	O
demonstrate	O
that	O
the	O
incoming	O
nucleotide	B-CHEMICAL
is	O
unable	O
to	O
induce	O
a	O
syn	B-CHEMICAL
-	I-CHEMICAL
8	I-CHEMICAL
-	I-CHEMICAL
oxoG	I-CHEMICAL
conformation	O
without	O
minor	B-GENE-N
groove	I-GENE-N
DNA	B-GENE-N
polymerase	I-GENE-N
interactions	O
that	O
influence	O
templating	O
(	O
anti	O
-	O
/	O
syn	O
-	O
equilibrium	O
)	O
of	O
8	B-CHEMICAL
-	I-CHEMICAL
oxoG	I-CHEMICAL
while	O
modulating	O
fidelity	O
.	O

NMDA	B-GENE-N
and	I-GENE-N
AMPA	I-GENE-N
receptor	I-GENE-N
mediated	O
excitotoxicity	O
in	O
cerebral	O
cortex	O
of	O
streptozotocin	B-CHEMICAL
induced	O
diabetic	O
rat	O
:	O
ameliorating	O
effects	O
of	O
curcumin	B-CHEMICAL
.	O

Functional	O
activity	O
of	O
neurotransmitter	B-GENE-N
receptor	I-GENE-N
and	O
their	O
sensitivity	O
to	O
regulation	O
are	O
altered	O
in	O
DM	O
.	O

We	O
evaluated	O
the	O
neuroprotective	O
effect	O
of	O
curcumin	B-CHEMICAL
in	O
glutamate	B-CHEMICAL
mediated	O
excitotoxicity	O
in	O
cerebral	O
cortex	O
of	O
streptozotocin	B-CHEMICAL
induced	O
diabetic	O
rats	O
.	O

Gene	O
expression	O
studies	O
in	O
diabetic	O
rats	O
showed	O
a	O
down	O
regulation	O
of	O
glutamate	B-GENE-Y
decarboxylase	I-GENE-Y
mRNA	O
leading	O
to	O
accumulation	O
of	O
glutamate	B-CHEMICAL
.	O

Radioreceptor	O
binding	O
assays	O
showed	O
a	O
significant	O
increase	O
in	O
	B-GENE-N
-	I-GENE-N
amino	I-GENE-N
-	I-GENE-N
3	I-GENE-N
-	I-GENE-N
hydroxy	I-GENE-N
-	I-GENE-N
5	I-GENE-N
-	I-GENE-N
methyl	I-GENE-N
-	I-GENE-N
4	I-GENE-N
-	I-GENE-N
isoxazole	I-GENE-N
propionate	I-GENE-N
and	I-GENE-N
N	I-GENE-N
-	I-GENE-N
methyl	I-GENE-N
-	I-GENE-N
D	I-GENE-N
-	I-GENE-N
aspartate	I-GENE-N
receptors	I-GENE-N
density	O
which	O
was	O
confirmed	O
by	O
immunohistochemical	O
studies	O
.	O

Decreased	O
glutathione	B-GENE-N
peroxidases	I-GENE-N
gene	O
expression	O
indicates	O
enhanced	O
oxidative	O
stress	O
in	O
diabetic	O
rats	O
.	O

This	O
leads	O
to	O
decreased	O
expression	O
of	O
glutamate	B-GENE-Y
aspartate	I-GENE-Y
transporter	I-GENE-Y
,	O
which	O
in	O
turn	O
reduces	O
glutamate	B-CHEMICAL
transport	O
.	O

All	O
these	O
events	O
lead	O
to	O
excitotoxic	O
neuronal	O
death	O
in	O
the	O
cerebral	O
cortex	O
,	O
which	O
was	O
confirmed	O
by	O
the	O
increased	O
expression	O
of	O
caspase	B-GENE-Y
3	I-GENE-Y
,	O
caspase	B-GENE-Y
8	I-GENE-Y
and	O
BCL2	B-GENE-Y
-	I-GENE-Y
associated	I-GENE-Y
X	I-GENE-Y
protein	I-GENE-Y
.	O

Curcumin	B-CHEMICAL
and	O
insulin	B-GENE-Y
treatment	O
reversed	O
these	O
altered	O
parameters	O
to	O
near	O
control	O
.	O

We	O
establish	O
,	O
a	O
novel	O
therapeutic	O
role	O
of	O
curcumin	B-CHEMICAL
by	O
reducing	O
the	O
glutamate	B-CHEMICAL
mediated	O
excitotoxicity	O
in	O
cerebral	O
cortex	O
of	O
diabetes	O
through	O
modulating	O
the	O
altered	O
neurochemical	O
parameters	O
.	O

AMPK	B-GENE-N
is	O
a	O
negative	O
regulator	O
of	O
the	O
Warburg	O
effect	O
and	O
suppresses	O
tumor	O
growth	O
in	O
vivo	O
.	O

AMPK	B-GENE-N
is	O
a	O
metabolic	O
sensor	O
that	O
helps	O
maintain	O
cellular	O
energy	O
homeostasis	O
.	O

Despite	O
evidence	O
linking	O
AMPK	B-GENE-N
with	O
tumor	O
suppressor	O
functions	O
,	O
the	O
role	O
of	O
AMPK	B-GENE-N
in	O
tumorigenesis	O
and	O
tumor	O
metabolism	O
is	O
unknown	O
.	O

Here	O
we	O
show	O
that	O
AMPK	B-GENE-N
negatively	O
regulates	O
aerobic	O
glycolysis	O
(	O
the	O
Warburg	O
effect	O
)	O
in	O
cancer	O
cells	O
and	O
suppresses	O
tumor	O
growth	O
in	O
vivo	O
.	O

Genetic	O
ablation	O
of	O
the	O
1	B-GENE-Y
catalytic	I-GENE-Y
subunit	I-GENE-Y
of	I-GENE-Y
AMPK	I-GENE-Y
accelerates	O
Myc	B-GENE-Y
-	O
induced	O
lymphomagenesis	O
.	O

Inactivation	O
of	O
AMPK	B-GENE-N
in	O
both	O
transformed	O
and	O
nontransformed	O
cells	O
promotes	O
a	O
metabolic	O
shift	O
to	O
aerobic	O
glycolysis	O
,	O
increased	O
allocation	O
of	O
glucose	B-CHEMICAL
carbon	B-CHEMICAL
into	O
lipids	O
,	O
and	O
biomass	O
accumulation	O
.	O

These	O
metabolic	O
effects	O
require	O
normoxic	O
stabilization	O
of	O
the	O
hypoxia	B-GENE-Y
-	I-GENE-Y
inducible	I-GENE-Y
factor	I-GENE-Y
-	I-GENE-Y
1	I-GENE-Y
(	O
HIF	B-GENE-Y
-	I-GENE-Y
1	I-GENE-Y
)	O
,	O
as	O
silencing	O
HIF	B-GENE-Y
-	I-GENE-Y
1	I-GENE-Y
reverses	O
the	O
shift	O
to	O
aerobic	O
glycolysis	O
and	O
the	O
biosynthetic	O
and	O
proliferative	O
advantages	O
conferred	O
by	O
reduced	O
AMPK	B-GENE-N
signaling	O
.	O

Together	O
our	O
findings	O
suggest	O
that	O
AMPK	B-GENE-N
activity	O
opposes	O
tumor	O
development	O
and	O
that	O
its	O
loss	O
fosters	O
tumor	O
progression	O
in	O
part	O
by	O
regulating	O
cellular	O
metabolic	O
pathways	O
that	O
support	O
cell	O
growth	O
and	O
proliferation	O
.	O

Tetrahydropyrroloquinolinone	B-CHEMICAL
type	O
dual	O
inhibitors	O
of	O
aromatase	B-GENE-Y
/	O
aldosterone	B-GENE-Y
synthase	I-GENE-Y
as	O
a	O
novel	O
strategy	O
for	O
breast	O
cancer	O
patients	O
with	O
elevated	O
cardiovascular	O
risks	O
.	O

The	O
application	O
of	O
aromatase	O
inhibitors	O
to	O
postmenopausal	O
breast	O
cancer	O
patients	O
increases	O
the	O
risk	O
of	O
cardiovascular	O
diseases	O
(	O
CVD	O
)	O
,	O
which	O
is	O
believed	O
to	O
be	O
caused	O
by	O
the	O
abnormally	O
high	O
concentrations	O
of	O
aldosterone	B-CHEMICAL
as	O
a	O
consequence	O
of	O
the	O
estrogen	B-CHEMICAL
deficiency	O
.	O

Dual	O
inhibitors	O
of	O
aromatase	B-GENE-Y
(	O
CYP19	B-GENE-Y
)	O
and	O
aldosterone	B-GENE-Y
synthase	I-GENE-Y
(	O
CYP11B2	B-GENE-Y
)	O
are	O
therefore	O
proposed	O
as	O
a	O
novel	O
strategy	O
for	O
the	O
adjuvant	O
therapy	O
to	O
reduce	O
the	O
CVD	O
risk	O
for	O
these	O
patients	O
.	O

By	O
combining	O
decisive	O
structural	O
features	O
of	O
CYP11B2	B-GENE-Y
and	O
CYP19	B-GENE-Y
inhibitors	O
into	O
a	O
common	O
template	O
,	O
a	O
series	O
of	O
pyridinylmethyl	B-CHEMICAL
substituted	I-CHEMICAL
1	I-CHEMICAL
,	I-CHEMICAL
2	I-CHEMICAL
,	I-CHEMICAL
5	I-CHEMICAL
,	I-CHEMICAL
6	I-CHEMICAL
-	I-CHEMICAL
tetrahydro	I-CHEMICAL
-	I-CHEMICAL
pyrrolo	I-CHEMICAL
[	I-CHEMICAL
3	I-CHEMICAL
,	I-CHEMICAL
2	I-CHEMICAL
,	I-CHEMICAL
1	I-CHEMICAL
-	I-CHEMICAL
ij	I-CHEMICAL
]	I-CHEMICAL
quinolin	I-CHEMICAL
-	I-CHEMICAL
4	I-CHEMICAL
-	I-CHEMICAL
ones	I-CHEMICAL
were	O
designed	O
and	O
synthesized	O
.	O

Interestingly	O
,	O
the	O
substituents	O
on	O
the	O
methylene	B-CHEMICAL
bridge	O
showed	O
strong	O
influences	O
on	O
the	O
inhibitory	O
activities	O
leading	O
to	O
opposite	O
effects	O
,	O
that	O
is	O
,	O
a	O
given	O
substituent	O
showed	O
an	O
increase	O
in	O
inhibition	O
of	O
one	O
enzyme	O
,	O
while	O
it	O
led	O
to	O
a	O
decrease	O
for	O
the	O
other	O
enzyme	O
.	O

The	O
compromise	O
of	O
this	O
conflict	O
led	O
to	O
compounds	O
3j	O
,	O
3k	O
,	O
3n	O
,	O
and	O
3p	O
as	O
potent	O
and	O
selective	O
dual	O
inhibitors	O
of	O
CYP19	B-GENE-Y
and	O
CYP11B2	B-GENE-Y
,	O
especially	O
compound	O
3p	O
,	O
which	O
exhibited	O
IC	O
(	O
50	O
)	O
values	O
of	O
32	O
and	O
41	O
nM	O
for	O
CYP19	B-GENE-Y
and	O
CYP11B2	B-GENE-Y
,	O
respectively	O
,	O
and	O
a	O
high	O
selectivity	O
toward	O
CYP17	B-GENE-Y
and	O
CYP11B1	B-GENE-Y
.	O

This	O
compound	O
is	O
considered	O
as	O
a	O
candidate	O
for	O
further	O
evaluation	O
in	O
vivo	O
.	O

Evaluation	O
of	O
animal	O
models	O
for	O
intestinal	O
first	O
-	O
pass	O
metabolism	O
of	O
drug	O
candidates	O
to	O
be	O
metabolized	O
by	O
CYP3A	B-GENE-Y
enzymes	O
via	O
in	O
vivo	O
and	O
in	O
vitro	O
oxidation	O
of	O
midazolam	B-CHEMICAL
and	O
triazolam	B-CHEMICAL
.	O

Abstract	O
1	O
.	O

To	O
search	O
an	O
appropriate	O
evaluation	O
methodology	O
for	O
the	O
intestinal	O
first	O
-	O
pass	O
metabolism	O
of	O
new	O
drug	O
candidates	O
,	O
grapefruit	O
juice	O
(	O
GFJ	O
)	O
-	O
and	O
vehicle	O
(	O
tap	O
water	O
)	O
-	O
pretreated	O
mice	O
or	O
rats	O
were	O
orally	O
administered	O
midazolam	B-CHEMICAL
(	O
MDZ	B-CHEMICAL
)	O
or	O
triazolam	B-CHEMICAL
(	O
TRZ	B-CHEMICAL
)	O
,	O
and	O
blood	O
levels	O
of	O
the	O
parent	O
compounds	O
and	O
their	O
metabolites	O
were	O
measured	O
by	O
liquid	O
chromatography	O
/	O
MS	O
/	O
MS	O
.	O

A	O
significant	O
effect	O
of	O
GFJ	O
to	O
elevate	O
the	O
blood	O
levels	O
was	O
observed	O
only	O
for	O
TRZ	B-CHEMICAL
in	O
mice	O
.	O

2	O
.	O

In	O
vitro	O
experiments	O
using	O
mouse	O
,	O
rat	O
and	O
human	O
intestinal	O
and	O
hepatic	O
microsomal	O
fractions	O
demonstrated	O
that	O
GFJ	O
suppressed	O
the	O
intestinal	O
microsomal	O
oxidation	O
of	O
MDZ	B-CHEMICAL
and	O
especially	O
TRZ	B-CHEMICAL
.	O

Substrate	O
inhibition	O
by	O
MDZ	B-CHEMICAL
caused	O
reduction	O
in	O
1	O
'	O
-	O
hydroxylation	O
but	O
not	O
4	O
-	O
hydroxylation	O
in	O
both	O
intestinal	O
and	O
hepatic	O
microsomal	O
fractions	O
.	O

The	O
kinetic	O
profiles	O
of	O
MDZ	B-CHEMICAL
oxidation	O
and	O
the	O
substrate	O
inhibition	O
in	O
mouse	O
intestinal	O
and	O
hepatic	O
microsomal	O
fractions	O
were	O
very	O
similar	O
to	O
those	O
in	O
human	O
microsomes	O
but	O
were	O
different	O
from	O
those	O
in	O
rat	O
microsomes	O
.	O

Furthermore	O
,	O
MDZ	B-CHEMICAL
caused	O
mechanism	O
-	O
based	O
inactivation	O
of	O
cytochrome	B-GENE-N
P450	I-GENE-N
3A	I-GENE-N
-	O
dependent	O
TRZ	B-CHEMICAL
1	O
'	O
-	O
hydroxylation	O
in	O
mouse	O
,	O
rat	O
and	O
human	O
intestinal	O
microsomes	O
with	O
similar	O
potencies	O
.	O

3	O
.	O

These	O
results	O
are	O
useful	O
information	O
in	O
the	O
analysis	O
of	O
data	O
obtained	O
in	O
mouse	O
and	O
rat	O
for	O
the	O
evaluation	O
of	O
first	O
-	O
pass	O
effects	O
of	O
drug	O
candidates	O
to	O
be	O
metabolized	O
by	O
CYP3A	B-GENE-N
enzymes	O
.	O

The	O
physico	O
-	O
chemical	O
"	O
anatomy	O
"	O
of	O
the	O
tautomerization	O
through	O
the	O
DPT	O
of	O
the	O
biologically	O
important	O
pairs	O
of	O
hypoxanthine	B-CHEMICAL
with	O
DNA	O
bases	O
:	O
QM	O
and	O
QTAIM	O
perspectives	O
.	O

The	O
biologically	O
important	O
tautomerization	O
of	O
the	O
Hyp	B-CHEMICAL
	O
Cyt	B-CHEMICAL
,	O
Hyp	B-CHEMICAL
*	O
	O
Thy	B-CHEMICAL
and	O
Hyp	B-CHEMICAL
	O
Hyp	B-CHEMICAL
base	O
pairs	O
to	O
the	O
Hyp	B-CHEMICAL
*	O
	O
Cyt	B-CHEMICAL
*	O
,	O
Hyp	B-CHEMICAL
	O
Thy	B-CHEMICAL
*	O
and	O
Hyp	B-CHEMICAL
*	O
	O
Hyp	B-CHEMICAL
*	O
base	O
pairs	O
,	O
respectively	O
,	O
by	O
the	O
double	O
proton	O
transfer	O
(	O
DPT	O
)	O
was	O
comprehensively	O
studied	O
in	O
vacuo	O
and	O
in	O
the	O
continuum	O
with	O
a	O
low	O
dielectric	O
constant	O
(	O
	O
=	O
4	O
)	O
corresponding	O
to	O
hydrophobic	O
interfaces	O
of	O
protein	O
-	O
nucleic	O
acid	O
interactions	O
by	O
combining	O
theoretical	O
investigations	O
at	O
the	O
B3LYP	O
/	O
6	O
-	O
311	O
+	O
+	O
G	O
(	O
d	O
,	O
p	O
)	O
level	O
of	O
QM	O
theory	O
with	O
QTAIM	O
topological	O
analysis	O
.	O

Based	O
on	O
the	O
sweeps	O
of	O
the	O
energetic	O
,	O
electron	O
-	O
topological	O
,	O
geometric	O
and	O
polar	O
parameters	O
,	O
which	O
describe	O
the	O
course	O
of	O
the	O
tautomerization	O
along	O
the	O
intrinsic	O
reaction	O
coordinate	O
(	O
IRC	O
)	O
,	O
it	O
was	O
proved	O
that	O
the	O
tautomerization	O
through	O
the	O
DPT	O
is	O
concerted	O
and	O
asynchronous	O
process	O
for	O
the	O
Hyp	B-CHEMICAL
	O
Cyt	B-CHEMICAL
and	O
Hyp	B-CHEMICAL
*	O
	O
Thy	B-CHEMICAL
base	O
pairs	O
,	O
while	O
concerted	O
and	O
synchronous	O
for	O
the	O
Hyp	B-CHEMICAL
	O
Hyp	B-CHEMICAL
homodimer	O
.	O

The	O
continuum	O
with	O
	O
=	O
4	O
does	O
not	O
affect	O
qualitatively	O
the	O
course	O
of	O
the	O
tautomerization	O
reaction	O
for	O
all	O
studied	O
complexes	O
.	O

The	O
nine	O
key	O
points	O
along	O
the	O
IRC	O
of	O
the	O
Hyp	B-CHEMICAL
	O
Cyt	B-CHEMICAL
	O
Hyp	B-CHEMICAL
*	O
	O
Cyt	B-CHEMICAL
*	O
and	O
Hyp	B-CHEMICAL
*	O
	O
Thy	B-CHEMICAL
	O
Hyp	B-CHEMICAL
	O
Thy	B-CHEMICAL
*	O
tautomerizations	O
and	O
the	O
six	O
key	O
points	O
of	O
the	O
Hyp	B-CHEMICAL
	O
Hyp	B-CHEMICAL
	O
Hyp	B-CHEMICAL
*	O
	O
Hyp	B-CHEMICAL
*	O
tautomerization	O
have	O
been	O
identified	O
and	O
fully	O
characterized	O
.	O

These	O
key	O
points	O
could	O
be	O
considered	O
as	O
electron	O
-	O
topological	O
"	O
fingerprints	O
"	O
of	O
concerted	O
asynchronous	O
(	O
for	O
Hyp	B-CHEMICAL
	O
Cyt	B-CHEMICAL
and	O
Hyp	B-CHEMICAL
*	O
	O
Thy	B-CHEMICAL
)	O
or	O
synchronous	O
(	O
for	O
Hyp	B-CHEMICAL
	O
Hyp	B-CHEMICAL
)	O
tautomerization	O
process	O
via	O
the	O
DPT	O
.	O

It	O
was	O
found	O
,	O
that	O
in	O
the	O
Hyp	B-CHEMICAL
*	O
	O
Cyt	B-CHEMICAL
*	O
,	O
Hyp	B-CHEMICAL
	O
Thy	B-CHEMICAL
*	O
,	O
Hyp	B-CHEMICAL
	O
Hyp	B-CHEMICAL
and	O
Hyp	B-CHEMICAL
*	O
	O
Hyp	B-CHEMICAL
*	O
base	O
pairs	O
all	O
H	B-CHEMICAL
-	O
bonds	O
are	O
significantly	O
cooperative	O
and	O
mutually	O
reinforce	O
each	O
other	O
,	O
while	O
the	O
C2H	B-CHEMICAL
	O
O2	B-CHEMICAL
H	I-CHEMICAL
-	O
bond	O
in	O
the	O
Hyp	B-CHEMICAL
	O
Cyt	B-CHEMICAL
base	O
pair	O
and	O
the	O
O6H	B-CHEMICAL
	O
O4	B-CHEMICAL
H	B-CHEMICAL
-	O
bond	O
in	O
the	O
Hyp	B-CHEMICAL
*	O
	O
Thy	B-CHEMICAL
base	O
pair	O
behave	O
anti	O
-	O
cooperatively	O
,	O
i	O
.	O
e	O
.	O
,	O
they	O
become	O
weakened	O
,	O
while	O
two	O
others	O
become	O
strengthened	O
.	O

Density	O
of	O
GM1	O
in	O
nanoclusters	O
is	O
a	O
critical	O
factor	O
in	O
the	O
formation	O
of	O
a	O
spherical	O
assembly	O
of	O
amyloid	B-GENE-Y
	I-GENE-Y
-	I-GENE-Y
protein	I-GENE-Y
on	O
synaptic	O
plasma	O
membranes	O
.	O

The	O
deposition	O
of	O
amyloid	B-GENE-Y
	I-GENE-Y
-	I-GENE-Y
protein	I-GENE-Y
(	O
A	B-GENE-Y
)	O
is	O
a	O
pathological	O
hallmark	O
of	O
Alzheimer	O
'	O
s	O
disease	O
(	O
AD	O
)	O
.	O

We	O
previously	O
found	O
that	O
the	O
ganglioside	B-CHEMICAL
-	O
enriched	O
microdomains	O
(	O
ganglioside	B-CHEMICAL
clusters	O
)	O
in	O
presynaptic	O
neuronal	O
membranes	O
play	O
a	O
key	O
role	O
in	O
the	O
initiation	O
of	O
the	O
A	B-GENE-Y
assembly	O
process	O
.	O

However	O
,	O
not	O
all	O
ganglioside	B-CHEMICAL
clusters	O
accelerate	O
A	B-GENE-Y
assembly	O
.	O

In	O
the	O
present	O
study	O
,	O
we	O
directly	O
observed	O
a	O
spherical	O
A	B-GENE-Y
in	O
an	O
atomic	O
force	O
microscopic	O
study	O
on	O
the	O
morphology	O
of	O
a	O
reconstituted	O
lipid	O
bilayer	O
composed	O
of	O
lipids	O
that	O
were	O
extracted	O
from	O
a	O
detergent	O
-	O
resistant	O
membrane	O
microdomain	O
(	O
DRM	O
)	O
fraction	O
of	O
synaptosomes	O
prepared	O
from	O
aged	O
mouse	O
brain	O
.	O

The	O
A	B-GENE-Y
assembly	O
was	O
generated	O
on	O
a	O
distinctive	O
GM1	B-GENE-N
domain	I-GENE-N
,	O
which	O
was	O
characterized	O
as	O
the	O
A	B-GENE-Y
-	O
sensitive	O
ganglioside	B-CHEMICAL
nanocluster	O
(	O
ASIGN	O
)	O
.	O

By	O
using	O
an	O
artificial	O
GM1	O
cluster	O
-	O
binding	O
peptide	O
,	O
ASIGN	O
was	O
found	O
to	O
have	O
a	O
high	O
density	O
of	O
GM1	O
;	O
therefore	O
,	O
there	O
would	O
be	O
a	O
critical	O
density	O
of	O
GM1	O
in	O
nanoclusters	O
to	O
induce	O
A	B-GENE-Y
binding	O
and	O
assembly	O
.	O

These	O
results	O
suggest	O
that	O
ganglioside	B-CHEMICAL
-	O
bound	O
A	B-GENE-Y
(	O
GA	B-GENE-Y
)	O
,	O
which	O
acts	O
as	O
an	O
endogenous	O
seed	O
for	O
A	B-GENE-Y
fibril	O
formation	O
in	O
AD	O
brains	O
,	O
is	O
generated	O
on	O
ASIGN	O
on	O
synaptosomal	O
membranes	O
.	O

Tamoxifen	B-CHEMICAL
represses	O
miR	B-GENE-N
-	I-GENE-N
200	I-GENE-N
microRNAs	O
and	O
promotes	O
epithelial	O
-	O
to	O
-	O
mesenchymal	O
transition	O
by	O
up	O
-	O
regulating	O
c	B-GENE-Y
-	I-GENE-Y
Myc	I-GENE-Y
in	O
endometrial	O
carcinoma	O
cell	O
lines	O
.	O

Although	O
tamoxifen	B-CHEMICAL
(	O
TAM	B-CHEMICAL
)	O
,	O
a	O
selective	O
estrogen	B-GENE-Y
receptor	I-GENE-Y
modulator	O
,	O
has	O
been	O
widely	O
used	O
in	O
the	O
treatment	O
of	O
hormone	O
-	O
responsive	O
breast	O
cancer	O
,	O
its	O
estrogen	B-CHEMICAL
-	O
like	O
effect	O
increases	O
the	O
risk	O
of	O
endometrial	O
cancer	O
.	O

However	O
,	O
the	O
molecular	O
mechanisms	O
of	O
TAM	B-CHEMICAL
-	O
induced	O
endometrial	O
carcinoma	O
still	O
remain	O
unclear	O
.	O

In	O
this	O
report	O
,	O
we	O
explored	O
the	O
role	O
of	O
microRNAs	O
(	O
miRNAs	O
)	O
in	O
TAM	B-CHEMICAL
-	O
induced	O
epithelial	O
-	O
mesenchymal	O
transition	O
(	O
EMT	O
)	O
in	O
ECC	O
-	O
1	O
and	O
Ishikawa	O
endometrial	O
cancer	O
cell	O
lines	O
and	O
found	O
miR	B-GENE-N
-	I-GENE-N
200	I-GENE-N
is	O
involved	O
in	O
this	O
process	O
via	O
the	O
regulation	O
of	O
c	B-GENE-Y
-	I-GENE-Y
Myc	I-GENE-Y
.	O

When	O
treated	O
with	O
TAM	B-CHEMICAL
,	O
ECC	O
-	O
1	O
and	O
Ishikawa	O
cells	O
were	O
characterized	O
by	O
higher	O
invasiveness	O
and	O
motility	O
and	O
underwent	O
EMT	O
.	O

miR	B-GENE-N
-	I-GENE-N
200	I-GENE-N
,	O
a	O
miRNA	O
family	O
with	O
tumor	O
suppressive	O
functions	O
in	O
a	O
wide	O
range	O
of	O
cancers	O
,	O
was	O
found	O
reduced	O
in	O
response	O
to	O
TAM	B-CHEMICAL
treatment	O
.	O

Consistent	O
with	O
zinc	B-GENE-Y
finger	I-GENE-Y
E	I-GENE-Y
-	I-GENE-Y
box	I-GENE-Y
binding	I-GENE-Y
homeobox	I-GENE-Y
2	I-GENE-Y
,	O
which	O
was	O
confirmed	O
as	O
a	O
direct	O
target	O
of	O
miR	B-GENE-Y
-	I-GENE-Y
200b	I-GENE-Y
in	O
endometrial	O
cancer	O
cell	O
lines	O
,	O
some	O
other	O
key	O
factors	O
of	O
EMT	O
such	O
as	O
Snail	B-GENE-Y
and	O
N	B-GENE-Y
-	I-GENE-Y
cadherin	I-GENE-Y
increased	O
,	O
whereas	O
E	B-GENE-Y
-	I-GENE-Y
cadherin	I-GENE-Y
decreased	O
in	O
the	O
TAM	B-CHEMICAL
-	O
treated	O
cells	O
,	O
contributing	O
to	O
TAM	B-CHEMICAL
-	O
induced	O
EMT	O
in	O
these	O
endometrial	O
cancer	O
cells	O
.	O

In	O
addition	O
,	O
we	O
showed	O
that	O
c	B-GENE-Y
-	I-GENE-Y
Myc	I-GENE-Y
directly	O
binds	O
to	O
and	O
represses	O
the	O
promoter	O
of	O
miR	B-GENE-N
-	I-GENE-N
200	I-GENE-N
miRNAs	O
,	O
and	O
its	O
up	O
-	O
regulation	O
in	O
TAM	B-CHEMICAL
-	O
treated	O
endometrial	O
cancer	O
cells	O
leads	O
to	O
the	O
down	O
-	O
regulation	O
of	O
miR	B-GENE-N
-	I-GENE-N
200	I-GENE-N
and	O
eventually	O
to	O
EMT	O
.	O

Collectively	O
,	O
our	O
data	O
suggest	O
that	O
TAM	B-CHEMICAL
can	O
repress	O
the	O
miR	B-GENE-N
-	I-GENE-N
200	I-GENE-N
family	O
and	O
induce	O
EMT	O
via	O
the	O
up	O
-	O
regulation	O
of	O
c	B-GENE-Y
-	I-GENE-Y
Myc	I-GENE-Y
in	O
endometrial	O
cancer	O
cells	O
.	O

These	O
findings	O
describe	O
a	O
possible	O
mechanism	O
of	O
TAM	B-CHEMICAL
-	O
induced	O
EMT	O
in	O
endometrial	O
cancer	O
and	O
provide	O
a	O
potential	O
new	O
therapeutic	O
strategy	O
for	O
it	O
.	O

Manganese	B-CHEMICAL
-	O
induced	O
oxidative	O
DNA	O
damage	O
in	O
neuronal	O
SH	O
-	O
SY5Y	O
cells	O
:	O
attenuation	O
of	O
thymine	B-CHEMICAL
base	O
lesions	O
by	O
glutathione	B-CHEMICAL
and	O
N	B-CHEMICAL
-	I-CHEMICAL
acetylcysteine	I-CHEMICAL
.	O

Manganese	B-CHEMICAL
(	O
Mn	B-CHEMICAL
)	O
is	O
an	O
essential	O
trace	O
element	O
required	O
for	O
normal	O
function	O
and	O
development	O
.	O

However	O
,	O
exposure	O
to	O
this	O
metal	O
at	O
elevated	O
levels	O
may	O
cause	O
manganism	O
,	O
a	O
progressive	O
neurodegenerative	O
disorder	O
with	O
neurological	O
symptoms	O
similar	O
to	O
idiopathic	O
Parkinson	O
'	O
s	O
disease	O
(	O
IPD	O
)	O
.	O

Elevated	O
body	O
burdens	O
of	O
Mn	B-CHEMICAL
from	O
exposure	O
to	O
parental	O
nutrition	O
,	O
vapors	O
in	O
mines	O
and	O
smelters	O
and	O
welding	O
fumes	O
have	O
been	O
associated	O
with	O
neurological	O
health	O
concerns	O
.	O

The	O
underlying	O
mechanism	O
of	O
Mn	B-CHEMICAL
neurotoxicity	O
remains	O
unclear	O
.	O

Accordingly	O
,	O
the	O
present	O
study	O
was	O
designed	O
to	O
investigate	O
the	O
toxic	O
effects	O
of	O
Mn	B-CHEMICAL
(	I-CHEMICAL
2	I-CHEMICAL
+	I-CHEMICAL
)	I-CHEMICAL
in	O
human	O
neuroblastoma	O
SH	O
-	O
SY5Y	O
cells	O
.	O

Mn	B-CHEMICAL
(	I-CHEMICAL
2	I-CHEMICAL
+	I-CHEMICAL
)	I-CHEMICAL
caused	O
a	O
concentration	O
dependent	O
decrease	O
in	O
SH	O
-	O
SY5Y	O
cellular	O
viability	O
compared	O
to	O
controls	O
.	O

The	O
LD50	O
value	O
was	O
12	O
.	O
98	O
M	O
Mn	B-CHEMICAL
(	I-CHEMICAL
2	I-CHEMICAL
+	I-CHEMICAL
)	I-CHEMICAL
(	O
p	O
<	O
0	O
.	O
001	O
for	O
control	O
vs	O
.	O
24h	O
Mn	B-CHEMICAL
treatment	O
)	O
.	O

Both	O
TUNEL	O
and	O
annexin	O
V	O
/	O
propidium	B-CHEMICAL
iodide	I-CHEMICAL
(	O
PI	O
)	O
apoptosis	O
assays	O
confirmed	O
the	O
induction	O
of	O
apoptosis	O
in	O
the	O
cells	O
following	O
exposure	O
to	O
Mn	B-CHEMICAL
(	I-CHEMICAL
2	I-CHEMICAL
+	I-CHEMICAL
)	I-CHEMICAL
(	O
2	O
M	O
,	O
62	O
M	O
or	O
125	O
M	O
)	O
.	O

In	O
addition	O
,	O
Mn	B-CHEMICAL
(	I-CHEMICAL
2	I-CHEMICAL
+	I-CHEMICAL
)	I-CHEMICAL
induced	O
both	O
the	O
formation	O
and	O
accumulation	O
of	O
DNA	O
single	O
strand	O
breaks	O
(	O
via	O
alkaline	O
comet	O
assay	O
analysis	O
)	O
and	O
oxidatively	O
modified	O
thymine	B-CHEMICAL
bases	O
(	O
via	O
gas	O
chromatography	O
/	O
mass	O
spectrometry	O
analysis	O
)	O
.	O

Pre	O
-	O
incubation	O
of	O
the	O
cells	O
with	O
characteristic	O
antioxidants	O
,	O
either	O
1mM	O
N	B-CHEMICAL
-	I-CHEMICAL
acetylcysteine	I-CHEMICAL
(	O
NAC	B-CHEMICAL
)	O
or	O
1mM	O
glutathione	B-CHEMICAL
(	O
GSH	B-CHEMICAL
)	O
reduced	O
the	O
level	O
of	O
DNA	O
strand	O
breaks	O
and	O
the	O
formation	O
of	O
thymine	B-CHEMICAL
base	O
lesions	O
,	O
suggesting	O
protection	O
against	O
oxidative	O
cellular	O
damage	O
.	O

Our	O
findings	O
indicate	O
that	O
(	O
1	O
)	O
exposure	O
of	O
SH	O
-	O
SY5Y	O
cells	O
to	O
Mn	B-CHEMICAL
promotes	O
both	O
the	O
formation	O
and	O
accumulation	O
of	O
oxidative	O
DNA	O
damage	O
,	O
(	O
2	O
)	O
SH	O
-	O
SY5Y	O
cells	O
with	O
accumulated	O
DNA	O
damage	O
are	O
more	O
likely	O
to	O
die	O
via	O
an	O
apoptotic	O
pathway	O
and	O
(	O
3	O
)	O
the	O
accumulated	O
levels	O
of	O
DNA	O
damage	O
can	O
be	O
abrogated	O
by	O
the	O
addition	O
of	O
exogenous	O
chemical	O
antioxidants	O
.	O

This	O
is	O
the	O
first	O
known	O
report	O
of	O
Mn	B-CHEMICAL
(	I-CHEMICAL
2	I-CHEMICAL
+	I-CHEMICAL
)	I-CHEMICAL
-	O
induction	O
and	O
antioxidant	O
protection	O
of	O
thymine	B-CHEMICAL
lesions	O
in	O
this	O
SH	O
-	O
SY5Y	O
cell	O
line	O
and	O
contributes	O
new	O
information	O
to	O
the	O
potential	O
use	O
of	O
antioxidants	O
as	O
a	O
therapeutic	O
strategy	O
for	O
protection	O
against	O
Mn	B-CHEMICAL
(	I-CHEMICAL
2	I-CHEMICAL
+	I-CHEMICAL
)	I-CHEMICAL
-	O
induced	O
oxidative	O
DNA	O
damage	O
.	O

Resveratrol	B-CHEMICAL
improves	O
cardiomyopathy	O
in	O
dystrophin	B-GENE-Y
-	O
deficient	O
mice	O
through	O
SIRT1	B-GENE-Y
protein	O
-	O
mediated	O
modulation	O
of	O
p300	B-GENE-Y
protein	O
.	O

Cardiomyopathy	O
is	O
the	O
main	O
cause	O
of	O
death	O
in	O
Duchenne	O
muscular	O
dystrophy	O
.	O

Here	O
,	O
we	O
show	O
that	O
oral	O
administration	O
of	O
resveratrol	B-CHEMICAL
,	O
which	O
leads	O
to	O
activation	O
of	O
an	O
NAD	B-GENE-Y
(	I-GENE-Y
+	I-GENE-Y
)	I-GENE-Y
-	I-GENE-Y
dependent	I-GENE-Y
protein	I-GENE-Y
deacetylase	I-GENE-Y
SIRT1	I-GENE-Y
,	O
suppresses	O
cardiac	O
hypertrophy	O
and	O
fibrosis	O
and	O
restores	O
cardiac	O
diastolic	O
function	O
in	O
dystrophin	B-GENE-Y
-	O
deficient	O
mdx	O
mice	O
.	O

The	O
pro	O
-	O
hypertrophic	O
co	O
-	O
activator	O
p300	B-GENE-Y
protein	O
but	O
not	O
p300	B-GENE-Y
mRNA	O
was	O
up	O
-	O
regulated	O
in	O
the	O
mdx	O
heart	O
,	O
and	O
resveratrol	B-CHEMICAL
administration	O
down	O
-	O
regulated	O
the	O
p300	B-GENE-Y
protein	O
level	O
.	O

In	O
cultured	O
cardiomyocytes	O
,	O
cardiomyocyte	O
hypertrophy	O
induced	O
by	O
the	O
	O
(	O
1	O
)	O
-	O
agonist	O
phenylephrine	B-CHEMICAL
was	O
inhibited	O
by	O
the	O
overexpression	O
of	O
SIRT1	B-GENE-Y
as	O
well	O
as	O
resveratrol	B-CHEMICAL
,	O
both	O
of	O
which	O
down	O
-	O
regulated	O
p300	B-GENE-Y
protein	O
levels	O
but	O
not	O
p300	B-GENE-Y
mRNA	O
levels	O
.	O

In	O
addition	O
,	O
activation	O
of	O
atrial	B-GENE-N
natriuretic	I-GENE-N
peptide	I-GENE-N
promoter	I-GENE-N
by	O
p300	B-GENE-Y
was	O
inhibited	O
by	O
SIRT1	B-GENE-Y
.	O

We	O
found	O
that	O
SIRT1	B-GENE-Y
induced	O
p300	B-GENE-Y
down	O
-	O
regulation	O
via	O
the	O
ubiquitin	B-GENE-N
-	O
proteasome	B-GENE-N
pathway	O
by	O
deacetylation	O
of	O
lysine	B-CHEMICAL
residues	O
for	O
ubiquitination	O
.	O

These	O
findings	O
indicate	O
the	O
pathological	O
significance	O
of	O
p300	B-GENE-Y
up	O
-	O
regulation	O
in	O
the	O
dystrophic	O
heart	O
and	O
indicate	O
that	O
SIRT1	B-GENE-Y
activation	O
has	O
therapeutic	O
potential	O
for	O
dystrophic	O
cardiomyopathy	O
.	O

Synthesis	O
,	O
characterization	O
and	O
targeting	O
potential	O
of	O
zidovudine	B-CHEMICAL
loaded	O
sialic	B-CHEMICAL
acid	I-CHEMICAL
conjugated	O
-	O
mannosylated	B-CHEMICAL
poly	I-CHEMICAL
(	I-CHEMICAL
propyleneimine	I-CHEMICAL
)	I-CHEMICAL
dendrimers	O
.	O

The	O
present	O
investigation	O
was	O
aimed	O
at	O
exploring	O
dual	O
targeting	O
of	O
anti	O
-	O
HIV	O
drug	O
,	O
zidovudine	B-CHEMICAL
(	O
ZDV	B-CHEMICAL
)	O
via	O
sialic	B-CHEMICAL
acid	I-CHEMICAL
conjugated	O
-	O
mannosylated	B-CHEMICAL
poly	I-CHEMICAL
(	I-CHEMICAL
propyleneimine	I-CHEMICAL
)	I-CHEMICAL
(	O
PPI	B-CHEMICAL
)	O
dendritic	O
nano	O
-	O
constructs	O
.	O

Fourth	O
generation	O
PPI	B-CHEMICAL
dendrimers	O
,	O
sialic	B-CHEMICAL
acid	I-CHEMICAL
conjugated	O
PPI	B-CHEMICAL
dendrimers	O
(	O
SPPI	O
)	O
,	O
mannose	B-CHEMICAL
conjugated	O
PPI	B-CHEMICAL
dendrimers	O
(	O
MPPI	O
)	O
and	O
dual	O
ligand	O
system	O
i	O
.	O
e	O
.	O
sialic	B-CHEMICAL
acid	I-CHEMICAL
conjugated	O
-	O
mannosylated	B-CHEMICAL
PPI	I-CHEMICAL
dendrimers	O
(	O
SMPPI	O
)	O
were	O
synthesized	O
and	O
characterized	O
by	O
FT	O
-	O
IR	O
and	O
(	B-CHEMICAL
1	I-CHEMICAL
)	I-CHEMICAL
H	I-CHEMICAL
NMR	O
spectroscopies	O
and	O
were	O
further	O
confirmed	O
by	O
size	O
exclusion	O
chromatography	O
and	O
differential	O
scanning	O
calorimetry	O
.	O

Various	O
parameters	O
like	O
drug	O
loading	O
,	O
pH	O
dependent	O
in	O
vitro	O
release	O
,	O
hemolytic	O
toxicity	O
,	O
macrophage	O
uptake	O
and	O
cytotoxicity	O
concerning	O
PPI	B-CHEMICAL
,	O
SPPI	O
,	O
MPPI	O
and	O
SMPPI	O
dendrimers	O
were	O
evaluated	O
.	O

ZDV	B-CHEMICAL
loaded	O
SMPPI	O
,	O
SPPI	O
and	O
MPPI	O
have	O
shown	O
reduced	O
hemolytic	O
toxicity	O
,	O
cytotoxicity	O
and	O
in	O
vitro	O
drug	O
release	O
at	O
pH	O
7	O
.	O
4	O
.	O

Extremely	O
significant	O
(	O
P	O
<	O
0	O
.	O
001	O
)	O
increase	O
in	O
cellular	O
uptake	O
of	O
ZDV	B-CHEMICAL
by	O
macrophage	O
cells	O
was	O
observed	O
in	O
case	O
of	O
SMPPI	O
as	O
compared	O
to	O
PPI	B-CHEMICAL
and	O
free	O
drug	O
.	O

The	O
in	O
vivo	O
blood	O
level	O
and	O
tissue	O
distribution	O
studies	O
in	O
albino	O
rats	O
also	O
demonstrated	O
potential	O
of	O
dual	O
targeted	O
system	O
towards	O
sialoadhesin	B-GENE-Y
and	O
carbohydrate	B-GENE-N
receptors	I-GENE-N
.	O

The	O
drug	O
concentration	O
in	O
lymph	O
nodes	O
was	O
increased	O
to	O
about	O
28	O
times	O
in	O
case	O
of	O
SMPPI	O
(	O
1335	O
	O
17	O
.	O
6	O
ng	O
/	O
g	O
)	O
as	O
compared	O
to	O
free	O
drug	O
(	O
48	O
	O
5	O
.	O
8	O
ng	O
/	O
g	O
)	O
at	O
6th	O
hr	O
.	O

The	O
results	O
suggested	O
that	O
such	O
dual	O
ligand	O
dendritic	O
system	O
(	O
SMPPI	O
)	O
hold	O
potential	O
to	O
enhance	O
biocompatibility	O
and	O
site	O
specific	O
delivery	O
of	O
antiretroviral	O
drug	O
,	O
ZDV	B-CHEMICAL
.	O

3D	O
structures	O
and	O
ligand	O
specificities	O
of	O
nuclear	O
xenobiotic	O
receptors	O
CAR	B-GENE-Y
,	O
PXR	B-GENE-Y
and	O
VDR	B-GENE-Y
.	O

The	O
nuclear	B-GENE-N
receptors	I-GENE-N
constitutive	B-GENE-Y
androstane	I-GENE-Y
receptor	I-GENE-Y
(	O
CAR	B-GENE-Y
)	O
,	O
pregnane	B-GENE-Y
X	I-GENE-Y
receptor	I-GENE-Y
(	O
PXR	B-GENE-Y
)	O
and	O
vitamin	B-GENE-Y
D	I-GENE-Y
receptor	I-GENE-Y
(	O
VDR	B-GENE-Y
)	O
control	O
a	O
large	O
array	O
of	O
genes	O
that	O
code	O
for	O
important	O
proteins	O
in	O
humans	O
including	O
metabolic	O
enzymes	O
and	O
transporters	O
.	O

3D	O
structures	O
for	O
the	O
ligand	B-GENE-N
-	I-GENE-N
binding	I-GENE-N
domain	I-GENE-N
(	O
LBD	B-GENE-N
)	O
of	O
these	O
receptors	O
are	O
abundantly	O
available	O
,	O
providing	O
valuable	O
insights	O
into	O
the	O
ligand	O
-	O
binding	O
specificity	O
as	O
well	O
as	O
the	O
activation	O
mechanisms	O
.	O

The	O
ligand	O
-	O
binding	O
site	O
of	O
PXR	B-GENE-Y
is	O
large	O
and	O
flexible	O
,	O
whereas	O
those	O
of	O
CAR	B-GENE-Y
and	O
VDR	B-GENE-Y
are	O
compact	O
and	O
rigid	O
,	O
respectively	O
.	O

In	O
general	O
,	O
the	O
ligand	O
profiles	O
of	O
the	O
receptors	O
are	O
in	O
agreement	O
with	O
the	O
LBD	B-GENE-N
structures	O
.	O

The	O
crystal	O
structures	O
have	O
greatly	O
helped	O
us	O
to	O
understand	O
the	O
promiscuity	O
and	O
/	O
or	O
specificity	O
of	O
CAR	B-GENE-Y
,	O
PXR	B-GENE-Y
and	O
VDR	B-GENE-Y
.	O

Synthesis	O
and	O
dual	O
biological	O
effects	O
of	O
hydroxycinnamoyl	B-CHEMICAL
phenylalanyl	I-CHEMICAL
/	O
prolyl	B-CHEMICAL
hydroxamic	I-CHEMICAL
acid	I-CHEMICAL
derivatives	O
as	O
tyrosinase	B-GENE-Y
inhibitor	O
and	O
antioxidant	O
.	O

We	O
previously	O
reported	O
that	O
caffeoyl	B-CHEMICAL
-	I-CHEMICAL
amino	I-CHEMICAL
acidyl	I-CHEMICAL
-	I-CHEMICAL
hydroxamic	I-CHEMICAL
acid	I-CHEMICAL
(	O
CA	B-CHEMICAL
-	I-CHEMICAL
Xaa	I-CHEMICAL
-	I-CHEMICAL
NHOH	I-CHEMICAL
)	O
acted	O
as	O
both	O
a	O
good	O
antioxidant	O
and	O
tyrosinase	B-GENE-Y
inhibitor	O
,	O
in	O
particular	O
when	O
caffeic	B-CHEMICAL
acid	I-CHEMICAL
was	O
conjugated	O
with	O
proline	B-CHEMICAL
or	O
amino	B-CHEMICAL
acids	I-CHEMICAL
having	O
aromatic	O
ring	O
like	O
phenylalanine	B-CHEMICAL
.	O

Here	O
,	O
various	O
hydroxycinnamic	B-CHEMICAL
acid	I-CHEMICAL
(	O
HCA	B-CHEMICAL
)	O
derivatives	O
were	O
further	O
conjugated	O
with	O
phenylalanyl	B-CHEMICAL
hydroxamic	I-CHEMICAL
acid	I-CHEMICAL
and	O
prolyl	B-CHEMICAL
hydroxamic	I-CHEMICAL
acid	I-CHEMICAL
(	O
HCA	B-CHEMICAL
-	I-CHEMICAL
Phe	I-CHEMICAL
-	I-CHEMICAL
NHOH	I-CHEMICAL
and	O
HCA	B-CHEMICAL
-	I-CHEMICAL
Pro	I-CHEMICAL
-	I-CHEMICAL
NHOH	I-CHEMICAL
)	O
to	O
study	O
the	O
structure	O
and	O
activity	O
relationship	O
as	O
both	O
antioxidants	O
and	O
tyrosinase	B-GENE-Y
inhibitors	O
.	O

When	O
their	O
biological	O
activities	O
were	O
evaluated	O
,	O
all	O
HCA	B-CHEMICAL
-	I-CHEMICAL
Phe	I-CHEMICAL
-	I-CHEMICAL
NHOH	I-CHEMICAL
and	O
HCA	B-CHEMICAL
-	I-CHEMICAL
Pro	I-CHEMICAL
-	I-CHEMICAL
NHOH	I-CHEMICAL
exhibited	O
enhanced	O
antioxidant	O
activity	O
compared	O
to	O
HCA	B-CHEMICAL
alone	O
.	O

Moreover	O
,	O
derivatives	O
of	O
caffeic	B-CHEMICAL
acid	I-CHEMICAL
,	O
ferulic	B-CHEMICAL
acid	I-CHEMICAL
,	O
and	O
sinapic	B-CHEMICAL
acid	I-CHEMICAL
inhibited	O
lipid	O
peroxidation	O
more	O
efficiently	O
than	O
vitamin	B-CHEMICAL
E	I-CHEMICAL
analogue	O
(	O
Trolox	B-CHEMICAL
)	O
.	O

In	O
addition	O
,	O
derivatives	O
of	O
caffeic	B-CHEMICAL
acid	I-CHEMICAL
and	O
sinapic	B-CHEMICAL
acid	I-CHEMICAL
efficiently	O
inhibited	O
tyrosinase	B-GENE-Y
activity	O
and	O
reduced	O
melanin	O
content	O
in	O
melanocytes	O
Mel	O
-	O
Ab	O
cell	O
.	O

Ruxolitinib	B-CHEMICAL
:	O
a	O
new	O
treatment	O
option	O
for	O
myelofibrosis	O
.	O

Myelofibrosis	O
is	O
a	O
myeloproliferative	O
neoplasm	O
characterized	O
by	O
bone	O
marrow	O
fibrosis	O
and	O
extramedullary	O
hematopoiesis	O
.	O

Evolution	O
of	O
myelofibrosis	O
can	O
lead	O
to	O
life	O
-	O
threatening	O
complications	O
,	O
including	O
transformation	O
to	O
leukemia	O
,	O
thrombotic	O
events	O
,	O
and	O
hemorrhagic	O
episodes	O
.	O

The	O
only	O
curative	O
therapy	O
for	O
myelofibrosis	O
is	O
allogeneic	O
hematopoietic	O
stem	O
cell	O
transplantation	O
.	O

Because	O
this	O
disease	O
manifests	O
primarily	O
in	O
the	O
older	O
population	O
,	O
many	O
patients	O
diagnosed	O
with	O
myelofibrosis	O
are	O
not	O
considered	O
medically	O
fit	O
for	O
such	O
aggressive	O
therapy	O
.	O

Other	O
available	O
medical	O
therapies	O
do	O
not	O
halt	O
disease	O
progression	O
;	O
instead	O
,	O
current	O
treatment	O
strategies	O
have	O
focused	O
on	O
targeting	O
specific	O
symptomology	O
,	O
although	O
with	O
limited	O
efficacy	O
.	O

The	O
lack	O
of	O
effective	O
treatment	O
options	O
for	O
patients	O
with	O
myelofibrosis	O
has	O
rendered	O
this	O
orphan	O
disease	O
state	O
an	O
unmet	O
medical	O
need	O
,	O
and	O
novel	O
approaches	O
to	O
improve	O
outcomes	O
are	O
necessary	O
.	O

Emerging	O
research	O
has	O
identified	O
numerous	O
molecular	O
mutations	O
in	O
patients	O
with	O
myelofibrosis	O
,	O
making	O
this	O
disease	O
a	O
potential	O
candidate	O
for	O
molecularly	O
targeted	O
therapy	O
.	O

The	O
most	O
prevalent	O
mutation	O
identified	O
is	O
a	O
gain	O
-	O
of	O
-	O
function	O
mutation	O
in	O
the	O
Janus	B-GENE-N
kinase	I-GENE-N
(	O
JAK	B-GENE-N
)	O
family	O
,	O
JAK2	B-GENE-Y
V617F	B-GENE-N
,	O
which	O
has	O
been	O
identified	O
in	O
more	O
than	O
half	O
of	O
patients	O
with	O
myelofibrosis	O
.	O

This	O
mutation	O
results	O
in	O
a	O
constitutively	O
active	O
JAK	B-GENE-N
-	O
signal	B-GENE-N
transducer	I-GENE-N
and	I-GENE-N
activator	I-GENE-N
of	I-GENE-N
transcription	I-GENE-N
pathway	O
resulting	O
in	O
dysregulated	O
cellular	O
proliferation	O
and	O
hematopoiesis	O
.	O

Ruxolitinib	B-CHEMICAL
is	O
a	O
small	O
-	O
molecule	O
inhibitor	O
of	O
JAK1	B-GENE-Y
and	O
JAK2	B-GENE-Y
and	O
recently	O
became	O
the	O
first	O
drug	O
approved	O
by	O
the	O
United	O
States	O
Food	O
and	O
Drug	O
Administration	O
for	O
the	O
treatment	O
of	O
symptomatic	O
intermediate	O
-	O
or	O
high	O
-	O
risk	O
myelofibrosis	O
.	O

In	O
clinical	O
trials	O
,	O
ruxolitinib	B-CHEMICAL
demonstrated	O
promising	O
efficacy	O
in	O
reducing	O
splenomegaly	O
and	O
myelofibrosis	O
-	O
related	O
symptoms	O
.	O

However	O
,	O
ruxolitinib	B-CHEMICAL
did	O
not	O
demonstrate	O
disease	O
-	O
modifying	O
potential	O
and	O
is	O
not	O
considered	O
a	O
curative	O
therapeutic	O
option	O
.	O

Adverse	O
events	O
associated	O
with	O
ruxolitinib	B-CHEMICAL
are	O
primarily	O
hematologic	O
,	O
with	O
thrombocytopenia	O
and	O
anemia	O
being	O
the	O
most	O
common	O
toxicologic	O
events	O
identified	O
.	O

Future	O
research	O
will	O
shed	O
light	O
on	O
whether	O
ruxolitinib	B-CHEMICAL
in	O
combination	O
with	O
other	O
treatments	O
will	O
further	O
enhance	O
outcomes	O
in	O
myelofibrosis	O
.	O

Tipping	O
the	O
energy	O
balance	O
toward	O
longevity	O
.	O

AMPK	B-GENE-Y
is	O
a	O
cellular	O
energy	O
sensor	O
conserved	O
across	O
eukaryotes	O
that	O
in	O
C	O
.	O
elegans	O
prolongs	O
life	O
span	O
and	O
mimics	O
dietary	O
restriction	O
.	O

Stenesen	O
and	O
colleagues	O
(	O
2012	O
)	O
activate	O
AMPK	B-GENE-N
both	O
directly	O
and	O
indirectly	O
by	O
altering	O
AMP	B-CHEMICAL
biosynthesis	O
to	O
slow	O
aging	O
in	O
Drosophila	O
,	O
highlighting	O
AMPK	B-GENE-N
as	O
a	O
conserved	O
life	O
span	O
modulator	O
that	O
links	O
energy	O
sensing	O
to	O
longevity	O
.	O

Oxidative	O
and	O
nitrosative	O
stress	O
and	O
apoptosis	O
in	O
oral	O
mucosa	O
cells	O
after	O
ex	O
vivo	O
exposure	O
to	O
lead	O
and	O
benzo	B-CHEMICAL
[	I-CHEMICAL
a	I-CHEMICAL
]	I-CHEMICAL
pyrene	I-CHEMICAL
.	O

Exposure	O
of	O
human	O
oral	O
mucosa	O
to	O
lead	O
(	O
Pb	B-CHEMICAL
)	O
and	O
benzo	B-CHEMICAL
[	I-CHEMICAL
a	I-CHEMICAL
]	I-CHEMICAL
pyrene	I-CHEMICAL
(	O
BaP	B-CHEMICAL
)	O
by	O
inhalation	O
and	O
ingestion	O
can	O
lead	O
to	O
pathological	O
conditions	O
via	O
apoptosis	O
and	O
oxidative	O
and	O
nitrosative	O
stress	O
.	O

However	O
,	O
few	O
studies	O
have	O
investigated	O
the	O
effects	O
of	O
Pb	B-CHEMICAL
and	O
BaP	B-CHEMICAL
on	O
oral	O
mucosa	O
cells	O
.	O

Furthermore	O
,	O
previous	O
studies	O
focused	O
on	O
chronic	O
Pb	B-CHEMICAL
and	O
BaP	B-CHEMICAL
exposure	O
.	O

Therefore	O
,	O
we	O
evaluated	O
important	O
markers	O
of	O
apoptosis	O
and	O
oxidative	O
and	O
nitrosative	O
stress	O
in	O
oral	O
mucosa	O
cells	O
by	O
incubating	O
the	O
cells	O
with	O
Pb	B-CHEMICAL
and	O
BaP	B-CHEMICAL
for	O
5	O
-	O
360	O
min	O
.	O

Ex	O
vivo	O
samples	O
of	O
human	O
oral	O
mucosa	O
were	O
exposed	O
to	O
Pb	B-CHEMICAL
or	O
BaP	B-CHEMICAL
,	O
and	O
immunohistochemical	O
staining	O
was	O
performed	O
to	O
evaluate	O
active	O
caspase	B-GENE-Y
-	I-GENE-Y
3	I-GENE-Y
,	O
8	B-CHEMICAL
-	I-CHEMICAL
epi	I-CHEMICAL
-	I-CHEMICAL
prostaglandin	I-CHEMICAL
F2	I-CHEMICAL
alpha	I-CHEMICAL
(	O
8	B-CHEMICAL
-	I-CHEMICAL
epi	I-CHEMICAL
-	I-CHEMICAL
PGF2a	I-CHEMICAL
)	O
,	O
and	O
3	B-CHEMICAL
-	I-CHEMICAL
nitrotyrosine	I-CHEMICAL
(	O
3	B-CHEMICAL
-	I-CHEMICAL
NT	I-CHEMICAL
)	O
.	O

Pb	B-CHEMICAL
and	O
BaP	B-CHEMICAL
treatments	O
significantly	O
increased	O
active	O
caspase	B-GENE-Y
-	I-GENE-Y
3	I-GENE-Y
levels	O
in	O
a	O
time	O
-	O
dependent	O
manner	O
.	O

Furthermore	O
,	O
the	O
treatments	O
induced	O
an	O
early	O
increase	O
in	O
3	B-CHEMICAL
-	I-CHEMICAL
NT	I-CHEMICAL
level	O
,	O
which	O
ceased	O
with	O
longer	O
incubation	O
times	O
.	O

8	B-CHEMICAL
-	I-CHEMICAL
Epi	I-CHEMICAL
-	I-CHEMICAL
PGF2a	I-CHEMICAL
level	O
increased	O
only	O
after	O
prolonged	O
incubation	O
with	O
Pb	B-CHEMICAL
,	O
and	O
this	O
elevation	O
was	O
irrespective	O
of	O
BaP	B-CHEMICAL
incubation	O
duration	O
.	O

Smokers	O
'	O
samples	O
had	O
significantly	O
lower	O
levels	O
of	O
markers	O
of	O
oxidative	O
and	O
nitrosative	O
stress	O
than	O
did	O
nonsmokers	O
'	O
samples	O
.	O

Thus	O
,	O
single	O
,	O
short	O
-	O
term	O
exposure	O
to	O
Pb	B-CHEMICAL
or	O
BaP	B-CHEMICAL
increases	O
the	O
levels	O
of	O
apoptosis	O
markers	O
and	O
markers	O
of	O
oxidative	O
and	O
nitrosative	O
stress	O
.	O

Effect	O
of	O
enzymatically	O
modified	O
isoquercitrin	B-CHEMICAL
on	O
preneoplastic	O
liver	O
cell	O
lesions	O
induced	O
by	O
thioacetamide	B-CHEMICAL
promotion	O
in	O
a	O
two	O
-	O
stage	O
hepatocarcinogenesis	O
model	O
using	O
rats	O
.	O

To	O
investigate	O
the	O
protective	O
effect	O
of	O
enzymatically	O
modified	O
isoquercitrin	B-CHEMICAL
(	O
EMIQ	O
)	O
on	O
the	O
hepatocarcinogenic	O
process	O
,	O
we	O
used	O
a	O
two	O
-	O
stage	O
hepatocarcinogenesis	O
model	O
in	O
N	B-CHEMICAL
-	I-CHEMICAL
diethylnitrosamine	I-CHEMICAL
-	O
initiated	O
and	O
thioacetamide	B-CHEMICAL
(	O
TAA	B-CHEMICAL
)	O
-	O
promoted	O
rats	O
.	O

We	O
examined	O
the	O
modifying	O
effect	O
of	O
co	O
-	O
administration	O
with	O
EMIQ	O
on	O
the	O
liver	O
tissue	O
environment	O
including	O
hepatic	O
macrophages	O
and	O
lymphocytes	O
and	O
on	O
the	O
induction	O
mechanism	O
of	O
preneoplastic	O
cell	O
apoptosis	O
during	O
early	O
stages	O
of	O
hepatocellular	O
tumor	O
promotion	O
.	O

TAA	B-CHEMICAL
increased	O
the	O
number	O
and	O
area	O
of	O
glutathione	B-GENE-N
S	I-GENE-N
-	I-GENE-N
transferase	I-GENE-N
placental	I-GENE-N
form	I-GENE-N
(	O
GST	B-GENE-N
-	I-GENE-N
P	I-GENE-N
)	O
(	O
+	O
)	O
liver	O
cell	O
foci	O
and	O
the	O
numbers	O
of	O
proliferating	O
and	O
apoptotic	O
cells	O
in	O
randomly	O
selected	O
areas	O
in	O
liver	O
sections	O
.	O

Co	O
-	O
administration	O
with	O
EMIQ	O
suppressed	O
these	O
effects	O
.	O

TAA	B-CHEMICAL
also	O
increased	O
the	O
numbers	O
of	O
ED2	O
(	O
+	O
)	O
,	O
cyclooxygenase	B-GENE-Y
-	I-GENE-Y
2	I-GENE-Y
(	O
+	O
)	O
,	O
and	O
heme	B-GENE-Y
oxygenase	I-GENE-Y
-	I-GENE-Y
1	I-GENE-Y
(	O
+	O
)	O
liver	O
cells	O
,	O
as	O
well	O
as	O
the	O
number	O
of	O
CD3	B-GENE-N
(	O
+	O
)	O
lymphocytes	O
.	O

These	O
effects	O
were	O
also	O
suppressed	O
by	O
EMIQ	O
.	O

EMIQ	O
increased	O
liver	O
levels	O
of	O
thiobarbituric	B-CHEMICAL
acid	I-CHEMICAL
-	O
reactive	O
substance	O
and	O
8	B-CHEMICAL
-	I-CHEMICAL
hydroxydeoxyguanosine	I-CHEMICAL
,	O
and	O
TUNEL	O
(	O
+	O
)	O
apoptotic	O
cells	O
,	O
death	B-GENE-Y
receptor	I-GENE-Y
5	I-GENE-Y
(	O
DR5	B-GENE-Y
)	O
(	O
+	O
)	O
cells	O
and	O
4	B-CHEMICAL
-	I-CHEMICAL
hydroxy	I-CHEMICAL
-	I-CHEMICAL
2	I-CHEMICAL
-	I-CHEMICAL
nonenal	I-CHEMICAL
(	O
+	O
)	O
cells	O
within	O
GST	B-GENE-N
-	I-GENE-N
P	I-GENE-N
(	O
+	O
)	O
foci	O
.	O

Outside	O
the	O
GST	B-GENE-N
-	I-GENE-N
P	I-GENE-N
(	O
+	O
)	O
foci	O
,	O
EMIQ	O
decreased	O
the	O
numbers	O
of	O
apoptotic	O
cells	O
and	O
DR5	B-GENE-Y
(	O
+	O
)	O
cells	O
.	O

These	O
results	O
suggest	O
that	O
TAA	B-CHEMICAL
-	O
induced	O
tumor	O
promotion	O
involves	O
activation	O
of	O
hepatic	O
macrophages	O
producing	O
proinflammatory	O
factors	O
.	O

EMIQ	O
may	O
suppress	O
the	O
TAA	B-CHEMICAL
-	O
induced	O
tumor	O
-	O
promoting	O
activity	O
by	O
an	O
anti	O
-	O
inflammatory	O
mechanism	O
mediated	O
by	O
suppressing	O
the	O
activation	O
of	O
these	O
macrophages	O
.	O

Furthermore	O
,	O
EMIQ	O
may	O
suppress	O
tumor	O
-	O
promoting	O
activity	O
differentially	O
between	O
the	O
inside	O
and	O
outside	O
of	O
GST	B-GENE-N
-	I-GENE-N
P	I-GENE-N
(	O
+	O
)	O
foci	O
.	O

Within	O
GST	B-GENE-N
-	I-GENE-N
P	I-GENE-N
(	O
+	O
)	O
foci	O
,	O
EMIQ	O
facilitates	O
the	O
apoptosis	O
of	O
preneoplastic	O
cells	O
through	O
the	O
upregulation	O
of	O
DR5	B-GENE-Y
.	O

Outside	O
the	O
GST	B-GENE-N
-	I-GENE-N
P	I-GENE-N
(	O
+	O
)	O
foci	O
,	O
EMIQ	O
suppresses	O
apoptosis	O
and	O
the	O
subsequent	O
regeneration	O
of	O
non	O
-	O
transformed	O
liver	O
cells	O
.	O

ICA	B-CHEMICAL
-	I-CHEMICAL
105574	I-CHEMICAL
interacts	O
with	O
a	O
common	O
binding	O
site	O
to	O
elicit	O
opposite	O
effects	O
on	O
inactivation	O
gating	O
of	O
EAG	B-GENE-Y
and	O
ERG	B-GENE-Y
potassium	B-GENE-N
channels	I-GENE-N
.	O

Rapid	O
and	O
voltage	O
-	O
dependent	O
inactivation	O
greatly	O
attenuates	O
outward	O
currents	O
in	O
ether	B-GENE-Y
-	I-GENE-Y
a	I-GENE-Y
-	I-GENE-Y
go	I-GENE-Y
-	I-GENE-Y
go	I-GENE-Y
-	I-GENE-Y
related	I-GENE-Y
gene	I-GENE-Y
(	O
ERG	B-GENE-Y
)	O
K	B-GENE-N
(	I-GENE-N
+	I-GENE-N
)	I-GENE-N
channels	I-GENE-N
.	O

In	O
contrast	O
,	O
inactivation	O
of	O
related	O
ether	B-GENE-Y
-	I-GENE-Y
a	I-GENE-Y
-	I-GENE-Y
go	I-GENE-Y
-	I-GENE-Y
go	I-GENE-Y
(	O
EAG	B-GENE-Y
)	O
K	B-GENE-N
(	I-GENE-N
+	I-GENE-N
)	I-GENE-N
channels	I-GENE-N
is	O
very	O
slow	O
and	O
minimally	O
reduces	O
outward	O
currents	O
.	O

ICA	B-CHEMICAL
-	I-CHEMICAL
105574	I-CHEMICAL
(	O
ICA	B-CHEMICAL
,	O
or	O
3	B-CHEMICAL
-	I-CHEMICAL
nitro	I-CHEMICAL
-	I-CHEMICAL
N	I-CHEMICAL
-	I-CHEMICAL
[	I-CHEMICAL
4	I-CHEMICAL
-	I-CHEMICAL
phenoxyphenyl	I-CHEMICAL
]	I-CHEMICAL
-	I-CHEMICAL
benzamide	I-CHEMICAL
)	O
has	O
opposite	O
effects	O
on	O
inactivation	O
of	O
these	O
two	O
channel	O
types	O
.	O

Although	O
ICA	B-CHEMICAL
greatly	O
attenuates	O
ERG	B-GENE-Y
inactivation	O
by	O
shifting	O
its	O
voltage	O
dependence	O
to	O
more	O
positive	O
potentials	O
,	O
it	O
enhances	O
the	O
rate	O
and	O
extent	O
of	O
EAG	B-GENE-Y
inactivation	O
without	O
altering	O
its	O
voltage	O
dependence	O
.	O

Here	O
,	O
we	O
investigate	O
whether	O
the	O
inverse	O
functional	O
response	O
to	O
ICA	B-CHEMICAL
in	O
EAG	B-GENE-Y
and	O
ERG	B-GENE-Y
channels	O
is	O
related	O
to	O
differences	O
in	O
ICA	B-CHEMICAL
binding	O
site	O
or	O
to	O
intrinsic	O
mechanisms	O
of	O
inactivation	O
.	O

Molecular	O
modeling	O
coupled	O
with	O
site	O
-	O
directed	O
mutagenesis	O
suggests	O
that	O
ICA	B-CHEMICAL
binds	O
in	O
a	O
channel	O
-	O
specific	O
orientation	O
to	O
a	O
hydrophobic	O
pocket	O
bounded	O
by	O
the	O
S5	O
/	O
pore	O
helix	O
/	O
S6	O
of	O
one	O
subunit	O
and	O
S6	O
of	O
an	O
adjacent	O
subunit	O
.	O

ICA	B-CHEMICAL
is	O
a	O
mixed	O
agonist	O
of	O
mutant	O
EAG	B-GENE-Y
and	O
EAG	B-GENE-Y
/	O
ERG	B-GENE-Y
chimera	O
channels	O
that	O
inactivate	O
by	O
a	O
combination	O
of	O
slow	O
and	O
fast	O
mechanisms	O
.	O

With	O
the	O
exception	O
of	O
three	O
residues	O
,	O
the	O
specific	O
amino	B-CHEMICAL
acids	I-CHEMICAL
that	O
form	O
the	O
putative	O
binding	O
pocket	O
for	O
ICA	B-CHEMICAL
in	O
ERG	B-GENE-Y
are	O
conserved	O
in	O
EAG	B-GENE-Y
.	O

Mutations	O
introduced	O
into	O
EAG	B-GENE-Y
to	O
replicate	O
the	O
ICA	B-CHEMICAL
binding	O
site	O
in	O
ERG	B-GENE-Y
did	O
not	O
alter	O
the	O
functional	O
response	O
to	O
ICA	B-CHEMICAL
.	O

Together	O
these	O
findings	O
suggest	O
that	O
ICA	B-CHEMICAL
binds	O
to	O
the	O
same	O
site	O
in	O
EAG	B-GENE-Y
and	O
ERG	B-GENE-Y
channels	O
to	O
elicit	O
opposite	O
functional	O
effects	O
.	O

The	O
resultant	O
agonist	O
or	O
antagonist	O
activity	O
is	O
determined	O
solely	O
by	O
channel	O
-	O
specific	O
differences	O
in	O
the	O
mechanisms	O
of	O
inactivation	O
gating	O
.	O

Methylation	O
of	O
histone	B-GENE-N
H3	I-GENE-N
on	O
lysine	B-CHEMICAL
4	O
by	O
the	O
lysine	B-GENE-N
methyltransferase	I-GENE-N
SET1	B-GENE-Y
protein	O
is	O
needed	O
for	O
normal	O
clock	O
gene	O
expression	O
.	O

The	O
circadian	O
oscillator	O
controls	O
time	O
-	O
of	O
-	O
day	O
gene	O
expression	O
by	O
a	O
network	O
of	O
interconnected	O
feedback	O
loops	O
and	O
is	O
reset	O
by	O
light	O
.	O

The	O
requisite	O
for	O
chromatin	O
regulation	O
in	O
eukaryotic	O
transcription	O
necessitates	O
temporal	O
regulation	O
of	O
histone	O
-	O
modifying	O
and	O
chromatin	O
-	O
remodeling	O
enzymes	O
for	O
proper	O
clock	O
function	O
.	O

CHD1	B-GENE-N
is	O
known	O
to	O
bind	O
H3K4me3	O
in	O
mammalian	O
cells	O
,	O
and	O
Neurospora	B-GENE-N
CHD1	I-GENE-N
is	O
required	O
for	O
proper	O
regulation	O
of	O
the	O
frequency	B-GENE-Y
(	O
frq	B-GENE-Y
)	O
gene	O
.	O

Based	O
on	O
this	O
,	O
we	O
examined	O
a	O
strain	O
lacking	O
SET1	B-GENE-Y
to	O
determine	O
the	O
role	O
of	O
H3K4	O
methylation	O
in	O
clock	O
-	O
and	O
light	O
-	O
mediated	O
frq	B-GENE-Y
regulation	O
.	O

Expression	O
of	O
frq	B-GENE-Y
was	O
altered	O
in	O
strains	O
lacking	O
set1	O
under	O
both	O
circadian	O
-	O
and	O
light	O
-	O
regulated	O
gene	O
expression	O
.	O

There	O
is	O
a	O
delay	O
in	O
the	O
phasing	O
of	O
H3K4me3	O
relative	O
to	O
the	O
peak	O
in	O
frq	B-GENE-Y
expression	O
.	O

White	O
Collar	O
2	O
(	O
WC	O
-	O
2	O
)	O
association	O
with	O
the	O
frq	B-GENE-N
promoter	I-GENE-N
persists	O
longer	O
in	O
set1	B-GENE-Y
,	O
suggesting	O
a	O
more	O
permissible	O
chromatin	O
state	O
.	O

Surprisingly	O
,	O
SET1	B-GENE-Y
is	O
required	O
for	O
DNA	O
methylation	O
in	O
the	O
frq	B-GENE-N
promoter	I-GENE-N
,	O
indicating	O
a	O
dependence	O
on	O
H3K4me	O
for	O
DNA	O
methylation	O
.	O

The	O
data	O
support	O
a	O
model	O
where	O
SET1	B-GENE-Y
is	O
needed	O
for	O
proper	O
regulation	O
by	O
modulating	O
chromatin	O
at	O
frq	B-GENE-Y
.	O

Activation	O
of	O
the	O
7	B-GENE-Y
nicotinic	I-GENE-Y
ACh	I-GENE-Y
receptor	I-GENE-Y
induces	O
anxiogenic	O
effects	O
in	O
rats	O
which	O
is	O
blocked	O
by	O
a	O
5	B-GENE-Y
-	I-GENE-Y
HT1a	I-GENE-Y
receptor	O
antagonist	O
.	O

The	O
7	B-GENE-Y
nicotinic	I-GENE-Y
acetylcholine	I-GENE-Y
receptor	I-GENE-Y
(	O
nAChR	B-GENE-N
)	O
is	O
highly	O
expressed	O
in	O
different	O
regions	O
of	O
the	O
brain	O
and	O
is	O
associated	O
with	O
cognitive	O
function	O
as	O
well	O
as	O
anxiety	O
.	O

Agonists	O
and	O
positive	O
allosteric	O
modulators	O
(	O
PAMs	O
)	O
of	O
the	O
7	B-GENE-Y
subtype	I-GENE-Y
of	I-GENE-Y
nAChRs	I-GENE-Y
have	O
been	O
shown	O
to	O
improve	O
cognition	O
.	O

Previously	O
nicotine	B-CHEMICAL
,	O
which	O
activates	O
both	O
7	B-GENE-N
and	I-GENE-N
non	I-GENE-N
-	I-GENE-N
7	I-GENE-N
subtypes	I-GENE-N
of	I-GENE-N
nAChRs	I-GENE-N
,	O
has	O
been	O
shown	O
to	O
have	O
an	O
anxiogenic	O
effect	O
in	O
behavioral	O
tests	O
.	O

In	O
this	O
study	O
,	O
we	O
compared	O
the	O
effects	O
of	O
the	O
7	O
-	O
selective	O
agonist	O
(	O
PNU	B-CHEMICAL
-	I-CHEMICAL
282987	I-CHEMICAL
)	O
and	O
PAM	O
(	O
PNU	B-CHEMICAL
-	I-CHEMICAL
120596	I-CHEMICAL
)	O
in	O
a	O
variety	O
of	O
behavioral	O
tests	O
in	O
Sprague	O
Dawley	O
rats	O
to	O
look	O
at	O
their	O
effects	O
on	O
learning	O
and	O
memory	O
as	O
well	O
as	O
anxiety	O
.	O

We	O
found	O
that	O
neither	O
PNU	B-CHEMICAL
-	I-CHEMICAL
282987	I-CHEMICAL
nor	O
PNU	B-CHEMICAL
-	I-CHEMICAL
120596	I-CHEMICAL
improved	O
spatial	O
-	O
learning	O
or	O
episodic	O
memory	O
by	O
themselves	O
.	O

However	O
when	O
cognitive	O
impairment	O
was	O
induced	O
in	O
the	O
rats	O
with	O
scopolamine	B-CHEMICAL
(	O
1	O
mg	O
/	O
kg	O
)	O
,	O
both	O
PNU	B-CHEMICAL
-	I-CHEMICAL
120596	I-CHEMICAL
and	O
PNU	B-CHEMICAL
-	I-CHEMICAL
282987	I-CHEMICAL
were	O
able	O
to	O
reverse	O
this	O
memory	O
impairment	O
and	O
restore	O
it	O
back	O
to	O
normal	O
levels	O
.	O

While	O
PNU	B-CHEMICAL
-	I-CHEMICAL
120596	I-CHEMICAL
reversed	O
the	O
scopolamine	O
-	O
induced	O
cognitive	O
impairment	O
,	O
it	O
did	O
not	O
have	O
any	O
adverse	O
effect	O
on	O
anxiety	O
.	O

PNU	B-CHEMICAL
-	I-CHEMICAL
282987	I-CHEMICAL
on	O
the	O
other	O
hand	O
displayed	O
an	O
increase	O
in	O
anxiety	O
-	O
like	O
behavior	O
at	O
a	O
higher	O
dose	O
(	O
10	O
mg	O
/	O
kg	O
)	O
that	O
was	O
significantly	O
reduced	O
by	O
the	O
serotonin	B-GENE-Y
5	I-GENE-Y
-	I-GENE-Y
HT1a	I-GENE-Y
receptor	I-GENE-Y
antagonist	O
WAY	B-CHEMICAL
-	I-CHEMICAL
100135	I-CHEMICAL
.	O

However	O
the	O
7	B-GENE-Y
receptor	I-GENE-Y
antagonist	O
methyllycaconitine	B-CHEMICAL
was	O
unable	O
to	O
reverse	O
these	O
anxiety	O
-	O
like	O
effects	O
seen	O
with	O
PNU	B-CHEMICAL
-	I-CHEMICAL
282987	I-CHEMICAL
.	O

These	O
results	O
suggest	O
that	O
7	B-GENE-Y
nAChR	I-GENE-Y
PAMs	O
are	O
pharmacologically	O
advantageous	O
over	O
agonists	O
,	O
and	O
should	O
be	O
considered	O
for	O
further	O
development	O
as	O
therapeutic	O
drugs	O
targeting	O
the	O
7	B-GENE-Y
receptors	I-GENE-Y
.	O

Carnitine	B-GENE-Y
palmitoyltransferase	I-GENE-Y
2	I-GENE-Y
and	O
carnitine	B-GENE-Y
/	I-GENE-Y
acylcarnitine	I-GENE-Y
translocase	I-GENE-Y
are	O
involved	O
in	O
the	O
mitochondrial	O
synthesis	O
and	O
export	O
of	O
acylcarnitines	B-CHEMICAL
.	O

Acylcarnitines	B-CHEMICAL
are	O
commonly	O
used	O
in	O
the	O
diagnosis	O
of	O
mitochondrial	O
fatty	B-CHEMICAL
acid	I-CHEMICAL
	O
-	O
oxidation	O
disorders	O
(	O
mFAODs	O
)	O
.	O

It	O
is	O
generally	O
assumed	O
that	O
this	O
plasma	O
acylcarnitine	B-CHEMICAL
profile	O
reflects	O
the	O
mitochondrial	O
accumulation	O
of	O
acyl	B-CHEMICAL
-	I-CHEMICAL
CoAs	I-CHEMICAL
.	O

The	O
identity	O
of	O
the	O
enzymes	O
and	O
the	O
mitochondrial	O
and	O
plasmalemmal	O
transporters	O
involved	O
in	O
the	O
synthesis	O
and	O
export	O
of	O
these	O
metabolites	O
have	O
remained	O
undefined	O
.	O

We	O
used	O
lentiviral	O
shRNA	O
to	O
knock	O
down	O
the	O
expression	O
of	O
medium	B-GENE-Y
-	I-GENE-Y
chain	I-GENE-Y
acyl	I-GENE-Y
-	I-GENE-Y
CoA	I-GENE-Y
dehydrogenase	I-GENE-Y
(	O
MCAD	B-GENE-Y
)	O
in	O
control	O
and	O
carnitine	B-GENE-Y
palmitoyltransferase	I-GENE-Y
2	I-GENE-Y
(	O
CPT2	B-GENE-Y
)	O
-	O
,	O
carnitine	B-GENE-Y
/	I-GENE-Y
acylcarnitine	I-GENE-Y
translocase	I-GENE-Y
(	O
CACT	B-GENE-Y
)	O
-	O
,	O
and	O
plasmalemmal	O
carnitine	B-GENE-N
transporter	I-GENE-N
(	O
OCTN2	B-GENE-Y
)	O
-	O
deficient	O
human	O
fibroblasts	O
.	O

These	O
cell	O
lines	O
,	O
including	O
mock	O
-	O
transduced	O
controls	O
,	O
were	O
loaded	O
with	O
decanoic	B-CHEMICAL
acid	I-CHEMICAL
and	O
carnitine	B-CHEMICAL
,	O
followed	O
by	O
the	O
measurement	O
of	O
the	O
acylcarnitine	B-CHEMICAL
profile	O
in	O
the	O
extracellular	O
medium	O
.	O

In	O
control	O
fibroblasts	O
,	O
MCAD	B-GENE-Y
knockdown	O
markedly	O
increased	O
the	O
production	O
of	O
octanoylcarnitine	B-CHEMICAL
(	O
3	O
-	O
fold	O
,	O
P	O
<	O
0	O
.	O
01	O
)	O
.	O

OCTN2	B-GENE-Y
-	O
deficient	O
cell	O
lines	O
also	O
showed	O
extracellular	O
accumulation	O
of	O
octanoylcarnitine	B-CHEMICAL
(	O
2	O
.	O
8	O
-	O
fold	O
,	O
P	O
<	O
0	O
.	O
01	O
)	O
,	O
suggesting	O
that	O
the	O
cellular	O
export	O
of	O
acylcarnitines	B-CHEMICAL
does	O
not	O
depend	O
on	O
OCTN2	B-GENE-Y
.	O

In	O
contrast	O
,	O
in	O
CPT2	B-GENE-Y
-	O
and	O
CACT	B-GENE-Y
-	O
deficient	O
cells	O
,	O
the	O
accumulation	O
of	O
octanoylcarnitine	B-CHEMICAL
in	O
the	O
medium	O
did	O
not	O
significantly	O
increase	O
in	O
the	O
MCAD	B-GENE-Y
knockdown	O
.	O

Similar	O
results	O
were	O
obtained	O
using	O
pharmacological	O
inhibition	O
of	O
CPT2	B-GENE-Y
in	O
fibroblasts	O
from	O
MCAD	B-GENE-Y
-	O
deficient	O
individuals	O
.	O

This	O
shows	O
that	O
CPT2	B-GENE-Y
and	O
CACT	B-GENE-Y
are	O
crucial	O
for	O
mitochondrial	O
acylcarnitine	B-CHEMICAL
formation	O
and	O
export	O
to	O
the	O
extracellular	O
fluids	O
in	O
mFAOD	O
.	O
-	O
Violante	O
,	O
S	O
.	O
,	O
IJlst	O
,	O
L	O
.	O
,	O
te	O
Brinke	O
,	O
H	O
.	O
,	O
Tavares	O
de	O
Almeida	O
,	O
I	O
.	O
,	O
Wanders	O
,	O
R	O
.	O

J	O
.	O

A	O
.	O
,	O
Ventura	O
,	O
F	O
.	O

V	O
.	O
,	O
Houten	O
,	O
S	O
.	O

M	O
.	O

Carnitine	B-GENE-Y
palmitoyltransferase	I-GENE-Y
2	I-GENE-Y
and	O
carnitine	B-GENE-Y
/	I-GENE-Y
acylcarnitine	I-GENE-Y
translocase	I-GENE-Y
are	O
involved	O
in	O
the	O
mitochondrial	O
synthesis	O
and	O
export	O
of	O
acylcarnitines	B-CHEMICAL
.	O

HOW	O
GOOD	O
IS	O
THE	O
LEVOTHYROXINE	B-CHEMICAL
REPLACEMENT	O
IN	O
PRIMARY	O
HYPOTHYROIDISM	O
PATIENTS	O
IN	O
BRAZIL	O
?	O
-	O
DATA	O
OF	O
A	O
MULTICENTRE	O
STUDY	O
.	O

Background	O
:	O
Studies	O
done	O
in	O
every	O
continent	O
has	O
shown	O
that	O
only	O
around	O
50	O
%	O
of	O
the	O
patients	O
subjected	O
to	O
thyroid	O
hormone	O
replacement	O
have	O
TSH	B-GENE-N
in	O
the	O
normal	O
range	O
.	O

However	O
,	O
until	O
to	O
date	O
,	O
there	O
are	O
no	O
consistent	O
data	O
about	O
Brazil	O
.	O

Objectives	O
:	O
To	O
evaluate	O
levothyroxine	B-CHEMICAL
(	O
LT4	B-CHEMICAL
)	O
replacement	O
treatment	O
in	O
patients	O
with	O
primary	O
hypothyroidism	O
followed	O
in	O
referral	O
centers	O
in	O
Brazil	O
.	O

Methods	O
:	O
Patients	O
with	O
primary	O
hypothyroidism	O
followed	O
in	O
referral	O
centers	O
(	O
University	O
Hospitals	O
from	O
Universidade	O
Federal	O
do	O
Rio	O
de	O
Janeiro	O
-	O
UFRJ	O
,	O
Unicamp	O
,	O
Universidade	O
Federal	O
do	O
Paran	O
-	O
UFPR	O
and	O
Universidade	O
Federal	O
do	O
Cear	O
-	O
UFC	O
)	O
answered	O
a	O
questionnairethat	O
inquired	O
about	O
clinical	O
and	O
biochemical	O
conditions	O
,	O
social	O
-	O
economic	O
status	O
,	O
life	O
quality	O
and	O
clinicians	O
'	O
orientations	O
as	O
well	O
as	O
their	O
understanding	O
about	O
the	O
information	O
given	O
.	O

Serum	O
TSH	B-GENE-N
was	O
checked	O
close	O
to	O
the	O
interview	O
.	O

Results	O
:	O
2292	O
consecutive	O
patients	O
met	O
the	O
inclusion	O
criteria	O
.	O

Mean	O
age	O
51	O
.	O
2	O
years	O
and	O
TSH	B-GENE-N
values	O
between	O
0	O
.	O
4	O
and	O
4	O
.	O
0	O
mUI	O
/	O
l	O
were	O
considered	O
to	O
be	O
within	O
the	O
reference	O
range	O
.	O

Among	O
all	O
patients	O
taking	O
thyroid	O
medication	O
,	O
42	O
.	O
7	O
%	O
%	O
had	O
an	O
abnormal	O
serum	O
TSH	B-GENE-N
(	O
28	O
.	O
3	O
%	O
were	O
undertreated	O
and	O
14	O
.	O
4	O
%	O
were	O
over	O
treated	O
)	O
.	O

Approximately	O
all	O
patients	O
(	O
99	O
%	O
)	O
took	O
LT4	B-CHEMICAL
in	O
the	O
morning	O
but	O
less	O
than	O
30	O
minutes	O
before	O
breakfast	O
(	O
85	O
.	O
4	O
%	O
)	O
.	O

Regarding	O
the	O
clinicians	O
	O
orientations	O
:	O
97	O
.	O
5	O
%	O
of	O
the	O
patients	O
were	O
instructed	O
to	O
take	O
the	O
medication	O
daily	O
,	O
and	O
92	O
.	O
6	O
%	O
to	O
take	O
30	O
minutes	O
before	O
breakfast	O
(	O
92	O
.	O
6	O
%	O
)	O
.	O

However	O
,	O
only	O
52	O
.	O
1	O
%	O
were	O
told	O
that	O
not	O
to	O
take	O
LT4	B-CHEMICAL
along	O
with	O
other	O
medication	O
.	O

Conclusions	O
:	O
Our	O
study	O
found	O
that	O
there	O
was	O
a	O
significant	O
number	O
of	O
patients	O
taking	O
thyroid	O
hormones	O
were	O
not	O
in	O
the	O
therapeutic	O
range	O
.	O

Clinicians	O
should	O
,	O
therefore	O
,	O
consider	O
monitoring	O
patients	O
on	O
thyroid	O
replacement	O
more	O
frequently	O
and	O
being	O
more	O
precise	O
on	O
giving	O
recommendations	O
about	O
the	O
correct	O
use	O
of	O
LT4	B-CHEMICAL
.	O

Bioactive	O
abietane	B-CHEMICAL
and	O
ent	B-CHEMICAL
-	I-CHEMICAL
kaurane	I-CHEMICAL
diterpenoids	B-CHEMICAL
from	O
Isodon	O
tenuifolius	O
.	O

Three	O
new	O
abietane	B-CHEMICAL
diterpenoids	B-CHEMICAL
,	O
isoabietenins	B-CHEMICAL
A	I-CHEMICAL
-	I-CHEMICAL
C	I-CHEMICAL
(	O
1	O
-	O
3	O
)	O
,	O
and	O
13	O
new	O
ent	B-CHEMICAL
-	I-CHEMICAL
kauranoids	I-CHEMICAL
,	O
tenuifolins	B-CHEMICAL
A	I-CHEMICAL
-	I-CHEMICAL
M	I-CHEMICAL
(	O
4	O
-	O
16	O
)	O
,	O
along	O
with	O
four	O
known	O
compounds	O
(	O
17	O
-	O
20	O
)	O
,	O
were	O
isolated	O
from	O
the	O
aerial	O
parts	O
of	O
Isodon	O
tenuifolius	O
.	O

The	O
structures	O
of	O
the	O
new	O
metabolites	O
were	O
established	O
on	O
the	O
basis	O
of	O
detailed	O
spectroscopic	O
analysis	O
.	O

The	O
absolute	O
configurations	O
of	O
1	O
,	O
15	O
,	O
and	O
16	O
were	O
confirmed	O
by	O
single	O
-	O
crystal	O
X	O
-	O
ray	O
diffraction	O
.	O

Selected	O
compounds	O
were	O
evaluated	O
for	O
their	O
cytotoxicity	O
against	O
a	O
small	O
panel	O
of	O
human	O
tumor	O
cell	O
lines	O
,	O
and	O
some	O
compounds	O
showed	O
inhibitory	O
effects	O
.	O

Furthermore	O
,	O
several	O
isolates	O
exhibited	O
inhibitory	O
activity	O
against	O
nitric	B-CHEMICAL
oxide	I-CHEMICAL
production	O
in	O
LPS	O
-	O
activated	O
RAW264	O
.	O
7	O
macrophages	O
.	O

Alkaloids	O
from	O
Microcos	O
paniculata	O
with	O
cytotoxic	O
and	O
nicotinic	B-GENE-N
receptor	I-GENE-N
antagonistic	O
activities	O
.	O

Microcos	O
paniculata	O
is	O
a	O
large	O
shrub	O
or	O
small	O
tree	O
that	O
grows	O
in	O
several	O
countries	O
in	O
South	O
and	O
Southeast	O
Asia	O
.	O

In	O
the	O
present	O
study	O
,	O
three	O
new	O
piperidine	B-CHEMICAL
alkaloids	I-CHEMICAL
,	O
microgrewiapines	B-CHEMICAL
A	I-CHEMICAL
-	I-CHEMICAL
C	I-CHEMICAL
(	O
1	O
-	O
3	O
)	O
,	O
as	O
well	O
as	O
three	O
known	O
compounds	O
,	O
inclusive	O
of	O
microcosamine	B-CHEMICAL
A	I-CHEMICAL
(	O
4	O
)	O
,	O
7	B-CHEMICAL
'	I-CHEMICAL
-	I-CHEMICAL
(	I-CHEMICAL
3	I-CHEMICAL
'	I-CHEMICAL
,	I-CHEMICAL
4	I-CHEMICAL
'	I-CHEMICAL
-	I-CHEMICAL
dihydroxyphenyl	I-CHEMICAL
)	I-CHEMICAL
-	I-CHEMICAL
N	I-CHEMICAL
-	I-CHEMICAL
[	I-CHEMICAL
4	I-CHEMICAL
-	I-CHEMICAL
methoxyphenyl	I-CHEMICAL
)	I-CHEMICAL
ethyl	I-CHEMICAL
]	I-CHEMICAL
propenamide	I-CHEMICAL
(	O
5	O
)	O
,	O
and	O
liriodenine	B-CHEMICAL
(	O
6	O
)	O
,	O
were	O
isolated	O
from	O
cytotoxic	O
fractions	O
of	O
the	O
separate	O
chloroform	B-CHEMICAL
-	O
soluble	O
extracts	O
of	O
the	O
stem	O
bark	O
,	O
branches	O
,	O
and	O
leaves	O
of	O
M	O
.	O
paniculata	O
.	O

Compounds	O
1	O
-	O
6	O
and	O
1a	O
(	O
microgrewiapine	B-CHEMICAL
A	I-CHEMICAL
3	I-CHEMICAL
-	I-CHEMICAL
acetate	I-CHEMICAL
)	O
showed	O
a	O
range	O
of	O
cytotoxicity	O
values	O
against	O
the	O
HT	O
-	O
29	O
human	O
colon	O
cancer	O
cell	O
line	O
.	O

When	O
evaluated	O
for	O
their	O
effects	O
on	O
human	B-GENE-N
34	I-GENE-N
or	I-GENE-N
42	I-GENE-N
nicotinic	I-GENE-N
acetylcholine	I-GENE-N
receptors	I-GENE-N
(	O
nAChRs	B-GENE-N
)	O
,	O
several	O
of	O
these	O
compounds	O
were	O
shown	O
to	O
be	O
active	O
as	O
nAChR	B-GENE-N
antagonists	O
.	O

As	O
a	O
result	O
of	O
this	O
study	O
,	O
microgrewiapine	B-CHEMICAL
A	I-CHEMICAL
(	O
1	O
)	O
was	O
found	O
to	O
be	O
a	O
selective	O
cytotoxic	O
agent	O
for	O
colon	O
cancer	O
cells	O
over	O
normal	O
colon	O
cells	O
and	O
to	O
exhibit	O
nicotinic	B-GENE-N
receptor	I-GENE-N
antagonistic	O
activity	O
for	O
both	O
the	O
h34	B-GENE-N
and	I-GENE-N
h42	I-GENE-N
receptor	I-GENE-N
subtypes	O
.	O

The	O
transcription	B-GENE-Y
factor	I-GENE-Y
Pitx3	I-GENE-Y
is	O
expressed	O
selectively	O
in	O
midbrain	O
dopaminergic	O
neurons	O
susceptible	O
to	O
neurodegenerative	O
stress	O
.	O

The	O
homeodomain	B-GENE-Y
transcription	I-GENE-Y
factor	I-GENE-Y
Pitx3	I-GENE-Y
is	O
critical	O
for	O
the	O
survival	O
of	O
midbrain	O
dopaminergic	O
(	O
mDA	O
)	O
neurons	O
.	O

Pitx3	B-GENE-Y
-	O
deficient	O
mice	O
exhibit	O
severe	O
but	O
selective	O
developmental	O
loss	O
of	O
mDA	O
neurons	O
,	O
with	O
accompanying	O
locomotor	O
deficits	O
resembling	O
those	O
seen	O
in	O
Parkinson	O
'	O
s	O
disease	O
(	O
PD	O
)	O
models	O
.	O

Here	O
,	O
we	O
identify	O
specific	O
mDA	O
cell	O
subpopulations	O
that	O
are	O
consistently	O
spared	O
in	O
adult	O
Pitx3	B-GENE-Y
-	O
hypomorphic	O
(	O
aphakia	O
)	O
mice	O
,	O
demonstrating	O
that	O
Pitx3	B-GENE-Y
is	O
not	O
indiscriminately	O
required	O
by	O
all	O
mDA	O
neurons	O
for	O
their	O
survival	O
.	O

In	O
aphakia	O
mice	O
,	O
virtually	O
all	O
surviving	O
mDA	O
neurons	O
in	O
the	O
substantia	O
nigra	O
(	O
SN	O
)	O
and	O
the	O
majority	O
of	O
neurons	O
in	O
the	O
adjacent	O
ventral	O
tegmental	O
area	O
(	O
VTA	O
)	O
also	O
express	O
calbindin	B-GENE-Y
-	O
D28k	B-GENE-Y
,	O
a	O
calcium	B-GENE-N
-	I-GENE-N
binding	I-GENE-N
protein	I-GENE-N
previously	O
associated	O
with	O
resistance	O
to	O
injury	O
in	O
PD	O
and	O
in	O
animal	O
models	O
.	O

Cell	O
-	O
mapping	O
studies	O
in	O
wild	O
-	O
type	O
mice	O
revealed	O
that	O
Pitx3	B-GENE-Y
is	O
primarily	O
expressed	O
in	O
the	O
ventral	O
SN	O
,	O
a	O
region	O
particularly	O
susceptible	O
to	O
MPTP	B-CHEMICAL
and	O
other	O
dopaminergic	O
neurotoxins	O
.	O

Furthermore	O
,	O
Pitx3	B-GENE-Y
-	O
expressing	O
SN	O
cells	O
are	O
preferentially	O
lost	O
following	O
MPTP	B-CHEMICAL
treatment	O
.	O

Finally	O
,	O
SN	O
mDA	O
neurons	O
in	O
Pitx3	B-GENE-Y
hemizygous	O
mice	O
show	O
increased	O
sensitivity	O
when	O
exposed	O
to	O
MPTP	B-CHEMICAL
.	O

Thus	O
,	O
SN	O
mDA	O
neurons	O
are	O
represented	O
by	O
at	O
least	O
two	O
distinct	O
subpopulations	O
including	O
MPTP	B-CHEMICAL
-	O
resistant	O
Pitx3	B-GENE-Y
-	O
autonomous	O
,	O
calbindin	B-GENE-Y
-	O
positive	O
neurons	O
,	O
and	O
calbindin	B-GENE-Y
-	O
negative	O
Pitx	B-GENE-Y
-	I-GENE-Y
3	I-GENE-Y
-	O
dependent	O
cells	O
that	O
display	O
elevated	O
vulnerability	O
to	O
toxic	O
injury	O
,	O
and	O
probably	O
correspond	O
to	O
the	O
subpopulation	O
that	O
degenerates	O
in	O
PD	O
.	O

Impairment	O
of	O
Pitx3	B-GENE-Y
-	O
dependent	O
pathways	O
therefore	O
increases	O
vulnerability	O
of	O
mDA	O
neurons	O
to	O
toxic	O
injury	O
.	O

Together	O
,	O
these	O
data	O
suggest	O
a	O
novel	O
link	O
between	O
Pitx3	B-GENE-Y
function	O
and	O
the	O
selective	O
pattern	O
of	O
mDA	O
cell	O
loss	O
observed	O
in	O
PD	O
.	O

Inactivation	O
of	O
BAD	B-GENE-Y
by	O
IKK	B-GENE-N
inhibits	O
TNF	B-GENE-Y
-	O
induced	O
apoptosis	O
independently	O
of	O
NF	B-GENE-N
-	I-GENE-N
B	I-GENE-N
activation	O
.	O

The	O
IB	B-GENE-N
kinase	I-GENE-N
complex	O
(	O
IKK	B-GENE-N
)	O
is	O
a	O
key	O
regulator	O
of	O
immune	O
responses	O
,	O
inflammation	O
,	O
cell	O
survival	O
,	O
and	O
tumorigenesis	O
.	O

The	O
prosurvival	O
function	O
of	O
IKK	B-GENE-N
centers	O
on	O
activation	O
of	O
the	O
transcription	O
factor	O
NF	B-GENE-N
-	I-GENE-N
B	I-GENE-N
,	O
whose	O
target	O
gene	O
products	O
inhibit	O
caspases	B-GENE-N
and	O
prevent	O
prolonged	O
JNK	B-GENE-N
activation	O
.	O

Here	O
,	O
we	O
report	O
that	O
inactivation	O
of	O
the	O
BH3	B-GENE-N
-	O
only	O
protein	O
BAD	B-GENE-Y
by	O
IKK	B-GENE-N
independently	O
of	O
NF	B-GENE-N
-	I-GENE-N
B	I-GENE-N
activation	O
suppresses	O
TNF	B-GENE-Y
-	O
induced	O
apoptosis	O
.	O

TNF	B-GENE-Y
-	O
treated	O
Ikk	B-GENE-Y
(	O
-	O
/	O
-	O
)	O
mouse	O
embryonic	O
fibroblasts	O
(	O
MEFs	O
)	O
undergo	O
apoptosis	O
significantly	O
faster	O
than	O
MEFs	O
deficient	O
in	O
both	O
RelA	B-GENE-Y
and	O
cRel	B-GENE-Y
due	O
to	O
lack	O
of	O
inhibition	O
of	O
BAD	B-GENE-Y
by	O
IKK	B-GENE-N
.	O

IKK	B-GENE-N
phosphorylates	O
BAD	B-GENE-Y
at	O
serine	B-CHEMICAL
-	O
26	O
(	O
Ser26	B-CHEMICAL
)	O
and	O
primes	O
it	O
for	O
inactivation	O
.	O

Elimination	O
of	O
Ser26	B-CHEMICAL
phosphorylation	O
promotes	O
BAD	B-GENE-Y
proapoptotic	O
activity	O
,	O
thereby	O
accelerating	O
TNF	B-GENE-Y
-	O
induced	O
apoptosis	O
in	O
cultured	O
cells	O
and	O
increasing	O
mortality	O
in	O
animals	O
.	O

Our	O
results	O
reveal	O
that	O
IKK	B-GENE-N
inhibits	O
TNF	B-GENE-Y
-	O
induced	O
apoptosis	O
through	O
two	O
distinct	O
but	O
cooperative	O
mechanisms	O
:	O
activation	O
of	O
the	O
survival	O
factor	O
NF	B-GENE-N
-	I-GENE-N
B	I-GENE-N
and	O
inactivation	O
of	O
the	O
proapoptotic	O
BH3	B-GENE-N
-	O
only	O
BAD	B-GENE-Y
protein	O
.	O

Almorexant	B-CHEMICAL
effects	O
on	O
CYP3A4	B-GENE-Y
activity	O
studied	O
by	O
its	O
simultaneous	O
and	O
time	O
-	O
separated	O
administration	O
with	O
simvastatin	B-CHEMICAL
and	O
atorvastatin	B-CHEMICAL
.	O

PURPOSE	O
:	O
To	O
characterise	O
further	O
the	O
previously	O
observed	O
cytochrome	B-GENE-Y
P450	I-GENE-Y
3A4	I-GENE-Y
(	O
CYP3A4	B-GENE-Y
)	O
interaction	O
of	O
the	O
dual	O
orexin	B-GENE-N
receptor	I-GENE-N
antagonist	O
almorexant	B-CHEMICAL
.	O

METHODS	O
:	O
Pharmacokinetic	O
interactions	O
were	O
investigated	O
(	O
n	O
=	O
14	O
healthy	O
male	O
subjects	O
in	O
two	O
treatment	O
groups	O
)	O
between	O
almorexant	B-CHEMICAL
at	O
steady	O
-	O
state	O
when	O
administered	O
either	O
concomitantly	O
or	O
2	O
h	O
after	O
administration	O
of	O
single	O
doses	O
of	O
simvastatin	B-CHEMICAL
(	O
40	O
mg	O
)	O
or	O
atorvastatin	B-CHEMICAL
(	O
40	O
mg	O
)	O
.	O

RESULTS	O
:	O
Almorexant	B-CHEMICAL
dose	O
-	O
dependently	O
increased	O
simvastatin	B-CHEMICAL
exposure	O
(	O
AUC	O
(	O
0	O
-	O
	O
)	O
)	O
when	O
administered	O
concomitantly	O
[	O
geometric	O
mean	O
ratios	O
(	O
90	O
%	O
CI	O
)	O
:	O
2	O
.	O
5	O
(	O
2	O
.	O
1	O
,	O
2	O
.	O
9	O
)	O
(	O
100	O
mg	O
)	O
,	O
3	O
.	O
9	O
(	O
3	O
.	O
3	O
,	O
4	O
.	O
6	O
)	O
(	O
200	O
mg	O
)	O
]	O
,	O
but	O
not	O
C	O
(	O
max	O
)	O
[	O
3	O
.	O
7	O
(	O
3	O
.	O
0	O
,	O
4	O
.	O
5	O
)	O
for	O
both	O
doses	O
]	O
.	O

Time	O
-	O
separated	O
administration	O
resulted	O
in	O
relevant	O
reductions	O
of	O
the	O
interaction	O
[	O
AUC	O
(	O
0	O
-	O
	O
)	O
:	O
1	O
.	O
4	O
(	O
1	O
.	O
2	O
,	O
1	O
.	O
7	O
)	O
(	O
100	O
mg	O
)	O
,	O
1	O
.	O
7	O
(	O
1	O
.	O
5	O
,	O
2	O
.	O
0	O
)	O
(	O
200	O
mg	O
)	O
;	O
C	O
(	O
max	O
)	O
:	O
1	O
.	O
5	O
(	O
1	O
.	O
3	O
,	O
1	O
.	O
9	O
)	O
(	O
100	O
mg	O
)	O
,	O
1	O
.	O
9	O
(	O
1	O
.	O
6	O
,	O
2	O
.	O
4	O
)	O
(	O
200	O
mg	O
)	O
]	O
.	O

Similar	O
results	O
were	O
obtained	O
for	O
hydroxyacid	B-CHEMICAL
simvastatin	I-CHEMICAL
.	O

Independent	O
of	O
almorexant	B-CHEMICAL
dose	O
and	O
relative	O
time	O
of	O
administration	O
,	O
AUC	O
(	O
0	O
-	O
	O
)	O
and	O
C	O
(	O
max	O
)	O
of	O
atorvastatin	B-CHEMICAL
increased	O
(	O
ratios	O
ranged	O
from	O
1	O
.	O
1	O
to	O
1	O
.	O
5	O
)	O
.	O

AUC	O
(	O
0	O
-	O
	O
)	O
and	O
C	O
(	O
max	O
)	O
of	O
o	B-CHEMICAL
-	I-CHEMICAL
hydroxy	I-CHEMICAL
atorvastatin	I-CHEMICAL
decreased	O
dose	O
-	O
independently	O
[	O
AUC	O
(	O
0	O
-	O
	O
)	O
:	O
0	O
.	O
8	O
(	O
0	O
.	O
8	O
,	O
0	O
.	O
9	O
)	O
(	O
100	O
mg	O
)	O
,	O
0	O
.	O
6	O
(	O
0	O
.	O
5	O
,	O
0	O
.	O
6	O
)	O
(	O
200	O
mg	O
)	O
;	O
C	O
(	O
max	O
)	O
:	O
0	O
.	O
3	O
(	O
0	O
.	O
3	O
,	O
0	O
.	O
4	O
)	O
(	O
100	O
mg	O
)	O
,	O
0	O
.	O
2	O
(	O
0	O
.	O
2	O
,	O
0	O
.	O
3	O
)	O
(	O
200	O
mg	O
)	O
]	O
when	O
atorvastatin	B-CHEMICAL
was	O
concomitantly	O
administered	O
.	O

C	O
(	O
max	O
)	O
of	O
o	B-CHEMICAL
-	I-CHEMICAL
hydroxy	I-CHEMICAL
atorvastatin	I-CHEMICAL
slightly	O
decreased	O
(	O
0	O
.	O
8	O
for	O
both	O
doses	O
)	O
following	O
time	O
-	O
separated	O
administration	O
;	O
AUC	O
(	O
0	O
-	O
	O
)	O
was	O
unchanged	O
.	O

CONCLUSIONS	O
:	O
Whereas	O
almorexant	B-CHEMICAL
increased	O
simvastatin	B-CHEMICAL
exposure	O
dose	O
-	O
and	O
relative	O
time	O
of	O
administration	O
-	O
dependently	O
,	O
atorvastatin	B-CHEMICAL
exposure	O
increased	O
to	O
a	O
smaller	O
extent	O
and	O
irrespective	O
of	O
dose	O
and	O
time	O
.	O

This	O
suggests	O
that	O
the	O
observed	O
interaction	O
of	O
almorexant	B-CHEMICAL
with	O
simvastatin	B-CHEMICAL
is	O
mainly	O
caused	O
by	O
intestinal	O
CYP3A4	B-GENE-Y
inhibition	O
,	O
whereas	O
the	O
interaction	O
with	O
atorvastatin	B-CHEMICAL
is	O
more	O
due	O
to	O
hepatic	O
CYP3A4	B-GENE-Y
inhibition	O
.	O

Assessment	O
of	O
effects	O
of	O
IR	O
and	O
IPC	O
on	O
activities	O
of	O
cytochrome	B-GENE-N
P450	I-GENE-N
isozymes	O
in	O
rats	O
by	O
a	O
five	O
-	O
drug	O
cocktail	O
approach	O
.	O

Abstract	O
Background	O
and	O
objective	O
:	O
To	O
evaluate	O
the	O
effects	O
of	O
ischemia	O
and	O
reperfusion	O
(	O
IR	O
)	O
and	O
ischemic	O
preconditioning	O
(	O
IPC	O
)	O
on	O
the	O
metabolic	O
activities	O
of	O
cytochrome	B-GENE-N
P450	I-GENE-N
(	O
CYP	B-GENE-N
)	O
isozymes	O
in	O
rats	O
by	O
a	O
five	O
-	O
drug	O
cocktail	O
approach	O
.	O

Methods	O
:	O
Cocktail	O
approach	O
was	O
used	O
to	O
evaluate	O
the	O
influence	O
of	O
IR	O
and	O
IPC	O
on	O
the	O
activities	O
of	O
CYP1A2	B-GENE-Y
,	O
CYP2C9	B-GENE-Y
,	O
CYP2E1	B-GENE-Y
,	O
CYP2D6	B-GENE-Y
and	O
CYP3A4	B-GENE-Y
,	O
which	O
were	O
reflected	O
by	O
the	O
changes	O
of	O
pharmacokinetic	O
parameters	O
of	O
five	O
specific	O
probe	O
drugs	O
:	O
caffeine	B-CHEMICAL
,	O
chlorzoxazone	B-CHEMICAL
,	O
tolbutamide	B-CHEMICAL
,	O
metoprolol	B-CHEMICAL
and	O
midazolam	B-CHEMICAL
,	O
respectively	O
.	O

Rats	O
were	O
randomly	O
divided	O
into	O
IR	O
,	O
IPC	O
and	O
sham	O
groups	O
,	O
and	O
then	O
injected	O
the	O
mixture	O
of	O
five	O
probe	O
drugs	O
.	O

Blood	O
samples	O
were	O
collected	O
at	O
a	O
series	O
of	O
time	O
-	O
points	O
and	O
the	O
concentrations	O
of	O
probe	O
drugs	O
in	O
plasma	O
were	O
determined	O
by	O
a	O
HPLC	O
method	O
with	O
UV	O
detection	O
.	O

The	O
pharmacokinetic	O
parameters	O
were	O
calculated	O
by	O
the	O
software	O
of	O
DAS	O
2	O
.	O
0	O
.	O

Results	O
:	O
The	O
parameters	O
including	O
t	O
(	O
1	O
/	O
2	O
)	O
,	O
CLs	O
,	O
AUC	O
,	O
MRT	O
and	O
K	O
(	O
10	O
)	O
exhibited	O
a	O
similar	O
tendency	O
for	O
both	O
IR	O
and	O
IPC	O
groups	O
.	O

Compared	O
with	O
sham	O
group	O
,	O
CLs	O
and	O
K	O
(	O
10	O
)	O
of	O
five	O
probe	O
drugs	O
were	O
significantly	O
lower	O
(	O
p	O
<	O
0	O
.	O
05	O
)	O
,	O
AUC	O
and	O
t	O
(	O
1	O
/	O
2	O
)	O
of	O
five	O
or	O
some	O
probe	O
drugs	O
were	O
significantly	O
increased	O
in	O
IR	O
and	O
IPC	O
groups	O
(	O
p	O
<	O
0	O
.	O
05	O
)	O
.	O

Compared	O
with	O
IPC	O
group	O
,	O
CLs	O
of	O
five	O
probe	O
drugs	O
were	O
decreased	O
and	O
AUC	O
were	O
significantly	O
increased	O
in	O
the	O
IR	O
group	O
(	O
p	O
<	O
0	O
.	O
05	O
)	O
.	O

Conclusion	O
:	O
IR	O
can	O
variably	O
decrease	O
the	O
activities	O
of	O
CYP	B-GENE-N
isozymes	I-GENE-N
in	O
rats	O
and	O
this	O
decrease	O
can	O
be	O
attenuated	O
by	O
IPC	O
.	O

The	O
factor	B-GENE-Y
VII	I-GENE-Y
-	I-GENE-Y
activating	I-GENE-Y
protease	I-GENE-Y
(	O
FSAP	B-GENE-Y
)	O
enhances	O
the	O
activity	O
of	O
bone	B-GENE-Y
morphogenetic	I-GENE-Y
protein	I-GENE-Y
-	I-GENE-Y
2	I-GENE-Y
(	O
BMP	B-GENE-Y
-	I-GENE-Y
2	I-GENE-Y
)	O
.	O

Factor	B-GENE-Y
VII	I-GENE-Y
-	I-GENE-Y
activating	I-GENE-Y
protease	I-GENE-Y
(	O
FSAP	B-GENE-Y
)	O
is	O
a	O
circulating	O
protease	B-GENE-N
involved	O
in	O
the	O
pathogenesis	O
of	O
atherosclerosis	O
,	O
calcification	O
,	O
and	O
fibrotic	O
processes	O
.	O

To	O
understand	O
how	O
FSAP	B-GENE-Y
controls	O
the	O
balance	O
of	O
local	O
growth	O
factors	O
,	O
we	O
have	O
investigated	O
its	O
effect	O
on	O
the	O
regulation	O
of	O
bone	B-GENE-N
morphogenetic	I-GENE-N
proteins	I-GENE-N
(	O
BMPs	B-GENE-N
)	O
.	O

BMP	B-GENE-Y
-	I-GENE-Y
2	I-GENE-Y
is	O
produced	O
as	O
a	O
large	O
pro	O
-	O
form	O
and	O
secreted	O
as	O
a	O
mature	O
heparin	B-GENE-Y
-	I-GENE-Y
binding	I-GENE-Y
growth	I-GENE-Y
factor	I-GENE-Y
after	O
intracellular	O
processing	O
by	O
pro	B-GENE-N
-	I-GENE-N
protein	I-GENE-N
convertases	I-GENE-N
(	O
PCs	B-GENE-N
)	O
.	O

In	O
this	O
study	O
,	O
we	O
discovered	O
that	O
FSAP	B-GENE-Y
enhances	O
the	O
biological	O
activity	O
of	O
mature	O
BMP	B-GENE-Y
-	I-GENE-Y
2	I-GENE-Y
as	O
well	O
as	O
its	O
pro	O
-	O
form	O
,	O
as	O
shown	O
by	O
osteogenic	O
differentiation	O
of	O
C2C12	O
myoblasts	O
.	O

These	O
findings	O
were	O
complemented	O
by	O
knockdown	O
of	O
FSAP	B-GENE-Y
in	O
hepatocytes	O
,	O
which	O
revealed	O
BMP	B-GENE-Y
-	I-GENE-Y
2	I-GENE-Y
processing	O
by	O
endogenous	O
FSAP	B-GENE-Y
.	O

N	B-CHEMICAL
-	O
terminal	O
sequencing	O
indicated	O
that	O
pro	B-GENE-Y
-	I-GENE-Y
BMP	I-GENE-Y
-	I-GENE-Y
2	I-GENE-Y
was	O
cleaved	O
by	O
FSAP	B-GENE-Y
at	O
the	O
canonical	O
PC	B-GENE-N
cleavage	I-GENE-N
site	I-GENE-N
,	O
giving	O
rise	O
to	O
mature	O
BMP	B-GENE-Y
-	I-GENE-Y
2	I-GENE-Y
(	O
Arg	B-CHEMICAL
(	O
282	O
)	O
	O
Gln	B-CHEMICAL
(	O
283	O
)	O
)	O
,	O
as	O
well	O
as	O
in	O
the	O
N	B-GENE-N
-	I-GENE-N
terminal	I-GENE-N
heparin	I-GENE-N
binding	I-GENE-N
region	I-GENE-N
of	O
mature	O
BMP	B-GENE-Y
-	I-GENE-Y
2	I-GENE-Y
,	O
generating	O
a	O
truncated	O
mature	O
BMP	B-GENE-Y
-	I-GENE-Y
2	I-GENE-Y
peptide	O
(	O
Arg	B-CHEMICAL
(	O
289	O
)	O
	O
Lys	B-CHEMICAL
(	O
290	O
)	O
)	O
.	O

Similarly	O
,	O
mature	O
BMP	B-GENE-Y
-	I-GENE-Y
2	I-GENE-Y
was	O
also	O
cleaved	O
to	O
a	O
truncated	O
peptide	O
within	O
its	O
N	B-CHEMICAL
-	O
terminal	O
region	O
(	O
Arg	B-CHEMICAL
(	O
289	O
)	O
	O
Lys	B-CHEMICAL
(	O
290	O
)	O
)	O
.	O

Plasmin	B-GENE-Y
exhibited	O
a	O
similar	O
activity	O
,	O
but	O
it	O
was	O
weaker	O
compared	O
with	O
FSAP	B-GENE-Y
.	O

Thrombin	B-GENE-Y
,	O
Factor	B-GENE-Y
VIIa	I-GENE-Y
,	O
Factor	B-GENE-Y
Xa	I-GENE-Y
,	O
and	O
activated	B-GENE-Y
protein	I-GENE-Y
C	I-GENE-Y
were	O
not	O
effective	O
.	O

These	O
results	O
were	O
further	O
supported	O
by	O
the	O
observation	O
that	O
the	O
mutation	O
of	O
the	O
heparin	B-GENE-N
binding	I-GENE-N
region	I-GENE-N
of	O
BMP	B-GENE-Y
-	I-GENE-Y
2	I-GENE-Y
inhibited	O
the	O
processing	O
by	O
FSAP	B-GENE-Y
but	O
not	O
by	O
PC	B-GENE-N
.	O

Thus	O
,	O
the	O
proteolysis	O
and	O
activation	O
of	O
pro	B-GENE-Y
-	I-GENE-Y
BMP	I-GENE-Y
-	I-GENE-Y
2	I-GENE-Y
and	O
mature	O
BMP	B-GENE-Y
-	I-GENE-Y
2	I-GENE-Y
by	O
FSAP	B-GENE-Y
can	O
regulate	O
cell	O
differentiation	O
and	O
calcification	O
in	O
vasculature	O
and	O
may	O
explain	O
why	O
polymorphisms	O
in	O
the	O
gene	O
encoding	O
for	O
FSAP	B-GENE-Y
are	O
related	O
to	O
vascular	O
diseases	O
.	O

A	O
brief	O
history	O
of	O
oxytocin	B-CHEMICAL
and	O
its	O
role	O
in	O
modulating	O
psychostimulant	O
effects	O
.	O

Over	O
the	O
past	O
century	O
,	O
the	O
polypeptide	O
oxytocin	B-CHEMICAL
has	O
played	O
an	O
important	O
role	O
in	O
medicine	O
with	O
major	O
highlights	O
including	O
the	O
identification	O
of	O
its	O
involvement	O
in	O
parturition	O
and	O
the	O
milk	O
let	O
-	O
down	O
reflex	O
.	O

Oxytocin	B-CHEMICAL
is	O
now	O
implicated	O
in	O
an	O
extensive	O
range	O
of	O
psychological	O
phenomena	O
including	O
reward	O
and	O
memory	O
processes	O
and	O
has	O
been	O
investigated	O
as	O
a	O
treatment	O
for	O
several	O
psychiatric	O
disorders	O
including	O
addiction	O
,	O
anxiety	O
,	O
autism	O
,	O
and	O
schizophrenia	O
.	O

In	O
this	O
review	O
,	O
we	O
first	O
provide	O
an	O
historical	O
overview	O
of	O
oxytocin	B-CHEMICAL
and	O
describe	O
key	O
aspects	O
of	O
its	O
physiological	O
activity	O
.	O

We	O
then	O
outline	O
some	O
pharmacological	O
limitations	O
in	O
this	O
field	O
of	O
research	O
before	O
highlighting	O
the	O
role	O
of	O
oxytocin	B-CHEMICAL
in	O
a	O
wide	O
range	O
of	O
behavioral	O
and	O
neuronal	O
processes	O
.	O

Finally	O
,	O
we	O
review	O
evidence	O
for	O
a	O
modulatory	O
role	O
of	O
oxytocin	B-CHEMICAL
with	O
regard	O
to	O
psychostimulant	O
effects	O
.	O

Key	O
findings	O
suggest	O
that	O
oxytocin	B-CHEMICAL
attenuates	O
a	O
broad	O
number	O
of	O
cocaine	B-CHEMICAL
and	O
methamphetamine	B-CHEMICAL
induced	O
behaviors	O
and	O
associated	O
neuronal	O
activity	O
in	O
rodents	O
.	O

Evidence	O
also	O
outlines	O
a	O
role	O
for	O
oxytocin	B-CHEMICAL
in	O
the	O
prosocial	O
effects	O
of	O
3	B-CHEMICAL
,	I-CHEMICAL
4	I-CHEMICAL
-	I-CHEMICAL
methylenedioxymethamphetamine	I-CHEMICAL
(	O
MDMA	B-CHEMICAL
,	O
Ecstasy	B-CHEMICAL
)	O
in	O
both	O
rodents	O
and	O
humans	O
.	O

Clinical	O
trials	O
should	O
now	O
investigate	O
the	O
effectiveness	O
of	O
oxytocin	B-CHEMICAL
as	O
a	O
novel	O
intervention	O
for	O
psychostimulant	O
addiction	O
and	O
should	O
aim	O
to	O
determine	O
its	O
specific	O
role	O
in	O
the	O
therapeutic	O
properties	O
of	O
MDMA	B-CHEMICAL
that	O
are	O
currently	O
being	O
investigated	O
.	O

The	O
type	O
2	O
diabetes	O
associated	O
gene	O
Ide	B-GENE-Y
is	O
required	O
for	O
insulin	B-GENE-N
secretion	O
and	O
suppression	O
of	O
	B-GENE-Y
-	I-GENE-Y
synuclein	I-GENE-Y
levels	O
in	O
	O
-	O
cells	O
.	O

Genome	O
wide	O
association	O
studies	O
have	O
identified	O
several	O
type	O
2	O
diabetes	O
(	O
T2D	O
)	O
risk	O
loci	O
linked	O
to	O
impaired	O
	O
-	O
cell	O
function	O
.	O

The	O
identity	O
and	O
function	O
of	O
the	O
causal	O
genes	O
in	O
these	O
susceptibility	O
loci	O
remain	O
,	O
however	O
,	O
elusive	O
.	O

The	O
HHEX	B-GENE-Y
/	O
IDE	B-GENE-Y
T2D	O
locus	O
is	O
associated	O
with	O
decreased	O
insulin	B-GENE-Y
secretion	O
in	O
response	O
to	O
oral	O
glucose	B-CHEMICAL
stimulation	O
in	O
humans	O
.	O

Here	O
we	O
have	O
assessed	O
	O
-	O
cell	O
function	O
in	O
Ide	B-GENE-Y
knock	O
-	O
out	O
(	O
KO	O
)	O
mice	O
.	O

We	O
find	O
that	O
glucose	B-CHEMICAL
stimulated	O
insulin	B-GENE-N
secretion	O
(	O
GSIS	O
)	O
is	O
decreased	O
in	O
Ide	B-GENE-Y
KO	O
mice	O
due	O
to	O
impaired	O
replenishment	O
of	O
the	O
releasable	O
pool	O
of	O
granules	O
and	O
that	O
the	O
Ide	B-GENE-Y
gene	O
is	O
haploinsufficient	O
.	O

We	O
also	O
show	O
that	O
autophagic	O
flux	O
and	O
microtubule	B-GENE-N
content	O
is	O
reduced	O
in	O
	O
-	O
cells	O
of	O
Ide	B-GENE-Y
KO	O
mice	O
.	O

One	O
important	O
cellular	O
role	O
for	O
IDE	B-GENE-Y
involves	O
the	O
neutralization	O
of	O
amyloidogenic	O
proteins	O
and	O
we	O
find	O
that	O
	B-GENE-Y
-	I-GENE-Y
synuclein	I-GENE-Y
and	O
IDE	B-GENE-Y
levels	O
are	O
inversely	O
correlated	O
in	O
	O
-	O
cells	O
of	O
Ide	B-GENE-Y
KO	O
mice	O
and	O
T2D	O
patients	O
.	O

Moreover	O
,	O
we	O
provide	O
evidence	O
that	O
both	O
gain	O
-	O
and	O
loss	O
-	O
of	O
-	O
function	O
of	O
	B-GENE-Y
-	I-GENE-Y
synuclein	I-GENE-Y
in	O
	O
-	O
cells	O
in	O
vivo	O
not	O
only	O
impair	O
GSIS	O
but	O
also	O
autophagy	O
.	O

Together	O
,	O
these	O
data	O
identify	O
the	O
Ide	B-GENE-Y
gene	O
as	O
a	O
regulator	O
of	O
GSIS	O
,	O
suggest	O
a	O
molecular	O
mechanism	O
for	O
	O
-	O
cell	O
degeneration	O
as	O
a	O
consequence	O
of	O
Ide	B-GENE-Y
deficiency	O
,	O
and	O
additionally	O
corroborates	O
and	O
extends	O
a	O
previously	O
established	O
important	O
role	O
for	O
	B-GENE-Y
-	I-GENE-Y
synuclein	I-GENE-Y
in	O
	O
-	O
cell	O
function	O
.	O

	O
-	O
Cells	O
Are	O
Not	O
Generated	O
in	O
Pancreatic	O
Duct	O
Ligation	O
-	O
Induced	O
Injury	O
in	O
Adult	O
Mice	O
.	O

The	O
existence	O
of	O
adult	O
	O
-	O
cell	O
progenitors	O
remains	O
the	O
most	O
controversial	O
developmental	O
biology	O
topic	O
in	O
diabetes	O
research	O
.	O

It	O
has	O
been	O
reported	O
that	O
	O
-	O
cell	O
progenitors	O
can	O
be	O
activated	O
by	O
ductal	O
ligation	O
-	O
induced	O
injury	O
of	O
adult	O
mouse	O
pancreas	O
and	O
apparently	O
act	O
in	O
a	O
cell	O
-	O
autonomous	O
manner	O
to	O
double	O
the	O
functional	O
	O
-	O
cell	O
mass	O
within	O
a	O
week	O
by	O
differentiation	O
and	O
proliferation	O
.	O

Here	O
,	O
we	O
demonstrate	O
that	O
pancreatic	O
duct	O
ligation	O
(	O
PDL	O
)	O
does	O
not	O
activate	O
progenitors	O
to	O
contribute	O
to	O
	O
-	O
cell	O
mass	O
expansion	O
.	O

Rather	O
,	O
PDL	O
stimulates	O
massive	O
pancreatic	O
injury	O
,	O
which	O
alters	O
pancreatic	O
composition	O
and	O
thus	O
complicates	O
accurate	O
measurement	O
of	O
	O
-	O
cell	O
content	O
via	O
traditional	O
morphometry	O
methodologies	O
that	O
superficially	O
sample	O
the	O
pancreas	O
.	O

To	O
overcome	O
this	O
potential	O
bias	O
,	O
we	O
quantified	O
	O
-	O
cells	O
from	O
the	O
entire	O
pancreas	O
and	O
observed	O
that	O
	O
-	O
cell	O
mass	O
and	O
insulin	B-GENE-N
content	O
are	O
totally	O
unchanged	O
by	O
PDL	O
-	O
induced	O
injury	O
.	O

Lineage	O
-	O
tracing	O
studies	O
using	O
sequential	O
administration	O
of	O
thymidine	B-CHEMICAL
analogs	O
,	O
rat	B-GENE-N
insulin	I-GENE-N
2	I-GENE-N
promoter	I-GENE-N
-	O
driven	O
cre	B-GENE-N
-	O
lox	B-GENE-N
,	O
and	O
low	O
-	O
frequency	O
ubiquitous	O
cre	B-GENE-N
-	O
lox	B-GENE-N
reveal	O
that	O
PDL	O
does	O
not	O
convert	O
progenitors	O
to	O
the	O
	O
-	O
cell	O
lineage	O
.	O

Thus	O
,	O
we	O
conclude	O
that	O
	O
-	O
cells	O
are	O
not	O
generated	O
in	O
injured	O
adult	O
mouse	O
pancreas	O
.	O

Support	O
for	O
5	B-GENE-Y
-	I-GENE-Y
HT2C	I-GENE-Y
receptor	O
functional	O
selectivity	O
in	O
vivo	O
utilizing	O
structurally	O
diverse	O
,	O
selective	O
5	B-GENE-Y
-	I-GENE-Y
HT2C	I-GENE-Y
receptor	O
ligands	O
and	O
the	O
2	B-CHEMICAL
,	I-CHEMICAL
5	I-CHEMICAL
-	I-CHEMICAL
dimethoxy	I-CHEMICAL
-	I-CHEMICAL
4	I-CHEMICAL
-	I-CHEMICAL
iodoamphetamine	I-CHEMICAL
elicited	O
head	O
-	O
twitch	O
response	O
model	O
.	O

There	O
are	O
seemingly	O
conflicting	O
data	O
in	O
the	O
literature	O
regarding	O
the	O
role	O
of	O
serotonin	B-CHEMICAL
(	O
5	B-CHEMICAL
-	I-CHEMICAL
HT	I-CHEMICAL
)	O
5	B-GENE-Y
-	I-GENE-Y
HT2C	I-GENE-Y
receptors	O
in	O
the	O
mouse	O
head	O
-	O
twitch	O
response	O
(	O
HTR	O
)	O
elicited	O
by	O
the	O
hallucinogenic	O
5	B-GENE-N
-	I-GENE-N
HT2A	I-GENE-N
/	I-GENE-N
2B	I-GENE-N
/	I-GENE-N
2C	I-GENE-N
receptor	I-GENE-N
agonist	O
2	B-CHEMICAL
,	I-CHEMICAL
5	I-CHEMICAL
-	I-CHEMICAL
dimethoxy	I-CHEMICAL
-	I-CHEMICAL
4	I-CHEMICAL
-	I-CHEMICAL
iodoamphetamine	I-CHEMICAL
(	O
DOI	B-CHEMICAL
)	O
.	O

Namely	O
,	O
both	O
5	B-GENE-Y
-	I-GENE-Y
HT2C	I-GENE-Y
receptor	O
agonists	O
and	O
antagonists	O
,	O
regarding	O
5	B-GENE-Y
-	I-GENE-Y
HT2C	I-GENE-Y
receptor	O
-	O
mediated	O
Gq	B-GENE-N
-	O
phospholipase	B-GENE-N
C	I-GENE-N
(	O
PLC	B-GENE-N
)	O
signaling	O
,	O
reportedly	O
attenuate	O
the	O
HTR	O
response	O
.	O

The	O
present	O
experiments	O
tested	O
the	O
hypothesis	O
that	O
both	O
classes	O
of	O
5	B-GENE-Y
-	I-GENE-Y
HT2C	I-GENE-Y
receptor	O
compounds	O
could	O
attenuate	O
the	O
DOI	B-CHEMICAL
-	O
elicited	O
-	O
HTR	O
in	O
a	O
single	O
strain	O
of	O
mice	O
,	O
C57Bl	O
/	O
6J	O
.	O

The	O
expected	O
results	O
were	O
considered	O
in	O
accordance	O
with	O
ligand	O
functional	O
selectivity	O
.	O

Commercially	O
-	O
available	O
5	B-GENE-Y
-	I-GENE-Y
HT2C	I-GENE-Y
agonists	O
(	O
CP	B-CHEMICAL
809101	I-CHEMICAL
,	O
Ro	B-CHEMICAL
60	I-CHEMICAL
-	I-CHEMICAL
0175	I-CHEMICAL
,	O
WAY	B-CHEMICAL
161503	I-CHEMICAL
,	O
mCPP	B-CHEMICAL
,	O
and	O
1	B-CHEMICAL
-	I-CHEMICAL
methylpsilocin	I-CHEMICAL
)	O
,	O
novel	O
4	B-CHEMICAL
-	I-CHEMICAL
phenyl	I-CHEMICAL
-	I-CHEMICAL
2	I-CHEMICAL
-	I-CHEMICAL
N	I-CHEMICAL
,	I-CHEMICAL
N	I-CHEMICAL
-	I-CHEMICAL
dimethyl	I-CHEMICAL
-	I-CHEMICAL
aminotetralin	I-CHEMICAL
(	O
PAT	B-CHEMICAL
)	O
-	O
type	O
5	B-GENE-Y
-	I-GENE-Y
HT2C	I-GENE-Y
agonists	O
(	O
with	O
5	B-GENE-N
-	I-GENE-N
HT2A	I-GENE-N
/	I-GENE-N
2B	I-GENE-N
antagonist	O
activity	O
)	O
,	O
and	O
antagonists	O
selective	O
for	O
5	B-GENE-Y
-	I-GENE-Y
HT2A	I-GENE-Y
(	O
M100907	B-CHEMICAL
)	O
,	O
5	B-GENE-Y
-	I-GENE-Y
HT2C	I-GENE-Y
(	O
SB	B-CHEMICAL
-	I-CHEMICAL
242084	I-CHEMICAL
)	O
,	O
and	O
5	B-GENE-N
-	I-GENE-N
HT2B	I-GENE-N
/	I-GENE-N
2C	I-GENE-N
(	O
SB	B-CHEMICAL
-	I-CHEMICAL
206553	I-CHEMICAL
)	O
receptors	O
attenuated	O
the	O
DOI	B-CHEMICAL
-	O
elicited	O
-	O
HTR	O
.	O

In	O
contrast	O
,	O
there	O
were	O
differential	O
effects	O
on	O
locomotion	O
across	O
classes	O
of	O
compounds	O
.	O

The	O
5	B-GENE-Y
-	I-GENE-Y
HT2C	I-GENE-Y
agonists	O
and	O
M100907	B-CHEMICAL
decreased	O
locomotion	O
,	O
SB	B-CHEMICAL
-	I-CHEMICAL
242084	I-CHEMICAL
increased	O
locomotion	O
,	O
SB	B-CHEMICAL
-	I-CHEMICAL
206553	I-CHEMICAL
resulted	O
in	O
dose	O
-	O
dependent	O
biphasic	O
effects	O
on	O
locomotion	O
,	O
and	O
the	O
PATs	O
did	O
not	O
alter	O
locomotion	O
.	O

In	O
vitro	O
molecular	O
pharmacology	O
studies	O
showed	O
that	O
5	B-GENE-Y
-	I-GENE-Y
HT2C	I-GENE-Y
agonists	O
potent	O
for	O
attenuating	O
the	O
DOI	B-CHEMICAL
-	O
elicited	O
-	O
HTR	O
also	O
reduced	O
the	O
efficacy	O
of	O
DOI	B-CHEMICAL
to	O
activate	O
mouse	B-GENE-Y
5	I-GENE-Y
-	I-GENE-Y
HT2C	I-GENE-Y
receptor	O
-	O
mediated	O
PLC	B-GENE-N
signaling	O
in	O
HEK	O
cells	O
.	O

Although	O
there	O
were	O
differences	O
in	O
affinities	O
of	O
a	O
few	O
compounds	O
at	O
mouse	O
compared	O
to	O
human	B-GENE-Y
5	I-GENE-Y
-	I-GENE-Y
HT2A	I-GENE-Y
or	O
5	B-GENE-Y
-	I-GENE-Y
HT2C	I-GENE-Y
receptors	O
,	O
all	O
compounds	O
tested	O
retained	O
their	O
selectivity	O
for	O
either	O
receptor	O
,	O
regardless	O
of	O
receptor	O
species	O
.	O

Results	O
indicate	O
that	O
5	B-GENE-N
-	I-GENE-N
HT2C	I-GENE-N
receptor	O
agonists	O
and	O
antagonists	O
attenuate	O
the	O
DOI	B-CHEMICAL
-	O
elicited	O
-	O
HTR	O
in	O
C57Bl	O
/	O
6J	O
mice	O
,	O
and	O
suggest	O
that	O
structurally	O
diverse	O
5	B-GENE-Y
-	I-GENE-Y
HT2C	I-GENE-Y
ligands	O
result	O
in	O
different	O
5	B-GENE-Y
-	I-GENE-Y
HT2C	I-GENE-Y
receptor	O
signaling	O
outcomes	O
compared	O
to	O
DOI	B-CHEMICAL
.	O

Role	O
of	O
cytochrome	B-GENE-Y
P4502B6	I-GENE-Y
in	O
methadone	B-CHEMICAL
metabolism	O
and	O
clearance	O
.	O

Methadone	B-CHEMICAL
N	B-CHEMICAL
-	O
demethylation	O
in	O
vitro	O
is	O
catalyzed	O
by	O
hepatic	O
cytochrome	B-GENE-Y
P4502B6	I-GENE-Y
(	O
CYP2B6	B-GENE-Y
)	O
and	O
CYP3A4	B-GENE-Y
,	O
but	O
clinical	O
disposition	O
is	O
often	O
attributed	O
to	O
CYP3A4	B-GENE-Y
.	O

This	O
investigation	O
tested	O
the	O
hypothesis	O
that	O
CYP2B6	B-GENE-Y
is	O
a	O
prominent	O
CYP	B-GENE-N
isoform	O
responsible	O
for	O
clinical	O
methadone	B-CHEMICAL
N	B-CHEMICAL
-	O
demethylation	O
and	O
clearance	O
,	O
using	O
the	O
in	O
vivo	O
mechanism	O
-	O
based	O
CYP2B6	B-GENE-Y
inhibitor	O
ticlopidine	B-CHEMICAL
,	O
given	O
orally	O
for	O
4	O
days	O
.	O

A	O
preliminary	O
clinical	O
investigation	O
with	O
the	O
CYP3A4	B-GENE-N
/	I-GENE-N
5	I-GENE-N
substrate	O
probe	O
alfentanil	B-CHEMICAL
established	O
that	O
ticlopidine	B-CHEMICAL
did	O
not	O
inhibit	O
intestinal	O
or	O
hepatic	O
CYP3A4	B-GENE-N
/	I-GENE-N
5	I-GENE-N
.	O

Subjects	O
received	O
intravenous	O
plus	O
oral	O
(	O
deuterium	B-CHEMICAL
-	O
labeled	O
)	O
racemic	B-CHEMICAL
methadone	I-CHEMICAL
before	O
and	O
after	O
ticlopidine	B-CHEMICAL
.	O

Ticlopidine	B-CHEMICAL
significantly	O
and	O
stereoselectively	O
(	O
S	O
>	O
R	O
)	O
inhibited	O
methadone	B-CHEMICAL
N	B-CHEMICAL
-	O
demethylation	O
,	O
decreasing	O
plasma	O
metabolite	O
/	O
methadone	B-CHEMICAL
area	O
under	O
the	O
curve	O
ratios	O
and	O
metabolite	O
formation	O
clearances	O
.	O

Ticlopidine	B-CHEMICAL
also	O
significantly	O
increased	O
the	O
dose	O
-	O
adjusted	O
plasma	O
area	O
under	O
the	O
curve	O
for	O
R	B-CHEMICAL
-	I-CHEMICAL
and	I-CHEMICAL
S	I-CHEMICAL
-	I-CHEMICAL
methadone	I-CHEMICAL
by	O
20	O
%	O
and	O
60	O
%	O
,	O
respectively	O
,	O
after	O
both	O
intravenous	O
and	O
oral	O
dosing	O
.	O

CYP2B6	B-GENE-Y
inhibition	O
reduces	O
methadone	B-CHEMICAL
N	B-CHEMICAL
-	O
demethylation	O
and	O
clearance	O
,	O
and	O
alters	O
methadone	B-CHEMICAL
concentrations	O
,	O
demonstrating	O
an	O
important	O
role	O
for	O
CYP2B6	B-GENE-Y
in	O
clinical	O
methadone	B-CHEMICAL
disposition	O
.	O

Computationally	O
assisted	O
assignment	O
of	O
kahalalide	B-CHEMICAL
Y	I-CHEMICAL
configuration	O
using	O
an	O
NMR	O
-	O
constrained	O
conformational	O
search	O
.	O

Assignment	O
of	O
the	O
absolute	O
configuration	O
of	O
cyclic	O
peptides	O
frequently	O
yields	O
challenges	O
,	O
leaving	O
one	O
or	O
more	O
stereogenic	O
centers	O
unassigned	O
due	O
to	O
small	O
quantities	O
of	O
sample	O
and	O
the	O
limited	O
utility	O
of	O
Marfey	O
'	O
s	O
or	O
other	O
methods	O
for	O
assigning	O
amino	B-CHEMICAL
or	I-CHEMICAL
hydroxy	I-CHEMICAL
acids	I-CHEMICAL
.	O

Here	O
,	O
we	O
report	O
isolation	O
of	O
kahalalide	B-CHEMICAL
Y	I-CHEMICAL
(	O
1	O
)	O
from	O
Bryopsis	O
pennata	O
for	O
the	O
first	O
time	O
;	O
in	O
addition	O
,	O
the	O
application	O
of	O
a	O
combination	O
of	O
molecular	O
modeling	O
and	O
NOE	O
distance	O
constraint	O
calculations	O
was	O
utilized	O
to	O
determine	O
the	O
conformation	O
of	O
1	O
and	O
the	O
absolute	O
configuration	O
of	O
the	O
final	O
stereogenic	O
center	O
of	O
1	O
.	O

Using	O
the	O
Schrdinger	O
suite	O
,	O
the	O
structure	O
of	O
1	O
was	O
sketched	O
in	O
Maestro	O
and	O
minimized	O
using	O
the	O
OPLS2005	O
force	O
field	O
in	O
Macromodel	O
.	O

A	O
conformational	O
search	O
was	O
performed	O
separately	O
for	O
structures	O
having	O
an	O
R	O
or	O
S	O
configuration	O
at	O
C	O
-	O
3	O
of	O
the	O
beta	B-CHEMICAL
-	I-CHEMICAL
hydroxy	I-CHEMICAL
fatty	I-CHEMICAL
acid	I-CHEMICAL
subunit	O
that	O
completes	O
the	O
cyclic	O
scaffold	O
of	O
1	O
,	O
after	O
which	O
multiple	O
minimizations	O
for	O
all	O
generated	O
conformers	O
were	O
carried	O
out	O
.	O

The	O
lowest	O
energy	O
conformers	O
of	O
R	O
and	O
S	O
stereoisomers	O
were	O
then	O
subjected	O
to	O
B3LYP	O
geometry	O
optimizations	O
including	O
solvent	O
effects	O
.	O

The	O
S	O
stereoisomer	O
was	O
shown	O
to	O
be	O
in	O
excellent	O
agreement	O
with	O
the	O
NOE	O
-	O
derived	O
distance	O
constraints	O
and	O
hydrogen	B-CHEMICAL
-	O
bonding	O
stability	O
studies	O
.	O

Green	O
approach	O
&	O
#	O
8212	O
;	O
multicomponent	O
production	O
of	O
boron	B-CHEMICAL
&	O
#	O
8212	O
;	O
containing	O
hantzsch	O
and	O
biginelli	O
esters	O
.	O

Multicomponent	O
reactions	O
are	O
excellent	O
methods	O
that	O
meet	O
the	O
requirements	O
of	O
green	O
chemistry	O
,	O
by	O
reducing	O
the	O
number	O
of	O
steps	O
,	O
and	O
consequently	O
reducing	O
purification	O
requirements	O
.	O

Accordingly	O
,	O
in	O
this	O
work	O
,	O
11	O
novel	O
hybrid	O
-	O
boron	B-CHEMICAL
-	O
containing	O
molecules	O
,	O
namely	O
eight	O
1	B-CHEMICAL
,	I-CHEMICAL
4	I-CHEMICAL
-	I-CHEMICAL
dihydropyridines	I-CHEMICAL
and	O
three	O
3	B-CHEMICAL
,	I-CHEMICAL
4	I-CHEMICAL
-	I-CHEMICAL
dihydropyrimidinones	I-CHEMICAL
,	O
derived	O
from	O
formylphenylboronic	B-CHEMICAL
acids	I-CHEMICAL
(	O
ortho	O
,	O
meta	O
and	O
para	O
)	O
,	O
were	O
obtained	O
using	O
a	O
green	O
approach	O
,	O
involving	O
H	O
-	O
4CR	O
and	O
B	O
-	O
3CR	O
practices	O
,	O
in	O
the	O
presence	O
of	O
ethanol	B-CHEMICAL
,	O
which	O
is	O
a	O
green	O
solvent	O
,	O
and	O
using	O
three	O
comparatively	O
different	O
modes	O
of	O
activation	O
(	O
mantle	O
heating	O
,	O
yield	O
3	O
%	O
-	O
7	O
%	O
in	O
24	O
h	O
,	O
Infrared	O
Radiation	O
(	O
IR	O
)	O
irradiation	O
,	O
yield	O
12	O
%	O
-	O
17	O
%	O
in	O
12	O
h	O
,	O
and	O
microwave	O
irradiation	O
,	O
yield	O
18	O
%	O
-	O
80	O
%	O
,	O
requiring	O
very	O
low	O
reaction	O
times	O
of	O
0	O
.	O
25	O
-	O
0	O
.	O
33	O
h	O
)	O
.	O

In	O
addition	O
,	O
as	O
a	O
green	O
-	O
approach	O
is	O
offered	O
,	O
a	O
convenient	O
analysis	O
,	O
of	O
the	O
12	O
green	O
chemistry	O
principles	O
for	O
the	O
overall	O
procedure	O
was	O
performed	O
.	O

Finally	O
,	O
since	O
all	O
the	O
products	O
are	O
new	O
,	O
characterizations	O
were	O
carried	O
out	O
using	O
common	O
analytic	O
procedures	O
(	O
1H	B-CHEMICAL
,	O
11B	B-CHEMICAL
,	O
and	O
13C	B-CHEMICAL
NMR	O
,	O
FAB	O
+	O
MS	O
,	O
HRMS	O
,	O
and	O
IR	O
)	O
.	O

The	O
accurate	O
mass	O
data	O
of	O
unexpected	O
ions	O
related	O
to	O
interactions	O
between	O
thioglycerol	B-CHEMICAL
and	O
the	O
expected	O
products	O
,	O
in	O
the	O
FAB	O
+	O
-	O
mode	O
,	O
enabled	O
unequivocal	O
characterization	O
of	O
the	O
target	O
molecules	O
.	O

Structures	O
and	O
cytotoxic	O
evaluation	O
of	O
new	O
and	O
known	O
acyclic	O
Ene	O
-	O
Ynes	O
from	O
an	O
American	O
Samoa	O
Petrosia	O
sp	O
.	O

Sponge	O
.	O

Four	O
new	O
compounds	O
,	O
(	B-CHEMICAL
-	I-CHEMICAL
)	I-CHEMICAL
-	I-CHEMICAL
petrosynoic	I-CHEMICAL
acids	I-CHEMICAL
A	I-CHEMICAL
-	I-CHEMICAL
D	I-CHEMICAL
(	O
1	O
-	O
4	O
)	O
,	O
and	O
five	O
known	O
congeners	O
,	O
pellynols	B-CHEMICAL
A	I-CHEMICAL
(	I-CHEMICAL
5	I-CHEMICAL
)	I-CHEMICAL
,	I-CHEMICAL
C	I-CHEMICAL
(	I-CHEMICAL
6	I-CHEMICAL
)	I-CHEMICAL
,	I-CHEMICAL
D	I-CHEMICAL
(	I-CHEMICAL
7	I-CHEMICAL
)	I-CHEMICAL
,	I-CHEMICAL
F	I-CHEMICAL
(	I-CHEMICAL
8	I-CHEMICAL
)	I-CHEMICAL
,	I-CHEMICAL
and	I-CHEMICAL
I	I-CHEMICAL
(	O
9	O
)	O
,	O
were	O
isolated	O
from	O
a	O
Petrosia	O
sp	O
.	O
marine	O
sponge	O
collected	O
in	O
American	O
Samoa	O
.	O

Isolation	O
work	O
was	O
guided	O
by	O
cytotoxicity	O
against	O
human	O
lung	O
cancer	O
cells	O
(	O
H460	O
)	O
.	O

The	O
structures	O
of	O
the	O
C31	B-CHEMICAL
-	I-CHEMICAL
C33	I-CHEMICAL
polyacetylenes	I-CHEMICAL
(	O
1	O
-	O
9	O
)	O
were	O
determined	O
on	O
the	O
basis	O
of	O
1D	O
-	O
and	O
2D	O
-	O
NMR	O
analysis	O
,	O
mass	O
spectrometry	O
,	O
and	O
comparison	O
of	O
specific	O
rotation	O
values	O
.	O

Compounds	O
1	O
-	O
9	O
were	O
found	O
to	O
be	O
broadly	O
cytotoxic	O
with	O
limited	O
selectivity	O
for	O
cancer	O
cells	O
,	O
as	O
they	O
were	O
all	O
moderately	O
active	O
against	O
the	O
A2058	O
(	O
melanoma	O
)	O
,	O
H522	O
-	O
T1	O
(	O
lung	O
)	O
,	O
and	O
H460	O
(	O
lung	O
)	O
human	O
cancer	O
cell	O
lines	O
as	O
well	O
as	O
IMR	O
-	O
90	O
quiescent	O
human	O
fibroblast	O
cells	O
.	O

Dopamine	B-GENE-Y
D2	I-GENE-Y
receptor	I-GENE-Y
activation	O
leads	O
to	O
an	O
up	O
-	O
regulation	O
of	O
glial	B-GENE-Y
cell	I-GENE-Y
line	I-GENE-Y
-	I-GENE-Y
derived	I-GENE-Y
neurotrophic	I-GENE-Y
factor	I-GENE-Y
via	O
G	O
-	O
Erk1	B-GENE-N
/	I-GENE-N
2	I-GENE-N
-	O
dependent	O
induction	O
of	O
Zif268	B-GENE-Y
.	O

Glial	B-GENE-Y
cell	I-GENE-Y
line	I-GENE-Y
-	I-GENE-Y
derived	I-GENE-Y
neurotrophic	I-GENE-Y
factor	I-GENE-Y
(	O
GDNF	B-GENE-Y
)	O
is	O
a	O
potent	O
growth	O
factor	O
essential	O
to	O
the	O
development	O
,	O
survival	O
,	O
and	O
function	O
of	O
dopaminergic	O
neurons	O
(	O
Airaksinen	O
and	O
Saarma	O
2002	O
)	O
.	O

The	O
molecular	O
mechanisms	O
underlying	O
GDNF	B-GENE-Y
expression	O
remain	O
elusive	O
;	O
thus	O
,	O
we	O
set	O
out	O
to	O
identify	O
a	O
signaling	O
pathway	O
that	O
governs	O
GDNF	B-GENE-Y
levels	O
.	O

We	O
found	O
that	O
treatment	O
of	O
both	O
differentiated	O
dopaminergic	O
-	O
like	O
SH	O
-	O
SY5Y	O
cells	O
and	O
rat	O
midbrain	O
slices	O
with	O
the	O
dopamine	B-GENE-N
D2	I-GENE-N
receptor	I-GENE-N
(	O
D2R	B-GENE-N
)	O
agonist	O
,	O
quinpirole	B-CHEMICAL
,	O
triggered	O
an	O
increase	O
in	O
the	O
expression	O
of	O
GDNF	B-GENE-N
that	O
was	O
temporally	O
preceded	O
by	O
an	O
increase	O
in	O
the	O
levels	O
of	O
zinc	B-GENE-N
-	I-GENE-N
finger	I-GENE-N
protein	I-GENE-N
268	I-GENE-N
(	O
Zif268	B-GENE-N
)	O
,	O
a	O
DNA	O
-	O
binding	O
transcription	O
factor	O
encoded	O
by	O
an	O
immediate	O
-	O
early	O
gene	O
.	O

Moreover	O
,	O
the	O
D2R	B-GENE-Y
inhibitor	O
raclopride	B-CHEMICAL
blocked	O
the	O
increase	O
of	O
both	O
GDNF	B-GENE-Y
and	O
Zif268	B-GENE-Y
expression	O
following	O
potassium	B-CHEMICAL
-	O
evoked	O
dopamine	B-CHEMICAL
release	O
in	O
SH	O
-	O
SY5Y	O
cells	O
.	O

We	O
used	O
adenoviral	O
delivery	O
of	O
small	O
hairpin	O
RNA	O
(	O
shRNA	O
)	O
targeting	O
Zif268	B-GENE-Y
to	O
down	O
-	O
regulate	O
its	O
expression	O
and	O
found	O
that	O
Zif268	B-GENE-Y
is	O
specifically	O
required	O
for	O
the	O
D2R	B-GENE-Y
-	O
mediated	O
up	O
-	O
regulation	O
of	O
GDNF	B-GENE-Y
.	O

Furthermore	O
,	O
the	O
D2R	B-GENE-Y
-	O
mediated	O
induction	O
of	O
GDNF	B-GENE-Y
and	O
Zif268	B-GENE-N
expression	O
was	O
dependent	O
on	O
G	O
-	O
mediated	O
signaling	O
and	O
activation	O
of	O
extracellular	B-GENE-N
signal	I-GENE-N
-	I-GENE-N
regulated	I-GENE-N
kinase	I-GENE-N
1	I-GENE-N
/	I-GENE-N
2	I-GENE-N
.	O

Importantly	O
,	O
using	O
chromatin	O
immunoprecipitation	O
assay	O
,	O
we	O
identified	O
a	O
direct	O
association	O
of	O
Zif268	B-GENE-Y
with	O
the	O
GDNF	B-GENE-N
promoter	I-GENE-N
.	O

These	O
results	O
suggest	O
that	O
D2R	B-GENE-Y
activation	O
induces	O
a	O
G	O
-	O
and	O
extracellular	B-GENE-N
signal	I-GENE-N
-	I-GENE-N
regulated	I-GENE-N
kinase	I-GENE-N
1	I-GENE-N
/	I-GENE-N
2	I-GENE-N
-	O
dependent	O
increase	O
in	O
the	O
level	O
of	O
Zif268	B-GENE-Y
,	O
which	O
functions	O
to	O
directly	O
up	O
-	O
regulate	O
the	O
expression	O
of	O
GDNF	B-GENE-Y
.	O

Fast	O
protein	O
motions	O
are	O
coupled	O
to	O
enzyme	O
H	B-CHEMICAL
-	O
transfer	O
reactions	O
.	O

Coupling	O
of	O
fast	O
protein	O
dynamics	O
to	O
enzyme	O
chemistry	O
is	O
controversial	O
and	O
has	O
ignited	O
considerable	O
debate	O
,	O
especially	O
over	O
the	O
past	O
15	O
years	O
in	O
relation	O
to	O
enzyme	O
-	O
catalyzed	O
H	B-CHEMICAL
-	O
transfer	O
.	O

H	B-CHEMICAL
-	O
transfer	O
can	O
occur	O
by	O
quantum	O
tunneling	O
,	O
and	O
the	O
temperature	O
dependence	O
of	O
kinetic	O
isotope	O
effects	O
(	O
KIEs	O
)	O
has	O
emerged	O
as	O
the	O
"	O
gold	O
standard	O
"	O
descriptor	O
of	O
these	O
reactions	O
.	O

The	O
anomalous	O
temperature	O
dependence	O
of	O
KIEs	O
is	O
often	O
rationalized	O
by	O
invoking	O
fast	O
motions	O
to	O
facilitate	O
H	B-CHEMICAL
-	O
transfer	O
,	O
yet	O
crucially	O
,	O
direct	O
evidence	O
for	O
coupled	O
motions	O
is	O
lacking	O
.	O

The	O
fast	O
motions	O
hypothesis	O
underpinning	O
the	O
temperature	O
dependence	O
of	O
KIEs	O
is	O
based	O
on	O
inference	O
.	O

Here	O
,	O
we	O
have	O
perturbed	O
vibrational	O
motions	O
in	O
pentaerythritol	B-GENE-N
tetranitrate	I-GENE-N
reductase	I-GENE-N
(	O
PETNR	B-GENE-N
)	O
by	O
isotopic	O
substitution	O
where	O
all	O
non	O
-	O
exchangeable	O
atoms	O
were	O
replaced	O
with	O
the	O
corresponding	O
heavy	O
isotope	O
(	O
(	B-CHEMICAL
13	I-CHEMICAL
)	I-CHEMICAL
C	I-CHEMICAL
,	O
(	B-CHEMICAL
15	I-CHEMICAL
)	I-CHEMICAL
N	I-CHEMICAL
,	O
and	O
(	B-CHEMICAL
2	I-CHEMICAL
)	I-CHEMICAL
H	I-CHEMICAL
)	O
.	O

The	O
KIE	O
temperature	O
dependence	O
is	O
perturbed	O
by	O
heavy	O
isotope	O
labeling	O
,	O
demonstrating	O
a	O
direct	O
link	O
between	O
(	O
promoting	O
)	O
vibrations	O
in	O
the	O
protein	O
and	O
the	O
observed	O
KIE	O
.	O

Further	O
we	O
show	O
that	O
temperature	O
-	O
independent	O
KIEs	O
do	O
not	O
necessarily	O
rule	O
out	O
a	O
role	O
for	O
fast	O
dynamics	O
coupled	O
to	O
reaction	O
chemistry	O
.	O

We	O
show	O
causality	O
between	O
fast	O
motions	O
and	O
enzyme	O
chemistry	O
and	O
demonstrate	O
how	O
this	O
impacts	O
on	O
experimental	O
KIEs	O
for	O
enzyme	O
reactions	O
.	O

Characterization	O
of	O
the	O
mouse	O
promoter	O
region	O
of	O
the	O
acyl	B-GENE-Y
-	I-GENE-Y
CoA	I-GENE-Y
synthetase	I-GENE-Y
4	I-GENE-Y
gene	O
:	O
role	O
of	O
Sp1	B-GENE-Y
and	O
CREB	B-GENE-N
.	O

Acyl	B-GENE-Y
-	I-GENE-Y
CoA	I-GENE-Y
synthetase	I-GENE-Y
4	I-GENE-Y
(	O
Acsl4	B-GENE-Y
)	O
is	O
involved	O
in	O
several	O
cellular	O
functions	O
including	O
steroidogenesis	O
,	O
synaptic	O
development	O
and	O
cancer	O
metastasis	O
.	O

Although	O
the	O
expression	O
of	O
Acsl4	B-GENE-Y
seems	O
to	O
be	O
regulated	O
by	O
tissue	O
-	O
and	O
cell	O
-	O
specific	O
factors	O
as	O
well	O
as	O
pituitary	O
hormones	O
and	O
growth	O
factors	O
,	O
the	O
transcriptional	O
mechanisms	O
involved	O
remain	O
unknown	O
.	O

We	O
demonstrated	O
hCG	B-GENE-N
and	O
cAMP	B-CHEMICAL
regulation	O
of	O
Acsl4	B-GENE-Y
mRNA	O
in	O
mouse	O
steroidogenic	O
MA	O
-	O
10	O
Leydig	O
cells	O
.	O

We	O
characterized	O
the	O
transcription	B-GENE-N
initiation	I-GENE-N
site	I-GENE-N
and	O
promoter	O
of	O
the	O
Acsl4	B-GENE-Y
mouse	O
gene	O
and	O
identified	O
three	O
alternative	O
splice	O
variants	O
present	O
in	O
MA	O
-	O
10	O
cells	O
.	O

Sequence	O
analysis	O
of	O
a	O
1	O
.	O
5	O
-	O
kb	O
fragment	O
of	O
the	O
Acsl4	B-GENE-N
promoter	I-GENE-N
revealed	O
the	O
absence	O
of	O
a	O
TATA	B-GENE-N
box	I-GENE-N
and	O
the	O
presence	O
of	O
many	O
putative	O
binding	O
sites	O
for	O
transcription	O
factors	O
including	O
Sp1	B-GENE-Y
and	O
CREB	B-GENE-N
.	O

Functional	O
characterization	O
revealed	O
that	O
the	O
specificity	B-GENE-N
protein	I-GENE-N
/	O
Krppel	B-GENE-N
-	I-GENE-N
like	I-GENE-N
factor	I-GENE-N
Sp1	B-GENE-Y
binding	O
site	O
in	O
the	O
proximal	O
promoter	O
is	O
involved	O
in	O
basal	O
activity	O
and	O
that	O
the	O
cAMP	B-GENE-N
response	I-GENE-N
element	I-GENE-N
-	O
binding	O
site	O
is	O
involved	O
in	O
cAMP	B-CHEMICAL
stimulation	O
of	O
Acsl4	B-GENE-Y
transcription	O
.	O

Synthesis	O
and	O
biological	O
evaluation	O
of	O
1	B-CHEMICAL
,	I-CHEMICAL
3	I-CHEMICAL
,	I-CHEMICAL
4	I-CHEMICAL
-	I-CHEMICAL
thiadiazole	I-CHEMICAL
analogues	O
as	O
novel	O
AChE	B-GENE-Y
and	O
BuChE	B-GENE-Y
inhibitors	O
.	O

In	O
this	O
paper	O
a	O
series	O
of	O
new	O
1	B-CHEMICAL
,	I-CHEMICAL
3	I-CHEMICAL
,	I-CHEMICAL
4	I-CHEMICAL
-	I-CHEMICAL
thiadiazole	I-CHEMICAL
derivatives	O
has	O
been	O
designed	O
,	O
synthesized	O
and	O
evaluated	O
as	O
the	O
acetyl	B-GENE-N
-	I-GENE-N
and	I-GENE-N
butyrylcholinesterase	I-GENE-N
inhibitors	O
.	O

Some	O
analogues	O
showed	O
promising	O
inhibition	O
of	O
both	O
enzymes	O
in	O
vitro	O
in	O
the	O
nM	O
range	O
.	O

Generally	O
,	O
inhibitory	O
potency	O
of	O
compounds	O
was	O
stronger	O
against	O
AChE	B-GENE-Y
than	O
BuChE	B-GENE-Y
,	O
and	O
one	O
of	O
them	O
was	O
1154	O
-	O
fold	O
more	O
active	O
inhibiting	O
AChE	B-GENE-Y
(	O
IC50	O
=	O
0	O
.	O
17	O
M	O
)	O
than	O
BuChE	B-GENE-Y
.	O

The	O
kinetic	O
studies	O
showed	O
that	O
one	O
of	O
the	O
most	O
active	O
analogues	O
8	O
(	O
IC50	O
=	O
0	O
.	O
09	O
M	O
,	O
AChE	B-GENE-Y
)	O
acted	O
as	O
a	O
non	O
-	O
competitive	O
AChE	B-GENE-Y
inhibitor	O
and	O
was	O
characterized	O
by	O
the	O
high	O
selectivity	O
index	O
(	O
300	O
)	O
.	O

The	O
other	O
derivative	O
(	O
1	O
)	O
exhibited	O
a	O
mixed	O
-	O
type	O
of	O
AChE	B-GENE-Y
inhibition	O
.	O

Docking	O
simulations	O
enabled	O
the	O
detection	O
of	O
key	O
binding	O
interactions	O
of	O
the	O
compounds	O
with	O
AChE	B-GENE-Y
and	O
revealed	O
that	O
they	O
occupied	O
mainly	O
the	O
catalytic	O
active	O
site	O
.	O

The	O
scoring	O
function	O
for	O
the	O
novel	O
compounds	O
was	O
similar	O
or	O
higher	O
than	O
for	O
the	O
reference	O
inhibitor	O
.	O

Additionally	O
,	O
based	O
on	O
Lipinski	O
and	O
other	O
filters	O
,	O
the	O
drug	O
-	O
likeness	O
of	O
compounds	O
was	O
assessed	O
.	O

They	O
revealed	O
that	O
the	O
compounds	O
possess	O
properties	O
which	O
can	O
suggest	O
the	O
favourable	O
pharmacokinetics	O
in	O
the	O
human	O
body	O
after	O
oral	O
admission	O
.	O

PI3	B-GENE-N
k	I-GENE-N
/	O
akt	B-GENE-N
inhibition	O
induces	O
apoptosis	O
through	O
p38	B-GENE-N
activation	O
in	O
neurons	O
.	O

Accumulating	O
evidence	O
suggests	O
that	O
the	O
PI3K	B-GENE-N
/	O
AKT	B-GENE-N
pathway	O
is	O
a	O
pro	O
-	O
survival	O
signalling	O
system	O
in	O
neurons	O
.	O

Therefore	O
,	O
the	O
inhibition	O
of	O
this	O
pathway	O
may	O
be	O
implicated	O
in	O
the	O
degeneration	O
of	O
neurons	O
in	O
Parkinson	O
'	O
s	O
disease	O
(	O
PD	O
)	O
,	O
Alzheimer	O
'	O
s	O
disease	O
(	O
AD	O
)	O
,	O
and	O
other	O
neurological	O
disorders	O
.	O

Here	O
we	O
study	O
the	O
participation	O
of	O
the	O
mitogen	B-GENE-N
-	I-GENE-N
activated	I-GENE-N
protein	I-GENE-N
kinase	I-GENE-N
(	O
MAPK	B-GENE-N
)	O
pathway	O
on	O
apoptosis	O
induced	O
by	O
PI3K	B-GENE-N
/	O
AKT	B-GENE-N
inhibition	O
in	O
cultured	O
cerebellar	O
granule	O
cells	O
(	O
CGCs	O
)	O
.	O

LY294002	B-CHEMICAL
,	O
a	O
specific	O
PI3K	B-GENE-N
/	O
AKT	B-GENE-N
inhibitor	O
,	O
selectively	O
activated	O
the	O
p38	B-GENE-N
MAPK	B-GENE-N
kinase	B-GENE-N
pathway	O
and	O
enhanced	O
c	B-GENE-Y
-	I-GENE-Y
Jun	I-GENE-Y
phosphorylation	O
,	O
but	O
did	O
not	O
activate	O
JNK	B-GENE-N
.	O

The	O
pharmacological	O
inhibitors	O
SB203580	B-CHEMICAL
(	O
p38	B-GENE-N
inhibitor	O
)	O
and	O
SP600125	B-CHEMICAL
(	O
a	O
JNK	B-GENE-N
inhibitor	O
)	O
protected	O
primary	O
cultures	O
of	O
rat	O
CGCs	O
from	O
LY294002	B-CHEMICAL
-	O
induced	O
apoptosis	O
.	O

Furthermore	O
,	O
both	O
compounds	O
decreased	O
the	O
phosphorylation	O
of	O
c	B-GENE-Y
-	I-GENE-Y
Jun	I-GENE-Y
and	O
lowered	O
mRNA	O
levels	O
of	O
the	O
pro	O
-	O
apoptotic	O
gene	O
dp5	B-GENE-Y
,	O
a	O
direct	O
target	O
of	O
c	B-GENE-Y
-	I-GENE-Y
Jun	I-GENE-Y
.	O

Taken	O
together	O
,	O
our	O
data	O
demonstrate	O
that	O
PI3K	B-GENE-N
/	O
AKT	B-GENE-N
inhibition	O
induces	O
neuronal	O
apoptosis	O
,	O
a	O
process	O
that	O
is	O
mediated	O
by	O
the	O
activation	O
of	O
p38	B-GENE-N
MAPK	B-GENE-N
/	O
c	B-GENE-Y
-	I-GENE-Y
Jun	I-GENE-Y
/	O
dp5	B-GENE-Y
.	O

Gender	O
and	O
strain	O
contributions	O
to	O
the	O
variability	O
of	O
buprenorphine	B-CHEMICAL
-	O
related	O
respiratory	O
toxicity	O
in	O
mice	O
.	O

While	O
most	O
deaths	O
from	O
asphyxia	O
related	O
to	O
buprenorphine	B-CHEMICAL
(	O
BUP	B-CHEMICAL
)	O
overdose	O
have	O
been	O
reported	O
in	O
males	O
,	O
higher	O
plasma	O
concentrations	O
of	O
BUP	B-CHEMICAL
and	O
its	O
toxic	O
metabolite	O
norbuprenorphine	B-CHEMICAL
(	O
NBUP	B-CHEMICAL
)	O
have	O
been	O
observed	O
in	O
females	O
.	O

We	O
previously	O
demonstrated	O
that	O
P	B-GENE-N
-	I-GENE-N
glycoprotein	I-GENE-N
(	O
P	B-GENE-N
-	I-GENE-N
gp	I-GENE-N
)	O
modulation	O
at	O
the	O
blood	O
-	O
brain	O
barrier	O
(	O
BBB	O
)	O
contributes	O
highly	O
to	O
BUP	B-CHEMICAL
-	O
related	O
respiratory	O
toxicity	O
,	O
by	O
limiting	O
NBUP	B-CHEMICAL
entrance	O
into	O
the	O
brain	O
.	O

In	O
this	O
work	O
,	O
we	O
sought	O
to	O
investigate	O
the	O
role	O
of	O
P	B-GENE-N
-	I-GENE-N
gp	I-GENE-N
-	O
mediated	O
transport	O
at	O
the	O
BBB	O
in	O
gender	O
and	O
strain	O
-	O
related	O
variability	O
of	O
BUP	B-CHEMICAL
and	O
NBUP	B-CHEMICAL
-	O
induced	O
respiratory	O
effects	O
in	O
mice	O
.	O

Ventilation	O
was	O
studied	O
using	O
plethysmography	O
,	O
P	B-GENE-N
-	I-GENE-N
gp	I-GENE-N
expression	O
using	O
western	O
blot	O
,	O
and	O
transport	O
at	O
the	O
BBB	O
using	O
in	O
situ	O
cerebral	O
perfusion	O
.	O

In	O
male	O
Fvb	O
and	O
Swiss	O
mice	O
,	O
BUP	B-CHEMICAL
was	O
responsible	O
for	O
ceiling	O
respiratory	O
effects	O
.	O

NBUP	B-CHEMICAL
-	O
related	O
reduction	O
in	O
minute	O
volume	O
was	O
dose	O
-	O
dependent	O
but	O
more	O
marked	O
in	O
Fvb	O
(	O
p	O
<	O
0	O
.	O
01	O
at	O
1mg	O
/	O
kg	O
NBUP	B-CHEMICAL
and	O
p	O
<	O
0	O
.	O
001	O
at	O
3	O
and	O
9mg	O
/	O
kg	O
NBUP	B-CHEMICAL
)	O
than	O
in	O
Swiss	O
mice	O
(	O
p	O
<	O
0	O
.	O
001	O
at	O
9mg	O
/	O
kg	O
NBUP	B-CHEMICAL
)	O
.	O

Female	O
Fvb	O
mice	O
were	O
more	O
susceptible	O
to	O
BUP	B-CHEMICAL
than	O
males	O
with	O
significantly	O
increased	O
inspiratory	O
time	O
(	O
p	O
<	O
0	O
.	O
05	O
)	O
and	O
to	O
NBUP	B-CHEMICAL
with	O
significantly	O
increased	O
expiratory	O
time	O
(	O
p	O
<	O
0	O
.	O
01	O
)	O
.	O

Following	O
BUP	B-CHEMICAL
administration	O
,	O
plasma	O
BUP	B-CHEMICAL
concentrations	O
were	O
significantly	O
higher	O
(	O
p	O
<	O
0	O
.	O
01	O
)	O
and	O
plasma	O
NBUP	B-CHEMICAL
concentrations	O
significantly	O
lower	O
(	O
p	O
<	O
0	O
.	O
001	O
)	O
in	O
Fvb	O
mice	O
compared	O
to	O
Swiss	O
mice	O
.	O

Plasma	O
BUP	B-CHEMICAL
concentrations	O
were	O
significantly	O
higher	O
(	O
p	O
<	O
0	O
.	O
05	O
)	O
and	O
plasma	O
NBUP	B-CHEMICAL
concentrations	O
significantly	O
lower	O
(	O
p	O
<	O
0	O
.	O
01	O
)	O
in	O
male	O
compared	O
to	O
female	O
Fvb	O
mice	O
.	O

In	O
contrast	O
,	O
following	O
NBUP	B-CHEMICAL
administration	O
,	O
comparable	O
plasma	O
NBUP	B-CHEMICAL
concentrations	O
were	O
observed	O
in	O
both	O
genders	O
and	O
strains	O
.	O

No	O
differences	O
in	O
P	B-GENE-N
-	I-GENE-N
gp	I-GENE-N
expression	O
or	O
BUP	B-CHEMICAL
and	O
NBUP	B-CHEMICAL
transport	O
across	O
the	O
BBB	O
were	O
observed	O
between	O
male	O
and	O
female	O
Fvb	O
mice	O
as	O
well	O
as	O
between	O
Swiss	O
and	O
Fvb	O
mice	O
.	O

Our	O
results	O
suggest	O
that	O
P	B-GENE-N
-	I-GENE-N
gp	I-GENE-N
-	O
mediated	O
transport	O
across	O
the	O
BBB	O
does	O
not	O
play	O
a	O
key	O
-	O
role	O
in	O
gender	O
and	O
strain	O
-	O
related	O
variability	O
in	O
BUP	B-CHEMICAL
and	O
NBUP	B-CHEMICAL
-	O
induced	O
respiratory	O
toxicity	O
in	O
mice	O
.	O

Both	O
gender	O
-	O
and	O
strain	O
-	O
related	O
differences	O
in	O
respiratory	O
effects	O
of	O
BUP	B-CHEMICAL
could	O
be	O
attributed	O
to	O
BUP	B-CHEMICAL
itself	O
rather	O
than	O
to	O
its	O
metabolite	O
,	O
NBUP	B-CHEMICAL
.	O

Autophagy	O
takes	O
place	O
in	O
mutated	O
p53	B-GENE-Y
neuroblastoma	O
cells	O
in	O
response	O
to	O
hypoxia	O
mimetic	O
CoCl	B-CHEMICAL
(	I-CHEMICAL
2	I-CHEMICAL
)	I-CHEMICAL
.	O

Solid	O
tumors	O
like	O
neuroblastoma	O
exhibit	O
hypoxic	O
areas	O
,	O
which	O
can	O
lead	O
both	O
to	O
cell	O
death	O
or	O
aggressiveness	O
increase	O
.	O

Hypoxia	O
is	O
a	O
known	O
stress	O
able	O
to	O
induce	O
stabilization	O
of	O
p53	B-GENE-Y
,	O
implicated	O
in	O
cell	O
fate	O
regulation	O
.	O

Recently	O
,	O
p53	B-GENE-Y
appeared	O
to	O
be	O
involved	O
in	O
autophagy	O
in	O
an	O
opposite	O
manner	O
,	O
depending	O
on	O
its	O
location	O
:	O
when	O
nuclear	O
,	O
it	O
enhanced	O
transcription	O
of	O
pro	O
-	O
autophagic	O
genes	O
whereas	O
when	O
cytoplasmic	O
,	O
it	O
inhibited	O
the	O
autophagic	O
process	O
.	O

Today	O
,	O
we	O
used	O
cobalt	B-CHEMICAL
chloride	I-CHEMICAL
,	O
a	O
hypoxia	O
mimetic	O
that	O
inhibits	O
proteasomal	O
HIF	B-GENE-Y
-	I-GENE-Y
1	I-GENE-Y
degradation	O
and	O
generates	O
reactive	O
oxygen	B-CHEMICAL
species	O
(	O
ROS	O
)	O
.	O

We	O
focused	O
on	O
CoCl2	B-CHEMICAL
-	O
induced	O
cell	O
death	O
in	O
a	O
DNA	O
-	O
binding	O
mutated	O
p53	B-GENE-Y
neuroblastoma	O
cell	O
line	O
(	O
SKNBE	O
(	O
2c	O
)	O
)	O
.	O

An	O
autophagic	O
signaling	O
was	O
evidenced	O
by	O
an	O
increase	O
of	O
Beclin	B-GENE-Y
-	I-GENE-Y
1	I-GENE-Y
,	O
ATG	B-GENE-N
5	I-GENE-N
-	I-GENE-N
12	I-GENE-N
,	O
and	O
LC3	B-GENE-Y
-	I-GENE-Y
II	I-GENE-Y
expression	O
whereas	O
the	O
p53	B-GENE-Y
(	O
mut	O
)	O
presence	O
decreased	O
with	O
CoCl2	B-CHEMICAL
time	O
exposure	O
.	O

Activation	O
of	O
the	O
pathway	O
seemed	O
to	O
protect	O
cells	O
from	O
ROS	O
production	O
and	O
,	O
at	O
least	O
in	O
part	O
,	O
from	O
death	O
.	O

The	O
autophagic	O
inhibitors	O
activated	O
the	O
apoptotic	O
signaling	O
and	O
the	O
death	O
was	O
enhanced	O
.	O

To	O
delineate	O
the	O
eventual	O
implication	O
of	O
the	O
p53	B-GENE-Y
(	O
mut	O
)	O
in	O
the	O
autophagic	O
process	O
in	O
response	O
to	O
hypoxia	O
,	O
we	O
monitored	O
signaling	O
in	O
p53	B-GENE-Y
(	O
WT	O
)	O
SHSY5Y	O
cells	O
,	O
after	O
either	O
shRNA	O
-	O
p53	B-GENE-Y
down	O
-	O
regulation	O
or	O
transcriptional	O
activity	O
inhibition	O
by	O
pifithrin	O
alpha	O
.	O

We	O
did	O
not	O
detect	O
autophagy	O
neither	O
with	O
p53	B-GENE-Y
(	O
wt	O
)	O
nor	O
when	O
p53	B-GENE-Y
was	O
lacking	O
whereas	O
such	O
a	O
response	O
was	O
effective	O
with	O
a	O
mutated	O
or	O
inactivated	O
p53	B-GENE-Y
.	O

To	O
conclude	O
,	O
mutated	O
p53	B-GENE-Y
in	O
neuroblastoma	O
cells	O
could	O
be	O
linked	O
with	O
the	O
switch	O
between	O
apoptotic	O
response	O
and	O
cell	O
death	O
by	O
autophagy	O
in	O
response	O
to	O
hypoxic	O
mimetic	O
stress	O
.	O

Mammalian	O
myosin	B-GENE-Y
-	I-GENE-Y
18A	I-GENE-Y
,	O
a	O
highly	O
divergent	O
myosin	B-GENE-N
.	O

The	O
Mus	B-GENE-Y
musculus	I-GENE-Y
myosin	I-GENE-Y
-	I-GENE-Y
18A	I-GENE-Y
gene	O
is	O
expressed	O
as	O
two	O
alternatively	O
spliced	O
isoforms	O
,	O
	O
and	O
	O
,	O
with	O
reported	O
roles	O
in	O
Golgi	O
localization	O
,	O
in	O
maintenance	O
of	O
cytoskeleton	O
,	O
and	O
as	O
receptors	O
for	O
immunological	O
surfactant	O
proteins	O
.	O

Both	O
myosin	B-GENE-Y
-	I-GENE-Y
18A	I-GENE-Y
isoforms	O
feature	O
a	O
myosin	B-GENE-N
motor	I-GENE-N
domain	I-GENE-N
,	O
a	O
single	O
predicted	O
IQ	B-GENE-N
motif	I-GENE-N
,	O
and	O
a	O
long	O
coiled	O
-	O
coil	O
reminiscent	O
of	O
myosin	B-GENE-Y
-	I-GENE-Y
2	I-GENE-Y
.	O

The	O
myosin	B-GENE-Y
-	I-GENE-Y
18A	I-GENE-Y
isoform	O
,	O
additionally	O
,	O
has	O
an	O
N	B-CHEMICAL
-	O
terminal	O
PDZ	B-GENE-N
domain	I-GENE-N
.	O

Recombinant	O
heavy	O
meromyosin	O
-	O
and	O
subfragment	O
-	O
1	O
(	O
S1	O
)	O
-	O
like	O
constructs	O
for	O
both	O
myosin	B-GENE-N
-	I-GENE-N
18A	I-GENE-N
and	I-GENE-N
-	I-GENE-N
18	I-GENE-N
species	O
were	O
purified	O
from	O
the	O
baculovirus	O
/	O
Sf9	O
cell	O
expression	O
system	O
.	O

These	O
constructs	O
bound	O
both	O
essential	O
and	O
regulatory	O
light	O
chains	O
,	O
indicating	O
an	O
additional	O
noncanonical	O
light	O
chain	O
binding	O
site	O
in	O
the	O
neck	O
.	O

Myosin	B-GENE-N
-	I-GENE-N
18A	I-GENE-N
-	I-GENE-N
S1	I-GENE-N
and	I-GENE-N
-	I-GENE-N
18A	I-GENE-N
-	I-GENE-N
S1	I-GENE-N
molecules	O
bound	O
actin	O
weakly	O
with	O
Kd	O
values	O
of	O
4	O
.	O
9	O
and	O
54	O
m	O
,	O
respectively	O
.	O

The	O
actin	O
binding	O
data	O
could	O
be	O
modeled	O
by	O
assuming	O
an	O
equilibrium	O
between	O
two	O
myosin	O
conformations	O
,	O
a	O
competent	O
and	O
an	O
incompetent	O
form	O
to	O
bind	O
actin	O
.	O

Actin	B-GENE-N
binding	O
was	O
unchanged	O
by	O
presence	O
of	O
nucleotide	B-CHEMICAL
.	O

Both	O
myosin	B-GENE-Y
-	I-GENE-Y
18A	I-GENE-Y
isoforms	O
bound	O
N	B-CHEMICAL
-	I-CHEMICAL
methylanthraniloyl	I-CHEMICAL
-	I-CHEMICAL
nucleotides	I-CHEMICAL
,	O
but	O
the	O
rate	O
of	O
ATP	B-CHEMICAL
hydrolysis	O
was	O
very	O
slow	O
(	O
<	O
0	O
.	O
002	O
s	O
(	O
-	O
1	O
)	O
)	O
and	O
not	O
significantly	O
enhanced	O
by	O
actin	B-GENE-N
.	O

Phosphorylation	O
of	O
the	O
regulatory	O
light	O
chain	O
had	O
no	O
effect	O
on	O
ATP	B-CHEMICAL
hydrolysis	O
,	O
and	O
neither	O
did	O
the	O
addition	O
of	O
tropomyosin	O
or	O
of	O
GOLPH3	O
,	O
a	O
myosin	B-GENE-Y
-	I-GENE-Y
18A	I-GENE-Y
binding	O
partner	O
.	O

Electron	O
microscopy	O
of	O
myosin	B-GENE-Y
-	I-GENE-Y
18A	I-GENE-Y
-	O
S1	O
showed	O
that	O
the	O
lever	O
is	O
strongly	O
angled	O
with	O
respect	O
to	O
the	O
long	O
axis	O
of	O
the	O
motor	O
domain	O
,	O
suggesting	O
a	O
pre	O
-	O
power	O
stroke	O
conformation	O
regardless	O
of	O
the	O
presence	O
of	O
ATP	B-CHEMICAL
.	O

These	O
data	O
lead	O
us	O
to	O
conclude	O
that	O
myosin	B-GENE-Y
-	I-GENE-Y
18A	I-GENE-Y
does	O
not	O
operate	O
as	O
a	O
traditional	O
molecular	O
motor	O
in	O
cells	O
.	O

Supervillin	B-GENE-Y
-	O
mediated	O
suppression	O
of	O
p53	B-GENE-Y
protein	O
enhances	O
cell	O
survival	O
.	O

Integrin	B-GENE-N
-	O
based	O
adhesions	O
promote	O
cell	O
survival	O
as	O
well	O
as	O
cell	O
motility	O
and	O
invasion	O
.	O

We	O
show	O
here	O
that	O
the	O
adhesion	B-GENE-N
regulatory	I-GENE-N
protein	I-GENE-N
supervillin	B-GENE-Y
increases	O
cell	O
survival	O
by	O
decreasing	O
levels	O
of	O
the	O
tumor	B-GENE-N
suppressor	I-GENE-N
protein	I-GENE-N
p53	B-GENE-Y
and	O
downstream	O
target	O
genes	O
.	O

RNAi	O
-	O
mediated	O
knockdown	O
of	O
a	O
new	O
splice	O
form	O
of	O
supervillin	B-GENE-N
(	I-GENE-N
isoform	I-GENE-N
4	I-GENE-N
)	I-GENE-N
or	I-GENE-N
both	I-GENE-N
isoforms	I-GENE-N
1	I-GENE-N
and	I-GENE-N
4	I-GENE-N
increases	O
the	O
amount	O
of	O
p53	B-GENE-Y
and	O
cell	O
death	O
,	O
whereas	O
p53	B-GENE-Y
levels	O
decrease	O
after	O
overexpression	O
of	O
either	O
supervillin	B-GENE-Y
isoform	O
.	O

Cellular	O
responses	O
to	O
DNA	O
damage	O
induced	O
by	O
etoposide	B-CHEMICAL
or	O
doxorubicin	B-CHEMICAL
include	O
down	O
-	O
regulation	O
of	O
endogenous	O
supervillin	B-GENE-Y
coincident	O
with	O
increases	O
in	O
p53	B-GENE-Y
.	O

In	O
DNA	O
-	O
damaged	O
supervillin	B-GENE-Y
knockdown	O
cells	O
,	O
p53	B-GENE-Y
knockdown	O
or	O
inhibition	O
partially	O
rescues	O
the	O
loss	O
of	O
cell	O
metabolic	O
activity	O
,	O
a	O
measure	O
of	O
cell	O
proliferation	O
.	O

Knockdown	O
of	O
the	O
p53	B-GENE-Y
deubiquitinating	O
enzyme	O
USP7	B-GENE-Y
/	O
HAUSP	B-GENE-Y
also	O
reverses	O
the	O
supervillin	B-GENE-Y
phenotype	O
,	O
blocking	O
the	O
increase	O
in	O
p53	B-GENE-Y
levels	O
seen	O
after	O
supervillin	B-GENE-Y
knockdown	O
and	O
accentuating	O
the	O
decrease	O
in	O
p53	B-GENE-Y
levels	O
triggered	O
by	O
supervillin	B-GENE-Y
overexpression	O
.	O

Conversely	O
,	O
supervillin	B-GENE-Y
overexpression	O
decreases	O
the	O
association	O
of	O
USP7	B-GENE-Y
and	O
p53	B-GENE-Y
and	O
attenuates	O
USP7	B-GENE-N
-	O
mediated	O
p53	B-GENE-Y
deubiquitination	O
.	O

USP7	B-GENE-N
binds	O
directly	O
to	O
the	O
supervillin	B-GENE-Y
N	B-CHEMICAL
terminus	O
and	O
can	O
deubiquitinate	O
and	O
stabilize	O
supervillin	B-GENE-Y
.	O

Supervillin	B-GENE-N
also	O
is	O
stabilized	O
by	O
derivatization	O
with	O
the	O
ubiquitin	B-GENE-N
-	O
like	O
protein	O
SUMO1	B-GENE-Y
.	O

These	O
results	O
show	O
that	O
supervillin	B-GENE-Y
regulates	O
cell	O
survival	O
through	O
control	O
of	O
p53	B-GENE-Y
levels	O
and	O
suggest	O
that	O
supervillin	B-GENE-Y
and	O
its	O
interaction	O
partners	O
at	O
sites	O
of	O
cell	O
-	O
substrate	O
adhesion	O
constitute	O
a	O
locus	O
for	O
cross	O
-	O
talk	O
between	O
survival	O
signaling	O
and	O
cell	O
motility	O
pathways	O
.	O

Novel	O
acylethanolamide	B-CHEMICAL
derivatives	O
that	O
modulate	O
body	O
weight	O
through	O
enhancement	O
of	O
hypothalamic	O
pro	B-GENE-Y
-	I-GENE-Y
opiomelanocortin	I-GENE-Y
(	O
POMC	B-GENE-Y
)	O
and	O
/	O
or	O
decreased	O
neuropeptide	B-GENE-Y
Y	I-GENE-Y
(	O
NPY	B-GENE-Y
)	O
.	O

Newly	O
synthesized	O
acylethanolamide	B-CHEMICAL
derivatives	O
oleoyl	B-CHEMICAL
-	I-CHEMICAL
L	I-CHEMICAL
-	I-CHEMICAL
valinolamide	I-CHEMICAL
(	O
1	O
)	O
,	O
oleoyl	B-CHEMICAL
-	I-CHEMICAL
D	I-CHEMICAL
-	I-CHEMICAL
valinolamide	I-CHEMICAL
(	O
2	O
)	O
,	O
elaidoyl	B-CHEMICAL
-	I-CHEMICAL
L	I-CHEMICAL
-	I-CHEMICAL
valinolamide	I-CHEMICAL
(	O
3	O
)	O
,	O
elaidoyl	B-CHEMICAL
-	I-CHEMICAL
D	I-CHEMICAL
-	I-CHEMICAL
valinolamide	I-CHEMICAL
(	O
4	O
)	O
stearoyl	B-CHEMICAL
-	I-CHEMICAL
L	I-CHEMICAL
-	I-CHEMICAL
valinolamide	I-CHEMICAL
(	O
5	O
)	O
,	O
and	O
palmitoyl	B-CHEMICAL
-	I-CHEMICAL
L	I-CHEMICAL
-	I-CHEMICAL
valinolamide	I-CHEMICAL
(	O
6	O
)	O
were	O
investigated	O
in	O
mice	O
as	O
antiobesity	O
compounds	O
.	O

Compounds	O
1	O
,	O
2	O
,	O
5	O
,	O
6	O
significantly	O
decreased	O
body	O
weight	O
by	O
6	O
.	O
57	O
%	O
following	O
eight	O
injections	O
of	O
1	O
mg	O
/	O
kg	O
i	O
.	O
p	O
.	O
during	O
39	O
days	O
,	O
while	O
3	O
and	O
4	O
showed	O
no	O
such	O
activity	O
.	O

Receptor	O
binding	O
indicated	O
that	O
no	O
compound	O
activated	O
CB1	B-GENE-Y
,	O
CB2	B-GENE-Y
,	O
PPAR	B-GENE-Y
,	O
or	O
TRPV1	B-GENE-Y
receptors	O
.	O

Hypothalamic	O
RT	O
-	O
PCR	O
showed	O
that	O
mRNA	O
expression	O
of	O
the	O
anorexigenic	O
genes	O
POMC	B-GENE-Y
and	O
CART	B-GENE-Y
was	O
up	O
-	O
regulated	O
by	O
1	O
,	O
2	O
,	O
5	O
and	O
1	O
,	O
2	O
,	O
respectively	O
,	O
while	O
that	O
of	O
the	O
orexigenic	O
genes	O
NPY	B-GENE-Y
and	O
CaMKK2	B-GENE-Y
was	O
down	O
-	O
regulated	O
by	O
the	O
respective	O
compounds	O
1	O
,	O
5	O
,	O
6	O
and	O
1	O
,	O
2	O
,	O
5	O
.	O

Oleoyl	B-CHEMICAL
-	I-CHEMICAL
L	I-CHEMICAL
-	I-CHEMICAL
valinolamide	I-CHEMICAL
enhances	O
anorectic	O
pathways	O
and	O
lead	O
to	O
decreased	O
glucose	B-CHEMICAL
levels	O
,	O
enhanced	O
locomotor	O
activity	O
,	O
and	O
improved	O
cognition	O
.	O

Effects	O
of	O
oleoyl	B-CHEMICAL
-	I-CHEMICAL
L	I-CHEMICAL
-	I-CHEMICAL
valinolamide	I-CHEMICAL
on	O
weight	O
were	O
dose	O
-	O
dependent	O
,	O
and	O
it	O
could	O
be	O
given	O
orally	O
.	O

1	O
,	O
2	O
,	O
4	O
,	O
5	O
down	O
-	O
regulated	O
FAAH	B-GENE-Y
mRNA	O
expression	O
.	O

Northern	O
contaminant	O
mixtures	O
induced	O
morphological	O
and	O
functional	O
changes	O
in	O
human	O
coronary	O
artery	O
endothelial	O
cells	O
under	O
culture	O
conditions	O
typifying	O
high	O
fat	O
/	O
sugar	B-CHEMICAL
diet	O
and	O
ethanol	B-CHEMICAL
exposure	O
.	O

It	O
has	O
been	O
reported	O
that	O
Northern	O
populations	O
are	O
exposed	O
to	O
mixtures	O
of	O
various	O
environmental	O
contaminants	O
unique	O
to	O
the	O
Arctic	O
(	O
Northern	O
contaminant	O
mixtures	O
-	O
NCM	O
)	O
at	O
a	O
large	O
range	O
of	O
concentrations	O
,	O
depending	O
on	O
their	O
geological	O
location	O
,	O
age	O
,	O
lifestyle	O
and	O
dietary	O
habits	O
.	O

To	O
determine	O
if	O
these	O
contaminants	O
may	O
contribute	O
to	O
a	O
cardiovascular	O
health	O
risk	O
,	O
especially	O
when	O
combined	O
with	O
a	O
high	O
fat	O
and	O
sugar	B-CHEMICAL
diet	O
and	O
ethanol	B-CHEMICAL
exposure	O
,	O
we	O
treated	O
human	O
coronary	O
artery	O
endothelial	O
cells	O
(	O
HCAEC	O
)	O
with	O
two	O
mixtures	O
of	O
4	O
organic	O
(	O
NCM1	O
)	O
or	O
22	O
organic	O
and	O
inorganic	O
(	O
NCM2	O
)	O
chemicals	O
detected	O
in	O
Northerners	O
'	O
blood	O
during	O
2004	O
-	O
2005	O
in	O
the	O
presence	O
or	O
absence	O
of	O
low	B-GENE-N
-	I-GENE-N
density	I-GENE-N
lipoprotein	I-GENE-N
(	O
1	O
.	O
5mg	O
/	O
ml	O
)	O
,	O
very	B-GENE-N
-	I-GENE-N
low	I-GENE-N
-	I-GENE-N
density	I-GENE-N
lipoprotein	I-GENE-N
(	O
1	O
.	O
0mg	O
/	O
ml	O
)	O
and	O
glucose	B-CHEMICAL
(	O
10mmol	O
/	O
L	O
)	O
(	O
LVG	O
)	O
,	O
and	O
in	O
the	O
absence	O
or	O
presence	O
of	O
0	O
.	O
1	O
%	O
ethanol	B-CHEMICAL
.	O

After	O
24h	O
of	O
exposure	O
,	O
cell	O
morphology	O
and	O
markers	O
of	O
cytotoxicity	O
and	O
endothelial	O
function	O
were	O
examined	O
.	O

NCM1	O
treatment	O
did	O
not	O
affect	O
cell	O
viability	O
,	O
but	O
increased	O
cell	O
size	O
,	O
disrupted	O
cell	O
membrane	O
integrity	O
,	O
and	O
decreased	O
cell	O
density	O
,	O
uptake	O
of	O
small	O
peptides	O
,	O
release	O
of	O
endothelin	B-GENE-Y
-	I-GENE-Y
1	I-GENE-Y
(	O
ET	B-GENE-Y
-	I-GENE-Y
1	I-GENE-Y
)	O
and	O
plasminogen	B-GENE-N
activator	I-GENE-N
inhibitor	I-GENE-N
(	O
PAI	B-GENE-N
)	O
,	O
while	O
causing	O
no	O
changes	O
in	O
endothelial	B-GENE-Y
nitric	I-GENE-Y
oxide	I-GENE-Y
synthase	I-GENE-Y
(	O
eNOS	B-GENE-Y
)	O
protein	O
expression	O
and	O
nitric	B-CHEMICAL
oxide	I-CHEMICAL
(	O
NO	B-CHEMICAL
)	O
release	O
.	O

In	O
contrast	O
,	O
NCM2	O
decreased	O
cell	O
viability	O
,	O
total	O
protein	O
yield	O
,	O
uptake	O
of	O
small	O
peptides	O
,	O
eNOS	B-GENE-Y
protein	O
expression	O
,	O
and	O
NO	B-CHEMICAL
release	O
and	O
caused	O
membrane	O
damage	O
,	O
but	O
caused	O
no	O
changes	O
in	O
the	O
secretion	O
of	O
ET	B-GENE-Y
-	I-GENE-Y
1	I-GENE-Y
,	O
prostacyclin	B-CHEMICAL
and	O
PAI	B-GENE-N
.	O

The	O
presence	O
of	O
LVG	O
and	O
/	O
or	O
alcohol	B-CHEMICAL
did	O
or	O
did	O
not	O
influence	O
the	O
effects	O
of	O
NCM1	O
or	O
NCM2	O
depending	O
on	O
the	O
endpoint	O
and	O
the	O
mixture	O
examined	O
.	O

These	O
results	O
suggested	O
that	O
the	O
effects	O
of	O
one	O
or	O
one	O
group	O
of	O
contaminants	O
may	O
be	O
altered	O
by	O
the	O
presence	O
of	O
other	O
contaminants	O
,	O
and	O
that	O
with	O
or	O
without	O
the	O
interaction	O
of	O
high	O
fat	O
and	O
sugar	B-CHEMICAL
diet	O
and	O
/	O
or	O
ethanol	B-CHEMICAL
exposure	O
,	O
NCMs	O
at	O
the	O
concentrations	O
used	O
caused	O
endothelial	O
dysfunction	O
in	O
vitro	O
.	O

It	O
remains	O
to	O
be	O
investigated	O
if	O
these	O
effects	O
of	O
NCMs	O
also	O
occur	O
in	O
vivo	O
.	O

QM	O
/	O
MM	O
simulations	O
of	O
vibrational	O
spectra	O
of	O
bacteriorhodopsin	B-GENE-N
and	O
channelrhodopsin	B-GENE-N
-	I-GENE-N
2	I-GENE-N
.	O

Channelrhodopsin	B-GENE-N
-	I-GENE-N
2	I-GENE-N
is	O
a	O
light	B-GENE-N
-	I-GENE-N
gated	I-GENE-N
ion	I-GENE-N
channel	I-GENE-N
,	O
which	O
has	O
been	O
studied	O
intensively	O
over	O
the	O
last	O
decade	O
.	O

Vibrational	O
spectroscopic	O
experiments	O
started	O
to	O
shed	O
light	O
on	O
the	O
structural	O
changes	O
,	O
that	O
occur	O
during	O
the	O
photocycle	O
,	O
especially	O
in	O
the	O
hydrogen	B-CHEMICAL
-	O
bonded	O
network	O
surrounding	O
the	O
protonated	O
D156	O
and	O
C128	O
-	O
the	O
DC	O
gate	O
.	O

However	O
,	O
the	O
interpretation	O
of	O
these	O
experiments	O
was	O
only	O
based	O
on	O
homology	O
models	O
.	O

Since	O
then	O
,	O
an	O
X	O
-	O
ray	O
structure	O
and	O
better	O
computational	O
models	O
became	O
available	O
.	O

In	O
this	O
article	O
,	O
we	O
show	O
that	O
in	O
combination	O
with	O
a	O
recent	O
reparametrization	O
,	O
the	O
approximate	O
DFT	O
method	O
,	O
DFTB	O
,	O
is	O
able	O
to	O
describe	O
the	O
effects	O
of	O
hydrogen	B-CHEMICAL
bonding	O
on	O
the	O
C	B-CHEMICAL
[	O
double	O
bond	O
,	O
length	O
as	O
m	O
-	O
dash	O
]	O
O	B-CHEMICAL
stretch	O
vibration	O
in	O
carboxylic	B-CHEMICAL
acids	I-CHEMICAL
reliably	O
and	O
agrees	O
well	O
with	O
full	O
DFT	O
results	O
.	O

We	O
apply	O
DFTB	O
in	O
a	O
QM	O
/	O
MM	O
framework	O
to	O
perform	O
vibrational	O
analysis	O
of	O
buried	O
aspartic	B-CHEMICAL
acids	I-CHEMICAL
in	O
bacteriorhodopsin	B-GENE-N
and	O
channelrhodopsin	B-GENE-N
-	I-GENE-N
2	I-GENE-N
.	O

Using	O
this	O
approach	O
,	O
we	O
can	O
simulate	O
the	O
FTIR	O
spectral	O
difference	O
between	O
D115	O
in	O
the	O
dark	O
-	O
adapted	O
and	O
K	O
states	O
of	O
bacteriorhodopsin	B-GENE-N
.	O

The	O
FTIR	O
experiments	O
on	O
the	O
DC	O
gate	O
in	O
channelrhodopsin	B-GENE-N
-	I-GENE-N
2	I-GENE-N
are	O
well	O
described	O
using	O
an	O
indirect	O
model	O
,	O
where	O
D156	O
and	O
C128	O
are	O
bridged	O
via	O
a	O
water	O
molecule	O
.	O

Refining	O
the	O
UGT1A	B-GENE-N
haplotype	O
associated	O
with	O
irinotecan	B-CHEMICAL
-	O
induced	O
hematological	O
toxicity	O
in	O
metastatic	O
colorectal	O
cancer	O
patients	O
treated	O
with	O
5	B-CHEMICAL
-	I-CHEMICAL
fluorouracil	I-CHEMICAL
/	O
irinotecan	B-CHEMICAL
-	O
based	O
regimens	O
.	O

Despite	O
the	O
importance	O
of	O
UDP	B-GENE-Y
-	I-GENE-Y
glucuronosyltransferase	I-GENE-Y
(	I-GENE-Y
UGT	I-GENE-Y
)	I-GENE-Y
1A1	I-GENE-Y
*	O
28	O
in	O
irinotecan	B-CHEMICAL
pharmacogenetics	O
,	O
our	O
capability	O
to	O
predict	O
drug	O
-	O
induced	O
severe	O
toxicity	O
remains	O
limited	O
.	O

We	O
aimed	O
at	O
identifying	O
novel	O
genetic	O
markers	O
that	O
would	O
improve	O
prediction	O
of	O
irinotecan	B-CHEMICAL
toxicity	O
and	O
response	O
in	O
advanced	O
colorectal	O
cancer	O
patients	O
treated	O
with	O
folic	B-CHEMICAL
acid	I-CHEMICAL
(	O
leucovorin	B-CHEMICAL
)	O
,	O
fluorouracil	B-CHEMICAL
(	O
5	B-CHEMICAL
-	I-CHEMICAL
FU	I-CHEMICAL
)	O
,	O
and	O
irinotecan	B-CHEMICAL
(	O
camptosar	B-CHEMICAL
)	O
-	O
based	O
regimens	O
.	O

The	O
relationships	O
between	O
UGT1A	B-GENE-N
candidate	O
markers	O
across	O
the	O
gene	O
(	O
n	O
=	O
21	O
)	O
and	O
toxicity	O
were	O
prospectively	O
evaluated	O
in	O
167	O
patients	O
.	O

We	O
included	O
variants	O
in	O
the	O
3	O
'	O
untranscribed	O
region	O
(	O
3	O
'	O
UTR	O
)	O
of	O
the	O
UGT1A	B-GENE-N
locus	O
,	O
not	O
studied	O
in	O
this	O
context	O
yet	O
.	O

These	O
genetic	O
markers	O
were	O
further	O
investigated	O
in	O
250	O
Italian	O
FOLFIRI	B-CHEMICAL
-	O
treated	O
patients	O
.	O

Several	O
functional	O
UGT1A	B-GENE-N
variants	O
,	O
including	O
UGT1A1	B-GENE-Y
*	O
28	O
,	O
significantly	O
influenced	O
risk	O
of	O
severe	O
hematologic	O
toxicity	O
.	O

As	O
previously	O
reported	O
in	O
the	O
Italian	O
cohort	O
,	O
a	O
5	O
-	O
marker	O
risk	O
haplotype	O
[	O
haplotype	O
II	O
(	O
HII	O
)	O
;	O
UGTs	B-GENE-N
1A9	O
/	O
1A7	O
/	O
1A1	O
]	O
was	O
associated	O
with	O
severe	O
neutropenia	O
in	O
our	O
cohort	O
[	O
odds	O
ratio	O
(	O
OR	O
)	O
=	O
2	O
.	O
43	O
;	O
P	O
=	O
0	O
.	O
004	O
]	O
.	O

The	O
inclusion	O
of	O
a	O
3	O
'	O
UTR	O
single	O
-	O
nucleotide	O
polymorphism	O
(	O
SNP	O
)	O
permitted	O
refinement	O
of	O
the	O
previously	O
defined	O
HI	O
,	O
in	O
which	O
HIa	O
was	O
associated	O
with	O
the	O
absence	O
of	O
severe	O
neutropenia	O
in	O
combined	O
cohorts	O
(	O
OR	O
=	O
0	O
.	O
55	O
;	O
P	O
=	O
0	O
.	O
038	O
)	O
.	O

Among	O
all	O
tested	O
UGT1A	B-GENE-N
variations	O
and	O
upon	O
multivariate	O
analyses	O
,	O
no	O
UGT1A1	B-GENE-Y
SNPs	O
remained	O
significant	O
,	O
whereas	O
three	O
SNPs	O
located	O
in	O
the	O
central	O
region	O
of	O
UGT1A	B-GENE-N
were	O
linked	O
to	O
neutropenia	O
grade	O
3	O
-	O
4	O
.	O

Haplotype	O
analyses	O
of	O
these	O
markers	O
with	O
the	O
3	O
'	O
UTR	O
SNP	O
allowed	O
the	O
identification	O
of	O
a	O
protective	O
HI	O
(	O
OR	O
=	O
0	O
.	O
50	O
;	O
P	O
=	O
0	O
.	O
048	O
)	O
and	O
two	O
risk	O
haplotypes	O
,	O
HII	O
and	O
HIII	O
,	O
characterized	O
by	O
2	O
and	O
3	O
unfavorable	O
alleles	O
,	O
respectively	O
,	O
revealing	O
a	O
dosage	O
effect	O
(	O
ORs	O
of	O
2	O
.	O
15	O
and	O
5	O
.	O
28	O
;	O
P	O
	O
0	O
.	O
030	O
)	O
.	O

Our	O
results	O
suggest	O
that	O
specific	O
SNPs	O
in	O
UGT1A	B-GENE-N
,	O
other	O
than	O
UGT1A1	B-GENE-Y
*	O
28	O
,	O
may	O
influence	O
irinotecan	B-CHEMICAL
toxicity	O
and	O
should	O
be	O
considered	O
to	O
refine	O
pharmacogenetic	O
testing	O
.	O

Androgen	B-GENE-Y
Receptor	I-GENE-Y
mRNA	O
Measured	O
by	O
Quantitative	O
Real	O
Time	O
PCR	O
is	O
Decreased	O
in	O
the	O
Urethral	O
Mucosa	O
of	O
Patients	O
with	O
Middle	O
Idiopathic	O
Hypospadias	O
.	O

Androgen	B-CHEMICAL
action	O
is	O
exerted	O
through	O
the	O
androgen	B-GENE-Y
receptor	I-GENE-Y
.	O

The	O
normal	O
46	O
,	O
XY	O
genital	O
virilization	O
depends	O
on	O
androgen	B-GENE-Y
receptor	I-GENE-Y
gene	O
expression	O
,	O
which	O
is	O
tissue	O
specific	O
,	O
and	O
requires	O
normal	O
androgen	B-GENE-Y
receptor	I-GENE-Y
mRNA	O
levels	O
in	O
androgen	B-CHEMICAL
sensitive	O
tissues	O
.	O

Hypospadias	O
is	O
a	O
frequent	O
male	O
genital	O
abnormality	O
,	O
potentially	O
related	O
to	O
reduced	O
androgen	B-CHEMICAL
sensitivity	O
in	O
genital	O
tissues	O
.	O

The	O
aim	O
of	O
this	O
study	O
was	O
to	O
compare	O
,	O
by	O
quantitative	O
real	O
time	O
PCR	O
,	O
the	O
amount	O
of	O
androgen	B-GENE-Y
receptor	I-GENE-Y
mRNA	O
in	O
cells	O
obtained	O
from	O
the	O
urethral	O
mucosa	O
of	O
patients	O
with	O
middle	O
idiopathic	O
hypospadias	O
with	O
the	O
androgen	B-GENE-Y
receptor	I-GENE-Y
mRNA	O
levels	O
observed	O
in	O
control	O
phimosis	O
subjects	O
with	O
eutopic	O
urethral	O
opening	O
.	O

Prepubertal	O
individuals	O
were	O
studied	O
,	O
including	O
41	O
controls	O
and	O
17	O
hypospadias	O
patients	O
with	O
mean	O
(	O
SD	O
)	O
ages	O
of	O
4	O
.	O
7	O
(	O
2	O
.	O
1	O
)	O
years	O
and	O
4	O
.	O
0	O
(	O
3	O
.	O
0	O
)	O
years	O
,	O
respectively	O
.	O

We	O
observed	O
significantly	O
less	O
androgen	B-GENE-Y
receptor	I-GENE-Y
mRNA	O
in	O
the	O
urethral	O
mucosa	O
of	O
patients	O
with	O
hypospadias	O
than	O
in	O
the	O
controls	O
(	O
p	O
=	O
0	O
.	O
002	O
)	O
.	O

The	O
correlation	O
between	O
the	O
level	O
of	O
androgen	B-GENE-Y
receptor	I-GENE-Y
mRNA	O
expression	O
and	O
the	O
penile	O
size	O
was	O
almost	O
statistically	O
significant	O
only	O
in	O
hypospadias	O
patients	O
(	O
r	O
=	O
0	O
.	O
47	O
;	O
p	O
=	O
0	O
.	O
053	O
)	O
.	O

We	O
also	O
established	O
the	O
number	O
of	O
CAG	B-GENE-N
repeats	I-GENE-N
in	O
exon	O
1	O
of	O
the	O
androgen	B-GENE-Y
receptor	I-GENE-Y
gene	O
by	O
GeneScan	O
analysis	O
.	O

No	O
significant	O
difference	O
was	O
observed	O
in	O
the	O
number	O
of	O
CAG	B-GENE-N
repeats	I-GENE-N
when	O
patients	O
and	O
controls	O
were	O
compared	O
.	O

A	O
negative	O
correlation	O
between	O
the	O
CAG	B-GENE-N
repeats	I-GENE-N
and	O
penile	O
size	O
was	O
detected	O
in	O
patients	O
with	O
hypospadias	O
,	O
but	O
not	O
in	O
controls	O
.	O

Our	O
data	O
suggest	O
that	O
a	O
critical	O
lower	O
level	O
of	O
androgen	B-GENE-Y
receptor	I-GENE-Y
mRNA	O
expression	O
could	O
be	O
a	O
determining	O
factor	O
in	O
the	O
development	O
of	O
middle	O
hypospadias	O
.	O

Oxidative	O
Stress	O
and	O
DNA	O
Damage	O
in	O
Human	O
Gastric	O
Carcinoma	O
:	O
8	B-CHEMICAL
-	I-CHEMICAL
Oxo	I-CHEMICAL
-	I-CHEMICAL
7	I-CHEMICAL
'	I-CHEMICAL
8	I-CHEMICAL
-	I-CHEMICAL
dihydro	I-CHEMICAL
-	I-CHEMICAL
2	I-CHEMICAL
'	I-CHEMICAL
-	I-CHEMICAL
deoxyguanosine	I-CHEMICAL
(	O
8	B-CHEMICAL
-	I-CHEMICAL
oxo	I-CHEMICAL
-	I-CHEMICAL
dG	I-CHEMICAL
)	O
as	O
a	O
Possible	O
Tumor	O
Marker	O
.	O

We	O
characterized	O
the	O
oxidative	O
stress	O
(	O
OS	O
)	O
status	O
by	O
the	O
levels	O
of	O
reduced	B-CHEMICAL
/	I-CHEMICAL
oxidized	I-CHEMICAL
glutathione	I-CHEMICAL
(	O
GSH	B-CHEMICAL
/	O
GSSG	B-CHEMICAL
)	O
,	O
malondialdehyde	B-CHEMICAL
(	O
MDA	B-CHEMICAL
)	O
and	O
the	O
mutagenic	O
base	O
8	B-CHEMICAL
-	I-CHEMICAL
oxo	I-CHEMICAL
-	I-CHEMICAL
7	I-CHEMICAL
'	I-CHEMICAL
8	I-CHEMICAL
-	I-CHEMICAL
dihydro	I-CHEMICAL
-	I-CHEMICAL
2	I-CHEMICAL
'	I-CHEMICAL
-	I-CHEMICAL
deoxyguanosine	I-CHEMICAL
(	O
8	B-CHEMICAL
-	I-CHEMICAL
oxo	I-CHEMICAL
-	I-CHEMICAL
dG	I-CHEMICAL
)	O
in	O
human	O
gastric	O
carcinoma	O
(	O
HGC	O
)	O
samples	O
and	O
compared	O
the	O
results	O
with	O
normal	O
tissue	O
from	O
the	O
same	O
patients	O
.	O

We	O
also	O
analyzed	O
8	B-CHEMICAL
-	I-CHEMICAL
oxo	I-CHEMICAL
-	I-CHEMICAL
dG	I-CHEMICAL
in	O
peripheral	O
mononuclear	O
cells	O
(	O
PMNC	O
)	O
and	O
urine	O
from	O
healthy	O
control	O
subjects	O
and	O
in	O
affected	O
patients	O
in	O
the	O
basal	O
state	O
and	O
one	O
,	O
three	O
,	O
six	O
,	O
nine	O
and	O
twelve	O
months	O
after	O
tumor	O
resection	O
.	O

The	O
levels	O
of	O
DNA	O
repair	O
enzyme	O
mRNA	O
expression	O
(	O
hOGG1	B-GENE-Y
,	O
RAD51	B-GENE-Y
,	O
MUYTH	B-GENE-Y
and	O
MTH1	B-GENE-Y
)	O
were	O
determined	O
in	O
tumor	O
specimens	O
and	O
compared	O
with	O
normal	O
mucosa	O
.	O

Tumor	O
specimens	O
exhibited	O
increased	O
levels	O
of	O
MDA	B-CHEMICAL
and	O
8	B-CHEMICAL
-	I-CHEMICAL
oxo	I-CHEMICAL
-	I-CHEMICAL
dG	I-CHEMICAL
compared	O
with	O
normal	O
gastric	O
tissue	O
.	O

GSH	B-CHEMICAL
levels	O
were	O
also	O
increased	O
,	O
while	O
GSSG	B-CHEMICAL
levels	O
remained	O
stable	O
.	O

DNA	O
repair	O
enzyme	O
mRNA	O
expression	O
was	O
induced	O
in	O
the	O
tumor	O
tissues	O
.	O

Levels	O
of	O
8	B-CHEMICAL
-	I-CHEMICAL
oxo	I-CHEMICAL
-	I-CHEMICAL
dG	I-CHEMICAL
were	O
significantly	O
elevated	O
in	O
both	O
urine	O
and	O
PMNC	O
of	O
gastric	O
cancer	O
patients	O
compared	O
with	O
healthy	O
controls	O
.	O

After	O
gastrectomy	O
,	O
the	O
levels	O
of	O
the	O
damaged	O
base	O
in	O
urine	O
and	O
PMNC	O
decreased	O
progressively	O
to	O
values	O
close	O
to	O
those	O
found	O
in	O
the	O
healthy	O
population	O
.	O

The	O
high	O
levels	O
of	O
8	B-CHEMICAL
-	I-CHEMICAL
oxo	I-CHEMICAL
-	I-CHEMICAL
dG	I-CHEMICAL
in	O
urine	O
may	O
be	O
related	O
to	O
the	O
increased	O
induction	O
of	O
DNA	O
repair	O
activity	O
in	O
tumor	O
tissue	O
,	O
and	O
the	O
changes	O
observed	O
after	O
tumor	O
resection	O
support	O
its	O
potential	O
use	O
as	O
a	O
tumor	O
marker	O
.	O

An	O
intra	O
-	O
articular	O
salmon	O
calcitonin	O
-	O
based	O
nanocomplex	O
reduces	O
experimental	O
inflammatory	O
arthritis	O
.	O

Prolonged	O
inappropriate	O
inflammatory	O
responses	O
contribute	O
to	O
the	O
pathogenesis	O
of	O
rheumatoid	O
arthritis	O
(	O
RA	O
)	O
and	O
to	O
aspects	O
of	O
osteoarthritis	O
(	O
OA	O
)	O
.	O

The	O
orphan	B-GENE-Y
nuclear	I-GENE-Y
receptor	I-GENE-Y
,	I-GENE-Y
NR4A2	I-GENE-Y
,	O
is	O
a	O
key	O
regulator	O
and	O
potential	O
biomarker	O
for	O
inflammation	O
and	O
represents	O
a	O
potentially	O
valuable	O
therapeutic	O
target	O
.	O

Both	O
salmon	O
calcitonin	O
(	O
sCT	O
)	O
and	O
hyaluronic	O
acid	O
(	O
HA	O
)	O
attenuated	O
activated	O
mRNA	O
expression	O
of	O
NR4A1	B-GENE-Y
,	O
NR4A2	B-GENE-Y
,	O
NR4A3	B-GENE-Y
,	O
and	O
matrix	B-GENE-N
metalloproteinases	I-GENE-N
(	I-GENE-N
MMPs	I-GENE-N
)	I-GENE-N
1	I-GENE-N
,	I-GENE-N
3	I-GENE-N
and	I-GENE-N
13	I-GENE-N
in	O
three	O
human	O
cell	O
lines	O
:	O
SW1353	O
chondrocytes	O
,	O
U937	O
and	O
THP	O
-	O
1	O
monocytes	O
.	O

Ad	O
-	O
mixtures	O
of	O
sCT	O
and	O
HA	O
further	O
down	O
-	O
regulated	O
expression	O
of	O
NR4A2	B-GENE-Y
compared	O
to	O
either	O
agent	O
alone	O
at	O
specific	O
concentrations	O
,	O
hence	O
the	O
rationale	O
for	O
their	O
formulation	O
in	O
nanocomplexes	O
(	O
NPs	O
)	O
using	O
chitosan	O
.	O

The	O
sCT	O
released	O
from	O
NP	O
stimulated	O
cAMP	B-CHEMICAL
production	O
in	O
human	O
T47D	O
breast	O
cancer	O
cells	O
expressing	O
sCT	B-GENE-Y
receptors	I-GENE-Y
.	O

When	O
NP	O
were	O
injected	O
by	O
the	O
intra	O
-	O
articular	O
(	O
I	O
.	O
A	O
.	O
)	O
route	O
to	O
the	O
mouse	O
knee	O
during	O
on	O
-	O
going	O
inflammatory	O
arthritis	O
of	O
the	O
K	O
/	O
BxN	O
serum	O
transfer	O
model	O
,	O
joint	O
inflammation	O
was	O
reduced	O
together	O
with	O
NR4A2	B-GENE-Y
expression	O
,	O
and	O
local	O
bone	O
architecture	O
was	O
preserved	O
.	O

These	O
data	O
highlight	O
remarkable	O
anti	O
-	O
inflammatory	O
effects	O
of	O
sCT	O
and	O
HA	O
at	O
the	O
level	O
of	O
reducing	O
NR4A2	B-GENE-Y
mRNA	O
expression	O
in	O
vitro	O
.	O

Combining	O
them	O
in	O
NP	O
elicits	O
anti	O
-	O
arthritic	O
effects	O
in	O
vivo	O
following	O
I	O
.	O
A	O
.	O
delivery	O
.	O

Prolactin	B-GENE-Y
regulates	O
transcription	O
of	O
the	O
ion	O
uptake	O
Na	B-GENE-Y
+	I-GENE-Y
/	I-GENE-Y
Cl	I-GENE-Y
-	I-GENE-Y
cotransporter	I-GENE-Y
(	O
ncc	B-GENE-Y
)	O
gene	O
in	O
zebrafish	O
gill	O
.	O

Prolactin	B-GENE-Y
(	O
PRL	B-GENE-Y
)	O
is	O
a	O
well	O
-	O
known	O
regulator	O
of	O
ion	O
and	O
water	O
transport	O
within	O
osmoregulatory	O
tissues	O
across	O
vertebrate	O
species	O
,	O
yet	O
how	O
PRL	B-GENE-Y
acts	O
on	O
some	O
of	O
its	O
target	O
tissues	O
remains	O
poorly	O
understood	O
.	O

Using	O
zebrafish	O
as	O
a	O
model	O
,	O
we	O
show	O
that	O
ionocytes	O
in	O
the	O
gill	O
directly	O
respond	O
to	O
systemic	O
PRL	B-GENE-Y
to	O
regulate	O
mechanisms	O
of	O
ion	O
uptake	O
.	O

Ion	O
-	O
poor	O
conditions	O
led	O
to	O
increases	O
in	O
the	O
expression	O
of	O
PRL	B-GENE-N
receptor	I-GENE-N
(	O
prlra	B-GENE-Y
)	O
,	O
Na	B-GENE-Y
(	I-GENE-Y
+	I-GENE-Y
)	I-GENE-Y
/	I-GENE-Y
Cl	I-GENE-Y
(	I-GENE-Y
-	I-GENE-Y
)	I-GENE-Y
cotransporter	I-GENE-Y
(	O
ncc	B-GENE-Y
;	O
slc12a10	B-GENE-Y
.	I-GENE-Y
2	I-GENE-Y
)	O
,	O
Na	B-GENE-Y
(	I-GENE-Y
+	I-GENE-Y
)	I-GENE-Y
/	I-GENE-Y
H	I-GENE-Y
(	I-GENE-Y
+	I-GENE-Y
)	I-GENE-Y
exchanger	I-GENE-Y
(	O
nhe3b	B-GENE-Y
;	O
slc9a3	B-GENE-Y
.	I-GENE-Y
2	I-GENE-Y
)	O
,	O
and	O
epithelial	B-GENE-Y
Ca	I-GENE-Y
(	I-GENE-Y
2	I-GENE-Y
+	I-GENE-Y
)	I-GENE-Y
channel	I-GENE-Y
(	O
ecac	B-GENE-Y
;	O
trpv6	B-GENE-Y
)	O
transcripts	O
within	O
the	O
gill	O
.	O

Intraperitoneal	O
injection	O
of	O
ovine	B-GENE-Y
PRL	I-GENE-Y
(	O
oPRL	B-GENE-Y
)	O
increased	O
ncc	B-GENE-Y
and	O
prlra	B-GENE-Y
transcripts	O
,	O
but	O
did	O
not	O
affect	O
nhe3b	B-GENE-Y
or	O
ecac	B-GENE-Y
.	O

Consistent	O
with	O
direct	O
PRL	B-GENE-Y
action	O
in	O
the	O
gill	O
,	O
addition	O
of	O
oPRL	B-GENE-Y
to	O
cultured	O
gill	O
filaments	O
stimulated	O
ncc	B-GENE-Y
in	O
a	O
concentration	O
-	O
dependent	O
manner	O
,	O
an	O
effect	O
blocked	O
by	O
a	O
pure	O
human	B-GENE-Y
PRL	I-GENE-Y
receptor	I-GENE-Y
antagonist	O
(	O
1	O
-	O
9	O
-	O
G129R	B-GENE-N
-	O
hPRL	B-GENE-Y
)	O
.	O

These	O
results	O
suggest	O
that	O
PRL	B-GENE-Y
signaling	O
through	O
PRL	B-GENE-N
receptors	I-GENE-N
in	O
the	O
gill	O
regulates	O
the	O
expression	O
of	O
ncc	B-GENE-Y
,	O
thereby	O
linking	O
this	O
pituitary	B-GENE-N
hormone	I-GENE-N
with	O
an	O
effector	O
of	O
Cl	B-CHEMICAL
(	I-CHEMICAL
-	I-CHEMICAL
)	I-CHEMICAL
uptake	O
in	O
zebrafish	O
for	O
the	O
first	O
time	O
.	O

Parathyroid	B-GENE-Y
hormone	I-GENE-Y
(	I-GENE-Y
1	I-GENE-Y
-	I-GENE-Y
34	I-GENE-Y
)	I-GENE-Y
counteracts	O
the	O
suppression	O
of	O
interleukin	B-GENE-Y
-	I-GENE-Y
11	I-GENE-Y
expression	O
by	O
glucocorticoid	O
in	O
murine	O
osteoblasts	O
:	O
a	O
possible	O
mechanism	O
for	O
stimulating	O
osteoblast	O
differentiation	O
against	O
glucocorticoid	O
excess	O
.	O

Glucocorticoid	O
(	O
GC	O
)	O
excess	O
causes	O
a	O
rapid	O
loss	O
of	O
bone	O
with	O
a	O
reduction	O
in	O
bone	O
formation	O
.	O

Intermittent	O
PTH	B-GENE-Y
(	I-GENE-Y
1	I-GENE-Y
-	I-GENE-Y
34	I-GENE-Y
)	I-GENE-Y
administration	O
stimulates	O
bone	O
formation	O
and	O
counteracts	O
the	O
inhibition	O
of	O
bone	O
formation	O
by	O
GC	O
excess	O
.	O

We	O
have	O
previously	O
demonstrated	O
that	O
mechanical	O
strain	O
enhances	O
interleukin	B-GENE-Y
(	I-GENE-Y
IL	I-GENE-Y
)	I-GENE-Y
-	I-GENE-Y
11	I-GENE-Y
gene	O
transcription	O
by	O
a	O
rapid	O
induction	O
of	O
FosB	B-GENE-Y
expression	O
and	O
protein	B-GENE-Y
kinase	I-GENE-Y
C	I-GENE-Y
(	I-GENE-Y
PKC	I-GENE-Y
)	I-GENE-Y
-	I-GENE-Y
	I-GENE-Y
-	O
mediated	O
phosphorylation	O
of	O
phosphorylated	O
mothers	O
against	O
decapentaplegic	O
(	O
Smad	O
)	O
-	O
1	O
.	O

Because	O
IL	B-GENE-Y
-	I-GENE-Y
11	I-GENE-Y
suppresses	O
the	O
expression	O
of	O
dickkopf	B-GENE-N
-	I-GENE-N
1	I-GENE-N
and	I-GENE-N
-	I-GENE-N
2	I-GENE-N
and	O
stimulates	O
Wnt	B-GENE-N
signaling	O
,	O
IL	B-GENE-Y
-	I-GENE-Y
11	I-GENE-Y
appears	O
to	O
mediate	O
at	O
least	O
a	O
part	O
of	O
the	O
effect	O
of	O
mechanical	O
strain	O
on	O
osteoblast	O
differentiation	O
and	O
bone	O
formation	O
.	O

The	O
present	O
study	O
was	O
undertaken	O
to	O
examine	O
the	O
effect	O
of	O
PTH	B-GENE-Y
(	I-GENE-Y
1	I-GENE-Y
-	I-GENE-Y
34	I-GENE-Y
)	I-GENE-Y
and	O
GCs	O
on	O
IL	B-GENE-Y
-	I-GENE-Y
11	I-GENE-Y
expression	O
in	O
murine	O
primary	O
osteoblasts	O
(	O
mPOBs	O
)	O
.	O

PTH	B-GENE-Y
(	I-GENE-Y
1	I-GENE-Y
-	I-GENE-Y
34	I-GENE-Y
)	I-GENE-Y
treatment	O
of	O
mPOBs	O
enhanced	O
IL	B-GENE-Y
-	I-GENE-Y
11	I-GENE-Y
expression	O
in	O
a	O
time	O
-	O
and	O
dose	O
-	O
dependent	O
manner	O
.	O

PTH	B-GENE-Y
(	I-GENE-Y
1	I-GENE-Y
-	I-GENE-Y
34	I-GENE-Y
)	I-GENE-Y
also	O
stimulated	O
FosB	B-GENE-Y
expression	O
and	O
Smad1	B-GENE-Y
phosphorylation	O
,	O
which	O
cooperatively	O
stimulated	O
IL	B-GENE-Y
-	I-GENE-Y
11	I-GENE-Y
gene	O
transcription	O
.	O

PTH	B-GENE-Y
(	I-GENE-Y
1	I-GENE-Y
-	I-GENE-Y
34	I-GENE-Y
)	I-GENE-Y
-	O
induced	O
Smad1	B-GENE-Y
phosphorylation	O
was	O
mediated	O
via	O
PKC	B-GENE-Y
and	O
was	O
abrogated	O
in	O
mPOBs	O
from	O
PKC	B-GENE-Y
knockout	O
mice	O
.	O

Dexamethasone	B-CHEMICAL
suppressed	O
IL	B-GENE-Y
-	I-GENE-Y
11	I-GENE-Y
gene	O
transcription	O
enhanced	O
by	O
PTH	B-GENE-Y
(	I-GENE-Y
1	I-GENE-Y
-	I-GENE-Y
34	I-GENE-Y
)	I-GENE-Y
without	O
affecting	O
FosB	B-GENE-Y
expression	O
or	O
Smad1	O
phosphorylation	O
,	O
and	O
dexamethasone	B-CHEMICAL
-	O
GC	B-GENE-Y
receptor	I-GENE-Y
complex	O
was	O
bound	O
to	O
JunD	B-GENE-Y
,	O
which	O
forms	O
heterodimers	O
with	O
FosB	B-GENE-Y
.	O

High	O
doses	O
of	O
PTH	B-GENE-Y
(	I-GENE-Y
1	I-GENE-Y
-	I-GENE-Y
34	I-GENE-Y
)	I-GENE-Y
counteracted	O
the	O
effect	O
of	O
dexamethasone	B-CHEMICAL
on	O
apoptosis	O
of	O
mPOBs	O
,	O
which	O
was	O
blunted	O
by	O
neutralizing	O
anti	O
-	O
IL	B-GENE-Y
-	I-GENE-Y
11	I-GENE-Y
antibody	O
or	O
IL	B-GENE-Y
-	I-GENE-Y
11	I-GENE-Y
small	O
interfering	O
RNA	O
.	O

These	O
results	O
demonstrate	O
that	O
PTH	B-GENE-Y
(	I-GENE-Y
1	I-GENE-Y
-	I-GENE-Y
34	I-GENE-Y
)	I-GENE-Y
and	O
GCs	O
interact	O
to	O
regulate	O
IL	B-GENE-Y
-	I-GENE-Y
11	I-GENE-Y
expression	O
in	O
parallel	O
with	O
osteoblast	O
differentiation	O
and	O
apoptosis	O
and	O
suggest	O
that	O
PTH	B-GENE-Y
(	I-GENE-Y
1	I-GENE-Y
-	I-GENE-Y
34	I-GENE-Y
)	I-GENE-Y
and	O
dexamethasone	B-CHEMICAL
may	O
regulate	O
osteoblast	O
differentiation	O
and	O
apoptosis	O
via	O
their	O
effect	O
on	O
IL	B-GENE-Y
-	I-GENE-Y
11	I-GENE-Y
expression	O
.	O

Effects	O
of	O
amlodipine	B-CHEMICAL
on	O
the	O
oral	O
bioavailability	O
of	O
cephalexin	B-CHEMICAL
and	O
cefuroxime	B-CHEMICAL
axetil	I-CHEMICAL
in	O
healthy	O
volunteers	O
.	O

In	O
this	O
study	O
,	O
the	O
authors	O
compared	O
the	O
effects	O
of	O
amlodipine	B-CHEMICAL
(	O
AML	B-CHEMICAL
)	O
on	O
the	O
bioavailability	O
of	O
cephalexin	B-CHEMICAL
(	O
LEX	B-CHEMICAL
)	O
and	O
cefuroxime	B-CHEMICAL
axetil	I-CHEMICAL
(	O
CXM	B-CHEMICAL
)	O
.	O

Twenty	O
-	O
four	O
healthy	O
men	O
were	O
randomized	O
to	O
4	O
treatments	O
according	O
to	O
a	O
crossover	O
design	O
with	O
a	O
14	O
-	O
day	O
washout	O
.	O

After	O
an	O
overnight	O
fast	O
,	O
they	O
were	O
administered	O
orally	O
LEX	B-CHEMICAL
500	O
mg	O
alone	O
,	O
LEX	B-CHEMICAL
500	O
mg	O
2	O
hours	O
after	O
oral	O
administration	O
of	O
AML	B-CHEMICAL
5	O
mg	O
,	O
CXM	B-CHEMICAL
500	O
mg	O
alone	O
,	O
and	O
CXM	B-CHEMICAL
500	O
mg	O
2	O
hours	O
after	O
oral	O
administration	O
of	O
AML	B-CHEMICAL
5	O
mg	O
.	O

All	O
participants	O
completed	O
the	O
whole	O
study	O
without	O
side	O
effects	O
being	O
observed	O
.	O

Pharmacokinetic	O
data	O
were	O
analyzed	O
by	O
noncompartmental	O
modeling	O
with	O
WinNonlin	O
software	O
.	O

The	O
geometric	O
mean	O
(	O
GM	O
)	O
ratios	O
were	O
1	O
.	O
38	O
(	O
90	O
%	O
confidence	O
interval	O
[	O
CI	O
]	O
,	O
1	O
.	O
32	O
-	O
1	O
.	O
45	O
)	O
for	O
the	O
area	O
under	O
the	O
concentration	O
-	O
time	O
curve	O
(	O
AUC	O
)	O
for	O
LEX	B-CHEMICAL
and	O
1	O
.	O
27	O
(	O
1	O
.	O
18	O
-	O
1	O
.	O
36	O
)	O
for	O
the	O
maximum	O
concentration	O
of	O
drug	O
in	O
serum	O
(	O
C	O
(	O
max	O
)	O
)	O
for	O
LEX	B-CHEMICAL
followed	O
by	O
AML	B-CHEMICAL
versus	O
alone	O
.	O

In	O
contrast	O
,	O
no	O
significant	O
differences	O
were	O
found	O
in	O
the	O
pharmacokinetic	O
parameters	O
of	O
CXM	B-CHEMICAL
between	O
treatments	O
(	O
P	O
<	O
.	O
05	O
)	O
.	O

They	O
authors	O
conclude	O
that	O
AML	B-CHEMICAL
possesses	O
an	O
enhancement	O
effect	O
in	O
	B-CHEMICAL
-	I-CHEMICAL
lactam	I-CHEMICAL
antibiotic	O
bioavailability	O
(	O
in	O
this	O
case	O
,	O
LEX	B-CHEMICAL
)	O
,	O
and	O
this	O
interaction	O
may	O
be	O
specific	O
to	O
the	O
peptidomimetic	O
	B-CHEMICAL
-	I-CHEMICAL
lactam	I-CHEMICAL
antibiotics	O
.	O

Binding	O
between	O
proteins	O
and	O
cationic	O
spherical	O
polyelectrolyte	O
brushes	O
:	O
effect	O
of	O
pH	O
,	O
ionic	O
strength	O
,	O
and	O
stoichiometry	O
.	O

Cationic	O
spherical	O
polyelectrolyte	O
brushes	O
(	O
SPBs	O
)	O
were	O
synthesized	O
by	O
photoemulsion	O
polymerization	O
,	O
consisting	O
of	O
a	O
polystyrene	B-CHEMICAL
core	O
with	O
a	O
diameter	O
around	O
80	O
nm	O
and	O
a	O
poly	B-CHEMICAL
(	I-CHEMICAL
2	I-CHEMICAL
-	I-CHEMICAL
aminoethylmethacrylate	I-CHEMICAL
hydrochloride	I-CHEMICAL
)	I-CHEMICAL
(	O
PAEMH	B-CHEMICAL
)	O
shell	O
with	O
a	O
thickness	O
from	O
10	O
to	O
50	O
nm	O
densely	O
grafted	O
on	O
the	O
core	O
surface	O
.	O

The	O
binding	O
of	O
various	O
proteins	O
onto	O
SPBs	O
was	O
observed	O
by	O
turbidimetric	O
titration	O
,	O
dynamic	O
light	O
scattering	O
(	O
DLS	O
)	O
,	O
zeta	O
potential	O
,	O
and	O
isothermal	O
titration	O
calorimetry	O
(	O
ITC	O
)	O
.	O

The	O
binding	O
,	O
aggregation	O
,	O
and	O
releasing	O
of	O
proteins	O
by	O
SPB	O
can	O
be	O
tuned	O
by	O
modulating	O
pH	O
.	O

The	O
pH	O
regions	O
of	O
binding	O
for	O
bovine	B-GENE-Y
serum	I-GENE-Y
albumin	I-GENE-Y
(	O
BSA	B-GENE-Y
)	O
,	O
	B-GENE-Y
-	I-GENE-Y
lactoglobulin	I-GENE-Y
(	O
BLG	B-GENE-Y
)	O
,	O
and	O
papain	B-GENE-Y
onto	O
SPBs	O
are	O
markedly	O
different	O
and	O
tunable	O
by	O
ionic	O
strength	O
and	O
stoichiometry	O
between	O
protein	O
and	O
SPB	O
.	O

Binding	O
energetics	O
,	O
affinity	O
,	O
and	O
amount	O
of	O
various	O
proteins	O
onto	O
cationic	O
SPBs	O
were	O
determined	O
by	O
ITC	O
.	O

These	O
findings	O
lay	O
the	O
foundation	O
for	O
SPB	O
applications	O
in	O
the	O
protein	O
purification	O
and	O
selective	O
immobilization	O
of	O
different	O
proteins	O
,	O
enzymes	O
,	O
and	O
antibodies	O
.	O

Combined	O
effects	O
of	O
organochlorine	B-CHEMICAL
pesticides	O
heptachlor	B-CHEMICAL
and	O
hexachlorobenzene	B-CHEMICAL
on	O
the	O
promotion	O
stage	O
of	O
hepatocarcinogenesis	O
in	O
rats	O
.	O

We	O
aimed	O
to	O
investigate	O
the	O
combined	O
effect	O
of	O
organochlorine	B-CHEMICAL
pesticides	O
heptachlor	B-CHEMICAL
(	O
HEP	B-CHEMICAL
)	O
and	O
hexachlorobenzene	B-CHEMICAL
(	O
HCB	B-CHEMICAL
)	O
by	O
using	O
a	O
medium	O
-	O
term	O
rat	O
liver	O
bioassay	O
.	O

Male	O
F344	O
rats	O
were	O
initially	O
administered	O
diethylnitrosamine	B-CHEMICAL
(	O
DEN	B-CHEMICAL
,	O
200mg	O
/	O
kgi	O
.	O
p	O
.	O
)	O
;	O
after	O
a	O
2	O
-	O
week	O
non	O
-	O
dosing	O
period	O
,	O
they	O
were	O
given	O
diets	O
containing	O
HEP	B-CHEMICAL
(	O
5	O
or	O
25ppm	O
)	O
,	O
HCB	B-CHEMICAL
(	O
70	O
or	O
350ppm	O
)	O
,	O
or	O
their	O
mixtures	O
(	O
5	O
and	O
70ppm	O
or	O
25	O
and	O
350ppm	O
)	O
for	O
6weeks	O
.	O

All	O
rats	O
were	O
subjected	O
to	O
partial	O
hepatectomy	O
at	O
week	O
3	O
and	O
killed	O
at	O
week	O
8	O
.	O

We	O
observed	O
additive	O
or	O
synergistic	O
effects	O
of	O
HEP	B-CHEMICAL
and	O
HCB	B-CHEMICAL
in	O
groups	O
treated	O
with	O
mixtures	O
of	O
these	O
pesticides	O
.	O

Number	O
and	O
area	O
of	O
preneoplastic	O
foci	O
positive	O
for	O
glutathione	B-GENE-N
S	I-GENE-N
-	I-GENE-N
transferase	I-GENE-N
placental	I-GENE-N
form	I-GENE-N
(	O
GST	B-GENE-N
-	I-GENE-N
P	I-GENE-N
)	O
were	O
consistently	O
higher	O
in	O
these	O
groups	O
than	O
the	O
sum	O
of	O
individual	O
values	O
in	O
the	O
groups	O
treated	O
with	O
HEP	B-CHEMICAL
or	O
HCB	B-CHEMICAL
alone	O
.	O

Consistent	O
with	O
these	O
findings	O
,	O
HEP	B-CHEMICAL
and	O
HCB	B-CHEMICAL
had	O
additive	O
or	O
synergistic	O
effects	O
on	O
cell	O
proliferation	O
induction	O
within	O
the	O
preneoplastic	O
foci	O
and	O
cytochrome	B-GENE-N
P450	I-GENE-N
(	I-GENE-N
CYP	I-GENE-N
)	I-GENE-N
2B1	I-GENE-N
and	I-GENE-N
3A1	I-GENE-N
induction	O
,	O
which	O
may	O
lead	O
to	O
more	O
efficient	O
metabolic	O
activation	O
of	O
HEP	B-CHEMICAL
and	O
HCB	B-CHEMICAL
.	O

On	O
the	O
basis	O
of	O
these	O
findings	O
,	O
we	O
conclude	O
that	O
HEP	B-CHEMICAL
and	O
HCB	B-CHEMICAL
have	O
additive	O
and	O
synergistic	O
effects	O
on	O
the	O
development	O
of	O
GST	B-GENE-N
-	I-GENE-N
P	I-GENE-N
-	O
positive	O
foci	O
and	O
that	O
higher	O
risks	O
are	O
associated	O
with	O
a	O
combination	O
of	O
residual	O
organochlorine	B-CHEMICAL
pesticides	O
in	O
foods	O
than	O
with	O
individual	O
residual	O
organochlorine	B-CHEMICAL
pesticides	O
.	O

The	O
food	O
contaminant	O
deoxynivalenol	B-CHEMICAL
activates	O
the	O
mitogen	B-GENE-N
activated	I-GENE-N
protein	I-GENE-N
kinases	I-GENE-N
in	O
the	O
intestine	O
:	O
interest	O
of	O
ex	O
vivo	O
models	O
as	O
an	O
alternative	O
to	O
in	O
vivo	O
experiments	O
.	O

Trichothecenes	B-CHEMICAL
induce	O
changes	O
in	O
the	O
intestinal	O
barrier	O
function	O
through	O
decreased	O
expression	O
of	O
cell	O
junction	O
proteins	O
and	O
apoptosis	O
of	O
enterocytes	O
.	O

The	O
mitogen	B-GENE-N
activated	I-GENE-N
protein	I-GENE-N
kinases	I-GENE-N
(	O
MAPK	B-GENE-N
)	O
play	O
an	O
important	O
role	O
in	O
the	O
signaling	O
pathways	O
of	O
cell	O
turnover	O
and	O
differentiation	O
.	O

Using	O
ex	O
vivo	O
and	O
in	O
vivo	O
approaches	O
,	O
the	O
purpose	O
of	O
this	O
study	O
was	O
to	O
investigate	O
the	O
ability	O
of	O
low	O
doses	O
of	O
DON	B-CHEMICAL
to	O
induce	O
histological	O
changes	O
in	O
the	O
intestine	O
and	O
to	O
activate	O
the	O
MAPK	B-GENE-N
ERK	B-GENE-N
1	I-GENE-N
/	I-GENE-N
2	I-GENE-N
,	O
p38	B-GENE-N
and	O
JNK	B-GENE-N
.	O

Twelve	O
weaning	O
piglets	O
received	O
during	O
four	O
weeks	O
a	O
control	O
diet	O
or	O
a	O
DON	B-CHEMICAL
-	O
contaminated	O
diet	O
(	O
2	O
.	O
3	O
mg	O
DON	B-CHEMICAL
/	O
kg	O
feed	O
)	O
.	O

Six	O
weaning	O
piglets	O
were	O
used	O
to	O
prepare	O
jejunal	O
explants	O
(	O
ex	O
vivo	O
model	O
)	O
.	O

Explants	O
were	O
exposed	O
during	O
4	O
h	O
to	O
vehicle	O
,	O
5	O
or	O
10	O
M	O
DON	B-CHEMICAL
.	O

Intestinal	O
changes	O
were	O
graded	O
using	O
a	O
histological	O
score	O
.	O

Pigs	O
fed	O
a	O
DON	B-CHEMICAL
-	O
diet	O
and	O
explants	O
exposed	O
to	O
DON	B-CHEMICAL
showed	O
a	O
significant	O
decrease	O
in	O
the	O
jejunal	O
score	O
.	O

In	O
both	O
models	O
,	O
the	O
toxin	O
significantly	O
enhanced	O
phosphorylation	O
of	O
ERK	B-GENE-N
1	I-GENE-N
/	I-GENE-N
2	I-GENE-N
and	O
p38	B-GENE-N
,	O
whereas	O
the	O
increased	O
phosphorylation	O
of	O
JNK	B-GENE-N
was	O
non	O
significant	O
.	O

Taken	O
together	O
these	O
results	O
indicate	O
that	O
in	O
vivo	O
or	O
ex	O
vivo	O
exposure	O
of	O
intestinal	O
tissue	O
to	O
DON	B-CHEMICAL
lead	O
to	O
similar	O
intestinal	O
lesions	O
and	O
activation	O
of	O
MAPK	B-GENE-N
.	O

These	O
effects	O
could	O
impair	O
the	O
homeostasis	O
of	O
intestinal	O
tissue	O
in	O
the	O
aspects	O
of	O
barrier	O
function	O
and	O
immune	O
protection	O
.	O

The	O
similarity	O
of	O
the	O
in	O
vivo	O
and	O
ex	O
vivo	O
results	O
provides	O
also	O
strong	O
evidence	O
that	O
the	O
jejunal	O
explant	O
model	O
is	O
a	O
good	O
alternative	O
for	O
toxicological	O
studies	O
in	O
intestinal	O
tissue	O
.	O

Paeoniflorin	B-CHEMICAL
protects	O
human	O
EA	O
.	O
hy926	O
endothelial	O
cells	O
against	O
gamma	O
-	O
radiation	O
induced	O
oxidative	O
injury	O
by	O
activating	O
the	O
NF	B-GENE-Y
-	I-GENE-Y
E2	I-GENE-Y
-	I-GENE-Y
related	I-GENE-Y
factor	I-GENE-Y
2	I-GENE-Y
/	O
heme	B-GENE-Y
oxygenase	I-GENE-Y
-	I-GENE-Y
1	I-GENE-Y
pathway	O
.	O

Pulmonary	O
endothelial	O
cells	O
have	O
been	O
demonstrated	O
to	O
have	O
a	O
critical	O
role	O
in	O
the	O
pathogenesis	O
of	O
radiation	O
-	O
induced	O
lung	O
injury	O
.	O

Our	O
preliminary	O
experiments	O
indicated	O
that	O
Paeoniflorin	B-CHEMICAL
protected	O
human	O
EA	O
.	O
hy926	O
endothelial	O
cells	O
from	O
radiation	O
-	O
induced	O
oxidative	O
injury	O
.	O

This	O
study	O
was	O
designed	O
to	O
confirm	O
the	O
protective	O
effect	O
of	O
Paeoniflorin	B-CHEMICAL
against	O
radiation	O
-	O
induced	O
endothelial	O
cellular	O
damage	O
and	O
to	O
elucidate	O
the	O
underlying	O
mechanisms	O
.	O

Preincubation	O
of	O
EA	O
.	O
hy926	O
cells	O
with	O
Paeoniflorin	B-CHEMICAL
before	O
	O
-	O
radiation	O
resulted	O
in	O
significant	O
inhibition	O
of	O
apoptosis	O
,	O
a	O
decrease	O
in	O
mitochondrial	O
membrane	O
potential	O
and	O
enhanced	O
cell	O
viability	O
.	O

In	O
particular	O
,	O
we	O
showed	O
that	O
Paeoniflorin	B-CHEMICAL
significantly	O
reduced	O
the	O
formation	O
of	O
intracellular	O
reactive	O
oxygen	B-CHEMICAL
species	O
(	O
ROS	O
)	O
,	O
the	O
level	O
of	O
malondialdehyde	B-CHEMICAL
(	O
MDA	B-CHEMICAL
)	O
and	O
lactate	B-GENE-N
dehydrogenase	I-GENE-N
(	O
LDH	B-GENE-N
)	O
leakage	O
,	O
and	O
enhanced	O
production	O
of	O
the	O
endogenous	O
antioxidants	O
,	O
glutathione	B-CHEMICAL
(	O
GSH	B-CHEMICAL
)	O
and	O
superoxide	B-GENE-N
dismutase	I-GENE-N
(	O
SOD	B-GENE-N
)	O
in	O
EA	O
.	O
hy926	O
cells	O
.	O

Treatment	O
of	O
these	O
cells	O
with	O
Paeoniflorin	B-CHEMICAL
significantly	O
induced	O
HO	B-GENE-Y
-	I-GENE-Y
1	I-GENE-Y
expression	O
.	O

Moreover	O
,	O
Paeoniflorin	B-CHEMICAL
promoted	O
the	O
nuclear	O
translocation	O
of	O
nuclear	B-GENE-Y
factor	I-GENE-Y
erythroid	I-GENE-Y
2	I-GENE-Y
related	I-GENE-Y
factor	I-GENE-Y
-	I-GENE-Y
2	I-GENE-Y
(	O
Nrf	B-GENE-Y
-	I-GENE-Y
2	I-GENE-Y
)	O
.	O

The	O
Paeoniflorin	B-CHEMICAL
-	O
induced	O
HO	B-GENE-Y
-	I-GENE-Y
1	I-GENE-Y
expression	O
was	O
abrogated	O
by	O
Nrf2	B-GENE-Y
siRNA	O
.	O

Furthermore	O
,	O
inhibition	O
of	O
HO	B-GENE-Y
-	I-GENE-Y
1	I-GENE-Y
with	O
zinc	B-CHEMICAL
protoporphyrin	I-CHEMICAL
IX	I-CHEMICAL
(	O
ZNPP	B-CHEMICAL
)	O
significantly	O
reversed	O
the	O
protective	O
effect	O
of	O
Paeoniflorin	B-CHEMICAL
against	O
radiation	O
-	O
induced	O
damage	O
in	O
EA	O
.	O
hy926	O
cells	O
.	O

Our	O
findings	O
confirmed	O
that	O
Paeoniflorin	B-CHEMICAL
protected	O
EA	O
.	O
hy926	O
cells	O
against	O
radiation	O
-	O
induced	O
injury	O
through	O
the	O
Nrf2	B-GENE-Y
/	O
HO	B-GENE-Y
-	I-GENE-Y
1	I-GENE-Y
pathway	O
.	O

Accurate	O
quantum	O
chemical	O
energies	O
for	O
tetrapeptide	B-CHEMICAL
conformations	O
:	O
why	O
MP2	O
data	O
with	O
an	O
insufficient	O
basis	O
set	O
should	O
be	O
handled	O
with	O
caution	O
.	O

High	O
-	O
level	O
quantum	O
chemical	O
calculations	O
have	O
been	O
carried	O
out	O
for	O
biologically	O
-	O
relevant	O
conformers	O
of	O
tetrapeptides	B-CHEMICAL
.	O

Our	O
results	O
indicate	O
potential	O
problems	O
if	O
the	O
widely	O
-	O
applied	O
MP2	O
approach	O
is	O
used	O
in	O
such	O
situations	O
with	O
basis	O
sets	O
of	O
insufficient	O
size	O
.	O

Efficient	O
alternatives	O
are	O
discussed	O
.	O

Management	O
of	O
chemotherapy	O
-	O
induced	O
nausea	O
and	O
vomiting	O
:	O
focus	O
on	O
newer	O
agents	O
and	O
new	O
uses	O
for	O
older	O
agents	O
.	O

Chemotherapy	O
-	O
induced	O
nausea	O
and	O
vomiting	O
(	O
CINV	O
)	O
is	O
associated	O
with	O
a	O
significant	O
deterioration	O
in	O
quality	O
of	O
life	O
.	O

The	O
emetogenicity	O
of	O
the	O
chemotherapeutic	O
agents	O
,	O
repeated	O
chemotherapy	O
cycles	O
,	O
and	O
patient	O
risk	O
factors	O
significantly	O
influence	O
CINV	O
.	O

The	O
use	O
of	O
a	O
combination	O
of	O
a	O
serotonin	B-CHEMICAL
5	B-GENE-Y
-	I-GENE-Y
HT3	I-GENE-Y
receptor	O
antagonist	O
,	O
dexamethasone	B-CHEMICAL
and	O
a	O
neurokinin	B-GENE-Y
1	I-GENE-Y
(	I-GENE-Y
NK1	I-GENE-Y
)	I-GENE-Y
receptor	I-GENE-Y
antagonist	O
has	O
significantly	O
improved	O
the	O
control	O
of	O
acute	O
and	O
delayed	O
emesis	O
in	O
single	O
-	O
day	O
chemotherapy	O
.	O

Palonosetron	B-CHEMICAL
,	O
a	O
second	O
-	O
generation	O
5	B-GENE-Y
-	I-GENE-Y
HT3	I-GENE-Y
receptor	O
antagonist	O
with	O
a	O
different	O
half	O
-	O
life	O
,	O
a	O
different	O
binding	O
capacity	O
and	O
a	O
different	O
mechanism	O
of	O
action	O
than	O
the	O
first	O
-	O
generation	O
5	B-GENE-Y
-	I-GENE-Y
HT3	I-GENE-Y
receptor	O
antagonists	O
appears	O
to	O
be	O
the	O
most	O
effective	O
agent	O
in	O
its	O
class	O
.	O

Aprepitant	B-CHEMICAL
,	O
the	O
first	O
and	O
only	O
agent	O
clinically	O
available	O
in	O
the	O
NK1	B-GENE-Y
receptor	I-GENE-Y
antagonist	O
drug	O
class	O
has	O
been	O
used	O
effectively	O
as	O
an	O
additive	O
agent	O
to	O
the	O
5	B-GENE-Y
-	I-GENE-Y
HT3	I-GENE-Y
receptor	O
antagonists	O
and	O
dexamethasone	B-CHEMICAL
to	O
control	O
CINV	O
.	O

Rolapitant	B-CHEMICAL
and	O
netupitant	B-CHEMICAL
are	O
other	O
NK1	B-GENE-Y
receptor	I-GENE-Y
antagonists	O
that	O
are	O
currently	O
in	O
phase	O
III	O
clinical	O
trials	O
.	O

Despite	O
the	O
control	O
of	O
emesis	O
,	O
nausea	O
has	O
not	O
been	O
well	O
controlled	O
by	O
current	O
agents	O
.	O

Olanzapine	B-CHEMICAL
,	O
a	O
US	O
-	O
FDA	O
approved	O
antipsychotic	O
,	O
has	O
emerged	O
in	O
recent	O
trials	O
as	O
an	O
effective	O
preventative	O
agent	O
for	O
CINV	O
,	O
as	O
well	O
as	O
a	O
very	O
effective	O
agent	O
for	O
the	O
treatment	O
of	O
breakthrough	O
emesis	O
and	O
nausea	O
.	O

Clinical	O
trials	O
using	O
gabapentin	B-CHEMICAL
,	O
cannabinoids	O
and	O
ginger	O
have	O
not	O
been	O
definitive	O
regarding	O
their	O
efficacy	O
in	O
the	O
prevention	O
of	O
CINV	O
.	O

Additional	O
studies	O
are	O
necessary	O
for	O
the	O
control	O
of	O
nausea	O
and	O
for	O
the	O
control	O
of	O
CINV	O
in	O
the	O
clinical	O
settings	O
of	O
multiple	O
-	O
day	O
chemotherapy	O
and	O
bone	O
marrow	O
transplantation	O
.	O

In	O
vitro	O
polyphenolics	B-CHEMICAL
erythrocyte	O
model	O
and	O
in	O
vivo	O
chicken	O
embryo	O
model	O
revealed	O
gallic	B-CHEMICAL
acid	I-CHEMICAL
to	O
be	O
a	O
potential	O
hemorrhage	O
inducer	O
:	O
physicochemical	O
action	O
mechanisms	O
.	O

The	O
in	O
vivo	O
chicken	O
embryo	O
model	O
(	O
CEM	O
)	O
demonstrated	O
that	O
gallic	B-CHEMICAL
acid	I-CHEMICAL
(	O
GA	O
)	O
induced	O
dysvascularization	O
and	O
hypoxia	O
.	O

Inflammatory	O
edema	O
,	O
Zenker	O
'	O
s	O
necrosis	O
,	O
hemolysis	O
,	O
and	O
liposis	O
of	O
cervical	O
muscles	O
were	O
the	O
common	O
symptoms	O
.	O

Levels	O
of	O
the	O
gene	O
hif	B-GENE-Y
-	I-GENE-Y
1	I-GENE-Y
,	O
HIF	B-GENE-Y
-	I-GENE-Y
1	I-GENE-Y
,	O
TNF	B-GENE-Y
-	I-GENE-Y
	I-GENE-Y
,	O
IL	B-GENE-Y
-	I-GENE-Y
6	I-GENE-Y
,	O
and	O
NFB	B-GENE-N
in	O
cervical	O
muscles	O
were	O
all	O
significantly	O
upregulated	O
,	O
while	O
the	O
vascular	B-GENE-Y
endothelial	I-GENE-Y
growth	I-GENE-Y
factor	I-GENE-Y
(	O
VEGF	B-GENE-Y
)	O
was	O
downregulated	O
in	O
a	O
dose	O
-	O
responsive	O
manner	O
.	O

Consequently	O
,	O
the	O
cervical	O
muscle	O
inflammation	O
and	O
hemolysis	O
could	O
have	O
been	O
stimulated	O
en	O
route	O
to	O
the	O
tissue	O
TNF	B-GENE-Y
-	I-GENE-Y
	I-GENE-Y
-	O
canonical	O
and	O
the	O
atypical	O
pathways	O
.	O

We	O
hypothesized	O
that	O
GA	O
could	O
deplete	O
the	O
dissolved	O
oxygen	B-CHEMICAL
(	O
DO	O
)	O
at	O
the	O
expense	O
of	O
semiquinone	B-CHEMICAL
and	O
quinone	B-CHEMICAL
formation	O
,	O
favoring	O
the	O
reactive	O
oxygen	B-CHEMICAL
species	O
(	O
ROS	O
)	O
production	O
to	O
induce	O
RBC	O
disruption	O
and	O
Fe	B-CHEMICAL
(	I-CHEMICAL
2	I-CHEMICAL
+	I-CHEMICAL
)	I-CHEMICAL
ion	O
release	O
.	O

To	O
explore	O
this	O
,	O
the	O
in	O
vitro	O
polyphenolics	B-CHEMICAL
-	O
erythrocyte	O
model	O
(	O
PEM	O
)	O
was	O
established	O
.	O

PEM	O
revealed	O
that	O
the	O
DO	O
was	O
rapidly	O
depleted	O
,	O
leading	O
to	O
the	O
release	O
of	O
a	O
huge	O
amount	O
of	O
Fe	B-CHEMICAL
(	I-CHEMICAL
II	I-CHEMICAL
)	I-CHEMICAL
ions	O
and	O
hydrogen	B-CHEMICAL
peroxide	I-CHEMICAL
(	O
HPO	B-CHEMICAL
)	O
in	O
a	O
two	O
-	O
phase	O
kinetic	O
pattern	O
.	O

The	O
kinetic	O
coefficients	O
for	O
Fe	B-CHEMICAL
(	I-CHEMICAL
II	I-CHEMICAL
)	I-CHEMICAL
ion	O
release	O
ranged	O
from	O
0	O
.	O
347	O
h	O
(	O
-	O
1	O
)	O
to	O
0	O
.	O
774	O
h	O
(	O
-	O
1	O
)	O
;	O
and	O
those	O
for	O
Fe	B-CHEMICAL
(	I-CHEMICAL
III	I-CHEMICAL
)	I-CHEMICAL
ion	O
production	O
were	O
from	O
6	O
.	O
66	O
	O
10	O
(	O
-	O
3	O
)	O
h	O
(	O
-	O
1	O
)	O
to	O
8	O
.	O
93	O
	O
10	O
(	O
-	O
3	O
)	O
h	O
(	O
-	O
1	O
)	O
.	O

For	O
phase	O
I	O
HPO	B-CHEMICAL
production	O
,	O
they	O
ranged	O
from	O
0	O
.	O
236	O
h	O
(	O
-	O
1	O
)	O
to	O
0	O
.	O
774	O
h	O
(	O
-	O
1	O
)	O
and	O
for	O
phase	O
II	O
HPO	B-CHEMICAL
production	O
from	O
0	O
.	O
764	O
h	O
(	O
-	O
1	O
)	O
to	O
2	O
.	O
560	O
h	O
(	O
-	O
1	O
)	O
at	O
GA	O
within	O
6	O
M	O
to	O
14	O
M	O
.	O

Thus	O
,	O
evidence	O
obtained	O
from	O
PEM	O
could	O
strongly	O
support	O
the	O
phenomena	O
of	O
CEM	O
.	O

To	O
conclude	O
,	O
GA	O
tends	O
to	O
elicit	O
hypoxia	O
-	O
related	O
inflammation	O
and	O
hemolysis	O
in	O
chicken	O
cervical	O
muscles	O
through	O
its	O
extremely	O
high	O
prooxidant	O
activity	O
.	O

Impact	O
of	O
quaternary	O
structure	O
dynamics	O
on	O
allosteric	O
drug	O
discovery	O
.	O

The	O
morpheein	O
model	O
of	O
allosteric	O
regulation	O
draws	O
attention	O
to	O
proteins	O
that	O
can	O
exist	O
as	O
an	O
equilibrium	O
of	O
functionally	O
distinct	O
assemblies	O
where	O
:	O
one	O
subunit	O
conformation	O
assembles	O
into	O
one	O
multimer	O
;	O
a	O
different	O
subunit	O
conformation	O
assembles	O
into	O
a	O
different	O
multimer	O
;	O
and	O
the	O
various	O
multimers	O
are	O
in	O
a	O
dynamic	O
equilibrium	O
whose	O
position	O
can	O
be	O
modulated	O
by	O
ligands	O
that	O
bind	O
to	O
a	O
multimer	O
-	O
specific	O
ligand	O
binding	O
site	O
.	O

The	O
case	O
study	O
of	O
porphobilinogen	B-GENE-Y
synthase	I-GENE-Y
(	O
PBGS	B-GENE-Y
)	O
illustrates	O
how	O
such	O
an	O
equilibrium	O
holds	O
lessons	O
for	O
disease	O
mechanisms	O
,	O
drug	O
discovery	O
,	O
understanding	O
drug	O
side	O
effects	O
,	O
and	O
identifying	O
proteins	O
wherein	O
drug	O
discovery	O
efforts	O
might	O
focus	O
on	O
quaternary	O
structure	O
dynamics	O
.	O

The	O
morpheein	O
model	O
of	O
allostery	O
has	O
been	O
proposed	O
as	O
applicable	O
for	O
a	O
wide	O
assortment	O
of	O
disease	O
-	O
associated	O
proteins	O
(	O
Selwood	O
,	O
T	O
.	O
,	O
Jaffe	O
,	O
E	O
.	O
,	O
(	O
2012	O
)	O
Arch	O
.	O
Bioch	O
.	O
Biophys	O
,	O
519	O
:	O
131	O
-	O
143	O
)	O
.	O

Herein	O
we	O
discuss	O
quaternary	O
structure	O
dynamics	O
aspects	O
to	O
drug	O
discovery	O
for	O
the	O
disease	O
-	O
associated	O
putative	O
morpheeins	O
phenylalanine	B-GENE-Y
hydroxylase	I-GENE-Y
,	O
HIV	B-GENE-Y
integrase	I-GENE-Y
,	O
pyruvate	B-GENE-N
kinase	I-GENE-N
,	O
and	O
tumor	B-GENE-Y
necrosis	I-GENE-Y
factor	I-GENE-Y
	I-GENE-Y
.	O

Also	O
highlighted	O
is	O
the	O
quaternary	O
structure	O
equilibrium	O
of	O
transthyretin	B-GENE-Y
and	O
successful	O
drug	O
discovery	O
efforts	O
focused	O
on	O
controlling	O
its	O
quaternary	O
structure	O
dynamics	O
.	O

Antioxidant	O
activity	O
of	O
phytosteryl	B-CHEMICAL
phenolates	I-CHEMICAL
in	O
different	O
model	O
systems	O
.	O

As	O
part	O
of	O
a	O
comprehensive	O
study	O
of	O
the	O
physiochemical	O
and	O
biological	O
properties	O
of	O
phytosteryl	B-CHEMICAL
phenolates	I-CHEMICAL
,	O
successfully	O
synthesized	O
chemoenzymatically	O
in	O
our	O
lab	O
,	O
their	O
antioxidant	O
activity	O
was	O
evaluated	O
using	O
three	O
different	O
in	O
vitro	O
model	O
systems	O
,	O
namely	O
bulk	O
oil	O
model	O
system	O
,	O
	B-CHEMICAL
-	I-CHEMICAL
carotene	I-CHEMICAL
-	O
linoleate	B-CHEMICAL
model	O
system	O
and	O
low	B-GENE-N
-	I-GENE-N
density	I-GENE-N
lipoprotein	I-GENE-N
cholesterol	B-CHEMICAL
(	O
LDL	B-GENE-N
-	O
C	O
)	O
oxidation	O
assay	O
.	O

In	O
the	O
bulk	O
oil	O
system	O
,	O
phytosteryl	B-CHEMICAL
phenolates	I-CHEMICAL
showed	O
similar	O
or	O
lower	O
antioxidant	O
activity	O
compared	O
with	O
those	O
of	O
phenolic	B-CHEMICAL
acids	I-CHEMICAL
.	O

However	O
,	O
in	O
	B-CHEMICAL
-	I-CHEMICAL
carotene	I-CHEMICAL
-	O
linoleate	B-CHEMICAL
assay	O
,	O
an	O
emulsion	O
model	O
system	O
,	O
phytosteryl	B-CHEMICAL
phenolates	I-CHEMICAL
showed	O
enhanced	O
antioxidant	O
activity	O
except	O
phytosteryl	B-CHEMICAL
ferulates	I-CHEMICAL
.	O

Moderate	O
inhibitory	O
effect	O
of	O
LDL	B-GENE-N
-	O
C	O
oxidation	O
by	O
phytosteryl	B-CHEMICAL
phenolates	I-CHEMICAL
was	O
observed	O
.	O

These	O
findings	O
demonstrate	O
that	O
use	O
of	O
multidimensional	O
antioxidant	O
activity	O
determinations	O
with	O
differing	O
reaction	O
mechanisms	O
is	O
necessary	O
to	O
provide	O
an	O
overall	O
understanding	O
of	O
the	O
mechanisms	O
of	O
antioxidant	O
action	O
of	O
phytosteryl	B-CHEMICAL
phenolates	I-CHEMICAL
.	O

Evaluation	O
of	O
antioxidant	O
activities	O
and	O
chemical	O
characterisation	O
of	O
staghorn	O
sumac	O
fruit	O
(	O
Rhus	O
hirta	O
L	O
.	O
)	O
.	O

Staghorn	O
sumac	O
(	O
Rhus	O
hirta	O
L	O
.	O
)	O
is	O
a	O
native	O
tree	O
in	O
Eastern	O
Canada	O
whose	O
fruit	O
has	O
been	O
used	O
by	O
aboriginal	O
peoples	O
to	O
treat	O
various	O
illnesses	O
,	O
and	O
has	O
recently	O
been	O
found	O
to	O
be	O
a	O
good	O
source	O
of	O
antioxidants	O
.	O

However	O
,	O
the	O
phytochemical	O
composition	O
of	O
R	O
.	O
hirta	O
is	O
not	O
known	O
.	O

In	O
this	O
study	O
,	O
we	O
used	O
Four	O
highly	O
accepted	O
assays	O
and	O
confirmed	O
its	O
FRAP	O
,	O
ORAC	O
,	O
	O
-	O
CLAMS	O
and	O
PCL	O
values	O
to	O
be	O
79	O
.	O
95	O
mol	O
AAE	O
/	O
g	O
DW	O
,	O
1544	O
mol	O
TE	O
/	O
g	O
DW	O
,	O
RAA	O
129	O
%	O
and	O
4513	O
mol	O
TE	O
/	O
g	O
DW	O
,	O
respectively	O
.	O

The	O
antioxidant	O
activities	O
correlated	O
positively	O
to	O
the	O
total	O
polyphenols	B-CHEMICAL
content	O
,	O
which	O
was	O
higher	O
in	O
the	O
ethanolic	O
extract	O
(	O
81	O
.	O
6	O
mg	O
GAE	O
/	O
g	O
DW	O
)	O
compared	O
to	O
the	O
water	O
extract	O
(	O
46	O
.	O
3mg	O
GAE	O
/	O
g	O
DW	O
)	O
,	O
suggesting	O
polyphenols	B-CHEMICAL
play	O
an	O
important	O
role	O
.	O

Quantitative	O
data	O
from	O
UHPLC	O
and	O
qualitative	O
studies	O
using	O
HPLC	O
-	O
DAD	O
-	O
MS	O
showed	O
that	O
in	O
addition	O
to	O
commonly	O
found	O
phenolic	B-CHEMICAL
acids	I-CHEMICAL
,	O
flavonoids	B-CHEMICAL
and	O
anthocyanins	B-CHEMICAL
,	O
R	O
.	O
hirta	O
fruit	O
contained	O
a	O
novel	O
group	O
of	O
unique	O
anthocyanins	B-CHEMICAL
with	O
aglycones	O
(	O
anthocyanidins	B-CHEMICAL
)	O
at	O
449	O
,	O
419	O
and	O
433	O
Da	O
.	O

Further	O
studies	O
on	O
the	O
identification	O
and	O
their	O
health	O
beneficial	O
effects	O
are	O
being	O
conducted	O
.	O

Phenolics	B-CHEMICAL
content	O
and	O
antioxidant	O
and	O
anti	O
-	O
inflammatory	O
activities	O
of	O
legume	O
fractions	O
.	O

Two	O
faba	O
bean	O
(	O
Vicia	O
faba	O
L	O
.	O
)	O
subspecies	O
major	O
and	O
minor	O
and	O
lentil	O
seeds	O
grown	O
in	O
Algeria	O
were	O
separated	O
into	O
cotyledons	O
and	O
hulls	O
.	O

These	O
fractions	O
,	O
together	O
with	O
their	O
corresponding	O
whole	O
seeds	O
,	O
were	O
extracted	O
with	O
two	O
solvents	O
,	O
aqueous	O
(	O
70	O
%	O
)	O
acetone	B-CHEMICAL
and	O
(	O
80	O
%	O
)	O
ethanol	B-CHEMICAL
,	O
and	O
evaluated	O
for	O
antioxidant	O
activity	O
in	O
relation	O
to	O
their	O
phenolic	B-CHEMICAL
contents	O
.	O

Acetone	B-CHEMICAL
selectively	O
extracted	O
tannins	B-CHEMICAL
from	O
faba	O
beans	O
.	O

The	O
hulls	O
always	O
exhibited	O
high	O
antioxidant	O
activity	O
,	O
measured	O
using	O
the	O
reducing	O
power	O
(	O
RP	O
)	O
,	O
antiradical	O
activity	O
(	O
DPPH	B-CHEMICAL
)	O
or	O
oxygen	B-CHEMICAL
radical	O
absorbance	O
capacity	O
(	O
ORAC	O
)	O
assays	O
.	O

Aqueous	O
ethanol	B-CHEMICAL
(	O
80	O
%	O
)	O
extract	O
of	O
lentil	O
hulls	O
exhibited	O
high	O
antioxidant	O
and	O
anti	O
-	O
inflammatory	O
activities	O
preferentially	O
inhibiting	O
15	B-GENE-Y
-	I-GENE-Y
LOX	I-GENE-Y
(	O
IC	O
(	O
50	O
)	O
,	O
55	O
g	O
/	O
ml	O
)	O
,	O
with	O
moderate	O
COX	B-GENE-Y
-	I-GENE-Y
1	I-GENE-Y
(	O
IC	O
(	O
50	O
)	O
,	O
66	O
g	O
/	O
ml	O
)	O
and	O
COX	B-GENE-Y
-	I-GENE-Y
2	I-GENE-Y
(	O
IC	O
(	O
50	O
)	O
,	O
119	O
g	O
/	O
ml	O
)	O
inhibitory	O
effects	O
on	O
the	O
COX	B-GENE-N
pathway	O
,	O
whereas	O
faba	O
bean	O
hull	O
extracts	O
exerted	O
relatively	O
mild	O
LOX	B-GENE-N
inhibitory	O
activity	O
.	O

Inhibitory	O
activity	O
of	O
Filipendula	O
ulmaria	O
constituents	O
on	O
recombinant	O
human	B-GENE-N
histidine	I-GENE-N
decarboxylase	I-GENE-N
.	O

Histidine	B-GENE-Y
decarboxylase	I-GENE-Y
(	O
HDC	B-GENE-Y
)	O
catalyses	O
the	O
formation	O
of	O
histamine	B-CHEMICAL
,	O
a	O
bioactive	O
amine	B-CHEMICAL
.	O

Agents	O
that	O
control	O
HDC	B-GENE-Y
activity	O
are	O
beneficial	O
for	O
treating	O
histamine	B-CHEMICAL
-	O
mediated	O
symptoms	O
,	O
such	O
as	O
allergies	O
and	O
stomach	O
ulceration	O
.	O

We	O
searched	O
for	O
inhibitors	O
of	O
HDC	B-GENE-Y
from	O
the	O
ethyl	B-CHEMICAL
acetate	I-CHEMICAL
extract	O
of	O
the	O
petal	O
of	O
Filipendula	O
ulmaria	O
,	O
also	O
called	O
meadowsweet	O
.	O

Rugosin	B-CHEMICAL
D	I-CHEMICAL
,	O
rugosin	B-CHEMICAL
A	I-CHEMICAL
,	O
rugosin	B-CHEMICAL
A	I-CHEMICAL
methyl	I-CHEMICAL
ester	I-CHEMICAL
(	O
a	O
novel	O
compound	O
)	O
,	O
and	O
tellimagrandin	B-CHEMICAL
II	I-CHEMICAL
were	O
the	O
main	O
components	O
;	O
these	O
4	O
ellagitannins	O
exhibited	O
a	O
non	O
-	O
competitive	O
type	O
of	O
inhibition	O
,	O
with	O
K	O
(	O
i	O
)	O
values	O
of	O
approximately	O
0	O
.	O
35	O
-	O
1	O
M	O
.	O

These	O
K	O
(	O
i	O
)	O
values	O
are	O
nearly	O
equal	O
to	O
that	O
of	O
histidine	B-CHEMICAL
methyl	I-CHEMICAL
ester	I-CHEMICAL
(	O
K	O
(	O
i	O
)	O
=	O
0	O
.	O
46	O
M	O
)	O
,	O
an	O
existing	O
substrate	O
analogue	O
inhibitor	O
.	O

Our	O
results	O
show	O
that	O
food	O
products	O
contain	O
potent	O
HDC	B-GENE-Y
inhibitors	O
and	O
that	O
these	O
active	O
food	O
constituents	O
might	O
be	O
useful	O
for	O
designing	O
clinically	O
available	O
HDC	B-GENE-Y
inhibitors	O
.	O

Discovery	O
of	O
a	O
novel	O
series	O
of	O
quinolone	B-CHEMICAL
7	B-GENE-Y
nicotinic	I-GENE-Y
acetylcholine	I-GENE-Y
receptor	I-GENE-Y
agonists	O
.	O

High	O
throughput	O
screening	O
led	O
to	O
the	O
identification	O
of	O
a	O
novel	O
series	O
of	O
quinolone	B-CHEMICAL
7	B-GENE-Y
nicotinic	I-GENE-Y
acetylcholine	I-GENE-Y
receptor	I-GENE-Y
(	O
nAChR	B-GENE-N
)	O
agonists	O
.	O

Optimization	O
of	O
an	O
HTS	O
hit	O
(	O
1	O
)	O
led	O
to	O
4	B-CHEMICAL
-	I-CHEMICAL
phenyl	I-CHEMICAL
-	I-CHEMICAL
1	I-CHEMICAL
-	I-CHEMICAL
(	I-CHEMICAL
quinuclidin	I-CHEMICAL
-	I-CHEMICAL
3	I-CHEMICAL
-	I-CHEMICAL
ylmethyl	I-CHEMICAL
)	I-CHEMICAL
quinolin	I-CHEMICAL
-	I-CHEMICAL
2	I-CHEMICAL
(	I-CHEMICAL
1H	I-CHEMICAL
)	I-CHEMICAL
-	I-CHEMICAL
one	I-CHEMICAL
,	O
which	O
was	O
found	O
to	O
be	O
potent	O
and	O
selective	O
.	O

Poor	O
brain	O
penetrance	O
in	O
this	O
series	O
was	O
attributed	O
to	O
transporter	O
-	O
mediated	O
efflux	O
,	O
which	O
was	O
in	O
turn	O
due	O
to	O
high	O
pKa	O
.	O

A	O
novel	O
4	B-CHEMICAL
-	I-CHEMICAL
fluoroquinuclidine	I-CHEMICAL
significantly	O
lowered	O
the	O
pKa	O
of	O
the	O
quinuclidine	B-CHEMICAL
moiety	O
,	O
reducing	O
efflux	O
as	O
measured	O
by	O
a	O
Caco	O
-	O
2	O
assay	O
.	O

Amino	B-CHEMICAL
acid	I-CHEMICAL
derived	O
quinazolines	B-CHEMICAL
as	O
Rock	B-GENE-N
/	O
PKA	B-GENE-N
inhibitors	O
.	O

SAR	O
and	O
lead	O
optimization	O
studies	O
for	O
Rock	B-GENE-N
inhibitors	O
based	O
on	O
amino	B-CHEMICAL
acid	I-CHEMICAL
-	O
derived	O
quinazolines	B-CHEMICAL
are	O
described	O
.	O

Studies	O
demonstrated	O
that	O
these	O
amino	B-CHEMICAL
acid	I-CHEMICAL
derived	O
quinazolinones	B-CHEMICAL
were	O
mainly	O
pan	O
-	O
Rock	B-GENE-N
(	I-GENE-N
I	I-GENE-N
&	I-GENE-N
II	I-GENE-N
)	I-GENE-N
inhibitors	O
.	O

While	O
selectivity	O
against	O
other	O
kinases	B-GENE-N
could	O
be	O
achieved	O
,	O
selectivity	O
for	O
most	O
of	O
these	O
compounds	O
against	O
PKA	B-GENE-N
was	O
not	O
achieved	O
.	O

This	O
is	O
distinct	O
from	O
Rock	B-GENE-N
inhibitors	O
based	O
on	O
non	O
-	O
amino	B-CHEMICAL
acid	I-CHEMICAL
derived	O
quinazolinones	B-CHEMICAL
,	O
where	O
high	O
selectivity	O
against	O
PKA	B-GENE-N
could	O
be	O
obtained	O
.	O
(	O
22	O
)	O
The	O
inhibitors	O
presented	O
here	O
in	O
some	O
cases	O
possessed	O
sub	O
-	O
nanomolar	O
inhibition	O
of	O
Rock	B-GENE-N
,	O
nanomolar	O
potency	O
in	O
ppMLC	O
cell	O
based	O
assays	O
,	O
low	O
to	O
fair	O
cytochrome	B-GENE-N
P	I-GENE-N
-	I-GENE-N
450	I-GENE-N
inhibition	O
,	O
and	O
good	O
human	O
microsomal	O
stability	O
.	O

Human	B-GENE-Y
serum	I-GENE-Y
albumin	I-GENE-Y
-	O
based	O
design	O
of	O
a	O
diflunisal	B-CHEMICAL
prodrug	O
.	O

The	O
cyclooxygenase	B-GENE-Y
-	I-GENE-Y
2	I-GENE-Y
inhibitor	O
,	O
diflunisal	B-CHEMICAL
,	O
is	O
used	O
in	O
the	O
clinic	O
for	O
its	O
anti	O
-	O
inflammatory	O
activity	O
.	O

About	O
99	O
%	O
of	O
a	O
dose	O
of	O
diflunisal	B-CHEMICAL
is	O
unavailable	O
for	O
reaction	O
with	O
the	O
target	O
enzyme	O
,	O
because	O
diflunisal	B-CHEMICAL
strongly	O
binds	O
to	O
human	B-GENE-Y
serum	I-GENE-Y
albumin	I-GENE-Y
(	O
HSA	B-GENE-Y
)	O
.	O

To	O
reduce	O
the	O
binding	O
affinity	O
of	O
diflunisal	B-CHEMICAL
to	O
albumin	B-GENE-Y
,	O
we	O
designed	O
and	O
synthesized	O
the	O
prodrug	O
acetyldiflunisal	B-CHEMICAL
.	O

The	O
crystal	O
structure	O
of	O
HSA	B-GENE-Y
complexed	O
with	O
fatty	B-CHEMICAL
acid	I-CHEMICAL
and	O
acetyldiflunisal	B-CHEMICAL
revealed	O
that	O
acetyldiflunisal	B-CHEMICAL
binds	O
to	O
the	O
IIA	B-GENE-N
subdomain	I-GENE-N
and	O
that	O
upon	O
binding	O
,	O
it	O
acetylates	O
lysine	B-CHEMICAL
199	O
.	O

Mass	O
spectrometry	O
confirmed	O
that	O
acetyldiflunisal	B-CHEMICAL
acetylates	O
Lys199	B-CHEMICAL
.	O

The	O
acetylated	B-GENE-Y
albumin	I-GENE-Y
had	O
twofold	O
weaker	O
binding	O
affinity	O
for	O
diflunisal	B-CHEMICAL
as	O
demonstrated	O
by	O
fluorescence	O
quenching	O
.	O

Reduced	O
binding	O
affinity	O
means	O
that	O
diflunisal	B-CHEMICAL
is	O
more	O
easily	O
released	O
from	O
acetylated	B-GENE-Y
albumin	I-GENE-Y
into	O
the	O
circulation	O
.	O

Therefore	O
,	O
lower	O
doses	O
of	O
acetyldiflunisal	B-CHEMICAL
compared	O
to	O
diflunisal	B-CHEMICAL
will	O
be	O
required	O
.	O

Taken	O
together	O
,	O
our	O
results	O
not	O
only	O
provide	O
a	O
template	O
for	O
design	O
of	O
HSA	B-GENE-Y
-	O
based	O
prodrugs	O
,	O
but	O
also	O
pave	O
the	O
way	O
toward	O
more	O
effective	O
use	O
of	O
diflunisal	B-CHEMICAL
in	O
the	O
clinic	O
.	O

Use	O
of	O
gene	O
expression	O
data	O
to	O
determine	O
effects	O
on	O
gonad	O
phenotype	O
in	O
japanese	O
medaka	O
after	O
exposure	O
to	O
trenbolone	B-CHEMICAL
or	O
estradiol	B-CHEMICAL
.	O

Various	O
aquatic	O
bioassays	O
using	O
one	O
of	O
several	O
fish	O
species	O
have	O
been	O
developed	O
or	O
are	O
in	O
the	O
process	O
of	O
being	O
developed	O
by	O
organizations	O
like	O
the	O
US	O
Environmental	O
Protection	O
Agency	O
and	O
the	O
Office	O
of	O
Economic	O
Cooperation	O
and	O
Development	O
for	O
testing	O
potential	O
endocrine	O
-	O
disrupting	O
chemicals	O
(	O
EDCs	O
)	O
.	O

Often	O
,	O
these	O
involve	O
assessment	O
of	O
the	O
gonad	O
phenotype	O
of	O
individuals	O
as	O
a	O
key	O
endpoint	O
that	O
is	O
inputted	O
into	O
a	O
risk	O
or	O
hazard	O
assessment	O
.	O

Typically	O
,	O
gonad	O
phenotype	O
is	O
determined	O
histologically	O
,	O
which	O
involves	O
specialized	O
and	O
time	O
-	O
consuming	O
techniques	O
.	O

The	O
methods	O
detailed	O
here	O
utilize	O
an	O
entirely	O
different	O
methodology	O
,	O
reverse	O
-	O
transcription	O
quantitative	O
polymerase	O
chain	O
reaction	O
,	O
to	O
determine	O
the	O
relative	O
expression	O
levels	O
of	O
4	O
genes	O
after	O
exposure	O
to	O
either	O
17	B-CHEMICAL
-	I-CHEMICAL
estradiol	I-CHEMICAL
or	O
17	B-CHEMICAL
-	I-CHEMICAL
trenbolone	I-CHEMICAL
and	O
,	O
by	O
extension	O
,	O
the	O
effects	O
of	O
EDCs	O
on	O
the	O
phenotypic	O
status	O
of	O
the	O
gonad	O
.	O

The	O
4	O
genes	O
quantified	O
,	O
Sox9b	B-GENE-Y
,	O
protamine	B-GENE-Y
,	O
Fig1	B-GENE-N
,	O
and	O
ZPC1	B-GENE-N
,	O
are	O
all	O
involved	O
in	O
gonad	O
development	O
and	O
maintenance	O
in	O
Japanese	O
medaka	O
(	O
Oryzias	O
latipes	O
)	O
;	O
these	O
data	O
were	O
then	O
inputted	O
into	O
a	O
permutational	O
multivariate	O
analysis	O
of	O
variance	O
to	O
determine	O
whether	O
significant	O
differences	O
exist	O
between	O
treatment	O
groups	O
.	O

This	O
information	O
in	O
conjunction	O
with	O
the	O
sexual	O
genotype	O
,	O
which	O
can	O
be	O
determined	O
in	O
medaka	O
,	O
can	O
be	O
used	O
to	O
determine	O
adverse	O
effects	O
of	O
exposure	O
to	O
EDCs	O
in	O
a	O
similar	O
fashion	O
to	O
the	O
histologically	O
determined	O
gonad	O
phenotype	O
.	O

Environ	O
Toxicol	O
Chem	O
2013	O
;	O
32	O
:	O
1344	O
-	O
1353	O
.	O

	O
2013	O
SETAC	O
.	O

Absorption	O
,	O
distribution	O
,	O
and	O
biotransformation	O
of	O
hexahydro	B-CHEMICAL
-	I-CHEMICAL
1	I-CHEMICAL
,	I-CHEMICAL
3	I-CHEMICAL
,	I-CHEMICAL
5	I-CHEMICAL
-	I-CHEMICAL
trinitro	I-CHEMICAL
-	I-CHEMICAL
1	I-CHEMICAL
,	I-CHEMICAL
3	I-CHEMICAL
,	I-CHEMICAL
5	I-CHEMICAL
-	I-CHEMICAL
triazine	I-CHEMICAL
in	O
B6C3F1	O
mice	O
(	O
Mus	O
musculus	O
)	O
.	O

Absorption	O
,	O
distribution	O
,	O
and	O
biotransformation	O
are	O
3	O
critical	O
aspects	O
affecting	O
toxicant	O
action	O
in	O
animals	O
.	O

In	O
the	O
present	O
study	O
,	O
B6C3F1	O
mice	O
(	O
Mus	O
musculus	O
)	O
were	O
exposed	O
for	O
28	O
d	O
to	O
contaminated	O
feed	O
that	O
contained	O
1	O
of	O
5	O
different	O
hexahydro	B-CHEMICAL
-	I-CHEMICAL
1	I-CHEMICAL
,	I-CHEMICAL
3	I-CHEMICAL
,	I-CHEMICAL
5	I-CHEMICAL
-	I-CHEMICAL
trinitro	I-CHEMICAL
-	I-CHEMICAL
1	I-CHEMICAL
,	I-CHEMICAL
3	I-CHEMICAL
,	I-CHEMICAL
5	I-CHEMICAL
-	I-CHEMICAL
triazine	I-CHEMICAL
(	O
RDX	O
)	O
concentrations	O
:	O
0	O
mg	O
/	O
kg	O
,	O
0	O
.	O
5	O
mg	O
/	O
kg	O
,	O
5	O
mg	O
/	O
kg	O
,	O
50	O
mg	O
/	O
kg	O
,	O
and	O
500	O
mg	O
/	O
kg	O
.	O

The	O
authors	O
quantified	O
RDX	O
and	O
its	O
reductive	O
transformation	O
products	O
hexahydro	B-CHEMICAL
-	I-CHEMICAL
1	I-CHEMICAL
-	I-CHEMICAL
nitroso	I-CHEMICAL
-	I-CHEMICAL
3	I-CHEMICAL
,	I-CHEMICAL
5	I-CHEMICAL
-	I-CHEMICAL
dinitro	I-CHEMICAL
-	I-CHEMICAL
1	I-CHEMICAL
,	I-CHEMICAL
3	I-CHEMICAL
,	I-CHEMICAL
5	I-CHEMICAL
-	I-CHEMICAL
triazine	I-CHEMICAL
(	O
MNX	O
)	O
,	O
hexahydro	B-CHEMICAL
-	I-CHEMICAL
1	I-CHEMICAL
,	I-CHEMICAL
3	I-CHEMICAL
-	I-CHEMICAL
dinitroso	I-CHEMICAL
-	I-CHEMICAL
5	I-CHEMICAL
-	I-CHEMICAL
nitro	I-CHEMICAL
-	I-CHEMICAL
1	I-CHEMICAL
,	I-CHEMICAL
3	I-CHEMICAL
,	I-CHEMICAL
5	I-CHEMICAL
-	I-CHEMICAL
triazine	I-CHEMICAL
(	O
DNX	O
)	O
,	O
and	O
hexahydro	B-CHEMICAL
-	I-CHEMICAL
1	I-CHEMICAL
,	I-CHEMICAL
3	I-CHEMICAL
,	I-CHEMICAL
5	I-CHEMICAL
-	I-CHEMICAL
trinitroso	I-CHEMICAL
-	I-CHEMICAL
1	I-CHEMICAL
,	I-CHEMICAL
3	I-CHEMICAL
,	I-CHEMICAL
5	I-CHEMICAL
-	I-CHEMICAL
triazine	I-CHEMICAL
(	O
TNX	O
)	O
in	O
the	O
stomach	O
,	O
intestine	O
,	O
plasma	O
,	O
liver	O
,	O
and	O
brain	O
of	O
these	O
mice	O
.	O

Average	O
RDX	O
concentrations	O
followed	O
a	O
dose	O
-	O
dependent	O
pattern	O
for	O
all	O
matrices	O
tested	O
.	O

No	O
controls	O
had	O
concentrations	O
above	O
limits	O
of	O
detection	O
.	O

Average	O
RDX	O
concentrations	O
in	O
tissues	O
of	O
exposed	O
mice	O
ranged	O
from	O
11	O
.	O
1	O
ng	O
/	O
mL	O
to	O
182	O
ng	O
/	O
mL	O
,	O
25	O
.	O
6	O
ng	O
/	O
g	O
to	O
3319	O
ng	O
/	O
g	O
,	O
123	O
ng	O
/	O
g	O
to	O
233	O
ng	O
/	O
g	O
,	O
144	O
ng	O
/	O
g	O
to	O
35	O
900	O
ng	O
/	O
g	O
,	O
and	O
51	O
.	O
1	O
ng	O
/	O
g	O
to	O
2697	O
ng	O
/	O
g	O
in	O
the	O
plasma	O
,	O
brain	O
,	O
liver	O
,	O
stomach	O
,	O
and	O
intestine	O
,	O
respectively	O
.	O

A	O
considerable	O
amount	O
of	O
RDX	O
was	O
present	O
in	O
the	O
brain	O
,	O
especially	O
in	O
the	O
highest	O
-	O
exposure	O
group	O
.	O

This	O
is	O
consistent	O
with	O
the	O
widely	O
observed	O
central	O
nervous	O
system	O
effects	O
caused	O
by	O
	B-CHEMICAL
-	I-CHEMICAL
aminobutyric	I-CHEMICAL
acid	I-CHEMICAL
inhibition	O
associated	O
with	O
RDX	O
exposure	O
.	O

N	B-CHEMICAL
-	I-CHEMICAL
nitroso	I-CHEMICAL
metabolites	O
of	O
RDX	O
were	O
also	O
present	O
in	O
tested	O
tissues	O
in	O
a	O
dose	O
-	O
dependent	O
pattern	O
.	O

Average	O
MNX	O
concentrations	O
in	O
the	O
stomachs	O
of	O
mice	O
exposed	O
to	O
RDX	O
ranged	O
from	O
nondetectable	O
in	O
control	O
exposures	O
to	O
490	O
ng	O
/	O
g	O
in	O
the	O
highest	O
-	O
exposure	O
groups	O
.	O

In	O
the	O
brain	O
,	O
MNX	O
accumulated	O
at	O
a	O
maximum	O
average	O
concentration	O
of	O
165	O
.	O
1	O
ng	O
/	O
g	O
,	O
suggesting	O
the	O
potential	O
formation	O
of	O
MNX	O
from	O
RDX	O
within	O
the	O
brain	O
.	O

At	O
higher	O
exposures	O
,	O
DNX	O
and	O
TNX	O
were	O
present	O
in	O
the	O
stomach	O
,	O
plasma	O
,	O
and	O
brain	O
of	O
mice	O
.	O

The	O
presence	O
of	O
RDX	O
metabolites	O
at	O
notable	O
amounts	O
in	O
different	O
tissues	O
suggests	O
that	O
RDX	O
can	O
transform	O
into	O
its	O
N	B-CHEMICAL
-	I-CHEMICAL
nitroso	I-CHEMICAL
metabolites	O
in	O
vivo	O
by	O
an	O
undefined	O
mechanism	O
.	O

Environ	O
Toxicol	O
Chem	O
2013	O
;	O
32	O
:	O
1295	O
-	O
1303	O
.	O

	O
2013	O
SETAC	O
.	O

Effect	O
of	O
bisphenol	B-CHEMICAL
-	I-CHEMICAL
A	I-CHEMICAL
on	O
insulin	B-GENE-N
signal	O
transduction	O
and	O
glucose	B-CHEMICAL
oxidation	O
in	O
skeletal	O
muscle	O
of	O
adult	O
male	O
albino	O
rat	O
.	O

The	O
estrogenic	O
monomer	O
bisphenol	B-CHEMICAL
-	I-CHEMICAL
A	I-CHEMICAL
(	O
BPA	B-CHEMICAL
)	O
is	O
an	O
endocrine	O
-	O
disrupting	O
chemical	O
used	O
in	O
the	O
production	O
of	O
epoxy	B-CHEMICAL
resins	O
,	O
plastic	O
food	O
and	O
beverage	O
containers	O
,	O
leading	O
to	O
ubiquitous	O
human	O
exposure	O
.	O

Environmentally	O
relevant	O
doses	O
of	O
BPA	B-CHEMICAL
have	O
profound	O
effects	O
on	O
mice	O
endocrine	O
pancreas	O
.	O

It	O
increases	O
pancreatic	O
insulin	B-GENE-N
content	O
and	O
favors	O
postprandial	O
hyperinsulinemia	O
and	O
insulin	B-GENE-N
resistance	O
in	O
male	O
mice	O
.	O

Skeletal	O
muscle	O
plays	O
a	O
crucial	O
role	O
in	O
maintaining	O
systemic	O
glucose	B-CHEMICAL
metabolism	O
.	O

In	O
the	O
present	O
study	O
,	O
we	O
investigated	O
the	O
possible	O
effects	O
of	O
BPA	B-CHEMICAL
on	O
insulin	B-GENE-N
-	O
signaling	O
molecules	O
and	O
glucose	B-CHEMICAL
oxidation	O
in	O
skeletal	O
muscle	O
of	O
male	O
rat	O
.	O

Adult	O
male	O
Wistar	O
albino	O
rats	O
were	O
divided	O
into	O
three	O
groups	O
.	O

Group	O
I	O
:	O
control	O
(	O
vehicle	O
treated	O
)	O
and	O
groups	O
II	O
and	O
III	O
were	O
administered	O
with	O
BPA	B-CHEMICAL
orally	O
(	O
20	O
and	O
200	O
mg	O
/	O
kg	O
bw	O
/	O
day	O
,	O
respectively	O
)	O
.	O

Although	O
there	O
was	O
no	O
change	O
in	O
the	O
levels	O
of	O
insulin	B-GENE-Y
receptor	I-GENE-Y
(	O
IR	B-GENE-Y
)	O
,	O
Akt	B-GENE-N
(	O
protein	B-GENE-N
kinase	I-GENE-N
B	I-GENE-N
)	O
and	O
glucose	B-GENE-Y
transporter	I-GENE-Y
-	I-GENE-Y
4	I-GENE-Y
(	O
GLUT4	B-GENE-Y
)	O
messenger	O
RNA	O
,	O
BPA	B-CHEMICAL
significantly	O
decreased	O
the	O
IR	B-GENE-Y
,	O
Akt	B-GENE-N
and	O
GLUT4	B-GENE-Y
protein	O
levels	O
(	O
both	O
plasma	O
membrane	O
and	O
cytosolic	O
fraction	O
)	O
of	O
the	O
gastrocnemius	O
muscle	O
.	O

There	O
was	O
an	O
increase	O
in	O
serum	O
insulin	B-GENE-N
and	O
decrease	O
in	O
serum	O
testosterone	B-CHEMICAL
levels	O
but	O
fasting	O
blood	O
glucose	B-CHEMICAL
level	O
remained	O
unaltered	O
.	O

In	O
conclusion	O
,	O
BPA	B-CHEMICAL
has	O
adverse	O
effects	O
on	O
phosphorylation	O
of	O
Akt	B-GENE-N
,	O
GLUT4	B-GENE-Y
translocation	O
and	O
(	B-CHEMICAL
14	I-CHEMICAL
)	I-CHEMICAL
C	I-CHEMICAL
-	I-CHEMICAL
glucose	I-CHEMICAL
oxidation	O
.	O

Rutin	B-CHEMICAL
-	O
and	O
Selenium	B-CHEMICAL
-	O
attenuated	O
cadmium	B-CHEMICAL
-	O
induced	O
testicular	O
pathophysiology	O
in	O
rats	O
.	O

Cadmium	B-CHEMICAL
(	O
Cd	B-CHEMICAL
)	O
is	O
known	O
to	O
cause	O
oxidative	O
damage	O
in	O
the	O
testes	O
of	O
rats	O
.	O

The	O
aim	O
of	O
this	O
study	O
was	O
to	O
investigate	O
the	O
protective	O
role	O
of	O
rutin	B-CHEMICAL
(	O
RUT	B-CHEMICAL
,	O
30	O
mg	O
/	O
kg	O
)	O
and	O
selenium	B-CHEMICAL
(	O
Se	B-CHEMICAL
,	O
0	O
.	O
15	O
ppm	O
)	O
alone	O
or	O
in	O
combination	O
against	O
Cd	B-CHEMICAL
(	O
200	O
ppm	O
)	O
-	O
induced	O
lipid	O
peroxidation	O
,	O
steroidogenesis	O
and	O
changes	O
in	O
antioxidant	O
defence	O
system	O
in	O
the	O
rat	O
testes	O
.	O

The	O
obtained	O
results	O
showed	O
that	O
Cd	B-CHEMICAL
increased	O
lipid	O
peroxidation	O
and	O
abnormal	O
sperm	O
count	O
and	O
decreased	O
plasma	O
testosterone	B-CHEMICAL
,	O
lactate	B-GENE-N
dehydrogenase	I-GENE-N
,	O
acid	B-GENE-N
phosphatase	I-GENE-N
,	O
alkaline	B-GENE-N
phosphatase	I-GENE-N
and	O
testicular	B-GENE-N
steroidogenic	I-GENE-N
enzymes	I-GENE-N
:	O
3	B-GENE-N
-	I-GENE-N
hydroxysteroid	I-GENE-N
dehydrogenase	I-GENE-N
(	O
HSD	B-GENE-N
)	O
,	O
17	B-GENE-N
-	I-GENE-N
HSD	I-GENE-N
activities	O
as	O
well	O
as	O
epididymal	O
sperm	O
counts	O
and	O
motility	O
,	O
while	O
RUT	B-CHEMICAL
and	O
Se	B-CHEMICAL
treatment	O
reversed	O
this	O
change	O
to	O
control	O
values	O
.	O

Acute	O
intoxication	O
with	O
Cd	B-CHEMICAL
was	O
also	O
followed	O
by	O
significantly	O
decreased	O
activity	O
of	O
the	O
antioxidant	O
defence	O
system	O
(	O
superoxide	B-GENE-N
dismutase	I-GENE-N
(	O
SOD	B-GENE-N
)	O
,	O
catalase	B-GENE-Y
(	O
CAT	B-GENE-Y
)	O
,	O
glutathione	B-GENE-N
peroxidase	I-GENE-N
(	O
GSH	B-GENE-N
-	I-GENE-N
Px	I-GENE-N
)	O
,	O
glutathione	B-GENE-Y
reductase	I-GENE-Y
(	O
GR	B-GENE-Y
)	O
,	O
glutathione	B-CHEMICAL
(	O
GSH	B-CHEMICAL
)	O
,	O
and	O
glutathione	B-GENE-N
-	I-GENE-N
S	I-GENE-N
-	I-GENE-N
transferase	I-GENE-N
(	O
GST	B-GENE-N
)	O
)	O
.	O

Treatment	O
with	O
RUT	B-CHEMICAL
and	O
Se	B-CHEMICAL
reversed	O
Cd	B-CHEMICAL
-	O
induced	O
alterations	O
of	O
antioxidant	O
defence	O
system	O
and	O
significantly	O
prevented	O
Cd	B-CHEMICAL
-	O
induced	O
testes	O
damage	O
and	O
depletion	O
of	O
plasma	O
and	O
testicular	O
Se	B-CHEMICAL
levels	O
.	O

RUT	B-CHEMICAL
and	O
Se	B-CHEMICAL
appear	O
not	O
to	O
have	O
more	O
profound	O
effects	O
than	O
their	O
separate	O
effects	O
against	O
Cd	B-CHEMICAL
-	O
induced	O
testicular	O
toxicity	O
,	O
although	O
Se	B-CHEMICAL
was	O
more	O
potent	O
than	O
RUT	B-CHEMICAL
in	O
the	O
recovery	O
of	O
testosterone	B-CHEMICAL
levels	O
.	O

These	O
results	O
suggest	O
that	O
both	O
RUT	B-CHEMICAL
and	O
Se	B-CHEMICAL
do	O
not	O
have	O
synergistic	O
role	O
against	O
Cd	B-CHEMICAL
-	O
induced	O
testicular	O
injury	O
.	O

The	O
role	O
of	O
de	O
novo	O
catecholamine	B-CHEMICAL
synthesis	O
in	O
mediating	O
methylmercury	B-CHEMICAL
-	O
induced	O
vesicular	O
dopamine	B-CHEMICAL
release	O
from	O
rat	O
pheochromocytoma	O
(	O
PC12	O
)	O
cells	O
.	O

The	O
purpose	O
of	O
this	O
study	O
was	O
to	O
characterize	O
methylmercury	B-CHEMICAL
(	O
MeHg	B-CHEMICAL
)	O
-	O
induced	O
dopamine	B-CHEMICAL
(	O
DA	O
)	O
release	O
from	O
undifferentiated	O
pheochromocytoma	O
(	O
PC12	O
)	O
cells	O
and	O
to	O
examine	O
the	O
potential	O
role	O
for	O
DA	O
synthesis	O
in	O
this	O
process	O
.	O

MeHg	B-CHEMICAL
caused	O
a	O
significant	O
increase	O
in	O
DA	O
release	O
that	O
was	O
both	O
concentration	O
-	O
and	O
time	O
-	O
dependent	O
.	O

DA	O
release	O
was	O
significantly	O
increased	O
by	O
2M	O
MeHg	B-CHEMICAL
at	O
60min	O
and	O
by	O
5M	O
MeHg	B-CHEMICAL
at	O
30min	O
;	O
1M	O
MeHg	B-CHEMICAL
was	O
without	O
effect	O
.	O

Because	O
DA	O
release	O
induced	O
by	O
5M	O
MeHg	B-CHEMICAL
was	O
associated	O
with	O
a	O
significant	O
percentage	O
of	O
cell	O
death	O
at	O
60	O
and	O
120min	O
,	O
2M	O
MeHg	B-CHEMICAL
was	O
chosen	O
for	O
further	O
characterization	O
of	O
release	O
mechanisms	O
.	O

MeHg	B-CHEMICAL
-	O
induced	O
DA	O
release	O
was	O
attenuated	O
but	O
not	O
abolished	O
in	O
the	O
absence	O
of	O
extracellular	O
calcium	B-CHEMICAL
,	O
whereas	O
the	O
vesicular	O
content	O
depleting	O
drug	O
reserpine	O
(	O
50nM	O
)	O
abolished	O
release	O
.	O

Thus	O
,	O
MeHg	B-CHEMICAL
-	O
induced	O
DA	O
release	O
requires	O
vesicular	O
exocytosis	O
but	O
not	O
extracellular	O
calcium	B-CHEMICAL
.	O

MeHg	B-CHEMICAL
also	O
increased	O
intracellular	O
DA	O
and	O
the	O
rate	O
of	O
DA	O
storage	O
utilization	O
,	O
suggesting	O
a	O
role	O
for	O
DA	O
synthesis	O
in	O
MeHg	B-CHEMICAL
-	O
induced	O
DA	O
release	O
.	O

The	O
tyrosine	B-GENE-Y
hydroxylase	I-GENE-Y
inhibitor	O
	B-CHEMICAL
-	I-CHEMICAL
methyltyrosine	I-CHEMICAL
(	O
300M	O
,	O
24h	O
)	O
completely	O
abolished	O
MeHg	B-CHEMICAL
-	O
induced	O
DA	O
release	O
.	O

MeHg	B-CHEMICAL
significantly	O
increased	O
DA	O
precursor	O
accumulation	O
in	O
cells	O
treated	O
with	O
3	B-CHEMICAL
-	I-CHEMICAL
hydroxybenzylhydrazine	I-CHEMICAL
(	O
10M	O
)	O
,	O
revealing	O
that	O
MeHg	B-CHEMICAL
increases	O
tyrosine	B-GENE-Y
hydroxylase	I-GENE-Y
activity	O
.	O

Overall	O
,	O
these	O
data	O
demonstrate	O
that	O
MeHg	B-CHEMICAL
facilitates	O
DA	O
synthesis	O
,	O
increases	O
intracellular	O
DA	O
,	O
and	O
augments	O
vesicular	O
exocytosis	O
.	O

Solubility	O
-	O
driven	O
optimization	O
of	O
(	B-CHEMICAL
pyridin	I-CHEMICAL
-	I-CHEMICAL
3	I-CHEMICAL
-	I-CHEMICAL
yl	I-CHEMICAL
)	I-CHEMICAL
benzoxazinyl	I-CHEMICAL
-	I-CHEMICAL
oxazolidinones	I-CHEMICAL
leading	O
to	O
a	O
promising	O
antibacterial	O
agent	O
.	O

The	O
solubility	O
-	O
driven	O
structural	O
modification	O
of	O
(	B-CHEMICAL
pyridin	I-CHEMICAL
-	I-CHEMICAL
3	I-CHEMICAL
-	I-CHEMICAL
yl	I-CHEMICAL
)	I-CHEMICAL
benzoxazinyl	I-CHEMICAL
-	I-CHEMICAL
oxazolidinones	I-CHEMICAL
is	O
described	O
,	O
which	O
resulted	O
in	O
the	O
development	O
of	O
a	O
new	O
series	O
of	O
benzoxazinyl	B-CHEMICAL
-	I-CHEMICAL
oxazolidinone	I-CHEMICAL
analogues	O
with	O
high	O
antibacterial	O
activity	O
against	O
Gram	O
-	O
positive	O
pathogens	O
,	O
including	O
that	O
against	O
linezolid	B-CHEMICAL
-	O
resistant	O
strains	O
and	O
low	O
hERG	B-GENE-Y
inhibition	O
.	O

With	O
regard	O
to	O
structure	O
-	O
activity	O
relationship	O
(	O
SAR	O
)	O
trends	O
among	O
the	O
various	O
substituents	O
on	O
the	O
pyridyl	B-CHEMICAL
ring	O
,	O
relatively	O
small	O
and	O
nonbasic	O
substituents	O
were	O
preferable	O
to	O
sterically	O
demanding	O
or	O
basic	O
substituents	O
.	O

Oxazolidinone	B-CHEMICAL
ring	O
substitution	O
on	O
the	O
pyridyl	B-CHEMICAL
ring	O
generated	O
analogues	O
with	O
antibacterial	O
activity	O
superior	O
to	O
imidazolidinone	B-CHEMICAL
ring	O
.	O

Solubility	O
was	O
enhanced	O
by	O
the	O
incorporation	O
of	O
polar	O
groups	O
,	O
especially	O
when	O
compounds	O
were	O
converted	O
to	O
their	O
prodrugs	O
.	O

Among	O
the	O
prodrugs	O
,	O
compound	O
85	O
exhibited	O
excellent	O
solubility	O
and	O
a	O
good	O
pharmacokinetic	O
profile	O
.	O

In	O
a	O
MRSA	O
systemic	O
infection	O
model	O
,	O
compound	O
85	O
displayed	O
an	O
ED50	O
=	O
5	O
.	O
00	O
mg	O
/	O
kg	O
,	O
a	O
potency	O
that	O
is	O
2	O
-	O
fold	O
better	O
than	O
that	O
of	O
linezolid	B-CHEMICAL
.	O

Activity	O
of	O
ponatinib	B-CHEMICAL
against	O
clinically	O
-	O
relevant	O
AC220	B-CHEMICAL
-	O
resistant	O
kinase	B-GENE-N
domain	I-GENE-N
mutants	O
of	O
FLT3	B-GENE-Y
-	O
ITD	O
.	O

Secondary	O
point	O
mutations	O
in	O
the	O
Fms	B-GENE-N
-	I-GENE-N
like	I-GENE-N
tyrosine	I-GENE-N
kinase	I-GENE-N
3	I-GENE-N
(	I-GENE-N
FLT3	I-GENE-N
)	I-GENE-N
tyrosine	I-GENE-N
kinase	I-GENE-N
domain	I-GENE-N
(	O
KD	B-GENE-N
)	O
are	O
common	O
causes	O
of	O
acquired	O
clinical	O
resistance	O
to	O
the	O
FLT3	B-GENE-Y
inhibitors	O
AC220	B-CHEMICAL
(	O
quizartinib	B-CHEMICAL
)	O
and	O
sorafenib	B-CHEMICAL
.	O

Ponatinib	B-CHEMICAL
(	O
AP24534	B-CHEMICAL
)	O
is	O
a	O
multikinase	B-GENE-N
inhibitor	O
with	O
in	O
vitro	O
and	O
clinical	O
activity	O
in	O
tyrosine	B-GENE-N
kinase	I-GENE-N
inhibitor	O
(	O
TKI	O
)	O
-	O
resistant	O
chronic	O
myeloid	O
leukemia	O
,	O
irrespective	O
of	O
BCR	B-GENE-N
-	I-GENE-N
ABL	I-GENE-N
KD	I-GENE-N
mutation	O
.	O

Ponatinib	B-CHEMICAL
has	O
demonstrated	O
early	O
clinical	O
efficacy	O
in	O
chemotherapy	O
-	O
resistant	O
acute	O
myeloid	O
leukemia	O
(	O
AML	O
)	O
patients	O
with	O
internal	O
tandem	O
duplication	O
(	O
ITD	O
)	O
mutations	O
in	O
FLT3	B-GENE-Y
.	O

We	O
assessed	O
the	O
in	O
vitro	O
activity	O
of	O
ponatinib	B-CHEMICAL
against	O
clinically	O
relevant	O
FLT3	B-GENE-Y
-	O
ITD	O
mutant	O
isoforms	O
that	O
confer	O
resistance	O
to	O
AC220	B-CHEMICAL
or	O
sorafenib	B-CHEMICAL
.	O

Substitution	O
of	O
the	O
FLT3	B-GENE-Y
"	O
gatekeeper	O
"	O
phenylalanine	B-CHEMICAL
with	O
leucine	B-CHEMICAL
(	O
F691L	B-GENE-N
)	O
conferred	O
mild	O
resistance	O
to	O
ponatinib	B-CHEMICAL
,	O
but	O
substitutions	O
at	O
the	O
FLT3	B-GENE-N
activation	I-GENE-N
loop	I-GENE-N
(	O
AL	B-GENE-N
)	O
residue	O
D835	O
conferred	O
a	O
high	O
degree	O
of	O
resistance	O
.	O

Saturation	O
mutagenesis	O
of	O
FLT3	B-GENE-Y
-	O
ITD	O
exclusively	O
identified	O
FLT3	B-GENE-Y
AL	O
mutations	O
at	O
positions	O
D835	O
,	O
D839	O
,	O
and	O
Y842	O
.	O

The	O
switch	O
control	O
inhibitor	O
DCC	B-CHEMICAL
-	I-CHEMICAL
2036	I-CHEMICAL
was	O
similarly	O
inactive	O
against	O
FLT3	B-GENE-Y
AL	O
mutations	O
.	O

On	O
the	O
basis	O
of	O
its	O
in	O
vitro	O
activity	O
against	O
FLT3	B-GENE-Y
TKI	O
-	O
resistant	O
F691	O
substitutions	O
,	O
further	O
clinical	O
evaluation	O
of	O
ponatinib	B-CHEMICAL
in	O
TKI	O
-	O
naive	O
and	O
select	O
TKI	O
-	O
resistant	O
FLT3	B-GENE-Y
-	O
ITD	O
+	O
AML	O
patients	O
is	O
warranted	O
.	O

Alternative	O
strategies	O
will	O
be	O
required	O
for	O
patients	O
with	O
TKI	O
-	O
resistant	O
FLT3	B-GENE-Y
-	O
ITD	O
D835	O
mutations	O
.	O

Bisacylimidoselenocarbamates	B-CHEMICAL
Cause	O
G2	O
/	O
M	O
Arrest	O
Associated	O
with	O
the	O
Modulation	O
of	O
CDK1	B-GENE-Y
and	O
Chk2	B-GENE-Y
in	O
Human	O
Breast	O
Cancer	O
MCF	O
-	O
7	O
Cells	O
.	O

Bisacylimidoselenocarbamate	B-CHEMICAL
derivatives	O
(	O
BSC	B-CHEMICAL
)	O
are	O
potent	O
anticancer	O
agents	O
with	O
a	O
strong	O
cytotoxic	O
activity	O
against	O
different	O
types	O
of	O
tumour	O
cells	O
.	O

Based	O
in	O
phosphatidylserine	B-CHEMICAL
exposure	O
on	O
the	O
cell	O
membranes	O
we	O
show	O
that	O
BSC	B-CHEMICAL
treatment	O
resulted	O
in	O
enhanced	O
cell	O
death	O
in	O
leukaemia	O
CCRF	O
-	O
CEM	O
cells	O
.	O

DNA	O
fragmentation	O
detection	O
in	O
breast	O
adenocarcinoma	O
MCF	O
-	O
7	O
cells	O
showed	O
that	O
BSC	B-CHEMICAL
triggered	O
cell	O
death	O
is	O
concentration	O
and	O
time	O
dependent	O
.	O

We	O
also	O
show	O
that	O
two	O
of	O
these	O
compounds	O
,	O
BSC	B-CHEMICAL
3g	O
and	O
3n	O
,	O
cause	O
cell	O
-	O
cycle	O
arrest	O
in	O
the	O
late	O
G2	O
/	O
M	O
in	O
MCF	O
-	O
7	O
cells	O
.	O

Consistent	O
with	O
this	O
,	O
a	O
reduction	O
in	O
CDK1	B-GENE-Y
and	O
CDK2	B-GENE-Y
expression	O
with	O
no	O
change	O
in	O
cyclin	B-GENE-N
A	I-GENE-N
an	I-GENE-N
B1	I-GENE-N
was	O
observed	O
in	O
this	O
cell	O
line	O
.	O

Activation	O
of	O
caspase	B-GENE-Y
-	I-GENE-Y
2	I-GENE-Y
was	O
also	O
detected	O
.	O

However	O
,	O
the	O
involvement	O
of	O
the	O
caspase	B-GENE-N
-	O
dependent	O
pathway	O
in	O
the	O
process	O
of	O
cell	O
death	O
induced	O
by	O
either	O
BSC	B-CHEMICAL
3g	O
or	O
3n	O
is	O
discarded	O
since	O
cell	O
death	O
could	O
not	O
be	O
prevented	O
by	O
pretreatment	O
with	O
the	O
pancaspase	B-GENE-N
inhibitor	O
z	B-CHEMICAL
-	I-CHEMICAL
VAD	I-CHEMICAL
-	I-CHEMICAL
fmk	I-CHEMICAL
.	O

Moreover	O
,	O
since	O
reduced	O
levels	O
of	O
p21CIP1	B-GENE-Y
and	O
Chk2	B-GENE-Y
proteins	O
but	O
no	O
change	O
in	O
p53	B-GENE-Y
levels	O
could	O
be	O
detected	O
in	O
MCF	O
-	O
7	O
cells	O
after	O
BSC	B-CHEMICAL
3g	O
or	O
3n	O
treatment	O
our	O
results	O
suggest	O
that	O
BSC	B-CHEMICAL
treated	O
cells	O
die	O
from	O
lethal	O
mitosis	O
.	O

A	O
one	O
-	O
pot	O
domino	O
synthesis	O
and	O
discovery	O
of	O
highly	O
functionalized	O
dihydrobenzo	B-CHEMICAL
[	I-CHEMICAL
b	I-CHEMICAL
]	I-CHEMICAL
thiophenes	I-CHEMICAL
as	O
AChE	B-GENE-Y
inhibitors	O
.	O

A	O
library	O
of	O
novel	O
5	B-CHEMICAL
-	I-CHEMICAL
amino	I-CHEMICAL
-	I-CHEMICAL
2	I-CHEMICAL
,	I-CHEMICAL
7	I-CHEMICAL
-	I-CHEMICAL
diaryl	I-CHEMICAL
-	I-CHEMICAL
2	I-CHEMICAL
,	I-CHEMICAL
3	I-CHEMICAL
-	I-CHEMICAL
dihydrobenzo	I-CHEMICAL
[	I-CHEMICAL
b	I-CHEMICAL
]	I-CHEMICAL
thiophene	I-CHEMICAL
-	I-CHEMICAL
4	I-CHEMICAL
,	I-CHEMICAL
6	I-CHEMICAL
-	I-CHEMICAL
dicarbonitriles	I-CHEMICAL
have	O
been	O
synthesized	O
regioselectively	O
in	O
good	O
yields	O
through	O
the	O
one	O
-	O
pot	O
domino	O
reactions	O
of	O
5	B-CHEMICAL
-	I-CHEMICAL
aryldihydro	I-CHEMICAL
-	I-CHEMICAL
3	I-CHEMICAL
(	I-CHEMICAL
2H	I-CHEMICAL
)	I-CHEMICAL
-	I-CHEMICAL
thiophenones	I-CHEMICAL
,	O
malononitrile	B-CHEMICAL
and	O
aromatic	B-CHEMICAL
aldehydes	I-CHEMICAL
in	O
the	O
presence	O
of	O
morpholine	B-CHEMICAL
.	O

This	O
transformation	O
presumably	O
involves	O
Knoevenagel	O
condensation	O
-	O
Michael	O
addition	O
-	O
intramolecular	O
Thorpe	O
-	O
Ziegler	O
cyclization	O
-	O
Tautomerization	O
-	O
Elimination	O
sequence	O
of	O
reactions	O
.	O

These	O
compounds	O
were	O
evaluated	O
for	O
their	O
acetylcholinesterase	B-GENE-Y
(	O
AChE	B-GENE-Y
)	O
inhibitory	O
activity	O
and	O
5	B-CHEMICAL
-	I-CHEMICAL
amino	I-CHEMICAL
-	I-CHEMICAL
2	I-CHEMICAL
,	I-CHEMICAL
7	I-CHEMICAL
-	I-CHEMICAL
bis	I-CHEMICAL
(	I-CHEMICAL
4	I-CHEMICAL
-	I-CHEMICAL
methoxyphenyl	I-CHEMICAL
)	I-CHEMICAL
-	I-CHEMICAL
2	I-CHEMICAL
,	I-CHEMICAL
3	I-CHEMICAL
-	I-CHEMICAL
dihydrobenzo	I-CHEMICAL
[	I-CHEMICAL
b	I-CHEMICAL
]	I-CHEMICAL
thiophene	I-CHEMICAL
-	I-CHEMICAL
4	I-CHEMICAL
,	I-CHEMICAL
6	I-CHEMICAL
-	I-CHEMICAL
dicarbonitrile	I-CHEMICAL
was	O
found	O
to	O
be	O
the	O
most	O
potent	O
against	O
AChE	B-GENE-Y
with	O
IC50	O
4	O
.	O
16	O
mol	O
/	O
L	O
.	O

Synthesis	O
and	O
cytotoxicity	O
of	O
3	B-CHEMICAL
-	I-CHEMICAL
aryl	I-CHEMICAL
acrylic	I-CHEMICAL
amide	I-CHEMICAL
derivatives	O
of	O
the	O
simplified	O
saframycin	B-CHEMICAL
-	O
ecteinascidin	B-CHEMICAL
skeleton	O
prepared	O
from	O
l	B-CHEMICAL
-	I-CHEMICAL
dopa	I-CHEMICAL
.	O

Twenty	O
four	O
compounds	O
with	O
diversified	O
3	B-CHEMICAL
-	I-CHEMICAL
aryl	I-CHEMICAL
acrylic	I-CHEMICAL
amide	I-CHEMICAL
side	O
chains	O
of	O
the	O
simplified	O
saframycin	B-CHEMICAL
-	O
ecteinascidin	B-CHEMICAL
pentacyclic	O
skeleton	O
were	O
synthesized	O
via	O
a	O
14	O
-	O
step	O
stereospecific	O
route	O
starting	O
from	O
l	B-CHEMICAL
-	I-CHEMICAL
dopa	I-CHEMICAL
.	O

The	O
cytotoxicities	O
of	O
these	O
compounds	O
were	O
tested	O
against	O
eight	O
human	O
tumor	O
cell	O
lines	O
including	O
HCT	O
-	O
8	O
,	O
BEL	O
-	O
7402	O
,	O
BGC	O
-	O
803	O
,	O
A549	O
,	O
A2780	O
,	O
MCF	O
-	O
7	O
,	O
MX	O
-	O
1	O
,	O
and	O
MDA	O
-	O
MB	O
-	O
231	O
.	O

Most	O
of	O
these	O
compounds	O
exhibited	O
potent	O
antitumor	O
activity	O
,	O
and	O
a	O
preliminary	O
structure	O
-	O
activity	O
relationship	O
(	O
SAR	O
)	O
was	O
discussed	O
.	O

Compound	O
28	O
with	O
3	B-CHEMICAL
-	I-CHEMICAL
thiophenyl	I-CHEMICAL
acrylic	I-CHEMICAL
amide	I-CHEMICAL
side	O
chain	O
exhibited	O
selective	O
cytotoxicity	O
against	O
MDA	O
-	O
MB	O
-	O
231	O
cell	O
line	O
with	O
the	O
IC50	O
value	O
of	O
50	O
nM	O
.	O

Upregulation	O
of	O
drug	O
transporter	O
expression	O
by	O
osteopontin	B-GENE-Y
in	O
prostate	O
cancer	O
cells	O
.	O

Multidrug	O
resistance	O
is	O
a	O
major	O
cause	O
of	O
chemotherapy	O
failure	O
.	O

Recent	O
studies	O
indicate	O
that	O
drug	O
resistance	O
can	O
be	O
rapidly	O
induced	O
by	O
some	O
soluble	O
factors	O
,	O
such	O
as	O
cytokines	B-GENE-N
,	O
chemokines	B-GENE-N
,	O
growth	O
factors	O
,	O
and	O
cell	B-GENE-N
adhesion	I-GENE-N
factors	I-GENE-N
in	O
the	O
tumor	O
microenvironment	O
.	O

Osteopontin	B-GENE-Y
(	O
OPN	B-GENE-Y
)	O
,	O
an	O
extracellular	O
matrix	O
protein	O
,	O
has	O
a	O
functional	O
arginine	B-GENE-N
-	I-GENE-N
glycine	I-GENE-N
-	I-GENE-N
aspartic	I-GENE-N
acid	I-GENE-N
(	I-GENE-N
RGD	I-GENE-N
)	I-GENE-N
domain	I-GENE-N
for	O
binding	O
to	O
integrin	B-GENE-N
.	O

Here	O
we	O
found	O
OPN	B-GENE-Y
expression	O
to	O
be	O
upregulated	O
by	O
hypoxic	O
condition	O
in	O
PC	O
-	O
3	O
prostate	O
tumor	O
cells	O
.	O

OPN	B-GENE-Y
increased	O
the	O
mRNA	O
and	O
protein	O
expression	O
of	O
p	B-GENE-N
-	I-GENE-N
glycoprotein	I-GENE-N
(	O
P	B-GENE-N
-	I-GENE-N
gp	I-GENE-N
)	O
,	O
a	O
subfamily	O
of	O
ATP	B-GENE-N
-	I-GENE-N
binding	I-GENE-N
cassette	I-GENE-N
transporter	I-GENE-N
in	O
a	O
concentration	O
-	O
and	O
time	O
-	O
dependent	O
manner	O
.	O

The	O
increase	O
in	O
P	B-GENE-N
-	I-GENE-N
gp	I-GENE-N
transporter	O
by	O
OPN	B-GENE-Y
was	O
mediated	O
by	O
binding	O
to	O
v3	B-GENE-N
integrin	I-GENE-N
.	O

Daunomycin	B-CHEMICAL
(	O
DUN	B-CHEMICAL
)	O
,	O
a	O
chemotherapeutic	O
agent	O
with	O
autofluorescence	O
,	O
was	O
used	O
to	O
evaluate	O
the	O
pump	O
activity	O
,	O
and	O
OPN	B-GENE-Y
increased	O
the	O
drug	O
pumping	O
-	O
out	O
activity	O
.	O

OPN	B-GENE-Y
inhibited	O
DUN	B-CHEMICAL
-	O
induced	O
cell	O
death	O
,	O
which	O
was	O
antagonized	O
by	O
v3	B-GENE-N
monoclonal	O
antibody	O
.	O

Long	O
-	O
term	O
treatment	O
with	O
DUN	B-CHEMICAL
further	O
enhanced	O
the	O
expression	O
of	O
OPN	B-GENE-Y
.	O

Knockdown	O
of	O
endogenous	O
OPN	B-GENE-Y
potentiated	O
the	O
DUN	B-CHEMICAL
-	O
induced	O
apoptosis	O
of	O
PC	O
-	O
3	O
cells	O
.	O

Furthermore	O
,	O
knockdown	O
of	O
OPN	B-GENE-Y
enhanced	O
cell	O
death	O
caused	O
by	O
other	O
drugs	O
,	O
including	O
paclitaxel	B-CHEMICAL
,	O
doxorubicin	B-CHEMICAL
,	O
actinomycin	B-CHEMICAL
-	I-CHEMICAL
D	I-CHEMICAL
,	O
and	O
rapamycin	B-CHEMICAL
,	O
which	O
are	O
also	O
P	B-GENE-N
-	I-GENE-N
gp	I-GENE-N
substrates	O
.	O

The	O
animal	O
studies	O
also	O
showed	O
that	O
OPN	B-GENE-Y
knockdown	O
enhanced	O
the	O
cytotoxic	O
action	O
of	O
DUN	B-CHEMICAL
.	O

These	O
results	O
indicate	O
that	O
OPN	B-GENE-Y
is	O
a	O
potential	O
therapeutic	O
target	O
for	O
cancer	O
therapy	O
to	O
reduce	O
drug	O
resistance	O
in	O
sensitive	O
tumors	O
.	O

A	O
combination	O
strategy	O
to	O
inhibit	O
Pim	B-GENE-Y
-	I-GENE-Y
1	I-GENE-Y
:	O
synergism	O
between	O
noncompetitive	O
and	O
ATP	B-CHEMICAL
-	O
competitive	O
inhibitors	O
.	O

Pim	B-GENE-Y
-	I-GENE-Y
1	I-GENE-Y
is	O
a	O
serine	B-GENE-N
/	I-GENE-N
threonine	I-GENE-N
kinase	I-GENE-N
critically	O
involved	O
in	O
the	O
initiation	O
and	O
progression	O
of	O
various	O
types	O
of	O
cancer	O
,	O
especially	O
leukemia	O
,	O
lymphomas	O
and	O
solid	O
tumors	O
such	O
as	O
prostate	O
,	O
pancreas	O
and	O
colon	O
,	O
and	O
is	O
considered	O
a	O
potential	O
drug	O
target	O
against	O
these	O
malignancies	O
.	O

In	O
an	O
effort	O
to	O
discover	O
new	O
potent	O
Pim	B-GENE-Y
-	I-GENE-Y
1	I-GENE-Y
inhibitors	O
,	O
a	O
previously	O
identified	O
ATP	B-CHEMICAL
-	O
competitive	O
indolyl	B-CHEMICAL
-	I-CHEMICAL
pyrrolone	I-CHEMICAL
scaffold	O
was	O
expanded	O
to	O
derive	O
structure	O
-	O
activity	O
relationship	O
data	O
.	O

A	O
virtual	O
screening	O
campaign	O
was	O
also	O
performed	O
,	O
which	O
led	O
to	O
the	O
discovery	O
of	O
additional	O
ATP	B-CHEMICAL
-	O
competitive	O
inhibitors	O
as	O
well	O
as	O
a	O
series	O
of	O
2	B-CHEMICAL
-	I-CHEMICAL
aminothiazole	I-CHEMICAL
derivatives	O
,	O
which	O
are	O
noncompetitive	O
with	O
respect	O
to	O
both	O
ATP	B-CHEMICAL
and	O
peptide	O
substrate	O
.	O

This	O
mechanism	O
of	O
action	O
,	O
which	O
resembles	O
allosteric	O
inhibition	O
,	O
has	O
not	O
previously	O
been	O
characterized	O
for	O
Pim	B-GENE-Y
-	I-GENE-Y
1	I-GENE-Y
.	O

Notably	O
,	O
further	O
evaluation	O
of	O
the	O
2	B-CHEMICAL
-	I-CHEMICAL
aminothiazoles	I-CHEMICAL
indicated	O
a	O
synergistic	O
inhibitory	O
effect	O
in	O
enzymatic	O
assays	O
when	O
tested	O
in	O
combination	O
with	O
ATP	B-CHEMICAL
-	O
competitive	O
inhibitors	O
.	O

A	O
synergistic	O
effect	O
in	O
the	O
inhibition	O
of	O
cell	O
proliferation	O
by	O
ATP	B-CHEMICAL
-	O
competitive	O
and	O
ATP	B-CHEMICAL
-	O
noncompetitive	O
compounds	O
was	O
also	O
observed	O
in	O
prostate	O
cancer	O
cell	O
lines	O
(	O
PC3	O
)	O
,	O
where	O
all	O
Pim	B-GENE-Y
-	I-GENE-Y
1	I-GENE-Y
inhibitors	O
tested	O
in	O
showed	O
synergism	O
with	O
the	O
known	O
anticancer	O
agent	O
,	O
paclitaxel	B-CHEMICAL
.	O

These	O
results	O
further	O
establish	O
Pim	B-GENE-Y
-	I-GENE-Y
1	I-GENE-Y
as	O
a	O
target	O
in	O
cancer	O
therapy	O
,	O
and	O
highlight	O
the	O
potential	O
of	O
these	O
agents	O
for	O
use	O
as	O
adjuvant	O
agents	O
in	O
the	O
treatment	O
of	O
cancer	O
diseases	O
in	O
which	O
Pim	B-GENE-Y
-	I-GENE-Y
1	I-GENE-Y
is	O
associated	O
with	O
chemotherapeutic	O
resistance	O
.	O

A	O
population	O
-	O
based	O
study	O
of	O
dosing	O
and	O
persistence	O
with	O
anti	O
-	O
dementia	O
medications	O
.	O

PURPOSE	O
:	O
Cholinesterase	B-GENE-Y
inhibitors	O
and	O
memantine	B-CHEMICAL
are	O
the	O
mainstay	O
of	O
pharmacological	O
intervention	O
for	O
the	O
cognitive	O
symptoms	O
of	O
Alzheimer	O
'	O
s	O
disease	O
(	O
AD	O
)	O
.	O

This	O
study	O
assessed	O
the	O
adequacy	O
of	O
dosing	O
and	O
persistence	O
with	O
AD	O
medications	O
and	O
the	O
predictors	O
of	O
these	O
variables	O
in	O
the	O
'	O
real	O
world	O
'	O
(	O
outside	O
the	O
clinical	O
trial	O
setting	O
)	O
.	O

METHODS	O
:	O
The	O
Health	O
Service	O
Executive	O
-	O
Primary	O
Care	O
Reimbursement	O
Services	O
prescription	O
claims	O
database	O
in	O
the	O
Republic	O
of	O
Ireland	O
contains	O
prescription	O
information	O
for	O
1	O
.	O
6	O
million	O
people	O
.	O

Patients	O
aged	O
>	O
70	O
years	O
who	O
received	O
at	O
least	O
two	O
prescriptions	O
for	O
donepezil	B-CHEMICAL
,	O
rivastigmine	B-CHEMICAL
,	O
galantamine	B-CHEMICAL
and	O
memantine	B-CHEMICAL
between	O
January	O
2006	O
and	O
December	O
2010	O
were	O
included	O
in	O
the	O
study	O
.	O

Rates	O
of	O
dose	O
-	O
maximisation	O
were	O
recorded	O
by	O
examining	O
the	O
initiation	O
dose	O
of	O
each	O
AD	O
drug	O
commenced	O
during	O
the	O
study	O
period	O
and	O
any	O
subsequent	O
dose	O
titrations	O
.	O

Non	O
-	O
persistence	O
was	O
defined	O
by	O
a	O
gap	O
in	O
prescribing	O
of	O
more	O
than	O
63	O
consecutive	O
days	O
.	O

Predictors	O
of	O
dose	O
-	O
maximisation	O
and	O
non	O
-	O
persistence	O
were	O
also	O
analysed	O
.	O

RESULTS	O
:	O
Between	O
January	O
2006	O
and	O
December	O
2010	O
,	O
20	O
,	O
729	O
patients	O
aged	O
>	O
70	O
years	O
received	O
a	O
prescription	O
for	O
an	O
AD	O
medication	O
.	O

Despite	O
most	O
patients	O
on	O
donepezil	B-CHEMICAL
and	O
memantine	B-CHEMICAL
receiving	O
a	O
prescription	O
for	O
the	O
maximum	O
drug	O
dose	O
,	O
this	O
dose	O
was	O
maintained	O
for	O
2	O
consecutive	O
months	O
in	O
only	O
two	O
-	O
thirds	O
of	O
patients	O
.	O

Patients	O
were	O
significantly	O
more	O
likely	O
to	O
have	O
their	O
doses	O
of	O
donepezil	B-CHEMICAL
and	O
memantine	B-CHEMICAL
maximised	O
if	O
prescribed	O
in	O
more	O
recent	O
years	O
(	O
2010	O
vs	O
.	O
2007	O
)	O
.	O

Rates	O
of	O
non	O
-	O
persistence	O
were	O
30	O
.	O
1	O
%	O
at	O
6	O
months	O
and	O
43	O
.	O
8	O
%	O
at	O
12	O
months	O
.	O

Older	O
age	O
[	O
75	O
+	O
vs	O
.	O
<	O
75	O
years	O
;	O
hazards	O
ratio	O
(	O
HR	O
)	O
1	O
.	O
16	O
,	O
95	O
%	O
confidence	O
interval	O
(	O
CI	O
)	O
1	O
.	O
06	O
-	O
1	O
.	O
27	O
]	O
and	O
drug	O
type	O
(	O
rivastigmine	B-CHEMICAL
vs	O
.	O
donepezil	B-CHEMICAL
;	O
HR	O
1	O
.	O
15	O
,	O
95	O
%	O
CI	O
1	O
.	O
03	O
-	O
1	O
.	O
27	O
)	O
increased	O
the	O
risk	O
of	O
non	O
-	O
persistence	O
.	O

Non	O
-	O
persistence	O
was	O
lower	O
for	O
those	O
commencing	O
therapy	O
in	O
more	O
recent	O
years	O
(	O
2010	O
vs	O
.	O
2007	O
;	O
HR	O
0	O
.	O
81	O
,	O
95	O
%	O
CI	O
0	O
.	O
73	O
-	O
0	O
.	O
89	O
,	O
p	O
<	O
0	O
.	O
001	O
)	O
and	O
for	O
those	O
on	O
multiple	O
anti	O
-	O
dementia	O
medications	O
(	O
HR	O
0	O
.	O
59	O
,	O
95	O
%	O
CI	O
0	O
.	O
54	O
-	O
0	O
.	O
65	O
,	O
p	O
<	O
0	O
.	O
001	O
)	O
.	O

Persistence	O
was	O
significantly	O
higher	O
when	O
memantine	B-CHEMICAL
was	O
co	O
-	O
prescribed	O
with	O
donepezil	B-CHEMICAL
(	O
p	O
<	O
0	O
.	O
0001	O
)	O
.	O

CONCLUSION	O
:	O
Future	O
studies	O
should	O
explore	O
the	O
reasons	O
underlying	O
non	O
-	O
persistence	O
and	O
failure	O
to	O
maintain	O
dose	O
-	O
maximisation	O
in	O
patients	O
on	O
AD	O
medications	O
.	O

There	O
may	O
be	O
scope	O
to	O
improve	O
the	O
dosing	O
and	O
persistence	O
with	O
these	O
medications	O
in	O
the	O
community	O
.	O

mGluR2	B-GENE-Y
positive	O
allosteric	O
modulators	O
:	O
a	O
patent	O
review	O
(	O
2009	O
-	O
present	O
)	O
.	O

Introduction	O
:	O
The	O
mGlu2	B-GENE-Y
receptor	I-GENE-Y
,	O
which	O
belongs	O
to	O
the	O
group	B-GENE-Y
II	I-GENE-Y
subfamily	I-GENE-Y
of	I-GENE-Y
metabotropic	I-GENE-Y
glutamate	I-GENE-Y
receptors	I-GENE-Y
(	O
mGlu	O
)	O
along	O
with	O
the	O
mGlu3	B-GENE-Y
receptor	I-GENE-Y
,	O
has	O
proven	O
to	O
be	O
of	O
particular	O
importance	O
in	O
neuropharmacology	O
.	O

Preferentially	O
expressed	O
on	O
presynaptic	O
nerve	O
terminals	O
,	O
the	O
mGlu2	B-GENE-Y
receptor	I-GENE-Y
negatively	O
modulates	O
glutamate	B-CHEMICAL
and	O
GABA	B-CHEMICAL
release	O
and	O
is	O
widely	O
distributed	O
in	O
the	O
brain	O
.	O

High	O
levels	O
of	O
mGlu2	B-GENE-Y
receptors	I-GENE-Y
are	O
seen	O
in	O
brain	O
areas	O
such	O
as	O
prefrontal	O
cortex	O
,	O
hippocampus	O
and	O
amygdala	O
where	O
glutamate	B-CHEMICAL
hyperfunction	O
may	O
be	O
implicated	O
in	O
disorders	O
and	O
diseases	O
such	O
as	O
anxiety	O
and	O
schizophrenia	O
.	O

Given	O
the	O
promise	O
offered	O
by	O
mGlu2	B-GENE-N
/	I-GENE-N
3	I-GENE-N
receptor	I-GENE-N
activation	O
,	O
there	O
is	O
increased	O
interest	O
in	O
identifying	O
small	O
molecules	O
which	O
activate	O
the	O
receptor	O
.	O

A	O
preferred	O
approach	O
is	O
via	O
positive	O
allosteric	O
modulators	O
(	O
PAMs	O
)	O
which	O
bind	O
at	O
an	O
alternative	O
site	O
to	O
agonists	O
.	O

Areas	O
covered	O
:	O
This	O
review	O
covers	O
the	O
patent	O
applications	O
which	O
were	O
published	O
between	O
April	O
2009	O
and	O
December	O
2012	O
on	O
PAMs	O
of	O
the	O
mGlu2	B-GENE-Y
,	O
and	O
it	O
is	O
a	O
continuation	O
of	O
an	O
earlier	O
review	O
published	O
in	O
this	O
journal	O
.	O

Expert	O
opinion	O
:	O
Advances	O
in	O
medicinal	O
chemistry	O
and	O
pharmacology	O
have	O
set	O
the	O
stage	O
in	O
the	O
field	O
of	O
mGlu2	B-GENE-Y
receptor	I-GENE-Y
PAMs	O
.	O

Compounds	O
currently	O
advancing	O
in	O
clinical	O
trials	O
will	O
soon	O
establish	O
the	O
therapeutic	O
potential	O
of	O
this	O
allosteric	O
approach	O
.	O

Effect	O
of	O
protein	O
malnutrition	O
on	O
the	O
metabolism	O
and	O
toxicity	O
of	O
cisplatin	B-CHEMICAL
,	O
5	B-CHEMICAL
-	I-CHEMICAL
fluorouracil	I-CHEMICAL
and	O
mitomycin	B-CHEMICAL
C	I-CHEMICAL
in	O
rat	O
stomach	O
.	O

This	O
study	O
investigated	O
the	O
effect	O
of	O
protein	O
malnutrition	O
on	O
metabolism	O
and	O
toxicity	O
of	O
cisplatin	B-CHEMICAL
(	O
CP	O
)	O
,	O
5	B-CHEMICAL
-	I-CHEMICAL
fluorouracil	I-CHEMICAL
(	O
FU	O
)	O
and	O
mitomycin	B-CHEMICAL
C	I-CHEMICAL
(	O
MMC	B-CHEMICAL
)	O
in	O
rat	O
stomach	O
.	O

Weanling	O
male	O
Wistar	O
rats	O
received	O
a	O
normal	O
(	O
24	O
%	O
)	O
or	O
low	O
(	O
2	O
.	O
5	O
%	O
)	O
protein	O
diet	O
for	O
28days	O
and	O
were	O
allocated	O
into	O
:	O
normally	O
-	O
fed	O
control	O
,	O
protein	O
-	O
malnourished	O
control	O
(	O
PM	O
)	O
,	O
3	O
normally	O
-	O
fed	O
drug	O
-	O
treated	O
groups	O
and	O
3	O
protein	O
-	O
malnourished	O
drug	O
-	O
treated	O
groups	O
(	O
PM	O
-	O
CP	O
,	O
PM	O
-	O
FU	O
and	O
PM	O
-	O
MMC	B-CHEMICAL
)	O
.	O

Cisplatin	B-CHEMICAL
and	O
MMC	B-CHEMICAL
were	O
injected	O
intraperitoneally	O
(	O
8mg	O
/	O
kg	O
on	O
day	O
26	O
and	O
1mg	O
/	O
kg	O
/	O
day	O
for	O
7days	O
,	O
respectively	O
)	O
.	O

5	B-CHEMICAL
-	I-CHEMICAL
Fluorouracil	I-CHEMICAL
was	O
given	O
orally	O
(	O
50mg	O
/	O
kg	O
/	O
day	O
for	O
5days	O
)	O
.	O

Compared	O
with	O
normally	O
-	O
fed	O
counterparts	O
,	O
PM	O
-	O
CP	O
rats	O
exhibited	O
higher	O
glutathione	B-GENE-N
S	I-GENE-N
-	I-GENE-N
transferase	I-GENE-N
,	O
aminopeptidase	B-GENE-Y
N	I-GENE-Y
and	O
cysteine	B-GENE-Y
S	I-GENE-Y
-	I-GENE-Y
conjugate	I-GENE-Y
beta	I-GENE-Y
-	I-GENE-Y
lyase	I-GENE-Y
(	O
CCBL	B-GENE-Y
)	O
and	O
lower	O
gamma	B-GENE-Y
-	I-GENE-Y
glutamyltransferase	I-GENE-Y
activities	O
,	O
PM	O
-	O
FU	O
rats	O
exhibited	O
decreased	O
dihydropyrimidine	B-GENE-Y
dehydrogenase	I-GENE-Y
and	O
cytochrome	B-GENE-N
P450	I-GENE-N
1A1	I-GENE-N
/	I-GENE-N
2	I-GENE-N
activities	O
and	O
PM	O
-	O
MMC	B-CHEMICAL
rats	O
showed	O
higher	O
quinone	B-GENE-N
reductase	I-GENE-N
and	O
depleted	O
xanthine	B-GENE-Y
oxidase	I-GENE-Y
activities	O
.	O

Protein	O
-	O
malnourished	O
drug	O
-	O
treated	O
groups	O
exhibited	O
exacerbated	O
gastrotoxicity	O
,	O
relative	O
to	O
normally	O
-	O
fed	O
counterparts	O
,	O
manifested	O
by	O
lower	O
mucus	O
levels	O
,	O
higher	O
permeability	O
and	O
histopathological	O
deterioration	O
,	O
along	O
with	O
increased	O
oxidative	O
stress	O
in	O
PM	O
-	O
CP	O
rats	O
and	O
exaggerated	O
prostaglandin	B-CHEMICAL
E2	I-CHEMICAL
production	O
in	O
PM	O
-	O
MMC	B-CHEMICAL
rats	O
.	O

Conclusively	O
,	O
protein	O
malnutrition	O
alters	O
CP	O
,	O
FU	O
and	O
MMC	B-CHEMICAL
metabolism	O
in	O
rat	O
stomach	O
by	O
enhancing	O
CCBL	B-GENE-Y
pathway	O
for	O
CP	O
activation	O
,	O
delaying	O
FU	O
elimination	O
and	O
activating	O
two	O
-	O
electron	O
reduction	O
of	O
MMC	B-CHEMICAL
,	O
potentiating	O
their	O
gastrotoxicity	O
.	O

Effect	O
of	O
serum	O
on	O
diesel	O
exhaust	O
particles	O
(	O
DEP	O
)	O
-	O
induced	O
apoptosis	O
of	O
airway	O
epithelial	O
cells	O
in	O
vitro	O
.	O

Patients	O
with	O
chronic	O
airway	O
diseases	O
may	O
be	O
more	O
susceptible	O
to	O
adverse	O
effects	O
of	O
air	O
pollutants	O
including	O
diesel	O
exhaust	O
particles	O
(	O
DEP	O
)	O
.	O

We	O
investigated	O
effects	O
of	O
foetal	O
calf	O
serum	O
(	O
FCS	O
)	O
on	O
DEP	O
-	O
induced	O
changes	O
in	O
airway	O
epithelial	O
cell	O
apoptosis	O
and	O
inflammation	O
.	O

DEP	O
(	O
50	O
-	O
200	O
g	O
/	O
ml	O
)	O
increased	O
A549	O
cell	O
viability	O
in	O
the	O
absence	O
of	O
FCS	O
.	O

In	O
the	O
presence	O
of	O
3	O
.	O
3	O
%	O
FCS	O
,	O
DEP	O
(	O
50	O
-	O
400	O
g	O
/	O
ml	O
)	O
decreased	O
A549	O
cell	O
viability	O
.	O

N	B-CHEMICAL
-	I-CHEMICAL
acetylcysteine	I-CHEMICAL
(	O
NAC	B-CHEMICAL
,	O
33	O
mM	O
)	O
and	O
the	O
c	B-GENE-N
-	I-GENE-N
jun	I-GENE-N
N	I-GENE-N
-	I-GENE-N
terminal	I-GENE-N
kinase	I-GENE-N
(	O
JNK	B-GENE-N
)	O
inhibitor	O
(	O
SP600125	B-CHEMICAL
,	O
33	O
M	O
)	O
further	O
decreased	O
the	O
viability	O
in	O
the	O
presence	O
of	O
DEP	O
(	O
200	O
g	O
/	O
ml	O
)	O
and	O
3	O
.	O
3	O
%	O
FCS	O
.	O

Under	O
serum	O
-	O
free	O
(	O
SF	O
)	O
condition	O
,	O
DEP	O
(	O
50	O
g	O
/	O
ml	O
)	O
reduced	O
apoptotic	O
cells	O
;	O
however	O
,	O
when	O
3	O
.	O
3	O
%	O
FCS	O
added	O
to	O
the	O
culture	O
medium	O
,	O
this	O
effect	O
was	O
abolished	O
.	O

DEP	O
(	O
200	O
g	O
/	O
ml	O
)	O
induced	O
mRNA	O
expression	O
of	O
p21	B-GENE-Y
(	O
CIP1	B-GENE-Y
/	O
WAF1	B-GENE-Y
)	O
both	O
in	O
absence	O
or	O
presence	O
of	O
3	O
.	O
3	O
%	O
FCS	O
and	O
enhanced	O
JNK2	B-GENE-Y
mRNA	O
expression	O
only	O
in	O
the	O
presence	O
of	O
3	O
.	O
3	O
%	O
FCS	O
.	O

Under	O
SF	O
condition	O
,	O
DEP	O
(	O
50	O
g	O
/	O
ml	O
)	O
induced	O
mRNA	O
expression	O
for	O
p27	B-GENE-Y
and	O
p53	B-GENE-Y
,	O
whereas	O
cyclin	B-GENE-Y
E	I-GENE-Y
mRNA	O
expression	O
was	O
inhibited	O
by	O
DEP	O
(	O
50	O
and	O
200	O
g	O
/	O
ml	O
)	O
.	O

Furthermore	O
,	O
DEP	O
(	O
200	O
g	O
/	O
ml	O
)	O
decreased	O
the	O
release	O
of	O
interleukin	B-GENE-Y
(	I-GENE-Y
IL	I-GENE-Y
)	I-GENE-Y
-	I-GENE-Y
8	I-GENE-Y
in	O
the	O
absence	O
of	O
FCS	O
.	O

In	O
conclusion	O
,	O
FCS	O
modulates	O
effects	O
of	O
DEP	O
on	O
cell	O
death	O
,	O
cell	O
cycle	O
and	O
apoptosis	O
regulating	O
proteins	O
,	O
and	O
IL	B-GENE-Y
-	I-GENE-Y
8	I-GENE-Y
release	O
by	O
activating	O
oxidant	O
stress	O
pathways	O
,	O
JNK	B-GENE-N
and	O
NF	B-GENE-N
-	I-GENE-N
B	I-GENE-N
.	O

Extravasation	O
of	O
serum	O
,	O
as	O
occurs	O
in	O
the	O
inflamed	O
airways	O
of	O
patients	O
with	O
chronic	O
airway	O
diseases	O
such	O
as	O
asthma	O
and	O
COPD	O
,	O
may	O
render	O
airway	O
epithelial	O
cells	O
more	O
susceptible	O
to	O
the	O
deleterious	O
effects	O
of	O
DEP	O
.	O

Cerebrovascular	O
Dilation	O
via	O
Selective	O
Targeting	O
of	O
the	O
Cholane	B-CHEMICAL
Steroid	B-CHEMICAL
-	O
Recognition	O
Site	O
in	O
the	O
BK	B-GENE-Y
Channel	I-GENE-Y
1	I-GENE-Y
-	I-GENE-Y
Subunit	I-GENE-Y
by	O
a	O
Novel	O
Nonsteroidal	O
Agent	O
.	O

The	O
Ca	B-GENE-Y
(	I-GENE-Y
2	I-GENE-Y
+	I-GENE-Y
)	I-GENE-Y
/	I-GENE-Y
voltage	I-GENE-Y
-	I-GENE-Y
gated	I-GENE-Y
K	I-GENE-Y
(	I-GENE-Y
+	I-GENE-Y
)	I-GENE-Y
large	I-GENE-Y
conductance	I-GENE-Y
(	I-GENE-Y
BK	I-GENE-Y
)	I-GENE-Y
channel	I-GENE-Y
1	I-GENE-Y
subunit	O
is	O
particularly	O
abundant	O
in	O
vascular	O
smooth	O
muscle	O
.	O

By	O
determining	O
their	O
phenotype	O
,	O
BK	B-GENE-Y
1	I-GENE-Y
allows	O
the	O
BK	B-GENE-N
channels	I-GENE-N
to	O
reduce	O
myogenic	O
tone	O
,	O
facilitating	O
vasodilation	O
.	O

The	O
endogenous	O
steroid	B-CHEMICAL
lithocholic	B-CHEMICAL
acid	I-CHEMICAL
(	O
LCA	B-CHEMICAL
)	O
dilates	O
cerebral	O
arteries	O
via	O
BK	B-GENE-N
channel	I-GENE-N
activation	O
,	O
which	O
requires	O
recognition	O
by	O
a	O
BK	B-GENE-Y
1	I-GENE-Y
site	O
that	O
includes	O
Thr169	B-CHEMICAL
.	O

Whether	O
exogenous	O
nonsteroidal	O
agents	O
can	O
access	O
this	O
site	O
to	O
selectively	O
activate	O
1	B-GENE-Y
-	I-GENE-Y
containing	I-GENE-Y
BK	I-GENE-Y
channels	I-GENE-Y
and	O
evoke	O
vasodilation	O
remain	O
unknown	O
.	O

We	O
performed	O
a	O
chemical	O
structure	O
database	O
similarity	O
search	O
using	O
LCA	B-CHEMICAL
as	O
a	O
template	O
,	O
along	O
with	O
a	O
two	O
-	O
step	O
reaction	O
to	O
generate	O
sodium	B-CHEMICAL
3	I-CHEMICAL
-	I-CHEMICAL
hydroxyolean	I-CHEMICAL
-	I-CHEMICAL
12	I-CHEMICAL
-	I-CHEMICAL
en	I-CHEMICAL
-	I-CHEMICAL
30	I-CHEMICAL
-	I-CHEMICAL
oate	I-CHEMICAL
(	O
HENA	B-CHEMICAL
)	O
.	O

HENA	B-CHEMICAL
activated	O
the	O
BK	B-GENE-Y
(	I-GENE-Y
cbv1	I-GENE-Y
+	I-GENE-Y
1	I-GENE-Y
)	I-GENE-Y
channels	I-GENE-Y
cloned	O
from	O
rat	O
cerebral	O
artery	O
myocytes	O
with	O
a	O
potency	O
(	O
EC50	O
=	O
53	O
M	O
)	O
similar	O
to	O
and	O
an	O
efficacy	O
(	O
	O
2	O
.	O
5	O
potentiation	O
)	O
significantly	O
greater	O
than	O
that	O
of	O
LCA	B-CHEMICAL
.	O

This	O
HENA	B-CHEMICAL
action	O
was	O
replicated	O
on	O
native	O
channels	O
in	O
rat	O
cerebral	O
artery	O
myocytes	O
.	O

HENA	B-CHEMICAL
failed	O
to	O
activate	O
the	O
channels	O
made	O
of	O
cbv1	O
+	O
2	O
,	O
3	O
,	O
4	O
,	O
or	O
1T169A	O
,	O
indicating	O
that	O
this	O
drug	O
selectively	O
targets	O
1	B-GENE-N
-	I-GENE-N
containing	I-GENE-N
BK	I-GENE-N
channels	I-GENE-N
via	O
the	O
BK	B-GENE-Y
1	I-GENE-Y
steroid	B-CHEMICAL
-	O
sensing	O
site	O
.	O

HENA	B-CHEMICAL
(	O
3	O
-	O
45	O
M	O
)	O
dilated	O
the	O
rat	O
and	O
C57BL	O
/	O
6	O
mouse	O
pressurized	O
cerebral	O
arteries	O
.	O

Consistent	O
with	O
the	O
electrophysiologic	O
results	O
,	O
this	O
effect	O
was	O
larger	O
than	O
that	O
of	O
LCA	B-CHEMICAL
.	O

HENA	B-CHEMICAL
failed	O
to	O
dilate	O
the	O
arteries	O
from	O
the	O
KCNMB1	B-GENE-Y
knockout	O
mouse	O
,	O
underscoring	O
BK	B-GENE-Y
1	I-GENE-Y
'	O
s	O
role	O
in	O
HENA	B-CHEMICAL
action	O
.	O

Finally	O
,	O
carotid	O
artery	O
-	O
infusion	O
of	O
HENA	B-CHEMICAL
(	O
45	O
M	O
)	O
dilated	O
the	O
pial	O
cerebral	O
arterioles	O
via	O
selective	O
BK	B-GENE-N
-	I-GENE-N
channel	I-GENE-N
targeting	O
.	O

In	O
conclusion	O
,	O
we	O
have	O
identified	O
for	O
the	O
first	O
time	O
a	O
nonsteroidal	O
agent	O
that	O
selectively	O
activates	O
1	B-GENE-N
-	I-GENE-N
containing	I-GENE-N
BK	I-GENE-N
channels	I-GENE-N
by	O
targeting	O
the	O
steroid	B-CHEMICAL
-	O
sensing	O
site	O
in	O
BK	B-GENE-Y
1	I-GENE-Y
,	O
rendering	O
vasodilation	O
.	O

Assessment	O
of	O
the	O
abuse	O
liability	O
of	O
ABT	B-CHEMICAL
-	I-CHEMICAL
288	I-CHEMICAL
,	O
a	O
novel	O
histamine	B-GENE-Y
H3	I-GENE-Y
receptor	I-GENE-Y
antagonist	O
.	O

RATIONALE	O
:	O
Histamine	B-GENE-Y
H3	I-GENE-Y
receptor	I-GENE-Y
antagonists	O
,	O
such	O
as	O
ABT	B-CHEMICAL
-	I-CHEMICAL
288	I-CHEMICAL
,	O
have	O
been	O
shown	O
to	O
possess	O
cognitive	O
-	O
enhancing	O
and	O
wakefulness	O
-	O
promoting	O
effects	O
.	O

On	O
the	O
surface	O
,	O
this	O
might	O
suggest	O
that	O
H3	B-GENE-Y
antagonists	O
possess	O
psychomotor	O
stimulant	O
-	O
like	O
effects	O
and	O
,	O
as	O
such	O
,	O
may	O
have	O
the	O
potential	O
for	O
abuse	O
.	O

OBJECTIVES	O
:	O
The	O
aim	O
of	O
the	O
present	O
study	O
was	O
to	O
further	O
characterize	O
whether	O
ABT	B-CHEMICAL
-	I-CHEMICAL
288	I-CHEMICAL
possesses	O
stimulant	O
-	O
like	O
properties	O
and	O
whether	O
its	O
pharmacology	O
gives	O
rise	O
to	O
abuse	O
liability	O
.	O

METHODS	O
:	O
The	O
locomotor	O
-	O
stimulant	O
effects	O
of	O
ABT	B-CHEMICAL
-	I-CHEMICAL
288	I-CHEMICAL
were	O
measured	O
in	O
mice	O
and	O
rats	O
,	O
and	O
potential	O
development	O
of	O
sensitization	O
was	O
addressed	O
.	O

Drug	O
discrimination	O
was	O
used	O
to	O
assess	O
amphetamine	B-CHEMICAL
-	O
like	O
stimulus	O
properties	O
,	O
and	O
drug	O
self	O
-	O
administration	O
was	O
used	O
to	O
evaluate	O
reinforcing	O
effects	O
of	O
ABT	B-CHEMICAL
-	I-CHEMICAL
288	I-CHEMICAL
.	O

The	O
potential	O
development	O
of	O
physical	O
dependence	O
was	O
also	O
studied	O
.	O

RESULTS	O
:	O
ABT	B-CHEMICAL
-	I-CHEMICAL
288	I-CHEMICAL
lacked	O
locomotor	O
-	O
stimulant	O
effects	O
in	O
both	O
rats	O
and	O
mice	O
.	O

Repeated	O
administration	O
of	O
ABT	B-CHEMICAL
-	I-CHEMICAL
288	I-CHEMICAL
did	O
not	O
result	O
in	O
cross	O
-	O
sensitization	O
to	O
the	O
stimulant	O
effects	O
of	O
d	B-CHEMICAL
-	I-CHEMICAL
amphetamine	I-CHEMICAL
in	O
mice	O
,	O
suggesting	O
that	O
there	O
is	O
little	O
overlap	O
in	O
circuitries	O
upon	O
which	O
the	O
two	O
drugs	O
interact	O
for	O
motor	O
activity	O
.	O

ABT	B-CHEMICAL
-	I-CHEMICAL
288	I-CHEMICAL
did	O
not	O
produce	O
amphetamine	B-CHEMICAL
-	O
like	O
discriminative	O
stimulus	O
effects	O
in	O
drug	O
discrimination	O
studies	O
nor	O
was	O
it	O
self	O
-	O
administered	O
by	O
rats	O
trained	O
to	O
self	O
-	O
administer	O
cocaine	B-CHEMICAL
.	O

There	O
were	O
no	O
signs	O
of	O
physical	O
dependence	O
upon	O
termination	O
of	O
repeated	O
administration	O
of	O
ABT	B-CHEMICAL
-	I-CHEMICAL
288	I-CHEMICAL
for	O
30	O
days	O
.	O

CONCLUSIONS	O
:	O
The	O
sum	O
of	O
these	O
preclinical	O
data	O
,	O
the	O
first	O
of	O
their	O
kind	O
applied	O
to	O
H3	B-GENE-Y
antagonists	O
,	O
indicates	O
that	O
ABT	B-CHEMICAL
-	I-CHEMICAL
288	I-CHEMICAL
is	O
unlikely	O
to	O
possess	O
a	O
high	O
potential	O
for	O
abuse	O
in	O
the	O
human	O
population	O
and	O
suggests	O
that	O
H3	B-GENE-Y
antagonists	O
,	O
as	O
a	O
class	O
,	O
are	O
similar	O
in	O
this	O
regard	O
.	O

Unraveling	O
a	O
phosphorylation	O
event	O
in	O
a	O
folded	O
protein	O
by	O
NMR	O
spectroscopy	O
:	O
phosphorylation	O
of	O
the	O
Pin1	B-GENE-N
WW	I-GENE-N
domain	I-GENE-N
by	O
PKA	B-GENE-N
.	O

The	O
Pin1	B-GENE-Y
protein	O
plays	O
a	O
critical	O
role	O
in	O
the	O
functional	O
regulation	O
of	O
the	O
hyperphosphorylated	O
neuronal	O
Tau	B-GENE-Y
protein	I-GENE-Y
in	O
Alzheimer	O
'	O
s	O
disease	O
and	O
is	O
by	O
itself	O
regulated	O
by	O
phosphorylation	O
.	O

We	O
have	O
used	O
Nuclear	O
Magnetic	O
Resonance	O
(	O
NMR	O
)	O
spectroscopy	O
to	O
both	O
identify	O
the	O
PKA	B-GENE-N
phosphorylation	O
site	O
in	O
the	O
Pin1	B-GENE-N
WW	I-GENE-N
domain	I-GENE-N
and	O
investigate	O
the	O
functional	O
consequences	O
of	O
this	O
phosphorylation	O
.	O

Detection	O
and	O
identification	O
of	O
phosphorylation	O
on	O
serine	B-CHEMICAL
/	O
threonine	B-CHEMICAL
residues	O
in	O
a	O
globular	O
protein	O
,	O
while	O
mostly	O
occurring	O
in	O
solvent	O
-	O
exposed	O
flexible	O
loops	O
,	O
does	O
not	O
lead	O
to	O
chemical	O
shift	O
changes	O
as	O
obvious	O
as	O
in	O
disordered	O
proteins	O
and	O
hence	O
does	O
not	O
necessarily	O
shift	O
the	O
resonances	O
outside	O
the	O
spectrum	O
of	O
the	O
folded	O
protein	O
.	O

Other	O
complications	O
were	O
encountered	O
to	O
characterize	O
the	O
extent	O
of	O
the	O
phosphorylation	O
,	O
as	O
part	O
of	O
the	O
(	B-CHEMICAL
1	I-CHEMICAL
)	I-CHEMICAL
H	I-CHEMICAL
,	O
(	B-CHEMICAL
15	I-CHEMICAL
)	I-CHEMICAL
N	I-CHEMICAL
amide	B-CHEMICAL
resonances	O
around	O
the	O
phosphorylation	O
site	O
are	O
specifically	O
broadened	O
in	O
the	O
unphosphorylated	O
state	O
.	O

Despite	O
these	O
obstacles	O
,	O
NMR	O
spectroscopy	O
was	O
an	O
efficient	O
tool	O
to	O
confirm	O
phosphorylation	O
on	O
S16	O
of	O
the	O
WW	B-GENE-N
domain	I-GENE-N
and	O
to	O
quantify	O
the	O
level	O
of	O
phosphorylation	O
.	O

Based	O
on	O
this	O
analytical	O
characterization	O
,	O
we	O
show	O
that	O
WW	B-GENE-N
phosphorylation	O
on	O
S16	O
abolishes	O
its	O
binding	O
capacity	O
to	O
a	O
phosphorylated	B-GENE-Y
Tau	I-GENE-Y
peptide	I-GENE-Y
.	O

A	O
reduced	O
conformational	O
heterogeneity	O
and	O
flexibility	O
of	O
the	O
phospho	B-CHEMICAL
-	O
binding	O
loop	O
upon	O
S16	O
phosphorylation	O
could	O
account	O
for	O
part	O
of	O
the	O
decreased	O
affinity	O
for	O
its	O
phosphorylated	O
partner	O
.	O

Additionally	O
,	O
a	O
structural	O
model	O
of	O
the	O
phospho	B-GENE-N
-	I-GENE-N
WW	I-GENE-N
obtained	O
by	O
molecular	O
dynamics	O
simulation	O
and	O
energy	O
minimization	O
suggests	O
that	O
the	O
phosphate	B-CHEMICAL
moiety	O
of	O
phospho	B-CHEMICAL
-	O
S16	O
could	O
compete	O
with	O
the	O
phospho	B-CHEMICAL
-	O
substrate	O
.	O

Dissecting	O
the	O
relative	O
contribution	O
of	O
OATP1B1	B-GENE-Y
-	O
mediated	O
uptake	O
of	O
xenobiotics	O
into	O
human	O
hepatocytes	O
using	O
siRNA	O
.	O

Abstract	O
1	O
.	O

Organic	B-GENE-Y
anion	I-GENE-Y
transporting	I-GENE-Y
polypeptide	I-GENE-Y
1B1	I-GENE-Y
plays	O
a	O
pivotal	O
role	O
in	O
the	O
disposition	O
of	O
many	O
anionic	O
drugs	O
.	O

Significant	O
overlap	O
in	O
substrate	O
specificity	O
between	O
individual	O
OATP	B-GENE-N
isoforms	O
has	O
hampered	O
the	O
identification	O
of	O
the	O
relative	O
importance	O
of	O
individual	O
isoforms	O
for	O
hepatic	O
uptake	O
of	O
xenobiotics	O
.	O

2	O
.	O

The	O
present	O
study	O
focused	O
on	O
the	O
use	O
of	O
siRNA	O
technology	O
to	O
decrease	O
OATP1B1	B-GENE-Y
selectively	O
in	O
human	O
hepatocytes	O
.	O

Following	O
delivery	O
of	O
siRNA	O
by	O
the	O
novel	O
lipid	O
,	O
AtuFECT01	O
,	O
mRNA	O
expression	O
of	O
OATP1B1	B-GENE-Y
was	O
reduced	O
by	O
94	O
%	O
-	O
98	O
%	O
with	O
no	O
significant	O
toxicity	O
.	O

Off	O
-	O
target	O
effects	O
were	O
also	O
shown	O
to	O
be	O
minimal	O
as	O
evidenced	O
by	O
the	O
expression	O
of	O
common	O
drug	O
metabolizing	O
enzymes	O
,	O
transporters	O
,	O
nuclear	O
receptors	O
and	O
associated	O
co	O
-	O
regulators	O
.	O

Uptake	O
of	O
estrone	B-CHEMICAL
-	I-CHEMICAL
3	I-CHEMICAL
-	I-CHEMICAL
sulfate	I-CHEMICAL
(	O
5	O
nM	O
)	O
by	O
OATP1B1	B-GENE-Y
was	O
reduced	O
by	O
82	O
%	O
-	O
95	O
%	O
.	O

This	O
methodology	O
was	O
subsequently	O
used	O
to	O
assess	O
the	O
relative	O
contribution	O
of	O
OATP1B1	B-GENE-Y
uptake	O
in	O
human	O
hepatocytes	O
for	O
olmesartan	B-CHEMICAL
(	O
42	O
%	O
-	O
62	O
%	O
)	O
,	O
valsartan	B-CHEMICAL
(	O
28	O
%	O
-	O
81	O
%	O
)	O
,	O
rosuvastatin	B-CHEMICAL
(	O
64	O
%	O
-	O
72	O
%	O
)	O
,	O
pitavastatin	B-CHEMICAL
(	O
84	O
%	O
-	O
98	O
%	O
)	O
and	O
lopinavir	B-CHEMICAL
(	O
64	O
%	O
-	O
89	O
%	O
)	O
.	O

These	O
data	O
are	O
consistent	O
with	O
previous	O
values	O
obtained	O
using	O
a	O
relative	O
activity	O
factor	O
approach	O
.	O

3	O
.	O

The	O
siRNA	O
approach	O
provides	O
a	O
robust	O
and	O
reproducible	O
method	O
for	O
assessing	O
the	O
relative	O
contribution	O
of	O
OATP1B1	B-GENE-Y
to	O
hepatic	O
uptake	O
of	O
new	O
chemical	O
entities	O
.	O

The	O
technique	O
also	O
has	O
potential	O
utility	O
in	O
facilitating	O
detailed	O
characterization	O
of	O
drug	O
-	O
drug	O
interactions	O
involving	O
hepatic	O
drug	O
transporters	O
.	O

Serum	O
free	O
fatty	B-CHEMICAL
acid	I-CHEMICAL
levels	O
in	O
PCOS	O
patients	O
treated	O
with	O
glucophage	O
,	O
magnesium	B-CHEMICAL
oxide	I-CHEMICAL
and	O
spironolactone	B-CHEMICAL
.	O

Abstract	O
To	O
assess	O
the	O
effect	O
of	O
glucophage	O
,	O
magnesium	B-CHEMICAL
oxide	I-CHEMICAL
and	O
spironolactone	B-CHEMICAL
in	O
altering	O
free	O
fatty	B-CHEMICAL
acids	I-CHEMICAL
(	O
FFAs	O
)	O
,	O
36	O
PCOS	O
women	O
were	O
randomly	O
divided	O
into	O
three	O
groups	O
.	O

Group	O
1	O
(	O
n	O
=	O
14	O
)	O
was	O
treated	O
with	O
500	O
mg	O
glucophage	O
po	O
bid	O
,	O
group	O
2	O
(	O
n	O
=	O
10	O
)	O
was	O
treated	O
with	O
400	O
mg	O
magnesium	B-CHEMICAL
oxide	I-CHEMICAL
po	O
bid	O
and	O
group	O
3	O
(	O
n	O
=	O
12	O
)	O
was	O
treated	O
with	O
50	O
mg	O
spironolactone	B-CHEMICAL
po	O
bid	O
for	O
12	O
weeks	O
.	O

A	O
glucose	B-CHEMICAL
tolerance	O
test	O
with	O
75	O
g	O
glucose	B-CHEMICAL
load	O
was	O
performed	O
before	O
and	O
after	O
treatment	O
,	O
collecting	O
blood	O
at	O
0	O
,	O
1	O
and	O
2	O
h	O
for	O
insulin	B-GENE-Y
,	O
glucose	B-CHEMICAL
,	O
FFA	O
and	O
aldosterone	B-CHEMICAL
.	O

Amount	O
of	O
FFA	O
before	O
and	O
after	O
treatment	O
were	O
compared	O
by	O
repeated	O
measure	O
ANOVA	O
and	O
represented	O
as	O
area	O
under	O
the	O
curve	O
.	O

FFA	O
levels	O
before	O
treatment	O
were	O
0	O
.	O
83	O
	O
0	O
.	O
23	O
,	O
0	O
.	O
77	O
	O
0	O
.	O
15	O
and	O
0	O
.	O
85	O
	O
0	O
.	O
28	O
and	O
after	O
treatment	O
were	O
0	O
.	O
77	O
	O
0	O
.	O
48	O
,	O
0	O
.	O
71	O
	O
0	O
.	O
18	O
and	O
0	O
.	O
66	O
	O
0	O
.	O
25	O
for	O
glucophage	O
,	O
magnesium	B-CHEMICAL
oxide	I-CHEMICAL
and	O
spironolactone	B-CHEMICAL
-	O
treated	O
patients	O
,	O
respectively	O
.	O

The	O
FFA	O
levels	O
were	O
unchanged	O
in	O
the	O
groups	O
treated	O
with	O
glucophage	O
and	O
magnesium	B-CHEMICAL
oxide	I-CHEMICAL
but	O
were	O
significantly	O
(	O
p	O
<	O
0	O
.	O
03	O
)	O
decreased	O
in	O
the	O
group	O
treated	O
with	O
spironolactone	B-CHEMICAL
.	O

Since	O
FFAs	O
are	O
known	O
to	O
be	O
involved	O
in	O
the	O
development	O
of	O
insulin	B-GENE-Y
resistance	O
,	O
these	O
results	O
suggest	O
that	O
spironolactone	B-CHEMICAL
may	O
be	O
useful	O
for	O
lowering	O
insulin	B-GENE-Y
resistance	O
in	O
PCOS	O
patients	O
.	O

Membranar	O
effects	O
exerted	O
in	O
vitro	O
by	O
polyphenols	B-CHEMICAL
-	O
quercetin	B-CHEMICAL
,	O
epigallocatechin	B-CHEMICAL
gallate	I-CHEMICAL
and	O
curcumin	B-CHEMICAL
-	O
on	O
HUVEC	O
and	O
Jurkat	O
cells	O
,	O
relevant	O
for	O
diabetes	O
mellitus	O
.	O

Polyphenols	B-CHEMICAL
are	O
largely	O
studied	O
for	O
their	O
beneficial	O
action	O
in	O
various	O
pathologies	O
,	O
but	O
the	O
correlation	O
with	O
their	O
effects	O
on	O
cell	O
membranes	O
is	O
still	O
elusive	O
.	O

In	O
the	O
present	O
study	O
we	O
assessed	O
the	O
effects	O
exerted	O
in	O
vitro	O
by	O
quercetin	B-CHEMICAL
,	O
epigallocatechin	B-CHEMICAL
gallate	I-CHEMICAL
and	O
curcumin	B-CHEMICAL
on	O
membrane	O
fluidity	O
and	O
transmembrane	O
potential	O
of	O
human	O
umbilical	O
vein	O
endothelial	O
cells	O
and	O
Jurkat	O
T	O
lymphoblasts	O
,	O
in	O
experimental	O
conditions	O
mimicking	O
diabetes	O
mellitus	O
,	O
i	O
.	O
e	O
.	O
high	O
glucose	B-CHEMICAL
conditions	O
or	O
increased	O
concentration	O
of	O
advanced	O
glycation	O
end	O
products	O
.	O

Results	O
showed	O
that	O
the	O
investigated	O
polyphenols	B-CHEMICAL
had	O
beneficial	O
effects	O
on	O
cell	O
membranes	O
altered	O
in	O
diabetic	O
conditions	O
,	O
by	O
restoring	O
transmembrane	O
potential	O
and	O
by	O
membrane	O
"	O
stiffening	O
"	O
.	O

Moreover	O
,	O
they	O
limited	O
the	O
release	O
of	O
pro	O
-	O
inflammatory	O
factors	O
,	O
like	O
monocyte	B-GENE-Y
chemotactic	I-GENE-Y
protein	I-GENE-Y
-	I-GENE-Y
1	I-GENE-Y
.	O

These	O
effects	O
were	O
more	O
obvious	O
for	O
cells	O
exposed	O
to	O
advanced	O
glycation	O
end	O
products	O
specific	O
for	O
the	O
late	O
stages	O
of	O
diabetes	O
.	O

Apparently	O
,	O
the	O
inhibitory	O
action	O
of	O
polyphenols	B-CHEMICAL
on	O
lipid	O
peroxidation	O
was	O
associated	O
with	O
a	O
decrease	O
of	O
membrane	O
fluidity	O
.	O

Concluding	O
,	O
our	O
in	O
vitro	O
study	O
highlighted	O
the	O
potential	O
beneficial	O
action	O
of	O
polyphenols	B-CHEMICAL
mainly	O
in	O
the	O
late	O
stages	O
of	O
diabetes	O
,	O
exerted	O
at	O
the	O
level	O
of	O
membrane	O
fluidity	O
and	O
transmembrane	O
potential	O
,	O
accompanied	O
by	O
an	O
anti	O
-	O
inflammatory	O
effect	O
on	O
endothelial	O
and	O
immune	O
cells	O
.	O

Oral	O
l	B-CHEMICAL
-	I-CHEMICAL
glutamine	I-CHEMICAL
increases	O
active	O
GLP	B-GENE-Y
-	I-GENE-Y
1	I-GENE-Y
(	O
7	O
-	O
36	O
)	O
amide	B-CHEMICAL
secretion	O
and	O
improves	O
glycemic	O
control	O
in	O
stretpozotocin	B-CHEMICAL
-	O
nicotinamide	B-CHEMICAL
induced	O
diabetic	O
rats	O
.	O

l	B-CHEMICAL
-	I-CHEMICAL
glutamine	I-CHEMICAL
is	O
a	O
non	O
-	O
essential	O
amino	B-CHEMICAL
acid	I-CHEMICAL
.	O

It	O
decreased	O
blood	O
sugar	B-CHEMICAL
,	O
stimulated	O
insulin	B-GENE-N
secretion	O
in	O
type	O
2	O
diabetic	O
patients	O
.	O

The	O
objective	O
of	O
the	O
present	O
investigation	O
was	O
to	O
evaluate	O
l	B-CHEMICAL
-	I-CHEMICAL
glutamine	I-CHEMICAL
increases	O
glucagon	B-GENE-Y
like	I-GENE-Y
peptide	I-GENE-Y
-	I-GENE-Y
1	I-GENE-Y
(	O
GLP	B-GENE-Y
-	I-GENE-Y
1	I-GENE-Y
)	O
(	O
7	O
-	O
36	O
)	O
amide	B-CHEMICAL
secretion	O
in	O
streptozotocin	B-CHEMICAL
-	O
nicotinamide	B-CHEMICAL
(	O
STZ	B-CHEMICAL
-	O
NTM	B-CHEMICAL
)	O
induced	O
diabetic	O
Sprague	O
Dawley	O
rats	O
.	O

Molecular	O
docking	O
study	O
was	O
performed	O
to	O
elucidate	O
the	O
molecular	O
basis	O
for	O
GLP	B-GENE-Y
-	I-GENE-Y
1	I-GENE-Y
receptor	I-GENE-Y
agonistic	O
activity	O
.	O

Type	O
2	O
diabetes	O
was	O
induced	O
in	O
overnight	O
fasted	O
Sprague	O
Dawley	O
rats	O
pre	O
-	O
treated	O
with	O
nicotinamide	B-CHEMICAL
(	O
100mg	O
/	O
kg	O
,	O
i	O
.	O
p	O
.	O
)	O
followed	O
by	O
20min	O
after	O
administration	O
of	O
streptozotocin	B-CHEMICAL
(	O
55mg	O
/	O
kg	O
,	O
i	O
.	O
p	O
.	O
)	O
.	O

The	O
rats	O
were	O
divided	O
into	O
;	O
I	O
-	O
nondiabetic	O
,	O
II	O
-	O
diabetic	O
control	O
,	O
III	O
-	O
sitagliptin	B-CHEMICAL
(	O
5mg	O
/	O
kg	O
,	O
p	O
.	O
o	O
.	O
)	O
,	O
IV	O
-	O
l	B-CHEMICAL
-	I-CHEMICAL
glutamine	I-CHEMICAL
(	O
250mg	O
/	O
kg	O
,	O
p	O
.	O
o	O
.	O
)	O
,	O
V	O
-	O
l	B-CHEMICAL
-	I-CHEMICAL
glutamine	I-CHEMICAL
(	O
500mg	O
/	O
kg	O
,	O
p	O
.	O
o	O
.	O
)	O
and	O
VI	O
-	O
l	B-CHEMICAL
-	I-CHEMICAL
glutamine	I-CHEMICAL
(	O
1000mg	O
/	O
kg	O
,	O
p	O
.	O
o	O
.	O
)	O
.	O

The	O
l	B-CHEMICAL
-	I-CHEMICAL
glutamine	I-CHEMICAL
and	O
sitagliptin	B-CHEMICAL
treatment	O
was	O
8week	O
.	O

Plasma	O
glucose	B-CHEMICAL
was	O
estimated	O
every	O
week	O
.	O

Body	O
weight	O
,	O
food	O
and	O
water	O
intake	O
were	O
recorded	O
daily	O
.	O

Glycosylated	O
haemoglobin	B-GENE-N
,	O
lipid	O
profile	O
,	O
plasma	O
and	O
colonic	O
active	O
(	O
GLP	B-GENE-Y
-	I-GENE-Y
1	I-GENE-Y
)	O
(	O
7	O
-	O
36	O
)	O
amide	B-CHEMICAL
,	O
mRNA	O
expression	O
of	O
proglucagon	O
GLP	B-GENE-Y
-	I-GENE-Y
1	I-GENE-Y
,	O
plasma	O
and	O
pancreatic	O
insulin	B-GENE-N
,	O
histology	O
of	O
pancreata	O
and	O
biomarkers	O
of	O
oxidative	O
stress	O
(	O
superoxidase	B-GENE-N
dismutase	I-GENE-N
,	O
reduced	O
glutathione	B-CHEMICAL
,	O
malondialdehyde	B-CHEMICAL
,	O
glutathione	B-GENE-N
peroxidase	I-GENE-N
,	O
glutathione	B-GENE-N
S	I-GENE-N
transferase	I-GENE-N
)	O
were	O
measured	O
after	O
8week	O
.	O

In	O
acute	O
study	O
,	O
the	O
rats	O
were	O
divided	O
into	O
I	O
-	O
glucose	B-CHEMICAL
(	O
2	O
.	O
5g	O
/	O
kg	O
,	O
p	O
.	O
o	O
.	O
)	O
,	O
II	O
-	O
sitagliptin	B-CHEMICAL
(	O
5mg	O
/	O
kg	O
,	O
p	O
.	O
o	O
.	O
)	O
,	O
III	O
-	O
l	B-CHEMICAL
-	I-CHEMICAL
glutamine	I-CHEMICAL
(	O
250mg	O
/	O
kg	O
,	O
p	O
.	O
o	O
.	O
)	O
,	O
IV	O
-	O
l	B-CHEMICAL
-	I-CHEMICAL
glutamine	I-CHEMICAL
(	O
500mg	O
/	O
kg	O
,	O
p	O
.	O
o	O
.	O
)	O
and	O
V	O
-	O
l	B-CHEMICAL
-	I-CHEMICAL
glutamine	I-CHEMICAL
(	O
1000mg	O
/	O
kg	O
,	O
p	O
.	O
o	O
.	O
)	O
.	O

Plasma	O
glucose	B-CHEMICAL
,	O
active	O
GLP	B-GENE-Y
-	I-GENE-Y
1	I-GENE-Y
(	O
7	O
-	O
36	O
)	O
amide	B-CHEMICAL
concentration	O
and	O
insulin	B-GENE-N
levels	O
were	O
measured	O
after	O
glucose	B-CHEMICAL
loading	O
.	O

The	O
docking	O
data	O
indicated	O
that	O
l	B-CHEMICAL
-	I-CHEMICAL
glutamine	I-CHEMICAL
bind	O
to	O
the	O
GLP	B-GENE-Y
-	I-GENE-Y
1	I-GENE-Y
receptor	I-GENE-Y
.	O

l	B-CHEMICAL
-	I-CHEMICAL
glutamine	I-CHEMICAL
decreased	O
plasma	O
glucose	B-CHEMICAL
,	O
increased	O
plasma	O
and	O
pancreatic	O
insulin	B-GENE-N
,	O
increased	O
plasma	O
and	O
colonic	O
active	O
GLP	B-GENE-Y
-	I-GENE-Y
1	I-GENE-Y
(	O
7	O
-	O
36	O
)	O
amide	B-CHEMICAL
secretion	O
as	O
well	O
as	O
decreased	O
oxidative	O
stress	O
in	O
streptozotocin	B-CHEMICAL
-	O
nicotinamide	B-CHEMICAL
induced	O
diabetic	O
rats	O
.	O

ZEB2	B-GENE-Y
zinc	B-GENE-N
-	I-GENE-N
finger	I-GENE-N
missense	O
mutations	O
lead	O
to	O
hypomorphic	O
alleles	O
and	O
a	O
mild	O
Mowat	O
-	O
Wilson	O
syndrome	O
.	O

Mowat	O
-	O
Wilson	O
syndrome	O
(	O
MWS	O
)	O
is	O
a	O
severe	O
intellectual	O
disability	O
(	O
ID	O
)	O
-	O
distinctive	O
facial	O
gestalt	O
-	O
multiple	O
congenital	O
anomaly	O
syndrome	O
,	O
commonly	O
associating	O
microcephaly	O
,	O
epilepsy	O
,	O
corpus	O
callosum	O
agenesis	O
,	O
conotruncal	O
heart	O
defects	O
,	O
urogenital	O
malformations	O
and	O
Hirschsprung	O
disease	O
(	O
HSCR	O
)	O
.	O

MWS	O
is	O
caused	O
by	O
de	O
novo	O
heterozygous	O
mutations	O
in	O
the	O
ZEB2	B-GENE-Y
gene	O
.	O

The	O
majority	O
of	O
mutations	O
lead	O
to	O
haplo	O
-	O
insufficiency	O
through	O
premature	O
stop	O
codons	O
or	O
large	O
gene	O
deletions	O
.	O

Only	O
three	O
missense	O
mutations	O
have	O
been	O
reported	O
so	O
far	O
;	O
none	O
of	O
which	O
resides	O
in	O
a	O
known	O
functional	O
domain	O
of	O
ZEB2	B-GENE-Y
.	O

In	O
this	O
study	O
,	O
we	O
report	O
and	O
analyze	O
the	O
functional	O
consequences	O
of	O
three	O
novel	O
missense	O
mutations	O
,	O
p	B-GENE-N
.	I-GENE-N
Tyr1055Cys	I-GENE-N
,	O
p	B-GENE-N
.	I-GENE-N
Ser1071Pro	I-GENE-N
and	O
p	B-GENE-N
.	I-GENE-N
His1045Arg	I-GENE-N
,	O
identified	O
in	O
the	O
highly	O
conserved	O
C	B-GENE-N
-	I-GENE-N
zinc	I-GENE-N
-	I-GENE-N
finger	I-GENE-N
(	I-GENE-N
C	I-GENE-N
-	I-GENE-N
ZF	I-GENE-N
)	I-GENE-N
domain	I-GENE-N
of	O
ZEB2	B-GENE-Y
.	O

Patients	O
'	O
phenotype	O
included	O
the	O
facial	O
gestalt	O
of	O
MWS	O
and	O
moderate	O
ID	O
,	O
but	O
no	O
microcephaly	O
,	O
heart	O
defects	O
or	O
HSCR	O
.	O

In	O
vitro	O
studies	O
showed	O
that	O
all	O
the	O
three	O
mutations	O
prevented	O
binding	O
and	O
repression	O
of	O
the	O
E	B-GENE-N
-	I-GENE-N
cadherin	I-GENE-N
promoter	I-GENE-N
,	O
a	O
characterized	O
ZEB2	B-GENE-Y
target	O
gene	O
.	O

Taking	O
advantage	O
of	O
the	O
zebrafish	O
morphant	O
technology	O
,	O
we	O
performed	O
rescue	O
experiments	O
using	O
wild	O
-	O
type	O
(	O
WT	O
)	O
and	O
mutant	O
human	B-GENE-Y
ZEB2	I-GENE-Y
mRNAs	O
.	O

Variable	O
,	O
mutation	O
-	O
dependent	O
,	O
embryo	O
rescue	O
,	O
correlating	O
with	O
the	O
severity	O
of	O
patients	O
'	O
phenotype	O
,	O
was	O
observed	O
.	O

Our	O
data	O
provide	O
evidence	O
that	O
these	O
missense	O
mutations	O
cause	O
a	O
partial	O
loss	O
of	O
function	O
of	O
ZEB2	B-GENE-Y
,	O
suggesting	O
that	O
its	O
role	O
is	O
not	O
restricted	O
to	O
repression	O
of	O
E	B-GENE-Y
-	I-GENE-Y
cadherin	I-GENE-Y
.	O

Functional	O
domains	O
other	O
than	O
C	B-GENE-N
-	I-GENE-N
ZF	I-GENE-N
may	O
play	O
a	O
role	O
in	O
early	O
embryonic	O
development	O
.	O

Finally	O
,	O
these	O
findings	O
broaden	O
the	O
clinical	O
spectrum	O
of	O
ZEB2	B-GENE-Y
mutations	O
,	O
indicating	O
that	O
MWS	O
ought	O
to	O
be	O
considered	O
in	O
patients	O
with	O
lesser	O
degrees	O
of	O
ID	O
and	O
a	O
suggestive	O
facial	O
gestalt	O
,	O
even	O
in	O
the	O
absence	O
of	O
congenital	O
malformation	O
.	O

Corticotropin	B-GENE-Y
releasing	I-GENE-Y
factor	I-GENE-Y
and	O
catecholamines	B-CHEMICAL
enhance	O
glutamatergic	O
neurotransmission	O
in	O
the	O
lateral	O
subdivision	O
of	O
the	O
central	O
amygdala	O
.	O

Glutamatergic	O
neurotransmission	O
in	O
the	O
central	O
nucleus	O
of	O
the	O
amygdala	O
(	O
CeA	O
)	O
plays	O
an	O
important	O
role	O
in	O
many	O
behaviors	O
including	O
anxiety	O
,	O
memory	O
consolidation	O
and	O
cardiovascular	O
responses	O
.	O

While	O
these	O
behaviors	O
can	O
be	O
modulated	O
by	O
corticotropin	B-GENE-Y
releasing	I-GENE-Y
factor	I-GENE-Y
(	O
CRF	B-GENE-Y
)	O
and	O
catecholamine	B-CHEMICAL
signaling	O
,	O
the	O
mechanism	O
(	O
s	O
)	O
by	O
which	O
these	O
signals	O
modify	O
CeA	O
glutamatergic	O
neurotransmission	O
remains	O
unclear	O
.	O

Utilizing	O
whole	O
-	O
cell	O
patch	O
-	O
clamp	O
electrophysiology	O
recordings	O
from	O
neurons	O
in	O
the	O
lateral	O
subdivision	O
of	O
the	O
CeA	O
(	O
CeAL	O
)	O
,	O
we	O
show	O
that	O
CRF	B-GENE-Y
,	O
dopamine	B-GENE-N
(	I-GENE-N
DA	I-GENE-N
)	I-GENE-N
and	I-GENE-N
the	I-GENE-N
	I-GENE-N
-	I-GENE-N
adrenergic	I-GENE-N
receptor	I-GENE-N
agonist	O
isoproterenol	B-CHEMICAL
(	O
ISO	B-CHEMICAL
)	O
all	O
enhance	O
the	O
frequency	O
of	O
spontaneous	O
excitatory	O
postsynaptic	O
currents	O
(	O
sEPSC	O
)	O
without	O
altering	O
sEPSC	O
kinetics	O
,	O
suggesting	O
they	O
increase	O
presynaptic	O
glutamate	B-CHEMICAL
release	O
.	O

The	O
effect	O
of	O
CRF	B-GENE-Y
on	O
sEPSCs	O
was	O
mediated	O
by	O
a	O
combination	O
of	O
CRFR1	B-GENE-Y
and	O
CRFR2	B-GENE-Y
receptors	O
.	O

While	O
previous	O
work	O
from	O
our	O
lab	O
suggests	O
that	O
CRFRs	B-GENE-N
mediate	O
the	O
effect	O
of	O
catecholamines	B-CHEMICAL
on	O
excitatory	O
transmission	O
in	O
other	O
subregions	O
of	O
the	O
extended	O
amygdala	O
,	O
blockade	O
of	O
CRFRs	B-GENE-N
in	O
the	O
CeAL	O
failed	O
to	O
significantly	O
alter	O
effects	O
of	O
DA	O
and	O
ISO	B-CHEMICAL
on	O
glutamatergic	O
transmission	O
.	O

These	O
findings	O
suggest	O
that	O
catecholamine	B-CHEMICAL
and	O
CRF	B-GENE-Y
enhancement	O
of	O
glutamatergic	O
transmission	O
onto	O
CeAL	O
neurons	O
occurs	O
via	O
distinct	O
mechanisms	O
.	O

While	O
CRF	B-GENE-Y
increased	O
spontaneous	O
glutamate	B-CHEMICAL
release	O
in	O
the	O
CeAL	O
,	O
CRF	B-GENE-Y
caused	O
no	O
significant	O
changes	O
to	O
optogenetically	O
evoked	O
glutamate	B-CHEMICAL
release	O
in	O
this	O
region	O
.	O

The	O
dissociable	O
effects	O
of	O
CRF	B-GENE-Y
on	O
different	O
types	O
of	O
glutamatergic	O
neurotransmission	O
suggest	O
that	O
CRF	B-GENE-Y
may	O
specifically	O
regulate	O
spontaneous	O
excitatory	O
transmission	O
.	O

Environmental	O
stress	O
,	O
oxytocin	B-GENE-Y
receptor	I-GENE-Y
gene	O
(	O
OXTR	B-GENE-Y
)	O
polymorphism	O
,	O
and	O
mental	O
health	O
following	O
collective	O
stress	O
.	O

We	O
examined	O
whether	O
the	O
oxytocin	B-GENE-Y
receptor	I-GENE-Y
gene	O
(	O
OXTR	B-GENE-Y
)	O
single	O
nucleotide	B-CHEMICAL
polymorphism	O
(	O
SNP	O
)	O
rs53576	O
genotype	O
buffers	O
the	O
combined	O
impact	O
of	O
negative	O
social	O
environments	O
(	O
e	O
.	O
g	O
.	O
,	O
interpersonal	O
conflict	O
/	O
constraint	O
)	O
and	O
economic	O
stress	O
on	O
post	O
-	O
traumatic	O
stress	O
(	O
PTS	O
)	O
symptoms	O
and	O
impaired	O
daily	O
functioning	O
following	O
collective	O
stress	O
(	O
September	O
11th	O
terrorist	O
attacks	O
)	O
.	O

Saliva	O
was	O
collected	O
by	O
mail	O
and	O
used	O
to	O
genotype	O
704	O
respondents	O
.	O

Participants	O
completed	O
Web	O
-	O
based	O
assessments	O
of	O
pre	O
-	O
9	O
/	O
11	O
mental	O
health	O
,	O
acute	O
stress	O
9	O
-	O
23days	O
after	O
9	O
/	O
11	O
,	O
the	O
quality	O
of	O
social	O
environments	O
1year	O
post	O
-	O
9	O
/	O
11	O
,	O
economic	O
stress	O
18months	O
post	O
-	O
9	O
/	O
11	O
,	O
and	O
PTS	O
symptoms	O
and	O
impaired	O
functioning	O
2	O
and	O
3years	O
post	O
-	O
9	O
/	O
11	O
.	O

Interactions	O
between	O
negative	O
social	O
environments	O
and	O
economic	O
stress	O
were	O
examined	O
separately	O
based	O
on	O
OXTR	B-GENE-Y
rs53576	O
genotype	O
(	O
GG	O
vs	O
.	O
any	O
A	O
allele	O
)	O
.	O

For	O
individuals	O
with	O
an	O
A	O
allele	O
,	O
a	O
negative	O
social	O
environment	O
significantly	O
increased	O
PTS	O
symptoms	O
without	O
regard	O
to	O
the	O
level	O
of	O
economic	O
stress	O
experienced	O
.	O

However	O
,	O
for	O
respondents	O
with	O
a	O
GG	O
genotype	O
,	O
negative	O
social	O
environments	O
predicted	O
elevated	O
PTS	O
symptoms	O
only	O
for	O
those	O
also	O
experiencing	O
high	O
economic	O
stress	O
.	O

Gender	O
moderated	O
associations	O
between	O
negative	O
social	O
environments	O
,	O
economic	O
stress	O
,	O
and	O
impaired	O
functioning	O
.	O

The	O
functioning	O
of	O
females	O
was	O
most	O
affected	O
by	O
negative	O
social	O
environments	O
regardless	O
of	O
genotype	O
and	O
economic	O
stress	O
,	O
whereas	O
the	O
functioning	O
of	O
males	O
was	O
differentially	O
susceptible	O
to	O
economic	O
stress	O
depending	O
on	O
OXTR	B-GENE-Y
genotype	O
and	O
negative	O
social	O
environments	O
.	O

These	O
findings	O
suggest	O
that	O
it	O
is	O
important	O
to	O
consider	O
the	O
combined	O
impact	O
of	O
gender	O
and	O
ongoing	O
stress	O
in	O
different	O
domains	O
as	O
moderators	O
of	O
genetic	O
vulnerability	O
following	O
collective	O
stress	O
.	O

Identification	O
of	O
a	O
SIRT1	B-GENE-Y
mutation	O
in	O
a	O
family	O
with	O
type	O
1	O
diabetes	O
.	O

Type	O
1	O
diabetes	O
is	O
caused	O
by	O
autoimmune	O
-	O
mediated	O
	O
cell	O
destruction	O
leading	O
to	O
insulin	B-GENE-Y
deficiency	O
.	O

The	O
histone	B-GENE-N
deacetylase	I-GENE-N
SIRT1	B-GENE-Y
plays	O
an	O
essential	O
role	O
in	O
modulating	O
several	O
age	O
-	O
related	O
diseases	O
.	O

Here	O
we	O
describe	O
a	O
family	O
carrying	O
a	O
mutation	O
in	O
the	O
SIRT1	B-GENE-Y
gene	O
,	O
in	O
which	O
all	O
five	O
affected	O
members	O
developed	O
an	O
autoimmune	O
disorder	O
:	O
four	O
developed	O
type	O
1	O
diabetes	O
,	O
and	O
one	O
developed	O
ulcerative	O
colitis	O
.	O

Initially	O
,	O
a	O
26	O
-	O
year	O
-	O
old	O
man	O
was	O
diagnosed	O
with	O
the	O
typical	O
features	O
of	O
type	O
1	O
diabetes	O
,	O
including	O
lean	O
body	O
mass	O
,	O
autoantibodies	O
,	O
T	O
cell	O
reactivity	O
to	O
	O
cell	O
antigens	O
,	O
and	O
a	O
rapid	O
dependence	O
on	O
insulin	B-GENE-Y
.	O

Direct	O
and	O
exome	O
sequencing	O
identified	O
the	O
presence	O
of	O
a	O
T	O
-	O
to	O
-	O
C	O
exchange	O
in	O
exon	O
1	O
of	O
SIRT1	B-GENE-Y
,	O
corresponding	O
to	O
a	O
leucine	B-GENE-N
-	I-GENE-N
to	I-GENE-N
-	I-GENE-N
proline	I-GENE-N
mutation	I-GENE-N
at	I-GENE-N
residue	I-GENE-N
107	I-GENE-N
.	O

Expression	O
of	O
SIRT1	B-GENE-Y
-	O
L107P	B-GENE-N
in	O
insulin	B-GENE-Y
-	O
producing	O
cells	O
resulted	O
in	O
overproduction	O
of	O
nitric	B-CHEMICAL
oxide	I-CHEMICAL
,	O
cytokines	B-GENE-N
,	O
and	O
chemokines	B-GENE-N
.	O

These	O
observations	O
identify	O
a	O
role	O
for	O
SIRT1	B-GENE-Y
in	O
human	O
autoimmunity	O
and	O
unveil	O
a	O
monogenic	O
form	O
of	O
type	O
1	O
diabetes	O
.	O

Melanoma	O
targeting	O
property	O
of	O
a	O
Lu	B-CHEMICAL
-	I-CHEMICAL
177	I-CHEMICAL
-	O
labeled	O
lactam	B-CHEMICAL
bridge	O
-	O
cyclized	O
alpha	B-GENE-Y
-	I-GENE-Y
MSH	I-GENE-Y
peptide	O
.	O

The	O
purpose	O
of	O
this	O
study	O
was	O
to	O
determine	O
the	O
melanoma	O
targeting	O
property	O
of	O
(	B-CHEMICAL
177	I-CHEMICAL
)	I-CHEMICAL
Lu	I-CHEMICAL
-	I-CHEMICAL
DOTA	I-CHEMICAL
-	I-CHEMICAL
GGNle	I-CHEMICAL
-	I-CHEMICAL
CycMSHhex	I-CHEMICAL
in	O
B16	O
/	O
F1	O
melanoma	O
-	O
bearing	O
C57	O
mice	O
.	O

(	B-CHEMICAL
177	I-CHEMICAL
)	I-CHEMICAL
Lu	I-CHEMICAL
-	I-CHEMICAL
DOTA	I-CHEMICAL
-	I-CHEMICAL
GGNle	I-CHEMICAL
-	I-CHEMICAL
CycMSHhex	I-CHEMICAL
exhibited	O
high	O
receptor	O
-	O
mediated	O
melanoma	O
uptake	O
and	O
fast	O
urinary	O
clearance	O
.	O

The	O
tumor	O
uptake	O
of	O
(	B-CHEMICAL
177	I-CHEMICAL
)	I-CHEMICAL
Lu	I-CHEMICAL
-	I-CHEMICAL
DOTA	I-CHEMICAL
-	I-CHEMICAL
GGNle	I-CHEMICAL
-	I-CHEMICAL
CycMSHhex	I-CHEMICAL
was	O
20	O
.	O
25	O
	O
4	O
.	O
59	O
and	O
21	O
.	O
63	O
	O
6	O
.	O
27	O
%	O
ID	O
/	O
g	O
at	O
0	O
.	O
5	O
and	O
2h	O
post	O
-	O
injection	O
,	O
respectively	O
.	O

Approximately	O
83	O
%	O
of	O
injected	O
dose	O
cleared	O
out	O
the	O
body	O
via	O
urinary	O
system	O
at	O
2h	O
post	O
-	O
injection	O
.	O

(	B-CHEMICAL
177	I-CHEMICAL
)	I-CHEMICAL
Lu	I-CHEMICAL
-	I-CHEMICAL
DOTA	I-CHEMICAL
-	I-CHEMICAL
GGNle	I-CHEMICAL
-	I-CHEMICAL
CycMSHhex	I-CHEMICAL
showed	O
high	O
tumor	O
to	O
normal	O
organ	O
uptake	O
ratios	O
except	O
for	O
the	O
kidneys	O
.	O

The	O
tumor	O
/	O
kidney	O
uptake	O
ratios	O
of	O
(	B-CHEMICAL
177	I-CHEMICAL
)	I-CHEMICAL
Lu	I-CHEMICAL
-	I-CHEMICAL
DOTA	I-CHEMICAL
-	I-CHEMICAL
GGNle	I-CHEMICAL
-	I-CHEMICAL
CycMSHhex	I-CHEMICAL
were	O
2	O
.	O
76	O
and	O
1	O
.	O
74	O
at	O
2	O
and	O
24h	O
post	O
-	O
injection	O
.	O

The	O
melanoma	O
lesions	O
were	O
clearly	O
visualized	O
by	O
SPECT	O
/	O
CT	O
using	O
(	B-CHEMICAL
177	I-CHEMICAL
)	I-CHEMICAL
Lu	I-CHEMICAL
-	I-CHEMICAL
DOTA	I-CHEMICAL
-	I-CHEMICAL
GGNle	I-CHEMICAL
-	I-CHEMICAL
CycMSHhex	I-CHEMICAL
as	O
an	O
imaging	O
probe	O
at	O
2h	O
post	O
-	O
injection	O
.	O

Overall	O
,	O
high	O
melanoma	O
uptake	O
coupled	O
with	O
fast	O
urinary	O
clearance	O
of	O
(	B-CHEMICAL
177	I-CHEMICAL
)	I-CHEMICAL
Lu	I-CHEMICAL
-	I-CHEMICAL
DOTA	I-CHEMICAL
-	I-CHEMICAL
GGNle	I-CHEMICAL
-	I-CHEMICAL
CycMSHhex	I-CHEMICAL
underscored	O
its	O
potential	O
for	O
melanoma	O
treatment	O
in	O
the	O
future	O
.	O

Hinokitiol	B-CHEMICAL
inhibits	O
platelet	O
activation	O
ex	O
vivo	O
and	O
thrombus	O
formation	O
in	O
vivo	O
.	O

Hinokitiol	B-CHEMICAL
is	O
a	O
tropolone	O
-	O
related	O
bioactive	O
compound	O
that	O
has	O
been	O
used	O
in	O
hair	O
tonics	O
,	O
cosmetics	O
,	O
and	O
food	O
as	O
an	O
antimicrobial	O
agent	O
.	O

Recently	O
,	O
hinokitiol	B-CHEMICAL
has	O
attracted	O
considerable	O
interest	O
because	O
of	O
its	O
anticancer	O
activities	O
.	O

Platelet	O
activation	O
plays	O
a	O
crucial	O
role	O
in	O
atherothrombotic	O
processes	O
.	O

We	O
examined	O
the	O
effects	O
of	O
hinokitiol	B-CHEMICAL
treatment	O
on	O
platelet	O
activation	O
using	O
human	O
platelets	O
.	O

In	O
the	O
present	O
study	O
,	O
hinokitiol	B-CHEMICAL
(	O
1	O
and	O
2M	O
)	O
inhibited	O
the	O
collagen	B-GENE-N
-	O
induced	O
aggregation	O
of	O
human	O
platelets	O
,	O
but	O
did	O
not	O
inhibit	O
the	O
activation	O
of	O
platelets	O
by	O
other	O
agonists	O
,	O
including	O
thrombin	B-GENE-Y
,	O
arachidonic	B-CHEMICAL
acid	I-CHEMICAL
,	O
and	O
ADP	B-CHEMICAL
.	O

Hinokitiol	B-CHEMICAL
inhibited	O
the	O
phosphorylation	O
of	O
phospholipase	B-GENE-Y
C	I-GENE-Y
(	I-GENE-Y
PLC	I-GENE-Y
)	I-GENE-Y
2	I-GENE-Y
,	O
protein	B-GENE-N
kinase	I-GENE-N
C	I-GENE-N
(	O
PKC	B-GENE-N
)	O
,	O
mitogen	B-GENE-N
-	I-GENE-N
activated	I-GENE-N
protein	I-GENE-N
kinases	I-GENE-N
(	O
MAPKs	B-GENE-N
)	O
,	O
and	O
Akt	B-GENE-N
in	O
collagen	B-GENE-N
-	O
activated	O
human	O
platelets	O
,	O
and	O
significantly	O
reduced	O
intracellular	O
calcium	B-CHEMICAL
mobilization	O
and	O
hydroxyl	B-CHEMICAL
radical	O
(	O
OH	B-CHEMICAL
)	O
formation	O
.	O

Hinokitiol	B-CHEMICAL
also	O
reduced	O
the	O
PKC	B-GENE-N
activation	O
and	O
platelet	O
aggregation	O
stimulated	O
by	O
PDBu	O
.	O

In	O
addition	O
,	O
hinokitiol	B-CHEMICAL
significantly	O
prolonged	O
thrombogenesis	O
in	O
mice	O
.	O

Hinokitiol	B-CHEMICAL
did	O
not	O
influence	O
the	O
binding	O
of	O
a	O
fluorescent	O
triflavin	O
probe	O
to	O
the	O
IIb3	B-GENE-Y
integrin	I-GENE-Y
on	O
platelet	O
membrane	O
,	O
and	O
neither	O
ODQ	B-CHEMICAL
nor	O
SQ22536	B-CHEMICAL
significantly	O
reversed	O
the	O
hinokitiol	B-CHEMICAL
-	O
mediated	O
inhibition	O
of	O
platelet	O
aggregation	O
.	O

In	O
conclusion	O
,	O
hinokitiol	B-CHEMICAL
may	O
inhibit	O
platelet	O
activation	O
by	O
inhibiting	O
the	O
PLC2	B-GENE-Y
-	O
PKC	B-GENE-N
cascade	O
and	O
hydroxyl	B-CHEMICAL
radical	O
formation	O
,	O
followed	O
by	O
suppressing	O
the	O
activation	O
of	O
MAPKs	B-GENE-N
and	O
Akt	B-GENE-N
.	O

Our	O
study	O
suggests	O
that	O
hinokitiol	B-CHEMICAL
may	O
represent	O
a	O
potential	O
therapeutic	O
agent	O
for	O
the	O
prevention	O
or	O
treatment	O
of	O
thromboembolic	O
disorders	O
.	O

Time	O
-	O
dependent	O
effects	O
of	O
corticosterone	B-CHEMICAL
on	O
reward	O
-	O
based	O
decision	O
-	O
making	O
in	O
a	O
rodent	O
model	O
of	O
the	O
Iowa	O
Gambling	O
Task	O
.	O

Corticosteroid	O
hormones	O
,	O
released	O
after	O
stress	O
,	O
are	O
known	O
to	O
change	O
neuronal	O
activity	O
in	O
two	O
time	O
-	O
domains	O
:	O
within	O
minutes	O
via	O
non	O
-	O
genomic	O
pathways	O
and	O
with	O
a	O
delay	O
of	O
>	O
1	O
h	O
through	O
pathways	O
involving	O
transcriptional	O
regulation	O
.	O

Recent	O
evidence	O
in	O
rodents	O
and	O
humans	O
indicates	O
that	O
these	O
two	O
modes	O
of	O
corticosteroid	O
action	O
differently	O
affect	O
cognitive	O
tasks	O
.	O

Here	O
,	O
we	O
investigated	O
whether	O
reward	O
-	O
based	O
decision	O
-	O
making	O
,	O
in	O
a	O
rat	O
model	O
of	O
the	O
Iowa	O
Gambling	O
Task	O
(	O
rIGT	O
)	O
,	O
is	O
also	O
differently	O
altered	O
by	O
rapid	O
versus	O
delayed	O
actions	O
of	O
corticosterone	B-CHEMICAL
.	O

We	O
targeted	O
the	O
rapid	O
and	O
delayed	O
time	O
domain	O
by	O
injecting	O
corticosterone	B-CHEMICAL
(	O
CORT	B-CHEMICAL
,	O
1	O
mg	O
/	O
kg	O
,	O
s	O
.	O
c	O
.	O
)	O
at	O
30	O
min	O
(	O
rapid	O
)	O
or	O
180	O
min	O
(	O
delayed	O
)	O
respectively	O
prior	O
to	O
behavioural	O
testing	O
,	O
during	O
the	O
final	O
3	O
days	O
of	O
the	O
behavioural	O
paradigm	O
.	O

In	O
saline	O
treated	O
rats	O
,	O
the	O
number	O
of	O
visits	O
to	O
the	O
disadvantageous	O
arm	O
decreased	O
over	O
trial	O
blocks	O
,	O
whilst	O
this	O
was	O
attenuated	O
when	O
CORT	B-CHEMICAL
was	O
administered	O
30	O
min	O
before	O
testing	O
.	O

This	O
attenuation	O
was	O
associated	O
with	O
a	O
significantly	O
increased	O
c	B-GENE-Y
-	I-GENE-Y
Fos	I-GENE-Y
expression	O
in	O
the	O
lateral	O
orbitofrontal	O
cortex	O
and	O
insular	O
cortex	O
,	O
and	O
a	O
trend	O
for	O
an	O
increase	O
in	O
the	O
infralimbic	O
cortex	O
.	O

The	O
rapid	O
corticosteroid	O
effect	O
contrasted	O
with	O
treatment	O
180	O
min	O
before	O
testing	O
,	O
where	O
the	O
number	O
of	O
visits	O
to	O
the	O
disadvantageous	O
arm	O
as	O
well	O
as	O
c	B-GENE-Y
-	I-GENE-Y
Fos	I-GENE-Y
labelling	O
was	O
not	O
affected	O
.	O

These	O
findings	O
indicate	O
that	O
rapid	O
corticosteroid	O
actions	O
impair	O
reward	O
-	O
based	O
decision	O
-	O
making	O
.	O

Novel	O
5	B-CHEMICAL
-	I-CHEMICAL
(	I-CHEMICAL
benzyloxy	I-CHEMICAL
)	I-CHEMICAL
pyridin	I-CHEMICAL
-	I-CHEMICAL
2	I-CHEMICAL
(	I-CHEMICAL
1H	I-CHEMICAL
)	I-CHEMICAL
-	I-CHEMICAL
one	I-CHEMICAL
derivatives	O
as	O
potent	O
c	B-GENE-Y
-	I-GENE-Y
Met	I-GENE-Y
inhibitors	O
.	O

A	O
series	O
of	O
novel	O
5	B-CHEMICAL
-	I-CHEMICAL
(	I-CHEMICAL
benzyloxy	I-CHEMICAL
)	I-CHEMICAL
pyridin	I-CHEMICAL
-	I-CHEMICAL
2	I-CHEMICAL
(	I-CHEMICAL
1H	I-CHEMICAL
)	I-CHEMICAL
-	I-CHEMICAL
ones	I-CHEMICAL
were	O
designed	O
,	O
synthesized	O
and	O
biologically	O
evaluated	O
for	O
c	B-GENE-Y
-	I-GENE-Y
Met	I-GENE-Y
inhibition	O
.	O

Various	O
amides	B-CHEMICAL
and	O
benzoimidazoles	B-CHEMICAL
at	O
C	O
-	O
3	O
position	O
were	O
investigated	O
.	O

A	O
potent	O
compound	O
12b	O
with	O
a	O
c	B-GENE-Y
-	I-GENE-Y
Met	I-GENE-Y
IC50	O
of	O
12nM	O
was	O
identified	O
.	O

This	O
compound	O
exhibited	O
potent	O
inhibition	O
of	O
EBC	O
-	O
1	O
cell	O
associated	O
with	O
c	B-GENE-Y
-	I-GENE-Y
Met	I-GENE-Y
constitutive	O
activation	O
and	O
showed	O
high	O
selectivity	O
for	O
c	B-GENE-Y
-	I-GENE-Y
Met	I-GENE-Y
than	O
other	O
tested	O
11	O
kinases	B-GENE-N
.	O

The	O
binding	O
model	O
12b	O
with	O
c	B-GENE-Y
-	I-GENE-Y
Met	I-GENE-Y
was	O
disclosed	O
by	O
docking	O
analysis	O
.	O

Design	O
,	O
Synthesis	O
,	O
and	O
Pharmacological	O
Characterization	O
of	O
Novel	O
Endomorphin	B-CHEMICAL
-	I-CHEMICAL
1	I-CHEMICAL
Analogues	O
as	O
Extremely	O
Potent	O
	B-GENE-Y
-	I-GENE-Y
Opioid	I-GENE-Y
Agonists	O
.	O

Recently	O
we	O
reported	O
the	O
synthesis	O
and	O
structure	O
-	O
activity	O
study	O
of	O
endomorphin	B-CHEMICAL
-	I-CHEMICAL
1	I-CHEMICAL
(	O
EM	B-CHEMICAL
-	I-CHEMICAL
1	I-CHEMICAL
)	O
analogues	O
containing	O
novel	O
,	O
unnatural	O
	B-CHEMICAL
-	I-CHEMICAL
methylene	I-CHEMICAL
-	I-CHEMICAL
	I-CHEMICAL
-	I-CHEMICAL
aminopropanoic	I-CHEMICAL
acids	I-CHEMICAL
(	O
Map	B-CHEMICAL
)	O
.	O

In	O
the	O
present	O
study	O
,	O
we	O
describe	O
new	O
EM	B-CHEMICAL
-	I-CHEMICAL
1	I-CHEMICAL
analogues	O
containing	O
Dmt	B-CHEMICAL
(	O
1	O
)	O
,	O
(	B-CHEMICAL
R	I-CHEMICAL
/	I-CHEMICAL
S	I-CHEMICAL
)	I-CHEMICAL
-	I-CHEMICAL
Pro	I-CHEMICAL
(	O
2	O
)	O
,	O
and	O
(	B-CHEMICAL
ph	I-CHEMICAL
)	I-CHEMICAL
Map	I-CHEMICAL
(	O
4	O
)	O
/	O
(	B-CHEMICAL
2	I-CHEMICAL
-	I-CHEMICAL
furyl	I-CHEMICAL
)	I-CHEMICAL
Map	I-CHEMICAL
(	O
4	O
)	O
.	O

All	O
of	O
the	O
analogues	O
showed	O
a	O
high	O
affinity	O
for	O
the	O
	B-GENE-Y
-	I-GENE-Y
opioid	I-GENE-Y
receptor	I-GENE-Y
(	O
MOR	B-GENE-Y
)	O
and	O
increased	O
stability	O
in	O
mouse	O
brain	O
homogenates	O
.	O

Of	O
the	O
new	O
compounds	O
,	O
Dmt	B-CHEMICAL
(	O
1	O
)	O
-	O
(	B-CHEMICAL
R	I-CHEMICAL
)	I-CHEMICAL
-	I-CHEMICAL
Pro	I-CHEMICAL
(	O
2	O
)	O
-	O
Trp	B-CHEMICAL
(	O
3	O
)	O
-	O
(	B-CHEMICAL
2	I-CHEMICAL
-	I-CHEMICAL
furyl	I-CHEMICAL
)	I-CHEMICAL
Map	I-CHEMICAL
(	O
4	O
)	O
(	O
analogue	O
12	O
)	O
displayed	O
the	O
highest	O
affinity	O
toward	O
MOR	B-GENE-Y
,	O
in	O
the	O
picomolar	O
range	O
(	O
Ki	O
(	O
	O
)	O
=	O
3	O
.	O
72	O
pM	O
)	O
.	O

Forskolin	B-CHEMICAL
-	O
induced	O
cAMP	B-CHEMICAL
accumulation	O
assays	O
indicated	O
that	O
this	O
analogue	O
displayed	O
an	O
extremely	O
high	O
agonistic	O
potency	O
,	O
in	O
the	O
subpicomolar	O
range	O
(	O
EC50	O
=	O
0	O
.	O
0421	O
pM	O
,	O
Emax	O
=	O
99	O
.	O
5	O
%	O
)	O
.	O

This	O
compound	O
also	O
displayed	O
stronger	O
in	O
vivo	O
antinociceptive	O
activity	O
after	O
iv	O
administration	O
when	O
compared	O
to	O
morphine	B-CHEMICAL
in	O
the	O
tail	O
-	O
flick	O
test	O
,	O
which	O
indicates	O
that	O
this	O
analogue	O
was	O
able	O
to	O
cross	O
the	O
blood	O
-	O
brain	O
barrier	O
.	O

Age	O
-	O
Related	O
Macular	O
Degeneration	O
-	O
Associated	O
Silent	O
Polymorphisms	O
in	O
HtrA1	B-GENE-Y
Impair	O
Its	O
Ability	O
To	O
Antagonize	O
Insulin	B-GENE-Y
-	I-GENE-Y
Like	I-GENE-Y
Growth	I-GENE-Y
Factor	I-GENE-Y
1	I-GENE-Y
.	O

Synonymous	O
single	O
nucleotide	O
polymorphisms	O
(	O
SNPs	O
)	O
within	O
a	O
transcript	O
'	O
s	O
coding	O
region	O
produce	O
no	O
change	O
in	O
the	O
amino	B-CHEMICAL
acid	I-CHEMICAL
sequence	O
of	O
the	O
protein	O
product	O
and	O
are	O
therefore	O
intuitively	O
assumed	O
to	O
have	O
a	O
neutral	O
effect	O
on	O
protein	O
function	O
.	O

We	O
report	O
that	O
two	O
common	O
variants	O
of	O
high	B-GENE-Y
-	I-GENE-Y
temperature	I-GENE-Y
requirement	I-GENE-Y
A1	I-GENE-Y
(	O
HTRA1	B-GENE-Y
)	O
that	O
increase	O
the	O
inherited	O
risk	O
of	O
neovascular	O
age	O
-	O
related	O
macular	O
degeneration	O
(	O
NvAMD	O
)	O
harbor	O
synonymous	O
SNPs	O
within	O
exon	O
1	O
of	O
HTRA1	B-GENE-Y
that	O
convert	O
common	O
codons	O
for	O
Ala34	B-CHEMICAL
and	O
Gly36	B-CHEMICAL
to	O
less	O
frequently	O
used	O
codons	O
.	O

The	O
frequent	O
-	O
to	O
-	O
rare	O
codon	O
conversion	O
reduced	O
the	O
mRNA	O
translation	O
rate	O
and	O
appeared	O
to	O
compromise	O
HtrA1	B-GENE-Y
'	I-GENE-Y
s	I-GENE-Y
conformation	O
and	O
function	O
.	O

The	O
protein	O
product	O
generated	O
from	O
the	O
SNP	O
-	O
containing	O
cDNA	O
displayed	O
enhanced	O
susceptibility	O
to	O
proteolysis	O
and	O
a	O
reduced	O
affinity	O
for	O
an	O
anti	O
-	O
HtrA1	B-GENE-Y
antibody	O
.	O

The	O
NvAMD	O
-	O
associated	O
synonymous	O
polymorphisms	O
lie	O
within	O
HtrA1	B-GENE-N
'	I-GENE-N
s	I-GENE-N
putative	I-GENE-N
insulin	I-GENE-N
-	I-GENE-N
like	I-GENE-N
growth	I-GENE-N
factor	I-GENE-N
1	I-GENE-N
(	I-GENE-N
IGF	I-GENE-N
-	I-GENE-N
1	I-GENE-N
)	I-GENE-N
binding	I-GENE-N
domain	I-GENE-N
.	O

They	O
reduced	O
HtrA1	B-GENE-Y
'	I-GENE-Y
s	I-GENE-Y
abilities	O
to	O
associate	O
with	O
IGF	B-GENE-Y
-	I-GENE-Y
1	I-GENE-Y
and	O
to	O
ameliorate	O
IGF	B-GENE-Y
-	I-GENE-Y
1	I-GENE-Y
-	O
stimulated	O
signaling	O
events	O
and	O
cellular	O
responses	O
.	O

These	O
observations	O
highlight	O
the	O
relevance	O
of	O
synonymous	O
codon	O
usage	O
to	O
protein	O
function	O
and	O
implicate	O
homeostatic	O
protein	O
quality	O
control	O
mechanisms	O
that	O
may	O
go	O
awry	O
in	O
NvAMD	O
.	O

Therapeutic	O
effectiveness	O
of	O
botulinum	B-GENE-Y
neurotoxin	I-GENE-Y
A	I-GENE-Y
:	O
Potent	O
blockade	O
of	O
autonomic	O
transmission	O
by	O
targeted	O
cleavage	O
of	O
only	O
the	O
pertinent	O
SNAP	B-GENE-Y
-	I-GENE-Y
25	I-GENE-Y
.	O

In	O
search	O
of	O
a	O
basis	O
for	O
the	O
impressive	O
potency	O
of	O
an	O
endoprotease	B-GENE-N
that	O
cleaves	O
SNAP	B-GENE-Y
-	I-GENE-Y
25	I-GENE-Y
,	O
botulinum	B-GENE-Y
neurotoxin	I-GENE-Y
type	I-GENE-Y
A	I-GENE-Y
(	O
BoNT	B-GENE-Y
/	I-GENE-Y
A	I-GENE-Y
)	O
,	O
in	O
treating	O
numerous	O
diseases	O
due	O
to	O
hyper	O
-	O
active	O
autonomic	O
nerves	O
,	O
truncation	O
of	O
its	O
target	O
and	O
inhibition	O
of	O
neurotransmission	O
were	O
studied	O
in	O
rat	O
sympathetic	O
neurons	O
.	O

Tetrodotoxin	B-CHEMICAL
-	O
sensitive	O
spontaneous	O
cholinergic	O
neurotransmission	O
was	O
blocked	O
>	O
80	O
%	O
by	O
1	O
pM	O
BoNT	B-GENE-Y
/	I-GENE-Y
A	I-GENE-Y
despite	O
cleaving	O
<	O
20	O
%	O
of	O
the	O
SNAP	B-GENE-Y
-	I-GENE-Y
25	I-GENE-Y
.	O

A	O
maximum	O
cleavage	O
of	O
	O
60	O
%	O
SNAP	B-GENE-Y
-	I-GENE-Y
25	I-GENE-Y
could	O
be	O
achieved	O
with	O
>	O
1	O
nM	O
BoNT	B-GENE-Y
/	I-GENE-Y
A	I-GENE-Y
,	O
despite	O
an	O
absence	O
of	O
non	O
-	O
cleavable	O
SNAP	B-GENE-Y
-	I-GENE-Y
25	I-GENE-Y
in	O
the	O
detergent	O
-	O
solubilised	O
neurons	O
.	O

In	O
contrast	O
,	O
BoNT	B-GENE-Y
/	I-GENE-Y
E	I-GENE-Y
(	O
100	O
nM	O
)	O
truncated	O
nearly	O
all	O
the	O
SNAP	B-GENE-Y
-	I-GENE-Y
25	I-GENE-Y
in	O
the	O
intact	O
cells	O
,	O
but	O
was	O
unable	O
to	O
block	O
neurotransmission	O
at	O
low	O
concentrations	O
like	O
BoNT	B-GENE-Y
/	I-GENE-Y
A	I-GENE-Y
.	O

Chimeras	O
created	O
by	O
inserting	O
the	O
acceptor	O
-	O
binding	O
HC	B-GENE-N
domain	I-GENE-N
of	O
BoNT	B-GENE-Y
/	I-GENE-Y
A	I-GENE-Y
into	O
BoNT	B-GENE-Y
/	I-GENE-Y
E	I-GENE-Y
still	O
cleaved	O
all	O
the	O
SNAP	B-GENE-Y
-	I-GENE-Y
25	I-GENE-Y
,	O
indicating	O
ubiquitous	O
expression	O
of	O
BoNT	B-GENE-Y
/	I-GENE-Y
A	I-GENE-Y
acceptors	O
.	O

Accordingly	O
,	O
SV2	B-GENE-N
and	O
SNAP	B-GENE-Y
-	I-GENE-Y
25	I-GENE-Y
were	O
found	O
to	O
be	O
co	O
-	O
expressed	O
and	O
broadly	O
co	O
-	O
localised	O
in	O
neurons	O
,	O
but	O
absent	O
from	O
non	O
-	O
neuronal	O
cells	O
.	O

On	O
the	O
other	O
hand	O
,	O
partial	O
cleavage	O
by	O
the	O
BoNT	B-GENE-Y
/	I-GENE-Y
A	I-GENE-Y
protease	O
persisted	O
upon	O
replacing	O
its	O
HC	O
with	O
counterparts	O
from	O
BoNT	B-GENE-Y
/	I-GENE-Y
E	I-GENE-Y
or	O
BoNT	B-GENE-Y
/	I-GENE-Y
B	I-GENE-Y
.	O

Moreover	O
,	O
limited	O
cleavage	O
of	O
SNAP	B-GENE-Y
-	I-GENE-Y
25	I-GENE-Y
was	O
conferred	O
onto	O
the	O
protease	B-GENE-N
from	O
BoNT	B-GENE-Y
/	I-GENE-Y
E	I-GENE-Y
when	O
fused	O
to	O
the	O
N	B-CHEMICAL
-	O
terminus	O
of	O
BoNT	B-GENE-Y
/	I-GENE-Y
A	I-GENE-Y
.	O

Thus	O
,	O
the	O
BoNT	B-GENE-Y
/	I-GENE-Y
A	I-GENE-Y
protease	B-GENE-N
is	O
uniquely	O
well	O
-	O
adapted	O
for	O
selectively	O
inactivating	O
the	O
SNAP	B-GENE-Y
-	I-GENE-Y
25	I-GENE-Y
directly	O
involved	O
in	O
neurotransmission	O
;	O
this	O
together	O
with	O
the	O
toxin	O
'	O
s	O
acceptor	O
and	O
its	O
target	O
being	O
localised	O
on	O
the	O
peri	O
-	O
somatic	O
boutons	O
likely	O
contribute	O
to	O
its	O
exceptional	O
therapeutic	O
utility	O
in	O
the	O
clinic	O
.	O

Dexamethasone	B-CHEMICAL
-	O
mediated	O
changes	O
in	O
adipose	O
triacylglycerol	B-CHEMICAL
metabolism	O
are	O
exaggerated	O
,	O
not	O
diminished	O
,	O
in	O
the	O
absence	O
of	O
a	O
functional	O
GR	B-GENE-N
dimerization	I-GENE-N
domain	I-GENE-N
.	O

The	O
glucocorticoid	B-GENE-Y
(	I-GENE-Y
GC	I-GENE-Y
)	I-GENE-Y
receptor	I-GENE-Y
(	O
GR	B-GENE-Y
)	O
has	O
multiple	O
effector	O
mechanisms	O
,	O
including	O
dimerization	O
-	O
mediated	O
transactivation	O
of	O
target	O
genes	O
via	O
DNA	O
binding	O
and	O
transcriptional	O
repression	O
mediated	O
by	O
protein	O
-	O
protein	O
interactions	O
.	O

Much	O
attention	O
has	O
been	O
focused	O
on	O
developing	O
selective	O
GR	B-GENE-Y
modulators	O
that	O
would	O
dissociate	O
adverse	O
effects	O
from	O
therapeutic	O
anti	O
-	O
inflammatory	O
effects	O
.	O

The	O
GR	B-GENE-Y
(	O
dim	O
/	O
dim	O
)	O
mouse	O
has	O
a	O
mutation	O
in	O
the	O
dimerization	O
domain	O
of	O
GR	B-GENE-Y
and	O
has	O
been	O
shown	O
to	O
have	O
attenuated	O
transactivation	O
with	O
intact	O
repression	O
.	O

To	O
understand	O
the	O
role	O
of	O
GR	B-GENE-Y
dimerization	O
-	O
dependent	O
targets	O
in	O
multiple	O
tissues	O
,	O
we	O
measured	O
metabolic	O
fluxes	O
through	O
several	O
disease	O
-	O
relevant	O
GC	O
target	O
pathways	O
using	O
heavy	O
water	O
labeling	O
and	O
mass	O
spectrometry	O
in	O
wild	O
-	O
type	O
and	O
GR	B-GENE-Y
(	O
dim	O
/	O
dim	O
)	O
mice	O
administered	O
the	O
potent	O
GC	O
dexamethasone	B-CHEMICAL
(	O
DEX	B-CHEMICAL
)	O
.	O

Absolute	O
triglyceride	B-CHEMICAL
synthesis	O
was	O
increased	O
in	O
both	O
wild	O
-	O
type	O
and	O
GR	B-GENE-Y
(	O
dim	O
/	O
dim	O
)	O
mice	O
by	O
DEX	B-CHEMICAL
in	O
the	O
inguinal	O
and	O
epididymal	O
fat	O
depots	O
.	O

GR	B-GENE-Y
(	O
dim	O
/	O
dim	O
)	O
mice	O
showed	O
an	O
exaggerated	O
response	O
to	O
DEX	B-CHEMICAL
in	O
both	O
depots	O
.	O

De	O
novo	O
lipogenesis	O
was	O
also	O
greatly	O
increased	O
in	O
both	O
depots	O
in	O
response	O
to	O
DEX	B-CHEMICAL
in	O
GR	B-GENE-Y
(	O
dim	O
/	O
dim	O
)	O
,	O
but	O
not	O
wild	O
-	O
type	O
mice	O
.	O

In	O
contrast	O
,	O
the	O
inhibitory	O
effect	O
of	O
DEX	B-CHEMICAL
on	O
bone	O
and	O
skin	O
collagen	O
synthesis	O
rates	O
was	O
greater	O
in	O
wild	O
-	O
type	O
compared	O
with	O
GR	B-GENE-Y
(	O
dim	O
/	O
dim	O
)	O
mice	O
.	O

Wild	O
-	O
type	O
mice	O
were	O
more	O
sensitive	O
to	O
DEX	B-CHEMICAL
-	O
dependent	O
decreases	O
in	O
insulin	B-GENE-N
sensitivity	O
than	O
GR	B-GENE-Y
(	O
dim	O
/	O
dim	O
)	O
mice	O
.	O

Wild	O
-	O
type	O
and	O
GR	B-GENE-Y
(	O
dim	O
/	O
dim	O
)	O
mice	O
were	O
equally	O
sensitive	O
to	O
DEX	B-CHEMICAL
-	O
dependent	O
decreases	O
in	O
muscle	O
protein	O
synthesis	O
.	O

Chronic	O
elevation	O
of	O
GCs	O
in	O
GR	B-GENE-Y
(	O
dim	O
/	O
dim	O
)	O
mice	O
results	O
in	O
severe	O
runting	O
and	O
lethality	O
.	O

In	O
conclusion	O
,	O
some	O
metabolic	O
effects	O
of	O
GC	O
treatment	O
are	O
exaggerated	O
in	O
adipose	O
tissue	O
of	O
GR	B-GENE-Y
(	O
dim	O
/	O
dim	O
)	O
mice	O
,	O
suggesting	O
that	O
selective	O
GR	B-GENE-Y
modulators	O
based	O
on	O
dissociating	O
GR	B-GENE-Y
transactivation	O
from	O
repression	O
should	O
be	O
evaluated	O
carefully	O
.	O

X	B-GENE-Y
-	I-GENE-Y
box	I-GENE-Y
binding	I-GENE-Y
protein	I-GENE-Y
1	I-GENE-Y
is	O
essential	O
for	O
insulin	B-GENE-Y
regulation	O
of	O
pancreatic	O
alpha	O
cell	O
function	O
.	O

Type	O
2	O
diabetes	O
mellitus	O
(	O
T2D	O
)	O
patients	O
often	O
exhibit	O
hyperglucagonemia	O
despite	O
hyperglycemia	O
suggesting	O
defective	O
	O
-	O
cell	O
function	O
.	O

While	O
endoplasmic	O
reticulum	O
(	O
ER	O
)	O
stress	O
has	O
been	O
suggested	O
to	O
underlie	O
	O
-	O
cell	O
dysfunction	O
in	O
T2D	O
,	O
its	O
role	O
in	O
	O
-	O
cell	O
biology	O
remains	O
unclear	O
.	O

X	B-GENE-Y
-	I-GENE-Y
box	I-GENE-Y
binding	I-GENE-Y
protein	I-GENE-Y
1	I-GENE-Y
(	O
XBP1	B-GENE-Y
)	O
is	O
a	O
transcription	O
factor	O
that	O
plays	O
a	O
crucial	O
role	O
in	O
the	O
unfolded	O
protein	O
response	O
(	O
UPR	O
)	O
and	O
its	O
deficiency	O
in	O
	O
-	O
cells	O
has	O
been	O
reported	O
to	O
impair	O
insulin	B-GENE-N
secretion	O
leading	O
to	O
glucose	B-CHEMICAL
intolerance	O
.	O

To	O
evaluate	O
the	O
role	O
of	O
XBP1	B-GENE-Y
in	O
	O
-	O
cells	O
,	O
we	O
created	O
complementary	O
in	O
vivo	O
(	O
	O
-	O
cell	O
specific	O
XBP1	B-GENE-Y
knockout	O
(	O
XBPKO	B-GENE-Y
)	O
mice	O
)	O
and	O
in	O
vitro	O
(	O
stable	O
XBP1	B-GENE-Y
knock	O
down	O
	O
-	O
cell	O
line	O
,	O
XBPKD	B-GENE-Y
)	O
models	O
.	O

XBPKO	B-GENE-Y
mice	O
exhibited	O
glucose	B-CHEMICAL
intolerance	O
,	O
mild	O
insulin	B-GENE-N
resistance	O
and	O
an	O
inability	O
to	O
suppress	O
glucagon	B-GENE-Y
secretion	O
following	O
glucose	B-CHEMICAL
stimulation	O
.	O

XBPKD	B-GENE-Y
cells	O
exhibited	O
activation	O
of	O
IRE1	B-GENE-Y
,	O
an	O
upstream	O
activator	O
of	O
XBP1	B-GENE-Y
,	O
leading	O
to	O
phosphorylation	O
of	O
JNK	B-GENE-N
.	O

Interestingly	O
,	O
insulin	B-GENE-Y
treatment	O
of	O
XBPKD	B-GENE-Y
cells	O
reduced	O
tyrosine	B-CHEMICAL
phosphorylation	O
of	O
IRS	B-GENE-Y
-	I-GENE-Y
1	I-GENE-Y
(	O
pY	O
(	O
896	O
)	O
)	O
,	O
and	O
phosphorylation	O
of	O
Akt	B-GENE-N
,	O
while	O
enhancing	O
serine	B-CHEMICAL
phosphorylation	O
(	O
pS	O
(	O
307	O
)	O
)	O
of	O
IRS	B-GENE-Y
-	I-GENE-Y
1	I-GENE-Y
.	O

Consequently	O
the	O
XBPKD	B-GENE-Y
cells	O
exhibited	O
blunted	O
suppression	O
of	O
glucagon	B-GENE-Y
secretion	O
following	O
insulin	B-GENE-Y
treatment	O
in	O
the	O
presence	O
of	O
high	O
glucose	B-CHEMICAL
.	O

Together	O
,	O
these	O
data	O
indicate	O
that	O
XBP1	B-GENE-Y
deficiency	O
in	O
pancreatic	O
	O
-	O
cells	O
induces	O
altered	O
insulin	B-GENE-Y
signaling	O
and	O
dysfunctional	O
glucagon	B-GENE-Y
secretion	O
.	O

Toxicological	O
profiles	O
of	O
selected	O
synthetic	O
cannabinoids	B-CHEMICAL
showing	O
high	O
binding	O
affinities	O
to	O
the	O
cannabinoid	B-GENE-Y
receptor	I-GENE-Y
subtype	I-GENE-Y
CB1	I-GENE-Y
.	O

Products	O
containing	O
synthetic	O
cannabinoids	B-CHEMICAL
are	O
consumed	O
as	O
a	O
surrogate	O
for	O
marihuana	O
due	O
to	O
their	O
non	O
-	O
detectability	O
with	O
commonly	O
used	O
drug	O
tests	O
and	O
their	O
strong	O
cannabimimetic	O
effects	O
.	O

Because	O
data	O
concerning	O
their	O
toxicological	O
properties	O
are	O
scarce	O
,	O
the	O
cytotoxic	O
,	O
genotoxic	O
,	O
immunomodulatory	O
,	O
and	O
hormonal	O
activities	O
of	O
four	O
naphthoylindole	B-CHEMICAL
compounds	O
(	O
JWH	B-CHEMICAL
-	I-CHEMICAL
018	I-CHEMICAL
,	O
JWH	B-CHEMICAL
-	I-CHEMICAL
073	I-CHEMICAL
,	O
JWH	B-CHEMICAL
-	I-CHEMICAL
122	I-CHEMICAL
and	O
JWH	B-CHEMICAL
-	I-CHEMICAL
210	I-CHEMICAL
)	O
and	O
of	O
one	O
benzoylindole	B-CHEMICAL
(	O
AM	B-CHEMICAL
-	I-CHEMICAL
694	I-CHEMICAL
)	O
were	O
studied	O
in	O
human	O
cell	O
lines	O
and	O
primary	O
cells	O
;	O
tetrahydrocannabinol	B-CHEMICAL
was	O
included	O
as	O
the	O
classical	O
non	O
-	O
endogenous	O
cannabinoid	B-GENE-N
receptor	I-GENE-N
ligand	O
.	O

All	O
compounds	O
induced	O
damage	O
to	O
the	O
cell	O
membranes	O
of	O
buccal	O
(	O
TR146	O
)	O
and	O
breast	O
(	O
MCF	O
-	O
7	O
)	O
derived	O
cells	O
at	O
concentrations	O
of	O
	O
75	O
-	O
100	O
M	O
.	O

No	O
cytotoxic	O
responses	O
were	O
seen	O
in	O
other	O
assays	O
which	O
reflect	O
mitochondrial	O
damage	O
,	O
protein	O
synthesis	O
,	O
and	O
lysosomal	O
activities	O
.	O

JWH	B-CHEMICAL
-	I-CHEMICAL
073	I-CHEMICAL
and	O
JWH	B-CHEMICAL
-	I-CHEMICAL
122	I-CHEMICAL
induced	O
DNA	O
migration	O
in	O
buccal	O
and	O
liver	O
cells	O
(	O
HepG2	O
)	O
in	O
single	O
cell	O
gel	O
electrophoresis	O
assays	O
,	O
while	O
JWH	B-CHEMICAL
-	I-CHEMICAL
210	I-CHEMICAL
was	O
only	O
in	O
the	O
latter	O
cell	O
line	O
active	O
.	O

No	O
estrogenic	O
activities	O
were	O
detected	O
in	O
bone	O
marrow	O
cells	O
(	O
U2	O
-	O
OS	O
)	O
,	O
but	O
all	O
compounds	O
caused	O
anti	O
-	O
estrogenic	O
effects	O
at	O
levels	O
between	O
2	O
.	O
1	O
and	O
23	O
.	O
0	O
M	O
.	O

Furthermore	O
,	O
no	O
impact	O
on	O
cytokine	B-GENE-N
release	O
(	O
i	O
.	O
e	O
.	O
,	O
on	O
IL	B-GENE-Y
-	I-GENE-Y
10	I-GENE-Y
,	O
IL	B-GENE-Y
-	I-GENE-Y
6	I-GENE-Y
,	O
IL	B-GENE-N
-	I-GENE-N
12	I-GENE-N
/	O
23p40	B-GENE-Y
and	O
TNF	B-GENE-Y
levels	O
)	O
was	O
seen	O
in	O
LPS	O
-	O
stimulated	O
human	O
PBMCs	O
,	O
except	O
with	O
JWH	B-CHEMICAL
-	I-CHEMICAL
210	I-CHEMICAL
and	O
JWH	B-CHEMICAL
-	I-CHEMICAL
122	I-CHEMICAL
which	O
caused	O
a	O
decrease	O
of	O
TNF	B-GENE-Y
and	O
IL	B-GENE-N
-	I-GENE-N
12	I-GENE-N
/	O
23p40	B-GENE-Y
.	O

All	O
toxic	O
effects	O
were	O
observed	O
with	O
concentrations	O
higher	O
than	O
those	O
expected	O
in	O
body	O
fluids	O
of	O
users	O
.	O

Since	O
genotoxic	O
effects	O
are	O
in	O
general	O
linear	O
over	O
a	O
wide	O
concentration	O
range	O
and	O
the	O
exposure	O
levels	O
may	O
be	O
higher	O
in	O
epithelial	O
cells	O
or	O
in	O
serum	O
,	O
further	O
experimental	O
work	O
is	O
required	O
to	O
find	O
out	O
if	O
DNA	O
damage	O
takes	O
place	O
in	O
drug	O
users	O
.	O

Curcuminoids	B-CHEMICAL
Modulate	O
Pro	O
-	O
Oxidant	O
-	O
Antioxidant	O
Balance	O
but	O
not	O
the	O
Immune	O
Response	O
to	O
Heat	B-GENE-Y
Shock	I-GENE-Y
Protein	I-GENE-Y
27	I-GENE-Y
and	O
Oxidized	B-GENE-N
LDL	I-GENE-N
in	O
Obese	O
Individuals	O
.	O

Curcuminoids	B-CHEMICAL
have	O
potentially	O
important	O
functional	O
qualities	O
including	O
anti	O
-	O
inflammatory	O
and	O
antioxidant	O
properties	O
.	O

In	O
this	O
randomized	O
double	O
-	O
blind	O
placebo	O
-	O
controlled	O
cross	O
-	O
over	O
trial	O
,	O
the	O
effects	O
of	O
a	O
curcuminoid	B-CHEMICAL
supplement	O
on	O
serum	O
pro	O
-	O
oxidant	O
-	O
antioxidant	O
balance	O
(	O
PAB	O
)	O
and	O
antibody	O
titres	O
to	O
Hsp27	B-GENE-Y
(	O
anti	O
-	O
Hsp27	B-GENE-Y
)	O
and	O
oxLDL	B-GENE-N
(	O
anti	O
-	O
oxLDL	B-GENE-N
)	O
were	O
investigated	O
.	O

Thirty	O
obese	O
individuals	O
were	O
randomized	O
to	O
receive	O
either	O
curcuminoids	B-CHEMICAL
(	O
1	O
g	O
/	O
day	O
)	O
or	O
placebo	O
for	O
a	O
period	O
of	O
30	O
days	O
.	O

After	O
a	O
wash	O
-	O
out	O
period	O
of	O
2	O
weeks	O
,	O
subjects	O
were	O
crossed	O
over	O
to	O
the	O
alternate	O
regimen	O
for	O
another	O
30	O
days	O
.	O

Serum	O
PAB	O
along	O
with	O
anti	O
-	O
Hsp27	B-GENE-Y
and	O
anti	O
-	O
oxLDL	B-GENE-N
titres	O
was	O
measured	O
at	O
the	O
beginning	O
and	O
at	O
the	O
end	O
of	O
each	O
study	O
period	O
.	O

There	O
was	O
no	O
significant	O
carry	O
-	O
over	O
effect	O
for	O
any	O
of	O
the	O
assessed	O
parameters	O
.	O

Curcuminoid	B-CHEMICAL
supplementation	O
was	O
associated	O
with	O
a	O
significant	O
decrease	O
in	O
PAB	O
(	O
p	O
=	O
0	O
.	O
044	O
)	O
.	O

However	O
,	O
no	O
significant	O
change	O
was	O
observed	O
in	O
serum	O
concentrations	O
of	O
anti	O
-	O
Hsp27	B-GENE-Y
or	O
anti	O
-	O
oxLDL	B-GENE-N
(	O
p	O
>	O
0	O
.	O
05	O
)	O
.	O

These	O
findings	O
suggest	O
that	O
oral	O
curcuminoids	B-CHEMICAL
supplementation	O
(	O
1g	O
/	O
day	O
)	O
is	O
effective	O
in	O
reducing	O
oxidative	O
stress	O
burden	O
,	O
though	O
this	O
needs	O
to	O
be	O
validated	O
in	O
larger	O
study	O
populations	O
.	O

Copyright	O
	O
2013	O
John	O
Wiley	O
&	O
Sons	O
,	O
Ltd	O
.	O

Influence	O
of	O
the	O
Green	O
Tea	O
Leaf	O
Extract	O
on	O
Neurotoxicity	O
of	O
Aluminium	B-CHEMICAL
Chloride	I-CHEMICAL
in	O
Rats	O
.	O

Aluminium	B-CHEMICAL
may	O
have	O
an	O
important	O
role	O
in	O
the	O
aetiology	O
/	O
pathogenesis	O
/	O
precipitation	O
of	O
Alzheimer	O
'	O
s	O
disease	O
.	O

Because	O
green	O
tea	O
(	O
Camellia	O
sinensis	O
L	O
.	O
)	O
reportedly	O
has	O
health	O
-	O
promoting	O
effects	O
in	O
the	O
central	O
nervous	O
system	O
,	O
we	O
evaluated	O
the	O
effects	O
of	O
green	O
tea	O
leaf	O
extract	O
(	O
GTLE	O
)	O
on	O
aluminium	B-CHEMICAL
chloride	I-CHEMICAL
(	O
AlCl3	B-CHEMICAL
)	O
neurotoxicity	O
in	O
rats	O
.	O

All	O
solutions	O
were	O
injected	O
into	O
the	O
cornu	O
ammonis	O
region	O
1	O
hippocampal	O
region	O
.	O

We	O
measured	O
the	O
performance	O
of	O
active	O
avoidance	O
(	O
AA	O
)	O
tasks	O
,	O
various	O
enzyme	O
activities	O
and	O
total	O
glutathione	B-CHEMICAL
content	O
(	O
TGC	O
)	O
in	O
the	O
forebrain	O
cortex	O
(	O
FbC	O
)	O
,	O
striatum	O
,	O
basal	O
forebrain	O
(	O
BFb	O
)	O
,	O
hippocampus	O
,	O
brain	O
stem	O
and	O
cerebellum	O
.	O

AlCl3	B-CHEMICAL
markedly	O
reduced	O
AA	O
performance	O
and	O
activities	O
of	O
cytochrome	B-GENE-N
c	I-GENE-N
oxidase	I-GENE-N
(	O
COX	B-GENE-N
)	O
and	O
acetylcholinesterase	B-GENE-Y
(	O
AChE	B-GENE-Y
)	O
in	O
all	O
regions	O
.	O

It	O
decreased	O
TGC	O
in	O
the	O
FbC	O
,	O
striatum	O
,	O
BFb	O
,	O
hippocampus	O
,	O
brain	O
stem	O
and	O
cerebellum	O
,	O
and	O
increased	O
superoxide	B-CHEMICAL
dismutase	O
activity	O
in	O
the	O
FbC	O
,	O
cerebellum	O
and	O
BFb	O
.	O

GTLE	O
pretreatment	O
completely	O
reversed	O
the	O
damaging	O
effects	O
of	O
AlCl3	B-CHEMICAL
on	O
AA	O
and	O
superoxide	B-GENE-N
dismutase	I-GENE-N
activity	O
,	O
markedly	O
corrected	O
COX	B-GENE-N
and	O
AChE	B-GENE-Y
activities	O
,	O
and	O
moderately	O
improved	O
TGC	O
.	O

GTLE	O
alone	O
increased	O
COX	B-GENE-N
and	O
AChE	B-GENE-Y
activities	O
in	O
almost	O
all	O
regions	O
.	O

GTLE	O
reduces	O
AlCl3	B-CHEMICAL
neurotoxicity	O
probably	O
via	O
antioxidative	O
effects	O
and	O
improves	O
mitochondrial	O
and	O
cholinergic	O
synaptic	O
functions	O
through	O
the	O
actions	O
of	O
(	B-CHEMICAL
-	I-CHEMICAL
)	I-CHEMICAL
-	I-CHEMICAL
epigallocatechin	I-CHEMICAL
gallate	I-CHEMICAL
and	O
(	B-CHEMICAL
-	I-CHEMICAL
)	I-CHEMICAL
-	I-CHEMICAL
epicatechin	I-CHEMICAL
,	O
compounds	O
most	O
abundantly	O
found	O
in	O
GTLE	O
.	O

Our	O
results	O
suggest	O
that	O
green	O
tea	O
might	O
be	O
beneficial	O
in	O
Alzheimer	O
'	O
s	O
disease	O
.	O

Copyright	O
	O
2013	O
John	O
Wiley	O
&	O
Sons	O
,	O
Ltd	O
.	O

From	O
synaptic	O
spines	O
to	O
nuclear	O
signaling	O
:	O
nuclear	O
and	O
synaptic	O
actions	O
of	O
the	O
amyloid	B-GENE-Y
precursor	I-GENE-Y
protein	I-GENE-Y
.	O

Despite	O
intensive	O
studies	O
of	O
the	O
secretase	B-GENE-N
-	O
mediated	O
processing	O
of	O
the	O
amyloid	B-GENE-Y
precursor	I-GENE-Y
protein	I-GENE-Y
(	O
APP	B-GENE-Y
)	O
to	O
form	O
the	O
amyloid	B-GENE-Y
	I-GENE-Y
-	I-GENE-Y
peptide	I-GENE-Y
(	O
A	B-GENE-Y
)	O
,	O
in	O
relation	O
to	O
Alzheimer	O
'	O
s	O
disease	O
(	O
AD	O
)	O
,	O
no	O
new	O
therapeutic	O
agents	O
have	O
reached	O
the	O
clinics	O
based	O
on	O
reducing	O
A	B-GENE-Y
levels	O
through	O
the	O
use	O
of	O
secretase	B-GENE-N
inhibitors	O
or	O
immunotherapy	O
.	O

Furthermore	O
,	O
the	O
normal	O
neuronal	O
functions	O
of	O
APP	B-GENE-Y
and	O
its	O
various	O
metabolites	O
still	O
remain	O
under	O
-	O
investigated	O
and	O
unclear	O
.	O

Here	O
,	O
we	O
highlight	O
emerging	O
areas	O
of	O
APP	B-GENE-Y
function	O
that	O
may	O
provide	O
new	O
insights	O
into	O
synaptic	O
development	O
,	O
cognition	O
,	O
and	O
gene	O
regulation	O
.	O

By	O
modulating	O
expression	O
levels	O
of	O
endogenous	O
APP	B-GENE-Y
in	O
primary	O
cortical	O
neurons	O
,	O
the	O
frequency	O
and	O
amplitude	O
of	O
calcium	B-CHEMICAL
oscillations	O
is	O
modified	O
,	O
implying	O
a	O
key	O
role	O
for	O
APP	B-GENE-Y
in	O
maintaining	O
neuronal	O
calcium	B-CHEMICAL
homeostasis	O
essential	O
for	O
synaptic	O
transmission	O
.	O

Disruption	O
of	O
this	O
homeostatic	O
mechanism	O
predisposes	O
to	O
aging	O
and	O
AD	O
.	O

Synaptic	O
spine	O
loss	O
is	O
a	O
feature	O
of	O
neurogeneration	O
resulting	O
in	O
learning	O
and	O
memory	O
deficits	O
,	O
and	O
emerging	O
evidence	O
indicates	O
a	O
role	O
for	O
APP	B-GENE-Y
,	O
probably	O
mediated	O
via	O
one	O
or	O
more	O
of	O
its	O
metabolites	O
,	O
in	O
spine	O
structure	O
and	O
functions	O
.	O

The	O
intracellular	B-GENE-N
domain	I-GENE-N
of	I-GENE-N
APP	I-GENE-N
(	O
AICD	B-GENE-N
)	O
has	O
also	O
emerged	O
as	O
a	O
key	O
epigenetic	O
regulator	O
of	O
gene	O
expression	O
controlling	O
a	O
diverse	O
range	O
of	O
genes	O
,	O
including	O
APP	B-GENE-Y
itself	O
,	O
the	O
amyloid	B-GENE-Y
-	O
degrading	O
enzyme	O
neprilysin	B-GENE-Y
,	O
and	O
aquaporin	B-GENE-Y
-	I-GENE-Y
1	I-GENE-Y
.	O

A	O
fuller	O
understanding	O
of	O
the	O
physiological	O
and	O
pathological	O
actions	O
of	O
APP	B-GENE-Y
and	O
its	O
metabolic	O
network	O
could	O
provide	O
new	O
opportunities	O
for	O
therapeutic	O
intervention	O
in	O
AD	O
.	O

The	O
influence	O
of	O
Goishi	O
tea	O
on	O
adipocytokines	B-GENE-N
in	O
obese	O
mice	O
.	O

This	O
study	O
investigated	O
the	O
influence	O
of	O
Goishi	O
-	O
tea	O
on	O
visceral	O
fat	O
weight	O
in	O
induced	O
obese	O
mice	O
.	O

Mice	O
were	O
divided	O
into	O
two	O
main	O
groups	O
,	O
normal	O
and	O
obesity	O
.	O

In	O
obesity	O
group	O
,	O
mice	O
were	O
fed	O
with	O
high	O
-	O
fat	O
diet	O
.	O

Goishi	O
-	O
tea	O
including	O
its	O
fractions	O
(	O
ethyl	B-CHEMICAL
-	I-CHEMICAL
acetate	I-CHEMICAL
layer	O
and	O
water	O
layer	O
)	O
was	O
administrated	O
in	O
normal	O
and	O
obesity	O
three	O
sub	O
-	O
groups	O
.	O

Results	O
showed	O
no	O
influence	O
of	O
Goishi	O
-	O
tea	O
in	O
normal	O
group	O
.	O

However	O
,	O
visceral	O
fat	O
weight	O
,	O
size	O
of	O
adipose	O
cell	O
and	O
cholesterol	B-CHEMICAL
level	O
were	O
significantly	O
decreased	O
in	O
obesity	O
group	O
fed	O
Goishi	O
-	O
tea	O
compared	O
to	O
control	O
group	O
.	O

Moreover	O
,	O
adiponectin	B-GENE-Y
levels	O
tended	O
to	O
increase	O
and	O
adipocytokines	B-GENE-N
has	O
significant	O
values	O
lower	O
in	O
obesity	O
group	O
fed	O
Goishi	O
-	O
tea	O
compared	O
to	O
control	O
group	O
.	O

Interestingly	O
,	O
Goishi	O
tea	O
involved	O
in	O
the	O
high	O
-	O
fat	O
diet	O
induced	O
-	O
obese	O
mice	O
can	O
inhibit	O
fat	O
accumulation	O
and	O
maintain	O
adiponectins	B-GENE-Y
without	O
increasing	O
tumor	B-GENE-Y
necrosis	I-GENE-Y
factor	I-GENE-Y
-	I-GENE-Y
alpha	I-GENE-Y
and	O
interleukin	B-GENE-Y
-	I-GENE-Y
6	I-GENE-Y
.	O

It	O
would	O
be	O
beneficial	O
for	O
the	O
prevention	O
of	O
metabolic	O
syndrome	O
and	O
obesity	O
-	O
related	O
disorder	O
.	O

Steroidal	B-CHEMICAL
glycosides	I-CHEMICAL
from	O
the	O
bulbs	O
of	O
Fritillaria	O
meleagris	O
and	O
their	O
cytotoxic	O
activities	O
.	O

Steroidal	B-CHEMICAL
glycosides	I-CHEMICAL
(	O
1	O
-	O
18	O
)	O
,	O
including	O
10	O
new	O
compounds	O
(	O
1	O
-	O
10	O
)	O
,	O
were	O
isolated	O
from	O
the	O
bulbs	O
of	O
Fritillaria	O
meleagris	O
(	O
Liliaceae	O
)	O
.	O

The	O
structures	O
of	O
the	O
new	O
compounds	O
were	O
determined	O
by	O
two	O
-	O
dimensional	O
(	O
2D	O
)	O
NMR	O
analysis	O
,	O
and	O
by	O
hydrolytic	O
cleavage	O
followed	O
by	O
spectroscopic	O
and	O
chromatographic	O
analysis	O
.	O

The	O
isolated	O
compounds	O
and	O
their	O
aglycones	O
were	O
evaluated	O
for	O
cytotoxic	O
activity	O
against	O
HL	O
-	O
60	O
human	O
promyelocytic	O
leukemia	O
cells	O
and	O
A549	O
human	O
lung	O
adenocarcinoma	O
cells	O
.	O

Morphological	O
observation	O
and	O
flow	O
cytometry	O
analysis	O
showed	O
that	O
5	B-CHEMICAL
-	I-CHEMICAL
spirostanol	I-CHEMICAL
glycoside	I-CHEMICAL
(	O
2	O
)	O
and	O
a	O
cholestane	B-CHEMICAL
derivative	O
(	O
17a	O
)	O
induced	O
apoptotic	O
cell	O
death	O
in	O
HL	O
-	O
60	O
cells	O
through	O
different	O
mechanisms	O
of	O
action	O
.	O

Furthermore	O
,	O
the	O
(	B-CHEMICAL
22R	I-CHEMICAL
)	I-CHEMICAL
-	I-CHEMICAL
spirosolanol	I-CHEMICAL
glycoside	I-CHEMICAL
(	O
11	O
)	O
selectively	O
induced	O
apoptosis	O
in	O
A549	O
cells	O
without	O
affecting	O
the	O
caspase	B-GENE-Y
-	I-GENE-Y
3	I-GENE-Y
activity	O
level	O
.	O

Gene	O
silencing	O
of	O
TNF	B-GENE-Y
-	I-GENE-Y
alpha	I-GENE-Y
in	O
a	O
murine	O
model	O
of	O
acute	O
colitis	O
using	O
a	O
modified	O
cyclodextrin	O
delivery	O
system	O
.	O

Inflammatory	O
bowel	O
disease	O
(	O
IBD	O
)	O
is	O
a	O
chronic	O
relapsing	O
inflammation	O
of	O
the	O
gastrointestinal	O
tract	O
.	O

The	O
cytokine	B-GENE-N
TNF	B-GENE-Y
-	I-GENE-Y
alpha	I-GENE-Y
(	O
TNF	B-GENE-Y
-	I-GENE-Y
	I-GENE-Y
)	O
plays	O
a	O
pivotal	O
role	O
in	O
mediating	O
this	O
inflammatory	O
response	O
.	O

RNA	O
interference	O
(	O
RNAi	O
)	O
holds	O
great	O
promise	O
for	O
the	O
specific	O
and	O
selective	O
silencing	O
of	O
aberrantly	O
expressed	O
genes	O
,	O
such	O
as	O
TNF	B-GENE-Y
-	I-GENE-Y
	I-GENE-Y
in	O
IBD	O
.	O

The	O
aim	O
of	O
this	O
study	O
was	O
to	O
investigate	O
the	O
efficacy	O
of	O
an	O
amphiphilic	O
cationic	O
cyclodextrin	O
(	O
CD	O
)	O
vector	O
for	O
effective	O
TNF	B-GENE-Y
-	I-GENE-Y
	I-GENE-Y
siRNA	O
delivery	O
to	O
macrophage	O
cells	O
and	O
to	O
mice	O
with	O
induced	O
acute	O
-	O
colitis	O
.	O

The	O
stability	O
of	O
CD	O
.	O
siRNA	O
was	O
examined	O
by	O
gel	O
electrophoresis	O
in	O
biorelevant	O
media	O
reflecting	O
colonic	O
fluids	O
.	O

RAW264	O
.	O
7	O
cells	O
were	O
transfected	O
with	O
CD	O
.	O
TNF	B-GENE-Y
-	I-GENE-Y
	I-GENE-Y
siRNA	O
,	O
stimulated	O
with	O
lipopolysaccharide	O
(	O
LPS	O
)	O
and	O
TNF	B-GENE-Y
-	I-GENE-Y
	I-GENE-Y
and	O
IL	B-GENE-Y
-	I-GENE-Y
6	I-GENE-Y
responses	O
were	O
measured	O
by	O
PCR	O
and	O
ELISA	O
.	O

Female	O
C57BL	O
/	O
6	O
mice	O
were	O
exposed	O
to	O
dextran	O
sodium	B-CHEMICAL
sulphate	I-CHEMICAL
(	O
DSS	O
)	O
and	O
treated	O
by	O
intrarectal	O
administration	O
with	O
either	O
CD	O
.	O
siRNA	O
TNF	B-GENE-Y
-	I-GENE-Y
	I-GENE-Y
or	O
a	O
control	O
solution	O
.	O

In	O
vitro	O
,	O
siRNA	O
in	O
CD	O
nanocomplexes	O
remained	O
intact	O
and	O
stable	O
in	O
both	O
fed	O
and	O
fasted	O
simulated	O
colonic	O
fluids	O
.	O

RAW264	O
.	O
7	O
cells	O
transfected	O
with	O
CD	O
.	O
TNF	B-GENE-Y
-	I-GENE-Y
	I-GENE-Y
siRNA	O
and	O
stimulated	O
with	O
LPS	O
displayed	O
a	O
significant	O
reduction	O
in	O
both	O
gene	O
and	O
protein	O
levels	O
of	O
TNF	B-GENE-Y
-	I-GENE-Y
	I-GENE-Y
and	O
IL	B-GENE-Y
-	I-GENE-Y
6	I-GENE-Y
.	O

CD	O
.	O
TNF	B-GENE-Y
-	I-GENE-Y
	I-GENE-Y
siRNA	O
-	O
treated	O
mice	O
revealed	O
a	O
mild	O
amelioration	O
in	O
clinical	O
signs	O
of	O
colitis	O
,	O
but	O
significant	O
reductions	O
in	O
total	O
colon	O
weight	O
and	O
colonic	O
mRNA	O
expression	O
of	O
TNF	B-GENE-Y
-	I-GENE-Y
	I-GENE-Y
and	O
IL	B-GENE-Y
-	I-GENE-Y
6	I-GENE-Y
compared	O
to	O
DSS	O
-	O
control	O
mice	O
were	O
detected	O
.	O

This	O
data	O
indicates	O
the	O
clinical	O
potential	O
of	O
a	O
local	O
CD	O
-	O
based	O
TNF	B-GENE-Y
-	I-GENE-Y
	I-GENE-Y
siRNA	O
delivery	O
system	O
for	O
the	O
treatment	O
of	O
IBD	O
.	O

Curcumin	B-CHEMICAL
attenuates	O
allergic	O
airway	O
inflammation	O
by	O
regulation	O
of	O
CD4	O
(	O
+	O
)	O
CD25	O
(	O
+	O
)	O
regulatory	O
T	O
cells	O
(	O
Tregs	O
)	O
/	O
Th17	O
balance	O
in	O
ovalbumin	B-GENE-Y
-	O
sensitized	O
mice	O
.	O

The	O
present	O
study	O
aimed	O
to	O
determine	O
the	O
protective	O
effects	O
and	O
the	O
underlying	O
mechanisms	O
of	O
curcumin	B-CHEMICAL
on	O
ovalbumin	B-GENE-Y
(	O
OVA	B-GENE-Y
)	O
-	O
induced	O
allergic	O
inflammation	O
in	O
a	O
mouse	O
model	O
of	O
allergic	O
asthma	O
.	O

Asthma	O
mice	O
model	O
was	O
established	O
by	O
ovalbumin	B-GENE-Y
.	O

A	O
total	O
of	O
60	O
mice	O
were	O
randomly	O
assigned	O
to	O
six	O
experimental	O
groups	O
:	O
control	O
,	O
model	O
,	O
dexamethasone	B-CHEMICAL
(	O
2mg	O
/	O
kg	O
)	O
,	O
and	O
curcumin	B-CHEMICAL
(	O
50mg	O
/	O
kg	O
,	O
100mg	O
/	O
kg	O
,	O
200mg	O
/	O
kg	O
)	O
.	O

Airway	O
resistance	O
(	O
Raw	O
)	O
was	O
measured	O
by	O
the	O
forced	O
oscillation	O
technique	O
,	O
differential	O
cell	O
count	O
in	O
BAL	O
fluid	O
(	O
BALF	O
)	O
was	O
measured	O
by	O
Wright	O
-	O
Giemsa	O
staining	O
,	O
histological	O
assessment	O
was	O
measured	O
by	O
hematoxylin	B-CHEMICAL
and	O
eosin	B-CHEMICAL
(	O
HE	O
)	O
staining	O
,	O
BALF	O
levels	O
of	O
Treg	O
/	O
Th17	O
cytokines	B-GENE-N
were	O
measured	O
by	O
enzyme	O
-	O
linked	O
immunosorbent	O
assay	O
,	O
Treg	O
cells	O
and	O
Th17	O
cells	O
were	O
evaluated	O
by	O
flow	O
cytometry	O
(	O
FCM	O
)	O
.	O

Our	O
study	O
demonstrated	O
that	O
curcumin	B-CHEMICAL
inhibited	O
OVA	B-GENE-Y
-	O
induced	O
increases	O
in	O
eosinophil	O
count	O
;	O
interleukin	B-GENE-Y
(	I-GENE-Y
IL	I-GENE-Y
)	I-GENE-Y
-	I-GENE-Y
17A	I-GENE-Y
level	O
were	O
recovered	O
in	O
bronchoalveolar	O
lavage	O
fluid	O
increased	O
IL	B-GENE-Y
-	I-GENE-Y
10	I-GENE-Y
level	O
in	O
bronchoalveolar	O
lavage	O
fluid	O
.	O

Histological	O
studies	O
demonstrated	O
that	O
curcumin	B-CHEMICAL
substantially	O
inhibited	O
OVA	B-GENE-Y
-	O
induced	O
eosinophilia	O
in	O
lung	O
tissue	O
.	O

Flow	O
cytometry	O
(	O
FCM	O
)	O
studies	O
demonstrated	O
that	O
curcumin	B-CHEMICAL
remarkably	O
inhibited	O
Th17	O
cells	O
and	O
significantly	O
increased	O
Treg	O
cells	O
.	O

The	O
results	O
in	O
vivo	O
show	O
ovalbumin	B-GENE-Y
-	O
induced	O
significantly	O
broke	O
Treg	O
/	O
Th17	O
balance	O
;	O
curcumin	B-CHEMICAL
treatments	O
markedly	O
attenuated	O
the	O
inflammatory	O
in	O
asthma	O
model	O
by	O
regulating	O
Treg	O
/	O
Th17	O
balance	O
.	O

Our	O
findings	O
support	O
the	O
possible	O
use	O
of	O
curcumin	B-CHEMICAL
as	O
a	O
therapeutic	O
drug	O
for	O
patients	O
with	O
allergic	O
asthma	O
.	O

Structural	O
Basis	O
for	O
the	O
ATP	B-CHEMICAL
-	O
Induced	O
Isomerization	O
of	O
Kinesin	B-GENE-N
.	O

Kinesin	B-GENE-N
superfamily	I-GENE-N
proteins	I-GENE-N
(	O
KIFs	B-GENE-N
)	O
are	O
microtubule	B-GENE-N
-	I-GENE-N
based	I-GENE-N
molecular	I-GENE-N
motors	I-GENE-N
driven	O
by	O
the	O
energy	O
derived	O
from	O
the	O
hydrolysis	O
of	O
ATP	B-CHEMICAL
.	O

Previous	O
studies	O
have	O
revealed	O
that	O
the	O
ATP	B-CHEMICAL
binding	O
step	O
is	O
crucial	O
both	O
for	O
the	O
power	O
stroke	O
to	O
produce	O
motility	O
and	O
for	O
the	O
inter	O
-	O
domain	O
regulation	O
of	O
ATPase	B-GENE-N
activity	O
to	O
guarantee	O
the	O
processive	O
movement	O
of	O
dimeric	O
KIFs	B-GENE-N
.	O

Here	O
,	O
we	O
report	O
the	O
first	O
crystal	O
structure	O
of	O
KIF4	B-GENE-Y
complexed	O
with	O
the	O
non	O
-	O
hydrolyzable	O
ATP	B-CHEMICAL
analog	O
,	O
AMPPNP	B-CHEMICAL
(	O
adenylyl	B-CHEMICAL
imidodiphosphate	I-CHEMICAL
)	O
,	O
at	O
1	O
.	O
7	O
resolution	O
.	O

By	O
combining	O
our	O
structure	O
with	O
previously	O
solved	O
KIF1A	B-GENE-Y
structures	O
complexed	O
with	O
two	O
ATP	B-CHEMICAL
analogs	O
,	O
molecular	O
snapshots	O
during	O
ATP	B-CHEMICAL
binding	O
reveal	O
that	O
the	O
closure	O
of	O
the	O
nucleotide	B-CHEMICAL
-	O
binding	O
pocket	O
during	O
ATP	B-CHEMICAL
binding	O
is	O
achieved	O
by	O
closure	O
of	O
the	O
backdoor	O
.	O

Closure	O
of	O
the	O
backdoor	O
stabilizes	O
two	O
mobile	O
regions	O
,	O
switch	O
I	O
and	O
switch	O
II	O
,	O
to	O
generate	O
the	O
phosphate	B-CHEMICAL
tube	O
from	O
which	O
hydrolyzed	O
phosphate	B-CHEMICAL
is	O
released	O
.	O

Through	O
the	O
stabilization	O
of	O
switch	O
II	O
,	O
the	O
local	O
conformational	O
change	O
at	O
the	O
catalytic	O
center	O
is	O
further	O
relayed	O
to	O
the	O
neck	O
-	O
linker	O
element	O
that	O
fully	O
docks	O
to	O
the	O
catalytic	O
core	O
to	O
produce	O
the	O
power	O
stroke	O
.	O

Because	O
the	O
neck	O
linker	O
is	O
a	O
sole	O
element	O
that	O
connects	O
the	O
partner	O
heads	O
in	O
dimeric	O
KIFs	B-GENE-N
,	O
this	O
tight	O
structural	O
coordination	O
between	O
the	O
catalytic	O
center	O
and	O
neck	O
linker	O
enables	O
inter	O
-	O
domain	O
communication	O
between	O
the	O
partner	O
heads	O
.	O

This	O
study	O
also	O
revealed	O
the	O
putative	O
microtubule	B-GENE-N
-	I-GENE-N
binding	I-GENE-N
site	I-GENE-N
of	O
KIF4	B-GENE-Y
,	O
thus	O
providing	O
structural	O
insights	O
that	O
describe	O
the	O
specific	O
binding	O
of	O
KIF4	B-GENE-Y
to	O
the	O
microtubule	O
.	O

Current	O
perspectives	O
on	O
parathyroid	B-GENE-Y
hormone	I-GENE-Y
(	O
PTH	B-GENE-Y
)	O
and	O
PTH	B-GENE-Y
-	I-GENE-Y
related	I-GENE-Y
protein	I-GENE-Y
(	O
PTHrP	B-GENE-Y
)	O
as	O
bone	O
anabolic	O
therapies	O
.	O

Osteoporosis	O
is	O
characterized	O
by	O
low	O
bone	O
mineral	O
density	O
and	O
/	O
or	O
poor	O
bone	O
microarchitecture	O
leading	O
to	O
an	O
increased	O
risk	O
of	O
fractures	O
.	O

The	O
skeletal	O
alterations	O
in	O
osteoporosis	O
are	O
a	O
consequence	O
of	O
a	O
relative	O
deficit	O
of	O
bone	O
formation	O
compared	O
to	O
bone	O
resorption	O
.	O

Osteoporosis	O
therapies	O
have	O
mostly	O
relied	O
on	O
antiresorptive	O
drugs	O
.	O

An	O
alternative	O
therapeutic	O
approach	O
for	O
osteoporosis	O
is	O
currently	O
available	O
,	O
based	O
on	O
the	O
intermittent	O
administration	O
of	O
parathyroid	B-GENE-Y
hormone	I-GENE-Y
(	O
PTH	B-GENE-Y
)	O
.	O

Bone	O
anabolism	O
caused	O
by	O
PTH	B-GENE-Y
therapy	O
is	O
mainly	O
accounted	O
for	O
by	O
the	O
ability	O
of	O
PTH	B-GENE-Y
to	O
increase	O
osteoblastogenesis	O
and	O
osteoblast	O
survival	O
.	O

PTH	B-GENE-Y
and	O
PTH	B-GENE-Y
-	I-GENE-Y
related	I-GENE-Y
protein	I-GENE-Y
(	O
PTHrP	B-GENE-Y
)	O
-	O
an	O
abundant	O
local	O
factor	O
in	O
bone	O
-	O
interact	O
with	O
the	O
common	O
PTH	B-GENE-Y
type	I-GENE-Y
1	I-GENE-Y
receptor	I-GENE-Y
with	O
similar	O
affinities	O
in	O
osteoblasts	O
.	O

Studies	O
mainly	O
in	O
osteoporosis	O
rodent	O
models	O
and	O
limited	O
data	O
in	O
postmenopausal	O
women	O
suggest	O
that	O
N	B-CHEMICAL
-	O
terminal	O
PTHrP	B-GENE-Y
peptides	O
might	O
be	O
considered	O
a	O
promising	O
bone	O
anabolic	O
therapy	O
.	O

In	O
addition	O
,	O
putative	O
osteogenic	O
actions	O
of	O
PTHrP	B-GENE-Y
might	O
be	O
ascribed	O
not	O
only	O
to	O
its	O
N	B-CHEMICAL
-	O
terminal	O
domain	O
but	O
also	O
to	O
its	O
PTH	B-GENE-Y
-	O
unrelated	O
C	B-CHEMICAL
-	O
terminal	O
region	O
.	O

In	O
this	O
review	O
,	O
we	O
discuss	O
the	O
underlying	O
cellular	O
and	O
molecular	O
mechanisms	O
of	O
the	O
anabolic	O
actions	O
of	O
PTH	B-GENE-Y
and	O
the	O
similar	O
potential	O
of	O
PTH	B-GENE-Y
-	I-GENE-Y
related	I-GENE-Y
protein	I-GENE-Y
(	O
PTHrP	B-GENE-Y
)	O
to	O
increase	O
bone	O
mass	O
and	O
improve	O
bone	O
regeneration	O
.	O

Pharmacotherapy	O
for	O
the	O
core	O
symptoms	O
in	O
autistic	O
disorder	O
:	O
current	O
status	O
of	O
the	O
research	O
.	O

The	O
current	O
review	O
covers	O
extant	O
literature	O
on	O
pharmacotherapy	O
for	O
core	O
symptoms	O
of	O
autism	O
.	O

The	O
core	O
symptoms	O
of	O
autism	O
include	O
impairments	O
in	O
social	O
interaction	O
and	O
communication	O
,	O
as	O
well	O
as	O
the	O
presence	O
of	O
restricted	O
and	O
repetitive	O
behaviors	O
.	O

There	O
are	O
no	O
known	O
efficacious	O
treatments	O
for	O
the	O
core	O
social	O
symptoms	O
,	O
although	O
effects	O
on	O
repetitive	O
behaviors	O
are	O
indicated	O
with	O
some	O
data	O
.	O

While	O
studies	O
of	O
fenfluramine	B-CHEMICAL
,	O
secretin	B-GENE-Y
,	O
opiates	O
,	O
and	O
mood	O
stabilizers	O
generally	O
find	O
no	O
effect	O
,	O
mixed	O
results	O
suggest	O
more	O
research	O
is	O
needed	O
on	O
antidepressants	O
and	O
atypical	O
antipsychotics	O
.	O

Newer	O
lines	O
of	O
research	O
,	O
including	O
cholinergic	O
and	O
glutamatergic	O
agents	O
and	O
oxytocin	B-CHEMICAL
,	O
will	O
be	O
of	O
considerable	O
interest	O
in	O
the	O
future	O
.	O

However	O
,	O
research	O
on	O
the	O
treatment	O
of	O
core	O
symptoms	O
is	O
plagued	O
by	O
limitations	O
in	O
study	O
design	O
,	O
statistical	O
power	O
,	O
and	O
other	O
issues	O
inherent	O
to	O
the	O
study	O
of	O
treatments	O
for	O
autism	O
(	O
e	O
.	O
g	O
.	O
,	O
heterogeneity	O
of	O
the	O
disorder	O
)	O
that	O
continue	O
to	O
prevent	O
the	O
elucidation	O
of	O
efficacious	O
treatments	O
.	O

Ectopic	O
Thyroid	O
Tissue	O
in	O
the	O
Adrenal	O
Gland	O
:	O
Report	O
of	O
2	O
Cases	O
with	O
Pathogenetic	O
Implications	O
.	O

Background	O
:	O
Ectopic	O
thyroid	O
tissue	O
is	O
usually	O
found	O
anywhere	O
along	O
the	O
embryonic	O
descent	O
pathway	O
of	O
the	O
medial	O
thyroid	O
anlage	O
from	O
the	O
tongue	O
to	O
the	O
trachea	O
(	O
Wlfler	O
area	O
)	O
.	O

However	O
,	O
ectopic	O
thyroid	O
tissue	O
in	O
the	O
adrenal	O
gland	O
(	O
ETTAG	O
)	O
is	O
not	O
easy	O
to	O
understand	O
on	O
the	O
basis	O
of	O
thyroid	O
embryology	O
;	O
because	O
it	O
is	O
so	O
rare	O
,	O
the	O
possibility	O
of	O
metastasis	O
should	O
first	O
be	O
considered	O
.	O

Here	O
,	O
we	O
describe	O
2	O
cases	O
of	O
ETTAG	O
with	O
pathogenetic	O
implications	O
and	O
review	O
the	O
literature	O
.	O

Patient	O
findings	O
:	O
Two	O
cases	O
of	O
ETTAG	O
presented	O
as	O
incidental	O
cystic	O
adrenal	O
masses	O
in	O
adult	O
females	O
,	O
one	O
having	O
a	O
congenital	O
hernia	O
of	O
Morgagni	O
.	O

The	O
ETTAG	O
was	O
histologically	O
indistinguishable	O
from	O
normal	O
orthotopic	O
thyroid	O
tissue	O
,	O
and	O
its	O
follicular	O
nature	O
was	O
confirmed	O
by	O
immunohistochemical	O
positivity	O
for	O
thyroglobulin	B-GENE-Y
,	O
thyroperoxidase	B-GENE-Y
,	O
thyroid	B-GENE-Y
transcription	I-GENE-Y
factor	I-GENE-Y
-	I-GENE-Y
1	I-GENE-Y
(	O
TTF	B-GENE-Y
-	I-GENE-Y
1	I-GENE-Y
/	O
Titf	B-GENE-Y
-	I-GENE-Y
1	I-GENE-Y
/	O
Nkx2	B-GENE-Y
.	I-GENE-Y
1	I-GENE-Y
)	O
,	O
cytokeratin	B-GENE-N
(	O
CK	B-GENE-N
)	O
AE1	O
/	O
AE3	O
,	O
CK	B-GENE-Y
7	I-GENE-Y
,	O
pendrin	B-GENE-Y
,	O
human	B-GENE-Y
sodium	I-GENE-Y
iodide	I-GENE-Y
symporter	I-GENE-Y
(	O
hNIS	B-GENE-Y
)	O
,	O
paired	B-GENE-Y
box	I-GENE-Y
gene	I-GENE-Y
8	I-GENE-Y
(	O
PAX8	B-GENE-Y
)	O
and	O
FOXE1	B-GENE-Y
(	O
TTF	B-GENE-Y
-	I-GENE-Y
2	I-GENE-Y
)	O
,	O
as	O
well	O
as	O
positivity	O
for	O
the	O
messenger	O
RNA	O
of	O
the	O
thyroglobulin	B-GENE-Y
gene	O
by	O
in	O
situ	O
hybridization	O
analysis	O
.	O

No	O
C	O
cells	O
(	O
negativity	O
for	O
calcitonin	B-GENE-Y
,	O
cromogranin	B-GENE-N
and	O
synaptophysin	B-GENE-Y
)	O
were	O
present	O
.	O

Neither	O
BRAF	B-GENE-Y
nor	O
KRAS	B-GENE-Y
mutations	O
were	O
detected	O
with	O
real	O
-	O
time	O
polymerase	O
chain	O
reaction	O
analysis	O
.	O

Further	O
work	O
-	O
up	O
did	O
not	O
show	O
evidence	O
of	O
thyroid	O
malignancy	O
.	O

Summary	O
:	O
ETTAG	O
is	O
a	O
rare	O
finding	O
,	O
with	O
only	O
7	O
cases	O
reported	O
;	O
women	O
are	O
much	O
more	O
frequently	O
affected	O
than	O
men	O
(	O
8	O
:	O
1	O
)	O
and	O
it	O
usually	O
clinically	O
presents	O
in	O
the	O
fifth	O
decade	O
(	O
mean	O
age	O
:	O
54	O
,	O
range	O
:	O
38	O
-	O
67	O
)	O
as	O
a	O
cystic	O
adrenal	O
mass	O
incidentally	O
discovered	O
on	O
abdominal	O
ultrasonography	O
and	O
/	O
or	O
in	O
computed	O
tomography	O
images	O
.	O

ETTAG	O
is	O
composed	O
of	O
normal	O
follicular	O
cells	O
without	O
C	O
cells	O
.	O

The	O
expression	O
of	O
some	O
transcription	O
factors	O
(	O
TTF	B-GENE-Y
-	I-GENE-Y
1	I-GENE-Y
,	O
PAX8	B-GENE-Y
and	O
FOXE1	B-GENE-Y
)	O
involved	O
in	O
development	O
and	O
/	O
or	O
migration	O
of	O
the	O
medial	O
thyroid	O
anlage	O
is	O
preserved	O
.	O

Coexistence	O
of	O
a	O
congenital	O
hernia	O
of	O
Morgagni	O
in	O
one	O
patient	O
suggests	O
an	O
over	O
-	O
descent	O
of	O
medial	O
thyroid	O
anlage	O
derived	O
cells	O
in	O
its	O
pathogenesis	O
.	O

Conclusion	O
:	O
Although	O
ETTAG	O
pathogenesis	O
remains	O
unknown	O
,	O
the	O
lack	O
of	O
C	O
cells	O
together	O
with	O
the	O
coexistence	O
of	O
a	O
congenital	O
defect	O
of	O
the	O
anterior	O
diaphragm	O
(	O
hernia	O
of	O
Morgagni	O
)	O
in	O
one	O
of	O
our	O
patients	O
could	O
suggest	O
an	O
over	O
-	O
descent	O
of	O
medial	O
thyroid	O
anlagen	O
derived	O
cells	O
in	O
the	O
origin	O
of	O
this	O
heterotopia	O
.	O

Synthesis	O
of	O
a	O
DOTA	B-CHEMICAL
(	O
Gd	B-CHEMICAL
(	I-CHEMICAL
3	I-CHEMICAL
+	I-CHEMICAL
)	I-CHEMICAL
)	O
-	O
conjugate	O
of	O
proton	B-GENE-N
-	I-GENE-N
pump	I-GENE-N
inhibitor	O
pantoprazole	B-CHEMICAL
for	O
gastric	O
wall	O
imaging	O
studies	O
.	O

Magnetic	O
resonance	O
imaging	O
(	O
MRI	O
)	O
is	O
used	O
to	O
evaluate	O
gastrointestinal	O
(	O
GI	O
)	O
structure	O
and	O
functions	O
in	O
humans	O
.	O

Despite	O
filling	O
the	O
viscus	O
lumen	O
with	O
a	O
contrast	O
agent	O
,	O
visualization	O
of	O
the	O
viscus	O
wall	O
is	O
limited	O
.	O

To	O
overcome	O
this	O
limitation	O
,	O
we	O
de	O
novo	O
synthesized	O
a	O
conjugate	O
that	O
covalently	O
combines	O
a	O
Gd	B-CHEMICAL
-	O
based	O
MRI	O
contrast	O
agent	O
,	O
encaged	O
with	O
a	O
chelating	O
agent	O
(	O
DOTA	B-CHEMICAL
)	O
,	O
with	O
pantoprazole	B-CHEMICAL
,	O
which	O
is	O
a	O
widely	O
used	O
proton	B-GENE-N
pump	I-GENE-N
inhibitor	O
that	O
binds	O
to	O
proton	B-GENE-N
pumps	I-GENE-N
in	O
the	O
stomach	O
and	O
colon	O
.	O

The	O
DOTA	B-CHEMICAL
linkage	O
was	O
installed	O
at	O
a	O
mechanism	O
-	O
based	O
strategic	O
location	O
in	O
the	O
pantoprazole	B-CHEMICAL
molecule	O
to	O
minimize	O
a	O
possible	O
negative	O
effect	O
of	O
the	O
structural	O
modification	O
on	O
the	O
drug	O
.	O

It	O
is	O
anticipated	O
that	O
by	O
defining	O
the	O
wall	O
of	O
the	O
stomach	O
and	O
colon	O
,	O
this	O
compound	O
will	O
facilitate	O
functional	O
MRI	O
of	O
the	O
GI	O
tract	O
in	O
humans	O
.	O

Acetylcholinesterase	B-GENE-Y
inhibition	O
reveals	O
endogenous	O
nicotinic	O
modulation	O
of	O
glutamate	B-CHEMICAL
inputs	O
to	O
CA1	O
stratum	O
radiatum	O
interneurons	O
in	O
hippocampal	O
slices	O
.	O

The	O
involvement	O
of	O
brain	O
nicotinic	B-GENE-N
acetylcholine	I-GENE-N
receptors	I-GENE-N
(	O
nAChRs	B-GENE-N
)	O
in	O
the	O
neurotoxicological	O
effects	O
of	O
soman	O
,	O
a	O
potent	O
acetylcholinesterase	B-GENE-Y
(	O
AChE	B-GENE-Y
)	O
inhibitor	O
and	O
a	O
chemical	O
warfare	O
agent	O
,	O
is	O
not	O
clear	O
.	O

This	O
is	O
partly	O
due	O
to	O
a	O
poor	O
understanding	O
of	O
the	O
role	O
of	O
AChE	B-GENE-Y
in	O
brain	O
nAChR	B-GENE-N
-	O
mediated	O
functions	O
.	O

To	O
test	O
the	O
hypothesis	O
that	O
AChE	B-GENE-Y
inhibition	O
builds	O
sufficient	O
acetylcholine	B-CHEMICAL
(	O
ACh	O
)	O
in	O
the	O
brain	O
and	O
facilitates	O
nAChR	B-GENE-N
-	O
dependent	O
glutamate	B-CHEMICAL
transmission	O
,	O
we	O
used	O
whole	O
-	O
cell	O
patch	O
-	O
clamp	O
technique	O
to	O
record	O
spontaneous	O
glutamate	B-CHEMICAL
excitatory	O
postsynaptic	O
currents	O
(	O
EPSCs	O
)	O
from	O
CA1	O
stratum	O
radiatum	O
interneurons	O
(	O
SRI	O
)	O
in	O
hippocampal	O
slices	O
.	O

First	O
,	O
the	O
frequency	O
,	O
amplitude	O
and	O
kinetics	O
of	O
EPSCs	O
recorded	O
from	O
slices	O
of	O
control	O
guinea	O
pigs	O
were	O
compared	O
to	O
those	O
recorded	O
from	O
slices	O
of	O
guinea	O
pigs	O
after	O
a	O
single	O
injection	O
of	O
the	O
irreversible	O
AChE	B-GENE-Y
inhibitor	O
soman	O
(	O
25	O
.	O
2g	O
/	O
kg	O
,	O
s	O
.	O
c	O
.	O
)	O
.	O

Second	O
,	O
EPSCs	O
were	O
recorded	O
from	O
rat	O
hippocampal	O
slices	O
before	O
and	O
after	O
their	O
superfusion	O
with	O
the	O
reversible	O
AChE	B-GENE-Y
inhibitor	O
donepezil	B-CHEMICAL
(	O
100nM	O
)	O
.	O

The	O
frequency	O
of	O
EPSCs	O
was	O
significantly	O
higher	O
in	O
slices	O
taken	O
from	O
guinea	O
pigs	O
24h	O
but	O
not	O
7	O
days	O
after	O
the	O
soman	O
injection	O
than	O
in	O
slices	O
from	O
control	O
animals	O
.	O

In	O
52	O
%	O
of	O
the	O
rat	O
hippocampal	O
slices	O
tested	O
,	O
bath	O
application	O
of	O
donepezil	B-CHEMICAL
increased	O
the	O
frequency	O
of	O
EPSCs	O
.	O

Further	O
,	O
exposure	O
to	O
donepezil	B-CHEMICAL
increased	O
both	O
burst	O
-	O
like	O
and	O
large	O
-	O
amplitude	O
EPSCs	O
,	O
and	O
increased	O
the	O
proportion	O
of	O
short	O
(	O
20	O
-	O
100ms	O
)	O
inter	O
-	O
event	O
intervals	O
.	O

Donepezil	B-CHEMICAL
'	O
s	O
effects	O
were	O
suppressed	O
significantly	O
in	O
presence	O
of	O
10M	O
mecamylamine	B-CHEMICAL
or	O
10nM	O
methyllycaconitine	B-CHEMICAL
.	O

These	O
results	O
support	O
the	O
concept	O
that	O
AChE	B-GENE-Y
inhibition	O
is	O
able	O
to	O
recruit	O
nAChR	B-GENE-N
-	O
dependent	O
glutamate	B-CHEMICAL
transmission	O
in	O
the	O
hippocampus	O
and	O
such	O
a	O
mechanism	O
can	O
contribute	O
to	O
the	O
acute	O
neurotoxicological	O
actions	O
of	O
soman	O
.	O

A	O
Nanogram	O
Dose	O
of	O
the	O
CYP3A	B-GENE-N
Probe	O
Substrate	O
Midazolam	B-CHEMICAL
to	O
Evaluate	O
Drug	O
Interactions	O
.	O

The	O
objective	O
of	O
the	O
study	O
was	O
to	O
establish	O
an	O
in	O
vivo	O
method	O
for	O
assessing	O
cytochrome	B-GENE-N
P450	I-GENE-N
3A	I-GENE-N
(	O
CYP3A	B-GENE-N
)	O
activity	O
using	O
therapeutically	O
inert	O
nanogram	O
doses	O
of	O
midazolam	B-CHEMICAL
.	O

We	O
administered	O
four	O
escalating	O
single	O
doses	O
of	O
oral	O
midazolam	B-CHEMICAL
(	O
0	O
.	O
0001	O
-	O
3	O
mg	O
)	O
to	O
12	O
healthy	O
participants	O
,	O
stratified	O
according	O
to	O
CYP3A5	B-GENE-Y
carrier	O
status	O
,	O
to	O
assess	O
pharmacokinetics	O
linearity	O
.	O

We	O
then	O
evaluated	O
the	O
interactions	O
with	O
the	O
CYP3A	B-GENE-N
inhibitor	O
ketoconazole	B-CHEMICAL
(	O
400	O
mg	O
q	O
.	O
d	O
.	O
)	O
after	O
nanogram	O
and	O
regular	O
doses	O
of	O
midazolam	B-CHEMICAL
.	O

Area	O
under	O
the	O
plasma	O
concentration	O
-	O
time	O
curve	O
(	O
AUC	O
)	O
and	O
peak	O
plasma	O
concentration	O
(	O
Cmax	O
)	O
were	O
linear	O
over	O
the	O
entire	O
range	O
of	O
doses	O
.	O

Ketoconazole	B-CHEMICAL
reduced	O
midazolam	B-CHEMICAL
oral	O
clearance	O
by	O
92	O
.	O
8	O
%	O
.	O

AUC	O
and	O
Cmax	O
increased	O
by	O
1	O
,	O
540	O
and	O
363	O
%	O
,	O
respectively	O
.	O

CYP3A5	B-GENE-Y
carrier	O
status	O
had	O
no	O
influence	O
on	O
midazolam	B-CHEMICAL
oral	O
clearance	O
or	O
its	O
inhibition	O
by	O
ketoconazole	B-CHEMICAL
.	O

This	O
is	O
the	O
first	O
study	O
showing	O
that	O
midazolam	B-CHEMICAL
pharmacokinetics	O
is	O
linear	O
in	O
a	O
30	O
,	O
000	O
-	O
fold	O
concentration	O
range	O
,	O
and	O
therefore	O
that	O
nano	O
-	O
and	O
microgram	O
doses	O
of	O
midazolam	B-CHEMICAL
can	O
reliably	O
predict	O
the	O
pharmacokinetics	O
of	O
midazolam	B-CHEMICAL
in	O
therapeutic	O
doses	O
and	O
can	O
be	O
used	O
to	O
assess	O
CYP3A	B-GENE-Y
activity	O
even	O
in	O
the	O
presence	O
of	O
strong	O
CYP3A	B-GENE-Y
inhibitors	O
.	O
Clinical	O
Pharmacology	O
&	O
Therapeutics	O
(	O
2013	O
)	O
;	O
advance	O
online	O
publication	O
20	O
March	O
2013	O
.	O
doi	O
:	O
10	O
.	O
1038	O
/	O
clpt	O
.	O
2013	O
.	O
27	O
.	O

NAD	B-GENE-Y
(	I-GENE-Y
P	I-GENE-Y
)	I-GENE-Y
H	I-GENE-Y
:	I-GENE-Y
Quinone	I-GENE-Y
Oxidoreductase	I-GENE-Y
1	I-GENE-Y
Inducer	O
Activity	O
of	O
Some	O
Saudi	O
Arabian	O
Medicinal	O
Plants	O
.	O

Medicinal	O
plants	O
are	O
a	O
rich	O
source	O
of	O
biologically	O
-	O
active	O
phytochemicals	O
and	O
have	O
been	O
used	O
in	O
traditional	O
medicine	O
for	O
centuries	O
.	O

Specific	O
phytochemicals	O
and	O
extracts	O
of	O
their	O
plant	O
sources	O
have	O
the	O
ability	O
to	O
reduce	O
the	O
risk	O
for	O
chronic	O
degenerative	O
diseases	O
by	O
induction	O
of	O
enzymes	O
involved	O
in	O
xenobiotic	O
metabolism	O
,	O
many	O
of	O
which	O
also	O
have	O
antioxidant	O
and	O
anti	O
-	O
inflammatory	O
functions	O
.	O

One	O
such	O
multifunctional	O
cytoprotective	O
enzyme	O
is	O
NAD	B-GENE-N
(	I-GENE-N
P	I-GENE-N
)	I-GENE-N
H	I-GENE-N
:	I-GENE-N
quinone	I-GENE-N
oxidoreductase	I-GENE-N
.	O

In	O
this	O
study	O
,	O
we	O
prepared	O
extracts	O
of	O
27	O
Saudi	O
Arabian	O
medicinal	O
plants	O
which	O
belong	O
to	O
18	O
different	O
plant	O
families	O
and	O
tested	O
their	O
ability	O
to	O
induce	O
NAD	B-GENE-N
(	I-GENE-N
P	I-GENE-N
)	I-GENE-N
H	I-GENE-N
:	I-GENE-N
quinone	I-GENE-N
oxidoreductase	I-GENE-N
in	O
murine	O
hepatoma	O
cells	O
grown	O
in	O
microtiter	O
plate	O
wells	O
.	O

In	O
addition	O
to	O
the	O
Brassicaceae	O
,	O
a	O
known	O
source	O
of	O
NAD	B-GENE-N
(	I-GENE-N
P	I-GENE-N
)	I-GENE-N
H	I-GENE-N
:	I-GENE-N
quinone	I-GENE-N
oxidoreductase	I-GENE-N
inducer	I-GENE-N
activity	I-GENE-N
,	O
we	O
found	O
substantial	O
inducer	O
activity	O
in	O
extracts	O
from	O
the	O
Apiaceae	O
,	O
Apocynaceae	O
,	O
and	O
the	O
Asteraceae	O
families	O
.	O

Five	O
out	O
of	O
a	O
total	O
of	O
eight	O
active	O
extracts	O
are	O
from	O
plants	O
which	O
belong	O
to	O
the	O
Asteraceae	O
family	O
.	O

We	O
further	O
show	O
that	O
artemisinin	B-CHEMICAL
,	O
an	O
agent	O
which	O
is	O
used	O
clinically	O
for	O
the	O
treatment	O
of	O
malaria	O
,	O
contributes	O
but	O
does	O
not	O
fully	O
account	O
for	O
the	O
inducer	O
activity	O
of	O
the	O
extract	O
of	O
Artemisia	O
monosperma	O
.	O

In	O
contrast	O
to	O
artemisinin	B-CHEMICAL
,	O
deoxyartemisinin	B-CHEMICAL
is	O
inactive	O
in	O
this	O
assay	O
,	O
demonstrating	O
the	O
critical	O
role	O
of	O
the	O
endoperoxide	O
moiety	O
of	O
artemisinin	B-CHEMICAL
for	O
inducer	O
activity	O
.	O

Thus	O
,	O
the	O
NAD	B-GENE-N
(	I-GENE-N
P	I-GENE-N
)	I-GENE-N
H	I-GENE-N
:	I-GENE-N
quinone	I-GENE-N
oxidoreductase	I-GENE-N
inducer	O
activity	O
of	O
extracts	O
of	O
some	O
Saudi	O
Arabian	O
medicinal	O
plants	O
indicates	O
the	O
presence	O
of	O
specific	O
phytochemicals	O
which	O
have	O
the	O
potential	O
to	O
protect	O
against	O
chronic	O
degenerative	O
diseases	O
.	O

Metabolism	O
of	O
Beclomethasone	B-CHEMICAL
Dipropionate	I-CHEMICAL
by	O
Cytochrome	B-GENE-N
P450	I-GENE-N
3A	I-GENE-N
Enzymes	O
.	O

Inhaled	O
glucocorticoids	O
,	O
such	O
as	O
beclomethasone	B-CHEMICAL
dipropionate	I-CHEMICAL
(	O
BDP	B-CHEMICAL
)	O
,	O
are	O
the	O
mainstay	O
treatment	O
of	O
asthma	O
.	O

However	O
,	O
	O
30	O
%	O
of	O
patients	O
exhibit	O
little	O
to	O
no	O
benefit	O
from	O
treatment	O
.	O

It	O
has	O
been	O
postulated	O
that	O
glucocorticoid	O
resistance	O
,	O
or	O
insensitivity	O
,	O
is	O
attributable	O
to	O
individual	O
differences	O
in	O
glucocorticoid	B-GENE-Y
receptor	I-GENE-Y
-	O
mediated	O
processes	O
.	O

It	O
is	O
possible	O
that	O
variations	O
in	O
cytochrome	B-GENE-N
P450	I-GENE-N
3A	I-GENE-N
enzyme	O
-	O
mediated	O
metabolism	O
of	O
BDP	B-CHEMICAL
may	O
contribute	O
to	O
this	O
phenomenon	O
.	O

This	O
hypothesis	O
was	O
explored	O
by	O
evaluating	O
the	O
contributions	O
of	O
CYP3A4	B-GENE-N
,	I-GENE-N
3A5	I-GENE-N
,	I-GENE-N
3A7	I-GENE-N
,	O
and	O
esterase	B-GENE-N
enzymes	O
in	O
the	O
metabolism	O
of	O
BDP	B-CHEMICAL
in	O
vitro	O
and	O
relating	O
metabolism	O
to	O
changes	O
in	O
CYP3A	B-GENE-N
enzyme	O
mRNA	O
expression	O
via	O
the	O
glucocorticoid	B-GENE-Y
receptor	I-GENE-Y
in	O
lung	O
and	O
liver	O
cells	O
.	O

CYP3A4	B-GENE-Y
and	O
CYP3A5	B-GENE-Y
metabolized	O
BDP	B-CHEMICAL
via	O
hydroxylation	O
(	O
[	O
M4	O
]	O
and	O
[	O
M6	O
]	O
)	O
and	O
dehydrogenation	O
(	O
[	O
M5	O
]	O
)	O
at	O
similar	O
rates	O
;	O
CYP3A7	B-GENE-Y
did	O
not	O
metabolize	O
BDP	B-CHEMICAL
.	O

A	O
new	O
metabolite	O
[	O
M6	O
]	O
,	O
formed	O
by	O
the	O
combined	O
action	O
of	O
esterases	O
and	O
CYP3A4	B-GENE-Y
hydroxylation	O
,	O
was	O
also	O
characterized	O
.	O

To	O
validate	O
the	O
results	O
observed	O
using	O
microsomes	O
and	O
recombinant	O
enzymes	O
,	O
studies	O
were	O
also	O
conducted	O
using	O
A549	O
lung	O
and	O
DPX2	O
liver	O
cells	O
.	O

Both	O
liver	O
and	O
lung	O
cells	O
produced	O
esterase	O
-	O
dependent	O
metabolites	O
[	O
M1	O
-	O
M3	O
]	O
,	O
with	O
[	O
M1	O
]	O
correlating	O
with	O
CYP3A5	B-GENE-Y
mRNA	O
induction	O
in	O
A549	O
cells	O
.	O

Liver	O
cells	O
produced	O
both	O
hydroxylated	O
and	O
dehydrogenated	O
metabolites	O
[	O
M4	O
,	O
M5	O
,	O
and	O
M6	O
]	O
,	O
but	O
lung	O
cells	O
produced	O
only	O
the	O
dehydrogenated	O
metabolite	O
[	O
M5	O
]	O
.	O

These	O
studies	O
show	O
that	O
CYP3A4	B-GENE-Y
and	O
CYP3A5	B-GENE-Y
metabolize	O
BDP	B-CHEMICAL
to	O
inactive	O
metabolites	O
and	O
suggest	O
that	O
differences	O
in	O
the	O
expression	O
or	O
function	O
of	O
these	O
enzymes	O
in	O
the	O
lung	O
and	O
/	O
or	O
liver	O
could	O
influence	O
BDP	B-CHEMICAL
disposition	O
in	O
humans	O
.	O

Effect	O
of	O
the	O
Potent	O
Antiviral	O
1	B-CHEMICAL
-	I-CHEMICAL
Cinnamoyl	I-CHEMICAL
-	I-CHEMICAL
3	I-CHEMICAL
,	I-CHEMICAL
11	I-CHEMICAL
-	I-CHEMICAL
Dihydroxymeliacarpin	I-CHEMICAL
on	O
Cytokine	B-GENE-N
Production	O
by	O
Murine	O
Macrophages	O
Stimulated	O
with	O
HSV	O
-	O
2	O
.	O

The	O
limonoid	O
1	B-CHEMICAL
-	I-CHEMICAL
cinnamoyl	I-CHEMICAL
-	I-CHEMICAL
3	I-CHEMICAL
,	I-CHEMICAL
11	I-CHEMICAL
-	I-CHEMICAL
dihydroxymeliacarpin	I-CHEMICAL
(	O
CDM	B-CHEMICAL
)	O
isolated	O
from	O
leaf	O
extracts	O
of	O
Melia	O
azedarach	O
L	O
,	O
has	O
potent	O
antiherpetic	O
effect	O
in	O
epithelial	O
cells	O
.	O

Since	O
Meliacine	O
,	O
the	O
partially	O
purified	O
extract	O
source	O
of	O
CDM	B-CHEMICAL
,	O
has	O
therapeutic	O
effect	O
on	O
murine	O
genital	O
herpes	O
,	O
the	O
potential	O
use	O
of	O
CDM	B-CHEMICAL
as	O
microbicide	O
against	O
herpetic	O
infections	O
was	O
studied	O
here	O
.	O

To	O
determine	O
the	O
cytotoxic	O
effect	O
of	O
CDM	B-CHEMICAL
,	O
the	O
MTT	B-CHEMICAL
assay	O
and	O
acridine	O
orange	O
staining	O
of	O
living	O
cells	O
were	O
performed	O
.	O

The	O
antiherpetic	O
action	O
of	O
CDM	B-CHEMICAL
was	O
measured	O
by	O
plaque	O
reduction	O
assay	O
,	O
and	O
the	O
immunomodulatory	O
effect	O
was	O
determined	O
by	O
measuring	O
the	O
cytokine	B-GENE-N
production	O
using	O
a	O
bioassay	O
and	O
ELISA	O
method	O
.	O

The	O
results	O
presented	O
here	O
showed	O
that	O
CDM	B-CHEMICAL
inhibited	O
Herpes	O
Simplex	O
Virus	O
type	O
2	O
(	O
HSV	O
-	O
2	O
)	O
multiplication	O
in	O
Vero	O
cells	O
but	O
did	O
not	O
affect	O
its	O
replication	O
in	O
macrophages	O
which	O
were	O
not	O
permissive	O
to	O
HSV	O
infection	O
.	O

In	O
macrophages	O
,	O
levels	O
of	O
TNF	B-GENE-Y
-	I-GENE-Y
	I-GENE-Y
,	O
IFN	B-GENE-Y
-	I-GENE-Y
	I-GENE-Y
,	O
NO	O
,	O
IL	B-GENE-Y
-	I-GENE-Y
6	I-GENE-Y
and	O
IL	B-GENE-Y
-	I-GENE-Y
10	I-GENE-Y
were	O
increased	O
by	O
CDM	B-CHEMICAL
used	O
alone	O
or	O
in	O
combination	O
with	O
HSV	O
-	O
2	O
.	O

Besides	O
,	O
CDM	B-CHEMICAL
not	O
only	O
synergized	O
TNF	B-GENE-Y
-	I-GENE-Y
	I-GENE-Y
production	O
combined	O
with	O
IFN	B-GENE-Y
-	I-GENE-Y
	I-GENE-Y
,	O
but	O
also	O
prolonged	O
its	O
expression	O
in	O
time	O
.	O

Results	O
indicate	O
that	O
CDM	B-CHEMICAL
inhibits	O
HSV	O
-	O
2	O
multiplication	O
in	O
epithelial	O
cells	O
and	O
also	O
increases	O
cytokine	B-GENE-N
production	O
in	O
macrophages	O
,	O
both	O
important	O
actions	O
to	O
the	O
clearance	O
of	O
infecting	O
virus	O
in	O
the	O
mouse	O
vagina	O
.	O

Copyright	O
	O
2013	O
John	O
Wiley	O
&	O
Sons	O
,	O
Ltd	O
.	O

Intestinal	O
and	O
hepatic	O
first	O
-	O
pass	O
extraction	O
of	O
the	O
11	B-GENE-Y
-	I-GENE-Y
HSD1	I-GENE-Y
inhibitor	O
AMG	B-CHEMICAL
221	I-CHEMICAL
in	O
rats	O
with	O
chronic	O
vascular	O
catheters	O
.	O

Abstract	O
1	O
.	O

A	O
catheterized	O
rat	O
model	O
was	O
used	O
to	O
define	O
the	O
intestinal	O
and	O
hepatic	O
components	O
of	O
oral	O
bioavailability	O
for	O
an	O
11	B-GENE-Y
-	I-GENE-Y
HSD1	I-GENE-Y
inhibitor	O
,	O
AMG	B-CHEMICAL
221	I-CHEMICAL
.	O

These	O
data	O
were	O
integrated	O
with	O
standard	O
in	O
vivo	O
metabolism	O
studies	O
to	O
elucidate	O
the	O
components	O
contributing	O
to	O
the	O
oral	O
disposition	O
of	O
a	O
novel	O
drug	O
candidate	O
.	O

2	O
.	O

Intestinal	O
and	O
hepatic	O
extraction	O
ratios	O
of	O
AMG	B-CHEMICAL
221	I-CHEMICAL
obtained	O
using	O
a	O
five	O
-	O
catheter	O
rat	O
model	O
were	O
0	O
.	O
56	O
and	O
0	O
.	O
32	O
,	O
respectively	O
.	O

Therefore	O
,	O
both	O
intestinal	O
and	O
hepatic	O
extraction	O
contributed	O
to	O
the	O
first	O
-	O
pass	O
component	O
of	O
oral	O
bioavailability	O
.	O

There	O
was	O
no	O
evidence	O
for	O
significant	O
gut	O
extraction	O
of	O
systemically	O
administered	O
drug	O
.	O

3	O
.	O

Mass	O
balance	O
data	O
and	O
in	O
vivo	O
metabolite	O
characterization	O
obtained	O
after	O
administration	O
of	O
[	B-CHEMICAL
(	I-CHEMICAL
14	I-CHEMICAL
)	I-CHEMICAL
C	I-CHEMICAL
]	I-CHEMICAL
AMG	I-CHEMICAL
221	I-CHEMICAL
to	O
rat	O
showed	O
that	O
AMG	B-CHEMICAL
221	I-CHEMICAL
was	O
completely	O
absorbed	O
from	O
the	O
gut	O
lumen	O
following	O
an	O
oral	O
dose	O
,	O
primarily	O
excreted	O
in	O
urine	O
and	O
was	O
almost	O
completely	O
metabolized	O
prior	O
to	O
excretion	O
.	O

4	O
.	O

Hepatic	O
bioavailability	O
(	O
FH	O
)	O
,	O
measured	O
in	O
two	O
animals	O
at	O
various	O
time	O
points	O
after	O
oral	O
dose	O
administration	O
was	O
somewhat	O
variable	O
but	O
generally	O
characterized	O
by	O
an	O
initial	O
reduction	O
during	O
the	O
absorption	O
phase	O
followed	O
by	O
an	O
increase	O
during	O
the	O
elimination	O
phase	O
,	O
consistent	O
with	O
hepatic	O
distribution	O
of	O
AMG	B-CHEMICAL
221	I-CHEMICAL
.	O

5	O
.	O

The	O
five	O
-	O
catheter	O
rat	O
model	O
afforded	O
estimates	O
of	O
hepatic	O
and	O
intestinal	O
contribution	O
to	O
oral	O
bioavailability	O
that	O
were	O
used	O
with	O
other	O
data	O
to	O
define	O
the	O
preclinical	O
ADME	O
characteristics	O
of	O
a	O
drug	O
candidate	O
.	O

Synthesis	O
and	O
selected	O
immunological	O
properties	O
of	O
substituted	O
quino	B-CHEMICAL
[	I-CHEMICAL
3	I-CHEMICAL
,	I-CHEMICAL
2	I-CHEMICAL
-	I-CHEMICAL
b	I-CHEMICAL
]	I-CHEMICAL
benzo	I-CHEMICAL
[	I-CHEMICAL
1	I-CHEMICAL
,	I-CHEMICAL
4	I-CHEMICAL
]	I-CHEMICAL
thiazines	I-CHEMICAL
.	O

A	O
new	O
type	O
of	O
azaphenothiazines	B-CHEMICAL
-	O
tetracyclic	B-CHEMICAL
quino	I-CHEMICAL
[	I-CHEMICAL
3	I-CHEMICAL
,	I-CHEMICAL
2	I-CHEMICAL
-	I-CHEMICAL
b	I-CHEMICAL
]	I-CHEMICAL
benzo	I-CHEMICAL
[	I-CHEMICAL
1	I-CHEMICAL
,	I-CHEMICAL
4	I-CHEMICAL
]	I-CHEMICAL
thiazines	I-CHEMICAL
,	O
possessing	O
common	O
substituents	O
(	O
H	B-CHEMICAL
,	O
CH3	B-CHEMICAL
,	O
Cl	B-CHEMICAL
,	O
Br	B-CHEMICAL
,	O
F	B-CHEMICAL
,	O
CF3	B-CHEMICAL
,	O
SCH3	B-CHEMICAL
)	O
in	O
positions	O
8	O
-	O
10	O
and	O
pharmacophoric	O
aminoalkyl	B-CHEMICAL
substituents	O
in	O
position	O
6	O
,	O
were	O
obtained	O
from	O
diquinodithiin	B-CHEMICAL
and	O
2	B-CHEMICAL
,	I-CHEMICAL
2	I-CHEMICAL
'	I-CHEMICAL
-	I-CHEMICAL
dichloro	I-CHEMICAL
-	I-CHEMICAL
3	I-CHEMICAL
,	I-CHEMICAL
3	I-CHEMICAL
'	I-CHEMICAL
-	I-CHEMICAL
diquinolinyl	I-CHEMICAL
disulfide	I-CHEMICAL
in	O
several	O
-	O
step	O
syntheses	O
.	O

Sixty	O
one	O
compounds	O
,	O
grouped	O
as	O
the	O
6H	O
,	O
6	B-CHEMICAL
-	I-CHEMICAL
dialkylaminoalkyl	I-CHEMICAL
,	O
6	B-CHEMICAL
-	I-CHEMICAL
acylaminoalkyl	I-CHEMICAL
and	O
sulfonylaminoalkyl	B-CHEMICAL
derivatives	O
,	O
were	O
tested	O
for	O
cytotoxicity	O
,	O
their	O
effects	O
on	O
phytohemagglutin	B-GENE-N
A	I-GENE-N
(	O
PHA	B-GENE-N
)	O
-	O
induced	O
proliferative	O
response	O
of	O
human	O
peripheral	O
blood	O
mononuclear	O
cells	O
(	O
PBMC	O
)	O
and	O
lipopolysaccharide	O
(	O
LPS	O
)	O
-	O
induced	O
tumor	B-GENE-Y
necrosis	I-GENE-Y
factor	I-GENE-Y
alpha	I-GENE-Y
(	O
TNF	B-GENE-Y
-	I-GENE-Y
	I-GENE-Y
)	O
production	O
by	O
these	O
cells	O
.	O

The	O
compounds	O
exhibited	O
differential	O
inhibitory	O
activities	O
in	O
these	O
tests	O
and	O
significantly	O
varied	O
in	O
terms	O
of	O
cytotoxicity	O
.	O

The	O
most	O
promising	O
compounds	O
were	O
tested	O
for	O
growth	O
inhibition	O
of	O
leukemia	O
L	O
-	O
1210	O
cells	O
,	O
colon	O
cancer	O
SV	O
-	O
948	O
cells	O
and	O
epidermal	O
carcinoma	O
A	O
-	O
341	O
cells	O
.	O

The	O
most	O
active	O
compounds	O
exhibited	O
anticancer	O
activity	O
against	O
these	O
cell	O
lines	O
comparable	O
to	O
that	O
of	O
cisplatin	B-CHEMICAL
.	O

The	O
structure	O
-	O
activity	O
relationship	O
of	O
the	O
compounds	O
were	O
discussed	O
.	O

Predictive	O
factors	O
of	O
sensitivity	O
to	O
elisidepsin	B-CHEMICAL
,	O
a	O
novel	O
kahalalide	B-CHEMICAL
f	I-CHEMICAL
-	O
derived	O
marine	O
compound	O
.	O

Elisidepsin	B-CHEMICAL
(	O
PM02734	B-CHEMICAL
,	O
Irvalec	B-CHEMICAL
	O
)	O
is	O
a	O
synthetic	O
marine	O
-	O
derived	O
cyclic	O
peptide	O
of	O
the	O
Kahalalide	B-CHEMICAL
F	I-CHEMICAL
family	O
currently	O
in	O
phase	O
II	O
clinical	O
development	O
.	O

Elisidepsin	B-CHEMICAL
was	O
shown	O
to	O
induce	O
rapid	O
oncosis	O
in	O
ErbB3	B-GENE-Y
-	O
expressing	O
cells	O
.	O

Other	O
predictive	O
factors	O
of	O
elisidepsin	B-CHEMICAL
sensitivity	O
remained	O
unknown	O
.	O

A	O
panel	O
of	O
23	O
cancer	O
cell	O
lines	O
of	O
different	O
origin	O
was	O
assessed	O
for	O
elisidepsin	B-CHEMICAL
cytotoxicity	O
and	O
correlated	O
with	O
mutational	O
state	O
,	O
mRNA	O
and	O
protein	O
expression	O
of	O
selected	O
genes	O
.	O

Elisidepsin	B-CHEMICAL
showed	O
potent	O
and	O
broad	O
cytotoxic	O
effects	O
in	O
our	O
cancer	O
cell	O
line	O
panel	O
,	O
being	O
active	O
at	O
concentrations	O
ranging	O
from	O
0	O
.	O
4	O
to	O
2	O
M	O
that	O
may	O
be	O
relevant	O
for	O
clinical	O
settings	O
.	O

We	O
have	O
shown	O
that	O
elisidepsin	B-CHEMICAL
is	O
more	O
active	O
in	O
cells	O
harboring	O
epithelial	O
phenotype	O
with	O
high	O
E	B-GENE-Y
-	I-GENE-Y
cadherin	I-GENE-Y
and	O
low	O
vimentin	B-GENE-Y
expression	O
.	O

In	O
addition	O
,	O
high	O
ErbB3	B-GENE-Y
and	O
Muc1	B-GENE-Y
expression	O
was	O
correlated	O
with	O
sensitivity	O
to	O
elisidepsin	B-CHEMICAL
,	O
whereas	O
the	O
presence	O
of	O
KRAS	B-GENE-Y
activating	O
mutations	O
was	O
associated	O
with	O
resistance	O
.	O

In	O
DU	O
-	O
PM	O
cells	O
with	O
acquired	O
resistance	O
to	O
elisidepsin	B-CHEMICAL
,	O
ErbB3	B-GENE-Y
expression	O
was	O
decreased	O
,	O
while	O
Bcl2	B-GENE-Y
was	O
increased	O
.	O

DU	O
-	O
PM	O
cells	O
displayed	O
higher	O
sensitivity	O
to	O
ErbB1	B-GENE-Y
-	O
inhibitors	O
suggesting	O
possible	O
cross	O
-	O
talk	O
of	O
ErbB1	B-GENE-Y
and	O
ErbB3	B-GENE-Y
signaling	O
pathways	O
.	O

Combinations	O
of	O
elisidepsin	B-CHEMICAL
with	O
lapatinib	B-CHEMICAL
and	O
several	O
chemotherapies	O
including	O
5	B-CHEMICAL
-	I-CHEMICAL
FU	I-CHEMICAL
and	O
oxaliplatin	B-CHEMICAL
resulted	O
in	O
synergistic	O
effects	O
that	O
offer	O
the	O
potential	O
of	O
clinical	O
use	O
of	O
elisidepsin	B-CHEMICAL
in	O
combination	O
settings	O
.	O

Controlled	O
Assembly	O
of	O
Gold	O
Nanoparticles	O
through	O
Antibody	O
Recognition	O
:	O
Study	O
and	O
Utilizing	O
the	O
Effect	O
of	O
Particle	O
Size	O
on	O
Interparticle	O
Distance	O
.	O

An	O
assembly	O
of	O
gold	O
nanoparticle	O
through	O
the	O
recognition	O
of	O
unmodified	O
antibody	O
was	O
developed	O
.	O

The	O
use	O
of	O
peptide	O
(	O
Cys	B-CHEMICAL
-	I-CHEMICAL
Ala	I-CHEMICAL
-	I-CHEMICAL
Leu	I-CHEMICAL
-	I-CHEMICAL
Asn	I-CHEMICAL
-	I-CHEMICAL
Asn	I-CHEMICAL
)	O
as	O
ligands	O
to	O
stabilize	O
and	O
functionalize	O
gold	O
nanoparticles	O
provides	O
technical	O
and	O
operational	O
convenience	O
.	O

These	O
peptide	O
-	O
capped	O
particles	O
in	O
different	O
sizes	O
are	O
recognized	O
by	O
antibody	O
and	O
assembly	O
to	O
form	O
dimers	O
and	O
expanded	O
hybrid	O
material	O
by	O
controlling	O
the	O
conditions	O
.	O

The	O
interparticle	O
spacing	O
of	O
these	O
assemblies	O
was	O
well	O
studied	O
with	O
small	O
-	O
angle	O
X	O
-	O
ray	O
scattering	O
measurements	O
,	O
and	O
it	O
was	O
found	O
that	O
the	O
interparticle	O
spacing	O
is	O
inversely	O
dependent	O
on	O
the	O
particle	O
size	O
.	O

This	O
relationship	O
of	O
interparticle	O
spacing	O
and	O
particle	O
size	O
is	O
closely	O
related	O
to	O
the	O
structure	O
of	O
antibody	O
linker	O
.	O

Therefore	O
,	O
analyzing	O
the	O
interparticle	O
spacing	O
of	O
assemblies	O
can	O
reveal	O
the	O
equilibrium	O
configuration	O
of	O
IgG	B-GENE-N
.	O

Based	O
on	O
the	O
investigation	O
,	O
the	O
Fab	O
-	O
Fab	O
angle	O
of	O
IgG	B-GENE-N
is	O
obtained	O
to	O
be	O
	O
102	O
	O
and	O
the	O
Fab	O
arms	O
are	O
	O
7	O
.	O
8	O
nm	O
.	O

These	O
results	O
provide	O
new	O
experimental	O
data	O
on	O
the	O
structure	O
of	O
flexible	O
IgG	B-GENE-N
.	O

Differential	O
responses	O
to	O
	B-GENE-Y
-	I-GENE-Y
agatoxin	I-GENE-Y
IVA	I-GENE-Y
in	O
murine	O
frontal	O
cortex	O
and	O
spinal	O
cord	O
derived	O
neuronal	O
networks	O
.	O

	B-GENE-Y
-	I-GENE-Y
Agatoxin	I-GENE-Y
-	I-GENE-Y
IVA	I-GENE-Y
is	O
a	O
well	O
known	O
P	B-GENE-N
/	I-GENE-N
Q	I-GENE-N
-	I-GENE-N
type	I-GENE-N
Ca	I-GENE-N
(	I-GENE-N
2	I-GENE-N
+	I-GENE-N
)	I-GENE-N
channel	I-GENE-N
blocker	O
and	O
has	O
been	O
shown	O
to	O
affect	O
presynaptic	O
Ca	B-CHEMICAL
(	I-CHEMICAL
2	I-CHEMICAL
+	I-CHEMICAL
)	I-CHEMICAL
currents	O
as	O
well	O
postsynaptic	O
potentials	O
.	O

P	B-GENE-N
/	I-GENE-N
Q	I-GENE-N
-	I-GENE-N
type	I-GENE-N
voltage	I-GENE-N
gated	I-GENE-N
Ca	I-GENE-N
(	I-GENE-N
2	I-GENE-N
+	I-GENE-N
)	I-GENE-N
channels	I-GENE-N
play	O
a	O
vital	O
role	O
in	O
presynaptic	O
neurotransmitter	O
release	O
and	O
thus	O
play	O
a	O
role	O
in	O
action	O
potential	O
generation	O
.	O

Monitoring	O
spontaneous	O
activity	O
of	O
neuronal	O
networks	O
on	O
microelectrode	O
arrays	O
(	O
MEAs	O
)	O
provides	O
an	O
important	O
tool	O
for	O
examining	O
this	O
neurotoxin	O
.	O

Changes	O
in	O
extracellular	O
action	O
potentials	O
are	O
readily	O
observed	O
and	O
are	O
dependent	O
on	O
synaptic	O
function	O
.	O

Given	O
the	O
efficacy	O
of	O
murine	O
frontal	O
cortex	O
and	O
spinal	O
cord	O
networks	O
to	O
detect	O
neuroactive	O
substances	O
,	O
we	O
investigated	O
the	O
effects	O
of	O
	B-GENE-N
-	I-GENE-N
agatoxin	I-GENE-N
on	O
spontaneous	O
action	O
potential	O
firing	O
within	O
these	O
networks	O
.	O

We	O
found	O
that	O
networks	O
derived	O
from	O
spinal	O
cord	O
are	O
more	O
sensitive	O
to	O
the	O
toxin	O
than	O
those	O
from	O
frontal	O
cortex	O
;	O
a	O
concentration	O
of	O
only	O
10nM	O
produced	O
statistically	O
significant	O
effects	O
on	O
activity	O
from	O
spinal	O
cord	O
networks	O
whereas	O
50nM	O
was	O
required	O
to	O
alter	O
activity	O
in	O
frontal	O
cortex	O
networks	O
.	O

Furthermore	O
,	O
the	O
effects	O
of	O
the	O
toxin	O
on	O
frontal	O
cortex	O
are	O
more	O
complex	O
as	O
unit	O
specific	O
responses	O
were	O
observed	O
.	O

These	O
manifested	O
as	O
either	O
a	O
decrease	O
or	O
increase	O
in	O
action	O
potential	O
firing	O
rate	O
which	O
could	O
be	O
statistically	O
separated	O
as	O
unique	O
clusters	O
.	O

Administration	O
of	O
bicuculline	B-CHEMICAL
,	O
a	O
GABAA	B-GENE-N
inhibitor	O
,	O
isolated	O
a	O
single	O
response	O
to	O
	B-GENE-N
-	I-GENE-N
agatoxin	I-GENE-N
,	O
which	O
was	O
characterized	O
by	O
a	O
reduction	O
in	O
network	O
activity	O
.	O

These	O
data	O
support	O
the	O
notion	O
that	O
the	O
two	O
clusters	O
detected	O
with	O
	B-GENE-N
-	I-GENE-N
agatoxin	I-GENE-N
exposure	O
represent	O
differential	O
responses	O
from	O
excitatory	O
and	O
inhibitory	O
neuronal	O
populations	O
.	O

Pharmacokinetic	O
,	O
neurochemical	O
,	O
stereological	O
and	O
neuropathological	O
studies	O
on	O
the	O
potential	O
effects	O
of	O
paraquat	B-CHEMICAL
in	O
the	O
substantia	O
nigra	O
pars	O
compacta	O
and	O
striatum	O
of	O
male	O
C57BL	O
/	O
6J	O
mice	O
.	O

The	O
pharmacokinetics	O
and	O
neurotoxicity	O
of	O
paraquat	B-CHEMICAL
dichloride	I-CHEMICAL
(	O
PQ	O
)	O
were	O
assessed	O
following	O
once	O
weekly	O
administration	O
to	O
C57BL	O
/	O
6J	O
male	O
mice	O
by	O
intraperitoneal	O
injection	O
for	O
1	O
,	O
2	O
or	O
3	O
weeks	O
at	O
doses	O
of	O
10	O
,	O
15	O
or	O
25mg	O
/	O
kg	O
/	O
week	O
.	O

Approximately	O
0	O
.	O
3	O
%	O
of	O
the	O
administered	O
dose	O
was	O
taken	O
up	O
by	O
the	O
brain	O
and	O
was	O
slowly	O
eliminated	O
,	O
with	O
a	O
half	O
-	O
life	O
of	O
approximately	O
3	O
weeks	O
.	O

PQ	O
did	O
not	O
alter	O
the	O
concentration	O
of	O
dopamine	B-CHEMICAL
(	O
DA	O
)	O
,	O
homovanillic	B-CHEMICAL
acid	I-CHEMICAL
(	O
HVA	B-CHEMICAL
)	O
or	O
3	B-CHEMICAL
,	I-CHEMICAL
4	I-CHEMICAL
-	I-CHEMICAL
dihydroxyphenylacetic	I-CHEMICAL
acid	I-CHEMICAL
(	O
DOPAC	B-CHEMICAL
)	O
,	O
or	O
increase	O
dopamine	B-CHEMICAL
turnover	O
in	O
the	O
striatum	O
.	O

There	O
was	O
inconsistent	O
stereological	O
evidence	O
of	O
a	O
loss	O
of	O
DA	O
neurons	O
,	O
as	O
identified	O
by	O
chromogenic	O
or	O
fluorescent	O
-	O
tagged	O
antibodies	O
to	O
tyrosine	B-GENE-Y
hydroxylase	I-GENE-Y
in	O
the	O
substantia	O
nigra	O
pars	O
compacta	O
(	O
SNpc	O
)	O
.	O

There	O
was	O
no	O
evidence	O
that	O
PQ	O
induced	O
neuronal	O
degeneration	O
in	O
the	O
SNpc	O
or	O
degenerating	O
neuronal	O
processes	O
in	O
the	O
striatum	O
,	O
as	O
indicated	O
by	O
the	O
absence	O
of	O
uptake	O
of	O
silver	B-CHEMICAL
stain	O
or	O
reduced	O
immunolabeling	O
of	O
tyrosine	B-GENE-Y
-	I-GENE-Y
hydroxylase	I-GENE-Y
-	O
positive	O
(	O
TH	B-GENE-Y
(	O
+	O
)	O
)	O
neurons	O
.	O

There	O
was	O
no	O
evidence	O
of	O
apoptotic	O
cell	O
death	O
,	O
which	O
was	O
evaluated	O
using	O
TUNEL	O
or	O
caspase	B-GENE-Y
3	I-GENE-Y
assays	O
.	O

Microglia	O
(	O
IBA	O
-	O
1	O
immunoreactivity	O
)	O
and	O
astrocytes	O
(	O
GFAP	O
immunoreactivity	O
)	O
were	O
not	O
activated	O
in	O
PQ	O
-	O
treated	O
mice	O
4	O
,	O
8	O
,	O
16	O
,	O
24	O
,	O
48	O
,	O
96	O
or	O
168h	O
after	O
1	O
,	O
2	O
or	O
3	O
doses	O
of	O
PQ	O
.	O

In	O
contrast	O
,	O
mice	O
dosed	O
with	O
the	O
positive	O
control	O
substance	O
,	O
1	B-CHEMICAL
-	I-CHEMICAL
methyl	I-CHEMICAL
-	I-CHEMICAL
4	I-CHEMICAL
-	I-CHEMICAL
phenyl	I-CHEMICAL
-	I-CHEMICAL
1	I-CHEMICAL
,	I-CHEMICAL
2	I-CHEMICAL
,	I-CHEMICAL
3	I-CHEMICAL
,	I-CHEMICAL
6	I-CHEMICAL
-	I-CHEMICAL
tetrahydropyridine	I-CHEMICAL
(	O
MPTP	B-CHEMICAL
;	O
10mg	O
/	O
kg	O
/	O
dose	O
	O
4	O
doses	O
,	O
2h	O
apart	O
)	O
,	O
displayed	O
significantly	O
reduced	O
DA	O
and	O
DOPAC	B-CHEMICAL
concentrations	O
and	O
increased	O
DA	O
turnover	O
in	O
the	O
striatum	O
7	O
days	O
after	O
dosing	O
.	O

The	O
number	O
of	O
TH	B-GENE-Y
(	O
+	O
)	O
neurons	O
in	O
the	O
SNpc	O
was	O
reduced	O
,	O
and	O
there	O
were	O
increased	O
numbers	O
of	O
degenerating	O
neurons	O
and	O
neuronal	O
processes	O
in	O
the	O
SNpc	O
and	O
striatum	O
.	O

MPTP	B-CHEMICAL
-	O
mediated	O
cell	O
death	O
was	O
not	O
attributed	O
to	O
apoptosis	O
.	O

MPTP	B-CHEMICAL
activated	O
microglia	O
and	O
astrocytes	O
within	O
4h	O
of	O
the	O
last	O
dose	O
,	O
reaching	O
a	O
peak	O
within	O
48h	O
.	O

The	O
microglial	O
response	O
ended	O
by	O
96h	O
in	O
the	O
SNpc	O
,	O
but	O
the	O
astrocytic	O
response	O
continued	O
through	O
168h	O
in	O
the	O
striatum	O
.	O

These	O
results	O
bring	O
into	O
question	O
previous	O
published	O
stereological	O
studies	O
that	O
report	O
loss	O
of	O
TH	B-GENE-Y
(	O
+	O
)	O
neurons	O
in	O
the	O
SNpc	O
of	O
PQ	O
-	O
treated	O
mice	O
.	O

This	O
study	O
also	O
suggests	O
that	O
even	O
if	O
the	O
reduction	O
in	O
TH	B-GENE-Y
(	O
+	O
)	O
neurons	O
reported	O
by	O
others	O
occurs	O
in	O
PQ	O
-	O
treated	O
mice	O
,	O
this	O
apparent	O
phenotypic	O
change	O
is	O
unaccompanied	O
by	O
neuronal	O
cell	O
death	O
or	O
by	O
modification	O
of	O
dopamine	B-CHEMICAL
levels	O
in	O
the	O
striatum	O
.	O

FGFR4	B-GENE-Y
genetic	O
polymorphisms	O
determine	O
the	O
chemotherapy	O
response	O
of	O
Chinese	O
patients	O
with	O
non	O
-	O
small	O
cell	O
lung	O
cancer	O
.	O

Aim	O
:	O
To	O
investigate	O
the	O
relationship	O
of	O
fibroblast	B-GENE-Y
growth	I-GENE-Y
factor	I-GENE-Y
receptor	I-GENE-Y
4	I-GENE-Y
(	O
FGFR4	B-GENE-Y
)	O
gene	O
polymorphisms	O
with	O
the	O
response	O
of	O
Chinese	O
patients	O
with	O
non	O
-	O
small	O
cell	O
lung	O
cancer	O
(	O
NSCLC	O
)	O
to	O
chemotherapy	O
.	O
Methods	O
:	O
A	O
total	O
of	O
629	O
patients	O
with	O
Stage	O
III	O
(	O
A	O
+	O
B	O
)	O
or	O
IV	O
NSCLC	O
,	O
as	O
well	O
as	O
729	O
age	O
-	O
and	O
gender	O
-	O
matched	O
healthy	O
controls	O
were	O
recruited	O
.	O

All	O
the	O
patients	O
received	O
platinum	B-CHEMICAL
-	O
based	O
chemotherapy	O
,	O
and	O
the	O
therapeutic	O
effects	O
were	O
evaluated	O
.	O

Three	O
polymorphisms	O
in	O
the	O
FGFR4	B-GENE-Y
gene	O
(	O
rs351855G	O
/	O
A	O
,	O
rs145302848C	O
/	O
G	O
,	O
and	O
rs147603016G	O
/	O
A	O
)	O
were	O
genotyped	O
,	O
and	O
the	O
association	O
between	O
the	O
3	O
polymorphisms	O
and	O
the	O
chemotherapy	O
effect	O
was	O
analyzed	O
using	O
SPSS	O
software	O
,	O
version	O
16	O
.	O
0	O
.	O
Results	O
:	O
The	O
genotype	O
frequencies	O
of	O
rs145302848C	O
/	O
G	O
and	O
rs147603016G	O
/	O
A	O
were	O
not	O
significantly	O
different	O
between	O
NSCLC	O
patients	O
and	O
healthy	O
controls	O
on	O
one	O
hand	O
,	O
and	O
between	O
the	O
responders	O
and	O
non	O
-	O
responders	O
to	O
the	O
chemotherapy	O
on	O
the	O
other	O
hand	O
.	O

The	O
distribution	O
of	O
AA	O
genotype	O
and	O
A	O
-	O
allele	O
of	O
rs351855G	O
/	O
A	O
was	O
significantly	O
lower	O
in	O
NSCLC	O
patients	O
than	O
in	O
healthy	O
controls	O
.	O

Using	O
patients	O
with	O
the	O
GG	O
genotype	O
as	O
a	O
reference	O
,	O
the	O
AA	O
carrier	O
had	O
a	O
significantly	O
reduced	O
risk	O
for	O
the	O
development	O
of	O
NSCLC	O
after	O
normalizing	O
to	O
age	O
,	O
sex	O
and	O
smoking	O
habits	O
.	O

In	O
NSCLC	O
patients	O
,	O
this	O
genotype	O
occurred	O
more	O
frequently	O
in	O
the	O
responders	O
to	O
the	O
chemotherapy	O
than	O
in	O
non	O
-	O
responders	O
.	O

The	O
chance	O
of	O
being	O
a	O
responder	O
was	O
significantly	O
increased	O
with	O
the	O
AA	O
genotype	O
as	O
compared	O
to	O
G	O
genotype	O
.	O

The	O
AA	O
genotype	O
of	O
rs351855G	O
/	O
A	O
had	O
a	O
better	O
prognosis	O
compared	O
with	O
GA	O
and	O
GG	O
genotype	O
carriers	O
:	O
the	O
overall	O
survival	O
of	O
patients	O
with	O
the	O
AA	O
genotype	O
of	O
rs351855G	O
/	O
A	O
was	O
significantly	O
longer	O
than	O
those	O
with	O
the	O
GG	O
+	O
GA	O
genotype	O
(	O
21	O
.	O
1	O
vs	O
16	O
.	O
5	O
months	O
)	O
.	O
Conclusion	O
:	O
The	O
rs351855G	O
/	O
A	O
polymorphisms	O
of	O
FGFR4	B-GENE-Y
gene	O
can	O
be	O
used	O
to	O
predict	O
the	O
occurrence	O
,	O
chemotherapy	O
response	O
and	O
prognosis	O
of	O
NSCLC	O
.	O

NMR	O
characterisation	O
of	O
dynamics	O
in	O
solvates	O
and	O
desolvates	O
of	O
formoterol	B-CHEMICAL
fumarate	I-CHEMICAL
.	O

Solid	O
-	O
state	O
NMR	O
is	O
used	O
to	O
characterise	O
dynamics	O
in	O
the	O
ethanol	B-CHEMICAL
solvate	O
of	O
the	O
pharmaceutical	O
material	O
formoterol	B-CHEMICAL
fumarate	I-CHEMICAL
and	O
its	O
associated	O
desolvate	O
.	O

Jump	O
rates	O
and	O
activation	O
barriers	O
for	O
dynamic	O
processes	O
such	O
as	O
phenyl	B-CHEMICAL
ring	O
rotation	O
and	O
methyl	B-CHEMICAL
group	O
rotational	O
diffusion	O
are	O
derived	O
from	O
1D	O
-	O
EXSY	O
and	O
(	B-CHEMICAL
13	I-CHEMICAL
)	I-CHEMICAL
C	I-CHEMICAL
spin	O
-	O
lattice	O
relaxation	O
times	O
respectively	O
.	O

(	B-CHEMICAL
2	I-CHEMICAL
)	I-CHEMICAL
H	I-CHEMICAL
and	O
(	B-CHEMICAL
13	I-CHEMICAL
)	I-CHEMICAL
C	I-CHEMICAL
spin	O
-	O
lattice	O
relaxation	O
times	O
measured	O
under	O
magic	O
-	O
angle	O
spinning	O
conditions	O
are	O
used	O
to	O
show	O
that	O
the	O
fumarate	B-CHEMICAL
ion	O
in	O
the	O
desolvate	O
is	O
undergoing	O
small	O
-	O
amplitude	O
motion	O
on	O
a	O
frequency	O
scale	O
of	O
100s	O
of	O
MHz	O
at	O
ambient	O
temperature	O
with	O
an	O
activation	O
parameter	O
of	O
about	O
32	O
kJ	O
mol	O
(	O
-	O
1	O
)	O
.	O

Exact	O
calculations	O
of	O
relaxation	O
times	O
under	O
MAS	O
provide	O
a	O
simple	O
and	O
robust	O
means	O
to	O
test	O
motional	O
models	O
in	O
cases	O
where	O
relaxation	O
rate	O
maxima	O
are	O
observed	O
,	O
including	O
for	O
systems	O
where	O
the	O
crystal	O
structure	O
of	O
the	O
material	O
is	O
unknown	O
.	O

tert	B-CHEMICAL
-	I-CHEMICAL
Butylcarbamate	I-CHEMICAL
-	O
Containing	O
Histone	B-GENE-N
Deacetylase	I-GENE-N
Inhibitors	O
:	O
Apoptosis	O
Induction	O
,	O
Cytodifferentiation	O
,	O
and	O
Antiproliferative	O
Activities	O
in	O
Cancer	O
Cells	O
.	O

Herein	O
we	O
report	O
novel	O
pyrrole	B-CHEMICAL
-	O
and	O
benzene	B-CHEMICAL
-	O
based	O
hydroxamates	B-CHEMICAL
(	O
8	O
,	O
10	O
)	O
and	O
2	B-CHEMICAL
'	I-CHEMICAL
-	I-CHEMICAL
aminoanilides	I-CHEMICAL
(	O
9	O
,	O
11	O
)	O
bearing	O
the	O
tert	B-CHEMICAL
-	I-CHEMICAL
butylcarbamate	I-CHEMICAL
group	O
at	O
the	O
CAP	O
moiety	O
as	O
histone	B-GENE-N
deacetylase	I-GENE-N
(	O
HDAC	B-GENE-N
)	O
inhibitors	O
.	O

Compounds	O
8	O
b	O
and	O
10	O
c	O
selectively	O
inhibited	O
HDAC6	B-GENE-Y
at	O
the	O
nanomolar	O
level	O
,	O
whereas	O
the	O
other	O
hydroxamates	B-CHEMICAL
effected	O
an	O
increase	O
in	O
acetyl	B-GENE-N
-	I-GENE-N
	I-GENE-N
-	I-GENE-N
tubulin	I-GENE-N
levels	O
in	O
human	O
acute	O
myeloid	O
leukemia	O
U937	O
cells	O
.	O

In	O
the	O
same	O
cell	O
line	O
,	O
compounds	O
8	O
b	O
and	O
10	O
c	O
elicited	O
18	O
.	O
4	O
and	O
21	O
.	O
4	O
%	O
apoptosis	O
,	O
respectively	O
(	O
SAHA	B-CHEMICAL
:	O
16	O
.	O
9	O
%	O
)	O
,	O
and	O
the	O
pyrrole	B-CHEMICAL
anilide	I-CHEMICAL
9	O
c	O
displayed	O
the	O
highest	O
cytodifferentiating	O
effect	O
(	O
90	O
.	O
9	O
%	O
)	O
.	O

In	O
tests	O
against	O
a	O
wide	O
range	O
of	O
various	O
cancer	O
cell	O
lines	O
to	O
determine	O
its	O
antiproliferative	O
effects	O
,	O
compound	O
10	O
c	O
exhibited	O
growth	O
inhibition	O
from	O
sub	O
-	O
micromolar	O
(	O
neuroblastoma	O
LAN	O
-	O
5	O
and	O
SH	O
-	O
SY5Y	O
cells	O
,	O
chronic	O
myeloid	O
leukemia	O
K562	O
cells	O
)	O
to	O
low	O
-	O
micromolar	O
(	O
lung	O
H1299	O
and	O
A549	O
,	O
colon	O
HCT116	O
and	O
HT29	O
cancer	O
cells	O
)	O
concentrations	O
.	O

In	O
HT29	O
cells	O
,	O
10	O
c	O
increased	O
histone	B-GENE-N
H3	I-GENE-N
acetylation	O
,	O
and	O
decreased	O
the	O
colony	O
-	O
forming	O
potential	O
of	O
the	O
cancer	O
cells	O
by	O
up	O
to	O
60	O
%	O
.	O

Discovery	O
of	O
a	O
synthetic	O
Aminopeptidase	B-GENE-Y
N	I-GENE-Y
inhibitor	O
LB	B-CHEMICAL
-	I-CHEMICAL
4b	I-CHEMICAL
as	O
a	O
potential	O
anticancer	O
agent	O
.	O

APN	B-GENE-Y
inhibitors	O
have	O
been	O
considered	O
as	O
potential	O
anticancer	O
agents	O
for	O
years	O
.	O

LB	B-CHEMICAL
-	I-CHEMICAL
4b	I-CHEMICAL
is	O
the	O
first	O
synthetic	O
APN	B-GENE-Y
inhibitor	O
to	O
be	O
evaluated	O
for	O
both	O
of	O
its	O
anti	O
-	O
invasion	O
and	O
anti	O
-	O
angiogenesis	O
effects	O
.	O

As	O
a	O
potent	O
synthetic	O
APN	B-GENE-Y
inhibitor	O
(	O
IC50	O
=	O
850nM	O
,	O
versus	O
bestatin	B-CHEMICAL
of	O
8	O
.	O
1M	O
)	O
,	O
LB	B-CHEMICAL
-	I-CHEMICAL
4b	I-CHEMICAL
was	O
determined	O
to	O
have	O
more	O
significant	O
block	O
effects	O
to	O
cancer	O
cell	O
invasion	O
and	O
angiogenesis	O
than	O
bestatin	B-CHEMICAL
.	O

Besides	O
,	O
it	O
is	O
able	O
to	O
be	O
easily	O
synthesized	O
with	O
a	O
high	O
total	O
yield	O
,	O
while	O
the	O
reported	O
synthetic	O
methods	O
of	O
bestatin	B-CHEMICAL
are	O
much	O
more	O
complex	O
.	O

Multipart	O
Copolyelectrolyte	O
Adhesive	O
of	O
the	O
Sandcastle	O
Worm	O
,	O
Phragmatopoma	O
californica	O
(	O
Fewkes	O
)	O
:	O
Catechol	B-GENE-N
Oxidase	I-GENE-N
Catalyzed	O
Curing	O
through	O
Peptidyl	O
-	O
DOPA	B-CHEMICAL
.	O

Tube	O
-	O
building	O
sabellariid	O
polychaetes	O
have	O
major	O
impacts	O
on	O
the	O
geology	O
and	O
ecology	O
of	O
shorelines	O
worldwide	O
.	O

Sandcastle	O
worms	O
,	O
Phragmatopoma	O
californica	O
(	O
Fewkes	O
)	O
,	O
live	O
along	O
the	O
western	O
coast	O
of	O
North	O
America	O
.	O

Individual	O
sabellariid	O
worms	O
build	O
tubular	O
shells	O
by	O
gluing	O
together	O
mineral	O
particles	O
with	O
a	O
multipart	O
polyelectrolytic	O
adhesive	O
.	O

Distinct	O
sets	O
of	O
oppositely	O
charged	O
components	O
are	O
packaged	O
and	O
stored	O
in	O
concentrated	O
granules	O
in	O
separate	O
cell	O
types	O
.	O

Homogeneous	O
granules	O
contain	O
sulfated	O
macromolecules	O
as	O
counter	O
-	O
polyanion	O
to	O
polycationic	O
Pc2	B-GENE-Y
and	O
Pc5	B-GENE-N
proteins	O
,	O
which	O
become	O
major	O
components	O
of	O
the	O
fully	O
cured	O
glue	O
.	O

Heterogeneous	O
granules	O
contain	O
polyphosphoproteins	O
,	O
Pc3A	B-GENE-N
/	I-GENE-N
B	I-GENE-N
,	O
paired	O
with	O
divalent	O
cations	O
and	O
polycationic	O
Pc1	B-GENE-Y
and	O
Pc4	B-GENE-N
proteins	O
.	O

Both	O
types	O
of	O
granules	O
contain	O
catechol	B-GENE-N
oxidase	I-GENE-N
that	O
catalyzes	O
oxidative	O
cross	O
-	O
linking	O
of	O
L	B-CHEMICAL
-	I-CHEMICAL
DOPA	I-CHEMICAL
.	O

Co	O
-	O
secretion	O
of	O
catechol	B-GENE-N
oxidase	I-GENE-N
guarantees	O
rapid	O
and	O
spatially	O
homogeneous	O
curing	O
with	O
limited	O
mixing	O
of	O
the	O
preassembled	O
adhesive	O
packets	O
.	O

Catechol	B-GENE-N
oxidase	I-GENE-N
remains	O
active	O
long	O
after	O
the	O
glue	O
is	O
fully	O
cured	O
,	O
perhaps	O
providing	O
an	O
active	O
cue	O
for	O
conspecific	O
larval	O
settlement	O
.	O

Disruption	O
of	O
AtWNK8	B-GENE-Y
Enhances	O
Tolerance	O
of	O
Arabidopsis	O
to	O
Salt	O
and	O
Osmotic	O
Stresses	O
via	O
Modulating	O
Proline	B-CHEMICAL
Content	O
and	O
Activities	O
of	O
Catalase	B-GENE-N
and	O
Peroxidase	B-GENE-N
.	O

With	B-GENE-N
no	I-GENE-N
lysine	I-GENE-N
kinases	I-GENE-N
(	O
WNKs	B-GENE-N
)	O
play	O
important	O
roles	O
in	O
plant	O
growth	O
and	O
development	O
.	O

However	O
,	O
its	O
role	O
in	O
salt	O
and	O
osmotic	O
stress	O
tolerance	O
is	O
unclear	O
.	O

Here	O
,	O
we	O
report	O
that	O
AtWNK8	B-GENE-Y
is	O
mainly	O
expressed	O
in	O
primary	O
root	O
,	O
hypocotyl	O
,	O
stamen	O
and	O
pistil	O
and	O
is	O
induced	O
by	O
NaCl	B-CHEMICAL
and	O
sorbitol	B-CHEMICAL
treatment	O
.	O

Compared	O
to	O
the	O
wild	O
-	O
type	O
,	O
the	O
T	O
-	O
DNA	O
knock	O
-	O
out	O
wnk8	B-GENE-Y
mutant	O
was	O
more	O
tolerant	O
to	O
severe	O
salinity	O
and	O
osmotic	O
stresses	O
,	O
as	O
indicated	O
by	O
27	O
%	O
and	O
198	O
%	O
more	O
fresh	O
weight	O
in	O
the	O
NaCl	B-CHEMICAL
and	O
sorbitol	B-CHEMICAL
treatment	O
,	O
respectively	O
.	O

The	O
wnk8	B-GENE-Y
mutant	O
also	O
accumulated	O
1	O
.	O
43	O
-	O
fold	O
more	O
proline	B-CHEMICAL
than	O
the	O
wild	O
-	O
type	O
in	O
the	O
sorbitol	B-CHEMICAL
treatment	O
.	O

Under	O
NaCl	B-CHEMICAL
and	O
sorbitol	B-CHEMICAL
stresses	O
,	O
catalase	B-GENE-N
(	O
CAT	B-GENE-N
)	O
activity	O
in	O
wnk8	B-GENE-Y
mutant	O
was	O
1	O
.	O
92	O
-	O
and	O
3	O
.	O
7	O
-	O
times	O
of	O
that	O
in	O
Col	O
-	O
0	O
,	O
respectively	O
.	O

Similarly	O
,	O
under	O
salt	O
and	O
osmotic	O
stress	O
conditions	O
,	O
peroxidase	B-GENE-N
(	O
POD	B-GENE-N
)	O
activities	O
in	O
wnk8	B-GENE-Y
mutant	O
were	O
1	O
.	O
81	O
-	O
and	O
1	O
.	O
58	O
-	O
times	O
of	O
that	O
in	O
Col	O
-	O
0	O
,	O
respectively	O
.	O

Taken	O
together	O
,	O
we	O
revealed	O
that	O
maintaining	O
higher	O
CAT	B-GENE-N
and	O
POD	B-GENE-N
activities	O
might	O
be	O
one	O
of	O
the	O
reasons	O
that	O
the	O
disruption	O
of	O
AtWNK8	B-GENE-Y
enhances	O
the	O
tolerance	O
to	O
salt	O
stress	O
,	O
and	O
accumulating	O
more	O
proline	B-CHEMICAL
and	O
higher	O
activities	O
of	O
CAT	B-GENE-N
and	O
POD	B-GENE-N
might	O
result	O
in	O
the	O
higher	O
tolerance	O
of	O
WNK8	B-GENE-Y
to	O
osmotic	O
stress	O
.	O

Neuroprotective	O
Effects	O
of	O
Cilostazol	B-CHEMICAL
on	O
Retinal	O
Ganglion	O
Cell	O
damage	O
in	O
Diabetic	O
Rats	O
.	O

Neurodegeneration	O
is	O
an	O
important	O
component	O
of	O
diabetic	O
retinopathy	O
with	O
increasing	O
evidence	O
that	O
retinal	O
ganglion	O
cell	O
(	O
RGC	O
)	O
death	O
occurs	O
early	O
in	O
diabetes	O
.	O

We	O
investigated	O
the	O
effects	O
of	O
cilostazol	B-CHEMICAL
,	O
which	O
has	O
been	O
widely	O
used	O
to	O
manage	O
diabetic	O
complications	O
,	O
on	O
retinal	O
ganglion	O
cell	O
death	O
in	O
diabetic	O
retina	O
.	O

Four	O
-	O
week	O
-	O
old	O
Otsuka	O
Long	O
-	O
Evans	O
Tokushima	O
Fatty	O
(	O
OLETF	O
)	O
rats	O
and	O
Long	O
-	O
Evans	O
Tokushima	O
Otsuka	O
(	O
LETO	O
)	O
rats	O
as	O
matched	O
nondiabetic	O
controls	O
were	O
treated	O
with	O
daily	O
oral	O
cilostazol	B-CHEMICAL
at	O
30mg	O
/	O
kg	O
or	O
0	O
.	O
9	O
%	O
saline	O
solution	O
.	O

In	O
OLETF	O
rats	O
at	O
the	O
age	O
of	O
40	O
weeks	O
,	O
glial	B-GENE-Y
fibrillary	I-GENE-Y
acidic	I-GENE-Y
protein	I-GENE-Y
(	O
GFAP	B-GENE-Y
)	O
immunofluorescence	O
staining	O
was	O
upregulated	O
in	O
vertical	O
sections	O
and	O
showed	O
a	O
more	O
ramified	O
pattern	O
in	O
whole	O
-	O
mount	O
retinas	O
compared	O
with	O
that	O
in	O
LETO	O
rats	O
.	O

Vascular	B-GENE-Y
endothelial	I-GENE-Y
growth	I-GENE-Y
factor	I-GENE-Y
(	O
VEGF	B-GENE-Y
)	O
expression	O
was	O
limited	O
to	O
the	O
ganglion	O
cell	O
layer	O
in	O
LETO	O
rats	O
,	O
but	O
extended	O
into	O
the	O
outer	O
plexiform	O
layer	O
in	O
OLETF	O
rats	O
.	O

Immunofluorescence	O
staining	O
and	O
western	O
blotting	O
demonstrated	O
that	O
cilostazol	B-CHEMICAL
treatment	O
reduced	O
GFAP	B-GENE-Y
and	O
VEGF	B-GENE-Y
expression	O
in	O
the	O
retinas	O
of	O
OLETF	O
rats	O
.	O

Terminal	O
deoxynucleotidyl	O
transferase	O
-	O
mediated	O
dUTP	B-CHEMICAL
nick	O
-	O
end	O
labeling	O
(	O
TUNLEL	O
)	O
staining	O
revealed	O
an	O
increase	O
in	O
the	O
RGC	O
layer	O
in	O
OLETF	O
compared	O
with	O
LETO	O
rats	O
(	O
P	O
<	O
0	O
.	O
05	O
)	O
,	O
and	O
cilostazol	B-CHEMICAL
treatment	O
reduced	O
the	O
number	O
of	O
TUNEL	O
-	O
positive	O
cells	O
in	O
OLETF	O
rats	O
(	O
P	O
<	O
0	O
.	O
05	O
)	O
.	O

Relieving	O
retinal	O
ischemia	O
by	O
systemic	O
cilostazol	B-CHEMICAL
treatment	O
had	O
a	O
noticeable	O
protective	O
effect	O
on	O
RGCs	O
in	O
diabetic	O
rats	O
.	O

Cilostazol	B-CHEMICAL
treatment	O
may	O
be	O
useful	O
for	O
the	O
management	O
of	O
diabetic	O
retinal	O
vascular	O
dysfunction	O
and	O
neuronal	O
degeneration	O
.	O

Effects	O
of	O
lactational	O
and	O
/	O
or	O
in	O
utero	O
exposure	O
to	O
environmental	O
contaminants	O
on	O
the	O
glucocorticoid	O
stress	O
-	O
response	O
and	O
DNA	O
methylation	O
of	O
the	O
glucocorticoid	B-GENE-N
receptor	I-GENE-N
promoter	I-GENE-N
in	O
male	O
rats	O
.	O

Perinatal	O
events	O
can	O
reprogram	O
the	O
hypothalamo	O
-	O
pituitary	O
-	O
adrenal	O
axis	O
for	O
the	O
entire	O
lifespan	O
leading	O
to	O
abnormal	O
glucocorticoid	O
stress	O
-	O
response	O
(	O
GSR	O
)	O
in	O
adulthood	O
:	O
a	O
phenomenon	O
reported	O
to	O
be	O
mediated	O
by	O
changes	O
in	O
DNA	O
methylation	O
of	O
the	O
glucocorticoid	B-GENE-N
receptor	I-GENE-N
(	I-GENE-N
GR	I-GENE-N
)	I-GENE-N
gene	I-GENE-N
promoter	I-GENE-N
.	O

We	O
examined	O
whether	O
in	O
utero	O
and	O
/	O
or	O
lactational	O
exposure	O
to	O
mixtures	O
of	O
environmental	O
contaminants	O
can	O
also	O
induce	O
abnormal	O
GSR	O
during	O
adulthood	O
.	O

The	O
experiment	O
included	O
nine	O
treatment	O
groups	O
.	O

From	O
gestation	O
day	O
(	O
GD	O
)	O
0	O
until	O
postnatal	O
day	O
(	O
PND	O
)	O
20	O
,	O
dams	O
were	O
fed	O
daily	O
with	O
a	O
cookie	O
laced	O
with	O
corn	O
oil	O
(	O
control	O
)	O
or	O
a	O
chemical	O
mixture	O
(	O
M	O
)	O
[	O
polychlorinated	B-CHEMICAL
biphenyls	I-CHEMICAL
(	O
PCBs	B-CHEMICAL
)	O
,	O
organochlorine	B-CHEMICAL
pesticides	O
,	O
and	O
methylmercury	B-CHEMICAL
]	O
at	O
0	O
.	O
5	O
or	O
1	O
.	O
0mg	O
/	O
kg	O
/	O
day	O
(	O
0	O
.	O
5M	O
,	O
and	O
M	O
)	O
.	O

At	O
birth	O
,	O
some	O
control	O
(	O
C	O
)	O
and	O
M	O
litters	O
were	O
cross	O
-	O
fostered	O
to	O
create	O
four	O
groups	O
with	O
the	O
following	O
in	O
utero	O
/	O
postnatal	O
exposure	O
:	O
C	O
/	O
C	O
,	O
M	O
/	O
C	O
,	O
C	O
/	O
M	O
,	O
M	O
/	O
M	O
.	O

Other	O
dams	O
received	O
1	O
.	O
8ng	O
/	O
kg	O
/	O
day	O
of	O
a	O
mixture	O
of	O
aryl	B-GENE-Y
hydrocarbon	I-GENE-Y
receptor	I-GENE-Y
(	O
AhR	B-GENE-Y
)	O
agonists	O
(	O
non	B-CHEMICAL
-	I-CHEMICAL
ortho	I-CHEMICAL
PCBs	I-CHEMICAL
,	O
PC	B-CHEMICAL
-	I-CHEMICAL
dibenzodioxins	I-CHEMICAL
and	O
PC	B-CHEMICAL
-	I-CHEMICAL
dibenzofurans	I-CHEMICAL
)	O
without	O
or	O
with	O
0	O
.	O
5M	O
(	O
0	O
.	O
5MAhR	B-GENE-Y
)	O
.	O

In	O
adult	O
male	O
offspring	O
the	O
abundance	O
of	O
GR	B-GENE-Y
in	O
treated	O
groups	O
was	O
not	O
different	O
from	O
the	O
control	O
,	O
but	O
the	O
AhR	B-GENE-Y
and	O
M	O
groups	O
were	O
significantly	O
different	O
from	O
each	O
other	O
with	O
opposite	O
effects	O
in	O
the	O
hippocampus	O
and	O
liver	O
.	O

There	O
was	O
no	O
change	O
in	O
DNA	O
methylation	O
of	O
the	O
GR	B-GENE-N
promoter	I-GENE-N
(	O
exon	O
-	O
17	O
and	O
-	O
110	O
)	O
.	O

Abnormal	O
GSRs	O
were	O
detected	O
in	O
the	O
AhR	B-GENE-Y
,	O
0	O
.	O
5MAhR	B-GENE-Y
,	O
CM	O
,	O
and	O
MM	O
groups	O
.	O

The	O
literature	O
associates	O
abnormal	O
GSR	O
with	O
metabolic	O
and	O
mental	O
health	O
impairments	O
,	O
thus	O
these	O
results	O
support	O
further	O
investigation	O
of	O
the	O
influence	O
of	O
developmental	O
exposure	O
to	O
environmental	O
contaminants	O
and	O
predisposition	O
to	O
stress	O
-	O
induced	O
diseases	O
.	O

Systematic	O
evaluation	O
of	O
640	O
FDA	O
drugs	O
for	O
their	O
effect	O
on	O
CD4	O
(	O
+	O
)	O
Foxp3	B-GENE-Y
(	O
+	O
)	O
regulatory	O
T	O
cells	O
using	O
a	O
novel	O
cell	O
-	O
based	O
high	O
throughput	O
screening	O
assay	O
.	O

Regulatory	O
T	O
cells	O
(	O
Treg	O
)	O
,	O
which	O
play	O
a	O
pivotal	O
role	O
in	O
maintaining	O
immune	O
homeostasis	O
by	O
suppressing	O
the	O
proliferation	O
of	O
effector	O
T	O
cells	O
,	O
have	O
great	O
therapeutic	O
potential	O
for	O
autoimmune	O
diseases	O
and	O
transplantation	O
.	O

However	O
,	O
progress	O
on	O
their	O
clinical	O
application	O
has	O
been	O
hampered	O
by	O
the	O
lack	O
of	O
high	O
throughput	O
screening	O
(	O
HTS	O
)	O
strategies	O
for	O
the	O
systematic	O
and	O
rapid	O
evaluation	O
of	O
existing	O
drugs	O
and	O
the	O
identification	O
of	O
novel	O
drug	O
candidates	O
.	O

In	O
this	O
report	O
,	O
we	O
present	O
an	O
innovative	O
in	O
vitro	O
HTS	O
assay	O
using	O
CD4	O
(	O
+	O
)	O
T	O
cells	O
from	O
Foxp3	B-GENE-Y
-	O
GFP	O
transgenic	O
mice	O
that	O
specifically	O
express	O
the	O
GFP	O
signal	O
in	O
Foxp3	B-GENE-Y
(	O
+	O
)	O
Treg	O
cells	O
detectable	O
by	O
FACS	O
analysis	O
in	O
a	O
high	O
throughput	O
manner	O
.	O

Systematic	O
evaluation	O
of	O
640	O
FDA	O
-	O
approved	O
drugs	O
revealed	O
that	O
70	O
drugs	O
increased	O
the	O
number	O
of	O
Treg	O
cells	O
with	O
suppression	O
function	O
only	O
in	O
the	O
presence	O
of	O
TGF	B-GENE-Y
,	O
75	O
drugs	O
increased	O
Treg	O
numbers	O
even	O
in	O
the	O
absence	O
of	O
TGF	B-GENE-Y
,	O
and	O
32	O
drugs	O
increased	O
Treg	O
numbers	O
synergistically	O
with	O
TGF	B-GENE-Y
.	O

The	O
identified	O
Treg	O
-	O
promoting	O
drugs	O
include	O
those	O
previously	O
known	O
to	O
induce	O
Treg	O
(	O
rapamycin	B-CHEMICAL
and	O
retinoic	B-CHEMICAL
acid	I-CHEMICAL
)	I-CHEMICAL
,	O
statins	O
,	O
glucocorticoids	O
and	O
drugs	O
in	O
many	O
other	O
categories	O
.	O

Furthermore	O
,	O
Treg	O
cells	O
cultured	O
with	O
the	O
identified	O
drugs	O
possess	O
surface	O
and	O
intracellular	O
markers	O
characteristic	O
of	O
natural	O
Treg	O
cells	O
and	O
possess	O
suppressive	O
function	O
.	O

These	O
results	O
suggest	O
that	O
this	O
Treg	O
HTS	O
assay	O
can	O
be	O
used	O
to	O
screen	O
compound	O
libraries	O
to	O
identify	O
novel	O
chemical	O
entities	O
for	O
Treg	O
-	O
based	O
immune	O
therapies	O
.	O

EZETIMIBE	B-CHEMICAL
INCREASES	O
HEPATIC	O
IRON	B-CHEMICAL
LEVELS	O
IN	O
MICE	O
FED	O
A	O
HIGH	O
-	O
FAT	O
DIET	O
.	O

Accumulating	O
evidence	O
suggests	O
that	O
ezetimibe	B-CHEMICAL
may	O
be	O
a	O
promising	O
agent	O
for	O
treatment	O
of	O
non	O
-	O
alcoholic	O
fatty	O
liver	O
disease	O
and	O
steatohepatitis	O
(	O
NAFLD	O
/	O
NASH	O
)	O
.	O

Phlebotomy	O
and	O
dietary	O
iron	B-CHEMICAL
restriction	O
reduces	O
serum	B-GENE-N
transaminase	I-GENE-N
in	O
NAFLD	O
/	O
NASH	O
patients	O
.	O

Recent	O
studies	O
showed	O
that	O
mutual	O
effects	O
exist	O
between	O
lipid	O
metabolism	O
and	O
iron	B-CHEMICAL
metabolism	O
.	O

Accordingly	O
,	O
the	O
effects	O
of	O
ezetimibe	B-CHEMICAL
on	O
iron	B-CHEMICAL
metabolism	O
were	O
examined	O
in	O
mice	O
fed	O
a	O
high	O
-	O
fat	O
diet	O
with	O
or	O
without	O
iron	B-CHEMICAL
.	O

C57BL	O
/	O
6	O
mice	O
were	O
fed	O
the	O
following	O
diets	O
for	O
12	O
weeks	O
.	O

Experiment	O
1	O
:	O
1	O
)	O
a	O
control	O
diet	O
;	O
C	O
2	O
)	O
C	O
plus	O
ezetimibe	B-CHEMICAL
(	O
0	O
.	O
3mg	O
/	O
day	O
;	O
4	O
weeks	O
)	O
;	O
CE	O
3	O
)	O
a	O
high	O
-	O
fat	O
diet	O
;	O
H	O
4	O
)	O
H	O
plus	O
ezetimibe	B-CHEMICAL
;	O
HE	O
.	O

Experiment	O
2	O
:	O
1	O
)	O
C	O
containing	O
carbonyl	B-CHEMICAL
iron	I-CHEMICAL
(	O
average	O
;	O
22	O
.	O
4mg	O
/	O
day	O
;	O
6	O
weeks	O
)	O
;	O
CI	O
2	O
)	O
CI	O
plus	O
ezetimibe	B-CHEMICAL
;	O
CIE	O
3	O
)	O
H	O
containing	O
carbonyl	B-CHEMICAL
iron	I-CHEMICAL
;	O
HI	O
4	O
)	O
HI	O
plus	O
ezetimibe	B-CHEMICAL
;	O
HIE	O
.	O

Blood	O
,	O
livers	O
,	O
and	O
duodenum	O
were	O
removed	O
after	O
12	O
weeks	O
.	O

In	O
Experiment	O
1	O
,	O
hepatic	O
iron	B-CHEMICAL
levels	O
were	O
higher	O
in	O
HE	O
than	O
H	O
,	O
whereas	O
there	O
was	O
no	O
difference	O
between	O
C	O
and	O
CE	O
.	O

Hepatic	O
mRNA	O
expression	O
of	O
transferrin	B-GENE-N
receptor	I-GENE-N
1	I-GENE-N
and	I-GENE-N
2	I-GENE-N
,	O
ferritins	B-GENE-N
,	O
and	O
hepcidin	B-GENE-Y
were	O
increased	O
more	O
in	O
CE	O
than	O
C	O
,	O
and	O
in	O
HE	O
than	O
H	O
.	O

In	O
duodenum	O
,	O
DMT1	B-GENE-Y
,	O
ferritinH	B-GENE-Y
,	O
and	O
hephaestin	B-GENE-Y
mRNA	O
levels	O
were	O
increased	O
in	O
CE	O
compared	O
to	O
C	O
.	O

In	O
Experiment	O
2	O
,	O
hepatic	O
iron	B-CHEMICAL
concentrations	O
were	O
higher	O
in	O
HIE	O
than	O
HI	O
.	O

Hepatic	O
mRNA	O
expression	O
of	O
ferritinL	B-GENE-Y
and	O
hepcidin	B-GENE-Y
were	O
increased	O
in	O
HIE	O
compared	O
to	O
HI	O
.	O

In	O
duodenum	O
,	O
ferritinL	B-GENE-Y
mRNA	O
was	O
increased	O
in	O
HIE	O
compared	O
to	O
CIE	O
.	O

Ezetimibe	B-CHEMICAL
induced	O
hepatic	O
iron	B-CHEMICAL
uptake	O
transporter	O
expression	O
in	O
mice	O
fed	O
a	O
high	O
-	O
fat	O
diet	O
,	O
causing	O
increased	O
hepatic	O
iron	B-CHEMICAL
concentrations	O
.	O

Androgen	B-CHEMICAL
deprivation	O
from	O
pre	O
-	O
puberty	O
to	O
peripuberty	O
interferes	O
in	O
proteins	O
expression	O
in	O
pubertal	O
and	O
adult	O
rat	O
epididymis	O
.	O

Few	O
studies	O
have	O
focused	O
on	O
experimental	O
testosterone	B-CHEMICAL
deprivation	O
in	O
immature	O
animals	O
.	O

Therefore	O
,	O
this	O
study	O
used	O
sexually	O
immature	O
rats	O
aiming	O
to	O
evaluate	O
the	O
testes	O
and	O
epididymis	O
histology	O
and	O
proteins	O
expression	O
in	O
these	O
organs	O
on	O
PND50	O
and	O
75	O
,	O
after	O
premature	O
antiandrogen	O
exposure	O
,	O
from	O
PND21	O
to	O
44	O
.	O

Although	O
the	O
androgen	B-CHEMICAL
deprivation	O
from	O
pre	O
-	O
puberty	O
up	O
to	O
peripuberty	O
did	O
not	O
alter	O
the	O
histological	O
organization	O
of	O
the	O
testes	O
and	O
epididymis	O
either	O
at	O
puberty	O
or	O
at	O
adulthood	O
,	O
the	O
treatment	O
impaired	O
the	O
expression	O
of	O
specific	O
proteins	O
in	O
epididymal	O
tissue	O
at	O
puberty	O
and	O
adulthood	O
(	O
androgen	B-GENE-Y
receptor	I-GENE-Y
,	O
calmodulin	B-GENE-N
,	O
Rab11A	B-GENE-Y
)	O
.	O

These	O
changes	O
may	O
be	O
related	O
to	O
impaired	O
epididymal	O
function	O
,	O
sperm	O
quality	O
and	O
fertility	O
capacity	O
as	O
observed	O
in	O
a	O
previous	O
study	O
.	O

Further	O
studies	O
are	O
necessary	O
to	O
better	O
investigate	O
the	O
molecular	O
mechanisms	O
involved	O
in	O
the	O
impairment	O
on	O
reproductive	O
competence	O
of	O
male	O
rats	O
after	O
precocious	O
hormonal	O
injury	O
.	O

Discovery	O
of	O
a	O
series	O
of	O
novel	O
5H	B-CHEMICAL
-	I-CHEMICAL
pyrrolo	I-CHEMICAL
[	I-CHEMICAL
2	I-CHEMICAL
,	I-CHEMICAL
3	I-CHEMICAL
-	I-CHEMICAL
b	I-CHEMICAL
]	I-CHEMICAL
pyrazine	I-CHEMICAL
-	I-CHEMICAL
2	I-CHEMICAL
-	I-CHEMICAL
phenyl	I-CHEMICAL
ethers	I-CHEMICAL
,	O
as	O
potent	O
JAK3	B-GENE-Y
kinase	B-GENE-N
inhibitors	O
.	O

We	O
report	O
the	O
discovery	O
of	O
a	O
novel	O
series	O
of	O
ATP	B-CHEMICAL
-	O
competitive	O
Janus	B-GENE-Y
kinase	I-GENE-Y
3	I-GENE-Y
(	O
JAK3	B-GENE-Y
)	O
inhibitors	O
based	O
on	O
the	O
5H	B-CHEMICAL
-	I-CHEMICAL
pyrrolo	I-CHEMICAL
[	I-CHEMICAL
2	I-CHEMICAL
,	I-CHEMICAL
3	I-CHEMICAL
-	I-CHEMICAL
b	I-CHEMICAL
]	I-CHEMICAL
pyrazine	I-CHEMICAL
scaffold	O
.	O

The	O
initial	O
leads	O
in	O
this	O
series	O
,	O
compounds	O
1a	O
and	O
1h	O
,	O
showed	O
promising	O
potencies	O
,	O
but	O
a	O
lack	O
of	O
selectivity	O
against	O
other	O
isoforms	O
in	O
the	O
JAK	B-GENE-N
family	O
.	O

Computational	O
and	O
crystallographic	O
analysis	O
suggested	O
that	O
the	O
phenyl	O
ether	O
moiety	O
possessed	O
a	O
favorable	O
vector	O
to	O
achieve	O
selectivity	O
.	O

Exploration	O
of	O
this	O
vector	O
resulted	O
in	O
the	O
identification	O
of	O
12b	O
and	O
12d	O
,	O
as	O
potent	O
JAK3	B-GENE-Y
inhibitors	O
,	O
demonstrating	O
improved	O
JAK	B-GENE-N
family	O
and	O
kinase	B-GENE-N
selectivity	O
.	O

Arsenic	B-CHEMICAL
trioxide	I-CHEMICAL
depletes	O
cancer	O
stem	O
-	O
like	O
cells	O
and	O
inhibits	O
repopulation	O
of	O
neurosphere	O
derived	O
from	O
glioblastoma	O
by	O
downregulation	O
of	O
Notch	B-GENE-N
pathway	O
.	O

Notch	B-GENE-N
signaling	O
has	O
been	O
demonstrated	O
to	O
have	O
a	O
central	O
role	O
in	O
cancer	O
stem	O
-	O
like	O
cells	O
(	O
CSLCs	O
)	O
in	O
glioblastoma	O
multiforme	O
(	O
GBM	O
)	O
.	O

We	O
have	O
recently	O
demonstrated	O
the	O
inhibitory	O
effect	O
of	O
arsenic	B-CHEMICAL
trioxide	I-CHEMICAL
(	O
ATO	B-CHEMICAL
)	O
on	O
CSLCs	O
in	O
glioblastoma	O
cell	O
lines	O
.	O

In	O
this	O
study	O
we	O
used	O
neurosphere	O
recovery	O
assay	O
that	O
measured	O
neurosphere	O
formation	O
at	O
three	O
time	O
points	O
to	O
assess	O
the	O
capacity	O
of	O
the	O
culture	O
to	O
repopulate	O
after	O
ATO	B-CHEMICAL
treatment	O
.	O

Our	O
results	O
provided	O
strong	O
evidence	O
that	O
ATO	B-CHEMICAL
depleted	O
CSLCs	O
in	O
GBM	O
,	O
and	O
inhibited	O
neurosphere	O
recovery	O
and	O
secondary	O
neurosphere	O
formation	O
.	O

ATO	B-CHEMICAL
inhibited	O
the	O
phosphorylation	O
and	O
activation	O
of	O
AKT	B-GENE-N
and	O
STAT3	B-GENE-Y
through	O
Notch	B-GENE-N
signaling	O
blockade	O
.	O

These	O
data	O
show	O
that	O
the	O
ATO	B-CHEMICAL
is	O
a	O
promising	O
new	O
approach	O
to	O
decrease	O
glioblastoma	O
proliferation	O
and	O
recurrence	O
by	O
downregulation	O
of	O
Notch	B-GENE-N
pathway	O
.	O

Total	O
saponins	B-CHEMICAL
of	O
Panax	O
notoginseng	O
enhance	O
VEGF	O
and	O
relative	O
receptors	O
signals	O
and	O
promote	O
angiogenesis	O
derived	O
from	O
rat	O
bone	O
marrow	O
mesenchymal	O
stem	O
cells	O
.	O

ETHNOPHARMACOLOGICAL	O
RELEVANCE	O
:	O
Total	O
saponins	O
of	O
Panax	O
notoginseng	O
(	O
tPNS	O
)	O
,	O
main	O
constituents	O
extracted	O
from	O
Panax	O
Notoginseng	O
,	O
a	O
highly	O
valued	O
traditional	O
Chinese	O
medicine	O
,	O
has	O
been	O
shown	O
to	O
increase	O
protein	O
expression	O
and	O
the	O
secretion	O
of	O
vascular	B-GENE-Y
endothelial	I-GENE-Y
growth	I-GENE-Y
factor	I-GENE-Y
(	O
VEGF	B-GENE-Y
)	O
in	O
human	O
umbilical	O
vein	O
endothelial	O
cells	O
.	O

AIMS	O
OF	O
THE	O
STUDY	O
:	O
The	O
effects	O
of	O
tPNS	O
on	O
angiogenesis	O
were	O
studied	O
in	O
rat	O
bone	O
marrow	O
mesenchymal	O
stem	O
cells	O
(	O
rBMSCs	O
)	O
.	O

MATERIALS	O
AND	O
METHODS	O
:	O
rBMSCs	O
were	O
stimulated	O
by	O
tPNS	O
of	O
48h	O
.	O

The	O
mRNA	O
expression	O
levels	O
of	O
VEGF	B-GENE-Y
-	I-GENE-Y
A	I-GENE-Y
,	O
Flt	B-GENE-Y
-	I-GENE-Y
1	I-GENE-Y
and	O
Kdr	B-GENE-Y
in	O
rBMSCs	O
were	O
determined	O
by	O
quantitative	O
real	O
time	O
PCR	O
(	O
qRT	O
-	O
PCR	O
)	O
.	O

rBMSCs	O
were	O
induced	O
to	O
differentiate	O
into	O
endothelial	O
-	O
like	O
cells	O
and	O
the	O
effects	O
of	O
tPNS	O
on	O
the	O
angiogenesis	O
ability	O
of	O
rBMSCs	O
and	O
rBMSCs	O
after	O
endothelial	O
differentiation	O
were	O
assayed	O
by	O
a	O
Matrigel	O
model	O
in	O
vivo	O
and	O
in	O
vitro	O
.	O

RESULTS	O
:	O
tPNS	O
(	O
100g	O
/	O
ml	O
)	O
significantly	O
enhanced	O
the	O
mRNA	O
expression	O
level	O
of	O
VEGF	B-GENE-Y
-	I-GENE-Y
A	I-GENE-Y
and	O
Kdr	B-GENE-Y
compared	O
to	O
the	O
control	O
group	O
,	O
while	O
they	O
had	O
no	O
obvious	O
effect	O
on	O
the	O
expression	O
of	O
Flt	B-GENE-Y
-	I-GENE-Y
1	I-GENE-Y
.	O

tPNS	O
(	O
1g	O
/	O
ml	O
and	O
100g	O
/	O
ml	O
)	O
significantly	O
increased	O
capillary	O
network	O
forming	O
of	O
rBMSCs	O
after	O
endothelial	O
differentiation	O
in	O
Matrigel	O
in	O
vitro	O
.	O

tPNS	O
(	O
50g	O
/	O
kg	O
,	O
100g	O
/	O
kg	O
and	O
150g	O
/	O
kg	O
)	O
also	O
significantly	O
increased	O
angiogenesis	O
induced	O
by	O
the	O
combination	O
with	O
implantation	O
of	O
rBMSCs	O
and	O
Matrigel	O
in	O
vivo	O
.	O

CONCLUSION	O
:	O
tPNS	O
up	O
-	O
regulate	O
VEGF	B-GENE-Y
-	I-GENE-Y
A	I-GENE-Y
and	O
Kdr	B-GENE-Y
expression	O
,	O
and	O
promote	O
angiogenesis	O
in	O
rat	O
bone	O
marrow	O
mesenchymal	O
stem	O
cells	O
.	O

Ovarian	O
Expression	O
of	O
Insulin	B-GENE-Y
-	I-GENE-Y
Like	I-GENE-Y
Peptide	I-GENE-Y
3	I-GENE-Y
(	O
INSL3	B-GENE-Y
)	O
and	O
Its	O
Receptor	O
(	O
RXFP2	B-GENE-Y
)	O
During	O
Development	O
of	O
Bovine	O
Antral	O
Follicles	O
and	O
Corpora	O
Lutea	O
and	O
Measurement	O
of	O
Circulating	O
INSL3	B-GENE-Y
Levels	O
During	O
Synchronized	O
Estrous	O
Cycles	O
.	O

Insulin	B-GENE-Y
-	I-GENE-Y
like	I-GENE-Y
peptide	I-GENE-Y
3	I-GENE-Y
(	O
INSL3	B-GENE-Y
)	O
,	O
a	O
major	O
product	O
of	O
testicular	O
Leydig	O
cells	O
,	O
is	O
also	O
expressed	O
by	O
the	O
ovary	O
,	O
but	O
its	O
functional	O
role	O
remains	O
poorly	O
understood	O
.	O

Here	O
,	O
we	O
quantified	O
expression	O
of	O
INSL3	B-GENE-Y
and	O
its	O
receptor	O
RXFP2	B-GENE-Y
in	O
theca	O
interna	O
cell	O
(	O
TIC	O
)	O
and	O
granulosa	O
cell	O
compartments	O
of	O
developing	O
bovine	O
antral	O
follicles	O
and	O
in	O
corpora	O
lutea	O
(	O
CL	O
)	O
.	O

INSL3	B-GENE-Y
and	O
RXFP2	B-GENE-Y
mRNA	O
levels	O
were	O
much	O
higher	O
in	O
TIC	O
than	O
granulosa	O
cell	O
and	O
increased	O
progressively	O
during	O
follicle	O
maturation	O
with	O
INSL3	B-GENE-Y
peaking	O
in	O
large	O
(	O
11	O
-	O
18	O
mm	O
)	O
estrogen	B-CHEMICAL
-	O
active	O
follicles	O
and	O
RXFP2	B-GENE-Y
peaking	O
in	O
9	O
-	O
to	O
10	O
-	O
mm	O
follicles	O
before	O
declining	O
in	O
larger	O
(	O
11	O
-	O
18	O
mm	O
)	O
follicles	O
.	O

Expression	O
of	O
both	O
INSL3	B-GENE-Y
and	O
RXFP2	B-GENE-Y
in	O
CL	O
was	O
much	O
lower	O
than	O
in	O
TIC	O
.	O

In	O
situ	O
hybridization	O
and	O
immunohistochemistry	O
confirmed	O
abundant	O
expression	O
of	O
INSL3	B-GENE-Y
mRNA	O
and	O
protein	O
in	O
TIC	O
.	O

These	O
observations	O
indicate	O
follicular	O
TIC	O
rather	O
than	O
CL	O
as	O
the	O
primary	O
site	O
of	O
both	O
INSL3	B-GENE-Y
production	O
and	O
action	O
,	O
implying	O
a	O
predominantly	O
autocrine	O
/	O
paracrine	O
role	O
in	O
TIC	O
.	O

To	O
corroborate	O
the	O
above	O
findings	O
,	O
we	O
showed	O
that	O
in	O
vitro	O
exposure	O
of	O
TIC	O
to	O
a	O
luteinizing	O
concentration	O
of	O
LH	B-GENE-N
greatly	O
attenuated	O
expression	O
of	O
both	O
INSL3	B-GENE-Y
and	O
its	O
receptor	O
while	O
increasing	O
progesterone	B-CHEMICAL
secretion	O
and	O
expression	O
of	O
STAR	B-GENE-Y
and	O
CYP11A1	B-GENE-Y
.	O

Moreover	O
,	O
in	O
vivo	O
,	O
a	O
significant	O
cyclic	O
variation	O
in	O
plasma	O
INSL3	B-GENE-Y
was	O
observed	O
during	O
synchronized	O
estrous	O
cycles	O
.	O

INSL3	B-GENE-Y
and	O
estradiol	B-CHEMICAL
-	I-CHEMICAL
17	I-CHEMICAL
followed	O
a	O
similar	O
pattern	O
,	O
both	O
increasing	O
after	O
luteolysis	O
,	O
before	O
falling	O
sharply	O
after	O
the	O
LH	B-GENE-N
surge	O
.	O

Thus	O
,	O
theca	O
-	O
derived	O
INSL3	B-GENE-Y
,	O
likely	O
from	O
the	O
dominant	O
preovulatory	O
follicle	O
,	O
is	O
detectable	O
in	O
peripheral	O
blood	O
of	O
cattle	O
,	O
and	O
expression	O
is	O
down	O
-	O
regulated	O
during	O
luteinization	O
induced	O
by	O
the	O
preovulatory	O
LH	B-GENE-N
surge	O
.	O

Collectively	O
,	O
these	O
findings	O
underscore	O
the	O
likely	O
role	O
of	O
INSL3	B-GENE-Y
as	O
an	O
important	O
intrafollicular	O
modulator	O
of	O
TIC	O
function	O
/	O
steroidogenesis	O
,	O
while	O
raising	O
doubts	O
about	O
its	O
potential	O
contribution	O
to	O
CL	O
function	O
.	O

Cytotoxicity	O
and	O
Modulation	O
of	O
Cancer	O
-	O
Related	O
Signaling	O
by	O
(	B-CHEMICAL
Z	I-CHEMICAL
)	I-CHEMICAL
-	I-CHEMICAL
and	I-CHEMICAL
(	I-CHEMICAL
E	I-CHEMICAL
)	I-CHEMICAL
-	I-CHEMICAL
3	I-CHEMICAL
,	I-CHEMICAL
4	I-CHEMICAL
,	I-CHEMICAL
3	I-CHEMICAL
'	I-CHEMICAL
,	I-CHEMICAL
5	I-CHEMICAL
'	I-CHEMICAL
-	I-CHEMICAL
Tetramethoxystilbene	I-CHEMICAL
Isolated	O
from	O
Eugenia	O
rigida	O
.	O

Bioassay	O
-	O
guided	O
fractionation	O
of	O
the	O
leaves	O
of	O
Eugenia	O
rigida	O
yielded	O
three	O
stilbenes	B-CHEMICAL
,	O
(	B-CHEMICAL
Z	I-CHEMICAL
)	I-CHEMICAL
-	I-CHEMICAL
3	I-CHEMICAL
,	I-CHEMICAL
4	I-CHEMICAL
,	I-CHEMICAL
3	I-CHEMICAL
'	I-CHEMICAL
,	I-CHEMICAL
5	I-CHEMICAL
'	I-CHEMICAL
-	I-CHEMICAL
tetramethoxystilbene	I-CHEMICAL
(	O
1	O
)	O
,	O
(	B-CHEMICAL
E	I-CHEMICAL
)	I-CHEMICAL
-	I-CHEMICAL
3	I-CHEMICAL
,	I-CHEMICAL
4	I-CHEMICAL
,	I-CHEMICAL
3	I-CHEMICAL
'	I-CHEMICAL
,	I-CHEMICAL
5	I-CHEMICAL
'	I-CHEMICAL
-	I-CHEMICAL
tetramethoxystilbene	I-CHEMICAL
(	O
2	O
)	O
,	O
and	O
(	B-CHEMICAL
E	I-CHEMICAL
)	I-CHEMICAL
-	I-CHEMICAL
3	I-CHEMICAL
,	I-CHEMICAL
5	I-CHEMICAL
,	I-CHEMICAL
4	I-CHEMICAL
'	I-CHEMICAL
-	I-CHEMICAL
trimethoxystilbene	I-CHEMICAL
(	O
3	O
)	O
.	O

Their	O
structures	O
were	O
determined	O
using	O
1D	O
-	O
and	O
2D	O
-	O
NMR	O
spectroscopy	O
and	O
HRESIMS	O
.	O

The	O
sterically	O
hindered	O
Z	O
-	O
stereoisomer	O
1	O
,	O
a	O
new	O
natural	O
product	O
,	O
was	O
prepared	O
by	O
time	O
-	O
dependent	O
photoisomerization	O
of	O
the	O
E	O
-	O
isomer	O
(	O
2	O
)	O
under	O
UV	O
irradiation	O
at	O
254	O
nm	O
,	O
while	O
2	B-CHEMICAL
,	I-CHEMICAL
3	I-CHEMICAL
,	I-CHEMICAL
5	I-CHEMICAL
,	I-CHEMICAL
7	I-CHEMICAL
-	I-CHEMICAL
tetramethoxyphenanthrene	I-CHEMICAL
(	O
5	O
)	O
was	O
identified	O
at	O
365	O
nm	O
by	O
UHPLC	O
/	O
APCI	O
-	O
MS	O
and	O
NMR	O
spectroscopy	O
.	O

Compounds	O
1	O
-	O
3	O
were	O
tested	O
against	O
a	O
panel	O
of	O
luciferase	O
reporter	O
gene	O
assays	O
that	O
assess	O
the	O
activity	O
of	O
many	O
cancer	O
-	O
related	O
signaling	O
pathways	O
,	O
and	O
the	O
Z	O
-	O
isomer	O
(	O
1	O
)	O
was	O
found	O
to	O
be	O
more	O
potent	O
than	O
the	O
E	O
-	O
isomer	O
(	O
2	O
)	O
in	O
inhibiting	O
the	O
activation	O
of	O
Stat3	B-GENE-Y
,	O
Smad3	B-GENE-N
/	I-GENE-N
4	I-GENE-N
,	O
myc	B-GENE-Y
,	O
Ets	B-GENE-N
,	O
Notch	B-GENE-N
,	O
and	O
Wnt	B-GENE-N
signaling	O
,	O
with	O
IC50	O
values	O
between	O
40	O
and	O
80	O
M	O
.	O

However	O
,	O
both	O
compounds	O
showed	O
similar	O
inhibition	O
against	O
Ap	B-GENE-Y
-	I-GENE-Y
1	I-GENE-Y
and	O
NF	B-GENE-N
-	I-GENE-N
B	I-GENE-N
signaling	O
.	O

In	O
addition	O
,	O
1	O
demonstrated	O
cytotoxic	O
activity	O
toward	O
human	O
leukemia	O
cells	O
,	O
solid	O
tumor	O
cells	O
of	O
epidermal	O
,	O
breast	O
,	O
and	O
cervical	O
carcinomas	O
,	O
and	O
skin	O
melanoma	O
,	O
with	O
IC50	O
values	O
between	O
3	O
.	O
6	O
and	O
4	O
.	O
3	O
M	O
,	O
while	O
2	O
was	O
weakly	O
active	O
against	O
leukemia	O
,	O
cervical	O
carcinoma	O
,	O
and	O
skin	O
melanoma	O
cells	O
.	O

Interestingly	O
,	O
2	O
showed	O
antioxidant	O
activity	O
by	O
inhibition	O
of	O
ROS	O
generation	O
to	O
50	O
%	O
at	O
33	O
.	O
3	O
M	O
in	O
PMA	B-CHEMICAL
-	O
induced	O
HL	O
-	O
60	O
cells	O
,	O
while	O
1	O
was	O
inactive	O
at	O
100	O
M	O
(	O
vs	O
Trolox	B-CHEMICAL
1	O
.	O
4	O
M	O
)	O
.	O

Genomic	O
variation	O
in	O
the	O
MAP3K5	B-GENE-Y
gene	O
is	O
associated	O
with	O
	O
-	O
thalassemia	O
disease	O
severity	O
and	O
hydroxyurea	B-CHEMICAL
treatment	O
efficacy	O
.	O

Aim	O
:	O
In	O
this	O
study	O
we	O
explored	O
the	O
association	O
between	O
genetic	O
variations	O
in	O
MAP3K5	B-GENE-Y
and	O
PDE7B	B-GENE-Y
genes	O
,	O
residing	O
on	O
chromosome	O
6q23	O
,	O
and	O
disease	O
severity	O
in	O
	O
-	O
hemoglobinopathy	O
patients	O
,	O
as	O
well	O
as	O
the	O
association	O
between	O
these	O
variants	O
with	O
response	O
to	O
hydroxyurea	B-CHEMICAL
(	O
HU	O
)	O
treatment	O
.	O

Furthermore	O
,	O
we	O
examined	O
MAP3K5	B-GENE-Y
expression	O
in	O
the	O
context	O
of	O
high	O
fetal	O
hemoglobin	O
(	O
HbF	O
)	O
and	O
upon	O
HU	O
treatment	O
in	O
erythroid	O
progenitor	O
cells	O
from	O
healthy	O
and	O
KLF1	O
haploinsufficient	O
individuals	O
.	O

Materials	O
&	O
methods	O
:	O
For	O
this	O
purpose	O
,	O
we	O
genotyped	O
	O
-	O
thalassemia	O
intermedia	O
and	O
major	O
patients	O
and	O
healthy	O
controls	O
,	O
as	O
well	O
as	O
a	O
cohort	O
of	O
compound	O
heterozygous	O
sickle	O
cell	O
disease	O
/	O
	O
-	O
thalassemia	O
patients	O
receiving	O
HU	O
as	O
HbF	O
augmentation	O
treatment	O
.	O

Furthermore	O
,	O
we	O
examined	O
MAP3K5	B-GENE-Y
expression	O
in	O
the	O
context	O
of	O
high	O
HbF	O
and	O
upon	O
HU	O
treatment	O
in	O
erythroid	O
progenitor	O
cells	O
from	O
healthy	O
and	O
KLF1	O
haploinsufficient	O
individuals	O
.	O

Results	O
:	O
A	O
short	O
tandem	O
repeat	O
in	O
the	O
MAP3K5	B-GENE-N
promoter	I-GENE-N
and	O
two	O
intronic	O
MAP3K5	B-GENE-Y
gene	O
variants	O
,	O
as	O
well	O
as	O
a	O
PDE7B	B-GENE-Y
variant	O
,	O
are	O
associated	O
with	O
low	O
HbF	O
levels	O
and	O
a	O
severe	O
disease	O
phenotype	O
.	O

Moreover	O
,	O
MAP3K5	B-GENE-Y
mRNA	O
expression	O
levels	O
are	O
altered	O
in	O
the	O
context	O
of	O
high	O
HbF	O
and	O
are	O
affected	O
by	O
the	O
presence	O
of	O
HU	O
.	O

Lastly	O
,	O
the	O
abovementioned	O
MAP3K5	B-GENE-Y
variants	O
are	O
associated	O
with	O
HU	O
treatment	O
efficacy	O
.	O

Conclusion	O
:	O
Our	O
data	O
suggest	O
that	O
these	O
MAP3K5	B-GENE-Y
variants	O
are	O
indicative	O
of	O
	O
-	O
thalassemia	O
disease	O
severity	O
and	O
response	O
to	O
HU	O
treatment	O
.	O

Original	O
submitted	O
24	O
September	O
2012	O
;	O
Revision	O
submitted	O
4	O
February	O
2013	O
.	O

Annexin	B-GENE-Y
A2	I-GENE-Y
regulates	O
1	B-GENE-Y
integrin	I-GENE-Y
internalization	O
and	O
intestinal	O
epithelial	O
cell	O
migration	O
.	O

The	O
gastrointestinal	O
epithelium	O
functions	O
as	O
an	O
important	O
barrier	O
that	O
separates	O
luminal	B-CHEMICAL
contents	O
from	O
the	O
underlying	O
tissue	O
compartment	O
and	O
is	O
vital	O
in	O
maintaining	O
mucosal	O
homeostasis	O
.	O

Mucosal	O
wounds	O
in	O
inflammatory	O
disorders	O
compromise	O
the	O
critical	O
epithelial	O
barrier	O
.	O

In	O
response	O
to	O
injury	O
,	O
intestinal	O
epithelial	O
cells	O
(	O
IECs	O
)	O
rapidly	O
migrate	O
to	O
reseal	O
wounds	O
.	O

We	O
have	O
previously	O
observed	O
that	O
a	O
membrane	O
associated	O
,	O
Actin	B-GENE-N
binding	I-GENE-N
protein	I-GENE-N
,	O
Annexin	B-GENE-N
A2	I-GENE-N
(	O
AnxA2	B-GENE-N
)	O
,	O
is	O
up	O
-	O
regulated	O
in	O
migrating	O
IECs	O
and	O
plays	O
an	O
important	O
role	O
in	O
promoting	O
wound	O
closure	O
.	O

To	O
identify	O
the	O
mechanisms	O
by	O
which	O
AnxA2	B-GENE-Y
promotes	O
IEC	O
movement	O
and	O
wound	O
closure	O
we	O
used	O
a	O
loss	O
of	O
function	O
approach	O
.	O

AnxA2	B-GENE-Y
specific	O
shRNA	O
was	O
utilized	O
to	O
generate	O
IECs	O
with	O
stable	O
down	O
-	O
regulation	O
of	O
AnxA2	B-GENE-Y
.	O

Loss	O
of	O
AnxA2	B-GENE-Y
inhibited	O
IEC	O
migration	O
while	O
promoting	O
enhanced	O
cell	O
-	O
matrix	O
adhesion	O
.	O

These	O
functional	O
effects	O
were	O
associated	O
with	O
increased	O
levels	O
of	O
1	B-GENE-Y
integrin	I-GENE-Y
protein	O
,	O
which	O
is	O
reported	O
to	O
play	O
an	O
important	O
role	O
in	O
mediating	O
the	O
cell	O
-	O
matrix	O
adhesive	O
properties	O
of	O
epithelial	O
cells	O
.	O

Since	O
cell	O
migration	O
requires	O
dynamic	O
turnover	O
of	O
integrin	O
based	O
adhesions	O
,	O
we	O
tested	O
if	O
AnxA2	B-GENE-Y
modulates	O
internalization	O
of	O
cell	O
surface	O
1	B-GENE-Y
integrin	I-GENE-Y
required	O
for	O
forward	O
cell	O
movement	O
.	O

Indeed	O
,	O
pulse	O
-	O
chase	O
biotinylation	O
experiments	O
in	O
IECs	O
lacking	O
AnxA2	B-GENE-Y
demonstrated	O
a	O
significant	O
increase	O
in	O
cell	O
surface	O
1	B-GENE-Y
integrin	I-GENE-Y
that	O
was	O
accompanied	O
by	O
decreased	O
1	B-GENE-Y
integrin	I-GENE-Y
internalization	O
and	O
degradation	O
.	O

These	O
findings	O
support	O
an	O
important	O
role	O
of	O
AnxA2	B-GENE-Y
in	O
controlling	O
dynamics	O
of	O
1	B-GENE-Y
integrin	I-GENE-Y
at	O
the	O
cell	O
surface	O
that	O
in	O
turn	O
is	O
required	O
for	O
the	O
active	O
turnover	O
of	O
cell	O
-	O
matrix	O
associations	O
,	O
cell	O
migration	O
and	O
wound	O
closure	O
.	O

Effects	O
of	O
fisetin	B-CHEMICAL
supplementation	O
on	O
hepatic	O
lipogenesis	O
and	O
glucose	B-CHEMICAL
metabolism	O
in	O
Sprague	O
-	O
Dawley	O
rats	O
fed	O
on	O
a	O
high	O
fat	O
diet	O
.	O

The	O
modulatory	O
effects	O
of	O
daily	O
fisetin	B-CHEMICAL
supplementation	O
for	O
8weeks	O
on	O
genes	O
involved	O
in	O
hepatic	O
lipogenesis	O
and	O
gluconeogenesis	O
and	O
hyperglycemia	O
in	O
rats	O
fed	O
a	O
high	O
fat	O
(	O
HF	O
)	O
diet	O
were	O
evaluated	O
.	O

Elevated	O
levels	O
of	O
triglyceride	B-CHEMICAL
(	O
TG	O
)	O
,	O
along	O
with	O
hepatic	O
TG	O
content	O
and	O
glucose	B-CHEMICAL
concentrations	O
in	O
a	O
high	O
fat	O
diet	O
group	O
were	O
found	O
to	O
be	O
reduced	O
by	O
fisetin	B-CHEMICAL
supplementation	O
.	O

The	O
high	O
fat	O
diet	O
significantly	O
increased	O
hepatic	O
mRNA	O
expressions	O
of	O
PPAR	B-GENE-Y
,	O
SREBP1C	B-GENE-Y
and	O
SCD	B-GENE-Y
-	I-GENE-Y
1	I-GENE-Y
genes	O
in	O
comparison	O
to	O
the	O
control	O
diet	O
,	O
which	O
was	O
subsequently	O
reversed	O
by	O
supplementation	O
with	O
fisetin	B-CHEMICAL
.	O

In	O
addition	O
,	O
fisetin	B-CHEMICAL
supplementation	O
significantly	O
reduced	O
hepatic	O
mRNA	O
abundance	O
of	O
FAS	B-GENE-Y
,	O
ATPCL	B-GENE-Y
and	O
G6Pase	B-GENE-Y
compared	O
to	O
the	O
control	O
group	O
.	O

Finally	O
,	O
epididymal	O
mRNA	O
abundance	O
of	O
GLUT4	B-GENE-Y
was	O
significantly	O
increased	O
by	O
fisetin	B-CHEMICAL
supplementation	O
,	O
compared	O
to	O
levels	O
in	O
the	O
control	O
and	O
HF	O
groups	O
.	O

Enhancement	O
of	O
GLUT4	B-GENE-Y
expression	O
by	O
fisetin	B-CHEMICAL
was	O
further	O
confirmed	O
in	O
differentiated	O
3T3	O
-	O
L1	O
adipocytes	O
.	O

Fisetin	B-CHEMICAL
supplementation	O
decreases	O
cardiovascular	O
risks	O
by	O
ameliorating	O
hepatic	O
steatosis	O
and	O
lowering	O
circulating	O
glucose	B-CHEMICAL
concentrations	O
.	O

Discovery	O
of	O
ML326	B-CHEMICAL
:	O
The	O
first	O
sub	O
-	O
micromolar	O
,	O
selective	O
M5	B-GENE-Y
PAM	O
.	O

This	O
Letter	O
describes	O
the	O
further	O
chemical	O
optimization	O
of	O
the	O
M5	B-GENE-Y
PAM	O
MLPCN	O
probes	O
ML129	B-CHEMICAL
and	O
ML172	B-CHEMICAL
.	O

A	O
multi	O
-	O
dimensional	O
iterative	O
parallel	O
synthesis	O
effort	O
quickly	O
explored	O
isatin	B-CHEMICAL
replacements	O
and	O
a	O
number	O
of	O
southern	O
heterobiaryl	O
variations	O
with	O
no	O
improvement	O
over	O
ML129	B-CHEMICAL
and	O
ML172	B-CHEMICAL
.	O

An	O
HTS	O
campaign	O
identified	O
several	O
weak	O
M5	B-GENE-Y
PAMs	O
(	O
M5	B-GENE-Y
EC50	O
>	O
10M	O
)	O
with	O
a	O
structurally	O
related	O
isatin	B-CHEMICAL
core	O
that	O
possessed	O
a	O
southern	O
phenethyl	B-CHEMICAL
ether	I-CHEMICAL
linkage	O
.	O

While	O
SAR	O
within	O
the	O
HTS	O
series	O
was	O
very	O
shallow	O
and	O
unable	O
to	O
be	O
optimized	O
,	O
grafting	O
the	O
phenethyl	B-CHEMICAL
ether	I-CHEMICAL
linkage	O
onto	O
the	O
ML129	B-CHEMICAL
/	O
ML172	B-CHEMICAL
cores	O
led	O
to	O
the	O
first	O
sub	O
-	O
micromolar	O
M5	B-GENE-Y
PAM	O
,	O
ML326	B-CHEMICAL
(	O
VU0467903	B-CHEMICAL
)	O
,	O
(	O
human	O
and	O
rat	O
M5	B-GENE-N
EC50s	O
of	O
409nM	O
and	O
500nM	O
,	O
respectively	O
)	O
with	O
excellent	O
mAChR	B-GENE-N
selectivity	O
(	O
M1	O
-	O
M4	O
EC50s	O
>	O
30M	O
)	O
and	O
a	O
robust	O
20	O
-	O
fold	O
leftward	O
shift	O
of	O
the	O
ACh	B-CHEMICAL
CRC	O
.	O

Improved	O
Insulin	B-GENE-N
Sensitivity	O
despite	O
Increased	O
Visceral	O
Adiposity	O
in	O
Mice	O
Deficient	O
for	O
the	O
Immune	B-GENE-N
Cell	I-GENE-N
Transcription	I-GENE-N
Factor	I-GENE-N
T	B-GENE-Y
-	I-GENE-Y
bet	I-GENE-Y
.	O

Low	O
-	O
grade	O
inflammation	O
in	O
fat	O
is	O
associated	O
with	O
insulin	B-GENE-N
resistance	O
,	O
although	O
the	O
mechanisms	O
are	O
unclear	O
.	O

We	O
report	O
that	O
mice	O
deficient	O
in	O
the	O
immune	B-GENE-N
cell	I-GENE-N
transcription	I-GENE-N
factor	I-GENE-N
T	B-GENE-Y
-	I-GENE-Y
bet	I-GENE-Y
have	O
lower	O
energy	O
expenditure	O
and	O
increased	O
visceral	O
fat	O
compared	O
with	O
wild	O
-	O
type	O
mice	O
,	O
yet	O
paradoxically	O
are	O
more	O
insulin	B-GENE-N
sensitive	O
.	O

This	O
striking	O
phenotype	O
,	O
present	O
in	O
young	O
T	B-GENE-Y
-	I-GENE-Y
bet	I-GENE-Y
(	O
-	O
/	O
-	O
)	O
mice	O
,	O
persisted	O
with	O
high	O
-	O
fat	O
diet	O
and	O
increasing	O
host	O
age	O
and	O
was	O
associated	O
with	O
altered	O
immune	O
cell	O
numbers	O
and	O
cytokine	B-GENE-N
secretion	O
specifically	O
in	O
visceral	O
adipose	O
tissue	O
.	O

However	O
,	O
the	O
favorable	O
metabolic	O
phenotype	O
observed	O
in	O
T	B-GENE-Y
-	I-GENE-Y
bet	I-GENE-Y
-	O
deficient	O
hosts	O
was	O
lost	O
in	O
T	B-GENE-Y
-	I-GENE-Y
bet	I-GENE-Y
(	O
-	O
/	O
-	O
)	O
mice	O
also	O
lacking	O
adaptive	O
immunity	O
(	O
T	B-GENE-Y
-	I-GENE-Y
bet	I-GENE-Y
(	O
-	O
/	O
-	O
)	O
xRag2	B-GENE-Y
(	O
-	O
/	O
-	O
)	O
)	O
,	O
demonstrating	O
that	O
T	B-GENE-Y
-	I-GENE-Y
bet	I-GENE-Y
expression	O
in	O
the	O
adaptive	O
rather	O
than	O
the	O
innate	O
immune	O
system	O
impacts	O
host	O
glucose	B-CHEMICAL
homeostasis	O
.	O

Indeed	O
,	O
adoptive	O
transfer	O
of	O
T	B-GENE-Y
-	I-GENE-Y
bet	I-GENE-Y
-	O
deficient	O
,	O
but	O
not	O
wild	O
-	O
type	O
,	O
CD4	O
(	O
+	O
)	O
T	O
cells	O
to	O
Rag2	B-GENE-Y
(	O
-	O
/	O
-	O
)	O
mice	O
improved	O
insulin	B-GENE-N
sensitivity	O
.	O

Our	O
results	O
reveal	O
a	O
role	O
for	O
T	B-GENE-Y
-	I-GENE-Y
bet	I-GENE-Y
in	O
metabolic	O
physiology	O
and	O
obesity	O
-	O
associated	O
insulin	B-GENE-N
resistance	O
.	O

Evidence	O
for	O
a	O
new	O
mechanism	O
behind	O
HIFU	O
-	O
triggered	O
release	O
from	O
liposomes	O
.	O

A	O
promising	O
approach	O
for	O
local	O
drug	O
delivery	O
is	O
high	O
-	O
intensity	O
focused	O
ultrasound	O
(	O
HIFU	O
)	O
-	O
triggered	O
release	O
of	O
drugs	O
from	O
stimuli	O
-	O
responsive	O
nanoparticles	O
such	O
as	O
liposomes	O
.	O

The	O
aim	O
of	O
this	O
study	O
was	O
to	O
investigate	O
whether	O
another	O
release	O
mechanism	O
is	O
involved	O
with	O
HIFU	O
-	O
triggered	O
release	O
from	O
liposomes	O
beside	O
cavitation	O
and	O
temperature	O
.	O

Furthermore	O
,	O
it	O
was	O
studied	O
whether	O
this	O
new	O
release	O
mechanism	O
allows	O
the	O
release	O
of	O
lipophilic	O
compounds	O
.	O

Therefore	O
,	O
both	O
a	O
lipophilic	O
(	O
Nile	B-CHEMICAL
red	I-CHEMICAL
)	O
and	O
a	O
hydrophilic	O
(	O
fluorescein	B-CHEMICAL
)	O
compound	O
were	O
loaded	O
into	O
thermosensitive	O
(	O
TSL	O
)	O
or	O
non	O
-	O
thermosensitive	O
liposomes	O
(	O
NTSL	O
)	O
and	O
the	O
liposomes	O
were	O
subjected	O
both	O
to	O
continuous	O
wave	O
-	O
(	O
CW	O
)	O
and	O
pulsed	O
wave	O
(	O
PW	O
)	O
-	O
HIFU	O
.	O

The	O
mean	O
liposome	O
size	O
varied	O
from	O
97	O
to	O
139nm	O
with	O
a	O
polydispersity	O
index	O
(	O
PDI	O
)	O
	O
0	O
.	O
06	O
for	O
the	O
different	O
formulations	O
.	O

The	O
Tm	O
of	O
the	O
phospholipid	O
bilayer	O
of	O
the	O
TSL	O
was	O
around	O
42	O
	O
C	O
.	O

Approximately	O
80	O
%	O
of	O
fluorescein	B-CHEMICAL
was	O
released	O
within	O
15min	O
from	O
TSL	O
at	O
temperatures	O
	O
42	O
	O
C	O
.	O

In	O
contrast	O
,	O
no	O
fluorescein	B-CHEMICAL
release	O
from	O
NTSL	O
and	O
NR	O
release	O
from	O
both	O
TSL	O
and	O
NTSL	O
was	O
observed	O
at	O
temperatures	O
up	O
to	O
60	O
	O
C	O
.	O

CW	O
-	O
HIFU	O
exposure	O
of	O
TSL	O
resulted	O
in	O
rapid	O
temperature	O
elevation	O
up	O
to	O
52	O
	O
C	O
and	O
subsequently	O
almost	O
quantitative	O
fluorescein	B-CHEMICAL
release	O
.	O

Fluorescein	B-CHEMICAL
release	O
from	O
NTSL	O
was	O
also	O
substantial	O
(	O
~	O
64	O
%	O
after	O
16min	O
at	O
20W	O
)	O
.	O

Surprisingly	O
,	O
CW	O
-	O
HIFU	O
exposure	O
(	O
20W	O
for	O
16min	O
)	O
resulted	O
in	O
the	O
release	O
of	O
NR	O
from	O
TSL	O
(	O
~	O
66	O
%	O
of	O
the	O
loaded	O
amount	O
)	O
,	O
and	O
this	O
was	O
even	O
higher	O
from	O
NTSL	O
(	O
~	O
78	O
%	O
)	O
.	O

PW	O
-	O
HIFU	O
exposure	O
did	O
not	O
result	O
in	O
temperatures	O
above	O
the	O
Tm	O
of	O
TSL	O
.	O

However	O
,	O
nearly	O
85	O
%	O
of	O
fluorescein	B-CHEMICAL
was	O
released	O
from	O
TSL	O
after	O
32min	O
at	O
20W	O
of	O
PW	O
-	O
HIFU	O
exposure	O
,	O
whereas	O
the	O
release	O
from	O
NTSL	O
was	O
around	O
27	O
%	O
.	O

Interestingly	O
,	O
NR	O
release	O
from	O
NTSL	O
was	O
~	O
30	O
%	O
after	O
2min	O
PW	O
-	O
HIFU	O
exposure	O
and	O
increased	O
to	O
~	O
70	O
%	O
after	O
32min	O
.	O

Furthermore	O
,	O
addition	O
of	O
microbubbles	O
to	O
the	O
liposomes	O
prior	O
to	O
PW	O
-	O
HIFU	O
exposure	O
did	O
not	O
result	O
in	O
more	O
release	O
,	O
which	O
suggests	O
that	O
cavitation	O
can	O
be	O
excluded	O
as	O
the	O
main	O
mechanism	O
responsible	O
for	O
the	O
triggered	O
release	O
of	O
both	O
a	O
hydrophilic	O
and	O
a	O
lipophilic	O
model	O
compound	O
from	O
liposomes	O
.	O

Dynamic	O
light	O
scattering	O
analysis	O
showed	O
that	O
the	O
mean	O
size	O
and	O
PDI	O
of	O
the	O
liposomes	O
did	O
not	O
significantly	O
change	O
after	O
CW	O
-	O
and	O
PW	O
-	O
HIFU	O
exposure	O
.	O

Taken	O
together	O
,	O
it	O
is	O
therefore	O
concluded	O
that	O
neither	O
temperature	O
elevation	O
nor	O
inertial	O
cavitation	O
is	O
essential	O
for	O
the	O
release	O
of	O
both	O
hydrophilic	O
and	O
lipophilic	O
compounds	O
from	O
liposomes	O
.	O

It	O
is	O
assumed	O
that	O
the	O
release	O
originates	O
from	O
radiation	O
force	O
-	O
induced	O
acoustic	O
streaming	O
,	O
causing	O
the	O
liposomes	O
to	O
collide	O
at	O
the	O
walls	O
of	O
the	O
exposure	O
chamber	O
leading	O
to	O
shear	O
forces	O
which	O
in	O
turn	O
results	O
in	O
reversible	O
liposome	O
destabilization	O
and	O
release	O
of	O
both	O
hydrophilic	O
and	O
lipophilic	O
compounds	O
.	O

DICO	B-CHEMICAL
,	O
a	O
novel	O
nonaromatic	O
B	O
-	O
ring	O
flavonoid	B-CHEMICAL
,	O
induces	O
G2	O
/	O
M	O
cell	O
cycle	O
arrest	O
and	O
apoptosis	O
in	O
human	O
hepatoma	O
cells	O
.	O

DICO	B-CHEMICAL
was	O
a	O
novel	O
nonaromatic	O
B	O
-	O
ring	O
flavonoid	B-CHEMICAL
obtained	O
from	O
Macrothelypteris	O
torresiana	O
.	O

In	O
the	O
present	O
work	O
,	O
we	O
investigated	O
the	O
antitumor	O
activity	O
and	O
the	O
antineoplastic	O
mechanism	O
of	O
DICO	B-CHEMICAL
.	O

Our	O
study	O
showed	O
that	O
DICO	B-CHEMICAL
inhibited	O
the	O
growth	O
of	O
HepG2	O
cells	O
in	O
dose	O
and	O
time	O
-	O
dependent	O
manners	O
.	O

As	O
well	O
as	O
DICO	B-CHEMICAL
induced	O
G2	O
/	O
M	O
cell	O
cycle	O
arrest	O
and	O
apoptosis	O
via	O
a	O
ROS	O
-	O
mediated	O
mitochondrial	O
pathway	O
.	O

Western	O
blot	O
assay	O
demonstrated	O
that	O
DICO	B-CHEMICAL
decreased	O
Bcl	B-GENE-Y
-	I-GENE-Y
2	I-GENE-Y
level	O
and	O
induced	O
Bax	B-GENE-Y
translocation	O
to	O
cause	O
cytochrome	B-GENE-Y
c	I-GENE-Y
release	O
.	O

Subsequently	O
,	O
caspase	B-GENE-Y
-	I-GENE-Y
9	I-GENE-Y
and	O
caspase	B-GENE-Y
-	I-GENE-Y
3	I-GENE-Y
were	O
activated	O
.	O

Meanwhile	O
,	O
the	O
alterations	O
of	O
cyclin	B-GENE-N
A	I-GENE-N
and	I-GENE-N
B1	I-GENE-N
,	O
p	B-GENE-Y
-	I-GENE-Y
CDK1	I-GENE-Y
and	O
p	B-GENE-Y
-	I-GENE-Y
cdc25c	I-GENE-Y
levels	O
were	O
also	O
observed	O
in	O
response	O
to	O
DICO	B-CHEMICAL
treatment	O
.	O

Taken	O
together	O
,	O
DICO	B-CHEMICAL
displayed	O
a	O
significant	O
antitumor	O
effect	O
through	O
G2	O
/	O
M	O
cell	O
cycle	O
arrest	O
and	O
apoptosis	O
induction	O
,	O
which	O
suggested	O
DICO	B-CHEMICAL
might	O
have	O
therapeutic	O
potential	O
against	O
tumors	O
.	O

Assessment	O
of	O
the	O
role	O
of	O
flavonoids	B-CHEMICAL
for	O
inducing	O
osteoblast	O
differentiation	O
in	O
isolated	O
mouse	O
bone	O
marrow	O
derived	O
mesenchymal	O
stem	O
cells	O
.	O

Quercetin	B-CHEMICAL
and	O
rutin	B-CHEMICAL
are	O
common	O
flavonoids	B-CHEMICAL
in	O
fruit	O
and	O
vegetables	O
,	O
and	O
have	O
been	O
reported	O
to	O
affect	O
bone	O
development	O
.	O

However	O
,	O
the	O
effect	O
of	O
flavonoids	B-CHEMICAL
on	O
osteoblast	O
differentiation	O
remains	O
a	O
matter	O
of	O
controversy	O
.	O

In	O
the	O
present	O
study	O
,	O
mouse	O
bone	O
marrow	O
mesenchymal	O
stem	O
cells	O
(	O
BMMSCs	O
)	O
were	O
isolated	O
and	O
characterized	O
for	O
their	O
use	O
in	O
osteoblast	O
differentiation	O
using	O
two	O
flavonoids	B-CHEMICAL
,	O
quercetin	B-CHEMICAL
and	O
rutin	B-CHEMICAL
.	O

BMMSCs	O
were	O
cultured	O
in	O
various	O
concentrations	O
of	O
quercetin	B-CHEMICAL
and	O
rutin	B-CHEMICAL
during	O
the	O
osteoblast	O
differentiation	O
period	O
of	O
10	O
days	O
.	O

Both	O
quercetin	B-CHEMICAL
and	O
rutin	B-CHEMICAL
were	O
found	O
to	O
up	O
regulate	O
the	O
osteoblast	O
differentiation	O
in	O
dose	O
dependent	O
manner	O
,	O
albeit	O
to	O
lesser	O
extent	O
in	O
case	O
of	O
former	O
than	O
that	O
of	O
latter	O
.	O

Quercetin	B-CHEMICAL
and	O
rutin	B-CHEMICAL
also	O
increased	O
alkaline	B-GENE-N
phosphatase	I-GENE-N
activity	O
by	O
about	O
150	O
and	O
240	O
%	O
and	O
demonstrated	O
mineralization	O
up	O
to	O
110	O
and	O
200	O
%	O
respectively	O
as	O
compared	O
to	O
control	O
(	O
which	O
was	O
considered	O
as	O
100	O
%	O
)	O
.	O

Further	O
,	O
both	O
the	O
flavonoids	B-CHEMICAL
were	O
also	O
found	O
to	O
increase	O
the	O
expression	O
of	O
some	O
of	O
the	O
prominent	O
markers	O
for	O
differentiation	O
of	O
osteoblast	O
like	O
osteopontin	B-GENE-Y
,	O
osterix	B-GENE-Y
,	O
RunX2	B-GENE-Y
,	O
osteoprotegerin	B-GENE-Y
and	O
osteocalcin	B-GENE-Y
.	O

The	O
current	O
data	O
suggests	O
that	O
certain	O
classes	O
of	O
flavonoids	B-CHEMICAL
like	O
rutin	B-CHEMICAL
and	O
quercetin	B-CHEMICAL
can	O
be	O
used	O
in	O
the	O
cure	O
and	O
management	O
of	O
osteodegenerative	O
disorders	O
due	O
to	O
their	O
osteoblast	O
specific	O
differentiation	O
activities	O
.	O

S	B-CHEMICAL
-	O
nitrosation	O
of	O
glutathione	B-GENE-Y
transferase	I-GENE-Y
P1	I-GENE-Y
-	I-GENE-Y
1	I-GENE-Y
is	O
controlled	O
by	O
the	O
conformation	O
of	O
a	O
dynamic	O
active	O
-	O
site	O
helix	O
.	O

S	B-CHEMICAL
-	O
nitrosation	O
is	O
a	O
post	O
-	O
translational	O
modification	O
of	O
protein	O
cysteine	B-CHEMICAL
residues	O
which	O
occurs	O
in	O
response	O
to	O
cellular	O
oxidative	O
stress	O
.	O

Although	O
it	O
is	O
increasingly	O
being	O
linked	O
to	O
physiologically	O
important	O
processes	O
,	O
the	O
molecular	O
basis	O
for	O
protein	O
regulation	O
by	O
this	O
modification	O
remains	O
poorly	O
understood	O
.	O

We	O
used	O
transient	O
kinetic	O
methods	O
to	O
determine	O
a	O
minimal	O
mechanism	O
for	O
spontaneous	O
GSNO	O
-	O
mediated	O
transnitrosation	O
of	O
human	B-GENE-Y
glutathione	I-GENE-Y
transferase	I-GENE-Y
(	I-GENE-Y
GST	I-GENE-Y
)	I-GENE-Y
P1	I-GENE-Y
-	I-GENE-Y
1	I-GENE-Y
,	O
a	O
major	O
detoxification	O
enzyme	O
and	O
key	O
regulator	O
of	O
cell	O
proliferation	O
.	O

C47	O
of	O
GSTP1	B-GENE-Y
-	I-GENE-Y
1	I-GENE-Y
is	O
S	B-CHEMICAL
-	O
nitrosated	O
in	O
two	O
steps	O
,	O
with	O
the	O
chemical	O
step	O
limited	O
by	O
a	O
pre	O
-	O
equilibrium	O
between	O
the	O
open	O
and	O
closed	O
conformations	O
of	O
helix	O
2	O
at	O
the	O
active	O
site	O
.	O

C101	O
,	O
in	O
contrast	O
,	O
is	O
S	B-CHEMICAL
-	O
nitrosated	O
in	O
a	O
single	O
step	O
but	O
is	O
subject	O
to	O
negative	O
cooperativity	O
due	O
to	O
steric	O
hindrance	O
at	O
the	O
dimer	O
interface	O
.	O

Despite	O
the	O
presence	O
of	O
a	O
GSNO	B-GENE-N
binding	I-GENE-N
site	I-GENE-N
at	O
the	O
active	O
site	O
of	O
GSTP1	B-GENE-Y
-	I-GENE-Y
1	I-GENE-Y
,	O
isothermal	O
titration	O
calorimetry	O
as	O
well	O
as	O
nitrosation	O
experiments	O
using	O
CysNO	B-CHEMICAL
demonstrate	O
that	O
GSNO	O
binding	O
does	O
not	O
precede	O
S	B-CHEMICAL
-	O
nitrosation	O
of	O
GSTP1	B-GENE-Y
-	I-GENE-Y
1	I-GENE-Y
.	O

Kinetics	O
experiments	O
using	O
the	O
cellular	O
reductant	O
GSH	B-CHEMICAL
show	O
that	O
C101	O
-	O
NO	B-CHEMICAL
is	O
substantially	O
more	O
resistant	O
to	O
denitrosation	O
than	O
C47	O
-	O
NO	B-CHEMICAL
,	O
suggesting	O
a	O
potential	O
role	O
for	O
C101	O
-	O
NO	B-CHEMICAL
in	O
long	O
term	O
nitric	B-CHEMICAL
oxide	I-CHEMICAL
storage	O
or	O
transfer	O
.	O

These	O
results	O
constitute	O
the	O
first	O
report	O
of	O
the	O
molecular	O
mechanism	O
of	O
spontaneous	O
protein	O
transnitrosation	O
,	O
providing	O
insight	O
into	O
the	O
post	O
-	O
translational	O
control	O
of	O
GSTP1	B-GENE-Y
-	I-GENE-Y
1	I-GENE-Y
as	O
well	O
as	O
the	O
process	O
of	O
protein	O
transnitrosation	O
in	O
general	O
.	O

Effect	O
of	O
N	B-CHEMICAL
-	I-CHEMICAL
acetyl	I-CHEMICAL
cysteine	I-CHEMICAL
(	O
NAC	B-CHEMICAL
)	O
,	O
an	O
organosulfur	B-CHEMICAL
compound	O
from	O
Allium	O
plants	O
,	O
on	O
experimentally	O
induced	O
hepatic	O
prefibrogenic	O
events	O
in	O
wistar	O
rat	O
.	O

Aim	O
of	O
present	O
study	O
was	O
to	O
investigate	O
the	O
effect	O
of	O
NAC	B-CHEMICAL
on	O
experimental	O
chronic	O
hepatotoxicity	O
models	O
induced	O
by	O
carbon	B-CHEMICAL
tetrachloride	I-CHEMICAL
(	O
CCl4	B-CHEMICAL
)	O
and	O
thioacetamide	B-CHEMICAL
(	O
TAA	B-CHEMICAL
)	O
.	O

CCl4	O
toxicity	O
was	O
induced	O
by	O
administering	O
200l	O
CCl4	B-CHEMICAL
(	O
diluted	O
2	O
:	O
3	O
in	O
coconut	O
oil	O
)	O
/	O
100g	O
body	O
weight	O
,	O
p	O
.	O
o	O
.	O
,	O
twice	O
weekly	O
for	O
8	O
weeks	O
.	O

TAA	B-CHEMICAL
toxicity	O
was	O
induced	O
by	O
administering	O
150mg	O
/	O
kg	O
b	O
.	O

wt	O
.	O
of	O
TAA	B-CHEMICAL
i	O
.	O
p	O
.	O
,	O
twice	O
weekly	O
for	O
8	O
weeks	O
.	O

NAC	B-CHEMICAL
treatment	O
was	O
started	O
along	O
with	O
toxicants	O
(	O
CCl4	B-CHEMICAL
and	O
TAA	B-CHEMICAL
)	O
for	O
8	O
weeks	O
and	O
continued	O
for	O
further	O
4	O
weeks	O
.	O

Self	O
reversal	O
group	O
was	O
kept	O
without	O
any	O
treatment	O
for	O
4	O
weeks	O
after	O
completion	O
of	O
toxicant	O
treatments	O
.	O

Alanine	B-GENE-N
aminotransferase	I-GENE-N
(	O
ALT	B-GENE-N
)	O
,	O
Aspartate	B-GENE-N
aminotransferase	I-GENE-N
(	O
AST	B-GENE-N
)	O
,	O
Alkaline	B-GENE-N
phosphatase	I-GENE-N
(	O
ALP	B-GENE-N
)	O
,	O
Bilirubin	B-CHEMICAL
were	O
measured	O
in	O
serum	O
.	O

Hydroxyproline	B-CHEMICAL
(	O
HP	O
)	O
,	O
lipid	O
peroxidation	O
(	O
LPO	O
)	O
,	O
catalase	B-GENE-Y
(	O
CAT	B-GENE-Y
)	O
,	O
Glutathione	B-GENE-N
peroxidase	I-GENE-N
(	O
GPx	B-GENE-N
)	O
and	O
Glutathione	B-CHEMICAL
(	O
GSH	B-CHEMICAL
)	O
were	O
determined	O
in	O
liver	O
samples	O
by	O
colorimetric	O
methods	O
.	O

Cytochrome	B-GENE-Y
P450	I-GENE-Y
2E1	I-GENE-Y
(	O
CYP	B-GENE-Y
450	I-GENE-Y
2E1	I-GENE-Y
)	O
,	O
activity	O
was	O
determined	O
as	O
hydroxylation	O
of	O
aniline	B-CHEMICAL
in	O
liver	O
microsomes	O
.	O

General	O
examination	O
and	O
histological	O
analysis	O
were	O
also	O
performed	O
.	O

Serum	O
markers	O
of	O
liver	O
damage	O
(	O
AST	B-GENE-N
,	O
ALT	B-GENE-N
,	O
ALP	B-GENE-N
and	O
Bilirubin	B-CHEMICAL
)	O
were	O
increased	O
by	O
CCl4	B-CHEMICAL
and	O
TAA	B-CHEMICAL
intoxication	O
(	O
p	O
<	O
0	O
.	O
001	O
)	O
,	O
whereas	O
co	O
-	O
treatment	O
with	O
NAC	B-CHEMICAL
reversed	O
such	O
changes	O
(	O
p	O
<	O
0	O
.	O
001	O
)	O
.	O

HP	O
was	O
enhanced	O
in	O
toxicant	O
groups	O
(	O
p	O
<	O
0	O
.	O
001	O
in	O
CCl4	B-CHEMICAL
and	O
TAA	B-CHEMICAL
)	O
,	O
but	O
inhibited	O
by	O
NAC	B-CHEMICAL
(	O
p	O
<	O
0	O
.	O
001	O
)	O
.	O

LPO	O
was	O
increased	O
while	O
as	O
GSH	B-CHEMICAL
,	O
CAT	B-GENE-Y
and	O
GPx	B-GENE-N
decreased	O
by	O
the	O
administration	O
of	O
CCl4	O
and	O
TAA	O
(	O
p	O
<	O
0	O
.	O
001	O
)	O
;	O
co	O
-	O
administration	O
of	O
NAC	B-CHEMICAL
restored	O
these	O
liver	O
markers	O
to	O
normal	O
levels	O
(	O
p	O
<	O
0	O
.	O
001	O
)	O
.	O

Biochemical	O
determinations	O
were	O
corroborated	O
by	O
general	O
and	O
histological	O
findings	O
.	O

Keeping	O
in	O
view	O
the	O
biochemical	O
and	O
histopathological	O
studies	O
,	O
it	O
was	O
concluded	O
that	O
CCl4	B-CHEMICAL
and	O
TAA	B-CHEMICAL
are	O
strong	O
hepatotoxic	O
agents	O
that	O
produce	O
liver	O
fibrosis	O
with	O
close	O
proximity	O
to	O
human	O
etiology	O
(	O
micronodular	O
cirrhosis	O
)	O
and	O
NAC	B-CHEMICAL
has	O
a	O
significant	O
protective	O
activity	O
against	O
CCl4	B-CHEMICAL
and	O
TAA	B-CHEMICAL
.	O

NAC	B-CHEMICAL
has	O
also	O
been	O
validated	O
as	O
a	O
model	O
against	O
oxidative	O
burden	O
in	O
chronic	O
liver	O
pathology	O
.	O

Phenolic	B-CHEMICAL
compounds	O
present	O
in	O
Sardinian	O
wine	O
extracts	O
protect	O
against	O
the	O
production	O
of	O
inflammatory	O
cytokines	O
induced	O
by	O
oxysterols	B-CHEMICAL
in	O
CaCo	O
-	O
2	O
human	O
enterocyte	O
-	O
like	O
cells	O
.	O

Cholesterol	B-CHEMICAL
auto	O
-	O
oxidation	O
products	O
,	O
namely	O
oxysterols	B-CHEMICAL
,	O
are	O
widely	O
present	O
in	O
cholesterol	B-CHEMICAL
-	O
rich	O
foods	O
.	O

They	O
are	O
thought	O
to	O
potentially	O
interfere	O
with	O
homeostasis	O
of	O
the	O
human	O
digestive	O
tract	O
,	O
playing	O
a	O
role	O
in	O
intestinal	O
mucosal	O
damage	O
.	O

This	O
report	O
concerns	O
the	O
marked	O
up	O
-	O
regulation	O
in	O
differentiated	O
CaCo	O
-	O
2	O
colonic	O
epithelial	O
cells	O
of	O
two	O
key	O
inflammatory	O
interleukins	B-GENE-N
,	O
IL	B-GENE-Y
-	I-GENE-Y
6	I-GENE-Y
and	O
IL	B-GENE-Y
-	I-GENE-Y
8	I-GENE-Y
,	O
caused	O
by	O
a	O
mixture	O
of	O
oxysterols	B-CHEMICAL
representative	O
of	O
a	O
high	O
cholesterol	B-CHEMICAL
diet	O
.	O

This	O
strong	O
pro	O
-	O
inflammatory	O
effect	O
appeared	O
to	O
be	O
dependent	O
on	O
the	O
net	O
imbalance	O
of	O
red	O
-	O
ox	O
equilibrium	O
with	O
the	O
production	O
of	O
excessive	O
levels	O
of	O
reactive	O
oxygen	B-CHEMICAL
species	O
through	O
the	O
colonic	O
NADPH	B-GENE-N
-	I-GENE-N
oxidase	I-GENE-N
NOX1	B-GENE-Y
activation	O
.	O

Induction	O
of	O
NOX1	B-GENE-Y
was	O
markedly	O
while	O
not	O
fully	O
inhibited	O
by	O
CaCo	O
-	O
2	O
cell	O
pre	O
-	O
incubation	O
with	O
phenolic	O
extracts	O
obtained	O
from	O
well	O
-	O
selected	O
wines	O
from	O
typical	O
grape	O
varieties	O
grown	O
in	O
Sardinia	O
.	O

Oxysterol	B-CHEMICAL
-	O
dependent	O
NOX1	B-GENE-Y
activation	O
,	O
as	O
well	O
as	O
interleukin	B-GENE-N
synthesis	O
,	O
were	O
completely	O
prevented	O
by	O
Cannonau	O
red	O
wine	O
extract	O
that	O
contains	O
an	O
abundant	O
phenolic	O
fraction	O
,	O
in	O
particular	O
phenolic	B-CHEMICAL
acids	I-CHEMICAL
and	O
flavonoids	B-CHEMICAL
.	O

Conversely	O
,	O
cell	O
pre	O
-	O
treatment	O
with	O
Vermentino	O
white	O
wine	O
extract	O
with	O
smaller	O
phenolic	O
fraction	O
showed	O
only	O
a	O
partial	O
NOX1	B-GENE-Y
down	O
-	O
regulation	O
and	O
was	O
ineffective	O
in	O
interleukin	B-GENE-N
synthesis	O
induced	O
by	O
dietary	O
oxysterols	B-CHEMICAL
.	O

It	O
is	O
thus	O
likely	O
that	O
the	O
effects	O
of	O
Sardinian	O
wine	O
extracts	O
against	O
intestinal	O
inflammation	O
induced	O
by	O
dietary	O
oxysterols	B-CHEMICAL
are	O
mainly	O
due	O
to	O
their	O
high	O
phenolic	O
content	O
:	O
low	O
doses	O
of	O
phenolics	B-CHEMICAL
would	O
be	O
responsible	O
only	O
for	O
direct	O
scavenging	O
oxysterol	B-CHEMICAL
-	O
dependent	O
ROS	O
production	O
.	O

Besides	O
this	O
direct	O
activity	O
,	O
an	O
excess	O
of	O
phenolic	B-CHEMICAL
compounds	O
detectable	O
in	O
red	O
wine	O
,	O
may	O
exert	O
an	O
additional	O
indirect	O
action	O
by	O
blocking	O
oxysterol	B-CHEMICAL
-	O
related	O
NOX1	B-GENE-Y
induction	O
,	O
thus	O
totally	O
preventing	O
the	O
pro	O
-	O
oxidant	O
and	O
pro	O
-	O
inflammatory	O
events	O
triggered	O
by	O
dietary	O
oxysterols	B-CHEMICAL
.	O

Tandem	O
Assays	O
of	O
Protein	O
and	O
Glucose	B-CHEMICAL
with	O
Functionalized	O
Core	O
/	O
Shell	O
Particles	O
Based	O
on	O
Magnetic	O
Separation	O
and	O
Surface	O
-	O
Enhanced	O
Raman	O
Scattering	O
.	O

Tandem	O
assays	O
of	O
protein	O
and	O
glucose	B-CHEMICAL
in	O
combination	O
with	O
mannose	B-CHEMICAL
-	O
functionalized	O
Fe3	B-CHEMICAL
O4	I-CHEMICAL
@	O
SiO2	B-CHEMICAL
and	O
Ag	B-CHEMICAL
@	O
SiO2	B-CHEMICAL
tag	O
particles	O
have	O
promising	O
potential	O
in	O
effective	O
magnetic	O
separation	O
and	O
highly	O
sensitive	O
and	O
selective	O
SERS	O
assays	O
of	O
biomaterials	O
.	O

It	O
is	O
for	O
the	O
first	O
time	O
that	O
tandem	O
assay	O
of	O
glucose	B-CHEMICAL
is	O
developed	O
using	O
SERS	O
based	O
on	O
the	O
Con	O
A	O
-	O
sandwiched	O
microstructures	O
between	O
the	O
functionalized	O
magnetic	O
and	O
tag	O
particles	O
.	O

Relationship	O
between	O
serum	B-GENE-N
thyrotropin	I-GENE-N
levels	O
and	O
intrarenal	O
hemodynamic	O
parameters	O
in	O
euthyroid	O
subjects	O
.	O

OBJECTIVE	O
:	O
Low	O
thyroid	O
function	O
may	O
be	O
associated	O
with	O
a	O
reduced	O
glomerular	O
filtration	O
rate	O
(	O
GFR	O
)	O
calculated	O
on	O
the	O
basis	O
of	O
creatinine	B-CHEMICAL
metabolism	O
.	O

Thyroid	B-CHEMICAL
hormone	I-CHEMICAL
directly	O
affects	O
serum	O
creatinine	B-CHEMICAL
in	O
muscle	O
and	O
low	O
thyroid	O
function	O
might	O
exert	O
a	O
similar	O
direct	O
effect	O
in	O
the	O
kidney	O
.	O

The	O
goal	O
of	O
the	O
study	O
was	O
to	O
evaluate	O
this	O
possibility	O
by	O
assessment	O
of	O
the	O
inulin	O
-	O
based	O
GFR	O
and	O
to	O
examine	O
the	O
mechanism	O
underlying	O
the	O
reduction	O
of	O
GFR	O
.	O

PATIENTS	O
AND	O
METHODS	O
:	O
Renal	O
and	O
glomerular	O
hemodynamics	O
were	O
assessed	O
by	O
simultaneous	O
measurements	O
of	O
plasma	O
clearance	O
of	O
para	B-CHEMICAL
-	I-CHEMICAL
aminohippurate	I-CHEMICAL
(	O
CPAH	O
)	O
and	O
inulin	O
(	O
Cin	O
)	O
in	O
26	O
patients	O
with	O
serum	O
creatinine	B-CHEMICAL
<	O
1	O
.	O
00	O
mg	O
/	O
dl	O
and	O
without	O
thyroid	O
disease	O
.	O

All	O
subjects	O
were	O
normotensive	O
with	O
or	O
without	O
antihypertensive	O
treatment	O
and	O
were	O
kept	O
in	O
a	O
sodium	B-CHEMICAL
-	O
replete	O
state	O
.	O

Renal	O
and	O
glomerular	O
hemodynamics	O
were	O
calculated	O
using	O
Gomez	O
`	O
s	O
formulae	O
.	O

RESULTS	O
:	O
Serum	B-GENE-N
thyroid	I-GENE-N
stimulating	I-GENE-N
hormone	I-GENE-N
(	O
TSH	B-GENE-N
)	O
,	O
including	O
within	O
the	O
normal	O
range	O
(	O
0	O
.	O
69	O
-	O
4	O
.	O
30	O
IU	O
/	O
ml	O
)	O
,	O
was	O
positively	O
correlated	O
with	O
vascular	O
resistance	O
at	O
the	O
afferent	O
arteriole	O
(	O
Ra	O
)	O
(	O
r	O
=	O
0	O
.	O
609	O
,	O
p	O
=	O
0	O
.	O
0010	O
)	O
,	O
but	O
not	O
at	O
the	O
efferent	O
arteriole	O
(	O
Re	O
)	O
.	O

Serum	B-GENE-N
TSH	I-GENE-N
was	O
significantly	O
and	O
negatively	O
correlated	O
with	O
renal	O
plasma	O
flow	O
(	O
RPF	O
)	O
,	O
renal	O
blood	O
flow	O
(	O
RBF	O
)	O
,	O
and	O
glomerular	O
filtration	O
rate	O
(	O
GFR	O
)	O
(	O
r	O
=	O
-	O
0	O
.	O
456	O
,	O
p	O
=	O
0	O
.	O
0192	O
;	O
r	O
=	O
-	O
0	O
.	O
438	O
,	O
p	O
=	O
0	O
.	O
0252	O
;	O
r	O
=	O
-	O
0	O
.	O
505	O
,	O
p	O
=	O
0	O
.	O
0086	O
,	O
respectively	O
)	O
.	O

In	O
multiple	O
regression	O
analysis	O
,	O
serum	B-GENE-N
TSH	I-GENE-N
was	O
significantly	O
positively	O
associated	O
with	O
Ra	O
after	O
adjustment	O
for	O
age	O
and	O
mean	O
blood	O
pressure	O
.	O

CONCLUSIONS	O
:	O
These	O
findings	O
suggest	O
that	O
low	O
thyroid	O
function	O
,	O
even	O
within	O
the	O
normal	O
range	O
,	O
is	O
associated	O
with	O
reduced	O
RPF	O
,	O
RBF	O
and	O
GFR	O
,	O
which	O
might	O
be	O
caused	O
by	O
a	O
preferential	O
increase	O
of	O
Ra	O
.	O

A	O
Physiologically	O
-	O
Based	O
Pharmacokinetic	O
Modelling	O
Approach	O
to	O
Predict	O
Disease	O
-	O
Drug	O
Interactions	O
:	O
Suppression	O
of	O
CYP3A	B-GENE-N
by	O
IL	B-GENE-Y
-	I-GENE-Y
6	I-GENE-Y
.	O

Elevated	O
cytokine	B-GENE-N
levels	O
can	O
down	O
-	O
regulate	O
expression	O
of	O
cytochrome	B-GENE-N
P450	I-GENE-N
enzymes	O
(	O
CYPs	B-GENE-N
)	O
and	O
suppress	O
their	O
activity	O
.	O

Treatment	O
of	O
inflammation	O
or	O
infection	O
with	O
cytokine	B-GENE-N
-	O
modulating	O
therapeutic	O
proteins	O
(	O
TP	O
)	O
could	O
reverse	O
suppression	O
manifesting	O
as	O
therapeutic	O
protein	O
-	O
drug	O
drug	O
interactions	O
(	O
TP	O
-	O
DDI	O
)	O
.	O

A	O
physiologically	O
-	O
based	O
pharmacokinetic	O
model	O
was	O
used	O
to	O
quantitatively	O
predict	O
the	O
impact	O
of	O
IL	B-GENE-Y
-	I-GENE-Y
6	I-GENE-Y
on	O
sensitive	O
CYP3A4	B-GENE-Y
substrates	O
.	O

Elevated	O
simvastatin	B-CHEMICAL
AUC	O
in	O
virtual	O
rheumatoid	O
arthritis	O
patients	O
,	O
following	O
100	O
pg	O
/	O
mL	O
of	O
IL	B-GENE-Y
-	I-GENE-Y
6	I-GENE-Y
was	O
comparable	O
to	O
observed	O
clinical	O
data	O
(	O
59	O
%	O
versus	O
58	O
%	O
)	O
.	O

In	O
virtual	O
bone	O
marrow	O
transplant	O
(	O
BMT	O
)	O
patients	O
,	O
500	O
pg	O
/	O
ml	O
of	O
IL	B-GENE-Y
-	I-GENE-Y
6	I-GENE-Y
resulted	O
in	O
increase	O
in	O
cyclosporine	B-CHEMICAL
AUC	O
that	O
was	O
in	O
good	O
agreement	O
with	O
the	O
observed	O
data	O
(	O
45	O
%	O
versus	O
39	O
%	O
)	O
.	O

In	O
a	O
different	O
group	O
of	O
BMT	O
patients	O
treated	O
with	O
cyclosporine	B-CHEMICAL
,	O
the	O
magnitude	O
of	O
interaction	O
with	O
IL	B-GENE-Y
-	I-GENE-Y
6	I-GENE-Y
was	O
under	O
predicted	O
~	O
3	O
-	O
fold	O
.	O

The	O
complexity	O
of	O
TP	O
-	O
DDI	O
highlights	O
underlying	O
pathophysiological	O
factors	O
to	O
be	O
considered	O
but	O
these	O
simulations	O
provide	O
valuable	O
first	O
steps	O
towards	O
predictions	O
of	O
TP	O
-	O
DDI	O
risk	O
.	O
Clinical	O
Pharmacology	O
&	O
Therapeutics	O
(	O
2013	O
)	O
;	O
accepted	O
article	O
preview	O
online	O
10	O
April	O
2013	O
doi	O
:	O
10	O
.	O
1038	O
/	O
clpt	O
.	O
2013	O
.	O
79	O
.	O

A	O
DPYD	B-GENE-Y
Variant	O
(	O
Y186C	B-GENE-N
)	O
in	O
Individuals	O
of	O
African	O
Ancestry	O
Is	O
Associated	O
With	O
Reduced	O
DPD	B-GENE-Y
Enzyme	O
Activity	O
.	O

5	B-CHEMICAL
-	I-CHEMICAL
Fluorouracil	I-CHEMICAL
(	O
5	B-CHEMICAL
-	I-CHEMICAL
FU	I-CHEMICAL
)	O
is	O
used	O
to	O
treat	O
many	O
aggressive	O
cancers	O
,	O
such	O
as	O
those	O
of	O
the	O
colon	O
,	O
breast	O
,	O
and	O
head	O
and	O
neck	O
.	O

The	O
responses	O
to	O
5	B-CHEMICAL
-	I-CHEMICAL
FU	I-CHEMICAL
,	O
with	O
respect	O
to	O
both	O
toxicity	O
and	O
efficacy	O
,	O
vary	O
among	O
racial	O
groups	O
,	O
potentially	O
because	O
of	O
variability	O
in	O
the	O
activity	O
levels	O
of	O
the	O
enzyme	O
dihydropyrimidine	B-GENE-Y
dehydrogenase	I-GENE-Y
(	O
DPD	B-GENE-Y
,	O
encoded	O
by	O
the	O
DPYD	B-GENE-Y
gene	O
)	O
.	O

In	O
this	O
study	O
,	O
the	O
genetic	O
associations	O
between	O
DPYD	B-GENE-Y
variations	O
and	O
circulating	O
mononuclear	O
-	O
cell	O
DPD	B-GENE-Y
enzyme	O
activity	O
were	O
evaluated	O
in	O
94	O
African	O
-	O
American	O
and	O
81	O
European	O
-	O
American	O
volunteers	O
.	O

The	O
DPYD	B-GENE-Y
-	O
Y186C	B-GENE-N
variant	O
was	O
unique	O
to	O
individuals	O
of	O
African	O
ancestry	O
,	O
and	O
DPD	B-GENE-Y
activity	O
was	O
46	O
%	O
lower	O
in	O
carriers	O
as	O
compared	O
with	O
noncarriers	O
(	O
279	O
	O
35	O
vs	O
.	O
514	O
	O
168	O
pmol	O
5	B-CHEMICAL
-	I-CHEMICAL
FU	I-CHEMICAL
min	O
(	O
-	O
1	O
)	O
mg	O
(	O
-	O
1	O
)	O
;	O
P	O
=	O
0	O
.	O
00029	O
)	O
.	O

In	O
this	O
study	O
,	O
26	O
%	O
of	O
the	O
African	O
Americans	O
with	O
reduced	O
DPD	B-GENE-Y
activity	O
were	O
carriers	O
of	O
Y186C	B-GENE-N
.	O

In	O
the	O
African	O
-	O
American	O
cohort	O
,	O
after	O
excluding	O
Y186C	B-GENE-N
carriers	O
,	O
homozygous	O
carriers	O
of	O
C29R	B-GENE-N
showed	O
27	O
%	O
higher	O
DPD	B-GENE-Y
activity	O
as	O
compared	O
with	O
noncarriers	O
(	O
609	O
	O
152	O
and	O
480	O
	O
152	O
pmol	O
5	B-CHEMICAL
-	I-CHEMICAL
FU	I-CHEMICAL
min	O
(	O
-	O
1	O
)	O
mg	O
(	O
-	O
1	O
)	O
,	O
respectively	O
;	O
P	O
=	O
0	O
.	O
013	O
)	O
.	O
Clinical	O
Pharmacology	O
&	O
Therapeutics	O
(	O
2013	O
)	O
;	O
advance	O
online	O
publication	O
1	O
May	O
2013	O
.	O
doi	O
:	O
10	O
.	O
1038	O
/	O
clpt	O
.	O
2013	O
.	O
69	O
.	O

Arsenic	B-CHEMICAL
inhibits	O
autophagic	O
flux	O
activating	O
the	O
Nrf2	B-GENE-Y
-	O
Keap1	B-GENE-Y
pathway	O
in	O
a	O
p62	B-GENE-Y
-	O
dependent	O
manner	O
.	O

The	O
Nrf2	B-GENE-Y
-	O
Keap1	B-GENE-Y
signaling	O
pathway	O
is	O
a	O
protective	O
mechanism	O
promoting	O
cell	O
survival	O
.	O

Activation	O
of	O
the	O
Nrf2	B-GENE-Y
pathway	O
by	O
natural	O
compounds	O
has	O
been	O
proven	O
to	O
be	O
an	O
effective	O
strategy	O
for	O
chemoprevention	O
.	O

Interestingly	O
,	O
a	O
cancer	O
-	O
promoting	O
function	O
of	O
Nrf2	B-GENE-Y
has	O
been	O
recently	O
observed	O
in	O
many	O
types	O
of	O
tumors	O
due	O
to	O
deregulation	O
of	O
the	O
Nrf2	B-GENE-Y
-	O
Keap1	B-GENE-Y
axis	O
,	O
which	O
leads	O
to	O
constitutive	O
activation	O
of	O
Nrf2	B-GENE-Y
.	O

Here	O
,	O
we	O
report	O
a	O
novel	O
mechanism	O
of	O
Nrf2	B-GENE-Y
activation	O
by	O
arsenic	O
that	O
is	O
distinct	O
from	O
that	O
of	O
chemopreventive	O
compounds	O
.	O

Arsenic	B-CHEMICAL
deregulates	O
the	O
autophagic	O
pathway	O
through	O
blockage	O
of	O
autophagic	O
flux	O
,	O
resulting	O
in	O
accumulation	O
of	O
autophagosomes	O
and	O
sequestration	O
of	O
p62	B-GENE-Y
,	O
Keap1	B-GENE-Y
,	O
and	O
LC3	B-GENE-N
.	O

Thus	O
,	O
arsenic	B-CHEMICAL
activates	O
Nrf2	B-GENE-Y
through	O
a	O
non	O
-	O
canonical	O
mechanism	O
(	O
p62	B-GENE-Y
-	O
dependent	O
)	O
,	O
leading	O
to	O
a	O
chronic	O
,	O
sustained	O
activation	O
of	O
Nrf2	B-GENE-Y
.	O

In	O
contrast	O
,	O
activation	O
of	O
Nrf2	B-GENE-Y
by	O
sulforaphane	B-CHEMICAL
and	O
tert	B-CHEMICAL
-	I-CHEMICAL
butylhydroquinone	I-CHEMICAL
depend	O
upon	O
Keap1	B-GENE-Y
-	O
C151	O
and	O
not	O
p62	B-GENE-Y
(	O
the	O
canonical	O
mechanism	O
)	O
.	O

More	O
importantly	O
,	O
SF	O
and	O
tBHQ	B-CHEMICAL
do	O
not	O
have	O
any	O
effect	O
on	O
autophagy	O
.	O

In	O
fact	O
,	O
SF	O
and	O
tBHQ	B-CHEMICAL
alleviate	O
arsenic	B-CHEMICAL
-	O
mediated	O
deregulation	O
of	O
autophagy	O
.	O

Collectively	O
,	O
these	O
findings	O
provide	O
evidence	O
that	O
arsenic	B-CHEMICAL
causes	O
prolonged	O
activation	O
of	O
Nrf2	B-GENE-Y
through	O
autophagy	O
dysfunction	O
,	O
possibly	O
providing	O
a	O
similar	O
scenario	O
to	O
constitutive	O
activation	O
of	O
Nrf2	B-GENE-Y
found	O
in	O
certain	O
human	O
cancers	O
.	O

This	O
may	O
represent	O
a	O
previously	O
unrecognized	O
mechanism	O
underlying	O
arsenic	B-CHEMICAL
toxicity	O
and	O
carcinogenicity	O
in	O
humans	O
.	O

Melatonin	B-CHEMICAL
and	O
ethanol	B-CHEMICAL
intake	O
exert	O
opposite	O
effects	O
on	O
circulating	O
estradiol	B-CHEMICAL
and	O
progesterone	B-CHEMICAL
and	O
differentially	O
regulate	O
sex	B-GENE-N
steroid	I-GENE-N
receptors	I-GENE-N
in	O
the	O
ovaries	O
,	O
oviducts	O
,	O
and	O
uteri	O
of	O
adult	O
rats	O
.	O

Chronic	O
ethanol	B-CHEMICAL
intake	O
is	O
associated	O
with	O
sex	O
hormone	O
disturbances	O
,	O
and	O
it	O
is	O
well	O
known	O
that	O
melatonin	B-CHEMICAL
plays	O
a	O
key	O
role	O
in	O
regulating	O
several	O
reproductive	O
processes	O
.	O

We	O
report	O
the	O
effects	O
of	O
ethanol	B-CHEMICAL
intake	O
and	O
melatonin	B-CHEMICAL
treatment	O
(	O
at	O
doses	O
of	O
100g	O
/	O
100gBW	O
/	O
day	O
)	O
on	O
sex	O
hormones	O
and	O
steroid	B-GENE-N
receptors	I-GENE-N
in	O
the	O
ovaries	O
,	O
oviducts	O
and	O
uteri	O
of	O
ethanol	B-CHEMICAL
-	O
preferring	O
rats	O
.	O

After	O
150	O
days	O
of	O
treatment	O
,	O
animals	O
were	O
euthanized	O
,	O
and	O
tissue	O
samples	O
were	O
harvested	O
to	O
evaluate	O
androgen	B-GENE-N
,	I-GENE-N
estrogen	I-GENE-N
,	I-GENE-N
progesterone	I-GENE-N
and	I-GENE-N
melatonin	I-GENE-N
receptor	I-GENE-N
subunits	O
(	O
AR	B-GENE-Y
,	O
ER	B-GENE-Y
-	I-GENE-Y
	I-GENE-Y
and	O
ER	B-GENE-Y
-	I-GENE-Y
	I-GENE-Y
,	O
PRA	B-GENE-Y
,	O
PRB	B-GENE-Y
and	O
MT1R	B-GENE-Y
,	O
respectively	O
)	O
.	O

Melatonin	B-CHEMICAL
decreased	O
estradiol	B-CHEMICAL
(	O
E2	O
)	O
and	O
increased	O
progesterone	B-CHEMICAL
(	O
P4	O
)	O
and	O
6	B-CHEMICAL
-	I-CHEMICAL
sulfatoxymelatonin	I-CHEMICAL
(	O
6	B-CHEMICAL
-	I-CHEMICAL
STM	I-CHEMICAL
)	O
,	O
while	O
an	O
ethanol	B-CHEMICAL
-	O
melatonin	B-CHEMICAL
combination	O
reduced	O
both	O
P4	O
and	O
E2	O
.	O

Ovarian	O
AR	B-GENE-Y
was	O
not	O
influenced	O
by	O
either	O
treatment	O
,	O
and	O
oviduct	O
AR	B-GENE-Y
was	O
reduced	O
after	O
ethanol	B-CHEMICAL
-	O
melatonin	B-CHEMICAL
combination	O
.	O

Oviduct	O
ER	B-GENE-Y
-	I-GENE-Y
	I-GENE-Y
,	O
ER	B-GENE-Y
-	I-GENE-Y
	I-GENE-Y
and	O
uterine	O
ER	B-GENE-Y
-	I-GENE-Y
	I-GENE-Y
were	O
down	O
-	O
regulated	O
by	O
either	O
ethanol	B-CHEMICAL
or	O
melatonin	B-CHEMICAL
.	O

Conversely	O
,	O
ovarian	O
PRA	B-GENE-Y
and	O
PRB	B-GENE-Y
were	O
positively	O
regulated	O
by	O
ethanol	B-CHEMICAL
and	O
ethanol	B-CHEMICAL
-	O
melatonin	B-CHEMICAL
combination	O
,	O
whereas	O
PRA	B-GENE-Y
was	O
down	O
-	O
regulated	O
in	O
the	O
uterus	O
and	O
oviduct	O
after	O
ethanol	B-CHEMICAL
consumption	O
.	O

MT1R	B-GENE-Y
was	O
increased	O
in	O
ovaries	O
and	O
uteri	O
of	O
melatonin	B-CHEMICAL
-	O
treated	O
rats	O
.	O

Ethanol	B-CHEMICAL
and	O
melatonin	B-CHEMICAL
exert	O
opposite	O
effects	O
on	O
E2	O
and	O
P4	O
,	O
and	O
they	O
differentially	O
regulate	O
the	O
expression	O
of	O
sex	B-GENE-N
steroid	I-GENE-N
receptors	I-GENE-N
in	O
female	O
reproductive	O
tissues	O
.	O

Ph1	O
toxin	O
prevents	O
capsaicin	B-CHEMICAL
-	O
induced	O
nociceptive	O
behavior	O
and	O
mechanical	O
hypersensitivity	O
without	O
acting	O
on	O
TRPV1	B-GENE-Y
channels	O
.	O

Ph1	O
toxin	O
is	O
a	O
peptide	O
purified	O
from	O
the	O
venom	O
of	O
the	O
armed	O
spider	O
Phoneutria	O
nigriventer	O
,	O
with	O
markedly	O
antinociceptive	O
action	O
in	O
models	O
of	O
acute	O
and	O
persistent	O
pain	O
in	O
rats	O
.	O

Similarly	O
to	O
ziconotide	O
,	O
its	O
analgesic	O
action	O
is	O
related	O
to	O
inhibition	O
of	O
high	O
voltage	O
activated	O
calcium	B-CHEMICAL
channels	O
with	O
more	O
selectivity	O
for	O
N	O
-	O
type	O
.	O

In	O
this	O
study	O
we	O
evaluated	O
the	O
effect	O
of	O
Ph1	O
when	O
injected	O
peripherally	O
or	O
intrathecally	O
in	O
a	O
rat	O
model	O
of	O
spontaneous	O
pain	O
induced	O
by	O
capsaicin	B-CHEMICAL
.	O

We	O
also	O
investigated	O
the	O
effect	O
of	O
Ph1	O
on	O
Ca	B-CHEMICAL
(	I-CHEMICAL
2	I-CHEMICAL
+	I-CHEMICAL
)	I-CHEMICAL
transients	O
in	O
cultured	O
dorsal	O
root	O
ganglia	O
(	O
DRG	O
)	O
neurons	O
and	O
HEK293	O
cells	O
expressing	O
the	O
TRPV1	B-GENE-Y
receptor	O
.	O

Intraplantar	O
or	O
intrathecal	O
administered	O
Ph1	O
reduced	O
both	O
nocifensive	O
behavior	O
and	O
mechanical	O
hypersensitivity	O
induced	O
by	O
capsaicin	B-CHEMICAL
similarly	O
to	O
that	O
observed	O
with	O
SB366791	B-CHEMICAL
,	O
a	O
specific	O
TRPV1	B-GENE-Y
antagonist	O
.	O

Peripheral	O
nifedipine	B-CHEMICAL
and	O
mibefradil	B-CHEMICAL
did	O
also	O
decrease	O
nociceptive	O
behavior	O
induced	O
by	O
intraplantar	O
capsaicin	B-CHEMICAL
.	O

In	O
contrast	O
,	O
	O
-	O
conotoxin	O
MVIIA	O
(	O
a	O
selective	O
N	B-GENE-N
-	I-GENE-N
type	I-GENE-N
Ca	I-GENE-N
(	I-GENE-N
2	I-GENE-N
+	I-GENE-N
)	I-GENE-N
channel	I-GENE-N
blocker	O
)	O
was	O
effective	O
only	O
when	O
administered	O
intrathecally	O
.	O

Ph1	O
,	O
MVIIA	O
and	O
SB366791	B-CHEMICAL
inhibited	O
,	O
with	O
similar	O
potency	O
,	O
the	O
capsaicin	B-CHEMICAL
-	O
induced	O
Ca	B-CHEMICAL
(	I-CHEMICAL
2	I-CHEMICAL
+	I-CHEMICAL
)	I-CHEMICAL
transients	O
in	O
DRG	O
neurons	O
.	O

The	O
simultaneous	O
administration	O
of	O
Ph1	O
and	O
SB366791	B-CHEMICAL
inhibited	O
the	O
capsaicin	B-CHEMICAL
-	O
induced	O
Ca	B-CHEMICAL
(	I-CHEMICAL
2	I-CHEMICAL
+	I-CHEMICAL
)	I-CHEMICAL
transients	O
that	O
were	O
additive	O
suggesting	O
that	O
they	O
act	O
through	O
different	O
targets	O
.	O

Moreover	O
,	O
Ph1	O
did	O
not	O
inhibit	O
capsaicin	B-CHEMICAL
-	O
activated	O
currents	O
in	O
patch	O
-	O
clamp	O
recordings	O
of	O
HEK293	O
cells	O
that	O
expressed	O
TRPV1	B-GENE-Y
receptors	O
.	O

Our	O
results	O
show	O
that	O
Ph1	O
may	O
be	O
effective	O
as	O
a	O
therapeutic	O
strategy	O
for	O
pain	O
and	O
this	O
effect	O
is	O
not	O
related	O
to	O
the	O
inhibition	O
of	O
TRPV1	B-GENE-Y
receptors	O
.	O

Rescue	O
of	O
platinum	B-CHEMICAL
-	O
damaged	O
oocytes	O
from	O
programmed	O
cell	O
death	O
through	O
inactivation	O
of	O
the	O
p53	B-GENE-Y
family	O
signaling	O
network	O
.	O

Non	O
-	O
proliferating	O
oocytes	O
within	O
avascular	O
regions	O
of	O
the	O
ovary	O
are	O
exquisitely	O
susceptible	O
to	O
chemotherapy	O
.	O

Early	O
menopause	O
and	O
sterility	O
are	O
unintended	O
consequences	O
of	O
chemotherapy	O
,	O
and	O
efforts	O
to	O
understand	O
the	O
oocyte	O
apoptotic	O
pathway	O
may	O
provide	O
new	O
targets	O
for	O
mitigating	O
this	O
outcome	O
.	O

Recently	O
,	O
the	O
c	B-GENE-Y
-	I-GENE-Y
Abl	I-GENE-Y
kinase	B-GENE-N
inhibitor	O
imatinib	B-CHEMICAL
mesylate	I-CHEMICAL
(	O
imatinib	B-CHEMICAL
)	O
has	O
become	O
the	O
focus	O
of	O
research	O
as	O
a	O
fertoprotective	O
drug	O
against	O
cisplatin	B-CHEMICAL
.	O

However	O
,	O
the	O
mechanism	O
by	O
which	O
imatinib	B-CHEMICAL
protects	O
oocytes	O
is	O
not	O
fully	O
understood	O
,	O
and	O
reports	O
of	O
the	O
drug	O
'	O
s	O
efficacy	O
have	O
been	O
contradictory	O
.	O

Using	O
in	O
vitro	O
culture	O
and	O
subrenal	O
grafting	O
of	O
mouse	O
ovaries	O
,	O
we	O
demonstrated	O
that	O
imatinib	B-CHEMICAL
inhibits	O
the	O
cisplatin	B-CHEMICAL
-	O
induced	O
apoptosis	O
of	O
oocytes	O
within	O
primordial	O
follicles	O
.	O

We	O
found	O
that	O
,	O
before	O
apoptosis	O
,	O
cisplatin	B-CHEMICAL
induces	O
c	B-GENE-Y
-	I-GENE-Y
Abl	I-GENE-Y
and	O
TAp73	B-GENE-Y
expression	O
in	O
the	O
oocyte	O
.	O

Oocytes	O
undergoing	O
apoptosis	O
showed	O
downregulation	O
of	O
TAp63	B-GENE-Y
and	O
upregulation	O
of	O
Bax	B-GENE-Y
.	O

While	O
imatinib	B-CHEMICAL
was	O
unable	O
to	O
block	O
cisplatin	B-CHEMICAL
-	O
induced	O
DNA	O
damage	O
and	O
damage	O
response	O
,	O
such	O
as	O
the	O
upregulation	O
of	O
p53	B-GENE-Y
,	O
imatinib	B-CHEMICAL
inhibited	O
the	O
cisplatin	B-CHEMICAL
-	O
induced	O
nuclear	O
accumulation	O
of	O
c	B-GENE-Y
-	I-GENE-Y
Abl	I-GENE-Y
/	O
TAp73	B-GENE-Y
and	O
the	O
subsequent	O
downregulation	O
of	O
TAp63	B-GENE-Y
and	O
upregulation	O
of	O
Bax	B-GENE-Y
,	O
thereby	O
abrogating	O
oocyte	O
cell	O
death	O
.	O

Surprisingly	O
,	O
the	O
conditional	O
deletion	O
of	O
Trp63	B-GENE-Y
,	O
but	O
not	O
Np63	B-GENE-Y
,	O
in	O
oocytes	O
inhibited	O
apoptosis	O
,	O
as	O
well	O
as	O
the	O
accumulation	O
of	O
c	B-GENE-Y
-	I-GENE-Y
Abl	I-GENE-Y
and	O
TAp73	B-GENE-Y
caused	O
by	O
cisplatin	B-CHEMICAL
.	O

These	O
data	O
suggest	O
that	O
TAp63	B-GENE-Y
is	O
the	O
master	O
regulator	O
of	O
cisplatin	B-CHEMICAL
-	O
induced	O
oocyte	O
death	O
.	O

The	O
expression	O
kinetics	O
of	O
TAp63	B-GENE-Y
,	O
c	B-GENE-Y
-	I-GENE-Y
Abl	I-GENE-Y
and	O
TAp73	B-GENE-Y
suggest	O
that	O
cisplatin	B-CHEMICAL
activates	O
TAp63	B-GENE-Y
-	O
dependent	O
expression	O
of	O
c	B-GENE-Y
-	I-GENE-Y
Abl	I-GENE-Y
and	O
TAp73	B-GENE-Y
and	O
,	O
in	O
turn	O
,	O
the	O
activation	O
of	O
TAp73	B-GENE-Y
by	O
c	B-GENE-Y
-	I-GENE-Y
Abl	I-GENE-Y
-	O
induced	O
BAX	B-GENE-Y
expression	O
.	O

Our	O
findings	O
indicate	O
that	O
imatinib	B-CHEMICAL
protects	O
oocytes	O
from	O
cisplatin	B-CHEMICAL
-	O
induced	O
cell	O
death	O
by	O
inhibiting	O
c	B-GENE-Y
-	I-GENE-Y
Abl	I-GENE-Y
kinase	B-GENE-N
,	O
which	O
would	O
otherwise	O
activate	O
TAp73	B-GENE-Y
-	O
BAX	B-GENE-Y
-	O
mediated	O
apoptosis	O
.	O

Thus	O
,	O
imatinib	B-CHEMICAL
and	O
other	O
c	B-GENE-Y
-	I-GENE-Y
Abl	I-GENE-Y
kinase	B-GENE-N
inhibitors	O
provide	O
an	O
intriguing	O
new	O
way	O
to	O
halt	O
cisplatin	B-CHEMICAL
-	O
induced	O
oocyte	O
death	O
in	O
early	O
follicles	O
and	O
perhaps	O
conserve	O
the	O
endocrine	O
function	O
of	O
the	O
ovary	O
against	O
chemotherapy	O
.	O
Cell	O
Death	O
and	O
Differentiation	O
advance	O
online	O
publication	O
,	O
19	O
April	O
2013	O
;	O
doi	O
:	O
10	O
.	O
1038	O
/	O
cdd	O
.	O
2013	O
.	O
31	O
.	O

Suppression	O
of	O
ZIP8	B-GENE-Y
expression	O
is	O
a	O
common	O
feature	O
of	O
cadmium	B-CHEMICAL
-	O
resistant	O
and	O
manganese	B-CHEMICAL
-	O
resistant	O
RBL	O
-	O
2H3	O
cells	O
.	O

Rat	O
basophilic	O
leukemia	O
RBL	O
-	O
2H3	O
cells	O
show	O
markedly	O
high	O
sensitivity	O
to	O
both	O
CdCl2	B-CHEMICAL
and	O
MnCl2	B-CHEMICAL
compared	O
with	O
other	O
rat	O
cell	O
lines	O
,	O
due	O
to	O
efficient	O
accumulation	O
of	O
cadmium	B-CHEMICAL
and	O
manganese	B-CHEMICAL
.	O

To	O
clarify	O
the	O
roles	O
of	O
metal	B-GENE-N
transporters	I-GENE-N
in	O
hyperaccumulation	O
of	O
cadmium	B-CHEMICAL
and	O
manganese	B-CHEMICAL
in	O
RBL	O
-	O
2H3	O
cells	O
,	O
Cd	B-CHEMICAL
-	O
resistant	O
and	O
Mn	B-CHEMICAL
-	O
resistant	O
cells	O
were	O
developed	O
from	O
RBL	O
-	O
2H3	O
cells	O
by	O
continuous	O
exposure	O
to	O
CdCl2	B-CHEMICAL
and	O
MnCl2	B-CHEMICAL
,	O
respectively	O
.	O

The	O
established	O
Cd	B-CHEMICAL
-	O
resistant	O
(	O
RBL	O
-	O
Cdr	O
)	O
and	O
Mn	B-CHEMICAL
-	O
resistant	O
(	O
RBL	O
-	O
Mnr	O
)	O
cells	O
exhibited	O
about	O
20	O
times	O
higher	O
LC50	O
values	O
of	O
CdCl2	B-CHEMICAL
and	O
MnCl2	B-CHEMICAL
,	O
respectively	O
,	O
than	O
parental	O
RBL	O
-	O
2H3	O
cells	O
,	O
and	O
showed	O
cross	O
-	O
resistance	O
to	O
each	O
metal	O
.	O

The	O
resistance	O
to	O
cadmium	B-CHEMICAL
and	O
manganese	B-CHEMICAL
was	O
primarily	O
conferred	O
by	O
a	O
marked	O
decrease	O
in	O
the	O
uptake	O
of	O
both	O
metals	O
.	O

RBL	O
-	O
Cdr	O
cells	O
also	O
showed	O
cross	O
-	O
resistance	O
to	O
HgCl2	B-CHEMICAL
and	O
AgNO3	B-CHEMICAL
probably	O
due	O
to	O
enhanced	O
expression	O
of	O
metallothionein	B-GENE-N
.	O

Among	O
the	O
possible	O
transporters	O
involved	O
in	O
the	O
uptake	O
of	O
Cd	B-CHEMICAL
(	I-CHEMICAL
2	I-CHEMICAL
+	I-CHEMICAL
)	I-CHEMICAL
and	O
Mn	B-CHEMICAL
(	I-CHEMICAL
2	I-CHEMICAL
+	I-CHEMICAL
)	I-CHEMICAL
,	O
the	O
expression	O
of	O
ZIP8	B-GENE-Y
(	O
Zrt	B-GENE-Y
-	I-GENE-Y
,	I-GENE-Y
Irt	I-GENE-Y
-	I-GENE-Y
related	I-GENE-Y
protein	I-GENE-Y
8	I-GENE-Y
)	O
,	O
encoded	O
by	O
Slc39a8	B-GENE-Y
,	O
showed	O
a	O
marked	O
suppression	O
in	O
both	O
RBL	O
-	O
Cdr	O
and	O
RBL	O
-	O
Mnr	O
cells	O
.	O

These	O
results	O
suggest	O
that	O
ZIP8	B-GENE-Y
plays	O
a	O
pivotal	O
role	O
in	O
the	O
transport	O
and	O
toxicity	O
of	O
Cd	B-CHEMICAL
(	I-CHEMICAL
2	I-CHEMICAL
+	I-CHEMICAL
)	I-CHEMICAL
and	O
Mn	B-CHEMICAL
(	I-CHEMICAL
2	I-CHEMICAL
+	I-CHEMICAL
)	I-CHEMICAL
in	O
RBL	O
-	O
2H3	O
cells	O
.	O

In	O
Vitro	O
Reconstitution	O
of	O
Complexes	O
between	O
proMatrix	B-GENE-Y
Metalloproteinase	I-GENE-Y
-	I-GENE-Y
9	I-GENE-Y
and	O
the	O
Proteoglycans	O
Serglycin	O
and	O
Versican	O
.	O

Previously	O
we	O
have	O
shown	O
that	O
a	O
fraction	O
of	O
the	O
matrix	B-GENE-Y
metalloproteinase	I-GENE-Y
-	I-GENE-Y
9	I-GENE-Y
(	O
MMP	B-GENE-Y
-	I-GENE-Y
9	I-GENE-Y
)	O
synthesized	O
by	O
the	O
macrophage	O
cell	O
line	O
THP	O
-	O
1	O
was	O
bound	O
to	O
a	O
chondroitin	B-GENE-N
sulphate	I-GENE-N
proteoglycan	I-GENE-N
(	I-GENE-N
CSPG	I-GENE-N
)	I-GENE-N
core	I-GENE-N
protein	I-GENE-N
as	O
a	O
reduction	O
sensitive	O
heteromer	O
.	O

It	O
was	O
also	O
shown	O
that	O
the	O
hemopexin	B-GENE-N
-	I-GENE-N
like	I-GENE-N
(	I-GENE-N
PEX	I-GENE-N
)	I-GENE-N
domain	I-GENE-N
and	O
the	O
fibronectin	B-GENE-N
-	I-GENE-N
like	I-GENE-N
(	I-GENE-N
FnII	I-GENE-N
)	I-GENE-N
module	I-GENE-N
in	O
the	O
enzyme	O
are	O
involved	O
in	O
the	O
heteromer	O
formation	O
.	O

In	O
the	O
present	O
work	O
we	O
show	O
that	O
reduction	O
sensitive	O
and	O
SDS	B-CHEMICAL
-	O
stable	O
heteromers	O
can	O
be	O
reconstituted	O
in	O
vitro	O
by	O
mixing	O
proMMP	B-GENE-Y
-	I-GENE-Y
9	I-GENE-Y
with	O
either	O
serglycin	O
,	O
versican	O
or	O
CSPGs	B-GENE-N
isolated	O
from	O
various	O
monocytic	O
cell	O
lines	O
.	O

In	O
addition	O
,	O
a	O
strong	O
but	O
SDS	B-CHEMICAL
-	O
soluble	O
proMMP	B-GENE-Y
-	I-GENE-Y
9	I-GENE-Y
	O
CSPG	B-GENE-N
heteromer	O
was	O
formed	O
.	O

The	O
two	O
macromolecules	O
in	O
the	O
SDS	B-CHEMICAL
-	O
stable	O
reduction	O
sensitive	O
heteromers	O
were	O
not	O
linked	O
together	O
by	O
disulphide	B-CHEMICAL
bonds	O
.	O

As	O
for	O
the	O
heteromer	O
isolated	O
from	O
THP	O
-	O
1	O
cells	O
,	O
the	O
in	O
vitro	O
reconstituted	O
SDS	B-CHEMICAL
-	O
stable	O
and	O
SDS	B-CHEMICAL
-	O
soluble	O
heteromers	O
had	O
a	O
weaker	O
binding	O
to	O
gelatin	O
than	O
the	O
proMMP	B-GENE-Y
-	I-GENE-Y
9	I-GENE-Y
monomer	O
.	O

Furthermore	O
,	O
gelatin	O
inhibited	O
the	O
in	O
vitro	O
reconstitution	O
of	O
the	O
heteromers	O
,	O
showing	O
that	O
the	O
FnII	B-GENE-N
module	I-GENE-N
is	O
involved	O
in	O
the	O
complex	O
formation	O
.	O

TIMP	B-GENE-Y
-	I-GENE-Y
1	I-GENE-Y
could	O
not	O
be	O
detected	O
in	O
the	O
formed	O
proMMP	B-GENE-Y
-	I-GENE-Y
9	I-GENE-Y
	O
CSPG	B-GENE-N
complexes	O
.	O

However	O
,	O
the	O
presence	O
of	O
TIMP	B-GENE-Y
-	I-GENE-Y
1	I-GENE-Y
inhibited	O
the	O
formation	O
of	O
the	O
SDS	B-CHEMICAL
-	O
soluble	O
heteromer	O
,	O
but	O
not	O
the	O
SDS	B-CHEMICAL
-	O
stable	O
reduction	O
sensitive	O
heteromer	O
.	O

This	O
indicates	O
that	O
different	O
regions	O
in	O
the	O
PEX	B-GENE-N
domain	I-GENE-N
are	O
involved	O
the	O
formation	O
of	O
these	O
heteromers	O
.	O

This	O
article	O
is	O
protected	O
by	O
copyright	O
.	O

All	O
rights	O
reserved	O
.	O

Optimization	O
of	O
a	O
1	B-CHEMICAL
,	I-CHEMICAL
5	I-CHEMICAL
-	I-CHEMICAL
dihydrobenzo	I-CHEMICAL
[	I-CHEMICAL
b	I-CHEMICAL
]	I-CHEMICAL
[	I-CHEMICAL
1	I-CHEMICAL
,	I-CHEMICAL
4	I-CHEMICAL
]	I-CHEMICAL
diazepine	I-CHEMICAL
-	I-CHEMICAL
2	I-CHEMICAL
,	I-CHEMICAL
4	I-CHEMICAL
-	I-CHEMICAL
dione	I-CHEMICAL
series	O
of	O
HIV	B-GENE-N
capsid	I-GENE-N
assembly	O
inhibitors	O
2	O
:	O
Structure	O
-	O
activity	O
relationships	O
(	O
SAR	O
)	O
of	O
the	O
C3	O
-	O
phenyl	B-CHEMICAL
moiety	O
.	O

Detailed	O
structure	O
-	O
activity	O
relationships	O
of	O
the	O
C3	O
-	O
phenyl	B-CHEMICAL
moiety	O
that	O
allow	O
for	O
the	O
optimization	O
of	O
antiviral	O
potency	O
of	O
a	O
series	O
of	O
1	B-CHEMICAL
,	I-CHEMICAL
5	I-CHEMICAL
-	I-CHEMICAL
dihydrobenzo	I-CHEMICAL
[	I-CHEMICAL
b	I-CHEMICAL
]	I-CHEMICAL
[	I-CHEMICAL
1	I-CHEMICAL
,	I-CHEMICAL
4	I-CHEMICAL
]	I-CHEMICAL
diazepine	I-CHEMICAL
-	I-CHEMICAL
2	I-CHEMICAL
,	I-CHEMICAL
4	I-CHEMICAL
-	I-CHEMICAL
dione	I-CHEMICAL
inhibitors	O
of	O
HIV	B-GENE-N
capsid	I-GENE-N
(	O
CA	B-GENE-N
)	O
assembly	O
are	O
described	O
.	O

Combination	O
of	O
favorable	O
substitutions	O
gave	O
additive	O
SAR	O
and	O
allowed	O
for	O
the	O
identification	O
of	O
the	O
most	O
potent	O
compound	O
in	O
the	O
series	O
,	O
analog	O
27	O
.	O

Productive	O
SAR	O
also	O
transferred	O
to	O
the	O
benzotriazepine	B-CHEMICAL
and	O
spirobenzodiazepine	B-CHEMICAL
scaffolds	O
,	O
providing	O
a	O
solution	O
to	O
the	O
labile	O
stereocenter	O
at	O
the	O
C3	O
position	O
.	O

The	O
molecular	O
basis	O
of	O
how	O
compound	O
27	O
inhibits	O
mature	O
CA	B-GENE-N
assembly	O
is	O
rationalized	O
using	O
high	O
-	O
resolution	O
structural	O
information	O
.	O

Our	O
understanding	O
of	O
how	O
compound	O
27	O
may	O
inhibit	O
immature	O
Gag	B-GENE-N
assembly	O
is	O
also	O
discussed	O
.	O

Neuroactive	O
effects	O
of	O
cotinine	B-CHEMICAL
on	O
the	O
hippocampus	O
:	O
Behavioral	O
and	O
biochemical	O
parameters	O
.	O

The	O
present	O
work	O
evaluated	O
the	O
effects	O
of	O
nicotine	B-CHEMICAL
(	O
NIC	B-CHEMICAL
)	O
,	O
cotinine	B-CHEMICAL
(	O
COT	B-CHEMICAL
)	O
,	O
mecamylamine	B-CHEMICAL
(	O
MEC	B-CHEMICAL
)	O
,	O
methyllycaconitine	B-CHEMICAL
(	O
MLA	B-CHEMICAL
)	O
and	O
dihydro	B-CHEMICAL
-	I-CHEMICAL
beta	I-CHEMICAL
-	I-CHEMICAL
eritroidine	I-CHEMICAL
(	O
DHE	B-CHEMICAL
)	O
on	O
memory	O
extinction	O
and	O
the	O
following	O
biochemical	O
parameters	O
of	O
the	O
hippocampus	O
:	O
lipid	O
peroxidation	O
(	O
LPO	O
)	O
,	O
antioxidant	O
capacity	O
(	O
AC	O
)	O
and	O
the	O
phosphorylation	O
of	O
Extracellular	B-GENE-N
-	I-GENE-N
Signal	I-GENE-N
-	I-GENE-N
Regulated	I-GENE-N
Kinase	I-GENE-N
(	O
ERK	B-GENE-N
1	I-GENE-N
/	I-GENE-N
2	I-GENE-N
)	O
.	O

Young	O
male	O
rats	O
that	O
were	O
implanted	O
bilaterally	O
with	O
cannulae	O
were	O
submitted	O
to	O
memory	O
extinction	O
tests	O
sessions	O
,	O
and	O
their	O
hippocampi	O
were	O
dissected	O
for	O
biochemical	O
assays	O
.	O

The	O
extinction	O
of	O
fear	O
memory	O
was	O
significantly	O
improved	O
by	O
both	O
nicotine	B-CHEMICAL
and	O
its	O
metabolite	O
.	O

Cotinine	B-CHEMICAL
significantly	O
increased	O
LPO	O
,	O
while	O
nicotine	B-CHEMICAL
significantly	O
decreased	O
it	O
.	O

Antioxidant	O
capacity	O
was	O
increased	O
by	O
all	O
treatments	O
.	O

Our	O
results	O
showed	O
that	O
cotinine	B-CHEMICAL
,	O
unlike	O
nicotine	B-CHEMICAL
,	O
may	O
increase	O
oxidative	O
stress	O
in	O
the	O
hippocampus	O
,	O
but	O
this	O
increase	O
depends	O
upon	O
the	O
dose	O
used	O
and	O
happens	O
without	O
causing	O
corresponding	O
impairments	O
in	O
cognitive	O
function	O
.	O

Cotinine	B-CHEMICAL
also	O
increased	O
the	O
phosphorylation	O
of	O
ERK	B-GENE-N
1	I-GENE-N
/	I-GENE-N
2	I-GENE-N
in	O
a	O
similar	O
fashion	O
as	O
nicotine	B-CHEMICAL
.	O

Considering	O
these	O
results	O
,	O
it	O
is	O
plausible	O
to	O
wonder	O
to	O
what	O
extent	O
nicotine	B-CHEMICAL
-	O
attributed	O
effects	O
are	O
really	O
due	O
to	O
the	O
actions	O
of	O
this	O
alkaloid	O
and	O
whether	O
they	O
could	O
be	O
due	O
instead	O
to	O
cotinine	B-CHEMICAL
or	O
to	O
cotinine	B-CHEMICAL
-	O
nicotine	B-CHEMICAL
interactions	O
within	O
the	O
brain	O
.	O

Arsenic	B-CHEMICAL
upregulates	O
the	O
expression	O
of	O
angiotensin	B-GENE-N
II	I-GENE-N
Type	I-GENE-N
I	I-GENE-N
receptor	I-GENE-N
in	O
mouse	O
aortic	O
endothelial	O
cells	O
.	O

Although	O
chronic	O
arsenic	B-CHEMICAL
exposure	O
is	O
a	O
well	O
-	O
known	O
risk	O
for	O
cardiovascular	O
disease	O
and	O
has	O
a	O
strong	O
correlation	O
with	O
hypertension	O
,	O
the	O
molecular	O
pathogenesis	O
underlying	O
arsenic	B-CHEMICAL
exposure	O
-	O
induced	O
hypertension	O
remains	O
poorly	O
understood	O
.	O

To	O
delineate	O
the	O
pathogenesis	O
,	O
we	O
examined	O
changes	O
in	O
the	O
mRNA	O
levels	O
of	O
2	O
angiotensin	B-GENE-N
II	I-GENE-N
Type	I-GENE-N
I	I-GENE-N
receptor	I-GENE-N
(	O
AT1R	B-GENE-N
)	O
subtypes	O
,	O
AT1AR	B-GENE-Y
and	O
AT1BR	B-GENE-Y
,	O
in	O
a	O
mouse	O
aortic	O
endothelial	O
cell	O
line	O
,	O
END	O
-	O
D	O
.	O

Quantitative	O
real	O
-	O
time	O
PCR	O
analysis	O
revealed	O
significant	O
increases	O
in	O
the	O
mRNA	O
levels	O
of	O
2	O
AT1R	B-GENE-N
subtypes	O
,	O
AT1AR	B-GENE-Y
and	O
AT1BR	B-GENE-Y
following	O
sodium	B-CHEMICAL
arsenite	I-CHEMICAL
(	O
SA	O
)	O
treatment	O
.	O

Flow	O
cytometry	O
analysis	O
revealed	O
that	O
SA	O
increases	O
the	O
generation	O
of	O
reactive	O
oxygen	B-CHEMICAL
species	O
(	O
ROS	O
)	O
in	O
a	O
dose	O
-	O
dependent	O
manner	O
.	O

In	O
addition	O
,	O
western	O
blot	O
analysis	O
revealed	O
that	O
SA	O
enhances	O
the	O
phosphorylations	O
of	O
c	B-GENE-N
-	I-GENE-N
Jun	I-GENE-N
N	I-GENE-N
-	I-GENE-N
terminal	I-GENE-N
kinases	I-GENE-N
(	O
JNK	B-GENE-N
)	O
and	O
activated	B-GENE-Y
protein	I-GENE-Y
1	I-GENE-Y
(	O
AP	B-GENE-Y
-	I-GENE-Y
1	I-GENE-Y
)	O
.	O

These	O
phosphorylations	O
were	O
inhibited	O
by	O
N	B-CHEMICAL
-	I-CHEMICAL
acetylcysteine	I-CHEMICAL
(	O
NAC	B-CHEMICAL
)	O
,	O
an	O
anti	O
-	O
oxidant	O
.	O

Finally	O
,	O
SA	O
-	O
induced	O
AT1R	B-GENE-N
expression	O
was	O
found	O
to	O
be	O
prevented	O
both	O
by	O
NAC	O
and	O
specific	O
JNK	B-GENE-N
inhibitor	O
,	O
SP6001325	B-CHEMICAL
,	O
strongly	O
indicating	O
that	O
AT1R	B-GENE-N
upregulation	O
is	O
a	O
result	O
of	O
the	O
ROS	O
-	O
mediated	O
activation	O
of	O
the	O
JNK	B-GENE-N
signaling	O
pathway	O
.	O

Taken	O
together	O
,	O
our	O
results	O
indicate	O
that	O
arsenic	B-CHEMICAL
indeed	O
upregulates	O
the	O
AT1R	B-GENE-N
expression	O
,	O
thus	O
highlighting	O
a	O
role	O
of	O
arsenic	B-CHEMICAL
-	O
induced	O
aberrant	O
AT1R	B-GENE-N
signaling	O
in	O
the	O
pathogenesis	O
of	O
hypertension	O
.	O

Protective	O
effects	O
of	O
selenium	B-CHEMICAL
on	O
oxidative	O
damage	O
and	O
oxidative	O
stress	O
related	O
gene	O
expression	O
in	O
rat	O
liver	O
under	O
chronic	O
poisoning	O
of	O
arsenic	B-CHEMICAL
.	O

Arsenic	B-CHEMICAL
(	O
As	B-CHEMICAL
)	O
is	O
a	O
toxic	O
metalloid	O
existing	O
widely	O
in	O
the	O
environment	O
,	O
and	O
chronic	O
exposure	O
to	O
it	O
through	O
contaminated	O
drinking	O
water	O
has	O
become	O
a	O
global	O
problem	O
of	O
public	O
health	O
.	O

The	O
present	O
study	O
focused	O
on	O
the	O
protective	O
effects	O
of	O
selenium	B-CHEMICAL
on	O
oxidative	O
damage	O
of	O
chronic	O
arsenic	B-CHEMICAL
poisoning	O
in	O
rat	O
liver	O
.	O

Rats	O
were	O
divided	O
into	O
four	O
groups	O
at	O
random	O
and	O
given	O
designed	O
treatments	O
for	O
20weeks	O
.	O

The	O
oxidative	O
damage	O
of	O
liver	O
tissue	O
was	O
evaluated	O
by	O
lipid	O
peroxidation	O
and	O
antioxidant	O
enzymes	O
.	O

Oxidative	O
stress	O
related	O
genes	O
were	O
detected	O
to	O
reflect	O
the	O
liver	O
stress	O
state	O
at	O
the	O
molecular	O
level	O
.	O

Compared	O
to	O
the	O
control	O
and	O
Na2SeO3	B-CHEMICAL
groups	O
,	O
the	O
MDA	B-CHEMICAL
content	O
in	O
liver	O
tissue	O
was	O
decreased	O
and	O
the	O
activities	O
of	O
antioxidant	O
enzymes	O
were	O
increased	O
in	O
the	O
Na2SeO3	B-CHEMICAL
intervention	O
group	O
.	O

The	O
mRNA	O
levels	O
of	O
SOD1	B-GENE-Y
,	O
CAT	B-GENE-Y
,	O
GPx	B-GENE-N
and	O
Txnrd1	B-GENE-Y
were	O
increased	O
significantly	O
(	O
P	O
<	O
0	O
.	O
05	O
)	O
in	O
the	O
combined	O
Na2SeO3	B-CHEMICAL
+	O
NaAsO2	B-CHEMICAL
treatment	O
group	O
.	O

The	O
expressions	O
of	O
HSP70	B-GENE-N
and	O
HO	B-GENE-Y
-	I-GENE-Y
1	I-GENE-Y
were	O
significantly	O
(	O
P	O
<	O
0	O
.	O
05	O
)	O
increased	O
in	O
the	O
NaAsO2	B-CHEMICAL
group	O
and	O
reduced	O
in	O
the	O
combined	O
treatment	O
group	O
.	O

The	O
results	O
indicate	O
that	O
long	O
-	O
term	O
intake	O
of	O
NaAsO2	B-CHEMICAL
causes	O
oxidative	O
damage	O
in	O
the	O
rat	O
liver	O
,	O
and	O
Na2SeO3	B-CHEMICAL
protects	O
liver	O
cells	O
by	O
adjusting	O
the	O
expression	O
of	O
oxidative	O
stress	O
related	O
genes	O
to	O
improve	O
the	O
activities	O
of	O
antioxidant	O
enzymes	O
.	O

Aldose	B-GENE-Y
Reductase	I-GENE-Y
Inhibitory	O
Compounds	O
from	O
Xanthium	O
strumarium	O
.	O

As	O
part	O
of	O
our	O
ongoing	O
search	O
for	O
natural	O
sources	O
of	O
therapeutic	O
and	O
preventive	O
agents	O
for	O
diabetic	O
complications	O
,	O
we	O
evaluated	O
the	O
inhibitory	O
effects	O
of	O
components	O
of	O
the	O
fruit	O
of	O
Xanthium	O
strumarium	O
(	O
X	O
.	O
strumarium	O
)	O
on	O
aldose	B-GENE-Y
reductase	I-GENE-Y
(	O
AR	B-GENE-Y
)	O
and	O
galactitol	B-CHEMICAL
formation	O
in	O
rat	O
lenses	O
with	O
high	O
levels	O
of	O
glucose	B-CHEMICAL
.	O

To	O
identify	O
the	O
bioactive	O
components	O
of	O
X	O
.	O
strumarium	O
,	O
7	O
caffeoylquinic	B-CHEMICAL
acids	I-CHEMICAL
and	O
3	O
phenolic	B-CHEMICAL
compounds	O
were	O
isolated	O
and	O
their	O
chemical	O
structures	O
were	O
elucidated	O
on	O
the	O
basis	O
of	O
spectroscopic	O
evidence	O
and	O
comparison	O
with	O
published	O
data	O
.	O

The	O
abilities	O
of	O
10	O
X	O
.	O
strumarium	O
-	O
derived	O
components	O
to	O
counteract	O
diabetic	O
complications	O
were	O
investigated	O
by	O
means	O
of	O
inhibitory	O
assays	O
with	O
rat	B-GENE-Y
lens	I-GENE-Y
AR	I-GENE-Y
(	O
rAR	B-GENE-Y
)	O
and	O
recombinant	O
human	B-GENE-Y
AR	I-GENE-Y
(	O
rhAR	B-GENE-Y
)	O
.	O

From	O
the	O
10	O
isolated	O
compounds	O
,	O
methyl	B-CHEMICAL
-	I-CHEMICAL
3	I-CHEMICAL
,	I-CHEMICAL
5	I-CHEMICAL
-	I-CHEMICAL
di	I-CHEMICAL
-	I-CHEMICAL
O	I-CHEMICAL
-	I-CHEMICAL
caffeoylquinate	I-CHEMICAL
showed	O
the	O
most	O
potent	O
inhibition	O
,	O
with	O
IC50	O
values	O
of	O
0	O
.	O
30	O
and	O
0	O
.	O
67	O
M	O
for	O
rAR	B-GENE-Y
and	O
rhAR	B-GENE-Y
,	O
respectively	O
.	O

In	O
the	O
kinetic	O
analyses	O
using	O
Lineweaver	O
-	O
Burk	O
plots	O
of	O
1	O
/	O
velocity	O
and	O
1	O
/	O
substrate	O
,	O
methyl	B-CHEMICAL
-	I-CHEMICAL
3	I-CHEMICAL
,	I-CHEMICAL
5	I-CHEMICAL
-	I-CHEMICAL
di	I-CHEMICAL
-	I-CHEMICAL
O	I-CHEMICAL
-	I-CHEMICAL
caffeoylquinate	I-CHEMICAL
showed	O
competitive	O
inhibition	O
of	O
rhAR	B-GENE-Y
.	O

Furthermore	O
,	O
methyl	B-CHEMICAL
-	I-CHEMICAL
3	I-CHEMICAL
,	I-CHEMICAL
5	I-CHEMICAL
-	I-CHEMICAL
di	I-CHEMICAL
-	I-CHEMICAL
O	I-CHEMICAL
-	I-CHEMICAL
caffeoylquinate	I-CHEMICAL
inhibited	O
galactitol	B-CHEMICAL
formation	O
in	O
the	O
rat	O
lens	O
and	O
in	O
erythrocytes	O
incubated	O
with	O
a	O
high	O
concentration	O
of	O
glucose	B-CHEMICAL
,	O
indicating	O
that	O
this	O
compound	O
may	O
be	O
effective	O
in	O
preventing	O
diabetic	O
complications	O
.	O

Synthesis	O
,	O
cytotoxicity	O
and	O
QSAR	O
study	O
of	O
N	B-CHEMICAL
-	I-CHEMICAL
tosyl	I-CHEMICAL
-	I-CHEMICAL
1	I-CHEMICAL
,	I-CHEMICAL
2	I-CHEMICAL
,	I-CHEMICAL
3	I-CHEMICAL
,	I-CHEMICAL
4	I-CHEMICAL
-	I-CHEMICAL
tetrahydroisoquinoline	I-CHEMICAL
derivatives	O
.	O

1	B-CHEMICAL
-	I-CHEMICAL
Substituted	I-CHEMICAL
-	I-CHEMICAL
N	I-CHEMICAL
-	I-CHEMICAL
tosyl	I-CHEMICAL
-	I-CHEMICAL
1	I-CHEMICAL
,	I-CHEMICAL
2	I-CHEMICAL
,	I-CHEMICAL
3	I-CHEMICAL
,	I-CHEMICAL
4	I-CHEMICAL
-	I-CHEMICAL
tetrahydroisoquinoline	I-CHEMICAL
analogs	O
(	O
4a	O
-	O
4l	O
)	O
were	O
synthesized	O
using	O
the	O
modified	O
Pictet	O
-	O
Spengler	O
reaction	O
and	O
evaluated	O
for	O
cytotoxicity	O
.	O

All	O
tetrahydroisoquinolines	B-CHEMICAL
displayed	O
cytotoxicity	O
against	O
MOLT	O
-	O
3	O
cell	O
lines	O
,	O
except	O
for	O
p	B-CHEMICAL
-	I-CHEMICAL
methoxy	I-CHEMICAL
analog	O
4d	O
.	O

Interestingly	O
,	O
the	O
o	B-CHEMICAL
-	I-CHEMICAL
hydroxy	I-CHEMICAL
derivative	O
4k	O
was	O
shown	O
to	O
be	O
the	O
most	O
potent	O
cytotoxic	O
against	O
HuCCA	O
-	O
1	O
,	O
A	O
-	O
549	O
and	O
MOLT	O
-	O
3	O
cell	O
lines	O
.	O

The	O
lowest	O
IC50	O
value	O
of	O
1	O
.	O
23	O
M	O
was	O
observed	O
for	O
MOLT	O
-	O
3	O
cells	O
.	O

Trimethoxy	B-CHEMICAL
analog	O
4f	O
exerted	O
the	O
most	O
potent	O
activity	O
against	O
HepG2	O
with	O
an	O
IC50	O
of	O
22	O
.	O
70	O
M	O
,	O
which	O
is	O
lower	O
than	O
the	O
reference	O
drug	O
,	O
etoposide	O
.	O

QSAR	O
studies	O
showed	O
that	O
total	O
symmetry	O
index	O
(	O
Gu	O
)	O
,	O
3D	O
-	O
MoRSE	O
(	O
Mor31v	O
and	O
Mor32u	O
)	O
and	O
3D	O
Petitjean	O
index	O
(	O
PJI3	O
)	O
were	O
the	O
most	O
important	O
descriptors	O
accounting	O
for	O
the	O
observed	O
cytotoxicities	O
.	O

The	O
most	O
potent	O
cytotoxic	O
compound	O
(	O
4k	O
)	O
against	O
MOLT	O
-	O
3	O
had	O
the	O
highest	O
Gu	O
value	O
,	O
correspondingly	O
the	O
inactive	O
p	B-CHEMICAL
-	I-CHEMICAL
methoxy	I-CHEMICAL
analog	O
(	O
4d	O
)	O
had	O
the	O
lowest	O
Gu	O
value	O
.	O

On	O
the	O
other	O
hand	O
,	O
the	O
highest	O
molecular	O
mass	O
compound	O
(	O
4f	O
)	O
was	O
shown	O
to	O
be	O
the	O
most	O
potent	O
cytotoxic	O
against	O
HepG2	O
cells	O
.	O

The	O
studies	O
disclose	O
that	O
tetrahydroisoquinolines	B-CHEMICAL
4f	O
and	O
4k	O
are	O
potentially	O
interesting	O
lead	O
pharmacophores	O
that	O
should	O
be	O
further	O
explored	O
.	O

The	O
QSAR	O
models	O
provided	O
insights	O
into	O
the	O
physicochemical	O
properties	O
of	O
the	O
investigated	O
compounds	O
.	O

Hydrothermal	O
Growth	O
of	O
TiO2	B-CHEMICAL
Nanorod	O
Arrays	O
and	O
In	O
Situ	O
Conversion	O
to	O
Nanotube	O
Arrays	O
for	O
Highly	O
Efficient	O
Quantum	O
Dot	O
-	O
Sensitized	O
Solar	O
Cells	O
.	O

TiO2	B-CHEMICAL
nanorod	O
(	O
NR	O
)	O
and	O
nanotube	O
(	O
NT	O
)	O
arrays	O
grown	O
on	O
transparent	O
conductive	O
substrates	O
are	O
attractive	O
electrode	O
for	O
solar	O
cells	O
.	O

In	O
this	O
paper	O
,	O
TiO2	B-CHEMICAL
NR	O
arrays	O
are	O
hydrothermally	O
grown	O
on	O
FTO	B-CHEMICAL
substrate	O
,	O
and	O
are	O
in	O
situ	O
converted	O
into	O
NT	O
arrays	O
by	O
hydrothermally	O
etching	O
.	O

The	O
TiO2	B-CHEMICAL
NR	O
arrays	O
are	O
reported	O
as	O
single	O
crystalline	O
,	O
but	O
the	O
TiO2	B-CHEMICAL
NR	O
arrays	O
are	O
demonstrated	O
to	O
be	O
polycrystalline	O
with	O
a	O
bundle	O
of	O
2	O
-	O
5	O
nm	O
single	O
crystalline	O
nanocolumns	O
grown	O
along	O
[	O
001	O
]	O
throughout	O
the	O
whole	O
NR	O
from	O
bottom	O
to	O
top	O
.	O

TiO2	B-CHEMICAL
NRs	O
can	O
be	O
converted	O
to	O
NTs	O
by	O
hydrothermal	O
selective	O
etching	O
of	O
the	O
(	O
001	O
)	O
core	O
and	O
remaining	O
the	O
inert	O
sidewall	O
of	O
(	O
110	O
)	O
face	O
.	O

A	O
growth	O
mechanism	O
of	O
the	O
NR	O
and	O
NT	O
arrays	O
is	O
proposed	O
.	O

Quantum	O
dot	O
-	O
sensitized	O
solar	O
cells	O
(	O
QDSCs	O
)	O
are	O
fabricated	O
by	O
coating	O
CdSe	B-CHEMICAL
QDs	O
on	O
to	O
the	O
TiO2	B-CHEMICAL
arrays	O
.	O

After	O
conversion	O
from	O
NRs	O
to	O
NTs	O
,	O
more	O
QDs	O
can	O
be	O
filled	O
in	O
the	O
NTs	O
and	O
the	O
energy	O
conversion	O
efficiency	O
of	O
the	O
QDSCs	O
almost	O
double	O
.	O

Protective	O
effect	O
of	O
ethyl	B-CHEMICAL
acetate	I-CHEMICAL
fraction	O
of	O
Acacia	O
ferruginea	O
DC	O
.	O
against	O
ethanol	B-CHEMICAL
-	O
induced	O
gastric	O
ulcer	O
in	O
rats	O
.	O

ETHNOPHARMACOLOGICAL	O
RELEVANCE	O
:	O
In	O
traditional	O
systems	O
of	O
medicine	O
,	O
stem	O
bark	O
of	O
Acacia	O
ferruginea	O
DC	O
.	O

is	O
used	O
for	O
the	O
treatment	O
of	O
itching	O
,	O
leucoderma	O
,	O
ulcers	O
,	O
stomatitis	O
and	O
diseases	O
of	O
the	O
blood	O
.	O

In	O
the	O
present	O
study	O
,	O
we	O
determined	O
antioxidant	O
and	O
anti	O
-	O
ulcerogenic	O
activities	O
of	O
Acacia	O
ferruginea	O
stem	O
bark	O
.	O

MATERIALS	O
AND	O
METHODS	O
:	O
Acetone	B-CHEMICAL
extract	O
and	O
its	O
sub	O
-	O
fractions	O
of	O
Acacia	O
ferruginea	O
stem	O
bark	O
were	O
subjected	O
to	O
assess	O
their	O
antioxidant	O
potential	O
using	O
various	O
in	O
vitro	O
systems	O
such	O
as	O
DPPH	B-CHEMICAL
(	I-CHEMICAL
	I-CHEMICAL
)	I-CHEMICAL
,	O
ABTS	B-CHEMICAL
(	I-CHEMICAL
	I-CHEMICAL
+	I-CHEMICAL
)	I-CHEMICAL
scavenging	O
,	O
FRAP	O
and	O
phosphomolybdenum	B-CHEMICAL
reduction	O
activities	O
.	O

Based	O
on	O
the	O
antioxidant	O
potential	O
,	O
the	O
ethyl	O
acetate	O
fraction	O
was	O
used	O
to	O
evaluate	O
the	O
protective	O
effect	O
of	O
ethanol	B-CHEMICAL
-	O
induced	O
gastric	O
damage	O
in	O
rat	O
model	O
.	O

Enzyme	O
activities	O
such	O
as	O
superoxide	B-GENE-N
dismutase	I-GENE-N
,	O
glutathione	B-CHEMICAL
,	O
catalase	B-GENE-Y
and	O
lipid	O
peroxidation	O
were	O
also	O
determined	O
in	O
the	O
stomach	O
tissues	O
.	O

RESULTS	O
:	O
Ethyl	B-CHEMICAL
acetate	I-CHEMICAL
fraction	O
(	O
AFE	O
)	O
of	O
Acacia	O
ferruginea	O
stem	O
bark	O
registered	O
higher	O
antioxidant	O
and	O
free	O
radical	O
scavenging	O
activities	O
than	O
the	O
crude	O
acetone	B-CHEMICAL
extract	O
and	O
other	O
fractions	O
.	O

In	O
addition	O
,	O
AFE	O
exhibited	O
that	O
the	O
IC50	O
values	O
of	O
DPPH	B-CHEMICAL
(	O
2	O
.	O
5g	O
/	O
ml	O
)	O
and	O
ABTS	B-CHEMICAL
(	O
1	O
.	O
8g	O
/	O
ml	O
)	O
were	O
lower	O
when	O
compared	O
to	O
the	O
standard	O
quercetin	B-CHEMICAL
(	O
12	O
.	O
4g	O
/	O
ml	O
and	O
4	O
.	O
7g	O
/	O
ml	O
,	O
respectively	O
)	O
.	O

In	O
ethanol	B-CHEMICAL
induced	O
gastric	O
ulcer	O
,	O
administration	O
of	O
AFE	O
at	O
doses	O
of	O
10mg	O
/	O
kg	O
,	O
50mg	O
/	O
kg	O
and	O
100mg	O
/	O
kg	O
body	O
weight	O
prior	O
to	O
ethanol	B-CHEMICAL
ingestion	O
significantly	O
protected	O
the	O
stomach	O
ulceration	O
.	O

Consequently	O
significant	O
changes	O
were	O
observed	O
in	O
enzyme	O
activities	O
such	O
as	O
SOD	B-GENE-N
,	O
CAT	B-GENE-Y
,	O
GSH	B-CHEMICAL
and	O
LPO	O
in	O
the	O
stomach	O
tissues	O
when	O
compared	O
with	O
ethanol	B-CHEMICAL
control	O
group	O
.	O

CONCLUSION	O
:	O
It	O
is	O
concluded	O
that	O
the	O
ethyl	B-CHEMICAL
acetate	I-CHEMICAL
fraction	O
of	O
Acacia	O
ferruginea	O
stem	O
bark	O
possessed	O
higher	O
antioxidant	O
and	O
anti	O
-	O
ulcerogenic	O
activities	O
.	O

Based	O
on	O
the	O
results	O
we	O
suggest	O
that	O
Acacia	O
ferruginea	O
stem	O
bark	O
has	O
potential	O
to	O
provide	O
a	O
therapeutic	O
approach	O
to	O
ethanol	B-CHEMICAL
mediated	O
ulcer	O
as	O
an	O
effective	O
anti	O
-	O
ulcer	O
agent	O
.	O

MAPKAPK2	B-GENE-N
/	I-GENE-N
3	I-GENE-N
Regulate	O
SERCA2a	B-GENE-Y
Expression	O
and	O
Fiber	O
Type	O
Composition	O
to	O
Modulate	O
Skeletal	O
Muscle	O
and	O
Cardiomyocyte	O
Function	O
.	O

The	O
MAPK	B-GENE-N
-	I-GENE-N
activated	I-GENE-N
protein	I-GENE-N
kinases	I-GENE-N
2	I-GENE-N
and	I-GENE-N
3	I-GENE-N
(	O
MAPKAPK2	B-GENE-N
/	I-GENE-N
3	I-GENE-N
,	O
MK2	B-GENE-N
/	I-GENE-N
3	I-GENE-N
)	O
represent	O
protein	B-GENE-N
kinases	I-GENE-N
downstream	O
of	O
the	O
p38	B-GENE-N
mitogen	B-GENE-N
-	I-GENE-N
activated	I-GENE-N
protein	I-GENE-N
kinase	I-GENE-N
(	O
MAPK	B-GENE-N
)	O
.	O

Using	O
MK2	B-GENE-N
/	I-GENE-N
3	I-GENE-N
double	O
knockout	O
mice	O
(	O
MK2	B-GENE-N
/	I-GENE-N
3	I-GENE-N
(	O
-	O
/	O
-	O
)	O
)	O
,	O
we	O
analyzed	O
the	O
role	O
of	O
MK2	B-GENE-N
/	I-GENE-N
3	I-GENE-N
in	O
cross	O
-	O
striated	O
muscle	O
by	O
transcriptome	O
and	O
proteome	O
analyses	O
,	O
and	O
by	O
histology	O
.	O

We	O
demonstrated	O
enhanced	O
expression	O
of	O
the	O
slow	O
oxidative	O
skeletal	O
muscle	O
myofiber	O
gene	O
program	O
,	O
including	O
the	O
PPAR	B-GENE-Y
coactivator	I-GENE-Y
1	I-GENE-Y
(	O
PGC	B-GENE-Y
-	I-GENE-Y
1	I-GENE-Y
)	O
.	O

Using	O
reporter	O
gene	O
and	O
electrophoretic	O
gel	O
mobility	O
shift	O
assays	O
we	O
demonstrated	O
that	O
MK2	B-GENE-Y
catalytic	O
activity	O
directly	O
regulated	O
the	O
promoters	O
of	O
the	O
fast	O
fiber	O
-	O
specific	O
myosin	B-GENE-N
heavy	I-GENE-N
chain	I-GENE-N
IId	I-GENE-N
/	I-GENE-N
x	I-GENE-N
and	O
the	O
slow	O
fiber	O
-	O
specific	O
sarco	B-GENE-Y
/	I-GENE-Y
endoplasmic	I-GENE-Y
reticulum	I-GENE-Y
Ca	I-GENE-Y
(	I-GENE-Y
2	I-GENE-Y
+	I-GENE-Y
)	I-GENE-Y
-	I-GENE-Y
ATPase	I-GENE-Y
(	I-GENE-Y
SERCA	I-GENE-Y
)	I-GENE-Y
2	I-GENE-Y
gene	O
.	O

Elevated	O
SERCA2a	B-GENE-Y
gene	O
expression	O
caused	O
by	O
a	O
decreased	O
transcription	O
factor	O
Egr	B-GENE-Y
-	I-GENE-Y
1	I-GENE-Y
to	O
Sp1	B-GENE-Y
ratio	O
was	O
associated	O
with	O
accelerated	O
relaxation	O
and	O
enhanced	O
contractility	O
in	O
MK2	B-GENE-N
/	I-GENE-N
3	I-GENE-N
(	O
-	O
/	O
-	O
)	O
cardiomyocytes	O
,	O
concomitant	O
with	O
improved	O
force	O
parameters	O
in	O
MK2	B-GENE-N
/	I-GENE-N
3	I-GENE-N
(	O
-	O
/	O
-	O
)	O
soleus	O
muscle	O
.	O

These	O
results	O
link	O
MK2	B-GENE-N
/	I-GENE-N
3	I-GENE-N
to	O
the	O
regulation	O
of	O
calcium	B-CHEMICAL
dynamics	O
and	O
identify	O
enzymatic	O
activity	O
of	O
MK2	B-GENE-N
/	I-GENE-N
3	I-GENE-N
as	O
a	O
critical	O
factor	O
for	O
modulating	O
cross	O
-	O
striated	O
muscle	O
function	O
by	O
generating	O
a	O
unique	O
muscle	O
phenotype	O
exhibiting	O
both	O
,	O
reduced	O
fatigability	O
and	O
enhanced	O
force	O
in	O
MK2	B-GENE-N
/	I-GENE-N
3	I-GENE-N
(	O
-	O
/	O
-	O
)	O
mice	O
.	O

Hence	O
,	O
the	O
p38	B-GENE-N
-	O
MK2	B-GENE-N
/	I-GENE-N
3	I-GENE-N
axis	O
may	O
represent	O
a	O
novel	O
target	O
for	O
the	O
design	O
of	O
therapeutic	O
strategies	O
for	O
diseases	O
related	O
to	O
fiber	O
type	O
changes	O
or	O
impaired	O
SERCA2	B-GENE-Y
function	O
.	O

Human	B-GENE-Y
UGT2B10	I-GENE-Y
in	O
Drug	O
N	O
-	O
glucuronidations	O
:	O
Substrate	O
Screening	O
and	O
Comparison	O
with	O
UGT1A3	B-GENE-Y
and	O
UGT1A4	B-GENE-Y
.	O

Recent	O
observations	O
revealed	O
that	O
human	B-GENE-Y
UDP	I-GENE-Y
-	I-GENE-Y
glucuronosyltransferase	I-GENE-Y
(	I-GENE-Y
UGT	I-GENE-Y
)	I-GENE-Y
2B10	I-GENE-Y
catalyzes	O
N	O
-	O
glucuronidation	O
of	O
amine	B-CHEMICAL
-	O
containing	O
compounds	O
.	O

Knowledge	O
of	O
the	O
substrate	O
specificity	O
and	O
clinical	O
significance	O
of	O
UGT2B10	B-GENE-Y
is	O
still	O
limited	O
.	O

The	O
purpose	O
of	O
this	O
study	O
was	O
to	O
expand	O
the	O
knowledge	O
of	O
UGT2B10	B-GENE-Y
substrates	O
and	O
to	O
evaluate	O
its	O
significance	O
in	O
drug	O
clearance	O
.	O

Using	O
recombinant	O
UGT2B10	B-GENE-Y
,	O
we	O
found	O
that	O
it	O
catalyzes	O
the	O
N	O
-	O
glucuronidation	O
of	O
amitriptyline	B-CHEMICAL
,	O
imipramine	B-CHEMICAL
,	O
ketotifen	B-CHEMICAL
,	O
pizotifen	B-CHEMICAL
,	O
olanzapine	B-CHEMICAL
,	O
diphenhydramine	B-CHEMICAL
,	O
tamoxifen	B-CHEMICAL
,	O
ketoconazole	B-CHEMICAL
and	O
midazolam	B-CHEMICAL
.	O

These	O
are	O
drugs	O
that	O
were	O
previously	O
reported	O
to	O
be	O
substrates	O
for	O
UGT1A4	B-GENE-Y
or	O
UGT1A3	B-GENE-Y
and	O
that	O
contain	O
in	O
their	O
structure	O
either	O
tertiary	B-CHEMICAL
aliphatic	I-CHEMICAL
amines	I-CHEMICAL
,	O
cyclic	B-CHEMICAL
amines	I-CHEMICAL
,	O
or	O
an	O
imidazole	B-CHEMICAL
group	O
.	O

UGT2B10	B-GENE-Y
was	O
inactive	O
in	O
the	O
glucuronidation	O
of	O
desipramine	B-CHEMICAL
,	O
nortriptyline	B-CHEMICAL
,	O
carbamazepine	B-CHEMICAL
and	O
afloqualone	B-CHEMICAL
.	O

This	O
group	O
of	O
drugs	O
contains	O
secondary	B-CHEMICAL
or	I-CHEMICAL
primary	I-CHEMICAL
amines	I-CHEMICAL
,	O
and	O
these	O
results	O
suggest	O
that	O
UGT2B10	B-GENE-Y
preferably	O
conjugates	O
tertiary	B-CHEMICAL
amines	I-CHEMICAL
.	O

This	O
preference	O
is	O
partial	O
because	O
UGT2B10	B-GENE-Y
did	O
not	O
conjugate	O
the	O
tertiary	B-CHEMICAL
cyclic	I-CHEMICAL
amine	I-CHEMICAL
in	O
trifluoperazine	B-CHEMICAL
.	O

Kinetic	O
analyses	O
revealed	O
that	O
the	O
affinity	O
and	O
clearance	O
of	O
UGT2B10	B-GENE-Y
for	O
amitriptyline	B-CHEMICAL
,	O
imipramine	B-CHEMICAL
,	O
and	O
diphenhydramine	B-CHEMICAL
are	O
significantly	O
higher	O
than	O
the	O
corresponding	O
values	O
of	O
UGT1A4	B-GENE-Y
and	O
UGT1A3	B-GENE-Y
,	O
although	O
the	O
Vmax	O
values	O
of	O
UGT1A4	B-GENE-Y
toward	O
these	O
drugs	O
are	O
considerably	O
higher	O
.	O

These	O
findings	O
suggest	O
that	O
UGT2B10	B-GENE-Y
plays	O
a	O
major	O
role	O
in	O
the	O
N	O
-	O
glucuronidation	O
of	O
these	O
drugs	O
at	O
therapeutic	O
concentrations	O
.	O

These	O
results	O
are	O
also	O
supported	O
by	O
inhibition	O
studies	O
with	O
nicotine	B-CHEMICAL
and	O
hecogenin	B-CHEMICAL
.	O

In	O
conclusion	O
,	O
this	O
study	O
expands	O
the	O
understanding	O
of	O
the	O
substrate	O
specificity	O
of	O
UGT2B10	B-GENE-Y
,	O
highlighting	O
its	O
preference	O
for	O
tertiary	B-CHEMICAL
amines	I-CHEMICAL
with	O
higher	O
affinities	O
and	O
clearance	O
values	O
than	O
those	O
of	O
UGT1A4	B-GENE-Y
and	O
UGT1A3	B-GENE-Y
.	O

Molecular	O
Mechanisms	O
of	O
the	O
antitumor	O
activity	O
of	O
SB225002	B-CHEMICAL
:	O
A	O
novel	O
microtubule	O
inhibitor	O
.	O

SB225002	B-CHEMICAL
(	O
SB	O
)	O
is	O
an	O
IL	B-GENE-Y
-	I-GENE-Y
8	I-GENE-Y
receptor	I-GENE-Y
B	I-GENE-Y
(	O
IL	B-GENE-Y
-	I-GENE-Y
8RB	I-GENE-Y
)	O
antagonist	O
that	O
has	O
previously	O
been	O
shown	O
to	O
inhibit	O
IL	B-GENE-Y
-	I-GENE-Y
8	I-GENE-Y
-	O
based	O
cancer	O
cell	O
invasion	O
,	O
and	O
to	O
possess	O
in	O
vivo	O
anti	O
-	O
inflammatory	O
and	O
anti	O
-	O
nociceptive	O
effects	O
.	O

The	O
present	O
study	O
presented	O
an	O
evidence	O
for	O
the	O
cell	O
cycle	O
-	O
targeting	O
activity	O
of	O
SB	O
in	O
a	O
panel	O
of	O
p53	B-GENE-Y
-	O
mutant	O
human	O
cancer	O
cell	O
lines	O
of	O
different	O
origin	O
,	O
and	O
investigated	O
the	O
underlying	O
molecular	O
mechanisms	O
.	O

A	O
combination	O
of	O
cell	O
cycle	O
analysis	O
,	O
immunocytometry	O
,	O
immunoblotting	O
,	O
and	O
RNA	O
interference	O
revealed	O
that	O
SB	O
induced	O
a	O
BubR1	B-GENE-Y
-	O
dependent	O
mitotic	O
arrest	O
.	O

Mechanistically	O
,	O
SB	O
was	O
shown	O
to	O
possess	O
a	O
microtubule	O
destabilizing	O
activity	O
evidenced	O
by	O
hyperphosphorylation	O
of	O
Bcl2	B-GENE-Y
and	O
BclxL	B-GENE-Y
,	O
suppression	O
of	O
microtubule	O
polymerization	O
and	O
induction	O
of	O
a	O
prometaphase	O
arrest	O
.	O

Molecular	O
docking	O
studies	O
suggested	O
that	O
SB	O
has	O
a	O
good	O
affinity	O
towards	O
vinblastine	B-CHEMICAL
-	O
binding	O
site	O
on	O
	B-GENE-Y
-	I-GENE-Y
tubulin	I-GENE-Y
subunit	O
.	O

Of	O
note	O
,	O
SB265610	B-CHEMICAL
which	O
is	O
a	O
close	O
structural	O
analogue	O
of	O
SB225002	B-CHEMICAL
with	O
a	O
potent	O
IL	B-GENE-Y
-	I-GENE-Y
8RB	I-GENE-Y
antagonistic	O
activity	O
did	O
not	O
exhibit	O
a	O
similar	O
antimitotic	O
activity	O
.	O

Importantly	O
,	O
in	O
P	B-GENE-Y
-	I-GENE-Y
glycoprotein	I-GENE-Y
overexpressing	O
NCI	O
/	O
Adr	O
-	O
Res	O
cells	O
the	O
antitumor	O
activity	O
of	O
SB	O
was	O
unaffected	O
by	O
multidrug	O
resistance	O
.	O

Interestingly	O
,	O
the	O
mechanisms	O
of	O
SB	O
-	O
induced	O
cell	O
death	O
were	O
cell	O
-	O
line	O
dependent	O
,	O
where	O
in	O
invasive	O
hepatocellular	O
carcinoma	O
HLE	O
cells	O
the	O
significant	O
contribution	O
of	O
BAK	B-GENE-Y
-	O
dependent	O
mitochondrial	O
apoptosis	O
was	O
demonstrated	O
.	O

Conversely	O
,	O
SB	O
activated	O
p38	B-GENE-N
MAPK	B-GENE-N
signaling	O
in	O
colorectal	O
adenocarcinoma	O
cells	O
SW480	O
,	O
and	O
pharmacologic	O
inhibition	O
of	O
p38	B-GENE-N
MAPK	B-GENE-N
activity	O
revealed	O
its	O
key	O
role	O
in	O
mediating	O
SB	O
-	O
induced	O
caspase	B-GENE-N
-	O
independent	O
cell	O
death	O
.	O

In	O
summary	O
,	O
the	O
present	O
study	O
introduced	O
SB	O
as	O
a	O
promising	O
antitumor	O
agent	O
which	O
has	O
the	O
potential	O
to	O
exert	O
its	O
activity	O
through	O
dual	O
mechanisms	O
involving	O
microtubules	O
targeting	O
and	O
interference	O
with	O
IL	B-GENE-Y
-	I-GENE-Y
8	I-GENE-Y
-	O
drivin	O
cancer	O
progression	O
.	O

Dimerized	O
Glycosaminoglycan	O
Chains	O
Increase	O
FGF	B-GENE-N
Signaling	O
during	O
Zebrafish	O
Development	O
.	O

Proteoglycans	O
(	O
PGs	O
)	O
modulate	O
numerous	O
signaling	O
pathways	O
during	O
development	O
through	O
binding	O
of	O
their	O
glycosaminoglycan	O
(	O
GAG	O
)	O
side	O
chains	O
to	O
various	O
signaling	O
molecules	O
,	O
including	O
fibroblast	B-GENE-N
growth	I-GENE-N
factors	I-GENE-N
(	O
FGFs	B-GENE-N
)	O
.	O

A	O
majority	O
of	O
PGs	O
possess	O
two	O
or	O
more	O
GAG	O
side	O
chains	O
,	O
suggesting	O
that	O
GAG	O
multivalency	O
is	O
imperative	O
for	O
biological	O
functions	O
in	O
vivo	O
.	O

However	O
,	O
only	O
a	O
few	O
studies	O
have	O
examined	O
the	O
biological	O
significance	O
of	O
GAG	O
multivalency	O
.	O

In	O
this	O
report	O
,	O
we	O
utilized	O
a	O
library	O
of	O
bis	B-CHEMICAL
-	I-CHEMICAL
and	I-CHEMICAL
tris	I-CHEMICAL
-	I-CHEMICAL
xylosides	I-CHEMICAL
that	O
produce	O
two	O
and	O
three	O
GAG	O
chains	O
on	O
the	O
same	O
scaffold	O
,	O
respectively	O
,	O
thus	O
mimicking	O
PGs	O
,	O
to	O
examine	O
the	O
importance	O
of	O
GAG	O
valency	O
and	O
chain	O
type	O
in	O
regulating	O
FGF	B-GENE-N
/	O
FGFR	B-GENE-N
interactions	O
in	O
vivo	O
in	O
zebrafish	O
.	O

A	O
number	O
of	O
bis	B-CHEMICAL
-	I-CHEMICAL
and	I-CHEMICAL
tris	I-CHEMICAL
-	I-CHEMICAL
xylosides	I-CHEMICAL
,	O
but	O
not	O
mono	B-CHEMICAL
-	I-CHEMICAL
xylosides	I-CHEMICAL
,	O
caused	O
an	O
elongation	O
phenotype	O
upon	O
their	O
injection	O
into	O
embryos	O
.	O

In	O
situ	O
hybridization	O
showed	O
that	O
elongated	O
embryos	O
have	O
elevated	O
expression	O
of	O
the	O
FGF	B-GENE-N
target	O
gene	O
mkp3	B-GENE-Y
but	O
unchanged	O
expression	O
of	O
reporters	O
for	O
other	O
pathways	O
,	O
indicating	O
that	O
FGF	B-GENE-N
/	O
FGFR	B-GENE-N
signaling	O
was	O
specifically	O
hyperactivated	O
.	O

In	O
support	O
of	O
this	O
observation	O
,	O
elongation	O
can	O
be	O
reversed	O
by	O
the	O
tyrosine	B-GENE-N
kinase	I-GENE-N
inhibitor	O
SU5402	B-CHEMICAL
,	O
mRNA	O
for	O
the	O
FGFR	B-GENE-N
antagonist	O
sprouty4	B-GENE-Y
,	O
or	O
FGF8	B-GENE-Y
morpholino	O
.	O

Endogenous	O
GAGs	O
seem	O
to	O
be	O
unaffected	O
after	O
xyloside	B-CHEMICAL
treatment	O
,	O
suggesting	O
that	O
this	O
is	O
a	O
gain	O
-	O
of	O
-	O
function	O
phenotype	O
.	O

Furthermore	O
,	O
expression	O
of	O
a	O
multivalent	O
but	O
not	O
a	O
monovalent	O
GAG	O
containing	O
syndecan	B-GENE-N
-	I-GENE-N
1	I-GENE-N
proteoglycan	O
recapitulates	O
the	O
elongation	O
phenotype	O
observed	O
with	O
the	O
bivalent	O
xylosides	B-CHEMICAL
.	O

On	O
the	O
basis	O
of	O
these	O
in	O
vivo	O
findings	O
,	O
we	O
propose	O
a	O
new	O
model	O
for	O
GAG	O
/	O
FGF	B-GENE-N
/	O
FGFR	B-GENE-N
interactions	O
in	O
which	O
dimerized	O
GAG	O
chains	O
can	O
activate	O
FGF	B-GENE-N
-	O
mediated	O
signal	O
transduction	O
pathways	O
.	O

Caffeic	B-CHEMICAL
Acid	I-CHEMICAL
Phenethyl	I-CHEMICAL
Ester	I-CHEMICAL
Suppresses	O
Proliferation	O
and	O
Survival	O
of	O
TW2	O
.	O
6	O
Human	O
Oral	O
Cancer	O
Cells	O
via	O
Inhibition	O
of	O
Akt	B-GENE-N
Signaling	O
.	O

Caffeic	B-CHEMICAL
acid	I-CHEMICAL
phenethyl	I-CHEMICAL
ester	I-CHEMICAL
(	O
CAPE	B-CHEMICAL
)	O
is	O
a	O
bioactive	O
component	O
extracted	O
from	O
honeybee	O
hive	O
propolis	O
.	O

Our	O
observations	O
indicated	O
that	O
CAPE	B-CHEMICAL
treatment	O
suppressed	O
cell	O
proliferation	O
and	O
colony	O
formation	O
of	O
TW2	O
.	O
6	O
human	O
oral	O
squamous	O
cell	O
carcinoma	O
(	O
OSCC	O
)	O
cells	O
dose	O
-	O
dependently	O
.	O

CAPE	B-CHEMICAL
treatment	O
decreased	O
G1	O
phase	O
cell	O
population	O
,	O
increased	O
G2	O
/	O
M	O
phase	O
cell	O
population	O
,	O
and	O
induced	O
apoptosis	O
in	O
TW2	O
.	O
6	O
cells	O
.	O

Treatment	O
with	O
CAPE	B-CHEMICAL
decreased	O
protein	O
abundance	O
of	O
Akt	B-GENE-N
,	O
Akt1	B-GENE-Y
,	O
Akt2	B-GENE-Y
,	O
Akt3	B-GENE-Y
,	O
phospho	B-GENE-N
-	I-GENE-N
Akt	I-GENE-N
Ser473	B-CHEMICAL
,	O
phospho	B-GENE-N
-	I-GENE-N
Akt	I-GENE-N
Thr	O
308	O
,	O
GSK3	B-GENE-Y
,	O
FOXO1	B-GENE-Y
,	O
FOXO3a	B-GENE-Y
,	O
phospho	B-GENE-Y
-	I-GENE-Y
FOXO1	I-GENE-Y
Thr24	O
,	O
phospho	B-GENE-Y
-	I-GENE-Y
FoxO3a	I-GENE-Y
Thr32	O
,	O
NF	B-GENE-N
-	I-GENE-N
B	I-GENE-N
,	O
phospho	B-GENE-N
-	I-GENE-N
NF	I-GENE-N
-	I-GENE-N
B	I-GENE-N
Ser536	O
,	O
Rb	B-GENE-Y
,	O
phospho	B-GENE-Y
-	I-GENE-Y
Rb	I-GENE-Y
Ser807	B-CHEMICAL
/	O
811	O
,	O
Skp2	B-GENE-Y
,	O
and	O
cyclin	B-GENE-Y
D1	I-GENE-Y
,	O
but	O
increased	O
cell	O
cycle	O
inhibitor	O
p27Kip	B-GENE-Y
.	O

Overexpression	O
of	O
Akt1	B-GENE-Y
or	O
Akt2	B-GENE-Y
in	O
TW2	O
.	O
6	O
cells	O
rescued	O
growth	O
inhibition	O
caused	O
by	O
CAPE	B-CHEMICAL
treatment	O
.	O

Co	O
-	O
treating	O
TW2	O
.	O
6	O
cells	O
with	O
CAPE	B-CHEMICAL
and	O
5	B-CHEMICAL
-	I-CHEMICAL
fluorouracil	I-CHEMICAL
,	O
a	O
commonly	O
used	O
chemotherapeutic	O
drug	O
for	O
oral	O
cancers	O
,	O
exhibited	O
additive	O
cell	O
proliferation	O
inhibition	O
.	O

Our	O
study	O
suggested	O
that	O
administration	O
of	O
CAPE	B-CHEMICAL
is	O
a	O
potential	O
adjuvant	O
therapy	O
for	O
patients	O
with	O
OSCC	O
oral	O
cancer	O
.	O

Concurrent	O
Regulation	O
of	O
the	O
Transcription	O
Factors	O
Nrf2	B-GENE-Y
and	O
ATF4	B-GENE-Y
Mediates	O
the	O
Enhancement	O
of	O
Glutathione	B-CHEMICAL
Levels	O
by	O
the	O
Flavonoid	B-CHEMICAL
Fisetin	B-CHEMICAL
.	O

Glutathione	B-CHEMICAL
(	O
GSH	B-CHEMICAL
)	O
and	O
GSH	B-CHEMICAL
-	O
associated	O
metabolism	O
provide	O
the	O
major	O
line	O
of	O
defense	O
for	O
the	O
protection	O
of	O
cells	O
from	O
various	O
forms	O
of	O
toxic	O
stress	O
.	O

GSH	B-CHEMICAL
also	O
plays	O
a	O
key	O
role	O
in	O
regulating	O
the	O
intracellular	O
redox	O
environment	O
.	O

Thus	O
,	O
maintenance	O
of	O
GSH	B-CHEMICAL
levels	O
is	O
developing	O
into	O
an	O
important	O
therapeutic	O
objective	O
for	O
the	O
treatment	O
of	O
a	O
variety	O
of	O
diseases	O
.	O

Among	O
the	O
transcription	O
factors	O
that	O
play	O
critical	O
roles	O
in	O
GSH	B-CHEMICAL
metabolism	O
are	O
NF	B-GENE-Y
-	I-GENE-Y
E2	I-GENE-Y
-	I-GENE-Y
related	I-GENE-Y
factor	I-GENE-Y
2	I-GENE-Y
(	O
Nrf2	B-GENE-Y
)	O
and	O
activating	B-GENE-Y
transcription	I-GENE-Y
factor	I-GENE-Y
4	I-GENE-Y
(	O
ATF4	B-GENE-Y
)	O
.	O

Thus	O
,	O
compounds	O
that	O
can	O
upregulate	O
these	O
transcription	O
factors	O
may	O
be	O
particularly	O
useful	O
as	O
treatment	O
options	O
through	O
their	O
effects	O
on	O
GSH	B-CHEMICAL
metabolism	O
.	O

We	O
previously	O
showed	O
that	O
the	O
flavonoid	B-CHEMICAL
fisetin	B-CHEMICAL
not	O
only	O
increases	O
basal	O
levels	O
of	O
GSH	B-CHEMICAL
but	O
also	O
maintains	O
GSH	B-CHEMICAL
levels	O
under	O
oxidative	O
stress	O
conditions	O
.	O

However	O
,	O
the	O
mechanisms	O
underlying	O
these	O
effects	O
have	O
remained	O
unknown	O
until	O
now	O
.	O

Here	O
we	O
show	O
that	O
fisetin	B-CHEMICAL
rapidly	O
increases	O
the	O
levels	O
of	O
both	O
Nrf2	B-GENE-Y
and	O
ATF4	B-GENE-Y
as	O
well	O
as	O
Nrf2	B-GENE-Y
-	O
and	O
ATF4	B-GENE-Y
-	O
dependent	O
gene	O
transcription	O
via	O
distinct	O
mechanisms	O
.	O

Although	O
fisetin	B-CHEMICAL
greatly	O
increases	O
the	O
stability	O
of	O
both	O
Nrf2	B-GENE-Y
and	O
ATF4	B-GENE-Y
,	O
only	O
the	O
effect	O
on	O
ATF4	B-GENE-Y
is	O
dependent	O
on	O
protein	B-GENE-N
kinase	I-GENE-N
activity	O
.	O

Using	O
siRNA	O
we	O
found	O
that	O
ATF4	B-GENE-Y
,	O
but	O
not	O
Nrf2	B-GENE-Y
,	O
is	O
important	O
for	O
fisetin	B-CHEMICAL
'	O
s	O
ability	O
to	O
increase	O
GSH	B-CHEMICAL
levels	O
under	O
basal	O
conditions	O
whereas	O
both	O
ATF4	B-GENE-Y
and	O
Nrf2	B-GENE-Y
appear	O
to	O
cooperate	O
to	O
increase	O
GSH	B-CHEMICAL
levels	O
under	O
oxidative	O
stress	O
conditions	O
.	O

Based	O
upon	O
these	O
results	O
,	O
we	O
hypothesize	O
that	O
compounds	O
able	O
to	O
increase	O
GSH	B-CHEMICAL
levels	O
via	O
multiple	O
mechanisms	O
,	O
such	O
as	O
fisetin	B-CHEMICAL
,	O
will	O
be	O
particularly	O
effective	O
for	O
maintaining	O
GSH	B-CHEMICAL
levels	O
under	O
a	O
variety	O
of	O
different	O
stresses	O
.	O

GALACTOSYLATED	O
MICELLES	O
FOR	O
A	O
RIBAVIRIN	B-CHEMICAL
PRODRUG	O
TARGETING	O
TO	O
HEPATOCYTES	O
.	O

Polymeric	O
micelles	O
potentially	O
able	O
to	O
carry	O
to	O
hepatocytes	O
a	O
ribavirin	B-CHEMICAL
(	O
RBV	B-CHEMICAL
)	O
prodrug	O
,	O
exploiting	O
the	O
presence	O
of	O
carbohydrate	B-GENE-N
receptors	I-GENE-N
,	O
i	O
.	O
e	O
.	O
,	O
ASGPR	B-GENE-N
,	O
were	O
prepared	O
starting	O
from	O
a	O
galactosylated	B-CHEMICAL
polylactide	I-CHEMICAL
-	I-CHEMICAL
polyaminoacid	I-CHEMICAL
conjugate	O
.	O

This	O
latter	O
was	O
obtained	O
by	O
chemical	O
reaction	O
of	O
alpha	B-CHEMICAL
,	I-CHEMICAL
beta	I-CHEMICAL
-	I-CHEMICAL
poly	I-CHEMICAL
(	I-CHEMICAL
N	I-CHEMICAL
-	I-CHEMICAL
2	I-CHEMICAL
-	I-CHEMICAL
hydroxyethyl	I-CHEMICAL
)	I-CHEMICAL
(	I-CHEMICAL
2	I-CHEMICAL
-	I-CHEMICAL
aminoethylcarbamate	I-CHEMICAL
)	I-CHEMICAL
-	I-CHEMICAL
DL	I-CHEMICAL
-	I-CHEMICAL
aspartamide	I-CHEMICAL
(	O
PHEA	B-CHEMICAL
-	I-CHEMICAL
EDA	I-CHEMICAL
)	O
with	O
polylactic	B-CHEMICAL
acid	I-CHEMICAL
(	O
PLA	B-CHEMICAL
)	O
,	O
and	O
subsequent	O
reaction	O
with	O
lactose	B-CHEMICAL
,	O
obtaining	O
PHEA	B-CHEMICAL
-	I-CHEMICAL
EDA	I-CHEMICAL
-	I-CHEMICAL
PLA	I-CHEMICAL
-	I-CHEMICAL
GAL	I-CHEMICAL
copolymer	O
.	O

To	O
enhance	O
the	O
entrapment	O
into	O
obtained	O
nanostructures	O
,	O
a	O
hydrophobic	O
RBV	B-CHEMICAL
prodrug	O
,	O
i	O
.	O
e	O
.	O
RBV	B-CHEMICAL
tripalmitate	I-CHEMICAL
,	O
was	O
synthesized	O
and	O
its	O
capability	O
to	O
release	O
RBV	B-CHEMICAL
in	O
the	O
presence	O
of	O
an	O
adequate	O
enzymatic	O
activity	O
was	O
demonstrated	O
.	O

Liver	O
-	O
targeted	O
RBV	B-CHEMICAL
tripalmitate	I-CHEMICAL
-	O
loaded	O
micelles	O
were	O
obtained	O
in	O
aqueous	O
media	O
at	O
low	O
PHEA	B-CHEMICAL
-	I-CHEMICAL
EDA	I-CHEMICAL
-	I-CHEMICAL
PLA	I-CHEMICAL
-	I-CHEMICAL
GAL	I-CHEMICAL
copolymer	O
concentration	O
value	O
with	O
nanometric	O
size	O
.	O

By	O
in	O
vitro	O
experiments	O
,	O
the	O
specificity	O
of	O
RBV	B-CHEMICAL
tripalmitate	I-CHEMICAL
-	O
loaded	O
PHEA	B-CHEMICAL
-	I-CHEMICAL
EDA	I-CHEMICAL
-	I-CHEMICAL
PLA	I-CHEMICAL
-	I-CHEMICAL
GAL	I-CHEMICAL
micelles	O
toward	O
HepG2	O
was	O
demonstrated	O
by	O
using	O
a	O
competitive	O
inhibition	O
assay	O
in	O
the	O
presence	O
of	O
free	O
GAL	B-CHEMICAL
.	O

This	O
finding	O
raises	O
hope	O
in	O
terms	O
of	O
future	O
micelles	O
-	O
based	O
liver	O
-	O
targeted	O
drug	O
delivery	O
strategy	O
for	O
the	O
hepatitis	O
C	O
treatment	O
.	O

Molecular	O
and	O
functional	O
characterization	O
of	O
flavin	B-GENE-N
-	I-GENE-N
containing	I-GENE-N
monooxygenases	I-GENE-N
in	O
cynomolgus	O
macaque	O
.	O

Flavin	B-GENE-N
-	I-GENE-N
containing	I-GENE-N
monooxygenases	I-GENE-N
(	O
FMOs	B-GENE-N
)	O
,	O
drug	O
-	O
metabolizing	O
enzymes	O
essential	O
for	O
the	O
metabolism	O
of	O
endogenous	O
biochemicals	O
and	O
foreign	O
compounds	O
,	O
have	O
been	O
characterized	O
in	O
human	O
(	O
including	O
FMO1	B-GENE-N
-	I-GENE-N
5	I-GENE-N
and	O
FMO6P	B-GENE-Y
)	O
,	O
but	O
remain	O
to	O
be	O
investigated	O
in	O
cynomolgus	O
macaque	O
.	O

In	O
this	O
study	O
,	O
cDNAs	O
of	O
cynomolgus	O
FMO1	B-GENE-N
-	I-GENE-N
5	I-GENE-N
and	O
FMO6	B-GENE-Y
were	O
isolated	O
and	O
characterized	O
.	O

Amino	B-CHEMICAL
acid	I-CHEMICAL
sequences	O
of	O
cynomolgus	O
FMO1	B-GENE-N
-	I-GENE-N
5	I-GENE-N
,	O
respectively	O
,	O
shared	O
high	O
sequence	O
identities	O
(	O
94	O
-	O
98	O
%	O
)	O
and	O
were	O
closely	O
clustered	O
in	O
a	O
phylogenetic	O
tree	O
,	O
with	O
human	B-GENE-N
FMO1	I-GENE-N
-	I-GENE-N
5	I-GENE-N
.	O

Eight	O
different	O
transcripts	O
,	O
due	O
to	O
alternative	O
splicing	O
,	O
were	O
isolated	O
for	O
cynomolgus	B-GENE-Y
FMO6	I-GENE-Y
,	O
which	O
is	O
highly	O
identical	O
(	O
	O
96	O
%	O
)	O
to	O
human	B-GENE-Y
FMO6P	I-GENE-Y
.	O

Among	O
the	O
10	O
tissue	O
types	O
analyzed	O
,	O
cynomolgus	O
FMO1	B-GENE-Y
,	O
FMO2	B-GENE-Y
,	O
FMO4	B-GENE-Y
,	O
and	O
FMO6	B-GENE-Y
were	O
most	O
abundantly	O
expressed	O
in	O
kidney	O
,	O
while	O
cynomolgus	B-GENE-Y
FMO3	I-GENE-Y
and	O
FMO5	B-GENE-Y
were	O
most	O
abundantly	O
expressed	O
in	O
liver	O
.	O

In	O
kidney	O
and	O
liver	O
,	O
the	O
most	O
abundantly	O
expressed	O
cynomolgus	B-GENE-N
FMO	I-GENE-N
genes	O
were	O
FMO1	B-GENE-Y
and	O
FMO3	B-GENE-Y
respectively	O
.	O

Cynomolgus	B-GENE-Y
FMO1	I-GENE-Y
,	O
FMO2	B-GENE-Y
,	O
FMO3	B-GENE-Y
,	O
and	O
FMO5	B-GENE-Y
metabolized	O
benzydamine	B-CHEMICAL
,	O
and	O
FMO1	B-GENE-Y
/	O
FMO3	B-GENE-Y
and	O
FMO3	B-GENE-Y
also	O
metabolized	O
methimazole	B-CHEMICAL
and	O
trimethylamine	B-CHEMICAL
,	O
respectively	O
.	O

Rates	O
of	O
benzydamine	B-CHEMICAL
N	B-CHEMICAL
-	O
oxygenation	O
(	O
catalyzed	O
by	O
FMO3	B-GENE-Y
)	O
varied	O
(	O
approximately	O
20	O
-	O
fold	O
)	O
among	O
the	O
28	O
cynomolgus	O
livers	O
and	O
were	O
significantly	O
correlated	O
with	O
FMO3	B-GENE-Y
protein	O
expression	O
,	O
indicating	O
that	O
the	O
inter	O
-	O
animal	O
variations	O
in	O
benzydamine	B-CHEMICAL
N	B-CHEMICAL
-	O
oxygenation	O
might	O
be	O
partly	O
accounted	O
for	O
by	O
the	O
variable	O
FMO3	B-GENE-Y
expression	O
.	O

Cynomolgus	B-GENE-Y
FMO6	I-GENE-Y
metabolized	O
benzydamine	B-CHEMICAL
only	O
slightly	O
,	O
but	O
minimal	O
expression	O
of	O
FMO6	B-GENE-Y
in	O
all	O
tissue	O
precludes	O
the	O
importance	O
of	O
FMO6	B-GENE-Y
in	O
drug	O
metabolism	O
,	O
unlike	O
cynomolgus	O
FMO1	B-GENE-Y
,	O
FMO2	B-GENE-Y
,	O
FMO3	B-GENE-Y
,	O
and	O
FMO5	B-GENE-Y
which	O
were	O
all	O
functional	O
.	O

Abundant	O
expression	O
of	O
FMO1	B-GENE-Y
and	O
FMO3	B-GENE-Y
in	O
kidney	O
and	O
liver	O
,	O
respectively	O
,	O
suggest	O
their	O
importance	O
in	O
drug	O
metabolism	O
in	O
cynomolgus	O
macaque	O
,	O
similar	O
to	O
human	O
.	O

Glomerular	O
Filtration	O
Rate	O
Equations	O
Overestimate	O
Creatinine	B-CHEMICAL
Clearance	O
in	O
Older	O
Individuals	O
Enrolled	O
in	O
the	O
Baltimore	O
Longitudinal	O
Study	O
on	O
Aging	O
:	O
Impact	O
on	O
Renal	O
Drug	O
Dosing	O
.	O

OBJECTIVES	O
:	O
To	O
evaluate	O
the	O
performance	O
of	O
kidney	O
function	O
estimation	O
equations	O
and	O
to	O
determine	O
the	O
frequency	O
of	O
drug	O
dose	O
discordance	O
in	O
an	O
older	O
population	O
.	O

DESIGN	O
:	O
Cross	O
-	O
sectional	O
analysis	O
of	O
data	O
from	O
community	O
-	O
dwelling	O
volunteers	O
randomly	O
selected	O
from	O
the	O
Baltimore	O
Longitudinal	O
Study	O
of	O
Aging	O
from	O
January	O
1	O
,	O
2005	O
,	O
to	O
December	O
31	O
,	O
2010	O
.	O

SUBJECTS	O
:	O
A	O
total	O
of	O
269	O
men	O
and	O
women	O
with	O
a	O
mean	O
	O
SD	O
age	O
of	O
81	O
	O
6	O
years	O
,	O
mean	O
serum	O
creatinine	B-CHEMICAL
concentration	O
(	O
Scr	O
)	O
of	O
1	O
.	O
1	O
	O
0	O
.	O
4	O
mg	O
/	O
dl	O
,	O
and	O
mean	O
24	O
-	O
hour	O
measured	O
creatinine	B-CHEMICAL
clearance	O
(	O
mClcr	O
)	O
of	O
53	O
	O
13	O
ml	O
/	O
minute	O
.	O

MEASUREMENTS	O
AND	O
MAIN	O
RESULTS	O
:	O
Kidney	O
function	O
was	O
estimated	O
by	O
using	O
the	O
following	O
equations	O
:	O
Cockcroft	O
-	O
Gault	O
(	O
CG	O
)	O
,	O
Modification	O
of	O
Diet	O
in	O
Renal	O
Disease	O
(	O
MDRD	O
)	O
,	O
and	O
Chronic	O
Kidney	O
Disease	O
Epidemiology	O
Collaboration	O
(	O
CKD	O
-	O
EPI	O
)	O
.	O

The	O
performance	O
of	O
each	O
equation	O
was	O
assessed	O
by	O
measuring	O
bias	O
and	O
precision	O
relative	O
to	O
mClcr	O
.	O

Dose	O
calculation	O
errors	O
(	O
discordance	O
)	O
were	O
determined	O
for	O
10	O
drugs	O
requiring	O
renal	O
dosage	O
adjustments	O
to	O
avoid	O
toxicity	O
when	O
compared	O
with	O
the	O
dosages	O
approved	O
by	O
the	O
Food	O
and	O
Drug	O
Administration	O
.	O

The	O
CG	O
equation	O
was	O
the	O
least	O
biased	O
estimate	O
of	O
mClcr	O
.	O

The	O
MDRD	O
and	O
CKD	O
-	O
EPI	O
equations	O
were	O
significantly	O
positively	O
biased	O
compared	O
with	O
CG	O
(	O
mean	O
	O
SD	O
34	O
	O
20	O
%	O
and	O
22	O
	O
15	O
%	O
,	O
respectively	O
,	O
p	O
<	O
0	O
.	O
001	O
)	O
and	O
mClcr	O
(	O
29	O
	O
47	O
%	O
and	O
18	O
	O
40	O
%	O
,	O
respectively	O
,	O
p	O
<	O
0	O
.	O
001	O
)	O
.	O

Rounding	O
low	O
Scr	O
values	O
(	O
less	O
than	O
1	O
.	O
0	O
mg	O
/	O
dl	O
)	O
up	O
to	O
an	O
arbitrary	O
value	O
of	O
1	O
.	O
0	O
mg	O
/	O
dl	O
resulted	O
in	O
CG	O
values	O
(	O
44	O
	O
10	O
ml	O
/	O
minute	O
)	O
that	O
were	O
significantly	O
lower	O
than	O
mClcr	O
(	O
56	O
	O
12	O
ml	O
/	O
minute	O
,	O
p	O
<	O
0	O
.	O
001	O
)	O
and	O
CG	O
(	O
56	O
	O
15	O
ml	O
/	O
minute	O
,	O
p	O
<	O
0	O
.	O
001	O
)	O
.	O

The	O
MDRD	O
and	O
CKD	O
-	O
EPI	O
equations	O
had	O
median	O
dose	O
discordance	O
rates	O
of	O
28	O
.	O
6	O
%	O
and	O
22	O
.	O
9	O
%	O
,	O
respectively	O
.	O

CONCLUSION	O
:	O
The	O
MDRD	O
and	O
CKD	O
-	O
EPI	O
equations	O
significantly	O
overestimated	O
creatinine	B-CHEMICAL
clearance	O
(	O
mClcr	O
and	O
CG	O
)	O
in	O
elderly	O
individuals	O
.	O

This	O
leads	O
to	O
dose	O
calculation	O
errors	O
for	O
many	O
drugs	O
,	O
particularly	O
in	O
individuals	O
with	O
severe	O
renal	O
impairment	O
.	O

Thus	O
equations	O
estimating	O
glomerular	O
filtration	O
rate	O
should	O
not	O
be	O
substituted	O
in	O
place	O
of	O
the	O
CG	O
equation	O
in	O
older	O
adults	O
for	O
the	O
purpose	O
of	O
renal	O
dosage	O
adjustments	O
.	O

In	O
addition	O
,	O
the	O
common	O
practice	O
of	O
rounding	O
or	O
replacing	O
low	O
Scr	O
values	O
with	O
an	O
arbitrary	O
value	O
of	O
1	O
.	O
0	O
mg	O
/	O
dl	O
for	O
use	O
in	O
the	O
CG	O
equation	O
should	O
be	O
avoided	O
.	O

Additional	O
studies	O
that	O
evaluate	O
alternative	O
eGFR	O
equations	O
in	O
the	O
older	O
populations	O
that	O
incorporate	O
pharmacokinetic	O
and	O
pharmacodynamic	O
outcomes	O
measures	O
are	O
needed	O
.	O

Effect	O
of	O
paraoxonase	B-GENE-Y
1	I-GENE-Y
192	B-GENE-N
Q	I-GENE-N
/	I-GENE-N
R	I-GENE-N
polymorphism	O
on	O
paraoxonase	B-GENE-Y
and	O
acetylcholinesterase	B-GENE-Y
enzyme	O
activities	O
in	O
Turkish	O
population	O
exposed	O
to	O
organophosphate	B-CHEMICAL
.	O

Organophosphate	B-CHEMICAL
(	O
OP	O
)	O
compounds	O
are	O
the	O
most	O
commonly	O
used	O
pesticide	O
groups	O
and	O
they	O
are	O
commercially	O
used	O
in	O
the	O
market	O
for	O
local	O
and	O
industrial	O
purposes	O
.	O

Paraoxonase	B-GENE-Y
1	I-GENE-Y
(	O
PON1	B-GENE-Y
)	O
enzyme	O
plays	O
an	O
important	O
role	O
in	O
biotransformation	O
of	O
OP	O
compounds	O
,	O
which	O
shows	O
toxic	O
effects	O
via	O
inhibiting	O
the	O
acetylcholinesterase	B-GENE-Y
(	O
AChE	B-GENE-Y
)	O
.	O

The	O
aim	O
of	O
this	O
study	O
was	O
to	O
determine	O
the	O
effects	O
of	O
PON1	B-GENE-Y
gene	O
polymorphism	O
and	O
its	O
effects	O
on	O
PON	B-GENE-Y
and	O
AChE	B-GENE-Y
enzyme	O
activities	O
in	O
individuals	O
who	O
were	O
exposed	O
to	O
organophosphorus	B-CHEMICAL
insecticides	O
due	O
to	O
occupational	O
reasons	O
,	O
and	O
to	O
profile	O
the	O
probability	O
of	O
susceptibility	O
to	O
organophosphorus	B-CHEMICAL
compounds	O
.	O

For	O
this	O
purpose	O
,	O
54	O
individuals	O
who	O
were	O
exposed	O
to	O
OPs	O
and	O
54	O
healthy	O
unrelated	O
controls	O
were	O
studied	O
.	O

First	O
,	O
PON1	B-GENE-Y
and	O
AChE	B-GENE-Y
enzyme	O
activities	O
were	O
measured	O
.	O

Second	O
,	O
PON1	B-GENE-Y
192	B-GENE-N
Q	I-GENE-N
/	I-GENE-N
R	I-GENE-N
polymorphism	O
was	O
determined	O
by	O
standard	O
polymerase	O
chain	O
reaction	O
-	O
restriction	O
fragment	O
length	O
polymorphism	O
technique	O
.	O

When	O
the	O
PON1	B-GENE-Y
192	B-GENE-N
Q	I-GENE-N
/	I-GENE-N
R	I-GENE-N
polymorphism	O
was	O
compared	O
with	O
PON1	B-GENE-Y
enzyme	O
activities	O
,	O
statistically	O
significant	O
association	O
was	O
found	O
in	O
both	O
OP	O
-	O
exposed	O
and	O
control	O
groups	O
(	O
p	O
<	O
0	O
.	O
05	O
)	O
.	O

PON1	B-GENE-Y
192	O
R	O
(	O
+	O
)	O
(	O
QR	O
+	O
RR	O
genotypes	O
)	O
genotype	O
carriers	O
had	O
higher	O
PON1	B-GENE-Y
activities	O
than	O
192	O
R	O
(	O
-	O
)	O
(	O
QQ	O
)	O
genotype	O
carriers	O
.	O

On	O
the	O
other	O
hand	O
,	O
results	O
were	O
statistically	O
analyzed	O
in	O
terms	O
of	O
AChE	B-GENE-Y
enzyme	O
activities	O
and	O
there	O
were	O
statistically	O
significant	O
differences	O
only	O
in	O
the	O
OP	O
-	O
exposed	O
group	O
(	O
p	O
<	O
0	O
.	O
05	O
)	O
.	O

The	O
mean	O
AChE	B-GENE-Y
concentration	O
in	O
the	O
OP	O
-	O
exposed	O
group	O
was	O
determined	O
as	O
33	O
.	O
79	O
	O
6	O
.	O
84	O
U	O
/	O
g	O
haemoglobin	B-GENE-N
(	O
Hb	B-GENE-N
)	O
for	O
PON1	B-GENE-Y
192	O
R	O
(	O
+	O
)	O
carriers	O
and	O
30	O
.	O
37	O
	O
7	O
.	O
62	O
U	O
/	O
g	O
Hb	B-GENE-N
for	O
PON1	B-GENE-Y
192	O
R	O
(	O
+	O
)	O
carriers	O
.	O

As	O
a	O
conclusion	O
,	O
PON1	B-GENE-Y
and	O
AChE	B-GENE-Y
activities	O
were	O
increasing	O
according	O
to	O
the	O
genotypes	O
found	O
in	O
individuals	O
having	O
been	O
exposed	O
to	O
OPs	O
at	O
a	O
chronic	O
level	O
;	O
192	O
R	O
(	O
+	O
)	O
>	O
192	O
R	O
(	O
-	O
)	O
,	O
respectively	O
.	O

Store	O
-	O
operated	O
Ca2	B-CHEMICAL
+	I-CHEMICAL
Entry	O
(	O
SOCE	O
)	O
Induced	O
by	O
Protease	B-GENE-Y
-	I-GENE-Y
activated	I-GENE-Y
Receptor	I-GENE-Y
-	I-GENE-Y
1	I-GENE-Y
mediates	O
STIM1	B-GENE-Y
Phosphorylation	O
to	O
inhibit	O
SOCE	O
in	O
Endothelial	O
Cells	O
through	O
AMP	B-GENE-Y
-	I-GENE-Y
activated	I-GENE-Y
Protein	I-GENE-Y
Kinase	I-GENE-Y
and	O
p38beta	B-GENE-Y
Mitogen	B-GENE-N
-	I-GENE-N
activated	I-GENE-N
Protein	I-GENE-N
Kinase	I-GENE-N
.	O

The	O
Ca2	B-CHEMICAL
+	I-CHEMICAL
sensor	O
STIM1	B-GENE-Y
is	O
crucial	O
for	O
activation	O
of	O
store	O
-	O
operated	O
Ca2	B-CHEMICAL
+	I-CHEMICAL
entry	O
(	O
SOCE	O
)	O
through	O
TRPC	B-GENE-N
and	O
Orai	B-GENE-N
channels	I-GENE-N
.	O

STIM1	B-GENE-Y
phosphorylation	O
serves	O
as	O
an	O
off	O
-	O
switch	O
for	O
SOCE	O
.	O

However	O
,	O
the	O
signaling	O
pathway	O
for	O
STIM1	B-GENE-Y
phosphorylation	O
is	O
unknown	O
.	O

Here	O
we	O
show	O
that	O
SOCE	O
activates	O
AMP	B-GENE-Y
-	I-GENE-Y
activated	I-GENE-Y
protein	I-GENE-Y
kinase	I-GENE-Y
(	O
AMPK	B-GENE-Y
)	O
;	O
its	O
effector	O
p38	B-GENE-Y
mitogen	B-GENE-N
-	I-GENE-N
activated	I-GENE-N
protein	I-GENE-N
kinase	I-GENE-N
(	O
p38	B-GENE-Y
MAPK	B-GENE-N
)	O
phosphorylates	O
STIM1	B-GENE-Y
,	O
thus	O
inhibiting	O
SOCE	O
in	O
human	O
lung	O
microvascular	O
endothelial	O
cells	O
(	O
ECs	O
)	O
.	O

Activation	O
of	O
AMPK	B-GENE-Y
using	O
AICAR	B-CHEMICAL
resulted	O
in	O
STIM1	B-GENE-Y
phosphorylation	O
on	O
serine	B-CHEMICAL
residues	O
and	O
prevented	O
PAR	B-GENE-Y
-	I-GENE-Y
1	I-GENE-Y
-	O
induced	O
Ca2	B-CHEMICAL
+	I-CHEMICAL
entry	O
.	O

Further	O
,	O
AICAR	B-CHEMICAL
pretreatment	O
blocked	O
PAR	B-GENE-Y
-	I-GENE-Y
1	I-GENE-Y
-	O
induced	O
increase	O
in	O
permeability	O
of	O
mouse	O
-	O
lung	O
microvessels	O
.	O

Activation	O
of	O
SOCE	O
with	O
thrombin	B-GENE-Y
caused	O
phosphorylation	O
of	O
isoform	O
1	O
,	O
but	O
not	O
2	O
of	O
the	O
AMPK	B-GENE-Y
catalytic	O
subunit	O
.	O

Moreover	O
,	O
knockdown	O
of	O
AMPK1	B-GENE-Y
augmented	O
SOCE	O
induced	O
by	O
thrombin	B-GENE-Y
.	O

Interestingly	O
,	O
SB203580	B-CHEMICAL
,	O
a	O
selective	O
inhibitor	O
of	O
p38	B-GENE-N
MAPK	B-GENE-N
,	O
blocked	O
STIM1	B-GENE-Y
phosphorylation	O
and	O
led	O
to	O
sustained	O
STIM1	B-GENE-Y
-	O
puncta	O
formation	O
and	O
Ca2	B-CHEMICAL
+	I-CHEMICAL
entry	O
.	O

Of	O
the	O
three	O
p38	B-GENE-N
MAPK	B-GENE-N
isoforms	O
expressed	O
in	O
ECs	O
,	O
p38	B-GENE-Y
knockdown	O
prevented	O
PAR	B-GENE-Y
-	I-GENE-Y
1	I-GENE-Y
-	O
mediated	O
STIM1	B-GENE-Y
phosphorylation	O
and	O
potentiated	O
SOCE	O
.	O

In	O
addition	O
,	O
inhibition	O
of	O
the	O
SOCE	O
downstream	O
target	O
CaMKK	B-GENE-Y
or	O
knockdown	O
of	O
AMPK1	B-GENE-Y
suppressed	O
PAR	B-GENE-Y
-	I-GENE-Y
1	I-GENE-Y
-	O
mediated	O
phosphorylation	O
of	O
p38	B-GENE-Y
and	O
hence	O
STIM1	B-GENE-Y
.	O

Thus	O
,	O
our	O
findings	O
demonstrate	O
that	O
SOCE	O
activates	O
CaMKK	B-GENE-Y
-	O
AMPK1	B-GENE-Y
-	O
p38	B-GENE-Y
MAPK	B-GENE-N
signaling	O
to	O
phosphorylate	O
STIM1	B-GENE-Y
,	O
thereby	O
suppressing	O
endothelial	O
SOCE	O
and	O
permeability	O
responses	O
.	O

Scientific	O
evidence	O
for	O
traditional	O
claim	O
of	O
antiobesity	O
activity	O
of	O
Tecomella	O
undulata	O
bark	O
.	O

ETHNOPHARMACOLOGICAL	O
RELEVANCE	O
:	O
The	O
bark	O
of	O
Tecomella	O
undulata	O
is	O
traditionally	O
claimed	O
in	O
the	O
treatment	O
of	O
various	O
disease	O
ailments	O
including	O
obesity	O
and	O
cancer	O
.	O

Till	O
now	O
there	O
are	O
no	O
studies	O
about	O
anti	O
obesity	O
activity	O
of	O
Tecomella	O
undulata	O
bark	O
.	O

AIM	O
OF	O
THE	O
STUDY	O
:	O
The	O
present	O
study	O
was	O
aimed	O
to	O
establish	O
a	O
scientific	O
evidence	O
for	O
anti	O
obesity	O
efficiency	O
of	O
ethyl	B-CHEMICAL
acetate	I-CHEMICAL
extract	O
of	O
Tecomella	O
undulata	O
bark	O
(	O
EATUB	O
)	O
.	O

Further	O
to	O
standardize	O
the	O
active	O
fractions	O
of	O
EATUB	O
using	O
different	O
biomarkers	O
.	O

MATERIALS	O
AND	O
METHODS	O
:	O
We	O
investigated	O
activity	O
of	O
EATUB	O
fractions	O
(	O
F1	O
-	O
F7	O
)	O
using	O
3T3	O
-	O
L1	O
fibroblasts	O
.	O

Further	O
,	O
F1	O
-	O
mediated	O
effects	O
were	O
characterized	O
by	O
determining	O
mRNA	O
and	O
protein	O
levels	O
of	O
SIRT1	B-GENE-Y
,	O
one	O
of	O
the	O
key	O
targets	O
for	O
the	O
treatment	O
of	O
obesity	O
,	O
using	O
semi	O
quantitative	O
RT	O
-	O
PCR	O
(	O
sqRT	O
-	O
PCR	O
)	O
and	O
western	O
blot	O
analysis	O
.	O

The	O
consequences	O
of	O
modulation	O
of	O
SIRT1	B-GENE-Y
on	O
mRNA	O
and	O
protein	O
levels	O
of	O
various	O
adipogenesis	O
mediators	O
like	O
PPAR	B-GENE-Y
,	O
C	B-GENE-Y
/	I-GENE-Y
EBP	I-GENE-Y
,	O
E2F1	B-GENE-Y
,	O
leptin	B-GENE-Y
,	O
adiponectin	B-GENE-Y
and	O
LPL	B-GENE-Y
were	O
also	O
studied	O
.	O

In	O
-	O
vivo	O
studies	O
were	O
performed	O
using	O
High	O
Fat	O
Diet	O
(	O
HFD	O
)	O
obese	O
mice	O
.	O

RESULTS	O
:	O
Our	O
data	O
showed	O
that	O
compared	O
to	O
controls	O
,	O
preadipocytes	O
and	O
adipocytes	O
incubated	O
with	O
F1	O
exhibited	O
a	O
significant	O
decrease	O
in	O
adipogenesis	O
and	O
lipogenesis	O
.	O

In	O
addition	O
,	O
sqRT	O
-	O
PCR	O
and	O
western	O
blot	O
analysis	O
showed	O
significant	O
increase	O
in	O
SIRT1	B-GENE-Y
and	O
adiponectin	B-GENE-Y
levels	O
and	O
decrease	O
in	O
PPAR	B-GENE-Y
,	O
C	B-GENE-Y
/	I-GENE-Y
EBP	I-GENE-Y
,	O
E2F1	B-GENE-Y
,	O
leptin	B-GENE-Y
and	O
LPL	B-GENE-Y
levels	O
in	O
preadipocytes	O
and	O
adipocytes	O
.	O

In	O
-	O
vivo	O
studies	O
of	O
F1	O
in	O
HFD	O
induced	O
obese	O
mice	O
showed	O
significant	O
improvement	O
in	O
lipid	O
profile	O
and	O
glucose	B-CHEMICAL
levels	O
.	O

The	O
bioactive	O
fraction	O
(	O
F1	O
)	O
was	O
determined	O
to	O
possess	O
4	O
.	O
95	O
%	O
of	O
ferulic	B-CHEMICAL
acid	I-CHEMICAL
.	O

CONCLUSION	O
:	O
Thus	O
,	O
our	O
findings	O
signified	O
the	O
beneficial	O
effects	O
of	O
Tecomella	O
undulata	O
bark	O
in	O
pharmacologic	O
interventions	O
related	O
to	O
obesity	O
and	O
metabolic	O
disorders	O
.	O

Ferulic	B-CHEMICAL
acid	I-CHEMICAL
and	O
rutin	B-CHEMICAL
are	O
being	O
reported	O
and	O
quantified	O
for	O
the	O
first	O
time	O
from	O
the	O
bark	O
of	O
Tecomella	O
undulata	O
.	O

Steroid	B-CHEMICAL
hormone	O
synthesis	O
in	O
mitochondria	O
.	O

Mitochondria	O
are	O
essential	O
sites	O
for	O
steroid	B-CHEMICAL
hormone	O
biosynthesis	O
.	O

Mitochondria	O
in	O
the	O
steroidogenic	O
cells	O
of	O
the	O
adrenal	O
,	O
gonad	O
,	O
placenta	O
and	O
brain	O
contain	O
the	O
cholesterol	B-CHEMICAL
side	O
-	O
chain	O
cleavage	O
enzyme	O
,	O
P450scc	B-GENE-Y
,	O
and	O
its	O
two	O
electron	O
-	O
transfer	O
partners	O
,	O
ferredoxin	B-GENE-N
reductase	I-GENE-N
and	O
ferredoxin	B-GENE-N
.	O

This	O
enzyme	O
system	O
converts	O
cholesterol	B-CHEMICAL
to	O
pregnenolone	B-CHEMICAL
and	O
determines	O
net	O
steroidogenic	O
capacity	O
,	O
so	O
that	O
it	O
serves	O
as	O
the	O
chronic	O
regulator	O
of	O
steroidogenesis	O
.	O

Several	O
other	O
steroidogenic	O
enzymes	O
,	O
including	O
3	B-GENE-Y
-	I-GENE-Y
hydroxysteroid	I-GENE-Y
dehydrogenase	I-GENE-Y
,	O
11	B-GENE-Y
-	I-GENE-Y
hydroxylase	I-GENE-Y
and	O
aldosterone	B-GENE-Y
synthase	I-GENE-Y
also	O
reside	O
in	O
mitochondria	O
.	O

Similarly	O
,	O
the	O
mitochondria	O
of	O
renal	O
tubular	O
cells	O
contain	O
two	O
key	O
enzymes	O
participating	O
in	O
the	O
activation	O
and	O
degradation	O
of	O
vitamin	B-CHEMICAL
D	I-CHEMICAL
.	O

The	O
access	O
of	O
cholesterol	B-CHEMICAL
to	O
the	O
mitochondria	O
is	O
regulated	O
by	O
the	O
steroidogenic	B-GENE-Y
acute	I-GENE-Y
regulatory	I-GENE-Y
protein	I-GENE-Y
,	O
StAR	B-GENE-Y
,	O
serving	O
as	O
the	O
acute	O
regulator	O
of	O
steroidogenesis	O
.	O

StAR	B-GENE-Y
action	O
requires	O
a	O
complex	O
multi	O
-	O
component	O
molecular	O
machine	O
on	O
the	O
outer	O
mitochondrial	O
membrane	O
(	O
OMM	O
)	O
.	O

Components	O
of	O
this	O
machine	O
include	O
the	O
18kDa	O
translocator	B-GENE-Y
protein	I-GENE-Y
(	O
TSPO	B-GENE-Y
)	O
,	O
the	O
voltage	B-GENE-N
-	I-GENE-N
dependent	I-GENE-N
anion	I-GENE-N
chanel	I-GENE-N
(	O
VDAC	B-GENE-Y
-	I-GENE-Y
1	I-GENE-Y
)	O
,	O
TSPO	B-GENE-Y
-	I-GENE-Y
associated	I-GENE-Y
protein	I-GENE-Y
7	I-GENE-Y
(	O
PAP7	B-GENE-Y
,	O
ACBD3	B-GENE-Y
)	O
,	O
and	O
protein	B-GENE-Y
kinase	I-GENE-Y
A	I-GENE-Y
regulatory	I-GENE-Y
subunit	I-GENE-Y
1	I-GENE-Y
(	O
PKAR1A	B-GENE-Y
)	O
.	O

The	O
precise	O
fashion	O
in	O
which	O
these	O
proteins	O
interact	O
and	O
move	O
cholesterol	B-CHEMICAL
from	O
the	O
OMM	O
to	O
P450scc	B-GENE-Y
,	O
and	O
the	O
means	O
by	O
which	O
cholesterol	B-CHEMICAL
is	O
loaded	O
into	O
the	O
OMM	O
,	O
remain	O
unclear	O
.	O

Human	O
deficiency	O
diseases	O
have	O
been	O
described	O
for	O
StAR	B-GENE-Y
and	O
for	O
all	O
the	O
mitochondrial	O
steroidogenic	O
enzymes	O
,	O
but	O
not	O
for	O
the	O
electron	O
transfer	O
proteins	O
or	O
for	O
the	O
components	O
of	O
the	O
cholesterol	B-CHEMICAL
import	O
machine	O
.	O

Matrix	B-GENE-N
Metalloproteinase	I-GENE-N
Inhibitors	O
Based	O
on	O
the	O
3	B-CHEMICAL
-	I-CHEMICAL
Mercaptopyrrolidine	I-CHEMICAL
Core	O
.	O

New	O
series	O
of	O
pyrrolidine	B-CHEMICAL
mercaptosulfide	I-CHEMICAL
,	O
2	B-CHEMICAL
-	I-CHEMICAL
mercaptocyclopentane	I-CHEMICAL
arylsulfonamide	I-CHEMICAL
,	O
and	O
3	B-CHEMICAL
-	I-CHEMICAL
mercapto	I-CHEMICAL
-	I-CHEMICAL
4	I-CHEMICAL
-	I-CHEMICAL
arylsulfonamido	I-CHEMICAL
pyrrolidine	I-CHEMICAL
matrix	B-GENE-N
metalloproteinase	I-GENE-N
inhibitors	O
(	O
MMPIs	O
)	O
were	O
designed	O
,	O
synthesized	O
,	O
and	O
evaluated	O
.	O

Exhibiting	O
unique	O
properties	O
over	O
other	O
MMPIs	O
(	O
e	O
.	O
g	O
.	O
,	O
hydroxamates	B-CHEMICAL
)	O
,	O
these	O
newly	O
reported	O
compounds	O
are	O
capable	O
of	O
modulating	O
activities	O
of	O
several	O
MMPs	B-GENE-N
in	O
the	O
low	O
nanomolar	O
range	O
,	O
including	O
MMP	B-GENE-Y
-	I-GENE-Y
2	I-GENE-Y
(	O
~	O
2	O
to	O
50	O
nM	O
)	O
,	O
MMP	B-GENE-Y
-	I-GENE-Y
13	I-GENE-Y
(	O
~	O
2	O
to	O
50	O
nM	O
)	O
,	O
and	O
MMP	B-GENE-Y
-	I-GENE-Y
14	I-GENE-Y
(	O
~	O
4	O
to	O
60	O
nM	O
)	O
.	O

Additionally	O
these	O
compounds	O
are	O
selective	O
to	O
intermediate	O
-	O
and	O
deep	O
-	O
pocket	O
MMPs	B-GENE-N
but	O
not	O
shallow	O
-	O
pocketed	O
MMPs	B-GENE-N
(	O
e	O
.	O
g	O
.	O
,	O
MMP	B-GENE-Y
-	I-GENE-Y
1	I-GENE-Y
,	O
~	O
850	O
to	O
>	O
50	O
,	O
000	O
nM	O
;	O
MMP	B-GENE-Y
-	I-GENE-Y
7	I-GENE-Y
,	O
~	O
4	O
,	O
000	O
to	O
>	O
25	O
,	O
000	O
nM	O
)	O
.	O

Our	O
previous	O
work	O
with	O
the	O
mercaptosulfide	B-CHEMICAL
functionality	O
attached	O
to	O
both	O
cyclopentane	B-CHEMICAL
and	O
pyrrolidine	B-CHEMICAL
frameworks	O
demonstrated	O
that	O
the	O
cis	O
-	O
(	O
3S	O
,	O
4R	O
)	O
-	O
stereochemistry	O
was	O
optimal	O
for	O
all	O
of	O
the	O
MMPs	B-GENE-N
tested	O
.	O

However	O
,	O
in	O
our	O
newest	O
compounds	O
an	O
interesting	O
shift	O
of	O
preference	O
to	O
the	O
trans	O
-	O
form	O
of	O
the	O
mercaptosulfonamides	B-CHEMICAL
was	O
observed	O
with	O
increased	O
oxidative	O
stability	O
and	O
biological	O
compatibility	O
.	O

We	O
also	O
report	O
several	O
kinetic	O
and	O
biological	O
characteristics	O
showing	O
that	O
these	O
compounds	O
may	O
be	O
used	O
to	O
probe	O
the	O
mechanistic	O
activities	O
of	O
MMPs	B-GENE-N
in	O
disease	O
.	O

A	O
Structural	O
Snapshot	O
of	O
Cytochrome	B-GENE-Y
P450	I-GENE-Y
2B4	I-GENE-Y
in	O
Complex	O
with	O
Paroxetine	B-CHEMICAL
Provides	O
Insights	O
into	O
Ligand	O
Binding	O
and	O
Clusters	O
of	O
Conformational	O
States	O
.	O

An	O
X	O
-	O
ray	O
crystal	O
structure	O
of	O
cytochrome	B-GENE-Y
P450	I-GENE-Y
2B4	I-GENE-Y
in	O
complex	O
with	O
the	O
drug	O
paroxetine	B-CHEMICAL
was	O
solved	O
at	O
2	O
.	O
14	O
	O
resolution	O
.	O

The	O
structure	O
revealed	O
a	O
conformation	O
intermediate	O
to	O
that	O
of	O
the	O
recently	O
solved	O
complex	O
with	O
amlodipine	B-CHEMICAL
and	O
of	O
the	O
more	O
compact	O
complex	O
with	O
4	B-CHEMICAL
-	I-CHEMICAL
(	I-CHEMICAL
4	I-CHEMICAL
-	I-CHEMICAL
chlorophenyl	I-CHEMICAL
)	I-CHEMICAL
imidazole	I-CHEMICAL
in	O
terms	O
of	O
the	O
placement	O
of	O
the	O
F	O
-	O
G	O
cassette	O
.	O

Moreover	O
,	O
the	O
comparison	O
of	O
the	O
new	O
structure	O
with	O
15	O
previously	O
solved	O
structures	O
of	O
P450	B-GENE-Y
2B4	I-GENE-Y
revealed	O
some	O
new	O
insights	O
into	O
determinants	O
of	O
active	O
site	O
size	O
and	O
shape	O
.	O

The	O
2B4	B-GENE-Y
-	O
paroxetine	B-CHEMICAL
structure	O
is	O
nearly	O
superimposable	O
on	O
a	O
previously	O
solved	O
closed	O
structure	O
in	O
a	O
ligand	O
free	O
state	O
.	O

Despite	O
the	O
overall	O
conformational	O
similarity	O
among	O
multiple	O
closed	O
structures	O
,	O
the	O
active	O
site	O
cavity	O
volume	O
of	O
the	O
paroxetine	B-CHEMICAL
complex	O
is	O
enlarged	O
.	O

Further	O
analysis	O
of	O
the	O
accessible	O
space	O
and	O
binding	O
pocket	O
near	O
the	O
heme	O
reveals	O
a	O
new	O
sub	O
-	O
chamber	O
that	O
resulted	O
from	O
the	O
movement	O
of	O
secondary	O
structural	O
elements	O
and	O
rearrangements	O
of	O
active	O
site	O
side	O
chains	O
.	O

Overall	O
,	O
the	O
results	O
from	O
the	O
comparison	O
of	O
all	O
the	O
16	O
structures	O
of	O
P450	B-GENE-Y
2B4	I-GENE-Y
demonstrate	O
a	O
cluster	O
of	O
protein	O
conformations	O
that	O
were	O
observed	O
in	O
the	O
presence	O
or	O
absence	O
of	O
various	O
ligands	O
.	O

Protective	O
Role	O
of	O
(	B-CHEMICAL
RS	I-CHEMICAL
)	I-CHEMICAL
-	I-CHEMICAL
glucoraphanin	I-CHEMICAL
Bioactivated	O
with	O
Myrosinase	B-GENE-N
in	O
an	O
Experimental	O
Model	O
of	O
Multiple	O
Sclerosis	O
.	O

AIM	O
:	O
The	O
discovery	O
of	O
new	O
natural	O
compounds	O
with	O
pharmacological	O
properties	O
is	O
a	O
field	O
of	O
interest	O
widely	O
growing	O
.	O

Recent	O
literature	O
shows	O
that	O
Brassica	O
vegetables	O
(	O
Cruciferae	O
)	O
possess	O
therapeutic	O
effects	O
particularly	O
ascribed	O
due	O
to	O
their	O
content	O
in	O
glucosinolates	B-CHEMICAL
,	O
which	O
upon	O
myrosinase	B-GENE-N
hydrolysis	O
release	O
the	O
corresponding	O
isothiocyanates	B-CHEMICAL
.	O

This	O
study	O
examines	O
the	O
potential	O
neuroprotective	O
and	O
immunomodulatory	O
effects	O
of	O
(	B-CHEMICAL
RS	I-CHEMICAL
)	I-CHEMICAL
-	I-CHEMICAL
glucoraphanin	I-CHEMICAL
from	O
Tuscan	O
black	O
kale	O
(	O
Brassica	O
oleracea	O
L	O
.	O
var	O
.	O
acephala	O
sabellica	O
)	O
bioactivated	O
with	O
myrosinase	B-GENE-N
(	O
bioactive	O
RS	B-CHEMICAL
-	I-CHEMICAL
GRA	I-CHEMICAL
)	O
(	O
10	O
mg	O
/	O
kg	O
/	O
day	O
intraperitoneally	O
)	O
,	O
in	O
an	O
experimental	O
autoimmune	O
encephalomyelitis	O
(	O
EAE	O
)	O
,	O
a	O
model	O
of	O
multiple	O
sclerosis	O
.	O

METHODS	O
:	O
EAE	O
was	O
induced	O
by	O
immunization	O
with	O
myelin	B-GENE-Y
oligodendroglial	I-GENE-Y
glycoprotein	I-GENE-Y
peptide	I-GENE-Y
(	O
MOG35	B-GENE-Y
-	I-GENE-Y
55	I-GENE-Y
)	O
in	O
mice	O
.	O

After	O
immunization	O
,	O
mice	O
were	O
observed	O
daily	O
for	O
signs	O
of	O
EAE	O
and	O
weight	O
loss	O
.	O

Clinical	O
score	O
was	O
evaluated	O
using	O
a	O
standardized	O
scoring	O
system	O
.	O

RESULTS	O
:	O
By	O
Western	O
blot	O
analysis	O
of	O
spinal	O
cord	O
tissues	O
,	O
we	O
have	O
demonstrated	O
that	O
treatment	O
with	O
bioactive	O
RS	B-CHEMICAL
-	I-CHEMICAL
GRA	I-CHEMICAL
significantly	O
decreased	O
nuclear	B-GENE-N
factor	I-GENE-N
(	I-GENE-N
NF	I-GENE-N
)	I-GENE-N
-	I-GENE-N
kB	I-GENE-N
translocation	O
,	O
pro	O
-	O
inflammatory	O
cytokine	B-GENE-N
production	O
such	O
as	O
interleukin	B-GENE-Y
-	I-GENE-Y
1	I-GENE-Y
(	O
IL	B-GENE-Y
-	I-GENE-Y
1	I-GENE-Y
)	O
,	O
and	O
apoptosis	O
(	O
Bax	B-GENE-Y
and	O
caspase	B-GENE-Y
3	I-GENE-Y
expression	O
)	O
.	O

CONCLUSION	O
:	O
Our	O
results	O
clearly	O
demonstrate	O
that	O
bioactive	O
RS	B-CHEMICAL
-	I-CHEMICAL
GRA	I-CHEMICAL
treatment	O
may	O
represent	O
a	O
useful	O
therapeutic	O
perspective	O
in	O
the	O
treatment	O
of	O
this	O
disease	O
.	O

Involvement	O
of	O
p	B-GENE-N
-	I-GENE-N
CREB	I-GENE-N
and	O
phase	B-GENE-N
II	I-GENE-N
detoxifying	I-GENE-N
enzyme	I-GENE-N
system	O
in	O
neuroprotection	O
mediated	O
by	O
the	O
flavonoid	O
calycopterin	B-CHEMICAL
isolated	O
from	O
Dracocephalum	O
kotschyi	O
.	O

PURPOSE	O
:	O
There	O
is	O
an	O
increasing	O
amount	O
of	O
experimental	O
evidence	O
that	O
oxidative	O
stress	O
has	O
a	O
central	O
role	O
in	O
the	O
neuropathology	O
of	O
neurodegenerative	O
diseases	O
.	O

It	O
has	O
been	O
suggested	O
that	O
the	O
loss	O
of	O
cell	O
function	O
results	O
from	O
the	O
increased	O
oxidative	O
damage	O
to	O
proteins	O
and	O
DNA	O
.	O

Herein	O
,	O
we	O
investigated	O
the	O
effect	O
of	O
a	O
natural	O
neuroprotective	O
flavonoid	O
,	O
calycopterin	B-CHEMICAL
,	O
on	O
H2O2	B-CHEMICAL
-	O
induced	O
disruption	O
of	O
phase	B-GENE-N
II	I-GENE-N
detoxifying	I-GENE-N
enzyme	I-GENE-N
system	O
and	O
cAMP	B-GENE-N
response	I-GENE-N
element	I-GENE-N
binding	I-GENE-N
protein	I-GENE-N
(	O
CREB	B-GENE-N
)	O
phosphorylation	O
.	O

METHODS	O
:	O
PC12	O
cells	O
were	O
treated	O
with	O
25	O
,	O
50	O
and	O
100M	O
of	O
calycopterin	B-CHEMICAL
for	O
3h	O
,	O
followed	O
by	O
adding	O
H2O2	B-CHEMICAL
(	O
150M	O
)	O
for	O
24h	O
.	O

The	O
extent	O
of	O
apoptosis	O
was	O
assessed	O
by	O
comet	O
assay	O
.	O

The	O
level	O
of	O
phosphorylated	B-GENE-N
CREB	I-GENE-N
,	O
nuclear	B-GENE-Y
factor	I-GENE-Y
erythroid	I-GENE-Y
2	I-GENE-Y
-	I-GENE-Y
related	I-GENE-Y
factor	I-GENE-Y
2	I-GENE-Y
(	O
Nrf2	B-GENE-Y
)	O
,	O
glutamylcysteine	B-GENE-Y
synthetase	I-GENE-Y
(	O
	B-GENE-Y
-	I-GENE-Y
GCS	I-GENE-Y
)	O
and	O
heme	B-GENE-Y
oxygenase	I-GENE-Y
1	I-GENE-Y
(	O
HO	B-GENE-Y
-	I-GENE-Y
1	I-GENE-Y
)	O
were	O
measured	O
by	O
western	O
blot	O
method	O
.	O

The	O
concentration	O
of	O
glutathione	B-CHEMICAL
(	O
GSH	B-CHEMICAL
)	O
was	O
determined	O
in	O
whole	O
cell	O
lysate	O
using	O
dithionitrobenzoic	O
acid	O
method	O
.	O

Superoxide	B-GENE-N
dismutase	I-GENE-N
(	O
SOD	B-GENE-N
)	O
activity	O
was	O
measured	O
by	O
colorimetric	O
assay	O
.	O

RESULT	O
:	O
Morphological	O
analysis	O
of	O
protection	O
induced	O
by	O
calycopterin	B-CHEMICAL
,	O
determined	O
by	O
comet	O
assay	O
,	O
showed	O
that	O
calycopterin	B-CHEMICAL
reduced	O
DNA	O
in	O
tail	O
.	O

We	O
found	O
that	O
H2O2	B-CHEMICAL
decreased	O
mitochondrial	O
membrane	O
potential	O
(	O
MMP	O
)	O
,	O
while	O
,	O
calycopterin	B-CHEMICAL
prevented	O
this	O
decrease	O
in	O
MMP	O
in	O
presence	O
of	O
H2O2	B-CHEMICAL
.	O

In	O
H2O2	B-CHEMICAL
-	O
treated	O
cells	O
,	O
calycopterin	B-CHEMICAL
also	O
suppressed	O
cytochrome	B-GENE-Y
C	I-GENE-Y
release	O
to	O
cytosol	O
that	O
is	O
necessary	O
for	O
maintaining	O
mitochondrial	O
homeostasis	O
in	O
survived	O
cells	O
.	O

Moreover	O
,	O
calycopterin	B-CHEMICAL
,	O
in	O
presence	O
of	O
H2O2	B-CHEMICAL
inhibited	O
the	O
decrease	O
caused	O
by	O
oxidative	O
stress	O
in	O
stress	O
-	O
sensing	O
transcription	O
factors	O
,	O
CREB	B-GENE-N
and	O
Nrf2	B-GENE-Y
,	O
which	O
play	O
an	O
important	O
role	O
in	O
antioxidant	O
capacity	O
of	O
the	O
cell	O
.	O

There	O
was	O
also	O
an	O
increase	O
in	O
	B-GENE-Y
-	I-GENE-Y
GCS	I-GENE-Y
and	O
HO	B-GENE-Y
-	I-GENE-Y
1	I-GENE-Y
levels	O
in	O
calycopterin	B-CHEMICAL
pretreated	O
cells	O
.	O

In	O
the	O
presence	O
of	O
H2O2	B-CHEMICAL
,	O
calycopterin	B-CHEMICAL
inhibited	O
decrease	O
in	O
GSH	B-CHEMICAL
level	O
and	O
SOD	B-GENE-N
activity	O
.	O

CONCLUSION	O
:	O
We	O
provided	O
documentation	O
of	O
neuroprotective	O
effect	O
of	O
a	O
natural	O
flavone	O
,	O
calycopterin	B-CHEMICAL
,	O
against	O
H2O2	B-CHEMICAL
-	O
induced	O
oxidative	O
stress	O
in	O
differentiated	O
PC12	O
cells	O
by	O
modulating	O
the	O
level	O
of	O
CREB	B-GENE-N
phosphorylation	O
and	O
Nrf2	B-GENE-Y
pathway	O
.	O

Indoxyl	B-CHEMICAL
3	I-CHEMICAL
-	I-CHEMICAL
sulfate	I-CHEMICAL
stimulates	O
Th17	O
differentiation	O
enhancing	O
phosphorylation	O
of	O
c	B-GENE-Y
-	I-GENE-Y
Src	I-GENE-Y
and	O
STAT3	B-GENE-Y
to	O
worsen	O
experimental	O
autoimmune	O
encephalomyelitis	O
.	O

Although	O
AhR	B-GENE-Y
activation	O
regulates	O
CD4T	O
cell	O
differentiation	O
,	O
how	O
it	O
works	O
has	O
yet	O
to	O
be	O
elucidated	O
.	O

In	O
the	O
present	O
study	O
,	O
using	O
in	O
vitro	O
Th17	O
differentiation	O
model	O
,	O
we	O
examined	O
effects	O
of	O
AhR	B-GENE-Y
activation	O
by	O
indoxyl	B-CHEMICAL
3	I-CHEMICAL
-	I-CHEMICAL
sulfate	I-CHEMICAL
(	O
I3S	B-CHEMICAL
)	O
,	O
a	O
uremic	O
toxin	O
,	O
on	O
Th17	O
differentiation	O
and	O
investigated	O
underlying	O
mechanisms	O
.	O

I3S	B-CHEMICAL
increased	O
expression	O
of	O
RORt	B-GENE-Y
,	O
the	O
master	O
transcription	O
factor	O
for	O
Th17	O
differentiation	O
,	O
and	O
stimulated	O
Th17	O
differentiation	O
,	O
in	O
a	O
comparative	O
manner	O
as	O
2	B-CHEMICAL
,	I-CHEMICAL
3	I-CHEMICAL
,	I-CHEMICAL
7	I-CHEMICAL
,	I-CHEMICAL
8	I-CHEMICAL
-	I-CHEMICAL
tetrachlorodibenzo	I-CHEMICAL
-	I-CHEMICAL
p	I-CHEMICAL
-	I-CHEMICAL
dioxin	I-CHEMICAL
(	O
TCDD	B-CHEMICAL
)	O
,	O
a	O
prototypical	O
AhR	B-GENE-Y
ligand	O
.	O

Activation	O
of	O
STAT3	B-GENE-Y
,	O
which	O
is	O
phosphorylated	O
by	O
the	O
IL	B-GENE-Y
-	I-GENE-Y
6	I-GENE-Y
signaling	O
pathways	O
and	O
thus	O
is	O
necessary	O
for	O
Th17	O
differentiation	O
,	O
was	O
strongly	O
stimulated	O
by	O
I3S	B-CHEMICAL
and	O
TCDD	B-CHEMICAL
.	O

Phosphorylation	O
of	O
c	B-GENE-Y
-	I-GENE-Y
Src	I-GENE-Y
,	O
which	O
was	O
shown	O
to	O
be	O
activated	O
by	O
AhR	B-GENE-Y
ligands	O
,	O
was	O
also	O
increased	O
by	O
I3S	B-CHEMICAL
and	O
TCDD	B-CHEMICAL
,	O
and	O
blocking	O
of	O
c	B-GENE-Y
-	I-GENE-Y
Src	I-GENE-Y
activity	O
by	O
4	B-CHEMICAL
-	I-CHEMICAL
amino	I-CHEMICAL
-	I-CHEMICAL
5	I-CHEMICAL
-	I-CHEMICAL
(	I-CHEMICAL
4	I-CHEMICAL
-	I-CHEMICAL
chlorophenyl	I-CHEMICAL
)	I-CHEMICAL
-	I-CHEMICAL
7	I-CHEMICAL
-	I-CHEMICAL
(	I-CHEMICAL
t	I-CHEMICAL
-	I-CHEMICAL
butyl	I-CHEMICAL
)	I-CHEMICAL
pyrazolo	I-CHEMICAL
[	I-CHEMICAL
3	I-CHEMICAL
,	I-CHEMICAL
4	I-CHEMICAL
-	I-CHEMICAL
d	I-CHEMICAL
]	I-CHEMICAL
pyrimidine	I-CHEMICAL
(	O
PP2	O
)	O
inhibited	O
phosphorylation	O
of	O
both	O
c	B-GENE-Y
-	I-GENE-Y
Src	I-GENE-Y
and	O
STAT3	B-GENE-Y
,	O
raising	O
a	O
possibility	O
that	O
stimulatory	O
activities	O
of	O
I3S	B-CHEMICAL
and	O
TCDD	B-CHEMICAL
on	O
Th17	O
differentiation	O
could	O
be	O
exerted	O
via	O
increased	O
phosphorylation	O
of	O
c	B-GENE-Y
-	I-GENE-Y
Src	I-GENE-Y
,	O
which	O
in	O
turn	O
stimulates	O
STAT3	B-GENE-Y
activation	O
.	O

Finally	O
,	O
we	O
found	O
that	O
I3S	B-CHEMICAL
worsened	O
experimental	O
autoimmune	O
encephalomyelitis	O
(	O
EAE	O
)	O
,	O
which	O
is	O
primarily	O
mediated	O
by	O
Th17	O
cells	O
,	O
enhancing	O
the	O
frequency	O
of	O
IL	B-GENE-Y
-	I-GENE-Y
17	I-GENE-Y
-	O
producing	O
cells	O
in	O
draining	O
lymph	O
nodes	O
.	O

Gene	O
expression	O
profiling	O
and	O
pathway	O
analysis	O
of	O
hepatotoxicity	O
induced	O
by	O
triptolide	B-CHEMICAL
in	O
Wistar	O
rats	O
.	O

Triptolide	B-CHEMICAL
(	O
TP	O
)	O
,	O
a	O
major	O
component	O
of	O
TWHF	O
,	O
is	O
widely	O
used	O
to	O
treat	O
rheumatoid	O
arthritis	O
,	O
systemic	O
lupus	O
erythematosus	O
,	O
nephritis	O
and	O
leprosy	O
.	O

However	O
,	O
its	O
clinical	O
use	O
is	O
limited	O
by	O
hepatotoxicity	O
.	O

To	O
further	O
elucidate	O
the	O
underlying	O
mechanism	O
of	O
its	O
hepatotoxic	O
effects	O
,	O
hepatic	O
gene	O
expression	O
profiles	O
were	O
analyzed	O
.	O

TP	O
(	O
1000	O
and	O
300g	O
/	O
kg	O
)	O
was	O
orally	O
administered	O
to	O
Wistar	O
rats	O
for	O
14days	O
.	O

Current	O
study	O
indicated	O
that	O
female	O
rats	O
were	O
more	O
sensitive	O
to	O
TP	O
-	O
induced	O
hepatotoxicity	O
than	O
males	O
.	O

Genome	O
-	O
wide	O
microarray	O
analyses	O
identified	O
3329	O
differentially	O
expressed	O
genes	O
in	O
liver	O
of	O
female	O
rats	O
.	O

Analyses	O
of	O
these	O
genes	O
identified	O
over	O
-	O
represented	O
functions	O
associated	O
with	O
insulin	B-GENE-N
signaling	O
pathway	O
,	O
glucose	B-CHEMICAL
metabolism	O
,	O
cell	O
cycle	O
,	O
oxidative	O
stress	O
and	O
apoptosis	O
,	O
which	O
were	O
consistent	O
with	O
the	O
results	O
of	O
significant	O
increase	O
of	O
Caspase	B-GENE-Y
-	I-GENE-Y
3	I-GENE-Y
activity	O
and	O
reduction	O
of	O
serum	O
glucose	B-CHEMICAL
,	O
GSH	B-CHEMICAL
/	O
GSSG	B-CHEMICAL
ratio	O
,	O
glucose	B-GENE-Y
-	I-GENE-Y
6	I-GENE-Y
-	I-GENE-Y
phosphatase	I-GENE-Y
and	O
phosphoenolpyruvate	B-GENE-Y
carboxykinase	I-GENE-Y
activities	O
,	O
liver	O
glycogen	O
.	O

In	O
addition	O
,	O
it	O
was	O
observed	O
for	O
the	O
first	O
time	O
that	O
glucocorticoids	O
and	O
IGF1	B-GENE-Y
might	O
get	O
involved	O
in	O
TP	O
-	O
induced	O
hepatotoxicity	O
.	O

These	O
data	O
suggest	O
that	O
TP	O
treatment	O
could	O
alter	O
the	O
hepatic	O
redox	O
status	O
,	O
reduce	O
serum	O
glucose	B-CHEMICAL
and	O
induce	O
hepatocyte	O
apoptosis	O
,	O
consistent	O
with	O
the	O
differential	O
expression	O
of	O
genes	O
involved	O
in	O
insulin	B-GENE-N
signaling	O
pathway	O
,	O
glucose	B-CHEMICAL
metabolism	O
pathway	O
and	O
cell	O
stress	O
pathway	O
,	O
all	O
of	O
which	O
might	O
contribute	O
to	O
the	O
overall	O
TP	O
-	O
induced	O
hepatotoxicity	O
.	O

TCDD	B-CHEMICAL
induces	O
the	O
expression	O
of	O
insulin	B-GENE-Y
-	I-GENE-Y
like	I-GENE-Y
growth	I-GENE-Y
factor	I-GENE-Y
binding	I-GENE-Y
protein	I-GENE-Y
4	I-GENE-Y
in	O
5L	O
rat	O
hepatoma	O
cells	O
:	O
a	O
cautionary	O
tale	O
of	O
the	O
use	O
of	O
this	O
cell	O
line	O
in	O
studies	O
on	O
dioxin	B-CHEMICAL
toxicity	O
.	O

Previous	O
quantitative	O
proteomic	O
studies	O
on	O
the	O
actions	O
of	O
2	B-CHEMICAL
,	I-CHEMICAL
3	I-CHEMICAL
,	I-CHEMICAL
7	I-CHEMICAL
,	I-CHEMICAL
8	I-CHEMICAL
-	I-CHEMICAL
tetrachlorodibenzo	I-CHEMICAL
-	I-CHEMICAL
p	I-CHEMICAL
-	I-CHEMICAL
dioxin	I-CHEMICAL
(	O
TCDD	B-CHEMICAL
)	O
in	O
5L	O
rat	O
hepatoma	O
cells	O
,	O
a	O
cell	O
model	O
frequently	O
used	O
for	O
investigating	O
the	O
mechanisms	O
of	O
TCDD	B-CHEMICAL
toxicity	O
,	O
had	O
indicated	O
that	O
dioxin	B-CHEMICAL
exposure	O
reduced	O
the	O
abundance	O
of	O
numerous	O
proteins	O
which	O
are	O
regulated	O
at	O
the	O
level	O
of	O
protein	O
synthesis	O
initiation	O
.	O

In	O
the	O
present	O
study	O
,	O
we	O
have	O
analysed	O
the	O
mechanism	O
mediating	O
this	O
inhibition	O
.	O

TCDD	B-CHEMICAL
treatment	O
of	O
the	O
cells	O
largely	O
prevented	O
the	O
activation	O
of	O
eukaryotic	B-GENE-Y
translation	I-GENE-Y
initiation	I-GENE-Y
factor	I-GENE-Y
4E	I-GENE-Y
-	I-GENE-Y
binding	I-GENE-Y
protein	I-GENE-Y
1	I-GENE-Y
,	O
a	O
regulator	O
of	O
translation	O
initiation	O
and	O
substrate	O
of	O
the	O
mammalian	B-GENE-Y
target	I-GENE-Y
of	I-GENE-Y
rapamycin	I-GENE-Y
(	O
mTOR	B-GENE-Y
)	O
.	O

By	O
"	O
working	O
upwards	O
"	O
from	O
mTOR	B-GENE-Y
,	O
we	O
observed	O
that	O
TCDD	B-CHEMICAL
inhibited	O
endogenous	O
and	O
IGF	B-GENE-Y
-	I-GENE-Y
I	I-GENE-Y
-	O
induced	O
AKT	B-GENE-N
and	O
ERK	B-GENE-N
activation	O
by	O
interfering	O
with	O
tyrosine	B-CHEMICAL
phosphorylation	O
of	O
insulin	B-GENE-Y
receptor	I-GENE-Y
substrate	I-GENE-Y
1	I-GENE-Y
.	O

This	O
inhibition	O
was	O
mediated	O
by	O
a	O
TCDD	B-CHEMICAL
-	O
induced	O
secreted	O
factor	O
which	O
was	O
identified	O
as	O
insulin	B-GENE-Y
-	I-GENE-Y
like	I-GENE-Y
growth	I-GENE-Y
factor	I-GENE-Y
binding	I-GENE-Y
protein	I-GENE-Y
4	I-GENE-Y
(	O
IGFBP	B-GENE-Y
-	I-GENE-Y
4	I-GENE-Y
)	O
.	O

The	O
induction	O
of	O
IGFBP	B-GENE-Y
-	I-GENE-Y
4	I-GENE-Y
protein	O
was	O
dependent	O
on	O
a	O
functional	O
aryl	B-GENE-Y
hydrocarbon	I-GENE-Y
receptor	I-GENE-Y
and	O
was	O
preceded	O
by	O
a	O
rapid	O
increase	O
in	O
the	O
level	O
of	O
IGFBP	B-GENE-Y
-	I-GENE-Y
4	I-GENE-Y
mRNA	O
indicating	O
that	O
IGFBP	B-GENE-Y
-	I-GENE-Y
4	I-GENE-Y
is	O
a	O
previously	O
unknown	O
transcriptional	O
target	O
of	O
TCDD	B-CHEMICAL
in	O
5L	O
cells	O
.	O

IGFBP	B-GENE-Y
-	I-GENE-Y
4	I-GENE-Y
was	O
not	O
induced	O
by	O
TCDD	B-CHEMICAL
in	O
the	O
parental	O
cell	O
line	O
of	O
5L	O
cells	O
,	O
Fao	O
,	O
and	O
in	O
various	O
closely	O
related	O
rat	O
hepatoma	O
cell	O
lines	O
as	O
well	O
as	O
in	O
other	O
unrelated	O
cell	O
types	O
.	O

Analysis	O
of	O
5L	O
cell	O
chromosomes	O
by	O
multicolour	O
spectral	O
karyotyping	O
(	O
SKY	O
)	O
revealed	O
that	O
the	O
cells	O
carry	O
several	O
hitherto	O
uncharacterised	O
chromosomal	O
translocations	O
.	O

The	O
observations	O
suggest	O
that	O
in	O
5L	O
cells	O
the	O
Igfbp	B-GENE-Y
-	I-GENE-Y
4	I-GENE-Y
gene	O
may	O
have	O
got	O
under	O
the	O
control	O
of	O
a	O
promoter	O
containing	O
dioxin	B-GENE-N
responsive	I-GENE-N
element	I-GENE-N
(	I-GENE-N
s	I-GENE-N
)	I-GENE-N
leading	O
to	O
the	O
induction	O
of	O
IGFBP	B-GENE-Y
-	I-GENE-Y
4	I-GENE-Y
by	O
TCDD	B-CHEMICAL
.	O

These	O
findings	O
emphasise	O
a	O
particular	O
caution	O
when	O
interpreting	O
and	O
extrapolating	O
results	O
on	O
the	O
action	O
mechanisms	O
of	O
TCDD	B-CHEMICAL
obtained	O
in	O
studies	O
using	O
5L	O
cells	O
as	O
a	O
model	O
system	O
.	O

Glycosylation	O
enhances	O
the	O
anti	O
-	O
migratory	O
activities	O
of	O
isomalyngamide	B-CHEMICAL
A	I-CHEMICAL
analogs	O
.	O

Three	O
,	O
new	O
,	O
fully	O
synthetic	O
glycosylated	B-CHEMICAL
isomalyngamide	I-CHEMICAL
A	I-CHEMICAL
analogs	O
4	O
-	O
6	O
were	O
prepared	O
and	O
evaluated	O
for	O
their	O
anti	O
-	O
migratory	O
activities	O
in	O
human	O
breast	O
cancer	O
cells	O
.	O

The	O
results	O
of	O
the	O
study	O
show	O
that	O
two	O
glycosylated	O
derivatives	O
4	O
and	O
5	O
,	O
containing	O
mannose	B-CHEMICAL
and	O
galactose	B-CHEMICAL
appendages	O
,	O
suppress	O
metastatic	O
events	O
(	O
e	O
.	O
g	O
.	O
,	O
migration	O
,	O
invasion	O
and	O
adhesion	O
)	O
in	O
human	O
breast	O
adenocarcinoma	O
MDA	O
-	O
MB	O
-	O
231	O
cells	O
at	O
"	O
nontoxic	O
"	O
concentration	O
levels	O
.	O

In	O
contrast	O
,	O
derivative	O
6	O
that	O
contains	O
a	O
lactose	B-CHEMICAL
moiety	O
,	O
displays	O
a	O
less	O
potent	O
activity	O
.	O

The	O
findings	O
show	O
that	O
monosaccharide	B-CHEMICAL
rather	O
than	O
disaccharide	B-CHEMICAL
appendages	O
to	O
the	O
isomalyngamide	B-CHEMICAL
A	I-CHEMICAL
backbone	O
more	O
greatly	O
influence	O
cell	O
migration	O
and	O
invasive	O
ability	O
.	O

Evidence	O
has	O
been	O
gained	O
for	O
a	O
mechanism	O
for	O
inhibition	O
of	O
metastatic	O
activities	O
in	O
MDA	O
-	O
MB	O
-	O
231	O
cells	O
by	O
4	O
and	O
5	O
,	O
involving	O
inactivation	O
of	O
the	O
expression	O
of	O
p	B-GENE-Y
-	I-GENE-Y
FAK	I-GENE-Y
and	O
paxillin	B-GENE-Y
through	O
the	O
integrin	O
-	O
mediated	O
antimetastatic	O
pathway	O
.	O

Inhibition	O
of	O
human	O
breast	O
cancer	O
cell	O
proliferation	O
in	O
tissue	O
culture	O
by	O
the	O
neuroleptic	O
agents	O
pimozide	B-CHEMICAL
and	O
thioridazine	B-CHEMICAL
.	O

Permanent	O
cell	O
culture	O
lines	O
derived	O
from	O
human	O
breast	O
cancer	O
tissue	O
are	O
important	O
experimental	O
models	O
in	O
the	O
study	O
of	O
human	O
breast	O
cancer	O
cell	O
proliferation	O
.	O

In	O
the	O
present	O
work	O
,	O
pimozide	B-CHEMICAL
,	O
thioridazine	B-CHEMICAL
,	O
W	B-CHEMICAL
-	I-CHEMICAL
13	I-CHEMICAL
,	O
and	O
W	B-CHEMICAL
-	I-CHEMICAL
12	I-CHEMICAL
were	O
shown	O
to	O
inhibit	O
MCF	O
-	O
7	O
human	O
breast	O
cancer	O
cell	O
growth	O
.	O

The	O
50	O
%	O
inhibition	O
concentration	O
values	O
determined	O
in	O
two	O
proliferation	O
assays	O
,	O
[	B-CHEMICAL
3H	I-CHEMICAL
]	I-CHEMICAL
thymidine	I-CHEMICAL
incorporation	O
and	O
cell	O
number	O
,	O
were	O
in	O
close	O
agreement	O
for	O
each	O
compound	O
tested	O
.	O

The	O
order	O
of	O
potency	O
for	O
growth	O
inhibition	O
in	O
the	O
presence	O
of	O
2	O
%	O
stripped	O
calf	O
serum	O
was	O
pimozide	B-CHEMICAL
(	O
Ki	O
2	O
microM	O
)	O
greater	O
than	O
thioridazine	B-CHEMICAL
(	O
Ki	O
5	O
microM	O
)	O
greater	O
than	O
W	B-CHEMICAL
-	I-CHEMICAL
13	I-CHEMICAL
(	O
Ki	O
15	O
microM	O
)	O
greater	O
than	O
W	B-CHEMICAL
-	I-CHEMICAL
12	I-CHEMICAL
(	O
Ki	O
39	O
microM	O
)	O
.	O

Similar	O
concentrations	O
of	O
these	O
compounds	O
blocked	O
estradiol	B-CHEMICAL
-	O
induced	O
growth	O
of	O
MCF	O
-	O
7	O
cells	O
,	O
but	O
estrogen	B-GENE-Y
receptor	I-GENE-Y
(	O
ER	B-GENE-Y
)	O
interactions	O
do	O
not	O
seem	O
to	O
be	O
involved	O
.	O

Pimozide	B-CHEMICAL
and	O
thioridazine	B-CHEMICAL
had	O
no	O
effect	O
on	O
the	O
estradiol	B-CHEMICAL
binding	O
properties	O
of	O
the	O
MCF	O
-	O
7	O
ER	B-GENE-Y
,	O
nor	O
did	O
pimozide	B-CHEMICAL
interfere	O
with	O
the	O
induction	O
of	O
progesterone	B-GENE-Y
receptors	I-GENE-Y
by	O
estradiol	B-CHEMICAL
.	O

Furthermore	O
,	O
pimozide	B-CHEMICAL
also	O
inhibited	O
incorporation	O
of	O
[	B-CHEMICAL
3H	I-CHEMICAL
]	I-CHEMICAL
thymidine	I-CHEMICAL
into	O
MCF	O
-	O
7	O
cells	O
stimulated	O
by	O
polypeptide	B-GENE-N
hormones	I-GENE-N
in	O
serum	O
-	O
free	O
medium	O
.	O

The	O
Ki	O
for	O
pimozide	B-CHEMICAL
in	O
serum	O
-	O
free	O
medium	O
alone	O
,	O
0	O
.	O
46	O
microM	O
,	O
was	O
similar	O
to	O
that	O
determined	O
in	O
the	O
presence	O
of	O
insulin	B-GENE-Y
(	O
0	O
.	O
42	O
microM	O
)	O
,	O
insulin	B-GENE-Y
-	I-GENE-Y
like	I-GENE-Y
growth	I-GENE-Y
factor	I-GENE-Y
I	I-GENE-Y
(	O
0	O
.	O
54	O
microM	O
)	O
,	O
and	O
epidermal	B-GENE-Y
growth	I-GENE-Y
factor	I-GENE-Y
(	O
0	O
.	O
43	O
microM	O
)	O
.	O

The	O
effects	O
of	O
pimozide	B-CHEMICAL
on	O
breast	O
cancer	O
cell	O
growth	O
were	O
not	O
limited	O
to	O
the	O
MCF	O
-	O
7	O
cell	O
line	O
.	O

Pimozide	B-CHEMICAL
also	O
blocked	O
cell	O
growth	O
and	O
[	B-CHEMICAL
3H	I-CHEMICAL
]	I-CHEMICAL
thymidine	I-CHEMICAL
incorporation	O
into	O
the	O
ER	B-GENE-Y
-	O
positive	O
T47D	O
and	O
ZR75	O
-	O
1B	O
human	O
breast	O
cancer	O
cell	O
lines	O
and	O
the	O
ER	B-GENE-Y
-	O
negative	O
human	O
breast	O
cancer	O
cell	O
line	O
,	O
MDA	O
-	O
MB	O
-	O
231	O
.	O

Although	O
numerous	O
mechanisms	O
of	O
action	O
of	O
pimozide	B-CHEMICAL
and	O
thioridazine	B-CHEMICAL
have	O
been	O
identified	O
,	O
both	O
drugs	O
are	O
calmodulin	B-GENE-Y
antagonists	O
at	O
drug	O
concentrations	O
that	O
inhibit	O
breast	O
cancer	O
cell	O
growth	O
in	O
vitro	O
.	O

Inhibition	O
of	O
MCF	O
-	O
7	O
cell	O
growth	O
by	O
the	O
selective	O
calmodulin	B-GENE-Y
antagonists	O
W	B-CHEMICAL
-	I-CHEMICAL
13	I-CHEMICAL
and	O
W	B-CHEMICAL
-	I-CHEMICAL
12	I-CHEMICAL
is	O
consistent	O
with	O
a	O
role	O
for	O
calmodulin	B-GENE-Y
antagonism	O
in	O
the	O
broad	O
growth	O
-	O
inhibitory	O
properties	O
of	O
pimozide	B-CHEMICAL
.	O

We	O
conclude	O
that	O
pimozide	B-CHEMICAL
and	O
thioridazine	B-CHEMICAL
may	O
be	O
useful	O
in	O
the	O
control	O
of	O
estradiol	B-CHEMICAL
-	O
and	O
polypeptide	B-GENE-N
hormone	I-GENE-N
-	O
induced	O
growth	O
of	O
ER	B-GENE-Y
-	O
positive	O
and	O
ER	B-GENE-Y
-	O
negative	O
human	O
breast	O
tumors	O
.	O

Effects	O
of	O
monoamine	B-GENE-N
oxidase	I-GENE-N
inhibitors	O
on	O
levels	O
of	O
catechols	B-CHEMICAL
and	O
homovanillic	B-CHEMICAL
acid	I-CHEMICAL
in	O
striatum	O
and	O
plasma	O
.	O

Levels	O
of	O
homovanillic	B-CHEMICAL
acid	I-CHEMICAL
(	O
HVA	B-CHEMICAL
)	O
,	O
dihydroxyphenylacetic	B-CHEMICAL
acid	I-CHEMICAL
(	O
DOPAC	B-CHEMICAL
)	O
and	O
dihydroxyphenylglycol	B-CHEMICAL
(	O
DHPG	B-CHEMICAL
)	O
in	O
plasma	O
and	O
the	O
striatium	O
were	O
measured	O
after	O
inhibition	O
of	O
monoamine	B-GENE-Y
oxidase	I-GENE-Y
type	I-GENE-Y
A	I-GENE-Y
(	O
MAO	B-GENE-Y
-	I-GENE-Y
A	I-GENE-Y
)	O
by	O
clorgyline	B-CHEMICAL
(	O
4	O
mg	O
/	O
kg	O
i	O
.	O
p	O
.	O
)	O
,	O
MAO	B-GENE-Y
-	I-GENE-Y
B	I-GENE-Y
by	O
(	B-CHEMICAL
-	I-CHEMICAL
)	I-CHEMICAL
deprenyl	I-CHEMICAL
(	O
1	O
mg	O
/	O
kg	O
i	O
.	O
p	O
.	O
)	O
,	O
both	O
MAO	B-GENE-Y
-	I-GENE-Y
A	I-GENE-Y
and	O
MAO	B-GENE-Y
-	I-GENE-Y
B	I-GENE-Y
by	O
nialamide	B-CHEMICAL
(	O
75	O
mg	O
/	O
kg	O
i	O
.	O
p	O
.	O
)	O
or	O
peripheral	O
neuronal	O
MAO	B-GENE-N
by	O
debrisoquin	B-CHEMICAL
(	O
40	O
mg	O
/	O
kg	O
i	O
.	O
p	O
.	O
)	O
.	O

Levels	O
of	O
HVA	B-CHEMICAL
in	O
plasma	O
decreased	O
by	O
about	O
60	O
%	O
after	O
single	O
doses	O
of	O
nialamide	B-CHEMICAL
or	O
clorgyline	B-CHEMICAL
,	O
by	O
about	O
80	O
%	O
after	O
repeated	O
doses	O
of	O
nialamide	B-CHEMICAL
,	O
by	O
about	O
40	O
%	O
after	O
a	O
single	O
dose	O
of	O
debrisoquin	B-CHEMICAL
and	O
by	O
about	O
50	O
%	O
after	O
repeated	O
doses	O
of	O
debrisoquin	B-CHEMICAL
.	O

The	O
administration	O
of	O
clorgyline	B-CHEMICAL
,	O
nialamide	B-CHEMICAL
or	O
debrisoquin	B-CHEMICAL
significantly	O
decreased	O
concentrations	O
of	O
DOPAC	B-CHEMICAL
and	O
DHPG	B-CHEMICAL
in	O
plasma	O
,	O
whereas	O
(	B-CHEMICAL
-	I-CHEMICAL
)	I-CHEMICAL
deprenyl	I-CHEMICAL
did	O
not	O
affect	O
levels	O
of	O
DHPG	B-CHEMICAL
or	O
HVA	B-CHEMICAL
.	O

None	O
of	O
the	O
MAO	B-GENE-N
inhibitors	O
produced	O
more	O
than	O
about	O
80	O
%	O
depression	O
of	O
levels	O
of	O
any	O
of	O
the	O
deaminated	O
metabolites	O
.	O

The	O
results	O
suggest	O
that	O
most	O
of	O
the	O
HVA	B-CHEMICAL
in	O
plasma	O
is	O
derived	O
from	O
deamination	O
of	O
DA	B-CHEMICAL
by	O
MAO	B-GENE-Y
-	I-GENE-Y
A	I-GENE-Y
in	O
peripheral	O
neurons	O
;	O
that	O
DOPAC	B-CHEMICAL
in	O
plasma	O
is	O
derived	O
from	O
cells	O
outside	O
the	O
central	O
nervous	O
system	O
;	O
that	O
DHPG	B-CHEMICAL
in	O
plasma	O
is	O
derived	O
virtually	O
exclusively	O
from	O
the	O
metabolism	O
of	O
norepinephrine	B-CHEMICAL
in	O
sympathetic	O
nerve	O
endings	O
and	O
that	O
residual	O
levels	O
of	O
HVA	B-CHEMICAL
after	O
treatment	O
with	O
debrisoquin	B-CHEMICAL
provide	O
an	O
improved	O
but	O
limited	O
indication	O
of	O
central	O
dopaminergic	O
activity	O
.	O

The	O
decrease	O
of	O
catalase	B-GENE-Y
or	O
esterase	B-GENE-Y
D	I-GENE-Y
activity	O
in	O
patients	O
with	O
microdeletions	O
of	O
11p	O
or	O
13q	O
does	O
not	O
increase	O
their	O
radiosensitivity	O
.	O

Lymphocyte	O
cultures	O
from	O
patients	O
affected	O
by	O
retinoblastoma	O
(	O
Rb	O
)	O
,	O
with	O
or	O
without	O
a	O
microdeletion	O
of	O
chromosome	O
13	O
,	O
and	O
Wilms	O
tumor	O
(	O
WT	O
)	O
,	O
with	O
a	O
microdeletion	O
of	O
chromosome	O
11p	O
where	O
exposed	O
to	O
gamma	O
-	O
ray	O
radiation	O
during	O
S	O
and	O
G2	O
phases	O
.	O

Chromatid	O
and	O
chromosome	O
lesions	O
were	O
scored	O
and	O
compared	O
to	O
those	O
observed	O
in	O
controls	O
.	O

No	O
significant	O
differences	O
were	O
detected	O
,	O
neither	O
between	O
patients	O
and	O
controls	O
,	O
nor	O
between	O
patients	O
carrying	O
or	O
not	O
a	O
microdeletion	O
.	O

This	O
lack	O
of	O
difference	O
was	O
unexpected	O
since	O
the	O
genes	O
for	O
catalase	B-GENE-Y
and	O
esterase	B-GENE-Y
D	I-GENE-Y
,	O
also	O
called	O
S	B-GENE-Y
-	I-GENE-Y
formyl	I-GENE-Y
glutathione	I-GENE-Y
hydrolase	I-GENE-Y
,	O
which	O
are	O
two	O
detoxication	O
enzymes	O
,	O
are	O
deleted	O
in	O
case	O
of	O
microdeletion	O
of	O
11p	O
and	O
13q	O
,	O
respectively	O
.	O

Developmental	O
changes	O
in	O
lactate	B-GENE-Y
dehydrogenase	I-GENE-Y
-	I-GENE-Y
X	I-GENE-Y
activity	O
in	O
young	O
jaundiced	O
male	O
rats	O
.	O

This	O
study	O
was	O
designed	O
to	O
examine	O
the	O
testicular	O
maturation	O
in	O
both	O
jaundiced	O
(	O
jj	O
)	O
and	O
nonjaundiced	O
(	O
Jj	O
)	O
male	O
Gunn	O
rats	O
as	O
indicated	O
by	O
the	O
activity	O
of	O
a	O
testis	O
and	O
sperm	O
-	O
specific	O
enzyme	O
,	O
lactate	B-GENE-Y
dehydrogenase	I-GENE-Y
-	I-GENE-Y
X	I-GENE-Y
(	O
LDH	B-GENE-Y
-	I-GENE-Y
X	I-GENE-Y
)	O
,	O
and	O
serum	O
testosterone	B-CHEMICAL
levels	O
.	O

Testicular	O
cytosolic	O
LDH	B-GENE-Y
-	I-GENE-Y
X	I-GENE-Y
activity	O
was	O
determined	O
by	O
oxidation	O
of	O
reduced	O
nicotinamide	B-CHEMICAL
adenine	I-CHEMICAL
dinucleotide	I-CHEMICAL
(	O
NADH	B-CHEMICAL
)	O
.	O

Serum	O
testosterone	B-CHEMICAL
levels	O
were	O
measured	O
by	O
radioimmunoassay	O
(	O
RIA	O
)	O
.	O

Testicular	O
LDH	B-GENE-Y
-	I-GENE-Y
X	I-GENE-Y
activity	O
increased	O
rapidly	O
between	O
30	O
and	O
50	O
days	O
of	O
age	O
in	O
both	O
Jj	O
and	O
jj	O
Gunn	O
rats	O
.	O

LDH	B-GENE-Y
-	I-GENE-Y
X	I-GENE-Y
activity	O
was	O
significantly	O
lower	O
in	O
the	O
jj	O
Gunn	O
rats	O
at	O
50	O
and	O
60	O
days	O
of	O
age	O
.	O

Testosterone	B-CHEMICAL
level	O
was	O
significantly	O
lower	O
in	O
the	O
jj	O
Gunn	O
rats	O
at	O
50	O
days	O
of	O
age	O
.	O

LDH	B-GENE-Y
-	I-GENE-Y
X	I-GENE-Y
activity	O
and	O
serum	O
testosterone	B-CHEMICAL
levels	O
were	O
similar	O
for	O
both	O
genotypes	O
at	O
180	O
days	O
of	O
age	O
.	O

The	O
delay	O
of	O
testicular	O
maturation	O
in	O
the	O
jaundiced	O
males	O
seems	O
to	O
be	O
due	O
to	O
lower	O
LDH	B-GENE-Y
-	I-GENE-Y
X	I-GENE-Y
activity	O
and	O
serum	O
testosterone	B-CHEMICAL
levels	O
.	O

Loperamide	B-CHEMICAL
modifies	O
but	O
does	O
not	O
block	O
the	O
corticotropin	B-GENE-Y
-	I-GENE-Y
releasing	I-GENE-Y
hormone	I-GENE-Y
-	O
induced	O
ACTH	B-GENE-Y
response	O
in	O
patients	O
with	O
Addison	O
'	O
s	O
disease	O
.	O

The	O
effect	O
of	O
loperamide	B-CHEMICAL
-	O
a	O
peripheral	O
opiate	O
agonist	O
-	O
on	O
plasma	O
ACTH	B-GENE-Y
response	O
to	O
Corticotropin	B-GENE-Y
-	I-GENE-Y
releasing	I-GENE-Y
Hormone	I-GENE-Y
(	O
CRH	B-GENE-Y
)	O
has	O
been	O
investigated	O
in	O
6	O
patients	O
with	O
Addison	O
'	O
s	O
disease	O
.	O

After	O
placebo	O
administration	O
CRH	B-GENE-Y
induced	O
a	O
marked	O
ACTH	B-GENE-Y
increase	O
.	O

After	O
loperamide	B-CHEMICAL
administration	O
ACTH	B-GENE-Y
levels	O
fell	O
to	O
a	O
nadir	O
of	O
135	O
+	O
/	O
-	O
76	O
pg	O
/	O
ml	O
,	O
and	O
then	O
CRH	B-GENE-Y
was	O
still	O
able	O
to	O
induce	O
an	O
ACTH	B-GENE-Y
increase	O
;	O
the	O
pattern	O
of	O
ACTH	B-GENE-Y
response	O
to	O
CRH	B-GENE-Y
was	O
slightly	O
delayed	O
.	O

There	O
was	O
a	O
significant	O
difference	O
between	O
the	O
two	O
ACTH	B-GENE-Y
curves	O
after	O
CRH	B-GENE-Y
only	O
in	O
the	O
early	O
phase	O
of	O
the	O
response	O
.	O

These	O
data	O
suggest	O
that	O
the	O
inhibitory	O
role	O
of	O
loperamide	O
on	O
ACTH	B-GENE-Y
secretion	O
is	O
exerted	O
at	O
supra	O
-	O
pituitary	O
level	O
,	O
although	O
a	O
pituitary	O
site	O
of	O
action	O
can	O
not	O
be	O
excluded	O
.	O

Self	O
-	O
cancellation	O
of	O
drug	O
properties	O
as	O
a	O
mode	O
of	O
organ	O
selectivity	O
:	O
the	O
antimuscarinic	O
effects	O
of	O
ambenonium	B-CHEMICAL
.	O

Ambenonium	B-CHEMICAL
is	O
known	O
to	O
be	O
an	O
inhibitor	O
of	O
acetylcholinesterase	B-GENE-Y
,	O
and	O
recent	O
data	O
have	O
shown	O
this	O
drug	O
to	O
antagonize	O
muscarinic	B-GENE-N
receptors	I-GENE-N
as	O
well	O
.	O

This	O
latter	O
property	O
was	O
confirmed	O
by	O
Schild	O
analyses	O
of	O
ambenonium	B-CHEMICAL
-	O
induced	O
blockade	O
of	O
responses	O
to	O
bethanechol	B-CHEMICAL
in	O
guinea	O
-	O
pig	O
ileal	O
longitudinal	O
smooth	O
muscle	O
,	O
taenia	O
caeci	O
,	O
trachea	O
and	O
rat	O
anococcygeus	O
muscle	O
.	O

Statistical	O
analysis	O
showed	O
ambenonium	B-CHEMICAL
to	O
be	O
a	O
simple	O
competitive	O
antagonist	O
of	O
responses	O
to	O
bethanechol	B-CHEMICAL
in	O
these	O
tissues	O
with	O
pKB	O
values	O
in	O
each	O
tissue	O
not	O
significantly	O
different	O
from	O
each	O
other	O
(	O
mean	O
pKB	O
=	O
6	O
.	O
0	O
)	O
.	O

However	O
,	O
considerable	O
variability	O
in	O
pKB	O
estimates	O
was	O
encountered	O
when	O
ambenonium	B-CHEMICAL
was	O
utilized	O
to	O
block	O
responses	O
to	O
acetylcholine	B-CHEMICAL
.	O

Ambenonium	B-CHEMICAL
was	O
a	O
less	O
potent	O
antagonist	O
of	O
tissue	O
responses	O
to	O
acetylcholine	B-CHEMICAL
,	O
and	O
the	O
underestimation	O
in	O
the	O
pKB	O
(	O
as	O
compared	O
to	O
that	O
obtained	O
with	O
bethanechol	B-CHEMICAL
)	O
could	O
be	O
eliminated	O
by	O
prior	O
treatment	O
of	O
tissues	O
with	O
the	O
acetylcholinesterase	B-GENE-Y
inhibitor	O
neostigmine	B-CHEMICAL
.	O

These	O
data	O
suggested	O
that	O
ambenonium	B-CHEMICAL
had	O
a	O
dual	O
effect	O
on	O
tissue	O
responses	O
to	O
acetylcholine	B-CHEMICAL
-	O
producing	O
potentiation	O
by	O
blockade	O
of	O
acetylcholinesterase	B-GENE-Y
and	O
concomitant	O
antagonism	O
by	O
blockade	O
of	O
muscarinic	B-GENE-N
receptors	I-GENE-N
.	O

The	O
Schild	O
regressions	O
obtained	O
for	O
ambenonium	B-CHEMICAL
antagonism	O
of	O
acetylcholine	B-CHEMICAL
responses	O
formally	O
satisfied	O
criteria	O
for	O
simple	O
competitive	O
antagonism	O
of	O
a	O
homogenous	O
population	O
of	O
receptors	O
(	O
linear	O
regression	O
,	O
slope	O
equal	O
to	O
unity	O
)	O
.	O

The	O
fact	O
that	O
these	O
regressions	O
yielded	O
erroneous	O
apparent	O
pKB	O
values	O
suggests	O
how	O
two	O
properties	O
of	O
a	O
drug	O
in	O
one	O
molecule	O
could	O
provide	O
misleading	O
information	O
about	O
drug	O
receptors	O
.	O
(	O
ABSTRACT	O
TRUNCATED	O
AT	O
250	O
WORDS	O
)	O

Comparison	O
of	O
ophthalmic	O
beta	O
-	O
blocking	O
agents	O
.	O

Glaucoma	O
is	O
described	O
,	O
and	O
the	O
chemistry	O
,	O
pharmacology	O
,	O
pharmacokinetics	O
,	O
clinical	O
efficacy	O
,	O
adverse	O
effects	O
,	O
and	O
dosage	O
and	O
administration	O
of	O
betaxolol	B-CHEMICAL
and	O
levobunolol	B-CHEMICAL
in	O
comparison	O
with	O
timolol	B-CHEMICAL
are	O
reviewed	O
.	O

Betaxolol	B-CHEMICAL
and	O
levobunolol	B-CHEMICAL
are	O
two	O
beta	O
-	O
adrenergic	O
blocking	O
agents	O
being	O
marketed	O
as	O
ophthalmic	O
solutions	O
for	O
treatment	O
of	O
primary	O
open	O
-	O
angle	O
glaucoma	O
(	O
POAG	O
)	O
and	O
ocular	O
hypertension	O
(	O
OHT	O
)	O
.	O

Betaxolol	B-CHEMICAL
is	O
a	O
relatively	O
cardioselective	O
beta	O
-	O
adrenergic	O
blocker	O
,	O
while	O
levobunolol	B-CHEMICAL
is	O
a	O
nonselective	O
beta	O
-	O
adrenergic	O
blocking	O
agent	O
.	O

Double	O
-	O
blind	O
comparative	O
trials	O
have	O
suggested	O
that	O
betaxolol	B-CHEMICAL
has	O
an	O
equal	O
to	O
slightly	O
lower	O
efficacy	O
and	O
levobunolol	B-CHEMICAL
has	O
equal	O
efficacy	O
in	O
reducing	O
intraocular	O
pressure	O
(	O
IOP	O
)	O
compared	O
with	O
timolol	B-CHEMICAL
,	O
the	O
first	O
ophthalmic	O
beta	O
blocker	O
.	O

A	O
mean	O
reduction	O
in	O
intraocular	O
pressure	O
of	O
15	O
-	O
35	O
%	O
occurs	O
with	O
both	O
betaxolol	B-CHEMICAL
and	O
levobunolol	B-CHEMICAL
and	O
is	O
reported	O
to	O
be	O
maintained	O
with	O
prolonged	O
use	O
.	O

Betaxolol	B-CHEMICAL
is	O
associated	O
with	O
a	O
higher	O
(	O
25	O
%	O
)	O
incidence	O
of	O
local	O
ocular	O
adverse	O
reactions	O
than	O
timolol	B-CHEMICAL
.	O

However	O
,	O
betaxolol	B-CHEMICAL
produces	O
less	O
systemic	O
beta	O
2	O
-	O
and	O
possibly	O
beta	B-GENE-Y
1	I-GENE-Y
-	I-GENE-Y
adrenergic	I-GENE-Y
receptor	I-GENE-Y
blockade	O
than	O
either	O
timolol	B-CHEMICAL
or	O
levobunolol	B-CHEMICAL
.	O

Betaxolol	B-CHEMICAL
may	O
be	O
relatively	O
safer	O
to	O
use	O
in	O
patients	O
with	O
reactive	O
airway	O
disease	O
than	O
either	O
timolol	B-CHEMICAL
or	O
levobunolol	B-CHEMICAL
.	O

Levobunolol	B-CHEMICAL
causes	O
a	O
similar	O
to	O
greater	O
incidence	O
of	O
local	O
ocular	O
adverse	O
reactions	O
and	O
similar	O
systemic	O
beta	O
blockade	O
compared	O
with	O
timolol	B-CHEMICAL
.	O

Levobunolol	B-CHEMICAL
may	O
possibly	O
be	O
longer	O
acting	O
than	O
timolol	B-CHEMICAL
,	O
allowing	O
more	O
patients	O
to	O
be	O
controlled	O
by	O
once	O
-	O
daily	O
dosing	O
.	O

Betaxolol	B-CHEMICAL
and	O
levobunolol	B-CHEMICAL
appear	O
to	O
be	O
similar	O
to	O
timolol	B-CHEMICAL
in	O
controlling	O
IOP	O
in	O
patients	O
with	O
POAG	O
and	O
OHT	O
;	O
additional	O
experience	O
with	O
these	O
agents	O
is	O
needed	O
to	O
assess	O
the	O
advantages	O
and	O
disadvantages	O
of	O
each	O
agent	O
.	O

Nucleotide	B-CHEMICAL
sequence	O
of	O
the	O
gene	O
for	O
human	B-GENE-Y
factor	I-GENE-Y
IX	I-GENE-Y
(	O
antihemophilic	B-GENE-Y
factor	I-GENE-Y
B	I-GENE-Y
)	O
.	O

Two	O
different	O
human	O
genomic	O
DNA	O
libraries	O
were	O
screened	O
for	O
the	O
gene	O
for	O
blood	O
coagulation	B-GENE-Y
factor	I-GENE-Y
IX	I-GENE-Y
by	O
employing	O
a	O
cDNA	O
for	O
the	O
human	O
protein	O
as	O
a	O
hybridization	O
probe	O
.	O

Five	O
overlapping	O
lambda	O
phages	O
were	O
identified	O
that	O
contained	O
the	O
gene	O
for	O
factor	B-GENE-Y
IX	I-GENE-Y
.	O

The	O
complete	O
DNA	O
sequence	O
of	O
about	O
38	O
kilobases	O
for	O
the	O
gene	O
and	O
the	O
adjacent	O
5	O
'	O
and	O
3	O
'	O
flanking	O
regions	O
was	O
established	O
by	O
the	O
dideoxy	O
chain	O
termination	O
and	O
chemical	O
degradation	O
methods	O
.	O

The	O
gene	O
contained	O
about	O
33	O
.	O
5	O
kilobases	O
of	O
DNA	O
,	O
including	O
seven	O
introns	O
and	O
eight	O
exons	O
within	O
the	O
coding	O
and	O
3	O
'	O
noncoding	O
regions	O
of	O
the	O
gene	O
.	O

The	O
eight	O
exons	O
code	O
for	O
a	O
prepro	O
leader	O
sequence	O
and	O
415	O
amino	B-CHEMICAL
acids	I-CHEMICAL
that	O
make	O
up	O
the	O
mature	O
protein	O
circulating	O
in	O
plasma	O
.	O

The	O
intervening	O
sequences	O
range	O
in	O
size	O
from	O
188	O
to	O
9473	O
nucleotides	B-CHEMICAL
and	O
contain	O
four	O
Alu	O
repetitive	O
sequences	O
,	O
including	O
one	O
in	O
intron	O
A	O
and	O
three	O
in	O
intron	O
F	O
.	O

A	O
fifth	O
Alu	O
repetitive	O
sequence	O
was	O
found	O
immediately	O
flanking	O
the	O
3	O
'	O
end	O
of	O
the	O
gene	O
.	O

A	O
50	O
base	O
pair	O
insert	O
in	O
intron	O
A	O
was	O
found	O
in	O
a	O
clone	O
from	O
one	O
of	O
the	O
genomic	O
libraries	O
but	O
was	O
absent	O
in	O
clones	O
from	O
the	O
other	O
library	O
.	O

Intron	O
A	O
as	O
well	O
as	O
the	O
3	O
'	O
noncoding	O
region	O
of	O
the	O
gene	O
also	O
contained	O
alternating	O
purine	B-CHEMICAL
-	O
pyrimidine	B-CHEMICAL
sequences	O
that	O
provide	O
potential	O
left	O
-	O
handed	O
helical	O
DNA	O
or	O
Z	O
-	O
DNA	O
structures	O
for	O
the	O
gene	O
.	O

KpnI	B-GENE-N
repetitive	I-GENE-N
sequences	I-GENE-N
were	O
identified	O
in	O
intron	O
D	O
and	O
the	O
region	O
flanking	O
the	O
5	O
'	O
end	O
of	O
the	O
gene	O
.	O

The	O
5	O
'	O
flanking	O
region	O
also	O
contained	O
a	O
1	O
.	O
9	O
-	O
kb	O
HindIII	O
subfamily	O
repeat	O
.	O

The	O
seven	O
introns	O
in	O
the	O
gene	O
for	O
factor	B-GENE-Y
IX	I-GENE-Y
were	O
located	O
in	O
essentially	O
the	O
same	O
position	O
as	O
the	O
seven	O
introns	O
in	O
the	O
gene	O
for	O
human	O
protein	O
C	O
,	O
while	O
the	O
first	O
three	O
were	O
found	O
in	O
positions	O
identical	O
with	O
those	O
in	O
the	O
gene	O
for	O
human	O
prothrombin	O
.	O

Purification	O
and	O
characterization	O
of	O
calcitonin	B-GENE-N
receptors	I-GENE-N
in	O
rat	O
kidney	O
membranes	O
by	O
covalent	O
cross	O
-	O
linking	O
techniques	O
.	O

We	O
have	O
characterized	O
the	O
binding	O
parameters	O
of	O
renal	B-GENE-N
receptors	I-GENE-N
(	O
Scatchard	O
analysis	O
revealed	O
the	O
presence	O
of	O
two	O
binding	O
sites	O
:	O
site	O
I	O
,	O
Ka1	O
=	O
1	O
.	O
29	O
X	O
10	O
(	O
9	O
)	O
M	O
-	O
1	O
,	O
number	O
of	O
binding	O
sites	O
=	O
9	O
.	O
9	O
X	O
10	O
(	O
6	O
)	O
/	O
micrograms	O
protein	O
;	O
site	O
II	O
,	O
Ka2	O
=	O
0	O
.	O
93	O
X	O
10	O
(	O
8	O
)	O
M	O
-	O
1	O
,	O
number	O
of	O
binding	O
sites	O
=	O
4	O
.	O
27	O
X	O
10	O
(	O
8	O
)	O
/	O
micrograms	O
protein	O
)	O
and	O
studied	O
the	O
effect	O
of	O
solubilization	O
.	O

The	O
high	O
-	O
affinity	O
sites	O
are	O
preserved	O
during	O
affinity	O
chromatography	O
and	O
the	O
process	O
results	O
in	O
a	O
6080	O
-	O
fold	O
purification	O
of	O
those	O
sites	O
.	O

The	O
lower	O
-	O
affinity	O
sites	O
are	O
also	O
preserved	O
but	O
the	O
overall	O
purification	O
factor	O
is	O
about	O
40	O
%	O
lower	O
than	O
that	O
obtained	O
using	O
molecular	O
sieving	O
.	O

The	O
purification	O
of	O
the	O
renal	O
calcitonin	B-GENE-N
receptor	I-GENE-N
by	O
molecular	O
sieving	O
(	O
Sephacryl	O
S	O
-	O
200	O
)	O
is	O
accompanied	O
by	O
total	O
loss	O
of	O
the	O
high	O
-	O
affinity	O
site	O
;	O
however	O
,	O
the	O
low	O
-	O
affinity	O
site	O
is	O
enriched	O
over	O
1642	O
-	O
fold	O
.	O

Binding	O
parameters	O
were	O
obtained	O
for	O
the	O
purified	O
fractions	O
.	O

Synthetic	O
salmon	O
calcitonin	O
was	O
also	O
bound	O
to	O
renal	O
membranes	O
using	O
the	O
bifunctional	O
reagent	O
disuccinimidyl	B-CHEMICAL
suberate	I-CHEMICAL
and	O
photo	O
-	O
affinity	O
cross	O
-	O
linking	O
using	O
hydroxysuccinimidyl	B-CHEMICAL
azidobenzonate	I-CHEMICAL
reagent	O
.	O

Cross	O
-	O
linked	O
receptor	O
eluted	O
in	O
the	O
same	O
volume	O
as	O
solubilized	O
membranes	O
specifically	O
binding	O
salmon	O
calcitonin	O
(	O
S	O
-	O
200	O
chromatography	O
)	O
.	O

Sodium	B-CHEMICAL
dodecyl	I-CHEMICAL
sulfate	I-CHEMICAL
polyacrylamide	B-CHEMICAL
gel	O
electrophoresis	O
analysis	O
of	O
purified	O
fractions	O
showed	O
several	O
protein	O
bands	O
with	O
apparent	O
molecular	O
masses	O
ranging	O
from	O
18	O
000	O
Da	O
to	O
100	O
000	O
Da	O
in	O
the	O
presence	O
or	O
absence	O
of	O
a	O
reducing	O
agent	O
(	O
2	B-CHEMICAL
-	I-CHEMICAL
mercaptoethanol	I-CHEMICAL
)	O
.	O

Autoradiography	O
of	O
polyacrylamide	B-CHEMICAL
gels	O
of	O
cross	O
-	O
linked	O
calcitonin	B-GENE-N
receptor	I-GENE-N
showed	O
only	O
three	O
protein	O
bands	O
specifically	O
binding	O
salmon	O
calcitonin	O
.	O

Their	O
molecular	O
masses	O
were	O
70	O
000	O
Da	O
,	O
40	O
000	O
Da	O
and	O
33	O
000	O
Da	O
respectively	O
.	O

The	O
40	O
000	O
-	O
Da	O
molecule	O
represents	O
a	O
major	O
band	O
(	O
47	O
%	O
total	O
binding	O
species	O
)	O
.	O

This	O
suggests	O
that	O
these	O
three	O
proteins	O
are	O
the	O
principal	O
components	O
of	O
the	O
calcitonin	O
receptor	O
and	O
that	O
S	B-CHEMICAL
-	I-CHEMICAL
S	I-CHEMICAL
bonds	O
are	O
not	O
involved	O
in	O
the	O
assembly	O
of	O
the	O
receptor	O
subunits	O
.	O

Tyrosinase	B-GENE-Y
catalyzes	O
an	O
unusual	O
oxidative	O
decarboxylation	O
of	O
3	B-CHEMICAL
,	I-CHEMICAL
4	I-CHEMICAL
-	I-CHEMICAL
dihydroxymandelate	I-CHEMICAL
.	O

Tyrosinase	B-GENE-Y
usually	O
catalyzes	O
the	O
conversion	O
of	O
monophenols	B-CHEMICAL
to	O
o	O
-	O
diphenols	O
and	O
oxidation	O
of	O
diphenols	B-CHEMICAL
to	O
the	O
corresponding	O
quinones	O
.	O

However	O
,	O
when	O
3	B-CHEMICAL
,	I-CHEMICAL
4	I-CHEMICAL
-	I-CHEMICAL
dihydroxymandelic	I-CHEMICAL
acid	I-CHEMICAL
was	O
provided	O
as	O
the	O
substrate	O
,	O
it	O
catalyzed	O
an	O
unusual	O
oxidative	O
decarboxylation	O
reaction	O
generating	O
3	B-CHEMICAL
,	I-CHEMICAL
4	I-CHEMICAL
-	I-CHEMICAL
dihydroxybenzaldehyde	I-CHEMICAL
as	O
the	O
sole	O
product	O
.	O

The	O
identity	O
of	O
the	O
product	O
was	O
confirmed	O
by	O
high	O
-	O
performance	O
liquid	O
chromatography	O
(	O
HPLC	O
)	O
as	O
well	O
as	O
ultraviolet	O
and	O
infrared	O
spectral	O
studies	O
.	O

None	O
of	O
the	O
following	O
enzymes	O
tested	O
catalyzed	O
the	O
new	O
reaction	O
:	O
galactose	B-GENE-N
oxidase	I-GENE-N
,	O
ceruloplasmin	B-GENE-Y
,	O
superoxide	B-GENE-N
dismutase	I-GENE-N
,	O
ascorbate	B-GENE-N
oxidase	I-GENE-N
,	O
dopamine	B-GENE-Y
beta	I-GENE-Y
-	I-GENE-Y
hydroxylase	I-GENE-Y
,	O
and	O
peroxidase	B-GENE-N
.	O

Phenol	B-GENE-N
oxidase	I-GENE-N
inhibitors	O
such	O
as	O
phenylthiourea	B-CHEMICAL
,	O
potassium	B-CHEMICAL
cyanide	I-CHEMICAL
,	O
and	O
sodium	B-CHEMICAL
azide	I-CHEMICAL
inhibited	O
the	O
reaction	O
drastically	O
,	O
suggesting	O
the	O
participation	O
of	O
the	O
active	O
site	O
copper	B-CHEMICAL
of	O
the	O
enzyme	O
in	O
the	O
catalysis	O
.	O

Mimosine	B-CHEMICAL
,	O
a	O
well	O
-	O
known	O
competitive	O
inhibitor	O
of	O
tyrosinase	B-GENE-Y
,	O
competitively	O
inhibited	O
the	O
new	O
reaction	O
also	O
.	O

4	B-CHEMICAL
-	I-CHEMICAL
Hydroxymandelic	I-CHEMICAL
acid	I-CHEMICAL
and	O
3	B-CHEMICAL
-	I-CHEMICAL
methoxy	I-CHEMICAL
-	I-CHEMICAL
4	I-CHEMICAL
-	I-CHEMICAL
hydroxymandelic	I-CHEMICAL
acid	I-CHEMICAL
neither	O
served	O
as	O
substrates	O
nor	O
inhibited	O
the	O
reaction	O
.	O

Putative	O
intermediates	O
such	O
as	O
3	B-CHEMICAL
,	I-CHEMICAL
4	I-CHEMICAL
-	I-CHEMICAL
dihydroxybenzyl	I-CHEMICAL
alcohol	I-CHEMICAL
and	O
(	B-CHEMICAL
3	I-CHEMICAL
,	I-CHEMICAL
4	I-CHEMICAL
-	I-CHEMICAL
dihydroxybenzoyl	I-CHEMICAL
)	I-CHEMICAL
formic	I-CHEMICAL
acid	I-CHEMICAL
did	O
not	O
accumulate	O
during	O
the	O
reaction	O
.	O

Oxidation	O
to	O
a	O
quinone	B-CHEMICAL
methide	I-CHEMICAL
derivative	O
rather	O
than	O
conventional	O
quinone	B-CHEMICAL
accounts	O
for	O
this	O
unusual	O
oxidative	O
decarboxylation	O
reaction	O
.	O

Earlier	O
from	O
this	O
laboratory	O
,	O
we	O
reported	O
the	O
conversion	O
of	O
4	B-CHEMICAL
-	I-CHEMICAL
alkylcatechols	I-CHEMICAL
to	O
quinone	B-CHEMICAL
methides	I-CHEMICAL
catalyzed	O
by	O
a	O
cuticular	O
phenol	B-CHEMICAL
oxidase	O
[	O
Sugumaran	O
,	O
M	O
.	O
,	O
&	O
Lipke	O
,	O
H	O
.	O
(	O
1983	O
)	O
FEBS	O
Lett	O
.	O
155	O
,	O
65	O
-	O
68	O
]	O
.	O

Present	O
studies	O
demonstrate	O
that	O
mushroom	B-GENE-N
tyrosinase	I-GENE-N
will	O
also	O
catalyze	O
quinone	B-CHEMICAL
methide	I-CHEMICAL
production	O
with	O
the	O
same	O
active	O
site	O
copper	O
if	O
a	O
suitable	O
substrate	O
such	O
as	O
3	B-CHEMICAL
,	I-CHEMICAL
4	I-CHEMICAL
-	I-CHEMICAL
dihydroxymandelic	I-CHEMICAL
acid	I-CHEMICAL
is	O
provided	O
.	O

Effectors	O
of	O
the	O
activation	O
of	O
human	B-GENE-Y
[	I-GENE-Y
Glu1	I-GENE-Y
]	I-GENE-Y
plasminogen	I-GENE-Y
by	O
human	B-GENE-Y
tissue	I-GENE-Y
plasminogen	I-GENE-Y
activator	I-GENE-Y
.	O

The	O
activation	O
of	O
human	B-GENE-Y
[	I-GENE-Y
Glu1	I-GENE-Y
]	I-GENE-Y
plasminogen	I-GENE-Y
[	O
(	B-GENE-Y
Glu1	I-GENE-Y
]	I-GENE-Y
Pg	I-GENE-Y
)	O
by	O
human	O
recombinant	O
(	O
rec	O
)	O
two	O
-	O
chain	O
tissue	B-GENE-Y
plasminogen	I-GENE-Y
activator	I-GENE-Y
(	O
t	B-GENE-Y
-	I-GENE-Y
PA	I-GENE-Y
)	O
is	O
inhibited	O
by	O
Cl	B-CHEMICAL
-	I-CHEMICAL
,	O
at	O
physiological	O
concentrations	O
,	O
and	O
stimulated	O
by	O
epsilon	B-CHEMICAL
-	I-CHEMICAL
aminocaproic	I-CHEMICAL
acid	I-CHEMICAL
(	O
EACA	B-CHEMICAL
)	O
,	O
as	O
well	O
as	O
fibrin	O
(	O
ogen	O
)	O
.	O

Chloride	B-CHEMICAL
functions	O
as	O
a	O
result	O
of	O
its	O
binding	O
to	O
[	B-GENE-Y
Glu1	I-GENE-Y
]	I-GENE-Y
Pg	I-GENE-Y
,	O
with	O
a	O
Ki	O
of	O
approximately	O
9	O
.	O
0	O
mM	O
,	O
thereby	O
rendering	O
[	B-GENE-Y
Glu1	I-GENE-Y
]	I-GENE-Y
Pg	I-GENE-Y
a	O
less	O
effective	O
substrate	O
for	O
two	O
-	O
chain	O
rec	O
-	O
t	B-GENE-Y
-	I-GENE-Y
PA	I-GENE-Y
.	O

EACA	B-CHEMICAL
stimulates	O
the	O
activation	O
in	O
Cl	B-CHEMICAL
-	I-CHEMICAL
(	I-CHEMICAL
-	I-CHEMICAL
)	I-CHEMICAL
containing	O
solutions	O
,	O
with	O
a	O
Ka	O
of	O
approximately	O
4	O
.	O
0	O
mM	O
,	O
primarily	O
by	O
reversal	O
of	O
the	O
Cl	B-CHEMICAL
-	I-CHEMICAL
(	I-CHEMICAL
-	I-CHEMICAL
)	I-CHEMICAL
inhibitory	O
effect	O
.	O

Fibrinogen	B-GENE-N
appears	O
to	O
exert	O
its	O
stimulatory	O
properties	O
mainly	O
through	O
effects	O
on	O
the	O
enzyme	O
,	O
two	O
-	O
chain	O
rec	O
-	O
t	B-GENE-Y
-	I-GENE-Y
PA	I-GENE-Y
,	O
with	O
a	O
Ka	O
of	O
approximately	O
3	O
.	O
7	O
microM	O
in	O
activation	O
systems	O
containing	O
physiological	O
levels	O
of	O
Cl	B-CHEMICAL
-	I-CHEMICAL
.	O

Analysis	O
of	O
the	O
results	O
of	O
this	O
paper	O
reveals	O
that	O
normal	O
plasma	O
components	O
,	O
Cl	B-CHEMICAL
-	I-CHEMICAL
and	O
fibrinogen	B-GENE-N
,	O
exert	O
major	O
regulatory	O
roles	O
on	O
the	O
ability	O
of	O
[	B-GENE-Y
Glu1	I-GENE-Y
]	I-GENE-Y
Pg	I-GENE-Y
to	O
be	O
activated	O
by	O
two	O
-	O
chain	O
rec	O
-	O
t	B-GENE-Y
-	I-GENE-Y
PA	I-GENE-Y
,	O
in	O
in	O
vitro	O
systems	O
.	O

The	O
presence	O
of	O
Cl	B-CHEMICAL
-	I-CHEMICAL
inhibits	O
the	O
stimulation	O
of	O
[	B-GENE-Y
Glu1	I-GENE-Y
]	I-GENE-Y
Pg	I-GENE-Y
activation	O
that	O
would	O
normally	O
occur	O
in	O
the	O
presence	O
of	O
fibrinogen	B-GENE-N
,	O
a	O
result	O
of	O
possible	O
importance	O
to	O
the	O
observation	O
that	O
some	O
degree	O
of	O
systemic	O
fibrinogenolysis	O
accompanies	O
therapeutic	O
use	O
of	O
tissue	B-GENE-Y
plasminogen	I-GENE-Y
activator	I-GENE-Y
.	O

Vitamin	B-CHEMICAL
B12	I-CHEMICAL
responsive	O
homocystinuria	O
and	O
megaloblastic	O
anemia	O
:	O
heterogeneity	O
in	O
methylcobalamin	B-CHEMICAL
deficiency	O
.	O

A	O
male	O
infant	O
with	O
methyl	B-CHEMICAL
-	I-CHEMICAL
B12	I-CHEMICAL
deficiency	O
(	O
cblE	O
)	O
presented	O
at	O
age	O
6	O
weeks	O
with	O
lethargy	O
,	O
staring	O
spells	O
,	O
and	O
vomiting	O
.	O

He	O
later	O
became	O
hypotonic	O
and	O
unresponsive	O
to	O
stimuli	O
and	O
required	O
intubation	O
and	O
ventilation	O
.	O

He	O
had	O
homocystinuria	O
and	O
hypomethioninemia	O
with	O
megaloblastic	O
anemia	O
but	O
normal	O
serum	O
folate	B-CHEMICAL
and	O
vitamin	B-CHEMICAL
B12	I-CHEMICAL
concentrations	O
.	O

No	O
methylmalonic	B-CHEMICAL
aciduria	I-CHEMICAL
was	O
detected	O
.	O

Fibroblasts	O
,	O
cultured	O
from	O
the	O
patient	O
,	O
were	O
unable	O
to	O
grow	O
in	O
medium	O
in	O
which	O
homocysteine	B-CHEMICAL
replaced	O
methionine	B-CHEMICAL
and	O
incorporated	O
abnormally	O
small	O
amounts	O
of	O
[	B-CHEMICAL
14C	I-CHEMICAL
]	I-CHEMICAL
-	I-CHEMICAL
methyl	I-CHEMICAL
-	I-CHEMICAL
tetrahydrofolate	I-CHEMICAL
but	O
normal	O
amounts	O
of	O
[	B-CHEMICAL
14C	I-CHEMICAL
]	I-CHEMICAL
-	I-CHEMICAL
propionate	I-CHEMICAL
into	O
protein	O
.	O

Methyl	B-CHEMICAL
-	I-CHEMICAL
B12	I-CHEMICAL
content	O
of	O
fibroblasts	O
was	O
low	O
,	O
while	O
the	O
adenosyl	B-CHEMICAL
-	I-CHEMICAL
B12	I-CHEMICAL
content	O
was	O
normal	O
.	O

Methionine	B-GENE-Y
synthase	I-GENE-Y
activity	O
was	O
decreased	O
when	O
the	O
assay	O
was	O
performed	O
under	O
both	O
optimal	O
and	O
suboptimal	O
reducing	O
conditions	O
,	O
suggesting	O
heterogeneity	O
in	O
the	O
cblE	O
disease	O
.	O

The	O
patient	O
responded	O
dramatically	O
to	O
hydroxocobalamin	B-CHEMICAL
treatment	O
.	O

Homocystinuria	O
disappeared	O
after	O
10	O
days	O
of	O
therapy	O
,	O
and	O
methionine	B-CHEMICAL
was	O
normalized	O
after	O
3	O
weeks	O
.	O

Psychometric	O
testing	O
at	O
age	O
15	O
months	O
showed	O
a	O
developmental	O
age	O
of	O
9	O
months	O
.	O

Inactivation	O
of	O
factor	B-GENE-Y
XII	I-GENE-Y
active	O
fragment	O
in	O
normal	O
plasma	O
.	O

Predominant	O
role	O
of	O
C	B-GENE-Y
-	I-GENE-Y
1	I-GENE-Y
-	I-GENE-Y
inhibitor	I-GENE-Y
.	O

To	O
define	O
the	O
factors	O
responsible	O
for	O
the	O
inactivation	O
of	O
the	O
active	O
fragment	O
derived	O
from	O
Factor	B-GENE-Y
XII	I-GENE-Y
(	O
Factor	B-GENE-Y
XIIf	I-GENE-Y
)	O
in	O
plasma	O
,	O
we	O
studied	O
the	O
inactivation	O
kinetics	O
of	O
Factor	B-GENE-Y
XIIf	I-GENE-Y
in	O
various	O
purified	O
and	O
plasma	O
mixtures	O
.	O

We	O
also	O
analyzed	O
the	O
formation	O
of	O
125I	B-CHEMICAL
-	O
Factor	B-GENE-Y
XIIf	I-GENE-Y
-	O
inhibitor	O
complexes	O
by	O
sodium	B-CHEMICAL
dodecyl	I-CHEMICAL
sulfate	I-CHEMICAL
polyacrylamide	B-CHEMICAL
gel	O
electrophoresis	O
(	O
SDS	O
-	O
PAGE	O
)	O
.	O

In	O
purified	O
systems	O
,	O
the	O
bimolecular	O
rate	O
constants	O
for	O
the	O
reactions	O
of	O
Factor	B-GENE-Y
XIIf	I-GENE-Y
with	O
C	B-GENE-Y
-	I-GENE-Y
1	I-GENE-Y
-	I-GENE-Y
inhibitor	I-GENE-Y
,	O
alpha	B-GENE-Y
2	I-GENE-Y
-	I-GENE-Y
antiplasmin	I-GENE-Y
,	O
and	O
antithrombin	B-GENE-Y
III	I-GENE-Y
were	O
18	O
.	O
5	O
,	O
0	O
.	O
91	O
,	O
and	O
0	O
.	O
32	O
X	O
10	O
(	O
4	O
)	O
M	O
-	O
1	O
min	O
-	O
1	O
,	O
respectively	O
.	O

Furthermore	O
,	O
SDS	O
-	O
PAGE	O
analysis	O
revealed	O
that	O
1	O
:	O
1	O
stoichiometric	O
complexes	O
were	O
formed	O
between	O
125I	B-CHEMICAL
-	O
Factor	B-GENE-Y
XIIf	I-GENE-Y
and	O
each	O
of	O
these	O
three	O
inhibitors	O
.	O

In	O
contrast	O
,	O
kinetic	O
and	O
SDS	O
-	O
PAGE	O
studies	O
indicated	O
that	O
Factor	B-GENE-Y
XIIf	I-GENE-Y
did	O
not	O
react	O
with	O
alpha	B-GENE-Y
1	I-GENE-Y
-	I-GENE-Y
antitrypsin	I-GENE-Y
or	O
alpha	B-GENE-Y
2	I-GENE-Y
-	I-GENE-Y
macroglobulin	I-GENE-Y
.	O

The	O
inactivation	O
rate	O
constant	O
of	O
Factor	B-GENE-Y
XIIf	I-GENE-Y
by	O
prekallikrein	B-GENE-Y
-	O
deficient	O
plasma	O
was	O
14	O
.	O
4	O
X	O
10	O
(	O
-	O
2	O
)	O
min	O
-	O
1	O
,	O
a	O
value	O
that	O
was	O
essentially	O
identical	O
to	O
the	O
value	O
predicted	O
from	O
the	O
studies	O
in	O
purified	O
systems	O
(	O
15	O
.	O
5	O
X	O
10	O
(	O
-	O
2	O
)	O
min	O
-	O
1	O
)	O
.	O

This	O
constant	O
was	O
reduced	O
to	O
1	O
.	O
8	O
X	O
10	O
(	O
-	O
2	O
)	O
min	O
-	O
1	O
when	O
Factor	B-GENE-Y
XIIf	I-GENE-Y
was	O
inactivated	O
by	O
prekallikrein	B-GENE-Y
-	O
deficient	O
plasma	O
that	O
had	O
been	O
immunodepleted	O
(	O
less	O
than	O
5	O
%	O
)	O
of	O
C	B-GENE-Y
-	I-GENE-Y
1	I-GENE-Y
-	I-GENE-Y
inhibitor	I-GENE-Y
.	O

In	O
addition	O
,	O
after	O
inactivation	O
in	O
normal	O
plasma	O
,	O
74	O
%	O
of	O
the	O
active	O
125I	B-CHEMICAL
-	O
Factor	B-GENE-Y
XIIf	I-GENE-Y
was	O
found	O
to	O
form	O
a	O
complex	O
with	O
C	B-GENE-Y
-	I-GENE-Y
1	I-GENE-Y
-	I-GENE-Y
inhibitor	I-GENE-Y
,	O
whereas	O
26	O
%	O
of	O
the	O
enzyme	O
formed	O
complexes	O
with	O
alpha	B-GENE-Y
2	I-GENE-Y
-	I-GENE-Y
antiplasmin	I-GENE-Y
and	O
antithrombin	B-GENE-Y
III	I-GENE-Y
.	O

Furthermore	O
,	O
42	O
%	O
of	O
the	O
labeled	O
enzyme	O
was	O
still	O
complexed	O
with	O
C	B-GENE-Y
-	I-GENE-Y
1	I-GENE-Y
-	I-GENE-Y
inhibitor	I-GENE-Y
when	O
125I	B-CHEMICAL
-	O
Factor	B-GENE-Y
XII	I-GENE-Y
was	O
inactivated	O
in	O
hereditary	O
angioedema	O
plasma	O
that	O
contained	O
32	O
%	O
of	O
functional	O
C	B-GENE-Y
-	I-GENE-Y
1	I-GENE-Y
-	I-GENE-Y
inhibitor	I-GENE-Y
.	O

This	O
study	O
quantitatively	O
demonstrates	O
the	O
dominant	O
role	O
of	O
C	B-GENE-Y
-	I-GENE-Y
1	I-GENE-Y
-	I-GENE-Y
inhibitor	I-GENE-Y
in	O
the	O
inactivation	O
of	O
Factor	B-GENE-Y
XIIf	I-GENE-Y
in	O
the	O
plasma	O
milieu	O
.	O

Sodium	B-CHEMICAL
-	O
dependent	O
norepinephrine	B-CHEMICAL
-	O
induced	O
currents	O
in	O
norepinephrine	B-GENE-Y
-	I-GENE-Y
transporter	I-GENE-Y
-	O
transfected	O
HEK	O
-	O
293	O
cells	O
blocked	O
by	O
cocaine	B-CHEMICAL
and	O
antidepressants	O
.	O

Transport	O
of	O
norepinephrine	B-CHEMICAL
(	O
NE	B-CHEMICAL
+	I-CHEMICAL
)	O
by	O
cocaine	B-CHEMICAL
-	O
and	O
antidepressant	O
-	O
sensitive	O
transporters	O
in	O
presynaptic	O
terminals	O
is	O
predicted	O
to	O
involve	O
the	O
cotransport	O
of	O
Na	B-CHEMICAL
+	I-CHEMICAL
and	O
Cl	B-CHEMICAL
-	I-CHEMICAL
,	O
resulting	O
in	O
a	O
net	O
movement	O
of	O
charge	O
per	O
transport	O
cycle	O
.	O

To	O
explore	O
the	O
relationship	O
between	O
catecholamine	B-CHEMICAL
transport	O
and	O
ion	O
permeation	O
through	O
the	O
NE	B-GENE-Y
transporter	I-GENE-Y
,	O
we	O
established	O
a	O
human	B-GENE-Y
norepinephrine	I-GENE-Y
transporter	I-GENE-Y
(	O
hNET	B-GENE-Y
)	O
cell	O
line	O
suitable	O
for	O
biochemical	O
analysis	O
and	O
patch	O
-	O
clamp	O
recording	O
.	O

Stable	O
transfection	O
of	O
hNET	B-GENE-Y
cDNA	O
into	O
HEK	O
-	O
293	O
(	O
human	O
embryonic	O
kidney	O
)	O
cells	O
results	O
in	O
lines	O
exhibiting	O
(	O
1	O
)	O
a	O
high	O
number	O
of	O
transporter	O
copies	O
per	O
cell	O
(	O
10	O
(	O
6	O
)	O
)	O
,	O
as	O
detected	O
by	O
radioligand	O
binding	O
and	O
hNET	B-GENE-Y
-	O
specific	O
antibodies	O
,	O
(	O
2	O
)	O
high	O
-	O
affinity	O
,	O
Na	B-CHEMICAL
(	I-CHEMICAL
+	I-CHEMICAL
)	I-CHEMICAL
-	O
dependent	O
transport	O
of	O
NE	B-CHEMICAL
,	O
and	O
(	O
3	O
)	O
inhibitor	O
sensitivities	O
similar	O
to	O
those	O
of	O
native	O
membranes	O
.	O

Whole	O
-	O
cell	O
voltage	O
-	O
clamp	O
of	O
hNET	B-GENE-Y
-	O
293	O
cells	O
reveals	O
NE	B-CHEMICAL
-	O
induced	O
,	O
Na	B-CHEMICAL
(	I-CHEMICAL
+	I-CHEMICAL
)	I-CHEMICAL
-	O
dependent	O
currents	O
blocked	O
by	O
antidepressants	O
and	O
cocaine	B-CHEMICAL
that	O
are	O
absent	O
in	O
parental	O
cells	O
.	O

In	O
addition	O
to	O
NE	B-CHEMICAL
-	O
dependent	O
currents	O
,	O
transfected	O
cells	O
posses	O
an	O
NE	B-CHEMICAL
-	O
independent	O
mode	O
of	O
charge	O
movement	O
mediated	O
by	O
hNET	B-GENE-Y
.	O

hNET	B-GENE-Y
antagonists	O
without	O
effect	O
in	O
non	O
-	O
transfected	O
cells	O
abolish	O
both	O
NE	B-CHEMICAL
-	O
dependent	O
and	O
NE	B-CHEMICAL
-	O
independent	O
modes	O
of	O
charge	O
movement	O
in	O
transfected	O
cells	O
.	O

The	O
magnitude	O
of	O
NE	B-CHEMICAL
-	O
dependent	O
currents	O
in	O
these	O
cells	O
exceeds	O
the	O
expectations	O
of	O
simple	O
carrier	O
models	O
using	O
previous	O
estimates	O
of	O
transport	O
rates	O
.	O

To	O
explain	O
our	O
observations	O
,	O
we	O
propose	O
that	O
hNETs	B-GENE-Y
function	O
as	O
ion	B-GENE-N
-	I-GENE-N
gated	I-GENE-N
ligand	I-GENE-N
channels	I-GENE-N
with	O
an	O
indefinite	O
stoichiometry	O
relating	O
ion	O
flux	O
to	O
NE	B-CHEMICAL
transport	O
.	O

In	O
this	O
view	O
,	O
external	O
Na	B-CHEMICAL
+	I-CHEMICAL
and	O
NE	B-CHEMICAL
bind	O
to	O
the	O
transporter	O
with	O
finite	O
affinities	O
in	O
a	O
cooperative	O
fashion	O
.	O

However	O
,	O
coupled	O
transport	O
may	O
not	O
predict	O
the	O
magnitude	O
or	O
the	O
kinetics	O
of	O
the	O
total	O
current	O
through	O
the	O
transporter	O
.	O

We	O
propose	O
instead	O
that	O
Na	B-CHEMICAL
+	I-CHEMICAL
gates	O
NE	B-CHEMICAL
transport	O
and	O
also	O
the	O
parallel	O
inward	O
flux	O
of	O
an	O
indeterminate	O
number	O
of	O
ions	O
through	O
a	O
channel	O
-	O
like	O
pore	O
.	O

TSG	B-GENE-Y
-	I-GENE-Y
6	I-GENE-Y
,	O
an	O
arthritis	O
-	O
associated	O
hyaluronan	B-GENE-N
binding	I-GENE-N
protein	I-GENE-N
,	O
forms	O
a	O
stable	O
complex	O
with	O
the	O
serum	B-GENE-N
protein	I-GENE-N
inter	I-GENE-N
-	I-GENE-N
alpha	I-GENE-N
-	I-GENE-N
inhibitor	I-GENE-N
.	O

TSG	B-GENE-Y
-	I-GENE-Y
6	I-GENE-Y
is	O
a	O
secreted	O
35	B-GENE-N
-	I-GENE-N
kDa	I-GENE-N
glycoprotein	I-GENE-N
,	O
inducible	O
by	O
TNF	B-GENE-Y
and	O
IL	B-GENE-N
-	I-GENE-N
1	I-GENE-N
.	O

The	O
N	B-CHEMICAL
-	O
terminal	O
portion	O
of	O
TSG	B-GENE-Y
-	I-GENE-Y
6	I-GENE-Y
shows	O
sequence	O
homology	O
to	O
members	O
of	O
the	O
cartilage	O
link	O
protein	O
family	O
of	O
hyaluronan	B-GENE-N
binding	I-GENE-N
proteins	I-GENE-N
.	O

The	O
C	B-CHEMICAL
-	O
terminal	O
half	O
of	O
TSG	B-GENE-Y
-	I-GENE-Y
6	I-GENE-Y
contains	O
a	O
so	O
-	O
called	O
CUB	B-GENE-N
domain	I-GENE-N
,	O
characteristic	O
for	O
developmentally	O
regulated	O
proteins	O
.	O

High	O
levels	O
of	O
TSG	B-GENE-Y
-	I-GENE-Y
6	I-GENE-Y
protein	O
are	O
found	O
in	O
the	O
synovial	O
fluid	O
of	O
patients	O
with	O
rheumatoid	O
arthritis	O
and	O
some	O
other	O
arthritic	O
diseases	O
.	O

Here	O
we	O
show	O
that	O
TSG	B-GENE-N
-	I-GENE-N
6	I-GENE-N
readily	O
formed	O
a	O
complex	O
with	O
a	O
protein	O
present	O
in	O
human	O
,	O
bovine	O
,	O
rabbit	O
,	O
and	O
mouse	O
serum	O
.	O

This	O
complex	O
was	O
stable	O
during	O
SDS	O
-	O
PAGE	O
under	O
reducing	O
conditions	O
,	O
and	O
in	O
the	O
presence	O
of	O
8	O
M	O
urea	B-CHEMICAL
.	O

The	O
protein	O
that	O
binds	O
TSG	B-GENE-Y
-	I-GENE-Y
6	I-GENE-Y
was	O
purified	O
from	O
human	O
serum	O
and	O
identified	O
as	O
inter	B-GENE-N
-	I-GENE-N
alpha	I-GENE-N
-	I-GENE-N
inhibitor	I-GENE-N
(	O
I	B-GENE-N
alpha	I-GENE-N
I	I-GENE-N
)	O
by	O
N	B-CHEMICAL
-	O
terminal	O
microsequencing	O
.	O

Microsequencing	O
of	O
the	O
complex	O
itself	O
revealed	O
the	O
presence	O
of	O
TSG	B-GENE-Y
-	I-GENE-Y
6	I-GENE-Y
and	O
two	O
of	O
the	O
three	O
polypeptide	O
chains	O
of	O
I	B-GENE-N
alpha	I-GENE-N
I	I-GENE-N
(	O
bikunin	B-GENE-Y
and	O
HC2	B-GENE-Y
)	O
.	O

Experiments	O
with	O
recombinant	O
TSG	B-GENE-Y
-	I-GENE-Y
6	I-GENE-Y
and	O
I	B-GENE-N
alpha	I-GENE-N
I	I-GENE-N
purified	O
from	O
human	O
serum	O
showed	O
that	O
the	O
TSG	B-GENE-Y
-	I-GENE-Y
6	I-GENE-Y
/	O
I	B-GENE-N
alpha	I-GENE-N
I	I-GENE-N
complex	O
is	O
rapidly	O
formed	O
even	O
in	O
the	O
apparent	O
absence	O
of	O
other	O
proteins	O
at	O
37	O
degrees	O
C	O
,	O
but	O
not	O
at	O
4	O
degrees	O
C	O
.	O

The	O
TSG	B-GENE-Y
-	I-GENE-Y
6	I-GENE-Y
/	O
I	B-GENE-N
alpha	I-GENE-N
I	I-GENE-N
complex	O
was	O
cleaved	O
by	O
chondroitin	B-GENE-N
sulfate	I-GENE-N
ABC	I-GENE-N
lyase	I-GENE-N
,	O
suggesting	O
that	O
cross	O
-	O
linking	O
by	O
chondroitin	O
sulfate	B-CHEMICAL
is	O
required	O
for	O
the	O
stability	O
of	O
the	O
complex	O
.	O
(	O
ABSTRACT	O
TRUNCATED	O
AT	O
250	O
WORDS	O
)	O

Effects	O
of	O
nabumetone	B-CHEMICAL
on	O
prostanoid	B-CHEMICAL
biosynthesis	O
in	O
humans	O
.	O

BACKGROUND	O
:	O
The	O
active	O
metabolite	O
of	O
the	O
anti	O
-	O
inflammatory	O
drug	O
nabumetone	B-CHEMICAL
has	O
been	O
characterized	O
as	O
a	O
selective	O
inhibitor	O
of	O
the	O
inducible	O
prostaglandin	B-GENE-N
H	I-GENE-N
synthase	I-GENE-N
(	O
PGHS	B-GENE-N
)	O
.	O

The	O
aim	O
of	O
this	O
study	O
was	O
to	O
investigate	O
the	O
rate	O
of	O
eicosanoid	B-CHEMICAL
biosynthesis	O
after	O
oral	O
dosing	O
with	O
nabumetone	B-CHEMICAL
in	O
nine	O
healthy	O
subjects	O
.	O

METHODS	O
:	O
We	O
measured	O
the	O
urinary	O
excretion	O
of	O
products	O
of	O
platelet	O
(	O
11	B-CHEMICAL
-	I-CHEMICAL
dehydro	I-CHEMICAL
-	I-CHEMICAL
thromboxane	I-CHEMICAL
B2	I-CHEMICAL
[	O
TXB2	B-CHEMICAL
]	O
)	O
and	O
renal	O
(	O
prostaglandin	B-CHEMICAL
IF2	I-CHEMICAL
alpha	I-CHEMICAL
[	O
PGF2	B-CHEMICAL
alpha	I-CHEMICAL
]	O
)	O
arachidonate	B-CHEMICAL
metabolism	O
as	O
in	O
vivo	O
indexes	O
of	O
the	O
constitutive	O
PGHS	B-GENE-Y
-	I-GENE-Y
1	I-GENE-Y
pathway	O
.	O

Moreover	O
,	O
the	O
production	O
of	O
TXB2	B-CHEMICAL
during	O
whole	O
blood	O
clotting	O
was	O
assessed	O
as	O
an	O
index	O
of	O
the	O
cyclooxygenase	B-GENE-N
activity	O
of	O
platelet	O
PGHS	B-GENE-Y
-	I-GENE-Y
1	I-GENE-Y
ex	O
vivo	O
.	O

RESULTS	O
:	O
At	O
steady	O
state	O
,	O
nabumetone	B-CHEMICAL
(	O
500	O
and	O
1000	O
mg	O
daily	O
for	O
7	O
days	O
)	O
was	O
associated	O
with	O
statistically	O
significant	O
dose	O
-	O
dependent	O
reduction	O
in	O
the	O
urinary	O
excretion	O
of	O
11	B-CHEMICAL
-	I-CHEMICAL
dehydro	I-CHEMICAL
-	I-CHEMICAL
TXB2	I-CHEMICAL
and	O
serum	O
TXB2	B-CHEMICAL
levels	O
by	O
approximately	O
50	O
%	O
to	O
70	O
%	O
.	O

However	O
,	O
the	O
drug	O
did	O
not	O
significantly	O
affect	O
the	O
urinary	O
excretion	O
of	O
PGF2	B-CHEMICAL
alpha	I-CHEMICAL
.	O

After	O
discontinuation	O
of	O
nabumetone	B-CHEMICAL
,	O
urinary	O
11	B-CHEMICAL
-	I-CHEMICAL
dehydro	I-CHEMICAL
-	I-CHEMICAL
TXB2	I-CHEMICAL
excretion	O
and	O
whole	O
blood	O
TXB2	B-CHEMICAL
production	O
returned	O
to	O
predrug	O
levels	O
with	O
a	O
similar	O
timecourse	O
that	O
was	O
consistent	O
with	O
the	O
elimination	O
half	O
-	O
life	O
of	O
its	O
active	O
metabolite	O
.	O

The	O
daily	O
administration	O
of	O
low	O
-	O
dose	O
aspirin	B-CHEMICAL
(	O
40	O
mg	O
)	O
,	O
a	O
selective	O
inhibitor	O
of	O
platelet	O
PGHS	B-GENE-Y
-	I-GENE-Y
1	I-GENE-Y
,	O
caused	O
a	O
cumulative	O
inhibition	O
of	O
urinary	O
11	B-CHEMICAL
-	I-CHEMICAL
dehydro	I-CHEMICAL
-	I-CHEMICAL
TXB2	I-CHEMICAL
and	O
whole	O
blood	O
TXB2	B-CHEMICAL
production	O
that	O
recovered	O
with	O
a	O
timecourse	O
consistent	O
with	O
platelet	O
turnover	O
.	O

CONCLUSIONS	O
:	O
Nabumetone	B-CHEMICAL
does	O
dose	O
-	O
dependently	O
inhibit	O
the	O
cyclooxygenase	B-GENE-N
activity	O
of	O
platelet	O
PGHS	B-GENE-Y
-	I-GENE-Y
1	I-GENE-Y
of	O
healthy	O
subjects	O
both	O
in	O
vivo	O
and	O
ex	O
vivo	O
.	O

Thus	O
it	O
is	O
unlikely	O
that	O
its	O
safety	O
profile	O
in	O
patients	O
may	O
be	O
related	O
to	O
selective	O
inhibition	O
of	O
the	O
inducible	O
PGHS	B-GENE-Y
-	I-GENE-Y
2	I-GENE-Y
.	O

Altered	O
gene	O
expression	O
in	O
murine	O
branchial	O
arches	O
following	O
in	O
utero	O
exposure	O
to	O
retinoic	B-CHEMICAL
acid	I-CHEMICAL
.	O

Retinoic	B-CHEMICAL
acid	I-CHEMICAL
(	O
RA	B-CHEMICAL
)	O
in	O
the	O
form	O
of	O
isotretinoin	B-CHEMICAL
(	O
Accutane	B-CHEMICAL
)	O
and	O
tretinoin	B-CHEMICAL
(	O
Retin	B-CHEMICAL
-	I-CHEMICAL
A	I-CHEMICAL
)	O
is	O
a	O
clinically	O
important	O
compound	O
in	O
the	O
treatment	O
of	O
dermatologic	O
disorders	O
.	O

However	O
,	O
it	O
is	O
also	O
a	O
potent	O
teratogen	O
associated	O
with	O
a	O
number	O
of	O
serious	O
congenital	O
malformations	O
.	O

Generally	O
,	O
these	O
malformations	O
involve	O
the	O
craniofacial	O
structures	O
derived	O
from	O
the	O
first	O
and	O
second	O
branchial	O
arches	O
.	O

To	O
determine	O
how	O
altered	O
gene	O
expression	O
may	O
contribute	O
to	O
the	O
observed	O
RA	B-CHEMICAL
-	O
induced	O
defects	O
,	O
pregnant	O
LM	O
/	O
Bc	O
mice	O
were	O
administered	O
(	O
5	O
mg	O
/	O
kg	O
)	O
all	B-CHEMICAL
-	I-CHEMICAL
trans	I-CHEMICAL
RA	I-CHEMICAL
on	O
gestational	O
day	O
(	O
GD	O
)	O
8	O
:	O
12	O
.	O

First	O
and	O
second	O
branchial	O
arches	O
were	O
removed	O
from	O
control	O
and	O
teratogen	O
-	O
treated	O
embryos	O
on	O
GD	O
10	O
:	O
00	O
10	O
:	O
12	O
,	O
or	O
12	O
:	O
00	O
,	O
processed	O
by	O
in	O
situ	O
transcription	O
/	O
aRNA	O
techniques	O
,	O
and	O
analyzed	O
for	O
alterations	O
in	O
gene	O
expression	O
.	O

In	O
these	O
studies	O
,	O
a	O
panel	O
of	O
40	O
candidate	O
genes	O
that	O
are	O
known	O
to	O
be	O
important	O
in	O
mammalian	O
craniofacial	O
development	O
were	O
examined	O
.	O

This	O
analysis	O
revealed	O
significant	O
differences	O
in	O
the	O
expression	O
level	O
of	O
the	O
nicotinic	B-GENE-Y
acetylcholine	I-GENE-Y
receptor	I-GENE-Y
subunit	I-GENE-Y
alpha	I-GENE-Y
(	O
NAChR	B-GENE-Y
)	O
,	O
transforming	B-GENE-Y
growth	I-GENE-Y
factor	I-GENE-Y
beta	I-GENE-Y
2	I-GENE-Y
(	O
TGF	B-GENE-Y
beta	I-GENE-Y
2	I-GENE-Y
)	O
,	O
type	B-GENE-Y
1	I-GENE-Y
cellular	I-GENE-Y
retinoid	I-GENE-Y
binding	I-GENE-Y
protein	I-GENE-Y
(	O
CRBP	B-GENE-Y
-	I-GENE-Y
1	I-GENE-Y
)	O
,	O
retinoic	B-GENE-Y
acid	I-GENE-Y
receptor	I-GENE-Y
gamma	I-GENE-Y
(	O
RAR	B-GENE-Y
gamma	I-GENE-Y
)	O
,	O
and	O
cAMP	B-GENE-N
response	I-GENE-N
element	I-GENE-N
binding	I-GENE-N
protein	I-GENE-N
(	O
CREB	B-GENE-N
)	O
.	O

The	O
alterations	O
observed	O
in	O
the	O
expression	O
of	O
these	O
genes	O
following	O
RA	B-CHEMICAL
exposure	O
may	O
prohibit	O
normal	O
morphogenetic	O
processes	O
within	O
the	O
second	O
branchial	O
arch	O
and	O
lead	O
to	O
the	O
observed	O
malformations	O
.	O

Estramustine	B-GENE-N
binding	I-GENE-N
protein	I-GENE-N
in	O
primary	O
tumours	O
and	O
metastases	O
of	O
malignant	O
melanoma	O
.	O

The	O
presence	O
of	O
estramustine	B-GENE-N
binding	I-GENE-N
protein	I-GENE-N
(	O
EMBP	B-GENE-N
)	O
,	O
a	O
54	O
kD	O
cytosolic	O
glycoprotein	O
,	O
which	O
is	O
distinct	O
from	O
the	O
estrogen	B-GENE-Y
receptor	I-GENE-Y
,	O
was	O
investigated	O
in	O
a	O
pilot	O
study	O
of	O
primary	O
malignant	O
melanomas	O
and	O
their	O
metastases	O
.	O

In	O
11	O
primary	O
melanomas	O
EMBP	B-GENE-N
was	O
demonstrated	O
by	O
immunohistochemistry	O
.	O

The	O
percentage	O
of	O
positive	O
melanoma	O
cells	O
ranged	O
between	O
11	O
-	O
91	O
%	O
with	O
a	O
mean	O
of	O
57	O
%	O
.	O

Radioimmunoassay	O
on	O
metastatic	O
tissue	O
revealed	O
significant	O
amounts	O
of	O
EMBP	B-GENE-N
,	O
with	O
values	O
ranging	O
between	O
0	O
.	O
6	O
-	O
4	O
.	O
2	O
with	O
a	O
mean	O
of	O
1	O
.	O
6	O
ng	O
/	O
mg	O
protein	O
.	O

A	O
high	O
number	O
of	O
cells	O
with	O
a	O
positive	O
stain	O
for	O
EMBP	B-GENE-N
in	O
the	O
primary	O
tumours	O
was	O
significantly	O
correlated	O
to	O
a	O
short	O
interval	O
between	O
diagnosis	O
and	O
the	O
occurrence	O
of	O
metastases	O
.	O

Presence	O
of	O
EMBP	B-GENE-N
in	O
malignant	O
melanoma	O
may	O
have	O
prognostic	O
significance	O
and	O
the	O
role	O
of	O
hormone	O
-	O
linked	O
cytostatic	O
drugs	O
in	O
the	O
treatment	O
of	O
this	O
disease	O
needs	O
further	O
investigation	O
.	O

Preclinical	O
efficacy	O
of	O
emedastine	B-CHEMICAL
,	O
a	O
potent	O
,	O
selective	O
histamine	B-GENE-Y
H1	I-GENE-Y
antagonist	O
for	O
topical	O
ocular	O
use	O
.	O

Emedastine	B-CHEMICAL
[	O
1	B-CHEMICAL
-	I-CHEMICAL
(	I-CHEMICAL
2	I-CHEMICAL
-	I-CHEMICAL
ethoxyethyl	I-CHEMICAL
)	I-CHEMICAL
-	I-CHEMICAL
2	I-CHEMICAL
-	I-CHEMICAL
(	I-CHEMICAL
4	I-CHEMICAL
-	I-CHEMICAL
methyl	I-CHEMICAL
-	I-CHEMICAL
1	I-CHEMICAL
-	I-CHEMICAL
homopiperazinyl	I-CHEMICAL
)	I-CHEMICAL
-	I-CHEMICAL
benzimidazole	I-CHEMICAL
difumarate	I-CHEMICAL
]	O
was	O
evaluated	O
for	O
topical	O
ocular	O
anti	O
-	O
histaminic	O
activity	O
in	O
histamine	B-CHEMICAL
and	O
antigen	O
stimulated	O
conjunctivitis	O
models	O
.	O

Concentration	O
-	O
dependent	O
inhibition	O
of	O
histamine	B-CHEMICAL
induced	O
vascular	O
permeability	O
changes	O
occurring	O
in	O
the	O
conjunctiva	O
was	O
observed	O
when	O
the	O
time	O
interval	O
between	O
topical	O
ocular	O
administration	O
and	O
histamine	B-CHEMICAL
challenge	O
ranged	O
from	O
1	O
min	O
to	O
8	O
hr	O
.	O

The	O
calculated	O
ED50	O
values	O
obtained	O
using	O
intervals	O
of	O
1	O
min	O
,	O
30	O
min	O
,	O
2	O
,	O
4	O
and	O
8	O
hr	O
were	O
0	O
.	O
0002	O
%	O
,	O
0	O
.	O
000035	O
%	O
,	O
0	O
.	O
0029	O
%	O
,	O
0	O
.	O
019	O
%	O
and	O
0	O
.	O
19	O
%	O
,	O
w	O
/	O
v	O
,	O
respectively	O
.	O

Comparisons	O
of	O
relative	O
potency	O
30	O
min	O
post	O
dosing	O
between	O
emedastine	O
and	O
other	O
anti	O
-	O
histamines	B-CHEMICAL
demonstrated	O
that	O
emedastine	B-CHEMICAL
is	O
equipotent	O
to	O
ketotifen	B-CHEMICAL
,	O
and	O
7	O
,	O
7	O
,	O
10	O
,	O
10	O
,	O
100	O
,	O
357	O
,	O
3333	O
,	O
and	O
5813	O
times	O
more	O
potent	O
than	O
brompheniramine	B-CHEMICAL
,	O
chlorpheniramine	B-CHEMICAL
,	O
clemastine	B-CHEMICAL
,	O
pyrilamine	B-CHEMICAL
,	O
levocabastine	B-CHEMICAL
,	O
pheniramine	B-CHEMICAL
,	O
diphenhydramine	B-CHEMICAL
,	O
and	O
antazoline	B-CHEMICAL
,	O
respectively	O
.	O

Emedastine	B-CHEMICAL
(	O
0	O
.	O
1	O
%	O
)	O
failed	O
to	O
significantly	O
attenuate	O
either	O
serotonin	O
or	O
platelet	O
-	O
activating	O
-	O
factor	O
induced	O
vascular	O
permeability	O
changes	O
indicating	O
high	O
selectivity	O
for	O
the	O
histamine	B-GENE-Y
H1	I-GENE-Y
receptor	I-GENE-Y
.	O

In	O
a	O
passive	O
conjunctival	O
anaphylaxis	O
model	O
in	O
guinea	O
pigs	O
,	O
significant	O
inhibition	O
of	O
the	O
allergic	O
response	O
was	O
observed	O
following	O
topical	O
ocular	O
administration	O
of	O
emedastine	B-CHEMICAL
5	O
min	O
or	O
30	O
min	O
prior	O
to	O
antigen	O
challenge	O
(	O
ED50s	O
0	O
.	O
0046	O
%	O
and	O
0	O
.	O
00022	O
%	O
,	O
respectively	O
)	O
.	O

These	O
data	O
clearly	O
indicate	O
that	O
emedastine	B-CHEMICAL
has	O
potential	O
as	O
a	O
topical	O
ocular	O
anti	O
-	O
histamine	B-CHEMICAL
for	O
treating	O
allergic	O
conjunctivitis	O
.	O

ALL	B-GENE-Y
-	I-GENE-Y
1	I-GENE-Y
gene	O
rearrangements	O
in	O
DNA	B-GENE-Y
topoisomerase	I-GENE-Y
II	I-GENE-Y
inhibitor	O
-	O
related	O
leukemia	O
in	O
children	O
.	O

We	O
examined	O
clinical	O
,	O
morphologic	O
,	O
and	O
cytogenetic	O
features	O
and	O
ALL	B-GENE-Y
-	I-GENE-Y
1	I-GENE-Y
(	O
MLL	B-GENE-Y
,	O
Htrxl	B-GENE-Y
,	O
HRX	B-GENE-Y
)	O
gene	O
rearrangements	O
in	O
17	O
cases	O
of	O
secondary	O
leukemia	O
that	O
occurred	O
11	O
months	O
to	O
9	O
years	O
from	O
diagnoses	O
of	O
primary	O
cancers	O
in	O
children	O
who	O
received	O
topoisomerase	B-GENE-Y
II	I-GENE-Y
inhibitors	O
or	O
developed	O
secondary	O
leukemias	O
typical	O
of	O
those	O
associated	O
with	O
this	O
therapy	O
.	O

Primary	O
diagnoses	O
included	O
nine	O
solid	O
tumors	O
and	O
eight	O
leukemias	O
.	O

Ten	O
secondary	O
leukemias	O
were	O
acute	O
myeloid	O
leukemia	O
(	O
AML	O
)	O
,	O
one	O
was	O
of	O
mixed	O
lineage	O
,	O
two	O
were	O
acute	O
lymphoblastic	O
leukemia	O
(	O
ALL	O
)	O
,	O
and	O
four	O
presented	O
as	O
myelodysplasia	O
.	O

Of	O
15	O
cases	O
with	O
11q23	O
involvement	O
,	O
11	O
(	O
73	O
%	O
)	O
were	O
cytogenetically	O
identifiable	O
;	O
four	O
cases	O
had	O
molecular	O
rearrangement	O
only	O
.	O

By	O
Southern	O
blot	O
,	O
rearrangements	O
within	O
the	O
ALL	B-GENE-Y
-	I-GENE-Y
1	I-GENE-Y
gene	O
were	O
similar	O
to	O
sporadic	O
cases	O
.	O

The	O
results	O
of	O
this	O
analysis	O
suggest	O
the	O
following	O
:	O
(	O
1	O
)	O
In	O
most	O
pediatric	O
cases	O
of	O
topoisomerase	B-GENE-Y
II	I-GENE-Y
inhibitor	O
-	O
associated	O
leukemia	O
,	O
there	O
is	O
disruption	O
of	O
the	O
breakpoint	O
cluster	O
region	O
of	O
the	O
ALL	B-GENE-Y
-	I-GENE-Y
1	I-GENE-Y
gene	O
at	O
chromosomal	O
band	O
11q23	O
.	O

(	O
2	O
)	O
Exposure	O
histories	O
vary	O
in	O
secondary	O
11q23	O
leukemia	O
,	O
as	O
the	O
only	O
topoisomerase	B-GENE-Y
II	I-GENE-Y
inhibitor	O
was	O
dactinomycin	B-CHEMICAL
in	O
one	O
case	O
,	O
and	O
,	O
in	O
another	O
case	O
,	O
no	O
topoisomerase	B-GENE-Y
II	I-GENE-Y
inhibitor	O
was	O
administered	O
.	O

(	O
3	O
)	O
There	O
is	O
clinical	O
,	O
morphologic	O
,	O
cytogenetic	O
,	O
and	O
molecular	O
heterogeneity	O
in	O
pediatric	O
secondary	O
11q23	O
leukemia	O
.	O

(	O
4	O
)	O
There	O
are	O
some	O
survivors	O
of	O
pediatric	O
secondary	O
11q23	O
leukemia	O
,	O
but	O
the	O
outcome	O
is	O
most	O
often	O
fatal	O
.	O

Interactions	O
of	O
PGH	B-GENE-N
synthase	I-GENE-N
isozymes	I-GENE-N
-	I-GENE-N
1	I-GENE-N
and	I-GENE-N
-	I-GENE-N
2	I-GENE-N
with	O
NSAIDs	O
.	O

There	O
are	O
two	O
isozymes	O
of	O
prostaglandin	B-GENE-N
endoperoxide	I-GENE-N
(	I-GENE-N
PGH	I-GENE-N
)	I-GENE-N
synthase	I-GENE-N
(	O
cyclooxygenase	B-GENE-N
)	O
called	O
PGH	B-GENE-N
synthase	I-GENE-N
-	I-GENE-N
1	I-GENE-N
and	I-GENE-N
-	I-GENE-N
2	I-GENE-N
or	O
COX	B-GENE-N
I	I-GENE-N
and	I-GENE-N
II	I-GENE-N
.	O

Both	O
isozymes	O
catalyze	O
the	O
same	O
two	O
reactions	O
:	O
oxygenation	O
of	O
arachidonate	B-CHEMICAL
to	O
yield	O
PGG2	O
and	O
reduction	O
of	O
PGG2	O
to	O
PGH2	O
.	O

PGH	B-GENE-Y
synthase	I-GENE-Y
-	I-GENE-Y
1	I-GENE-Y
is	O
expressed	O
constitutively	O
and	O
is	O
found	O
in	O
most	O
tissues	O
.	O

PGH	B-GENE-Y
synthase	I-GENE-Y
-	I-GENE-Y
2	I-GENE-Y
is	O
undetectable	O
in	O
most	O
cells	O
but	O
can	O
be	O
induced	O
in	O
fibroblasts	O
,	O
endothelial	O
cells	O
,	O
ovarian	O
follicles	O
,	O
and	O
macrophages	O
by	O
various	O
mitogens	O
,	O
cytokines	B-GENE-N
,	O
and	O
tumor	O
promoters	O
.	O

PGH	B-GENE-Y
synthase	I-GENE-Y
-	I-GENE-Y
1	I-GENE-Y
(	O
PGHS	B-GENE-Y
-	I-GENE-Y
1	I-GENE-Y
)	O
has	O
been	O
presumed	O
to	O
be	O
the	O
site	O
of	O
action	O
of	O
nonsteroidal	O
antiinflammatory	O
drugs	O
(	O
NSAIDs	O
)	O
.	O

However	O
,	O
the	O
discovery	O
of	O
the	O
second	O
isozyme	O
,	O
PGH	B-GENE-Y
synthase	I-GENE-Y
-	I-GENE-Y
2	I-GENE-Y
(	O
PGHS	B-GENE-Y
-	I-GENE-Y
2	I-GENE-Y
)	O
,	O
and	O
its	O
association	O
with	O
inflammation	O
has	O
suggested	O
that	O
this	O
latter	O
enzyme	O
may	O
be	O
the	O
therapeutic	O
target	O
of	O
NSAIDs	O
functioning	O
in	O
their	O
antiinflammatory	O
capacities	O
.	O

We	O
have	O
cloned	O
cDNAs	O
for	O
murine	O
PGHS	B-GENE-Y
-	I-GENE-Y
1	I-GENE-Y
and	O
PGHS	B-GENE-Y
-	I-GENE-Y
2	I-GENE-Y
,	O
expressed	O
these	O
enzymes	O
in	O
cos	O
-	O
1	O
cells	O
,	O
and	O
compared	O
the	O
relative	O
sensitivities	O
of	O
the	O
two	O
isozymes	O
to	O
some	O
common	O
NSAIDs	O
.	O

Indomethacin	B-CHEMICAL
,	O
piroxicam	B-CHEMICAL
,	O
and	O
sulindac	B-CHEMICAL
sulfide	I-CHEMICAL
were	O
found	O
to	O
preferentially	O
inhibit	O
PGHS	B-GENE-Y
-	I-GENE-Y
1	I-GENE-Y
.	O

Ibuprofen	B-CHEMICAL
and	O
meclofenamate	O
inhibit	O
both	O
enzymes	O
with	O
comparable	O
potencies	O
.	O

6	B-CHEMICAL
-	I-CHEMICAL
Methoxy	I-CHEMICAL
-	I-CHEMICAL
2	I-CHEMICAL
-	I-CHEMICAL
naphthylacetic	I-CHEMICAL
acid	I-CHEMICAL
,	O
the	O
active	O
metabolite	O
of	O
Relafen	B-CHEMICAL
,	O
inhibits	O
murine	O
PGHS	B-GENE-Y
-	I-GENE-Y
2	I-GENE-Y
preferentially	O
.	O

Aspirin	B-CHEMICAL
irreversibly	O
inhibits	O
PGHS	B-GENE-Y
-	I-GENE-Y
1	I-GENE-Y
,	O
preventing	O
this	O
isozyme	O
from	O
forming	O
PGH2	O
or	O
any	O
other	O
oxygenated	O
product	O
;	O
in	O
contrast	O
,	O
aspirin	B-CHEMICAL
treatment	O
of	O
PGHS	B-GENE-Y
-	I-GENE-Y
2	I-GENE-Y
causes	O
this	O
enzyme	O
to	O
form	O
15	B-CHEMICAL
-	I-CHEMICAL
hydroxy	I-CHEMICAL
-	I-CHEMICAL
5c	I-CHEMICAL
,	I-CHEMICAL
8c	I-CHEMICAL
,	I-CHEMICAL
11c	I-CHEMICAL
,	I-CHEMICAL
13t	I-CHEMICAL
-	I-CHEMICAL
eicosatetraenoic	I-CHEMICAL
acid	I-CHEMICAL
(	O
15	B-CHEMICAL
-	I-CHEMICAL
HETE	I-CHEMICAL
)	O
instead	O
of	O
PGH2	O
.	O

Our	O
results	O
indicate	O
mouse	O
PGHS	B-GENE-Y
-	I-GENE-Y
1	I-GENE-Y
and	O
PGHS	B-GENE-Y
-	I-GENE-Y
2	I-GENE-Y
are	O
pharmacologically	O
distinct	O
.	O

Thus	O
,	O
it	O
should	O
be	O
possible	O
to	O
develop	O
agents	O
highly	O
selective	O
for	O
each	O
PGHS	B-GENE-N
isozyme	O
.	O

PGHS	B-GENE-Y
-	I-GENE-Y
2	I-GENE-Y
is	O
not	O
expressed	O
in	O
stomach	O
but	O
is	O
increased	O
by	O
inflammatory	O
cytokines	B-GENE-N
in	O
cells	O
such	O
as	O
macrophages	O
.	O

Thus	O
,	O
a	O
selective	O
inhibitor	O
of	O
PGHS	B-GENE-Y
-	I-GENE-Y
2	I-GENE-Y
could	O
be	O
an	O
antiinflammatory	O
agent	O
but	O
without	O
being	O
ulcerogenic	O
.	O

Neurochemical	O
mechanism	O
of	O
action	O
of	O
anorectic	O
drugs	O
.	O

Studies	O
with	O
dexfenfluramine	B-CHEMICAL
,	O
an	O
anorectic	O
agent	O
which	O
releases	O
5	B-CHEMICAL
-	I-CHEMICAL
hydroxytryptamine	I-CHEMICAL
(	O
5	B-CHEMICAL
-	I-CHEMICAL
HT	I-CHEMICAL
)	O
from	O
nerve	O
terminals	O
and	O
inhibits	O
its	O
reuptake	O
,	O
have	O
considerably	O
increased	O
our	O
knowledge	O
of	O
the	O
role	O
of	O
5	B-CHEMICAL
-	I-CHEMICAL
HT	I-CHEMICAL
in	O
feeding	O
control	O
.	O

5	B-GENE-Y
-	I-GENE-Y
HT1B	I-GENE-Y
receptors	O
mediate	O
the	O
satiating	O
effect	O
of	O
dexfenfluramine	B-CHEMICAL
,	O
whereas	O
the	O
mechanism	O
by	O
which	O
5	B-CHEMICAL
-	I-CHEMICAL
HT	I-CHEMICAL
uptake	O
inhibitors	O
such	O
as	O
fluoxetine	B-CHEMICAL
and	O
sertraline	B-CHEMICAL
cause	O
anorexia	O
is	O
not	O
clear	O
.	O

Anorexia	O
induced	O
by	O
(	B-CHEMICAL
+	I-CHEMICAL
)	I-CHEMICAL
-	I-CHEMICAL
amphetamine	I-CHEMICAL
,	O
phentermine	B-CHEMICAL
,	O
diethylpropion	B-CHEMICAL
and	O
phenylpropanolamine	B-CHEMICAL
seems	O
to	O
be	O
the	O
result	O
of	O
their	O
ability	O
to	O
increase	O
the	O
release	O
of	O
noradrenaline	B-CHEMICAL
and	O
/	O
or	O
dopamine	B-CHEMICAL
from	O
nerve	O
terminals	O
and	O
inhibit	O
their	O
reuptake	O
or	O
,	O
in	O
the	O
case	O
of	O
phenylpropanolamine	B-CHEMICAL
,	O
to	O
stimulate	O
directly	O
alpha	B-GENE-N
1	I-GENE-N
-	I-GENE-N
adrenoceptors	I-GENE-N
.	O

It	O
has	O
been	O
suggested	O
that	O
beta	B-GENE-N
-	I-GENE-N
and	I-GENE-N
alpha	I-GENE-N
1	I-GENE-N
-	I-GENE-N
adrenoceptors	I-GENE-N
and	O
D1	B-GENE-Y
dopamine	I-GENE-Y
receptors	I-GENE-Y
are	O
involved	O
in	O
their	O
effect	O
on	O
food	O
intake	O
.	O

The	O
difficulties	O
of	O
extrapolation	O
across	O
species	O
limit	O
our	O
knowledge	O
of	O
the	O
mechanism	O
of	O
the	O
anorectic	O
action	O
in	O
humans	O
.	O

Significant	O
advances	O
in	O
the	O
treatment	O
of	O
feeding	O
pathology	O
will	O
be	O
linked	O
to	O
identifying	O
new	O
receptor	O
types	O
and	O
subtypes	O
for	O
neurotransmitters	O
and	O
quantifying	O
and	O
modelling	O
eating	O
disorders	O
such	O
as	O
binge	O
-	O
eating	O
and	O
food	O
craving	O
.	O

Further	O
characterization	O
of	O
5	B-GENE-N
-	I-GENE-N
hydroxytryptamine	I-GENE-N
receptors	I-GENE-N
(	O
putative	O
5	B-GENE-Y
-	I-GENE-Y
HT2B	I-GENE-Y
)	O
in	O
rat	O
stomach	O
fundus	O
longitudinal	O
muscle	O
.	O

1	O
.	O

The	O
present	O
study	O
was	O
undertaken	O
to	O
isolate	O
and	O
characterize	O
pharmacologically	O
homogeneous	O
populations	O
of	O
5	B-GENE-N
-	I-GENE-N
hydroxytryptamine	I-GENE-N
(	I-GENE-N
5	I-GENE-N
-	I-GENE-N
HT	I-GENE-N
)	I-GENE-N
receptors	I-GENE-N
from	O
a	O
possible	O
mixed	O
receptor	O
population	O
mediating	O
concentration	O
of	O
the	O
longitudinal	O
muscle	O
of	O
rat	O
stomach	O
fundus	O
.	O

Our	O
aim	O
was	O
to	O
extend	O
the	O
pharmacological	O
characterization	O
of	O
the	O
5	B-GENE-Y
-	I-GENE-Y
HT2B	I-GENE-Y
receptor	O
which	O
is	O
reported	O
to	O
be	O
expressed	O
in	O
this	O
preparation	O
.	O

2	O
.	O

To	O
minimize	O
spontaneous	O
activity	O
and	O
any	O
influence	O
of	O
circular	O
muscle	O
on	O
the	O
contractile	O
response	O
,	O
narrow	O
(	O
1	O
-	O
1	O
.	O
5	O
x	O
20	O
mm	O
)	O
segments	O
of	O
mucosa	O
-	O
denuded	O
longitudinal	O
muscle	O
were	O
used	O
.	O

Under	O
these	O
conditions	O
,	O
blockade	O
of	O
monoamine	B-GENE-N
oxidase	I-GENE-N
with	O
pargyline	B-CHEMICAL
(	O
100	O
microM	O
for	O
15	O
min	O
)	O
caused	O
a	O
leftward	O
displacement	O
of	O
concentration	O
-	O
effect	O
curves	O
for	O
both	O
5	B-CHEMICAL
-	I-CHEMICAL
methoxytryptamine	I-CHEMICAL
(	O
5	B-CHEMICAL
-	I-CHEMICAL
MeO	I-CHEMICAL
-	I-CHEMICAL
T	I-CHEMICAL
)	O
and	O
tryptamine	B-CHEMICAL
.	O

Neither	O
pargyline	B-CHEMICAL
nor	O
a	O
number	O
of	O
uptake	O
inhibitors	O
affected	O
responses	O
to	O
5	B-CHEMICAL
-	I-CHEMICAL
HT	I-CHEMICAL
.	O

3	O
.	O

In	O
pargyline	B-CHEMICAL
pretreated	O
preparations	O
,	O
the	O
order	O
of	O
potency	O
of	O
a	O
number	O
of	O
tryptamine	B-CHEMICAL
analogues	O
was	O
as	O
follows	O
:	O
5	B-CHEMICAL
-	I-CHEMICAL
MeO	I-CHEMICAL
-	I-CHEMICAL
T	I-CHEMICAL
>	O
or	O
=	O
alpha	B-CHEMICAL
-	I-CHEMICAL
Me	I-CHEMICAL
-	I-CHEMICAL
5	I-CHEMICAL
-	I-CHEMICAL
HT	I-CHEMICAL
>	O
or	O
=	O
5	B-CHEMICAL
-	I-CHEMICAL
HT	I-CHEMICAL
>	O
5	B-CHEMICAL
-	I-CHEMICAL
carboxamidotryptamine	I-CHEMICAL
(	O
5	B-CHEMICAL
-	I-CHEMICAL
CT	I-CHEMICAL
)	O
>	O
tryptamine	B-CHEMICAL
>	O
2	B-CHEMICAL
-	I-CHEMICAL
Me	I-CHEMICAL
-	I-CHEMICAL
5	I-CHEMICAL
-	I-CHEMICAL
HT	I-CHEMICAL
.	O

In	O
addition	O
several	O
ligands	O
known	O
to	O
act	O
as	O
agonists	O
at	O
either	O
5	B-GENE-Y
-	I-GENE-Y
HT2A	I-GENE-Y
or	O
5	B-GENE-Y
-	I-GENE-Y
HT2C	I-GENE-Y
receptors	O
including	O
1	B-CHEMICAL
-	I-CHEMICAL
m	I-CHEMICAL
-	I-CHEMICAL
chlorophenylpiperazine	I-CHEMICAL
(	O
m	B-CHEMICAL
-	I-CHEMICAL
CPP	I-CHEMICAL
)	O
,	O
Ru	B-CHEMICAL
24969	I-CHEMICAL
,	O
MK	B-CHEMICAL
212	I-CHEMICAL
and	O
SCH	B-CHEMICAL
23390	I-CHEMICAL
were	O
also	O
agonists	O
in	O
rat	O
fundus	O
whilst	O
sumatriptan	B-CHEMICAL
,	O
renzapride	B-CHEMICAL
and	O
8	B-CHEMICAL
-	I-CHEMICAL
hydroxy	I-CHEMICAL
-	I-CHEMICAL
2	I-CHEMICAL
-	I-CHEMICAL
(	I-CHEMICAL
di	I-CHEMICAL
-	I-CHEMICAL
n	I-CHEMICAL
-	I-CHEMICAL
propylamino	I-CHEMICAL
)	I-CHEMICAL
tetralin	I-CHEMICAL
(	O
8	B-CHEMICAL
-	I-CHEMICAL
OH	I-CHEMICAL
-	I-CHEMICAL
DPAT	I-CHEMICAL
)	O
were	O
very	O
weak	O
or	O
inactive	O
.	O

With	O
the	O
exception	O
of	O
2	B-CHEMICAL
-	I-CHEMICAL
Me	I-CHEMICAL
-	I-CHEMICAL
5	I-CHEMICAL
-	I-CHEMICAL
HT	I-CHEMICAL
and	O
m	B-CHEMICAL
-	I-CHEMICAL
CPP	I-CHEMICAL
,	O
most	O
agonists	O
produced	O
monophasic	O
concentration	O
-	O
effect	O
curves	O
consistent	O
with	O
an	O
interaction	O
at	O
a	O
single	O
site	O
.	O

High	O
concentrations	O
of	O
2	O
-	O
Me	O
-	O
5	O
-	O
HT	O
evoked	O
relaxations	O
which	O
were	O
blocked	O
by	O
phentolamine	O
(	O
1	O
MicroM	O
)	O
suggesting	O
an	O
interaction	O
with	O
alpha	B-GENE-N
-	I-GENE-N
adrenoceptors	I-GENE-N
.	O

m	O
-	O
CPP	O
often	O
evoked	O
biphasic	O
concentration	O
-	O
effect	O
curves	O
with	O
a	O
second	O
contractile	O
phase	O
which	O
was	O
insensitive	O
to	O
yohimbine	B-CHEMICAL
at	O
concentrations	O
higher	O
than	O
required	O
for	O
antagonism	O
of	O
responses	O
to	O
5	B-CHEMICAL
-	I-CHEMICAL
HT	I-CHEMICAL
.	O
4	O
.	O

LY	B-CHEMICAL
53857	I-CHEMICAL
,	O
methiothepin	B-CHEMICAL
,	O
methysergide	B-CHEMICAL
,	O
ritanserin	B-CHEMICAL
and	O
ICI	B-CHEMICAL
170809	I-CHEMICAL
were	O
potent	O
but	O
non	O
-	O
surmountable	O
antagonists	O
of	O
5	B-CHEMICAL
-	I-CHEMICAL
HT	I-CHEMICAL
in	O
rat	O
fundus	O
.	O

In	O
contrast	O
,	O
several	O
ligands	O
behaved	O
as	O
surmountable	O
antagonists	O
with	O
the	O
following	O
order	O
of	O
potency	O
:	O
rauwolscine	B-CHEMICAL
>	O
yohimbine	B-CHEMICAL
=	O
mesulergine	B-CHEMICAL
>	O
mianserin	B-CHEMICAL
=	O
SB	B-CHEMICAL
204070	I-CHEMICAL
>	O
WY	B-CHEMICAL
26703	I-CHEMICAL
>	O
SB	B-CHEMICAL
200646	I-CHEMICAL
>	O
pirenpirone	B-CHEMICAL
>	O
renzapride	B-CHEMICAL
.	O

DAU	B-CHEMICAL
6285	I-CHEMICAL
,	O
granisetron	B-CHEMICAL
,	O
spiperone	B-CHEMICAL
,	O
ketanserin	B-CHEMICAL
,	O
phentolamine	B-CHEMICAL
and	O
GR	B-CHEMICAL
127935	I-CHEMICAL
did	O
not	O
affect	O
responses	O
to	O
5	B-CHEMICAL
-	I-CHEMICAL
HT	I-CHEMICAL
at	O
concentrations	O
up	O
to	O
1	O
pM	O
.	O

The	O
agonist	O
and	O
concentration	O
independent	O
profile	O
of	O
antagonism	O
supported	O
a	O
single	O
site	O
interaction	O
for	O
both	O
agonists	O
and	O
antagonists	O
.	O
5	O
.	O

We	O
conclude	O
that	O
despite	O
small	O
differences	O
concerning	O
the	O
enantiomeric	O
selectivity	O
and	O
affinity	O
of	O
rauwolscine	B-CHEMICAL
and	O
yohimbine	B-CHEMICAL
,	O
the	O
close	O
pharmacological	O
identity	O
of	O
5	B-GENE-N
-	I-GENE-N
HT	I-GENE-N
receptors	I-GENE-N
in	O
rat	O
stomach	O
fundus	O
and	O
the	O
recently	O
cloned	O
5	B-GENE-Y
-	I-GENE-Y
HT2B	I-GENE-Y
receptor	O
is	O
maintained	O
.	O

SB	B-CHEMICAL
200646	I-CHEMICAL
,	O
which	O
demonstrates	O
some	O
selectivity	O
for	O
5	B-GENE-N
-	I-GENE-N
HT	I-GENE-N
receptors	I-GENE-N
in	O
rat	O
stomach	O
fundus	O
,	O
should	O
provide	O
a	O
useful	O
ligand	O
for	O
confirmation	O
of	O
this	O
view	O
and	O
allow	O
discrimination	O
of	O
5	B-GENE-Y
-	I-GENE-Y
HT2B	I-GENE-Y
function	O
both	O
in	O
vitro	O
and	O
in	O
vivo	O
.	O

Cefepime	B-CHEMICAL
:	O
overview	O
of	O
activity	O
in	O
vitro	O
and	O
in	O
vivo	O
.	O

Cefepime	B-CHEMICAL
is	O
a	O
novel	O
methoxyimino	B-CHEMICAL
-	I-CHEMICAL
aminothiazolyl	I-CHEMICAL
cephalosporin	I-CHEMICAL
with	O
a	O
quaternized	O
N	B-CHEMICAL
-	I-CHEMICAL
methyl	I-CHEMICAL
-	I-CHEMICAL
pyrrolidine	I-CHEMICAL
moiety	O
at	O
the	O
3	O
'	O
position	O
conferring	O
zwitterionic	O
properties	O
.	O

Because	O
of	O
this	O
the	O
molecule	O
penetrates	O
the	O
outer	O
cell	O
membrane	O
of	O
Gram	O
-	O
negative	O
bacteria	O
rapidly	O
.	O

In	O
addition	O
it	O
is	O
resistant	O
to	O
degradation	O
by	O
several	O
plasmid	O
and	O
chromosomally	O
-	O
mediated	O
beta	B-GENE-N
-	I-GENE-N
lactamases	I-GENE-N
,	O
for	O
which	O
it	O
also	O
shows	O
very	O
low	O
affinity	O
and	O
no	O
inducing	O
capacity	O
.	O

It	O
has	O
good	O
affinity	O
for	O
PBPs	B-GENE-N
2	I-GENE-N
and	I-GENE-N
3	I-GENE-N
of	O
Escherichia	O
coli	O
and	O
for	O
PBP	B-GENE-Y
3	I-GENE-Y
of	O
Pseudomonas	O
aeruginosa	O
.	O

Its	O
broad	O
-	O
spectrum	O
of	O
activity	O
includes	O
Gram	O
-	O
positive	O
and	O
Gram	O
-	O
negative	O
pathogens	O
.	O

It	O
is	O
more	O
active	O
than	O
cefotaxime	B-CHEMICAL
or	O
ceftazidime	B-CHEMICAL
,	O
against	O
Enterobacteriaceae	O
.	O

The	O
MIC90	O
for	O
P	O
.	O
aeruginosa	O
is	O
higher	O
than	O
that	O
of	O
ceftazidime	B-CHEMICAL
,	O
but	O
lower	O
than	O
those	O
of	O
cefpirome	B-CHEMICAL
,	O
cefoperazone	B-CHEMICAL
and	O
latamoxef	B-CHEMICAL
.	O

Other	O
Gram	O
-	O
negative	O
organisms	O
,	O
Haemophilus	O
influenzae	O
,	O
Neiserria	O
meningitidis	O
,	O
Neiserria	O
gonorrhoeae	O
,	O
Moraxella	O
catarrhalis	O
are	O
highly	O
susceptible	O
to	O
cefepime	B-CHEMICAL
.	O

Among	O
Gram	O
-	O
positive	O
species	O
methicillin	O
-	O
susceptible	O
Staphylococcus	O
aureus	O
and	O
coagulase	B-GENE-N
-	O
negative	O
staphylococci	O
,	O
whether	O
beta	B-GENE-N
-	I-GENE-N
lactamase	I-GENE-N
producers	O
or	O
not	O
,	O
Streptococcus	O
pneumoniae	O
and	O
Streptococcus	O
pyogenes	O
are	O
susceptible	O
.	O

Cefepime	B-CHEMICAL
is	O
active	O
against	O
cefotaxime	B-CHEMICAL
-	O
and	O
/	O
or	O
ceftazidime	B-CHEMICAL
-	O
resistant	O
Enterobacteriaceae	O
.	O

Only	O
strains	O
of	O
P	O
.	O
aeruginosa	O
producing	O
large	O
amounts	O
of	O
beta	B-GENE-N
-	I-GENE-N
lactamase	I-GENE-N
may	O
be	O
resistant	O
to	O
both	O
ceftazidime	B-CHEMICAL
and	O
cefepime	B-CHEMICAL
.	O

In	O
experimental	O
infections	O
such	O
as	O
meningitis	O
,	O
induced	O
with	O
various	O
bacterial	O
species	O
in	O
neonatal	O
rats	O
and	O
chronic	O
staphylococcal	O
osteomyelitis	O
in	O
rabbits	O
,	O
cefepime	B-CHEMICAL
has	O
shown	O
good	O
efficacy	O
.	O

Phorbol	O
esters	O
and	O
norepinephrine	B-CHEMICAL
destabilize	O
alpha	B-GENE-Y
1B	I-GENE-Y
-	I-GENE-Y
adrenergic	I-GENE-Y
receptor	I-GENE-Y
mRNA	O
in	O
vascular	O
smooth	O
muscle	O
cells	O
.	O

The	O
mechanism	O
by	O
which	O
norepinephrine	B-CHEMICAL
(	O
NE	B-CHEMICAL
)	O
down	O
-	O
regulates	O
alpha	B-GENE-Y
1B	I-GENE-Y
-	I-GENE-Y
adrenergic	I-GENE-Y
receptor	I-GENE-Y
(	O
alpha	B-GENE-N
-	I-GENE-N
AR	I-GENE-N
)	O
mRNA	O
was	O
studied	O
in	O
rabbit	O
aortic	O
smooth	O
muscle	O
cells	O
.	O

NE	B-CHEMICAL
,	O
phorbol	B-CHEMICAL
esters	I-CHEMICAL
,	O
and	O
bradykinin	B-GENE-Y
each	O
decreased	O
alpha	B-GENE-N
-	I-GENE-N
AR	I-GENE-N
mRNA	O
levels	O
by	O
70	O
-	O
80	O
%	O
.	O

The	O
protein	B-GENE-N
kinase	I-GENE-N
C	I-GENE-N
inhibitor	O
(	B-CHEMICAL
+	I-CHEMICAL
)	I-CHEMICAL
-	I-CHEMICAL
1	I-CHEMICAL
-	I-CHEMICAL
(	I-CHEMICAL
5	I-CHEMICAL
-	I-CHEMICAL
isoquinolinesulfonyl	I-CHEMICAL
)	I-CHEMICAL
-	I-CHEMICAL
2	I-CHEMICAL
-	I-CHEMICAL
methylpiperazine	I-CHEMICAL
dihydrochloride	I-CHEMICAL
(	O
H	B-CHEMICAL
-	I-CHEMICAL
7	I-CHEMICAL
)	O
abolished	O
the	O
effects	O
of	O
phorbol	B-CHEMICAL
esters	I-CHEMICAL
and	O
NE	B-CHEMICAL
and	O
decreased	O
basal	O
mRNA	O
levels	O
by	O
52	O
+	O
/	O
-	O
3	O
%	O
.	O

Neither	O
ryanodine	B-CHEMICAL
nor	O
EGTA	B-CHEMICAL
inhibited	O
down	O
-	O
regulation	O
of	O
alpha	B-GENE-N
-	I-GENE-N
AR	I-GENE-N
mRNA	O
by	O
NE	B-CHEMICAL
.	O

Actinomycin	B-CHEMICAL
D	I-CHEMICAL
caused	O
alpha	B-GENE-N
-	I-GENE-N
AR	I-GENE-N
mRNA	O
level	O
to	O
decrease	O
with	O
a	O
half	O
-	O
life	O
of	O
3	O
.	O
2	O
+	O
/	O
-	O
0	O
.	O
4	O
h	O
and	O
blocked	O
the	O
effect	O
of	O
H	B-CHEMICAL
-	I-CHEMICAL
7	I-CHEMICAL
to	O
decrease	O
basal	O
alpha	B-GENE-N
-	I-GENE-N
AR	I-GENE-N
mRNA	O
level	O
.	O

Both	O
NE	B-CHEMICAL
and	O
phorbol	B-CHEMICAL
esters	I-CHEMICAL
increased	O
the	O
rate	O
of	O
alpha	B-GENE-N
-	I-GENE-N
AR	I-GENE-N
mRNA	O
degradation	O
.	O

In	O
NE	B-CHEMICAL
-	O
desensitized	O
cells	O
,	O
phorbol	B-CHEMICAL
esters	I-CHEMICAL
and	O
bradykinin	B-GENE-Y
each	O
caused	O
the	O
expected	O
down	O
-	O
regulation	O
of	O
alpha	B-GENE-N
-	I-GENE-N
AR	I-GENE-N
mRNA	O
.	O

The	O
protein	B-GENE-N
phosphatase	I-GENE-N
inhibitor	O
okadaic	B-CHEMICAL
acid	I-CHEMICAL
prolonged	O
the	O
normally	O
transient	O
effect	O
of	O
NE	B-CHEMICAL
for	O
at	O
least	O
24	O
h	O
.	O

We	O
conclude	O
that	O
protein	B-GENE-N
kinase	I-GENE-N
C	I-GENE-N
exerts	O
two	O
opposing	O
effects	O
on	O
alpha	B-GENE-N
-	I-GENE-N
AR	I-GENE-N
mRNA	O
levels	O
,	O
1	O
)	O
a	O
decrease	O
in	O
the	O
stability	O
of	O
the	O
mRNA	O
that	O
requires	O
the	O
sustained	O
phosphorylation	O
of	O
a	O
protein	B-GENE-N
kinase	I-GENE-N
C	I-GENE-N
substrate	O
and	O
2	O
)	O
a	O
permissive	O
effect	O
on	O
alpha	B-GENE-N
-	I-GENE-N
AR	I-GENE-N
gene	O
transcription	O
.	O

Molecular	O
cloning	O
and	O
functional	O
expression	O
of	O
5	B-GENE-N
-	I-GENE-N
HT1E	I-GENE-N
-	O
like	O
rat	B-GENE-N
and	I-GENE-N
human	I-GENE-N
5	I-GENE-N
-	I-GENE-N
hydroxytryptamine	I-GENE-N
receptor	I-GENE-N
genes	O
.	O

Sequential	O
polymerase	O
chain	O
reaction	O
experiments	O
were	O
performed	O
to	O
amplify	O
a	O
unique	O
sequence	O
representing	O
a	O
guanine	B-GENE-N
nucleotide	I-GENE-N
-	I-GENE-N
binding	I-GENE-N
protein	I-GENE-N
(	I-GENE-N
G	I-GENE-N
-	I-GENE-N
protein	I-GENE-N
)	I-GENE-N
-	I-GENE-N
coupled	I-GENE-N
receptor	I-GENE-N
from	O
rat	O
hypothalamic	O
cDNA	O
.	O

Degenerate	O
oligonucleotides	B-CHEMICAL
corresponding	O
to	O
conserved	O
amino	B-CHEMICAL
acids	I-CHEMICAL
from	O
transmembrane	O
domains	O
III	O
,	O
V	O
,	O
and	O
VI	O
of	O
known	O
receptors	O
[	O
5	B-GENE-Y
-	I-GENE-Y
HT1A	I-GENE-Y
,	O
5	B-GENE-Y
-	I-GENE-Y
HT1C	I-GENE-Y
,	O
and	O
5	B-GENE-Y
-	I-GENE-Y
HT2	I-GENE-Y
;	O
5	B-CHEMICAL
-	I-CHEMICAL
HT	I-CHEMICAL
is	O
serotonin	B-CHEMICAL
(	O
5	B-CHEMICAL
-	I-CHEMICAL
hydroxytryptamine	I-CHEMICAL
)	O
]	O
were	O
used	O
as	O
primers	O
for	O
the	O
sequential	O
reactions	O
.	O

The	O
resulting	O
product	O
was	O
subcloned	O
and	O
used	O
to	O
screen	O
a	O
rat	O
genomic	O
library	O
to	O
identify	O
a	O
full	O
-	O
length	O
clone	O
(	O
MR77	B-GENE-Y
)	O
containing	O
an	O
intronless	B-GENE-N
open	I-GENE-N
reading	I-GENE-N
frame	I-GENE-N
encoding	O
a	O
366	B-GENE-N
-	I-GENE-N
amino	I-GENE-N
acid	I-GENE-N
seven	I-GENE-N
-	I-GENE-N
transmembrane	I-GENE-N
domain	I-GENE-N
protein	I-GENE-N
.	O

The	O
human	O
homolog	O
was	O
isolated	O
,	O
and	O
its	O
encoded	O
protein	O
had	O
93	O
%	O
overall	O
amino	B-CHEMICAL
acid	I-CHEMICAL
identity	O
with	O
the	O
rat	O
sequence	O
.	O

Within	O
the	O
conserved	O
transmembrane	O
domains	O
,	O
the	O
sequences	O
exhibit	O
approximately	O
52	O
%	O
,	O
59	O
%	O
,	O
65	O
%	O
,	O
and	O
68	O
%	O
amino	B-CHEMICAL
acid	I-CHEMICAL
identity	O
with	O
the	O
known	O
rat	B-GENE-Y
5	I-GENE-Y
-	I-GENE-Y
HT1A	I-GENE-Y
,	O
rat	B-GENE-Y
5	I-GENE-Y
-	I-GENE-Y
HT1B	I-GENE-Y
,	O
rat	B-GENE-Y
5	I-GENE-Y
-	I-GENE-Y
HT1D	I-GENE-Y
,	O
and	O
human	B-GENE-Y
5	I-GENE-Y
-	I-GENE-Y
HT1E	I-GENE-Y
receptors	O
,	O
respectively	O
.	O

MR77	B-GENE-Y
was	O
subcloned	O
into	O
a	O
eukaryotic	O
expression	O
vector	O
system	O
and	O
expressed	O
in	O
CosM6	O
cells	O
.	O

Studies	O
on	O
broken	O
cell	O
preparations	O
indicate	O
that	O
the	O
expressed	O
receptor	O
exhibits	O
125I	B-CHEMICAL
-	I-CHEMICAL
labeled	I-CHEMICAL
d	I-CHEMICAL
-	I-CHEMICAL
lysergic	I-CHEMICAL
acid	I-CHEMICAL
diethylamide	I-CHEMICAL
(	O
LSD	B-CHEMICAL
)	O
binding	O
that	O
can	O
be	O
displaced	O
by	O
serotonin	B-CHEMICAL
but	O
not	O
by	O
other	O
biogenic	O
amines	B-CHEMICAL
.	O

The	O
specific	O
binding	O
is	O
displaced	O
by	O
the	O
selective	O
5	B-GENE-Y
-	I-GENE-Y
HT1D	I-GENE-Y
agonist	O
sumatriptan	B-CHEMICAL
but	O
not	O
by	O
the	O
mixed	O
5	B-GENE-N
-	I-GENE-N
HT1A	I-GENE-N
/	I-GENE-N
1D	I-GENE-N
agonist	O
5	B-CHEMICAL
-	I-CHEMICAL
carboxyamidotryptamine	I-CHEMICAL
.	O

125I	B-CHEMICAL
-	I-CHEMICAL
labeled	I-CHEMICAL
LSD	I-CHEMICAL
binding	O
was	O
competitively	O
antagonized	O
by	O
the	O
ergot	O
alkaloids	O
methysergide	B-CHEMICAL
and	O
ergotamine	B-CHEMICAL
.	O

HeLa	O
cells	O
transfected	O
with	O
the	O
MR77	B-GENE-Y
gene	O
exhibited	O
inhibition	O
of	O
adenylate	B-GENE-N
cyclase	I-GENE-N
in	O
response	O
to	O
serotonin	B-CHEMICAL
.	O

MR77	B-GENE-Y
is	O
expressed	O
at	O
low	O
levels	O
throughout	O
the	O
brain	O
,	O
with	O
the	O
greatest	O
expression	O
in	O
the	O
cortex	O
,	O
hippocampus	O
,	O
and	O
striatum	O
.	O

MR77	B-GENE-Y
thus	O
represents	O
a	O
5	B-GENE-N
-	I-GENE-N
HT	I-GENE-N
receptor	I-GENE-N
of	O
the	O
5	B-GENE-N
-	I-GENE-N
HT1	I-GENE-N
class	O
,	O
and	O
we	O
propose	O
that	O
,	O
based	O
on	O
the	O
pharmacological	O
characterization	O
,	O
MR77	B-GENE-Y
represents	O
an	O
additional	O
5	B-GENE-Y
-	I-GENE-Y
HT1E	I-GENE-Y
-	O
like	O
receptor	O
.	O

Response	O
of	O
nonreentrant	O
catecholamine	B-CHEMICAL
-	O
mediated	O
ventricular	O
tachycardia	O
to	O
endogenous	O
adenosine	B-CHEMICAL
and	O
acetylcholine	B-CHEMICAL
.	O

Evidence	O
for	O
myocardial	O
receptor	O
-	O
mediated	O
effects	O
.	O

BACKGROUND	O
:	O
Reentrant	O
ventricular	O
tachycardia	O
(	O
VT	O
)	O
is	O
known	O
to	O
be	O
insensitive	O
to	O
the	O
nucleoside	B-CHEMICAL
adenosine	B-CHEMICAL
.	O

However	O
,	O
we	O
have	O
previously	O
identified	O
a	O
form	O
of	O
nonreentrant	O
,	O
catecholamine	B-CHEMICAL
-	O
mediated	O
VT	O
that	O
can	O
be	O
initiated	O
with	O
rapid	O
pacing	O
,	O
demonstrates	O
cycle	O
length	O
dependence	O
,	O
and	O
is	O
sensitive	O
to	O
exogenous	O
adenosine	B-CHEMICAL
as	O
well	O
as	O
to	O
the	O
Valsalva	O
maneuver	O
.	O

The	O
mechanism	O
of	O
this	O
tachycardia	O
is	O
thought	O
to	O
be	O
due	O
to	O
a	O
catecholamine	B-CHEMICAL
-	O
induced	O
,	O
cAMP	B-CHEMICAL
-	O
mediated	O
increase	O
in	O
intracellular	O
calcium	B-CHEMICAL
,	O
resulting	O
in	O
delayed	O
afterdepolarizations	O
and	O
triggered	O
activity	O
.	O

The	O
antiarrhythmic	O
effects	O
of	O
exogenous	O
adenosine	B-CHEMICAL
and	O
Valsalva	O
on	O
this	O
form	O
of	O
VT	O
may	O
be	O
due	O
to	O
receptor	O
-	O
mediated	O
inhibition	O
of	O
adenylate	B-GENE-N
cyclase	I-GENE-N
or	O
to	O
noncardiac	O
receptor	O
-	O
mediated	O
effects	O
,	O
i	O
.	O
e	O
.	O
,	O
exogenous	O
adenosine	B-CHEMICAL
may	O
modulate	O
VT	O
through	O
alterations	O
in	O
autonomic	O
tone	O
by	O
activation	O
of	O
arterial	O
chemoreceptors	B-GENE-N
,	O
and	O
Valsalva	O
has	O
been	O
shown	O
to	O
decrease	O
venous	O
return	O
,	O
resulting	O
in	O
a	O
reduction	O
in	O
cardiac	O
dimensions	O
and	O
myocardial	O
stretch	O
.	O

To	O
clarify	O
this	O
issue	O
and	O
circumvent	O
both	O
autonomic	O
and	O
noncardiac	O
receptor	O
effects	O
,	O
the	O
response	O
of	O
nonreentrant	O
catecholamine	B-CHEMICAL
-	O
mediated	O
VT	O
to	O
endogenous	O
adenosine	B-CHEMICAL
and	O
acetylcholine	B-CHEMICAL
was	O
evaluated	O
.	O

METHODS	O
AND	O
RESULTS	O
:	O
Group	O
1	O
(	O
n	O
=	O
8	O
)	O
:	O
Dipyridamole	B-CHEMICAL
(	O
0	O
.	O
56	O
mg	O
/	O
kg	O
i	O
.	O
v	O
.	O
)	O
,	O
a	O
nucleoside	B-CHEMICAL
transport	O
blocker	O
that	O
potentiates	O
the	O
effects	O
of	O
endogenous	O
adenosine	B-CHEMICAL
,	O
reproducibly	O
abolished	O
sustained	O
nonreentrant	O
,	O
nonautomatic	O
,	O
catecholamine	B-CHEMICAL
-	O
mediated	O
VT	O
in	O
the	O
five	O
patients	O
in	O
whom	O
it	O
was	O
evaluated	O
.	O

VT	O
recurred	O
with	O
the	O
addition	O
of	O
aminophylline	B-CHEMICAL
,	O
a	O
competitive	B-CHEMICAL
adenosine	B-GENE-Y
A1	I-GENE-Y
-	I-GENE-Y
receptor	I-GENE-Y
antagonist	O
.	O

Edrophonium	B-CHEMICAL
(	O
10	O
mg	O
i	O
.	O
v	O
.	O
)	O
,	O
a	O
cholinesterase	B-GENE-Y
inhibitor	O
that	O
potentiates	O
the	O
effects	O
of	O
acetylcholine	B-CHEMICAL
at	O
the	O
muscarinic	B-GENE-N
cholinergic	I-GENE-N
receptor	I-GENE-N
,	O
terminated	O
VT	O
in	O
four	O
of	O
four	O
patients	O
,	O
an	O
effect	O
that	O
was	O
reversed	O
by	O
atropine	B-CHEMICAL
.	O

Group	O
2	O
(	O
n	O
=	O
6	O
)	O
:	O
In	O
patients	O
with	O
reentrant	O
VT	O
,	O
dipyridamole	B-CHEMICAL
and	O
edrophonium	B-CHEMICAL
had	O
no	O
effect	O
on	O
VT	O
cycle	O
length	O
or	O
duration	O
.	O

Group	O
3	O
(	O
n	O
=	O
4	O
)	O
:	O
Adenosine	B-CHEMICAL
and	O
vagal	O
maneuvers	O
had	O
no	O
effect	O
on	O
catecholamine	B-CHEMICAL
-	O
mediated	O
VT	O
caused	O
by	O
automaticity	O
in	O
three	O
of	O
four	O
patients	O
tested	O
.	O

In	O
one	O
patient	O
,	O
adenosine	B-CHEMICAL
transiently	O
suppressed	O
VT	O
(	O
<	O
5	O
seconds	O
)	O
,	O
after	O
which	O
it	O
spontaneously	O
resumed	O
.	O

CONCLUSIONS	O
:	O
The	O
results	O
of	O
this	O
study	O
further	O
delineate	O
the	O
mechanism	O
of	O
a	O
newly	O
recognized	O
form	O
of	O
clinical	O
VT	O
.	O

It	O
can	O
be	O
identified	O
by	O
termination	O
of	O
the	O
tachycardia	O
in	O
response	O
to	O
activation	O
of	O
the	O
adenosine	B-GENE-Y
A1	I-GENE-Y
or	O
muscarinic	B-GENE-N
cholinergic	I-GENE-N
receptor	I-GENE-N
,	O
which	O
results	O
in	O
inhibition	O
of	O
adenylate	B-GENE-N
cyclase	I-GENE-N
.	O

These	O
receptor	O
-	O
mediated	O
effects	O
appear	O
to	O
be	O
specific	O
for	O
identifying	O
nonreentrant	O
,	O
nonautomatic	O
,	O
catecholamine	B-CHEMICAL
-	O
mediated	O
VT	O
.	O

Amantadine	B-CHEMICAL
induces	O
c	B-GENE-Y
-	I-GENE-Y
fos	I-GENE-Y
in	O
rat	O
striatum	O
:	O
reversal	O
with	O
dopamine	B-GENE-Y
D1	I-GENE-Y
and	O
NMDA	B-GENE-N
receptor	I-GENE-N
antagonists	O
.	O

Amantadine	B-CHEMICAL
(	O
1	B-CHEMICAL
-	I-CHEMICAL
aminoadamantane	I-CHEMICAL
)	O
induced	O
Fos	B-GENE-Y
expression	O
in	O
the	O
central	O
,	O
dorsal	O
-	O
medial	O
and	O
ventral	O
-	O
medial	O
part	O
of	O
the	O
striatum	O
.	O

The	O
distribution	O
pattern	O
of	O
Fos	B-GENE-Y
induced	O
by	O
amantadine	B-CHEMICAL
was	O
more	O
similar	O
to	O
those	O
seen	O
with	O
dopaminomimetics	O
than	O
with	O
N	B-GENE-N
-	I-GENE-N
methyl	I-GENE-N
-	I-GENE-N
D	I-GENE-N
-	I-GENE-N
aspartate	I-GENE-N
(	I-GENE-N
NMDA	I-GENE-N
)	I-GENE-N
receptor	I-GENE-N
antagonists	O
.	O

Pretreatment	O
with	O
the	O
dopamine	B-GENE-Y
D1	I-GENE-Y
receptor	I-GENE-Y
antagonist	O
,	O
SCH23390	B-CHEMICAL
,	O
and	O
the	O
NMDA	B-GENE-N
receptor	I-GENE-N
antagonist	O
,	O
MK	B-CHEMICAL
-	I-CHEMICAL
801	I-CHEMICAL
,	O
blocked	O
amantadine	B-CHEMICAL
induction	O
of	O
Fos	B-GENE-Y
in	O
the	O
striatum	O
.	O

However	O
,	O
amantadine	B-CHEMICAL
induction	O
of	O
Fos	B-GENE-Y
in	O
the	O
striatum	O
was	O
unaffected	O
by	O
the	O
dopamine	B-GENE-Y
D2	I-GENE-Y
receptor	I-GENE-Y
antagonist	O
,	O
sulpiride	B-CHEMICAL
.	O

These	O
results	O
suggest	O
that	O
amantadine	B-CHEMICAL
induction	O
of	O
Fos	B-GENE-Y
in	O
the	O
rat	O
striatum	O
is	O
related	O
to	O
dopamine	B-GENE-Y
D1	I-GENE-Y
and	O
NMDA	B-GENE-N
receptors	I-GENE-N
.	O

[	O
Inactivated	B-GENE-Y
factor	I-GENE-Y
VII	I-GENE-Y
exercises	O
a	O
powerful	O
antithrombotic	O
activity	O
in	O
an	O
experimental	O
model	O
of	O
recurrent	O
arterial	O
thrombosis	O
]	O
.	O

The	O
extrinsic	O
coagulation	O
pathway	O
is	O
activated	O
when	O
tissue	B-GENE-Y
factor	I-GENE-Y
(	O
TF	B-GENE-Y
)	O
is	O
exposed	O
as	O
a	O
consequence	O
of	O
arterial	O
damage	O
.	O

TF	B-GENE-Y
binds	O
to	O
factor	B-GENE-Y
VII	I-GENE-Y
(	O
FVII	B-GENE-Y
)	O
or	O
activated	B-GENE-Y
FVII	I-GENE-Y
(	O
FVIIa	B-GENE-Y
)	O
,	O
generating	O
a	O
complex	O
that	O
activates	O
both	O
FX	B-GENE-Y
and	O
FIX	B-GENE-Y
,	O
ultimately	O
leading	O
to	O
thrombin	B-GENE-Y
formation	O
.	O

To	O
determine	O
whether	O
inhibition	O
of	O
FVII	B-GENE-Y
binding	O
to	O
TF	B-GENE-Y
would	O
result	O
in	O
antithrombotic	O
effects	O
,	O
active	B-GENE-Y
site	I-GENE-Y
-	I-GENE-Y
blocked	I-GENE-Y
FVIIa	I-GENE-Y
(	O
FVIIai	B-GENE-Y
)	O
was	O
used	O
in	O
a	O
rabbit	O
model	O
of	O
intravascular	O
thrombus	O
formation	O
.	O

In	O
addition	O
,	O
to	O
study	O
the	O
interaction	O
between	O
extrinsic	O
coagulation	O
pathway	O
activation	O
and	O
platelet	O
aggregation	O
,	O
in	O
the	O
same	O
model	O
of	O
intravascular	O
thrombus	O
formation	O
,	O
recombinant	O
human	B-GENE-Y
FVIIa	I-GENE-Y
was	O
administered	O
in	O
antiplatelet	O
-	O
treated	O
rabbits	O
.	O

Cyclic	O
flow	O
variations	O
(	O
CFVs	O
)	O
,	O
due	O
to	O
recurrent	O
thrombus	O
formation	O
,	O
were	O
initiated	O
by	O
placing	O
an	O
external	O
constrictor	O
around	O
the	O
endothelially	O
-	O
injured	O
rabbit	O
carotid	O
arteries	O
(	O
Folt	O
'	O
s	O
model	O
)	O
.	O

Carotid	O
blood	O
flow	O
was	O
measured	O
continuously	O
by	O
a	O
Doppler	O
flow	O
probe	O
placed	O
proximally	O
to	O
the	O
constrictor	O
.	O

CFVs	O
were	O
induced	O
in	O
29	O
New	O
Zealand	O
White	O
rabbits	O
.	O

After	O
CFVs	O
were	O
observed	O
for	O
30	O
min	O
,	O
the	O
animals	O
were	O
randomly	O
divided	O
in	O
four	O
groups	O
:	O
5	O
animals	O
received	O
via	O
a	O
small	O
catheter	O
(	O
26G	O
)	O
placed	O
proximally	O
to	O
the	O
stenosis	O
,	O
an	O
intra	O
-	O
arterial	O
infusion	O
of	O
human	B-GENE-Y
recombinant	I-GENE-Y
FVIIai	I-GENE-Y
(	O
0	O
.	O
1	O
mg	O
/	O
kg	O
/	O
min	O
for	O
10	O
min	O
)	O
;	O
9	O
animals	O
received	O
AP	O
-	O
1	O
,	O
a	O
monoclonal	O
antibody	O
against	O
rabbit	B-GENE-Y
TF	I-GENE-Y
(	O
0	O
.	O
1	O
mg	O
/	O
kg	O
i	O
.	O
v	O
.	O
bolus	O
)	O
;	O
7	O
animals	O
received	O
ridogrel	O
,	O
a	O
dual	O
thromboxane	B-GENE-Y
A2	I-GENE-Y
synthetase	I-GENE-Y
inhibitor	O
and	O
thromboxane	B-GENE-Y
A2	I-GENE-Y
receptor	I-GENE-Y
antagonist	O
(	O
10	O
mg	O
/	O
kg	O
i	O
.	O
v	O
.	O
bolus	O
)	O
;	O
finally	O
,	O
8	O
rabbits	O
received	O
aurintrycarboxilic	B-CHEMICAL
acid	I-CHEMICAL
(	O
ATA	B-CHEMICAL
)	O
,	O
an	O
inhibitor	O
of	O
platelet	O
glycoprotein	B-GENE-N
Ib	I-GENE-N
/	O
von	B-GENE-Y
Willebrand	I-GENE-Y
factor	I-GENE-Y
interaction	O
(	O
10	O
mg	O
/	O
kg	O
i	O
.	O
v	O
.	O
bolus	O
)	O
.	O

FVIIai	B-GENE-Y
abolished	O
CFVs	O
in	O
5	O
of	O
5	O
animals	O
(	O
CFV	O
frequency	O
minutes	O
0	O
cycles	O
/	O
hour	O
;	O
p	O
<	O
0	O
.	O
05	O
;	O
carotid	O
blood	O
flow	O
velocity	O
minutes	O
106	O
+	O
/	O
-	O
9	O
%	O
of	O
the	O
baseline	O
values	O
;	O
NS	O
vs	O
baseline	O
)	O
.	O

AP	O
-	O
1	O
abolished	O
CFVs	O
in	O
7	O
of	O
9	O
animals	O
(	O
CFV	O
frequency	O
minutes	O
0	O
cycles	O
/	O
hour	O
;	O
p	O
<	O
0	O
.	O
05	O
;	O
carotid	O
blood	O
flow	O
velocity	O
minutes	O
58	O
+	O
/	O
-	O
35	O
%	O
of	O
the	O
baseline	O
values	O
;	O
NS	O
vs	O
baseline	O
)	O
.	O

Finally	O
,	O
in	O
all	O
the	O
animals	O
receiving	O
ridogrel	O
or	O
ATA	B-CHEMICAL
CFVs	O
were	O
abolished	O
(	O
CFV	O
frequency	O
0	O
cycles	O
/	O
hour	O
;	O
p	O
<	O
0	O
.	O
05	O
in	O
both	O
groups	O
;	O
carotid	O
blood	O
flow	O
velocity	O
,	O
respectively	O
62	O
+	O
/	O
-	O
32	O
and	O
66	O
+	O
/	O
-	O
40	O
%	O
of	O
the	O
baseline	O
values	O
;	O
NS	O
vs	O
baseline	O
in	O
both	O
groups	O
)	O
.	O

Thirty	O
minutes	O
following	O
inhibition	O
of	O
CFVs	O
,	O
in	O
the	O
FVIIai	B-GENE-Y
treated	O
rabbits	O
,	O
human	B-GENE-Y
recombinant	I-GENE-Y
FVIIa	I-GENE-Y
was	O
infused	O
,	O
via	O
the	O
small	O
catheter	O
placed	O
proximally	O
to	O
the	O
stenosis	O
,	O
at	O
the	O
dose	O
of	O
0	O
.	O
1	O
mg	O
/	O
kg	O
/	O
min	O
for	O
10	O
min	O
.	O

In	O
the	O
other	O
three	O
groups	O
,	O
FVIIa	B-GENE-Y
,	O
at	O
the	O
same	O
dose	O
,	O
was	O
infused	O
i	O
.	O
v	O
.	O
Infusion	O
of	O
FVIIa	B-GENE-Y
restored	O
CFVs	O
in	O
all	O
FVIIai	B-GENE-Y
treated	O
animals	O
and	O
in	O
6	O
of	O
7	O
AP	O
-	O
1	O
treated	O
animals	O
,	O
thus	O
indicating	O
that	O
AP	O
-	O
1	O
and	O
FVIIai	B-GENE-Y
bindings	O
to	O
TF	B-GENE-Y
was	O
competitive	O
and	O
was	O
replaced	O
by	O
FVIIa	B-GENE-Y
.	O

Infusion	O
of	O
FVIIa	B-GENE-Y
failed	O
to	O
restore	O
CFVs	O
in	O
ridogrel	O
e	O
ATA	B-CHEMICAL
treated	O
rabbits	O
(	O
1	O
of	O
7	O
and	O
0	O
of	O
8	O
rabbits	O
,	O
respectively	O
)	O
,	O
showing	O
that	O
activation	O
of	O
extrinsic	O
coagulation	O
by	O
FVIIa	B-GENE-Y
was	O
overcome	O
by	O
inhibition	O
of	O
platelet	O
function	O
.	O

Activated	O
partial	O
thromboplastin	O
time	O
,	O
and	O
ex	O
vivo	O
platelet	O
aggregation	O
in	O
response	O
to	O
ADP	B-CHEMICAL
and	O
thrombin	B-GENE-Y
,	O
were	O
not	O
different	O
after	O
FVIIai	B-GENE-Y
infusion	O
,	O
while	O
prothrombin	O
time	O
was	O
slightly	O
but	O
significantly	O
prolonged	O
as	O
compared	O
to	O
baseline	O
values	O
.	O

Thus	O
,	O
FVII	B-GENE-N
-	I-GENE-N
VIIa	I-GENE-N
plays	O
an	O
important	O
role	O
in	O
initiating	O
thrombus	O
formation	O
in	O
vivo	O
.	O

Administration	O
of	O
FVIIai	B-GENE-Y
exerts	O
a	O
potent	O
antithrombotic	O
effects	O
in	O
this	O
model	O
without	O
affecting	O
systemic	O
coagulation	O
.	O

In	O
addition	O
,	O
in	O
this	O
model	O
platelets	O
exert	O
an	O
important	O
role	O
in	O
arterial	O
thrombosis	O
,	O
since	O
in	O
the	O
presence	O
of	O
inhibition	O
of	O
platelet	O
function	O
,	O
activation	O
of	O
the	O
extrinsic	O
coagulation	O
pathway	O
failed	O
to	O
restore	O
thrombus	O
formation	O
.	O

Norepinephrine	B-GENE-Y
transporters	I-GENE-Y
have	O
channel	O
modes	O
of	O
conduction	O
.	O

Neurotransmitter	B-GENE-N
transporters	I-GENE-N
couple	O
to	O
existing	O
ion	O
gradients	O
to	O
achieve	O
reuptake	O
of	O
transmitter	O
into	O
presynaptic	O
terminals	O
.	O

For	O
coupled	O
cotransport	O
,	O
substrates	O
and	O
ions	O
cross	O
the	O
membrane	O
in	O
fixed	O
stoichiometry	O
.	O

This	O
is	O
in	O
contrast	O
to	O
ion	B-GENE-N
channels	I-GENE-N
,	O
which	O
carry	O
an	O
arbitrary	O
number	O
of	O
ions	O
depending	O
on	O
the	O
channel	O
open	O
time	O
.	O

Members	O
of	O
the	O
gamma	B-GENE-N
-	I-GENE-N
aminobutyric	I-GENE-N
acid	I-GENE-N
transporter	I-GENE-N
gene	O
family	O
presumably	O
function	O
with	O
fixed	O
stoichiometry	O
in	O
which	O
a	O
set	O
number	O
of	O
ions	O
cotransport	O
with	O
one	O
transmitter	O
molecule	O
.	O

Here	O
we	O
report	O
channel	O
-	O
like	O
events	O
from	O
a	O
presumably	O
fixed	O
stoichiometry	O
[	O
norepinephrine	B-CHEMICAL
(	O
NE	B-CHEMICAL
)	O
+	O
,	O
Na	B-CHEMICAL
+	I-CHEMICAL
,	O
and	O
Cl	B-CHEMICAL
-	I-CHEMICAL
]	O
,	O
human	O
NE	B-CHEMICAL
(	O
hNET	B-GENE-Y
)	O
in	O
the	O
gamma	B-GENE-N
-	I-GENE-N
aminobutyric	I-GENE-N
acid	I-GENE-N
transporter	I-GENE-N
gene	O
family	O
.	O

These	O
events	O
are	O
stimulated	O
by	O
NE	B-CHEMICAL
and	O
by	O
guanethidine	B-CHEMICAL
,	O
an	O
hNET	B-GENE-Y
substrate	O
,	O
and	O
they	O
are	O
blocked	O
by	O
cocaine	B-CHEMICAL
and	O
the	O
antidepressant	O
desipramine	B-CHEMICAL
.	O

Voltage	O
-	O
clamp	O
data	O
combined	O
with	O
NE	B-CHEMICAL
uptake	O
data	O
from	O
these	O
same	O
cells	O
indicate	O
that	O
hNETs	B-GENE-Y
have	O
two	O
functional	O
modes	O
of	O
conduction	O
:	O
a	O
classical	O
transporter	O
mode	O
(	O
T	O
-	O
mode	O
)	O
and	O
a	O
novel	O
channel	O
mode	O
(	O
C	O
-	O
mode	O
)	O
.	O

Both	O
T	O
-	O
mode	O
and	O
C	O
-	O
mode	O
are	O
gated	O
by	O
the	O
same	O
substrates	O
and	O
antagonized	O
by	O
the	O
same	O
blockers	O
.	O

T	O
-	O
mode	O
is	O
putatively	O
electrogenic	O
because	O
the	O
transmitter	O
and	O
cotransported	O
ions	O
sum	O
to	O
one	O
net	O
charge	O
.	O

However	O
,	O
C	O
-	O
mode	O
carries	O
virtually	O
all	O
of	O
the	O
transmitter	O
-	O
induced	O
current	O
,	O
even	O
though	O
it	O
occurs	O
with	O
low	O
probability	O
.	O

This	O
is	O
because	O
each	O
C	O
-	O
mode	O
opening	O
transports	O
hundreds	O
of	O
charges	O
per	O
event	O
.	O

The	O
existence	O
of	O
a	O
channel	O
mode	O
of	O
conduction	O
in	O
a	O
previously	O
established	O
fixed	O
-	O
stoichiometry	O
transporter	O
suggests	O
the	O
appearance	O
of	O
an	O
aqueous	O
pore	O
through	O
the	O
transporter	O
protein	O
during	O
the	O
transport	O
cycle	O
and	O
may	O
have	O
significance	O
for	O
transporter	O
regulation	O
.	O

Mineralocorticoids	O
,	O
salt	O
,	O
hypertension	O
:	O
effects	O
on	O
the	O
heart	O
.	O

In	O
uninephrectomized	O
rats	O
on	O
1	O
%	O
NaCl	B-CHEMICAL
solution	O
to	O
drink	O
,	O
aldosterone	B-CHEMICAL
(	O
0	O
.	O
75	O
micrograms	O
/	O
h	O
subcutaneously	O
for	O
8	O
weeks	O
)	O
raises	O
blood	O
pressure	O
and	O
causes	O
marked	O
interstitial	O
and	O
perivascular	O
cardiac	O
fibrosis	O
,	O
effects	O
not	O
seen	O
in	O
animals	O
on	O
a	O
low	O
salt	O
intake	O
.	O

In	O
extending	O
these	O
initial	O
findings	O
,	O
we	O
have	O
shown	O
that	O
cardiac	O
fibrosis	O
(	O
i	O
)	O
is	O
not	O
reversed	O
by	O
correction	O
of	O
mineralocorticoid	O
-	O
induced	O
hypokalemia	O
;	O
(	O
ii	O
)	O
appears	O
not	O
to	O
involve	O
the	O
plasma	O
or	O
tissue	O
renin	B-GENE-Y
-	O
angiotensin	B-CHEMICAL
systems	O
,	O
as	O
fibrosis	O
is	O
largely	O
unaffected	O
by	O
concurrent	O
administration	O
of	O
Losartan	B-CHEMICAL
or	O
Perindopril	B-CHEMICAL
;	O
(	O
iii	O
)	O
is	O
independent	O
of	O
cardiac	O
hypertrophy	O
,	O
in	O
that	O
it	O
is	O
equally	O
seen	O
in	O
right	O
and	O
left	O
ventricles	O
,	O
and	O
in	O
rats	O
rendered	O
hypertensive	O
without	O
cardiac	O
hypertrophy	O
by	O
the	O
administration	O
of	O
9	B-CHEMICAL
alpha	I-CHEMICAL
-	I-CHEMICAL
fluorocortisol	I-CHEMICAL
;	O
(	O
iv	O
)	O
is	O
independent	O
of	O
elevated	O
blood	O
pressure	O
,	O
in	O
that	O
it	O
is	O
found	O
in	O
normotensive	O
animals	O
infused	O
peripherally	O
with	O
aldosterone	B-CHEMICAL
and	O
intracerebroventricularly	O
with	O
the	O
mineralocorticoid	B-GENE-Y
receptor	I-GENE-Y
(	O
MR	B-GENE-Y
)	O
antagonist	O
RU28318	B-CHEMICAL
;	O
(	O
v	O
)	O
is	O
via	O
classical	O
MR	B-GENE-Y
,	O
in	O
that	O
it	O
is	O
blocked	O
by	O
concurrent	O
administration	O
of	O
the	O
MR	B-GENE-Y
antagonist	O
potassium	B-CHEMICAL
canrenoate	I-CHEMICAL
;	O
and	O
(	O
vi	O
)	O
may	O
or	O
may	O
not	O
be	O
a	O
direct	O
cardiac	O
effect	O
,	O
inasmuch	O
as	O
data	O
for	O
in	O
vivo	O
effects	O
on	O
collagen	B-GENE-N
formation	O
by	O
cardiac	O
fibroblasts	O
are	O
conflicting	O
.	O

Although	O
there	O
is	O
a	O
high	O
probability	O
that	O
the	O
action	O
of	O
aldosterone	B-CHEMICAL
to	O
cause	O
cardiac	O
fibrosis	O
in	O
this	O
experimental	O
model	O
is	O
an	O
effect	O
via	O
non	O
-	O
epithelial	O
MR	B-GENE-Y
,	O
the	O
locus	O
of	O
aldosterone	B-CHEMICAL
action	O
remains	O
to	O
be	O
established	O
,	O
as	O
do	O
the	O
molecular	O
mechanisms	O
linking	O
MR	B-GENE-Y
occupancy	O
by	O
aldosterone	B-CHEMICAL
and	O
collagen	O
deposition	O
.	O

In	O
addition	O
,	O
and	O
in	O
particular	O
,	O
the	O
mechanisms	O
underlying	O
the	O
crucial	O
contribution	O
of	O
high	O
salt	O
intake	O
in	O
this	O
model	O
of	O
mineralocorticoid	O
excess	O
await	O
exploration	O
.	O

Amezinium	B-CHEMICAL
and	O
debrisoquine	B-CHEMICAL
are	O
substrates	O
of	O
uptake1	B-GENE-N
and	O
potent	O
inhibitors	O
of	O
monoamine	B-GENE-N
oxidase	I-GENE-N
in	O
perfused	O
lungs	O
of	O
rats	O
.	O

Previous	O
studies	O
have	O
resulted	O
in	O
the	O
classification	O
of	O
amezinium	B-CHEMICAL
as	O
a	O
selective	O
inhibitor	O
of	O
neuronal	O
monoamine	B-GENE-N
oxidase	I-GENE-N
(	O
MAO	B-GENE-N
)	O
,	O
because	O
it	O
is	O
a	O
much	O
more	O
potent	O
MAO	B-GENE-N
inhibitor	O
in	O
intact	O
tissues	O
,	O
in	O
which	O
it	O
is	O
accumulated	O
in	O
noradrenergic	O
neurones	O
by	O
uptake1	O
,	O
than	O
in	O
tissue	O
homogenates	O
.	O

In	O
the	O
present	O
study	O
,	O
the	O
effects	O
of	O
amezinium	B-CHEMICAL
on	O
the	O
deamination	O
of	O
noradrenaline	B-CHEMICAL
were	O
investigated	O
in	O
intact	O
lungs	O
of	O
rats	O
,	O
since	O
the	O
pulmonary	O
endothelial	O
cells	O
are	O
a	O
site	O
where	O
the	O
catecholamine	B-CHEMICAL
transporter	O
is	O
non	O
-	O
neuronal	O
uptake1	B-GENE-N
.	O

In	O
addition	O
,	O
another	O
drug	O
that	O
is	O
both	O
a	O
substrate	O
of	O
uptake1	B-GENE-N
and	O
a	O
MAO	B-GENE-N
inhibitor	O
,	O
debrisoquine	B-CHEMICAL
,	O
was	O
investigated	O
in	O
the	O
study	O
.	O

The	O
first	O
aim	O
of	O
the	O
study	O
was	O
to	O
show	O
whether	O
amezinium	B-CHEMICAL
and	O
debrisoquine	B-CHEMICAL
are	O
substrates	O
of	O
uptake1	B-GENE-N
in	O
rat	O
lungs	O
.	O

After	O
loading	O
of	O
isolated	O
perfused	O
lungs	O
with	O
3H	B-CHEMICAL
-	I-CHEMICAL
noradrenaline	I-CHEMICAL
(	O
MAO	B-GENE-N
and	O
catechol	B-GENE-Y
-	I-GENE-Y
O	I-GENE-Y
-	I-GENE-Y
methyltransferase	I-GENE-Y
(	O
COMT	B-GENE-Y
)	O
inhibited	O
)	O
,	O
the	O
efflux	O
of	O
3H	B-CHEMICAL
-	I-CHEMICAL
noradrenaline	I-CHEMICAL
was	O
measured	O
for	O
30	O
min	O
.	O

When	O
1	O
mumol	O
/	O
l	O
amezinium	B-CHEMICAL
or	O
15	O
mumol	O
/	O
l	O
debrisoquine	B-CHEMICAL
was	O
added	O
for	O
the	O
last	O
15	O
min	O
of	O
efflux	O
,	O
there	O
was	O
a	O
rapid	O
and	O
marked	O
increase	O
in	O
the	O
fractional	O
rate	O
of	O
loss	O
of	O
3H	B-CHEMICAL
-	I-CHEMICAL
noradrenaline	I-CHEMICAL
,	O
which	O
was	O
reduced	O
by	O
about	O
70	O
%	O
when	O
1	O
mumol	O
/	O
l	O
desipramine	B-CHEMICAL
was	O
present	O
throughout	O
the	O
efflux	O
period	O
.	O

These	O
results	O
showed	O
that	O
both	O
drugs	O
were	O
substrates	O
for	O
uptake1	B-GENE-N
in	O
rat	O
lungs	O
.	O

In	O
lungs	O
perfused	O
with	O
1	O
nmol	O
/	O
l	O
3H	B-CHEMICAL
-	I-CHEMICAL
noradrenaline	I-CHEMICAL
(	O
COMT	B-GENE-Y
inhibited	O
)	O
,	O
10	O
,	O
30	O
and	O
300	O
nmol	O
/	O
l	O
amezinium	B-CHEMICAL
caused	O
58	O
%	O
,	O
76	O
%	O
and	O
74	O
%	O
inhibition	O
of	O
noradrenaline	B-CHEMICAL
deamination	O
,	O
respectively	O
,	O
and	O
30	O
,	O
300	O
and	O
3000	O
nmol	O
/	O
l	O
debrisoquine	B-CHEMICAL
caused	O
56	O
%	O
,	O
89	O
%	O
and	O
96	O
%	O
inhibition	O
of	O
noradrenaline	B-CHEMICAL
deamination	O
,	O
respectively	O
.	O

When	O
MAO	B-GENE-Y
-	I-GENE-Y
B	I-GENE-Y
was	O
also	O
inhibited	O
,	O
10	O
nmol	O
/	O
l	O
amezinium	B-CHEMICAL
caused	O
84	O
%	O
inhibition	O
of	O
the	O
deamination	O
of	O
noradrenaline	B-CHEMICAL
by	O
MAO	B-GENE-Y
-	I-GENE-Y
A	I-GENE-Y
in	O
the	O
lungs	O
.	O

In	O
contrast	O
,	O
in	O
hearts	O
perfused	O
with	O
10	O
nmol	O
/	O
l	O
3H	B-CHEMICAL
-	I-CHEMICAL
noradrenaline	I-CHEMICAL
under	O
conditions	O
where	O
the	O
amine	O
was	O
accumulated	O
by	O
uptake2	B-GENE-N
(	O
COMT	B-GENE-Y
,	O
uptake1	B-GENE-N
and	O
vesicular	O
transport	O
inhibited	O
)	O
,	O
10	O
nmol	O
/	O
l	O
amezinium	B-CHEMICAL
had	O
no	O
effect	O
and	O
300	O
nmol	O
/	O
l	O
amezinium	B-CHEMICAL
caused	O
only	O
36	O
%	O
inhibition	O
of	O
deamination	O
of	O
noradrenaline	B-CHEMICAL
.	O

The	O
results	O
when	O
considered	O
with	O
previous	O
reports	O
in	O
the	O
literature	O
show	O
that	O
amezinium	B-CHEMICAL
is	O
about	O
1000	O
times	O
more	O
potent	O
and	O
debrisoquine	B-CHEMICAL
is	O
about	O
20	O
times	O
more	O
potent	O
for	O
MAO	B-GENE-N
inhibition	O
in	O
rat	O
lungs	O
than	O
in	O
tissue	O
homogenates	O
,	O
and	O
the	O
reason	O
for	O
their	O
high	O
potencies	O
in	O
the	O
intact	O
lungs	O
is	O
transport	O
and	O
accumulation	O
of	O
the	O
drugs	O
in	O
the	O
pulmonary	O
endothelial	O
cells	O
by	O
uptake1	B-GENE-N
.	O

Amezinium	B-CHEMICAL
is	O
much	O
less	O
potent	O
as	O
a	O
MAO	B-GENE-N
inhibitor	O
in	O
cells	O
with	O
the	O
uptake2	B-GENE-N
transporter	I-GENE-N
,	O
such	O
as	O
the	O
myocardial	O
cells	O
of	O
the	O
heart	O
.	O

The	O
results	O
also	O
confirmed	O
previous	O
reports	O
that	O
amezinium	B-CHEMICAL
is	O
highly	O
selective	O
for	O
MAO	B-GENE-Y
-	I-GENE-Y
A	I-GENE-Y
.	O

Role	O
of	O
tachykinin	B-GENE-N
and	I-GENE-N
bradykinin	I-GENE-N
receptors	I-GENE-N
and	O
mast	O
cells	O
in	O
gaseous	O
formaldehyde	B-CHEMICAL
-	O
induced	O
airway	O
microvascular	O
leakage	O
in	O
rats	O
.	O

We	O
have	O
investigated	O
the	O
effects	O
of	O
CP	B-CHEMICAL
-	I-CHEMICAL
99	I-CHEMICAL
,	I-CHEMICAL
994	I-CHEMICAL
[	B-CHEMICAL
(	I-CHEMICAL
+	I-CHEMICAL
)	I-CHEMICAL
-	I-CHEMICAL
(	I-CHEMICAL
2s	I-CHEMICAL
,	I-CHEMICAL
3s	I-CHEMICAL
)	I-CHEMICAL
-	I-CHEMICAL
3	I-CHEMICAL
-	I-CHEMICAL
(	I-CHEMICAL
2	I-CHEMICAL
-	I-CHEMICAL
methoxybenzylamino	I-CHEMICAL
)	I-CHEMICAL
-	I-CHEMICAL
2	I-CHEMICAL
-	I-CHEMICAL
phenylpiperidine	I-CHEMICAL
]	I-CHEMICAL
,	O
a	O
tachykinin	B-GENE-Y
NK1	I-GENE-Y
receptor	I-GENE-Y
antagonist	O
,	O
HOE	B-CHEMICAL
140	I-CHEMICAL
(	B-CHEMICAL
D	I-CHEMICAL
-	I-CHEMICAL
Arg	I-CHEMICAL
[	I-CHEMICAL
Hyp3	I-CHEMICAL
,	I-CHEMICAL
Thi5	I-CHEMICAL
,	I-CHEMICAL
D	I-CHEMICAL
-	I-CHEMICAL
Tic7	I-CHEMICAL
,	I-CHEMICAL
Oic8	I-CHEMICAL
]	I-CHEMICAL
bradykinin	I-CHEMICAL
)	I-CHEMICAL
,	O
a	O
bradykinin	B-GENE-Y
B2	I-GENE-Y
receptor	I-GENE-Y
antagonist	O
,	O
and	O
ketotifen	B-CHEMICAL
(	B-CHEMICAL
4	I-CHEMICAL
-	I-CHEMICAL
(	I-CHEMICAL
1	I-CHEMICAL
-	I-CHEMICAL
methyl	I-CHEMICAL
-	I-CHEMICAL
4	I-CHEMICAL
-	I-CHEMICAL
piperidylidene	I-CHEMICAL
)	I-CHEMICAL
4	I-CHEMICAL
H	I-CHEMICAL
-	I-CHEMICAL
benzo	I-CHEMICAL
[	I-CHEMICAL
4	I-CHEMICAL
,	I-CHEMICAL
5	I-CHEMICAL
]	I-CHEMICAL
cycloheptal	I-CHEMICAL
[	I-CHEMICAL
1	I-CHEMICAL
,	I-CHEMICAL
2	I-CHEMICAL
-	I-CHEMICAL
b	I-CHEMICAL
]	I-CHEMICAL
thiophen	I-CHEMICAL
-	I-CHEMICAL
10	I-CHEMICAL
(	I-CHEMICAL
9H	I-CHEMICAL
)	I-CHEMICAL
-	I-CHEMICAL
one	I-CHEMICAL
hydrogen	I-CHEMICAL
fumarate	I-CHEMICAL
)	I-CHEMICAL
,	O
a	O
histamine	B-GENE-Y
H1	I-GENE-Y
receptor	I-GENE-Y
antagonist	O
with	O
mast	O
cell	O
-	O
stabilizing	O
properties	O
,	O
on	O
microvascular	O
leakage	O
induced	O
by	O
gaseous	O
formaldehyde	B-CHEMICAL
.	O

Extravasation	O
of	O
Evans	B-CHEMICAL
blue	I-CHEMICAL
dye	I-CHEMICAL
into	O
airway	O
tissues	O
was	O
used	O
as	O
an	O
index	O
of	O
airway	O
microvascular	O
leakage	O
.	O

Leakage	O
of	O
dye	O
in	O
the	O
trachea	O
and	O
main	O
bronchi	O
increased	O
significantly	O
in	O
a	O
concentration	O
-	O
dependent	O
fashion	O
after	O
10	O
min	O
inhalation	O
of	O
formaldehyde	B-CHEMICAL
(	O
5	O
-	O
45	O
parts	O
per	O
million	O
(	O
ppm	O
)	O
)	O
.	O

The	O
airway	O
response	O
induced	O
by	O
10	O
min	O
inhalation	O
of	O
15	O
ppm	O
formaldehyde	B-CHEMICAL
(	O
trachea	O
:	O
119	O
.	O
5	O
+	O
/	O
-	O
13	O
.	O
9	O
ng	O
/	O
mg	O
,	O
n	O
=	O
7	O
;	O
main	O
bronchi	O
:	O
139	O
.	O
6	O
+	O
/	O
-	O
7	O
.	O
9	O
ng	O
/	O
mg	O
,	O
n	O
=	O
7	O
)	O
was	O
abolished	O
by	O
the	O
administration	O
of	O
CP	B-CHEMICAL
-	I-CHEMICAL
99	I-CHEMICAL
,	I-CHEMICAL
994	I-CHEMICAL
(	O
3	O
and	O
6	O
mg	O
/	O
kg	O
i	O
.	O
v	O
.	O
)	O
,	O
but	O
not	O
by	O
the	O
administration	O
of	O
HOE	B-CHEMICAL
140	I-CHEMICAL
(	O
0	O
.	O
65	O
mg	O
/	O
kg	O
i	O
.	O
v	O
.	O
)	O
nor	O
ketotifen	B-CHEMICAL
(	O
1	O
mg	O
/	O
kg	O
i	O
.	O
v	O
.	O
)	O
.	O

The	O
increase	O
in	O
vascular	O
permeability	O
induced	O
by	O
formaldehyde	B-CHEMICAL
in	O
the	O
rat	O
airway	O
was	O
mediated	O
predominantly	O
by	O
NK1	B-GENE-Y
receptor	I-GENE-Y
stimulation	O
.	O

Activation	O
of	O
bradykinin	B-GENE-N
receptors	I-GENE-N
and	O
mast	O
cells	O
did	O
not	O
appear	O
to	O
play	O
an	O
important	O
role	O
in	O
this	O
airway	O
response	O
.	O

Molecular	O
determinants	O
of	O
dofetilide	B-CHEMICAL
block	O
of	O
HERG	B-GENE-Y
K	B-GENE-N
+	I-GENE-N
channels	I-GENE-N
.	O

The	O
human	B-GENE-Y
ether	I-GENE-Y
-	I-GENE-Y
a	I-GENE-Y
-	I-GENE-Y
go	I-GENE-Y
-	I-GENE-Y
go	I-GENE-Y
-	I-GENE-Y
related	I-GENE-Y
gene	I-GENE-Y
(	O
HERG	B-GENE-Y
)	O
encodes	O
a	O
K	B-GENE-N
+	I-GENE-N
channel	I-GENE-N
with	O
biophysical	O
properties	O
nearly	O
identical	O
to	O
the	O
rapid	B-GENE-N
component	I-GENE-N
of	I-GENE-N
the	I-GENE-N
cardiac	I-GENE-N
delayed	I-GENE-N
rectifier	I-GENE-N
K	I-GENE-N
+	I-GENE-N
current	I-GENE-N
(	O
IKr	B-GENE-N
)	O
.	O

HERG	B-GENE-Y
/	O
IKr	B-GENE-N
channels	O
are	O
a	O
prime	O
target	O
for	O
the	O
pharmacological	O
management	O
of	O
arrhythmias	O
and	O
are	O
selectively	O
blocked	O
by	O
class	O
III	O
antiarrhythmic	O
methanesulfonanilide	B-CHEMICAL
drugs	O
,	O
such	O
as	O
dofetilide	B-CHEMICAL
,	O
E4031	B-CHEMICAL
,	O
and	O
MK	B-CHEMICAL
-	I-CHEMICAL
499	I-CHEMICAL
,	O
at	O
submicromolar	O
concentrations	O
.	O

By	O
contrast	O
,	O
the	O
closely	O
related	O
bovine	B-GENE-Y
ether	I-GENE-Y
-	I-GENE-Y
a	I-GENE-Y
-	I-GENE-Y
go	I-GENE-Y
-	I-GENE-Y
go	I-GENE-Y
channel	I-GENE-Y
(	O
BEAG	B-GENE-Y
)	O
is	O
100	O
-	O
fold	O
less	O
sensitive	O
to	O
dofetilide	B-CHEMICAL
.	O

To	O
identify	O
the	O
molecular	O
determinants	O
for	O
dofetilide	B-CHEMICAL
block	O
,	O
we	O
first	O
engineered	O
chimeras	O
between	O
HERG	B-GENE-Y
and	O
BEAG	B-GENE-Y
and	O
then	O
used	O
site	O
-	O
directed	O
mutagenesis	O
to	O
localize	O
single	O
amino	B-CHEMICAL
acid	I-CHEMICAL
residues	O
responsible	O
for	O
block	O
.	O

Using	O
constructs	O
heterologously	O
expressed	O
in	O
Xenopus	O
oocytes	O
,	O
we	O
found	O
that	O
transplantation	O
of	O
the	O
S5	O
-	O
S6	O
linker	O
from	O
BEAG	B-GENE-Y
into	O
HERG	B-GENE-Y
removed	O
high	O
-	O
affinity	O
block	O
by	O
dofetilide	O
.	O

A	O
point	O
mutation	O
in	O
the	O
S5	O
-	O
S6	O
linker	O
region	O
,	O
HERG	B-GENE-Y
S620T	B-GENE-N
,	O
abolished	O
high	O
-	O
affinity	O
block	O
and	O
interfered	O
with	O
C	O
-	O
type	O
inactivation	O
.	O

Thus	O
,	O
our	O
results	O
indicate	O
that	O
important	O
determinants	O
of	O
dofetilide	B-CHEMICAL
binding	O
are	O
localized	O
to	O
the	O
pore	O
region	O
of	O
HERG	B-GENE-Y
.	O

Since	O
the	O
loss	O
of	O
high	O
-	O
affinity	O
drug	O
binding	O
was	O
always	O
correlated	O
with	O
a	O
loss	O
of	O
C	O
-	O
type	O
inactivation	O
,	O
it	O
is	O
possible	O
that	O
the	O
changes	O
observed	O
in	O
drug	O
binding	O
are	O
due	O
to	O
indirect	O
allosteric	O
modifications	O
in	O
the	O
structure	O
of	O
the	O
channel	O
protein	O
and	O
not	O
to	O
the	O
direct	O
interaction	O
of	O
dofetilide	B-CHEMICAL
with	O
the	O
respective	O
mutated	O
site	O
chains	O
.	O

However	O
,	O
the	O
chimeric	O
approach	O
was	O
not	O
able	O
to	O
identify	O
domains	O
outside	O
the	O
S5	O
-	O
S6	O
linker	O
region	O
of	O
the	O
HERG	B-GENE-Y
channel	O
as	O
putative	O
candidates	O
involved	O
in	O
drug	O
binding	O
.	O

Moreover	O
,	O
the	O
reverse	O
mutation	O
BEAG	B-GENE-Y
T432S	B-GENE-N
increased	O
the	O
affinity	O
of	O
BEAG	B-GENE-Y
K	B-GENE-N
+	I-GENE-N
channels	I-GENE-N
for	O
dofetilide	B-CHEMICAL
,	O
whereas	O
C	O
-	O
type	O
inactivation	O
could	O
not	O
be	O
recovered	O
.	O

Thus	O
,	O
the	O
serine	B-CHEMICAL
in	O
position	O
HERG	B-GENE-Y
620	O
may	O
participate	O
directly	O
in	O
dofetilide	B-CHEMICAL
binding	O
;	O
however	O
,	O
an	O
intact	O
C	O
-	O
type	O
inactivation	O
process	O
seems	O
to	O
be	O
crucial	O
for	O
high	O
-	O
affinity	O
drug	O
binding	O
.	O

Testosterone	B-CHEMICAL
versus	O
testosterone	B-CHEMICAL
and	O
testolactone	B-CHEMICAL
in	O
treating	O
reproductive	O
and	O
sexual	O
dysfunction	O
in	O
men	O
with	O
epilepsy	O
and	O
hypogonadism	O
.	O

Antiepileptic	O
drug	O
-	O
induced	O
reductions	O
in	O
serum	O
levels	O
of	O
biologically	O
active	O
testosterone	B-CHEMICAL
and	O
elevations	O
in	O
serum	O
estradiol	B-CHEMICAL
(	O
E2	B-CHEMICAL
)	O
may	O
contribute	O
to	O
sexual	O
dysfunction	O
among	O
men	O
with	O
epilepsy	O
.	O

Treatment	O
using	O
a	O
combination	O
of	O
testosterone	B-CHEMICAL
and	O
the	O
aromatase	B-GENE-Y
inhibitor	O
testolactone	B-CHEMICAL
may	O
have	O
significantly	O
better	O
effects	O
on	O
sexual	O
function	O
and	O
also	O
seizure	O
frequency	O
than	O
testosterone	B-CHEMICAL
alone	O
.	O

Identification	O
of	O
binding	O
sites	O
for	O
bepridil	B-CHEMICAL
and	O
trifluoperazine	B-CHEMICAL
on	O
cardiac	B-GENE-Y
troponin	I-GENE-Y
C	I-GENE-Y
.	O

The	O
solution	O
structure	O
of	O
cardiac	B-GENE-Y
troponin	I-GENE-Y
C	I-GENE-Y
(	O
cTnC	B-GENE-Y
)	O
(	O
Sia	O
,	O
S	O
.	O
,	O
Li	O
,	O
M	O
.	O
X	O
.	O
,	O
Spyracopoulos	O
,	O
L	O
.	O
,	O
Gagne	O
,	O
S	O
.	O
M	O
.	O
,	O
Liu	O
,	O
W	O
.	O
,	O
Putkey	O
,	O
J	O
.	O
A	O
.	O
&	O
Sykes	O
,	O
B	O
.	O
D	O
.	O
(	O
1997	O
)	O
J	O
.	O
Biol	O
.	O
Chem	O
.	O
272	O
,	O
18216	O
-	O
18221	O
)	O
challenges	O
existing	O
structure	O
/	O
function	O
models	O
for	O
this	O
critical	O
regulatory	O
protein	O
.	O

For	O
example	O
,	O
it	O
is	O
clear	O
that	O
the	O
closed	O
conformation	O
of	O
the	O
regulatory	O
N	B-CHEMICAL
-	O
terminal	O
domain	O
in	O
Ca2	B-CHEMICAL
+	I-CHEMICAL
-	O
bound	O
cardiac	B-GENE-Y
troponin	I-GENE-Y
C	I-GENE-Y
(	O
cTnC	B-GENE-Y
)	O
presents	O
a	O
much	O
different	O
binding	O
surface	O
for	O
Ca2	B-CHEMICAL
+	I-CHEMICAL
-	O
sensitizing	O
compounds	O
than	O
previously	O
thought	O
.	O

We	O
report	O
here	O
the	O
use	O
of	O
Met	O
methyl	O
groups	O
as	O
site	O
-	O
specific	O
structural	O
markers	O
to	O
identify	O
drug	O
binding	O
sites	O
for	O
trifluoperazine	B-CHEMICAL
and	O
bepridil	B-CHEMICAL
on	O
cTnC	B-GENE-Y
.	O

Drug	O
dependent	O
changes	O
in	O
the	O
NMR	O
heteronuclear	O
single	O
-	O
quantum	O
coherence	O
spectra	O
of	O
[	O
methyl	B-CHEMICAL
-	I-CHEMICAL
13C	I-CHEMICAL
]	O
Met	O
-	O
labeled	O
cTnC	B-GENE-Y
indicate	O
that	O
bepridil	B-CHEMICAL
and	O
trifluoperazine	B-CHEMICAL
bind	O
to	O
similar	O
sites	O
but	O
only	O
in	O
the	O
presence	O
of	O
Ca2	B-CHEMICAL
+	I-CHEMICAL
.	O

There	O
are	O
3	O
-	O
4	O
drug	O
binding	O
sites	O
in	O
the	O
N	B-CHEMICAL
-	O
and	O
C	B-CHEMICAL
-	O
terminal	O
domains	O
of	O
intact	O
cTnC	B-GENE-Y
that	O
exhibit	O
fast	O
exchange	O
on	O
the	O
NMR	O
time	O
scale	O
.	O

Use	O
of	O
a	O
novel	O
spin	O
-	O
labeled	O
phenothiazine	B-CHEMICAL
and	O
detection	O
of	O
isotope	O
-	O
filtered	O
nuclear	O
Overhauser	O
effects	O
allowed	O
identification	O
of	O
drug	O
binding	O
sites	O
in	O
the	O
shallow	O
hydrophobic	O
cup	O
in	O
the	O
C	O
-	O
terminal	O
domain	O
and	O
on	O
two	O
hydrophobic	O
surfaces	O
on	O
the	O
N	B-CHEMICAL
-	O
terminal	O
regulatory	O
domain	O
.	O

The	O
data	O
presented	O
here	O
,	O
coupled	O
with	O
our	O
previous	O
study	O
using	O
covalent	O
blocking	O
groups	O
,	O
support	O
a	O
model	O
in	O
which	O
the	O
Ca2	B-CHEMICAL
+	I-CHEMICAL
-	O
sensitizing	O
binding	O
site	O
includes	O
Met	O
-	O
45	O
in	O
helix	O
B	O
of	O
site	O
I	O
,	O
and	O
Met	O
-	O
60	O
and	O
-	O
80	O
in	O
helices	O
B	O
and	O
C	O
of	O
the	O
regulatory	O
site	O
II	O
.	O

This	O
subregion	O
in	O
cTnC	B-GENE-Y
makes	O
a	O
likely	O
target	O
against	O
which	O
to	O
design	O
new	O
and	O
selective	O
Ca2	B-CHEMICAL
+	I-CHEMICAL
-	O
sensitizing	O
compounds	O
.	O

Peripheral	O
blood	O
mononuclear	O
cells	O
express	O
mutated	O
NCCT	B-GENE-Y
mRNA	O
in	O
Gitelman	O
'	O
s	O
syndrome	O
:	O
evidence	O
for	O
abnormal	O
thiazide	B-CHEMICAL
-	O
sensitive	O
NaCl	B-CHEMICAL
cotransport	O
.	O

Genetic	O
analysis	O
has	O
demonstrated	O
complete	O
linkage	O
between	O
the	O
human	B-GENE-Y
thiazide	I-GENE-Y
-	I-GENE-Y
sensitive	I-GENE-Y
sodium	I-GENE-Y
chloride	I-GENE-Y
cotransporter	I-GENE-Y
gene	O
(	O
NCCT	B-GENE-Y
or	O
TSC	B-GENE-Y
)	O
and	O
Gitelman	O
'	O
s	O
syndrome	O
(	O
GS	O
)	O
.	O

Several	O
genomic	O
NCCT	B-GENE-Y
mutations	O
have	O
been	O
reported	O
.	O

This	O
study	O
was	O
performed	O
to	O
determine	O
whether	O
peripheral	O
blood	O
mononuclear	O
cells	O
(	O
PBMC	O
)	O
express	O
NCCT	B-GENE-Y
mRNA	O
and	O
whether	O
defective	O
PBMC	O
NaCl	B-CHEMICAL
cotransport	O
could	O
be	O
demonstrated	O
in	O
GS	O
.	O

PBMC	O
were	O
isolated	O
from	O
two	O
brothers	O
with	O
GS	O
,	O
their	O
parents	O
,	O
and	O
healthy	O
control	O
subjects	O
.	O

Northern	O
analysis	O
revealed	O
that	O
NCCT	B-GENE-Y
mRNA	O
is	O
expressed	O
in	O
PBMC	O
.	O

The	O
sequence	O
of	O
full	O
-	O
length	O
NCCT	B-GENE-Y
cDNA	O
amplified	O
from	O
normal	O
PBMC	O
was	O
identical	O
to	O
human	B-GENE-Y
renal	I-GENE-Y
NCCT	I-GENE-Y
cDNA	O
.	O

Two	O
different	O
mutations	O
were	O
detected	O
in	O
the	O
patients	O
'	O
NCCT	B-GENE-Y
cDNA	O
(	O
compound	O
heterozygote	O
)	O
.	O

In	O
cDNA	O
derived	O
from	O
the	O
patient	O
'	O
s	O
maternal	O
allele	O
,	O
exon	O
24	O
was	O
deleted	O
,	O
resulting	O
in	O
a	O
premature	O
stop	O
codon	O
(	O
after	O
amino	B-CHEMICAL
acid	I-CHEMICAL
920	O
)	O
.	O

cDNA	O
derived	O
from	O
the	O
patient	O
'	O
s	O
paternal	O
allele	O
had	O
an	O
additional	O
119	O
-	O
bp	O
insertion	O
between	O
exons	O
3	O
and	O
4	O
,	O
generating	O
a	O
premature	O
stop	O
codon	O
(	O
after	O
amino	B-CHEMICAL
acid	I-CHEMICAL
187	O
)	O
.	O

The	O
patient	O
'	O
s	O
genomic	O
DNA	O
had	O
a	O
previously	O
described	O
5	O
'	O
splice	O
site	O
mutation	O
in	O
intron	O
24	O
,	O
GGT	B-GENE-N
-	I-GENE-N
-	I-GENE-N
>	I-GENE-N
GTT	I-GENE-N
(	O
maternal	O
allele	O
)	O
,	O
and	O
a	O
new	O
3	O
'	O
splice	O
site	O
mutation	O
in	O
intron	O
3	O
,	O
CAG	B-GENE-N
-	I-GENE-N
-	I-GENE-N
>	I-GENE-N
CAA	I-GENE-N
(	O
paternal	O
allele	O
)	O
,	O
which	O
resulted	O
in	O
the	O
activation	O
of	O
a	O
nearby	O
cryptic	O
splice	O
site	O
in	O
intron	O
3	O
.	O

The	O
latter	O
mutation	O
was	O
not	O
present	O
in	O
300	O
normal	O
chromosomes	O
.	O

To	O
determine	O
the	O
functional	O
significance	O
of	O
these	O
findings	O
,	O
chlorothiazide	B-CHEMICAL
-	O
inhibitable	O
22Na	B-CHEMICAL
uptake	O
was	O
measured	O
in	O
PBMC	O
from	O
control	O
subjects	O
,	O
the	O
parents	O
,	O
and	O
the	O
patients	O
with	O
GS	O
in	O
the	O
presence	O
of	O
bumetanide	B-CHEMICAL
.	O

In	O
control	O
PBMC	O
,	O
chlorothiazide	B-CHEMICAL
inhibited	O
22Na	B-CHEMICAL
uptake	O
by	O
approximately	O
9	O
%	O
.	O

PBMC	O
from	O
the	O
two	O
patients	O
with	O
GS	O
failed	O
to	O
respond	O
to	O
chlorothiazide	B-CHEMICAL
.	O

These	O
results	O
demonstrate	O
that	O
PBMC	O
can	O
be	O
used	O
for	O
mutational	O
analysis	O
of	O
NCCT	B-GENE-Y
mRNA	O
in	O
patients	O
with	O
GS	O
.	O

Furthermore	O
,	O
functional	O
evidence	O
is	O
provided	O
that	O
the	O
underlying	O
cause	O
of	O
GS	O
is	O
defective	O
NCCT	B-GENE-Y
NaCl	B-CHEMICAL
cotransport	O
.	O

A	O
case	O
of	O
therapy	O
-	O
related	O
acute	O
myeloblastic	O
leukemia	O
with	O
t	O
(	O
16	O
;	O
21	O
)	O
(	O
q24	O
;	O
q22	O
)	O
after	O
chemotherapy	O
with	O
DNA	B-GENE-Y
-	I-GENE-Y
topoisomerase	I-GENE-Y
II	I-GENE-Y
inhibitors	O
,	O
etoposide	B-CHEMICAL
and	O
mitoxantrone	B-CHEMICAL
,	O
and	O
the	O
alkylating	O
agent	O
,	O
cyclophosphamide	B-CHEMICAL
.	O

A	O
59	O
-	O
year	O
-	O
old	O
female	O
suffering	O
from	O
malignant	O
lymphoma	O
developed	O
therapy	O
-	O
related	O
acute	O
myeloblastic	O
leukemia	O
(	O
t	O
-	O
AML	O
)	O
after	O
chemotherapy	O
consisting	O
of	O
treatment	O
with	O
DNA	B-GENE-Y
-	I-GENE-Y
topoisomerase	I-GENE-Y
II	I-GENE-Y
inhibitors	O
,	O
etoposide	B-CHEMICAL
and	O
mitoxantrone	B-CHEMICAL
,	O
and	O
an	O
alkylating	O
agent	O
,	O
cyclophosphamide	B-CHEMICAL
.	O

The	O
cumulative	O
dose	O
of	O
etoposide	B-CHEMICAL
administration	O
was	O
5500	O
mg	O
;	O
1500	O
mg	O
given	O
intravenously	O
and	O
4000	O
mg	O
orally	O
.	O

One	O
year	O
later	O
,	O
she	O
suddenly	O
developed	O
AML	O
of	O
FAB	O
M2	O
.	O

Cytogenetic	O
analysis	O
of	O
bone	O
marrow	O
cells	O
revealed	O
deletion	O
of	O
7q	O
and	O
a	O
rare	O
translocation	O
,	O
t	O
(	O
16	O
;	O
21	O
)	O
(	O
q24	O
;	O
q22	O
)	O
.	O

Southern	O
blot	O
analysis	O
of	O
bone	O
marrow	O
cells	O
did	O
not	O
detect	O
rearrangement	O
of	O
the	O
AML1	B-GENE-Y
gene	O
,	O
however	O
,	O
fluorescence	O
in	O
situ	O
hybridization	O
(	O
FISH	O
)	O
analysis	O
of	O
bone	O
marrow	O
cells	O
at	O
interphase	O
and	O
metaphase	O
revealed	O
a	O
translocational	O
splitting	O
between	O
chromosome	O
21	O
involving	O
AML1	B-GENE-Y
gene	O
and	O
chromosome	O
16	O
.	O

These	O
results	O
suggest	O
that	O
the	O
breakpoint	O
is	O
not	O
located	O
in	O
the	O
breakpoint	B-GENE-N
cluster	I-GENE-N
region	I-GENE-N
for	O
t	O
(	O
8	O
;	O
21	O
)	O
.	O

The	O
patient	O
was	O
treated	O
with	O
chemotherapy	O
and	O
entered	O
complete	O
remission	O
.	O

Safety	O
of	O
selegiline	B-CHEMICAL
(	O
deprenyl	B-CHEMICAL
)	O
in	O
the	O
treatment	O
of	O
Parkinson	O
'	O
s	O
disease	O
.	O

Selegiline	B-CHEMICAL
(	O
deprenyl	B-CHEMICAL
)	O
,	O
a	O
selective	O
,	O
irreversible	O
inhibitor	O
of	O
monoamine	B-GENE-Y
oxidase	I-GENE-Y
type	I-GENE-Y
B	I-GENE-Y
(	O
MAO	B-GENE-Y
-	I-GENE-Y
B	I-GENE-Y
)	O
is	O
widely	O
used	O
in	O
the	O
treatment	O
of	O
Parkinson	O
'	O
s	O
disease	O
.	O

As	O
the	O
first	O
MAO	B-GENE-Y
-	I-GENE-Y
B	I-GENE-Y
inhibitor	O
approved	O
for	O
the	O
treatment	O
of	O
Parkinson	O
'	O
s	O
disease	O
,	O
concerns	O
were	O
raised	O
about	O
the	O
safety	O
of	O
the	O
drug	O
based	O
on	O
the	O
adverse	O
effect	O
profiles	O
of	O
older	O
,	O
nonselective	O
MAO	B-GENE-N
inhibitors	O
.	O

Unlike	O
the	O
nonselective	O
MAO	B-GENE-N
inhibitors	O
,	O
selegiline	B-CHEMICAL
does	O
not	O
significantly	O
potentiate	O
tyramine	B-CHEMICAL
-	O
induced	O
hypertension	O
(	O
the	O
'	O
cheese	O
effect	O
'	O
)	O
at	O
the	O
dosages	O
(	O
5	O
to	O
10	O
mg	O
daily	O
)	O
used	O
for	O
the	O
treatment	O
of	O
Parkinson	O
'	O
s	O
disease	O
.	O

Selegiline	B-CHEMICAL
has	O
been	O
well	O
tolerated	O
when	O
given	O
alone	O
.	O

The	O
most	O
frequent	O
adverse	O
events	O
seen	O
during	O
monotherapy	O
have	O
been	O
insomnia	O
,	O
nausea	O
,	O
benign	O
cardiac	O
arrhythmias	O
,	O
dizziness	O
and	O
headache	O
.	O

When	O
combined	O
with	O
levodopa	B-CHEMICAL
,	O
selegiline	B-CHEMICAL
can	O
potentiate	O
the	O
typical	O
adverse	O
effects	O
of	O
levodopa	B-CHEMICAL
,	O
if	O
the	O
dose	O
of	O
levodopa	B-CHEMICAL
is	O
not	O
reduced	O
sufficiently	O
.	O

Thus	O
,	O
the	O
most	O
common	O
adverse	O
effects	O
associated	O
with	O
this	O
combination	O
are	O
nausea	O
,	O
dizziness	O
,	O
fatigue	O
,	O
constipation	O
and	O
insomnia	O
.	O

At	O
the	O
later	O
stages	O
of	O
Parkinson	O
'	O
s	O
disease	O
when	O
fluctuations	O
in	O
disability	O
occur	O
,	O
peak	O
dose	O
dyskinesias	O
,	O
psychiatric	O
complications	O
like	O
hallucinations	O
and	O
insomnia	O
,	O
and	O
orthostatic	O
hypotension	O
are	O
further	O
potentiated	O
by	O
selegiline	B-CHEMICAL
.	O

Mortality	O
was	O
recently	O
reported	O
to	O
be	O
increased	O
when	O
selegiline	B-CHEMICAL
and	O
levodopa	B-CHEMICAL
were	O
given	O
together	O
in	O
comparison	O
with	O
treatment	O
with	O
levodopa	B-CHEMICAL
alone	O
,	O
but	O
a	O
large	O
meta	O
-	O
analysis	O
of	O
5	O
long	O
term	O
studies	O
and	O
4	O
separate	O
studies	O
did	O
not	O
support	O
this	O
conclusion	O
.	O

Selegiline	B-CHEMICAL
seems	O
to	O
be	O
generally	O
well	O
tolerated	O
in	O
combination	O
with	O
other	O
drugs	O
.	O

However	O
,	O
when	O
pethidine	B-CHEMICAL
(	O
meperidine	B-CHEMICAL
)	O
has	O
been	O
given	O
to	O
patients	O
who	O
are	O
receiving	O
selegiline	B-CHEMICAL
therapy	O
,	O
severe	O
adverse	O
effects	O
have	O
been	O
reported	O
.	O

Thus	O
,	O
the	O
concomitant	O
use	O
of	O
these	O
drugs	O
is	O
not	O
recommended	O
.	O

A	O
low	O
tyramine	B-CHEMICAL
diet	O
is	O
recommended	O
if	O
selegiline	B-CHEMICAL
is	O
used	O
together	O
with	O
nonselective	O
MAO	B-GENE-N
inhibitors	O
or	O
the	O
selective	O
,	O
reversible	O
MAO	B-GENE-Y
-	I-GENE-Y
A	I-GENE-Y
inhibitor	O
,	O
moclobemide	B-CHEMICAL
.	O

Several	O
adverse	O
effects	O
have	O
been	O
reported	O
when	O
fluoxetine	B-CHEMICAL
and	O
selegiline	B-CHEMICAL
have	O
been	O
used	O
together	O
.	O

A	O
recent	O
survey	O
revealed	O
that	O
the	O
incidence	O
of	O
a	O
true	O
serotonin	B-CHEMICAL
syndrome	O
is	O
,	O
however	O
,	O
very	O
low	O
with	O
this	O
combination	O
.	O

Concomitant	O
use	O
of	O
selegiline	B-CHEMICAL
and	O
other	O
selective	O
serotonin	B-CHEMICAL
(	O
5	B-CHEMICAL
-	I-CHEMICAL
hydroxytryptamine	I-CHEMICAL
;	O
5	B-CHEMICAL
-	I-CHEMICAL
HT	I-CHEMICAL
)	O
reuptake	O
inhibitors	O
(	O
SSRIs	O
)	O
like	O
citalopram	B-CHEMICAL
,	O
which	O
have	O
generally	O
less	O
interactions	O
than	O
fluoxetine	B-CHEMICAL
,	O
seems	O
to	O
be	O
well	O
tolerated	O
.	O

Nevertheless	O
,	O
caution	O
is	O
advised	O
when	O
combining	O
a	O
SSRI	O
or	O
a	O
tricyclic	B-CHEMICAL
antidepressant	O
and	O
selegiline	B-CHEMICAL
.	O

Ibuprofen	B-CHEMICAL
inhibits	O
cystic	B-GENE-Y
fibrosis	I-GENE-Y
transmembrane	I-GENE-Y
conductance	I-GENE-Y
regulator	I-GENE-Y
-	O
mediated	O
Cl	O
-	O
secretion	O
.	O

We	O
evaluated	O
the	O
acute	O
effects	O
of	O
ibuprofen	B-CHEMICAL
and	O
salicylic	B-CHEMICAL
acid	I-CHEMICAL
on	O
cAMP	B-CHEMICAL
-	O
mediated	O
Cl	O
-	O
secretion	O
(	O
Isc	O
)	O
in	O
both	O
colonic	O
and	O
airway	O
epithelia	O
.	O

In	O
T84	O
cells	O
,	O
ibuprofen	B-CHEMICAL
inhibited	O
the	O
forskolin	B-CHEMICAL
-	O
dependent	O
Isc	O
in	O
a	O
concentration	O
-	O
dependent	O
manner	O
,	O
having	O
an	O
apparent	O
Ki	O
of	O
142	O
microM	O
.	O

Salicylic	B-CHEMICAL
acid	I-CHEMICAL
inhibited	O
Isc	O
with	O
an	O
apparent	O
Ki	O
of	O
646	O
microM	O
.	O

We	O
determined	O
whether	O
ibuprofen	B-CHEMICAL
would	O
also	O
inhibit	O
the	O
forskolin	B-CHEMICAL
-	O
stimulated	O
Isc	O
in	O
primary	O
cultures	O
of	O
mouse	O
trachea	O
epithelia	O
(	O
MTE	O
)	O
and	O
human	O
bronchial	O
epithelia	O
(	O
HBE	O
)	O
.	O

Similar	O
to	O
our	O
results	O
in	O
T84	O
cells	O
,	O
ibuprofen	B-CHEMICAL
(	O
500	O
microM	O
)	O
inhibited	O
the	O
forskolin	B-CHEMICAL
-	O
induced	O
Isc	O
in	O
MTEs	O
and	O
HBEs	O
by	O
59	O
+	O
/	O
-	O
4	O
%	O
(	O
n	O
=	O
11	O
)	O
and	O
39	O
+	O
/	O
-	O
6	O
%	O
(	O
n	O
=	O
8	O
)	O
,	O
respectively	O
.	O

Nystatin	B-CHEMICAL
was	O
employed	O
to	O
selectively	O
permeabilize	O
the	O
basolateral	O
or	O
apical	O
membrane	O
to	O
determine	O
the	O
effect	O
of	O
ibuprofen	B-CHEMICAL
on	O
apical	O
Cl	O
-	O
(	O
ICl	O
)	O
and	O
basolateral	O
K	B-CHEMICAL
+	I-CHEMICAL
(	O
IK	O
)	O
currents	O
after	O
stimulation	O
by	O
forskolin	B-CHEMICAL
.	O

After	O
forskolin	B-CHEMICAL
stimulation	O
,	O
ibuprofen	B-CHEMICAL
(	O
500	O
microM	O
)	O
reduced	O
both	O
the	O
ICl	O
and	O
IK	O
;	O
reducing	O
ICl	O
and	O
IK	O
by	O
60	O
and	O
15	O
%	O
,	O
respectively	O
.	O

To	O
determine	O
whether	O
this	O
inhibition	O
of	O
ICl	O
was	O
due	O
to	O
the	O
inhibition	O
of	O
CFTR	B-GENE-Y
,	O
the	O
effects	O
of	O
ibuprofen	B-CHEMICAL
and	O
salicylic	B-CHEMICAL
acid	I-CHEMICAL
on	O
CFTR	B-GENE-Y
Cl	B-GENE-N
-	I-GENE-N
channels	I-GENE-N
in	O
excised	O
,	O
inside	O
-	O
out	O
patches	O
from	O
L	O
-	O
cells	O
were	O
evaluated	O
.	O

Ibuprofen	B-CHEMICAL
(	O
300	O
microM	O
)	O
reduced	O
CFTR	B-GENE-Y
Cl	O
-	O
current	O
by	O
60	O
+	O
/	O
-	O
16	O
%	O
and	O
this	O
was	O
explained	O
by	O
a	O
short	O
-	O
lived	O
block	O
(	O
approximately	O
1	O
.	O
2	O
ms	O
)	O
which	O
causes	O
an	O
apparent	O
reduction	O
in	O
single	O
channel	O
amplitude	O
from	O
1	O
.	O
07	O
+	O
/	O
-	O
0	O
.	O
04	O
pA	O
to	O
0	O
.	O
59	O
+	O
/	O
-	O
0	O
.	O
04	O
pA	O
(	O
n	O
=	O
3	O
)	O
.	O

Similarly	O
,	O
salicylic	B-CHEMICAL
acid	I-CHEMICAL
(	O
3	O
mM	O
)	O
reduced	O
CFTR	B-GENE-Y
Cl	O
-	O
current	O
by	O
50	O
+	O
/	O
-	O
8	O
%	O
with	O
an	O
apparent	O
reduction	O
in	O
single	O
channel	O
amplitude	O
from	O
1	O
.	O
08	O
+	O
/	O
-	O
0	O
.	O
03	O
pA	O
to	O
0	O
.	O
48	O
+	O
/	O
-	O
0	O
.	O
06	O
pA	O
(	O
n	O
=	O
4	O
)	O
.	O

Based	O
on	O
these	O
results	O
,	O
we	O
conclude	O
that	O
the	O
NSAIDs	O
ibuprofen	B-CHEMICAL
and	O
salicylic	B-CHEMICAL
acid	I-CHEMICAL
inhibit	O
cAMP	B-CHEMICAL
-	O
mediated	O
Cl	O
-	O
secretion	O
in	O
human	O
colonic	O
and	O
airway	O
epithelia	O
via	O
a	O
direct	O
inhibition	O
of	O
CFTR	B-GENE-Y
Cl	B-GENE-N
-	I-GENE-N
channels	I-GENE-N
as	O
well	O
as	O
basolateral	O
membrane	O
K	B-GENE-N
+	I-GENE-N
channels	I-GENE-N
.	O

This	O
may	O
reduce	O
their	O
efficacy	O
in	O
conjunction	O
with	O
other	O
therapeutic	O
strategies	O
designed	O
to	O
increase	O
CFTR	B-GENE-Y
expression	O
and	O
/	O
or	O
function	O
in	O
secretory	O
epithelia	O
.	O

Antagonism	O
of	O
meta	B-CHEMICAL
-	I-CHEMICAL
chlorophenylpiperazine	I-CHEMICAL
-	O
induced	O
inhibition	O
of	O
exploratory	O
activity	O
in	O
an	O
emergence	O
procedure	O
,	O
the	O
open	O
field	O
test	O
,	O
in	O
rats	O
.	O

The	O
effects	O
of	O
meta	B-CHEMICAL
-	I-CHEMICAL
chlorophenylpiperazine	I-CHEMICAL
(	O
mCPP	B-CHEMICAL
)	O
were	O
studied	O
on	O
exploratory	O
behaviour	O
in	O
the	O
open	O
field	O
test	O
,	O
using	O
a	O
procedure	O
designed	O
to	O
evaluate	O
the	O
emergence	O
of	O
rats	O
into	O
a	O
novel	O
environment	O
.	O

mCPP	B-CHEMICAL
reduced	O
the	O
exploratory	O
activity	O
in	O
a	O
dose	O
-	O
related	O
manner	O
after	O
subcutaneous	O
(	O
s	O
.	O
c	O
.	O
)	O
,	O
intraperitoneal	O
(	O
i	O
.	O
p	O
.	O
)	O
and	O
intravenous	O
(	O
i	O
.	O
v	O
.	O
)	O
administration	O
.	O

The	O
inhibition	O
was	O
manifest	O
in	O
all	O
the	O
parameters	O
used	O
to	O
quantify	O
the	O
exploration	O
of	O
the	O
open	O
field	O
area	O
.	O

Additional	O
neuroendocrine	O
experiments	O
in	O
a	O
parallel	O
group	O
of	O
rats	O
revealed	O
a	O
dose	O
-	O
related	O
increase	O
in	O
plasma	B-GENE-Y
prolactin	I-GENE-Y
and	O
ACTH	B-GENE-Y
levels	O
after	O
i	O
.	O
v	O
.	O
mCPP	B-CHEMICAL
,	O
pointing	O
to	O
a	O
general	O
state	O
of	O
arousal	O
in	O
these	O
mCPP	B-CHEMICAL
-	O
treated	O
animals	O
.	O

A	O
number	O
of	O
5	B-CHEMICAL
-	I-CHEMICAL
HT	I-CHEMICAL
antagonists	O
were	O
tested	O
for	O
their	O
ability	O
to	O
prevent	O
or	O
reverse	O
the	O
behavioural	O
inhibition	O
induced	O
by	O
an	O
i	O
.	O
v	O
.	O
injection	O
of	O
1	O
.	O
0	O
g	O
/	O
kg	O
mCPP	B-CHEMICAL
given	O
15	O
min	O
before	O
testing	O
in	O
the	O
open	O
field	O
.	O

The	O
antagonists	O
were	O
injected	O
s	O
.	O
c	O
.	O
or	O
given	O
orally	O
at	O
various	O
time	O
intervals	O
before	O
mCPP	B-CHEMICAL
,	O
or	O
they	O
were	O
injected	O
i	O
.	O
v	O
.	O
10	O
min	O
after	O
mCPP	B-CHEMICAL
.	O

The	O
lowest	O
active	O
doses	O
for	O
the	O
attentuation	O
of	O
the	O
mCPP	B-CHEMICAL
-	O
induced	O
behavioural	O
inhibition	O
after	O
s	O
.	O
c	O
.	O
,	O
oral	O
and	O
i	O
.	O
v	O
.	O
administration	O
,	O
respectively	O
,	O
were	O
0	O
.	O
04	O
,	O
40	O
and	O
10	O
mg	O
/	O
kg	O
for	O
pizotifen	O
;	O
0	O
.	O
16	O
,	O
0	O
.	O
16	O
and	O
0	O
.	O
16	O
mg	O
/	O
kg	O
for	O
mianserin	O
;	O
0	O
.	O
63	O
,	O
0	O
.	O
16	O
and	O
0	O
.	O
16	O
mg	O
/	O
kg	O
for	O
methysergide	B-CHEMICAL
,	O
and	O
0	O
.	O
16	O
,	O
2	O
.	O
5	O
and	O
2	O
.	O
5	O
mg	O
/	O
kg	O
for	O
ritanserin	B-CHEMICAL
.	O

The	O
lowest	O
active	O
doses	O
of	O
mirtazapine	B-CHEMICAL
after	O
s	O
.	O
c	O
.	O
and	O
i	O
.	O
v	O
.	O
treatment	O
were	O
0	O
.	O
01	O
and	O
0	O
.	O
16	O
mg	O
/	O
kg	O
.	O

These	O
data	O
indicate	O
that	O
mixed	O
5	B-GENE-N
-	I-GENE-N
HT1	I-GENE-N
/	O
5	B-GENE-Y
-	I-GENE-Y
HT2	I-GENE-Y
receptor	O
antagonists	O
such	O
as	O
pizotifen	B-CHEMICAL
and	O
methysergide	B-CHEMICAL
,	O
and	O
mixed	O
5	B-CHEMICAL
-	I-CHEMICAL
HT	I-CHEMICAL
and	O
catecholamine	B-CHEMICAL
antagonists	O
such	O
as	O
mianserin	B-CHEMICAL
and	O
mirtazapine	B-CHEMICAL
are	O
more	O
potent	O
antagonists	O
of	O
mCPP	B-CHEMICAL
-	O
induced	O
behavioural	O
inhibition	O
in	O
rats	O
than	O
the	O
more	O
selective	O
5	B-GENE-Y
-	I-GENE-Y
HT2A	I-GENE-Y
/	O
5	B-GENE-Y
-	I-GENE-Y
HT2C	I-GENE-Y
antagonist	O
ritanserin	B-CHEMICAL
.	O

Pressor	O
and	O
bradycardic	O
effects	O
of	O
tacrine	B-CHEMICAL
and	O
other	O
acetylcholinesterase	B-GENE-Y
inhibitors	O
in	O
the	O
rat	O
.	O

The	O
cardiovascular	O
effects	O
of	O
three	O
different	O
acetylcholinesterase	B-GENE-Y
inhibitors	O
:	O
physostigmine	B-CHEMICAL
,	O
tacrine	B-CHEMICAL
and	O
rivastigmine	B-CHEMICAL
injected	O
by	O
intravenous	O
(	O
i	O
.	O
v	O
.	O
)	O
route	O
were	O
compared	O
in	O
freely	O
moving	O
Wistar	O
rats	O
.	O

The	O
three	O
drugs	O
significantly	O
increased	O
both	O
systolic	O
and	O
diastolic	O
blood	O
pressure	O
and	O
decreased	O
heart	O
rate	O
.	O

Compared	O
to	O
physostigmine	B-CHEMICAL
,	O
a	O
20	O
-	O
fold	O
higher	O
dose	O
of	O
tacrine	B-CHEMICAL
and	O
a	O
40	O
-	O
fold	O
higher	O
dose	O
of	O
rivastigmine	B-CHEMICAL
was	O
necessary	O
to	O
induce	O
a	O
comparable	O
pressor	O
effect	O
.	O

Tacrine	B-CHEMICAL
was	O
chosen	O
as	O
a	O
model	O
to	O
study	O
the	O
mechanisms	O
underlying	O
the	O
cardiovascular	O
effects	O
of	O
i	O
.	O
v	O
.	O
cholinesterase	B-GENE-Y
inhibitors	O
.	O

Atropine	B-CHEMICAL
totally	O
abolished	O
while	O
methylatropine	B-CHEMICAL
did	O
not	O
affect	O
tacrine	B-CHEMICAL
pressor	O
effects	O
.	O

Conversely	O
,	O
both	O
drugs	O
abolished	O
tacrine	B-CHEMICAL
-	O
induced	O
bradycardia	O
.	O

The	O
alpha1	B-GENE-N
-	I-GENE-N
adrenoceptor	I-GENE-N
antagonist	O
prazosin	B-CHEMICAL
or	O
the	O
vasopressin	B-GENE-N
V1	I-GENE-N
receptor	I-GENE-N
antagonist	O
,	O
[	B-CHEMICAL
beta	I-CHEMICAL
-	I-CHEMICAL
mercapto	I-CHEMICAL
-	I-CHEMICAL
beta	I-CHEMICAL
,	I-CHEMICAL
beta	I-CHEMICAL
-	I-CHEMICAL
cyclopenta	I-CHEMICAL
-	I-CHEMICAL
methylenepropionyl1	I-CHEMICAL
,	I-CHEMICAL
O	I-CHEMICAL
-	I-CHEMICAL
Me	I-CHEMICAL
-	I-CHEMICAL
Tyr2	I-CHEMICAL
,	I-CHEMICAL
Arg8	I-CHEMICAL
]	I-CHEMICAL
vasopressin	I-CHEMICAL
partially	O
but	O
significantly	O
reduced	O
tacrine	B-CHEMICAL
pressor	O
effect	O
and	O
mostly	O
abolished	O
it	O
when	O
administered	O
concomitantly	O
.	O

The	O
tacrine	B-CHEMICAL
pressor	O
response	O
was	O
inhibited	O
in	O
a	O
dose	O
-	O
dependent	O
manner	O
by	O
the	O
i	O
.	O
c	O
.	O
v	O
.	O
administration	O
of	O
the	O
non	O
-	O
selective	O
muscarinic	B-GENE-N
receptor	I-GENE-N
antagonist	O
atropine	B-CHEMICAL
(	O
ID50	O
=	O
1	O
.	O
45	O
microg	O
)	O
,	O
the	O
muscarinic	B-GENE-Y
M1	I-GENE-Y
receptor	I-GENE-Y
antagonist	O
pirenzepine	B-CHEMICAL
(	O
ID50	O
=	O
4	O
.	O
33	O
microg	O
)	O
,	O
the	O
muscarinic	B-GENE-Y
M2	I-GENE-Y
receptor	I-GENE-Y
antagonist	O
methoctramine	B-CHEMICAL
(	O
ID50	O
=	O
1	O
.	O
39	O
microg	O
)	O
and	O
the	O
muscarinic	B-GENE-Y
M3	I-GENE-Y
receptor	I-GENE-Y
antagonist	O
para	B-CHEMICAL
-	I-CHEMICAL
fluoro	I-CHEMICAL
-	I-CHEMICAL
hexahydro	I-CHEMICAL
-	I-CHEMICAL
sila	I-CHEMICAL
-	I-CHEMICAL
difenidol	I-CHEMICAL
(	O
ID50	O
=	O
31	O
.	O
19	O
microg	O
)	O
.	O

Central	O
injection	O
of	O
such	O
muscarinic	B-GENE-N
receptor	I-GENE-N
antagonists	O
did	O
not	O
affect	O
tacrine	B-CHEMICAL
-	O
induced	O
bradycardia	O
.	O

Our	O
results	O
show	O
that	O
acetylcholinesterase	B-GENE-Y
inhibitors	O
induce	O
significant	O
cardiovascular	O
effects	O
with	O
a	O
pressor	O
response	O
mediated	O
mainly	O
by	O
the	O
stimulation	O
of	O
central	O
muscarinic	B-GENE-Y
M2	I-GENE-Y
receptors	I-GENE-Y
inducing	O
a	O
secondary	O
increase	O
in	O
sympathetic	O
outflow	O
and	O
vasopressin	B-CHEMICAL
release	O
.	O

Conversely	O
,	O
acetylcholinesterase	B-GENE-Y
inhibitor	O
-	O
induced	O
bradycardia	O
appears	O
to	O
be	O
mediated	O
by	O
peripheral	O
muscarinic	O
mechanisms	O
.	O

State	O
-	O
dependent	O
cocaine	B-CHEMICAL
block	O
of	O
sodium	B-GENE-N
channel	I-GENE-N
isoforms	O
,	O
chimeras	O
,	O
and	O
channels	O
coexpressed	O
with	O
the	O
beta1	O
subunit	O
.	O

Cocaine	B-CHEMICAL
block	O
of	O
human	B-GENE-Y
cardiac	I-GENE-Y
(	I-GENE-Y
hH1	I-GENE-Y
)	I-GENE-Y
and	O
rat	B-GENE-Y
skeletal	I-GENE-Y
(	I-GENE-Y
mu1	I-GENE-Y
)	I-GENE-Y
muscle	I-GENE-Y
sodium	I-GENE-Y
channels	I-GENE-Y
was	O
examined	O
under	O
whole	O
-	O
cell	O
voltage	O
clamp	O
in	O
transiently	O
transfected	O
HEK293t	O
cells	O
.	O

Low	O
affinity	O
block	O
of	O
resting	O
mu1	B-GENE-Y
and	O
hH1	B-GENE-Y
channels	I-GENE-Y
at	O
-	O
180	O
mV	O
was	O
the	O
same	O
,	O
and	O
high	O
affinity	O
block	O
of	O
inactivated	O
channels	O
at	O
-	O
70	O
mV	O
was	O
the	O
same	O
.	O

Cocaine	B-CHEMICAL
block	O
of	O
hH1	B-GENE-Y
channels	I-GENE-Y
was	O
greater	O
than	O
block	O
of	O
mu1	B-GENE-Y
channels	I-GENE-Y
at	O
voltages	O
between	O
-	O
120	O
mV	O
and	O
-	O
90	O
mV	O
,	O
suggesting	O
that	O
greater	O
steady	O
-	O
state	O
inactivation	O
of	O
hH1	B-GENE-Y
channels	I-GENE-Y
in	O
this	O
voltage	O
range	O
makes	O
them	O
more	O
susceptible	O
to	O
cocaine	B-CHEMICAL
block	O
.	O

We	O
induced	O
shifts	O
in	O
the	O
voltage	O
dependence	O
of	O
steady	O
-	O
state	O
inactivation	O
at	O
mu1	B-GENE-Y
and	O
hH1	B-GENE-Y
channels	I-GENE-Y
by	O
constructing	O
mu1	B-GENE-Y
/	O
hH1	B-GENE-Y
channel	I-GENE-Y
chimeras	O
or	O
by	O
coexpressing	O
the	O
wild	O
-	O
type	O
channels	O
with	O
the	O
rat	O
brain	O
beta1	O
subunit	O
.	O

In	O
contrast	O
to	O
several	O
previous	O
reports	O
,	O
coexpression	O
of	O
the	O
rat	O
brain	O
beta1	O
subunit	O
with	O
mu1	B-GENE-Y
or	O
hH1	B-GENE-Y
produced	O
large	O
positive	O
shifts	O
in	O
steady	O
-	O
state	O
inactivation	O
.	O

Shifts	O
in	O
the	O
voltage	O
dependence	O
of	O
steady	O
-	O
state	O
inactivation	O
elicited	O
linear	O
shifts	O
in	O
steady	O
-	O
state	O
cocaine	B-CHEMICAL
block	O
,	O
yet	O
these	O
manipulations	O
did	O
not	O
affect	O
the	O
cocaine	B-CHEMICAL
affinity	O
of	O
resting	O
or	O
inactivated	O
channels	O
.	O

These	O
data	O
,	O
as	O
well	O
as	O
simulations	O
used	O
to	O
predict	O
block	O
,	O
indicate	O
that	O
state	O
-	O
dependent	O
cocaine	B-CHEMICAL
block	O
depends	O
on	O
both	O
steady	O
-	O
state	O
inactivation	O
and	O
channel	O
activation	O
,	O
although	O
inactivation	O
appears	O
to	O
have	O
the	O
predominant	O
role	O
.	O

